LGND-USA,PGNX-USA,ILMN-USA,SPPI-USA,ENDP-USA,ARWR-USA,BDSI-USA,TECH-USA,REGN-USA,SIGA-USA,OPK-USA,IONS-USA,BMRN-USA,ALXN-USA,NBIX-USA,SGEN-USA,IMMU-USA,BIIB-USA,IMGN-USA,BCRX-USA,GILD-USA,ARNA-USA,MYL-USA,CGEN-USA,AKRX-USA,AMGN-USA,MYGN-USA,LXRX-USA,MGTX-USA,INSM-USA,AUPH-USA,INO-USA,NKTR-USA,RIGL-USA,GERN-USA,AERI-USA,AMRN-USA,INCY-USA,UTHR-USA,SRPT-USA,ALKS-USA,CERS-USA,AMAG-USA,ARQL-USA,LMNX-USA,SGMO-USA,EXEL-USA,SNY-USA,VRTX-USA,ALLO-USA,ASND-USA,BLUE-USA,ACAD-USA,AFMD-USA,PTGX-USA,PRQR-USA,TXMD-USA,ZGNX-USA,ALLK-USA,OMER-USA,RVNC-USA,XON-USA,IRWD-USA,ADVM-USA,RARE-USA,AGLE-USA,NSTG-USA,PDLI-USA,SYRS-USA,RDUS-USA,ASMB-USA,ANIP-USA,ENTA-USA,ALNY-USA,WVE-USA,AKCA-USA,MRTX-USA,PCRX-USA,RTRX-USA,PACB-USA,EDIT-USA,CHMA-USA,MGNX-USA,BPMC-USA,AKBA-USA,EIGR-USA,MNTA-USA,PRTA-USA,ZLAB-USA,SAGE-USA,CTMX-USA,GMAB-USA,VNDA-USA,MEDP-USA,CBAY-USA,INVA-USA,CCXI-USA,HALO-USA,CBPO-USA,MNKD-USA,URGN-USA,CYTK-USA,ESPR-USA,AMRS-USA,PTCT-USA,ACHN-USA,SYNH-USA,FOLD-USA,EGRX-USA,DCPH-USA,ADMA-USA,GWPH-USA,EPZM-USA,JAZZ-USA,MYOK-USA,GRFS-USA,GLPG-USA,PTLA-USA,VCYT-USA,DRNA-USA,CLLS-USA,CARA-USA,FLXN-USA,QURE-USA,AGIO-USA,IOVA-USA,ANAB-USA,XLRN-USA,FATE-USA,HZNP-USA,CSTL-USA,ICPT-USA,KPTI-USA,GLYC-USA,XNCR-USA,ITCI-USA,TBPH-USA,NVCR-USA,ARDX-USA,AMPH-USA,ATRA-USA,RCKT-USA,DERM-USA,FOMX-USA,PRAH-USA,SUPN-USA,FGEN-USA,PBYI-USA,CHRS-USA,CRBP-USA,BOLD-USA,COLL-USA,XBIT-USA,MCRB-USA,AIMT-USA,GBT-USA,RGNX-USA,KURA-USA,APLS-USA,AXSM-USA,VYGR-USA,BGNE-USA,RARX-USA,RETA-USA,HCM-USA,NTLA-USA,ACIU-USA,CRSP-USA,GTHX-USA,ARGX-USA,RUBY-USA,ATNX-USA,PETQ-USA,RYTM-USA,OPTN-USA,TORC-USA,DNLI-USA,QTRX-USA,SLDB-USA,EOLS-USA,FIXX-USA,EYPT-USA,SRRK-USA,UBX-USA,AXNX-USA,TCDA-USA,EIDX-USA,AVRO-USA,MGTA-USA,XERS-USA,AUTL-USA,FTSV-USA,TBIO-USA,MRNA-USA,PRNB-USA,ARVN-USA,YMAB-USA,KOD-USA,GRTS-USA,GH-USA,OSMT-USA,NGM-USA,TWST-USA,ORTX-USA,GOSS-USA,ALEC-USA,DTIL-USA,TPTX-USA,PRVL-USA,AKRO-USA,BCEL-USA,PSNL-USA,STOK-USA,BBIO-USA,ADPT-USA,KRTX-USA,
 1/13/2020 LGND-US   BW   Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics," 1/06/2020 PGNX-US     BW   INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 1/13/2020 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020",12/26/2019 84763A10  BW   Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs," 1/12/2018 ENDP-US  BW   Glancy Prongay & Murray LLP Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Endo International, PLC (ENDP)", 1/06/2020 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer,10/09/2019 BDSI-US  BW   Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors,#N/A," 4/08/2019 ALNY-US  BW   Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases",11/16/2016 SIGA-US  BW   SIGA Announces Successful Completion of Rights Offering; Funding of Loan; Completion of Payment of PharmAthene Obligation, 9/05/2019 OPK-US   BW   OPKO Health adopte la solution multicanal Veeva CRM pour améliorer sa relation clients," 9/24/2018 IONS-US     BW   Cerveau Technologies Inc. Signs Research Agreement with Ionis Pharmaceuticals, Inc. for Novel Tau Imaging Agent", 1/26/2018 BMRN-US  BW   GAMCO Expects to Report Fourth Quarter Earnings of $0.44 to $0.46 Per Fully Diluted Share, 1/14/2020 ALXN-US  BW   Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS, 5/11/2016 NBIX-US  BW   OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs, 1/06/2020 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference," 9/03/2019 IMMU-US     BW   Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders", 1/10/2020 0H68GC-E    BW   CAMP4 Announces Collaboration to Discover Novel Targets to Address Neurodegenerative and Neurological Diseases, 1/02/2020 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference," 7/11/2018 BCRX-US  BW   BioCryst Provides Update on Strategy, Pipeline and Outlook", 1/09/2020 GILD-US      BW   Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University, 9/28/2015 KERX-US  BW   Wall St. Analyst Announces Investment Opinion: Weekly Screener – Biotech Stocks Publication,"12/20/2019 MYL-US   BW   MYLAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mylan N.V. - MYL",10/11/2018 BMY-US   BW   Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors, 4/22/2019 AKRX-US   BW   Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX),11/22/2019 4503-JP      BW   Inaugural STAT Summit Convened 300+ Health Care Leaders,"11/20/2019 MYGN-US     BW   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm"," 3/19/2019 LXRX-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm",#N/A," 9/02/2016 INSM-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Insmed Incorporated of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 13, 2016",12/12/2019 05156V10 BW   Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares, 1/07/2020 0062LC-E BW   BLS Pharma Alleges Inovio’s Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender Community, 1/10/2020 NKTR-US  BW   Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders," 6/18/2018 RIGL-US  BW   US Bioservices Selected by Rigel Pharmaceuticals, Inc. to Dispense TAVALISSE™ (fostamatinib disodium hexahydrate) Tablets", 1/13/2020 GERN-US      BW   Geron Announces 2019 Accomplishments and Key Development Priorities for 2020, 1/02/2020 AERI-US    BW   Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe, 9/25/2019 ADR-AU   BW   Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman, 1/07/2020 INCY-US  BW   Incyte annonce la validation par l'Agence européenne des médicaments de sa demande d'autorisation de mise sur le marché du pemigatinib pour les patients atteints de cholangiocarcinome," 4/30/2018 STDY-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of SteadyMed Ltd. to United Therapeutics Corporation is Fair to Shareholders", 1/13/2020 07DWMY-E BW   Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells’ DNA,11/22/2019 4503-JP  BW   Inaugural STAT Summit Convened 300+ Health Care Leaders, 1/13/2020 CERS-US  BW   Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue, 9/26/2019 AMAG-US  BW   Caligan Partners Issues Letter to AMAG Shareholders,12/17/2019 ARQL-US  BW   Merck Begins Tender Offer to Acquire ArQule, 1/16/2019 LMNX-US  BW   AllerGenis Granted Rights to Develop and Market Its Precision Food Allergy Diagnostic Using Luminex xMAP® Technology, 1/09/2020 80067710 BW   Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference," 1/12/2020 EXEL-US  BW   Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance", 1/14/2020 ALCOR-FR  BW   BIOCORP and SANOFI Strengthen Their Partnership With Mallya Smart Sensors, 1/08/2020 VRTX-US   BW   Vertex to Present at the J.P. Morgan Healthcare Conference on January 13,11/22/2019 4503-JP  BW   Inaugural STAT Summit Convened 300+ Health Care Leaders, 6/22/2017 ASND-US BW   Ascendis Pharma Adopts New Global Communications Model With Fuze, 1/13/2020 BLUE-US  BW   bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype," 1/07/2020 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020",10/27/2015 00CTMP-E BW   AbCheck Achieves First Milestone in Pierre Fabre Partnership, 1/15/2013 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update,#N/A," 1/07/2020 TXMD-US  BW   TherapeuticsMD, an Innovative Women’s Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women’s Health Products","11/21/2019 ZGNX-US  BW   Shareholder Alert: Robbins LLP Reminds Investors Zogenix, Inc. (ZGNX) Sued for Misleading Shareholders", 1/07/2020 ALLK-US  BW   The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Allakos Inc. (ALLK) Investors,12/18/2019 0DZ85K-E BW   myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab, 1/10/2020 0C064X-E BW   Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA, 3/22/2018 EVT-DE   BW   Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer, 1/06/2020 00619R-E BW   Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation," 8/17/2015 ADVM-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Avalanche Biotechnologies, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of September 8, 2015", 1/18/2018 00B2S4-E BW   Anokion Announces Appointment of Dr. John Hohneker as Chief Executive Officer," 4/26/2017 AGLE-US  BW   Proclara Biosciences Appoints Suzanne Bruhn, Ph.D., as Chief Executive Officer to Guide Development of Novel Approach for Neurodegenerative Diseases", 1:28p     63009R10    BW   Two Landmark Nature Publications use NanoString’s GeoMx Digital Spatial Profiling to Dissect Mechanisms of Response to Immunotherapy, 5/02/2019 PDLI-US  BW   LENSAR® Laser System Receives FDA Clearance to Perform Micro Radial Incisions to Optimize Outcomes of Refractive Cataract Procedures, 1/12/2020 SYRS-US  BW   Syros Announces Strategic Priorities and Expected Milestones, 5/03/2016 EDIT-US  BW   Editas Medicine and Radius Health Choose Mass Innovation Labs for Rapid Start and Operational Capabilities," 4/08/2013 04539610 BW   Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc."," 8/13/2018 066FWZ-E     BW   Ancor Capital Partners Sells WellSpring Pharma Services, Inc.", 1/09/2020 ENTA-US    BW   Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference, 1/12/2020 ALNY-US   BW   Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates,11/25/2019 008541-E BW   Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntington’s Disease,#N/A, 6/20/2018 ZYME-US BW   Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance, 6/13/2018 MD-US    BW   MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use,"10/29/2018 RTRX-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders", 1/02/2020 ILMN-US  BW   Illumina and Pacific Biosciences Announce Termination of Merger Agreement, 2/19/2019 GMDA-US  BW   Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells," 8/03/2016 CHMA-US BW   STOCK ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Chiasma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016","10/29/2019 MGNX-US  BW   Notice of Lead Plaintiff Deadline for Shareholders in the Macrogenics, Inc. Securities Class Action Lawsuit"," 2/07/2017 0BP4MZ-E BW   Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence", 1/06/2020 AKBA-US  BW   Akebia Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference, 3/04/2019 CLIN-GB  BW   Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies," 1/08/2018 MNTA-US   BW   INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc.", 8/28/2018 PRTA-US  BW   The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA), 1/09/2020 NVCR-US   BW   Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer, 1/03/2020 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ,12/05/2017 CTMX-US  BW   Medidata Expands Partnership with CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content, 3/29/2019 GMAB-DK  BW   Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer, 4/19/2019 VNDA-US  BW   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vanda Pharmaceuticals Inc.," 1/14/2020 MEDP-US  BW   Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2019 Financial Results on February 24, 2020"," 1/03/2017 061FZY-E BW   Kowa Pharmaceuticals America, Inc. Announces Agreement with CymaBay Therapeutics to License Gout Compound",10/30/2019 INVA-US     BW   Innoviva Reports Third Quarter 2019 Financial Results,11/26/2019 CCXI-US  BW   VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis," 3/05/2019 HALO-CA  BW   Halo Labs Awarded Annual Cannabis Manufacturing License by California, among the First to Implement Track and Trace (METRC)",12/17/2018 CBPO-US  BW   David Gao Issues Statement Following Decision by the Grand Court of the Cayman Islands, 3/19/2019 KPTI-US  BW   Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance, 1/08/2020 URGN-US  BW   UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference, 7/24/2019 CYTK-US BW   Kilroy Realty Leases 35% of Its South San Francisco Development Project Four Months After Construction Commencement," 7/02/2018 ESPR-US     BW   DEADLINE REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","10/24/2019 AMRS-US  BW   Haeggquist & Eck, LLP Investigates Amyris Officers and Directors Regarding Restatement of Financial Results"," 5/18/2018 PTCT-US  BW   Notice to Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval of Derivative Settlement on Behalf of PTC Therapeutics, Inc.",10/16/2019 ACHN-US  BW   Alexion to Acquire Achillion, 5/08/2019 SYNH-US BW   Genprex Retains Addison Whitney for Drug Nomenclature Branding, 2/11/2019 FOLD-US  BW   bluebird bio Appoints Chip Baird as Chief Financial Officer, 1/13/2020 EGRX-US  BW   Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania, 1/13/2020 DCPH-US BW   Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones," 8/01/2016 ADMA-US  BW   INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against ADMA Biologics, Inc. and Advises Investors with Losses to Contact the Firm", 9/25/2019 ADR-AU   BW   Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman, 1/06/2020 072LZ4-E BW   Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value, 6/04/2018 JAZZ-US  BW   Tricida Announces Kathryn Falberg Joins Board of Directors,10/28/2015 MYOK-US  BW   MyoKardia Announces Pricing of Initial Public Offering, 4/24/2018 ENZ-US   BW   Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement Case,11/09/2019 GILD-US     BW   New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile," 1/14/2020 PTLA-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Portola Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm", 1/08/2020 0D652K-E BW   Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma, 1/02/2020 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), 1/12/2020 15117K10 BW   Iovance Biotherapeutics et Cellectis ont signé un partenariat de recherche et un accord de licence mondiale exclusive, 8/08/2011 007V62-E BW   Unigene Reports Second Quarter 2011 Financial Results, 5/15/2017 FLXN-US  BW   Scientist.com Raises $24M to Expand Next Generation Pharmaceutical Outsourcing Marketplace, 4/06/2015 BMY-US   BW   Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases," 1/13/2020 AGIO-US  BW   TIO Bioventures Expands and Strengthens Team with the Appointment of Industry Veteran Rachel W. Humphrey, M.D., as Head of R&D at TIO Discovery"," 2/23/2018 IOVA-US  BW   IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA",10/11/2011 008X00-E BW   AnaptysBio Appoints Carol G. Gallagher as Executive Chair and Promotes Senior Leaders Hamza Suria and David J. King, 1/09/2020 BMY-US   BW   New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial, 6/20/2018 ZYME-US  BW   Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance, 1/13/2020 HZNP-US  BW   Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs," 1/09/2020 14843C10  BW   Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019","11/16/2017 ICPT-US  BW   INTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Intercept Pharmaceuticals, Inc. to Contact the Firm",10/24/2019 KPTI-US  BW   Shareholder Alert: Robbins Arroyo LLP Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders, 1/06/2020 0GHBVF-E BW   GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China, 1/08/2020 98401F10 BW   Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV," 1/10/2018 0D272H-E BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI",#N/A, 1/13/2020 G6674U10 BW   Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update,#N/A," 9/13/2010 03209R10 BW   Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of American Physicians Service Group, Inc.", 4/08/2014 0DHGMT-E BW   Atara Biotherapeutics Strengthens Board and Senior Management Team, 1/06/2020 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference,12/10/2019 DERM-US  BW   Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"11/22/2019 FOMX-US  BW   FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX",10/24/2017 0CT8H5-E BW   Care Innovations® and PRA Health Sciences Announce Strategic Partnership,"10/20/2017 SUPN-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus Pharmaceuticals, Inc.","11/14/2019 FGEN-US    BW   FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm", 1/13/2020 74587V10 BW   Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference,11/05/2018 CHRS-US  BW   Vizient Applauds FDA Approval of Biosimilar UDENYCA," 6/10/2019 CRBP-US BW   Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders","12/16/2019 BOLD-US  BW   AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm", 3/07/2017 LLY-US   BW   Trevi Therapeutics Names Michael Heffernan to Its Board of Directors,"12/11/2017 XBIT-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.",12/16/2019 MCRB-US  BW   Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors, 1/06/2020 AIMT-US  BW   Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference," 9/14/2018 GBT-US   BW   INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",11/26/2018 RCKT-US  BW   Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,#N/A," 8/24/2017 00CLR1-E BW   Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration",#N/A,10/23/2018 09SG9V-E BW   Ablexis Announces Licensing Agreement with Voyager Therapeutics,11/05/2019 BGNE-US BW   Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate,12/04/2019 RARX-US  BW   Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM, 1/05/2011 4508-JP  BW   Research and Markets: Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016," 3/12/2018 HCM-GB   BW   Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs", 9/04/2018 0FZ9LD-E BW   Tmunity Names Graeme Bell as Chief Financial Officer and Executive Vice President,12/12/2018 ACIU-US  BW   AC Immune and Lilly Announce License and Collaboration Agreement,10/15/2019 0GPQYV-E BW   CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology," 5/30/2018 GTHX-US  BW   Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX)", 4/21/2016 00DYYX-E BW   argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target," 6/06/2018 0FYJ81-E BW   Rubius Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Executive Officer",#N/A," 5/13/2019 PETQ-US BW   INVESTIGATION REMINDER: The Schall Law Firm Announces It is Investigating Claims Against PetIQ, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 1/05/2016 065WCH-E BW   Camurus AB: Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide, 9/18/2017 00CN92-E    BW   Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps, 1/03/2018 0H91DS-E BW   resTORbio Appoints Lynne Sullivan to Its Board of Directors,10/02/2019 AXLA-US  BW   Torque Therapeutics Announces the Appointment of John Cox as Chief Executive Officer, 1/10/2020 QTRX-US  BW   Quanterix Corporation to Present at 38th Annual J.P. Morgan Healthcare Conference," 5/29/2018 SLDB-US  BW   DEADLINE TODAY: Kaskela Law Alerts Solid Biosciences, Inc. Investors of Important Deadline", 5/16/2018 EOLS-US  BW   INVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer, 5/02/2016 0FZZYY-E BW   Homology Medicines Inc. Launches as a Newly-Formed Genetic Medicines Company Founded Upon a Unique City of Hope Gene Editing and Gene Transfer Platform Technology, 9/28/2015 EYPT-US  BW   pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs,12/19/2018 GILD-US BW   Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases,#N/A, 1/09/2020 AXNX-US  BW   Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue, 1/07/2020 TCDA-US  BW   Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference,10/14/2019 BBIO-US  BW   BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics, 1/14/2020 AVRO-US  BW   AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program," 1/13/2020 MGTA-US  BW   Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals", 1/06/2020 XERS-US  BW   Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise," 9/16/2019 0GDPJK-E BW   PPF erweitert Beteiligung im Gesundheitssektor durch den Erwerb eines bedeutenden Anteils an Autolus Therapeutics, einem Unternehmen für T-Zell-Therapien", 7/28/2016 05G06K-E BW   New Cancer-Focused Biotech Forty Seven Inc. Selects Medidata to Accelerate Novel Immuno-Oncology R&D," 9/04/2018 00GMRW-E BW   Macrolide Pharmaceuticals Expands Leadership and Strengthens Expertise in Drug Development, Clinical Strategy, Finance and Business Development", 1/12/2020 MRNA-US BW   Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area, 7/26/2018 00D1VN-E BW   Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246,#N/A,11/29/2017 005GTL-E BW   YmAbs Announces Closing of $30 Million Extension of Private Equity Placement,#N/A, 8/23/2018 0FTYWS-E BW   bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies, 7/18/2018 FMI-US   BW   Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit, 4/11/2019 OSMT-US BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors," 3/20/2019 MRK-US   BW   Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022",12:00p     TWST-US  BW   Twist Bioscience Selected as DNA Synthesis Provider for DNA Data Storage Project Under Intelligence Advanced Research Projects Activity (IARPA) Molecular Information Storage (MIST) Program,11/06/2018 C-US   BW   Citi Appointed as Depositary Bank for Orchard Therapeutics’ ADR Programme,11/26/2019 GOSS-US  BW   Gossamer Bio Announces Participation in Upcoming Investor Conferences, 2/06/2019 ALEC-US  BW   Alector Announces Pricing of Initial Public Offering, 3/14/2019 0084LG-E  BW   Raymond Schinazi Joins Precision BioSciences Board of Directors, 4/16/2019 TPTX-US  BW   Turning Point Therapeutics Announces Pricing of Initial Public Offering, 6/19/2019 PRVL-US  BW   Prevail Therapeutics Announces Pricing of Initial Public Offering,#N/A, 3/04/2019 00DHGL-E BW   Atreca to Present at the Cowen and Company Annual Health Care Conference," 1/07/2020 PSNL-US  BW   Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment", 1/07/2020 86150R10 BW   Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference, 1/08/2020 BBIO-US  BW   PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma, 7/19/2019 ADPT-US  BW   Medicxi clôture un nouveau fonds de 400 millions d’euros (Medicxi III) pour propulser la nouvelle vague d’entrepreneurs biopharmaceutiques et de chasseurs de médicaments, 1/09/2020 KRTX-US  BW   Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference,#N/A
 1/09/2020 LGND-US   BW   Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th,"12/20/2019 PGNX-US     BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 1/13/2020 45232710    BW   Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics",11/14/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st," 1/08/2018 ENDP-US  BW   ENDP INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Endo International, PLC Investors",12/20/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,"11/02/2017 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.",#N/A, 8/16/2018 REGN-US  BW   Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip,10/21/2016 SIGA-US  BW   SIGA Announces Commencement of Rights Offering, 9/05/2019 OPK-US   BW   OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement, 4/20/2018 BIIB-US     BW   Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases, 1/10/2017 0731W3-E BW   BioMarin Transfers Duchenne Natural History Database to CureDuchenne To Improve Knowledge of Duchenne Patients and Improve Clinical Outcomes, 1/06/2020 ALXN-US  BW   Alexion to Present at the 38th Annual J.P Morgan Healthcare Conference," 6/16/2011 AMBTQ-US BW   Santarus Appoints Wendell Wierenga Executive Vice President, Research and Development",12/23/2019 SGEN-US     BW   Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer," 2/24/2019 IMMU-US     BW   IMMUNOMEDICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU",11/06/2019 0FMFTQ-E    BW   Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates,12/31/2019 IMGN-US  BW   ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), 7/10/2018 BCRX-US  BW   BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals,"12/24/2019 GILD-US      BW   Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval", 7/03/2012 TSRX-US  BW   Corporate Directors Forum Hosts Open Breakfast Event: ‘Power and Politics Inside the Boardroom’,"12/20/2019 MYL-US   BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 3/07/2018 07J4DM-E BW   Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics," 4/02/2019 AKRX-US   BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm",11/05/2019 0H10HZ-E     BW   Innovative Targeting Solutions and Former Amgen Executive Team up to Launch A2 Biotherapeutics With a $57 Million Series A,"11/10/2019 MYGN-US     BW   ROSEN, A LEADING GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN"," 1/30/2019 LXRX-US  BW   Robbins Arroyo LLP: Lexicon Pharmaceuticals, Inc. (LXRX) Misled Shareholders According to a Recently Filed Class Action",#N/A," 8/19/2016 INSM-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Insmed Incorporated of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 13, 2016",12/09/2019 05156V10 BW   Aurinia Prices US$166.7 Million Public Offering of Common Shares, 5/16/2019 QGEN-US  BW   QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions, 1/10/2020 BMY-US   BW   Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)," 5/29/2018 00CLKM-E BW   TAVALISSE™ (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics, Inc.",12/19/2019 GERN-US      BW   Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),"12/09/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance", 3/22/2019 AMRN-US  BW   AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights, 1/07/2020 INCY-US  BW   Incyte gibt Validierung des Antrags auf Marktzulassung für Pemigatinib bei Patienten mit Cholangiokarzinom durch die Europäische Arzneimittelagentur bekannt, 2/24/2018 UTHR-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against United Therapeutics Corporation - UTHR," 1/09/2020 SRPT-US  BW   Shareholder Alert: Robbins LLP Announces Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders", 2/13/2019 ALKS-US  BW   Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS),12/12/2019 CERS-US  BW   Cerus Corporation Announces New Five-Year INTERCEPT Blood System Agreement With Swiss Transfusion SRC, 9/16/2019 AMAG-US  BW   Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders,"12/09/2019 04269E10 BW   ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting",10/30/2018 LMNX-US  BW   XCR Diagnostics and Luminex Enter into License Agreement,12/23/2019 PFE-US   BW   Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment," 1/07/2020 EXEL-US  BW   Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020",12/12/2019 ALCOR-FR  BW   BIOCORP und SANOFI kooperieren bei der weltweiten Ausstattung des Insulinpens SoloStar mit Mallya-Technologie,12/13/2019 VRTX-US   BW   Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed,12/06/2018 09SG9V-E BW   Ablexis Announces Licensing Agreement with Allogene Therapeutics,#N/A,12/19/2019 BLUE-US  BW   bluebird bio Announces Investor Events in January,"12/18/2019 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer",#N/A,12/06/2012 IRWD-US  BW   Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration,#N/A, 1/06/2020 TXMD-US  BW   TherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference," 6/05/2019 ZGNX-US  BW   ZGNX NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Investigation of Securities Claims Against Zogenix, Inc. Investors with Losses in Excess of $100K are Encouraged to Contact the Firm – ZGNX", 1/03/2020 ALLK-US  BW   Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Allakos Inc. Investors,12/16/2019 OMER-US  BW   Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors, 1/09/2020 RVNC-US  BW   Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference, 3/13/2018 XON-US   BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON, 1/02/2020 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference," 7/10/2015 00773U10 BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc. And Advises Shareholders To Contact The Firm Prior To The Lead Plaintiff Deadline", 1/08/2018 0D272H-E BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE, 4/07/2016 AGLE-US  BW   Aeglea BioTherapeutics Announces Pricing of Initial Public Offering, 1/12/2020 63009R10    BW   NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019,11/10/2017 PDLI-US  BW   LENSAR® Receives FDA Clearance for IntelliAxis™-L - LENSAR Laser System’s Novel Toric Intraocular Lens Alignment Guidance,12/20/2019 SYRS-US  BW   Syros Announces Appointment of Mark Alles to Its Board of Directors,"12/20/2012 RDUS-US  BW   Radius, 3M Drug Delivery Systems Announce Exclusive Agreement for Development, Commercialization of Transdermal Delivery of BA058 for Osteoporosis"," 2/12/2013 04539610 BW   Holzer Holzer & Fistel, LLC Announces Investigation into Ventrus Biosciences, Inc.", 6/21/2013 05MW5D-E     BW   BioSante Pharmaceuticals Receives NASDAQ Delisting Determination Letter,12/30/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference, 1/10/2020 ALNY-US   BW   Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1), 2/20/2018 WVE-US   BW   Takeda Deepens Commitment to Develop Innovative Treatments for Neurological Diseases,#N/A, 1/05/2011 WLA-US  BW   Maven Semantic: Weight Loss Research Database," 2/22/2016 0FNJVF-E BW   PixarBio Corporation Turns Focus To Commercialization in 2018 for NeuroRelease a Non Opiate, Non Addictive Pain Treatment, Adding Industry Sales Veteran Taunia Markvicka as Chief Commercial Officer (CCO)", 9/07/2016 LGND-US  BW   Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis,"12/07/2018 PACB-US  BW   PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout", 4/09/2018 003Q3K-E BW   Scholar Rock Appoints Rhonda Chicko as Chief Financial Officer," 7/20/2016 CHMA-US BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Chiasma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016"," 9/30/2019 MGNX-US  BW   ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Class Action - MGNX", 1/08/2014 0BP4MZ-E BW   Blueprint Medicines to Present at 32nd Annual J.P. Morgan Healthcare Conference, 1/03/2020 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 7/13/2015 28249U10 BW   SECURITIES FRAUD ALERT: The Law Firm of Andrews & Springer LLC Announces That A Securities Fraud Class Action Has Been Filed Against Celladon Corporation - CLDN," 2/24/2017 MNTA-US   BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors", 7/20/2018 PRTA-US  BW   Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA), 8/12/2019 NVCR-US   BW   China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China,"12/23/2019 SAGE-US     BW   Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020", 3/20/2017 BMY-US   BW   Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases,10/08/2018 GMAB-DK  BW   Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress," 4/09/2019 VNDA-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm","10/31/2019 MEDP-US  BW   Medpace Holdings, Inc. to Present at Credit Suisse Healthcare Conference", 1/02/2013 IMUC-US  BW   ImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of Directors,10/02/2019 INVA-US     BW   GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma,10/17/2012 GSK-GB   BW   Research and Markets: ChemoCentryx's and GSK's Traficet-EN (Vercirnon) for Crohn's Disease, 3/01/2019 HALO-CA  BW   Halo Labs Reports Record Monthly Revenue of Approximately US$2.6 Million (CDN $3.4 Million) In the Shortened Month of February, 8/29/2018 008V29-E BW   David Gao Confirms Lawsuit Against China Biologic Products to Protect Shareholders’ Best Interests, 3/19/2019 MNKD-US  BW   Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance,12/19/2019 URGN-US  BW   UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101,12/14/2010 LLY-US  BW   Maven Semantic: Cellular Imaging Database," 6/16/2018 ESPR-US     BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPR"," 9/26/2019 AMRS-US  BW   Scott+Scott Attorneys at Law LLP Continues to Investigate Amyris, Inc.’s Directors and Officers for Breach of Fiduciary Duty – AMRS","10/20/2017 PTCT-US  BW   PTC THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)", 9/28/2015 AGEN-US  BW   Wall St. Analyst Announces Investment Opinion: Biotech Stocks Coverage," 4/25/2019 SYNH-US BW   5-DAY DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Syneos Health, Inc.", 9/19/2017 FOLD-US  BW   Orphan Technologies Applauds Margaret McGlynn for Trailblazer Lifetime Achievement Award, 1/09/2020 EGRX-US  BW   Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke, 1/06/2020 DCPH-US BW   Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference," 8/01/2016 ADMA-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of ADMA Biologics, Inc.",11/29/2018 TLRY-US  BW   FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston,12/18/2019 EPZM-US  BW   Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma," 8/29/2017 IMGN-US  BW   Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products","10/14/2015 00F0GV-E BW   MyoKardia Appoints Renowned Cardiovascular Medicine Expert Eric Topol, M.D., to Board of Directors",10/20/2016 GRF-ES   BW   The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests,10/31/2019 GILD-US     BW   Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting," 1/10/2020 PTLA-US  BW   The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Portola Pharmaceuticals, Inc., (PTLA)","12/03/2019 VCYT-US  BW   Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally", 1/02/2020 DRNA-US  BW   Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases, 1/09/2020 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A, 5/05/2016 009T7W-E BW   Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta, 2/13/2014 N9006410 BW   Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure," 1/13/2020 AGIO-US  BW   TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets"," 1/19/2018 IOVA-US  BW   IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA", 9/29/2011 008H33-E BW   DARPA Extends Contract with AnaptysBio to Generate Additional High Affinity Thermally Stable Antibodies, 1/06/2020 XLRN-US  BW   Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference," 1/17/2013 07GVF3-E BW   Research and Markets: Hearing Disorders - Pipeline Review, H2 2012", 1/13/2020 HZNP-US  BW   MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate,12/30/2019 14843C10  BW   Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology,"11/11/2017 ICPT-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT"," 9/21/2019 KPTI-US  BW   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm",11/29/2019 GLYC-US  BW   GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019,12/20/2019 98401F10 BW   Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors," 7/07/2017 ITCI-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intra-Cellular Therapies, Inc. of Class Action Lawsuit and Upcoming Deadline – ITCI",#N/A, 1/09/2020 G6674U10 BW   Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer,#N/A," 9/03/2010 03209R10 BW   Bull & Lifshitz, LLP Announces Investigation of the Acquisition of American Physicians Service Group, Inc.", 1/10/2014 0DHGMT-E BW   Atara Biotherapeutics Announces Second Closing of $52 Million Series B Financing,12/16/2019 RCKT-US  BW   Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia,12/10/2019 DERM-US  BW   Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis, 6/16/2015 008XK0-E BW   MERZ North America Makes Milestone Payment to Foamix, 9/12/2016 4502-JP  BW   Takeda und PRA Health Sciences geben Partnerschaft für transformierende klinische Entwicklung und vermarktete Produkte bekannt," 4/01/2016 SUPN-US  BW   Supernus Pharmaceuticals Selects DSG, Inc. for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder (ADHD)","11/13/2019 FGEN-US    BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors", 1/09/2020 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4), 9/03/2013 BAX-US   BW   Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars," 4/24/2019 CRBP-US BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",12/02/2019 BOLD-US  BW   Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics,10/05/2012 00772J-E BW   Collegium Pharmaceutical to Present at 11th Annual BIO Investor Forum,"11/17/2017 XBIT-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.",11/14/2019 MCRB-US  BW   Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference,11/15/2019 AIMT-US  BW   Aimmune to Participate in Three Upcoming Investor Conferences," 9/13/2018 GBT-US   BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Global Blood Therapeutics, Inc. – GBT"," 8/31/2017 RGNX-US  BW   INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information",#N/A, 8/10/2017 07ST71-E BW   Apellis Pharmaceuticals Announces $60 Million Series E Financing,#N/A, 7/19/2018 0FVF03-E BW   Turnstone Biologics Announces Key Appointments to Senior Leadership Team,"11/01/2019 BGNE-US BW   BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm",11/07/2019 RARX-US  BW   Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update, 7/12/2010 0085JM-E BW   Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl, 3/06/2018 HCM-GB   BW   Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China, 2/06/2018 NTLA-US  BW   Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner," 3/14/2013 07GVF3-E BW   Research and Markets: Down Syndrome - Pipeline Review, H1 2013", 6/06/2019 CRSP-US  BW   Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics," 5/29/2018 GTHX-US  BW   Glancy Prongay & Murray LLP Begins Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX)",12/17/2015 ARGX-BE  BW   Tetragenetics Launches Partnership Program For Discovery and Development of Therapeutic Monoclonal Antibodies, 5/02/2018 0FYJ81-E BW   Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors,#N/A," 5/10/2019 PETQ-US BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PetIQ, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,12/21/2016 00CN92-E    BW   CORRECTING and REPLACING OptiNose to Present at the 35th Annual J.P. Morgan Healthcare Conference,11/30/2017 0H91DS-E BW   resTORbio Raises $40 Million to Advance Selective TORC1 Inhibitors for Aging-Related Diseases and Conditions, 1/09/2019 DNLI-US  BW   SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System,11/06/2019 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Third Quarter 2019," 5/27/2018 SLDB-US  BW   SOLID BIOSCIENCES 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB","12/05/2017 00FCVN-E BW   Medytox, Inc. Files Citizen Petition with FDA Requesting Investigation of Application for Botulinum Drug Product",#N/A," 9/14/2015 EYPT-US  BW   pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015",#N/A,#N/A,12/19/2019 AXNX-US  BW   Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology,"12/03/2019 TCDA-US  BW   Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs"," 9/16/2019 EIDX-US  BW   EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty", 1/09/2020 AVRO-US  BW   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)," 1/06/2020 MGTA-US  BW   Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco",12/10/2019 XERS-US  BW   Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery, 9/16/2019 05JX6Q-E BW   PPF développe ses investissements dans le secteur des soins de santé en faisant l’acquisition d’une participation importante dans la société Autolus Therapeutics spécialisée dans les thérapies à base de lymphocytes T,#N/A, 6/27/2018 TBIO-US  BW   Translate Bio Announces Pricing of Initial Public Offering, 1/09/2020 MRNA-US BW   Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study,12/13/2017 00D1VN-E BW   Principia Biopharma Initiates Clinical Trial for PRN1008 in Patients With Immune Thrombocytopenia Purpura,#N/A,10/24/2017 0GJSDY-E BW   YmAbs Raises $50 Million in Equity Financing,#N/A," 8/09/2018 0FTYWS-E BW   Gritstone Oncology Appoints Experienced Financial Executive, Steve E. Krognes, to its Board of Directors", 5/19/2014 00FYYJ-E BW   N-of-One Selected by Guardant Health to Provide Clinical Interpretation for Guardant360™ Tests," 3/28/2019 OSMT-US BW   SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC"," 1/03/2019 MRK-US   BW   Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes", 8:00a     TWST-US  BW   Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery,#N/A,11/14/2019 GOSS-US  BW   Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day,"11/16/2018 0DDYP2-E BW   Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne", 3/11/2019 0084LG-E  BW   Precision BioSciences Enters Into Private Convertible Note Financing, 4/08/2019 00FWLP-E BW   Turning Point Therapeutics Appoints Annette North as Executive Vice President and General Counsel, 6/04/2019 0J5W38-E BW   Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations,#N/A, 2/25/2019 00DHGL-E BW   Atreca Announces Retirement of Susan Berland and Appoints Herb Cross as Chief Financial Officer,"12/11/2019 PSNL-US  BW   Personalis, Inc. participará en el Congreso de Inmunooncología 2019 de la ESMO",12/23/2019 86150R10 BW   Stoke Therapeutics Added to NASDAQ Biotechnology Index,12/02/2019 00G7CH-E BW   PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome, 7/19/2019 ADPT-US  BW   Medicxi schließt neuen auf 400 Mio. Euro bezifferten Fonds (Medicxi III) als Antriebskraft der nächsten Welle von Biopharma-Unternehmern und „Arzneimittel-Aufspürern“,11/26/2019 KRTX-US  BW   Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference,#N/A
12/23/2019 LGND-US   BW   Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine,11/08/2019 0LDDK2-E    BW   Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board, 1/13/2020 ILMN-US     BW   Illumina and Roche Partner to Broaden Patient Access to Genomic Testing,11/07/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update," 1/05/2018 ENDP-US  BW   ENDO INTERNATIONAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Endo International, PLC. To Contact The Firm",12/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)," 2/28/2013 09060J10 BW   INVESTOR ALERT: Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate BioDelivery Sciences International, Inc., Following Notice of Non-Reliance of Financial Statements and Restatement",#N/A," 8/06/2018 BLUE-US  BW   bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer","10/13/2016 003Q3K-E BW   SIGA Announces Dr. Phil Gomez Joins Company as New CEO, Dr. Eric Rose to Serve as Executive Chairman of the Board","10/26/2018 OPK-US   BW   Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against OPKO Health, Inc.", 2/14/2018 BIIB-US     BW   The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy, 4/05/2016 BMRN-US  BW   PSI and BioMarin Named Finalists for 2016 PharmaTimes Strategic Partnership Competition,12/16/2019 ALXN-US  BW   Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™, 3/17/2011 005YZ9-E BW   KaloBios Announces Two Significant Additions to Its Management Team,"12/18/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval"," 2/22/2019 IMMU-US     BW   Immunomedics 72 Hour Deadline Alert: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU"," 2/12/2019 LLY-US      BW   ShareholderDemocracy.com: Six Top U.S. Pharmaceutical Companies to Feel the Heat on Runaway Drug Prices, as More Americans Get a Voice on Proxy Ballot Measures",12/17/2019 IMGN-US  BW   ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer, 6/05/2018 BCRX-US  BW   BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera,"12/23/2019 GILD-US      BW   Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020", 1/18/2011 TLRK-US  BW   Maven Semantic: Signal Transduction Database,"12/19/2019 MYL-US   BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",12/11/2015 CGEN-IL  BW   Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer," 3/29/2019 AKRX-US   BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm", 8/26/2019 CELG-US      BW   Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion,"10/08/2019 MYGN-US     BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Myriad Genetics, Inc. Investors"," 1/29/2019 LXRX-US  BW   Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc.",#N/A," 7/26/2016 INSM-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Insmed Incorporated To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",12/09/2019 05156V10 BW   Aurinia Announces Public Offering of Common Shares, 5/16/2019 QGEN-US  BW   QIAGEN und Inovio arbeiten an der Entwicklung eines Begleitdiagnostikums für eine neue Immuntherapie zur Behandlung präkanzeröser zervikaler Läsionen,"10/16/2019 NKTR-US  BW   FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics", 9/09/2015 ACRS-US  BW   Aclaris Therapeutics International and Rigel Sign License Agreement for JAK Inhibitors to Treat Skin Disorders,12/18/2019 GERN-US      BW   Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis,12/03/2019 AERI-US    BW   Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe, 3/15/2019 AMRN-US  BW   Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders, 1/07/2020 INCY-US  BW   Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma," 2/21/2018 0CJTL1-E BW   Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders",11/20/2019 SRPT-US  BW   Lysogene annonce sa position de trésorerie au 30 septembre 2019," 2/12/2019 ALKS-US  BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)",11/13/2019 CERS-US  BW   Cerus Corporation to Present at the Stifel 2019 Healthcare Conference,"11/19/2015 AMAG-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by AMAG Pharmaceuticals, Inc. and Certain Officers and Directors","12/09/2019 ARQL-US  BW   Merck to Acquire ArQule, Advancing Leadership in Oncology",10/31/2017 LMNX-US  BW   Michael K. McGarrity Named Chief Executive Officer of Sterilis Medical,12/17/2019 PFE-US   BW   Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day, 1/07/2020 EXEL-US  BW   Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors,12/11/2019 001J1Y-E  BW   PSE : Sanofi rejoint l'Alliance pharmaceutique basée sur les systèmes,12/10/2019 06QNN6-E  BW   Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene,11/01/2018 ALLO-US  BW   Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting,#N/A,12/09/2019 BLUE-US  BW   bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition,12/04/2019 ACAD-US  BW   ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting,#N/A, 6/18/2012 07F0YZ-E BW   Zealand Pharma and Protagonist Therapeutics Team up for Peptide Drug Discovery and Development,#N/A,12/30/2019 0H4RZK-E BW   TherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners," 5/03/2019 ZGNX-US  BW   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.","12/19/2019 ALLK-US  BW   ALLAKOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Allakos, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm",12/13/2019 OMER-US  BW   Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares, 1/09/2020 RVNC-US  BW   Revance Provides Corporate Update and Anticipated Milestones for 2020,12/15/2016 OGEN-US  BW   Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development,11/05/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference," 7/09/2015 00773U10 BW   EQUITY ALERT: The Rosen Law Firm Files Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc.", 5/15/2017 RARE-US  BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc., 3/15/2016 00FWPM-E BW   Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors, 1/02/2020 63009R10    BW   NanoString to Present at the 38th Annual JP Morgan Healthcare Conference, 1/26/2017 PDLI-US  BW   LENSAR® Launches Streamline™ III to Assist Cataract Surgeons in Managing and Improving Astigmatism Treatment for Optimal Visual Outcomes,12/08/2019 SYRS-US  BW   Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting," 5/24/2011 006TCJ-E BW   GE Capital is Agent on $25 Million Term Loan Facility to Radius Health, Inc.",#N/A, 6/20/2013 00182C10     BW   BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Completion of Merger,"11/21/2019 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019", 1/06/2020 ALNY-US   BW   Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference,11/09/2017 WVE-US   BW   Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update,#N/A,#N/A, 9/08/2015 PCRX-US  BW   Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication, 8/04/2015 RTRX-US  BW   Retrophin Reports Second Quarter 2015 Financial Results,"11/01/2018 ILMN-US  BW   Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery", 1/09/2017 0FTYWS-E BW   Emerging Life Science and Biotech Companies Find Critical Success at Mass Innovation Labs," 7/07/2016 CHMA-US BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Chiasma, Inc. And Reminds Investors With Losses To Contact The Firm"," 9/23/2019 MGNX-US  BW   Shareholder Alert: Robbins Arroyo LLP Announces MacroGenics, Inc. (MGNX) Sued for Misleading Shareholders", 1/07/2014 0BP4MZ-E BW   Blueprint Medicines Announces $25 Million Series B Financing,12/03/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A," 2/22/2017 MNTA-US   BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Momenta Pharmaceuticals, Inc., and Encourages Investors to Contact the Firm"," 7/06/2018 PRTA-US  BW   DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 7/02/2019 INCY-US   BW   Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China,12/10/2019 SAGE-US     BW   Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP),12/16/2015 0DZ2BK-E BW   Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance, 7/12/2018 GMAB-DK  BW   Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors, 4/06/2019 VNDA-US  BW   INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Vanda Pharmaceuticals Inc. and Encourages Investors to Contact the Firm Before April 26,"10/28/2019 MEDP-US  BW   Medpace Holdings, Inc. Reports Third Quarter 2019 Results",#N/A, 7/24/2019 INVA-US     BW   Innoviva Reports Second Quarter 2019 Financial Results,"10/09/2012 060RWY-E BW   Significantly More Biologic-Treated Patients Have Seen an Improvement in Their Disease over the Past Year than Non-Biologic-Treated Patients, According to a New BioTrends Report Which Analyzes “Real World” Crohn’s Disease Patient Charts", 1/31/2019 HALO-CA  BW   Halo Labs Provides Operational Update & Announces Closing of Promissory Note, 8/24/2018 CBPO-US  BW   Leading Investor Group Issues Statement Following China Biologic’s Dilutive Private Placement of Shares, 8/02/2018 MNKD-US  BW   Tanner Pharma Group Signs Distribution Agreement with MannKind Corporation,12/06/2019 URGN-US  BW   UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),#N/A," 6/04/2018 0DBJVZ-E    BW   INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Esperion Therapeutics, Inc."," 8/22/2019 AMRS-US  BW   Scott+Scott Attorneys at Law LLP Continues Investigation into Amyris, Inc.’s Directors and Officers for Breach of Fiduciary Duty – (NASDAQ: AMRS)","10/06/2017 PTCT-US  BW   PTC THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)","11/22/2013 00448Q20 BW   ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013"," 4/03/2019 SYNH-US BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm","11/29/2016 FOLD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Amicus Therapeutics, Inc.", 1/07/2020 EGRX-US  BW   Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer,12/16/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors,10/16/2014 ADMA-US  BW   ADMA Biologics to Present “Ascending Company” Presentation at BioNJ CEO Summit," 3/03/2017 MNTR-US  BW   Mentor Capital Acquires $1.0 Million of GW Pharmaceuticals, Plc",12/18/2019 EPZM-US  BW   Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma," 5/27/2016 JAZZ-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc",10/06/2015 00F0GV-E BW   MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy, 6/09/2016 GRF-ES   BW   Grifols to Install the Kiro® Oncology Robot at Smilow Cancer Hospital,10/16/2019 GLPG-NL     BW   HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV," 1/10/2020 PTLA-US  BW   Lost Money in Portola Pharmaceuticals, Inc.?",11/02/2019 VCYT-US  BW   Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer,12/19/2019 DRNA-US  BW   Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection, 1/09/2020 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A, 1/29/2010 009T7W-E BW   Flexion Therapeutics Announces Agreements with Four Major Pharmaceutical Companies,#N/A," 7/23/2018 00CLKM-E BW   TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc."," 1/05/2018 IOVA-US  BW   IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA", 9/01/2011 008H33-E BW   AnaptysBio Successfully Generates Therapeutic Antibodies in Partnership with a Leading Global Pharma,12/30/2019 FULC-US  BW   Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement,#N/A,12/13/2019 HZNP-US  BW   FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED),12/18/2019 14843C10  BW   Castle Biosciences Added to NASDAQ Biotechnology Index,"11/01/2017 ICPT-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Investors to Contact the Firm"," 9/20/2019 KPTI-US  BW   KARYOPHARM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI",11/13/2019 GLYC-US  BW   GlycoMimetics to Present at Two Upcoming Investor Conferences,"12/18/2019 98401F10 BW   Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer"," 7/05/2017 ITCI-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Intra-Cellular Therapies, Inc. to Contact the Firm",#N/A,12/26/2019 G6674U10 BW   Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference,#N/A, 9/01/2010 03209R10 BW   The Law Office of Abe Shainberg Announces an Investigation into the Possible Breaches of Fiduciary Duty by the Board of American Physicians Service Group Inc. in Connection with Sale to ProAssurance Corporation - AMPH,12/17/2013 0DHGMT-E BW   Atara Biotherapeutics Secures $38.5 Million Series B Financing,12/13/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Closing of Public Offering,11/27/2019 DERM-US  BW   Dermira to Participate in December Investor Conferences," 7/08/2013 008XK0-E BW   Merz North America and Foamix, Ltd. to Develop an Innovative Medicated Foam", 9/12/2016 4502-JP  BW   Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership, 3/12/2014 86845910 BW   Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™,"11/13/2019 FGEN-US    BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors", 1/07/2020 74587V10 BW   Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference," 6/13/2012 19249H10 BW   Ascena Retail Group, Inc. Successfully Completes Tender Offer for Shares of Charming Shoppes, Inc."," 3/29/2019 CRBP-US BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.",11/26/2019 BOLD-US  BW   Audentes Therapeutics to Participate in Upcoming Investor Conferences,"10/05/2012 00772J-E BW   Collegium Announces Poster Presentation for Oxycodone DETERx®, a Tamper-Resistant, Extended-Release Opioid at 6th Annual Pain Therapeutics Summit","11/08/2017 XBIT-US  BW   XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.",11/05/2019 MCRB-US  BW   Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update,11/08/2019 AIMT-US  BW   Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments," 8/04/2014 0CM1LJ-E BW   Global Blood Therapeutics Names Hing Sham Senior Vice President of Chemistry, Promotes Uma Sinha to Chief Scientific Officer"," 5/24/2016 RGNX-US  BW   ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501",#N/A,#N/A,#N/A," 1/16/2018 VYGR-US  BW   Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors","10/28/2019 BGNE-US BW   ROSEN, A HIGHLY RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. – BGNE","10/14/2019 RARX-US  BW   RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX",#N/A, 2/13/2018 HCM-GB   BW   Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer, 4/22/2016 0DZX54-E BW   Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors, 9/19/2012 0077NC-E BW   2012 “Fierce 15” — The Best and Brightest in Biotech — Announced Today at BioPharm America™ in Boston,12/12/2017 CRSP-US  BW   Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia, 1/03/2018 GTHX-US  BW   GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cancer, 7/09/2014 07N3G8-E BW   Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X, 3/01/2018 0FYJ81-E BW   Rubius Therapeutics Closes $100 Million Financing,#N/A," 5/09/2019 PETQ-US BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against PetIQ, Inc. – PETQ",#N/A, 9/29/2016 TKPYY-JP    BW   Tom Gibbs Joins OptiNose™ as Chief Commercial Officer,11/20/2017 0H91DS-E BW   resTORbio Advances to Part 2 of a Phase 2b Clinical Study of RTB101 Immunotherapy Following Unanimous Recommendation of Independent Data Monitoring Committee Overseeing the Study,10/03/2018 0DLJDW-E BW   CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials,11/04/2019 QTRX-US  BW   Siemens Healthineers Enters into License and Supply Arrangement with Quanterix for Access to Neurofilament Light (Nf-L) Antibodies to Develop Nf-L Assays," 5/25/2018 SLDB-US  BW   SOLID BIOSCIENCES 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Solid Biosciences Inc.",#N/A,#N/A, 9/09/2015 30233G10 BW   pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results,#N/A,#N/A,12/12/2019 AXNX-US  BW   Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,11/25/2019 TCDA-US  BW   Tricida to Present at the Evercore Annual Global Healthcare Conference, 9/12/2019 28249H10 BW   Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares,12/19/2019 AVRO-US  BW   AVROBIO Announces First Patient Dosed Using plato™ Platform,12/09/2019 MGTA-US  BW   Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate, 9/19/2019 XERS-US  BW   Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes,11/29/2018 0FD9Z1-E BW   AbCellera kooperiert mit Autolus bei Antikörper-Entdeckungs-Projekt,#N/A, 6/18/2018 00DL17-E BW   Translate Bio Launches Proposed Initial Public Offering, 1/06/2020 MRNA-US BW   Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference, 9/18/2017 00D1VN-E BW   Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting,#N/A,#N/A,#N/A, 7/19/2018 0FTYWS-E BW   Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors,#N/A,#N/A," 6/17/2013 MEDI-US  BW   AstraZeneca: MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity", 1/13/2020 TWST-US  BW   Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer Setting Stage for Future Growth,#N/A,11/12/2019 GOSS-US  BW   Gossamer Bio Announces Third Quarter 2019 Financial Results,11/15/2018 ABBV-US  BW   Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease," 1/16/2019 0084LG-E  BW   Precision BioSciences Announces Formation of Scientific Advisory Board with Anderson, Kantarjian, Schinazi and Turtle", 4/01/2019 00FWLP-E BW   Turning Point Therapeutics’ Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations, 5/16/2019 0J5W38-E BW   Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of Directors,#N/A, 1/02/2019 00DHGL-E BW   Atreca to Present at the 37th Annual J.P. Morgan Healthcare Conference,"12/11/2019 PSNL-US  BW   Personalis, Inc. hält Präsentation auf ESMO-Immunonkologie-Kongress 2019","12/08/2019 86150R10 BW   Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome",10/14/2019 BBIO-US  BW   BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics, 7/18/2019 ADPT-US  BW   Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters,11/20/2019 KRTX-US  BW   Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock,#N/A
12/02/2019 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi,11/07/2019 LNTH-US     BW   Lantheus Releases Comprehensive Strategic Plan for Progenics, 1/10/2020 45232710    BW   Illumina dépose des actions en contrefaçon de brevet contre BGI en Suède et au Royaume-Uni,10/31/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call," 1/03/2018 ENDP-US  BW   Glancy Prongay & Murray Announces Filing of a Securities Class Action on Behalf of Endo International, PLC Investors and Encourages Investors to Contact the Firm",12/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease," 1/17/2013 09565S-E BW   Research and Markets: Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2012",#N/A,10/16/2017 AIMT-US  BW   Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy,10/10/2016 SIGA-US  BW   SIGA Announces Oct. 12 Record Date for Rights Offering,"10/23/2018 OPK-US   BW   Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against OPKO Health, Inc.",12/19/2017 BIIB-US     BW   Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy,12/10/2014 BMRN-US  BW   Cure Duchenne Offers Continued Support to BioMarin for Duchenne Research,12/09/2019 001TK8-E BW   Elliott Statement on Alexion, 1/10/2011 VRTX-US  BW,"12/18/2019 4503-JP     BW   FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer"," 2/15/2019 IMMU-US     BW   INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Immunomedics, Inc."," 1/11/2019 0H4QHH-E    BW   AbelsonTaylor Launches ICONS.HEALTH™, a Content Channel Exploring Innovation at the Intersection of Healthcare and Technology",12/09/2019 IMGN-US  BW   ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting, 4/10/2018 BCRX-US  BW   BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger,"12/20/2019 GILD-US      BW   China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment","12/09/2010 WU-US    BW   Zacks Analyst Blog Highlights: Orexigen Therapeutics, Arena Pharmaceuticals, Vivus, MoneyGram International and Western Union",12/18/2019 MYL-US   BW   Pfizer and Mylan Announce Two Future Viatris Board Members,11/24/2015 CGEN-IL  BW   Compugen to Present at the Oppenheimer Healthcare Conference in New York," 3/28/2019 AKRX-US   BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. (AKRX)"," 6/10/2019 CQB-US       BW   ADDING MULTIMEDIA Socati Board of Director Appointments Bring Significant Leadership Experience to Accelerate Company Growth, Advance Hemp Industry","10/06/2019 MYGN-US     BW   ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN"," 8/03/2015 IPN-FR   BW   Ipsen’s Partner, Lexicon Pharmaceuticals, Announces Positive Results from TELESTAR Phase 3 Study Showing That Telotristat Etiprate is Effective in the Treatment of Carcinoid Syndrome Caused by Neuroendocrine Tumors Not Adequately Controlled by Somatostatin ...",#N/A, 7/21/2016 INSM-US  BW   SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Insmed Incorporated and Reminds Investors With Losses to Contact the Firm,12/04/2019 05156V10 BW   Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis," 8/21/2018 INO-US   BW   Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer","10/15/2019 NKTR-US  BW   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm", 1/21/2013 07G69B-E BW   Research and Markets: Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis,12/10/2019 GERN-US      BW   Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting,11/26/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference," 3/11/2019 AMRN-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm", 1/02/2020 INCY-US  BW   Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease," 8/23/2017 CELG-US  BW   A Celularity, Inc. felgyorsítja a placentális vizsgálatok és terápia céljára szolgáló platform fejlesztését",11/20/2019 SRPT-US  BW   Lysogene Reports its Cash Position as of 30 September 2019," 2/05/2019 ALKS-US  BW   Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)",11/08/2019 CERS-US  BW   Cerus Corporation to Present at the Stephens Nashville Investment Conference, 8/17/2015 05L030-E BW   GTCR Completes Sale of Cord Blood Registry to AMAG Pharmaceuticals,"11/25/2019 04269E10 BW   ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting"," 4/12/2017 LMNX-US  BW   Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman",12/09/2019 80067710 BW   Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia,12/19/2019 EXEL-US  BW   Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors,12/11/2019 001J1Y-E  BW   PSE: Sanofi joins Systems-based Pharmaceutics Alliance,11/22/2019 4503-JP   BW   Inaugural STAT Summit Convened 300+ Health Care Leaders,10/15/2018 ALLO-US  BW   Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,12/09/2019 BLUE-US  BW   bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition,11/25/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia,#N/A, 1/18/2011 IRWD-US  BW   Ironwood and Protagonist Establish Collaboration for Peptide Drug Discovery and Development,#N/A,11/26/2019 GUD-CA   BW   Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada," 5/02/2019 ZGNX-US  BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.",12/19/2019 ALLK-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Allakos Inc. Investors,12/10/2019 OMER-US  BW   Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva,12/05/2019 RVNC-US  BW   Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology,11/21/2016 OGEN-US  BW   U.S. FDA Grants Fast Track Designation for the Development of Oragenics’ AG013 for Oral Mucositis,10/31/2019 IRWD-US  BW   Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance," 6/19/2015 00773U10 BW   INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Avalanche Biotechnologies, Inc. On Behalf Of Investors", 6/20/2011 00D326-E BW   Ultragenyx Announces Series A Financing, 3/14/2016 00FWPM-E BW   Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies,12/11/2019 63009R10    BW   NanoString Announces the Creation of the GeoMx Breast Cancer Consortium,"12/19/2016 PDLI-US  BW   LENSAR® Strategic Restructure in Partnership with PDL BioPharma, Inc.",11/26/2019 SYRS-US  BW   Syros to Present at Piper Jaffray 31st Annual Healthcare Conference,#N/A,#N/A," 6/10/2013 00182C10     BW   Leading Independent Proxy Advisory Firms ISS and Glass, Lewis & Co., LLC Recommend Vote “FOR” BioSante/ANI Merger",11/11/2019 ENTA-US    BW   Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019,12/17/2019 ALNY-US   BW   Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1,11/06/2017 WVE-US   BW   Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy (DMD),#N/A,#N/A," 8/19/2015 PCRX-US  BW   Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer", 7/21/2015 RTRX-US  BW   Retrophin to Report Second Quarter 2015 Financial Results, 3/02/2015 69404D10 BW   DNAnexus Enables Seamless Assembly of PacBio Data for J. Craig Venter Genome, 5/03/2016 EDIT-US  BW   Editas Medicine and Radius Health Choose Mass Innovation Labs for Rapid Start and Operational Capabilities," 7/01/2016 CHMA-US BW   INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Chiasma, Inc. and Encourages Investors with Losses to Contact the Firm"," 9/16/2019 MGNX-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. (NASDAQ: MGNX) and Encourages MacroGenics Investors to Contact the Firm", 9/17/2013 0BP4MZ-E BW   Blueprint Medicines Appoints Oncology Business Leader Kyle Kuvalanka as Chief Business Officer,11/21/2019 AKBA-US  BW   Akebia Therapeutics to Present at Upcoming Investor Conferences,#N/A," 2/22/2017 MNTA-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA", 6/23/2018 PRTA-US  BW   PRTA ALERT: Rosen Law Firm Reminds Prothena Corporation plc Investors of Important Deadline in Case– PRTA," 6/11/2019 DCPH-US   BW   Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China","12/05/2019 SAGE-US     BW   Lost Money in Sage Therapeutics, Inc.?",#N/A, 6/13/2018 GMAB-DK  BW   Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer, 3/07/2019 VNDA-US  BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)," 9/24/2019 MEDP-US  BW   Medpace Holdings, Inc. to Report Third Quarter 2019 Financial Results on October 28, 2019",#N/A, 5/02/2019 INVA-US     BW   Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint, 1/11/2011 PFE-US   BW   Maven Semantic: Cell Adhesion Research Database," 3/22/2018 HALO-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.", 8/20/2018 CBPO-US  BW   Leading Investor Group Proposes to Acquire China Biologic Products for US$118.00 Per Share in Cash, 9/21/2016 06RG47-E BW   SetPoint Medical’s Progress Fuels Corporate Headquarters Relocation,11/18/2019 URGN-US  BW   UroGen to Present at November 2019 Investor Conferences,#N/A," 5/30/2018 ESPR-US     BW   The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR)", 8/08/2019 AMRS-US  BW   LAVVAN Appoints Neil Closner as Chief Executive Officer, 3/21/2017 PTCT-US  BW   Knopp Biosciences meldet Wahl der Biotech-Führungskraft Shane Kovacs in das Board of Managers, 9/30/2013 00448Q20 BW   Wolf Haldenstein Announces Investigation of Achillion Pharmaceuticals Inc.," 3/19/2019 SYNH-US BW   Robbins Arroyo LLP: Syneos Health, Inc. (SYNH) Misled Shareholders According to a Class Action",11/29/2016 FOLD-US  BW   BioNJ's First-Ever Beyond Value Frameworks Workshop Defining the Value of Medical Innovation, 1/06/2020 05MCR2-E BW   Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury,12/04/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors," 9/10/2014 ADMA-US  BW   ADMA Biologics’ Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence"," 7/21/2016 0CGNRJ-E BW   Beyond Cannabis, Many Other Plants Produce Compounds Targeting Body's Endocannabinoid System, According to New Review by Phytecs' Dr. Ethan B. Russo in Trends in Pharmacological Sciences",12/18/2019 EPZM-US  BW   Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today, 5/25/2016 00DH0S-E BW   Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million in Committed Funding," 4/30/2015 00F0GV-E BW   MyoKardia, Inc. Completes $46 Million Series B Financing"," 3/22/2016 GRF-ES   BW   Lurie Children’s Hospital Selects Grifols KIRO® Robot to Increase Precision, Safety, and Compliance of Pediatric IV Chemotherapy Handling and Compounding",10/10/2019 GILD-US     BW   Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis," 1/10/2020 PTLA-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors",10/30/2019 VCYT-US  BW   Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association,12/17/2019 DRNA-US  BW   Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency, 1/06/2020 15117K10 BW   Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery,#N/A,#N/A,#N/A, 5/21/2018 DCPH-US  BW   Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director,"12/28/2017 IOVA-US  BW   Robbins Arroyo LLP: Iovance Biotherapeutics, Inc. (f/k/a Lion Biotechnologies, Inc.) (IOVA) Misled Shareholders According to a Recently Filed Shareholder Derivative Action", 7/12/2011 008H33-E BW   AnaptysBio Selects Novel Anti-IL17 mAb with Best-in-Class Potential,12/09/2019 BMY-US   BW   Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting,#N/A,12/13/2019 HZNP-US  BW   Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease,12/03/2019 14843C10  BW   Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx,"11/01/2017 ICPT-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017"," 8/09/2019 KPTI-US  BW   ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – KPTI",11/07/2019 GLYC-US  BW   GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments,12/09/2019 98401F10 BW   Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting," 6/19/2017 ITCI-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Intra-Cellular Therapies, Inc. to Contact the Firm",#N/A,12/02/2019 06P9WL-E BW   Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program,#N/A," 9/01/2010 03209R10 BW   The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of American Physicians Service Group, Inc. by ProAssurance Corporation",#N/A,12/10/2019 RCKT-US  BW   Rocket Pharmaceuticals Prices Public Offering of Common Stock,11/14/2019 DERM-US  BW   Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference,#N/A, 9/12/2016 4502-JP  BW   Takeda et PRA Health Sciences annoncent un partenariat de développement clinique transformationnel et de produits commercialisés, 2/25/2014 86845910 BW   Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call,11/08/2019 AZN-GB     BW   Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators,12/16/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)," 5/10/2012 19249H10 BW   Law Office of Brodsky & Smith, LLC Announces Investigation of Charming Shoppes, Inc."," 3/28/2019 CRBP-US BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors (CRBP)",11/07/2019 BOLD-US  BW   Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update," 9/27/2012 00772J-E BW   Collegium Announces Poster Presentation for Oxycodone DETERx®, a Tamper-Resistant, Extended-Release Opioid at American Academy of Pain Management’s 23rd Annual Clinical Meeting","11/03/2017 0BXWRQ-E BW   XBIT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.","10/31/2019 MCRB-US  BW   Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019",11/08/2019 AIMT-US  BW   New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge, 6/17/2014 0CM1LJ-E BW   Global Blood Therapeutics Names Ted W. Love as CEO,10/31/2013 00BXRX-E BW   Fidelity Biosciences and REGENX Biosciences Launch Dimension Therapeutics to Develop and Commercialize Novel AAV Gene Therapy Products,#N/A,#N/A,#N/A," 9/17/2015 0DL69Y-E BW   Voyager Therapeutics Appoints Neuroscience Expert Steven Hyman, M.D., to Board of Directors"," 9/23/2019 BGNE-US BW   BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. – BGNE",10/10/2019 RARX-US  BW   UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases,#N/A,12/15/2017 HCM-GB   BW   Chi-Med Initiates Fruquintinib U.S. Clinical Trials, 1/12/2016 0DZX54-E BW   Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/Cas9,#N/A, 9/08/2017 BAYN-DE  BW   Casebia Therapeutics Strengthens Leadership Team with Two Key Appointments,10/16/2013 0CRRZ8-E BW   BASi Signs Preferred Provider Agreement with G1 Therapeutics.,#N/A, 2/20/2018 0FYJ81-E BW   Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing,#N/A,10/03/2018 PETQ-US BW   FDB and PetIQ Announce Upcoming Release of Industry’s First Veterinary Medications Database,#N/A, 9/19/2016 00CN92-E    BW   New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients,#N/A, 6/12/2018 DNLI-US  BW   AbCellera Announces Collaboration with Denali Therapeutics to Discover New Antibodies to Treat Neurodegenerative Diseases,10/25/2019 QTRX-US  BW   Quanterix Simoa Technology Unlocks Low-Level Markers Critical to Rapid Triage Test in Study for Active Pulmonary Tuberculosis," 5/25/2018 SLDB-US  BW   FINAL DEADLINE NOTICE: Shareholder Class Action Lawsuit Against Solid Biosciences, Inc.",#N/A,#N/A, 9/03/2015 30233G10 BW   pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium,#N/A,#N/A,12/09/2019 AXNX-US  BW   Axonics® Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM® System,11/14/2019 TCDA-US  BW   Tricida Announces Third Quarter 2019 Financial Results, 9/09/2019 EIDX-US  BW   Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine,12/16/2019 AVRO-US  BW   AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),12/07/2019 MGTA-US  BW   First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers, 9/10/2019 XERS-US  BW   Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank,11/29/2018 0FD9Z1-E BW   AbCellera Collaborates with Autolus on Antibody Discovery Project,#N/A, 6/11/2018 SAN-FR   BW   Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology,12/11/2019 MRNA-US BW   Moderna Announces Key 2020 Investor and Analyst Events, 7/11/2017 00D1VN-E BW   Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris,#N/A,#N/A,#N/A, 4/12/2018 0FTYWS-E BW   Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting,#N/A,#N/A,"10/06/2011 077JML-E BW   CytomX Therapeutics Promotes Henry Lowman, Ph.D., to Chief Scientific Officer", 1/06/2020 TWST-US  BW   Twist Bioscience to Present at the 38th Annual J.P. Morgan Healthcare Conference,#N/A,11/12/2019 MRK-US   BW   Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors, 9/19/2018 0DDYP2-E BW   Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia,12/20/2018 0084LG-E  BW   Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors, 3/25/2019 00FWLP-E BW   Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor Relations, 3/27/2019 0J5W38-E BW   Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative Diseases,#N/A,"11/15/2018 00DHGL-E BW   Atreca to Present Analyses of Active B Cell Responses in Nearly 200 Cancer Patients Leading to Identification of More Than 1,000 Antibodies Targeting Non-Autologous Tumor","12/11/2019 PSNL-US  BW   Personalis, Inc. réalisera une présentation lors du Congrès 2019 ESMO de l’immuno-oncologie",12/07/2019 STOK-US  BW   Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome, 9/09/2019 EIDX-US  BW   Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine," 6/20/2019 ADPT-US  BW   Adaptive Biotechnologies Announces Private Payor Coverage of clonoSEQ for Detecting and Monitoring MRD in Patients with Lymphoid Blood Cancers, Expanding Access to Over 140 Million People in the United States",11/18/2019 KRTX-US  BW   Karuna Therapeutics Announces Proposed Public Offering of Common Stock,#N/A
11/12/2019 05MFY1-E  BW   Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™,11/04/2019 PGNX-US     BW   Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board, 1/10/2020 45232710    BW   Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein,10/24/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS®,12/23/2017 ENDP-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP,12/13/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors, 2/08/2011 09060J10 BW   BioDelivery Sciences to Present at the 13th Annual BIO CEO & Investor Conference,#N/A, 6/19/2017 VEEV-US  BW   Standardizing on Veeva Vault Enhances Regeneron’s Clinical and Regulatory Operations Processes, 9/21/2016 06ZQG4-E BW   SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full,"10/08/2018 OPK-US   BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Opko Health, Inc.",11/01/2017 BIIB-US     BW   The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy,"12/04/2014 BMRN-US  BW   RNA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc.",12/06/2019 ALXN-US  BW   Alexion Issues Statement on Path to Value Creation,"11/01/2010 NBIX-US  BW   Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Jacobs Engineering, Ford, Kellogg and Honda Motor Co.",12/18/2019 SGEN-US     BW   Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer," 2/07/2019 IMMU-US     BW   Robbins Geller Rudman & Dowd LLP Announces a Securities Case Has Been Filed on Behalf of Purchasers of Immunomedics, Inc. Securities",11/21/2018 BIIB-US     BW   HitGen and Biogen enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration,11/26/2019 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference, 4/02/2018 BCRX-US  BW   BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals,12/19/2019 GILD-US      BW   Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment,"11/16/2010 ARNA-US  BW   Bramson Plutzik and Sherman Business Law File Class Action on Behalf of Purchasers of Arena Pharmaceuticals, Inc. Securities",11/12/2019 MYL-US   BW   Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination,11/12/2015 CGEN-US  BW   Compugen to Present at Jefferies 2015 Global Healthcare Conference in London," 3/27/2019 AKRX-US   BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Akorn, Inc. Investors", 2/27/2019 06T3CZ-E     BW   Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy,"10/03/2019 MYGN-US     BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Myriad Genetics, Inc. Investors",10/22/2014 52887230 BW   Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate,#N/A," 7/18/2016 INSM-US  BW   Robbins Arroyo LLP: Insmed, Inc. (INSM) Misled Shareholders According to a Recently Filed Class Action",12/03/2019 05156V10 BW   Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference, 4/17/2017 INO-US   BW   Inovio Pharmaceuticals to Implement Pilgrim Quality Solutions in the Cloud," 9/04/2019 NKTR-US  BW   Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics", 1/21/2013 07G69B-E BW   Research and Markets: Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis,12/03/2019 GERN-US      BW   Geron Announces Appointment of New Executive to Focus on Corporate Strategy,11/21/2019 AERI-US    BW   Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%, 3/05/2019 AMRN-US  BW   Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN),12/19/2019 INCY-US  BW   Incyte Names New Member to Its Board of Directors, 8/03/2017 UTHR-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of Shareholders,"10/23/2019 SRPT-US  BW   SAREPTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm"," 1/25/2019 ALKS-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm",10/30/2019 CERS-US  BW   Cerus Corporation Announces Third Quarter 2019 Results, 6/29/2015 05L030-E BW   GTCR Announces Sale of Cord Blood Registry to AMAG Pharmaceuticals,"11/13/2019 04269E10 BW   ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019",12/20/2016 LMNX-US  BW   ChipCare Corporation Expands Scientific Team,12/07/2019 80067710 BW   Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment,"12/13/2019 EXEL-US  BW   Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma",12/02/2019 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi,11/20/2019 VRTX-US   BW   French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis,10/10/2018 ALLO-US  BW   Allogene Therapeutics Announces Pricing of Initial Public Offering,#N/A,12/07/2019 BLUE-US  BW   bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition,"11/11/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019",#N/A,#N/A,#N/A,11/12/2019 TXMD-US  BW   TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference," 4/30/2019 ZGNX-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Zogenix, Inc. to Contact the Firm",12/19/2019 ALLK-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Allakos Inc. Investors,12/05/2019 OMER-US  BW   Omeros Announces Pricing of Upsized Public Offering of Common Stock,12/04/2019 RVNC-US  BW   Revance Announces Pricing of Public Offering of Common Stock," 6/15/2016 XON-US   BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intrexon Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 5, 2016",10/28/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting," 6/16/2015 00773U10 BW   EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Avalanche Biotechnologies, Inc.",#N/A, 1/07/2016 AGLE-US  BW   Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency,12/03/2019 63009R10    BW   NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte,10/13/2015 CRVW-US  BW   CareView Communications Announces $20 Million Drawdown under Its Credit Agreement with PDL BioPharma,11/19/2019 SYRS-US  BW   Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium,#N/A,#N/A," 5/10/2013 00182C10     BW   BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results","11/05/2019 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019",11/26/2019 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming December Investor Conferences,"10/26/2017 WVE-US   BW   Wave Life Sciences Unveils New Manufacturing Facility in Lexington, MA",#N/A,#N/A," 8/03/2015 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August", 7/06/2015 RTRX-US  BW   Retrophin Closes Sale of Priority Review Voucher," 1/31/2013 0CNWYH-E BW   Research and Markets: Global DNA Sequencing Products Market 2012-2016 with Hoffmann-La Roche Ltd., Knome Inc. and RainDance Technologies Inc. Dominating"," 1/28/2016 0DFYQH-E BW   Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors"," 6/24/2016 CHMA-US BW   INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm"," 9/14/2019 MGNX-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 3/19/2013 0BP4MZ-E BW   Blueprint Medicines Announces First Collaboration with Wellcome Trust Sanger Institute and Massachusetts General Hospital Cancer Center,11/12/2019 AKBA-US  BW   Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results,#N/A," 2/22/2017 MNTA-US   BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors", 6/08/2018 PRTA-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Prothena Corporation Investors,"11/14/2018 NVCR-US   BW   Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China",12/05/2019 SAGE-US     BW   Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder,#N/A,10/10/2017 GMAB-DK  BW   Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer, 3/05/2019 VNDA-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors," 8/13/2019 MEDP-US  BW   Medpace Holdings, Inc. to Present at Baird Global Healthcare Conference",#N/A, 5/01/2019 INVA-US     BW   Innoviva Reports First Quarter 2019 Financial Results,#N/A," 1/19/2018 HALO-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)"," 4/08/2014 G2151510 BW   China Biologic Products, Inc. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of China Biologic Products, Inc.", 3/14/2016 MNKD-US  BW   March 15 Deadline Alert: Law Offices of Howard G. Smith Reminds MannKind Corp. Investors of Upcoming Lead Plaintiff Deadline,11/12/2019 URGN-US  BW   UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments,#N/A," 5/27/2018 ESPR-US     BW   ESPR EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of July 6, 2018"," 5/31/2019 AMRS-US  BW   AMYRIS 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Amyris, Inc. - AMRS"," 3/21/2017 PTCT-US  BW   Knopp Biosciences annonce l’élection à son conseil de gestion de Shane Kovacs, dirigeant de Biotech",10/01/2012 GRST-CA  BW   GreeneStone Muskoka Once Again Featured on Intervention Canada," 3/19/2019 SYNH-US BW   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc.",10/13/2016 FOLD-US  BW   Millendo Therapeutics Announces Appointment of Three Vice Presidents,12/23/2019 EGRX-US  BW   Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference,11/26/2019 DCPH-US BW   Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman, 8/11/2014 ADMA-US  BW   ADMA Biologics Reports Second Quarter 2014 Financial and Operational Results, 3/21/2016 MNTR-US  BW   Mentor Capital Cannabis Index Gains During Election Cycle,12/07/2019 EPZM-US  BW   Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma," 5/12/2016 05TSC0-E BW   Zebra Technologies, Saudi Aramco, Pfizer, Jazz, and Merck KGaA Among Industry Leaders Presenting at the 2016 Planisware User Summit", 3/03/2015 00F0GV-E BW   MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy, 4/10/2014 FLR-US   BW   Fluor-Designed and Built Plasma Fractionation Facility Awarded ISPE 2014 Facility of the Year for Project Execution, 8/23/2019 GILD-US     BW   Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration," 9/07/2017 PTLA-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors (PTLA)",10/22/2019 VCYT-US  BW   Veracyte Announces Third Quarter 2019 Financial Results and Business Progress,12/16/2019 ALXN-US  BW   Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™, 1/06/2020 15117K10 BW   Cellectis : Des experts publient une étude sur les CAR T allogéniques pour lutter contre le cancer dans la revue Nature Reviews Drug Discovery,#N/A,#N/A,#N/A, 1/08/2018 0D272H-E BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO," 6/08/2017 IOVA-US  BW   Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Lion Biotechnologies, Inc. (NASDAQ:LBIO) Securities Case", 1/04/2011 MRK-US   BW   AnaptysBio Receives Milestone Payment from Merck for Successful Delivery of Candidate Antibodies for Therapeutic Use,"12/09/2019 XLRN-US  BW   Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development",#N/A,12/09/2019 HZNP-US  BW   Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference,11/25/2019 14843C10  BW   Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations,"11/01/2017 ICPT-US  BW   DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. To Contact The Firm"," 8/02/2019 KPTI-US  BW   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.",11/06/2019 GLYC-US  BW   GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting,11/13/2019 98401F10 BW   Xencor to Present at Upcoming Investor Conferences," 6/07/2017 ITCI-US  BW   The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017",#N/A,11/26/2019 G6674U10 BW   Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference,#N/A," 9/01/2010 03209R10 BW   Ryan & Maniskas, LLP Announces Investigation of American Physicians Service Group Inc.",#N/A,12/10/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,11/13/2019 DERM-US  BW   Dermira Elects Halley E. Gilbert to its Board of Directors,#N/A," 6/20/2016 PRAH-US  BW   Global Genes Hosts 5th Annual RARE Patient Advocacy Summit and Tribute to Champions of Hope, Presented by PRA Health Sciences", 2/20/2014 86845910 BW   Supernus to Present at Cowen and Company Healthcare Conference in March,12/20/2018 AZN-GB     BW   Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia,12/13/2019 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS," 5/07/2012 19249H10 BW   Faruqi & Faruqi, LLP Announces Investigation of Charming Shoppers Inc."," 3/27/2019 CRBP-US BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors (CRBP)","10/31/2019 BOLD-US  BW   Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019", 8/29/2012 00772J-E BW   Collegium Pharmaceutical Announces Initiation of Enrollment in Phase 3 Efficacy Study of Oxycodone DETERx® in Subjects with Moderate to Severe Chronic Lower Back Pain," 9/18/2017 XBIT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.", 8/06/2019 MCRB-US  BW   Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update,11/08/2019 AIMT-US  BW   New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots,"12/09/2013 0CM1LJ-E BW   Global Blood Therapeutics Presents New Preclinical Data on Lead Sickle Cell Disease Drug Candidate, GTx011, at American Society of Hematology Annual Meeting"," 7/30/2013 00BXRX-E BW   REGENX Biosciences and Audentes Therapeutics Enter into Exclusive License Agreement for Development of Treatments for Serious, Rare Muscle Diseases Using NAVTM Vectors",#N/A,#N/A,#N/A, 7/22/2015 0DL69Y-E BW   Voyager Therapeutics Appoints Michael Higgins to Board of Directors," 9/16/2019 BGNE-US BW   Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors",10/02/2019 RARX-US  BW   Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG,#N/A,"10/31/2017 HCM-GB   BW   Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer",12/14/2015 0DZX54-E BW   Intellia Therapeutics Appoints Caroline Dorsa to Company’s Board of Directors,#N/A," 2/16/2017 CRSP-US  BW   CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences et ERS Genomics fournissent une mise à jour relative à la procédure d'interférence de brevet américain CRISPR/Cas9..."," 9/21/2012 0CRRZ8-E BW   Company Profile for G1 Therapeutics, Inc.",#N/A, 2/01/2018 0FYJ81-E BW   Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors,#N/A,#N/A,#N/A," 2/02/2016 00CN92-E    BW   OptiNose® meldet, dass Pipeline-Projekt zur Untersuchung der Bi-Directional™ Breath Powered®-Technologie zur Wirkstoffverabreichung von der Nase zum Gehirn für norwegische staatliche Fördermittel ausgewählt wurde",#N/A, 3/05/2018 DNLI-US  BW   Parkinson’s Institute and Clinical Center Collaborates With Denali Therapeutics to Explore New Endpoints for Clinical Studies,"10/22/2019 QTRX-US  BW   Quanterix to Release Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019", 5/22/2018 SLDB-US  BW   The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB),#N/A,#N/A, 9/02/2015 30233G10 BW   pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information,#N/A,#N/A,12/02/2019 AXNX-US  BW   Health Canada Approves Full-Body MRI Labeling for the Axonics® Sacral Neuromodulation System,11/14/2019 TCDA-US  BW   Tricida Announces FDA Acceptance of New Drug Application for Veverimer, 8/12/2019 EIDX-US  BW   Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares,"11/07/2019 AVRO-US  BW   AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update","11/26/2019 MGTA-US  BW   Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd"," 9/10/2019 XERS-US  BW   Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia", 6/08/2018 0JJ6HQ-E BW   Autolus startet Roadshow zum Börsengang,#N/A, 6/07/2018 00DL17-E BW   Translate Bio to Present Preclinical Data at the 41st Annual European Cystic Fibrosis Conference,"12/10/2019 MRNA-US BW   François Nader, M.D., Joins Moderna’s Board of Directors", 6/06/2016 00D1VN-E BW   Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,#N/A,#N/A," 3/19/2018 0FTYWS-E BW   Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations",#N/A,#N/A, 8/29/2011 IMUC-US  BW   ImmunoCellular Appoints Helen Kim to Board of Directors,12/11/2019 TWST-US  BW   Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results,#N/A,11/11/2019 GOSS-US  BW   Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019, 8/08/2018 0DDYP2-E BW   Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia,12/06/2018 0084LG-E  BW   Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space, 1/28/2019 00FWLP-E BW   Turning Point Therapeutics Appoints Dr. Robert Xin as Senior Vice President of Clinical Development,12/05/2018 0J5W38-E BW   Prevail Therapeutics Announces Executive Leadership Appointments,#N/A,11/06/2018 00DHGL-E BW   Atreca to Present Data Further Demonstrating Ability of the Company’s Discovery Engine to Identify Patient-Derived Antibodies that Target Non-Autologous Tumor Tissue,"12/11/2019 PSNL-US  BW   Personalis, Inc. presenteert op het ESMO Immuno-Oncology Congress 2019",11/26/2019 86150R10 BW   Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference, 8/12/2019 EIDX-US  BW   Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares, 5/30/2019 0DMSKV-E BW   Adaptive Biotechnologies Appoints Seasoned Biotechnology Executives Kevin Conroy and Michelle Griffin to Board of Directors,11/18/2019 KRTX-US  BW   Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia,#N/A
11/08/2019 LGND-US   BW   Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol,10/28/2019 0LDDK2-E    BW   ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO, 1/10/2020 0KYC2K-E    BW   Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom,10/09/2019 BDSI-US   BW   Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors,12/05/2017 ENDP-US  BW   Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action,12/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma, 1/21/2011 008SRQ-E BW   BioDelivery Sciences Refutes Patent Claim,#N/A," 1/23/2017 UGNEQ-US BW   Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research", 8/29/2016 SIGA-US  BW   SIGA Announces Completion of Enrollment and Dosing in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat),"10/05/2018 OPK-US   BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In OPKO Health, Inc. To Contact The Firm",10/05/2017 BIIB-US     BW   Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy,"11/24/2014 BMRN-US  BW   RNA INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc. -- RNA",11/26/2019 ALXN-US  BW   Alexion to Present at the 2019 Evercore ISI HealthCONx," 8/03/2010 NBIX-US  BW   Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Big 5 Sporting Goods, Aetna, CVS Caremark and Express Scripts",12/12/2019 4502-JP     BW   Seattle Genetics y Takeda anuncian análisis adicionales de los ensayos clínicos de fase III ECHELON-1 y ECHELON-2 con ADCETRIS® (brentuximab vedotina) en la Reunión Anual 2019 de la ASH," 2/01/2019 IMMU-US     BW   IMMUNOMEDICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Immunomedics, Inc. - IMMU","10/17/2018 BIIB-US     BW   Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market",11/06/2019 IMGN-US  BW   ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting," 1/24/2018 BCRX-US  BW   IDERA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger",12/16/2019 GILD-US      BW    Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH),10/08/2010 04004760 BW   Arena Pharmaceuticals Investigated by Goldfarb Branham Law Firm LLP," 7/29/2019 MYL-US   BW   Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT",11/09/2015 CGEN-US  BW   Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis," 3/26/2019 AKRX-US   BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akorn, Inc. Investors (AKRX)",11/27/2018 09TGVY-E     BW   Amgen Selects AWS for the Vast Majority of Its Cloud Infrastructure,"10/02/2019 MYGN-US     BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",10/22/2014 52887230 BW   Lexicon et Ipsen concluent un accord de licence et de commercialisation pour telotristat etiprate hors Amérique du Nord / Japon,#N/A, 7/15/2016 INSM-US  BW   IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Insmed Incorporated and Reminds Investors with Losses to Contact the Firm,11/14/2019 05156V10 BW   Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights, 2/03/2015 45773H20 BW   U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum, 8/26/2019 NKTR-US  BW   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics, 1/21/2013 07GVF3-E BW   Research and Markets: Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis, 9/28/2018 GERN-US      BW   INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Geron Corp.,"11/18/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program", 3/04/2019 AMRN-US  BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN),12/05/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conference, 8/02/2017 UTHR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of United Therapeutics Corporation," 9/16/2019 SRPT-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Encourages Sarepta Investors to Contact the Firm"," 1/03/2019 ALKS-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","10/21/2019 CERS-US  BW   Cerus Corporation to Release Third Quarter 2019 Results and to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on October 30, 2019", 4/26/2013 00163U10 BW   AMAG Pharmaceuticals to Present at the Needham Healthcare Conference,"11/06/2019 ARQL-US  BW   ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies",10/15/2015 AFFX-US  BW   Affymetrix and Luminex Announce Distribution Agreement for Multiplexed Assay Instrument Platform,"12/06/2019 80067710 BW   Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day",11/26/2019 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in December,11/22/2019 4503-JP   BW   Inaugural STAT Summit Convened 300+ Health Care Leaders,11/13/2019 VRTX-US   BW   Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines," 9/27/2018 0JBQJ2-E BW   Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to Its Board of Directors",#N/A,12/06/2019 BLUE-US  BW   Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma,"11/04/2019 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer",#N/A,#N/A,#N/A,11/06/2019 TXMD-US  BW   TherapeuticsMD Announces Third Quarter 2019 Financial Results," 4/26/2019 ZGNX-US  BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors",12/18/2019 ALLK-US  BW   ALLK LOSSES ALERT: Bernstein Liebhard LLP Announces an Investigation of Allakos Inc.,12/04/2019 OMER-US  BW   Omeros Announces Proposed Public Offering of Common Stock,12/03/2019 RVNC-US  BW   Revance Announces Proposed Public Offering of Common Stock," 6/03/2016 XON-US   BW   INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intrexon Corporation",10/17/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call,#N/A,#N/A,10/26/2015 00FWPM-E BW   Aeglea BioTherapeutics Doses First Patient in Phase 1 Study of AEB1102 for Treatment of Solid Tumors,12/03/2019 63009R10    BW   Nature Medicine Publication Highlights Use of NanoString’s Hyb & Seq Technology to Perform Rapid Genotypic and Phenotypic Antibiotic Susceptibility Testing, 7/29/2015 ARIA-US  BW   ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma,11/12/2019 SYRS-US  BW   Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A, 5/08/2013 00182C10     BW   BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger,10/21/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference,11/22/2019 ALNY-US   BW   Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day,10/12/2017 WVE-US   BW   Wave Life Sciences to Present at the Jefferies Gene Technology Investor Summit,#N/A,#N/A," 7/30/2015 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results", 6/04/2015 76129910 BW   Retrophin Receives Fast Track Designation for RE-024 for the Treatment of Pantothenate Kinase-Associated Neurodegeneration,"12/10/2012 0CJTKW-E BW   Rigrodsky & Long, P.A. Announces Class Action Asserting Violations of the Federal Securities Laws by Pacific Biosciences of California, Inc.", 1/05/2016 0DFYQH-E BW   Editas Medicine Expands Leadership Team with Key Organizational Appointments," 6/24/2016 CHMA-US BW   INVESTOR ALERT: Investigation of Chiasma, Inc. Announced by the Law Firm Goldman Scarlato & Penny, P.C.; Investors Encouraged to Contact the Firm"," 9/13/2019 MGNX-US  BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against MacroGenics, Inc."," 2/25/2013 0BP4MZ-E BW   Blueprint Medicines Welcomes David Schenkein, M.D., to Its Board of Directors",11/09/2019 AKBA-US  BW   Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease,#N/A, 6/23/2012 00619R-E  BW   Teva Announces Favorable Court Ruling in COPAXONE® Patent Infringement Litigation," 6/08/2018 PRTA-US  BW   The Klein Law Firm Announces a Class Action Commenced on Behalf of Prothena Corporation Shareholders and a Lead Plaintiff Deadline of July 16, 2018 (PRTA)","10/01/2018 FPRX-US   BW   Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers",12/03/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A, 9/08/2017 GMAB-DK  BW   Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress," 3/04/2019 VNDA-US  BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 7/29/2019 MEDP-US  BW   Medpace Holdings, Inc. Reports Second Quarter 2019 Results",#N/A, 2/06/2019 INVA-US     BW   Innoviva Reports Fourth Quarter 2018 Financial Results,#N/A,12/07/2017 ALXN-US  BW   Alexion and Halozyme Enter License Agreement for ENHANZE Technology,#N/A, 3/04/2016 MNKD-US  BW   Glancy Prongay & Murray Commences Investigation on Behalf of MannKind Corp. Investors,11/11/2019 URGN-US  BW   UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers,#N/A," 5/25/2018 0882RC-E    BW   INVESTOR ALERT: Kirby McInerney LLP Advises Esperion Therapeutics, Inc. (ESPR) Investors of Potential Claims"," 5/28/2019 AMRS-US  BW   INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Amyris, Inc.", 3/21/2017 PTCT-US  BW   Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers, 2/06/2012 00448Q20 BW," 3/12/2019 SYNH-US BW   Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Syneos Health, Inc. to Contact the Firm","12/03/2015 FOLD-US  BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Amicus Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2015",12/16/2019 EGRX-US  BW   Eagle Pharmaceuticals Granted Orphan Drug Designation for RYANODEX (dantrolene sodium) for Treatment of Organophosphate Exposure (Nerve Agents),"11/13/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting"," 6/16/2014 ADMA-US  BW   ADMA Biologics Forms Scientific Advisory Board with Expertise in Immune Deficiencies, Infectious Diseases and Transplantation"," 3/15/2016 GWPH-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of GW Pharmaceuticals plc of Class Action and a Lead Plaintiff Deadline of March 21, 2016",12/02/2019 EPZM-US  BW   Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma, 7/08/2015 AGLE-US  BW   Aeglea Biotherapeutics Appoints Sandy Mahatme and Russell Cox to Board of Directors, 1/07/2015 00F0GV-E BW   MyoKardia to Present at the 33rd Annual J.P. Morgan Healthcare Conference, 9/18/2013 39843840 BW   Aradigm Announces Changes to Its Board of Directors, 8/15/2019 GILD-US     BW   European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis," 9/06/2017 PTLA-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Portola Pharmaceuticals, Inc.",10/22/2019 VCYT-US  BW   Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis,12/02/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),12/05/2019 15117K10 BW   Cellectis:  Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A," 8/01/2017 AGIO-US  BW   FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation"," 6/07/2017 IOVA-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Lion Biotechnologies, Inc. Shareholders and a Lead Plaintiff Deadline of June 13, 2017","11/16/2010 008H33-E BW   AnaptysBio Begins Receiving Funds from Qualifying Therapeutic Discovery Project Awards Totaling $860,482",12/06/2019 BMY-US   BW   Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt),#N/A,11/22/2019 HZNP-US  BW   Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco,11/20/2019 14843C10  BW   Castle Biosciences to Present at Upcoming Investor Conferences,"10/31/2017 ICPT-US  BW   ICPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017"," 8/01/2019 KPTI-US  BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.","10/31/2019 GLYC-US  BW   GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019",11/06/2019 98401F10 BW   Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting," 6/06/2017 ITCI-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intra-Cellular Therapies, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,11/20/2019 G6674U10 BW   Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology,#N/A," 9/01/2010 03209R10 BW   The Briscoe Law Firm Investigates American Physicians Service Group, Inc. on Behalf of Shareholders for Possible Breaches of Fiduciary Duties by Its Officers and Directors",#N/A,12/09/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I,"11/11/2019 DERM-US  BW   Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day",#N/A, 9/24/2013 KKR-US   BW   PRA and RPS Merger Completed, 2/07/2014 86845910 BW   Supernus at Citibank and RBC Global Healthcare Conferences in February, 1/16/2018 AGN.XX2-US BW   Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations,12/12/2019 74587V10 BW   plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer," 5/02/2012 19249H10 BW   Robbins Umeda LLP Announces an Investigation of Charming Shoppes, Inc."," 3/14/2019 CRBP-US BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors","10/05/2019 BOLD-US  BW   Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society", 7/24/2012 00772J-E BW   Collegium Pharmaceutical Announces the Appointment of Gino Santini to Board of Directors, 7/11/2017 XBIT-US  BW   Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action, 8/06/2019 MCRB-US  BW   Seres Therapeutics Appoints Stephen Berenson to its Board of Directors,11/08/2019 AIMT-US  BW   AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data,11/07/2013 0CM1LJ-E BW   Global Blood Therapeutics to Present First Data on its Lead Sickle Cell Disease Program at 55th ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A, 7/01/2015 0DL69Y-E BW   Voyager Therapeutics Appoints Perry A. Karsen to Board of Directors," 9/13/2019 BGNE-US BW   Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm", 9/18/2019 RARX-US  BW   Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General,#N/A,10/30/2017 HCM-GB   BW   Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market, 9/30/2015 0DZX54-E BW   FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015,#N/A," 2/16/2017 CRSP-US  BW   CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences und ERS Genomics liefern Update zum Interferenzverfahren bezüglich des Patents für CRISPR/Cas9 in den USA und die Erteilung entsprechender Patente in Großbritannien",#N/A,#N/A, 1/02/2018 0FYJ81-E BW   Rubius Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 2/01/2016 00CN92-E    BW   OptiNose® annonce un projet en voie de commercialisation pour évaluer l’application de la technologie Bi-Directional™ Breath Powered® du nez au cerveau sélectionnée à des fins de financement par le gouvernement norvégien,#N/A, 1/05/2018 4502-JP  BW   Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases,10/03/2019 QTRX-US  BW   Quanterix Announces Recipients of Annual Accelerator Grant Program, 5/21/2018 SLDB-US  BW   Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB),#N/A,#N/A," 7/21/2015 30233G10 BW   pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend",#N/A,#N/A,11/26/2019 AXNX-US  BW   Axonics® to Present at Upcoming Investor Conferences,"11/05/2019 TCDA-US  BW   Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019"," 4/01/2019 EIDX-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",10/24/2019 AVRO-US  BW   AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease,11/13/2019 MGTA-US  BW   Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights, 6/27/2019 XERS-US  BW   Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery, 6/08/2018 0JJ6HQ-E BW   Autolus meldet Berufung von Andrew J. Oakley zum Senior Vice President und Chief Financial Officer,#N/A," 5/23/2018 00DL17-E BW   Translate Bio Names John R. Schroer, CFA, Chief Financial Officer",11/26/2019 MRNA-US BW   Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference, 1/07/2016 00D1VN-E BW   Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology,#N/A,#N/A,#N/A, 3/07/2018 0FTYWS-E BW   Gritstone Oncology to Present at Cowen and Company 38th Annual Health Care Conference,#N/A,#N/A, 4/19/2010 009Z8P-E BW   Arthur Levinson Joins Amyris Board of Directors,12/11/2019 TWST-US  BW   Twist Bioscience and Pandion Therapeutics Expand Antibody Optimization Collaboration,#N/A,"11/08/2019 GOSS-US  BW   Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019", 7/25/2018 0DDYP2-E BW   Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs,11/27/2018 0084LG-E  BW   Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy,"11/28/2018 00FWLP-E BW   Turning Point Therapeutics Appoints Jacob Chacko, M.D., to its Board of Directors"," 5/24/2018 NPSP-US  BW   Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors",#N/A, 9/12/2018 00DHGL-E BW   Atreca Raises $125 Million to Expand its Preclinical Pipeline and Advance its First Program into Clinical Trials,"12/11/2019 PSNL-US  BW   Personalis, Inc. interverrà all’edizione 2019 del Congresso di immuno-oncologia della ESMO",11/25/2019 86150R10 BW   Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting,#N/A, 5/29/2019 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Highlight New clonoSEQ and immunoSEQ Data at ASCO 2019,11/17/2019 KRTX-US  BW   Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia,#N/A
11/07/2019 LGND-US   BW   Ligand to Participate in the Stephens 2019 Nashville Investment Conference,10/24/2019 0LDDK2-E    BW   Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders," 1/06/2020 0JGNNP-E    BW   NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO, and Established Collaboration with Illumina",10/04/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell,"11/15/2017 ENDP-US  BW   ENDO INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Endo International, Plc to Contact the Firm",12/06/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million, 1/06/2011 05WV00-E BW   BioDelivery Sciences Hires Head of Manufacturing Operations,#N/A,10/17/2016 06CR5C-E BW   Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs, 8/08/2016 SIGA-US  BW   SIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat),"10/04/2018 OPK-US   BW   Cohen Milstein Sellers & Toll PLLC Announces Investigation of OPKO Health, Inc.", 3/08/2017 IONS-US     BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ionis Pharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm,10/24/2013 003W29-E BW   US Oncology Research Collaborates with BioMarin Pharmaceutical to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients,11/22/2019 01535110 BW   SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)," 6/23/2010 NBIX-US  BW   Zacks Bull and Bear of the Day Highlights: Neurocrine Bio, Interactive Brokers, Hess, Total SA, BP and Royal Dutch Shell",12/11/2019 SGEN-US     BW   Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine," 1/18/2019 IMMU-US     BW   IMMUNOMEDICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU", 7/26/2018 CAT-US      BW   State Street Global Advisors Announces Annual Rebalancing of the SSGA Gender Diversity Index,11/01/2019 IMGN-US  BW   ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results," 1/22/2018 BCRX-US  BW   Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm",12/11/2019 GILD-US      BW   Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy," 9/29/2010 04004760 BW   Girard Gibbs LLP Files Class Action Lawsuit Against Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)"," 7/29/2019 MYL-US   BW   Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine",11/03/2015 CGEN-US  BW   Compugen Ltd. Reports 3rd Quarter 2015 Financial Results," 3/22/2019 AKRX-US   BW   AKRX INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Akorn, Inc. Investors", 9/24/2018 0JGWYJ-E     BW   MedTech Innovator Announces Newest Industry Partners,"10/02/2019 MYGN-US     BW   ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN"," 9/18/2014 LXRX-US  BW   Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer",#N/A," 6/22/2016 INSM-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Insmed Incorporated",11/13/2019 05156V10 BW   Aurinia Announces Updates to the Board of Directors, 1/29/2015 APOG-US  BW   Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum," 8/21/2019 NKTR-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 1/18/2013 07GVF3-E BW   Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis: Event-Driven Update, 4/03/2018 GERN-US      BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Geron Corporation Investors (GERN),11/12/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference, 3/01/2019 AMRN-US  BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Amarin Corporation plc Investors (AMRN),11/27/2019 INCY-US  BW   Incyte gibt Annahme von NDA mit vorrangiger Prüfung für Pemigatinib zur Behandlung von Patienten mit Cholangiokarzinom bekannt, 7/31/2017 UTHR-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of United Therapeutics Corporation and Encourages Investors with Losses to Contact the Firm," 9/05/2019 SRPT-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","11/15/2018 ALKS-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",10/18/2019 CERS-US  BW   Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting, 4/23/2013 00163U10 BW   AMAG Announces First Quarter 2013 Financial Results,10/30/2019 04269E10 BW   ArQule Reports Third Quarter 2019 Financial Results, 7/06/2015 ENZ-US   BW   Enzo Biochem Reaches $7.1 Million Patent Infringement Settlement with Luminex Corporation,11/26/2019 80067710 BW   Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors,"11/12/2019 EXEL-US  BW   Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019",10/03/2019 SAN-FR    BW   Hagens Berman: Law Firm Taking on Drug Makers in Zantac Class Action Condemns FDA’s “Reckless” Cover-up of Ranitidine Carcinogen,11/12/2019 VRTX-US   BW    Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines, 9/14/2018 0JBQJ2-E BW   Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering,#N/A,12/02/2019 BLUE-US  BW   bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting,"10/30/2019 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder",#N/A,#N/A,#N/A,"11/01/2019 TXMD-US  BW   TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019"," 4/25/2019 ZGNX-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Investors (ZGNX)",11/29/2016 0616DB-E BW   Allakos Expands License Agreement with The Johns Hopkins University School of Medicine,12/04/2019 OMER-US  BW   Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab,"12/02/2019 RVNC-US  BW   Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics"," 6/01/2016 XON-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intrexon Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 5, 2016", 9/18/2019 IRWD-US  BW   Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China,#N/A,#N/A, 9/28/2015 00FWPM-E BW   Aeglea BioTherapeutics Announces Promotion of Charles N. York to Chief Financial Officer,11/25/2019 63009R10    BW   NanoString to Present at the Evercore ISI 2nd Annual HealthCONx Conference,"11/14/2014 69329Y10 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against PDL BioPharma Inc. and Its Board of Directors and a Lead Plaintiff Deadline of November 17, 2014",11/06/2019 SYRS-US  BW   Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting,#N/A,#N/A," 4/12/2013 00182C10     BW   BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger Agreement","10/03/2019 ENTA-US    BW   New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay",11/20/2019 ALNY-US   BW   Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran), 8/22/2017 WVE-US   BW   Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of Stereochemical Purity in Oligonucleotide Drug Design,#N/A,#N/A," 7/15/2015 PCRX-US  BW   Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs", 5/27/2015 0D0JWQ-E BW   Retrophin Agrees to Sell Priority Review Voucher to Sanofi, 7/23/2012 PACB-US  BW   Pacific Biosciences and Imec Announce Collaboration to Develop Advanced Microchips for Single Molecule Sequencing Applications, 8/10/2015 0DFYQH-E BW   Editas Medicine Raises $120 Million to Advance Genome Editing," 6/24/2016 CHMA-US BW   AUGUST 8, 2016 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit Against Chiasma, Inc. And Reminds Investors With Losses To Contact The Firm"," 8/23/2019 MGNX-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","11/13/2012 0BP4MZ-E BW   Blueprint Medicines Welcomes Daniel S. Lynch to its Board of Directors as Executive Chairman; Announces Permanent Appointment of Chris Varma, Ph.D., as Chief Executive Officer",11/04/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A," 5/18/2012 VSTM-US   BW   Globe 100 Annual List to Feature 100 Companies for First Time since 2009, Illustrating Resurgence of the Massachusetts Economy"," 6/04/2018 PRTA-US  BW   INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Prothena Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 9/12/2018 NVCR-US   BW   Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China,"11/25/2019 SAGE-US     BW   Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders",#N/A, 8/29/2017 GMAB-DK  BW   Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors, 3/03/2019 VNDA-US  BW   VNDA INVESTOR ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors of Important Deadline in First-Filed Case – VNDA," 6/25/2019 MEDP-US  BW   Medpace Holdings, Inc. to Report Second Quarter 2019 Financial Results on July 29, 2019",#N/A,11/09/2018 INVA-US     BW   Once-daily Trelegy Ellipta gains expanded COPD indication in Europe,#N/A, 9/14/2017 BMY-US   BW   Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology,#N/A," 3/02/2016 MNKD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of MannKind Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 15, 2016","11/06/2019 URGN-US  BW   UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019",#N/A," 5/25/2018 0BGL4K-E    BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018"," 4/23/2019 AMRS-US  BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amyris, Inc."," 1/05/2017 06KW57-E BW   IoT Tech Expo: Shell, Verizon, Arm, Reliance, Barclays, PTC, Rolls-Royce and Heathrow Airport Lead Stellar Speaker Line-up for This Month’s Global IoT Conference in London",11/22/2011 008SHY-E BW   BIO Announces Presenting Companies for 14th Annual BIO CEO & Investor Conference," 3/11/2019 SYNH-US BW   IMPORTANT SHAREHOLDER NOTICE: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Syneos Health, Inc.","12/01/2015 FOLD-US  BW   IMPORTANT INVESTOR ALERT: Marcus & Boxerman Announces an Ongoing Investigation of Amicus Therapeutics, Inc. and Encourages Investors to Contact the Firm",12/13/2019 EGRX-US  BW   Eagle Pharmaceuticals Reaches Settlement Agreement with Eli Lilly for PEMFEXY (pemetrexed for injection),"11/13/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 6/13/2014 ADMA-US  BW   ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24," 3/12/2016 GWP-GB   BW   SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of GW Pharmaceuticals plc",11/04/2019 0CX9J5-E BW   Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement, 5/07/2015 G5087110 BW   Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update, 5/14/2014 00F0GV-E BW   MyoKardia Announces Launch of SHaRe Patient Registry for Genetic Heart Disease in Collaboration with World-Leading Cardiovascular Patient Care Centers, 8/28/2013 39843840 BW   Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®, 7/14/2019 GILD-US     BW   Gilead and Galapagos Enter Into Transformative Research and Development Collaboration, 2/01/2016 BMY-US   BW   Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan,10/21/2019 VCYT-US  BW   Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive,11/26/2019 DRNA-US  BW   Dicerna™ to Present at Evercore ISI 2nd Annual HealthCONx Conference,12/05/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 7/12/2017 AGIO-US  BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO," 6/06/2017 IOVA-US  BW   The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Lion Biotechnologies, Inc. Shareholders and a Lead Plaintiff Deadline of June 13, 2017","11/10/2010 008H33-E BW   AnaptysBio Adds Dr. Jan de Vries, Dr. Nicholas Lydon and Dr. Phillip Patten to Advisory Boards","12/06/2019 XLRN-US  BW   Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors",#N/A,11/21/2019 HZNP-US  BW   Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to “Listen to Your Eyes”,11/11/2019 14843C10  BW   Castle Biosciences Reports Third Quarter 2019 Results,"10/31/2017 ICPT-US  BW   ICPT INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intercept Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm"," 7/26/2019 KPTI-US  BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors", 9/05/2019 GLYC-US  BW   GlycoMimetics to Present at Two Upcoming Investor Conferences,11/05/2019 98401F10 BW   Xencor Reports Third Quarter 2019 Financial Results," 6/06/2017 ITCI-US  BW   The Klein Law Firm Announces a Class Action Filed on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017",#N/A,10/31/2019 G6674U10 BW   Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update,#N/A," 9/01/2010 03209R10 BW   Faruqi & Faruqi, LLP Announces Investigation Related to the Acquisition of American Physicians Service Group, Inc. - AMPH",#N/A,12/08/2019 RCKT-US  BW   Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting,11/08/2019 DERM-US  BW   Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A, 6/24/2013 PRAI-US  BW   KKR to Acquire PRA International, 2/03/2014 86845910 BW   Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR®,12/12/2016 AKBA-US    BW   Akebia Prevails in Additional European Patent Dispute,"12/11/2019 74587V10 BW   Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium"," 5/02/2012 19249H10 BW   The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Charming Shoppes, Inc. in Connection with the Sale of the Company to Ascena Retail Group, Inc."," 3/13/2019 CRBP-US BW   EQUITY ALERT: Rosen Law Firm Encourages Corbus Pharmaceuticals Holdings, Inc. Investors with Over $100K in Losses to Contact the Firm – CRBP",10/04/2019 BOLD-US  BW   Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)," 7/09/2012 00772J-E BW   Collegium Pharmaceutical Expands its Management Team to Support Continued Development of DETERx® Tamper-Resistant, Extended-Release Opioid Program"," 4/21/2017 XBIT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.", 8/01/2019 MCRB-US  BW   Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference,11/06/2019 AIMT-US  BW   Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights," 9/19/2013 0CM1LJ-E BW   Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company’s Board of Directors",#N/A,#N/A,#N/A,#N/A, 5/05/2015 0DL69Y-E BW   Voyager Therapeutics to Present at the American Society of Gene & Cell Therapy 18th Annual Meeting," 9/12/2019 BGNE-US BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of BeiGene, Ltd. Investors (BGNE)", 9/04/2019 RARX-US  BW   Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis,#N/A,10/27/2017 HCM-GB   BW   Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option, 9/01/2015 0DZX54-E BW   Intellia Therapeutics Secures $70 Million in Series B Financing,#N/A," 2/15/2017 CRSP-US  BW   CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.",#N/A,#N/A,12/14/2017 0FYJ81-E BW   Rubius Therapeutics Strengthens Leadership Team with Appointment of Andrew Oh as Chief Financial Officer,#N/A,#N/A,#N/A, 2/01/2016 00CN92-E    BW   OptiNose® Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional™ Breath Powered® Technology Selected for Norwegian Government Funding,#N/A,#N/A, 9/16/2019 QTRX-US  BW   Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019," 5/19/2018 SLDB-US  BW   FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Solid Biosciences Inc. to Contact the Firm",#N/A,#N/A, 7/13/2015 EYPT-US  BW   pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis,#N/A,#N/A,11/25/2019 AXNX-US  BW   Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems,"10/04/2019 TCDA-US  BW   Tricida to Host Investor Day on October 15, 2019"," 4/01/2019 EIDX-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDX",10/22/2019 AVRO-US  BW   AVROBIO Appoints Holly May as Chief Commercial Officer,11/11/2019 MGTA-US  BW   Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR, 6/17/2019 XERS-US  BW   Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon, 6/08/2018 0JJ6HQ-E BW   Autolus lance sa tournée d’information pour son introduction en bourse,#N/A, 4/12/2018 00DL17-E BW   Translate Bio Announces FDA Clearance to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis (CF),11/06/2019 MRNA-US BW   Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results," 6/15/2015 00D1VN-E BW   Principia Biopharma Presents Full Phase 1 Clinical Trial Results for PRN1008, a Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development in Autoimmune and Inflammatory Diseases",#N/A,#N/A,#N/A, 1/23/2018 0FTYWS-E BW   Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer,#N/A,#N/A,#N/A,"11/20/2019 TWST-US  BW   Twist Bioscience to Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on Wednesday, December 11, 2019",#N/A,11/07/2019 GOSS-US  BW   Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting, 3/08/2018 0DDYP2-E BW   Alector to Present at Cowen and Company 38th Annual Health Care Conference, 9/04/2018 0084LG-E  BW   Precision Biosciences Announces Collaboration with University of Pennsylvania to Develop Genome Editing Therapeutics,10/24/2018 00FWLP-E BW   TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion Diagnostic,#N/A,#N/A, 6/07/2018 00DHGL-E BW   Atreca to Present Immuno-Oncology Research Findings at 2018 World Preclinical Congress,"12/10/2019 PSNL-US  BW   Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019",11/12/2019 86150R10 BW   Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update,#N/A, 5/03/2019 0DMSKV-E BW   Adaptive Biotechnologies Appoints Francis Lo as Chief People Officer,11/07/2019 KRTX-US  BW   Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update,#N/A
11/05/2019 LGND-US   BW   Ligand Reports Third Quarter 2019 Financial Results,10/23/2019 PGNX-US     BW   Velan Responds to Misleading Communications from Progenics, 1/02/2020 45232710    BW   Illumina and Pacific Biosciences Announce Termination of Merger Agreement, 9/25/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd," 9/25/2017 ENDP-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017",12/04/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock,12/09/2010 09060J10 BW   BioDelivery Sciences Announces Enrollment of the First Patient in the Phase 3 BEMA Buprenorphine Clinical Program,#N/A,10/13/2016 06CR5C-E BW   Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases, 4/25/2016 SIGA-US  BW   SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat," 9/24/2018 OPK-US   BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In OPKO Health, Inc. To Contact The Firm"," 3/06/2017 IONS-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation of Ionis Pharmaceuticals, Inc."," 3/22/2013 07GVF3-E BW   Research and Markets: Bone Disorders - Pipeline Review, H1 2013",11/13/2019 ALXN-US  BW   Alexion to Present at the 2019 Stifel Healthcare Conference,#N/A,12/10/2019 4502-JP     BW   Seattle Genetics und Takeda geben zusätzliche Analysen der klinischen Phase-III-Studien ECHELON-1 und ECHELON-2 für ADCETRIS® (Brentuximab Vedotin) auf der ASH-Jahrestagung 2019 bekannt," 1/16/2019 IMMU-US     BW   Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Immunomedics, Inc. (IMMU)"," 6/13/2018 207940-KR   BW   Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018",10/18/2019 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results," 1/22/2018 BCRX-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Idera Pharmaceuticals, Inc. to BioCryst Pharmaceuticals, Inc. is Fair to Shareholders",12/11/2019 GILD-US      BW   Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma," 9/28/2010 04004760 BW   Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against Arena Pharmaceuticals, Inc. (Nasdaq: ARNA)", 4/12/2018 MYL-US   BW   Fujifilm Kyowa Kirin Biologics s'associe à Mylan pour commercialiser un biosimilaire de l'Humira® (adalimumab),"10/27/2015 CGEN-US  BW   Compugen Third Quarter 2015 Conference Call Scheduled for Tuesday, November 3, 2015 at 10:00 AM ET"," 3/04/2019 AKRX-US   BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 6/04/2018 JAZZ-US      BW   Tricida Announces Kathryn Falberg Joins Board of Directors," 9/30/2019 MYGN-US     BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (NASDAQ: MYGN) and Encourages Myriad Genetics Investors to Contact the Firm", 9/09/2014 0CFKXC-E BW   BioSurplus to Auction Lab Equipment from Lexicon Pharmaceuticals,#N/A, 6/17/2015 INSM-US  BW   Insmed to Participate at the JMP Securities Life Sciences Conference,11/07/2019 05156V10 BW   Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil, 3/15/2013 BBI-US   BW   Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013, 8/19/2019 NKTR-US  BW   Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)," 8/03/2012 07G69B-E BW   Research and Markets: 2012 Rheumatology Reimbursement Report Provides Precise Data, Stakeholder Insights and Dependable Forecasts on What's In Store for the RA Sector"," 4/03/2018 GERN-US      BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Geron Corporation","11/06/2019 AERI-US    BW   Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update", 3/01/2019 AMRN-US  BW   AMARIN INVESTOR ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights,11/27/2019 INCY-US  BW   Incyte annonce l’acceptation de sa demande d’examen prioritaire NDA du pemigatinib pour le traitement des patients atteints d’un cholangiocarcinome," 7/31/2017 UTHR-US  BW   UNITED THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm"," 8/30/2019 SRPT-US  BW   INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc.",11/15/2018 ALKS-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS, 9/30/2019 CERS-US  BW   Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion," 4/19/2013 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013",10/29/2019 04269E10 BW   ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 5/19/2014 LMNX-US  BW   LabCorp Announces the Availability of Luminex xTAG® CYP2D6 Genotype Assay,11/19/2019 80067710 BW   Sangamo annonce l'autorisation britannique d'un essai clinique de phase 1/2 évaluant la thérapie cellulaire CAR-Treg TX200 dans le cadre de la transplantation rénale,11/12/2019 EXEL-US  BW   Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma, 9/20/2019 SAN-FR    BW   Hagens Berman Files Second Class-Action Lawsuit Regarding Concealed Zantac Cancer Risk,11/07/2019 VRTX-US   BW   Vertex to Present at the Credit Suisse Healthcare Conference on November 12, 9/06/2018 0JBQJ2-E BW   Allogene Therapeutics Completes a $120 Million Private Financing,#N/A,11/12/2019 BLUE-US  BW   bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy,10/30/2019 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results,#N/A,#N/A,#N/A,10/30/2019 GUD-CA   BW   Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada," 4/19/2019 ZGNX-US  BW   ZGNX CLASS ACTION ALERT: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action – ZGNX",11/03/2016 0CX82G-E BW   Allakos Appoints Steven P. James to Board of Directors,11/20/2019 OMER-US  BW   Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online,11/25/2019 RVNC-US  BW   Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines, 5/24/2016 XON-US   BW   SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Intrexon Corporation and Advises Investors With Losses to Contact the Firm, 8/28/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences,#N/A,#N/A," 9/16/2015 00FWPM-E BW   Aeglea BioTherapeutics Announces Publication of Nonclinical Data on Lead Molecule, AEB1102, in Human Molecular Genetics",11/13/2019 63009R10    BW   NanoString to Present at the Stifel 2019 Healthcare Conference,"11/10/2014 69329Y10 BW   INVESTOR ALERT: Class Action Lawsuit Against PDL BioPharma, Inc. Announced by Law Offices of Howard G. Smith","11/05/2019 SYRS-US  BW   Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019",#N/A,#N/A," 3/19/2013 00182C10     BW   BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders to Vote “FOR” Proposed Merger with ANI Pharmaceuticals, Inc."," 9/25/2019 ENTA-US    BW   Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH",11/20/2019 ALNY-US   BW   Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA), 8/09/2017 WVE-US   BW   Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update,#N/A,#N/A, 7/14/2015 69512710 BW   Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call, 5/20/2015 0D0JWQ-E BW   Retrophin to Present at the Jefferies 2015 Global Healthcare Conference, 7/02/2012 PACB-US  BW   Nature Biotechnology Publications Showcase Value of PacBio RS in De Novo Genome Assembly, 8/05/2015 0DFYQH-E BW   Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum," 6/21/2016 CHMA-US BW   SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm",10/25/2017 INCY-US  BW   Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012, 5/24/2012 0BP4MZ-E BW   Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate,10/28/2019 AKBA-US  BW   Akebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business Highlights,#N/A, 4/19/2012 MNTA-US   BW   Baxter Exceeds Revenue and EPS Guidance with Solid First Quarter Financial Results," 6/04/2018 PRTA-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Prothena Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 16, 2018", 4/25/2018 ZLAB-US   BW   Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514,11/12/2019 SAGE-US     BW   Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress,#N/A, 4/19/2016 GMAB-DK  BW   Validation d’une étape dans le cadre de l’accord sur l’anticorps DR5, 3/02/2019 VNDA-US  BW   INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.," 5/21/2019 MEDP-US  BW   Medpace Holdings, Inc. to Present at Jefferies 2019 Healthcare Conference",#N/A,10/31/2018 INVA-US     BW   Innoviva Reports Third Quarter 2018 Financial Results,#N/A, 5/18/2016 06SJH8-E BW   Bellicum Appoints Jim Daly to its Board of Directors,#N/A," 2/23/2016 MNKD-US  BW   IMPORTANT SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in MannKind Corp. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit", 9/30/2019 URGN-US  BW   UroGen To Present at October 2019 Investor Conference,#N/A," 5/24/2018 ESPR-US     BW   The Klein Law Firm Announces a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR)"," 4/18/2019 AMRS-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 9/07/2016 0731W3-E BW   CureDuchenne Receives Global Duchenne Muscular Dystrophy Patient Group Award,#N/A," 3/11/2019 SYNH-US BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc.","11/17/2015 FOLD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Amicus Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2015",12/09/2019 EGRX-US  BW   Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate,"11/04/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results", 5/12/2014 ADMA-US  BW   ADMA Biologics Reports First Quarter 2014 Financial and Operational Results," 3/11/2016 GWP-GB   BW   SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Lawsuit Involving GW Pharmaceuticals plc and a Lead Plaintiff Deadline of March 21, 2016","10/30/2019 EPZM-US  BW   Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results", 4/21/2015 0DFTQ2-E BW   Allergen Research Corporation Announces New CFO Warren DeSouza and Board of Directors Audit Committee Chair Kate Falberg,11/25/2013 00F0GV-E BW   MyoKardia Appoints Biotech Veteran Mark L. Perry to Board of Directors," 7/16/2013 GRF-ES   BW   Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin", 5/29/2019 GILD-US     BW   Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)," 8/29/2013 73701010 BW   Portola Pharmaceuticals Announces Presentation of Preclinical Data on Andexanet Alfa (PRT44545), Factor Xa Inhibitor Antidote, at 2013 European Society of Cardiology Congress",10/21/2019 VCYT-US  BW   Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis,11/18/2019 DRNA-US  BW   Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases,12/02/2019 15117K10 BW   1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia,#N/A,#N/A,#N/A, 6/15/2017 AGIO-US  BW   I dati aggiornati dello studio clinico di fase I su IDHIFA® (enasidenib) orale dimostrano che il trattamento ha portato a risposte complete e durature nei pazienti con Leucemia Mieloide Acuta recidivata o refrattaria e mutazione IDH2," 6/05/2017 IOVA-US  BW   LBIO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Lion Biotechnologies, Inc. and a Lead Plaintiff Deadline of June 13, 2017",10/27/2010 008H33-E BW   AnaptysBio Expands Global Leadership in Somatic Hypermutation for Antibody Discovery and Optimization with Newly Issued Patents,12/04/2019 XLRN-US  BW   Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings,#N/A,11/14/2019 HZNP-US  BW   FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List,10/31/2019 14843C10  BW   Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk,"10/30/2017 ICPT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017"," 7/26/2019 KPTI-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)", 8/02/2019 GLYC-US  BW   GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease  ,"10/29/2019 98401F10 BW   Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019"," 6/05/2017 ITCI-US  BW   ITCI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intra-Cellular Therapies, Inc. and a Lead Plaintiff Deadline of July 11, 2017",#N/A,10/16/2019 G6674U10 BW   Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology,#N/A, 9/01/2010 03209R10 BW   Goldfarb Branham Law Firm LLP Investigating Shareholder Claims Against American Physicians Group Board,#N/A,12/06/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia,11/05/2019 DERM-US  BW   Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update,#N/A,#N/A," 6/06/2012 07GVF3-E BW   Research and Markets: Childhood Epilepsy Therapeutics Market is Forecast To Register Slow Growth at a Compound Annual Growth Rate (CAGR) Of 5.0% to Reach $1,065m By 2019", 3/09/2016 AKBA-US    BW   Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat,12/02/2019 74587V10 BW   Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer," 5/02/2012 19249H10 BW   Pomerantz Law Firm Investigates Claims on Behalf of Investors of Charming Shoppes, Inc."," 2/28/2019 CRBP-US BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Corbus Pharmaceuticals Holdings, Inc. – CRBP",10/01/2019 BOLD-US  BW   Audentes Therapeutics to Participate in Upcoming Investor Conferences, 4/09/2012 OCAT-US  BW   ACT Appoints Michael Heffernan to Board of Directors," 7/18/2016 XBIT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of XBiotech, Inc."," 8/01/2019 MCRB-US  BW   Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019",11/04/2019 AIMT-US  BW   Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2015 0DL69Y-E BW   Voyager Therapeutics Promotes Jeff Goater to Senior Vice President, Finance and Business Development"," 9/12/2019 BGNE-US BW   INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 8/21/2019 MRK-US   BW   Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck,#N/A,10/25/2017 HCM-GB   BW   Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market, 4/22/2015 0DZX54-E BW   Intellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance & Strategy Officer,#N/A, 1/09/2017 0FTYWS-E BW   Emerging Life Science and Biotech Companies Find Critical Success at Mass Innovation Labs,#N/A,#N/A, 9/27/2017 0FYJ81-E BW   Rubius Therapeutics Appoints Chief Medical Officer; Other Key Leadership Team Hires,#N/A,#N/A,#N/A," 1/28/2016 00CN92-E    BW   OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology",#N/A,#N/A, 9/11/2019 QTRX-US  BW   Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019," 5/14/2018 SLDB-US  BW   Bragar Eagel & Squire, P.C. Remind Investors That a Class Action Lawsuit Has Been Filed Against Solid Biosciences, Inc. (SLDB) and Encourages Investors to Contact the Firm",#N/A,#N/A, 7/07/2015 30233G10 BW   pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week,#N/A,#N/A,11/22/2019 AXNX-US  BW   Axonics® Announces Closing of $110 Million Public Offering of Common Stock,10/02/2019 TCDA-US  BW   Tricida Announces Multiple Data Presentations on Metabolic Acidosis to be Given at ASN Kidney Week 2019, 7/11/2018 HTGC-US  BW   Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018,10/08/2019 AVRO-US  BW   AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis,11/06/2019 MGTA-US  BW   Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting, 3/25/2019 XERS-US  BW   Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon, 6/08/2018 0JJ6HQ-E BW   Autolus gibt Bestellung von Linda Bain in das Board of Directors bekannt,#N/A,10/04/2017 00DL17-E BW   Translate Bio Names Daniella Beckman to Board of Directors,11/05/2019 MRNA-US BW   Moderna to Present at Credit Suisse 28th Annual Healthcare Conference, 5/26/2015 00D1VN-E BW   Principia Biopharma and UCSF Scientists Announce Publication of Seminal Paper on Reversible Covalent Drugs in Nature Chemical Biology,#N/A,#N/A,#N/A,11/28/2017 0FTYWS-E BW   Gritstone Oncology Opens New State-of-the-Art Personalized Cancer Immunotherapy Manufacturing Facility,#N/A,#N/A,#N/A,"11/20/2019 TWST-US  BW   Twist Bioscience Promotes Patrick J. Finn, Ph.D., to Chief Commercial Officer",#N/A,"11/05/2019 GOSS-US  BW   Gossamer Bio to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 12, 2019", 1/07/2016 0DDYP2-E BW   Alector Announces Closing of Series D Financing, 6/26/2018 0084LG-E  BW   Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs,10/19/2018 00FWLP-E BW   TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners,#N/A,#N/A, 5/30/2018 00DHGL-E BW   Atreca to Present at the Jefferies 2018 Global Healthcare Conference,"11/21/2019 PSNL-US  BW   Personalis, Inc. to Present at NeoAg Summit US 2019",11/05/2019 86150R10 BW   Stoke Therapeutics to Present at Upcoming Investor Conferences in November,#N/A," 4/26/2019 0DMSKV-E BW   Adaptive Biotechnologies Appoints Lance Baldo, M.D., as Chief Medical Officer", 8/28/2019 KRTX-US  BW   Karuna Therapeutics to Present at Upcoming Investor Conferences,#N/A
10/22/2019 LGND-US   BW   Ligand to Report Third Quarter 2019 Results on November 5th,10/22/2019 PGNX-US     BW   Velan Sends Letter to Progenics Stockholders,12/23/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 9/06/2019 84763A10  BW   Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer," 9/20/2017 ENDP-US  BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017",12/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock,11/23/2010 09060J10 BW   BioDelivery Sciences Announces Resumption of ONSOLIS Manufacturing,#N/A," 9/20/2016 REGN-US  BW   Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain", 4/12/2016 SIGA-US  BW   SIGA Emerges from Chapter 11 Bankruptcy Protection," 9/20/2018 OPK-US   BW   Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed against OPKO Health, Inc.",11/07/2016 BIIB-US     BW   Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy, 1/23/2013 008SHY-E BW   CORRECTING and REPLACING 15th Annual BIO CEO & Investor Conference to Feature Fireside Chats Between Biopharma Executives and Analysts,11/06/2019 ALXN-US  BW   Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting,#N/A,12/10/2019 4502-JP     BW   Seattle Genetics et Takeda annoncent des analyses additionnelles des essais cliniques de phase 3 ECHELON-1 et ECHELON-2 portant sur ADCETRIS® (brentuximab védotine) à la réunion annuelle 2019 de l'ASH," 1/10/2019 IMMU-US     BW   Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunomedics, Inc.", 5/07/2018 BIIB-US     BW   Biogen Celebrates 40 Years as a Pioneer in Neuroscience, 9/29/2019 IMGN-US  BW   ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO," 2/08/2016 BCRX-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX",12/09/2019 GILD-US      BW   Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma," 9/22/2010 04004760 BW   Investor Notice: The Rosen Law Firm Announces Filing of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA", 4/11/2018 MYL-US   BW   Fujifilm Kyowa Kirin Biologics arbeitet mit Mylan zusammen an Vermarktung von Biosimilar zu Humira® (Adalimumab),10/19/2015 CGEN-US  BW   Compugen Discloses Antibody Drug Conjugate Program Results at the World ADC Summit in San Diego," 3/01/2019 AKRX-US   BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 5/02/2018 06S9LL-E     BW   The Multiple Myeloma Research Foundation and Partners Announce a Hike Through Grand Canyon National Park To Raise Funds For Cancer Research," 9/30/2019 MYGN-US     BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 6/27/2012 HAR-US   BW   HARMAN Appoints Frank Sklarsky to Board of Directors,#N/A, 5/13/2015 INSM-US  BW   Insmed Announces Upcoming Data Presentations at the American Thoracic Society 2015 International Meeting,"11/06/2019 05156V10 BW   Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019"," 4/18/2011 CTEC-SE  BW   Transgene, ChronTech Pharma and Inovio Pharmaceuticals to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination against Hepatitis C"," 8/10/2019 NKTR-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 5/30/2012 00B8PL-E BW   Six Months Post-Launch, Trial and Usage of Orencia SC is Continuing to Increase, Yet It is Still Viewed as a Second-Line Therapy After Anti-TNF Agents for Rheumatoid Arthritis Based on a Recent BioTrends Report", 3/28/2018 GERN-US      BW   GERON CORPORATION INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations,11/05/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan," 2/26/2019 AMRN-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",11/27/2019 INCY-US  BW   Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma, 7/28/2017 UTHR-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of United Therapeutics Corporation, 2/28/2019 0DLJDW-E BW   CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics," 4/03/2018 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc", 9/27/2019 CERS-US  BW   Cerus Corporation to Present at the 2019 Cantor Global Healthcare Conference," 3/15/2013 00163U10 BW   AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause",10/21/2019 04269E10 BW   ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting, 3/13/2013 55027E10 BW   Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease,11/19/2019 80067710 BW   Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation,11/07/2019 EXEL-US  BW   Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy, 9/13/2019 SAN-FR    BW   Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk,10/31/2019 VRTX-US   BW   Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet," 8/28/2018 0JBQJ2-E BW   Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality",#N/A,11/06/2019 BLUE-US  BW   bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition,"10/16/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019",#N/A,#N/A,#N/A,10/29/2019 TXMD-US  BW   TherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock," 4/18/2019 ZGNX-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 9/26/2016 0CX82G-E BW   Allakos Antibodies Shown to Inhibit Fibrosis, a Common Cause of Organ Failure",11/19/2019 OMER-US  BW   Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston,11/12/2019 RVNC-US  BW   Revance to Participate in the Stifel 2019 Healthcare Conference, 5/20/2016 XON-US   BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intrexon Corporation and Advises Investors with Losses to Contact the Firm, 8/13/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment,#N/A,#N/A, 9/14/2015 AGLE-US  BW   Aeglea BioTherapeutics Announces FDA Acceptance of Investigational New Drug Application for AEB1102,11/07/2019 63009R10    BW   NanoString Highlights the Results of Research Presented at the 2019 Annual Meeting of the Society of Immunotherapy for Cancer (SITC),"11/03/2014 69329Y10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In PDL BioPharma, Inc. To Contact Brower Piven Before The November 17, 2014 Lead Plaintiff Deadline In Class Action Lawsuit","10/29/2019 SYRS-US  BW   Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference",#N/A,#N/A," 3/15/2013 00182C10     BW   BioSante Pharmaceuticals Announces Adjournment of Its Stockholders Meeting Until April 12, 2013", 9/10/2019 ENTA-US    BW   New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019,11/19/2019 ALNY-US   BW   Alnylam Announces Second Annual Advocacy for Impact Grants Program, 7/17/2017 WVE-US   BW   Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease,#N/A,#N/A," 7/14/2015 69512710 BW   Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development", 5/11/2015 76129910 BW   Retrophin Reports First Quarter 2015 Financial Results, 6/18/2012 PACB-US  BW   Pacific Biosciences Releases Software to Detect DNA Base Modifications Using the PacBio® RS," 7/01/2015 0DFYQH-E BW   Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer"," 6/20/2016 CHMA-US BW   CHIASMA, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 3/13/2017 MGNX-US  BW   GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors," 5/08/2012 0BP4MZ-E BW   Oncology Expert George Demetri, M.D., Joins Blueprint Medicines as a Clinical Advisor",10/24/2019 AKBA-US  BW   Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting,#N/A,12/22/2011 60877T10  BW   Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics," 6/01/2018 PRTA-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Prothena Corporation plc to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit", 9/29/2017 ZLAB-US   BW   Citi Appointed Depositary Bank for Zai Lab Limited’s Sponsored ADR Program,11/11/2019 SAGE-US     BW   Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference,#N/A, 9/10/2014 GMAB-DK  BW   Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration," 3/01/2019 VNDA-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 4/29/2019 MEDP-US  BW   Medpace Holdings, Inc. Reports First Quarter 2019 Results",#N/A, 9/21/2018 INVA-US     BW   Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe,#N/A,10/20/2014 BAX-US   BW   Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency,#N/A," 2/19/2016 MNKD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MannKind Corp. of Class Action and a Lead Plaintiff Deadline of March 15, 2016"," 9/24/2019 URGN-US  BW   UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances",#N/A," 5/22/2018 ESPR-US     BW   ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of July 6, 2018"," 4/17/2019 AMRS-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amyris, Inc. Investors (AMRS)"," 4/29/2016 PTCT-US  BW   GPM Reminds Investors of the May 2 Deadline in the Class Action Lawsuit Against PTC Therapeutics, Inc. and Encourages Investors to Contact the Firm",#N/A," 3/08/2019 SYNH-US BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Syneos Health, Inc. Investors (SYNH)","10/21/2015 FOLD-US  BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. And Encourages Investors To Contact The Firm",11/20/2019 EGRX-US  BW   Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference,10/29/2019 DCPH-US BW   Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 4/03/2014 ADMA-US  BW   ADMA Biologics to Present Data at the 2014 Clinical Immunology Society (CIS) Meeting," 2/26/2016 GWPH-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of GW Pharmaceuticals plc of Class Action and a Lead Plaintiff Deadline of March 21, 2016", 9/04/2019 EPZM-US  BW   Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth,12/09/2014 G5087110 BW   Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update,10/30/2013 00F0GV-E BW   MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer," 5/21/2013 39843840 BW   Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™", 3/28/2019 GILD-US     BW   Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients, 8/15/2013 73701010 BW   Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update,"10/08/2019 VCYT-US  BW   Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019",11/13/2019 DRNA-US  BW   Dicerna™ to Present at the Stifel 2019 Healthcare Conference,12/02/2019 15117K10 BW   1ère administration d’UCART22 à un patient ayant la leucémie lymphoblastique aiguë à cellules B en rechute ou réfractaire,#N/A,#N/A,#N/A, 6/15/2017 AGIO-US  BW   Les données mises à jour de l'essai de phase 1 du traitement oral IDHIFA® (enasidenib) montrent des réponses cliniques durables chez les patients atteints d’une leucémie aiguë myéloïde en rechute ou réfractaire avec mutation IDH2," 6/05/2017 IOVA-US  BW   SHAREHOLDER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Lion Biotechnologies, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline", 7/12/2010 008H33-E BW   DARPA Awards AnaptysBio up to $1.5 Million to Generate High Affinity Thermally Stable Antibodies,12/03/2019 BMY-US   BW   Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes,#N/A,11/13/2019 HZNP-US  BW   Horizon Therapeutics plc to Participate in Upcoming Investor Conferences,10/29/2019 14843C10  BW   Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting,"10/29/2017 ICPT-US  BW   The Klein Law Firm Announces a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017"," 7/25/2019 KPTI-US  BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 8/01/2019 GLYC-US  BW   GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights, 9/26/2019 98401F10 BW   Xencor to Present at the 2019 Cantor Global Healthcare Conference," 6/02/2017 ITCI-US  BW   ITCI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Intra-Cellular Therapies, Inc. and a Lead Plaintiff Deadline of July 11, 2017",#N/A,10/01/2019 G6674U10 BW   Novocure to Report Third Quarter 2019 Financial Results,#N/A, 9/01/2010 03209R10 BW   Kendall Law Group Investigates American Physicians Service Group Acquisition for Shareholders,#N/A,12/05/2019 RCKT-US  BW   Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting,"10/29/2019 DERM-US  BW   Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019",#N/A,#N/A, 1/06/2012 06C8FT-E BW   Supernus Pharmaceuticals Raises $42 Million to Prepare for Launch of Product Candidates in Epilepsy and Develop Pipeline in ADHD, 5/12/2015 31572Q80   BW   FibroGen Announces First Quarter 2015 Financial Results,12/02/2019 0970D2-E BW   CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries," 5/02/2012 19249H10 BW   Charming Shoppes Investor Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate Charming Shoppes, Inc. Sale to Ascena Retail Group, Inc.", 9/20/2017 CBRE-US BW   CBRE/NE Announces Corbus Pharmaceuticals Triples Its Footprint in Norwood," 9/30/2019 BOLD-US  BW   Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)"," 2/22/2012 06WNGW-E BW   Collegium Pharmaceutical Announces Series B Financing and Advancement of Development Program for its DETERx® Tamper-Resistant, Extended-Release Opioid"," 1/22/2016 XBIT-US  BW   SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of XBiotech Inc.", 6/19/2019 MCRB-US  BW   Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation,"10/31/2019 AIMT-US  BW   Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019",#N/A,#N/A,#N/A,#N/A,#N/A, 4/13/2015 0DL69Y-E BW   Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing," 9/11/2019 BGNE-US BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 8/07/2019 RARX-US  BW   Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update,#N/A,10/24/2017 HCM-GB   BW   Chi-Med Announces Proposed Offering of ADSs, 4/22/2015 0DZX54-E BW   Intellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company,#N/A,"11/01/2016 BAYN-DE  BW   Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer",#N/A,#N/A, 8/08/2017 0FYJ81-E BW   Cell Therapy Pioneer David Epstein Expands Role with Rubius Therapeutics to Become Executive Chairman,#N/A,#N/A,#N/A,12/17/2015 00CN92-E    BW   OptiNose to Present at the 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 8/13/2019 QTRX-US  BW   Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares, 5/12/2018 SLDB-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline,#N/A,#N/A, 6/24/2015 30233G10 BW   pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015,#N/A,#N/A,11/21/2019 AXNX-US  BW   Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical Center," 9/12/2019 TCDA-US  BW   Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community",#N/A,"10/03/2019 AVRO-US  BW   AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference","10/16/2019 MGTA-US  BW   Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer", 3/14/2019 XERS-US  BW   Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia, 6/08/2018 0JJ6HQ-E BW   Autolus annonce la nomination d'Andrew J. Oakley au poste de vice-président sénior et directeur financier de la société,#N/A, 5/15/2017 00DL17-E BW   RaNA Therapeutics to Present at 2017 UBS Global Healthcare Conference,10/24/2019 MRNA-US BW   Moderna Named Top Employer by Science for Fifth Consecutive Year, 1/12/2015 00D1VN-E BW   Principia Biopharma Appoints Roy Hardiman as Chief Business Officer and Lewis Shuster to Board of Directors,#N/A,#N/A,#N/A, 9/07/2017 0FTYWS-E BW   Gritstone Oncology Secures $92.7 Million in Series B Financing,#N/A,#N/A,#N/A,11/13/2019 TWST-US  BW   Twist Bioscience to Present at Upcoming Investor Conferences,#N/A, 9/25/2019 GOSS-US  BW   Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference, 9/30/2015 0DDYP2-E BW   FierceBiotech Names Alector as One of Its “Fierce 15” Biotech Companies of 2015, 6/20/2018 0084LG-E  BW   Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018, 9/24/2018 00FWLP-E BW   TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung Cancer,#N/A,#N/A, 5/03/2018 00DHGL-E BW   Atreca Announces Publication of HIV Research in Cell,"11/20/2019 PSNL-US  BW   Personalis, Inc. anuncia colaboración con Merck KGaA, Darmstadt, Alemania, para identificar y desarrollar nuevos biomarcadores para tratamientos del cáncer","10/16/2019 86150R10 BW   Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources",#N/A, 3/28/2019 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Highlight New immunoSEQ Data at AACR 2019, 8/08/2019 KRTX-US  BW   Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update,#N/A
10/15/2019 LGND-US   BW   Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors,10/21/2019 PGNX-US     BW   Velan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save Progenics,12/19/2019 000KYD-E    BW   Denodo Announces Winners of Second Annual Data Innovation Award During Datafest 2019, 9/03/2019 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September," 9/18/2017 ENDP-US  BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017",11/26/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences,"11/12/2010 09060J10 BW   BioDelivery Sciences to Hold Investor Conference Call on Monday, November 15, 2010",#N/A,11/24/2015 REGN-US  BW   ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals, 3/17/2016 SIGA-US  BW   SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX," 9/14/2018 OPK-US   BW   Robbins Arroyo LLP: OPKO Health, Inc. (OPK) Misled Shareholders According to a Recently Filed Shareholder Lawsuit",10/08/2016 BIIB-US     BW   New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy,10/09/2012 MEDS-US  BW   Biopharmaceutical Executive Dr. Alan Lewis Appointed as CEO of Medistem,10/23/2019 ALXN-US  BW   Alexion Reports Third Quarter 2019 Results,#N/A,12/10/2019 4502-JP     BW   Seattle Genetics e Takeda anunciam análise adicional do ADCETRIS® (Brentuximabe vedotina) com os ensaios clínicos ECHELON-1 e ECHELON-2 da Fase 3 no Encontro Anual da ASH 2019," 1/09/2019 IMMU-US     BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Immunomedics, Inc. Investors (IMMU)", 5/01/2018 09062X10    BW   Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab, 9/29/2019 IMGN-US  BW   ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO,12/30/2013 09058V10 BW   BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease,12/09/2019 GILD-US      BW   Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma," 9/22/2010 04004760 BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Arena Pharmaceuticals, Inc.", 4/11/2018 MYL-US   BW   Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab), 9/16/2015 CGEN-US  BW   Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer," 2/21/2019 AKRX-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Akorn, Inc. – AKRX", 4/02/2018 0DMSKV-E     BW   FDA Approves First Therapy for Patients with MRD-Positive ALL," 9/27/2019 MYGN-US     BW   MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN", 5/22/2012 DGEN-US  BW   Deltagen Reports 2012 First Quarter Financial Results,#N/A, 5/11/2015 INSM-US  BW   Insmed to Participate at the UBS Global Healthcare Conference,10/31/2019 05156V10 BW   Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome, 1/26/2011 45773H20 BW   Inovio Pharmaceuticals’ Minimally Invasive Intradermal Electroporation Technology Showcased at Vaccine Forum, 8/09/2019 NKTR-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors, 3/17/2011 005YZ9-E BW   KaloBios Announces Two Significant Additions to Its Management Team, 3/28/2018 GERN-US      BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Geron Corporation - GERN,"10/30/2019 AERI-US    BW   Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019", 2/26/2019 AMRN-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Amarin Corporation plc – AMRN,11/25/2019 INCY-US  BW   Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting, 7/28/2017 UTHR-US  BW   UTHR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of United Therapeutics Corporation, 2/27/2019 SRPT-US  BW   Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics," 1/17/2018 ALKS-US  BW   ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm", 8/28/2019 CERS-US  BW   Cerus Corporation to Participate in Upcoming Investor Conferences, 3/06/2013 00163U10 BW   AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron,"10/16/2019 04269E10 BW   ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019", 9/10/2012 082KY6-E BW   congatec Opens Office in Australia As Next Step in Global Expansion Plan,11/18/2019 80067710 BW   Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference,10/31/2019 EXEL-US  BW   Invenra Announces Expansion of Collaboration with Exelixis, 7/09/2019 CTLT-US   BW   Catalent Extends Global Commercial Spray Drying Capabilities in Europe,"10/31/2019 VRTX-US   BW   Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis"," 8/14/2018 0JBQJ2-E BW   Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer",#N/A,10/31/2019 BLUE-US  BW   bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress,10/07/2019 ACAD-US  BW   ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress,#N/A,#N/A,#N/A,10/24/2019 TXMD-US  BW   TherapeuticsMD Announces Pricing of Its Underwritten Public Offering of 26 Million Shares of Common Stock," 4/16/2019 ZGNX-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX", 9/15/2016 0CX82G-E BW   Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis,11/12/2019 OMER-US  BW   Omeros Corporation Reports Third Quarter 2019 Financial Results,11/06/2019 RVNC-US  BW   Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference," 5/06/2016 XON-US   BW   INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intrexon Corporation", 8/13/2019 ALNY-US  BW   Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP),#N/A,#N/A, 7/08/2015 AGLE-US  BW   Aeglea Biotherapeutics Appoints Sandy Mahatme and Russell Cox to Board of Directors,11/04/2019 63009R10    BW   NanoString Technologies Releases Operating Results for Third Quarter of 2019,"10/28/2014 69329Y10 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against PDL BioPharma, Inc.","10/24/2019 SYRS-US  BW   Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients",#N/A,#N/A," 3/04/2013 00182C10     BW   Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger", 8/21/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference,11/12/2019 ALNY-US   BW   Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference, 6/08/2017 WVE-US   BW   ReadCoor and WAVE Life Sciences Initiate Research Collaboration,#N/A,#N/A, 5/28/2015 69512710 BW   Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block, 5/05/2015 76129910 BW   Retrophin Receives FDA Orphan Drug Designation for RE-024 for the Treatment of Pantothenate Kinase-Associated Neurodegeneration," 5/14/2012 HLCSQ-US BW   Helicos BioSciences Corporation Settles its Patent Litigation Against Pacific Biosciences, Inc.", 5/27/2015 0DFYQH-E BW   Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies," 6/16/2016 CHMA-US BW   SHAREHOLDER ALERT: Lundin Law PC Announces Investigation Of Chiasma, Inc. And Advises Investors With Losses to Contact the Firm"," 7/29/2011 07G69B-E BW   Research and Markets: West Nile Virus Global Clinical Trials Review, Q1, 2011 - Examine Trial Performance, Success Rates & Clinical Trial Status Globally", 1/24/2012 0BP4MZ-E BW   Blueprint Medicines Appoints Oncology Drug Development Leader Christoph Lengauer as Chief Scientific Officer,10/15/2019 AKBA-US  BW   Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication,#N/A, 8/29/2011 524816-IN BW   Teva Announces Court Adopts All Relevant Teva Claim Construction Interpretations in Copaxone® Patent Infringement Case against Sandoz/Momenta and Mylan/Natco; Court Denies Mylan’s Summary Judgment Motion of Invalidity, 5/31/2018 PRTA-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc – PRTA,11/23/2015 128940-KR BW   ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted Therapy for Lung Cancer in China,11/05/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A, 6/17/2013 GMAB-DK  BW   Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead, 2/26/2019 VNDA-US  BW   Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Shareholders," 4/08/2019 MEDP-US  BW   Medpace Holdings, Inc. to Report First Quarter 2019 Financial Results on April 29, 2019",#N/A, 7/26/2018 INVA-US     BW   Innoviva Reports Second Quarter 2018 Financial Results,#N/A, 9/12/2014 40637H10 BW   FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency,#N/A, 2/09/2016 MNKD-US  BW   IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against MannKind Corp. and Encourages Investors with Losses to Contact the Firm, 9/24/2019 URGN-US  BW   UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer,#N/A," 5/22/2018 0DBJVZ-E    BW   Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Esperion Therapeutics, Inc."," 4/16/2019 AMRS-US  BW   Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Amyris, Inc."," 4/22/2016 PTCT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 – PTCT",#N/A," 3/08/2019 SYNH-US BW   Robbins Arroyo LLP: Syneos Health, Inc. (SYNH) Misled Shareholders According to a Recently Filed Class Action","10/14/2015 FOLD-US  BW   Amicus Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors",11/14/2019 EGRX-US  BW   Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors,10/28/2019 DCPH-US BW   Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 3/31/2014 ADMA-US  BW   ADMA Biologics to Present Company Overview at the 13th Annual Needham Healthcare Conference," 2/23/2016 GWP-GB   BW   IMPORTANT SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in GW Pharmaceuticals PLC to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit", 8/29/2019 EPZM-US  BW   Epizyme to Participate in Upcoming September Conferences, 7/28/2014 JAZZ-IE  BW   CANbridge Life Sciences And EUSA Pharma Form Agreement to Commericalize Caphosol® in China," 1/30/2013 00F0GV-E BW   MyoKardia Appoints Industry Veteran Jonathan Fox, M.D., Ph.D., as Chief Medical Officer", 4/11/2013 07G69B-E BW   Research and Markets: The Global Plasma Market to Grow At A CAGR Of 10.31 Percent over the Period 2012-2016, 3/28/2019 GILD-US     BW   Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study," 8/07/2013 73701010 BW   Portola Pharmaceuticals to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 15, 2013",10/07/2019 VCYT-US  BW   Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019,11/07/2019 DRNA-US  BW   Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress,11/20/2019 15117K10 BW   Cellectis remporte une procédure de contestation en Europe concernant un brevet couvrant une méthode d’édition du génome utilisant CRISPR-Cas9 dans les cellules T,#N/A,#N/A,#N/A, 6/15/2017 AGIO-US  BW   Celgene presenta en ASCO 2017 datos actualizados de un ensayo fase I Enasidenib (IDHIFA®) vía oral demuestra respuestas completas y duración de las respuestas en pacientes con Leucemia Mieloide Aguda...," 6/03/2017 IOVA-US  BW   DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Investors with Losses in Excess of $100,000 from Investment in Lion Biotechnologies, Inc. to Contact the Firm", 4/05/2010 008H33-E BW   AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics,12/02/2019 XLRN-US  BW   Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meeting,#N/A,11/11/2019 HZNP-US  BW   Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes,10/28/2019 14843C10  BW   Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis,"10/26/2017 ICPT-US  BW   ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017"," 7/25/2019 KPTI-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)"," 7/25/2019 GLYC-US  BW   GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019"," 9/10/2019 98401F10 BW   Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary"," 5/30/2017 ITCI-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017",#N/A, 9/09/2019 G6674U10 BW   Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting,#N/A," 9/01/2010 03209R10 BW   Levi & Korsinsky, LLP Initiates an Investigation into the Possible Breaches of Fiduciary Duty by the Board of American Physicians Service Group Inc. in Connection with Sale to ProAssurance Corporation - AMPH",#N/A,11/27/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,10/17/2019 DERM-US  BW   Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference,#N/A,#N/A,11/28/2011 06C8FT-E BW   Supernus Pharmaceuticals Initiates Phase IIb Clinical Trial for SPN-810 in Impulsive Aggression, 5/07/2015 05SVDW-E   BW   FibroGen Announces Receipt of Milestone Payment from AstraZeneca for Successful Completion of Long-Term Pre-Clinical Safety Studies of Roxadustat,11/06/2019 74587V10 BW   Puma Biotechnology Reports Third Quarter 2019 Financial Results," 5/02/2012 19249H10 BW   Ascena Retail Group, Inc. Reaches Agreement to Acquire Charming Shoppes, Inc."," 4/07/2017 CRBP-US BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corbus Pharmaceuticals Holdings, Inc.", 9/06/2019 BOLD-US  BW   Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)," 9/26/2011 00772J-E BW   Collegium Pharmaceutical Inc. Announces Successful Type A Meeting with FDA for Tamper-Resistant, Extended Release Opioid"," 1/21/2016 XBIT-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of XBiotech Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 1, 2016"," 6/13/2019 MCRB-US  BW   Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock",10/30/2019 AIMT-US  BW   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2015 0DL69Y-E BW   Voyager Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference," 9/11/2019 BGNE-US BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against BeiGene, Ltd.; Encourages Investors with Losses over $100K to Contact the Firm – BGNE", 7/26/2019 RARX-US  BW   Ra Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,10/17/2017 HCM-GB   BW   Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification, 2/26/2015 0DZX54-E BW   Intellia Therapeutics to Present at 35th Annual Cowen and Company Healthcare Conference,#N/A,"11/01/2016 BAYN-DE  BW   Casebia Therapeutics annonce la nomination de James W. Burns, Ph. D., au poste de président et directeur général",#N/A,#N/A, 6/21/2017 0FYJ81-E BW   Rubius Therapeutics Closes $120 Million Financing,#N/A,#N/A,#N/A,10/06/2015 00CN92-E    BW   OptiNose Closes New Round of Financing,#N/A,#N/A, 8/09/2019 QTRX-US  BW   Quanterix Prices Public Offering of Common Stock," 5/04/2018 SLDB-US  BW   SOLID BIOSCIENCES SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB",#N/A,#N/A, 5/19/2015 30233G10 BW   pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis,#N/A,#N/A,11/19/2019 AXNX-US  BW   Axonics® Announces Pricing of Public Offering of Common Stock, 9/04/2019 TCDA-US  BW   Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease,#N/A," 8/29/2019 AVRO-US  BW   AVROBIO, Inc. to Present at Upcoming Investor Conferences", 9/04/2019 MGTA-US  BW   Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders,12/19/2018 XERS-US  BW   European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS), 6/08/2018 0JJ6HQ-E BW   Autolus annonce la nomination de Linda Bain à son Conseil d'administration,#N/A, 3/28/2017 00DL17-E BW   RaNA Therapeutics to Present at Upcoming Conferences,10/22/2019 MRNA-US BW   Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)," 1/08/2015 00D1VN-E BW   Principia Biopharma Successfully Completes Phase 1 Clinical Trial of PRN1008, a Novel Oral BTK Inhibitor for Autoimmune Diseases",#N/A,#N/A,#N/A, 6/01/2017 0FTYWS-E BW   Gritstone Oncology Expands Scientific Advisory Board with Appointment of Immuno-Oncology Experts James L. Gulley and Alessandro Sette,#N/A,#N/A,#N/A,11/08/2019 TWST-US  BW   Twist Biopharma Implements Genedata Biologics to Advance Synthetic Biology-driven Antibody Discovery,#N/A, 9/13/2019 GOSS-US  BW    Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors, 9/16/2015 0DDYP2-E BW   Alector Raises $32 Million Series C to Advance Immuno-Modulation Approach for Neurodegenerative Diseases, 6/04/2018 0084LG-E  BW   Precision PlantSciences renamed Elo Life Systems, 9/05/2018 00FWLP-E BW   TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer,#N/A,#N/A, 4/19/2018 00DHGL-E BW   Atreca Announces John A. Orwin Appointed President and CEO,"11/19/2019 PSNL-US  BW   Personalis, Inc. maakt samenwerking bekend met Merck KGaA, Darmstadt, Duitsland, voor het identificeren en ontwikkelen van nieuwe biomarkers voor kankerbehandelingen", 9/30/2019 86150R10 BW   Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference,#N/A, 1/17/2019 0DMSKV-E BW   Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia at Multiple Timepoints Throughout Treatment and Remission, 8/06/2019 KRTX-US  BW   Karuna Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference,#N/A
 8/29/2019 LGND-US   BW   Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference,10/08/2019 PGNX-US     BW   Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement,11/20/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations, 8/08/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update, 9/18/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,11/25/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results,11/10/2010 09060J10 BW   BioDelivery Sciences to Present at Lazard and Piper Jaffray Investor Conferences,#N/A,11/20/2015 06NNTP-E BW   Regeneron’s Dr. George D. Yancopoulos Elected to Cold Spring Harbor Laboratory Board of Trustees, 3/15/2016 SIGA-US  BW   SIGA Technologies Engages PiperJaffray as Financial Advisor, 9/14/2018 OPK-US   BW   OPKO Confirms Resumption of Common Stock Trading on Nasdaq, 9/26/2016 BIIB-US     BW   Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy, 9/10/2012 0BVHZK-E BW   Retrophin Names Stephen Aselage as Chief Executive Officer,10/18/2019 ALXN-US  BW   Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS),#N/A,12/09/2019 4502-JP     BW   Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting," 1/09/2019 IMMU-US     BW   IMMU LOSS NOTICE: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Deadline in Case Seeking to Recover Investor Losses – IMMU", 4/24/2018 09062X10    BW   Biogen Reports Quarterly Revenues of $3.1 Billion, 9/17/2019 IMGN-US  BW   ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO,12/20/2013 09058V10 BW   BioCryst Files Peramivir NDA for the Treatment of Influenza,12/07/2019 GILD-US      BW   Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment," 9/22/2010 04004760 BW   The Law Office of Robbins Umeda LLP Announces an Investigation of Arena Pharmaceuticals, Inc.",10/04/2017 MYL-US   BW   Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL, 9/09/2015 CGEN-US  BW   Compugen to Present at Upcoming Immuno-Oncology and Rheumatology Conferences," 1/30/2019 AKRX-US   BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm", 3/29/2018 AMGN-US      BW   Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer," 8/29/2019 MYGN-US     BW   Bragar Eagel & Squire, P.C. Is Investigating Myriad Genetics, Inc. (NASDAQ: MYGN) on Behalf of Stockholders and Encourages Myriad Investors to Contact the Firm",11/22/2011 06N6TT-E BW   Research and Markets: Understanding Nanomedicine: an Introductory Textbook - The Only Medical Nanomedicine Introductory Textbook Currently Available,#N/A, 5/07/2015 45766930 BW   Insmed Reports First Quarter 2015 Financial Results,10/16/2019 05156V10 BW   Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility, 1/24/2011 INO-US   BW   Inovio Pharmaceuticals Announces $24.3 Million Registered Offering, 8/09/2019 NKTR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors, 1/18/2011 RIGL-US  BW   PrognosDx Announces Appointments of Dr. Garry Nolan to Board of Directors and Dr. Joseph Presti to Scientific Advisory Board, 9/28/2015 AGEN-US      BW   Wall St. Analyst Announces Investment Opinion: Biotech Stocks Coverage,"10/30/2019 AERI-US    BW   Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer", 2/26/2019 AMRN-US  BW   Robbins Arroyo LLP: Amarin Corporation plc (AMRN) Sued for Misleading Shareholders,11/14/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conference, 7/28/2017 UTHR-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of United Therapeutics Corporation,11/15/2018 SRPT-US  BW   Strengthening Lysogene’s Board of Directors," 1/17/2018 0DGVHF-E BW   Scott+Scott, Attorneys at Law, LLP Reminds Investors of January 22 Deadline in Securities Class Action Against Alkermes plc (ALKS)", 8/01/2019 CERS-US  BW   Cerus Corporation Announces Record Second Quarter 2019 Results, 3/01/2013 00163U10 BW   AMAG Announces Fourth Quarter and Year End 2012 Financial Results,10/16/2019 04269E10 BW   ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 8/07/2012 09KLV6-E BW   Upgrade Autoimmune Diagnostic Testing Using Multiplex Technology,11/08/2019 80067710 BW   Sangamo Therapeutics Announces New Scientific Advisory Board,10/30/2019 EXEL-US  BW   Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update, 7/03/2019 SAN-FR    BW   BIOCORP beginnt exklusive Verhandlungen mit SANOFI zur Nutzung des verbundenen Geräts MallyaTM mit Sanofis integrierter Diabetesplattform,10/30/2019 VRTX-US   BW   Vertex Reports Third-Quarter 2019 Financial Results, 7/10/2018 0JBQJ2-E BW   Allogene Therapeutics Announces Scientific Advisory Board,#N/A,10/23/2019 BLUE-US  BW   bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh,10/03/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting,#N/A,#N/A,#N/A,10/23/2019 TXMD-US  BW   TherapeuticsMD Announces Proposed Underwritten Public Offering of 22 Million Shares of Common Stock," 4/11/2019 ZGNX-US  BW   INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,11/08/2019 OMER-US  BW   Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy,"11/04/2019 RVNC-US  BW   Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update", 4/14/2016 XON-US   BW   AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon, 8/13/2019 ALNY-US  BW   Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP),#N/A,#N/A, 3/23/2015 00FWPM-E BW   Aeglea Biotherapeutics Raises $44 Million in Series B Financing,11/04/2019 63009R10    BW   NanoString Technologies Supports the Human Cell Atlas (HCA) to Enable High-plex Spatial Analysis Across Discovery Programs,"10/21/2014 69329Y10 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action against PDL BioPharma Inc. and Its Board of Directors and a Lead Plaintiff Deadline of November 17, 2014",10/17/2019 SYRS-US  BW   Syros Announces Update on Selective CDK7 Inhibitor Portfolio,#N/A,#N/A, 3/01/2013 00182C10     BW   BioSante Pharmaceuticals Provides Merger Update and Reports 2012 Financial Results," 8/06/2019 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019",11/09/2019 ALNY-US   BW   Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study, 6/08/2017 WVE-US   BW   ReadCoor and WAVE Life Sciences Initiate Research Collaboration,#N/A,#N/A," 5/20/2015 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June", 4/30/2015 76129910 BW   Retrophin Announces FDA Review of IND for RE-024 and Clearance to Proceed With Phase 1 Clinical Study in Healthy Adult Volunteers," 2/16/2012 69404D10 BW   The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Pacific Biosciences of California, Inc. of Class Action Lawsuit and the Deadline of February 27, 2012 to Seek a Lead Plaintiff Position", 5/18/2015 0DFYQH-E BW   Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference," 6/15/2016 CHMA-US BW   Chiasma, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors", 4/07/2011 05LJZC-E BW   Biotech Leader Provides Testimony at Congressional Hearing on SBIR/STTR Renewal, 9/06/2011 06S6MV-E BW   Blueprint Medicines Named One of FierceBiotech’s “Fierce 15” Leading Biotech Companies of 2011,10/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A," 4/05/2011 071HFG-E  BW   In Europe, Emerging Novel Factor Xa Inhibitors Are Set to Displace Use of Low-Molecular-Weight Heparins and Unfractionated Heparins in the Management of Ischemic Complications Associated with Acute Coronary Syndrome", 5/31/2018 PRTA-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA),#N/A,"10/09/2019 SAGE-US     BW   Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019",#N/A,11/01/2012 4502-JP  BW   Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma," 2/26/2019 VNDA-US  BW   Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Vanda Pharmaceuticals, Inc."," 2/25/2019 MEDP-US  BW   Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Results",#N/A, 5/29/2018 GSK-GB      BW   GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD,#N/A, 7/31/2014 40637H10 BW   FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary Immunodeficiency,#N/A, 1/25/2016 MNKD-US  BW   MannKind Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors," 9/10/2019 URGN-US  BW   UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness",#N/A," 5/17/2018 0BGL4K-E    BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018"," 4/15/2019 AMRS-US  BW   EQUITY ALERT: Rosen Law Firm Reminds Investors of Amyris, Inc. of Important Deadline in Securities Class Action; Encourages Investors with Over $100K in Losses to Contact the Firm – AMRS"," 4/12/2016 PTCT-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016",#N/A," 3/07/2019 SYNH-US BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Syneos Health, Inc. Investors","10/09/2015 FOLD-US  BW   Kirby McInerney LLP Advises Amicus Therapeutics, Inc. Investors of Potential Claims",11/12/2019 EGRX-US  BW   Eagle Pharmaceuticals Reports Third Quarter 2019 Results,"10/28/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019", 3/28/2014 ADMA-US  BW   ADMA Biologics Reports Year End 2013 Results," 2/22/2016 GWP-GB   BW   INVESTOR ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving GW Pharmaceuticals plc and a Lead Plaintiff Deadline of March 21, 2016", 8/09/2019 EPZM-US  BW   Epizyme Reports Business Progress and Second Quarter 2019 Results, 7/21/2014 G5087110 BW   Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386, 9/20/2012 06XJML-E BW   Third Rock Ventures Launches MyoKardia with $38 Million to Address Genetic Heart Disease," 9/20/2011 081BR5-E BW   Apperian Names Former Citrix Executive, David Baeza, as Chief Marketing Officer", 3/28/2019 GILD-US     BW   Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA), 2/27/2013 006RGD-E BW   Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications, 9/11/2019 VCYT-US  BW   Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas,"11/04/2019 DRNA-US  BW   Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019",11/20/2019 15117K10 BW   Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells,#N/A,#N/A,#N/A, 6/06/2017 AGIO-US  BW   Dados atualizados do ensaio da Fase 1 do IDHIFA® oral (enasidenib) demonstram respostas completas e duração da resposta em pacientes com leucemia mieloide aguda (LMA) recorrente ou refratária e uma mutação do gene IDH2," 6/02/2017 IOVA-US  BW   LBIO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Lion Biotechnologies, Inc. and a Lead Plaintiff Deadline of June 13, 2017", 3/01/2010 008H33-E BW   AnaptysBio Adds Strategic Collaboration with Another Leading Global Pharmaceutical Company,11/08/2019 CELG-US  BW   FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions,#N/A,11/08/2019 HZNP-US  BW   The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace,"10/28/2019 14843C10  BW   Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019","10/24/2017 ICPT-US  BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intercept Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm (ICPT)"," 7/25/2019 KPTI-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)", 5/29/2019 GLYC-US  BW   GlycoMimetics to Present at Jefferies 2019 Healthcare Conference, 8/06/2019 98401F10 BW   Xencor Reports Second Quarter 2019 Financial Results," 5/26/2017 ITCI-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intra-Cellular Therapies, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017",#N/A, 8/12/2019 G6674U10 BW   China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China,#N/A," 9/01/2010 03209R10 BW   A.M. Best Comments on ProAssurance’s Planned Acquisition of American Physicians Service Group, Inc.",#N/A,11/07/2019 RCKT-US  BW   Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights,10/10/2019 DERM-US  BW   Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference,#N/A,#N/A, 3/11/2011 06C8FT-E BW   Supernus Pharmaceuticals Announces Positive Results from Phase IIa Clinical Trial for SPN-812 in Adults with ADHD, 3/26/2015 31572Q80   BW   FibroGen Announces 2014 Financial Results and Provides Corporate Update,11/05/2019 74587V10 BW   Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer," 3/28/2011 19249H10 BW   Inter Parfums, Inc. Signs Exclusive Agreement for Lane Bryant®, the Flagship Brand of Charming Shoppes, Inc.",#N/A, 5/04/2016 05H9RB-E BW   Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease,12/01/2010 00772J-E BW   Collegium Pharmaceutical Announces the Spin-out of Onset Therapeutics and the Launch of PreCision Dermatology Inc," 1/19/2016 XBIT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of XBiotech Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 1, 2016"," 6/12/2019 MCRB-US  BW   Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock", 9/26/2019 AIMT-US  BW   Aimmune to Present at the Cantor Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2015 0DL69Y-E BW   Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders,"11/27/2018 BGNE-US BW   Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally", 7/23/2019 RARX-US  BW   Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock,#N/A,10/16/2017 HCM-GB   BW   Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer," 1/07/2015 0DZX54-E BW   Intellia Therapeutics, Novartis Form Partnership to Develop New Cell Therapies Using CRISPR/Cas9 Technology",#N/A, 6/24/2016 0DP3CK-E BW   CRISPR Therapeutics realisiert weitere 38 Millionen US-Dollar im Rahmen der Serie-B-Finanzierungsrunde,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2015 00CN92-E    BW   OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-375,#N/A,#N/A, 8/07/2019 QTRX-US  BW   Quanterix Announces Proposed Public Offering of Common Stock, 4/27/2018 SLDB-US  BW   SLDB LOSS NOTICE: Rosen Law Firm Reminds Solid Biosciences Inc. Investors of Important Deadline in Class Action,#N/A,#N/A, 5/12/2015 30233G10 BW   pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company,#N/A,#N/A,11/19/2019 AXNX-US  BW   Axonics® Announces Proposed Public Offering of Common Stock, 8/08/2019 TCDA-US  BW   Tricida Announces Second Quarter 2019 Financial Results,#N/A, 8/16/2019 AVRO-US  BW   AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer, 8/08/2019 MGTA-US  BW   Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights,11/12/2018 XERS-US  BW   Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen, 6/08/2018 0JJ6HQ-E BW   Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer,#N/A, 2/28/2017 00DL17-E BW   RaNA Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference,"10/22/2019 MRNA-US BW   Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019", 4/22/2014 00D1VN-E BW   Principia Biopharma Secures $50 Million Series B Financing,#N/A,#N/A,#N/A, 3/31/2017 0FTYWS-E BW   First Public Data Presented from Gritstone Oncology’s Tumor Antigen Identification Platform for Personalized Cancer Immunotherapy,#N/A,#N/A,#N/A,10/30/2019 TWST-US  BW   Twist Bioscience to Provide Target Enrichment Products for MGI in Europe and Asia Pacific,#N/A, 8/08/2019 GOSS-US  BW   Gossamer Bio Announces Second Quarter 2019 Financial Results,10/31/2013 0DDYP2-E BW   Alector LLC Secures Series A Financing to Find Cure for Alzheimer’s and Related Diseases, 5/14/2018 0084LG-E  BW   Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting," 8/10/2018 00FWLP-E BW   Cancer Discovery Highlights Potent Effects of TP Therapeutics’ Novel, Lead Investigational Compound Repotrectinib in Tumors Harboring ROS1, TRK or ALK Fusions with Solvent Front Mutations",#N/A,#N/A, 3/14/2018 00DHGL-E BW   Atreca to Present at 2018 American Association for Cancer Research Annual Meeting,"11/19/2019 PSNL-US  BW   Personalis, Inc. gibt die Zusammenarbeit mit der Merck KGaA, Darmstadt, Deutschland, zur Identifizierung und Entwicklung neuer Biomarker für Krebstherapien bekannt", 9/11/2019 86150R10 BW   Stoke Therapeutics Added to Russell 2000 and 3000 Indexes,#N/A, 1/04/2019 0DMSKV-E BW   Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies for the Treatment of Cancer, 7/02/2019 KRTX-US  BW   Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares,#N/A
 8/12/2019 LGND-US   BW   Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China,"10/03/2019 PGNX-US     BW   PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX",10/24/2019 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019, 8/01/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call, 9/15/2017 ENDP-US  BW   ENDO LOSS NOTICE: Rosen Law Firm Reminds Endo International plc Investors of Important Deadline in Class Action – ENDP,11/18/2019 ARWR-US  BW   Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019,10/27/2010 09060J10 BW   BioDelivery Sciences Announces Positive End-of-Phase 2 Meeting with FDA for BEMA Buprenorphine in Chronic Pain,#N/A," 7/08/2015 0B17BB-E BW   Kendall Law Group Investigating Potential Breaches of Fiduciary Duties By Regeneron Pharmaceuticals, Inc. (REGN) Officials on Behalf of Shareholders", 2/24/2016 06CR5C-E BW   FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral," 9/13/2018 OPK-US   BW   OPK LOSS NOTICE: Rosen Law Firm Reminds OPKO Health, Inc. Investors of Important Deadline in First Filed Case by Firm", 8/01/2016 BIIB-US     BW   Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy, 7/10/2012 005YZ9-E BW   Jeff Cooper Joins KaloBios as Chief Financial Officer,10/16/2019 ACHN-US  BW   Alexion to Acquire Achillion,#N/A,12/09/2019 4502-JP     BW   Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting," 1/04/2019 IMMU-US     BW   Robbins Arroyo LLP: Immunomedics, Inc. (IMMU) Misled Shareholders According to a Recently Filed Class Action", 4/23/2018 09062X10    BW   New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants, 8/02/2019 IMGN-US  BW   ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results,12/18/2013 09058V10 BW   BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development,11/27/2019 GILD-US      BW   National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco," 2/25/2010 ARNA-US  BW   Zacks Analyst Blog Highlights: Amylin Pharmaceuticals, Inc., Arena Pharmaceuticals, Vivus Inc., Orexigen Therapeutics and CVS Caremark Corporation", 8/30/2017 MDT-US   BW   SuperCare Health Acquires LifeCare Solutions California Assets, 8/04/2015 CGEN-US  BW   Compugen Ltd. Reports 2nd Quarter 2015 Financial Results,"12/21/2018 AKRX-US   BW   Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)", 1/12/2018 IPN-FR       BW   Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America," 8/20/2019 MYGN-US     BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Myriad Genetics, Inc. – MYGN",#N/A,#N/A, 4/06/2015 45766930 BW   Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares, 9/26/2019 05156V10 BW   Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference, 1/20/2011 45773H20 BW   Inovio Pharmaceuticals to Present at Phacilitate Vaccine Forum Washington 2011,"12/12/2018 NKTR-US  BW   Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.",#N/A, 4/21/2015 37416310     BW   Law Offices of Howard G. Smith Announces Investigation of Geron Corporation,10/24/2019 AERI-US    BW   Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule, 2/22/2019 AMRN-US  BW   AMARIN CORPORATION INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws,10/29/2019 INCY-US  BW   Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs," 7/28/2017 UTHR-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of United Therapeutics Corporation -- UTHR",11/06/2018 SRPT-US  BW   FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination," 1/09/2018 ALKS-US  BW   ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm"," 7/22/2019 CERS-US  BW   Cerus Corporation to Release Second Quarter 2019 Results on August 1, 2019"," 2/21/2013 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences",10/08/2019 04269E10 BW    ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting,11/15/2011 07287F-E BW   Iris Pharma Acquires Ultra-Top of the Range Evaluation Equipment,"11/07/2019 80067710 BW   Sangamo annonce des présentations de données portant sur la thérapie génique et sur la thérapie cellulaire ex vivo à base de gènes modifiés, qui seront données au Congrès annuel de l’American Society of Hematology","10/16/2019 EXEL-US  BW   Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019"," 5/21/2019 0FYFQF-E  BW   Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research",10/24/2019 VRTX-US   BW   Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines," 6/18/2018 0024VM-E BW   Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer",#N/A,10/22/2019 BLUE-US  BW   European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™," 9/25/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019",#N/A,#N/A,#N/A,10/23/2019 TXMD-US  BW   TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results," 4/11/2019 ZGNX-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)",#N/A,11/07/2019 OMER-US  BW   Omeros Scientists Win 2019 Prix Galien Research Award,11/04/2019 RVNC-US  BW   Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia, 2/29/2016 XON-US   BW   INTREXON CORPORATION (XON) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Intrexon Corporation For Potential Breach of Fiduciary Duty, 8/08/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering,#N/A,#N/A,#N/A,11/04/2019 63009R10    BW   NanoString Announces Availability of the GeoMx Cancer Transcriptome Atlas Through the Technology Access Program for Digital Spatial Profiling,"10/17/2014 69329Y10 BW   SHAREHOLDER ALERT: Investigation on Behalf of PDL BioPharma, Inc. Investors Announced by Law Offices of Howard G. Smith", 8/06/2019 SYRS-US  BW   Syros to Present at 2019 Wedbush PacGrow Healthcare Conference,#N/A,#N/A, 2/26/2013 00182C10     BW   Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones in Recommending “FOR” BioSante/ANI Merger, 8/02/2019 ENTA-US    BW   Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis,10/31/2019 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity, 6/06/2017 WVE-US   BW   WAVE Life Sciences to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/19/2015 69512710 BW   Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures, 4/27/2015 76129910 BW   Retrophin to Report First Quarter 2015 Financial Results, 2/15/2012 69404D10 BW   PacBio® RS Compatible Products Now Available Through Pacific Biosciences Partner Program, 5/06/2015 0DFYQH-E BW   Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting," 4/18/2016 CHMA-US BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Chiasma, Inc.",#N/A,#N/A, 9/24/2019 AKBA-US  BW   Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference,#N/A,12/27/2010 SIRT-US   BW   Longwood Launches First Fund, 5/25/2018 PRTA-US  BW    The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA),#N/A,10/02/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A, 7/17/2012 0CGRYV-E BW   ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D, 2/25/2019 VNDA-US  BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA," 2/07/2019 MEDP-US  BW   Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019",#N/A, 5/22/2018 INVA-US     BW   Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer,#N/A," 5/21/2014 BAX-US   BW   Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency",#N/A," 1/22/2016 MNKD-US  BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Ongoing Investigation of Claims against MannKind Corp. and Advises Investors with Losses in Excess of $500,000 to Contact the Firm", 9/06/2019 URGN-US  BW   UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),#N/A," 5/16/2018 008G5M-E    BW   ESPR ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important July 6 Deadline in Class Action"," 4/15/2019 AMRS-US  BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Amyris, Inc. To Contact The Firm"," 3/04/2016 PTCT-US  BW   SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A," 3/07/2019 SYNH-US BW   SHAREHOLDER ALERT: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Syneos Health, Inc.",10/05/2015 ARIA-US  BW   Wall St. Analyst Announces Investment Opinion: Weekly Screener – Biotech Stocks Publication,11/12/2019 EGRX-US  BW   Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage,10/16/2019 DCPH-US BW   Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2/27/2014 ADMA-US  BW   ADMA Biologics Secures up to $15 Million Loan Commitment from Hercules Technology Growth Capital, 2/10/2016 GWP-GB   BW   STOCK ALERT: Rosen Law Firm Reminds GW Pharmaceuticals plc Investors of Important Deadline in Class Action – GWPH, 8/06/2019 EPZM-US  BW   Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference, 2/26/2013 G5087110 BW   Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate,#N/A," 6/08/2011 GRF-ES   BW   Deutsche Bank Appointed as Depositary Bank for the Sponsored Level III American Depositary Receipt Program of Grifols, S.A.",10/22/2018 GILD-US     BW   Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet," 1/18/2013 07GVF3-E BW   Research and Markets: Heart Transplantation - Pipeline Review, H2 2012 Considers Companies and Universities Involved", 9/03/2019 VCYT-US  BW   Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer,11/01/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"11/13/2019 15117K10 BW   Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications",#N/A,#N/A,#N/A, 6/06/2017 AGIO-US  BW   Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation," 6/02/2017 IOVA-US  BW   June 13 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lion Biotechnologies, Inc."," 2/08/2010 008H33-E BW   AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc.",11/06/2019 XLRN-US  BW   Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting,#N/A,11/06/2019 HZNP-US  BW   Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results,10/18/2019 14843C10  BW   Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node,"10/24/2017 ICPT-US  BW   EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 – ICPT", 7/11/2019 KPTI-US  BW   Ivy Brain Tumor Center and Karyopharm Therapeutics Collaborate to Develop Tissue-Based Clinical Trial for Brain Cancer," 5/06/2019 GLYC-US  BW   GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease", 8/01/2019 98401F10 BW   Xencor to Present at Upcoming Investor Conferences," 5/23/2017 ITCI-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Intra-Cellular Therapies, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit",#N/A, 8/06/2019 G6674U10 BW   Novocure to Participate in Three Upcoming Investor Conferences,#N/A,#N/A,#N/A,11/06/2019 RCKT-US  BW   Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting,10/09/2019 DERM-US  BW   Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis,#N/A,#N/A, 7/13/2010 06C8FT-E BW   Supernus Pharmaceuticals Advances SPN812 into Phase IIa U.S. Clinical Trial for ADHD," 3/19/2015 31572Q80   BW   FibroGen to Report Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015",11/04/2019 74587V10 BW   Puma Biotechnology to Present at the Credit Suisse Healthcare Conference,#N/A,#N/A, 4/27/2016 0F9D18-E BW   Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting, 8/18/2010 00772J-E BW   Collegium Pharmaceutical Inc. Announces Second U.S. Patent Issued Covering DETERx™ Technology,"12/14/2015 XBIT-US  BW   SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against XBiotech, Inc. And Reminds Investors To Contact The Firm Before Deadline", 5/29/2019 MCRB-US  BW   Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference, 9/13/2019 AIMT-US  BW   FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2014 0DL69Y-E BW   Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing, 9/06/2018 BGNE-US BW   BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors, 7/22/2019 RARX-US  BW   Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,10/12/2017 HCM-GB   BW   Hutchison China MediTech: Appointment of Director,12/19/2014 0DZX54-E BW   Intellia Therapeutics to Present at Biotech Showcase 2015,#N/A, 6/24/2016 0DP3CK-E BW   CRISPR Therapeutics a levé 38 millions de dollars additionnels lors du deuxième tour de table,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/15/2015 00CN92-E    BW   OptiNose Announces Positive Early Phase Clinical Trial with OPN-300, an Investigational Product in Development for Treatment of Autism Spectrum Disorders",#N/A,#N/A, 8/06/2019 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Second Quarter 2019," 4/24/2018 SLDB-US  BW   SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Solid Biosciences, Inc.",#N/A,#N/A, 5/08/2015 30233G10 BW   pSivida Corp. Reports Third Quarter FY 2015 Results,#N/A,#N/A,"11/15/2019 AXNX-US  BW   Axonics® annonce l’approbation, par l’administration américaine chargée de l'alimentation et des médicaments (Food and Drug Administration) de son système de neuromodulation sacrée pour les indications cliniques de la dysfonction urinaire"," 8/01/2019 TCDA-US  BW   Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Thursday, August 8, 2019",#N/A, 8/12/2019 AVRO-US  BW   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)," 8/06/2019 MGTA-US  BW   Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th",10/23/2018 XERS-US  BW   Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen, 6/08/2018 0JJ6HQ-E BW   Autolus Announces Appointment of Linda Bain to its Board of Directors,#N/A, 2/07/2017 008SHY-E BW   RaNA Therapeutics to Present at BIO CEO & Investor Conference,10/02/2019 MRNA-US BW   Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019, 2/13/2014 00D1VN-E BW   Principia Biopharma Expands Executive Management Team,#N/A,#N/A,#N/A, 1/09/2017 0FTYWS-E BW   Emerging Life Science and Biotech Companies Find Critical Success at Mass Innovation Labs,#N/A,#N/A,#N/A,"10/26/2019 TWST-US  BW   Praesens Foundation, Institut Pasteur, Institut Pasteur de Dakar, University of Nebraska Medical Center, Twist Bioscience Consortium winnen de Prix Galien MedStartUp Award",#N/A," 8/05/2019 GOSS-US  BW   Gossamer Bio to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019",#N/A, 7/10/2017 0084LG-E  BW   David Thomson Joins Precision BioSciences as Chief Development Officer, 6/04/2018 00FWLP-E BW   TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study,#N/A,#N/A, 2/08/2018 00DHGL-E BW   Atreca to Participate at the 2018 BIO CEO & Investor Conference,"11/19/2019 PSNL-US  BW   Personalis, Inc. annuncia una collaborazione con Merck KGaA, Darmstadt, Germania per l’identificazione e lo sviluppo di nuovi biomarcatori per le terapie oncologiche", 8/20/2019 STOK-US  BW   Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome,#N/A, 1/03/2019 0DMSKV-E BW   Adaptive Biotechnologies to Present at the 37th Annual J.P. Morgan Healthcare Conference, 6/27/2019 KRTX-US  BW   Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering,#N/A
 7/30/2019 LGND-US   BW   Ligand Reports Second Quarter 2019 Financial Results,10/02/2019 PGNX-US     BW   Velan Comments on Announced Sale of Progenics to Lantheus,"10/08/2019 45232710    BW   Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019", 7/22/2019 84763A10  BW   Spectrum Announces Expansion of the Poziotinib Clinical Program, 9/15/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,11/15/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Planned Management Transition,10/20/2010 09060J10 BW   BioDelivery Sciences and Meda Announce European Approval of BEMA Fentanyl (BREAKYL),#N/A, 5/21/2013 ALCLS-FR BW   Cellectis : Compact TALENTM : La nouvelle génération de nucléases effectrices TAL,12/23/2015 SIGA-US  BW   SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion," 9/13/2018 OPK-US   BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of OPKO Health, Inc. Investors"," 1/09/2015 ALNY-US     BW   Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics", 2/01/2012 06YXQQ-E BW   AmpliPhi Shareholder Update,"10/10/2019 ALXN-US  BW   Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer",#N/A,12/07/2019 SGEN-US     BW   Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting," 1/04/2019 IMMU-US     BW   Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Immunomedics, Inc. Investors", 4/20/2018 09062X10    BW   Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases, 7/18/2019 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results,11/20/2013 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences,11/21/2019 GILD-US      BW   Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite,#N/A," 7/18/2017 ESRX-US  BW   Keller Rohrback L.L.P. Investigates the Role of Pharmacy Benefit Managers Express Scripts, OptumRx, and CVS Caremark in the EpiPen Pricing Scandal"," 7/27/2015 CGEN-US  BW   Compugen Second Quarter 2015 Conference Call Scheduled for Tuesday, August 4, 2015 at 10:00 AM ET","12/10/2018 AKRX-US   BW   Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)",12/06/2017 09P83W-E     BW   Carmot Enters a Multi-Year Drug Discovery Collaboration With Amgen," 6/18/2018 MYGN-US     BW   MYRIAD GENETICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN",#N/A,#N/A, 3/31/2015 45766930 BW   Insmed Announces Pricing of Public Offering of Common Stock, 9/13/2019 05156V10 BW   Aurinia Establishes At-the-Market Facility, 1/12/2011 45773H20 BW   Preclinical Efficacy of Inovio Pharmaceuticals’ Chikungunya DNA Vaccine Featured in PLoS Neglected Tropical Diseases,"12/11/2018 NKTR-US  BW   Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc.",#N/A, 5/06/2014 37416310     BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation,"10/07/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer","12/20/2013 02311120 BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Amarin Corporation plc of Upcoming Deadline",10/22/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conference, 7/27/2017 UTHR-US  BW   UNITED THERAPEUTICS CORPORATION (UTHR) INVESTOR ALERT: Legal Investigation for Potential Securities Law Violations,"10/15/2018 SRPT-US  BW   Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate",12/23/2017 ALKS-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline – ALKS, 6/24/2019 CERS-US  BW   Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT," 2/11/2013 00163U10 BW   Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders",10/02/2019 04269E10 BW   ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum,12/07/2010 LMNX-US  BW   One Lambda and Luminex Renew Long-Term Strategic Partnership,11/06/2019 80067710 BW   Sangamo Therapeutics Reports Third Quarter 2019 Financial Results," 9/25/2019 EXEL-US  BW   Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019", 1/23/2019 SAN-FR    BW   Journée Internationale des Maladies Rares 2019,10/21/2019 VRTX-US   BW   Vertex to Announce Third-Quarter 2019 Financial Results on October 30," 6/04/2018 0JBQJ2-E BW   Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer",#N/A,10/09/2019 BLUE-US  BW   bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases, 9/24/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder,#N/A,#N/A,#N/A,10/11/2019 TXMD-US  BW   TherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine," 4/10/2019 ZGNX-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)",#N/A,"11/06/2019 OMER-US  BW   Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019",11/04/2019 RVNC-US  BW   Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery, 1/12/2016 JMP-US   BW   JMP Group Announces Closing of Harvest Intrexon Enterprise Fund, 8/06/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes,#N/A,#N/A,#N/A,"10/31/2019 63009R10    BW   NanoString Appoints Don Kania, Ph.D. to its Board of Directors"," 9/29/2014 69329Y10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In PDL BioPharma, Inc. To Contact Brower Piven Before The November 17, 2014 Lead Plaintiff Deadline In Class Action Lawsuit", 8/01/2019 SYRS-US  BW   Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A, 2/19/2013 00182C10     BW   Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante and ANI Merger," 7/15/2019 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019",10/24/2019 ALNY-US   BW   Alnylam Named #1 Biopharma Employer by Science Magazine, 5/10/2017 WVE-US   BW   WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update,#N/A,#N/A," 5/07/2015 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference"," 4/01/2015 76129910 BW   Retrophin’s Board of Directors Appoints John W. Kozarich, Ph.D. as Independent Director and Names Jeffrey A. Meckler as Chairman", 2/13/2012 69404D10 BW   Pacific Biosciences Releases Next Generation Chemistry and Software for PacBio® RS DNA Sequencing System," 4/27/2015 0DFYQH-E BW   Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer",#N/A,#N/A,#N/A, 9/04/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A, 5/24/2018 PRTA-US  BW   PRTA INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Prothena Corporation Investors,#N/A,10/02/2019 SAGE-US     BW   Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series,#N/A, 6/02/2012 SGEN-US  BW   Seattle Genetics Announces ADCETRIS® Clinical Data to be Reported in Multiple Presentations at ASCO Annual Meeting," 2/21/2019 VNDA-US  BW   VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm","11/01/2018 MEDP-US  BW   Medpace Holdings, Inc. to Present at Credit Suisse Healthcare Conference",#N/A, 4/26/2018 INVA-US     BW   Innoviva Reports First Quarter 2018 Financial Results,#N/A," 4/21/2014 40637H10 BW   Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Halozyme Therapeutics, Inc.",#N/A," 1/08/2016 MNKD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by MannKind Corp. and Certain Officers and Directors", 8/09/2019 URGN-US  BW   UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments,#N/A," 5/15/2018 ESPR-US     BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)"," 4/12/2019 AMRS-US  BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"," 2/23/2016 PTCT-US  BW   PTC INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates PTC Therapeutics, Inc. for Possible Securities Fraud",#N/A," 3/06/2019 SYNH-US BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Syneos Health, Inc. Investors", 7/05/2012 07GVF3-E BW   Research and Markets: Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012,"10/31/2019 EGRX-US  BW   Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019","10/02/2019 DCPH-US BW   Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer", 2/03/2014 ADMA-US  BW   ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters," 1/26/2016 GWP-GB   BW   SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against GW Pharmaceuticals plc and Advises Investors with Losses in Excess of $100,000 to Contact the Firm", 7/25/2019 EPZM-US  BW   Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma,"10/08/2012 ANIP-US  BW   BioSante Pharmaceuticals, Inc. to Present at BIO Investor Forum",#N/A,#N/A,10/20/2018 GILD-US     BW   Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting,"11/01/2012 006RGD-E BW   Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445", 8/28/2019 VCYT-US  BW   Veracyte to Present at Upcoming Investor Conferences,10/31/2019 DRNA-US  BW   Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection,11/13/2019 15117K10 BW   Cellectis publie dans Nature Communications la création de cellules CAR-T intelligentes pour potentiellement permettre aux traitements anticancéreux d’être plus sûrs et plus efficaces,#N/A,#N/A,#N/A, 3/01/2017 AGIO-US  BW   FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation," 5/30/2017 IOVA-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Lion Biotechnologies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 13, 2017",#N/A,11/06/2019 XLRN-US  BW   Acceleron Reports Third Quarter 2019 Operating and Financial Results,#N/A,11/05/2019 HZNP-US  BW   Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019,"10/16/2019 14843C10  BW   Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma","10/23/2017 ICPT-US  BW   ICPT LOSS NOTICE: Rosen Law Firm Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – ICPT"," 7/08/2019 0K91W5-E BW   CVS Health, Pfizer, UPMC Health Plan, Karyopharm Therapeutics, Trestle Compliance, Asembia, and More to Speak at World Congress' Integrate19 Congress in Philadelphia", 5/02/2019 GLYC-US  BW   GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights," 7/30/2019 98401F10 BW   Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019"," 5/18/2017 ITCI-US  BW   Robbins Arroyo LLP: Intra-Cellular Therapies, Inc. (ITCI) Misled Shareholders According to a Recently Filed Class Action",#N/A, 7/25/2019 G6674U10 BW   Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,11/05/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit,10/08/2019 DERM-US  BW   Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A, 1/27/2010 06C8FT-E BW   Supernus Announces Positive Results from Phase IIa Clinical Trial for SPN 810 in Children with ADHD and Serious Conduct Problems,"11/17/2014 31572Q80   BW   FibroGen, Inc. Announces Full Exercise of Greenshoe Option",10/23/2019 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results,#N/A,#N/A, 1/05/2016 0D7WM8-E BW   Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors," 6/10/2010 00772J-E BW   Collegium Pharmaceutical Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172","11/24/2015 XBIT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by XBiotech Inc. and Certain Officers and Directors", 5/02/2019 MCRB-US  BW   Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update, 9/13/2019 AIMT-US  BW   Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A, 9/22/2014 06S6MV-E BW   FierceBiotech Names Voyager Therapeutics as one of its “Fierce 15” Biotech Companies of 2014, 7/05/2017 BGNE-US BW   Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers, 7/16/2019 CAMX-SE  BW   Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan,#N/A, 9/29/2017 HCM-GB   BW   Chi-Med Highlights Oral Presentations at CSCO Annual Meeting,11/18/2014 0DZX54-E BW   Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology,#N/A, 6/24/2016 0DP3CK-E BW   CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2015 00CN92-E    BW   OptiNose Announces Positive Results of Phase III Trial for OPN-375,#N/A,#N/A, 7/31/2019 QTRX-US  BW   Quanterix to Present at the Canaccord Genuity 39th Annual Growth Conference," 4/20/2018 SLDB-US  BW   SOLID BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB",#N/A,#N/A, 5/01/2015 30233G10 BW   pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information,#N/A,#N/A,11/15/2019 AXNX-US  BW   Axonics® gibt die Zulassung der US-amerikanischen Food & Drug Administration für sein System für sakrale Neuromodulation für klinische Indikationen im Urin bekannt, 6/25/2019 TCDA-US  BW   Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet,#N/A, 8/08/2019 AVRO-US  BW   AVROBIO Reports Second Quarter 2019 Financial Results and Provides Business Update, 6/24/2019 MGTA-US  BW   CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors, 8/17/2018 XERS-US  BW   Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon, 6/08/2018 0JJ6HQ-E BW   Autolus Launches Roadshow for Initial Public Offering,#N/A, 1/04/2017 SHPG-IE  BW   RaNA Acquires Shire’s Industry Leading Messenger RNA Platform, 9/30/2019 MRNA-US BW   Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927),#N/A,#N/A,#N/A,#N/A, 2/17/2016 0G02KK-E BW   Mass Innovation Labs Helps New Member Companies’ Rapid Transition to Research,#N/A,#N/A,#N/A,"10/26/2019 TWST-US  BW   Le consortium regroupant la Fondation Praesens, l’Institut Pasteur, l’Institut Pasteur de Dakar, le Centre médical de l’université du Nebraska et Twist Bioscience a reçu le Prix Galien MedStartUp",#N/A, 5/14/2019 GOSS-US  BW   Gossamer Bio Announces First Quarter 2019 Financial Results,#N/A," 6/19/2017 0084LG-E  BW   Precision BioSciences Welcomes Fayaz Khazi, Ph.D. as President of PlantSciences", 5/17/2018 00FWLP-E BW   TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology Meeting,#N/A,#N/A, 1/19/2018 00DHGL-E BW   Atreca to Participate in Immunotherapy Showcase at the 2018 Precision Medicine World Conference,"11/19/2019 PSNL-US  BW   Personalis, Inc. annonce sa collaboration avec Merck KGaA, Darmstadt, Allemagne, pour identifier et développer de nouveaux biomarqueurs pour les traitements contre le cancer", 8/14/2019 86150R10 BW   Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update,#N/A,11/30/2018 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Present 28 Studies at ASH 2018 that Support the Use of the clonoSEQ® Assay to Detect and Monitor Minimal Residual Disease in Patients with Blood Cancers, 4/26/2019 09ZBXZ-E BW   Karuna Therapeutics Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering,#N/A
" 7/23/2019 LGND-US   BW   Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company",10/02/2019 LNTH-US     BW   Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company,10/07/2019 ILMN-US     BW   QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests, 6/20/2019 84763A10  BW   Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors, 9/15/2017 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc,11/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results,10/07/2010 09060J10 BW   BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in Taiwan,#N/A,"10/17/2012 000KXY-E BW   Genentech’s Lucentis 0.3mg for Diabetic Macular Edema Has Experienced Robust Trial and Uptake During the First Month of Commercial Availability, According to a Recent BioTrends Report",12/15/2015 SIGA-US  BW   SIGA Files Consensual Plan of Reorganization," 9/12/2018 OPK-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against OPKO Health, Inc. – OPK",11/18/2014 46222210    BW   Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association,"10/14/2010 TEVA-IL  BW   Zacks Bull and Bear of the Day Highlights: SFLY, BMRN, LLY, AMGN, TEVA",10/10/2019 ALXN-US  BW   Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases,#N/A,12/02/2019 4503-JP     BW   Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer," 1/02/2019 IMMU-US     BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Immunomedics, Inc. Investors (IMMU)", 4/17/2018 09062X10    BW   Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases, 6/27/2019 IMGN-US  BW   ImmunoGen Announces Completion of Operational Review,11/07/2013 09058V10 BW   BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema,11/09/2019 GILD-US      BW   New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile,#N/A," 4/03/2017 MYL-US   BW   Hagens Berman: EpiPen Purchasers Accuse Drug Maker Mylan of Fraud, RICO Enterprise in National Class-Action Lawsuit over EpiPen Pricing", 6/15/2015 CGEN-IL  BW   Compugen to Present at JMP Securities Life Sciences Conference in New York,"10/11/2018 AKRX-US   BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders",11/17/2017 KBH-US       BW   KB Home Announces the Grand Opening of Mariposa at Springville in Camarillo," 6/15/2018 MYGN-US     BW   MYRIAD GENETICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Myriad Genetics, Inc.- MYGN",#N/A,#N/A, 3/30/2015 45766930 BW   Insmed Announces Proposed Public Offering of Common Stock, 9/06/2019 05156V10 BW   Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference, 1/10/2011 45773H20 BW   Inovio Pharmaceuticals’ Novel DNA Vaccine for Clade C HIV Achieves Immune Responses and Protection in Non-Human Primates,"12/10/2018 NKTR-US  BW   Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors",#N/A, 4/24/2014 37416310     BW   Lieff Cabraser Reminds Geron Corporation Investors of Upcoming Deadline in Class Action Litigation – GERN, 9/25/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference,11/27/2013 02311120 BW   Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Amarin Corporation plc,10/16/2019 NOVN-CH  BW   Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease, 7/27/2017 UTHR-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of United Therapeutics Corporation and Encourages Investors with Losses to Contact the Firm," 8/13/2018 SRPT-US  BW   UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round","12/21/2017 ALKS-US  BW   The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018", 6/03/2019 CERS-US  BW   Cerus Corporation Announces New Corporate Brand and Global Headquarters," 2/07/2013 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference"," 9/26/2019 04269E10 BW   ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019",11/10/2010 LMNX-US  BW   edō Interactive Elects Jim Kever Chairman of the Board of Directors,11/06/2019 80067710 BW   Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting," 9/03/2019 EXEL-US  BW   Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019", 1/04/2019 07N3P3-E  BW   Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors,10/21/2019 VRTX-US   BW   ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation, 5/30/2018 PFE-US   BW   Allogene Therapeutics Announces Board of Directors,#N/A," 9/27/2019 BLUE-US  BW   bluebird bio Appoints William R. Sellers, M.D. to Board of Directors", 9/23/2019 ACAD-US  BW   ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders,#N/A,#N/A,#N/A,10/10/2019 TXMD-US  BW   TherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business," 4/10/2019 ZGNX-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zogenix, Inc. Investors",#N/A,11/04/2019 OMER-US  BW   Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain,"10/28/2019 RVNC-US  BW   Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019", 7/28/2015 OGEN-US  BW   Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study, 7/30/2019 IRWD-US  BW   Ironwood Pharmaceuticals Reports Second Quarter 2019 Results,#N/A,#N/A,#N/A,"10/07/2019 63009R10    BW   NanoString to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 4, 2019", 9/24/2014 69329Y10 BW   PDL BioPharma Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors," 7/25/2019 SYRS-US  BW   Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019",#N/A,#N/A, 2/04/2013 ANIP-US      BW   Aduro Announces Acquisition of GVAX Assets From BioSante," 7/08/2019 ENTA-US    BW   Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)",10/23/2019 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results," 4/12/2017 WVE-US   BW   WAVE Life Sciences Prices Public Offering of 4,166,667 Ordinary Shares",#N/A,#N/A," 4/30/2015 69512710 BW   Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results"," 3/24/2015 76129910 BW   Retrophin Closes Public Offering of 7,866,000 Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares"," 1/06/2012 69404D10 BW   Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Pacific Biosciences of California, Inc.", 3/02/2015 0DFYQH-E BW   Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism,#N/A,#N/A,#N/A, 9/03/2019 AKBA-US  BW   Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease,#N/A,#N/A, 5/24/2018 PRTA-US  BW   PRTA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation,#N/A, 9/05/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A, 5/11/2012 07GVF3-E BW   Research and Markets: Waldenstrm's Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019," 2/12/2019 VNDA-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","10/29/2018 MEDP-US  BW   Medpace Holdings, Inc. Reports Third Quarter 2018 Results",#N/A, 4/24/2018 GSK-GB      BW   Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD,#N/A,12/02/2013 40637H10 BW   Baxter Submits Amended BLA to U.S. FDA for HyQvia for Primary Immunodeficiency,#N/A,11/27/2013 56400P70 BW   MannKind Corporation to Present at The Piper Jaffray 25th Annual Healthcare Conference," 8/05/2019 URGN-US  BW   UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019",#N/A," 5/14/2018 0B1C3M-E    BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)"," 4/11/2019 AMRS-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Amyris, Inc. – AMRS"," 2/23/2016 PTCT-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Ongoing Investigation of Claims Against PTC Therapeutics, Inc. and Strongly Encourages Investors With Losses to Contact the Firm",#N/A," 3/05/2019 SYNH-US BW   IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Syneos Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","12/15/2011 077VL7-E BW   BioNJ Presents Fifth Annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership to Paul G. Thomas of Roka Bioscience",10/07/2019 4582-JP  BW   Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation, 9/30/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors,12/02/2013 ADMA-US  BW   ADMA Biologics to Present at the Oppenheimer 24th Annual Healthcare Conference, 1/26/2016 GWP-GB   BW   Robbins Arroyo LLP: GW Pharmaceuticals plc (GWPH) Misled Shareholders According to a Recently Filed Class Action, 7/22/2019 EPZM-US  BW   Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer," 8/17/2012 ANIP-US  BW   BioSante Pharmaceuticals to Raise $3,475,000 in Registered Direct Offering",#N/A,#N/A, 9/11/2018 GILD-US     BW   Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis, 6/14/2012 06XJML-E BW   Third Rock Ventures Launches Global Blood Therapeutics with $40.7 Million to Revolutionize the Treatment of Chronic Blood-Based Diseases, 7/30/2019 VCYT-US  BW   Veracyte Announces Second Quarter 2019 Financial Results,10/01/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),11/08/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,"12/12/2016 RXDX-US  BW   Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals, Inc., to Board of Directors"," 5/26/2017 IOVA-US  BW   Law Offices of Howard G. Smith Reminds Lion Biotechnologies, Inc. Investors of Pending Lawsuit And Upcoming Lead Plaintiff Deadline",#N/A,"10/29/2019 XLRN-US  BW   Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019",#N/A,11/04/2019 HZNP-US  BW   Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting,10/07/2019 14843C10  BW   Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma,"10/23/2017 ICPT-US  BW   Important Investor Alert: JFJN Law Announces Filing of a Class Action against Intercept Pharmaceuticals, Inc.", 3/19/2019 KPTI-US  BW   Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance," 4/29/2019 GLYC-US  BW   GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel"," 6/27/2019 98401F10 BW   Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D."," 5/18/2017 ITCI-US  BW   ITCI LOSS NOTICE: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important Deadline in First Filed Class Action",#N/A, 7/22/2019 G6674U10 BW   Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference,#N/A,#N/A,#N/A,10/24/2019 RCKT-US  BW   Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia, 9/26/2019 DERM-US  BW   Dermira to Participate in the 2019 Cantor Global Healthcare Conference,#N/A,#N/A,#N/A,"11/13/2014 31572Q80   BW   FibroGen, Inc. Announces Pricing of Its Initial Public Offering",10/03/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,10/13/2015 0D7WM8-E BW   Audentes Therapeutics Raises $65 Million in Series C Financing," 5/20/2010 00772J-E BW   Washington Trust Finances Highland CCC II, LLC",#N/A," 4/29/2019 MCRB-US  BW   Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019", 8/28/2019 AIMT-US  BW   Aimmune to Participate in Three Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A," 9/03/2014 0DL69Y-E BW   Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer"," 2/08/2016 C-US    BW   Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program", 6/04/2019 RARX-US  BW   Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy,#N/A, 9/29/2017 HCM-GB   BW   Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting,#N/A,#N/A, 6/08/2016 0DP3CK-E BW   CRISPR Therapeutics und Anagenesis Biotechnologies geben strategische Einlizenzierungs- und Kooperationsvereinbarung zur Entwicklung von CRISPR-Cas9-basierten Zelltherapien für Muskelerkrankungen bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/19/2015 00CN92-E    BW   OptiNose to Present at Nasal and Respiratory Drug Delivery Conferences,#N/A,#N/A," 7/30/2019 QTRX-US  BW   Quanterix to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, August 6, 2019"," 4/19/2018 SLDB-US  BW   The Klein Law Firm Reminds Investors of a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018",#N/A,#N/A, 4/14/2015 30233G10 BW   pSivida Corp. Reports ILUVIEN® for DME Approved in Poland,#N/A,#N/A,11/14/2019 AXNX-US  BW   Axonics® Announces Third Quarter 2019 Financial Results and Operational Update, 6/05/2019 TCDA-US  BW   Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference,#N/A," 8/06/2019 AVRO-US  BW   AVROBIO, Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference"," 6/06/2019 MGTA-US  BW   Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th", 6/25/2018 XERS-US  BW   Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen,#N/A,#N/A, 9/12/2016 SHPG-IE  BW   RaNA Therapeutics Names Thomas McCauley as Chief Scientific Officer, 9/26/2019 MRNA-US BW   Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2019 TWST-US  BW   Twist Bioscience Appoints Seasoned Life Sciences Industry Executive Nicolas M. Barthelemy to Board of Directors,#N/A," 5/09/2019 GOSS-US  BW   Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019",#N/A, 2/25/2016 0084LG-E  BW   Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology," 5/14/2018 00FWLP-E BW   TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer",#N/A,#N/A,12/19/2017 05G06K-E BW   Atreca Reports on Tumor-Fighting Responses in B Cells from Patients with Non-Progressing Metastatic Cancers,11/19/2019 PSNL-US  BW   Personalis to Present at Upcoming Investor Conferences," 8/06/2019 STOK-US  BW   Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome",#N/A,"10/05/2018 0DMSKV-E BW   Une nouvelle étude publiée dans la revue Blood démontre que mesurer la négativité à la maladie résiduelle minimale à l'aide de la plateforme de séquençage de nouvelle génération d’Adaptive Biotechnologies, constitue un indicateur...", 4/01/2019 09ZBXZ-E BW   Karuna Completes $80 Million Series B Financing,#N/A
 7/15/2019 LGND-US   BW   Ligand to Report Second Quarter 2019 Results on July 30th," 9/18/2019 0LDDK2-E    BW   Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees",10/07/2019 ILMN-US     BW   QIAGEN und Illumina gehen Partnerschaft zur Einführung sequenzierungsbasierter In-vitro-Diagnostik-Tests ein, 6/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting," 9/15/2017 ENDP-US  BW   The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017",11/08/2019 ARWR-US  BW   Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019," 9/08/2010 09060J10 BW   BioDelivery Sciences to Present at Rodman & Renshaw, Baird, and Stifel Nicolaus Investor Conferences",#N/A," 7/04/2012 REGN-US  BW   Research and Markets: Regeneron Pharmaceuticals, Inc.: Pharmavitae 2012 Report - Approval for Eylea Is Expected In the EU in Late 2012 or Early 2013", 3/18/2015 82691710 BW   SIGA Technologies Receives NASDAQ Delisting Notification, 9/11/2018 OPK-US   BW   OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock, 5/08/2014 SNY-FR      BW   Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®,#N/A,"10/08/2019 ALXN-US  BW   Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019",#N/A,11/25/2019 SGEN-US     BW   Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma," 5/05/2017 IMMU-US     BW   Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value", 4/13/2018 BIIB-US     BW   BIOGEN annonce la nomination de Martin Dubuc au poste de Président Directeur Général de Biogen France, 5/15/2019 IMGN-US  BW   ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer,11/05/2013 09058V10 BW   BioCryst Provides Corporate Update and Reports Third Quarter 2013 Financial Results,11/08/2019 GILD-US      BW   Did You Invest in Gilead Sciences?,#N/A,"12/09/2016 MYL-US   BW   MYLAN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Mylan N.V. – MYL", 6/08/2015 M2572210 BW   Compugen to Disclose Novel Cancer Immunotherapy Target Candidate and Comprehensive Target Characterization Infrastructure at Today’s Analyst and Investor Day,10/01/2018 05NTQT-E  BW   Akorn Comments on Delaware Chancery Court Ruling,11/06/2017 0DMSKV-E     BW   Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ® Assay in Multiple Myeloma," 6/08/2018 MYGN-US     BW   MYGN Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Myriad Genetics, Inc. Investors",#N/A,#N/A, 3/27/2015 45766930 BW   Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 8/06/2019 05156V10 BW   Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights, 1/04/2011 45773H20 BW   Inovio Pharmaceuticals to Present at Biotech Showcase 2011,"12/06/2018 NKTR-US  BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",#N/A, 4/10/2014 37416310     BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation, 9/20/2019 AERI-US    BW   Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union,"11/27/2013 02311120 BW   Kantrowitz, Goldhamer & Graifman, P.C. Files Class Action Suit Against Amarin Corporation plc",10/12/2019 INCY-US  BW   Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo, 7/27/2017 UTHR-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of United Therapeutics Corporation," 7/23/2018 SRPT-US  BW   Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sarepta’s RNA-Targeted Technology Platforms","12/20/2017 0BXWRQ-E BW   ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018", 5/14/2019 CERS-US  BW   Cerus’ INTERCEPT Blood System Provides Alternative to Year-Round Babesia Testing in Latest FDA Guidance Document, 1/06/2013 AMAG-US  BW   AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results and 2013 Financial Guidance," 9/17/2019 04269E10 BW   ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019",#N/A,11/01/2019 80067710 BW   Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer, 7/31/2019 EXEL-US  BW   Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update,"12/04/2018 SAN-FR    BW   Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind",10/21/2019 VRTX-US   BW   Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor), 5/14/2018 0JBQJ2-E BW   Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting,#N/A, 9/18/2019 BLUE-US  BW   bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress, 9/20/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 9/26/2019 TXMD-US  BW   TherapeuticsMD Announces Participation at the 2019 Cantor Healthcare Conference," 4/10/2019 ZGNX-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,10/29/2019 OMER-US  BW   Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission,10/23/2019 RVNC-US  BW   Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting, 6/10/2015 ORNI-US  BW   Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral Cavity, 7/18/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call,#N/A,#N/A,#N/A,10/04/2019 63009R10    BW   NanoString Reports Inducement Grant Under NASDAQ Listing Rules," 9/19/2014 69329Y10 BW   INVESTOR ALERT: Investigation on Behalf of PDL BioPharma, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP", 6/12/2019 SYRS-US  BW   Syros Announces Appointment of Alice T. Shaw to its Board of Directors,#N/A,#N/A, 1/22/2013 00182C10     BW   BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger, 6/14/2019 ENTA-US    BW   Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV),10/15/2019 ALNY-US   BW   Alnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society, 4/11/2017 WVE-US   BW   WAVE Life Sciences Announces Proposed Public Offering of Ordinary Shares,#N/A,#N/A, 4/16/2015 69512710 BW   Glancy Binkow & Goldberg LLP Investigates Claims on Behalf of Pacira Pharmaceuticals Shareholders," 3/19/2015 76129910 BW   Retrophin Prices Public Offering of 6,840,000 Shares of Common Stock", 1/06/2012 69404D10 BW   Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer, 1/12/2015 0DFYQH-E BW   Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering,#N/A,#N/A,#N/A, 8/09/2019 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A, 5/22/2018 PRTA-US  BW   PRTA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation,#N/A, 9/04/2019 SAGE-US     BW   Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder,#N/A,"12/15/2011 077VL7-E BW   BioNJ Presents Fifth Annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership to Paul G. Thomas of Roka Bioscience", 2/11/2019 VNDA-US  BW   INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Vanda Pharmaceuticals Inc.,"10/03/2018 MEDP-US  BW   Medpace Holdings, Inc. to Report Third Quarter 2018 Financial Results on October 29, 2018",#N/A, 4/18/2018 GSK-GB      BW   Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD,#N/A, 5/21/2013 40637H10 BW   Baxter Receives Marketing Authorization for HyQvia in European Union,#N/A,11/07/2013 56400P70 BW   MannKind Corporation to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum, 7/01/2019 URGN-US  BW   UroGen Pharma Joins Russell 3000® Index,#N/A," 5/14/2018 ESPR-US     BW   Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm"," 4/08/2019 AMRS-US  BW   Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Amyris, Inc."," 2/23/2016 PTCT-US  BW   Zeldes Haeggquist & Eck, LLP Announces Investigation of PTC Therapeutics, Inc.",#N/A," 3/03/2019 SYNH-US BW   SYNH INVESTOR ALERT: Rosen Law Firm Reminds Syneos Health, Inc. Investors of Important Deadline in First-Filed Securities Class Action Lawsuit Commenced by the Firm– SYNH", 1/14/2011 PFE-US   BW   Maven Semantic: Single Cell Analysis Research Database," 9/23/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference"," 9/25/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference",11/12/2013 ADMA-US  BW   ADMA Biologics Reports Third Quarter 2013 Financial and Operational Results, 1/25/2016 GWPH-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against GW Pharmaceuticals plc – GWPH, 6/21/2019 EPZM-US  BW   Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma, 8/08/2012 AIS-US   BW   Antares Pharma Reports Second Quarter 2012 Financial and Operating Results,#N/A,#N/A, 9/06/2018 GILD-US     BW   Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint, 5/21/2012 07ZLD5-E BW   iPierian Appoints Pamela B. Conley as Vice President of Research, 7/01/2019 VCYT-US  BW   Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer, 9/25/2019 DRNA-US  BW    Dicerna™ to Present at Two Upcoming Investor Conferences,11/08/2019 15117K10 BW   Cellectis: Monthly information on share capital and company voting rights,#N/A,#N/A,#N/A,"12/08/2016 AGIO-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Agios Pharmaceuticals, Inc."," 5/26/2017 IOVA-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Lion Biotechnologies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 13, 2017",#N/A, 9/16/2019 XLRN-US  BW   Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy,#N/A,11/04/2019 HZNP-US  BW   New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting, 9/19/2019 CSTL-US   BW   Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index,"10/20/2017 0B1C3M-E BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.", 3/19/2019 MNKD-US  BW   Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance," 4/25/2019 GLYC-US  BW   GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019", 6/03/2019 98401F10 BW   Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors," 5/18/2017 ITCI-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc.",#N/A, 7/18/2019 G6674U10 BW   CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®,#N/A,#N/A,#N/A,10/22/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency, 8/29/2019 DERM-US  BW   Dermira to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,10/02/2014 05SVDW-E   BW   FibroGen Files Registration Statement for Proposed Initial Public Offering,10/02/2019 74587V10 BW   FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A, 9/29/2015 0D7WM8-E BW   Audentes Therapeutics Expands Senior Leadership Team, 5/20/2010 00772J-E BW   Collegium Pharmaceutical Inc. Announces Notice of Allowance for Second DETERx™ Technology Patent,#N/A, 4/02/2019 MCRB-US  BW   Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting, 8/21/2019 AIMT-US  BW   Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy,#N/A,#N/A,#N/A,#N/A,#N/A," 8/01/2014 0DL69Y-E BW   Dinah Sah, Senior Vice President of Neuroscience and Rob Kotin, Vice President of Production Honored Among PharmaVOICE 100 Most Inspiring People",#N/A, 5/28/2019 RARX-US  BW   Ra Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A, 8/29/2017 HCM-GB   BW   Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in China,#N/A,#N/A, 6/08/2016 0DP3CK-E BW   CRISPR Therapeutics et Anagenesis Biotechnologies annoncent un accord stratégique de licence et de collaboration pour développer une thérapie cellulaire basée sur la technologie CRISPR/Cas9 pour les maladies musculaires.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 00CN92-E    BW   OptiNose to Present at the 35th Annual Cowen Healthcare Conference,#N/A,#N/A, 7/26/2019 QTRX-US  BW   Sarah Hlavinka Elected to Quanterix Board of Directors," 4/19/2018 SLDB-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Solid Biosciences Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit",#N/A,#N/A, 3/26/2015 30233G10 BW   pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis,#N/A,#N/A,11/14/2019 AXNX-US  BW   Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications, 5/08/2019 TCDA-US  BW   Tricida Announces First Quarter 2019 Financial Results,#N/A, 7/19/2019 AVRO-US  BW   AVROBIO Announces Closing of Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, 5/09/2019 MGTA-US  BW   Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights,12/12/2011 075SMW-E BW   Xeris Pharmaceuticals Closes US$1.5 Million Series A Financing with Central Texas Angel Network,#N/A,#N/A, 6/14/2016 002N2S-E BW   RaNA Therapeutics to Present at Upcoming Conferences, 9/26/2019 MRNA-US BW   Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/24/2019 TWST-US  BW   Praesens Foundation, Institut Pasteur, Institut Pasteur de Dakar, University of Nebraska Medical Center, Twist Bioscience Consortium Win Prix Galien MedStartUp Award",#N/A, 5/02/2019 GOSS-US  BW   Gossamer Bio Secures Debt Facility for up to $150 Million,#N/A," 9/02/2015 0084LG-E  BW   Precision BioSciences Announces Appointment of Gene Liau, Ph.D. and Bruce McCreedy, Ph.D. to Management Team", 2/27/2018 00FWLP-E BW   TP Therapeutics Appoints Lewis Shuster to Board of Directors,#N/A,#N/A, 8/17/2017 0D5N8T-E BW   Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer Immunotherapies,"11/19/2019 PSNL-US  BW   Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies", 8/01/2019 STOK-US  BW   Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference,#N/A,"10/05/2018 0DMSKV-E BW   Eine neue im Fachmagazin Blood veröffentlichte Studie zeigt, dass die Messung der Negativität der minimalen Resterkrankung mittels der Sequenzierungsplattform der nächsten Generation von Adaptive Biotechnologies ein wichtiger...", 3/13/2019 09ZBXZ-E BW   Karuna Bolsters Research and Development Team,#N/A
 7/10/2019 LGND-US   BW   Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol," 6/21/2016 07J4DM-E    BW   Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform",10/07/2019 45232710    BW   Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests, 5/29/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th, 9/14/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/31/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference, 9/07/2010 09060J10 BW   BioDelivery Sciences Adds New Executive to Lead Business and Strategic Development,#N/A, 6/25/2012 063WMX-E BW   NextBio and Cancer Care Institute Form Strategic Partnership Focused on Clinical Use of Genomics," 1/16/2015 82691710 BW   SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery"," 9/10/2018 OPK-US   BW   OPK INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Opko Health, Inc. Investors", 3/06/2013 USAT-US     BW,#N/A, 9/17/2019 ALXN-US  BW   Alexion Announces CFO Succession,#N/A,11/12/2019 SGEN-US     BW   Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership, 3/03/2017 IMMU-US     BW   Stockholders Endorse venBio’s Case for Meaningful Change at Immunomedics, 4/05/2018 207940-KR   BW   Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe, 5/15/2019 IMGN-US  BW   ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer,10/23/2013 09058V10 BW   BioCryst to Announce Third Quarter 2013 Financial Results November 5,11/08/2019 GILD-US      BW   Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019,#N/A,"11/18/2016 MYL-US   BW   DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Mylan N.V. To Contact The Firm", 5/28/2015 CGEN-IL  BW   Compugen to Present at Jefferies 2015 Global Healthcare Conference in New York," 5/02/2018 AKRX-US   BW   SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX", 5/26/2017 AMGN-US      BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amgen Inc. and Encourages Investors with Losses to Contact the Firm," 6/02/2018 MYGN-US     BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN",#N/A,#N/A, 3/23/2015 45766930 BW   Insmed Appoints Dr. Eugene Sullivan as Chief Medical and Scientific Officer," 8/01/2019 05156V10 BW   Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019",12/14/2010 INO-US   BW   Profectus Biosciences’ GENEVAX IL-12 Adjuvant Significantly Improves pDNA Vaccine Performance in Phase I Human Trial,"11/28/2018 NKTR-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors",#N/A," 4/09/2014 37416310     BW   Hagens Berman Reminds Investors of May 13, 2014, Lead Plaintiff Deadline in Geron Securities Class Action", 9/19/2019 AERI-US    BW   Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility,"11/22/2013 02311120 BW   Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Amarin Corporation plc",10/10/2019 INCY-US  BW   Incyte to Report Third Quarter Financial Results," 7/27/2017 UTHR-US  BW   Bragar Eagel & Squire, P.C. Is Investigating United Therapeutics Corporation (UTHR) on Behalf of Stockholders and Encourages Investors to Contact the Firm", 1/04/2018 SRPT-US  BW   Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Diseases,"12/19/2017 ALKS-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018", 5/07/2019 CERS-US  BW   Cerus Corporation Announces Record First Quarter 2019 Results, 1/02/2013 AMAG-US  BW   AMAG Pharmaceuticals Appoints Greg Madison as Chief Commercial Officer," 8/28/2019 04269E10 BW   ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019",#N/A,10/30/2019 80067710 BW   Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast," 7/31/2019 08VQ6X-E BW   Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer",12/03/2018 BIVV-US   BW   BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A,"10/19/2019 VRTX-US   BW    Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia", 4/09/2018 0JBQJ2-E BW   Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio,#N/A, 9/03/2019 BLUE-US  BW   bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress, 9/19/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings,#N/A,#N/A,#N/A, 9/24/2019 TXMD-US  BW   TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society, 1/04/2018 ZGNX-US  BW   Counsyl Appoints Ann Rhoads to Board of Directors,#N/A,10/28/2019 OMER-US  BW   Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA,"10/14/2019 RVNC-US  BW   Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne", 9/24/2014 FCSC-US  BW   Fibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis Bullosa, 6/18/2019 AGN-US   BW   Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C),#N/A,#N/A,#N/A,10/02/2019 63009R10    BW   NanoString Appoints Mark Winham Senior Vice President of Operations, 4/22/2013 69329Y10 BW   Avinger Completes Mezzanine Financing with PDL Biopharma, 6/12/2019 SYRS-US  BW   Syros to Present at JMP Securities Life Sciences Conference,#N/A,#N/A,11/08/2012 05MW5D-E     BW   BioSante Pharmaceuticals Reports Third Quarter Financial Results and Merger Update, 6/10/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences,10/10/2019 ALNY-US   BW   Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy, 3/16/2017 WVE-US   BW   WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update,#N/A,#N/A, 4/16/2015 69512710 BW   Pacira Receives Subpoena from the U.S. Department of Justice, 3/18/2015 76129910 BW   U.S. Food and Drug Administration Approves Cholbam for the Treatment of Rare Bile Acid Synthesis Disorders and Grants Rare Pediatric Disease Priority Review Voucher," 1/06/2012 69404D10 BW   Holzer Holzer & Fistel, LLC Announces Investigation into Potential Claims for Breach of Fiduciary Duties by Certain Officers and Directors of Pacific Biosciences of California, Inc.",12/01/2014 0DFYQH-E BW   Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital,#N/A,#N/A,#N/A, 8/08/2019 AKBA-US  BW   Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights,#N/A,#N/A," 5/18/2018 PRTA-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation",#N/A, 9/03/2019 SAGE-US     BW   Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference,#N/A,"10/26/2011 SGEN-US  BW   Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion", 2/11/2019 VNDA-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)," 8/22/2018 0CFGSR-E BW   Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder",#N/A, 3/08/2018 GSK-GB      BW   GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma,#N/A, 3/22/2013 HALO-US  BW   Baxter and Halozyme Announce Positive Opinion for HyQvia for Treatment of Primary and Secondary Immunodeficiencies in the European Union,#N/A,11/04/2013 56400P70 BW   MannKind Corporation Reports 2013 Third Quarter Financial Results, 5/30/2019 URGN-US  BW   UroGen Pharma to Present at June 2019 Investor Conferences,#N/A," 5/11/2018 ESPR-US     BW   ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc."," 4/03/2019 AMRS-US  BW   Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Amyris, Inc. Investors (AMRS)"," 2/23/2016 PTCT-US  BW   INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims Against PTC Therapeutics, Inc. and Strongly Encourages Investors to Contact the Firm",#N/A," 3/01/2019 SYNH-US BW   INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Syneos Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A," 8/28/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference", 9/05/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress,11/04/2013 ADMA-US  BW   ADMA Biologics Completes Enrollment of Phase III Study for RI-002," 1/11/2016 GWPH-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by GW Pharmaceuticals plc and Certain Officers and Directors", 6/12/2019 EPZM-US  BW   Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data, 6/27/2012 09VWJJ-E BW   GenesisCare Announces Investment by KKR,#N/A,#N/A, 5/30/2018 GILD-US     BW   Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis,10/27/2011 BIIB-US  BW   Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases," 6/27/2019 VCYT-US  BW   Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019", 9/19/2019 DRNA-US  BW   Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth,11/06/2019 15117K10 BW   Cellectis publie ses résultats financiers du troisième trimestre 2019 et des neuf premiers mois de l’année 2019,#N/A,#N/A,#N/A,"12/08/2016 AGIO-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Agios Pharmaceuticals, Inc. (AGIO) on Behalf of Shareholders"," 5/24/2017 IOVA-US  BW   Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Lion Biotechnologies, Inc. (LBIO) and Encourages Investors with Losses to Contact the Firm Before June 13, 2017",#N/A, 9/09/2019 XLRN-US  BW   Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension,#N/A,"10/31/2019 HZNP-US  BW   Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life", 9/03/2019 14843C10  BW   Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference,"10/19/2017 ICPT-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.", 4/04/2017 KPTI-US  BW   Karyopharm and Medidata Expand Clinical Trial Partnership, 4/23/2019 GLYC-US  BW   GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML," 5/23/2019 98401F10 BW   Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development"," 5/16/2017 ITCI-US  BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc.",#N/A, 7/18/2019 G6674U10 BW   Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,10/15/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress, 8/07/2019 DERM-US  BW   Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A, 9/20/2014 05SVDW-E   BW   FibroGen Announces One-Year Data Supporting the Safety and Efficacy Profile of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis, 9/25/2019 74587V10 BW   Puma Biotechnology to Present at Cantor Global Healthcare Conference,#N/A,#N/A, 9/01/2015 0D7WM8-E BW   Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences, 3/31/2010 00772J-E BW   Collegium Pharmaceutical Receives Notice of Allowance for US Patent Covering Novel Once-a-Day Formulation of Milnacipran,#N/A, 3/11/2019 MCRB-US  BW   Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca, 8/08/2019 AIMT-US  BW   Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A," 6/26/2014 0DL69Y-E BW   Voyager Therapeutics Appoints Industry Veteran Robert G. Pietrusko, Pharm.D., to Senior Vice President of Regulatory Affairs",#N/A, 5/14/2019 RARX-US  BW   Ra Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A, 7/31/2017 HCM-GB   BW   Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 6/08/2016 0DP3CK-E BW   CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2013 07RJZM-E    BW   Pharma Tech Industries Selected to Manufacture Innovative Nasal Delivery System for NDA Submission,#N/A,#N/A, 7/11/2019 QTRX-US  BW   Quanterix to Convene Leading Industry Researchers at Alzheimer’s Association International Conference 2019 Following Closing of UmanDiagnostics Acquisition," 4/18/2018 RC-US    BW   SLDB EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018",#N/A,#N/A, 2/17/2015 30233G10 BW   pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23,#N/A,#N/A,11/07/2019 AXNX-US  BW   Axonics® to Report 2019 Third Quarter and Nine-Month Financial Results and Host a Conference Call on November 14," 4/30/2019 TCDA-US  BW   Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019",#N/A, 7/16/2019 AVRO-US  BW   AVROBIO Announces Pricing of Underwritten Public Offering of $120.25 Million of Common Stock, 5/09/2019 MGTA-US  BW   Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting,#N/A,#N/A,#N/A, 5/03/2016 007HPS-E BW   RaNA Awarded First Patent for Transcriptional Activation Platform, 9/25/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2019 TWST-US  BW   Twist Bioscience Showcases Next-Generation Sequencing Products and Results at American Society for Human Genetics 2019 Annual Meeting,#N/A, 5/01/2019 GOSS-US  BW   Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019,#N/A, 5/11/2015 0084LG-E  BW   Precision BioSciences Announces $25.6 Million Series A Financing,"12/04/2017 00FWLP-E BW   TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor",#N/A,#N/A, 6/14/2017 00DHGL-E BW   Atreca to Participate in Immuno-Oncology Panel at the 2017 BIO International Convention,"11/17/2019 PSNL-US  BW   Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference", 6/21/2019 STOK-US  BW   Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,10/05/2018 0DMSKV-E BW   Un nuovo studio pubblicato sulla rivista Blood dimostra che il valore negativo della malattia minima residua (MMR) misurata attraverso la piattaforma di sequenziamento di Adaptive Biotechnologies è un indicatore predittivo...," 7/29/2016 09ZBXZ-E BW   Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors",#N/A
 7/08/2019 LGND-US   BW   Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation, 9/29/2014 74318710    BW   FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain, 9/30/2019 45232710    BW   Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools, 5/28/2019 84763A10  BW   Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target, 9/13/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/18/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics, 9/02/2010 09060J10 BW   BioDelivery Sciences Announces Positive Meeting with FDA on a Streamlined ONSOLIS REMS with Broadened Distribution,#N/A, 6/22/2012 07G69B-E BW   Research and Markets: Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019," 1/07/2015 82691710 BW   Delaware Court Decision Regarding SIGA Technologies, Inc.", 9/07/2018 OPK-US   BW   OPKO Comments on SEC Complaint, 2/21/2013 003KZ5-E    BW,#N/A, 9/09/2019 EIDX-US  BW   Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine,#N/A,11/07/2019 SGEN-US     BW   Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting, 3/02/2017 IMMU-US     BW   venBio Encourages Stockholders to Vote for Change," 3/28/2018 09062X10    BW   Biogen to Report First Quarter 2018 Financial Results on April 24, 2018", 5/03/2019 IMGN-US  BW   ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results, 9/17/2013 09058V10 BW   BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop BCX4430 for the Treatment of Marburg Virus Disease,11/08/2019 GILD-US      BW   Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy,#N/A,"11/18/2016 MYL-US   BW   MYLAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Mylan N.V. – MYL", 5/27/2015 M2572210 BW   Compugen to Hold Analyst and Investor Day in New York," 4/23/2018 AKRX-US   BW   AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Akorn, Inc.To Contact The Firm", 5/26/2017 AMGN-US      BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Amgen Inc. Investors," 6/01/2018 MYGN-US     BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm",#N/A,#N/A, 2/27/2015 45766930 BW   Insmed Reports 2014 Fourth Quarter and Full Year Financial Results, 7/18/2019 05156V10 BW   Aurinia Announces Further Strengthening of the Senior Management Team,12/07/2010 45773H20 BW   Preclinical Efficacy of Inovio Pharmaceuticals’ Smallpox DNA Vaccine Featured in The Journal of Infectious Diseases,"11/27/2018 NKTR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",#N/A, 4/07/2014 37416310     BW   Lieff Cabraser Announces Class Action Litigation Against Geron Corporation - GERN, 9/10/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024,"11/19/2013 02311120 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000 in Losses from Investment in Amarin Corporation plc to Contact Brower Piven Before the January 3, 2014 Lead Plaintiff Deadline", 9/27/2019 INCY-US  BW   Incyte annonce les résultats actualisés positifs de l’essai de Phase 2 sur le pemigatinib administré à des patients atteints d’un cholangiocarcinome précédemment traité et à un stade avancé, 7/27/2017 UTHR-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of United Therapeutics Corporation, 7/19/2017 SRPT-US  BW   Clinigen and Sarepta Therapeutics launch a Managed Access Program to treat patients with Duchenne Muscular Dystrophy amenable to exon 51 skipping,"12/18/2017 ALKS-US  BW   The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018"," 4/25/2019 CERS-US  BW   Cerus Corporation to Release First Quarter 2019 Results on May 7, 2019","12/26/2012 AMAG-US  BW   AMAG Pharmaceuticals, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference", 8/07/2019 04269E10 BW   ArQule Reports Second Quarter 2019 Financial Results,#N/A," 9/30/2019 80067710 BW   Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer"," 7/17/2019 EXEL-US  BW   Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019",11/01/2018 BIVV-US   BW   New Data at ASH Showcase Bioverativ’s Commitment to Transforming Care for People with Hemophilia and Other Rare Blood Disorders,10/18/2019 VRTX-US   BW   Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age,#N/A,#N/A, 8/23/2019 06XJML-E BW   Errant Gene Therapeutics (EGT) Wins Major Victory in New York Court, 9/17/2019 ACAD-US  BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A, 8/06/2019 TXMD-US  BW   TherapeuticsMD Announces Second Quarter 2019 Financial Results, 4/24/2015 PTXTQ-US BW   Pernix Therapeutics Closes Acquisition of Zohydro ER Franchise,#N/A,10/01/2019 OMER-US  BW   Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect,10/02/2019 RVNC-US  BW   Revance Earns Great Place to Work® Certification for Second Year," 9/10/2014 FCSC-US  BW   Fibrocell Science Hosting R&D Day on September 24, 2014", 6/13/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston,#N/A,#N/A,#N/A, 9/23/2019 63009R10    BW   NanoString Introduces New Gene Expression Research Panel for Human Organ Transplantation,"10/09/2012 AXGN-US  BW   AxoGen, Inc. Completes $20.8 Million Financing with PDL BioPharma, Inc."," 5/07/2019 SYRS-US  BW   New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers",#N/A,#N/A,"10/08/2012 ANIP-US      BW   BioSante Pharmaceuticals, Inc. to Present at BIO Investor Forum", 5/14/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at Upcoming Investor Conference, 9/26/2019 ALNY-US   BW   Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference, 2/06/2017 WVE-US   BW   WAVE Life Sciences to Present at Upcoming Investor Conferences,#N/A,#N/A, 4/13/2015 69512710 BW   Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call," 3/16/2015 76129910 BW   Retrophin Announces Proposed Public Offering of 5,100,000 Shares of Common Stock"," 1/05/2012 69404D10 BW   The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Pacific Biosciences of California, Inc. of Class Action Lawsuit and the Deadline of February 27, 2012 to Seek a Lead Plaintiff Position",12/01/2014 05G05S-E BW   Editas Medicine Licenses Genome Editing Technology from Duke University,#N/A,#N/A,#N/A, 8/05/2019 AKBA-US  BW   Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical,#N/A,#N/A," 5/17/2018 PRTA-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Prothena Corporation",#N/A, 8/06/2019 SAGE-US     BW   Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress,#N/A,#N/A, 2/11/2019 VNDA-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Vanda Pharmaceuticals Inc.," 8/22/2018 MEDP-US  BW   Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder",#N/A, 2/14/2018 GSK-GB      BW   GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta,#N/A, 2/15/2013 00DHD3-E BW   Ignyta Appoints Jerry Hurst to Executive Advisory Board,#N/A,10/30/2013 56400P70 BW   MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA, 5/09/2019 URGN-US  BW   UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments,#N/A," 5/10/2018 ESPR-US     BW   ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc."," 3/21/2019 AMRS-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)"," 2/23/2016 PTCT-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against PTC Therapeutics, Inc. - PTCT",#N/A," 6/27/2018 SYNH-US BW   Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health",#N/A," 8/08/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results", 9/03/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock,10/29/2013 ADMA-US  BW   RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics’ Human and Animal Study Experience,12/11/2015 MNTR-US  BW   Mentor Capital Releases Cannabis Index for Value Investors, 6/03/2019 EPZM-US  BW   Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting, 6/26/2012 AIS-US   BW   Antares Pharma Announces Positive Results from VIBEX MTX Usability Study,#N/A,#N/A, 3/09/2017 ALPHA-FR    BW   Pharnext Announces R&D Agreement with Galapagos to Generate a New Pipeline of Synergistic Drug Combinations," 3/15/2010 006RGD-E BW   Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation", 6/26/2019 VCYT-US  BW   Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis, 9/04/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),11/06/2019 15117K10 BW   Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019,#N/A,#N/A,#N/A,"12/06/2016 AGIO-US  BW   EQUITY ALERT: Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm"," 5/23/2017 IOVA-US  BW   Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Lion Biotechnologies, Inc. (NASDAQ:LBIO) Securities Case",#N/A, 8/05/2019 XLRN-US  BW   Acceleron Reports Second Quarter 2019 Operating and Financial Results,#N/A,10/24/2019 HZNP-US  BW   Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business, 9/03/2019 14843C10  BW   Castle Biosciences Reports Second Quarter 2019 Results,"10/18/2017 ICPT-US  BW   ICPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.", 6/15/2014 48576U10 BW   Veristat and Karyopharm Therapeutics Inc. Enter into Preferred Provider Agreement for Oncology and Novel Therapeutic Advancement, 4/22/2019 GLYC-US  BW   GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359, 5/09/2019 98401F10 BW   Xencor Reports First Quarter 2019 Financial Results," 5/16/2017 ITCI-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A," 7/05/2019 G6674U10 BW   Deutsches Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) veröffentlicht Rapid Report, der Überlebensvorteil durch Optune bei Patienten mit neu diagnostiziertem Glioblastom konstatiert",#N/A,#N/A,#N/A,10/01/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference," 7/31/2019 DERM-US  BW   Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019",#N/A,#N/A,#N/A, 5/31/2014 05SVDW-E   BW   FibroGen Announces Results of Phase 2 Study of FG-3019 Indicating Positive Activity Against Pancreatic Cancer, 9/11/2019 74587V10 BW   Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer,#N/A,#N/A, 8/26/2015 0D7WM8-E BW   Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe," 3/26/2010 00772J-E BW   Collegium Pharmaceutical Inc. Announces Filing of IND for Second Chronic Pain Product Using DETERx™ Tamper-Resistant, Extended Release Technology",#N/A, 3/06/2019 MCRB-US  BW   Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates, 8/06/2019 AIMT-US  BW   Aimmune to Present at the Wedbush PacGrow Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/25/2014 0DL69Y-E BW   Voyager Therapeutics Expands and Strengthens Scientific and Clinical Leadership to Advance Life-Changing Gene Therapies for CNS Disorders,#N/A, 5/09/2019 RARX-US  BW   Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update,#N/A, 6/29/2017 HCM-GB   BW   Chi-Med to Announce 2017 Half-Year Financial Results,#N/A,#N/A, 5/17/2016 0DP3CK-E BW   Bayer and ERS Genomics Announce Licensing Agreement for Genome Editing Patents,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2012 07G69B-E    BW   Research and Markets: Advances in Delivery to the Central Nervous System,#N/A,#N/A," 6/28/2019 QTRX-US  BW   Quanterix Announces Kevin Hrusovsky, Chairman and Chief Executive Officer, and Founder of Powering Precision Health, as EY Entrepreneur Of The Year® 2019 Award Winner in New England"," 4/17/2018 0BGL4K-E BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018",#N/A,#N/A, 2/05/2015 30233G10 BW   pSivida Corp. Reports Second Quarter FY 2015 Results,#N/A,#N/A,11/05/2019 0GXNH8-E BW   Axonics® Responds to Patent Action by Medtronic, 4/08/2019 TCDA-US  BW   Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A, 7/16/2019 AVRO-US  BW   AVROBIO Announces Proposed Public Offering of Common Stock, 5/06/2019 MGTA-US  BW   Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 3/23/2016 00DL17-E BW   RaNA Therapeutics Presents Data on Advances in RNA Therapy Targeting Spinal Muscular Atrophy, 9/12/2019 MRNA-US BW   Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2019 TWST-US  BW   Twist Bioscience Showcases New Innovation Lab at SynBioBeta 2019,#N/A, 3/22/2019 GOSS-US  BW   Gossamer Bio Announces 2018 Annual Financial Results,#N/A, 3/20/2014 0084LG-E  BW   Danziger Innovations and Precision BioSciences Announce Successful Genome Modification Collaboration in Ornamental Plants," 6/27/2017 00FWLP-E BW   TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements",#N/A,#N/A, 6/01/2017 00DHGL-E BW   Atreca to Present at the Jefferies 2017 Global Healthcare Conference,11/13/2019 PSNL-US  BW   Personalis Reports Third Quarter 2019 Financial Results, 6/18/2019 STOK-US  BW   Stoke Therapeutics Announces Pricing of Initial Public Offering,#N/A,10/05/2018 0DMSKV-E BW   La FDA accorde la désignation De Novo pour le test clonoSEQ d’Adaptive Biotechnologies servant à détecter et à surveiller la maladie résiduelle minimale (MRM) chez les patients atteints de myélome multiple et de leucémie aiguë lymphoblastique,#N/A,#N/A
" 7/01/2019 LGND-US   BW   ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics"," 8/11/2014 74318710    BW   FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain", 9/23/2019 45232710    BW   Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning, 5/16/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd," 9/13/2017 ENDP-US  BW   ENDP EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017",10/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics, 8/30/2010 09060J10 BW   BEMA Buprenorphine Phase 2 Study Results Selected for Presentation at Pain Week 2010,#N/A, 5/31/2012 07GVF3-E BW   Research and Markets: Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019," 9/17/2014 82691710 BW   SIGA Technologies, Inc. Receives Bankruptcy Court Approval for First-Day Motions in Connection with Chapter 11 Case","11/02/2017 OPK-US   BW   Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc", 1/29/2013 46222210    BW,#N/A, 9/04/2019 ALXN-US  BW   Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference,#N/A,11/05/2019 BGNE-US     BW   Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate, 2/22/2017 IMMU-US     BW   venBio Sends Letter to Immunomedics Stockholders, 3/15/2018 BIIB-US     BW   Healthcare Veterans Launch Martin Pharmaceuticals to Repurpose Drugs for Orphan Indications; Seed Round Oversubscribed, 4/18/2019 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results, 9/03/2013 09058V10 BW   BioCryst to Present at Morgan Stanley Global Healthcare Conference,11/08/2019 GILD-US      BW   Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019,#N/A,11/15/2016 05M7WL-E BW   Fitch Rates Mylan's Euro Bond Offering 'BBB-', 5/05/2015 M2572210 BW   Compugen Ltd. Reports First Quarter 2015 Results," 4/23/2018 0F98BD-E  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX", 5/23/2017 AMGN-US      BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Amgen Inc. and Advises Investors with Losses to Contact the Firm," 5/26/2018 MYGN-US     BW   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN",#N/A,#N/A, 2/24/2015 45766930 BW   Insmed to Participate at Cowen & Company’s 35th Annual Health Care Conference, 6/27/2019 AUP-CA   BW   ILJIN Comments on Aurinia Pharmaceutical’s Annual Meeting,11/17/2010 45773H20 BW   Inovio Pharmaceuticals’ HIV DNA Vaccine Achieves Strong T-Cell Immune Responses in Phase I Human Trial,11/20/2018 NKTR-US  BW   NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses – NKTR,#N/A," 3/31/2014 37416310     BW   Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron Corporation Securities Lawsuit and Investigation", 9/04/2019 AERI-US    BW   Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024,11/07/2013 02311120 BW   Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Amarin Corporation plc," 9/27/2019 INCY-US  BW   CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma", 7/27/2017 UTHR-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against United Therapeutics Corporation - UTHR," 6/21/2017 SRPT-US  BW   Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc.","12/13/2017 ALKS-US  BW   ALKS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018", 4/01/2019 CERS-US  BW   Cerus Corporation Strengthens Balance Sheet with an Expandable Debt Facility of up to $90 Million,12/24/2012 00163U10 BW   AMAG Pharmaceuticals Announces FDA Submission of a Supplemental New Drug Application for Feraheme," 8/05/2019 04269E10 BW   ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019",#N/A, 9/30/2019 80067710 BW   Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences, 7/15/2019 EXEL-US  BW   Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors,10/10/2018 SAN-FR    BW   Sanofi presents new data on Aubagio® (teriflunomide),"10/01/2019 VRTX-US   BW   Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer",#N/A,#N/A, 8/22/2019 BLUE-US  BW   bluebird bio Announces Investor Events in September, 9/17/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A," 7/25/2019 TXMD-US  BW   TherapeuticsMD to Report Second Quarter 2019 Results on August 6, 2019"," 3/10/2015 PTXTQ-US BW   Pernix to Acquire Zohydro® ER Franchise from Zogenix, Inc.",#N/A," 9/25/2019 OMER-US  BW   Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria", 9/25/2019 RVNC-US  BW   Revance to Participate in the 2019 Cantor Global Healthcare Conference," 5/28/2014 CLBS-US  BW   Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEB", 6/03/2019 IRWD-US  BW   Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D,#N/A,#N/A,#N/A, 5/28/2015 MRK-US      BW   Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)," 4/05/2012 ZLTQ-US  BW   ZELTIQ® Aesthetics, Inc. Appoints Sergio Garcia Senior Vice President, General Counsel, and Corporate Secretary", 5/01/2019 SYRS-US  BW   Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A,10/04/2012 09GP25-E     BW   BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement," 5/07/2019 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019", 9/16/2019 ALNY-US   BW   Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy, 1/06/2017 WVE-US   BW   WAVE Life Sciences 2017 Pipeline Update,#N/A,#N/A, 4/10/2015 PCRX-US  BW   Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery, 3/05/2015 76129910 BW   Retrophin Reports Fourth Quarter and Full Year 2014 Financial Results," 1/03/2012 69404D10 BW   Robbins Umeda LLP Announces an Investigation of Pacific Biosciences of California, Inc.",12/01/2014 0DFYQH-E BW   Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University,#N/A,#N/A,#N/A, 8/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A, 4/23/2018 PRTA-US  BW   PROTHENA CORPORATION INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations,#N/A, 8/05/2019 SAGE-US     BW   Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference,#N/A,#N/A," 8/12/2013 92165910 BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Vanda Pharmaceuticals Inc. of Upcoming Deadline"," 8/15/2018 MEDP-US  BW   Medpace Holdings, Inc. to Present at Baird Global Healthcare Conference",#N/A, 2/08/2018 INVA-US     BW   Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results,#N/A, 4/16/2012 40637H10 BW   Baxter and Halozyme Provide Update on HyQ Biologics License Application,#N/A,"10/28/2013 56400P70 BW   MannKind Corporation to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013", 5/05/2019 URGN-US  BW   UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial,#N/A," 5/09/2018 0BGL4K-E    BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc."," 3/20/2019 AMRS-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)"," 2/23/2016 PTCT-US  BW   GPM Announces Investigation On Behalf Of PTC Therapeutics, Inc. Investors",#N/A," 3/06/2018 SYNH-US BW   Robbins Arroyo LLP: Syneos Health, Inc. (SYNH) Misled Shareholders According to a Recently Filed Class Action",#N/A, 8/05/2019 EGRX-US  BW   Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer, 8/19/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock,"10/22/2013 ADMA-US  BW   ADMA Biologics, Inc. Announces Closing of Initial Public Offering", 8/14/2014 NTRR-US  BW   NTRR Leadership Plans Overseas Trip to Source New Product Suppliers, 5/30/2019 EPZM-US  BW   Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma, 5/31/2012 ANIP-US  BW   BioSante Pharmaceuticals Announces Reverse Stock Split in Order to Maintain NASDAQ Listing,#N/A,#N/A, 3/09/2017 ALPHA-FR    BW   Pharnext annonce un partenariat de R&D avec Galapagos en vue de créer un nouveau pipeline de combinaisons de médicaments synergiques,#N/A, 6/24/2019 VCYT-US  BW   Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year, 9/03/2019 DRNA-US  BW   Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference,"10/31/2019 15117K10 BW   Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST",#N/A,#N/A,#N/A,"12/06/2016 AGIO-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors"," 5/16/2017 IOVA-US  BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A," 7/24/2019 XLRN-US  BW   Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019",#N/A,10/24/2019 HZNP-US  BW   New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting, 8/27/2019 14843C10  BW   Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference,"10/17/2017 ICPT-US  BW   ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.", 4/09/2014 KPTI-US  BW   Karyopharm Therapeutics Inc. Enters into Preferred Provider Agreement with Clinipace Worldwide, 4/12/2019 GLYC-US  BW   GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359, 5/08/2019 98401F10 BW   Xencor to Present at Upcoming Investor Conferences," 5/15/2017 ITCI-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 7/02/2019 G6674U10 BW   Novocure to Report Second Quarter 2019 Financial Results,#N/A,#N/A,#N/A, 9/23/2019 08GCVF-E BW    Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency, 6/25/2019 DERM-US  BW   Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis,#N/A,#N/A,#N/A, 5/18/2014 05SVDW-E   BW   FibroGen Announces Phase 2 Data Supporting Longer-Term Safety and Efficacy Profile of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis, 9/05/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A, 5/14/2015 0D7WM8-E BW   Audentes Therapeutics to Participate in 2015 Piper Jaffray GenomeRx Symposium & 1x1 Day," 2/03/2010 00772J-E BW   Collegium Pharmaceutical Inc. Presents Scientific Poster for DETERx™ Tamper-Resistant, Extended Release Technology at American Academy of Pain Medicine’s 26th Annual Meeting",#N/A, 3/05/2019 MCRB-US  BW   Seres Therapeutics to Present at Three Upcoming March Conferences, 8/01/2019 AIMT-US  BW   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/07/2019 RARX-US  BW   Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting",#N/A," 6/29/2017 HCM-GB   BW   Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma",#N/A,#N/A," 3/17/2016 0DP3CK-E BW   CRISPR Therapeutics nomme Pablo J. Cagnoni, M.D., au conseil d’administration et Tony Coles, M.D., au poste de président du conseil d’administration en vue de faire progresser la mise au point de médicaments et de renforcer…",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2011 BIOC.XX1-US BW,#N/A,#N/A," 6/27/2019 QTRX-US  BW   Quanterix annonce un accord pour acquérir UmanDiagnostics, premier fournisseur mondial d'anticorps de neurofilaments légers (Nf-L)"," 4/16/2018 RC-US    BW   The Klein Law Firm Announces a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (SLDB)",#N/A,#N/A, 2/03/2015 30233G10 BW   pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9,#N/A,#N/A,11/01/2019 AXNX-US  BW   Axonics® Announces First Commercial U.S. Patient Implanted with its Sacral Neuromodulation System, 4/03/2019 TCDA-US  BW   Tricida Announces Pricing of Public Offering of Common Stock,#N/A, 7/15/2019 AVRO-US  BW   AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease, 5/01/2019 MGTA-US  BW   Magenta Therapeutics Announces Pricing of Public Offering,#N/A,#N/A,#N/A, 3/01/2016 0024VM-E BW   RaNA Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference, 9/12/2019 MRNA-US BW   Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2019 TWST-US  BW   Twist Bioscience to Present at SynBioBeta 2019,#N/A, 2/22/2019 GOSS-US  BW   Gossamer Bio Announces Participation in Upcoming Investor Conferences,#N/A," 3/12/2014 0084LG-E  BW   Nova Synthetix and Precision BioSciences Announce Collaboration to Develop Non-GM, Ricin-Free Castor with Customizable Oil Content", 5/23/2017 00FWLP-E BW   TP Therapeutics Closes $45M Series C Financing,#N/A,#N/A," 5/31/2017 00DHGL-E BW   Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration","11/12/2019 PSNL-US  BW   Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services", 6/14/2019 STOK-US  BW   Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors,#N/A,"10/05/2018 0DMSKV-E BW   FDA gewährt De-Novo-Bezeichnung für clonoSEQ-Assay von Adaptive Biotechnologie zur Erkennung und Überwachung von Minimaler Resterkrankung (Minimal Residual Disease, MRD) bei Patienten mit...",#N/A,#N/A
 6/12/2019 LGND-US   BW   Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target, 7/14/2014 74318710    BW   FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain, 9/12/2019 45232710    BW   Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation, 5/09/2019 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update, 9/12/2017 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc, 9/30/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences, 8/10/2010 09060J10 BW   BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference,#N/A, 5/30/2012 060RWY-E BW   Russia’s Colorectal Cancer Drug Market Projected to Grow to More Than $480 Million in 2016," 9/16/2014 82691710 BW   SIGA Technologies, Inc. Files for Chapter 11 Reorganization", 8/15/2017 OPK-US   BW   Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update, 1/26/2013 46222210    BW,#N/A, 8/28/2019 ALXN-US  BW   Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis,#N/A,11/04/2019 SGEN-US     BW   Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment, 2/14/2017 0BWYJ5-E    BW   venBio Takes Steps to Protect Rights of Immunomedics Stockholders, 3/15/2018 09062X10    BW   Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting, 3/01/2019 IMGN-US  BW   ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer, 8/08/2013 09058V10 BW   BioCryst Provides Corporate Update and Reports Second Quarter 2013 Financial Results,11/06/2019 GILD-US      BW   Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019,#N/A,11/03/2016 MYL-US   BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Mylan NV Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices," 4/28/2015 M2572210 BW   Compugen First Quarter 2015 Conference Call Scheduled for Tuesday, May 5, 2015 at 10:00 AM ET", 4/23/2018 AKRX-US   BW   Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement, 5/22/2017 AMGN-US      BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amgen Inc.," 5/25/2018 MYGN-US     BW   MYRIAD GENETICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Myriad Genetics, Inc. - MYGN",#N/A,#N/A, 1/28/2015 45766930 BW   Insmed to Participate at February Investment Conferences, 6/26/2019 05156V10 BW   Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting,11/15/2010 45773H20 BW   Inovio Pharmaceuticals Reports Third Quarter 2010 Financial Results,11/09/2018 NKTR-US  BW   Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action,#N/A, 3/20/2014 37416310     BW   INVESTOR ALERT: Class Action Lawsuit Against Geron Corporation Announced by Law Offices of Howard G. Smith, 9/03/2019 AERI-US    BW   Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024,"11/06/2013 02311120 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000 in Losses from Investment in Amarin Corporation plc to Contact Brower Piven Before the January 3, 2014 Lead Plaintiff Deadline"," 9/27/2019 INCY-US  BW   ACHTUNG - KORREKTUR : Volltext der Pressemitteilung folgt: Incyte meldet positive aktualisierte Ergebnisse der Phase-2-Studie zu Pemigatinib bei Patienten mit bereits behandeltem, fortgeschrittenem Cholangiokarzinom", 7/27/2017 UTHR-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of United Therapeutics Corporation Investors, 2/28/2017 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"12/11/2017 ALKS-US  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 3/05/2019 CERS-US  BW   Cerus Corporation Announces Appointment of Jami Nachtsheim to Board of Directors,12/10/2012 AMAG-US  BW   AMAG Pharmaceuticals Announces New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program Presented at ASH," 8/01/2019 04269E10 BW   ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019",#N/A, 8/30/2019 80067710 BW   Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences, 5/29/2019 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in June 2019, 7/18/2018 0FB9CW-E  BW   Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers, 9/30/2019 VRTX-US   BW   Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics,#N/A,#N/A, 8/01/2019 BLUE-US  BW   bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress, 9/09/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis,#N/A,#N/A,#N/A, 6/10/2019 TXMD-US  BW   TherapeuticsMD to Host Investor and Analyst Day Today, 1/09/2014 MNK-US   BW   Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement,#N/A, 9/16/2019 OMER-US  BW   Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction, 9/04/2019 RVNC-US  BW   Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference, 5/06/2014 OGEN-US  BW   Oragenics Advances Towards Identification of Lead Antibiotic Clinical Candidate, 5/09/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019,#N/A,#N/A,#N/A,12/15/2014 63009R10    BW   NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium,11/08/2011 07BKYW-E BW   Oceana Therapeutics Announces Definitive Agreement to be Acquired by Salix Pharmaceuticals," 4/24/2019 SYRS-US  BW   Syros to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019",#N/A,#N/A," 9/11/2012 0C7VFP-E     BW   Cold Genesys, Inc. Announces Agreement with FDA on Special Protocol Assessment of a Phase 2/3 Pivotal Trial of CG0070 as an Intravesical Treatment for Non-Muscle Invasive Bladder Cancer"," 4/22/2019 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019"," 9/13/2019 ALNY-US   BW   Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy",11/10/2016 WVE-US   BW   WAVE Life Sciences Appoints Christian Henry to its Board of Directors,#N/A,#N/A, 3/26/2015 69512710 BW   Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery, 3/04/2015 76129910 BW   Tim Coughlin Joins Retrophin’s Board of Directors,"12/28/2011 PRMW-US  BW   Rigrodsky & Long, P.A. Files Securities Fraud Class Action Lawsuit Against Pacific Biosciences of California, Inc.", 9/22/2014 06S6MV-E BW   FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014,#N/A,#N/A,#N/A, 7/25/2019 AKBA-US  BW   Akebia Therapeutics to Report Second Quarter 2019 Financial Results,#N/A,#N/A,12/21/2012 0CXBJZ-E BW   Elan Announces Completion of Demerger of Prothena Corporation plc,#N/A, 8/05/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A," 8/12/2013 92165910 BW   UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 26, 2013 to Seek a Lead Plaintiff Position"," 8/07/2018 0CFGSR-E BW   Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder",#N/A, 2/02/2018 INVA-US     BW   Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT,#N/A, 7/08/2011 40637H10 BW   Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency,#N/A,10/14/2013 56400P70 BW   MannKind Resubmits New Drug Application to U.S. FDA for AFREZZA for the Treatment of Adults with Diabetes," 5/02/2019 URGN-US  BW   UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019",#N/A," 5/08/2018 ESPR-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc."," 7/12/2017 AMRS-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Amyris, Inc. (AMRS) on Behalf of Shareholders"," 2/23/2016 PTCT-US  BW   SHAREHOLDER ALERT: Scott + Scott, LLP Investigating PTC Therapeutics (PTCT) for Possible Securities Fraud",#N/A," 2/22/2018 SYNH-US BW   SYNH INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Syneos Health, Inc. Investors",#N/A," 7/29/2019 EGRX-US  BW   Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019", 8/14/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock,"10/17/2013 ADMA-US  BW   ADMA Biologics, Inc. Announces Pricing of Initial Public Offering", 1/14/2014 36197T10 BW   Accord entre Ipsen et GW Pharmaceuticals plc pour la promotion et la distribution de Sativex® en Amérique Latine, 5/29/2019 EPZM-US  BW   Epizyme to Present at Jefferies 2019 Healthcare Conference, 5/10/2012 ATRS-US  BW   Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch Health Care Conference,#N/A,#N/A, 1/20/2016 GILD-US     BW   Galapagos und Gilead vollziehen Abschluss ihrer globalen Kooperation bei Filgotinib,#N/A, 6/17/2019 VCYT-US  BW   Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment, 8/08/2019 DRNA-US  BW   Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update,10/31/2019 15117K10 BW   Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du troisième trimestre 2019 et des neuf premiers mois de l’année 2019 le Jeudi 7 Novembre à 14h00 CET,#N/A,#N/A,#N/A,"12/05/2016 AGIO-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm"," 5/16/2017 IOVA-US  BW   Cohen Milstein Sellers & Toll PLLC Announces Investigation of Lion Biotechnologies, Inc.",#N/A, 6/26/2019 XLRN-US  BW   Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension,#N/A,10/17/2019 HZNP-US  BW   FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year," 8/22/2019 14843C10  BW   Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019","10/16/2017 0BGL4K-E BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc. -- ICPT", 1/06/2011 0844XQ-E BW   Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation Treatments, 4/04/2019 GLYC-US  BW   GlycoMimetics to Present at Upcoming Investor Conferences, 5/06/2019 98401F10 BW   Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors," 5/15/2017 ITCI-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 6/26/2019 G6674U10 BW   German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 9/10/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine, 6/11/2019 DERM-US  BW   Dermira to Present at the Raymond James Life Sciences and MedTech Conference,#N/A,#N/A,#N/A,12/20/2013 05SVDW-E   BW   FibroGen Announces Patient Enrollment in New Phase 2 Clinical Study of FG-3019 for the Treatment of Idiopathic Pulmonary Fibrosis," 9/04/2019 74587V10 BW   Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer",#N/A,#N/A, 5/11/2015 0D7WM8-E BW   Audentes Therapeutics Announces New Data to be Presented at American Society of Cell and Gene Therapy Annual Meeting,#N/A,#N/A," 3/04/2019 MCRB-US  BW   Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019", 7/11/2019 AIMT-US  BW   Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2019 RARX-US  BW   Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress,#N/A, 6/22/2017 HCM-GB   BW   Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China,#N/A,#N/A," 3/17/2016 0DP3CK-E BW   CRISPR Therapeutics meldet Aufnahme von Dr. med. Pablo J. Cagnoni in das Board of Directors und ernennt Dr. med. Tony Coles zum Chairman of the Board, um Arzneimittelentwicklung und Vermarktungskompetenz zu verbessern",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2011 MDSO-US     BW   OptiNose Standardizes on Medidata Rave Clinical Technology,#N/A,#N/A," 6/27/2019 QTRX-US  BW   Quanterix anuncia acuerdo para la adquisición de UmanDiagnostics, proveedor líder mundial de anticuerpos de neurofilamentos ligeros (Nf-L)"," 4/12/2018 SLDB-US  BW   SLDB INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018",#N/A,#N/A, 1/30/2015 30233G10 BW   pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information,#N/A,#N/A,10/15/2019 AXNX-US  BW   Axonics® Provides Update on U.S. Launch Activities, 4/01/2019 TCDA-US  BW   Tricida Announces Proposed Public Offering of Common Stock,#N/A," 5/13/2019 AVRO-US  BW   AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update", 4/29/2019 MGTA-US  BW   Magenta Therapeutics Launches Proposed Public Offering,#N/A,#N/A,#N/A, 2/01/2016 00DL17-E BW   RaNA Therapeutics to Present at BIO CEO & Investor Conference and Leerink Partners Global Healthcare Conference, 9/04/2019 MRNA-US BW   Moderna Appoints Tracey Franklin as Chief Human Resources Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2019 TWST-US  BW   Twist Bioscience to Present at Two Investor Conferences in September,#N/A, 2/12/2019 GOSS-US  BW   Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A, 3/12/2014 0084LG-E  BW   Precision BioSciences and Agrivida Announce Collaborative Trait Development Agreement and Successful Genetic Modification,#N/A,#N/A,#N/A, 3/03/2017 00DHGL-E BW   Atreca to Present at the Cowen & Company 37th Annual Health Care Conference,"11/06/2019 PSNL-US  BW   Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting", 3/19/2019 0GRDFC-E BW   Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer,#N/A,"10/05/2018 0DMSKV-E BW   L’FDA concede la designazione de novo al test clonoSEQ di Adaptive Biotechnologies, utile per rilevare a controllare la malattia minima residua (MMR) su pazienti con mieloma multiplo e leucemia linfoblastica acuta",#N/A,#N/A
 5/17/2019 LGND-US   BW   Ligand Licenses VER250840 to Cumulus Oncology, 6/12/2014 PGNX-US     BW   FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC, 7/29/2019 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019, 5/09/2019 0GHV9Q-E  BW   Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets, 9/08/2017 ENDP-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endo International plc – ENDP, 9/20/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4), 5/27/2010 09060J10 BW   BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in South Korea,#N/A, 9/26/2011 09W3PW-E BW   Impact of CATT Study Findings Evident in Significant Reported Changes in Prescribing of Genentech’s Avastin and Lucentis for the Treatment of Wet AMD According to a BioTrends Report, 4/23/2014 0CFKXC-E BW   BioSurplus To Auction Lab Equipment from SIGA Technologies, 8/14/2017 OPK-US   BW   Xenetic Biosciences Announces Appointment of Three Directors to the Board, 1/14/2013 46222210    BW,#N/A, 8/28/2019 ALXN-US  BW   Alexion to Present at the 14th Annual Citi Biotech Conference,#N/A,11/04/2019 SGEN-US     BW   Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference, 2/10/2017 IMMU-US     BW   venBio Comments on Immunomedics Partnership Announcement," 3/15/2018 09062X10    BW   Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting", 2/27/2019 IMGN-US  BW   ImmunoGen Announces Multiple Presentations at AACR Annual Meeting, 8/05/2013 09058V10 BW   BioCryst Announces Full Exercise of over Allotment Option,11/06/2019 GILD-US      BW   Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials,#N/A,11/02/2016 MYL-US   BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Mylan N.V. Investors and Encourages Investors to Contact the Firm, 4/14/2015 CGEN-IL  BW   Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health, 4/22/2018 AKRX-US   BW   Akorn Issues Statement, 5/02/2017 AMGN-US      BW   Harvard Pilgrim Signs Second Groundbreaking Contract with Amgen For Repatha," 5/23/2018 MYGN-US     BW   DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Myriad Genetics, Inc. to Contact the Firm",#N/A,#N/A, 1/13/2015 45766930 BW   Insmed Incorporated Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 6/21/2019 AUP-CA   BW   ILJIN Chairman Issues Open Letter to Aurinia Shareholders,11/12/2010 45773H20 BW   Inovio Pharmaceuticals HIV Study Update to be Presented at HVTN Conference,"11/08/2018 NKTR-US  BW   Kessler Topaz Meltzer & Check, LLP – Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics",#N/A," 3/18/2014 37416310     BW   Goldman Scarlato Karon & Penny, P.C. Announces Investigation of Geron Corporation", 9/03/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference,"10/16/2013 02311120 BW   AMARIN CORPORATION SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Claims on Behalf of Shareholders of Amarin Corporation in Connection with FDA Release", 9/25/2019 INCY-US  BW   Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo, 1/06/2017 05KYJB-E BW   Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th Annual J.P. Morgan Healthcare Conference, 2/28/2017 SRPT-US  BW   Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments,"12/11/2017 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018", 2/26/2019 CERS-US  BW   Cerus Corporation Announces Record Fourth Quarter and Full Year 2018 Results,"11/07/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference"," 7/24/2019 04269E10 BW   ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019",#N/A, 8/07/2019 80067710 BW   Sangamo Therapeutics Reports Second Quarter 2019 Financial Results, 5/16/2019 0062Q1-E BW   Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program," 6/26/2018 0FYFQF-E  BW   Sensile Medical bildet strategische Allianz mit Sanofi und Verily, für die Entwicklung und Vermarktung einer konnektiven Insulin Patch Pumpe", 9/12/2019 VRTX-US   BW   Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor),#N/A,#N/A, 6/14/2019 BLUE-US  BW   bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress," 9/04/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019",#N/A,#N/A,#N/A, 6/07/2019 TXMD-US  BW   TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States,10/01/2012 GRST-CA  BW   GreeneStone Muskoka Once Again Featured on Intervention Canada,#N/A, 9/11/2019 OMER-US  BW   FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA, 8/28/2019 RVNC-US  BW   Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference," 3/05/2014 XON-US   BW   Dr. James J. Collins, a Pioneer in Synthetic Biology, Joins the Scientific Advisory Board of Agilis Biotherapeutics", 5/07/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference,#N/A,#N/A,#N/A,12/08/2014 63009R10    BW   NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis, 9/19/2011 072LKP-E BW," 4/17/2019 SYRS-US  BW   Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019",#N/A,#N/A, 9/04/2012 ANIP-US      BW   BioSante Pharmaceuticals Announces Positive LibiGel® Phase III Safety Data Review and Decision to Conclude the Safety Study, 4/11/2019 ENTA-US    BW   Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019," 9/11/2019 ALNY-US   BW   1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day",11/09/2016 WVE-US   BW   WAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update,#N/A,#N/A, 3/23/2015 69512710 BW   New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures, 2/19/2015 76129910 BW   Retrophin to Report Fourth Quarter and Full Year 2014 Financial Results,"12/02/2011 69404D10 BW   Faruqi & Faruqi, LLP Announces Investigation of Pacific Biosciences of California, Inc.", 2/07/2014 0DFYQH-E BW   Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science,#N/A,#N/A,#N/A," 7/23/2019 AKBA-US  BW   Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC",#N/A,#N/A,12/19/2012 0CXBJZ-E BW   Elan Announces Availability of Information Statement in Respect of Prothena Corporation plc,#N/A, 7/24/2019 SAGE-US     BW   Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”,#N/A,#N/A," 7/03/2013 92165910 BW   Law Offices of Todd M. Garber Announces Investigation of Vanda Pharmaceuticals, Inc."," 8/07/2018 0CFGSR-E BW   Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder",#N/A, 1/26/2018 GSK-GB      BW   GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma,#N/A, 3/17/2011 005YZ9-E BW   KaloBios Announces Two Significant Additions to Its Management Team,#N/A, 9/03/2013 56400P70 BW   MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference, 4/23/2019 URGN-US  BW   UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen,#N/A," 5/08/2018 ESPR-US     BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm"," 6/14/2017 AMRS-US  BW   IMMINENT LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Amyris, Inc. To Contact The Firm"," 2/23/2016 PTCT-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of PTC Therapeutics, Inc.",#N/A, 1/30/2018 SYNH-US BW   Axiom Launches Contracts Intelligence Platform to Drive Radical Transparency in Corporate Transactions,#N/A," 5/28/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference", 8/13/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock, 8/12/2013 ADMA-US  BW   ADMA Biologics Reports Second Quarter 2013 Financial and Operational Results, 1/14/2014 36197T10 BW   Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex® in Latin America, 5/16/2019 EPZM-US  BW   Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings,#N/A,#N/A,#N/A, 1/20/2016 GILD-US     BW   Galapagos en Gilead hebben de overeenkomst voor hun mondiale samenwerking voor filgotinib afgerond,#N/A, 6/10/2019 VCYT-US  BW   Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis, 8/02/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),10/29/2019 15117K10 BW   First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma,#N/A,#N/A,#N/A,10/12/2016 AGIO-US  BW   Celgene et Agios annoncent des collaborations avec Abbott pour l’identification diagnostique des mutations IDH dans la LMA," 5/11/2017 IOVA-US  BW   Robbins Arroyo LLP: Lion Biotechnologies, Inc. (LBIO) Misled Shareholders According to a Recently Filed Class Action",#N/A, 6/10/2019 XLRN-US  BW   Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis,#N/A,10/17/2019 HZNP-US  BW   Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant, 7/29/2019 14843C10  BW   Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,"10/12/2017 ICPT-US  BW   SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline",#N/A, 3/07/2019 GLYC-US  BW   GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019," 5/02/2019 98401F10 BW   Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019"," 5/15/2017 ITCI-US  BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intra-Cellular Therapies, Inc. Investors and Encourages Investors to Contact the Firm",#N/A, 5/24/2019 G6674U10 BW   Novocure to Participate in the Jefferies 2019 Global Healthcare Conference,#N/A,#N/A,#N/A, 9/05/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I, 5/07/2019 DERM-US  BW   Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,11/27/2013 05SVDW-E   BW   FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019 as Treatment for Idiopathic Pulmonary Fibrosis, 9/03/2019 74587V10 BW   Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference,#N/A,#N/A," 4/21/2015 0D7WM8-E BW   Audentes Therapeutics Appoints Stephen Squinto, Ph.D. to its Board of Directors",#N/A,#N/A, 2/07/2019 MCRB-US  BW   Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets, 6/28/2019 AIMT-US  BW   Aimmune dépose une demande d'autorisation de mise sur le marché auprès de l'Agence européenne des médicaments pour l'AR101 contre l'allergie aux arachides,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2019 RARX-US  BW   Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study,#N/A, 6/12/2017 HCM-GB   BW   Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer,#N/A,#N/A," 3/17/2016 0DP3CK-E BW   CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2011 00CN92-E    BW   OptiNose Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application,#N/A,#N/A," 6/27/2019 QTRX-US  BW   Quanterix meldet Vereinbarung zur Übernahme von UmanDiagnostics, dem weltweit führenden Anbieter von Neurofilament-Leichtkette (Nf-L)-Antikörpern"," 4/09/2018 SLDB-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Solid Biosciences Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018",#N/A,#N/A, 1/26/2015 30233G10 BW   pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries,#N/A,#N/A,10/08/2019 AXNX-US  BW   Axonics® erweitert die geschäftliche Präsenz in der EU mit einer Kostenerstattungsempfehlung in Frankreich und einem Liefervertrag in Norwegen, 3/28/2019 TCDA-US  BW   Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis,#N/A," 4/29/2019 AVRO-US  BW   AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease", 4/29/2019 MGTA-US  BW   Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy,#N/A,#N/A,#N/A, 7/23/2015 00DL17-E BW   RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing," 8/29/2019 MRNA-US BW   Moderna to Host R&D Day on September 12, 2019",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2019 TWST-US  BW   Twist Bioscience Reports Third Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress,#N/A, 2/07/2019 GOSS-US  BW   Gossamer Bio Announces Pricing of Initial Public Offering,#N/A, 1/30/2014 ALCLS-FR  BW   Precision BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology,#N/A,#N/A,#N/A," 2/22/2017 00DHGL-E BW   Atreca, Inc. Presents New Preclinical Findings for Novel Cancer Immunotherapy Platform at Molecular Medicine Tri-Conference 2017","10/30/2019 PSNL-US  BW   Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019", 3/07/2019 0GRDFC-E BW   Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference,#N/A, 9/28/2018 0DMSKV-E BW   CORRECTING and REPLACING VIDEO FDA Grants De Novo Designation for Adaptive Biotechnologies’ clonoSEQ Assay to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia,#N/A,#N/A
" 5/06/2019 LGND-US   BW   Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.", 4/22/2014 74318710    BW   Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of RELISTOR in Chronic Non-Cancer Pain by the European Medicines Agency," 7/16/2019 45232710    BW   Illumina Expands Genomics Accelerator to Cambridge, UK", 5/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call, 9/05/2017 ENDP-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc, 9/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3, 5/26/2010 09060J10 BW   BioDelivery Sciences to Host Analyst & Investor Day June 3rd in New York City,#N/A, 9/23/2011 07GVF3-E BW   Research and Markets: Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018,11/08/2011 09ZX1M-E BW, 5/01/2017 OPK-US   BW   Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston, 1/07/2013 46222210    BW,#N/A, 8/27/2019 ALXN-US  BW   European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD),#N/A,10/29/2019 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2019 Financial Results, 2/07/2017 IMMU-US     BW   Glass Lewis Endorses Full Slate of venBio Nominees at Immunomedics," 3/12/2018 BIIB-US     BW   New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)", 2/08/2019 IMGN-US  BW   ImmunoGen Reports Recent Progress and 2018 Operating Results, 8/01/2013 09058V10 BW   BioCryst to Announce Second Quarter 2013 Financial Results August 8,11/06/2019 GILD-US      BW   Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®,#N/A,"10/24/2016 MYL-US   BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Mylan N.V. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 4/06/2015 M2572210 BW   Compugen to Present at Two Immuno-Oncology Conferences in April," 4/21/2018 AKRX-US   BW   AKRX INVESTOR ALERT: Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action – AKRX", 5/01/2017 UNH-US       BW   UnitedHealthcare Pro Cycling Team to Bring Awareness to UnitedHealthcare Children's Foundation," 5/22/2018 0DBJVZ-E    BW   INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Myriad Genetics, Inc.",#N/A,#N/A, 1/06/2015 45766930 BW   Insmed to Present at the 33rd Annual J.P. Morgan Healthcare Conference, 6/21/2019 05156V10 BW   Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline,"11/01/2010 45773H20 BW   Inovio Pharmaceuticals Receives $733,438 Grant Under the Patient Protection and Affordable Care Program",10/30/2018 NKTR-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR,#N/A, 3/14/2014 37416310     BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Files Class Action Lawsuit Against Geron Corporation," 8/26/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs","10/14/2013 02311120 BW   AMARIN CORPORATION SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Claims on Behalf of Shareholders of Amarin Corporation", 9/23/2019 INCY-US  BW   Incyte to Host Investor Conference Call from ESMO 2019,11/16/2015 UTHR-US  BW   Shreveport Treatment Center Studies Impact of UV Light on Flu Virus, 2/21/2017 SRPT-US  BW   Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M,12/06/2017 ALKS-US  BW   Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action, 2/22/2019 CERS-US  BW   Cerus to Participate In Upcoming Investor Conferences,"11/06/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the American Society of Hematology Annual Meeting are Now Available", 6/27/2019 04269E10 BW   ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares,#N/A, 8/06/2019 80067710 BW   Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences," 5/14/2019 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019", 6/26/2018 0FYFQF-E  BW   Sensile Medical formed a strategic alliance with Sanofi and Verily to develop and commercialize a connected insulin patch pump, 9/10/2019 VRTX-US   BW   Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11,#N/A,#N/A, 6/14/2019 BLUE-US  BW   bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress, 7/31/2019 ACAD-US  BW   ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results,#N/A,#N/A,#N/A," 5/29/2019 TXMD-US  BW   TherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City", 8/09/2012 ARDMQ-US BW   Aradigm Announces Second Quarter 2012 Financial Results,#N/A, 9/10/2019 OMER-US  BW   Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174," 8/05/2019 RVNC-US  BW   Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update", 2/10/2014 46122T10 BW   Corporate Leaders Receive Fourteenth Annual Emerald Asset Management “E-3 Awards”, 5/02/2019 IRWD-US  BW   Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance,#N/A,#N/A,#N/A,12/01/2014 63009R10    BW   NanoString Technologies Announces Prosigna Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium,10/28/2010 PDLI-US  BW   Oceana Therapeutics Announces Andrew J. Einhorn Named 2010 NJBIZ CFO of the Year for Company Growth, 4/09/2019 SYRS-US  BW   Syros Announces Closing of Concurrent Public Offerings,#N/A,#N/A," 8/30/2012 ANIP-US      BW   BioSante Pharmaceuticals, Inc. to Present at Stifel Nicolaus Healthcare Conference and Rodman & Renshaw Global Investment Conference", 3/27/2019 ENTA-US    BW   Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019, 9/10/2019 ALNY-US   BW   Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias,11/07/2016 05F9ZW-E BW   WAVE Life Sciences to Present at the Jefferies 2016 London Healthcare Conference,#N/A,#N/A," 3/04/2015 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference", 2/05/2015 76129910 BW   Retrophin to Present at the 2015 Leerink Global Healthcare Conference,"12/02/2011 69404D10 BW   Rigrodsky & Long, P.A. Announces Its Investigation of Possible Violations of the Federal Securities Laws by Pacific Biosciences of California, Inc.", 1/27/2014 0DFYQH-E BW   Editas Medicine Co-Founder Develops Novel Approach to Increase Specificity of CRISPR/Cas9 Technology; Findings Published in Nature Biotechnology,#N/A,#N/A,#N/A," 7/11/2019 AKBA-US  BW   Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners",#N/A,#N/A,#N/A,#N/A," 7/11/2019 SAGE-US     BW   Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019",#N/A,#N/A," 7/03/2013 0CJTKW-E BW   Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vanda Pharmaceuticals Inc."," 7/30/2018 MEDP-US  BW   Medpace Holdings, Inc. Reports Second Quarter 2018 Results",#N/A,12/19/2017 INVA-US     BW   Innoviva and Sarissa Implement Court Order,#N/A,10/06/2010 40637H10 BW   Baxter Presents Data from Interim Analyses of Phase III Clinical Trial of HyQ at European Society for Immunodeficiencies Meeting,#N/A, 8/16/2013 0BM5D2-E BW   MannKind Satisfies Conditions for Second Tranche of Convertible Note Financing, 4/05/2019 URGN-US  BW   UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer,#N/A," 5/08/2018 008G5M-E    BW   EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. – ESPR"," 6/14/2017 AMRS-US  BW   Law Offices of Howard G. Smith Reminds Amyris, Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff Deadline", 4/30/2015 008SHY-E BW   Biotech Leader Provides Testimony on Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens,#N/A," 1/25/2018 SYNH-US BW   Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Syneos Health (SYNH) (Formerly INC Research Holdings, Inc.) and Encourages Investors to Contact the Firm Before January 30th",#N/A," 5/15/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference", 8/13/2019 DCPH-US BW   Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors, 6/18/2013 ADMA-US  BW   ADMA Biologic’s Plasma Collection Facility Receives GHA Certification for the Sale of Source Plasma in Europe, 9/19/2011 CBIS-US  BW   Cannabis Science Announces the Appointment Of Robert Kane Formerly Of Stifel Nicolaus for Investor Relations Management, 5/06/2019 EPZM-US  BW   Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results,#N/A,#N/A,#N/A, 1/20/2016 GILD-US     BW   Galapagos et Gilead finalisent leur collaboration mondiale portant sur le filgotinib,#N/A, 6/01/2019 VCYT-US  BW   Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis," 8/01/2019 DRNA-US  BW   Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019",10/29/2019 15117K10 BW   Le produit candidat sur étagère UCARTCS1 a été administré à un premier patient pour traiter le myélome multiple en rechute ou réfractaire,#N/A,#N/A,#N/A,10/12/2016 CELG-US  BW   Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML," 5/09/2017 IOVA-US  BW   Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Lion Biotechnologies, Inc. (LBIO) Securities Case",#N/A, 6/04/2019 CELG-US  BW   Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia,#N/A,10/11/2019 HZNP-US  BW   New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease, 7/24/2019 14843C10  BW   Castle Biosciences Announces Pricing of Initial Public Offering,"10/12/2017 ICPT-US  BW   Glancy Prongay & Murray LLP Continues Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)",#N/A, 3/06/2019 GLYC-US  BW   GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results, 4/30/2019 98401F10 BW   Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045," 5/15/2017 ITCI-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc.",#N/A, 5/23/2019 G6674U10 BW   FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma,#N/A,#N/A,#N/A, 9/04/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting," 4/30/2019 DERM-US  BW   Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019",#N/A,#N/A,#N/A,11/12/2013 05SVDW-E   BW   FibroGen Announces Analysis of Peritoneal Dialysis Patients With Chronic Kidney Disease From Roxadustat (FG-4592) Incident Dialysis Study, 9/03/2019 74587V10 BW   FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases,#N/A,#N/A, 2/26/2015 0D7WM8-E BW   Audentes Therapeutics Joins Global Organizations in Celebrating Rare Disease Day® 2015,#N/A,#N/A, 1/15/2019 MCRB-US  BW   Seres Therapeutics Announces Chief Executive Officer Transition, 6/28/2019 AIMT-US  BW   Aimmune reicht bei der Europäischen Arzneimittelagentur Antrag auf Marktzulassung für AR101 zur Behandlung der Erdnussallergie ein,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/01/2019 RARX-US  BW   Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting",#N/A, 6/05/2017 HCM-GB   BW   Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO,#N/A,#N/A, 3/10/2016 0DP3CK-E BW   CRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/03/2010 00CN92-E    BW   OptiNose Receives Nearly $489,000 Grant Award under U.S. Government Qualifying Therapeutic Discovery Project Program",#N/A,#N/A," 6/26/2019 QTRX-US  BW   Quanterix kondigt overeenkomst aan voor overname van UmanDiagnostics, 's werelds vooraanstaande leverancier van neurofilament light (Nf-L)-antilichamen", 4/03/2018 SLDB-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Solid Biosciences Inc.,#N/A,#N/A, 1/14/2015 30233G10 BW   pSivida Reports Commencement of ILUVIEN® Sales in Portugal,#N/A,#N/A,10/07/2019 AXNX-US  BW   Axonics® élargit sa présence commerciale dans l’U.E. avec une recommandation de remboursement en France et un contrat d’approvisionnement en Norvège, 3/28/2019 TCDA-US  BW   Tricida Announces $200 Million Debt Facility With Hercules Capital,#N/A, 4/26/2019 AVRO-US  BW   AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy," 4/24/2019 MGTA-US  BW   Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate",#N/A,#N/A,#N/A," 2/26/2015 00DL17-E BW   RaNA Therapeutics to Present at Cowen and Company 35th Annual Healthcare Conference on Monday, March 2nd", 8/27/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2019 TWST-US  BW   Twist Bioscience Launches Long Oligos to Fuel Drug Development, DNA Data Storage and Gene Editing Research",#N/A, 1/30/2019 0HVBMD-E BW   Gossamer Bio Announces Updates Regarding its Initial Public Offering,#N/A,10/31/2013 DD.XX1-US BW   Precision BioSciences and DuPont Pioneer Announce Publication of Plant Genome Engineering Success,#N/A,#N/A,#N/A," 1/09/2017 00DHGL-E BW   Atreca, Inc. to Present Cancer Immunotherapy Platform and Data at the PepTalk 2017 Conference","10/24/2019 PSNL-US  BW   Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019", 1/03/2019 0GRDFC-E BW   Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference,#N/A, 9/28/2018 0DMSKV-E BW   A New Study Published in the Journal Blood Demonstrates that Measuring Minimal Residual Disease Negativity Using Adaptive Biotechnologies’ Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma,#N/A,#N/A
 5/02/2019 LGND-US   BW   Ligand Reports First Quarter 2019 Financial Results,10/01/2013 74318710    BW   Salix and Progenics Announce FDA Advisory Committee Scheduled to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain, 7/11/2019 45232710    BW   Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019, 4/02/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9, 8/31/2017 ENDP-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc, 8/30/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences, 5/10/2010 09060J10 BW   BioDelivery Sciences and Meda Announce the Approval of ONSOLIS in Canada,#N/A, 1/25/2011 SGEN-US  BW   Maven Semantic: Age-Related Macular Degeneration Research Database, 2/03/2011 SIGA-US  BW,11/07/2016 OPK-US   BW   Xenetic Biosciences Announces the Closing of its $10M Public Offering, 1/04/2013 09Y0ZH-E    BW,#N/A, 7/26/2019 ALXN-US  BW   Alexion Receives Positive CHMP Opinion for SOLIRIS® (eculizumab) for the Treatment of NMOSD,#N/A,10/21/2019 SGEN-US     BW   Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer, 2/06/2017 0BWYJ5-E    BW   ISS Endorses Full Slate of venBio Nominees at Immunomedics, 3/12/2018 BIIB-US     BW   Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia, 1/24/2019 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results, 7/31/2013 09058V10 BW   BioCryst Pharmaceuticals Prices Public Offering of Common Stock,10/31/2019 GILD-US      BW   Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting,#N/A,10/19/2016 MYL-US   BW   MYL NOTICE: Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline in Class Action Filed by Firm - MYL, 3/19/2015 M2572210 BW   Compugen Announces Planned Relocation of Headquarters to Larger Facilities," 4/12/2018 AKRX-US   BW   DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Akorn, Inc. to Contact the Firm", 4/06/2017 AZN-GB       BW   e-Therapeutics plc: Appointment of Chief Executive Officer," 5/17/2018 MYGN-US     BW   Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors",#N/A,#N/A,12/15/2014 45766930 BW   Insmed Appoints Myrtle Potter to its Board of Directors, 6/20/2019 AUP-CA   BW   As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential,10/28/2010 45773H20 BW   Inovio Pharmaceuticals to Present at Investor Conferences In New York and Miami," 2/14/2018 BMY-US   BW   Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214",#N/A," 3/13/2014 37416310     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of GERON CORPORATION for Possible Breaches of Fiduciary Duty", 8/20/2019 AERI-US    BW   Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema,12/21/2012 IJF-IE   BW   Mr. Thomas Lynch Elected as Chairman of ICON plc, 9/03/2019 INCY-US  BW   Les données du portefeuille d'oncologie d'Incyte seront présentées au congrès de l'ESMO de 2019," 6/19/2014 91307C10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty"," 2/15/2017 SRPT-US  BW   Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017",12/05/2017 ALKS-US  BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plc," 2/13/2019 CERS-US  BW   Cerus to Release Fourth Quarter and Full Year 2018 Results on February 26, 2019",11/05/2012 AMAG-US  BW   Rienso® (Ferumoxytol) Launched in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease, 6/25/2019 04269E10 BW   ArQule Announces Pricing of $90 Million Public Offering of Common Stock,#N/A, 7/31/2019 80067710 BW   Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel, 5/13/2019 EXEL-US  BW   Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan, 6/18/2018 SAN-FR    BW   Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel, 9/03/2019 VRTX-US   BW   Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes,#N/A,#N/A, 6/06/2019 BLUE-US  BW   bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval, 7/22/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia,#N/A,#N/A,#N/A, 5/08/2019 TXMD-US  BW   TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference, 6/07/2012 06VJRT-E BW   Mallinckrodt and Zogenix Announce Exclusive Co-Promotion Arrangement on SUMAVEL® DosePro®,#N/A, 9/06/2019 OMER-US  BW   Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference," 7/29/2019 RVNC-US  BW   Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019"," 2/04/2014 46122T10 BW   Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th", 4/18/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call,#N/A,#N/A,#N/A,10/21/2014 63009R10    BW   NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer,#N/A, 4/05/2019 SYRS-US  BW   Syros Announces Pricing of $70 Million Concurrent Public Offerings,#N/A,#N/A," 8/20/2012 ANIP-US      BW   BioSante Pharmaceuticals Closes $3,475,000 Registered Direct Offering", 3/18/2019 ENTA-US    BW   Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies, 9/06/2019 ALNY-US   BW   Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series, 9/14/2016 05LK9B-E BW   WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable,#N/A,#N/A, 3/02/2015 69512710 BW   Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia, 2/03/2015 76129910 BW   Retrophin Announces Voting Results of Special Meeting of Stockholders,11/30/2011 05M967-E BW   Research and Markets: Strategic Analysis of the U.S. Next-Generation Sequencing Services. A Convergence of Favorable Market Dynamics,#N/A,#N/A,#N/A,#N/A, 7/10/2019 AKBA-US  BW   Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan,#N/A,#N/A,#N/A,#N/A, 7/03/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A, 7/03/2013 92165910 BW   Vanda Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors," 7/11/2018 MEDP-US  BW   Medpace Holdings, Inc. to Report Second Quarter 2018 Financial Results on July 30, 2018",#N/A,11/23/2017 INVA-US     BW   GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta,#N/A, 4/07/2010 40637H10 BW   New Survey Reveals That Parents Lack Information about Dehydration and Its Treatment,#N/A, 8/14/2013 56400P70 BW   CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes, 3/05/2019 URGN-US  BW   UroGen Pharma to Present at March 2019 Investor Conferences,#N/A," 3/11/2016 ESPR-US     BW   INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc."," 6/13/2017 AMRS-US  BW   June 19 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amyris, Inc."," 2/13/2013 077VL7-E BW   NORD, BioNJ and Patient Advocacy Groups to Collaborate on Rare Disease Day Event at New Jersey State House",#N/A," 1/22/2018 SYNH-US BW   INCR Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (formerly INC Research Holdings, Inc.) Investors",#N/A," 5/07/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results", 8/13/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors, 5/14/2013 ADMA-US  BW   ADMA Biologics Reports First Quarter 2013 Financial and Operational Results,#N/A, 3/12/2019 EPZM-US  BW   Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 1/20/2016 GILD-US     BW   Galapagos y Gilead cierran su acuerdo de colaboración mundial para filgotinib,#N/A, 5/29/2019 VCYT-US  BW   Veracyte Announces Participation in Two Upcoming Investor Conferences, 7/15/2019 DRNA-US  BW   Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1),10/07/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A," 6/12/2015 00847X10 BW   Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency"," 5/02/2017 IOVA-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Lion Biotechnologies, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A, 5/14/2019 XLRN-US  BW   Acceleron to Present at the UBS Global Healthcare Conference,#N/A,"10/10/2019 HZNP-US  BW   For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”", 7/11/2019 00BJ80-E  BW   Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients With Thin Cutaneous Melanoma Tumors,"10/10/2017 008G5M-E BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.",#N/A, 3/05/2019 GLYC-US  BW   GlycoMimetics Announces Transition Plan for Board of Directors, 4/02/2019 98401F10 BW   Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program," 5/12/2017 ITCI-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 5/14/2019 G6674U10 BW   Novocure mit 13 Präsentationen und einem Symposium zu Tumortherapiefeldern auf der 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie vertreten,#N/A,#N/A,#N/A, 8/28/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Conferences, 4/03/2019 DERM-US  BW   Dermira to Present at the 18th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,11/12/2013 05SVDW-E   BW   FibroGen Reports Data from Phase 2 Hemoglobin Correction Study of Roxadustat (FG-4592) in Chinese Patients with Chronic Kidney Disease, 8/08/2019 74587V10 BW   Puma Biotechnology Reports Second Quarter 2019 Financial Results,#N/A,#N/A,12/02/2014 0D7WM8-E BW   Audentes Therapeutics Raises $42.5 Million in Series B Financing,#N/A,#N/A,11/09/2018 MCRB-US  BW   Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference, 6/28/2019 AIMT-US  BW   Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2019 RARX-US  BW   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update,#N/A, 5/18/2017 HCM-GB   BW   Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting,#N/A,#N/A, 3/10/2016 0DP3CK-E BW   CRISPR Therapeutics verstärkt Führungsteam durch Ernennung von Marc Becker zum Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2010 00CN92-E    BW   Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose’s Novel Drug Delivery Technology,#N/A,#N/A," 6/26/2019 QTRX-US  BW   Quanterix annuncia un accordo per l'acquisizione di UmanDiagnostics, il principale fornitore a livello mondiale di anticorpi Neurofilament Light (Nf-L, Neurofilamento leggero)", 4/02/2018 SLDB-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Solid Biosciences Inc. (SLDB),#N/A,#N/A,12/01/2014 30233G10 BW   pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands,#N/A,#N/A,10/07/2019 AXNX-US  BW   Axonics® Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway, 3/28/2019 TCDA-US  BW   Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results,#N/A," 3/25/2019 AVRO-US  BW   AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update", 3/19/2019 MGTA-US  BW   Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights,#N/A,#N/A,#N/A, 2/05/2015 00DL17-E BW   RaNA Therapeutics to Present at the 2015 Leerink Global Healthcare Conference, 8/19/2019 MRNA-US BW   Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/25/2019 TWST-US  BW   Twist Bioscience Enhances DNA Storage Capabilities Through Agreement With Imagene SA,#N/A, 1/23/2019 0HVBMD-E BW   Gossamer Bio Announces Commencement of Initial Public Offering,#N/A, 8/19/2013 0084LG-E  BW   Precision BioSciences Announces Publication of Cotton Genome Engineering in Collaboration with Bayer CropScience,#N/A,#N/A,#N/A," 1/06/2017 06ZK37-E BW   Atreca, Inc. to Participate in Immuno-Oncology Panel at 9th Annual Biotech Showcase","10/08/2019 PSNL-US  BW   Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019","12/18/2018 0GRDFC-E BW   Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations",#N/A," 5/30/2018 0DMSKV-E BW   Adaptive Biotechnologies kündigt Zusammenarbeit mit Sanofi an, um den Assay clonoSEQ® von Adaptive zur Messung der minimalen Resterkrankung in laufenden und zukünftigen Studien zu Isatuximab gegen das multiple Myelom zu nutzen",#N/A,#N/A
 5/02/2019 LGND-US   BW   Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol, 6/11/2013 74318710    BW   Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain," 6/28/2019 GNOM.XX2-US BW   Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US", 3/15/2019 84763A10  BW   Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)," 8/18/2017 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017", 8/28/2019 005Y9C-E BW   Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection, 4/20/2010 09060J10 BW   BioDelivery Sciences to Raise $10 Million in Registered Direct Offering From Institutional Investors,#N/A, 1/19/2011 REGN-US  BW   Maven Semantic: Immunohistochemistry Research Database, 1/10/2011 SIGA-US  BW, 9/27/2016 OPK-US   BW   OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx, 1/03/2013 46222210    BW,#N/A, 7/24/2019 ALXN-US  BW   Alexion Reports Second Quarter 2019 Results,#N/A,"10/10/2019 SGEN-US     BW   Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer", 1/30/2017 0BWYJ5-E    BW   venBio Calls on Immunomedics Stockholders to Support Meaningful Change, 3/02/2018 09062X10    BW   Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis, 1/08/2019 IMGN-US  BW   ImmunoGen Announces Sale of Residual Kadcyla Royalties, 7/30/2013 09058V10 BW   BioCryst Announces Proposed Public Offering of Common Stock,10/28/2019 GILD-US      BW   Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development,#N/A,10/11/2016 MYL-US   BW   INVESTOR ALERT: Investigation of Mylan N.V. Announced by Law Offices of Howard G. Smith, 3/02/2015 M2572210 BW   Compugen to Present at Two Oncology Conferences in March," 4/11/2018 AKRX-US   BW   AKRX INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Akorn, Inc. Investors", 2/15/2017 AMGN-US      BW   Amgen’s Repatha CVOT Results Are Potential Game-Changer for Lipid-Lowering Treatment," 5/16/2018 0DGVHF-E    BW   Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Myriad Genetics, Inc. (MYGN) and June 19 Lead Plaintiff Deadline",#N/A,#N/A,12/15/2014 45766930 BW   Insmed Provides End of Year Regulatory and Clinical Update, 6/19/2019 05156V10 BW   Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees,10/25/2010 45773H20 BW   Inovio Pharmaceuticals Minimally-Invasive DNA Vaccine Delivery Device Featured in the Journal Gene Therapy,12/20/2017 NKTR-US  BW   Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance,#N/A," 3/12/2014 37416310     BW   GERON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Geron Corporation Following FDA Clinical Hold of Blood Medicine and Analyst Downgrade"," 8/07/2019 AERI-US    BW   Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update",#N/A, 9/03/2019 INCY-US  BW   Daten aus dem Onkologieportfolio von Incyte werden auf dem Kongress 2019 der ESMO vorgestellt,"10/08/2012 066807-E BW   Through 2021, the Launch of Emerging Agents Will Boost Major-Market Sales of Therapies to Pulmonary Arterial Hypertension to $3.5 Billion", 1/31/2017 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),12/04/2017 ALKS-US  BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Alkermes plc, 1/07/2019 CERS-US  BW   Cerus Announces Preliminary Fourth Quarter and Full Year 2018 Product Revenue,"11/01/2012 AMAG-US  BW   AMAG Pharmaceuticals Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2012", 6/24/2019 04269E10 BW   ArQule Announces Commencement of Proposed Public Offering of Common Stock,#N/A, 7/31/2019 80067710 BW   Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast, 5/01/2019 EXEL-US  BW   Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma," 6/13/2018 DTHR-US   BW   DTxDM - the Home of Validated Digital Healthcare, Announces Its Founding Partners at the Launch of the New Hub for Everyone Working in Digital Therapeutics and Digital Medicine"," 8/20/2019 VRTX-US   BW   FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment",#N/A,#N/A, 6/03/2019 BLUE-US  BW   bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype," 7/17/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019",#N/A,#N/A,#N/A, 5/06/2019 TXMD-US  BW   TherapeuticsMD Announces First Quarter 2019 Financial Results, 1/11/2011 ZGNX-US  BW   SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom,#N/A, 8/09/2019 OMER-US  BW   Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference, 7/17/2019 RVNC-US  BW   Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors, 1/30/2014 0BQS10-E BW   Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum, 4/16/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020,#N/A,#N/A,#N/A,10/06/2014 63009R10    BW   NanoString Collaborates with Brigham and Women’s Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology,#N/A, 4/04/2019 SYRS-US  BW   Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock,#N/A,#N/A," 8/17/2012 ANIP-US      BW   BioSante Pharmaceuticals to Raise $3,475,000 in Registered Direct Offering", 3/11/2019 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 9/03/2019 ALNY-US   BW   Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients, 8/17/2016 WVE-US   BW   WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer,#N/A,#N/A," 2/24/2015 69512710 BW   Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results", 1/12/2015 76129910 BW   Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion Pharmaceuticals,10/27/2011 079BHK-E BW   Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman,#N/A,#N/A,#N/A,#N/A, 7/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/27/2019 SAGE-US     BW   Sage Therapeutics to Host “Sage FutureCast” Webcast,#N/A,#N/A," 6/27/2013 92165910 BW   Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Vanda Pharmaceuticals, Inc."," 6/12/2018 068ZG6-E BW   Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder",#N/A,11/16/2017 GSK-GB      BW   Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD,#N/A, 1/19/2010 40637H10 BW   Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologics,#N/A, 8/14/2013 56400P70 BW   MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes, 2/28/2019 URGN-US  BW   UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results,#N/A," 2/26/2016 ESPR-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016"," 6/05/2017 AMRS-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Amyris, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017",11/07/2011 007HSM-E BW   Pyxis Mobile Strengthens Marketing Team to Capitalize on New Market Opportunities,#N/A, 1/11/2018 SYNH-US BW   HealthPrize Appoints Michael Griffith as Executive Chairman,#N/A, 5/07/2019 EGRX-US  BW   Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure," 8/02/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results", 3/07/2013 008FZT-E BW   ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients,#N/A, 3/06/2019 EPZM-US  BW   Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock,#N/A,#N/A,#N/A, 1/19/2016 GILD-US     BW   Galapagos e Gilead perfezionano il loro contratto di collaborazione globale per filgotinib,#N/A, 5/23/2019 VCYT-US  BW   Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting, 7/02/2019 DRNA-US  BW   Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease,10/07/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 6/12/2015 00BBFF-E BW   Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies," 5/01/2017 IOVA-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Lion Biotechnologies, Inc. Investors and Encourages Investors to Contact the Firm",#N/A, 5/09/2019 XLRN-US  BW   Acceleron Reports First Quarter 2019 Operating and Financial Results,#N/A,"10/09/2019 HZNP-US  BW   Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019", 6/06/2019 00BJ80-E  BW   Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma,"10/09/2017 0FKPTT-E BW   Robbins Arroyo LLP: Intercept Pharmaceuticals, Inc. (ICPT) Misled Shareholders According to a Recently Filed Class Action",#N/A," 2/27/2019 GLYC-US  BW   GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019", 4/01/2019 98401F10 BW   Xencor to Participate in Upcoming Investor Conferences," 5/12/2017 ITCI-US  BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. – ITCI",#N/A, 5/10/2019 G6674U10 BW   Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 8/22/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia, 8/19/2014 0C5GYQ-E BW   Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors,#N/A,#N/A,#N/A,"11/04/2013 05SVDW-E   BW   FibroGen to Present Data for Roxadustat (FG-4592), an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Oral Presentations at American Society of Nephrology - Kidney Week 2013", 8/06/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,11/20/2014 0D7WM8-E BW   Audentes Therapeutics to Present at the Piper Jaffray Healthcare Conference,#N/A,#N/A,11/08/2018 MCRB-US  BW   Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates, 6/12/2019 AIMT-US  BW   Aimmune to Present at the JMP Securities Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2019 RARX-US  BW   Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference,#N/A, 4/07/2017 HCM-GB   BW   Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017,#N/A,#N/A, 3/10/2016 0DP3CK-E BW   CRISPR Therapeutics renforce son équipe de leadership avec la nomination de Marc Becker au poste de directeur financier,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2010 00CN92-E    BW   New Data Show Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose’s Novel Delivery Technology,#N/A,#N/A," 6/26/2019 QTRX-US  BW   Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier"," 4/02/2018 0DBJVZ-E BW   Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed against Solid Biosciences, Inc.",#N/A,#N/A,11/26/2014 30233G10 BW   pSivida CEO to Present at LD Micro Investor Conference,#N/A,#N/A,10/03/2019 AXNX-US  BW   Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting," 3/27/2019 TCDA-US  BW   Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019",#N/A," 3/05/2019 AVRO-US  BW   AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference", 3/06/2019 MGTA-US  BW   Magenta Therapeutics to Present at Investor Conferences in March,#N/A,#N/A,#N/A,"12/01/2014 00DL17-E BW   RaNA Therapeutics Appoints Ronald C. Renaud, Jr., as Chief Executive Officer", 8/07/2019 MRNA-US BW   Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/25/2019 TWST-US  BW   Twist Bioscience to Report Fiscal 2019 Third Quarter Financial Results on Thursday, August 1, 2019",#N/A,12/19/2018 0HVBMD-E BW   Gossamer Bio Announces Appointment of New Independent Directors,#N/A, 6/05/2013 0084LG-E  BW   Precision BioSciences Files Patent Infringement Lawsuit against Lonza Related to GS XceedTM Gene Expression System,#N/A,#N/A,#N/A,12/13/2016 00DHGL-E BW   Atreca and A*STAR’s Genome Institute of Singapore Establish Joint Laboratory for Immuno-Oncology, 9/26/2019 PSNL-US  BW   Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M,12/01/2018 0GRDFC-E BW   Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy,#N/A, 5/29/2018 0DMSKV-E BW   Adaptive Biotechnologies annonce une collaboration avec Sanofi pour utiliser le test clonoSEQ® d'Adaptive afin d'évaluer la maladie résiduelle minimale dans le cadre d'essais en cours et futurs portant sur les myélomes multiples...,#N/A,#N/A
 4/18/2019 LGND-US   BW   Ligand to Report First Quarter 2019 Results on May 2nd," 5/10/2013 74318710    BW   Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors"," 6/17/2019 45232710    BW   Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc.", 3/13/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20, 7/12/2017 ENDP-US  BW   ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc, 8/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease, 3/22/2010 09060J10 BW   BioDelivery Sciences Announces Positive Pre-IND Meeting on BEMA Granisetron Development Program,#N/A, 1/18/2011 TLRK-US  BW   Maven Semantic: Signal Transduction Database,#N/A, 9/19/2016 OPK-US   BW   OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference, 1/03/2013 ALNY-US     BW,#N/A," 7/10/2019 ALXN-US  BW   Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019",#N/A,"10/08/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019", 1/26/2017 IMMU-US     BW   venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics, 2/28/2018 09062X10    BW   Biogen to Present at the Cowen and Company 38th Annual Health Care Conference, 1/02/2019 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference, 7/23/2013 09058V10 BW   Fred Cohen Appointed to BioCryst’s Board of Directors,10/24/2019 GILD-US      BW   Gilead Sciences Announces Fourth Quarter 2019 Dividend,#N/A,10/11/2016 MYL-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Mylan N.V. - MYL, 2/23/2015 M2572210 BW   Compugen Expands and Strengthens Business Development Team," 4/10/2018 AKRX-US   BW   The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018", 1/06/2017 0DMSKV-E     BW   Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Development of clonoSEQ® Assay in Acute Lymphoblastic Leukemia," 5/14/2018 MYGN-US     BW   Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Contact the Firm",#N/A,#N/A,11/26/2014 45766930 BW   Insmed to Participate at December Investment Conferences," 6/12/2019 AUP-CA   BW   ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts",10/22/2010 45773H20 BW   Inovio Pharmaceuticals to Present at Global Vaccine Forums,10/18/2016 NKTR-US  BW   Technologie von Aerogen reduziert Klinikeinlieferungen aus der Notaufnahme um 32 Prozent1,#N/A, 3/12/2014 37416310     BW   SHAREHOLDER ALERT: Investigation of Geron Corporation Announced by Law Offices of Howard G. Smith," 7/25/2019 AERI-US    BW   Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019",#N/A, 9/03/2019 INCY-US  BW   Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month,"12/13/2011 09CMZ9-E BW   BASF, GlaxoSmithKline, Merck and Novartis Among Companies to Schedule Partnering Sessions at CED Life Science Conference 2012", 1/10/2017 SRPT-US  BW   Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program,12/01/2017 ALKS-US  BW   ALKS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc, 1/04/2019 CERS-US  BW   William Moore Appointed as Cerus Corporation’s Senior Vice President of Manufacturing Operations and Supply Chain,"10/26/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on November 1, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2012"," 6/18/2019 04269E10 BW   ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019",#N/A, 7/29/2019 80067710 BW   Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases, 5/01/2019 EXEL-US  BW   Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update, 6/11/2018 SAN-FR    BW   Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology, 7/31/2019 VRTX-US   BW   Vertex Reports Second-Quarter 2019 Financial Results,#N/A,#N/A, 5/31/2019 BLUE-US  BW   bluebird bio Announces Investor Events in June, 6/04/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference,#N/A,#N/A,#N/A, 5/06/2019 TXMD-US  BW   TherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men,12/07/2010 ZGNX-US  BW   SUMAVEL DosePro is Granted First European Approval,#N/A, 8/08/2019 OMER-US  BW   Omeros Corporation Reports Second Quarter 2019 Financial Results, 6/06/2019 RVNC-US  BW   Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors,12/19/2013 46122T10 BW   OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience’s OvaTure℠ Technology for Infertility Treatments, 4/01/2019 IRWD-US  BW   Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company,#N/A,#N/A,#N/A, 9/09/2014 63009R10    BW   NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research,#N/A, 4/02/2019 SYRS-US  BW   Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting,#N/A,#N/A, 8/01/2012 ANIP-US      BW   BioSante Pharmaceuticals Reports Second Quarter Financial Results and Pipeline Update," 2/06/2019 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018", 9/02/2019 ALNY-US   BW   Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran, 8/15/2016 WVE-US   BW   WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update,#N/A,#N/A," 2/11/2015 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion"," 1/09/2015 76129910 BW   The Shuman Law Firm Investigates Retrophin, Inc.",10/04/2011 PACB-US  BW   Pacific Biosciences Appoints Michael J. Glynn as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A," 6/11/2019 AKBA-US  BW   Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease",#N/A,#N/A,#N/A,#N/A, 6/18/2019 SAGE-US     BW   Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference,#N/A,#N/A," 6/25/2013 92165910 BW   Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc."," 6/11/2018 0B3H3F-E BW   Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder",#N/A,11/01/2017 INVA-US     BW   Innoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in November,#N/A,#N/A,#N/A, 8/14/2013 56400P70 BW   MannKind Announces Positive Clinical Data for AFREZZA; Both AFFINITY Phase 3 Studies Meet Primary Endpoints," 2/21/2019 URGN-US  BW   UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019",#N/A," 2/23/2016 ESPR-US     BW   SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Lawsuit Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016"," 6/02/2017 AMRS-US  BW   The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Amyris, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017", 3/03/2010 GENZ-US  BW   PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren for Nonsense Mutation Duchenne/Becker Muscular Dystrophy,#N/A,#N/A,#N/A," 4/29/2019 EGRX-US  BW   Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019"," 7/08/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors", 3/06/2013 008FZT-E BW   ADMA Biologics Reports 2012 Year End Financial and Operational Results,#N/A, 3/06/2019 EPZM-US  BW   Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock,#N/A,#N/A,#N/A, 1/19/2016 GILD-US     BW   Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib,#N/A, 5/20/2019 VCYT-US  BW   Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis, 7/01/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),10/01/2019 15117K10 BW   Cellectis et Lonza signent un accord de production cGMP pour les produits candidats UCART allogéniques de Cellectis,#N/A,#N/A,#N/A, 6/12/2015 00847X10 BW   Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies," 4/28/2017 IOVA-US  BW   SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Lion Biotechnologies, Inc. to Contact the Firm",#N/A," 5/01/2019 XLRN-US  BW   Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019",#N/A,10/08/2019 HZNP-US  BW   New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium," 6/04/2019 00BJ80-E  BW   Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes","10/02/2017 ICPT-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,12/04/2018 GLYC-US  BW   GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates, 3/08/2019 XNCR-US  BW   Xencor Announces Closing of Research Collaboration and License Agreement with Genentech," 5/11/2017 ITCI-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 5/02/2019 G6674U10 BW   Novocure Reports First Quarter 2019 Financial Results and Provides Company Update,#N/A,#N/A,#N/A, 8/07/2019 RCKT-US  BW   Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights, 2/12/2014 0C5GYQ-E BW   Dermira Announces Development and Corporate Progress,#N/A,#N/A,#N/A," 7/31/2013 AZN-GB     BW   AstraZeneca and FibroGen Collaborate to Develop and Commercialize FG-4592, a Treatment for Anemia in Chronic Kidney Disease and End-Stage Renal Disease", 7/25/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,10/01/2014 0D7WM8-E BW   Audentes Therapeutics Announces Continued Expansion of Senior Management Team,#N/A,#N/A,"11/05/2018 MCRB-US  BW   Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018", 6/11/2019 AIMT-US  BW   Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2019 RARX-US  BW   Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases,#N/A," 3/24/2017 HCM-GB   BW   Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors",#N/A,#N/A,"12/11/2015 0DP3CK-E BW   CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2010 00CN92-E    BW   OptiNose Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology,#N/A,#N/A, 6/04/2019 QTRX-US  BW   Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention, 3/30/2018 SLDB-US  BW   Robbins Arroyo LLP: Solid Biosciences Inc. (SLDB) Misled Shareholders According to a Recently Filed Class Action,#N/A,#N/A,11/17/2014 30233G10 BW   pSivida Reports ILUVIEN® Granted Marketing Authorization in Ireland,#N/A,#N/A,10/02/2019 AXNX-US  BW   Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group, 3/11/2019 TCDA-US  BW   Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet,#N/A," 2/06/2019 AVRO-US  BW   AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease"," 2/25/2019 MGTA-US  BW   Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate",#N/A,#N/A,#N/A, 1/18/2012 MON-US   BW   RaNA Therapeutics Raises $20.7 Million to Harness the Potential of Long Non-coding RNA," 7/24/2019 MRNA-US BW   Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/17/2019 TWST-US  BW   Twist Bioscience Launches Mouse Exome to Power Genetic Research,#N/A,"12/17/2018 0HVBMD-E BW   Gossamer Bio Announces Appointment of Jakob Dupont, M.D. as Chief Medical Officer",#N/A, 5/06/2013 0084LG-E  BW   Precision BioSciences Wins Patent Infringement Lawsuit against Cellectis,#N/A,#N/A,#N/A,12/12/2016 00DHGL-E BW   Atreca Announces Lead Preclinical Projects in Cancer Immunotherapy and Additional Disease Indications, 9/12/2019 PSNL-US  BW   Personalis Appoints Karin Eastham to Its Board of Directors,11/27/2018 0GRDFC-E BW   Stoke Therapeutics to Present New Data on Lead Program at American Epilepsy Society's 2018 Annual Meeting,#N/A, 5/29/2018 0DMSKV-E BW   Adaptive Biotechnologies Announces a Collaboration with Sanofi to Use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials,#N/A,#N/A
 3/21/2019 LGND-US   BW   Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection,12/07/2012 0C7XF4-E    BW   CytoDyn Expands Outreach Through Increased Online Presence," 6/04/2019 45232710    BW   Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions", 3/01/2019 84763A10  BW   Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio, 7/07/2017 ENDP-US  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc - ENDP, 8/05/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results, 3/19/2010 09060J10 BW   BioDelivery Sciences Files Annual Report 10-K and Complies with Nasdaq Marketplace Rule 5250(b)(2),#N/A," 1/06/2011 05WSX6-E BW   Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development",#N/A, 9/13/2016 OPK-US   BW   OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories,12/14/2012 46222210    BW,#N/A, 7/03/2019 ALXN-US  BW   ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 9/29/2019 SGEN-US     BW   Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer, 1/18/2017 IMMU-US     BW   CORRECTING and REPLACING venBio Sends Letter to Immunomedics Stockholders, 2/14/2018 09062X10    BW   The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy,12/01/2018 IMGN-US  BW   ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting, 7/22/2013 09058V10 BW   BioCryst Successfully Completes Its Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema,10/24/2019 GILD-US      BW   Gilead Sciences Announces Third Quarter 2019 Financial Results,#N/A,10/07/2016 MYL-US   BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Mylan N.V. - MYL, 2/10/2015 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results," 4/09/2018 AKRX-US   BW   AKRX EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018",12/01/2016 DIS-US       BW   Big Pharma Beats Out Google and Disney as the CareerBliss Happiest Companies of 2017," 5/11/2018 MYGN-US     BW   MYRIAD GENETICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN",#N/A,#N/A,11/06/2014 45766930 BW   Insmed Reports Third Quarter 2014 Financial Results, 6/10/2019 0KSTQ4-E BW   ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information,10/15/2010 45773H20 BW   Inovio Pharmaceuticals Chief Medical Officer to Present at Cancer Immunotherapy Conference,10/18/2016 NKTR-US  BW   La technologie Aerogen réduit de 32 % les admissions en services d'urgence1,#N/A,"10/01/2013 00FFW1-E     BW   Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets", 7/09/2019 AERI-US    BW   Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule,#N/A, 9/03/2019 INCY-US  BW   Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress, 8/25/2010 UTHR-US  BW   MedThink Communications Names Brian Peters Group Account Director, 1/10/2017 SRPT-US  BW   Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program,11/30/2017 ALKS-US  BW   ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc,12/19/2018 CERS-US  BW   Cerus Announces First Patient Enrolled in the Phase 3 ReCePI Study,10/22/2012 00B23Z-E BW   CloudLock Introduces Industry’s First Application Firewall for Google Apps," 6/17/2019 04269E10 BW   ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference",#N/A," 7/08/2019 80067710 BW   Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémophilie A, SB-525, qui indiquent des taux accrus et durables des taux de facteur VIII", 4/25/2019 EXEL-US  BW   Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma, 5/30/2018 ACN-US    BW   Sanofi Chooses Accenture Interactive to Create UWell’s Healthcare Platform to Better Serve Consumers," 7/25/2019 VRTX-US   BW   Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer",#N/A,#N/A, 5/16/2019 BLUE-US  BW   bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress, 5/18/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting,#N/A,#N/A,#N/A, 5/03/2019 TXMD-US  BW   TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting,#N/A,#N/A," 8/05/2019 OMER-US  BW   Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019", 6/04/2019 RVNC-US  BW   Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference,10/31/2013 OGEN-US  BW   Oragenics Announces Breakthrough Antibiotic Analog Generation in Intrexon Collaboration, 3/14/2019 IRWD-US  BW   Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement,#N/A,#N/A,#N/A, 8/05/2014 63009R10    BW   NanoString Technologies Receives Market Approval From the Australian Therapeutic Goods Administration for Its Prosigna Breast Cancer Prognostic Gene Signature Assay,#N/A, 3/07/2019 SYRS-US  BW   Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs,#N/A,#N/A, 6/19/2012 00182C10     BW   BioSante Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement," 1/22/2019 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018", 8/30/2019 ALNY-US   BW   Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference, 7/12/2016 WVE-US   BW   WAVE Life Sciences Appoints Dr. Michael Panzara as Head of Neurology Franchise,#N/A,#N/A, 2/10/2015 69512710 BW   Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call, 1/09/2015 76129910 BW   Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan," 9/27/2011 69404D10 BW   Zeldes & Haeggquist, LLP Announces Investigation of Pacific Biosciences of California",#N/A,#N/A,#N/A,#N/A, 6/04/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/14/2019 SAGE-US     BW   Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection,#N/A,#N/A," 6/20/2013 0BGL4K-E BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by Vanda Pharmaceuticals, Inc."," 5/24/2018 MEDP-US  BW   Medpace Holdings, Inc. to Present at Jefferies Global Healthcare Conference",#N/A,11/01/2017 GSK-GB      BW   GSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary Disease,#N/A,#N/A,#N/A, 8/09/2013 56400P70 BW   MannKind Corporation Reports 2013 Second Quarter Financial Results, 1/28/2019 URGN-US  BW   UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares,#N/A," 2/16/2016 ESPR-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016"," 6/02/2017 AMRS-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amyris, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A,#N/A, 4/22/2019 EGRX-US  BW   CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)," 6/11/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China"," 1/10/2013 06XBV2-E BW   ADMA Biologics Executes Long-Term Manufacturing, Supply and License Agreements with Biotest",#N/A, 3/05/2019 EPZM-US  BW   Epizyme Announces Presentations at Upcoming March Investor Conferences,#N/A,#N/A,#N/A, 1/13/2016 GILD-US     BW   Galapagos et Gilead autorisés par la Commission fédérale du commerce des États-Unis à clôturer leur partenariat mondial sur le filgotinib,#N/A," 5/14/2019 VCYT-US  BW   Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology", 6/21/2019 DRNA-US  BW   Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2),10/01/2019 15117K10 BW   Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates,#N/A,#N/A,#N/A, 6/10/2015 00847X10 BW   Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia," 4/26/2017 IOVA-US  BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Lion Biotechnologies, Inc. Investors and Encourages Investors to Contact the Firm",#N/A, 4/26/2019 CELG-US  BW   Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia,#N/A,10/03/2019 HZNP-US  BW   Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption, 5/07/2019 00BJ80-E  BW   Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting," 9/29/2017 ICPT-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm",#N/A,12/03/2018 GLYC-US  BW   GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting, 2/26/2018 07J4DM-E BW   Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates," 5/02/2017 ITCI-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Intra-Cellular Therapies, Inc. and Advises Investors with Losses to Contact the Firm",#N/A," 4/30/2019 G6674U10 BW   Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients",#N/A,#N/A,#N/A, 7/31/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference," 6/14/2013 0C5GYQ-E BW   Company Profile for Dermira, Inc.",#N/A,#N/A,#N/A, 7/30/2013 4503-JP    BW   Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease, 7/24/2019 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results,#N/A,#N/A, 9/24/2014 0D7WM8-E BW   Audentes Therapeutics to Present at the Leerink Partners Rare Disease Roundtable,#N/A,#N/A,"10/22/2018 MCRB-US  BW   Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer", 6/06/2019 AIMT-US  BW   Neue Daten zur Phase-3-Folgestudie PALISADE zu AR101 gegen Erdnussallergie zeigt Fortführung der Immunmodulation durch länger als einjährige tägliche Einnahme,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2019 RARX-US  BW   Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference,#N/A," 3/21/2017 HCM-GB   BW   Chi-Med To Host R&D Briefings on March 29 & 30, 2017",#N/A,#N/A,10/26/2015 VRTX-US  BW   Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/29/2019 QTRX-US  BW   Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms", 3/30/2018 SLDB-US  BW   SLDB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc.,#N/A,#N/A,11/12/2014 EYPT-US  BW   pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium,#N/A,#N/A, 9/24/2019 AXNX-US  BW   Axonics® to Exhibit its Sacral Neuromodulation System at the AUGS/IUGA Joint Scientific Meeting on September 24 – 28 in Nashville," 3/07/2019 TCDA-US  BW   Tricida to Report Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 28, 2019",#N/A, 9/17/2018 AVRO-US  BW   Industry leader Geoff Mackay to Chair board of Satellos Bioscience, 2/25/2019 MGTA-US  BW   Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting,#N/A,#N/A,#N/A,#N/A, 7/10/2019 MRNA-US BW   Moderna to Present at ROTH RNA Revolution Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2019 TWST-US  BW   Twist Bioscience to Present at the Jefferies 2019 Global Healthcare Conference,#N/A,10/02/2018 0HVBMD-E BW   FierceBiotech Names Gossamer Bio as One of its “Fierce 15” Biotech Companies of 2018,#N/A, 2/19/2013 0084LG-E  BW   Precision BioSciences Awarded Patent for Genetically Modifying Cells by the United States Patent Office,#N/A,#N/A,#N/A,11/15/2016 00DHGL-E BW   Atreca to Present at the Stifel 2016 Healthcare Conference," 9/11/2019 PSNL-US  BW   Personalis, Inc. conclut un accord de recherche avec Invectys visant à fournir un profil complet d’immunogénomique des tumeurs dans le cadre d’essais cliniques",10/23/2018 0GRDFC-E BW   Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines,#N/A, 4/02/2018 0DMSKV-E BW   FDA Approves First Therapy for Patients with MRD-Positive ALL,#N/A,#N/A
 3/12/2019 LGND-US   BW   Ligand to Participate in Four Upcoming Investor Conferences,10/26/2012 CYDY-US     BW   CytoDyn Moves Corporate Headquarters to Oregon, 5/29/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 2/28/2019 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update, 7/06/2017 ENDP-US  BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc, 7/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results, 3/09/2010 09060J10 BW   BioDelivery Sciences to Present at the 22nd Annual ROTH OC Growth Stock Conference,#N/A,12/21/2010 TGEN-US  BW,#N/A, 9/06/2016 OPK-US   BW   OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology,11/26/2012 ALNY-US     BW,#N/A, 6/27/2019 ALXN-US  BW   ADDING MULTIMEDIA Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive,#N/A, 9/28/2019 SGEN-US     BW   Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer, 1/11/2017 0BWYJ5-E    BW   venBio Sends Letter to Immunomedics Stockholders, 2/07/2018 09062X10    BW   Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke,11/26/2018 IMGN-US  BW   ImmunoGen Announces Resignation of Chief Financial Officer, 7/11/2013 09058V10 BW   BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding,10/15/2019 GILD-US      BW   Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer,#N/A,10/06/2016 MYL-US   BW   Keller Rohrback L.L.P. Investigates EpiPen Overcharges, 2/09/2015 M2572210 BW   Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target," 4/09/2018 064TLJ-E  BW   AKRX INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action against Akorn, Inc.",11/21/2016 ARWR-US      BW   Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen," 5/11/2018 MYGN-US     BW   Robbins Geller Rudman & Dowd LLP Announces a Securities Case Has Been Filed on Behalf of Purchasers of Myriad Genetics, Inc. Stock",#N/A,#N/A,"10/31/2014 45766930 BW   Insmed to Host Third Quarter 2014 Financial Results Conference Call on Thursday, November 6, 2014", 6/07/2019 05156V10 BW   Aurinia Issues Letter to Shareholders,10/14/2010 45773H20 BW   Scientific Paper on Inovio Pharmaceuticals SynCon™ DNA Vaccines and Intradermal DNA Delivery Technology One of Most Cited Articles in the Journal Vaccine, 9/27/2016 BMY-US   BW   Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214,#N/A, 1/18/2013 LCTX-US      BW   BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference," 6/17/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting",#N/A, 8/22/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences, 5/25/2010 UTHR-US  BW   United Therapeutics Launches Living PAH Program for Patients with Pulmonary Arterial Hypertension, 1/03/2017 SRPT-US  BW   Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference,"11/29/2017 0DGVHF-E BW   Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Alkermes plc (ALKS)",12/18/2018 CERS-US  BW   Cerus Completes CE Mark Submission for INTERCEPT Red Blood Cells, 9/05/2012 AMAG-US  BW   Rienso® (Ferumoxytol) Receives Swiss Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease," 6/14/2019 04269E10 BW   ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting",#N/A, 7/05/2019 80067710 BW   Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels," 4/17/2019 EXEL-US  BW   Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019", 5/16/2018 BIVV-US   BW   Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease," 7/22/2019 VRTX-US   BW   Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis",#N/A,#N/A, 5/09/2019 BLUE-US  BW   bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies, 5/07/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019,#N/A,#N/A,#N/A," 4/29/2019 TXMD-US  BW   TherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019",#N/A,#N/A, 7/31/2019 LONN-CH  BW   Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab, 5/14/2019 RVNC-US  BW   Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference, 8/26/2013 XON-US   BW   Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project, 3/07/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A, 7/29/2014 63009R10    BW   NanoString Technologies Introduces New Universal Junction Probe Design for Detecting Gene Fusions,#N/A, 3/06/2019 SYRS-US  BW   Syros to Participate in Upcoming Investor Conferences in March,#N/A,#N/A, 6/15/2012 07G69B-E     BW   Research and Markets: Gene Therapy - Global Strategic Business Report - 2012, 1/03/2019 ENTA-US    BW   Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference, 8/14/2019 ALNY-US   BW   Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias, 6/27/2016 WVE-US   BW   WAVE Life Sciences Added to the Russell 2000® Index,#N/A,#N/A," 1/08/2015 69512710 BW   Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York", 1/09/2015 76129910 BW   Retrophin Provides Corporate Update, 9/19/2011 69404D10 BW   Pacific Biosciences Partners With Cycle Computing to Bring SMRT DNA Analysis to the Cloud,#N/A,#N/A,#N/A,#N/A, 5/29/2019 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 6/05/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A," 6/19/2013 92165910 BW   Law Firm of Wohl & Fruchter LLP Announces Investigation of Vanda Pharmaceuticals, Inc."," 5/02/2018 MEDP-US  BW   Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder",#N/A,10/25/2017 INVA-US     BW   Innoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates,#N/A,#N/A,#N/A, 7/03/2013 56400P70 BW   MannKind Corporation to Present at 8th Annual JMP Securities Healthcare Conference, 1/23/2019 URGN-US  BW   UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares,#N/A," 1/22/2016 ESPR-US     BW   Investor Alert: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. And Encourages Investors To Contact The Firm Before The Deadline"," 6/01/2017 AMRS-US  BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Amyris, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A,#N/A," 4/15/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH"," 6/10/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers", 1/07/2013 HTGZ*-US BW   ADMA Biologics Secures Up To $6 Million Term Loan Commitment To Advance Phase III Study,#N/A, 2/26/2019 EPZM-US  BW   Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results,#N/A,#N/A,#N/A, 1/13/2016 GILD-US     BW   Galapagos und Gilead erhalten von US-amerikanischer Federal Trade Commission Genehmigung zu internationaler Partnerschaft bei Filgotinib,#N/A, 5/09/2019 VCYT-US  BW   Veracyte to Present at the UBS Global Healthcare Conference, 6/20/2019 DRNA-US  BW   Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria, 9/06/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 5/21/2015 00847X10 BW   Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association," 4/20/2017 IOVA-US  BW   LBIO LOSS NOTICE: Rosen Law Firm Reminds Lion Biotechnologies, Inc. Investors of Important First Filed Class Action – LBIO",#N/A, 4/05/2019 XLRN-US  BW   Acceleron Announces Departure of Chief Medical Officer,#N/A, 9/09/2019 HZNP-US  BW   Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED), 4/24/2019 00BJ80-E  BW   Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association," 9/29/2017 ICPT-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)",#N/A,"11/29/2018 GLYC-US  BW   GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018","11/03/2016 07J4DM-E BW   Selexis and Xencor Enter Strategic Agreement, Strengthening Existing Relationship for Multi-Specific Antibody Cell Line Development"," 5/02/2017 ITCI-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Intra-Cellular Therapies, Inc.",#N/A," 4/15/2019 G6674U10 BW   Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values",#N/A,#N/A,#N/A," 6/18/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome", 6/11/2013 0C5GYQ-E BW   Dermira Raises $35m to Fund Innovation in Dermatology,#N/A,#N/A,#N/A,12/11/2012 4503-JP    BW   FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease," 7/16/2019 74587V10 BW   Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer",#N/A,#N/A," 5/19/2014 0D7WM8-E BW   Audentes Therapeutics Announces Six Abstracts to be Presented at the American Society of Gene and Cell Therapy Meeting May 21-24, 2014",#N/A,#N/A,10/03/2018 MCRB-US  BW   Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018," 6/06/2019 AIMT-US  BW   Nuovi dati dallo studio di follow-on di PALISADE, un trial di fase 3 su AR101 per l'allergia alle arachidi, dimostrano l'immunomodulazione continuativa tramite dosaggio giornaliero a oltre un anno",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2018 RARX-US  BW   Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock,#N/A, 3/16/2017 HCM-GB   BW   Chi-Med: Grant of Awards under Long Term Incentive Plan,#N/A,#N/A, 9/30/2015 0DP3CK-E BW   FierceBiotech Names CRISPR Therapeutics as One of Its “Fierce 15” Biotech Companies of 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/16/2019 QTRX-US  BW   Quanterix Announces $50,000 in Grants to Support Promising Oncology Research", 3/29/2018 SLDB-US  BW   SLDB INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Solid Biosciences Inc. Investors,#N/A,#N/A,11/07/2014 30233G10 BW   pSivida Corp. Reports First Quarter FY 2015 Results,#N/A,#N/A, 9/10/2019 AXNX-US  BW   Axonics® gibt die Zulassung der U.S. Food & Drug Administration für sein System für sakrale Neuromodulation bekannt, 2/27/2019 TCDA-US  BW   Tricida to Present at the Cowen and Company 39th Annual Health Care Conference,#N/A," 4/04/2018 SERO-CH  BW   AVROBIO, Inc. Appoints Annalisa Jenkins to its Board of Directors"," 2/21/2019 MGTA-US  BW   Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant",#N/A,#N/A,#N/A,#N/A, 6/18/2019 MRNA-US BW   Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2019 TWST-US  BW   Collaboration of Four Biotech Companies Showcases High Throughput DNA Assembly Platform for Diverse Applications,#N/A," 9/05/2018 0HVBMD-E BW   Gossamer Bio Announces Appointment of Luisa Salter-Cid, Ph.D. as Chief Scientific Officer",#N/A,12/11/2012 0084LG-E  BW   Precision BioSciences Announces First Publication of Targeted Knockout Rats Using Engineered Meganuclease Technology,#N/A,#N/A,#N/A,11/11/2016 00DHGL-E BW   Atreca Presents Promising Findings from Lead Antibody Program at Society for Immunotherapy of Cancer (SITC) Annual Meeting," 9/10/2019 PSNL-US  BW   Personalis, Inc. concluye un contrato de investigación con Invectys para proporcionar soluciones integrales de caracterización inmunogenómica tumoral para un ensayo clínico", 9/27/2018 0GRDFC-E BW   Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society,#N/A," 2/13/2018 0DMSKV-E BW   Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors",#N/A,#N/A
 3/12/2019 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event, 9/05/2012 SLXP-US     BW   Salix Pharmaceuticals Outlines Data Presentations at PAINWeek, 5/15/2019 45232710    BW   Illumina Files Patent Infringement Suit Against BGI in Denmark, 2/21/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call, 7/03/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Endo International plc and Encourages Investors with Losses to Contact the Firm, 7/16/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3, 3/03/2010 09060J10 BW   BioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care Conference,#N/A," 5/05/2010 TRI-CA   BW   Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals Inc., Sanofi-Aventis, AstraZeneca, Interactive Data Corp. and Thompson Reuters",#N/A, 9/01/2016 OPK-US   BW   OPKO Health to Participate in Upcoming September Conferences,10/18/2012 46222210    BW,#N/A, 6/20/2019 ALXN-US  BW   U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS),#N/A, 9/17/2019 SGEN-US     BW   Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress, 1/10/2017 0BWYJ5-E    BW   venBio Responds to Immunomedics Announcement, 2/05/2018 BIIB-US     BW   Biogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference,11/06/2018 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences, 7/01/2013 BCRX-US  BW   BioCryst to Present at the Eighth Annual JMP Securities Healthcare Conference,10/10/2019 GILD-US      BW   Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis,#N/A, 9/13/2016 CSL-US   BW   Carlisle Companies Elects Jonathan Collins to Board of Directors," 2/03/2015 M2572210 BW   Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST"," 4/04/2018 0BGL4K-E  BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018",10/03/2016 0880D9-E     BW   Exosome Diagnostics Enters Agreement with Amgen," 5/11/2018 0B1C3M-E    BW   The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 9/24/2014 45766930 BW   Insmed to Participate in Leerink Partners’ Rare Disease Roundtable, 6/04/2019 05156V10 BW   Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences, 9/30/2010 45773H20 BW   Inovio’s SynCon™ Universal Influenza DNA Vaccine Technology Recognized with NIH Director’s Transformative Research Award, 5/21/2013 NKTR-US  BW   Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013,#N/A, 1/07/2013 GERN-US      BW   BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets, 6/11/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences,#N/A, 7/30/2019 INCY-US  BW   Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs," 2/03/2010 91307C10 BW   Lung Rx LLC, société du groupe United Therapeutics Corporation, et mondoBIOTECH holding AG annoncent aujourd’hui un accord de partenariat global pour le développement de la plateforme Aviptadil",12/30/2016 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"11/27/2017 0BGL4K-E BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc",12/10/2018 CERS-US  BW   American Red Cross Receives Biologics License Application Approval For INTERCEPT Platelets," 8/29/2012 AMAG-US  BW   AMAG Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences"," 6/10/2019 04269E10 BW   ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference",#N/A, 7/01/2019 80067710 BW    Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease," 4/05/2019 EXEL-US  BW   Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019", 4/23/2018 SAN-FR    BW   Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada® (alemtuzumab) in Clinical Trials, 7/17/2019 VRTX-US   BW   Vertex to Announce Second-Quarter 2019 Financial Results on July 31,#N/A,#N/A, 5/03/2019 BLUE-US  BW   bluebird bio Announces Investor Events in May, 5/01/2019 ACAD-US  BW   ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results,#N/A,#N/A,#N/A, 4/24/2019 TXMD-US  BW   TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners,#N/A,#N/A, 7/24/2019 OMER-US  BW   Omeros’ OMIDRIA® Receives Product-Specific J-Code from CMS, 5/08/2019 RVNC-US  BW   Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update, 7/01/2013 FCSC-US  BW   Fibrocell Science and Intrexon Expand Collaboration for Potential New Class of Therapeutics, 3/04/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Cowen Health Care Conference,#N/A,#N/A,#N/A, 6/03/2014 63009R10    BW   NanoString Technologies Enters into Biomarker Companion Diagnostic Collaboration with Celgene Corporation to Support Development of REVLIMID as Treatment for Patients with Diffuse Large B-Cell Lymphoma,#N/A," 2/28/2019 SYRS-US  BW   Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019",#N/A,#N/A, 6/11/2012 ANIP-US      BW   BioSante Pharmaceuticals Announces New LibiGel® Phase III Efficacy Trials,12/19/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference, 8/13/2019 ALNY-US   BW   Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP), 6/21/2016 06CR5C-E BW   WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease,#N/A,#N/A," 1/08/2015 69512710 BW   Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million", 1/06/2015 76129910 BW   Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4), 9/13/2011 69404D10 BW   German Chancellor Angela Merkel Starts the New PacBio RS at the Max Delbrück Center of Molecular Medicine,#N/A,#N/A,#N/A,#N/A, 5/09/2019 AKBA-US  BW   Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments,#N/A,#N/A,#N/A,#N/A, 6/04/2019 SAGE-US     BW   Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference,#N/A,#N/A, 6/02/2011 SCMP-US  BW   Akonni Biosystems Announces the Appointment of CFO," 4/30/2018 MEDP-US  BW   Medpace Holdings, Inc. Reports First Quarter 2018 Results",#N/A,10/18/2017 INVA-US     BW   Innoviva to Report Third Quarter Financial Results on October 25 at 5:00 p.m. EDT,#N/A,#N/A,#N/A, 7/01/2013 MNKD-US  BW   Deerfield Invests $160 Million in MannKind Corporation, 1/22/2019 URGN-US  BW   UroGen Pharma Announces Proposed Public Offering of Ordinary Shares,#N/A," 1/19/2016 ESPR-US     BW   Esperion Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors"," 5/30/2017 AMRS-US  BW   DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Amyris, Inc. to Contact the Firm",#N/A,#N/A,#N/A,#N/A," 2/28/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results"," 5/30/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference",11/13/2012 008FZT-E BW   ADMA Biologics Reports 2012 Third Quarter Results,#N/A, 2/19/2019 EPZM-US  BW   Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference,#N/A,#N/A,#N/A, 1/13/2016 GILD-US     BW   Galapagos e Gilead autorizzate dalla Commissione Federale per il Commercio degli Stati Uniti a finalizzare la collaborazione a livello globale per lo sviluppo di filgotinib,#N/A, 5/07/2019 VCYT-US  BW   Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares, 6/13/2019 DRNA-US  BW   Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy, 9/06/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 9/26/2014 00847X10 BW   Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014," 4/19/2017 IOVA-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Lion Biotechnologies, Inc.",#N/A, 4/05/2019 CELG-US  BW   Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA,#N/A," 8/28/2019 HZNP-US  BW   Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer", 4/18/2019 08B3MC-E  BW   American Cancer Society’s Newly Formed Philanthropic Impact Fund Makes First Investment," 9/29/2017 ICPT-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc.",#N/A,"11/28/2018 GLYC-US  BW   Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors", 1/12/2016 0643XB-E BW   Emergent Technologies Portfolio Company Enters into License Agreement with Xencor," 5/01/2017 ITCI-US  BW   INTRA-CELLULAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Intra-Cellular Therapies, Inc. to Contact the Firm",#N/A, 4/03/2019 G6674U10 BW   Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019,#N/A,#N/A,#N/A, 5/29/2019 RCKT-US  BW   Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients’ Forum,#N/A,#N/A,#N/A,#N/A,"11/05/2012 05SVDW-E   BW   FibroGen Announces Results Showing That FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Corrects Anemia Without Intravenous Iron Supplementation in Incident Dialysis Patients", 7/03/2019 74587V10 BW   Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019,#N/A,#N/A, 3/04/2014 0D7WM8-E BW   Audentes Therapeutics Announces Significant Additions to Leadership Team,#N/A,#N/A," 9/04/2018 MCRB-US  BW   Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader", 6/05/2019 AIMT-US  BW   Datos de dos estudios confirman la calidad de vida y la carga psicosocial de vivir con alergia al cacahuete,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2018 RARX-US  BW   Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A," 3/15/2017 HCM-GB   BW   Publication of Annual Report and Financial Results for the Year Ended December 31, 2016",#N/A,#N/A," 8/11/2015 0DP3CK-E BW   CRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer and Michael Bruce as Senior Vice President, Program Portfolio and Alliance Management",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2019 QTRX-US  BW   Quanterix Corporation Releases Operating Results for First Quarter 2019, 3/29/2018 RC-US    BW   SLDB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc.,#N/A,#N/A,10/31/2014 30233G10 BW   pSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 9/10/2019 AXNX-US  BW   Axonics® annonce l’approbation de son système de neuromodulation sacrée par la Food and Drug Administration américaine," 1/17/2019 TCDA-US  BW   Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer",#N/A," 2/01/2018 0D5N8T-E BW   AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases", 2/07/2019 MGTA-US  BW   Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference,#N/A,#N/A,#N/A,#N/A, 6/07/2019 MRNA-US BW   Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2019 TWST-US  BW   Twist Bioscience Strengthens Board With Semiconductor and Storage Expert Nelson C. Chan,#N/A, 7/23/2018 0HVBMD-E BW   Gossamer Bio Announces $230 Million Series B Financing,#N/A,11/26/2012 0084LG-E  BW   Precision BioSciences Announces Publication of Cotton Trait Stacking Success in Collaboration with Bayer CropScience,#N/A,#N/A,#N/A,10/26/2016 00DHGL-E BW   Atreca Describes Ebola Antibody Research Findings in Collaboration with Emory University," 9/09/2019 PSNL-US  BW   Personalis, Inc. gaat een onderzoeksovereenkomst aan met Invectys ten behoeve van het verstrekken van uitgebreide tumor immunogenomische profilering voor klinisch onderzoek"," 9/17/2018 0GRDFC-E BW   Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors",#N/A, 1/04/2018 MSFT-US  BW   Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease,#N/A,#N/A
 3/05/2019 LGND-US   BW   Ligand Sells Promacta Assets and Royalty for $827 Million," 7/30/2012 PGNX-US     BW   CytoDyn Announces Entry into Agreement with Progenics Pharmaceuticals, Inc. to Acquire PRO 140", 5/01/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 2/07/2019 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14, 6/28/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 7/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference, 2/26/2010 09060J10 BW   BioDelivery Sciences Business Update: Plans for Three Products Entering Phase 3 Next Year,#N/A,#N/A,#N/A, 8/31/2016 OPK-US   BW   OPKO Health Completes Acquisition of Transition Therapeutics,10/03/2012 07GVF3-E    BW,#N/A," 6/18/2019 ALXN-US  BW   ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)",#N/A, 9/16/2019 4503-JP     BW   Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer,11/29/2016 0BWYJ5-E    BW   venBio Responds to Immunomedics’ Postponement of Annual Meeting," 1/25/2018 09062X10    BW   Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively",11/02/2018 IMGN-US  BW   ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results, 5/09/2013 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences,"10/10/2019 GILD-US      BW   Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019",#N/A, 8/29/2016 MYL-GB   BW   Fitch: EpiPen Illustrates Pharma's Pricing Power Peril, 2/02/2015 M2572210 BW   Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month," 4/02/2018 AKRX-US   BW   The Klein Law Firm Announces a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)", 9/16/2016 RDY-IN       BW   Dr. Reddy’s Expands Strategic Collaboration with Amgen in India," 5/10/2018 MYGN-US     BW   MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 8/18/2014 45766930 BW   Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares," 6/03/2019 0KSTQ4-E BW   Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders", 9/29/2010 45773H20 BW   Inovio Pharmaceuticals’ Chief Executive Named Life Sciences CEO of the Year by the Philadelphia Business Journal,10/01/2012 GRST-CA  BW   GreeneStone Muskoka Once Again Featured on Intervention Canada,#N/A,11/15/2012 GERN-US      BW   BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets, 5/28/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference,#N/A, 7/11/2019 INCY-US  BW   Incyte to Report Second Quarter Financial Results," 2/03/2010 91307C10 BW   Lung Rx LLC, società del gruppo biotech United Therapeutic Corporation, e mondoBIOTECH holding AG annunciano oggi un accordo di collaborazione strategica globale per lo sviluppo della piattaforma di Aviptadil",12/19/2016 SRPT-US  BW   Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51,11/27/2017 ALKS-US  BW   Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis,12/04/2018 CERS-US  BW   Cerus Supports FDA’s Continuing Efforts to Enhance the Safety of the U.S. Platelet Supply," 7/26/2012 AMAG-US  BW   AMAG Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2012"," 6/07/2019 04269E10 BW   ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)",#N/A, 4/02/2019 PFE-US   BW   Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy, 3/05/2019 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in March, 4/17/2018 BIVV-US   BW   Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia, 6/21/2019 VRTX-US   BW   FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene,#N/A,#N/A, 5/02/2019 BLUE-US  BW   bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress, 4/25/2019 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder,#N/A,#N/A,#N/A, 4/17/2019 TXMD-US  BW   TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners,#N/A,#N/A, 7/11/2019 OMER-US  BW   Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA," 4/24/2019 RVNC-US  BW   Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019", 4/16/2013 ARMP-US  BW   AmpliPhi Establishes Collaboration with Intrexon," 2/26/2019 IRWD-US  BW   Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering",#N/A,#N/A,#N/A, 5/06/2014 63009R10    BW   NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay,#N/A," 2/27/2019 SYRS-US  BW   Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting",#N/A,#N/A," 6/04/2012 ANIP-US      BW   BioSante Pharmaceuticals, Inc. to Present at Jefferies Global Healthcare Conference","11/26/2018 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018", 8/13/2019 ALNY-US   BW   Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP), 6/01/2016 05F9ZW-E BW   WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference,#N/A,#N/A,12/12/2014 69512710 BW   Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label,12/16/2014 76129910 BW   Retrophin Announces Addition to the NASDAQ Biotechnology Index, 7/27/2011 69404D10 BW   Pacific Biosciences DNA Sequencing Technology Yields New Insights into Virulence and Evolution of German E. coli Pathogen,#N/A,#N/A,#N/A,#N/A, 5/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 5/14/2019 SAGE-US     BW   Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference,#N/A,#N/A, 1/13/2011 VNDA-US  BW   Sucampo Announces Resignation of Chief Financial Officer," 4/27/2018 MEDP-US  BW   Medpace Holdings, Inc. to Report First Quarter 2018 Financial Results on April 30, 2018",#N/A, 9/21/2017 INVA-US     BW   Innoviva to Participate in Cantor Fitzgerald’s Global Healthcare Conference on September 26,#N/A,#N/A,#N/A, 7/01/2013 56400P70 BW   MannKind Announces $160 Million Debt Financing, 1/08/2019 URGN-US  BW   UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC),#N/A," 1/15/2016 ESPR-US     BW   The Former Attorney General of Louisiana & Kahn Swick & Foti, LLC Remind Large Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against Esperion Therapeutics, Inc."," 5/30/2017 AMRS-US  BW   SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Amyris, Inc. To Contact The Firm",#N/A,#N/A,#N/A,#N/A," 2/19/2019 EGRX-US  BW   Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019"," 5/14/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference", 9/06/2012 008FZT-E BW   ADMA Biologics to Present at the Rodman & Renshaw Annual Global Investment Conference,#N/A, 1/04/2019 EPZM-US  BW   Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance,#N/A,#N/A,#N/A," 1/13/2016 GILD-US     BW   Galapagos y Gilead, autorizados por la Comisión Federal de Comercio de Estados Unidos para cerrar la alianza mundial sobre filgotinib",#N/A," 5/02/2019 VCYT-US  BW   Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock", 6/04/2019 DRNA-US  BW   Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer, 8/07/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A," 8/12/2014 00847X10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty"," 4/18/2017 IOVA-US  BW   INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Lion Biotechnologies, Inc. and Encourages Investors With Losses to Contact the Firm",#N/A, 4/04/2019 XLRN-US  BW   Acceleron Discontinues Development of Phase 1 Molecule ACE-2494,#N/A, 8/19/2019 HZNP-US  BW   American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)," 4/11/2019 00BJ80-E  BW   Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma"," 9/28/2017 ICPT-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,11/19/2018 GLYC-US  BW   GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia,12/16/2015 0DZ2BK-E BW   Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance," 5/01/2017 ITCI-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Intra-Cellular Therapies, Inc. Limited Investors",#N/A, 4/02/2019 G6674U10 BW   Novocure to Report First Quarter 2019 Financial Results,#N/A,#N/A,#N/A, 5/08/2019 RCKT-US  BW   Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A,11/05/2012 05SVDW-E   BW   FibroGen Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients, 7/01/2019 74587V10 BW   Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer,#N/A,#N/A, 2/05/2014 0D7WM8-E BW   Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X-Linked Myotubular Myopathy,#N/A,#N/A, 8/02/2018 MCRB-US  BW   Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates, 6/05/2019 AIMT-US  BW   Dados de Dois Estudos Confirmam Qualidade de Vida e Fardo Psicossocial de Viver com Alergia ao Amendoim,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2018 RARX-US  BW   Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis,#N/A, 3/10/2017 HCM-GB   BW   Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society,#N/A,#N/A, 4/29/2015 0DP3CK-E BW   CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2019 QTRX-US  BW   Quanterix’ Simoa Technology Powers More Than 85 Percent of Neurofilament Light Biomarker Research to be Unveiled at American Academy of Neurology Annual Meeting, 3/28/2018 SLDB-US  BW   INVESTOR ALERT: Kirby McInerney LLP Advises Solid Biosciences Inc. (SLDB) Investors of Potential Claims,#N/A,#N/A,10/27/2014 30233G10 BW   pSivida Corp. Receives $25 Million Milestone Payment,#N/A,#N/A, 9/09/2019 AXNX-US  BW   Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System, 1/02/2019 TCDA-US  BW   Tricida to Present at the 37th Annual J. P. Morgan Healthcare Conference,#N/A,"11/09/2017 0G2LJD-E BW   AVROBIO, Inc. Appoints Ian Clark to Its Board of Directors"," 1/02/2019 MGTA-US  BW   Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019",#N/A,#N/A,#N/A,#N/A, 6/01/2019 MRNA-US BW   Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2019 TWST-US  BW   Twist Bioscience to Present at the UBS Global Healthcare Conference,#N/A," 6/25/2018 ARPO-US  BW   Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease",#N/A,11/06/2012 0084LG-E  BW   Precision BioSciences Files Patent Infringement Lawsuit Against Cellectis Related to Gene Editing Technology,#N/A,#N/A,#N/A, 9/19/2016 06S6MV-E BW   FierceBiotech Names Atreca as One of Its “Fierce 15” Biotech Companies of 2016," 9/09/2019 PSNL-US  BW   Personalis, Inc. geht Forschungsvereinbarung mit Invectys für umfassendes Profiling der Tumorgenomik für klinische Studie ein", 5/08/2018 0GRDFC-E BW   Stoke Therapeutics to Present Research Supporting Its Novel Approach to Oligonucleotide Mediated Gene Up-Regulation at TIDES and ASGCT Conferences,#N/A,12/08/2017 06QBQ2-E BW   Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017,#N/A,#N/A
 2/21/2019 LGND-US   BW   Reminder: Ligand to Host Analyst Day on March 12th in New York City, 7/27/2012 SLXP-US     BW   Salix and Progenics Receive Complete Response Letter from FDA for RELISTOR® sNDA, 4/25/2019 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2019, 1/17/2019 068W2B-E  BW   Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients," 6/13/2017 ADGO-GB  BW   Albert Identified as One of Gartner’s “Cool Vendors in Advertising, 2017”", 6/27/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease, 2/18/2010 09060J10 BW   BioDelivery Sciences to Host Business Update Conference Call and Webcast on February 25,#N/A,#N/A,#N/A, 8/26/2016 OPK-US   BW   Transition Therapeutics Shareholders Approve Acquisition by OPKO Health, 9/06/2012 BIOC.XX1-US BW,#N/A, 6/14/2019 ALXN-US  BW   Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress,#N/A, 7/26/2019 SGEN-US     BW   Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares,"11/22/2016 0BWYJ5-E    BW   venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of Immunomedics, Inc."," 1/04/2018 09062X10    BW   Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing",11/01/2018 IMGN-US  BW   ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting, 5/07/2013 09058V10 BW   BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results,10/08/2019 GILD-US      BW   Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan,#N/A, 8/05/2016 MDABY-SE BW   MEDA: Notice to noteholders regarding change of control, 1/12/2015 CGEN-US  BW   Neviah Genomics Achieves Key Development Milestone for PropheTox™ Bioassay for Early Prediction of Drug-Induced Liver Toxicity and Secures Additional Financing," 3/28/2018 AKRX-US   BW   AKRX INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018", 8/11/2016 AMGN-US      BW   Fitch Rates Amgen Inc.'s Notes Offering 'BBB'," 5/09/2018 MYGN-US     BW   EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 8/12/2014 45766930 BW   Insmed Announces Pricing of Public Offering of Common Stock, 5/31/2019 05156V10 BW   Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders, 9/28/2010 45773H20 BW   Inovio Pharmaceuticals’ HIV DNA Vaccine/Electroporation Delivery Technology Selected for NIH-Sponsored U.S. Army Human Clinical Trial, 5/18/2012 0CJ49J-E BW   Fitch Affirms RPI Finance Trust's Ratings at 'BBB-',#N/A,"10/18/2012 GERN-US      BW   BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation", 5/07/2019 AERI-US    BW   Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update,#N/A, 7/02/2019 INCY-US  BW   Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China, 2/03/2010 91307C10 BW,11/30/2016 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/27/2017 ALKS-US  BW   Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis,11/09/2018 CERS-US  BW   Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum," 7/19/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on July 26, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended June 30, 2012"," 5/30/2019 04269E10 BW   ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019",#N/A,10/31/2018 80067710 BW   OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE visant les actions de la société TxCell initiée par Sangamo Therapeutics présentée par ALANTRA, 2/12/2019 EXEL-US  BW   Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update, 3/08/2018 EVT-DE    BW   Evotec and Sanofi in Exclusive Talks to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform, 6/06/2019 CRSP-US   BW   Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics,#N/A,#N/A, 5/01/2019 BLUE-US  BW   Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine," 4/17/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019",#N/A,#N/A,#N/A, 4/17/2019 TXMD-US  BW   TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.,#N/A,#N/A, 6/05/2019 OMER-US  BW   Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA, 4/09/2019 76133010 BW   Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing, 2/12/2013 008349-E BW   Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140, 2/21/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference,#N/A,#N/A,#N/A, 4/07/2014 63009R10    BW   NanoString Technologies Introduces Novel PanCancer Gene Expression Panel for Multiplexed Pathway Analysis,#N/A, 1/06/2019 SYRS-US  BW   Syros Announces Strategic Priorities and Expected Milestones,#N/A,#N/A, 5/31/2012 ANIP-US      BW   BioSante Pharmaceuticals Announces Reverse Stock Split in Order to Maintain NASDAQ Listing,11/13/2018 ENTA-US    BW   Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis, 8/06/2019 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity, 5/16/2016 WVE-US   BW   WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update,#N/A,#N/A,"11/25/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference","12/12/2014 76129910 BW   INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Law Offices of Howard G. Smith", 7/06/2011 69404D10 BW   Pacific Biosciences Contributes Whole Genome Sequence Data for German E. Coli Outbreak Strain and 11 Related Strains for Comparative Analysis,#N/A,#N/A,#N/A,#N/A, 5/02/2019 AKBA-US  BW   Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings,#N/A,#N/A,#N/A,#N/A, 5/07/2019 SAGE-US     BW   Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference,#N/A,#N/A,#N/A," 2/26/2018 MEDP-US  BW   Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2017 Results",#N/A, 9/20/2017 GSK-GB      BW   GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations,#N/A,#N/A,#N/A, 6/17/2013 56400P70 BW   MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes, 1/03/2019 URGN-US  BW   UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer,#N/A," 1/13/2016 ESPR-US     BW   Kirby McInerney LLP Advises Esperion Therapeutics, Inc. Investors of Potential Claims"," 5/30/2017 AMRS-US  BW   AMRS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Amyris, Inc. and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A,#N/A,#N/A," 1/02/2019 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference"," 5/09/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results", 8/14/2012 008FZT-E BW   ADMA Biologics Reports 2012 Second Quarter Results,#N/A,12/18/2018 EPZM-US  BW   Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor,#N/A,#N/A,#N/A, 1/13/2016 GILD-US     BW   Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib,#N/A, 5/01/2019 VCYT-US  BW   Veracyte Announces Proposed Public Offering of Common Stock, 6/03/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), 8/07/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A," 7/31/2014 00847X10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty"," 4/18/2017 IOVA-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lion Biotechnologies, Inc. and Encourages Investors With Losses to Contact the Firm",#N/A, 3/05/2019 XLRN-US  BW   Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease,#N/A, 8/19/2019 HZNP-US  BW   Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference," 3/25/2019 00BJ80-E  BW   Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test"," 9/27/2017 ICPT-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,11/02/2018 GLYC-US  BW   GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements, 3/09/2011 00780K-E BW   Xencor’s Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology," 5/01/2017 ITCI-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intra-Cellular Therapies, Inc. – ITCI",#N/A, 3/22/2019 G6674U10 BW   Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer,#N/A,#N/A,#N/A, 5/07/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,"10/31/2012 05SVDW-E   BW   FibroGen to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology (ASN) Kidney Week 2012", 6/05/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A," 7/30/2013 00BXRX-E BW   REGENX Biosciences and Audentes Therapeutics Enter into Exclusive License Agreement for Development of Treatments for Serious, Rare Muscle Diseases Using NAVTM Vectors",#N/A,#N/A," 7/25/2018 MCRB-US  BW   Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018", 6/05/2019 AIMT-US  BW   Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2018 MRK-US   BW   Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck,#N/A," 3/03/2017 HCM-GB   BW   Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer",#N/A,#N/A," 4/07/2015 0DP3CK-E BW   CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2019 QTRX-US  BW   Quanterix to Release First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019"," 3/28/2018 0BGL4K-E BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc. -- SLDB",#N/A,#N/A, 9/26/2014 30233G10 BW   pSivida Corp. Reports FDA Approval of ILUVIEN® for Diabetic Macular Edema,#N/A,#N/A, 8/27/2019 AXNX-US  BW   Axonics® to Present at Upcoming Investor Conferences,11/08/2018 TCDA-US  BW   Tricida Announces Third Quarter 2018 Financial Results,#N/A,"10/04/2017 0G2LJD-E BW   AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis",12/02/2018 MGTA-US  BW   Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders,#N/A,#N/A,#N/A,#N/A, 5/17/2019 MRNA-US BW   Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2019 TWST-US  BW   Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A," 1/04/2018 0057B5-E BW   Former Receptos Executives Launch Gossamer Bio, Inc., a New Biopharma Company Focused on Discovering and Developing a Pipeline of Novel and Differentiated Drug Candidates",#N/A,10/29/2012 0084LG-E  BW   Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases,#N/A,#N/A,#N/A," 8/10/2016 00DHGL-E BW   Atreca Appoints Acclaimed Immunology Researcher Mark M. Davis, Ph.D., as a Technical Advisor"," 9/09/2019 PSNL-US  BW   Personalis, Inc. stipula un contratto di ricerca con Invectys per la fornitura di soluzioni complete di caratterizzazione immunogenomica dei tumori per una sperimentazione clinica"," 4/17/2018 NOVN-CH  BW   Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development",#N/A,11/06/2017 0DMSKV-E BW   Adaptive Biotechnologies kündigt Kooperation mit Amgen für den Fortschritt der klinischen Entwicklung des clonoSEQ®-Assays bei Multiplem Myelom an,#N/A,#N/A
 2/07/2019 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2018 Financial Results, 5/11/2012 SGEN-US     BW   Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference," 4/09/2019 45232710    BW   Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019", 1/02/2019 84763A10  BW   Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations, 6/12/2017 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Endo International plc, 6/21/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 8/23/2016 OPK-US   BW   OPKO Health Responds to Law Firm Notice of Investigation, 8/06/2012 ALNY-US     BW,#N/A, 5/13/2019 ALXN-US  BW   Alexion to Present at the RBC Capital Markets Annual Healthcare Conference,#N/A, 7/23/2019 SGEN-US     BW   Seattle Genetics Announces Pricing of Public Offering of Common Stock," 7/29/2016 IMMU-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016", 1/03/2018 0H91DS-E    BW   resTORbio Appoints Lynne Sullivan to Its Board of Directors,10/20/2018 IMGN-US  BW   ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress, 4/23/2013 09058V10 BW   BioCryst to Announce First Quarter 2013 Financial Results May 7,"10/07/2019 GILD-US      BW   Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer",#N/A, 8/02/2016 MDABY-SE BW   Meda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meeting, 1/05/2015 M2572210 BW   Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets," 3/26/2018 0BGL4K-E  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018", 8/03/2016 AMGN-US      BW   Fitch Affirms Amgen Inc.'s IDR at 'BBB'; Outlook Stable," 5/08/2018 MYGN-US     BW   The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 8/11/2014 45766930 BW   Insmed Announces Proposed Public Offering of Common Stock, 5/17/2019 05156V10 BW   Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference, 9/23/2010 45773H20 BW   Inovio Invited to Present at International Vaccine Conferences, 1/05/2012 NKTR-US  BW   Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A,#N/A, 9/28/2012 LCTX-US      BW   BioTime Forms BioTime Acquisition Corporation," 5/02/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M",#N/A, 6/15/2019 INCY-US  BW   Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo," 2/03/2010 91307C10 BW   Lung Rx LLC, ein Tochterunternehmen der United Therapeutics Corporation, und mondoBIOTECH holding AG melden heute eine globale strategische Partnerschaft für die Entwicklung der Aviptadil Plattform",11/04/2016 SRPT-US  BW   Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference,11/22/2017 ALKS-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alkermes plc Investors (ALKS),11/02/2018 CERS-US  BW   Cerus to Present at the 2018 Stephens NY Investment Conference, 7/18/2012 00163U10 BW   AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia," 5/15/2019 04269E10 BW   ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019",#N/A,10/02/2018 80067710 BW   SANGAMO THERAPEUTICS : COMMUNIQUE RELATIF AU DEPOT D’UN PROJET DE NOTE D’INFORMATION RELATIF A L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE," 2/12/2019 EXEL-US  BW   Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts", 2/08/2018 SAN-FR    BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity, 6/04/2019 VRTX-US   BW   Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF,#N/A,#N/A," 5/01/2019 BLUE-US  BW   bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer", 4/11/2019 ACAD-US  BW   ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country,#N/A,#N/A,#N/A, 3/25/2019 TXMD-US  BW   TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting,#N/A,#N/A, 5/15/2019 OMER-US  BW   Omeros to Present at the UBS Global Healthcare Conference, 4/08/2019 76133010 BW   SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference, 2/11/2013 ORNI-US  BW   Oragenics Receives European Union CPNP Notifications for ProBiora3® Cosmetic Tablets, 2/13/2019 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update,#N/A,#N/A,#N/A, 3/13/2014 63009R10    BW   Newly Published Analytical Validation Study Shows Precision and Reproducibility of PAM50-Based Prosigna Breast Cancer Assay in Multiple Clinical Testing Laboratories,#N/A, 1/03/2019 SYRS-US  BW   Syros to Present at 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A," 5/09/2012 00182C10     BW   Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Biosante Pharmaceuticals, Inc. for Securities Fraud","10/29/2018 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018", 8/05/2019 ALNY-US   BW   Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria, 5/09/2016 WVE-US   BW   WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy,#N/A,#N/A,"11/19/2014 69512710 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit","12/11/2014 76129910 BW   SHAREHOLDER ALERT: Investigation on Behalf of Retrophin, Inc. Investors Announced by Law Offices of Howard G. Smith", 6/07/2011 PACB-US  BW   Expression Analysis Launches PacBio RS Sequencing Services,#N/A,#N/A,#N/A,#N/A, 4/30/2019 AKBA-US  BW   Akebia Therapeutics to Report First Quarter 2019 Financial Results,#N/A,#N/A,#N/A,#N/A, 5/06/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A," 2/05/2018 MEDP-US  BW   Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on February 26, 2018",#N/A, 9/18/2017 GSK-GB      BW   Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US,#N/A,#N/A,#N/A, 6/11/2013 56400P70 BW   MannKind to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference,12/17/2018 URGN-US  BW   UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC),#N/A, 1/05/2015 29664W10    BW   Esperion Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference," 5/26/2017 AMRS-US  BW   EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Amyris, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A,#N/A,#N/A,11/27/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)," 3/14/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results", 7/24/2012 06SFYB-E BW   ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors,#N/A,11/15/2018 EPZM-US  BW   Epizyme Announces Conference Call to Discuss Corporate Updates,#N/A,#N/A,#N/A, 1/13/2016 GILD-US     BW   Galapagos en Gilead krijgen toestemming van de US FTC om hun wereldwijde overeenkomst voor filgotinib af te ronden,#N/A, 4/30/2019 VCYT-US  BW   Veracyte Announces First Quarter 2019 Financial Results, 5/28/2019 DRNA-US  BW   Dicerna™ to Present at the Jefferies 2019 Healthcare Conference, 8/06/2019 15117K10 BW   Cellectis publie ses résultats financiers du deuxième trimestre 2019 et des six premiers mois de l’année 2019,#N/A,#N/A,#N/A, 6/16/2014 00847X10 BW   Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia," 4/17/2017 IOVA-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Lion Biotechnologies, Inc.",#N/A, 2/27/2019 XLRN-US  BW   Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results,#N/A, 8/14/2019 HZNP-US  BW   Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website," 3/06/2019 00BJ80-E  BW   Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction"," 9/27/2017 ICPT-US  BW   INTERCEPT PHARMACEUTICALS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm",#N/A,11/01/2018 GLYC-US  BW   GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting, 1/05/2011 WLA-US   BW   Maven Semantic: Weight Loss Research Database,#N/A,#N/A, 3/21/2019 G6674U10 BW   Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019,#N/A,#N/A,#N/A, 5/02/2019 RCKT-US  BW   Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting,#N/A,#N/A,#N/A,#N/A, 9/05/2012 05SVDW-E   BW   FibroGen Announces Presentation of Updated Results at European Respiratory Society Annual Congress, 6/04/2019 74587V10 BW   Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2018 MCRB-US  BW   Seres Therapeutics to Present at Two Upcoming June Conferences, 6/05/2019 AIMT-US  BW   Nieuwe uitkomsten van vervolgstudie op PALISADE Fase 3 betreffende AR101 voor pinda-allergie tonen verdere immunomodulatie door dagelijkse dosering gedurende meer dan één jaar,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2018 RARX-US  BW   Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors,#N/A, 2/28/2017 HCM-GB   BW   Chi Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/28/2019 QTRX-US  BW   Quanterix Appoints Amol Chaubal as Chief Financial Officer," 3/28/2018 SLDB-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Solid Biosciences, Inc. (SLDB) and Encourages Investors to Contact the Firm",#N/A,#N/A, 9/10/2014 30233G10 BW   pSivida Corp. Names James Barry to Board of Directors,#N/A,#N/A, 8/05/2019 AXNX-US  BW   Axonics® Announces Second Quarter 2019 Financial Results and Operational Update,"11/01/2018 TCDA-US  BW   Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 8, 2018",#N/A," 9/26/2017 0G2LJD-E BW   AVROBIO, Inc. Appoints Katina Dorton as Chief Financial Officer",12/02/2018 MGTA-US  BW   Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit,#N/A,#N/A,#N/A,#N/A, 5/10/2019 MRNA-US BW   Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2019 TWST-US  BW   Twist Bioscience Announces Pricing of $78.8 Million Public Offering of Common Stock,#N/A,#N/A,#N/A, 3/06/2012 0084LG-E  BW   Precision BioSciences Files Fifth Patent Infringement Lawsuit against Cellectis Related to Engineered Meganucleases,#N/A,#N/A,#N/A," 7/19/2016 00DHGL-E BW   Atreca Appoints Clinical Development Leader Lori Kunkel, M.D., as a Technical Advisor"," 9/09/2019 PSNL-US  BW   Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial", 3/26/2018 0GRDFC-E BW   Stoke Therapeutics Presents Early Research on its Novel ASO Pipeline for Severe Genetic Diseases at OPT Boston,#N/A,11/06/2017 0DMSKV-E BW   Adaptive Biotechnologies annonce une collaboration avec Amgen pour faire avancer le développement clinique du test clonoSEQ® dans le cadre du myélome multiple,#N/A,#N/A
 2/07/2019 0G2BGD-E  BW   Ligand Announces OmniAb® Partnership with Genagon Therapeutics," 4/25/2012 SLXP-US     BW   Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012", 3/29/2019 45232710    BW   Illumina Files Patent Infringement Suit Against BGI in Germany,12/27/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia, 6/12/2017 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 6/21/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3,#N/A,#N/A,#N/A,#N/A, 8/16/2016 0DPMBR-E BW   Arno Completes $2.8 Million Private Placement, 7/10/2012 07FZFC-E    BW,#N/A, 5/13/2019 ALXN-US  BW   Alexion to Present at the UBS Global Healthcare Conference,#N/A, 7/23/2019 SGEN-US     BW   Seattle Genetics Announces Proposed Public Offering of Common Stock," 7/22/2016 IMMU-US     BW   IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Immunomedics Inc.",12/21/2017 09062X10    BW   Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint,10/18/2018 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results, 4/16/2013 09058V10 BW   BioCryst Pharmaceuticals Completes Peramivir Type C Meeting,10/04/2019 GILD-US      BW   Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019,#N/A, 8/02/2016 MDABY-SE BW   Extraordinary General Meeting of Meda Aktiebolag (publ),12/18/2014 M2572210 BW   Compugen Enters Immuno-Oncology Research Collaboration with Johns Hopkins University," 3/23/2018 AKRX-US   BW   Robbins Arroyo LLP: Akorn, Inc. (AKRX) Misled Shareholders According to a Recently Filed Class Action", 5/13/2016 AMGN-US      BW   Fitch Rates Amgen Inc. Notes Offering 'BBB'; Outlook Stable," 5/06/2018 MYGN-US     BW   MYGN INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 8/06/2014 45766930 BW   Insmed Reports Second Quarter 2014 Financial Results, 5/14/2019 05156V10 BW   Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights, 9/22/2010 45773H20 BW   Inovio Pharmaceuticals to Present at Investor Conferences In New York and San Francisco, 7/25/2011 06JG2X-E BW   TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer,#N/A, 9/19/2012 0647R4-E     BW   Angiochem Named as One of the “Fierce 15” Biotech Companies of 2012, 5/01/2019 AERI-US    BW   Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives,#N/A, 6/04/2019 INCY-US  BW   Incyte annonce le premier patient traité dans le cadre de l'essai clinique de phase 3 portant sur le traitement de première ligne du cholangiocarcinome par le pemigatinib,#N/A,10/31/2016 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"11/22/2017 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc",11/01/2018 CERS-US  BW   Cerus Corporation Reports Third Quarter 2018 Results, 6/25/2012 00163U10 BW   AMAG Pharmaceuticals Realigns Operating Cost Structure to Focus on Continued Feraheme Growth and Business Development Activities," 5/14/2019 04269E10 BW   ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019",#N/A,10/02/2018 80067710 BW   Sangamo Therapeutics: Communiqué Normé Related to the Offeror’s Draft Prospectus Related to the Simplified Public Tender Offer Targeting the Shares of the Company," 2/07/2019 EXEL-US  BW   Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019"," 2/05/2018 SAN-FR    BW   InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer"," 5/30/2019 VRTX-US   BW   Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis",#N/A,#N/A, 3/29/2019 BLUE-US  BW   bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype," 4/02/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019",#N/A,#N/A,#N/A," 3/08/2019 TXMD-US  BW   TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting",#N/A,#N/A, 5/09/2019 OMER-US  BW   Omeros Corporation Reports First Quarter 2019 Financial Results, 4/02/2019 76133010 BW   Revance to Participate in the Needham Healthcare Conference, 2/11/2013 ORNI-US  BW   Oragenics CEO To Present at The BIO CEO & Investor Conference on February 12th 2013, 1/28/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call,#N/A,#N/A,#N/A, 2/12/2014 63009R10    BW   Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer,#N/A,12/21/2018 SYRS-US  BW   Syros Added to NASDAQ Biotechnology Index,#N/A,#N/A, 5/08/2012 00182C10     BW   BioSante Pharmaceuticals Reports First Quarter Financial Results,10/23/2018 ENTA-US    BW   Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus, 7/23/2019 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results, 5/05/2016 WVE-SG   BW   WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases,#N/A,#N/A,11/18/2014 69512710 BW   Pacira Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,"12/10/2014 76129910 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Retrophin, Inc.", 5/16/2011 69404D10 BW   Mount Sinai School of Medicine and Pacific Biosciences Partner to Advance Clinical Research through Institute for Genomics and Multiscale Biology,#N/A,#N/A,#N/A,#N/A, 4/09/2019 AKBA-US  BW   Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement,#N/A,#N/A,#N/A,#N/A, 5/02/2019 SAGE.XX1-US BW   Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress,#N/A,#N/A,#N/A,"11/30/2017 MEDP-US  BW   Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder",#N/A, 9/15/2017 GSK-GB      BW   Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD,#N/A,#N/A,#N/A, 5/31/2013 56400P70 BW   MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes,11/12/2018 URGN-US  BW   UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment,#N/A,11/12/2014 29664W10    BW   Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference," 5/15/2017 AMRS-US  BW   AMRS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Amyris, Inc. and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A,#N/A,#N/A,"11/19/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference"," 3/04/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D."," 7/23/2012 061YTY-E BW   ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer",#N/A,11/15/2018 EPZM-US  BW   Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies,#N/A,#N/A,#N/A,12/18/2015 GILD-US     BW   Galapagos e Gilead annunciano una collaborazione a livello globale per lo sviluppo di Filgotinib per il trattamento dell’artrite reumatoide e di altre malattie infiammatorie,#N/A, 4/22/2019 VCYT-US  BW   Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State, 5/16/2019 DRNA-US  BW   Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus, 8/06/2019 15117K10 BW   Cellectis Reports Financial Results for Second Quarter and First Six Months 2019,#N/A,#N/A,#N/A, 6/14/2014 00847X10 BW   New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies," 4/17/2017 IOVA-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Lion Biotechnologies, Inc. (LBIO) and Encourages Investors with Losses to Contact the Firm",#N/A," 2/19/2019 XLRN-US  BW   Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019",#N/A," 8/07/2019 HZNP-US  BW   Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results;
Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance"," 3/04/2019 00BJ80-E  BW   Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting"," 9/27/2017 ICPT-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.",#N/A,"10/26/2018 GLYC-US  BW   GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018",12/22/2010 SIAL-US  BW   Research and Markets: Proteomics - Global Strategic Business Report Reveals Vital Forecasts up to 2015 and Profiles of 168 Companies,#N/A,#N/A, 3/21/2019 G6674U10 BW   Novocure’s Chief Science Officer Retires after 17 Years of Service,#N/A,#N/A,#N/A, 4/30/2019 RCKT-US  BW   Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM),#N/A,#N/A,#N/A,#N/A, 7/31/2012 05SVDW-E   BW   FibroGen’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients with Idiopathic Pulmonary Fibrosis, 6/02/2019 74587V10 BW   CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A," 5/17/2018 MCRB-US  BW   Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018", 6/04/2019 AIMT-US  BW   Novos Dados do Estudo de Acompanhamento do AR101 do PALISADE Fase 3 sobre Alergia ao Amendoim Revelam Imunomodulação Contínua Através de Dosagem Diária Superior a um Ano,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2018 RARX-US  BW   ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update,#N/A, 2/20/2017 HCM-GB   BW   Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2019 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018, 3/28/2018 SLDB-US  BW   Scott+Scott Attorneys at Law LLP Announces the Filing of Investor Class Action Lawsuit Against Solid Biosciences Inc.,#N/A,#N/A, 9/09/2014 30233G10 BW   pSivida Corp. Reports Fourth Quarter and FY 2014 Results,#N/A,#N/A, 8/01/2019 AXNX-US  BW   Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study,"10/04/2018 TCDA-US  BW   Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28",#N/A," 9/21/2017 0G2LJD-E BW   AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease",12/01/2018 MGTA-US  BW   Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate,#N/A,#N/A,#N/A,#N/A, 5/08/2019 MRNA-US BW   Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2019 TWST-US  BW   Twist Bioscience Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 2/23/2012 0084LG-E  BW   Precision BioSciences Announces Allowance of Five Additional U.S. Patent Applications Related to Engineered Meganucleases,#N/A,#N/A,#N/A," 6/22/2016 00DHGL-E BW   Atreca Appoints Leading Cancer Clinical Researcher Lawrence Fong, M.D., as a Technical Advisor", 8/26/2019 PSNL-US  BW   Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference, 1/04/2018 SRPT-US  BW   Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Diseases,#N/A,11/06/2017 0DMSKV-E BW   Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ® Assay in Multiple Myeloma,#N/A,#N/A
 2/04/2019 LGND-US   BW   Ligand Announces Investment in Dianomi Therapeutics,"12/20/2011 74318710    BW   Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation", 3/27/2019 45232710    BW   Illumina et le Centre de géogénétique de la Fondation Lundbeck collaborent pour générer l’un des plus grands ensembles de données sur le génome ancien afin de décoder les origines génétiques et l’évolution des problèmes de santé mentale,12/19/2018 84763A10  BW   Spectrum Pharmaceuticals Provides Poziotinib Update," 6/12/2017 ENDP-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc -- ENDP", 5/31/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences,#N/A,#N/A,#N/A,#N/A, 8/08/2016 OPK-US   BW   OPKO Health Reports Improved Financial and Operating Results, 6/29/2012 IONS-US     BW,#N/A, 5/03/2019 ALXN-US  BW   New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD),#N/A, 7/16/2019 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2019 Financial Results," 7/15/2016 IMMU-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016","12/20/2017 09062X10    BW   Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018",10/08/2018 IMGN-US  BW   ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO, 4/01/2013 BCRX-US  BW   BioCryst Pharmaceuticals Provides Update Regarding Peramivir,10/03/2019 GILD-US      BW   U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP),#N/A, 5/31/2016 MDABY-SE BW   Fitch Rates Mylan's Notes Offering 'BBB-',12/03/2014 M2572210 BW   Compugen to Present at Oppenheimer 25th Annual Healthcare Conference," 3/23/2018 AKRX-US   BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Akorn, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit", 5/10/2016 OPK-US       BW   OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access," 5/03/2018 0BGL4K-E    BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018",#N/A,#N/A, 8/04/2014 45766930 BW   Insmed Provides Regulatory Update for ARIKAYCE, 5/10/2019 05156V10 BW   Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis, 9/21/2010 45773H20 BW   Inovio Completes Enrollment of HIV Clinical Trial for DNA Vaccine Delivered Using Electroporation,#N/A,#N/A," 8/27/2012 07GVF3-E     BW   Research and Markets: Liver Failure - Pipeline Review, H2 2012"," 4/30/2019 AERI-US    BW   Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019",#N/A, 6/04/2019 INCY-US  BW   Incyte gibt Behandlung des ersten Patienten mit Pemigatinib als Erstlinientherapie bei Cholangiokarzinom in klinischer Phase-3-Studie bekannt,#N/A,10/27/2016 SRPT-US  BW   Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments,11/20/2017 06LSRV-E BW   Alkermes Named a Top Place to Work by The Boston Globe,10/31/2018 CERS-US  BW   Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate, 6/22/2012 AMAG-US  BW   Rienso® (Ferumoxytol) Receives European Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease," 5/08/2019 04269E10 BW   ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019",#N/A,10/01/2018 SGMO-US  BW   Sangamo et TxCell annoncent la réalisation de l'acquisition par Sangamo de la majorité des actions ordinaires de TxCell," 1/29/2019 EXEL-US  BW   Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019", 1/25/2018 LLY-US    BW   Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes, 5/15/2019 0HKMJ5-E  BW   Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases,#N/A,#N/A, 3/25/2019 BLUE-US  BW   Erklärung von bluebird bio zum europäischen Zulassungsstatus von LentiGlobin™," 4/01/2019 ACAD-US  BW   ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer",#N/A,#N/A,#N/A, 2/28/2019 TXMD-US  BW   TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences,#N/A,#N/A, 5/07/2019 OMER-US  BW   Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting, 3/05/2019 76133010 BW   Revance to Participate in Upcoming Investor Conferences, 1/07/2013 ORNI-US  BW   Oragenics CEO To Present at 6th Annual OneMedForum Investor Conference, 1/28/2019 IRWD-US  BW   Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation,#N/A,#N/A,#N/A, 2/11/2014 63009R10    BW   NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests From Translational Research Discoveries,#N/A,12/07/2018 SYRS-US  BW   Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium,#N/A,#N/A," 4/17/2012 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at BioCentury Future Leaders in the Biotech Industry Conference", 9/05/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium, 7/16/2019 ALNY-US   BW   Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis, 4/29/2016 WVE-US   BW   WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference,#N/A,#N/A,"11/17/2014 69512710 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014","12/01/2014 76129910 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Retrophin, Inc. To Contact Brower Piven Before The December 19, 2014 Lead Plaintiff Deadline In Class Action Lawsuit", 4/27/2011 69404D10 BW   Pacific Biosciences Begins Shipments of Commercial PacBio RS Systems,#N/A,#N/A,#N/A,#N/A, 4/09/2019 AKBA-US  BW   Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement,#N/A,#N/A,#N/A,#N/A," 4/18/2019 SAGE.XX1-US BW   Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019",#N/A,#N/A,#N/A,"11/27/2017 0CFGSR-E BW   Medpace Holdings, Inc. Announces Commencement of Proposed Secondary Offering of Common Stock by Selling Shareholder",#N/A," 9/11/2017 GSK-GB      BW   Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress",#N/A,#N/A,#N/A, 5/29/2013 56400P70 BW   MannKind to Present at Jefferies 2013 Global Healthcare Conference,11/06/2018 URGN-US  BW   UroGen Pharma to Present at November 2018 Investor Conferences,#N/A,11/11/2014 29664W10    BW   Esperion Therapeutics to Host and Webcast Live Investor Event," 5/08/2017 AMRS-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Amyris, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A,#N/A,#N/A,"11/01/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results"," 2/07/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day", 5/03/2012 008FZT-E BW   ADMA Biologics Appoints Brian Lenz as Chief Financial Officer,#N/A,11/02/2018 EPZM-US  BW   Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress,#N/A,#N/A,#N/A,12/18/2015 GILD-US     BW   Galapagos y Gilead suscriben alianza mundial para desarrollar Filgotinib para el tratamiento de la artritis reumatoide y otras enfermedades inflamatorias,#N/A," 4/22/2019 VCYT-US  BW   Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development", 5/09/2019 DRNA-US  BW   Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update, 7/08/2019 15117K10 BW   Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way,#N/A,#N/A,#N/A, 6/13/2014 00847X10 BW   Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration," 4/14/2017 IOVA-US  BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 2/13/2019 XLRN-US  BW   Acceleron to Present at Two Upcoming Healthcare Investor Conferences,#N/A, 8/01/2019 HZNP-US  BW   Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program, 2/07/2019 00BJ80-E  BW   Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck," 9/25/2017 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc. -- ICPT",#N/A,10/24/2018 GLYC-US  BW   GlycoMimetics to Present at Upcoming Investor Conferences,12/02/2010 00780K-E BW   Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia,#N/A,#N/A, 3/18/2019 G6674U10 BW   Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference,#N/A,#N/A,#N/A, 4/18/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A," 7/23/2012 00B8PL-E   BW   U.S. Nephrologists Continue to Report a Decreasing Treatment Prevalence for ESAs and an Increasing Treatment Prevalence Trend for IV Iron, According to a Recent BioTrends Report", 5/29/2019 74587V10 BW   Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 MCRB-US  BW   Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates, 6/04/2019 AIMT-US  BW   Nuevos datos del estudio de seguimiento PALISADE de tercera fase sobre el AR101 para la alergia al cacahuete revelan una inmunomodulación continua con una dosificación diaria mantenida después del año,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2018 RARX-US  BW   Ra Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A, 2/14/2017 AZN-GB   BW   Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/26/2019 QTRX-US  BW   Quanterix to Release Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Thursday, March 7, 2019", 3/27/2018 SLDB-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Solid Biosciences Inc. (SLDB) on Behalf of Shareholders,#N/A,#N/A, 9/03/2014 30233G10 BW   pSivida Corp Announces Fourth Quarter and Fiscal Year 2014 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 7/29/2019 AXNX-US  BW   Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology, 8/08/2018 TCDA-US  BW   Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives,#N/A," 3/22/2017 0G2LJD-E BW   AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease",11/26/2018 MGTA-US  BW   Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH,#N/A,#N/A,#N/A,#N/A, 5/06/2019 MRNA-US BW   Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2019 TWST-US  BW   Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress,#N/A,#N/A,#N/A," 2/21/2012 ALCLS-FR  BW   Precision BioSciences Files Two New Infringement Lawsuits against Cellectis, Requests Permanent Injunction against Importation of Infringing Materials into U.S.",#N/A,#N/A,#N/A," 6/17/2016 00DHGL-E BW   Atreca Appoints Acclaimed Immunologist Lewis L. Lanier, Ph.D., as a Technical Advisor", 8/13/2019 PSNL-US  BW   Personalis Reports Second Quarter 2019 Financial Results,#N/A,#N/A, 7/26/2017 0DMSKV-E BW   Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting,#N/A,#N/A
 1/25/2019 LGND-US   BW   Ligand Partner Seelos Therapeutics Becomes a Public Company,"10/26/2011 SGEN-US     BW   Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion", 3/26/2019 45232710    BW   Illumina und Lundbeck Foundation GeoGenetics Centre arbeiten gemeinsam an der Erstellung eines der größten Datensätze historischer Genome zur Entschlüsselung der genetischen Ursachen und Entwicklung von psychischen Gesundheitsproblemen,12/06/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting, 6/09/2017 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Endo International plc and Encourages Investors with Losses to Contact the Firm, 5/08/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results,#N/A,#N/A,#N/A,#N/A," 8/03/2016 OPK-US   BW   OPKO to Announce Second Quarter Operating and Financial Results on August 8, 2016", 6/14/2012 07G69B-E    BW,#N/A, 4/26/2019 ALXN-US  BW   Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 7/16/2019 4503-JP     BW   Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer," 7/09/2016 IMMU-US     BW   UPCOMING DEADLINE ALERT - Immunomedics, Inc. - Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 To Contact The Firm",12/19/2017 09062X10    BW   Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy, 9/24/2018 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences, 3/25/2013 09058V10 BW   BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema, 9/09/2019 GILD-US      BW   Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA),#N/A, 3/21/2016 ACOR-US  BW   Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation to Continue in Delaware District Court,12/02/2014 M2572210 BW   Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints," 3/21/2018 FRE-DE    BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Akorn, Inc. (AKRX)", 4/08/2016 CELG-US      BW   Flatiron Health Announces Strategic Relationships with Celgene and Amgen to Further Advance Personalized Medicine for Cancer Patients and Accelerate Clinical Research," 5/03/2018 MYGN-US     BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Myriad Genetics, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit",#N/A,#N/A, 5/20/2014 45766930 BW   Insmed Announces Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE for Treatment Resistant Nontuberculous Mycobacterial Lung Infections," 5/09/2019 05156V10 BW   Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019", 9/15/2010 45773H20 BW   Inovio Pharmaceuticals Awarded Follow-on Funding from the PATH Malaria Vaccine Initiative for DNA Vaccine Development,#N/A,#N/A, 5/16/2012 NVIV-US      BW   InVivo Therapeutics Chief Science Officer Edward Wirth to Discuss Biopolymers and Hydrogels for SCI at Rick Hansen’s Interdependence 2012, 4/25/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant,#N/A, 6/04/2019 INCY-US  BW   Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma,#N/A,"10/24/2016 SRPT-US  BW   Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016",11/16/2017 ALKS-US  BW   Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® Accepted for Filing by U.S. FDA,"10/23/2018 CERS-US  BW   Cerus to Release Third Quarter 2018 Results on November 1, 2018", 6/12/2012 00B23Z-E BW   CloudLock Unveils the Industry’s First PII and PCI Compliance Scan for Google Drive, 5/01/2019 04269E10 BW   ArQule Reports First Quarter 2019 Financial Results,#N/A,10/01/2018 SGMO-US  BW   Sangamo and TxCell Announce the Completion of the Acquisition by Sangamo of Majority of TxCell Ordinary Shares, 1/14/2019 EXEL-US  BW   Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma," 1/23/2018 BIVV-US   BW   SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout", 4/30/2019 VRTX-US   BW   Vertex Reports First-Quarter 2019 Financial Results,#N/A,#N/A, 3/25/2019 BLUE-US  BW   La déclaration de bluebird bio sur le statut réglementaire européen du LentiGlobin™," 3/27/2019 ACAD-US  BW   Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology",#N/A,#N/A,#N/A, 2/21/2019 TXMD-US  BW   TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results,#N/A,#N/A," 5/06/2019 OMER-US  BW   Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019", 2/26/2019 76133010 BW   Revance Releases Fourth Quarter and Full Year 2018 Results,11/28/2012 ORNI-US  BW   Griffin Securities Initiates Research Coverage on Oragenics," 1/24/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation",#N/A,#N/A,#N/A,12/18/2013 63009R10    BW   NanoString Technologies Announces Publication of Pivotal ABCSG-8 Study of the Prosigna Breast Cancer Assay,#N/A,12/02/2018 SYRS-US  BW   Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting,#N/A,#N/A," 4/03/2012 00182C10     BW   Deadline Approaching: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in BioSante Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 6, 2012 to Seek a Lead Plaintiff Position", 8/27/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 7/11/2019 ALNY-US   BW   Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer, 3/30/2016 WVE-US   BW   WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update,#N/A,#N/A,"11/17/2014 69512710 BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Pacira Pharmaceuticals, Inc. Of Upcoming Deadline","12/01/2014 76129910 BW   UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Retrophin, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX", 4/27/2011 69404D10 BW   Pacific Biosciences commence les expéditions commerciales des systèmes PacBio RS,#N/A,#N/A,#N/A,#N/A, 4/05/2019 AKBA-US  BW   Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 4/03/2019 SAGE.XX1-US BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,"10/30/2017 MEDP-US  BW   Medpace Holdings, Inc. to Present at Credit Suisse Healthcare Conference",#N/A, 9/07/2017 INVA-US     BW   Innoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12,#N/A,#N/A,#N/A, 5/09/2013 56400P70 BW   MannKind Corporation Reports 2013 First Quarter Financial Results,"11/05/2018 URGN-US  BW   UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018",#N/A,11/10/2014 29664W10    BW   Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results," 5/04/2017 AMRS-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Amyris, Inc. Investors",#N/A,#N/A,#N/A,#N/A,10/30/2018 EGRX-US  BW   Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization, 1/03/2019 DCPH-US BW   Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors, 2/14/2012 077K85-E BW   ADMA Biologics Completes Merger and Closes $17.5 Million Private Placement,#N/A,10/22/2018 EPZM-US  BW   Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO,#N/A,#N/A,#N/A,12/18/2015 GILD-US     BW   Galapagos et Gilead annoncent un partenariat mondial pour développer Filgotinib en vue du traitement de l'arthrite rhumatoïde et d'autres malades inflammatoires,#N/A, 4/08/2019 VCYT-US  BW   Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype, 5/03/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), 7/08/2019 15117K10 BW   Cellectis publie une nouvelle architecture de CAR visant à contrôler les cellules CAR-T sans les éliminer,#N/A,#N/A,#N/A," 6/09/2014 00847X10 BW   Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia"," 4/14/2017 IOVA-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 1/16/2019 XLRN-US  BW   Acceleron Announces Pricing of Public Offering of Common Stock,#N/A, 8/01/2019 HZNP-US  BW   Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors, 1/30/2019 00BJ80-E  BW   Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions," 9/22/2017 ICPT-US  BW   Arons & Arons, LLC. Announces Investigation on Behalf of Intercept Pharmaceuticals Inc. Investors",#N/A, 8/14/2018 GLYC-US  BW   GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271),10/12/2010 00780K-E BW   Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement,#N/A,#N/A, 2/28/2019 G6674U10 BW   Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update,#N/A,#N/A,#N/A, 4/15/2019 RCKT-US  BW   Rocket Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A," 6/04/2012 05SVDW-E   BW   FibroGen Announces Preliminary Clinical Findings on the Positive Effects of FG-4592, Its Investigational HIF-PHI Therapy for Anemia, on Lowering Blood Pressure and Cholesterol in Patients With Chronic Kidney Disease", 5/09/2019 74587V10 BW   Puma Biotechnology Reports First Quarter 2019 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A," 5/07/2018 MCRB-US  BW   Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018", 6/04/2019 AIMT-US  BW   Dei dati da due nuove ricerche confermano il livello della qualità della vita e dello stress psicologico per chi vive con l'allergia alle arachidi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2018 RARX-US  BW   Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment,#N/A, 2/14/2017 HCM-GB   BW   Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2019 QTRX-US  BW   Quanterix to Present at Multiple Upcoming Healthcare Conferences, 3/27/2018 RC-US    BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Solid Biosciences Inc. – SLDB,#N/A,#N/A," 9/03/2014 30233G10 BW   pSivida Corp. Reports ILUVIEN® for Chronic Diabetic Macular Edema Receives Marketing Authorization in Sweden, 10th EU Approval",#N/A,#N/A, 7/22/2019 AXNX-US  BW   Axonics® to Report 2019 Second Quarter and Six-Month Financial Results and Host a Conference Call on August 5, 8/01/2018 TCDA-US  BW   Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical Development,#N/A,"11/09/2016 0G2LJD-E BW   AVROBIO, Inc. Expands Senior Management Team with Three Key Hires",11/19/2018 MGTA-US  BW   Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer,#N/A,#N/A,#N/A,#N/A, 4/29/2019 MRNA-US BW   Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2019 TWST-US  BW   Twist Bioscience Announces Synthetic DNA Biosecurity Publication in Frontiers,#N/A,#N/A,#N/A, 2/14/2012 0084LG-E  BW   Precision BioSciences Receives Notice of Intent to Grant for New European Patent Covering Engineered Meganucleases,#N/A,#N/A,#N/A," 6/07/2016 00DHGL-E BW   Atreca, Inc. Announces Election of Industry Leader David Lacey, M.D., to Its Board of Directors"," 8/07/2019 PSNL-US  BW   Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study",#N/A,#N/A, 7/26/2017 0DMSKV-E BW   Adaptive Biotechnologies Announces Translational Collaboration with National Cancer Institute,#N/A,#N/A
 1/17/2019 LGND-US   BW   INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated, 8/30/2011 74318710    BW   Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain, 3/26/2019 45232710    BW   Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues,12/03/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)," 6/09/2017 ENDP-US  BW   Arons & Arons, LLC. Announces Investigation on Behalf of Endo International plc Investors", 5/02/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences,#N/A,#N/A,#N/A,#N/A, 6/30/2016 OPK-US   BW   OPKO Health to Acquire Transition Therapeutics, 5/29/2012 SNY-FR      BW,#N/A, 4/25/2019 ALXN-US  BW   Alexion Reports First Quarter 2019 Results,#N/A," 7/02/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019", 7/01/2016 IMMU-US     BW   IMPORTANT INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. and Encourages Investors With Losses to Contact the Firm,12/18/2017 09062X10    BW   Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference, 8/27/2018 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences, 2/19/2013 09058V10 BW   BioCryst Reports Fourth Quarter and Full Year 2012 Financial Results," 8/26/2019 GILD-US      BW   Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10",#N/A, 2/11/2016 MYL-GB   BW   Correction: Fitch Affirms Mylan at 'BBB-' on Meda Acquisition Announcement; Outlook Stable,11/12/2014 M2572210 BW   Compugen to Present at Jefferies 2014 Global Healthcare Conference in London," 3/16/2018 AKRX-US   BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Akorn, Inc.", 3/14/2016 PTI-CA       BW   Patheon Signs Flexible Manufacturing Agreement with Amgen," 4/30/2018 0DBJVZ-E    BW   Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Myriad Genetics, Inc.",#N/A,#N/A, 3/26/2014 45766930 BW   Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections, 4/30/2019 05156V10 BW   Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen, 9/13/2010 45773H20 BW   Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV,#N/A,#N/A,12/12/2011 37416310     BW   Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer, 4/02/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference,#N/A, 6/03/2019 INCY-US  BW   New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib,#N/A,10/06/2016 0731W3-E BW   CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sarepta’s Patient Support Program for Duchenne Families,11/14/2017 ALKS-US  BW   VIVITROL® and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse,10/16/2018 CERS-US  BW   Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting," 5/29/2012 AMAG-US  BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 4/30/2019 04269E10 BW   Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration,#N/A," 7/23/2018 SGMO-US  BW   TxCell améliore de nouveau son programme de financement par OCABSA, sous réserve de la réalisation de l’acquisition d’une participation majoritaire par Sangamo Therapeutics, Inc.", 1/08/2019 4568-JP  BW   Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan," 1/22/2018 BIVV-US   BW   Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm", 4/30/2019 VRTX-US   BW   FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age,#N/A,#N/A, 3/25/2019 BLUE-US  BW   bluebird bio Statement on European Regulatory Status of LentiGlobin™," 3/04/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019",#N/A,#N/A,#N/A," 2/08/2019 TXMD-US  BW   TherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019",#N/A,#N/A, 5/01/2019 OMER-US  BW   Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting," 2/12/2019 76133010 BW   Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019","10/12/2012 008349-E BW   Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business Update"," 1/23/2019 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials",#N/A,#N/A,#N/A,"12/13/2013 63009R10    BW   PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients",#N/A,11/20/2018 SYRS-US  BW   Syros to Present at 30th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A," 3/29/2012 00182C10     BW   BioSante Pharmaceuticals Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate Possible Breaches of Fiduciary Duty by the Officers and Directors of BioSante Pharmaceuticals, Inc."," 8/07/2018 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018", 7/01/2019 ALNY-US   BW   Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria, 2/16/2016 WVE-SG   BW   WAVE Life Sciences to Present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day Conference,#N/A,#N/A,"11/11/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference","11/24/2014 76129910 BW   UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action against Retrophin, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 19, 2014", 4/27/2011 69404D10 BW   Pacific Biosciences beginnt Versand von kommerziellen PacBio RS Systemen,#N/A,#N/A,#N/A,#N/A, 4/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A," 3/19/2019 SAGE-US     BW   Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression",#N/A,#N/A,#N/A,"10/30/2017 MEDP-US  BW   Medpace Holdings, Inc. Reports Third Quarter 2017 Results",#N/A, 8/30/2017 INVA.XX1-US BW   Innoviva to Participate in Baird Global Healthcare Conference on September 7,#N/A,#N/A,#N/A, 5/08/2013 56400P70 BW   MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference,10/30/2018 URGN-US  BW   FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC),#N/A,11/05/2014 29664W10    BW   Esperion Therapeutics to Present at Credit Suisse Healthcare Conference," 5/03/2017 AMRS-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Amyris, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A,10/30/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces Results of Study for Fulvestrant," 1/02/2019 DCPH-US BW   Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans",#N/A,#N/A,10/10/2018 EPZM-US  BW   Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO,#N/A,#N/A,#N/A,12/18/2015 GILD-US     BW   Galapagos und Gilead geben globale Partnerschaft zur Entwicklung von Filgotinib zur Behandlung von rheumatoider Arthritis und anderen entzündlichen Erkrankungen bekannt,#N/A," 4/03/2019 VCYT-US  BW   Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019"," 5/02/2019 DRNA-US  BW   Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019", 7/04/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 6/04/2014 00847X10 BW   Agios Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference," 4/14/2017 IOVA-US  BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Lion Biotechnologies, Inc.",#N/A, 1/14/2019 XLRN-US  BW   Acceleron Announces Proposed Public Offering of Common Stock,#N/A, 7/25/2019 HZNP-US  BW   Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy, 1/07/2019 00BJ80-E  BW   Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study," 4/10/2014 45845P10 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.",#N/A, 8/09/2018 GLYC-US  BW   GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements, 6/28/2010 MOR-DE   BW   MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program,#N/A,#N/A," 1/07/2019 G6674U10 BW   Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update",#N/A,#N/A,#N/A, 4/15/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 5/03/2012 05SVDW-E   BW   FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update, 5/08/2019 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2018 MCRB-US  BW   Seres Therapeutics to Present at Two Upcoming May Conferences, 6/04/2019 AIMT-US  BW   Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference,#N/A, 2/01/2017 HCM-GB   BW   Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/14/2019 QTRX-US  BW   Quanterix to Present at 21st Annual Needham Growth Conference, 3/27/2018 RC-US    BW   Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Solid Biosciences Inc. Investors (SLDB),#N/A,#N/A," 7/31/2014 30233G10 BW   pSivida Corp. Reports ILUVIEN® for Chronic Diabetic Macular Edema Receives Marketing Authorization in Denmark, 9th EU Approval",#N/A,#N/A," 6/18/2019 AXNX-US  BW   Axonics® gibt bekannt, dass die US-amerikanische Zulassungsbehörde FDA die Nutzung von Ganzkörper-MRT für Patienten in Pivotstudie genehmigt hat"," 7/31/2018 TCDA-US  BW   Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Wednesday, August 8, 2018",#N/A," 8/02/2016 0G2LJD-E BW   AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases and Cancer",11/08/2018 MGTA-US  BW   Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A," 4/16/2019 MRNA-US BW   Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/18/2019 TWST-US  BW   Twist Bioscience to Report Fiscal 2019 Second Quarter Financial Results on Tuesday, April 30, 2019",#N/A,#N/A,#N/A, 2/06/2012 0084LG-E  BW   Precision BioSciences Announces Allowances in Fifth and Sixth U.S. Patent Applications Related to Engineered Meganucleases,#N/A,#N/A,#N/A, 6/01/2016 00DHGL-E BW   Atreca to Present at the Jefferies 2016 Global Healthcare Conference," 8/01/2019 PSNL-US  BW   Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications",#N/A,#N/A," 6/22/2017 0DMSKV-E BW   Adaptive Biotechnologies annonce une collaboration avec Janssen Biotech, Inc. pour utiliser le test clonoSEQ® afin de mesurer la maladie résiduelle minimale … sur les myélomes multiples traités avec du DARZALEX®",#N/A,#N/A
 1/15/2019 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th, 4/04/2011 74318710    BW   Progenics Pharmaceuticals to Webcast Upcoming Presentations, 2/28/2019 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation,11/30/2018 84763A10  BW   Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology, 6/09/2017 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Endo International plc, 4/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results,#N/A,#N/A,#N/A,#N/A, 6/21/2016 OPK-US   BW   FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease, 5/10/2012 ALNY-US     BW,#N/A," 4/12/2019 ALXN-US  BW   Alexion to Report First Quarter Results on Thursday, April 25, 2019",#N/A, 6/12/2019 SGEN-US     BW   Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML), 6/23/2016 IMMU-US     BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Immunomedics Inc. And Reminds Investors With Losses To Contact The Firm,12/07/2017 09062X10    BW   Biogen to Present at the Guggenheim 5th Annual Healthcare Conference, 7/31/2018 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference," 2/05/2013 09058V10 BW   BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013", 8/23/2019 GILD-US      BW   Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration,#N/A, 2/11/2016 MYL-GB   BW   Fitch Affirms Mylan at 'BBB-' on Meda Acquisition Announcement; Outlook Stable,10/29/2014 M2572210 BW   Compugen Ltd. Reports Third Quarter 2014 Financial Results," 3/16/2018 AKRX-US   BW   AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Akorn, Inc. to Contact the Firm", 2/23/2016 AMGN-US      BW   Fitch Rates Amgen Inc. Swiss Franc Notes 'BBB'; Outlook Stable," 4/29/2018 MYGN-US     BW   MYGN LOSS NOTICE: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action – MYGN",#N/A,#N/A," 2/19/2014 45766930 BW   Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients", 4/24/2019 05156V10 BW   Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference, 9/10/2010 45773H20 BW   Inovio Pharmaceuticals to Host Clinical Trials Update Conference Call,#N/A,#N/A,11/23/2011 GNOM.XX2-US  BW   A Tribute to Alex Barkas, 4/01/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe,#N/A, 5/24/2019 INCY-US  BW   FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease,#N/A, 9/29/2016 CATB-US  BW   Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy,11/09/2017 ALKS-US  BW   Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence,10/12/2018 CERS-US  BW   Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting, 5/09/2012 00163U10 BW   AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer," 4/17/2019 04269E10 BW   ArQule to Report First Quarter 2019 Financial Results on May 1, 2019",#N/A, 7/23/2018 SGMO-US  BW   Sangamo Therapeutics to Acquire TxCell,12/05/2018 EXEL-US  BW   Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma," 1/22/2018 BIVV-US   BW   BIOVERATIV INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout", 4/12/2019 VRTX-US   BW   Vertex to Announce First-Quarter 2019 Financial Results on April 30,#N/A,#N/A," 3/22/2019 BLUE-US  BW   bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina", 2/26/2019 ACAD-US  BW   ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results,#N/A,#N/A,#N/A, 1/03/2019 TXMD-US  BW   TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 4/03/2019 OMER-US  BW   Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment, 1/22/2019 76133010 BW   Revance Announces Closing of Public Offering of Common Stock,"10/08/2012 008349-E BW   Fibrocell Science, Inc. Announces $45 Million Private Placement and Enters Strategic Collaboration with Intrexon", 1/15/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C,#N/A,#N/A,#N/A,12/10/2013 63009R10    BW   NanoString Technologies Announces Adoption of the Prosigna Breast Cancer Assay by Leading US Clinical Laboratories and Cancer Centers,#N/A,11/15/2018 SYRS-US  BW   Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors,#N/A,#N/A," 3/29/2012 060RWY-E     BW   Despite Significant Advances in the Treatment of Chronic Myeloid Leukemia (CML) Over the Last Decade, Hematologist-Oncologists Report High Unmet Need for New Therapies in TKI Treatment-Resistant Patients"," 7/16/2018 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018", 6/24/2019 ALNY-US   BW   Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting, 2/03/2016 WVE-SG   BW   WAVE Life Sciences to Present at the LEERINK Partners 5th Annual Global Healthcare Conference,#N/A,#N/A,11/06/2014 69512710 BW   Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty,"11/19/2014 76129910 BW   Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel", 2/02/2011 69404D10 BW   Pacific Biosciences Reports Progress Toward Providing the Premier Third Generation DNA Sequencing Solution,#N/A,#N/A,#N/A,#N/A, 3/18/2019 AKBA-US  BW   Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights,#N/A,#N/A,#N/A,#N/A, 3/05/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,"10/04/2017 MEDP-US  BW   Medpace Holdings, Inc. to Report Third Quarter 2017 Financial Results on October 30, 2017",#N/A, 8/21/2017 INVA-US     BW   Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes,#N/A,#N/A,#N/A," 5/02/2013 56400P70 BW   MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call on May 9, 2013", 9/25/2018 URGN-US  BW   UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference,#N/A,11/03/2014 29664W10    BW   Esperion Therapeutics to Provide Third Quarter 2014 Results," 4/27/2017 AMRS-US  BW   AMRS LOSS NOTICE: Rosen Law Firm Reminds Amyris, Inc. Investors of the Important Deadline in First Filed Class Action – AMRS",#N/A,#N/A,#N/A,#N/A,"10/25/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018"," 1/02/2019 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference",#N/A,#N/A,10/05/2018 EPZM-US  BW   Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares,#N/A,#N/A,#N/A,12/17/2015 GILD-US     BW   Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases,#N/A, 4/01/2019 VCYT-US  BW   Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF, 5/02/2019 DRNA-US  BW   Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial, 7/04/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 5/22/2014 00847X10 BW   Agios Pharmaceuticals to Present New Clinical Data from AG-221 Ongoing Phase 1 Study at the 19th Congress of the European Hematology Association," 4/14/2017 IOVA-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Lion Biotechnologies, Inc. Investors",#N/A, 1/10/2019 XLRN-US  BW   Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood,#N/A, 7/18/2019 HZNP-US  BW   Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets,12/06/2018 00BJ80-E  BW   Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to Its Board of Directors," 4/03/2014 45845P10 BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.",#N/A," 8/02/2018 GLYC-US  BW   GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018"," 2/09/2010 00780K-E BW   Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer",#N/A,#N/A,12/21/2018 G6674U10 BW   Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 4/15/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting,#N/A,#N/A,#N/A,#N/A,11/15/2011 05SVDW-E   BW   FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia Correction and Maintenance in Chronic Kidney Disease Patients, 5/03/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2018 MCRB-US  BW   Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting, 6/04/2019 AIMT-US  BW   Gegevens uit twee studies bevestigen gevolgen voor levenskwaliteit en psychosociale belasting van leven met pinda-allergie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/25/2018 RARX-US  BW   Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors",#N/A, 1/16/2017 HCM-GB   BW   Chi-Med appoints Industry Veteran Paul Carter to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/10/2019 QTRX-US  BW   Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex," 3/21/2018 SLDB-US  BW   INVESTOR ALERT: Holzer & Holzer Continues Investigation of Solid Biosciences, Inc.",#N/A,#N/A, 7/28/2014 30233G10 BW   pSivida Announces ILUVIEN® Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal,#N/A,#N/A, 6/18/2019 AXNX-US  BW   Axonics® annonce l’approbation par la Food & Drug Administration américaine des IRM du corps entier pour les patients enrôlés dans une étude pivot, 7/11/2018 HTGC-US  BW   Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018,#N/A, 5/13/2016 0G2LJD-E BW   AVROBIO Awarded Johnson & Johnson Coveted J-Labs Incubator Space,"11/01/2018 MGTA-US  BW   Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs",#N/A,#N/A,#N/A,#N/A, 4/03/2019 MRNA-US BW   Moderna to Present at 18th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2019 TWST-US  BW   Twist Bioscience et iGEM s’associent pour fournir de l’ADN synthétique destiné au concours et au Registre de l’iGEM,#N/A,#N/A,#N/A, 2/02/2012 0084LG-E  BW   Precision BioSciences Announces Allowance of Fourth U.S. Patent Related to Engineered Meganucleases,#N/A,#N/A,#N/A," 5/02/2016 00DHGL-E BW   Atreca Expands Leadership Team, Appoints Accomplished Cancer Immunotherapy Researcher and Drug Developer Norman M. Greenberg, Ph.D., as Chief Scientific Officer"," 7/30/2019 PSNL-US  BW   Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019",#N/A,#N/A," 6/22/2017 0DMSKV-E BW   Adaptive Biotechnologies kündigt eine Zusammenarbeit mit Janssen Biotech, Inc. an, um das clonoSEQ®-Assay zur Messung der minimalen Resterkrankung in DARZALEX® Studien zu Multiplem Myelom zu nutzen",#N/A,#N/A
12/18/2018 LGND-US   BW   Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance, 3/15/2011 74318710    BW   Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2010 Financial Results, 2/06/2019 45232710    BW   Illumina Names Susan E. Siegel to Its Board of Directors,11/13/2018 84763A10  BW   Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors," 6/09/2017 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc", 4/24/2019 ARWR-US  BW   Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen,#N/A,#N/A,#N/A,#N/A, 6/14/2016 OPK-US   BW   OPKO Health to Host Analyst & Investor Day in New York City on June 15, 3/29/2012 46222210    BW,#N/A, 3/20/2019 ALXN-US  BW   Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases,#N/A," 6/10/2019 ROG-CH      BW   Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA"," 6/20/2016 IMMU-US     BW   IMMUNOMEDICS, INC. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit","12/04/2017 4502-JP     BW   Biogen Appoints Mark Hernon as SVP, Chief Information Officer", 7/27/2018 IMGN-US  BW   ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results, 1/02/2013 BCRX-US  BW   BioCryst to Present at J.P. Morgan Healthcare Conference, 8/15/2019 GILD-US      BW   European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis,#N/A, 2/10/2016 MDABY-SE BW   Statement by the Board of Directors of Meda in relation to the public offer by Mylan,10/27/2014 M2572210 BW   Compugen Discloses Successful Validation Results for Novel B7/CD28–like Cancer Immunotherapy Target Candidate," 3/15/2018 FRE-DE    BW   AKRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Akorn, Inc.", 2/16/2016 09P83W-E     BW   Carmot Therapeutics Extends Drug Discovery Collaboration with Amgen," 4/26/2018 MYGN-US     BW   The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Myriad Genetics, Inc.",#N/A,#N/A, 7/01/2013 45766930 BW   ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients," 4/11/2019 05156V10 BW   Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board", 9/07/2010 45773H20 BW   Inovio Pharmaceuticals to Present at Investor Conferences,#N/A,#N/A,11/15/2011 008MNB-E     BW   California Stem Cell’s Hans Keirstead Weighs in on Geron News, 3/25/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Four Appointments,#N/A, 5/23/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A, 9/28/2016 SRPT-US  BW   Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping,11/09/2017 ALKS-US  BW   Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders,10/11/2018 CERS-US  BW   Dr. Laurence Corash Recognized With the Prestigious Dale A. Smith Memorial Award, 5/01/2012 00163U10 BW   AMAG Pharmaceuticals Announces First Quarter 2012 Financial Results," 4/02/2019 04269E10 BW   ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019",#N/A," 7/23/2018 SGMO-US  BW   TxCell Further Improves Terms of Its OCABSA Financing Program, Subject to Closing of Its Acquisition by Sangamo Therapeutics, Inc.",11/20/2018 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in November, 1/22/2018 05P1S7-E  BW   IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma, 4/02/2019 VRTX-US   BW   Vertex Appoints Charles Wagner as Chief Financial Officer,#N/A,#N/A, 3/08/2019 BLUE-US  BW   bluebird bio to Present at Investor Conferences in March," 2/21/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019",#N/A,#N/A,#N/A,11/12/2018 TXMD-US  BW   TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences,#N/A,#N/A, 3/19/2019 OMER-US  BW   Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation, 1/17/2019 76133010 BW   Revance Announces Pricing of Public Offering of Common Stock, 8/06/2012 OGEN-US  BW   Oragenics Announces New Strategic Partnership with Central Business USA for South America," 1/06/2019 IRWD-US  BW   Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer",#N/A,#N/A,#N/A,"11/20/2013 63009R10    BW   NanoString Technologies Names David W. Ghesquiere Senior Vice President, Corporate & Business Development",#N/A,11/13/2018 SYRS-US  BW   Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical Data from Oral CDK7 Inhibitor Program at EORTC-NCI-AACR Meeting,#N/A,#N/A, 3/20/2012 00182C10     BW   BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation, 6/12/2018 ENTA-US    BW   Enanta Pharmaceuticals Recognizes the 1st International NASH Day," 6/21/2019 ALNY-US   BW   Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery", 1/29/2016 WVE-US   BW   WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018,#N/A,#N/A,"10/30/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results",11/17/2014 76129910 BW   Retrophin Names Laura M. Clague as Chief Financial Officer, 1/31/2011 69404D10 BW   Pacific Biosciences Announces Favorable Ruling in Patent Interference Case With Life Technologies,#N/A,#N/A,#N/A,#N/A, 3/12/2019 AKBA-US  BW   Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A," 2/27/2019 SAGE-US     BW   Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares",#N/A,#N/A,#N/A," 8/23/2017 MEDP-US  BW   Medpace Holdings, Inc. to Present at Wells Fargo Healthcare Conference",#N/A," 8/07/2017 INVA.XX1-US BW   Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers’ $17.5 million Over-Allotment Option",#N/A,#N/A,#N/A, 2/26/2013 56400P70 BW   MannKind Corporation to Present at the Cowen and Company 33rd Annual Health Care Conference, 9/11/2018 URGN-US  BW   Jones “Woody” Bryan Joins UroGen Pharma as Senior Vice President of Business Development,#N/A,10/21/2014 29664W10    BW   Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock," 4/26/2017 AMRS-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Amyris, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A,10/03/2018 EGRX-US  BW   Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure,12/19/2018 DCPH-US BW   Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study),#N/A,#N/A,10/02/2018 EPZM-US  BW   Epizyme Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A, 3/13/2014 CRL-US      BW   Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV,#N/A, 3/28/2019 VCYT-US  BW   Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference, 4/01/2019 DRNA-US  BW   Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)," 6/26/2019 15117K10 BW   Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019",#N/A,#N/A,#N/A," 5/14/2014 00847X10 BW   Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer"," 4/13/2017 IOVA-US  BW   INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Lion Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 1/02/2019 XLRN-US  BW   Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference,#N/A," 7/16/2019 HZNP-US  BW   Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019",11/21/2018 00BJ80-E  BW   Castle Biosciences to Present at the 2018 Piper Jaffray Healthcare Conference," 2/27/2014 45845P10 BW   INVESTOR ALERT: Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. Announced by Glancy Binkow & Goldberg LLP",#N/A, 7/25/2018 008SHY-E BW   Biotech CEO Testifies Before the Joint Economic Committee on Pro-Growth Policies, 1/19/2010 00780K-E BW   Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience,#N/A,#N/A,12/17/2018 NVCR-US  BW   Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields,#N/A,#N/A,#N/A, 3/15/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting,#N/A,#N/A,#N/A,#N/A," 9/12/2011 05SVDW-E   BW   FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development", 4/25/2019 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2018 MCRB-US  BW   Seres Therapeutics to Present at Two Upcoming March Conferences, 6/04/2019 AIMT-US  BW   Les données provenant de deux études confirment le fardeau psychosocial et en termes de qualité de vie subi par les personnes allergiques aux arachides,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/05/2018 RARX-US  BW   Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program,#N/A, 1/16/2017 HCM-HK   BW   Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2019 QTRX-US  BW   Quanterix Marks One-Year Anniversary of IPO with Key Milestones Accelerating Healthcare Disruption Ahead of Presentation at the 37th Annual J.P. Morgan Healthcare Conference, 3/20/2018 SLDB-US  BW   Glancy Prongay & Murray LLP Continues Investigation on Behalf of Solid Biosciences Inc. Investors (SLDB),#N/A,#N/A, 6/30/2014 30233G10 BW   pSivida Corp. Reports Positive Regulatory Outcome for ILUVIEN®; Moves to National Phase for Marketing Authorizations in 10 More EU Countries,#N/A,#N/A, 6/18/2019 AXNX-US  BW   Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients, 7/02/2018 TCDA-US  BW   Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A, 9/24/2018 0DK6LR-E BW   Magenta Therapeutics Added to Russell 2000 and 3000 Indexes,#N/A,#N/A,#N/A,#N/A, 3/06/2019 MRNA-US BW   Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2019 TWST-US  BW   Twist Bioscience and iGEM Partner to Provide Synthetic DNA for iGEM Competition and Registry,#N/A,#N/A,#N/A, 1/30/2012 0084LG-E  BW   Precision BioSciences Announces Allowance of Third U.S. Patent Related to Engineered Meganucleases,#N/A,#N/A,#N/A, 3/31/2016 00DHGL-E BW   Atreca Announces Presentation of Preclinical Data for Antibody Discovery Program, 6/24/2019 PSNL-US  BW   Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option,#N/A,#N/A," 6/21/2017 0DMSKV-E BW   Adaptive Biotechnologies Announces a Collaboration with Janssen Biotech, Inc. to use the clonoSEQ® Assay to Measure Minimal Residual Disease in Ongoing and Future DARZALEX® Multiple Myeloma Trials",#N/A,#N/A
12/17/2018 0HBC56-E  BW   Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics, 3/09/2011 74318710    BW   Progenics Pharmaceuticals Announces Changes in Executive Responsibilities, 1/29/2019 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018,11/08/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results, 6/09/2017 ENDP-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Endo International plc Investors, 4/15/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A, 6/13/2016 68375N10 BW   OPKO Health Announces Move to NASDAQ Stock Market, 3/29/2012 SAN-FR      BW,#N/A, 3/20/2019 ALXN-US  BW   Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule,#N/A, 6/03/2019 SGEN-US     BW   Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting," 6/17/2016 IMMU-US     BW   IMMUNOMEDICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Immunomedics Inc.",11/27/2017 ALKS-US     BW   Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, 7/12/2018 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results,12/07/2012 09058V10 BW   BioCryst Pharmaceuticals Announces Focused Corporate Strategy and Restructuring," 8/09/2019 GILD-US      BW   China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection",#N/A,"12/07/2015 MYL-GB   BW   Edward J. Borkowski, Former CFO of Mylan, N.V. Joins Transdermal Delivery Solutions Board of Directors","10/22/2014 M2572210 BW   Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET"," 3/14/2018 AKRX-US   BW   AKRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Akorn, Inc.", 1/11/2016 00F9LC-E     BW   Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer," 4/25/2018 MYGN-US     BW   Robbins Arroyo LLP: Myriad Genetics, Inc. (MYGN) Misled Shareholders According to a Recently Filed Class Action",#N/A,#N/A," 2/13/2013 077VL7-E BW   BioNJ Installs New Chair, Members on its Board of Trustees", 3/19/2019 05156V10 BW   Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights, 8/16/2010 45773H20 BW   Inovio Pharmaceuticals Reports Second Quarter 2010 Financial Results,#N/A,#N/A,11/15/2011 37416310     BW   Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC, 3/21/2019 AERI-US    BW   Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing,#N/A, 5/20/2019 INCY-US  BW   Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology,#N/A, 9/22/2016 SRPT-US  BW   Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock,11/08/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare Conference,10/09/2018 CERS-US  BW   Cerus Appoints Eric Bjerkholt to Board of Directors," 4/24/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on May 1, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2012", 3/15/2019 04269E10 BW   ArQule Announces Management Team Changes,#N/A, 5/16/2018 BIVV-US  BW   Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease,11/15/2018 EXEL-US  BW   Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib, 1/08/2018 EVT-DE    BW   Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi," 3/12/2019 VRTX-US   BW   Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations",#N/A,#N/A, 2/21/2019 BLUE-US  BW   bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress," 2/12/2019 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019",#N/A,#N/A,#N/A,11/07/2018 TXMD-US  BW   TherapeuticsMD Announces Third Quarter 2018 Financial Results,#N/A,#N/A, 3/01/2019 OMER-US  BW   Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results, 1/15/2019 76133010 BW   Revance Announces Proposed Public Offering of Common Stock, 7/31/2012 OGEN-US  BW   Oragenics Announces $12.86 Million Private Placement Financing," 1/04/2019 IRWD-US  BW   Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation",#N/A,#N/A,#N/A,11/12/2013 63009R10    BW   NanoString Launches the nCounter Dx Analysis System for U.S. Market,#N/A,11/09/2018 SYRS-US  BW   Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium,#N/A,#N/A, 3/13/2012 00182C10     BW   BioSante Pharmaceuticals Reports Financial Results for 2011 and Corporate Highlights, 6/01/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT, 6/18/2019 ALNY-US   BW   Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy,11/11/2015 WVE-US   BW   WAVE Life Sciences Announces Pricing of Initial Public Offering,#N/A,#N/A,10/27/2014 69512710 BW   New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events,11/13/2014 76129910 BW   Retrophin Reports Third Quarter 2014 Financial Results,12/09/2010 69404D10 BW   Pacific Biosciences and Harvard Scientists Decode Genome of Haitian Cholera Pathogen,#N/A,#N/A,#N/A,#N/A, 3/06/2019 AKBA-US  BW   Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast,#N/A,#N/A,#N/A,#N/A, 2/25/2019 SAGE-US     BW   Sage Therapeutics Prices Public Offering of Common Stock,#N/A,#N/A,#N/A," 8/16/2017 MEDP-US  BW   Medpace Holdings, Inc. Announces Stock Repurchase Agreement with Cinven",#N/A," 8/01/2017 INVA.XX1-US BW   Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes",#N/A,#N/A,#N/A, 2/11/2013 56400P70 BW   MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results, 5/22/2013 0CV67B-E BW   TheraCoat Has Completed a Capital Raising of $7M led by Pontifax and Chaim Hurvitz's CHealth Fund,#N/A,10/15/2014 29664W10    BW   Esperion Therapeutics Prices Public Offering of Common Stock," 4/24/2017 AMRS-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Amyris, Inc.",#N/A,#N/A,#N/A,#N/A," 9/27/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference","11/20/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference",#N/A,#N/A,10/02/2018 EPZM-US  BW   Epizyme Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 7/26/2012 LIFE.XX5-US BW   Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry,#N/A, 3/25/2019 VCYT-US  BW   Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer, 4/01/2019 DRNA-US  BW   Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference, 6/26/2019 15117K10 BW   Résultats de l’Assemblée Générale Mixte des actionnaires de Cellectis S.A. du 25 juin 2019,#N/A,#N/A,#N/A, 5/08/2014 00847X10 BW   Agios Pharmaceuticals Reports First Quarter 2014 Financial Results," 4/12/2017 IOVA-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Lion Biotechnologies, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,12/19/2018 CELG-US  BW   Die Celgene Corporation und Acceleron Pharma geben bei der ASH-Jahrestagung 2018 die Ergebnisse der Phase-III-Studie BELIEVE zu Luspatercept bei erwachsenen Patienten mit Beta-Thalassämie bekannt,#N/A, 7/11/2019 HZNP-US  BW   Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes,11/13/2018 00BJ80-E  BW   Study Demonstrating Accuracy of DecisionDx-Melanoma Prognostic Test Across Melanoma Tissue Sources Presented at the American Society of Dermatopathology 55th Annual Meeting," 2/25/2014 45845P10 BW   Law Offices of Howard G. Smith Announces a Shareholder Class Action Lawsuit Has Been Filed against Intercept Pharmaceuticals, Inc.",#N/A, 6/01/2018 GLYC-US  BW   GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference,#N/A,#N/A,#N/A,12/06/2018 G6674U10 BW   Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival,#N/A,#N/A,#N/A, 3/12/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.,#N/A,#N/A,#N/A,#N/A," 6/06/2011 05SVDW-E   BW   FibroGen Appoints R. Wayne Frost, Pharm.D., J.D., Vice President of Regulatory Affairs", 4/09/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 3/08/2018 065BPX-E BW   Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates," 6/04/2019 AIMT-US  BW   Daten aus zwei Studien bestätigen die Lebensqualität und psychosoziale Belastung von Menschen, die an einer Erdnussallergie leiden",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2018 RARX-US  BW   Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program,#N/A, 1/16/2017 HCM-GB   BW   Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/26/2018 QTRX-US  BW   Quanterix to Present at the Evercore ISI HealthCONx Conference," 3/19/2018 SLDB-US  BW   Bragar Eagel & Squire, P.C. is Investigating Solid Biosciences Inc. (SLDB) on Behalf of Stockholders and Encourages Investors to Contact the Firm",#N/A,#N/A, 6/23/2014 30233G10 BW   pSivida Announces ILUVIEN® Receives Marketing Authorization in Italy for Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 5/08/2019 AXNX-US  BW   Axonics® Announces First Quarter 2019 Financial Results and Operational Update, 6/27/2018 TCDA-US  BW   Tricida Announces Pricing of Initial Public Offering,#N/A,#N/A, 8/09/2018 MGTA-US  BW   Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A, 3/04/2019 MRNA-US BW   Moderna to Present at Upcoming Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2019 TWST-US  BW   Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics,#N/A,#N/A,#N/A, 1/25/2012 0084LG-E  BW   Precision BioSciences Announces Allowance of Second U.S. Patent for Engineered Meganucleases,#N/A,#N/A,#N/A, 3/11/2016 06X6GX-E BW   Atreca Announces Presentation of Preclinical Data for Cancer Immunotherapy Program, 6/19/2019 PSNL-US  BW   Personalis Prices Initial Public Offering of Common Stock,#N/A,#N/A, 4/04/2017 0DMSKV-E BW   Adaptive Biotechnologies® Publishes Ground-Breaking Proof-of-Principle Experiment in Nature Genetics,#N/A,#N/A
"12/17/2018 LGND-US   BW   Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma", 2/17/2011 74318710    BW   Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC," 1/15/2019 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019",11/07/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14,"12/07/2016 ENDP-US  BW   DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Endo International plc To Contact The Firm", 4/12/2019 ARWR-US  BW   Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A, 6/07/2016 OPK-US   BW   OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference, 2/22/2012 066807-E    BW,#N/A, 3/08/2019 ALXN-US  BW   Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve,#N/A, 6/03/2019 SGEN-US     BW   Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer, 6/03/2016 IMMU-US     BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Immunomedics Inc. and Advises Investors with Losses to Contact the Firm,11/27/2017 09062X10    BW   Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, 6/21/2018 IMGN-US  BW   ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,11/30/2012 06WWL5-E BW   BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction, 8/07/2019 GILD-US      BW   Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™,#N/A,12/04/2015 MYL-GB   BW   Fitch Rates Mylan's Bond Offering 'BBB-'; Outlook Stable,10/14/2014 M2572210 BW   Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer," 3/13/2018 AKRX-US   BW   AKRX LOSS NOTICE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Class Action",12/02/2015 008K6T-E     BW   Box Announces Record Third Quarter Fiscal 2016 Results," 4/25/2018 MYGN-US     BW   The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Myriad Genetics, Inc. (MYGN)",#N/A,#N/A,11/08/2011 INSM-US  BW   AmpliPhi Biosciences Appoints Philip J. Young as President & CEO, 3/14/2019 05156V10 BW   Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease, 6/29/2010 45773H20 BW   Inovio Pharmaceuticals’ Novel Gene Immunoadjuvant Significantly Improves DNA Vaccine Immune Responses in Non-Human Primates,#N/A,#N/A,11/14/2011 37416310     BW   Geron to Focus on Its Novel Cancer Programs, 3/18/2019 AERI-US    BW   Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion,#N/A," 5/16/2019 INCY-US  BW   Incyte kündigt Abstracts an, die zur Präsentation auf der ASCO-Jahrestagung 2019 und dem 24. EHA-Kongress angenommen wurden",#N/A, 9/21/2016 SRPT-US  BW   Sarepta Therapeutics Announces Proposed Public Offering of Common Stock,11/08/2017 ALKS-US  BW   Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting,10/02/2018 CERS-US  BW   Cerus to Host Institutional Investor Meeting, 4/20/2012 AMAG-US  BW   AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease," 3/13/2019 04269E10 BW   ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019",#N/A," 3/21/2018 SGMO-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO)","11/06/2018 EXEL-US  BW   Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018",12/18/2017 SAN-FR    BW   InVivo Therapeutics Announces Executive Management and Board Changes," 3/06/2019 VRTX-US   BW   CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis",#N/A,#N/A, 2/11/2019 FOLD-US  BW   bluebird bio Appoints Chip Baird as Chief Financial Officer,"12/20/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019",#N/A,#N/A,#N/A,"10/30/2018 TXMD-US  BW   TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018",#N/A,#N/A," 2/26/2019 OMER-US  BW   Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019", 1/15/2019 76133010 BW   Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference, 6/06/2012 OGEN-US  BW   Oragenics and Intrexon Announce Worldwide Exclusive Collaboration for Lantibiotics, 1/02/2019 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,10/01/2013 FLDM-US     BW   Fluidigm and NanoString Agree to Litigation Settlement,#N/A,11/01/2018 SYRS-US  BW   Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting,#N/A,#N/A," 3/09/2012 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at Roth Health Care Conference"," 5/08/2018 ABBV-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018", 6/17/2019 ALNY-US   BW   Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1), 8/18/2015 00GL7P-E BW   WAVE Life Sciences Raises $66 Million in Series B Financing,#N/A,#N/A,"10/15/2014 69512710 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit",11/10/2014 76129910 BW   Retrophin Announces Appointment of Stephen Aselage as Chief Executive Officer,10/26/2010 69404D10 BW   Pacific Biosciences Announces Pricing of Initial Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 3/04/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/25/2019 SAGE-US     BW   Sage Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A," 7/31/2017 MEDP-US  BW   Medpace Holdings, Inc. Reports Second Quarter 2017 Results",#N/A, 7/31/2017 INVA.XX1-US BW   Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes,#N/A,#N/A,#N/A," 2/04/2013 56400P70 BW   MannKind Corporation to Hold 2012 Fourth Quarter and Full Year Financial Results Conference Call on February 11, 2013",#N/A,#N/A,10/14/2014 29664W10    BW   Esperion Therapeutics Announces Proposed Public Offering of Common Stock," 4/24/2017 AMRS-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Amyris, Inc. (AMRS) on Behalf of Shareholders",#N/A,#N/A,#N/A,#N/A, 9/26/2018 EGRX-US  BW   Eagle Appoints David Pernock to Position of Chief Operating Officer,11/15/2018 DCPH-US BW   Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors,#N/A,#N/A, 9/24/2018 EPZM-US  BW   Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program,#N/A,#N/A,#N/A, 7/25/2012 0BLKXR-E    BW   BioFocus Expands Its Drug Discovery Offering with Proteomics Technology from Activiomics,#N/A, 3/19/2019 VCYT-US  BW   Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition, 3/29/2019 DRNA-US  BW   Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2), 6/05/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A," 4/30/2014 00847X10 BW   Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014"," 4/12/2017 IOVA-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Lion Biotechnologies, Inc. Investors",#N/A,12/19/2018 CELG-US  BW   Die Celgene Corporation und Acceleron Pharma legen Ergebnisse der Phase-III-Studie MEDALIST zur Prüfung von Luspatercept bei Patienten mit myelodysplastischen Syndromen auf dem ASH-Kongress 2018 vor,#N/A, 7/10/2019 HZNP-US  BW   Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes,11/08/2018 00BJ80-E  BW   Castle Biosciences to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum," 2/23/2014 45845P10 BW   ICPT SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Announces Investigation of Intercept Pharmaceuticals, Inc.",#N/A," 5/30/2018 GLYC-US  BW   GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy",#N/A,#N/A,#N/A,"11/14/2018 NVCR-US  BW   Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China",#N/A,#N/A,#N/A," 3/11/2019 RCKT-US  BW   Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)",#N/A,#N/A,#N/A,#N/A, 5/03/2011 05SVDW-E   BW   FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study, 4/04/2019 74587V10 BW   Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations,#N/A,#N/A,#N/A,#N/A,#N/A," 3/02/2018 MCRB-US  BW   Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018"," 6/04/2019 AIMT-US  BW   De nouvelles données provenant de l'étude de suivi de l'essai de Phase 3 PALISADE portant sur AR101 dans le traitement de l'allergie aux arachides ont montré une immunomodulation continue via des doses quotidiennes, après la première année",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/15/2018 RARX-US  BW   Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association",#N/A, 1/16/2017 HCM-GB   BW   Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2018 QTRX-US  BW   Quanterix to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum, 3/19/2018 SLDB-US  BW   SLDB INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Solid Biosciences Inc. Investors,#N/A,#N/A, 5/13/2014 30233G10 BW   pSivida Corp. Reports Third Quarter 2014 Results,#N/A,#N/A, 5/06/2019 AXNX-US  BW   Axonics® Announces ARTISAN-SNM Pivotal Study Results Presented at the American Urological Association Annual Meeting, 6/05/2018 00FY1L-E BW   Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis,#N/A,#N/A, 8/08/2018 MGTA-US  BW   Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference,#N/A,#N/A,#N/A,#N/A," 2/21/2019 MRNA-US BW   Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2019 TWST-US  BW   Twist Bioscience Customized Libraries for Biologics Discovery Highlighted at PEGS Boston 2019,#N/A,#N/A,#N/A, 1/23/2012 ALCLS-FR  BW   Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent,#N/A,#N/A,#N/A," 2/16/2016 00DHGL-E BW   Atreca Expands Leadership Team, Appoints Industry Leader Susan Berland as Executive Vice President and Chief Financial Officer"," 5/22/2019 00DD8T-E BW   Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for Immunotherapy Biomarker Discovery in Clinical Trial Participants",#N/A,#N/A, 1/06/2017 0DMSKV-E BW   Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Development of clonoSEQ® Assay in Acute Lymphoblastic Leukemia,#N/A,#N/A
11/21/2018 LGND-US   BW   Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation, 2/07/2011 SLXP-US     BW   Salix Pharmaceuticals and Progenics Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®,12/20/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,11/01/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast,"11/18/2016 ENDP-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Endo International plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit", 4/12/2019 ARWR-US  BW   Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A, 6/02/2016 68375N10 BW   OPKO Health to Present at the 2016 Jefferies Healthcare Conference, 1/08/2012 06FW0H-E    BW,#N/A, 3/05/2019 ALXN-US  BW   Alexion to Present at the Cowen 39th Annual Health Care Conference,#N/A," 5/21/2019 SGEN-US     BW   Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer"," 7/28/2015 IMMU-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Immunomedics Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws",11/21/2017 09062X10    BW   Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer, 6/18/2018 IMGN-US  BW   ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer,11/12/2012 BCRX-US  BW   BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model, 8/06/2019 GILD-US      BW   Ontario Provides Access to Biktarvy® for the Treatment of HIV,#N/A,11/20/2015 MYL-GB   BW   Fitch Assigns 'BBB-' First-Time Ratings to Mylan,10/06/2014 M2572210 BW   Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences," 3/12/2018 FRE-DE    BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Akorn, Inc.",11/09/2015 0625VS-E     BW   Harvard Pilgrim Negotiates First-In-The Nation Innovative Contract for Blockbuster Cholesterol Drug Repatha," 4/24/2018 MYGN-US     BW   INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Myriad Genetics, Inc.",#N/A,#N/A,#N/A," 3/07/2019 05156V10 BW   Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019", 6/22/2010 45773H20 BW   Inovio Pharmaceuticals’ Optimized DNA Vaccine Demonstrates Significant Advantages in Non-Human Primates Compared to Leading Viral Vector Based Vaccine,#N/A,#N/A,11/03/2011 37416310     BW   Geron Corporation Reports 2011 Third Quarter Financial Results and Events, 3/12/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance,#N/A, 5/16/2019 INCY-US  BW   Incyte annonce les résumés acceptés pour présentation à la réunion annuelle 2019 de l'ASCO et au 24ème Congrès de l'EHA,#N/A," 9/21/2016 06CR5C-E BW   Option Care Selected to Provide Exondys 51™, First Approved Treatment for Most Common Form of Muscular Dystrophy",11/07/2017 008G5M-E BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS, 9/26/2018 CERS-US  BW   Cerus to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference, 3/07/2012 00163U10 BW   AMAG Pharmaceuticals Announces Preliminary Results from its Phase III Study Evaluating Feraheme Compared to IV Iron Sucrose in Patients with Iron Deficiency Anemia," 3/11/2019 04269E10 BW   ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019",#N/A," 2/22/2018 SGMO-US  BW   Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer",11/01/2018 EXEL-US  BW   Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update,12/18/2017 SAN-FR    BW   Alnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis, 2/21/2019 VRTX-US   BW   Vertex Appoints Lloyd Carney to its Board of Directors,#N/A,#N/A," 1/07/2019 BLUE-US  BW   bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies",11/30/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,10/29/2018 TXMD-US  BW   TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause,#N/A,#N/A, 2/20/2019 OMER-US  BW   Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721, 1/07/2019 76133010 BW   Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones, 8/30/2011 ZIOP-US  BW   ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma, 1/02/2019 IRWD-US  BW   Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation,#N/A,#N/A,#N/A," 9/16/2013 63009R10    BW   Study Published Showing Advantages of the PAM50 Gene Signature, the Basis for Prosigna, in Helping to Estimate Risk of Late Distant Recurrence in Postmenopausal Estrogen Receptor Positive Breast Cancer Patients",#N/A,11/01/2018 SYRS-US  BW   Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A, 3/05/2012 00182C10     BW   BioSante’s Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study," 4/24/2018 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2018", 6/13/2019 ALNY-US   BW   Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)," 4/07/2015 00GL7P-E BW   WaVe Life Sciences Appoints Roberto Guerciolini, M.D., as Senior Vice President and Head of Early Development",#N/A,#N/A,10/15/2014 69512710 BW   Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call,11/07/2014 76129910 BW   Retrophin Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors, 9/01/2010 PACB-US  BW   Pacific Biosciences Responds to Patent Infringement Complaint by Helicos Biosciences,#N/A,#N/A,#N/A,#N/A, 2/04/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/19/2019 SAGE-US     BW   Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress,#N/A,#N/A,#N/A," 7/11/2017 MEDP-US  BW   Medpace Holdings, Inc. to Report Second Quarter 2017 Financial Results on July 31, 2017",#N/A, 7/26/2017 INVA.XX1-US BW   Innoviva Reports Strong Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A, 1/03/2013 MNKD-US  BW   MannKind Corporation to Present at The 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,"10/01/2014 29664W10    BW   Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia"," 4/24/2017 AMRS-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Amyris, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A," 9/04/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference","11/08/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results",#N/A,#N/A, 8/29/2018 EPZM-US  BW   Epizyme to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A, 3/14/2012 0608LT-E    BW   BioFocus and Argenta Announce Drug Discovery Collaboration With AstraZeneca in Respiratory and Inflammatory Disease,#N/A, 3/18/2019 VCYT-US  BW   Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019," 3/11/2019 DRNA-US  BW   Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update", 6/05/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 4/23/2014 00847X10 BW   Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock," 4/11/2017 IOVA-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Lion Biotechnologies, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,12/07/2018 CELG-US  BW   ASH 2018: Celgene Corporation e Acceleron Pharma annunciano i risultati dello studio di fase 3 BELIEVE per la valutazione di luspatercept nei pazienti adulti con beta talassemia,#N/A, 7/10/2019 HZNP-US  BW   Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED),10/30/2018 00BJ80-E  BW   Study Demonstrates DecisionDx-Melanoma Prognostic Test Accuracy in Patients with Stage II-IIIA Melanoma," 2/22/2014 45845P10 BW   SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Has Filed a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Certain Officers",#N/A, 5/23/2018 008SHY-E BW   Biotech Leader Testifies before House Capital Markets Subcommittee,#N/A,#N/A,#N/A,11/13/2018 G6674U10 BW   Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A, 3/07/2019 RCKT-US  BW   Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A," 3/17/2011 4503-JP    BW   FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF Prolyl Hydroxylase Inhibitor, for Treatment of Anemia in Chronic Kidney Disease", 4/02/2019 05JJH8-E BW   Puma Biotechnology und Pierre Fabre schließen exklusiven Lizenzvertrag zur Entwicklung und Vermarktung von NERLYNX® (Neratinib) in Europa ab,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2018 MCRB-US  BW   Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer, 6/04/2019 AIMT-US  BW   New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology,#N/A, 1/10/2017 HCM-GB   BW   Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2018 QTRX-US  BW   Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology, 3/16/2018 SLDB-US  BW   INVESTOR ALERT: Kirby McInerney LLP Announces Investigation on Behalf of Solid Biosciences Inc. (SLDB) Investors,#N/A,#N/A, 5/05/2014 30233G10 BW   pSivida Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur at ARVO Annual Meeting,#N/A,#N/A, 5/01/2019 AXNX-US  BW   Axonics® to Present at Upcoming Investor Conferences, 6/04/2018 JAZZ-US  BW   Tricida Announces Kathryn Falberg Joins Board of Directors,#N/A,#N/A, 6/25/2018 MGTA-US  BW   Magenta Therapeutics Announces Closing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A, 2/20/2019 MRNA-US BW   Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2019 TWST-US  BW   Twist Bioscience Adopts Battelle’s ThreatSEQ™ DNA Screening Web Service for Advanced Biosecurity,#N/A,#N/A,#N/A, 1/19/2012 0084LG-E  BW   Precision BioSciences Announces Establishment of Precision PlantSciences for Development of Advanced Agricultural Biotechnology,#N/A,#N/A,#N/A," 2/05/2016 00DHGL-E BW   Atreca, Inc. to Present at the 18th Annual BIO CEO & Investor Conference"," 5/20/2019 00DD8T-E BW   Personalis, Inc. hält Präsentation auf Kongress zu Fortschritten in der Immuno-Onkologie 2019 im Vereinten Königreich (Advances in Immuno-Oncology Congress UK 2019)",#N/A,#N/A,11/29/2016 06QBQ2-E BW   Adaptive Biotechnologies and Collaborators to Present Eighteen Studies at the American Society of Hematology Annual Meeting 2016,#N/A,#N/A
"11/13/2018 LGND-US   BW   Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo", 2/07/2011 74318710    BW   Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®,12/06/2018 45232710    BW   Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program,10/23/2018 84763A10  BW   Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection,11/10/2016 ENDP-US  BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/29/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 5/27/2016 OPK-US   BW   OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test, 1/04/2012 46222210    BW,#N/A, 2/28/2019 ALXN-US  BW   Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day,#N/A, 5/15/2019 SGEN-US     BW   Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting," 4/10/2014 45290710    BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position",11/20/2017 09062X10    BW   Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference, 6/11/2018 IMGN-US  BW   ImmunoGen Announces Closing of Public Offering of Common Stock,11/08/2012 06WWL5-E BW   BioCryst Provides Corporate Update and Reports Third Quarter 2012 Financial Results, 7/30/2019 GILD-US      BW   Gilead Sciences Announces Third Quarter 2019 Dividend,#N/A, 7/27/2015 TEVA-IL  BW   Teva Withdraws Proposal to Acquire Mylan,10/01/2014 M2572210 BW   Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy," 3/12/2018 FRE-DE    BW   AKRX INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Akorn, Inc. Investors",10/26/2015 NCAP-US      BW   Northsight Capital Appoints Pharmaceutical and Biotech Sales Industry Veteran John B. Hollister as Chief Executive Officer," 4/23/2018 MYGN-US     BW   SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc.",#N/A,#N/A,#N/A, 2/27/2019 05F9ZW-E BW   Aurinia Closes At-The-Market Facility, 6/21/2010 45773H20 BW   Inovio Pharmaceuticals Set to Join Russell 3000 Index,#N/A,#N/A,10/25/2011 37416310     BW   Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights, 3/12/2019 AERI-US    BW   Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension,#N/A, 5/16/2019 INCY-US  BW   Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA,#N/A, 9/20/2016 SRPT-US  BW   Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical,10/31/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare Conference, 9/06/2018 CERS-US  BW   Cerus Appoints Timothy L. Moore to Board of Directors," 3/06/2012 00163U10 BW   CORRECTING and REPLACING AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results", 3/07/2019 04269E10 BW   ArQule Reports Fourth Quarter and Full Year 2018 Financial Results,#N/A, 8/07/2012 SGMO-US  BW   Sangamo BioSciences Announces Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference,10/22/2018 EXEL-US  BW   Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma,12/14/2017 06VY62-E  BW   Viral Vaccine Development Gets Major Boost from xCELLigence RTCA, 2/14/2019 VRTX-US   BW   Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission,#N/A,#N/A, 1/03/2019 BLUE-US  BW   bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference,11/27/2018 ACAD-US  BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A, 9/28/2018 TXMD-US  BW   TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society,#N/A,#N/A, 2/14/2019 OMER-US  BW   Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA,12/04/2018 0F0P0N-E BW   Revance Announces China Market License Agreement with Fosun Pharma for RT002, 7/01/2011 ZIOP-US  BW   ZIOPHARM Amends Resale Registration Statement for Intrexon Shares,11/08/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A, 9/09/2013 63009R10    BW   NanoString Technologies Receives FDA 510(k) Clearance for Prosigna™ Breast Cancer Prognostic Gene Signature Assay,#N/A,10/30/2018 SYRS-US  BW   Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting,#N/A,#N/A, 2/27/2012 00182C10     BW   BioSante’s Pancreas Cancer Vaccine Shows over 60% Survival Increase in Newly Presented Study, 4/12/2018 ENTA-US    BW   Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress™ 2018, 6/05/2019 ALNY-US   BW   Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria,#N/A,#N/A,#N/A,"10/13/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block","10/31/2014 76129910 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Retrophin, Inc. To Contact Brower Piven Before The December 19, 2014 Lead Plaintiff Deadline In Class Action Lawsuit"," 8/11/2010 PACB-US  BW   Pacific Biosciences to Co-Host “New Biology Summit” in Beijing on August 19, 2010",#N/A,#N/A,#N/A,#N/A, 1/02/2019 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/07/2019 SEND-US     BW   Celonis Wins Best SaaS in U.S. Category in 2018-19 Cloud Award,#N/A,#N/A,#N/A," 6/01/2017 MEDP-US  BW   Medpace Holdings, Inc. to Present at Two Upcoming Investor Conferences",#N/A, 7/21/2017 INVA-US     BW   GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination,#N/A,#N/A,#N/A,11/20/2012 MNKD-US  BW   MannKind Corporation to Present at The 24th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A, 9/22/2014 29664W10    BW   Esperion Therapeutics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference," 4/21/2017 AMRS-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Amyris, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A, 8/30/2018 EGRX-US  BW   Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke,"10/23/2018 DCPH-US BW   Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors",#N/A,#N/A, 8/02/2018 EPZM-US  BW   Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates,#N/A,#N/A,#N/A, 7/19/2011 07Q8KB-E    BW   BioFocus and InterMed Discovery Announce Marketing Collaboration,#N/A, 3/04/2019 VCYT-US  BW   Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier," 3/04/2019 DRNA-US  BW   Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019", 5/09/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 4/21/2014 00847X10 BW   Agios Pharmaceuticals Announces Proposed Offering of Common Stock," 4/10/2017 IOVA-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Lion Biotechnologies, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,12/05/2018 XLRN-US  BW   Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology,#N/A, 6/27/2019 HZNP-US  BW   Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease,10/18/2018 00BJ80-E  BW   Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma," 2/21/2014 45845P10 BW   Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Intercept Pharmaceuticals, Inc.",#N/A, 5/03/2018 GLYC-US  BW   GlycoMimetics Reports First Quarter 2018 Results,#N/A,#N/A,#N/A,11/07/2018 G6674U10 BW   Novocure and Zai Lab to Host Investor Event,#N/A,#N/A,#N/A, 3/05/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A, 1/21/2011 05SVDW-E   BW   FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer, 4/01/2019 74587V10 BW   Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2018 MCRB-US  BW   Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis, 6/04/2019 AIMT-US  BW   Dados do Ensaio Pivô ARTEMIS Fase 3 Revelam Segurança e Eficácia Consistentes do AR101 em Crianças e Adolescentes com Alergia ao Amendoim,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference,#N/A,12/06/2016 HCM-GB   BW   Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2018 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Third Quarter 2018, 3/15/2018 SLDB-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Solid Biosciences Inc. Investors (SLDB),#N/A,#N/A, 5/02/2014 30233G10 BW   pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 4/24/2019 AXNX-US  BW   Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8, 3/02/2018 HTGC-US  BW   Tricida Announces $100 Million Venture Debt Financing From Hercules Capital,#N/A,#N/A, 6/20/2018 MGTA-US  BW   Magenta Therapeutics Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A, 2/12/2019 MRNA-US BW   Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2019 TWST-US  BW   Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development Services,#N/A,#N/A,#N/A,10/06/2011 ALCLS-FR  BW   Precision BioSciences Sues Cellectis for Patent Infringement,#N/A,#N/A,#N/A,"11/04/2015 00DHGL-E BW   Atreca, Inc., Completes Oversubscribed $56 Million Series A Funding to Advance Pipeline of Novel Cancer Immunotherapies"," 5/20/2019 00DD8T-E BW   Personalis, Inc. sera présente au Congrès britannique 2019 des progrès de l’immuno-oncologie",#N/A,#N/A,10/27/2016 0DMSKV-E BW   Adaptive Biotechnologies Announces the Inclusion of NGS-Based MRD Assessment in the NCCN Clinical Practice Guidelines for Multiple Myeloma,#N/A,#N/A
11/08/2018 LGND-US   BW   Ligand Reports Third Quarter 2018 Financial Results, 1/25/2011 74318710    BW   Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging,11/13/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,10/18/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer,11/09/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/18/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A, 5/11/2016 NBIX-US  BW   OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs,11/14/2011 068F8W-E    BW,#N/A, 2/22/2019 ALXN-US  BW   FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD),#N/A, 5/15/2019 SGEN-US     BW   Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference," 4/08/2014 45290710    BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Immunomedics, Inc.",11/14/2017 BIIB-US     BW   THERADIAG et BIOGEN signent un accord de partenariat, 6/06/2018 IMGN-US  BW   ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock,11/07/2012 BCRX-US  BW   BioCryst Announces Outcome from the Peramivir Phase 3 Interim Analysis, 7/30/2019 GILD-US      BW   Gilead Sciences Announces Second Quarter 2019 Financial Results,#N/A, 7/23/2015 TEVA-IL  BW   Teva Issues Statement, 9/29/2014 M2572210 BW   Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction," 3/08/2018 AKRX-US   BW   AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Akorn, Inc. to Contact the Firm", 9/16/2015 0D0WPX-E     BW   Amgen acquires Forbion portfolio company Dezima Pharma," 4/23/2018 MYGN-US     BW   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Myriad Genetics, Inc. Investors (MYGN)",#N/A,#N/A,#N/A, 2/25/2019 05156V10 BW   Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis, 6/16/2010 45773H20 BW   Scientific American Article Says DNA Vaccines Are Reaching Their Potential,#N/A,#N/A,10/25/2011 37416310     BW   Geron Announces Presentation At ECTRIMS/ACTRIMS, 3/05/2019 AERI-US    BW   Aerie Pharmaceuticals to Present at Two Investor Conferences in March,#N/A, 5/02/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A," 9/19/2016 SRPT-US  BW   Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51",10/27/2017 ALKS-US  BW   Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis, 8/30/2018 CERS-US  BW   Cerus to Present at the Baird 2018 Global Healthcare Conference, 3/05/2012 00163U10 BW   AMAG Announces Fourth Quarter and Year End 2011 Financial Results, 2/25/2019 04269E10 BW   ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome,#N/A, 6/19/2012 0B7PKX-E BW   BayBio: Ten U.S. High School Students Win Biotechnology Research Competition,10/20/2018 EXEL-US  BW   Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma,12/07/2017 SAN-FR    BW   Sanofi Genzyme reprend la mer avec « Solidaires En Peloton - ARSEP » pour les patients atteints de Sclérose en Plaques, 2/05/2019 VRTX-US   BW   Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results,#N/A,#N/A,"12/19/2018 BLUE-US  BW   Robbins Arroyo LLP: bluebird bio, Inc. (BLUE) Misled Shareholders According to Class Action",11/26/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 9/27/2018 TXMD-US  BW   TherapeuticsMD Enters Into Label Discussions for TX-001HR,#N/A,#N/A," 2/12/2019 OMER-US  BW   Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors",12/04/2018 76133010 BW   Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program, 5/31/2011 008349-E BW   Intrexon Corporation Raises $100 Million for Synthetic Biology Initiatives,11/06/2018 IRWD-US  BW   Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update,#N/A,#N/A,#N/A, 7/29/2013 63009R10    BW   NanoString Technologies Introduces nCounter Elements™ Reagents to Support Needs of Translational Research and Clinical Laboratory Testing,#N/A,"10/25/2018 SYRS-US  BW   Syros to Report Third Quarter 2018 Financial Results on Thursday, November 1, 2018",#N/A,#N/A," 2/23/2012 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at Citi 2012 Global Health Care Conference", 3/28/2018 ENTA-US    BW   Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018," 5/31/2019 ALNY-US   BW   Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension",#N/A,#N/A,#N/A,"10/07/2014 69512710 BW   Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Pacira Pharmaceuticals, Inc.",10/30/2014 76129910 BW   Retrophin to Report Third Quarter 2014 Financial Results, 8/03/2010 PACB-US  BW   Pacific Biosciences Expands Into European Union,#N/A,#N/A,#N/A,#N/A, 1/02/2019 AKBA-US  BW   Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 2/07/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A," 5/01/2017 MEDP-US  BW   Medpace Holdings, Inc. Reports First Quarter 2017 Results; Board Authorizes $50 Million Share Repurchase Program",#N/A, 7/19/2017 INVA-US     BW   Innoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT,#N/A,#N/A,#N/A,"11/19/2012 0CJTL1-E BW   Faruqi & Faruqi, LLP Launches An Investigation Against Mannkind Corp. (MNKD) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors",#N/A,#N/A, 8/12/2014 29664W10    BW   Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results," 4/21/2017 AMRS-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Amyris, Inc. Investors",#N/A,#N/A,#N/A,#N/A, 8/23/2018 EGRX-US  BW   Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies,10/19/2018 DCPH-US BW   Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress,#N/A,#N/A, 6/22/2016 000KXY-E BW   Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq™ (atezolizumab) for Treatment of Non-Hodgkin Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2019 VCYT-US  BW   Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook," 3/01/2019 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)", 5/09/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A," 4/17/2014 00847X10 BW   Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency"," 4/10/2017 IOVA-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Lion Biotechnologies, Inc. – LBIO",#N/A,12/05/2018 CELG-US  BW   Celgene Corporation y Acceleron Pharma anuncian los resultados del ensayo de fase 3 BELIEVE que evalúa el fármaco luspatercept en pacientes adultos con beta-talasemia en el ASH 2018,#N/A, 6/20/2019 HZNP-US  BW   Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy,10/17/2018 00BJ80-E  BW   Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Progress Highlighted in Oral Presentation at American Society for Dermatologic Surgery Annual Meeting," 2/21/2014 45845P10 BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Intercept Pharmaceuticals, Inc.",#N/A," 4/26/2018 GLYC-US  BW   GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018",#N/A,#N/A,#N/A,10/25/2018 G6674U10 BW   Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update,#N/A,#N/A,#N/A, 2/28/2019 RCKT-US  BW   Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019,#N/A,#N/A,#N/A,#N/A, 1/12/2011 05SVDW-E   BW   FibroGen Announces the Initiation of an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis, 4/01/2019 74587V10 BW   Puma Biotechnology et Pierre Fabre concluent un accord de licence exclusive pour le développement et la commercialisation de NERLYNX® (nératinib) en Europe,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2018 MCRB-US  BW   Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference, 6/04/2019 AIMT-US  BW   Los datos del ensayo fundamental ARTEMIS de tercera fase demuestran la seguridad y eficacia consistentes del AR101 en niños y adolescentes con alergia al cacahuete,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association,#N/A,11/29/2016 HCM-GB   BW   Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/25/2018 QTRX-US  BW   Quanterix to Release Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 1, 2018", 3/15/2018 SLDB-US  BW   SLDB INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Solid Biosciences Inc. Investors,#N/A,#N/A, 4/28/2014 30233G10 BW   pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN® for DME,#N/A,#N/A, 4/08/2019 AXNX-US  BW   Welkin Health Announces Partnership to Implement an Innovative Program to Support Commercialization of the Axonics® Cutting-Edge Sacral Neuromodulation Therapy," 1/08/2018 00FY1L-E BW   Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President",#N/A,#N/A, 6/08/2018 0GNB9B-E BW   Magenta Therapeutics Launches Proposed Initial Public Offering,#N/A,#N/A,#N/A,#N/A, 2/05/2019 MRNA-US BW   Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/01/2019 TWST-US  BW   Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019,#N/A,#N/A,#N/A,10/04/2011 0084LG-E  BW   Bayer CropScience and Precision BioSciences: Successful Insertion of Transgene into a Specific Desired Location in Cotton,#N/A,#N/A,#N/A,"12/02/2014 00DHGL-E BW   Atreca, Inc., Establishes Strategic Collaboration with Johnson & Johnson Innovation and Janssen to Apply Immune Repertoire Capture™ Technology to Autoimmune Disease", 5/20/2019 00DD8T-E BW   Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study,#N/A,#N/A,10/03/2016 0DMSKV-E BW   World’s Leading Experts to Discuss the Advances of Immune Profiling in Health and Disease During Unparalleled Conference,#N/A,#N/A
11/02/2018 LGND-US   BW   Ligand to Participate in Stephens NY Investment Conference, 1/18/2011 PGNX-US     BW   Maven Semantic: Protein Structure and Function Research Database,"11/01/2018 45232710    BW   Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery", 9/27/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2,11/07/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm, 3/11/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia,#N/A,#N/A,#N/A,#N/A, 5/10/2016 OPK-US   BW   OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access, 9/26/2011 0753R2-E    BW,#N/A, 2/21/2019 ALXN-US  BW   Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference,#N/A, 5/03/2019 SGEN-US     BW   Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada," 3/28/2014 45290710    BW   Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Immunomedics, Inc.",11/14/2017 BIIB-US     BW   Theradiag and Biogen Sign a Partnership Agreement, 6/05/2018 IMGN-US  BW   ImmunoGen Announces Proposed Public Offering of Common Stock,"11/01/2012 09058V10 BW   BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012", 7/23/2019 GILD-US      BW   Gilead Announces Latest Data in Ongoing HIV Cure Research Program,#N/A, 6/29/2015 BMS-US   BW   Bemis Company Announces the Election of Ms. Adele Gulfo to Its Board of Directors, 8/25/2014 M2572210 BW   Compugen Appoints Mr. Ari Krashin as Chief Financial Officer," 3/08/2018 AKRX-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Akorn, Inc. – AKRX", 9/14/2015 0C5THF-E     BW   NantWorks Enters into Exclusive License Agreement with Amgen to Target Cancer c-Met Receptor," 4/23/2018 MYGN-US     BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A, 2/20/2019 05156V10 BW   Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City, 6/15/2010 45773H20 BW   Inovio Pharmaceuticals Immunizes First Subject in U.S. Influenza DNA Vaccine Clinical Trial,#N/A,#N/A,10/20/2011 37416310     BW   Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial," 2/25/2019 AERI-US    BW   Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update",#N/A, 4/30/2019 INCY-US  BW   Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs,#N/A, 9/19/2016 0731W3-E BW   CureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy,10/26/2017 ALKS-US  BW   Alkermes to Initiate New Clinical Study Evaluating ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia, 8/02/2018 CERS-US  BW   Cerus Corporation Reports Second Quarter 2018 Results," 3/02/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the 24th Annual ROTH Conference"," 2/21/2019 04269E10 BW   ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019",#N/A, 1/28/2011 SGMO-US  BW   Research and Markets: Cell-Based Assays for Drug Discovery,"10/18/2018 EXEL-US  BW   Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018",12/07/2017 80105N10  BW   Sanofi explores combination treatments for multiple myeloma in new late-stage trials, 1/28/2019 VRTX-US   BW   Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene,#N/A,#N/A,"12/12/2018 BLUE-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)",11/06/2018 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A, 9/25/2018 TXMD-US  BW   TherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference,#N/A,#N/A, 1/17/2019 OMER-US  BW   Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy,11/20/2018 76133010 BW   Revance to Participate in Upcoming Investor Conferences, 5/20/2011 ZIOP-US  BW   ZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity,10/25/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call,#N/A,#N/A,#N/A, 7/02/2013 63009R10    BW   Eine in The Journal of Clinical Oncology veröffentlichte Studie weist Vorteile von NanoStrings Prosigna™ Brustkrebsanalyse nach,#N/A, 9/26/2018 SYRS-US  BW   Syros to Present at 2018 Cantor Global Healthcare Conference,#N/A,#N/A," 2/21/2012 00182C10     BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against BioSante Pharmaceuticals, Inc.", 3/06/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference, 5/30/2019 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming June Investor Conferences,#N/A,#N/A,#N/A,"10/06/2014 69512710 BW   Roy Jacobs & Associates Announces Investigation into Possible Wrongdoing at Pacira Pharmaceuticals, Inc. (PCRX)","10/22/2014 76129910 BW   INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Glancy Binkow & Goldberg LLP", 7/14/2010 PACB-US  BW   Pacific Biosciences Announces $109 Million Financing,#N/A,#N/A,#N/A,#N/A,"12/13/2018 AKBA-US  BW   Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company",#N/A,#N/A,#N/A,#N/A," 2/05/2019 SAGE-US     BW   Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019",#N/A,#N/A,#N/A," 4/12/2017 MEDP-US  BW   Medpace Holdings, Inc. to Report First Quarter 2017 Financial Results on May 1, 2017",#N/A, 5/10/2017 INVA-US     BW   Innoviva to Participate in Bank of America Merrill Lynch Healthcare Conference on May 17,#N/A,#N/A,#N/A,11/13/2012 0842YW-E BW   Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products,#N/A,#N/A, 8/05/2014 29664W10    BW   Esperion Therapeutics to Provide Second Quarter 2014 Results," 4/21/2017 AMRS-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Amyris, Inc.",#N/A,#N/A,#N/A,#N/A, 8/22/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA," 9/25/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference",#N/A,#N/A, 6/19/2016 EPZM-US  BW   Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2019 VCYT-US  BW   Veracyte Announces Participation in Upcoming Investor Conferences, 2/22/2019 DRNA-US  BW   Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences, 5/07/2019 15117K10 BW   Cellectis Reports Financial Results for First Quarter 2019,#N/A,#N/A,#N/A," 4/06/2014 00847X10 BW   Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers"," 1/24/2014 IOVA-US  BW   Lion Biotechnologies’ CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate’s Immunotherapy Forum on January 27",#N/A,12/01/2018 CELG-US  BW   Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018,#N/A, 6/12/2019 HZNP-US  BW   Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019, 8/30/2018 00BJ80-E  BW   Castle Biosciences to Present at the Baird 2018 Global Healthcare Conference," 1/14/2014 45845P10 BW   Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Intercept Pharmaceuticals, Inc.",#N/A, 3/20/2018 GLYC-US  BW   GlycoMimetics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,"10/24/2018 G6674U10 BW   Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors",#N/A,#N/A,#N/A, 2/26/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology,#N/A,#N/A,#N/A,#N/A, 1/11/2011 05SVDW-E   BW   Burson-Marsteller Appoints Pharmaceutical and Biotechnology Industry Veteran Melissa Grigorieff Koomey as Head of West Coast Healthcare Practice, 3/28/2019 74587V10 BW   Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2017 MCRB-US  BW   Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis, 6/03/2019 AIMT-US  BW   ARTEMIS-studiegegevens uit pivotale Fase 3 tonen consistente veiligheid en werkzaamheid van AR101 bij kinderen en adolescenten met pinda-allergie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 RARX-US  BW   Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update,#N/A,11/14/2016 0793RM-E BW   Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2018 QTRX-US  BW   Quanterix Announces Collaboration with OncoGenesis to Develop Cervical Screening Test," 3/15/2018 0BGL4K-E BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc.",#N/A,#N/A, 4/23/2014 30233G10 BW   pSivida Selected to Present at 2014 Opthalmology Innovation Summit,#N/A,#N/A," 4/08/2019 AXNX-US  BW   Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors",12/21/2017 00FY1L-E BW   Tricida to Present at 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 4/09/2018 0GNB9B-E BW   Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics,#N/A,#N/A,#N/A,#N/A, 1/30/2019 MRNA-US BW   Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2019 TWST-US  BW   Twist Bioscience to Present at Cowen 39th Annual Healthcare Conference,#N/A,#N/A,#N/A,10/03/2011 ALCLS-FR  BW   Cellectis Issues Statement Regarding Patent Suits on Meganuclease Technology,#N/A,#N/A,#N/A," 9/25/2012 00DHGL-E BW   Atreca, Inc. Receives $6 Million Investment to Apply Immune Repertoire CaptureTM Technology to Prevent and Treat Human Infectious Diseases"," 5/20/2019 00DD8T-E BW   Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019",#N/A,#N/A, 8/23/2016 0DMSKV-E BW   Adaptive Biotechnologies Provides Open-Access to the Deepest Immunosequencing Dataset of Unique B-cell Receptors (BCRs) for Immunology Research,#N/A,#N/A
10/15/2018 LGND-US   BW   Ligand to Report Third Quarter 2018 Results on November 8th, 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Prostate Cancer Research Database,"10/30/2018 45232710    BW   Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling", 9/24/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients,11/03/2016 ENDP-US  BW   IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm, 3/01/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences,#N/A,#N/A,#N/A,#N/A, 5/09/2016 OPK-US   BW   OPKO Health Reports First Quarter Financial and Operating Results, 7/28/2011 SAN-FR      BW,#N/A, 2/12/2019 ALXN-US  BW   Alexion Announces Creation of New Roles on Executive Leadership Team,#N/A, 4/25/2019 SGEN-US     BW   Seattle Genetics Reports First Quarter 2019 Financial Results," 3/25/2014 45290710    BW   INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced By Glancy Binkow & Goldberg LLP","11/02/2017 09062X10    BW   Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation", 5/30/2018 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference,10/30/2012 09058V10 BW   BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA, 7/23/2019 GILD-US      BW   Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®,#N/A, 5/05/2015 TEVA-IL  BW   Teva Provides Additional Detail on Proposed Acquisition of Mylan, 8/21/2014 M2572210 BW   Compugen Reacquires Baize’s Financial Interest in Pipeline Product Candidates," 2/27/2018 FRE-DE    BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Akorn, Inc.", 9/11/2015 AZN-GB       BW   AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline," 4/23/2018 MYGN-US     BW   SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Myriad Genetics, Inc.",#N/A,#N/A,#N/A, 1/22/2019 05156V10 BW   Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome, 6/07/2010 45773H20 BW   Inovio Biomedical to Present at Vaccine Technology III Conference,#N/A,#N/A, 9/29/2011 37416310     BW   Geron Corporation Appoints John A. Scarlett as Chief Executive Officer and Director," 2/19/2019 AERI-US    BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019",#N/A, 4/11/2019 INCY-US  BW   Incyte to Report First Quarter Financial Results,#N/A, 7/19/2016 SRPT-US  BW   Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments,10/26/2017 ALKS-US  BW   Alkermes Unveils Investigational Product Designed for Initiation Onto ARISTADA® for Treatment of Schizophrenia," 7/19/2018 CERS-US  BW   Cerus to Release Second Quarter 2018 Results on August 2, 2018"," 2/23/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on March 5, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2011"," 2/21/2019 04269E10 BW   ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019",#N/A,12/21/2010 TGEN-US  BW,10/08/2018 EXEL-US  BW   Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress,11/02/2017 SAN-FR    BW   Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy," 1/23/2019 VRTX-US   BW   Vertex Announces Departure of Ian Smith, Names Interim CFO",#N/A,#N/A,12/03/2018 BLUE-US  BW   bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology,10/31/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD),#N/A,#N/A,#N/A, 9/20/2018 TXMD-US  BW   TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity,#N/A,#N/A, 1/14/2019 OMER-US  BW   Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018,11/07/2018 76133010 BW   Revance to Participate in the Credit Suisse Healthcare Conference, 5/09/2011 08F9LP-E BW   Intrexon to Deploy Novici Biotech GRAMMR® Technology for Industrial Applications,10/08/2018 IRWD-US  BW   Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting,#N/A,#N/A,#N/A, 7/02/2013 63009R10    BW   L’étude publiée dans le Journal of Clinical Oncology démontre les avantages du test du cancer du sein Prosigna™ de NanoString,#N/A, 9/06/2018 SYRS-US  BW   Syros to Present at Morgan Stanley 16th Annual Global Healthcare Conference,#N/A,#N/A, 2/16/2012 00182C10     BW   BioSante Exchanges $4 Million Aggregate Principal Amount of Convertible Senior Notes for 4.5 Million Shares of Common Stock, 2/12/2018 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 5/29/2019 ALNY-US   BW   Alnylam Announces New Leadership Appointments,#N/A,#N/A,#N/A," 9/25/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter",10/14/2014 76129910 BW   Retrophin Announces Divestment of Non-Core Assets to Turing Pharmaceuticals, 7/09/2010 PACB-US  BW   Pacific Biosciences Launches Software Developer’s Network,#N/A,#N/A,#N/A,#N/A,12/11/2018 AKBA-US  BW   Akebia Therapeutics Shareholders Approve Merger with Keryx,#N/A,#N/A,#N/A,#N/A, 1/23/2019 SAGE-US     BW   Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors,#N/A,#N/A,#N/A," 2/27/2017 MEDP-US  BW   Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2016 Results",#N/A, 5/05/2017 GSK-GB      BW   Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care,#N/A,#N/A,#N/A,11/01/2012 56400P70 BW   MannKind Corporation Reports 2012 Third Quarter Financial Results,#N/A,#N/A, 7/24/2014 29664W10    BW   Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension," 4/20/2017 AMRS-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Amyris, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A," 8/07/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results"," 8/29/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference",#N/A,#N/A, 5/12/2016 EPZM-US  BW   Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology,#N/A,#N/A,#N/A,#N/A,#N/A," 1/28/2019 VCYT-US  BW   Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019", 2/21/2019 DRNA-US  BW   ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth, 5/07/2019 15117K10 BW   Cellectis publie ses résultats financiers du premier trimestre 2019,#N/A,#N/A,#N/A, 3/31/2014 00847X10 BW   Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014, 1/13/2014 IOVA-US  BW   Lion Biotechnologies to Present at the Biotech Showcase on January 15,#N/A,11/28/2018 XLRN-US  BW   Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease,#N/A, 6/04/2019 HZNP-US  BW   Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference, 8/09/2018 00BJ80-E  BW   Newly Published Independent Study on a Prospective Cohort Highlights DecisionDx-Melanoma Prognostic Test’s Ability to Accurately Identify High-Risk Melanoma Patients, 7/01/2013 ICPT-US  BW   Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public Offering,#N/A, 3/19/2018 GLYC-US  BW   GlycoMimetics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,10/23/2018 G6674U10 BW   Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 2/20/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,11/19/2010 05SVDW-E   BW   FibroGen Announces Phase 2a Results for Investigational Oral Anemia Therapy FG-4592 Will Be Presented at American Society of Nephrology (ASN) Renal Week," 3/18/2019 74587V10 BW   Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,"11/14/2017 MCRB-US  BW   Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology", 6/03/2019 AIMT-US  BW   Daten der ARTEMIS-Zulassungsstudie Phase 3 belegen durchgängige Sicherheit und Wirksamkeit von AR101 bei Kindern und Jugendlichen mit Erdnussallergie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference,#N/A,10/31/2016 HCM-GB   BW   Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2018 QTRX-US  BW   Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018," 3/15/2018 SLDB-US  BW   INVESTOR ALERT: Investigation of Solid Biosciences, Inc. Announced by Holzer & Holzer",#N/A,#N/A," 4/14/2014 30233G10 BW   pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN®",#N/A,#N/A, 4/02/2019 AXNX-US  BW   Axonics® to Present at the Needham Healthcare Conference,11/08/2017 0D5N8T-E BW   Tricida Announces Closing of $57.5 Million Series D Financing,#N/A,#N/A, 4/09/2018 0GNB9B-E BW   Magenta Therapeutics Secures $52 Million in Series C Financing,#N/A,#N/A,#N/A,#N/A, 1/18/2019 MRNA-US BW   Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2019 TWST-US  BW   Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting,#N/A,#N/A,#N/A, 9/27/2011 05G05S-E  BW   Precision BioSciences Awarded Broad Meganuclease Patent by the USPTO,#N/A,#N/A,#N/A," 8/14/2012 05G06K-E BW   Atreca, Inc., Licenses Transformational “Immune Repertoire Capture” Technology from Stanford University"," 4/24/2019 00DD8T-E BW   Personalis, Inc. va exposer au So‎‎mmet européen NeoAG 2019",#N/A,#N/A, 6/10/2016 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Present Data Demonstrating High-Throughput Sequencing for Minimal Residual Disease (MRD) is More Sensitive Than Flow Cytometry and Can Be Used as a Determinant of Early Response to Therapy,#N/A,#N/A
10/10/2018 LGND-US   BW   Ligand Announces the Close of its Acquisition of Vernalis, 1/10/2011 SIGA-US     BW,10/23/2018 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2018, 9/12/2018 84763A10  BW   Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient,11/03/2016 ENDP-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Endo International PLC Investors Concerning Recent Revelations Regarding an Alleged Illegal Conspiracy to Fix Drug Prices, 2/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 5/09/2016 OPK-US   BW   Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE®, 6/28/2011 SAN-FR      BW,#N/A, 2/04/2019 ALXN-US  BW   Alexion Reports Fourth Quarter and Full Year 2018 Results,#N/A," 4/04/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019"," 3/18/2014 45290710    BW   INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced by Law Offices of Howard G. Smith",11/02/2017 09062X10    BW   Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab, 5/16/2018 IMGN-US  BW   ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer,10/18/2012 09058V10 BW   BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge, 7/22/2019 GILD-US      BW   Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance,#N/A, 4/27/2015 TEVA-IL  BW   Teva Reiterates Commitment to Cash-and-Stock Acquisition of Mylan for $82.00 Per Share, 8/06/2014 M2572210 BW   Compugen Ltd. Reports 2nd Quarter 2014 Financial Results," 2/27/2018 FRE-DE    BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, Inc.", 8/06/2015 500124-IN    BW   Dr. Reddy’s Announces Strategic Collaboration with Amgen in India," 4/23/2018 008G5M-E    BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN",#N/A,#N/A,#N/A, 1/21/2019 05156V10 BW   Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome, 6/02/2010 45773H20 BW   Inovio Pharmaceuticals to Present at Investor Conferences,#N/A,#N/A, 9/12/2011 37416310     BW   Geron to Webcast Presentations at Upcoming Investor Conferences, 1/17/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant),#N/A, 3/01/2019 INCY-US  BW   Los datos de la cartera de investigación del cáncer de Incyte se presentarán en siete resúmenes en el Congreso anual de la AACR 2019,#N/A, 6/09/2016 SRPT-US  BW   Sarepta Therapeutics Announces Common Stock Offering,10/26/2017 ALKS-US  BW   Alkermes plc Reports Third Quarter 2017 Financial Results, 7/10/2018 CERS-US  BW   New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis Platelets Collected at U.S. Navy Blood Donor Centers," 2/13/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 1/24/2019 ARQL-US  BW   Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer,#N/A,#N/A,10/08/2018 EXEL-US  BW   Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy,10/27/2017 SAN-FR    BW   Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a, 1/22/2019 VRTX-US   BW   Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5,#N/A,#N/A,12/03/2018 BLUE-US  BW   bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology,10/29/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Executive Leadership Change,#N/A,#N/A,#N/A, 9/13/2018 TXMD-US  BW   TherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg,#N/A,#N/A,12/20/2018 OMER-US  BW   Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy,11/01/2018 76133010 BW   Revance Releases Third Quarter 2018 Results, 4/27/2011 008349-E BW   Intrexon Launches Animal Science Division, 9/13/2018 IRWD-US  BW   Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF),#N/A,#N/A,#N/A, 7/02/2013 63009R10    BW   Study Published in The Journal of Clinical Oncology Demonstrates Advantages of NanoString’s ProsignaTM Breast Cancer Assay,#N/A, 8/08/2018 SYRS-US  BW   Syros to Present at 2018 Wedbush PacGrow Healthcare Conference,#N/A,#N/A, 2/15/2012 0657G1-E     BW   BioSante Pharmaceuticals Announces FDA Approval for Bio-T-Gel™," 2/07/2018 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017", 5/09/2019 ALNY-US   BW   Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019,#N/A,#N/A,#N/A," 8/05/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference",10/10/2014 RTRX-US  BW   RETROPHIN SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Retrophin Inc. For Potential Securities Fraud and Breaches of Fiduciary Duty, 3/03/2010 PACB-US  BW   Pacific Biosciences Appoints Susan K. Barnes as Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,12/03/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 1/07/2019 SAGE-US     BW   Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A," 2/06/2017 MEDP-US  BW   Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2016 Financial Results on February 27, 2017",#N/A, 4/27/2017 INVA-US     BW   Innoviva Reports First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,"10/29/2012 56400P70 BW   MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call to November 1, 2012 Due to Hurricane Sandy",#N/A,#N/A, 7/16/2014 29664W10    BW   Esperion Therapeutics to Host Inaugural Analyst and Investor Day," 4/20/2017 AMRS-US  BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Amyris, Inc. – AMRS",#N/A,#N/A,#N/A,#N/A," 7/25/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018"," 8/07/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results",#N/A,#N/A, 5/09/2016 EPZM-US  BW   Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2019 VCYT-US  BW   Veracyte to Present at the 21st Annual Needham Growth Conference," 2/01/2019 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)", 4/17/2019 15117K10 BW   Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting,#N/A,#N/A,#N/A, 3/24/2014 00847X10 BW   Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation," 1/09/2014 IOVA-US  BW   Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing",#N/A,11/27/2018 XLRN-US  BW   Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting,#N/A, 5/29/2019 HZNP-US  BW   Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program, 7/30/2018 00BJ80-E  BW   Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis, 2/21/2013 0835JB-E BW   La communauté de capital-risque se prépare en vue de la conférence BIO-Europe Spring® 2013,#N/A, 3/14/2018 GLYC-US  BW   GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018,#N/A,#N/A,#N/A,10/22/2018 G6674U10 BW   Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields,#N/A,#N/A,#N/A, 1/22/2019 RCKT-US  BW   Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease,#N/A,#N/A,#N/A,#N/A,"10/14/2010 05SVDW-E   BW   FibroGen Initiates Phase 2 Clinical Study to Evaluate Efficacy of FG-3019, Human Monoclonal Antibody Against CTGF, in Reversing Liver Fibrosis", 3/18/2019 74587V10 BW   Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2017 MCRB-US  BW   Seres Therapeutics to Participate in Three Upcoming November Conferences, 6/03/2019 AIMT-US  BW   Les données de l'essai pivot ARTEMIS de Phase 3 démontrent le profil d'innocuité et d'efficacité cohérent d'AR101 chez les enfants et les adolescents allergiques aux arachides,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2018 RARX-US  BW   Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting,#N/A, 8/02/2016 HCM-GB   BW   Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2018 QTRX-US  BW   Quanterix’ Simoa Technology Reveals Link Between Soccer Headers and Concussions for the First Time,11/30/2017 0G9J11-E BW   Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy,#N/A,#N/A, 4/01/2014 30233G10 BW   pSivida CEO to Discuss Company’s Sustained Release Delivery System for Biologics at Two Upcoming Conferences,#N/A,#N/A, 3/07/2019 AXNX-US  BW   Axonics® to Participate in Upcoming Investor Events,11/01/2017 00FY1L-E BW   Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase 1/2 Study Results in Patients with Metabolic Acidosis Associated with Chronic Kidney Disease,#N/A,#N/A," 4/06/2018 0GNB9B-E BW   Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors",#N/A,#N/A,#N/A,#N/A, 1/08/2019 MRNA-US BW   Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2019 TWST-US  BW   Twist Bioscience Reports First Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress,#N/A,#N/A,#N/A,12/16/2010 0084LG-E  BW   Precision BioSciences Awarded Over $3 Million from Four Government Grants,#N/A,#N/A,#N/A,#N/A," 4/24/2019 00DD8T-E BW   Personalis, Inc. präsentiert auf dem European NeoAG Summit 2019",#N/A,#N/A, 6/04/2016 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Present Seven Studies Demonstrating the Use of Immunosequencing to Identify Prognostic Biomarkers and Potential Biomarkers of Response at the 2016 American Society of Clinical Oncology Annual Meeting,#N/A,#N/A
 8/29/2018 LGND-US   BW   Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference,11/16/2010 74318710    BW   Progenics Pharmaceuticals Announces Phase 2 Clinical Trial of Subcutaneous Methylnaltrexone in Japan by Ono Pharmaceutical,"10/09/2018 45232710    BW   Illumina to Announce Third Quarter 2018 Financial Results on Tuesday, October 23, 2018", 9/05/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer," 7/12/2016 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endo International plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2016 – ENDP", 1/24/2019 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results,#N/A,#N/A,#N/A,#N/A," 4/28/2016 OPK-US   BW   OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016", 5/18/2011 46222210    BW,#N/A, 2/01/2019 ALXN-US  BW   Alexion to Highlight Rare Disease Portfolio at Investor Day,#N/A, 3/29/2019 GMAB-DK     BW   Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer," 2/28/2014 45290710    BW   Girard Gibbs Announces Class Action Lawsuit on Behalf of Investors of Immunomedics, Inc.",11/01/2017 09062X10    BW   The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy," 5/14/2018 0DLHDL-E BW   Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen", 8/02/2012 09058V10 BW   BioCryst Provides Corporate Update and Reports Second Quarter 2012 Financial Results," 7/22/2019 GILD-US      BW   Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV",#N/A, 4/22/2015 TEVA-IL  BW   Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan," 7/31/2014 M2572210 BW   CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT"," 1/26/2018 AKRX-US   BW   Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX", 7/15/2015 AMGN-US      BW   Fitch Affirms Amgen Inc.'s Ratings at 'BBB'; Outlook Revised to Stable," 3/20/2018 0BGL4K-E    BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Myriad Genetics, Inc.",#N/A,#N/A,#N/A,12/19/2018 05156V10 BW   Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, 5/17/2010 45773H20 BW   Inovio Pharmaceuticals Reports First Quarter 2010 Financial Results,#N/A,#N/A, 7/28/2011 37416310     BW   Geron Corporation Reports 2011 Second Quarter Financial Results and Events, 1/04/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan,#N/A, 2/28/2019 INCY-US  BW   Les données du portefeuille de recherche sur le cancer d'Incyte seront présentées dans sept abstracts lors du congrès annuel 2019 de l'AACR,#N/A, 6/08/2016 SRPT-US  BW   Sarepta Therapeutics Announces Proposed Offering,10/19/2017 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Third Quarter 2017 Financial Results, 6/15/2018 CERS-US  BW   Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association, 2/07/2012 00163U10 BW   AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board, 1/09/2019 ARQL-US  BW   Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA),#N/A,#N/A," 9/25/2018 EXEL-US  BW   Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018",10/16/2017 AIMT-US   BW   Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy, 1/21/2019 VRTX-US   BW   Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease,#N/A,#N/A,12/02/2018 BLUE-US  BW   bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting,"10/23/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018",#N/A,#N/A,#N/A, 8/22/2018 TXMD-US  BW   TherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference,#N/A,#N/A,12/11/2018 OMER-US  BW   Omeros Announces Research Collaboration with University of Cambridge,"10/18/2018 76133010 BW   Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018", 4/21/2011 008349-E BW   Intrexon Acquires Neugenesis Corporation and Establishes Industrial Products Location, 8/28/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences,#N/A,#N/A,#N/A, 6/25/2013 63009R10    BW   NanoString Technologies Prices Initial Public Offering,#N/A, 8/07/2018 SYRS-US  BW   Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A," 2/13/2012 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference"," 1/24/2018 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017", 5/01/2019 ALNY-US   BW   Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A," 7/31/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter",10/10/2014 76129910 BW   Retrophin Announces Appointment of Jeffrey A. Meckler to Board of Directors, 2/23/2010 PACB-US  BW   Pacific Biosciences Announces Early Access Customers for Its Single Molecule Real Time System,#N/A,#N/A,#N/A,#N/A,11/30/2018 AKBA-US  BW   Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx,#N/A,#N/A,#N/A,#N/A, 1/07/2019 SAGE-US     BW   Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression,#N/A,#N/A,#N/A,"11/03/2016 MEDP-US  BW   Medpace Holdings, Inc. Reports Third Quarter 2016 Results",#N/A, 4/21/2017 INVA-US     BW   Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT,#N/A,#N/A,#N/A,"10/22/2012 56400P70 BW   MannKind Corporation to Hold 2012 Third Quarter Financial Results Conference Call on October 29, 2012",#N/A,#N/A," 6/26/2014 29664W10    BW   Esperion Therapeutics Announces the Appointment of Gilbert S. Omenn, M.D., Ph.D. to Board of Directors"," 4/19/2017 AMRS-US  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Amyris, Inc.",#N/A,#N/A,#N/A,#N/A, 7/09/2018 EGRX-US  BW   FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)," 8/01/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference",#N/A,#N/A, 5/09/2016 EPZM-US  BW   Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2019 VCYT-US  BW   Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer, 1/28/2019 DRNA-US  BW   Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus, 4/17/2019 15117K10 BW   Cellectis présentera des données sur ses programmes allogéniques innovants à la conférence annuelle de l’ASGCT,#N/A,#N/A,#N/A, 3/19/2014 00847X10 BW   Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation,11/26/2013 09N40F-E BW   Lion Biotechnologies to Present at the LD MICRO Conference on December 3,#N/A,11/26/2018 XLRN-US  BW   Acceleron to Participate in Two Upcoming Healthcare Investor Conferences,#N/A, 5/21/2019 HZNP-US  BW   Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE, 6/04/2018 00BJ80-E  BW   Castle Biosciences Presents Data at ASCO 2018 Supporting Accuracy and Performance of the DecisionDx-Melanoma Test in Predicting Risk of Melanoma Recurrence,10/21/2011 0BHZ59-E BW   EKR Therapeutics Announces Robert P. Roche Jr. Joins Board of Directors,#N/A, 3/07/2018 GLYC-US  BW   GlycoMimetics to Present at Four Investor Conferences This Month,#N/A,#N/A,#N/A,10/18/2018 G6674U10 BW   Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®,#N/A,#N/A,#N/A,12/21/2018 RCKT-US  BW   Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index,#N/A,#N/A,#N/A,#N/A," 9/20/2010 05SVDW-E   BW   FibroGen Announces Chinese State FDA Approval of Phase 1 and 2 Development of FibroGen Oral Anemia Therapy, FG-4592", 3/14/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2017 MCRB-US  BW   Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress, 6/03/2019 AIMT-US  BW   I dati dello studio pivotale di fase III ARTEMIS dimostrano la costante sicurezza ed efficacia di AR101 per i bambini e gli adolescenti affetti da allergia alle arachidi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2018 RARX-US  BW   Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer,#N/A," 8/02/2016 HCM-GB   BW   Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/18/2018 QTRX-US  BW   Quanterix CEO Leads Webinar on How Digital Biomarkers are Empowering Drug Development, 6/07/2017 0G9J11-E BW   Solid Biosciences Strengthens Leadership Team to Advance Programs for Duchenne Muscular Dystrophy,#N/A,#N/A, 3/27/2014 30233G10 BW   pSivida Announces Resubmission of New Drug Application for ILUVIEN®,#N/A,#N/A, 3/05/2019 AXNX-US  BW   Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update, 9/28/2017 00FY1L-E BW   Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney Disease,#N/A,#N/A, 4/05/2018 0GNB9B-E BW   Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders,#N/A,#N/A,#N/A,#N/A, 1/02/2019 MRNA-US BW   Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/07/2019 TWST-US  BW   Twist Bioscience Announces Appointment of Martin Kunz as Senior Vice President, Operations",#N/A,#N/A,#N/A,11/01/2010 0084LG-E  BW   BASF Plant Science Licenses Precision BioSciences’ Site-Specific Genome Modification Technology,#N/A,#N/A,#N/A,#N/A," 4/23/2019 00DD8T-E BW   Personalis, Inc. to Present at European NeoAG Summit 2019",#N/A,#N/A, 5/14/2016 0DMSKV-E BW   Adaptive Biotechnologies to Present 2 Studies Demonstrating Utility of Immunosequencing to Propel Diagnostic Development and Therapeutic Discovery at the 2016 American Association of Immunologists Annual Meeting,#N/A,#N/A
" 8/09/2018 LGND-US   BW   Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash",11/08/2010 74318710    BW   Progenics Pharmaceuticals Announces Third Quarter 2010 Financial Results, 9/28/2018 45232710    BW   Illumina Announces Conversion Period for 0% Convertible Senior Notes due 2019 and 0.5% Convertible Senior Notes due 2021, 8/30/2018 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September," 7/08/2016 00FV7G-E BW   ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of July 25, 2016", 1/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases,#N/A,#N/A,#N/A,#N/A, 4/28/2016 68375N10 BW   OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings 2016, 4/28/2011 46222210    BW,#N/A, 1/31/2019 0H9PHY-E BW   Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis,#N/A, 3/28/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin," 2/27/2014 45290710    BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Immunomedics, Inc.",10/30/2017 09062X10    BW   Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference, 5/04/2018 IMGN-US  BW   ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results, 7/24/2012 09058V10 BW   BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout, 7/19/2019 NOVN-CH      BW   Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis,#N/A,#N/A," 7/29/2014 M2572210 BW   Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT","12/28/2017 0F98BD-E  BW   Pomerantz LLP and Glancy Prongay & Murray LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX", 6/14/2015 07CZPT-E     BW   Open Monoclonal Technology Announces OmniAb Alliance With Amgen," 3/19/2018 MYGN-US     BW   Glancy Prongay & Murray LLP Continues Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN)",#N/A,#N/A,#N/A,11/30/2018 05156V10 BW   Aurinia Establishes at-the-Market Facility, 5/17/2010 45773H20 BW   DNA Vaccine Developer Inovio Biomedical Changes Name to Inovio Pharmaceuticals,#N/A,#N/A, 7/26/2011 37416310     BW   Geron Announces Conference Call to Discuss Second Quarter Financial Results and Highlights," 1/02/2019 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access",#N/A, 2/28/2019 INCY-US  BW   Daten aus dem Krebsforschungsportfolio von Incyte werden auf der Jahreskonferenz 2019 der AACR in sieben Abstracts vorgestellt,#N/A, 6/06/2016 SRPT-US  BW   Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA,10/18/2017 ALKS-US  BW   New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry, 6/01/2018 CERS-US  BW   Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion, 1/30/2012 00163U10 BW   AMAG Pharmaceuticals Announces Completion of Enrollment in its Phase III Program Evaluating Feraheme for a Broader Iron Deficiency Anemia Indication,12/19/2018 04269E10 BW   ArQule Added to the NASDAQ Biotechnology Index,#N/A,#N/A, 9/21/2018 EXEL-US  BW   Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma, 9/25/2017 AET-US    BW   Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 Diabetes, 1/04/2019 0C6ZGM-E  BW   X-Chem and Vertex Expand Existing Partnership,#N/A,#N/A,12/01/2018 BLUE-US  BW   bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology, 9/26/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science,#N/A,#N/A,#N/A, 8/10/2018 TXMD-US  BW   TherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control,#N/A,#N/A,12/06/2018 OMER-US  BW   Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA),10/11/2018 76133010 BW   Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer, 2/09/2011 008349-E BW   Intrexon Appoints Vice President of Alliance Management for Human Therapeutics, 8/21/2018 IRWD-US  BW   Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation,#N/A,#N/A,#N/A, 6/03/2013 065C1X-E    BW   Results of New Analysis Support Use of NanoString’s Prosigna™ Assay to Help Identify Node-Positive Early-Stage Breast Cancer Patients at Low Risk of Recurrence,#N/A," 7/31/2018 SYRS-US  BW   Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018",#N/A,#N/A, 2/09/2012 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review for Phase III Program, 1/05/2018 ENTA-US    BW   Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2018 during the 36th Annual J.P. Morgan Healthcare Conference, 4/30/2019 ALNY-US   BW   Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran),#N/A,#N/A,#N/A, 7/17/2014 69512710 BW   Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call,10/09/2014 76129910 BW   Retrophin Announces Appointment of Gary Lyons to Board of Directors, 2/16/2010 PACB-US  BW   Pacific Biosciences Announces Partner Program for Its Single Molecule Real Time System,#N/A,#N/A,#N/A,#N/A,11/29/2018 AKBA-US  BW   Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx,#N/A,#N/A,#N/A,#N/A, 1/04/2019 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,"10/24/2016 CS-CH    BW   Medpace Holdings, Inc. to Present at Credit Suisse Healthcare Conference",#N/A, 4/20/2017 INVA-US     BW   Innoviva Announces Preliminary Results of Annual Meeting,#N/A,#N/A,#N/A,10/18/2012 56400P70 BW   MannKind Announces Pricing of Public Offering of Common Stock and Warrants,#N/A,#N/A, 6/17/2014 29664W10    BW   Esperion Therapeutics to Present at JMP Securities Healthcare Conference, 6/02/2016 AMRS-US  BW   Gen9 and Amyris Announce Supply Agreement for Synthetic DNA,#N/A,#N/A,#N/A,#N/A, 7/03/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA, 6/20/2018 DCPH-US BW   Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares,#N/A,#N/A, 5/06/2016 EPZM-US  BW   Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2019 VCYT-US  BW   Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference, 1/24/2019 DRNA-US  BW   Dicerna Evolves Its Board of Directors to Support Continued Growth, 4/05/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 3/06/2014 00847X10 BW   Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results,10/23/2013 46226010 BW   Lion Biotechnologies to Trade Under New Ticker Symbol ‘LBIO’ Beginning Today,#N/A,11/07/2018 XLRN-US  BW   Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session,#N/A, 5/16/2019 HZNP-US  BW   Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout, 5/30/2018 00BJ80-E  BW   Castle Biosciences Launches Next-Generation Sequencing Test DecisionDx-CMSeq for Cutaneous Melanoma,#N/A,#N/A, 3/06/2018 GLYC-US  BW   GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results,#N/A,#N/A,#N/A,10/04/2018 G6674U10 BW   Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018,#N/A,#N/A,#N/A,11/30/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A, 8/25/2010 05SVDW-E   BW   FibroGen Announces Results of 2-Year Study Demonstrating that Biosynthetic Corneas Formulated with Recombinant Human Type III Collagen Restore Vision and Promote Nerve Regeneration, 3/05/2019 74587V10 BW   Puma Biotechnology to Present at Cowen’s Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2017 MCRB-US  BW   Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate, 6/02/2019 AIMT-US  BW   Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2018 RARX-US  BW   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update,#N/A, 8/01/2016 HCM-GB   BW   Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2018 QTRX-US  BW   Quanterix Announces Termination of License Agreement with bioMérieux, 5/11/2017 0G9J11-E BW   New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy,#N/A,#N/A, 3/13/2014 30233G10 BW   pSivida Corp. Announces $7.0 Million Investment by RA Capital,#N/A,#N/A, 3/04/2019 AXNX-US  BW   Axonics® Appoints Michael H. Carrel to its Board of Directors, 4/11/2017 00FY1L-E BW   Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice President,#N/A,#N/A," 4/03/2018 0GNB9B-E BW   Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.",#N/A,#N/A,#N/A,#N/A,12/06/2018 MRNA-US BW   Moderna Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2019 TWST-US  BW   Twist Bioscience Chief Technology Officer Presented at Praesens Foundation Future Health Threats Initiative 2019,#N/A,#N/A,#N/A,10/28/2010 0084LG-E  BW   Precision BioSciences Announces that the US Patent Office Issues Final Decisions Rejecting Claims of Four Cellectis Patents,#N/A,#N/A,#N/A,#N/A, 4/02/2019 00DD8T-E BW   Personalis Appoints Industry Executive Aaron Tachibana as Chief Financial Officer,#N/A,#N/A, 4/16/2016 06P9WL-E BW   Adaptive Biotechnologies and Collaborators to Present 10 Studies Demonstrating the Utility of Immunosequencing in Both Tissue and Blood Samples at 2016 American Association of Cancer Research Annual Meeting,#N/A,#N/A
 8/06/2018 LGND-US   BW   Ligand Reports Second Quarter 2018 Financial Results,10/19/2010 PGNX-US     BW   Medidata Solutions Selected by Progenics Pharmaceuticals for Seamless Integration of EDC and IVRS, 8/30/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 8/09/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update," 7/07/2016 ENDP-US  BW   JULY 25, 2016 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm", 1/07/2019 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia,#N/A,#N/A,#N/A,#N/A, 4/27/2016 OPK-US   BW   FDA Accepts Resubmission of New Drug Application for RAYALDEE®, 4/18/2011 46222210    BW,#N/A, 1/28/2019 ALXN-US  BW   Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS™ (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS),#N/A, 3/28/2019 4503-JP     BW   Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer," 2/04/2014 45290710    BW   Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Immunomedics, Inc.",10/27/2017 09062X10    BW   Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product, 5/02/2018 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference," 7/19/2012 09058V10 BW   BioCryst to Report Second Quarter 2012 Financial Results on August 2, 2012"," 7/18/2019 GILD-US      BW   Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019",#N/A,#N/A, 7/24/2014 M2572210 BW   Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences," 4/30/2017 AKRX-US   BW   INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and Encourages Shareholders to Contact the Firm for Additional Information", 4/28/2015 AMGN-US      BW   Fitch Assigns a 'BBB' Rating to Amgen's Notes Offering," 3/19/2018 MYGN-US     BW   MYGN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Myriad Genetics, Inc. Investors",#N/A,#N/A,#N/A,11/09/2018 05156V10 BW   Aurinia to Participate in November Investor Conferences, 5/12/2010 45773H20 BW   Inovio Biomedical to Present at American Society of Gene & Cell Therapy Annual Meeting,#N/A,#N/A, 6/07/2011 37416310     BW   Geron Presents Data from GRNOPC1 Trial at International Conferences on Spinal Cord Medicine and Rehabilitation,11/07/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference,#N/A, 2/28/2019 INCY-US  BW   Gegevens van Incyte's portfolio voor kankeronderzoek worden uitgelicht in zeven abstracts tijdens de jaarlijkse bijeenkomst van de AACR 2019,#N/A, 5/25/2016 SRPT-US  BW   Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date,"10/16/2017 ALKS-US  BW   Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting", 5/16/2018 CERS-US  BW   Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells, 1/09/2012 00163U10 BW   AMAG Pharmaceuticals Provides Business Update,"12/03/2018 04269E10 BW   ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting",#N/A,#N/A, 9/19/2018 0DKPY7-E BW   Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma, 9/20/2017 SAN-FR    BW   Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy, 1/03/2019 0H2YHT-E  BW   Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies,#N/A,#N/A,11/30/2018 BLUE-US  BW   bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology," 9/25/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018",#N/A,#N/A,#N/A, 8/06/2018 TXMD-US  BW   TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock,#N/A,#N/A,12/03/2018 OMER-US  BW   Omeros Announces Additions to Senior Management Team, 9/24/2018 76133010 BW   Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference, 2/08/2011 ZIOP-US  BW   ZIOPHARM Announces Full Exercise of Underwriter’s Option; Completion of Public Offering, 8/06/2018 IRWD-US  BW   Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update,#N/A,#N/A,#N/A, 5/20/2013 065C1X-E    BW   NanoString Technologies Files Registration Statement with the Securities and Exchange Commission for an Initial Public Offering,#N/A," 7/10/2018 SYRS-US  BW   Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018",#N/A,#N/A, 2/08/2012 00182C10     BW   BioSante Exchanges $5 Million Aggregate Principal Amount of Convertible Senior Notes for 6.7 Million Shares of Common Stock,12/28/2017 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference, 4/23/2019 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results,#N/A,#N/A,#N/A," 6/26/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®",10/03/2014 76129910 BW   Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,11/20/2018 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,"12/27/2018 SAGE-US     BW   Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019",#N/A,#N/A,#N/A,"10/17/2016 MEDP-US  BW   Medpace Holdings, Inc. to Report Third Quarter 2016 Financial Results on November 3, 2016",#N/A, 4/19/2017 INVA-US     BW   Innoviva Urges Shareholders to Vote “FOR” All of Innoviva’s Value-Creating Directors On the WHITE Proxy Card TODAY,#N/A,#N/A,#N/A,"10/18/2012 56400P70 BW   MannKind Receives Commitment from The Mann Group to Acquire 40,000,000 Shares of Common Stock and Warrants to Purchase Common Stock",#N/A,#N/A, 5/29/2014 29664W10    BW   Esperion Therapeutics to Present at Jefferies 2014 Global Healthcare Conference," 7/09/2013 03236M20 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors With Losses on Their Investment in Amyris, Inc. of Class Action Lawsuit and the Deadline of July 15, 2013 to Seek a Lead Plaintiff Position",#N/A,#N/A,#N/A,#N/A, 6/11/2018 EGRX-US  BW   Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)," 6/13/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference",#N/A,#N/A, 5/04/2016 EPZM-US  BW   Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2018 VCYT-US  BW   Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program," 1/08/2019 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)", 4/05/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A," 2/27/2014 00847X10 BW   Agios Pharmaceuticals to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014",10/07/2013 46226010 BW   Lion Biotechnologies to Present at the 12th Annual BIO Investor Forum on October 9,#N/A,11/01/2018 XLRN-US  BW   Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting,#N/A, 5/09/2019 HZNP-US  BW   Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary, 5/07/2018 00BJ80-E  BW   Castle Biosciences Presents Prospective Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations,#N/A,#N/A, 3/05/2018 GLYC-US  BW   GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML,#N/A,#N/A,#N/A,10/01/2018 G6674U10 BW   Novocure to Report Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A,"11/28/2018 RCKT-US  BW   RTW Investments Announces Private Placement Transaction with Rocket Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A," 5/25/2010 05SVDW-E   BW   Two Join Board of Directors of FibroGen, Inc.", 2/28/2019 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,"11/02/2017 MCRB-US  BW   Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017", 5/24/2019 AIMT-US  BW   Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference,#N/A, 7/05/2016 HCM-GB   BW   Chi-Med to Announce 2016 Half-Year Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/11/2018 QTRX-US  BW   Quanterix CEO Kevin Hrusovsky Leads Webinar on How Biomarkers are Empowering Drug Development, 3/30/2017 0G9J11-E BW   Solid Biosciences Raises up to $50 Million in Series C Financing,#N/A,#N/A, 2/10/2014 30233G10 BW   pSivida Announces ILUVIEN® for DME Accepted by National Health Service Scotland,#N/A,#N/A, 2/27/2019 AXNX-US  BW   Axonics® legt US-amerikanischer Food & Drug Administration entscheidende klinische Daten für System zur sakralen Neuromodulation vor, 2/15/2017 00FY1L-E BW   Tricida Announces Hiring of Wilhelm Stahl as Chief Technology Officer and Senior Vice President,#N/A,#N/A," 3/08/2018 0GNB9B-E BW   Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/28/2019 TWST-US  BW   Twist Bioscience to Report Fiscal 2019 First Quarter Financial Results on Thursday, February 7, 2019",#N/A,#N/A,#N/A, 9/07/2010 0084LG-E  BW   Precision BioSciences Wins Stay of Patent Litigation Brought by Cellectis,#N/A,#N/A,#N/A,#N/A," 3/31/2019 00DD8T-E BW   Personalis, Inc. to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019",#N/A,#N/A, 4/11/2016 0DMSKV-E BW   Adaptive Biotechnologies Welcomes Charles Sang as Senior Vice President of Diagnostics,#N/A,#N/A
 7/09/2018 LGND-US   BW   Ligand to Report Second Quarter 2018 Results on August 6th,10/06/2010 74318710    BW   Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile Antibody Therapy, 8/27/2018 45232710    BW   Illumina Receives Approval of MiSeq™Dx System in China, 8/02/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast, 7/06/2016 AYTU-US  BW   Acerus Completes NATESTO® U.S. Transition,12/17/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 4/25/2016 68375N10 BW   OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales, 4/14/2011 078VWR-E    BW,#N/A," 1/07/2019 ALXN-US  BW   Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019",#N/A, 3/27/2019 SGEN-US     BW   Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting," 1/27/2014 45290710    BW   Investor Alert: Immunomedics, Inc. Investigation Announced by Holzer & Holzer, LLC",10/25/2017 09062X10    BW   Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis, 4/26/2018 IMGN-US  BW   ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, 6/28/2012 BCRX-US  BW   BioCryst to Present at the 7th Annual JMP Securities Healthcare Conference, 7/17/2019 0056YC-E     BW   AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs,#N/A,#N/A, 7/14/2014 M2572210 BW   Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins," 4/26/2017 AKRX-US   BW   SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and Encourages Investors to Contact the Firm for Additional Information", 4/21/2015 0DFTQ2-E     BW   Allergen Research Corporation Announces New CFO Warren DeSouza and Board of Directors Audit Committee Chair Kate Falberg," 3/19/2018 MYGN-US     BW   Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. (MYGN) on Behalf of Stockholders and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A,"11/08/2018 05156V10 BW   Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development", 5/05/2010 45773H20 BW   Inovio Biomedical to Present at Investor Conferences,#N/A,#N/A, 6/06/2011 37416310     BW   Geron to Present at Jefferies 2011 Global Healthcare Conference,11/06/2018 AERI-US    BW   Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update,#N/A," 2/28/2019 INCY-US  BW   Presentazione in sette abstract, al congresso annuale 2019 dell'AACR, di dati dal portafoglio di studi per la ricerca di Incyte sui tumori",#N/A, 5/05/2016 SRPT-US  BW   Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments, 9/28/2017 ALKS-US  BW   Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis, 5/08/2018 CERS-US  BW   Cerus Corporation Reports First Quarter 2018 Results," 1/04/2012 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference","11/29/2018 04269E10 BW   ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies",#N/A,#N/A, 9/07/2018 EXEL-US  BW   Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines, 7/10/2017 ALNY-US   BW   Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors, 1/02/2019 VRTX-US   BW   Vertex to Present at the J.P. Morgan Healthcare Conference on January 7,#N/A,#N/A,11/27/2018 CELG-US  BW   Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma, 9/20/2018 ACAD-US  BW   FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 8/01/2018 TXMD-US  BW   TherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million,#N/A,#N/A,11/09/2018 OMER-US  BW   Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023, 9/20/2018 76133010 BW   Revance Receives Great Place to Work Certification," 2/01/2011 008349-E BW   Intrexon Launches AgBio Division and Acquires Agarigen, Inc.", 7/23/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call,#N/A,#N/A,#N/A, 5/15/2013 065C1X-E    BW   NanoString Technologies Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology,#N/A, 6/14/2018 SYRS-US  BW   Syros Announces Appointment of Michael W. Bonney to Its Board of Directors,#N/A,#N/A," 2/07/2012 00182C10     BW   Investor Alert: Kahn Swick & Foti, LLC and Partner Former Louisiana Attorney General Remind Investors With Large Financial Interests of Lead Plaintiff Deadline in Lawsuit Against BioSante Pharmaceuticals, Inc.",12/21/2017 ENTA-US    BW   Enanta Pharmaceuticals Announces Data Presentations at the 2018 NASH-TAG Conference, 4/15/2019 ALNY-US   BW   Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study,#N/A,#N/A,#N/A," 5/27/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences", 9/30/2014 76129910 BW   Retrophin Announces Leadership Reorganization,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2018 AKBA-US  BW   Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company,#N/A,#N/A,#N/A,#N/A,12/05/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A," 8/17/2016 MEDP-US  BW   Medpace Holdings, Inc. to Present at Two Upcoming Investor Conferences",#N/A, 4/18/2017 INVA-US     BW   Innoviva Issues Statement on Upcoming Annual Meeting of Stockholders,#N/A,#N/A,#N/A,10/17/2012 56400P70 BW   MannKind Announces Proposed Public Offering of Common Stock and Warrants,#N/A,#N/A, 5/12/2014 29664W10    BW   Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results," 6/18/2013 0BKJXM-E BW   Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. and Accretive Health, Inc.",#N/A,#N/A,#N/A,#N/A," 5/29/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June", 6/11/2018 DCPH-US BW   Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock,#N/A,#N/A," 5/02/2016 EPZM-US  BW   Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences",#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2018 VCYT-US  BW   Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum, 1/04/2019 DRNA-US  BW   Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna," 4/02/2019 15117K10 BW   La FDA autorise l’essai clinique pour UCARTCS1, la première thérapie CAR-T allogénique pour le traitement de patients atteints de myélome multiple",#N/A,#N/A,#N/A, 2/24/2014 00847X10 BW   Agios Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference, 9/30/2013 46226010 BW   Lion Biotechnologies Provides Update on Phase II Results for Metastatic Melanoma,#N/A,10/30/2018 XLRN-US  BW   Acceleron Reports Third Quarter 2018 Operating and Financial Results,#N/A, 5/08/2019 HZNP-US  BW   Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance, 4/23/2018 00BJ80-E  BW   DecisionDx-Melanoma Test Independently Improved Identification of High-Risk Patients Compared to AJCC Staging in Stage I-II Cutaneous Melanoma,#N/A,#N/A," 2/27/2018 GLYC-US  BW   GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018",#N/A,#N/A,#N/A, 9/25/2018 G6674U10 BW   Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer,#N/A,#N/A,#N/A,11/27/2018 RCKT-US  BW   Rocket Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 5/17/2010 05SVDW-E   BW   FibroGen Reports Preclinical Data Showing that FG-3019 Reversed the Process of Fibrosis in the Lung, 2/15/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2017 MCRB-US  BW   CORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis," 5/21/2019 AIMT-US  BW   New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2018 RARX-US  BW   Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting,#N/A, 6/20/2016 HCM-GB   BW   Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/05/2018 QTRX-US  BW   Quanterix to Speak at Wells Fargo Securities 2018 Healthcare Conference,10/24/2016 0G9J11-E BW   Solid Biosciences Granted U.S. and E.U. Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy,#N/A,#N/A, 2/07/2014 30233G10 BW   pSivida Corp. Reports Second Quarter 2014 Results,#N/A,#N/A, 2/26/2019 AXNX-US  BW   Axonics® soumet des données cliniques pivot à la Food & Drug Administration américaine pour son système de neuromodulation sacrée, 1/09/2017 00FY1L-E BW   Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis,#N/A,#N/A, 3/05/2018 0GNB9B-E BW   Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2019 TWST-US  BW   Twist Bioscience Receives ISO 13485:2016 and 9001:2015 Certifications of its Quality Management Systems for NGS Target Enrichment Panels,#N/A,#N/A,#N/A, 6/17/2010 0084LG-E  BW   Precision BioSciences Announces that the US Patent Office Action Issues Second Actions Rejecting All Claims Asserted by Cellectis in Litigation,#N/A,#N/A,#N/A,#N/A," 3/18/2019 00DD8T-E BW   Personalis, Inc. to Present at ICI-IO Combinations Summit 2019",#N/A,#N/A," 3/15/2016 0DMSKV-E BW   Innovation Leader, Diego Miralles, M.D., Joins Adaptive Biotechnologies as President of Adaptive Therapeutics",#N/A,#N/A
 6/27/2018 0H50DZ-E  BW   Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement," 9/29/2010 74318710    BW   Progenics Announces Approvals of New Ready-to-Use Pre-Filled Syringes for RELISTOR in U.S., E.U. and Canada", 8/16/2018 45232710    BW   Illumina Announces Pricing of Convertible Senior Notes, 6/29/2018 84763A10  BW   Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint, 7/01/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Endo International plc and Reminds Investors with Losses to Contact the Firm,12/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results,#N/A,#N/A,#N/A,#N/A, 4/01/2016 68375N10 BW   OPKO Presents Additional Data on RAYALDEE® at ENDO 2016, 4/05/2011 46222210    BW,#N/A, 1/02/2019 ALXN-US  BW   Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference,#N/A, 3/05/2019 SGEN-US     BW   Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference,12/21/2011 00B8PL-E    BW   Newly Released Study by BioTrends Highlights “Real World” Use of Benlysta in Patients with Systemic Lupus Erythematosus (SLE),10/24/2017 09062X10    BW   Biogen Reports Quarterly Revenues of $3.1 Billion, 4/25/2018 IMGN-US  BW   ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer, 6/06/2012 09058V10 BW   BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology, 7/17/2019 GILD-US      BW   Gilead Sciences Announces Changes to Senior Leadership Team,#N/A,#N/A, 7/07/2014 00528Z-E BW   Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer," 4/25/2017 AKRX-US   BW   AKORN, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to Fresenius Kabi", 9/08/2014 AMGN-US      BW   Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative," 3/16/2018 MYGN-US     BW   MYGN INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Myriad Genetics, Inc. Investors",#N/A,#N/A,#N/A,"10/25/2018 05156V10 BW   Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018", 4/30/2010 45773H20 BW   Inovio Biomedical CEO to Present at 2010 BIO International Convention,#N/A,#N/A, 6/06/2011 37416310     BW   Geron Highlights ASCO/AACR Joint Session: Telomeres and Telomerase in Cancer,"10/30/2018 AERI-US    BW   Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018",#N/A, 2/28/2019 INCY-US  BW   Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019,#N/A, 4/25/2016 SRPT-US  BW   Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy, 9/18/2017 ALKS-US  BW   Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®," 5/03/2018 CERS-US  BW   Cerus to Present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday May 9, 2018",12/12/2011 00163U10 BW   Health Canada Approves Feraheme® (ferumoxytol) to Treat Iron Deficiency Anemia in Adults with Chronic Kidney Disease,"11/19/2018 04269E10 BW   ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting",#N/A,#N/A," 9/05/2018 EXEL-US  BW   Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018", 7/07/2017 SAN-FR    BW   Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors,"12/19/2018 VRTX-US   BW   Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal",#N/A,#N/A,11/15/2018 BLUE-US  BW   bluebird bio to Present at the Evercore ISI HealthCONx Conference," 9/16/2018 ACAD-US  BW   ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD",#N/A,#N/A,#N/A, 7/31/2018 TXMD-US  BW   TherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System,#N/A,#N/A,11/08/2018 OMER-US  BW   Omeros Corporation Reports Third Quarter 2018 Financial Results, 8/02/2018 76133010 BW   Revance Releases Second Quarter 2018 Results," 1/20/2011 ZIOP-US  BW   Griffin Securities, Inc. Announces Investment Opinion on ZIOPHARM Oncology, Inc.", 7/16/2018 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C),#N/A,#N/A,#N/A, 5/02/2013 065C1X-E    BW   Les résultats d'une étude indiquent que le test de signature génétique pour le pronostic du cancer du sein Prosigna™ par NanoString Technologies estime le risque de récidive tardive chez des patientes postménopausées atteintes...,#N/A, 5/30/2018 SYRS-US  BW   Syros to Present at Upcoming Investor Conferences,#N/A,#N/A," 2/06/2012 00182C10     BW   Robbins Umeda LLP Announces Class Action Suit Against BioSante Pharmaceuticals, Inc.",11/30/2017 ABBV-US    BW   Enanta Announces That AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available in Japan for the Treatment of Chronic Hepatitis C Across All Major Genotypes (GT1-6)," 4/12/2019 ALNY-US   BW   Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria",#N/A,#N/A,#N/A," 5/07/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication"," 9/17/2014 76129910 BW   INVESTOR ALERT: Investigation on Behalf of Retrophin, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP",#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2018 AKBA-US  BW   Akebia Therapeutics Sends Letter to Shareholders,#N/A,#N/A,#N/A,#N/A,11/21/2018 SAGE-US     BW   Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference,#N/A,#N/A,#N/A," 8/16/2016 MEDP-US  BW   Medpace Holdings, Inc. Announces Closing of Initial Public Offering",#N/A, 4/17/2017 INVA-US     BW   Innoviva Board Recommends Shareholders Vote “FOR” All of Innoviva’s Qualified Directors on the WHITE Proxy Card,#N/A,#N/A,#N/A,10/05/2012 56400P70 BW   MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA,#N/A,#N/A, 5/06/2014 29664W10    BW   Esperion Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference," 5/24/2013 03236M20 BW   Law Offices of Todd M. Garber Announces Investigation of Amyris, Inc.",#N/A,#N/A,#N/A,#N/A," 5/16/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture", 6/06/2018 DCPH-US BW   Deciphera Pharmaceuticals Announces Pricing of Public Offering,#N/A,#N/A, 4/25/2016 EPZM-US  BW   Epizyme Broadens Executive Leadership Team with Experienced New Officer and Senior Management,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2018 VCYT-US  BW   Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis, 1/04/2019 DRNA-US  BW   Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna," 4/02/2019 15117K10 BW   FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients",#N/A,#N/A,#N/A, 2/06/2014 00847X10 BW   Agios Pharmaceuticals to Present at the 2014 Leerink Swann Global Healthcare Conference, 9/27/2013 46226010 BW   Lion Biotechnologies to Present at the LD Micro Invitational on October 2,#N/A,"10/23/2018 XLRN-US  BW   Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018",#N/A, 5/06/2019 HZNP-US  BW   Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 4/10/2018 00BJ80-E  BW   New Publication Shows Strong Analytic Validity of Castle Biosciences’ DecisionDx-Melanoma Test for Cutaneous Melanoma,#N/A,#N/A, 2/08/2018 GLYC-US  BW   GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy,#N/A,#N/A,#N/A, 9/12/2018 NVCR-US  BW   Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China,#N/A,#N/A,#N/A,11/27/2018 RCKT-US  BW   Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2019 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2017 MCRB-US  BW   Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference, 5/16/2019 AIMT-US  BW   Aimmune to Present at RBC Capital Markets Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2018 RARX-US  BW   Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases,#N/A, 5/13/2016 HCM-GB   BW   Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2018 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Second Quarter 2018,#N/A,#N/A,#N/A, 2/06/2014 30233G10 BW   pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 12,#N/A,#N/A, 2/26/2019 AXNX-US  BW   Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System, 1/04/2017 JPM-US   BW   Tricida to Present at 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A," 2/26/2018 0GNB9B-E BW   Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2019 TWST-US  BW   Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface,#N/A,#N/A,#N/A, 4/09/2010 0084LG-E  BW   Precision BioSciences Inc. Announces Successful Collaboration Results and Extension of Partnership with Bayer CropScience,#N/A,#N/A,#N/A,#N/A," 2/28/2019 00DD8T-E BW   Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019",#N/A,#N/A, 1/08/2016 PFE-US   BW   Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions,#N/A,#N/A
 5/18/2018 LGND-US   BW   Ligand Prices Offering of $650 Million of Convertible Senior Notes, 9/27/2010 74318710    BW   Progenics Extends Agreement with Pfizer for RELISTOR Commercialization, 8/15/2018 45232710    BW   Illumina to Offer $650 Million Convertible Senior Notes, 6/25/2018 84763A10  BW   Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)," 6/29/2016 ENDP-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endo International plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2016",11/27/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results,#N/A,#N/A,#N/A,#N/A, 3/31/2016 68375N10 BW   OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease, 3/30/2011 46222210    BW,#N/A,12/21/2018 ALXN-US  BW   Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference,#N/A, 2/11/2019 4502-JP     BW   Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma, 1/25/2011 0B31SR-E    BW   Maven Semantic: Colorectal Cancer Research Database Update,10/24/2017 BIIB-US     BW   Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG, 4/20/2018 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results, 5/22/2012 BCRX-US  BW   BioCryst to Present at Two Upcoming Investor Conferences, 7/17/2019 GILD-US      BW   Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company,#N/A,#N/A, 6/16/2014 M2572210 BW   Compugen Discloses Experimental Results for Novel Checkpoint Candidate for Cancer Immunotherapy and Discovery of Two New Candidates, 4/24/2017 AKRX-US   BW   Fresenius Kabi to Acquire Akorn, 8/11/2014 AMGN-US      BW   Amgen Receives CEO Cancer Gold Standard Accreditation," 3/16/2018 MYGN-US     BW   INVESTOR ALERT: Kirby McInerney LLP Announces Investigation on Behalf of Myriad Genetics, Inc. (MYGN) Investors",#N/A,#N/A,#N/A," 9/25/2018 05156V10 BW   Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis", 4/21/2010 45773H20 BW   Inovio Biomedical Named “Best Early Stage Biotech” Company at World Vaccine Congress 2010,#N/A,#N/A, 5/19/2011 37416310     BW   Geron Announces Senior Management Appointments,10/23/2018 AERI-US    BW   Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters,#N/A, 2/28/2019 INCY-US  BW   Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019,#N/A, 3/14/2016 SRPT-US  BW   Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping, 9/06/2017 ALKS-US  BW   Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders, 4/25/2018 CERS-US  BW   Cerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets,12/12/2011 00163U10 BW   AMAG Pharmaceuticals Announces Preliminary Data Regarding the Safety and Efficacy of a Single Infusion of 1020 mg Ferumoxytol (Feraheme®) in Patients with Iron Deficiency Anemia,11/16/2018 04269E10 BW   ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium,#N/A,#N/A, 8/01/2018 EXEL-US  BW   Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update, 6/23/2017 MRK-US    BW   Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian President for International Region,12/18/2018 VRTX-US   BW   Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150,#N/A,#N/A,11/01/2018 BLUE-US  BW   bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress," 9/14/2018 ACAD-US  BW   ACADIA PHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD",#N/A,#N/A,#N/A, 7/31/2018 GUD-CA   BW   Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership,#N/A,#N/A,"11/05/2018 OMER-US  BW   Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018"," 7/19/2018 76133010 BW   Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018", 1/06/2011 008349-E BW   ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics, 6/23/2018 IRWD-US  BW   Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions,#N/A,#N/A,#N/A, 5/02/2013 065C1X-E    BW   Study Results Show Prosigna™ Breast Cancer Prognostic Gene Signature Assay by NanoString Technologies Estimates Risk of Late Recurrence in Postmenopausal Hormone Receptor Positive Breast Cancer Patients,#N/A, 5/16/2018 SYRS-US  BW   Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting,#N/A,#N/A, 1/31/2012 00182C10     BW   BioSante Pharmaceuticals Provides Corporate Update,"11/20/2017 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017"," 4/08/2019 ALNY-US   BW   Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases",#N/A,#N/A,#N/A," 5/05/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference", 9/16/2014 76129910 BW   Retrophin Announces Changes to Board of Directors and Management Team,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2018 AKBA-US  BW   Akebia Therapeutics Announces Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,11/20/2018 SAGE-US     BW   Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection,#N/A,#N/A,#N/A," 8/10/2016 MEDP-US  BW   Medpace Holdings, Inc. Announces Pricing of Initial Public Offering",#N/A, 4/13/2017 INVA-US     BW   Innoviva to Undertake Comprehensive Review of its Cost and Executive Compensation Structures,#N/A,#N/A,#N/A, 9/04/2012 MNKD-US  BW   MannKind Corporation to Present at Upcoming Conferences,#N/A,#N/A, 5/05/2014 29664W10    BW   Esperion Therapeutics to Provide First Quarter 2014 Financial Results," 5/20/2013 03236M20 BW   The Law Firm of Wohl & Fruchter Has Filed a Complaint Against Amyris, Inc.",#N/A,#N/A,#N/A,#N/A," 5/10/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results", 6/04/2018 DCPH-US BW   Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A, 4/18/2016 06P9WL-E BW   Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2018 VCYT-US  BW   Veracyte Announces Third Quarter 2018 Financial Results,12/19/2018 DRNA-US  BW   Dicerna to Join NASDAQ Biotechnology Index, 3/11/2019 15117K10 BW   Cellectis Reports 4th Quarter and Full Year 2018 Financial Results,#N/A,#N/A,#N/A, 2/03/2014 00847X10 BW   Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration," 9/25/2013 46226010 BW   Genesis Biopharma Announces 1-for-100 Reverse Stock Split and Corporate Name Change to ‘Lion Biotechnologies, Inc.’",#N/A,"10/16/2018 XLRN-US  BW   Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City",#N/A, 5/01/2019 HZNP-US  BW   Currax™ Holdings USA LLC Announces Launch and Close of Acquisition, 4/04/2018 00BJ80-E  BW   New Publication Highlights Significant Impact of DecisionDx-Melanoma Prognostic Test on Clinical Management of Patients with Melanoma,#N/A,#N/A,12/15/2017 GLYC-US  BW   GlycoMimetics Added To NASDAQ Biotechnology Index,#N/A,#N/A,#N/A, 9/05/2018 G6674U10 BW   Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control,#N/A,#N/A,#N/A,11/26/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2019 74587V10 BW   Puma Biotechnology Announces Litigation Victory with Jury’s Decision,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2017 MCRB-US  BW   Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress, 5/16/2019 AIMT-US  BW   Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2018 RARX-US  BW   Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference,#N/A, 5/03/2016 DB-DE    BW   Chi-Med to Participate in Two Healthcare Investor Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2018 QTRX-US  BW   Simoa Technology Unlocks Insights from Previously Obscure Biomarker,#N/A,#N/A,#N/A, 1/30/2014 30233G10 BW   pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 2/23/2019 AXNX-US  BW   Axonics® erteilte erweitertes CE-Zeichen; Erstes und einziges sakrales Neuromodulationssystem zur Verwendung mit Ganzkörper-MRT-Scans zugelassen, 7/25/2016 0FNT62-E BW   Tricida Announces $55M Series C Financing,#N/A,#N/A," 2/21/2018 0GNB9B-E BW   Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2019 TWST-US  BW   Twist Bioscience to Present at the 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 3/11/2010 0084LG-E  BW   Precision BioSciences Announces that the European Patent Office Issues Written Decision Confirming Cellectis’ Loss of Patent Protection for Single-Chain Meganucleases in Europe,#N/A,#N/A,#N/A,#N/A," 2/05/2019 00DD8T-E BW   Personalis, Inc. to Present at the 2019 Immuno-Oncology 360 Conference in New York",#N/A,#N/A, 1/06/2016 0DMSKV-E BW   Adaptive Biotechnologies To Present At The 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A
 5/16/2018 LGND-US   BW   Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes, 9/21/2010 74318710    BW   Progenics Announces Clinical Completion of Subcutaneous Methylnaltrexone Safety Study in Chronic Non-Malignant Pain Patients, 7/30/2018 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018, 5/30/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th," 6/24/2016 00FV7G-E BW   SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of July 25, 2016",11/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A, 3/30/2016 OPK-US   BW   OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application, 3/21/2011 46222210    BW,#N/A,12/21/2018 ALXN-US  BW   Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 2/07/2019 SGEN-US     BW   Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results, 1/18/2011 WLA-US      BW   Maven Semantic: Parkinsons Disease Research Database,10/23/2017 4523-JP     BW   Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab, 3/24/2018 IMGN-US  BW   ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting, 5/07/2012 09058V10 BW   BioCryst Provides Corporate Update and Reports First Quarter 2012 Financial Results," 7/16/2019 GILD-US      BW   Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019",#N/A,#N/A, 5/19/2014 M2572210 BW   Compugen Ltd. Reports First Quarter 2014 Results," 4/30/2015 00972810  BW   AKORN ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Potential Violations of Law By Certain Officers and Directors of Akorn, Inc.", 7/02/2014 008WTX-E     BW   BIND Therapeutics Announces Completion of Collaboration Agreement with Amgen," 3/16/2018 MYGN-US     BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN)",#N/A,#N/A,#N/A, 9/19/2018 05156V10 BW   Aurinia to Participate in Upcoming Investor Conferences, 4/14/2010 45773H20 BW   Inovio Biomedical to Present at World Vaccine Congress 2010,#N/A,#N/A, 5/10/2011 37416310     BW   Nation’s Second Participant Enrolls in Human Embryonic Stem Cell Trial,"10/09/2018 AERI-US    BW   Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe",#N/A, 2/19/2019 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A, 3/08/2016 SRPT-US  BW   Sarepta Therapeutics Announces Long Term Plan to Consolidate Facilities within Massachusetts, 9/05/2017 ALKS-US  BW   Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference," 4/25/2018 CERS-US  BW   Cerus to Release First Quarter 2018 Results on May 8, 2018","11/22/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Healthcare Conference","11/14/2018 04269E10 BW   ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018",#N/A,#N/A," 7/17/2018 EXEL-US  BW   Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018", 6/20/2017 SAN-FR    BW   Rosa & Co. Announces Renewal of Multi-Year Research Agreement with Sanofi,12/13/2018 VRTX-US   BW   Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease,#N/A,#N/A,11/01/2018 BLUE-US  BW   bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting, 9/12/2018 ACAD-US  BW   Investors: The Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD),#N/A,#N/A,#N/A, 7/31/2018 TXMD-US  BW   TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock,#N/A,#N/A,10/23/2018 OMER-US  BW   FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, 6/21/2018 76133010 BW   Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia,10/13/2010 008349-E BW   Intrexon Expands Its Commercial Leadership Team, 6/21/2018 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease,#N/A,#N/A,#N/A, 4/17/2013 065C1X-E    BW   NanoString Technologies Secures Option From The Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature,#N/A, 5/10/2018 SYRS-US  BW   Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A," 1/11/2012 0BGL4K-E     BW   The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Laws Violations by BioSante Pharmaceuticals, Inc.","11/13/2017 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017", 4/08/2019 ALNY-US   BW   Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration,#N/A,#N/A,#N/A," 5/01/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results", 8/12/2014 76129910 BW   Retrophin Reports Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,11/07/2018 SAGE-US     BW   Sage Therapeutics to Present at Stifel 2018 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2017 INVA-US     BW   Innoviva Comments on ISS and Glass Lewis Reports,#N/A,#N/A,#N/A, 8/07/2012 56400P70 BW   MannKind Corporation Reports 2012 Second Quarter Financial Results,#N/A,#N/A, 5/01/2014 29664W10    BW   Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association," 5/16/2013 03236M20 BW   Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Amyris, Inc.",#N/A,#N/A,#N/A,#N/A," 5/01/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018", 6/02/2018 DCPH-US BW   Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618,#N/A,#N/A, 3/17/2016 06P9WL-E BW   Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program,#N/A,#N/A,#N/A,#N/A,#N/A,"10/15/2018 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018",12/19/2018 DRNA-US  BW   Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company, 3/11/2019 15117K10 BW   Cellectis publie ses résultats financiers du quatrième trimestre 2018 et de l’exercice 2018,#N/A,#N/A,#N/A, 1/06/2014 00847X10 BW   Agios Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference, 9/05/2013 46226010 BW   Genesis Biopharma Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th,#N/A, 9/27/2018 XLRN-US  BW   Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society,#N/A," 4/26/2019 HZNP-US  BW   New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)", 3/26/2018 074K1Y-E  BW   Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma,#N/A,#N/A,12/12/2017 GLYC-US  BW   GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271,#N/A,#N/A,#N/A, 8/15/2018 G6674U10 BW   Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer,#N/A,#N/A,#N/A,11/26/2018 RCKT-US  BW   Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2019 GUD-CA   BW   Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2017 MCRB-US  BW   Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference, 5/08/2019 AIMT-US  BW   Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2018 RARX-US  BW   Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock,#N/A, 4/13/2016 HCM-GB   BW   Hutchison China MediTech Limited Announces Exercise of Overallotment Option,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2018 QTRX-US  BW   Quanterix to Present at the Canaccord Genuity 38th Annual Growth Conference,#N/A,#N/A,#N/A, 1/13/2014 EYPT-US  BW   pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance,#N/A,#N/A," 2/23/2019 AXNX-US  BW   Axonics® se voit accorder un marquage CE élargi ; il s’agit du premier et unique système de neuromodulation sacrée, approuvé pour une utilisation avec les examens IRM complets du corps", 1/12/2016 00FY1L-E BW   Tricida Announces FDA Acceptance of Investigational New Drug Application for Lead Candidate TRC101 and Hiring of Claire Lockey as Chief Development Officer and Edward J. Hejlek as General Counsel,#N/A,#N/A," 1/05/2018 0GNB9B-E BW   Magenta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2018 TWST-US  BW   Twist Bioscience Reports Fiscal 2018 Fourth Quarter and Full Year Financial Results and Highlights Commercial and Operational Progress,#N/A,#N/A,#N/A, 3/08/2010 0084LG-E  BW   Precision BioSciences Announces that the US Patent Office Issues Second Actions Rejecting Previously Granted Claims to Cellectis’ Core Technology,#N/A,#N/A,#N/A,#N/A, 1/03/2019 00DD8T-E BW   Personalis Appoints Biotech Industry Executive Clinton Musil as Chief Business Officer,#N/A,#N/A,12/07/2015 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators Present New Data Showing Minimal Residual Disease (MRD) Predicts Relapse and Survival in Chronic Lymphocytic Leukemia (CLL) Patients,#N/A,#N/A
 5/11/2018 LGND-US   BW   Ligand to Participate in Upcoming Investor Conferences, 9/13/2010 74318710    BW   Progenics’ Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease," 7/10/2018 45232710    BW   Illumina to Announce Second Quarter 2018 Financial Results on Monday, July 30, 2018", 5/16/2018 84763A10  BW   CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract," 6/20/2016 ENDP-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Endo International plc and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm",11/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A, 3/28/2016 68375N10 BW   OPKO Health Announces Executive Appointment, 3/16/2011 IONS-US     BW,#N/A,12/03/2018 ALXN-US  BW   Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood,#N/A, 2/06/2019 SGEN-US     BW   Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day, 1/10/2011 SIGA-US     BW,10/18/2017 09062X10    BW   Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach, 3/14/2018 IMGN-US  BW   ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs, 5/01/2012 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences, 7/16/2019 KITE-US      BW   Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility,#N/A,#N/A, 5/12/2014 M2572210 BW   Compugen Appoints Mr. Avihai Shen Interim CFO," 4/29/2015 00972810  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 4, 2015", 5/19/2014 AMGN-US      BW   Fitch Rates Amgen's Unsecured Debt Issuance 'BBB'," 3/16/2018 0BGL4K-E    BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Myriad Genetics, Inc.",#N/A,#N/A,#N/A," 8/28/2018 05156V10 BW   Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018", 4/09/2010 45773H20 BW   Inovio Biomedical Awarded Grant from Pennsylvania Department of Health for Hepatitis C Virus DNA Vaccine Research,#N/A,#N/A, 5/09/2011 37416310     BW   Geron Statement Regarding European Cancer Vaccine Patents, 9/25/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference,#N/A," 2/14/2019 INCY-US  BW   Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs",#N/A, 2/25/2016 SRPT-US  BW   Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results and Recent Corporate Developments, 9/05/2017 ALKS-US  BW   Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress, 4/02/2018 CERS-US  BW   Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.,11/17/2011 AMAG-US  BW   AMAG Pharmaceuticals Hires Financial Advisor as the Company Explores All Opportunities to Enhance Stockholder Value,11/08/2018 04269E10 BW   ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium,#N/A,#N/A, 7/04/2018 EXEL-US  BW   Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine, 5/30/2017 SAN-FR    BW   ImmunoGen and Sanofi Amend License Agreements,11/29/2018 VRTX-US   BW   Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene,#N/A,#N/A,10/05/2018 BLUE-US  BW   bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia, 9/10/2018 ACAD-US  BW   Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis,#N/A,#N/A,#N/A, 7/30/2018 TXMD-US  BW   TherapeuticsMD Announces Second Quarter 2018 Financial Results,#N/A,#N/A,10/01/2018 OMER-US  BW   Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy, 6/14/2018 76133010 BW   Revance to Participate in the JMP Securities Life Sciences Conference 2018,10/12/2010 008349-E BW   Intrexon Announces Appointment of Top Business Development Executive, 6/20/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions,#N/A,#N/A,#N/A, 3/06/2013 065C1X-E    BW   NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna™ Breast Cancer Prognostic Gene Signature Assay,#N/A," 5/03/2018 SYRS-US  BW   Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018",#N/A,#N/A," 1/11/2012 00182C10     BW   Robbins Umeda LLP Announces an Investigation of BioSante Pharmaceuticals, Inc.",11/10/2017 05MFY1-E   BW   Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™, 3/27/2019 ALNY-US   BW   Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™,#N/A,#N/A,#N/A, 4/17/2014 69512710 BW   Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call, 8/05/2014 76129910 BW   Retrophin to Report Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2018 AKBA-US  BW   Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals,#N/A,#N/A,#N/A,#N/A,11/06/2018 SAGE-US     BW   Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2017 INVA-US     BW   Innoviva Announces $50 Million Partial Royalty Notes Redemption,#N/A,#N/A,#N/A," 7/31/2012 56400P70 BW   MannKind Corporation to Hold 2012 Second Quarter Financial Results Conference Call on August 7, 2012",#N/A,#N/A, 3/24/2014 29664W10    BW   Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference," 5/15/2013 03236M20 BW   Milberg LLP Files Class Action Against Amyris, Inc. Alleging Violations of U.S. Federal Securities Laws",#N/A,#N/A,#N/A,#N/A," 4/30/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference"," 5/29/2018 DCPH-US BW   Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer",#N/A,#N/A, 3/09/2016 EPZM-US  BW   Epizyme Announces 2015 Financial Results and Financial Guidance,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2018 VCYT-US  BW   Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis,11/29/2018 DRNA-US  BW   Dicerna to Participate in Citi’s 2018 Global Healthcare Conference, 3/08/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,12/23/2013 00847X10 BW   Agios Pharmaceuticals Added to NASDAQ Biotechnology Index, 8/08/2013 46226010 BW   Genesis Biopharma Issues Letter to Shareholders,#N/A, 9/04/2018 XLRN-US  BW   Acceleron to Participate in Three Upcoming Healthcare Investor Conferences,#N/A, 4/16/2019 HZNP-US  BW   Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases, 3/21/2018 00BJ80-E  BW   Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in Melanoma,#N/A,#N/A,11/09/2017 GLYC-US  BW   GlycoMimetics to Present at Upcoming Healthcare Investor Conferences,#N/A,#N/A,#N/A, 8/03/2018 G6674U10 BW   Novocure to Present at Two Upcoming Investor Conferences,#N/A,#N/A,#N/A,"11/26/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome",#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2019 74587V10 BW   Puma Biotechnology to Present at J. P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 7/27/2017 MCRB-US  BW   Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017", 5/01/2019 AIMT-US  BW   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2018 RARX-US  BW   Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A, 4/12/2016 07DMQP-E BW   Chi-Med Initiates First-in-Human Clinical Trial of Novel PI3K Inhibitor HMPL-689,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/26/2018 QTRX-US  BW   Quanterix to Release Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018",#N/A,#N/A,#N/A,12/18/2013 30233G10 BW   pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory Committee Meeting No Longer Necessary,#N/A,#N/A, 2/22/2019 AXNX-US  BW   Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans, 3/04/2015 00FY1L-E BW   Tricida Announces Closing of $30M Series B Financing,#N/A,#N/A,12/11/2017 0GNB9B-E BW   Magenta Therapeutics Presents Preclinical Data from Stem Cell Mobilization and Expansion Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/05/2018 TWST-US  BW   Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/27/2018 00DD8T-E BW   Personalis, Inc. to Present at the 4th Annual ICI Europe Summit 2018 in Berlin",#N/A,#N/A,12/06/2015 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators Present New Data Demonstrating Potential Utility of Next-Generation Sequencing Based Minimal Residual Disease (MRD) Testing as a Surrogate Endpoint for Multiple Myeloma Clinical Trials,#N/A,#N/A
 5/08/2018 LGND-US   BW   Ligand Reports First Quarter 2018 Financial Results, 9/08/2010 74318710    BW   Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain, 5/29/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations, 5/09/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th, 6/16/2016 ENDP-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Endo International plc and Encourages Investors With Losses to Contact the Firm,11/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences,#N/A,#N/A,#N/A,#N/A, 3/24/2016 68375N10 BW   OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016, 2/28/2011 46222210    BW,#N/A,11/20/2018 ALXN-US  BW   Alexion to Present at the Evercore ISI Healthcare Conference,#N/A," 1/22/2019 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019", 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Molecular Imaging Research Database,10/05/2017 09062X10    BW   Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy, 2/09/2018 IMGN-US  BW   ImmunoGen Reports Pipeline Progress and 2017 Operating Results," 4/25/2012 09058V10 BW   BioCryst to Report First Quarter 2012 Financial Results on May 7, 2012", 7/14/2019 GILD-US      BW   Gilead and Galapagos Enter Into Transformative Research and Development Collaboration,#N/A,#N/A," 5/05/2014 M2572210 BW   Compugen First Quarter 2014 Conference Call Scheduled for Monday, May 19, 2014 at 10:00 AM EST"," 4/27/2015 00972810  BW   AKRX Investor Alert: Class Action Lawsuit Against Akorn, Inc. Announced by Glancy Binkow & Goldberg LLP", 5/09/2014 AMGN-US      BW   BayBio Names Henry M. Gunn High School Senior Amgen Bay Area BioGENEius Finalist, 2/05/2014 MYGN-US     BW   Safeguard Scientifics Partner Company Crescendo Bioscience to Be Acquired by Myriad Genetics,#N/A,#N/A,#N/A, 8/09/2018 05156V10 BW   Aurinia Reports Second Quarter Financial Results and Operational Highlights, 4/08/2010 45773H20 BW   Inovio Biomedical Completes Enrollment of Cervical Cancer Therapeutic Vaccine Study,#N/A,#N/A, 5/04/2011 37416310     BW   Geron Announces $25 Million in Funding from California Institute of Regenerative Medicine," 9/24/2018 0CWG6Z-E   BW   Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director",#N/A, 2/07/2019 INCY-US  BW   Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease,#N/A, 2/08/2016 SRPT-US  BW   Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen, 8/21/2017 ALKS-US  BW   Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder, 3/13/2018 0776GK-E BW   Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer,"11/12/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. Announces Positive Data from the FIRST Trial, A Head-to-Head Comparison Trial of Ferumoxytol (Feraheme®) Compared to Iron Sucrose",10/31/2018 04269E10 BW   ArQule Reports Third Quarter 2018 Financial Results,#N/A,#N/A, 6/27/2018 06SKH5-E BW   Exelixis to Be Added to the S&P MidCap 400 Index, 5/08/2017 SAN-FR    BW   Ipsen Completes Acquisition of Select Consumer Healthcare Products from Sanofi,"11/27/2018 VRTX-US   BW   Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis",#N/A,#N/A,10/01/2018 BLUE-US  BW   bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology," 9/04/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018",#N/A,#N/A,#N/A," 7/25/2018 TXMD-US  BW   TherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018",#N/A,#N/A,10/01/2018 OMER-US  BW   Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®, 6/05/2018 76133010 BW   Revance to Participate in Upcoming Investor Conferences,10/07/2010 008349-E BW   Intrexon Appoints Former NIH Investigator to Identify High Value Therapeutic Opportunities, 6/07/2018 IRWD-US  BW   Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease,#N/A,#N/A,#N/A, 2/28/2013 065C1X-E    BW   NanoString Expands Leadership Team With the Hiring of Two Seasoned Executives,#N/A, 4/16/2018 SYRS-US  BW   Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer,#N/A,#N/A,12/14/2011 00182C10     BW   BioSante Pharmaceuticals Announces Results from LibiGel® Efficacy Trials,"10/23/2017 ENTA-US    BW   Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305"," 3/11/2019 ALNY-US   BW   Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings",#N/A,#N/A,#N/A, 4/15/2014 69512710 BW   Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4), 7/27/2014 76129910 BW   Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2018 AKBA-US  BW   Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting,#N/A,#N/A,#N/A,#N/A,11/05/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A," 4/03/2017 INVA-US     BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Innoviva, Inc. - INVA",#N/A,#N/A,#N/A, 7/05/2012 MNKD-US  BW   MannKind Corporation to Present at JMP Securities 7th Annual Healthcare Conference,#N/A,#N/A, 3/05/2014 29664W10    BW   Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results,"10/05/2012 03236M20 BW   The Law Firm of Wohl & Fruchter LLP Announces Investigation of Amyris, Inc.",#N/A,#N/A,#N/A,#N/A, 4/16/2018 EGRX-US  BW   Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA, 5/21/2018 DCPH-US BW   Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director,#N/A,#N/A, 3/09/2016 EPZM-US  BW   Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2018 VCYT-US  BW   Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis,"11/09/2018 DRNA-US  BW   Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018", 3/08/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,12/11/2013 00847X10 BW   Agios Advances Cancer Metabolism Collaboration with Celgene, 7/30/2013 46226010 BW   Genesis Biopharma Appoints New Members to Board of Directors,#N/A, 8/02/2018 XLRN-US  BW   Acceleron Reports Second Quarter 2018 Operating and Financial Results,#N/A, 4/12/2019 HZNP-US  BW   Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress, 3/15/2018 00BJ80-E  BW   Castle Biosciences Announces Receipt of New York Laboratory Permit,#N/A,#N/A,11/08/2017 GLYC-US  BW   GlycoMimetics Reports Program Updates and Third Quarter 2017 Results,#N/A,#N/A,#N/A, 8/02/2018 G6674U10 BW   Novocure Announces Addition to Its Board of Directors,#N/A,#N/A,#N/A,11/25/2018 RCKT-US  BW   Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2019 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A," 7/10/2017 MCRB-US  BW   Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer", 4/03/2019 AIMT-US  BW   Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2018 RARX-US  BW   Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria,#N/A, 3/23/2016 DB-DE    BW   Deutsche Bank Appointed as Depositary Bank for the Sponsored Level III American Depositary Receipt Program of Hutchison China MediTech Limited,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2018 QTRX-US  BW   Quanterix’ Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans,#N/A,#N/A,#N/A,12/04/2013 30233G10 BW   pSivida Executives to Present at Two Upcoming Investor Conferences This Month,#N/A,#N/A, 2/20/2019 AXNX-US  BW   Axonics® gibt positive erste klinische Ergebnisdaten aus seiner ARTISAN-SNM-Pivotstudie bekannt, 9/04/2014 00FY1L-E BW   Tricida Announces In-House Discovered Clinical Candidate in Cardiorenal Disease,#N/A,#N/A,"12/11/2017 0GNB9B-E BW   Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2018 TWST-US  BW   Twist Bioscience to Present at the Evercore ISI HealthCONx Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/14/2018 00DD8T-E BW   Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston",#N/A,#N/A,12/05/2015 0DMSKV-E BW   Adaptive Biotechnologies’ clonoSEQ® MRD Test Can Be Used to Guide Post-Transplant Treatment Decisions in Multiple Myeloma Patients,#N/A,#N/A
 4/24/2018 LGND-US   BW   Ligand to Report First Quarter 2018 Results on May 8th, 8/31/2010 74318710    BW   Progenics Pharmaceuticals to Present Preclinical Study of Novel Monoclonal Antibodies Against C. difficile at 2010 ICAAC," 5/24/2018 ILMN-US     BW   Kaskela Law LLC Announces Investigation of Illumina, Inc. on Behalf of Stockholders", 5/03/2018 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update, 6/15/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm,10/31/2018 005Y9C-E BW   Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen,#N/A,#N/A,#N/A,#N/A, 3/16/2016 68375N10 BW   OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes, 2/10/2011 078VWR-E    BW,#N/A,11/07/2018 ALXN-US  BW   Alexion to Present at Credit Suisse’s 27th Annual Healthcare Conference,#N/A, 1/09/2019 SGEN-US     BW   Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma, 1/10/2011 VRTX-US     BW," 9/26/2017 09062X10    BW   Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017", 2/06/2018 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences, 2/23/2012 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences, 7/11/2019 GILD-US      BW   Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite,#N/A,#N/A, 4/29/2014 M2572210 BW   Compugen to Present at Immunology 2014 Conference," 4/24/2015 00972810  BW   EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, Inc.", 2/26/2014 AMGN-US      BW   2014 Amgen Tour of California Media Credential Application Now Available Online,12/02/2013 MYGN-US     BW   Invitae Files Suit Against Myriad Genetics,#N/A,#N/A,#N/A," 7/30/2018 05156V10 BW   Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018", 3/31/2010 45773H20 BW   Inovio Biomedical to Present at Future Leaders in the Biotech Industry Conference,#N/A,#N/A, 4/27/2011 37416310     BW   Geron Corporation Reports 2011 First Quarter Financial Results and Highlights," 9/13/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria",#N/A, 1/24/2019 INCY-US  BW   Incyte to Report Fourth Quarter and Year-end Financial Results,#N/A, 2/02/2016 SRPT-US  BW   CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 7/27/2017 ALKS-US  BW   Alkermes plc Reports Second Quarter 2017 Financial Results, 3/08/2018 CERS-US  BW   Cerus Corporation Reports Record Fourth Quarter and Year End 2017 Results,"11/04/2011 00163U10 BW   AMAG Announces Financial Results for the Third Quarter Ended September 30, 2011","10/19/2018 04269E10 BW   ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)",#N/A,#N/A," 6/05/2018 EXEL-US  BW   Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018", 5/08/2017 SAN-FR    BW   Ipsen finalise l’acquisition d’une sélection de produits de santé grand public de Sanofi,11/16/2018 VRTX-US   BW   Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease,#N/A,#N/A, 9/05/2018 BLUE-US  BW   bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM, 8/30/2018 ACAD-US  BW   September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.,#N/A,#N/A,#N/A, 6/07/2018 TXMD-US  BW   TherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial,#N/A,#N/A, 9/27/2018 OMER-US  BW   Omeros to Present at the 2018 Cantor Global Healthcare Conference, 5/29/2018 76133010 BW   Revance to Participate in the Jefferies 2018 Global Healthcare Conference, 4/06/2010 008349-E BW   Intrexon Division on the Move, 6/06/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference,#N/A,#N/A,#N/A, 2/19/2013 065C1X-E    BW   NanoString Launches Its First Commercial Diagnostic Product in the European Union and Israel,#N/A, 3/14/2018 SYRS-US  BW   Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting,#N/A,#N/A,11/29/2011 00182C10     BW   BioSante Pharmaceuticals Announces Issuance of New LibiGel® Method of Use Patent,"10/20/2017 ENTA-US    BW   Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017", 3/07/2019 ALNY-US   BW   Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference,#N/A,#N/A,#N/A, 4/08/2014 69512710 BW   Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock, 7/01/2014 76129910 BW   Retrophin Closes $91 Million Financing,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,11/02/2018 SAGE-US     BW   Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A, 4/03/2017 INVA-US     BW   Innoviva Board Sends Letter to Shareholders,#N/A,#N/A,#N/A, 6/12/2012 MNKD-US  BW   MannKind to Present at 2012 Wells Fargo Securities Healthcare Conference,#N/A,#N/A, 2/26/2014 29664W10    BW   Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results, 7/12/2012 CERE-US  BW   Ceres Announces Fiscal Third Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A, 3/27/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces New Patent for Eagle Biologics," 5/14/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences",#N/A,#N/A," 3/02/2016 EPZM-US  BW   Epizyme to Report 2015 Financial Results and Provide Business Updates on March 9, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2018 VCYT-US  BW   Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis,11/06/2018 DRNA-US  BW   Dicerna to Participate in Upcoming Investor Conferences," 3/07/2019 15117K10 BW   Cellectis conclut un contrat de location pour la construction d’une usine de production, en préparation de la commercialisation de ses produits UCART",#N/A,#N/A,#N/A,12/09/2013 00847X10 BW   Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting, 7/25/2013 46226010 BW   Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies,#N/A," 7/26/2018 XLRN-US  BW   Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018",#N/A, 4/11/2019 HZNP-US  BW   Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work®, 2/16/2018 00BJ80-E  BW   DecisionDx-Melanoma Test for Cutaneous Melanoma Validated in Two Prospective Multicenter Study Cohorts to Provide Guidance for Sentinel Lymph Node Biopsy Recommendations,#N/A,#N/A,"11/01/2017 GLYC-US  BW   GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017",#N/A,#N/A,#N/A, 7/31/2018 G6674U10 BW   Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer,#N/A,#N/A,#N/A,11/19/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I),#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2018 74587V10 BW   Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2017 MCRB-US  BW   Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection, 3/25/2019 00900T10 BW   European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2018 RARX-US  BW   Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment,#N/A, 3/22/2016 HCM-GB   BW   Hutchison China MediTech Limited Announces Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/13/2018 002PSJ-E BW   EY Announces Kevin Hrusovsky, President, Chairman and Chief Executive Officer of Quanterix and Founder of Powering Precision Health as an Entrepreneur Of The Year® 2018 Award Finalist in the New England Region",#N/A,#N/A,#N/A,12/02/2013 30233G10 BW   pSivida Reports ILUVIEN® to Be Funded by UK’s National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance,#N/A,#N/A, 2/20/2019 AXNX-US  BW   Axonics® annonce les premiers résultats cliniques positifs de son étude pivot ARTISAN-SNM,#N/A,#N/A,#N/A,12/09/2017 0GNB9B-E BW   Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/26/2018 TWST-US  BW   Twist Bioscience Appoints Experienced Technology Executive Jan Johannessen to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/09/2018 00DD8T-E BW   Personalis, Inc. Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and Its Microenvironment From a Single Sample",#N/A,#N/A,12/04/2015 0DMSKV-E BW   Adaptive Biotechnologies Announces Expansion of clonoSEQ® Minimal Residual Disease (MRD) Test,#N/A,#N/A
 3/30/2018 07ST71-E  BW   Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies, 8/09/2010 74318710    BW   Progenics Pharmaceuticals Announces Second Quarter 2010 Financial Results, 5/15/2018 45232710    BW   Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis, 5/03/2018 065BPX-E  BW   Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center," 6/10/2016 00FV7G-E BW   ENDO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Endo International plc",10/16/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A, 3/15/2016 OPK-US   BW   OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines, 1/10/2011 RICHT-HU    BW,#N/A,11/02/2018 00GDBT-E BW   Alexion Completes Acquisition of Syntimmune,#N/A,12/19/2018 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference, 1/10/2011 RICHT-HU    BW," 9/25/2017 09062X10    BW   Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area", 1/26/2018 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results, 2/16/2012 09058V10 BW   BioCryst Reports Fourth Quarter and Full Year 2011 Financial Results, 7/11/2019 GILD-US      BW   Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH),#N/A,#N/A, 4/07/2014 M2572210 BW   Compugen Statement Regarding Insider Trading Allegations," 4/15/2015 00972810  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Akorn, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 4, 2015", 1/14/2014 AMGN-US      BW   Carmot Therapeutics Enters into Drug Discovery Collaboration with Amgen,11/26/2013 00CSRH-E    BW   Invitae Responds to Myriad Genetics Lawsuit,#N/A,#N/A,#N/A, 7/11/2018 05156V10 BW   Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome, 3/29/2010 45773H20 BW   DNA Vaccine Company Inovio Biomedical Reports Fourth Quarter and Year-Ended 2009 Financial Results,#N/A,#N/A, 4/25/2011 37416310     BW   Geron Announces Conference Call to Discuss First Quarter Financial Results and Highlights, 9/12/2018 AERI-US    BW   Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors,#N/A, 1/22/2019 INCY-US  BW   Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease,#N/A," 1/26/2016 SRPT-US  BW   Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Stockholders and Encourages Investors to Contact the Firm", 7/20/2017 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results," 3/07/2018 CERS-US  BW   Cerus to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018","11/03/2011 00163U10 BW   AMAG Pharmaceuticals Reschedules Third Quarter Financial Results Conference Call to November 4, 2011 at 8:00 a.m. ET","10/17/2018 04269E10 BW   ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018",#N/A,#N/A, 6/03/2018 EXEL-US  BW   Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018, 4/25/2017 NOVN-CH   BW   Science 37 Raises $29M to Bring Clinical Trials Directly into Patients’ Homes,"11/01/2018 VRTX-US   BW   Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene",#N/A,#N/A, 8/29/2018 BLUE-US  BW   bluebird bio to Present at Investor Conferences in September, 8/28/2018 ACAD-US  BW   Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors,#N/A,#N/A,#N/A, 6/07/2018 TXMD-US  BW   TherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference,#N/A,#N/A, 9/07/2018 OMER-US  BW   Omeros to Present at the Morgan Stanley Global Healthcare Conference, 5/29/2018 76133010 BW   Revance Announces Departure of Chief Financial Officer,#N/A, 6/05/2018 IRWD-US  BW   Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018,#N/A,#N/A,#N/A, 2/19/2013 065C1X-E    BW   NanoString lance son premier produit de diagnostic commercial dans l'Union européenne et en Israël,#N/A, 3/12/2018 SYRS-US  BW   Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones,#N/A,#N/A,11/21/2011 00182C10     BW   BioSante Pharmaceuticals Added to NASDAQ Biotechnology Index,10/11/2017 ABBV-US    BW   Enanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017, 3/06/2019 ALNY-US   BW   Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria,#N/A,#N/A,#N/A, 4/07/2014 69512710 BW   Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock, 5/29/2014 76129910 BW   Retrophin Announces $80 Million Term Loan and Convertible Note Issuance,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2018 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,11/02/2018 SAGE-US     BW   Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A, 3/29/2017 INVA-US     BW   Innoviva Board Sends Letter to Shareholders,#N/A,#N/A,#N/A, 5/31/2012 MNKD-US  BW   Pre-Clinical Data Demonstrates Promising Potential of MannKind’s IRE1α Inhibitor to Treat Multiple Myeloma,#N/A,#N/A," 2/13/2014 29664W10    BW   Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director", 5/15/2012 RDSA-NL  BW,#N/A,#N/A,#N/A,#N/A," 2/26/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results"," 5/08/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results",#N/A,#N/A, 2/08/2016 EPZM-US  BW   Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2018 VCYT-US  BW   Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference,11/05/2018 DRNA-US  BW   Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update," 3/07/2019 15117K10 BW   Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio",#N/A,#N/A,#N/A,11/07/2013 00847X10 BW   Agios Pharmaceuticals to Present Preclinical Research at the 2013 American Society of Hematology Annual Meeting,10/11/2012 46226010 BW   Genesis Biopharma Receives FDA Meeting Minutes from Cōntego™ Pre-IND Meeting,#N/A, 7/23/2018 XLRN-US  BW   Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society,#N/A," 4/09/2019 HZNP-US  BW   Horizon Pharma plc to Release First-Quarter 2019 Financial Results and Host Webcast on May 8, 2019", 2/16/2018 00BJ80-E  BW   Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma,#N/A,#N/A,"11/01/2017 GLYC-US  BW   GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting",#N/A,#N/A,#N/A, 7/26/2018 G6674U10 BW   Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,11/07/2018 RCKT-US  BW   Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2018 74587V10 BW   Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2017 MCRB-US  BW   Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference, 3/18/2019 00900T10 BW   U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/21/2017 RARX-US  BW   Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients,#N/A, 3/21/2016 07DMQP-E BW   Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic Neuroendocrine Tumor Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 QTRX-US  BW   Quanterix Corporation Releases Operating Results for First Quarter 2018,#N/A,#N/A,#N/A,11/12/2013 30233G10 BW   pSivida Corp. Reports First Quarter 2014 Results,#N/A,#N/A, 2/19/2019 AXNX-US  BW   Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study,#N/A,#N/A,#N/A,12/07/2017 0GNB9B-E BW   New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2018 TWST-US  BW   Twist Bioscience Corporation Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/06/2018 00DD8T-E BW   Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting",#N/A,#N/A,11/05/2015 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators to Present Eleven Studies at American Society of Hematology Annual Meeting,#N/A,#N/A
 3/06/2018 LGND-US   BW   Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences, 8/05/2010 74318710    BW   Progenics Announces Positive Opinion Issued by a Committee of the European Medicines Agency for Relistor in Pre-Filled Syringes, 5/02/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 5/01/2018 TMO-US    BW   Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific, 6/06/2016 ENDP-US  BW   SHAREHOLDER ALERT: Lundin Law PC Announces Investigation Of Endo International plc And Advises Investors With Losses to Contact the Firm,10/15/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3,#N/A,#N/A,#N/A,#N/A, 3/15/2016 OPK-US   BW   OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories, 1/07/2011 LLY-US      BW,#N/A,11/01/2018 ALXN-US  BW   Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting,#N/A,12/07/2018 4502-JP     BW   Seattle Genetics e Takeda apresentam dados positivos do ensaio clínico ECHELON-2 de Fase 3 para o ADCETRIS® (brentuximab vedotin) no tratamento de primeira linha dos linfomas periféricos de células T que expressam CD30, 1/07/2011 LLY-US      BW," 9/12/2017 09062X10    BW   Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical", 1/24/2018 IMGN-US  BW   ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors, 2/15/2012 09058V10 BW   BioCryst Announces Promising Results from Preclinical Studies of BCX5191 for Hepatitis C, 7/01/2019 GILD-US      BW   Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year,#N/A,#N/A, 3/05/2014 M2572210 BW   Compugen Ltd. Closes Public Offering of Ordinary Shares," 4/10/2015 00972810  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Akorn, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",12/12/2013 008WTX-E     BW   BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase Inhibitor Nanomedicine, 8/06/2013 07V9WH-E    BW   Ambry Genetics Sues Myriad Genetics for Violating Federal Antitrust Laws,#N/A,#N/A,#N/A, 6/25/2018 05156V10 BW   Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin, 3/09/2010 45773H20 BW   Inovio Biomedical to Present at Roth Capital Partners Growth Stock Investor Conference,#N/A,#N/A, 4/19/2011 37416310     BW   Geron Announces the Appointment of Melanie Nallicheri as Senior Vice President of Corporate Development for Cell Therapies, 9/11/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance,#N/A, 1/03/2019 INCY-US  BW   Incyte Appoints Christiana Stamoulis as Chief Financial Officer,#N/A, 1/20/2016 SRPT-US  BW   FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area, 6/29/2017 ALKS-US  BW   Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia," 2/22/2018 CERS-US  BW   Cerus to Release Fourth Quarter and Year End 2017 Results on March 8, 2018",11/02/2011 AMAG-US  BW   MSMB Files Revised Preliminary Consent Solicitation Statement to Replace the Board of Directors of AMAG Pharmaceuticals,10/04/2018 04269E10 BW   ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting,#N/A,#N/A, 6/01/2018 EXEL-US  BW   Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors, 4/25/2017 80105N10  BW   New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy,10/24/2018 VRTX-US   BW   Vertex Reports Third-Quarter 2018 Financial Results,#N/A,#N/A, 8/23/2018 0FTYWS-E BW   bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies," 8/24/2018 ACAD-US  BW   ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD",#N/A,#N/A,#N/A, 6/06/2018 TXMD-US  BW   TherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress,#N/A,#N/A, 8/28/2018 OMER-US  BW   European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation, 5/24/2018 76133010 BW   Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice,#N/A, 5/31/2018 IRWD-US  BW   Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders,#N/A,#N/A,#N/A,12/06/2012 065C1X-E    BW   NanoString Technologies Announces Positive Results From Second Validation Study of PAM50-based Breast Cancer Assay,#N/A, 3/12/2018 SYRS-US  BW   Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer,#N/A,#N/A,11/16/2011 00182C10     BW   BioSante Pharmaceuticals Announces Positive LibiGel® Pharmacokinetic Study Results," 9/27/2017 ENTA-US    BW   Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017", 2/28/2019 ALNY-US   BW   Alnylam annonce les bénéficiaires du premier programme annuel de subventions Advocacy for Impact,#N/A,#N/A,#N/A, 4/07/2014 69512710 BW   Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity, 5/29/2014 76129910 BW   Retrophin Enters into U.S. License Agreement for Thiola® (Tiopronin),#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,"10/23/2018 SAGE-US     BW   Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018",#N/A,#N/A,#N/A,#N/A,#N/A, 3/22/2017 INVA-US     BW   Innoviva Files Definitive Proxy and Sends Letter to Shareholders,#N/A,#N/A,#N/A, 5/31/2012 MNKD-US  BW   MannKind to Present at Jefferies 2012 Global Healthcare Conference,#N/A,#N/A," 1/13/2014 29664W10    BW   Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director", 5/03/2012 CERE-US  BW   Ceres Sweet Sorghum Hybrids Processed by Amyris,#N/A,#N/A,#N/A,#N/A, 2/20/2018 EGRX-US  BW   Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel," 4/25/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting",#N/A,#N/A, 2/01/2016 EPZM-US  BW   Epizyme to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2018 VCYT-US  BW   Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018,"10/30/2018 DRNA-US  BW   Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018", 2/25/2019 15117K10 BW   Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry,#N/A,#N/A,#N/A,11/07/2013 00847X10 BW   Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results, 9/24/2012 46226010 BW   Base Technology for Genesis Biopharma’s Contego™ Featured in CNN Report on MD Anderson’s Commitment to Reduce Cancer Deaths,#N/A, 7/12/2018 XLRN-US  BW   Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy,#N/A, 4/04/2019 HZNP-US  BW   Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 1/08/2018 00BJ80-E  BW   Castle Biosciences Launches Next-Generation Sequencing Panel DecisionDx-UMSeq for Uveal Melanoma,#N/A,#N/A, 9/05/2017 GLYC-US  BW   GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference,#N/A,#N/A,#N/A, 7/19/2018 G6674U10 BW   Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting,#N/A,#N/A,#N/A,11/07/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2018 74587V10 BW   Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2017 MCRB-US  BW   Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis, 3/05/2019 AIMT-US  BW   Aimmune Therapeutics to Participate in Three Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference,#N/A, 3/16/2016 HCM-GB   BW   Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2018 QTRX-US  BW   Quanterix to Release First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018",#N/A,#N/A,#N/A,11/05/2013 30233G10 BW   pSivida Corp Announces First Quarter 2014 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 2/14/2019 AXNX-US  BW   Axonics® to Report 2018 Fourth Quarter and Full-Year Financial Results and Host a Conference Call on March 5,#N/A,#N/A,#N/A,11/01/2017 0GNB9B-E BW   Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2018 TWST-US  BW   Agilent Sends Letter to the SEC Regarding Material Misstatements in Twist Bioscience’s S-1 Registration Statement,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/09/2018 00DD8T-E BW   Personalis Receives New Order From the VA’s Million Veteran Program – Total Contracted Now Almost 80,000 Whole Human Genomes",#N/A,#N/A,10/28/2015 0DMSKV-E BW   Adaptive Biotechnologies Publishes Study on New Multiplex Technology to Identify Antigen Specificity of Immune Receptors,#N/A,#N/A
 3/05/2018 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences, 6/10/2010 74318710    BW   Peter Crowley Elected Progenics Chairman of the Board," 4/29/2018 ILMN-US     BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties By Management of Illumina, Inc. – ILMN", 4/30/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes, 6/02/2016 ENDP-US  BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm,10/11/2018 ARWR-US  BW   Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018,#N/A,#N/A,#N/A,#N/A, 3/07/2016 OPK-US   BW   OPKO Health to Present at the 2016 Barclays Global Healthcare Conference, 1/05/2011 46222210    BW,#N/A,10/24/2018 ALXN-US  BW   Alexion Reports Third Quarter 2018 Results,#N/A,12/06/2018 4502-JP     BW   Seattle Genetics und Takeda präsentieren positive Daten aus der klinischen Phase-3-Studie ECHELON-2 zu ADCETRIS® (Brentuximab Vedotin) bei der Erstbehandlung des CD30-exprimierenden peripheren T-Zell-Lymphoms,12/14/2010 LLY-US      BW   Maven Semantic: Cellular Imaging Database, 9/06/2017 09062X10    BW   Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference, 1/17/2018 0B8HQZ-E BW   Glythera Appoints Chief Scientific Officer and Strengthens SAB," 2/06/2012 09058V10 BW   BioCryst to Announce Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012"," 6/26/2019 0KSN5V-E     BW   Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease",#N/A,#N/A, 2/28/2014 M2572210 BW   Compugen Ltd. Prices Public Offering of Ordinary Shares," 4/02/2015 00972810  BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Akorn, Inc. Of Upcoming Deadline",10/15/2013 003KZ5-E     BW   KineMed Announces Agreement with Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies, 6/14/2013 MYGN-US     BW   Fitch: DNA Patent Decision Benign for Pharmaceutical Ratings,#N/A,#N/A,#N/A, 6/22/2018 05156V10 BW   Aurinia Announces Results of Annual General Meeting, 3/03/2010 45773H20 BW   Inovio Develops Cordless Electroporation Device for Delivering DNA Vaccines,#N/A,#N/A," 4/14/2011 37416310     BW   Geron to Webcast Analyst and Investor Meeting on Company’s Cell Therapy Programs on April 19, 2011"," 9/10/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing",#N/A,12/20/2018 INCY-US  BW   Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis,#N/A, 1/04/2016 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 6/12/2017 ALKS-US  BW   Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder, 2/02/2018 CERS-US  BW   Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares,"11/02/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. Announces Data Presentations at the American Society of Nephrology Kidney Week 2011"," 9/24/2018 04269E10 BW   ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018",#N/A,#N/A, 5/29/2018 EXEL-US  BW   Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma, 4/25/2017 80105N10  BW   New Investigational Data on Six-Year Efficacy of Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN,10/19/2018 VRTX-US   BW   Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene,#N/A,#N/A," 8/06/2018 BLUE-US  BW   bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer"," 8/10/2018 ACAD-US  BW   ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD",#N/A,#N/A,#N/A, 6/04/2018 TXMD-US  BW   TherapeuticsMD to Present at Jefferies 2018 Healthcare Conference,#N/A,#N/A, 8/10/2018 OMER-US  BW   Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference, 5/15/2018 76133010 BW   Revance to Participate in the UBS Global Healthcare Conference,#N/A, 5/23/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018,#N/A,#N/A,#N/A,12/03/2012 065C1X-E    BW   NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer Symposium,#N/A, 3/05/2018 SYRS-US  BW   Syros to Present at Upcoming Investor Conferences,#N/A,#N/A,11/09/2011 00182C10     BW   BioSante Pharmaceuticals Reports Financial Results for Third Quarter 2011 and Pipeline Update, 9/27/2017 ABBV-US    BW   Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C, 2/28/2019 ALNY-US   BW   Alnylam anuncia los destinatarios de subvenciones del primer programa anual «Advocacy for Impact Grants»,#N/A,#N/A,#N/A," 4/04/2014 69512710 BW   EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014"," 5/29/2014 76129910 BW   Retrophin Names Alvin Shih, M.D. Executive Vice President of Research and Development",#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2018 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,10/03/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 3/13/2017 INVA-US     BW   Innoviva Issues Press Statement,#N/A,#N/A,#N/A, 5/09/2012 56400P70 BW   MannKind Corporation Reports 2012 First Quarter Financial Results,#N/A,#N/A,12/23/2013 29664W10    BW   Esperion Therapeutics Added to the NASDAQ Biotechnology Index, 4/17/2012 0BZK6L-E BW,#N/A,#N/A,#N/A,#N/A," 2/15/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018", 4/17/2018 DCPH-US BW   Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents,#N/A,#N/A, 1/12/2016 EPZM-US  BW   Epizyme Announces Closing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2018 VCYT-US  BW   Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis,10/25/2018 DRNA-US  BW   Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2), 2/25/2019 15117K10 BW   Cellectis publie de nouvelles méthodes pour améliorer la sécurité des traitements CAR T et prevenir le CRS dans le Journal of Biological Chemistry,#N/A,#N/A,#N/A,"10/31/2013 00847X10 BW   Agios Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2013 Financial Results on November 7, 2013", 1/09/2012 IOVA-US  BW   Genesis Biopharma Appoints Biotech Industry Veteran Hans E. Bishop to Its Board of Directors,#N/A, 7/09/2018 CELG-US  BW   Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia,#N/A, 3/18/2019 HZNP-US  BW   Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy,12/07/2017 00BJ80-E  BW   Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer,#N/A,#N/A, 8/03/2017 GLYC-US  BW   GlycoMimetics Reports Program Updates and Second Quarter 2017 Results,#N/A,#N/A,#N/A, 7/17/2018 G6674U10 BW   Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society,#N/A,#N/A,#N/A,11/01/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2018 74587V10 BW   Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2017 MCRB-US  BW   Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress, 2/28/2019 AIMT-US  BW   Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2017 RARX-US  BW   Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria,#N/A, 3/04/2016 HCM-HK   BW   Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2018 QTRX-US  BW   Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone,#N/A,#N/A,#N/A,10/18/2013 EYPT-US  BW   pSivida Reports Complete Response Letter From FDA for ILUVIEN®,#N/A,#N/A, 2/13/2019 AXNX-US  BW   Axonics® soumet des données d'IRM du corps entier à l’Agence américaine des produits alimentaires et médicamenteux pour son système de neuromodulation sacrée,#N/A,#N/A,#N/A,10/26/2017 0GNB9B-E BW   Magenta Therapeutics Strengthens Leadership Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/24/2018 TWST-US  BW   Twist Bioscience Adds Ray Tabibiazar, M.D., as Senior Vice President, Corporate Development and Business Strategy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/12/2018 00DD8T-E BW   Personalis, Inc. to Present at Rational Combinations 360o in Philadelphia",#N/A,#N/A,"10/14/2015 0DMSKV-E BW   Adaptive Biotechnologies Honored by Goldman Sachs for Entrepreneurship – Chad and Harlan Robins, among 100 Most Intriguing Entrepreneurs at 2015 Builders + Innovators Summit",#N/A,#N/A
 2/21/2018 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2017 Financial Results, 6/07/2010 74318710    BW   Progenics Phase 1 PSMA ADC Study Presented in New “Trials in Progress” Poster Session at ASCO Annual Meeting, 4/24/2018 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2018, 4/27/2018 SPPI-US   BW   Company Profile for SPECTRUM PHARMACEUTICALS, 6/02/2016 ENDP-US  BW   Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action,10/04/2018 005Y9C-E BW   Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen,#N/A,#N/A,#N/A,#N/A, 3/02/2016 OPK-US   BW   OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting,12/21/2010 TGEN-US     BW,#N/A,10/24/2018 ALXN-US  BW   Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases,#N/A,12/05/2018 4502-JP     BW   Seattle Genetics et Takeda présentent des données positives de l'essai clinique ECHELON-2 de Phase 3 pour ADCETRIS® (brentuximab védotine) dans le traitement de première intention des lymphomes périphériques à cellules...," 6/22/2010 IMMU-US     BW   Zacks Analyst Blog Highlights: Immunomedics, Human Genome, GlaxoSmithKline, CNOOC and Devon Energy", 8/28/2017 09062X10    BW   Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab, 1/09/2018 IMGN-US  BW   MabPlex Announces Xinfang Li as Vice President of Process Development, 1/19/2012 09058V10 BW   Nancy Hutson Appointed to BioCryst’s Board of Directors, 6/24/2019 4572-JP      BW   Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies,#N/A,#N/A, 2/27/2014 M2572210 BW   Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares," 3/13/2015 00972810  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Akorn, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit"," 9/19/2013 05MW68-E     BW   Amgen Renews Title Sponsorship of America’s Largest Professional Cycling Stage Race, the Amgen Tour of California", 4/30/2013 07G69B-E    BW   Research and Markets: MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts,#N/A,#N/A,#N/A, 5/10/2018 05156V10 BW   Aurinia Reports First Quarter Financial Results and Operational Highlights, 3/02/2010 45773H20 BW   Inovio Biomedical H5N1 Avian Influenza DNA Vaccine Receives Korean Approval to Begin Clinical Trials,#N/A,#N/A," 3/24/2011 37416310     BW   Geron to Webcast Analyst and Investor Meeting on Company’s Oncology Programs on March 29, 2011"," 8/20/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics",#N/A,12/16/2018 1801-HK  BW   Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China,#N/A,12/18/2015 SRPT-US  BW   Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping, 6/08/2017 ALKS-US  BW   Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference, 1/31/2018 CERS-US  BW   Cerus Announces Pricing of Public Offering of Common Stock,"10/31/2011 00163U10 BW   AMAG Pharmaceuticals to Host Conference Call on November 7, 2011 at 5:00 p.m. ET to Discuss Financial Results for the Third Quarter and Nine Months Ended September 30, 2011"," 9/24/2018 04269E10 BW   ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018",#N/A,#N/A," 5/22/2018 EXEL-US  BW   Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy", 4/11/2017 SAN-FR    BW   More than 30 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured at AAN,10/18/2018 VRTX-US   BW   Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis,#N/A,#N/A, 8/03/2018 BLUE-US  BW   bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium, 8/08/2018 ACAD-US  BW   ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A, 5/31/2018 TXMD-US  BW   TherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting,#N/A,#N/A, 8/09/2018 OMER-US  BW   Omeros Corporation Reports Second Quarter 2018 Financial Results, 5/09/2018 76133010 BW   Revance Therapeutics Announces Two Recent Additions to Its Management Team,#N/A, 5/14/2018 IRWD-US  BW   Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees,#N/A,#N/A,#N/A,12/03/2012 065C1X-E    BW   NanoString Technologies Completes $15.3 Million Series E Financing,#N/A, 2/08/2018 SYRS-US  BW   Syros to Present at Leerink Partners 7th Annual Global Healthcare Conference,#N/A,#N/A,"10/17/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at BioCentury and BIO Healthcare Conferences", 9/13/2017 ENTA-US    BW   Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors, 2/28/2019 ALNY-US   BW   Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program,#N/A,#N/A,#N/A," 3/31/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL", 5/28/2014 76129910 BW   Retrophin Names Stephen Aselage President and Chief Operations Officer,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2018 AKBA-US  BW   Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors,#N/A,#N/A,#N/A,#N/A, 9/06/2018 SAGE-US     BW   Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2017 INVA-US     BW   Innoviva Files Preliminary Proxy Materials for 2017 Annual Meeting,#N/A,#N/A,#N/A, 5/08/2012 56400P70 BW   MannKind to Present at Bank of America Merrill Lynch 2012 Health Care Conference,#N/A,#N/A,11/18/2013 29664W10    BW   Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance, 3/30/2012 AMRS-US  BW   Amyris to Participate in Investor Conferences,#N/A,#N/A,#N/A,#N/A," 2/12/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference"," 4/16/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1 Clinical Trial of DCC-2618 at 2018 American Association for Cancer Research (AACR) Annual Meeting",#N/A,#N/A, 1/06/2016 EPZM-US  BW   Epizyme Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2018 VCYT-US  BW   Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier,10/24/2018 ALXN-US  BW   Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases, 2/04/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,10/18/2013 00847X10 BW   Agios to Present IDH Program Insights at AACR-NCI-EORTC International Conference,12/08/2011 46226010 BW   Genesis Biopharma to Host Investor Meetings in San Francisco in January 2012,#N/A," 7/05/2018 ABLX-BE  BW   Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer",#N/A, 3/11/2019 HZNP-US  BW   Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares,11/20/2017 00BJ80-E  BW   Castle Biosciences to Present at the Piper Jaffray 29th Annual Healthcare Conference,#N/A,#N/A, 7/06/2017 GLYC-US  BW   GlycoMimetics to Receive European Patent for GMI-1271,#N/A,#N/A,#N/A, 7/02/2018 G6674U10 BW   Novocure Appoints Pritesh Shah as Chief Commercial Officer,#N/A,#N/A,#N/A,10/19/2018 RCKT-US  BW   Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),#N/A,#N/A,#N/A,#N/A,#N/A,"12/06/2018 74587V10 BW   Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium",#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2017 MCRB-US  BW   Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences," 2/25/2019 00900T10 BW   Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2017 RARX-US  BW   Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update,#N/A, 3/02/2016 07DMQP-E BW   Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/21/2018 QTRX-US  BW   Quanterix to Present at Needham and Company’s 17th Annual Healthcare Conference,#N/A,#N/A,#N/A, 9/30/2013 30233G10 BW   pSivida Announces That U.K.’s NICE Recommends ILUVIEN® for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to Follow,#N/A,#N/A, 2/12/2019 AXNX-US  BW   Axonics® legt amerikanischer Zulassungsbehörde FDA Ganzkörper-MRT-Daten für System zur sakralen Neuromodulation vor,#N/A,#N/A,#N/A,"10/24/2017 0GNB9B-E BW   Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/18/2018 00FLML-E BW   Twist Bioscience Responds to Agilent’s Latest Specious Claims,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/30/2018 00DD8T-E BW   Personalis, Inc. to Present at the 6th Annual Immuno-Oncology Summit, Boston, MA",#N/A,#N/A,10/07/2015 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators Demonstrate Value of Immunosequencing for Diagnosis of Cutaneous T-Cell Lymphoma,#N/A,#N/A
 2/05/2018 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st, 5/27/2010 74318710    BW   Progenics Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society for Microbiology Conference, 4/13/2018 45232710    BW   Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies, 4/26/2018 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast," 5/16/2016 ENDP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Endo International plc", 9/25/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences,#N/A,#N/A,#N/A,#N/A, 2/29/2016 68375N10 BW   OPKO Announces Financial and Operating Results,12/02/2010 46222210    BW,#N/A,"10/04/2018 ALXN-US  BW   Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018",#N/A,12/05/2018 4502-JP     BW   Seattle Genetics y Takeda presentan datos positivos del estudio clínico de fase 3 ECHELON-2 para ADCETRIS® (brentuximab vedotina) en el tratamiento de primera línea de linfoma periférico de células T con expresión CD30,#N/A," 8/24/2017 09062X10    BW   IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union", 1/04/2018 IMGN-US  BW   ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies, 1/08/2012 09058V10 BW   BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout, 6/19/2019 00DY47-E     BW   Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases,#N/A,#N/A, 2/20/2014 M2572210 BW   Compugen to Present Cancer Immunotherapy Programs at Three International Cancer Conferences in March," 3/09/2015 00972810  BW   Akorn, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors", 8/27/2013 ONXX-US      BW   Fitch Revises Amgen's Rating Outlook to Negative, 4/22/2013 MYGN-US     BW   Research and Markets: MediPoint: Predictive Breast Cancer Gene Testing - APAC Analysis and Market Forecasts Report - 2013 Edition,#N/A,#N/A,#N/A, 5/10/2018 0H2MNF-E BW   Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis, 2/23/2010 45773H20 BW   Inovio Biomedical to Present at DNA Vaccines 2010 Conference,#N/A,#N/A, 3/01/2011 GERN-US      BW   Geron Announces Preclinical Study Data of GRNCM1, 8/15/2018 AERI-US    BW   Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study,#N/A,12/13/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,12/01/2015 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 6/08/2017 ALKS-US  BW   Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients, 1/30/2018 CERS-US  BW   Cerus Announces Public Offering of Common Stock,10/21/2011 00163U10 BW   AMAG Pharmaceuticals Announces Results of Special Stockholder Meeting Regarding Proposed Merger, 9/13/2018 04269E10 BW   Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS),#N/A,#N/A, 5/17/2018 EXEL-US  BW   Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma, 4/05/2017 SAN-FR    BW   Boehringer Ingelheim: A New World Leader in Animal Health,10/16/2018 VRTX-US   BW   Vertex to Announce Third Quarter 2018 Financial Results on October 24,#N/A,#N/A, 8/03/2018 BLUE-US  BW   bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference, 8/06/2018 ACAD-US  BW   ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome,#N/A,#N/A,#N/A," 5/30/2018 TXMD-US  BW   TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, Due to Menopause",#N/A,#N/A," 8/03/2018 OMER-US  BW   Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018", 5/08/2018 76133010 BW   Revance Releases First Quarter 2018 Results,#N/A, 5/09/2018 IRWD-US  BW   Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value,#N/A,#N/A,#N/A,11/07/2012 065C1X-E    BW   Fluidigm Files Lawsuit against NanoString’s Deceptive Marketing,#N/A, 2/07/2018 SYRS-US  BW   Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A,10/11/2011 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review in Phase III Program, 8/30/2017 ENTA-US    BW   Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences, 2/07/2019 ALNY-US   BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A, 3/14/2014 69512710 BW   Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement, 5/14/2014 76129910 BW   Retrophin Reports First Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2018 AKBA-US  BW   Akebia Therapeutics Announces Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/06/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2017 INVA-US     BW   Innoviva to Present at the Cowen & Co. 37th Annual Health Care Conference,#N/A,#N/A,#N/A," 5/02/2012 56400P70 BW   MannKind Corporation to Hold 2012 First Quarter Financial Results Conference Call on May 9, 2012",#N/A,#N/A,11/11/2013 29664W10    BW   Esperion Therapeutics Announces Oral Presentation on ETC-1002 at 2013 Scientific Sessions of the American Heart Association, 3/28/2012 03236M20 BW   Amyris Names Steven R. Mills as New Chief Financial Officer,#N/A,#N/A,#N/A,#N/A, 2/07/2018 EGRX-US  BW   Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX," 3/28/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights",#N/A,#N/A, 1/05/2016 EPZM-US  BW   Epizyme Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2018 VCYT-US  BW   Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference,10/05/2018 DRNA-US  BW   Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018, 2/04/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,"10/01/2013 00847X10 BW   Agios Pharmaceuticals Added to Russell 2000®, 3000® and Global Indexes",#N/A,#N/A, 6/28/2018 CELG-US  BW   Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes,#N/A, 3/06/2019 HZNP-US  BW   Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares,11/02/2017 00BJ80-E  BW   Castle Biosciences to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum,#N/A,#N/A, 6/12/2017 GLYC-US  BW   GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors,#N/A,#N/A,#N/A, 7/02/2018 G6674U10 BW   Novocure to Report Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A,10/18/2018 RCKT-US  BW   Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),#N/A,#N/A,#N/A,#N/A,#N/A,"12/06/2018 74587V10 BW   Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium",#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2017 MCRB-US  BW   Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017", 2/21/2019 AIMT-US  BW   Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2017 RARX-US  BW   Ra Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A, 1/15/2016 HCM-HK   BW   Chi-Med initiates HMPL-523 Phase I clinical trial in hematological cancer in Australia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2018 QTRX-US  BW   Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection,#N/A,#N/A,#N/A, 9/27/2013 30233G10 BW   pSivida to Present at 4th Annual Conference on Biosimilars & Biobetters,#N/A,#N/A, 2/12/2019 AXNX-US  BW   Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System,#N/A,#N/A,#N/A, 9/26/2017 0GNB9B-E BW   FierceBiotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/07/2018 00FLML-E BW   Emily Leproust, Ph.D., Recognized as 2018 Upstart 50",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/26/2018 00DD8T-E BW   Personalis, Inc. Receives Approval From the New York State Department of Health for Use of its ACE ImmunoID™ Platform in Cancer Immunotherapeutic Clinical Trials",#N/A,#N/A, 9/09/2015 0DMSKV-E BW   World’s Leading Experts To Discuss The Advances Of Immune Profiling In Health And Disease During Unprecedented Conference,#N/A,#N/A
 1/22/2018 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals, 5/10/2010 74318710    BW   Progenics Pharmaceuticals Announces First Quarter 2010 Financial Results, 4/10/2018 45232710    BW   Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics, 4/23/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine, 5/16/2016 ENDP-US  BW   INVESTOR ALERT: Investigation of Endo International plc Announced by Law Offices of Howard G. Smith, 9/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A, 2/24/2016 OPK-US   BW   OPKO's GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco,11/16/2010 JNJ-US      BW,#N/A, 9/26/2018 00GDBT-E BW   Alexion to Acquire Syntimmune,#N/A,12/03/2018 4502-JP     BW   Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas,#N/A," 7/31/2017 09062X10    BW   Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences", 1/02/2018 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation and Q&A at the 36th Annual J.P. Morgan Healthcare Conference,11/08/2011 09058V10 BW   BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting, 6/03/2019 GILD-US      BW   Kite Announces New Yescarta® Data From ZUMA-1,#N/A,#N/A, 2/11/2014 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2013 Results," 9/30/2014 AKRX-US   BW   Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.", 5/31/2013 NPSP-US      BW   NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day, 4/19/2013 07G69B-E    BW   Research and Markets: MediPoint Report: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts 2013-2018,#N/A,#N/A,#N/A," 5/01/2018 05156V10 BW   Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018", 2/08/2010 45773H20 BW   Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial,#N/A,#N/A, 2/24/2011 37416310     BW   Geron Corporation Reports Fourth Quarter and Annual 2010 Financial Results, 8/08/2018 AERI-US    BW   Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update,#N/A,12/03/2018 INCY-US  BW   Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit,#N/A,11/17/2015 SRPT-US  BW   Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology, 6/06/2017 ALKS-US  BW   FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia, 1/23/2018 CERS-US  BW   Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients,"10/20/2011 00163U10 BW   AMAG Pharmaceuticals to Host Conference Call on October 21, 2011 at 10:00 a.m. ET to Discuss the Results of the Special Meeting of Stockholders Vote"," 8/30/2018 04269E10 BW   ArQule to Participate in Citi’s 13th Annual Biotech Conference on September 6, 2018",#N/A,#N/A, 5/10/2018 EXEL-US  BW   Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer, 3/25/2017 CVS-US    BW   Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin,10/01/2018 VRTX-US   BW   Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines,#N/A,#N/A, 8/02/2018 BLUE-US  BW   bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress, 8/04/2018 ACAD-US  BW   ACAD ALERT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline – ACAD,#N/A,#N/A,#N/A, 5/23/2018 TXMD-US  BW   TherapeuticsMD Comments on Media Reports Regarding TX-004HR,#N/A,#N/A, 8/02/2018 OMER-US  BW   Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer," 5/01/2018 76133010 BW   Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary",#N/A, 5/03/2018 AGN-US   BW   Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation,#N/A,#N/A,#N/A,10/03/2012 065C1X-E    BW   NanoString Technologies Appoints James A. Johnson as Chief Financial Officer,#N/A, 1/30/2018 SYRS-US  BW   Syros Announces Pricing of $40 Million Public Offering of Common Stock,#N/A,#N/A,10/11/2011 ANIP-US      BW   Aduro BioTech Announces First Patient Treated in Phase 2 Pancreatic Cancer Trial," 8/07/2017 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017", 2/06/2019 ALNY-US   BW   Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine,#N/A,#N/A,#N/A, 3/06/2014 69512710 BW   Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors, 5/12/2014 76129910 BW   Retrophin to Report First Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 8/31/2018 SAGE-US     BW   Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2017 GSK-GB      BW   Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma,#N/A,#N/A,#N/A, 4/30/2012 56400P70 BW   Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases,#N/A,#N/A,11/06/2013 29664W10    BW   Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates, 2/27/2012 03236M20 BW   Amyris Reports Fourth Quarter and 2011 Year-End Financial Results,#N/A,#N/A,#N/A,#N/A," 1/02/2018 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference"," 3/15/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Report Clinical and Preclinical Data with DCC-2618 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting",#N/A,#N/A,12/30/2015 EPZM-US  BW   Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors,#N/A,#N/A,#N/A,#N/A,#N/A," 8/29/2018 VCYT-US  BW   Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications", 9/24/2018 DRNA-US  BW   Dicerna to Participate in Two Upcoming Investor Conferences, 1/09/2019 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 9/26/2013 00847X10 BW   Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors,#N/A,#N/A, 6/26/2018 XLRN-US  BW   Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society,#N/A, 3/04/2019 HZNP-US  BW   Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares, 9/05/2017 00BJ80-E  BW   New Publication Highlights First Prospective Performance Assessment of the DecisionDx-Melanoma Gene Expression Profile Test,#N/A,#N/A, 6/05/2017 GLYC-US  BW   GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference,#N/A,#N/A,#N/A, 6/04/2018 G6674U10 BW   Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018,#N/A,#N/A,#N/A, 9/25/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2018 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2017 MCRB-US  BW   Seres Therapeutics to Initiate New SER-109 Clinical Study," 2/04/2019 00900T10 BW   Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2018 QTRX-US  BW   Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017,#N/A,#N/A,#N/A, 9/25/2013 30233G10 BW   pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 Results,#N/A,#N/A, 1/03/2019 AXNX-US  BW   Axonics® legt amerikanischer Zulassungsbehörde FDA klinische Interimsdaten für System zur sakralen Neuromodulation vor,#N/A,#N/A,#N/A," 5/10/2017 0GNB9B-E BW   Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/20/2018 00FLML-E BW   Twist Bioscience Expands Executive Team with Industry Veterans,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/15/2018 00DD8T-E BW   Personalis, Inc. Expands International Recognition of ACE© Technology with the Issuance of Chinese Patent, adding to US and UK Patents",#N/A,#N/A, 8/19/2015 0DMSKV-E BW   Adaptive Biotechnologies Publishes Ground-Breaking Discovery Platform To Advance T-Cell Therapy Development,#N/A,#N/A
" 1/18/2018 LGND-US   BW   Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging", 3/15/2010 74318710    BW   Progenics Announces Fourth Quarter and Year-End 2009 Financial Results," 4/10/2018 45232710    BW   Illumina to Announce First Quarter 2018 Financial Results on Tuesday, April 24, 2018", 4/17/2018 84763A10  BW   Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago, 5/06/2016 ENDP-US  BW   Hagens Berman Investigates Potential Securities Law Violations by Endo International plc, 9/21/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/23/2016 68375N10 BW   OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia,11/03/2010 46222210    BW,#N/A, 9/25/2018 ALXN-US  BW   Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology,#N/A,12/02/2018 SGEN-US     BW   Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting,#N/A," 7/25/2017 BMY-US      BW   Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance",12/09/2017 IMGN-US  BW   ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting,11/02/2011 09058V10 BW   BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results, 6/01/2019 GILD-US      BW   Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia,#N/A,#N/A," 2/04/2014 M2572210 BW   Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST", 6/20/2014 00972810  BW   Akorn Divests ECR Pharmaceuticals to Valeant, 5/16/2013 PRPO-US      BW   Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment, 9/19/2012 VSTM-US     BW   Louise Phanstiel Joins Verastem Board of Directors,#N/A,#N/A,#N/A," 4/25/2018 05156V10 BW   Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018", 2/03/2010 45773H20 BW   Inovio Biomedical to Present at BIO CEO & Investor Conference,#N/A,#N/A, 2/22/2011 37416310     BW   Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2010 Financial Results and Highlights, 8/02/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,#N/A,11/27/2018 INCY-US  BW   Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer,#N/A,11/05/2015 SRPT-US  BW   Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments, 5/30/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference, 1/08/2018 CERS-US  BW   Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017,10/19/2011 07WD07-E BW   MSMB Files Definitive Proxy Statement in Opposition to AMAG Proposed Stock Issuance," 8/30/2018 04269E10 BW   ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018",#N/A,#N/A," 5/08/2018 EXEL-US  BW   Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018", 2/28/2017 SAN-FR    BW   Sanofi Genzyme Recognizes Rare Disease Day 2017 with Programs of Events around the World, 9/11/2018 VRTX-US   BW   Vertex to Present at the Morgan Stanley Healthcare Conference on September 14,#N/A,#N/A, 7/27/2018 BLUE-US  BW   bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares," 7/30/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018",#N/A,#N/A,#N/A, 5/16/2018 TXMD-US  BW   TherapeuticsMD Announces Investor and Analyst Day on June 4,#N/A,#N/A, 7/26/2018 00619R-E BW   Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire, 4/25/2018 76133010 BW   Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018,#N/A, 5/02/2018 IRWD-US  BW   Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders,#N/A,#N/A,#N/A, 9/27/2012 065C1X-E    BW   NanoString Technologies Obtains CE Mark for PAM50-based Test for Breast Cancer,#N/A, 1/30/2018 SYRS-US  BW   Syros Announces Proposed Offering of Common Stock,#N/A,#N/A,10/04/2011 00182C10     BW   BioSante Pharmaceuticals Completes Both Pivotal LibiGel® Efficacy Trials, 8/03/2017 ENTA-US    BW   Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks, 2/04/2019 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming February Investor Conferences,#N/A,#N/A,#N/A, 3/05/2014 69512710 BW   Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons, 5/12/2014 76129910 BW   Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN),#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2018 AKBA-US  BW   Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast,#N/A,#N/A,#N/A,#N/A, 8/07/2018 SAGE-US     BW   Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2017 INVA-US     BW   Innoviva Reports Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A, 4/10/2012 MNKD-US  BW   MannKind to Present at Imperial Capital 2012 Healthcare Investor Forum,#N/A,#N/A,11/05/2013 29664W10    BW   Esperion Therapeutics to Present at Credit Suisse Healthcare Conference, 2/27/2012 03236M20 BW   Amyris Secures $83.7 Million in Additional Financing,#N/A,#N/A,#N/A,#N/A,12/07/2017 EGRX-US  BW   Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant, 1/04/2018 DCPH-US BW   Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study),#N/A,#N/A,12/28/2015 EPZM-US  BW   Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2018 VCYT-US  BW   Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference, 9/06/2018 DRNA-US  BW   Dicerna Announces Pricing of Follow-On Public Offering of Common Stock, 1/09/2019 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 9/23/2013 00847X10 BW   Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation,#N/A,#N/A, 6/15/2018 CELG-US  BW   Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association,#N/A, 3/01/2019 HZNP-US  BW   Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 8/29/2017 00BJ80-E  BW   Castle Biosciences’ DecisionDx-Melanoma Test Performance Demonstrated in Newly Expanded Multicenter Cohort of 782 Patients,#N/A,#N/A, 6/05/2017 GLYC-US  BW   GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting,#N/A,#N/A,#N/A, 5/31/2018 G6674U10 BW   Novocure Announces Changes to Its Board of Directors,#N/A,#N/A,#N/A, 8/30/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2018 74587V10 BW   Puma Biotechnology to Present at Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2017 MCRB-US  BW   Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update, 1/18/2019 00900T10 BW   Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2017 RARX-US  BW   Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/08/2018 QTRX-US  BW   New Research Demonstrates Enhanced Sensitivity for Acute HIV Detection Using Quanterix’ Simoa Technology,#N/A,#N/A,#N/A, 9/18/2013 30233G10 BW   pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 1/02/2019 AXNX-US  BW   Axonics® soumet des données cliniques intermédiaires à la Food & Drug Administration américaine pour son système de neuromodulation sacrée,#N/A,#N/A,#N/A,"12/02/2016 0GNB9B-E BW   Magenta Therapeutics Cofounder David Scadden Honored at the American Society of Hematology Annual Meeting, as Scientific Founders Present New Stem Cell Biology Data",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2018 00FLML-E BW   Twist Bioscience Expands Human Core Exome and Custom Next-Generation Sequencing Solutions with High Throughput Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2018 07338T-E BW   Personalis Clinical Laboratory Receives Accreditation from College of American Pathologists,#N/A,#N/A, 8/10/2015 0DMSKV-E BW   Adaptive Biotechnologies Welcomes Chad Cohen as Its New Chief Financial Officer,#N/A,#N/A
 1/11/2018 073W4T-E  BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals, 3/12/2010 74318710    BW   Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development," 3/30/2018 ILMN-US     BW   ILLUMINA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN", 4/10/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients,12/31/2015 TRL-CA   BW   Acerus Announces Termination of NATESTO™ Agreement with Endo, 9/06/2018 ARWR-US  BW   Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit,#N/A,#N/A,#N/A,#N/A," 2/23/2016 OPK-US   BW   OPKO to Announce 2015 Fourth Quarter and Full Year Financial Results on February 29, 2016",10/28/2010 46222210    BW,#N/A, 9/24/2018 ALXN-US  BW   Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD),#N/A,12/01/2018 SGEN-US     BW   Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting,#N/A, 7/24/2017 09062X10    BW   Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations,11/07/2017 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences,10/24/2011 09058V10 BW   BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting, 5/31/2019 GILD-US      BW   Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,#N/A,#N/A, 1/22/2014 M2572210 BW   Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum, 5/09/2014 00972810  BW   Akorn to Acquire VersaPharm for $440 Million, 5/06/2013 PRPO-US      BW   Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer, 6/25/2012 MYGN-US     BW   Myriad Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012,#N/A,#N/A,#N/A," 4/02/2018 05156V10 BW   Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018", 1/27/2010 45773H20 BW   Inovio Unveils Skin Electroporation Technology for Delivering DNA Vaccines,#N/A,#N/A, 2/14/2011 37416310     BW   Geron to Present at 13th Annual BIO CEO & Investor Conference," 8/01/2018 AERI-US    BW   Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018",#N/A,11/07/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A,10/30/2015 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)," 5/30/2017 ALKS-US  BW   Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs",11/02/2017 CERS-US  BW   Cerus Corporation Reports Third Quarter 2017 Results,10/13/2011 AMAG-US  BW   Allos Therapeutics Announces Settlement with Putative Class Action Plaintiffs Regarding Merger with AMAG Pharmaceuticals," 8/29/2018 04269E10 BW   ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018",#N/A,#N/A, 5/02/2018 00DPL4-E BW   Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer, 2/22/2017 07J4DM-E  BW   Selexis SA firma un acuerdo sobre aplicaciones para cáncer y enfermedades infecciosas, 9/10/2018 VRTX-US   BW   Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility,#N/A,#N/A, 7/26/2018 BLUE-US  BW   bluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia, 7/20/2018 ACAD-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. – ACAD,#N/A,#N/A,#N/A, 5/03/2018 TXMD-US  BW   TherapeuticsMD Announces First Quarter 2018 Financial Results,#N/A,#N/A, 7/25/2018 OMER-US  BW   Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation," 4/24/2018 76133010 BW   Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018",#N/A, 5/01/2018 IRWD-US  BW   Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business,#N/A,#N/A,#N/A, 9/25/2012 065C1X-E    BW   NanoString Launches Single Cell Gene Expression Solution for its nCounter® Analysis System,#N/A," 1/22/2018 SYRS-US  BW   Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist",#N/A,#N/A,"10/03/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Cancer Immunotherapy Conference", 7/28/2017 ENTA-US    BW   Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6), 1/31/2019 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results,#N/A,#N/A,#N/A," 2/27/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint", 4/14/2014 76129910 BW   Retrophin Updates Financial Guidance for 2014 and 2015 and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A, 7/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 8/03/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A," 2/02/2017 INVA-US     BW   Innoviva to Report Fourth Quarter and Full Year 2016 Financial Results on February 9, 2017 at 5:00 p.m. EST",#N/A,#N/A,#N/A, 2/29/2012 56400P70 BW   MannKind to Present at Cowen and Company 32nd Annual Health Care Conference,#N/A,#N/A,10/30/2013 29664W10    BW   Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia, 2/06/2012 03236M20 BW   Amyris to Hold Conference Calls and Participate in Investor Conferences,#N/A,#N/A,#N/A,#N/A,"11/20/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference"," 1/03/2018 DCPH-US BW   Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference",#N/A,#N/A,"12/07/2015 EPZM-US  BW   Epizyme Presents Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed or Refractory Non-Hodgkin Lymphoma",#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2018 VCYT-US  BW   Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares, 9/05/2018 DRNA-US  BW   Dicerna Announces Proposed Follow-On Public Offering of Common Stock,12/10/2018 15117K10 BW   Cellectis nomme William Monteith en tant que Vice-Président Senior U.S. Manufacturing,#N/A,#N/A,#N/A, 9/05/2013 00847X10 BW   Agios Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference,#N/A,#N/A, 6/04/2018 CELG-US  BW   Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting,#N/A, 2/28/2019 HZNP-US  BW   Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints, 8/10/2017 00BJ80-E  BW   New Publication Confirms Analytic Validity of Castle Biosciences’ DecisionDx-UM Test for Uveal Melanoma in its Clinical Laboratory,#N/A,#N/A, 5/31/2017 GLYC-US  BW   GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271,#N/A,#N/A,#N/A, 4/26/2018 G6674U10 BW   Novocure Reports First Quarter 2018 Financial Results and Provides Company Update,#N/A,#N/A,#N/A, 8/08/2018 RCKT-US  BW   Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2018 74587V10 BW   Puma Biotechnology Reports Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A," 3/13/2017 MCRB-US  BW   Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017", 1/04/2019 00900T10 BW   Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2017 RARX-US  BW   Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/07/2018 QTRX-US  BW   Quanterix to Release Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call on Wednesday, March 14, 2018",#N/A,#N/A,#N/A, 9/04/2013 30233G10 BW   pSivida to Present At Two Investment Conferences in September,#N/A,#N/A, 1/02/2019 AXNX-US  BW   Axonics® Submits Interim Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2018 00FLML-E BW   Twist Bioscience Accelerates Global Expansion with Strategic Asia Pacific Distribution Agreements,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/16/2018 00DD8T-E BW   Personalis, Inc. to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2018",#N/A,#N/A, 7/15/2015 0DMSKV-E BW   Adaptive Biotechnologies and Collaborators Demonstrate Importance of Minimal Residual Disease Measurement in Response Evaluation for Multiple Myeloma,#N/A,#N/A
 1/03/2018 009420-KR BW   Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects, 2/04/2010 74318710    BW   Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer," 3/22/2018 ILMN-US     BW   The Shuman Law Firm Investigates Illumina, Inc.", 4/03/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th, 6/10/2015 G3040110 BW   ARIAD Et Laboratoires Paladin Annoncent La Signature D’une Entente De Distribution Commerciale D’iclusig (Ponatinib) Au Canada, 8/31/2018 ARWR-US  BW   Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A, 2/18/2016 OPK-US   BW   OPKO Health to Present at the RBC Capital Markets Global Healthcare Conference,10/21/2010 46222210    BW,#N/A, 9/07/2018 ALXN-US  BW   Alexion to Present at Morgan Stanley’s 16th Annual Global Healthcare Conference,#N/A,11/26/2018 SGEN-US     BW   Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,#N/A, 7/17/2017 ACN-US      BW   Les laboratoires de R&D d’Accenture et 1QBit collaborent avec Biogen pour accélérer la découverte de médicaments grâce à l’informatique quantique,11/03/2017 IMGN-US  BW   ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results,"10/19/2011 09058V10 BW   BioCryst Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 2, 2011", 5/29/2019 GILD-US      BW   Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019),#N/A,#N/A, 1/21/2014 M2572210 BW   Compugen Announces Addition of Prof. Drew Pardoll to Its Scientific Advisory Board, 5/06/2014 00972810  BW   Akorn Reports 2014 First Quarter Results, 5/05/2013 IT-US        BW   Reveille nommé dans la liste Cool Vendor 2013 de Gartner pour la gestion de contenu, 4/18/2012 05LPYZ-E    BW   Biotechnology Patenting and Intellectual Property to be Highlighted at 2012 BIO International Convention,#N/A,#N/A,#N/A, 3/15/2018 05156V10 BW   Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights, 1/19/2010 45773H20 BW   Inovio Biomedical to Present at Partnering and Vaccine Conferences,#N/A,#N/A," 2/09/2011 37416310     BW   Geron Appoints David Greenwood President, Interim CEO and Director"," 8/01/2018 KNSY-US    BW   Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology",#N/A,11/01/2018 INCY-US  BW   Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting,#N/A,"10/27/2015 SRPT-US  BW   Sarepta Therapeutics to Announce Third Quarter 2015 Financial Results and Recent Corporate Developments on November 5, 2015", 5/11/2017 ALKS-US  BW   Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting,10/31/2017 063WPF-E BW   Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy,10/11/2011 07WD07-E BW   MSMB Capital Announces that ISS Recommends that AMAG Shareholders Vote AGAINST the Allos Transaction," 8/13/2018 04269E10 BW   ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK",#N/A,#N/A, 5/02/2018 EXEL-US  BW   Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update, 2/21/2017 07J4DM-E  BW   Selexis SA sluit overeenkomst voor toepassingen voor kanker en infectieziekten, 9/06/2018 VRTX-US   BW   Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis,#N/A,#N/A, 7/24/2018 BLUE-US  BW   bluebird bio Announces Pricing of Public Offering of Common Stock, 7/19/2018 ACAD-US  BW   Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD),#N/A,#N/A,#N/A, 5/01/2018 TXMD-US  BW   TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3,#N/A,#N/A, 7/23/2018 OMER-US  BW   Omeros Corporation Initiates Sales of OMIDRIA® in Europe, 4/19/2018 76133010 BW   Revance Investor Day Highlights New Neuroscience Indications in Development,#N/A, 5/01/2018 IRWD-US  BW   Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update,#N/A,#N/A,#N/A, 9/24/2012 065C1X-E    BW   The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50,#N/A, 1/08/2018 SYRS-US  BW   Syros Announces 2018 Strategic Priorities and Expected Milestones,#N/A,#N/A, 9/12/2011 00182C10     BW   BioSante Pharmaceuticals Successfully Completes LibiGel® Pharmacokinetic Study," 7/25/2017 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2017", 1/23/2019 0H68GC-E  BW   CAMP4 Therapeutics Announces Rare Disease Research Collaboration with Alnylam,#N/A,#N/A,#N/A," 2/26/2014 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference", 3/27/2014 76129910 BW   Retrophin Reports Full-Year 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A," 6/28/2018 AKBA-US  BW   Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease",#N/A,#N/A,#N/A,#N/A, 8/01/2018 SAGE-US     BW   Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2016 GSK-GB      BW   GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma,#N/A,#N/A,#N/A, 2/22/2012 56400P70 BW   MannKind Corporation Reports 2011 Fourth Quarter and Full Year Financial Results,#N/A,#N/A, 9/24/2013 29664W10    BW   Esperion Therapeutics to Present at BioCentury Newsmakers in the Biotech Industry Conference,11/30/2011 AMRS-US  BW   Total and Amyris Partner to Produce Renewable Fuels,#N/A,#N/A,#N/A,#N/A,"11/08/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results",#N/A,#N/A,#N/A,"11/24/2015 EPZM-US  BW   Epizyme, Inc. to Present at Piper Jaffray Conference on December 1, 2015",#N/A,#N/A,#N/A,#N/A,#N/A," 7/25/2018 VCYT-US  BW   Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock", 9/05/2018 DRNA-US  BW   Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria,12/10/2018 15117K10 BW   Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing,#N/A,#N/A,#N/A, 9/03/2013 00847X10 BW   Agios Pharmaceuticals to Present New Research at the 12th International Congress of Inborn Errors of Metabolism,#N/A,#N/A," 5/24/2018 NPSP-US  BW   Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors",#N/A, 2/27/2019 HZNP-US  BW   Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance, 7/18/2017 00BJ80-E  BW   Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies,#N/A,#N/A, 5/30/2017 GLYC-US  BW   GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 4/17/2018 G6674U10 BW   Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma,#N/A,#N/A,#N/A, 6/22/2018 0BWGV3-E BW   Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes,#N/A,#N/A,#N/A,#N/A,#N/A,10/18/2018 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2017 MCRB-US  BW   Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference," 1/02/2019 00900T10 BW   Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/19/2017 RARX-US  BW   Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2018 QTRX-US  BW   Quanterix to Present at the Cowen and Company 38th Annual Healthcare Conference,#N/A,#N/A,#N/A, 7/29/2013 30233G10 BW   pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and Systemic Disease at International Symposium on Integrated Functionalities,#N/A,#N/A,12/11/2018 AXNX-US  BW   Axonics® Announces Third Quarter 2018 Financial Results and Operational Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2018 00FLML-E BW   Twist Bioscience Completes $50 Million Financing to Fuel Advancement of Digital Storage in DNA and Drug Discovery,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/08/2018 00DD8T-E BW   Personalis, Inc. Releases the Latest Version of NeoantigenID for Enhanced Neoantigen Identification on the ACE ImmunoID Platform",#N/A,#N/A, 6/12/2015 0DMSKV-E BW   Adaptive Biotechnologies to Present Data from Largest Study to Date Demonstrating Superior Sensitivity and Prognostic Value of Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Detection in Pediatric Acute Lymphoblastic Leukemia,#N/A,#N/A
11/14/2017 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A, 3/12/2018 45232710    BW   Illumina Names Dr. Phil Febbo Chief Medical Officer, 3/07/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th, 6/10/2015 ARIA-US  BW   ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada, 8/30/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences,#N/A,#N/A,#N/A,#N/A, 2/09/2016 68375N10 BW   Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer, 9/23/2010 46222210    BW,#N/A, 8/29/2018 ALXN-US  BW   Alexion to Present at Citi’s 13th Annual Biotech Conference,#N/A,11/16/2018 SGEN-US     BW   Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas,#N/A, 7/14/2017 09062X10    BW   Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®),11/01/2017 IMGN-US  BW   ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting,10/11/2011 09058V10 BW   Biocryst Pharmaceuticals Announces Changes to Its Board of Directors, 5/29/2019 GILD-US      BW   Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer,#N/A,#N/A, 1/07/2014 M2572210 BW   Compugen to Significantly Expand Immuno-Oncology Activities During 2014, 4/17/2014 00972810  BW   Akorn Completes Acquisition of Hi-Tech Pharmacal, 4/29/2013 AMGN-US      BW   2013 Amgen Tour of California Media Credential Application Now Available Online," 1/25/2011 MRK-US      BW   John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age",#N/A,#N/A,#N/A," 2/28/2018 05156V10 BW   Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018",#N/A,#N/A,#N/A, 2/07/2011 005Z10-E     BW   Cellerant Therapeutics Announces Key Additions to Sr. Management Team, 7/23/2018 0016FN-E   BW   Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield,#N/A,10/30/2018 INCY-US  BW   Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs,#N/A,10/14/2015 SRPT-US  BW   Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy, 5/01/2017 ALKS-US  BW   Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia,10/31/2017 CERS-US  BW   Cerus to Present at Two Upcoming Conferences,10/10/2011 AMAG-US  BW   Allos Therapeutics Continues to Work Toward Completion of Merger with AMAG Pharmaceuticals, 8/01/2018 04269E10 BW   ArQule Reports Second Quarter 2018 Financial Results,#N/A,#N/A, 4/26/2018 EXEL-US  BW   Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting, 2/21/2017 07J4DM-E  BW   Selexis SA signe un Accord d’applications dans le domaine du cancer et des maladies infectieuses, 9/03/2018 VRTX-US   BW   Vertex meldet Erstattungsvereinbarung in Australien für ORKAMBI® (Lumacaftor/Ivacaftor) für Mukoviszidose-Patienten im Alter von mindestens sechs Jahren mit zwei Kopien der F508del-Mutation,#N/A,#N/A, 7/23/2018 BLUE-US  BW   bluebird bio Announces Proposed Public Offering of Common Stock," 7/19/2018 ACAD-US  BW   ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,#N/A,#N/A, 4/11/2018 TXMD-US  BW   TherapeuticsMD Enters Into Label Negotiations for TX-004HR,#N/A,#N/A, 7/17/2018 OMER-US  BW   Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction, 4/02/2018 76133010 BW   Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable,#N/A, 4/17/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call,#N/A,#N/A,#N/A, 8/07/2012 065C1X-E    BW   NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences,#N/A, 1/08/2018 INCY-US  BW   Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms,#N/A,#N/A," 9/01/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Three September Healthcare Conferences"," 6/26/2017 ENTA-US    BW   Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX International Symposium on Respiratory Viral Infections", 1/21/2019 ALNY-US   BW   Alnylam Pharmaceuticals et Medison Pharma s'associent en vue de la commercialisation des agents thérapeutiques iARN en Israël,#N/A,#N/A,#N/A," 2/25/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter", 3/27/2014 76129910 BW   Retrophin Completes Acquisition of Manchester Pharmaceuticals,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A," 7/24/2018 SAGE-US     BW   Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018",#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2016 INVA-US     BW   GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD,#N/A,#N/A,#N/A," 2/15/2012 56400P70 BW   MannKind Corporation to Hold 2011 Fourth Quarter and Full Year Financial Results Conference Call on February 22, 2012",#N/A,#N/A, 9/10/2013 29664W10    BW   Esperion Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference,11/30/2011 AMRS-US  BW   Total and Amyris Partner to Produce Renewable Fuels,#N/A,#N/A,#N/A,#N/A,"11/07/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference",#N/A,#N/A,#N/A,11/09/2015 EPZM-US  BW   Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2018 VCYT-US  BW   Veracyte Announces Proposed Public Offering of Common Stock, 8/29/2018 DRNA-US  BW   Dicerna to Participate in Upcoming Investor Conferences,12/06/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 8/27/2013 00847X10 BW   Agios Pharmaceuticals Named 2014 World Economic Forum Technology Pioneer,#N/A,#N/A, 5/22/2018 XLRN-US  BW   Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension,#N/A, 2/25/2019 HZNP-US  BW   Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference, 6/05/2017 00BJ80-E  BW   Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma,#N/A,#N/A, 5/25/2017 GLYC-US  BW   GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia,#N/A,#N/A,#N/A, 4/13/2018 G6674U10 BW   Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting,#N/A,#N/A,#N/A, 5/30/2018 RCKT-US  BW   Rocket Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2018 CELC-US  BW   Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2017 MCRB-US  BW   Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences,12/21/2018 00900T10 BW   Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2017 RARX-US  BW   Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2018 QTRX-US  BW   Quanterix to Present at The LEERINK Partners 7th Annual Global Healthcare Conference,#N/A,#N/A,#N/A, 7/24/2013 30233G10 BW   pSivida Announces France’s Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN,#N/A,#N/A,12/11/2018 AXNX-US  BW   Axonics® gibt Veröffentlichung von NICE-Briefing bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2018 00FLML-E BW   Twist Bioscience Expands North American Presence With Office in San Diego, California",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/06/2018 00DD8T-E BW   Personalis, Inc. Launches ImmunogenomicsID™ for Multidimensional Immuno-Oncology Biomarker Analysis as the Latest Enhancement to the ACE ImmunoID™ Platform",#N/A,#N/A,#N/A,#N/A,#N/A
11/09/2017 0G9V6N-E  BW   Ligand Reports Third Quarter 2017 Financial Results,#N/A, 2/27/2018 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation, 3/06/2018 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update," 3/11/2015 SLXP-US  BW   Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from Endo International plc", 8/07/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 1/22/2016 OPK-US   BW   OPKO’s GeneDx to Present at Personalized Medicine World Conference, 9/01/2010 46222210    BW,#N/A, 8/20/2018 ALXN-US  BW   FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US,#N/A,11/15/2018 SGEN-US     BW   FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas,#N/A, 7/10/2017 09062X10    BW   Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs,10/20/2017 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results,10/05/2011 09058V10 BW   BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone," 5/21/2019 GILD-US      BW   Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5",#N/A,#N/A,12/11/2013 M2572210 BW   Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy, 4/14/2014 00972810  BW   Akorn Receives FTC Clearance for Hi-Tech Pharmacal Acquisition, 4/19/2013 AMGN-US      BW   Fitch Affirms Amgen's IDR at 'BBB'; Ratings Outlook Stable, 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Prostate Cancer Research Database,#N/A,#N/A,#N/A," 2/22/2018 05156V10 BW   Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors",#N/A,#N/A,#N/A," 1/21/2011 37416310     BW   Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation"," 7/23/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019",#N/A,10/25/2018 INCY-US  BW   Incyte Named a 2018 Top Employer by Science Magazine,#N/A,10/09/2015 SRPT-US  BW   Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock, 4/27/2017 ALKS-US  BW   Alkermes plc Reports First Quarter 2017 Financial Results,10/30/2017 0D556V-E BW   Cerus Announces Agreement with Transfusion Center of the Community of Madrid, 9/26/2011 07WD07-E BW   AMAG Pharmaceuticals Urges Stockholders to Postpone Making Any Decision Regarding the MSMB Capital Preliminary Consent Solicitation," 7/18/2018 04269E10 BW   ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018",#N/A,#N/A," 4/11/2018 EXEL-US  BW   Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018", 2/21/2017 07J4DM-E  BW   Selexis SA Inks Agreement for Applications in Cancer and Infectious Disease, 9/03/2018 VRTX-US   BW   Vertex annonce un accord de remboursement pour l'ORKAMBI ® (lumacaftor/ivacaftor) en Australie pour les personnes de six ans et plus souffrant de fibrose kystique et possédant deux copies de la mutation F508del,#N/A,#N/A, 6/15/2018 BLUE-US  BW   bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association," 7/19/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary",#N/A,#N/A,#N/A, 4/02/2018 TXMD-US  BW   TherapeuticsMD Announces Expansion of Board of Directors,#N/A,#N/A, 6/27/2018 OMER-US  BW   Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment," 3/26/2018 76133010 BW   Revance to Host Investor Day on April 19, 2018",#N/A, 4/09/2018 IRWD-US  BW   Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital,#N/A,#N/A,#N/A, 7/18/2012 065C1X-E    BW   NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors,#N/A, 1/04/2018 SYRS-US  BW   Syros to Present at 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 8/02/2011 00182C10     BW   BioSante Pharmaceuticals Closes $48.0 Million Public Offering of Common Stock, 6/23/2017 ENTA-US    BW   Enanta Announces that AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6), 1/21/2019 ALNY-US   BW   Alnylam Pharmaceuticals und Medison Pharma kooperieren bei der Vermarktung von RNAi-Therapeutika in Israel,#N/A,#N/A,#N/A," 2/11/2014 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call", 2/12/2014 76129910 BW   Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2018 AKBA-US  BW   Akebia Therapeutics to Present at Upcoming Investor Conference,#N/A,#N/A,#N/A,#N/A, 7/05/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2016 GSK-GB      BW   Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD,#N/A,#N/A,#N/A, 2/08/2012 56400P70 BW   MannKind Announces Exercise In Full of Over-Allotment Option and Completion of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock,#N/A,#N/A, 9/03/2013 29664W10    BW   Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia,11/30/2011 03236M20 BW   Amyris to Participate in Investor Conferences,#N/A,#N/A,#N/A,#N/A,"10/30/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017",#N/A,#N/A,#N/A,11/05/2015 EPZM-US  BW   Epizyme Announces Presentations at 57th American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2018 VCYT-US  BW   Veracyte Announces Second Quarter 2018 Financial Results, 8/16/2018 DRNA-US  BW   Dicerna Strengthens Board of Directors with Two New Appointments,12/06/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 7/29/2013 00847X10 BW   Agios Pharmaceuticals Closes Initial Public Offering,#N/A,#N/A, 5/17/2018 XLRN-US  BW   Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association,#N/A," 1/29/2019 HZNP-US  BW   Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019", 5/15/2017 00BJ80-E  BW   Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions,#N/A,#N/A, 5/24/2017 GLYC-US  BW   GlycoMimetics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A, 4/03/2018 G6674U10 BW   Novocure to Report First Quarter 2018 Financial Results,#N/A,#N/A,#N/A, 5/18/2018 RCKT-US  BW   Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,10/10/2018 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2017 MCRB-US  BW   Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses,12/20/2018 AIMT-US  BW   Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2017 RARX-US  BW   Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2018 QTRX-US  BW   Quanterix Corporation to Present at 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 7/19/2013 30233G10 BW   pSivida Announces Pricing of $10.8 Million Offering of Common Stock,#N/A,#N/A,12/10/2018 AXNX-US  BW   Axonics® annonce la publication d'un bulletin d'information par le NICE,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2018 00FLML-E BW   Twist Bioscience Launches Exome and Custom Target Enrichment Solutions for Genomics and Clinical Researchers Conducting Next-Generation Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2017 00DD8T-E BW   Personalis Awarded New Contract with the US Department of Veterans Affairs to Provide Clinical Cancer Genomic Testing and Analysis for the Precision Oncology Program,#N/A,#N/A,#N/A,#N/A,#N/A
11/06/2017 LGND-US   BW   Reminder: Ligand to Host Analyst Day on November 14th in New York City,#N/A, 1/30/2018 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2017, 2/27/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors, 6/18/2014 ENDP-US  BW   Trendlines Acquires Intellectual Property from Collaboration with Endo, 8/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen,#N/A,#N/A,#N/A,#N/A, 1/06/2016 OPK-US   BW   OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference, 8/10/2010 46222210    BW,#N/A, 7/26/2018 ALXN-US  BW   Alexion Reports Second Quarter 2018 Results,#N/A,11/14/2018 SGEN-US     BW   Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma,#N/A, 6/29/2017 BIIB-US     BW   New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity,10/16/2017 IMGN-US  BW   ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active, 9/17/2011 09058V10 BW   BioCryst To Present New Peramivir Data at the 51st Annual ICAAC Meeting, 5/15/2019 GILD-US      BW   Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019,#N/A,#N/A,10/29/2013 M2572210 BW   Compugen Ltd. Reports Third Quarter 2013 Financial Results, 3/03/2014 00972810  BW   Akorn Reports 2013 Fourth Quarter and Year-End Financial Results, 3/20/2013 AMGN-US      BW   PsiOxus Therapeutics Comments on Phase III Results from Amgen’s Oncolytic Vaccine," 1/03/2011 0020J6-E    BW   Davidson 99 Regional Stock Index® Outperforms Major Indices for Year, Quarter",#N/A,#N/A,#N/A, 2/20/2018 05156V10 BW   Aurinia Named Company of the Year by LifeSciences BC,#N/A,#N/A,#N/A, 1/19/2011 0615NY-E     BW   Geron Initiates Phase 2 Clinical Trial of Imetelstat in Essential Thrombocythemia," 7/16/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing",#N/A,10/25/2018 INCY-US  BW   FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease,#N/A,10/06/2015 SRPT-US  BW   Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock, 4/26/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference,10/23/2017 CERS-US  BW   Cerus Announces National German Reimbursement for Pathogen Inactivated Platelets," 9/12/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 7/13/2018 04269E10 BW   ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A, 4/09/2018 EXEL-US  BW   Exelixis Elects Dr. Maria Freire to Its Board of Directors, 2/14/2017 0GBP93-E  BW   Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease, 9/03/2018 VRTX-US   BW   Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation,#N/A,#N/A, 6/15/2018 BLUE-US  BW   bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association," 7/17/2018 ACAD-US  BW   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,#N/A,#N/A, 3/08/2018 TXMD-US  BW   TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR,#N/A,#N/A, 5/24/2018 OMER-US  BW   Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin, 3/20/2018 76133010 BW   Revance to Participate in the Needham Healthcare Conference,#N/A, 4/09/2018 003Q3K-E BW   Scholar Rock Appoints Rhonda Chicko as Chief Financial Officer,#N/A,#N/A,#N/A," 5/29/2012 065C1X-E    BW   NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics",#N/A," 1/02/2018 SYRS-US  BW   Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients",#N/A,#N/A," 7/28/2011 MKTSQ.XX1-US BW   Rodman & Renshaw, LLC acts as a Co-Manager to BioSante Pharmaceuticals, Inc. in Public Offering of Common Stock"," 5/08/2017 ENTA-US    BW   CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017", 1/21/2019 ALNY-US   BW   Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel,#N/A,#N/A,#N/A, 1/29/2014 69512710 BW   Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management, 2/04/2014 76129910 BW   Retrophin to Present at the 16th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 AKBA-US  BW   Akebia Therapeutics Announces First Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A," 6/13/2018 SAGE-US     BW   Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea",#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2016 GSK-GB      BW   GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD,#N/A,#N/A,#N/A, 2/07/2012 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A," 8/30/2013 29664W10    BW   Esperion Therapeutics to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia",11/30/2011 03236M20 BW   Total e Amyris em Parceria para Produzir Combustível Renovável,#N/A,#N/A,#N/A,#N/A,10/27/2017 EGRX-US  BW   Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute,#N/A,#N/A,#N/A,11/04/2015 EPZM-US  BW   Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer,#N/A,#N/A,#N/A,#N/A,#N/A," 7/09/2018 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018", 8/08/2018 DRNA-US  BW   Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update,11/13/2018 15117K10 BW   Cellectis publie ses résultats financiers du troisième trimestre 2018 et des neuf mois de l’année 2018,#N/A,#N/A,#N/A, 7/23/2013 00847X10 BW   Agios Pharmaceuticals Prices Initial Public Offering,#N/A,#N/A, 5/08/2018 CELG-US  BW   Acceleron Reports First Quarter 2018 Operating and Financial Results,#N/A, 1/03/2019 HZNP-US  BW   Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout, 5/01/2017 00BJ80-E  BW   Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma,#N/A,#N/A, 5/22/2017 GLYC-US  BW   GlycoMimetics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 3/20/2018 NVCR-US  BW   NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 5/17/2018 0DFS7Q-E BW   Rocket Pharmaceuticals Announces Strategic Research Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2018 74587V10 BW   Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2017 MCRB-US  BW   Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses,12/19/2018 00900T10 BW   Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/21/2017 RARX-US  BW   Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2018 QTRX-US  BW   Quanterix Announces Commercial Availability of New SR-X Ultra-Sensitive Biomarker Detection System™,#N/A,#N/A,#N/A, 7/18/2013 30233G10 BW   pSivida Announces Proposed Public Offering of Common Stock,#N/A,#N/A,12/10/2018 AXNX-US  BW   Axonics® Announces Publication of NICE Briefing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/25/2018 ALINT-FR BW   IntegraGen s’associe à Twist Bioscience pour utiliser le Core Exome Kit de Twist Bioscience, solution de synthèse d’ADN à forte valeur ajoutée",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/16/2017 00DD8T-E BW   Personalis, Inc. Launches Early Access Program for Cell-Free DNA ACE Exome for Tumor Neoantigens",#N/A,#N/A,#N/A,#N/A,#N/A
11/02/2017 LGND-US   BW   Ligand to Participate in the Stephens Fall Investment Conference,#N/A," 1/26/2018 45232710    BW   Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.", 2/26/2018 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Teleconference and Webcast," 5/11/2010 G3040110 BW   Bull & Lifshitz, LLP Announces Investigation of the Acquisition of HealthTronics, Inc. by Endo Pharmaceuticals Holdings Inc.", 7/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 1/05/2016 68375N10 BW   Conversion Right Extended on OPKO 3.0% Convertible Senior Notes, 8/04/2010 46222210    BW,#N/A," 6/28/2018 ALXN-US  BW   Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018",#N/A,11/06/2018 SGEN-US     BW   Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference,#N/A, 6/28/2017 09062X10    BW   Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs,"10/11/2017 IMGN-US  BW   ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares", 9/06/2011 09058V10 BW   BioCryst to Present at Three Upcoming Investor Conferences, 5/09/2019 GILD-US      BW   Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic,#N/A,#N/A,"10/22/2013 M2572210 BW   Compugen Third Quarter 2013 Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 AM EST", 1/09/2014 4536-JP   BW   Akorn Acquires Betimol® from Santen," 3/07/2013 06NCQ3-E     BW   L’Institut pour l’administration appliquée de médicaments de Catalent accueille le Dr Ralph Lipp, chef de file accompli du secteur des sciences de la vie, au Comité consultatif et Terry Robinson au poste de directrice exécutive"," 5/27/2010 TXN-US      BW   Zacks Bull and Bear of the Day Highlights: Molex, Myriad Genetics, Texas Instruments, Intel and Qualcomm",#N/A,#N/A,#N/A, 2/14/2018 05156V10 BW   Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program,#N/A,#N/A,#N/A," 1/18/2011 37416310     BW   Holzer Holzer & Fistel, LLC Announces Investigation into Potential Claims for Breach of Fiduciary Duties by Certain Officers and Directors of Geron Corporation", 6/18/2018 SAN-FR     BW   Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel,#N/A,"10/23/2018 INCY-US  BW   Incyte anuncia datos intermedios positivos del ensayo de Fase 2 para el Pemigatinib, su inhibidor selectivo del FGFR, en pacientes de colangiocarcinoma",#N/A,10/05/2015 SRPT-US  BW   Sarepta Therapeutics Announces Proposed Public Offering of Common Stock, 4/20/2017 ALKS-US  BW   Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial Results,"10/19/2017 CERS-US  BW   Cerus to Release Third Quarter 2017 Results on November 2, 2017"," 9/07/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the Baird 2011 Healthcare Conference", 7/11/2018 04269E10 BW   ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock,#N/A,#N/A, 3/28/2018 EXEL-US  BW   Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma, 2/09/2017 0GBP93-E  BW   Sanofi Genzyme Commitment to Patients with Rare Diseases Highlighted at WORLDSymposium 2017, 8/30/2018 VRTX-US   BW   Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines,#N/A,#N/A, 6/05/2018 BLUE-US  BW   bluebird bio Announces Investor Events in June, 7/13/2018 ACAD-US  BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD),#N/A,#N/A,#N/A, 3/06/2018 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A, 5/10/2018 OMER-US  BW   Omeros Corporation Reports First Quarter 2018 Financial Results, 3/06/2018 76133010 BW   Revance to Participate in Upcoming Investor Conferences,#N/A, 3/05/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences,#N/A,#N/A,#N/A, 5/16/2012 065C1X-E    BW   NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay,#N/A,"12/10/2017 SYRS-US  BW   Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach",#N/A,#N/A, 7/28/2011 00182C10     BW   BioSante Pharmaceuticals Prices Public Offering of Common Stock," 4/21/2017 ENTA-US    BW   Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients", 1/14/2019 ALNY-US   BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A," 1/07/2014 69512710 BW   Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery", 1/10/2014 76129910 BW   Retrophin Announces Pricing of Public Offering of Common Shares,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/12/2018 SAGE-US     BW   Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 INVA-US     BW   Innoviva to Present at the CreditSuisse and Stifel Healthcare Conferences in November,#N/A,#N/A,#N/A," 2/02/2012 56400P70 BW   MannKind Receives Commitment from The Mann Group to Acquire 31,250,000 Shares of Common Stock",#N/A,#N/A, 8/12/2013 29664W10    BW   Esperion Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update,11/01/2011 03236M20 BW   Amyris Reports Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,10/17/2017 EGRX-US  BW   Eagle Pharmaceuticals Announces New Patent for RYANODEX,#N/A,#N/A,#N/A,"11/02/2015 EPZM-US  BW   Epizyme to Report Third Quarter 2015 Financial Results and Provide Corporate Update on November 9, 2015",#N/A,#N/A,#N/A,#N/A,#N/A, 7/02/2018 VCYT-US  BW   Veracyte Chairman and CEO to Speak at MedCity CONVERGE," 8/01/2018 DRNA-US  BW   Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018",11/13/2018 15117K10 BW   Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018,#N/A,#N/A,#N/A, 4/05/2013 00BBFF-E BW   Agios Research in Cancer Metabolism Highlighted at AACR Annual Meeting 2013,#N/A,#N/A, 5/02/2018 XLRN-US  BW   Acceleron to Participate in Two Healthcare Investor Conferences in May,#N/A,12/27/2018 HZNP-US  BW   Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns, 3/29/2017 00BJ80-E  BW   Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment of Castle Biosciences’ Uveal Melanoma Gene Expression Test,#N/A,#N/A," 5/18/2017 GLYC-US  BW   GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML",#N/A,#N/A,#N/A, 3/15/2018 G6674U10 BW   Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018,#N/A,#N/A,#N/A," 5/15/2018 RCKT-US  BW   Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy",#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2018 74587V10 BW   Puma Biotechnology to Present at Cantor Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,"11/23/2016 MCRB-US  BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2016","12/06/2018 00900T10 BW   Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2017 QTRX-US  BW   Quanterix Corporation Announces Closing of Initial Public Offering,#N/A,#N/A,#N/A, 7/11/2013 30233G10 BW   pSivida Corp. Announces Interim Data From Investigator-Sponsored Uveitis Study,#N/A,#N/A,12/05/2018 AXNX-US  BW   Axonics® beantragt die Zulassung bei der U.S. Food & Drug Administration für sein System für sakrale Neuromodulation.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2018 00FLML-E BW   Twist Bioscience to Present at the 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/14/2017 00DD8T-E BW   Dr. Richard Chen, Chief Scientific Officer, Personalis, Inc. to Present Data and Discuss Tumor Immuno-genomics and Personalized Vaccines Solutions at 2017 Neoantigen Summit",#N/A,#N/A,#N/A,#N/A,#N/A
10/24/2017 LGND-US   BW   Ligand to Report Third Quarter 2017 Results on November 9th,#N/A," 1/16/2018 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, January 30, 2018", 2/15/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd,#N/A, 6/29/2018 ARWR-US  BW   Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference,#N/A,#N/A,#N/A,#N/A,"12/21/2015 OPK-US   BW   OPKO’s GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer Panel Reveals New Risks", 6/22/2010 46222210    BW,#N/A, 6/28/2018 ALXN-US  BW   Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU),#N/A,11/05/2018 SGEN-US     BW   Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas,#N/A," 6/23/2017 09062X10    BW   Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use",10/05/2017 IMGN-US  BW   ImmunoGen Announces Pricing of Public Offering of Common Stock," 9/01/2011 4502-JP  BW   Takeda’s Uloric Continues to Make Inroads among Moderate to Severe Gout Patients, but Allopurinol Holds a Vast Market Share Lead Overall According to Latest BioTrends Report", 5/08/2019 GILD-US      BW   Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease,#N/A,#N/A,10/16/2013 M2572210 BW   Compugen Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate,11/15/2013 002VHL-E  BW   Akorn Acquires Three Branded Ophthalmic Products from Merck, 3/04/2013 07G69B-E     BW   Research and Markets: The Osteoporosis Market Outlook to 2021," 5/19/2010 PRU-GB      BW   Zacks Bull and Bear of the Day Highlights: Capella, Myriad Genetics Inc., American International Group Inc., Prudential PLC and MetLife Inc.",#N/A,#N/A,#N/A, 2/08/2018 05156V10 BW   Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors,#N/A,#N/A,#N/A, 1/10/2011 RICHT-HU     BW, 6/14/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference,#N/A,"10/21/2018 INCY-US  BW   Incyte veröffentlicht positive Interimsdaten aus einer Phase-2-Studie zu Pemigatinib, seinem selektiven FGFR-Hemmer bei Patienten mit Cholangiokarzinom",#N/A,10/01/2015 SRPT-US  BW   Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher, 3/27/2017 ALKS-US  BW   Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting,10/05/2017 CERS-US  BW   Cerus Announces First Biologics License Application Approval for U.S. Blood Center Customer," 8/08/2011 07WD07-E BW   AMAG Pharmaceuticals, Inc. Board of Directors Unanimously Opposes Unsolicited Proposal from MSMB Capital", 7/10/2018 04269E10 BW   ArQule Announces Commencement of Proposed Public Offering of Common Stock,#N/A,#N/A, 3/23/2018 EXEL-US  BW   Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma, 1/30/2017 SAN-FR    BW   Hagens Berman: Insulin Manufacturers Hit with Class-Action Lawsuit over Drug Price Inflation Scheme and RICO Violations – Time to Break up the Insulin Racket, 8/23/2018 VRTX-US   BW   Vertex nomme Ludovic Fenaux au poste de vice-président directeur en charge des opérations commerciales internationales,#N/A,#N/A, 6/01/2018 BLUE-US  BW   Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting, 7/09/2018 ACAD-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors,#N/A,#N/A,#N/A, 2/20/2018 TXMD-US  BW   TherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A," 5/07/2018 OMER-US  BW   Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018", 2/28/2018 76133010 BW   Revance Releases Fourth Quarter and Full Year 2017 Results,#N/A, 2/15/2018 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update,#N/A,#N/A,#N/A, 4/09/2012 LIFE.XX5-US BW   NanoString Technologies Names Joseph M. Beechem Senior Vice President of R&D,#N/A,12/10/2017 SYRS-US  BW   Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients,#N/A,#N/A, 7/27/2011 00182C10     BW   BioSante Pharmaceuticals Announces Proposed Public Offering of Common Stock," 4/20/2017 ENTA-US    BW   Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)", 1/14/2019 ALNY-US   BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,"12/05/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Submission of Prior Approval Supplement for Additional EXPAREL® Manufacturing Suite", 1/07/2014 RTRX-US  BW   Retrophin Announces Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 4/03/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/08/2018 SAGE-US     BW   Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2016 INVA-US     BW   Innoviva Reports Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A, 2/02/2012 56400P70 BW   MannKind Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock,#N/A,#N/A," 7/11/2013 29664W10    BW   Esperion Therapeutics, Inc. Announces Exercise of Underwriters’ Over-Allotment Option for Initial Public Offering",11/01/2011 03236M20 BW   Amyris Receives Approval for R$ 22 Million Funding from Brazil’s Development Bank,#N/A,#N/A,#N/A,#N/A, 9/20/2017 4582-JP  BW   Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited,#N/A,#N/A,#N/A, 9/26/2015 EPZM-US  BW   Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors,#N/A,#N/A,#N/A,#N/A,#N/A, 6/25/2018 VCYT-US  BW   Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year, 7/11/2018 DRNA-US  BW   Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU,11/09/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 4/04/2013 00BBFF-E BW   Agios Publishes Two Articles in Science Demonstrating the Effects of Mutant IDH1 and IDH2 Inhibitors in Primary Tumor Models,#N/A,#N/A, 5/01/2018 XLRN-US  BW   Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD),#N/A,12/17/2018 HZNP-US  BW   Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference, 3/20/2017 00BJ80-E  BW   Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma,#N/A,#N/A, 5/17/2017 GLYC-US  BW   GlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia,#N/A,#N/A,#N/A, 2/22/2018 G6674U10 BW   Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update,#N/A,#N/A,#N/A, 5/11/2018 RCKT-US  BW   Rocket Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2018 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2016 MCRB-US  BW   Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update,11/28/2018 00900T10 BW   Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2017 QTRX-US  BW   Quanterix Corporation Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A, 7/01/2013 30233G10 BW   pSivida Corp. Announces Initiation of Phase III Clinical Trial in Posterior Uveitis,#N/A,#N/A,12/05/2018 AXNX-US  BW   Axonics® gibt am 11. Dezember die Ergebnisse des dritten Quartals 2018 und ein Update zur Geschäftsentwicklung bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2017 00FLML-E BW   Oxford Genetics Licenses SnapFast Expression Vectors to Twist Bioscience,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/07/2017 00DD8T-E BW   Personalis Wins New Contract to Sequence >34,000 Whole Human Genomes for the VA’s Million Veteran Program",#N/A,#N/A,#N/A,#N/A,#N/A
"10/04/2017 LGND-US   BW   Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments",#N/A, 1/09/2018 ILMN-US     BW   Helix To Help Expand Healthy Nevada Project, 2/05/2018 84763A10  BW   Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study,#N/A, 6/27/2018 ARWR-US  BW   Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A,12/09/2015 OPK-US   BW   OPKO’s GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders, 6/22/2010 46222210    BW,#N/A, 6/19/2018 ALXN-US  BW   Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.,#N/A,11/01/2018 SGEN-US     BW   Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program,#N/A," 6/20/2017 09062X10    BW   Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017",10/04/2017 IMGN-US  BW   ImmunoGen Announces Proposed Public Offering of Common Stock, 8/04/2011 09058V10 BW   CORRECTING and REPLACING BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results," 5/06/2019 GILD-US      BW   Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14",#N/A,#N/A,10/09/2013 M2572210 BW   Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model,11/05/2013 00972810  BW   Akorn Reports Third Quarter 2013 Financial Results, 2/28/2013 07G69B-E     BW   Research and Markets: The Osteoporosis Market Forecast to 2021," 5/12/2010 BKNG-US     BW   Zacks Bull and Bear of the Day Highlights: Chipotle Mexican Grill, Myriad Genetics Inc., Apple, China Mobile and Priceline.com",#N/A,#N/A,#N/A, 2/06/2018 05156V10 BW   Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference,#N/A,#N/A,#N/A, 1/10/2011 37416310     BW   Geron Announces Publication Demonstrating Activity of Imetelstat Against Cancer Stem Cells From Pediatric Neural Tumors, 6/06/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference,#N/A,"10/21/2018 INCY-US  BW   Incyte annonce des résultats intermédiaires positifs de l'essai de phase II du Pemigatinib, son inhibiteur sélectif de FGFR, chez les patients atteints de cholangiocarcinome",#N/A,10/01/2015 SRPT-US  BW   Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy, 3/20/2017 ALKS-US  BW   Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research,10/02/2017 CERS-US  BW   Cerus Announces Schedule of Presentations at the 2017 AABB Annual Meeting, 8/03/2011 07WD07-E BW   MSMB Capital Proposes Acquisition of Amag Pharmaceuticals for $18 Per Share, 6/25/2018 0BWGV3-E BW   ArQule Added to the Russell 2000® Index,#N/A,#N/A, 3/15/2018 EXEL-US  BW   Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma, 1/02/2017 09BQTY-E  BW   Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017," 8/23/2018 VRTX-US   BW   Vertex beruft Ludovic Fenaux zum Senior Vice President, International Commercial Operations",#N/A,#N/A, 5/23/2018 BLUE-US  BW   FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy, 6/29/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin),#N/A,#N/A,#N/A, 2/06/2018 TXMD-US  BW   TherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20,#N/A,#N/A, 4/26/2018 OMER-US  BW   FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy," 2/22/2018 76133010 BW   Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018",#N/A, 2/01/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call,#N/A,#N/A,#N/A, 3/30/2012 065C1X-E    BW   NanoString Introduces Three New Products at AACR Annual Meeting,#N/A,"12/07/2017 SYRS-US  BW   Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium",#N/A,#N/A, 7/25/2011 00182C10     BW   BioSante Pharmaceuticals Reports Second Quarter 2011 Financial Results, 4/19/2017 ENTA-US    BW   Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017, 1/07/2019 ALNY-US   BW   Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates,#N/A,#N/A,#N/A,"11/25/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference","12/17/2013 RTRX-US  BW   Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog",#N/A,#N/A,#N/A,#N/A,#N/A, 3/23/2018 AKBA-US  BW   Akebia Therapeutics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 6/07/2018 0HVBJ7-E    BW   Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2016 INVA-US     BW   Innoviva to Report Third Quarter 2016 Financial Results on October 27 at 5:00 p.m. EDT,#N/A,#N/A,#N/A, 1/31/2012 56400P70 BW   MannKind Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock,#N/A,#N/A," 6/26/2013 29664W10    BW   Esperion Therapeutics, Inc. Announces Pricing of Initial Public Offering",11/01/2011 03236M20 BW   Amyris recebe aprovação para financiamento de R$ 22 milhões do Banco Nacional de Desenvolvimento Econômico e Social do Brasil,#N/A,#N/A,#N/A,#N/A," 9/06/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at September Investor Conferences",#N/A,#N/A,#N/A," 8/31/2015 EPZM-US  BW   Epizyme, Inc. to Present at Upcoming Events in September",#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2018 VCYT-US  BW   Veracyte to Present at the William Blair 38th Annual Growth Stock Conference, 6/19/2018 0BWGV3-E BW   Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes,11/09/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 4/04/2013 00BBFF-E BW   Foundation Medicine and Agios Announce Diagnostic Discovery Collaboration for IDH1 and IDH2 Cancer Metabolism Programs,#N/A,#N/A," 4/30/2018 XLRN-US  BW   Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018",#N/A,11/16/2018 HZNP-US  BW   Horizon Pharma plc to Participate in Upcoming Conferences, 1/23/2017 00BJ80-E  BW   Study Demonstrates that DecisionDx-Melanoma Test Improves Identification of High Risk Skin Melanoma When Used with AJCC Outcome Prediction Tool,#N/A,#N/A, 5/08/2017 GLYC-US  BW   GlycoMimetics Reports Program Updates and First Quarter 2017 Results,#N/A,#N/A,#N/A, 2/07/2018 G6674U10 BW   Novocure Secures New $150 Million Non-Dilutive Term Loan Financing,#N/A,#N/A,#N/A, 5/08/2018 RCKT-US  BW   Rocket Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2018 74587V10 BW   European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,"11/09/2016 MCRB-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2016",11/18/2018 00900T10 BW   Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the UBS 2017 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2017 009FRV-E BW   Quanterix Corporation Announces Launch of Initial Public Offering,#N/A,#N/A,#N/A, 6/14/2013 30233G10 BW   pSivida Corp. Announces UK’s NICE Says Yes to ILUVIEN® in Some Patients with Diabetic Macular Edema in New Draft Guidance,#N/A,#N/A,12/05/2018 AXNX-US  BW   Axonics® va déclarer ses résultats pour le troisième trimestre 2018 et faire le point sur ses activités le 11 décembre,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/03/2017 00FLML-E BW   Twist Bioscience to Provide One Billion Base Pairs of Synthetic DNA to Ginkgo Bioworks to Support Expansion into New Industries,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/24/2017 00DD8T-E BW   Personalis, Inc. Receives Approval from the New York State Department of Health for Clinical Tests Based on the ACE Exome",#N/A,#N/A,#N/A,#N/A,#N/A
 9/25/2017 LGND-US   BW   Ligand to Host Analyst Day on November 14th in New York City,#N/A, 1/08/2018 45232710    BW   Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology, 1/23/2018 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital Markets' Fourteenth Annual Investor Conference,#N/A, 6/18/2018 ARWR-US  BW   Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A,12/02/2015 OPK-US   BW   OPKO Health to Present at the Oppenheimer 26th Annual Healthcare Conference, 5/27/2010 46222210    BW,#N/A, 6/14/2018 ALXN-US  BW   Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA),#N/A,10/26/2018 SGEN-US     BW   Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018,#N/A," 6/20/2017 09062X10    BW   Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer", 9/05/2017 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences," 7/26/2011 09058V10 BW   BioCryst Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011", 5/02/2019 GILD-US      BW   Gilead Sciences Announces Second Quarter 2019 Dividend,#N/A,#N/A, 9/17/2013 M2572210 BW   Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types Involved in Tumor Progression,10/28/2013 00972810  BW   Akorn Announces Certain Preliminary Financial Results for Q3 2013, 2/21/2013 ARIA-US      BW   ARIAD annonce la nomination du directeur général européen et d'autres membres importants de la haute direction,#N/A,#N/A,#N/A,#N/A, 1/04/2018 05156V10 BW   Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus,#N/A,#N/A,#N/A," 1/07/2011 37416310     BW   Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Geron Corporation, Announces Class Action Lawsuit and Seeks to Recover Losses", 5/31/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference,#N/A,"10/21/2018 INCY-US  BW   Incyte annuncia dati intermedi positivi dello studio di fase 2 su pemigatinib, il suo inibitore selettivo dell'FGFR, nei pazienti con colangiocarcinoma",#N/A, 9/30/2015 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 3/16/2017 ALKS-US  BW   Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis," 9/20/2017 CERS-US  BW   Cerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017"," 8/02/2011 07WD07-E BW   AMAG Pharmaceuticals, Inc. Receives Unsolicited Proposal from MSMB Capital Management"," 6/15/2018 04269E10 BW   ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531",#N/A,#N/A, 3/06/2018 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in March,12/15/2016 MRK-US    BW   ABIVAX Appoints Didier Blondel as Chief Financial Officer," 8/23/2018 VRTX-US   BW   Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations",#N/A,#N/A, 5/17/2018 BLUE-US  BW   bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association," 6/13/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018",#N/A,#N/A,#N/A, 1/03/2018 TXMD-US  BW   TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10,#N/A,#N/A, 4/19/2018 OMER-US  BW   Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting, 2/14/2018 76133010 BW   Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference,#N/A, 1/16/2018 IRWD-US  BW   Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation,#N/A,#N/A,#N/A,12/08/2011 065C1X-E    BW   NanoString Technologies Announces Positive Results From First Validation Study of PAM50-based Breast Cancer Assay,#N/A,11/21/2017 SYRS-US  BW   Syros to Present at 29th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A, 7/21/2011 00182C10     BW   BioSante Pharmaceuticals Signs Melanoma Vaccine License," 4/18/2017 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017",12/28/2018 ALNY-US   BW   Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,"11/01/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at November Investor Conferences",12/16/2013 0D0JWQ-E BW   Retrophin Withdraws Offer for Transcept Pharmaceuticals,#N/A,#N/A,#N/A,#N/A,#N/A, 3/22/2018 AKBA-US  BW   Akebia Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 6/04/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2016 INVA-US     BW   Innoviva to Present at Morgan Stanley Global Healthcare Conference and Rodman & Renshaw 19th Annual Global Investment Conference,#N/A,#N/A,#N/A, 1/05/2012 56400P70 BW   MannKind to Present at 30th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 6/07/2013 ESPR.XX1-US BW   Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of Novel Oral Therapy in Patients with Hypercholesterolemia and a History of Statin Intolerance,10/28/2011 03236M20 BW   Amyris and Method Partner to Develop Renewable Ingredients for Household & Personal Care Products,#N/A,#N/A,#N/A,#N/A, 9/05/2017 EGRX-US  BW   Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure,#N/A,#N/A,#N/A, 8/24/2015 EPZM-US  BW   Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2018 VCYT-US  BW   Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis, 5/30/2018 DRNA-US  BW   Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial,10/03/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 2/26/2013 00BBFF-E BW   Agios Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference,#N/A,#N/A, 4/26/2018 XLRN-US  BW   Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting,#N/A,11/07/2018 HZNP-US  BW   Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance, 1/17/2017 06400C-E  BW   Castle Biosciences’ New Laboratory Receives Accreditation from College of American Pathologists,#N/A,#N/A, 5/02/2017 GLYC-US  BW   GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma,#N/A,#N/A,#N/A, 2/01/2018 G6674U10 BW   JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients,#N/A,#N/A,#N/A, 4/30/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2018 74587V10 BW   Puma Biotechnology Reports Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,"11/04/2016 MCRB-US  BW   Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016",11/12/2018 AIMT-US  BW   Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2017 RARX-US  BW   Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2017 009FRV-E BW   Quanterix to Showcase New SR-X Ultra-Sensitive Biomarker Detection System™ at Neuroscience 2017,#N/A,#N/A,#N/A, 5/29/2013 30233G10 BW   pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company,#N/A,#N/A,12/04/2018 AXNX-US  BW   Axonics® dépose auprès de la Food and Drug Administration américaine une demande d'approbation préalable à la commercialisation de son système de neuromodulation sacrée,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/29/2017 00FLML-E BW   Twist Bioscience and Collaborators Microsoft, University of Washington Preserve Archive-Quality Audio Recordings for UNESCO’s Memory of the World Collection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2017 00DD8T-E BW   Personalis Inc. Orders Ten Illumina NovaSeqTM 6000 Systems for Immuno-Oncology Genomics and Large-Scale Whole Genome Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A
 9/05/2017 LGND-US   BW   Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes,#N/A, 1/08/2018 45232710    BW   Illumina Launches iSeq 100 Sequencing System,12/17/2017 SPPI-US   BW   Spectrum Pharmaceuticals Announces Leadership Changes,#N/A, 6/08/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,11/17/2015 OPK-US   BW   OPKO Health to Present at the Jefferies Autumn 2015 Global Healthcare Conference, 4/15/2010 46222210    BW,#N/A, 6/11/2018 ALXN-US  BW   Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders,#N/A,10/25/2018 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2018 Financial Results,#N/A," 6/14/2017 09062X10    BW   Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations", 9/01/2017 IMGN-US  BW   ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock, 6/27/2011 09058V10 BW   Kenneth Lee Appointed to BioCryst Pharmaceuticals’ Board of Directors, 5/02/2019 GILD-US      BW   Gilead Sciences Announces First Quarter 2019 Financial Results,#N/A,#N/A, 8/26/2013 M2572210 BW   Compugen Establishes Scientific Advisory Board to Guide Pipeline Program Development, 8/27/2013 HITK-US   BW   Akorn to Acquire Hi-Tech Pharmacal for $640 Million," 2/14/2013 07G69B-E     BW   Research and Markets: Global and Chinese Monoclonal Antibody Industry Report, 2013",#N/A,#N/A,#N/A,#N/A,12/11/2017 05156V10 BW   Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index,#N/A,#N/A,#N/A, 1/07/2011 37416310     BW   Geron to Present at J.P. Morgan Annual Healthcare Conference," 5/30/2018 0F0P74-E   BW   Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management",#N/A,"10/21/2018 INCY-US  BW   Incyte maakt positieve tussentijdse gegevens bekend van Fase 2-onderzoek van pemigatinib, haar selectieve FGFR-remmer, bij patiënten met cholangiocarcinoom",#N/A," 9/30/2015 SRPT-US  BW   Sarepta Therapeutics Announces Appointment of Jean-Paul Kress, M.D. to the Company’s Board of Directors", 3/07/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference, 8/30/2017 CERS-US  BW   Cerus to Present at Two Upcoming Conferences," 8/01/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. Appoints Frank E. Thomas as Executive Vice President and Chief Financial Officer"," 6/14/2018 04269E10 BW   ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018",#N/A,#N/A, 2/26/2018 4568-JP  BW   Exelixis Announces Collaborator Daiichi Sankyo’s Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan,12/07/2016 0GBP93-E  BW   Cancer de la prostate : Une bande dessinée pour briser les tabous, 8/20/2018 VRTX-US   BW   Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation,#N/A,#N/A, 5/16/2018 BLUE-US  BW   bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting," 6/06/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018",#N/A,#N/A,#N/A,12/28/2017 TXMD-US  BW   TherapeuticsMD Announces Submission of New Drug Application for TX-001HR,#N/A,#N/A, 4/13/2018 OMER-US  BW   Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting, 2/01/2018 RVNC-US  BW   Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018,#N/A, 1/02/2018 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,11/07/2011 065C1X-E    BW   NanoString Secures $20M in Series D Financing,#N/A,11/13/2017 SYRS-US  BW   Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium,#N/A,#N/A, 7/18/2011 00182C10     BW   BioSante Pharmaceuticals Announces Management Team Additions, 4/05/2017 ENTA-US    BW   Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017,"12/20/2018 ALNY-US   BW   Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders",#N/A,#N/A,#N/A,"10/31/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results",12/12/2013 RTRX-US  BW   Retrophin Announces Agreement to Acquire Kyalin Biosciences,#N/A,#N/A,#N/A,#N/A,#N/A, 3/21/2018 AKBA-US  BW   Akebia Therapeutics to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 5/30/2018 SAGE-US     BW   Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2016 INVA-US     BW   GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress,#N/A,#N/A,#N/A, 1/04/2012 0098J6-E BW   Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer,#N/A,#N/A, 5/02/2013 ESPR.XX1-US BW   CORRECTING and REPLACING Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Percent in Hypercholesterolemic Patients with Type 2 Diabetes,10/20/2011 03236M20 BW   Amyris & ETH Bioenergia Sign Agreement to Produce Biofene® in Brazil,#N/A,#N/A,#N/A,#N/A," 8/09/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results",#N/A,#N/A,#N/A, 8/06/2015 EPZM-US  BW   Epizyme Announces Second Quarter 2015 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2018 VCYT-US  BW   Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis, 5/29/2018 DRNA-US  BW   Dicerna to Present at the Jefferies 2018 Global Healthcare Conference,10/03/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 2/22/2013 00BBFF-E BW   Agios to Present IDH Program Insights at Tumor Metabolism Keystone Symposia,#N/A,#N/A, 4/26/2018 XLRN-US  BW   Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting,#N/A,11/02/2018 HZNP-US  BW   The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace,11/22/2016 PIPR-US   BW   Castle Biosciences to Present at the Piper Jaffray 28th Annual Healthcare Conference,#N/A,#N/A, 4/20/2017 GLYC-US  BW   GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting,#N/A,#N/A,#N/A, 1/09/2018 G6674U10 BW   Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue,#N/A,#N/A,#N/A, 3/06/2018 RCKT-US  BW   Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2018 74587V10 BW   Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada,#N/A,#N/A,#N/A,#N/A,#N/A,"10/31/2016 MCRB-US  BW   Seres Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors",11/08/2018 00900T10 BW   Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2017 RARX-US  BW   Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2017 009FRV-E BW   Quanterix to Host Webinar on Predicting the Progression of Neurodegeneration with a Blood Test,#N/A,#N/A,#N/A, 5/13/2013 30233G10 BW   pSivida Corp. Reports Third Quarter Fiscal Year 2013 Results,#N/A,#N/A,12/04/2018 AXNX-US  BW   Axonics® to Report Third Quarter 2018 Results and Provide Business Update on December 11,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2017 00FLML-E BW   Twist Bioscience collabore avec Microsoft et l’Université de Washington afin de préserver des enregistrements audio de qualité archive pour la Collection Mémoire du Monde de l’UNESCO,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2016 00DD8T-E BW   Personalis Launches Report Providing In-Depth Characterization of Tumor Neoantigen Peptides,#N/A,#N/A,#N/A,#N/A,#N/A
 9/01/2017 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A, 1/04/2018 07MCDV-E    BW   Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval,12/13/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH),#N/A, 5/30/2018 ARWR-US  BW   Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A,11/16/2015 OPK-US   BW   OPKO Licensee TESARO Announces the Launch of VARUBI(TM) (Rolapitant) in the United States, 3/29/2010 46222210    BW,#N/A, 6/05/2018 ALXN-US  BW   Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference,#N/A,10/08/2018 GMAB-DK     BW   Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress,#N/A, 6/13/2017 09062X10    BW   Biogen Announces Management Change," 8/29/2017 IMGN-US  BW   Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products", 5/31/2011 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences, 4/30/2019 GILD-US      BW   Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020,#N/A,#N/A," 8/05/2013 CGEN-IL  BW   Compugen Second Quarter 2013 Conference Call Scheduled for Wednesday, August 7, 2013 at 10:00 AM EDT", 8/06/2013 00972810  BW   Akorn Reports Second Quarter 2013 Financial Results, 1/24/2013 0835JB-E     BW   BIO-Europe Spring® 2013 à Barcelone aura comme intervenants au programme des cadres dirigeants de premier rang,#N/A,#N/A,#N/A,#N/A,11/14/2017 05156V10 BW   Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights,#N/A,#N/A,#N/A,12/27/2010 37416310     BW   Shareholder Claims Against Geron Corporation Investigated by Goldfarb Branham LLP, 5/15/2018 AERI-US    BW   Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,#N/A,"10/21/2018 INCY-US  BW   Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma",#N/A, 9/30/2015 SRPT-US  BW   Sarepta Therapeutics Announces USPTO Decision in Patent Interference Case with BioMarin Pharmaceutical, 2/28/2017 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference, 8/03/2017 CERS-US  BW   Cerus Corporation Reports Second Quarter 2017 Results," 7/26/2011 00163U10 BW   AMAG Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2011"," 6/07/2018 04269E10 BW   ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)",#N/A,#N/A, 2/26/2018 EXEL-US  BW   Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update,12/05/2016 0GBP93-E  BW   Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma, 8/16/2018 VRTX-US   BW   Vertex Awards Two College Students Full Scholarships to the University of Massachusetts,#N/A,#N/A, 5/08/2018 BLUE-US  BW   bluebird bio to Present at Investor Conferences in May, 5/08/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018,#N/A,#N/A,#N/A,12/19/2017 TXMD-US  BW   TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR,#N/A,#N/A, 4/12/2018 OMER-US  BW   OMIDRIA® Added to Veterans Health Administration National Formulary, 1/08/2018 76133010 BW   Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis,#N/A,12/21/2017 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease,#N/A,#N/A,#N/A,"11/07/2011 GE-US       BW   GE healthymagination Fund Invests in NanoString Technologies, a Translational Research Company with Emerging Molecular Diagnostic Applications",#N/A,11/13/2017 SYRS-US  BW   Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer,#N/A,#N/A," 6/07/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Jefferies Global Healthcare Conference", 3/27/2017 ENTA-US    BW   Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference,12/10/2018 ALNY-US   BW   Alnylam Announces Settlement of Litigation with Silence Therapeutics,#N/A,#N/A,#N/A,"10/17/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call",12/12/2013 RTRX-US  BW   Retrophin to Co-Sponsor Clinical Trial of Intranasal Oxytocin for Schizophrenia,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2018 AKBA-US  BW   Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A, 5/23/2018 SAGE-US     BW   Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2016 GSK-GB      BW   Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress,#N/A,#N/A,#N/A,12/13/2011 56400P70 BW   MannKind Resolves All Claims in Arbitration with Former Employee,#N/A,#N/A, 4/25/2013 ESPR.XX1-US BW   Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials,"10/18/2011 03236M20 BW   Amyris to Announce 2011 Third Quarter Financial Results on Tuesday, November 1",#N/A,#N/A,#N/A,#N/A," 7/31/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2017 Financial Results on August 9, 2017",#N/A,#N/A,#N/A, 8/05/2015 EPZM-US  BW   Epizyme Appoints Robert Bazemore President and Chief Executive Officer,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2018 VCYT-US  BW   Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF, 5/14/2018 DRNA-US  BW   Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update, 9/19/2018 15117K10 BW   CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board,#N/A,#N/A,#N/A, 2/13/2013 00BBFF-E BW   New Publication in Science Shows That Agios IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2-HG in Leukemia Model,#N/A,#N/A, 3/12/2018 XLRN-US  BW   Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial,#N/A,10/29/2018 HZNP-US  BW   Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting,11/17/2016 CF.PRA-CA BW   Castle Biosciences to Present at the Canaccord Genuity 2016 Medical Technology & Diagnostics Forum,#N/A,#N/A, 3/22/2017 GLYC-US  BW   Biotech Leader Testifies Before House Capital Markets Subcommittee,#N/A,#N/A,#N/A,12/20/2017 NVCR-US  BW   JAMA veröffentlicht die Schlussanalyse der zulassungsrelevanten Phase-3-Studie EF-14 zu Optune® gemeinsam mit Temozolomid; die Daten belegen das beispiellose Überleben beim neu diagnostizierten Glioblastom,#N/A,#N/A,#N/A, 3/05/2018 RCKT-US  BW   Rocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 7/26/2018 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,"10/05/2016 MCRB-US  BW   EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm",11/08/2018 00900T10 BW   Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2017 RARX-US  BW   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/15/2017 009FRV-E BW   Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection,#N/A,#N/A,#N/A, 5/07/2013 30233G10 BW   pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient Treated,#N/A,#N/A,12/04/2018 AXNX-US  BW   Axonics® Files for Premarket Approval with U.S. Food & Drug Administration for its Sacral Neuromodulation System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/13/2016 00DD8T-E BW   Personalis Announces Scaling Sequencing Capacity, Information Systems and Operations to Support Immuno-Oncology Clinical Trials for 2017",#N/A,#N/A,#N/A,#N/A,#N/A
 8/21/2017 LGND-US   BW   Ligand Appoints Dr. Nancy Gray to its Board of Directors,#N/A,12/19/2017 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentations,"12/04/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017",#N/A, 5/30/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences,#N/A,#N/A,#N/A,#N/A,11/12/2015 OPK-US   BW   OPKO 4Kscore Test Receives Category I CPT Code Approval, 3/17/2010 46222210    BW,#N/A, 5/25/2018 ALXN-US  BW   Alexion Offer for Wilson Therapeutics Accepted,#N/A,10/03/2018 4502-JP     BW   Takeda und Seattle Genetics veröffentlichen positive Ergebnisse aus der klinischen ECHELON-2-Studie der Phase 3 zur Evaluierung von ADCETRIS® (Brentuximab Vedotin) bei der Erstbehandlung des...,#N/A, 6/01/2017 BIIB-US     BW   SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy, 8/01/2017 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference, 5/26/2011 09058V10 BW   BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology, 4/25/2019 GILD-US      BW   Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH),#N/A,#N/A, 8/05/2013 07RWL7-E BW   Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies, 5/07/2013 00972810  BW   Akorn Reports First Quarter 2013 Financial Results," 1/17/2013 07GVF3-E     BW   Research and Markets: Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.",#N/A,#N/A,#N/A,#N/A,"11/06/2017 05156V10 BW   Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017",#N/A,#N/A,#N/A,12/23/2010 37416310     BW   Hagens Berman Investigates Geron Corporation for Securities Violations, 5/08/2018 AERI-US    BW   Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update,#N/A,10/19/2018 INCY-US  BW   Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC,#N/A, 9/25/2015 SRPT-US  BW   Sarepta Therapeutics Announces Corporate Update and Report on Recent Data from Phase IIb Study of Eteplirsen for Duchenne Muscular Dystrophy," 2/15/2017 ALKS-US  BW   Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017", 8/02/2017 CERS-US  BW   Cerus Enters Into $40 Million Amended Growth Capital Agreement," 7/22/2011 00163U10 BW   AMAG Pharmaceuticals to Host Conference Call on July 26, 2011 at 4:30 p.m. ET to Discuss Financial Results for the Second Quarter and Six Months Ended June 30, 2011"," 5/31/2018 04269E10 BW   ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018",#N/A,#N/A," 2/14/2018 EXEL-US  BW   Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018",11/04/2016 0GBP93-E  BW   Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease, 8/15/2018 VRTX-US   BW   FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene,#N/A,#N/A, 5/02/2018 BLUE-US  BW   bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress, 5/04/2018 ACAD-US  BW   ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results,#N/A,#N/A,#N/A,11/29/2017 TXMD-US  BW   TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR,#N/A,#N/A, 4/11/2018 OMER-US  BW   Omeros Announces Amendment of Credit Facility, 1/04/2018 76133010 BW   Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018,#N/A,"12/04/2017 IRWD-US  BW   Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects",#N/A,#N/A,#N/A,10/12/2011 065C1X-E    BW   NanoString Announces Launch of Second Generation nCounter Analysis System,#N/A,11/08/2017 SYRS-US  BW   Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones,#N/A,#N/A, 6/06/2011 06R5X7-E     BW   BioSante Pharmaceuticals Announces Lifting of Clinical Hold on GVAX Prostate Cancer Vaccine," 3/14/2017 ABBV-US    BW   Enanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C",12/06/2018 ALNY-US   BW   Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day,#N/A,#N/A,#N/A,"10/01/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace",12/12/2013 0D0JWQ-E BW   Retrophin Signs U.S. License Agreement for Syntocinon™ Nasal Spray (Oxytocin),#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2018 AKBA-US  BW   Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast,#N/A,#N/A,#N/A,#N/A, 5/08/2018 SAGE-US     BW   Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2016 INVA-US     BW   Innoviva to Present at Wells Fargo and Baird Healthcare Conferences in Early September,#N/A,#N/A,#N/A,11/08/2011 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A,#N/A, 9/28/2011 03236M20 BW   Michelin et Amyris s’associent en vue de développer et de commercialiser de l'isoprène renouvelable,#N/A,#N/A,#N/A,#N/A, 7/26/2017 EGRX-US  BW   Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application,#N/A,#N/A,#N/A," 8/04/2015 EPZM-US  BW   Epizyme, Inc. to Present at 2015 Wedbush PacGrow Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2018 VCYT-US  BW   Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress," 5/07/2018 DRNA-US  BW   Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018"," 9/19/2018 15117K10 BW   Le Dr. Stephan A. Grupp, pionnier des CAR-T, rejoint le conseil scientifique de Cellectis",#N/A,#N/A,#N/A, 2/06/2013 00BBFF-E BW   Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference,#N/A,#N/A, 2/28/2018 XLRN-US  BW   Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve,#N/A,10/25/2018 HZNP-US  BW   Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity,11/14/2016 0B2HRB-E  BW   Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma,#N/A,#N/A, 3/13/2017 MGNX-US  BW   GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors,#N/A,#N/A,#N/A,12/20/2017 G6674U10 BW   Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 2/07/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 7/17/2018 0G3F3C-E BW   Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial),#N/A,#N/A,#N/A,#N/A,#N/A,"10/03/2016 MCRB-US  BW   SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",11/02/2018 00900T10 BW   Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 RARX-US  BW   Ra Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2017 009FRV-E BW   Quanterix Raises $8.5 Million in Private Financing Led by T. Rowe Price Associates; Also Appoints Dr. Marijn Dekkers to Company’s Board of Directors and Several Key Executives to Its Leadership Team,#N/A,#N/A,#N/A, 5/06/2013 30233G10 BW   pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call Information,#N/A,#N/A,11/29/2018 AXNX-US  BW   Axonics® annonce l’entrée de son système de neuromodulation sacrée dans la chaîne d’approvisionnement du Service national de santé au Royaume-Uni,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2016 06GTQW-E BW   Personalis Awarded US Department of Veterans Affairs Contract for Whole Genome Sequencing and Data Analysis for the Million Veteran Program,#N/A,#N/A,#N/A,#N/A,#N/A
 8/18/2017 002437-CN BW   Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology,#N/A,"12/11/2017 45232710    BW   Illumina Names Aimee Hoyt Chief People Officer, Bringing 20+ Years of Senior Human Resources Leadership from Global Technology Companies",11/08/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th,#N/A, 5/21/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,11/09/2015 68375N10 BW   OPKO Announces Third Quarter Financial and Operating Results, 3/15/2010 46222210    BW,#N/A," 5/24/2018 NPSP-US  BW   Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors",#N/A,"10/03/2018 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018",#N/A, 5/31/2017 09062X10    BW   Biogen Announces Webcast of Virtual Annual Meeting of Stockholders, 7/28/2017 IMGN-US  BW   ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results, 5/25/2011 002VHL-E BW   BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer, 4/24/2019 KITE-US      BW   Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities,#N/A,#N/A, 7/17/2013 M2572210 BW   Compugen Discloses Predictive Structural Biology Infrastructure Platform for Enhanced Discovery of Novel Drugs, 2/26/2013 00972810  BW   Akorn Reports 2012 Fourth Quarter and Year-End Financial Results, 1/14/2013 0C8BZH-E     BW   RBCC Explores ‘Target-Rich Environment’ as Biotechnology Takes Over San Francisco,#N/A,#N/A,#N/A,#N/A,10/20/2017 05156V10 BW   Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome,#N/A,#N/A,#N/A,12/22/2010 37416310     BW   Bernstein Liebhard LLP Announces Class Action Filed on Behalf of Investors in Geron Corporation, 5/01/2018 05Z5D4-E   BW   Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel,#N/A,10/11/2018 INCY-US  BW   Incyte to Report Third Quarter Financial Results,#N/A, 9/10/2015 SRPT-US  BW   Sarepta Therapeutics to Present Company Overview at the 2015 Morgan Stanley Global Healthcare Conference, 2/08/2017 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results, 8/01/2017 CERS-US  BW   Cerus Announces Expanded Supply Agreement with French National Blood Service," 7/21/2011 AMAG-US  BW   The Law Firm of Weiss & Lurie Announces Investigation of Allos Therapeutics, Inc.", 5/24/2018 04269E10 BW   ArQule Strengthens Executive Team with Two Key Appointments,#N/A,#N/A, 2/13/2018 EXEL-US  BW   Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma,10/06/2016 0GBP93-E  BW   BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine® (sargramostim) for Potential Public Health Emergency, 8/07/2018 VRTX-US   BW   FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease,#N/A,#N/A, 4/18/2018 BLUE-US  BW   bluebird bio gibt im New England Journal of Medicine veröffentlichte Zwischendaten aus zwei klinischen Studien der Phase I/II zur LentiGlobinTM-Gentherapie bei Patienten mit transfusionsabhängiger β-Thalassämie bekannt," 5/02/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations",#N/A,#N/A,#N/A,11/07/2017 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A, 3/01/2018 OMER-US  BW   Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results,12/11/2017 76133010 BW   Revance Announces Closing of Public Offering of Common Stock,#N/A,11/28/2017 IRWD-US  BW   Ironwood Pharmaceuticals Strengthens Executive Leadership Team,#N/A,#N/A,#N/A, 9/21/2011 065C1X-E    BW   NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels,#N/A,11/01/2017 SYRS-US  BW   Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting,#N/A,#N/A, 5/31/2011 00182C10     BW   BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Safety Study, 2/27/2017 ABBV-US    BW   Enanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C,11/29/2018 ALNY-US   BW   Alnylam to Webcast R&D Day,#N/A,#N/A,#N/A," 9/12/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of Directors","11/18/2013 RTRX-US  BW   Retrophin, Inc. Reports Third Quarter 2013 Operational and Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 5/03/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2016 INVA-US     BW   Innoviva Reports Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,11/03/2011 56400P70 BW   MannKind Corporation Reports 2011 Third Quarter Financial Results,#N/A,#N/A,#N/A, 9/28/2011 03236M20 BW   Amyris e Michelin Anunciam Colaboração para Desenvolver e Comercializar Isopreno de Fontes Renováveis,#N/A,#N/A,#N/A,#N/A," 7/25/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke",#N/A,#N/A,#N/A," 7/30/2015 EPZM-US  BW   Epizyme to Report Second Quarter 2015 Financial Results and Provide Corporate Update on August 6, 2015",#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2018 VCYT-US  BW   Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting, 4/20/2018 DRNA-US  BW   Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation," 9/18/2018 ALCLS-FR BW   Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP",#N/A,#N/A,#N/A, 1/28/2013 00BBFF-E BW   Target Cancer Metabolism Conference to Feature Three Presentations by Agios Scientists,#N/A,#N/A, 2/27/2018 XLRN-US  BW   Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results,#N/A,10/25/2018 HZNP-US  BW   Horizon Pharma plc to Participate in Investor Conferences in November,11/10/2016 00BJ80-E  BW   Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management,#N/A,#N/A, 3/07/2017 GLYC-US  BW   GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271,#N/A,#N/A,#N/A,12/19/2017 NVCR-US  BW   JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 1/24/2018 RCKT-US  BW   Rocket Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2018 74587V10 BW   Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,"10/01/2016 MCRB-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm",11/01/2018 00900T10 BW   Aimmune Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2017 RARX-US  BW   Ra Pharma Supports 10th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/18/2017 009FRV-E BW   Quanterix Boosts Investments in its Accelerator Lab to Support Rapid Growth of Simoa Technology,#N/A,#N/A,#N/A," 5/01/2013 30233G10 BW   pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013",#N/A,#N/A,11/29/2018 AXNX-US  BW   Axonics® gibt Aufnahme seines sakralen Neuromodulationssystems in National Health Service Supply Chain bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2016 0D1STZ-E BW   Personalis Announces Partnership with Mt. Sinai Services to Offer its ACE Platform for Next Generation Sequencing and Interpretation to Support Tumor Molecular Profiling and Immuno-Oncology Clinical Trials in Canada,#N/A,#N/A,#N/A,#N/A,#N/A
 8/07/2017 LGND-US   BW   Ligand Reports Second Quarter 2017 Financial Results,#N/A,12/07/2017 DIS-US      BW   Disney Board Elects Oracle’s Safra Catz and Illumina’s Francis A. deSouza as Directors,11/02/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update,#N/A, 5/14/2018 ARWR-US  BW   Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A,11/06/2015 OPK-US   BW   OPKO Health Refinances Bio-Reference Laboratories Credit Facility, 2/10/2010 46222210    BW,#N/A, 5/08/2018 ALXN-US  BW   Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference,#N/A,"10/02/2018 4502-JP     BW   Seattle Genetics e Takeda anunciam resultados positivos da Fase 3 do ensaio clínico ECHELON-2, avaliando o ADCETRIS® (Brentuximab Vedotin) na linha de frente de CD30 - Expressando linfoma de células T periféricas",#N/A," 5/31/2017 BIIB-US     BW   Biogen : Journée mondiale de la Sclérose en Plaques : La sclérose en plaques, parlons-en.", 7/14/2017 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results, 5/04/2011 09058V10 BW   BioCryst Provides Corporate Update and Reports First Quarter 2011 Financial Results," 4/18/2019 GILD-US      BW   Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019",#N/A,#N/A, 7/15/2013 M2572210 BW   Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting, 1/17/2013 00972810  BW   Akorn Provides Financial Guidance for 2013, 1/11/2013 SPPI-US      BW   Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years,#N/A,#N/A,#N/A,#N/A,10/12/2017 06V3WH-E BW   Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America,#N/A,#N/A,#N/A,12/10/2010 37416310     BW   Geron Corporation Announces Closing of Its Public Offering of Common Stock, 4/30/2018 AERI-US    BW   Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%,#N/A,"10/10/2018 INCY-US  BW   Incyte presenta los datos para pemigatinib, su inhibidor selectivo del FGFR, que se darán a conocer en el congreso ESMO 2018",#N/A, 8/31/2015 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 1/03/2017 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference, 7/27/2017 CERS-US  BW   Cerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate, 7/21/2011 0BRX2Y-E BW   Goldfarb Branham Law Firm LLP Investigates Allos Therapeutics Inc Company, 5/07/2018 04269E10 BW   ArQule Reports First Quarter 2018 Financial Results,#N/A,#N/A," 2/08/2018 EXEL-US  BW   Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018"," 9/20/2016 LLY-US    BW   Adocia Launches a New Clinical Study of BioChaperone® Combo, Its Combination of Long-Acting Insulin Glargine and Fast-Acting Insulin Lispro, in People with Type 2 Diabetes", 7/30/2018 VRTX-US   BW   Vertex recibe una opinión positiva del CHMP acerca el uso de SYMKEVI® (tezacaftor /ivacaftor) en pacientes mayores de 12 años que sufren fibrosis quística con determinadas mutaciones del gen CFTR,#N/A,#N/A, 4/18/2018 BLUE-US  BW   Bluebird bio annonce la publication dans la revue scientifique New England Journal of Medicine des données intermédiaires de deux études cliniques de phase 1/2 sur la thérapie génique par LentiGlobinTM chez des patients atteints...," 5/01/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018",#N/A,#N/A,#N/A,11/06/2017 TXMD-US  BW   TherapeuticsMD Announces Third Quarter 2017 Financial Results,#N/A,#N/A," 2/26/2018 OMER-US  BW   Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018",12/07/2017 76133010 BW   Revance Announces Pricing of Public Offering of Common Stock,#N/A,11/02/2017 IRWD-US  BW   Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update,#N/A,#N/A,#N/A, 8/09/2011 065C1X-E    BW   NanoString Introduces Rat miRNA Expression Assays,#N/A,"10/30/2017 SYRS-US  BW   Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference",#N/A,#N/A," 5/18/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences"," 2/08/2017 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016","11/26/2018 ALNY-US   BW   DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,#N/A,#N/A," 8/06/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results","11/18/2013 RTRX-US  BW   Retrophin, Inc. Announces New Hires",#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2018 AKBA-US  BW   Akebia Therapeutics Provides Update on Vadadustat Development Program,#N/A,#N/A,#N/A,#N/A, 5/03/2018 SAGE-US     BW   Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness,#N/A,#N/A,#N/A,#N/A,#N/A, 7/20/2016 INVA-US     BW   Innoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT,#N/A,#N/A,#N/A,"10/28/2011 56400P70 BW   MannKind Corporation to Hold 2011 Third Quarter Financial Results Conference Call on November 3, 2011",#N/A,#N/A,#N/A, 9/28/2011 03236M20 BW   Amyris and Michelin Announce Collaboration to Develop and Commercialize Renewable Isoprene,#N/A,#N/A,#N/A,#N/A," 5/31/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June",#N/A,#N/A,#N/A, 7/09/2015 29428V10 BW   Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 VCYT-US  BW   **UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference, 4/20/2018 DRNA-US  BW   Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam," 9/18/2018 15117K10 BW   Calyxt nomme Jim Blome, ancien Président-directeur général de Bayer CropScience LP, au poste de directeur général",#N/A,#N/A,#N/A," 1/03/2013 00BBFF-E BW   Agios Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference",#N/A,#N/A," 2/20/2018 XLRN-US  BW   Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018",#N/A,10/22/2018 HZNP-US  BW   Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting,10/10/2016 00BJ80-E  BW   Castle Biosciences Announces Launch of New Eye Cancer Test to Measure Expression of PRAME Gene,#N/A,#N/A, 3/01/2017 GLYC-US  BW   GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017,#N/A,#N/A,#N/A,12/18/2017 G6674U10 BW   Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer,#N/A,#N/A,#N/A, 1/23/2018 RCKT-US  BW   Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 6/26/2018 74587V10 BW   Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A," 9/29/2016 MCRB-US  BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",10/15/2018 00900T10 BW   Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2016 RARX-US  BW   Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/26/2017 009FRV-E BW   EY Announces Kevin Hrusovsky, Executive Chairman and Chief Executive Officer of Quanterix, as an Entrepreneur Of The Year® New England 2017 Finalist",#N/A,#N/A,#N/A, 4/29/2013 EYPT-US  BW   pSivida Reports ILUVIEN® Available in UK,#N/A,#N/A,11/29/2018 AXNX-US  BW   Axonics® Announces Listing on the U.K.’s National Health Service Supply Chain for Its Sacral Neuromodulation System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2015 00DD8T-E BW   Personalis Selected by the LSU Health New Orleans Precision Medicine Program to Provide Comprehensive Clinical Genomic Testing for Cancer and Inherited Genetic Disease,#N/A,#N/A,#N/A,#N/A,#N/A
 7/20/2017 LGND-US   BW   Ligand to Report Second Quarter 2017 Results on August 7th,#N/A,11/29/2017 45232710    BW   Illumina eröffnet in Frankreich erstes Vertriebs- und Kundenschulungszentrum,10/30/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2,#N/A, 5/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline,#N/A,#N/A,#N/A,#N/A,"11/05/2015 OPK-US   BW   OPKO to Announce Third Quarter Operating and Financial Results on November 9, 2015", 1/25/2010 46222210    BW,#N/A, 4/26/2018 WTX-SE   BW   Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study,#N/A,10/02/2018 4502-JP     BW   Seattle Genetics et Takeda annoncent les résultats positifs de l’essai clinique de phase 3 ECHELON-2 évaluant ADCETRIS® (Brentuximab Vedotin) pour le traitement de première ligne du lymphome périphérique à cellules T exprimant...,#N/A, 5/24/2017 09062X10    BW   Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS, 6/26/2017 IMGN-US  BW   ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia, 5/03/2011 09058V10 BW   BioCryst Pharmaceuticals Announces Changes to Its Board of Directors, 4/16/2019 0JJ26T-E     BW   Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis,#N/A,#N/A, 5/30/2013 OXB-GB   BW   Skin Cancer Pipeline Examined in New Topical Global Markets Direct Report Recently Published at MarketPublishers.com,11/06/2012 AKRX-US   BW   Akorn Reports Third Quarter 2012 Financial Results, 1/08/2013 008WTX-E     BW   BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine,#N/A,#N/A,#N/A,#N/A," 9/19/2017 05156V10 BW   Aurinia to Host R&D Day and Webcast on October 20th in New York, NY",#N/A,#N/A,#N/A,12/09/2010 37416310     BW   Bernstein Liebhard LLP Announces Investigation of Geron Corporation," 4/26/2018 AERI-US    BW   Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018",#N/A,"10/09/2018 INCY-US  BW   Incyte veröffentlicht Daten zu Pemigatinib, einem selektiven FGFR-Hemmstoff, die im Rahmen des ESMO 2018 Congress vorgestellt werden",#N/A, 8/25/2015 SRPT-US  BW   Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping,11/09/2016 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference," 7/21/2017 CERS-US  BW   Cerus to Release Second Quarter 2017 Results on August 3, 2017"," 7/20/2011 AMAG-US  BW   MURRAY FRANK LLP Investigates Allos Therapeutics, Inc."," 4/23/2018 04269E10 BW   ArQule to Report First Quarter 2018 Financial Results on May 7, 2018",#N/A,#N/A, 2/07/2018 EXEL-US  BW   Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors, 9/16/2016 0GBP93-E  BW   Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials, 7/27/2018 VRTX-US   BW   Vertex erhält positive Stellungnahme des europäischen Ausschusses für Humanarzneimittel (CHMP) für SYMKEVI® (Tezacaftor/Ivacaftor) zur Behandlung von Mukoviszidose-Patienten im Alter von mindestens 12 Jahren mit speziellen Mutationen des...,#N/A,#N/A, 4/18/2018 BLUE-US  BW   bluebird bio annuncia la pubblicazione sul New England Journal of Medicine dei dati ad interim di due studi clinici di Fase 1/2 con Terapia Genica basata su LentiGlobinTM in pazienti con β-talassemia trasfusione-dipendente, 4/27/2018 ACAD-US  BW   ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID,#N/A,#N/A,#N/A,11/06/2017 TXMD-US  BW   TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR,#N/A,#N/A, 2/15/2018 OMER-US  BW   Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy,12/05/2017 76133010 BW   Revance Announces Proposed Public Offering of Common Stock,#N/A,11/01/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference,#N/A,#N/A,#N/A, 8/03/2011 065C1X-E    BW   NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay,#N/A,10/26/2017 SYRS-US  BW   Syros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress,#N/A,#N/A, 5/10/2011 00182C10     BW   BioSante Pharmaceuticals Reports First Quarter Financial Results and Recent Developments, 2/06/2017 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences,11/26/2018 ALNY-US   BW   Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218,#N/A,#N/A,#N/A," 8/06/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference","11/15/2013 RTRX-US  BW   Retrophin, Inc. to Hold Third Quarter Operational and Financial Results Conference Call On Monday, November 18, 2013 at 4:30pm EST",#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2018 AKBA-US  BW   Akebia Therapeutics to Present at Upcoming February Investor Conferences,#N/A,#N/A,#N/A,#N/A," 4/24/2018 SAGE-US     BW   Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018",#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2013 0CJ49J-E    BW,#N/A,#N/A,#N/A,10/14/2011 56400P70 BW   MannKind to Present at The 18th Annual Newsmakers in the BioTech Industry Conference,#N/A,#N/A,#N/A," 9/06/2011 03236M20 BW   Amyris to Hold Analyst/Investor Day on September 12, 2011",#N/A,#N/A,#N/A,#N/A, 5/15/2017 EGRX-US  BW   Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer,#N/A,#N/A,#N/A, 7/09/2015 EPZM-US  BW   Epizyme Announces Extension of Celgene Research Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 VCYT-US  BW   Veracyte to Present at the 2018 UBS Global Healthcare Conference, 4/03/2018 DRNA-US  BW   Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference," 9/18/2018 15117K10 BW   Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP",#N/A,#N/A,#N/A,10/11/2012 00BBFF-E BW   Agios Publication Identifies First Potent Inhibitors of Mutant IDH1 that Lower Tumor Oncometabolite,#N/A,#N/A, 2/08/2018 INFI-US  BW   Acceleron Announces Appointment of Chief Commercial Officer,#N/A,10/18/2018 HZNP-US  BW   FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year, 8/10/2016 00BJ80-E  BW   Study Results with Castle Biosciences’ Uveal Melanoma Gene Expression Test Published in Journal of Oncology,#N/A,#N/A, 3/01/2017 GLYC-US  BW   GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results,#N/A,#N/A,#N/A,12/01/2017 G6674U10 BW   Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A, 5/15/2015 77313F10 BW   Inotek Pharmaceuticals Corporation Reports First Quarter 2015 Operational and Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2018 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2016 MCRB-US  BW   Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update," 9/26/2018 00900T10 BW   Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2016 RARX-US  BW   Ra Pharmaceuticals to Present Overview of RA101495 and Oral C5 Inhibitor at the International PNH Interest Group Annual Scientific Assembly,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/22/2017 009FRV-E BW   Quanterix’ CEO to Host Webinar on the Importance of Biomarkers for the Transformation of Precision Health,#N/A,#N/A,#N/A, 4/10/2013 30233G10 BW   pSivida Announces Launch of New Online Corporate Communication Channels,#N/A,#N/A,11/19/2018 AXNX-US  BW   Axonics® annonce la levée intégrale par les preneurs fermes de leur option d’achat d’actions supplémentaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2015 00DD8T-E BW   Personalis Launches ACE ImmunoID NGS Services for Immuno-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A
 7/17/2017 LGND-US   BW   Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330,#N/A,11/29/2017 45232710    BW   Illumina Opens First Commercial and Customer Training Center in France,10/26/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast,#N/A, 5/08/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results,#N/A,#N/A,#N/A,#N/A,11/05/2015 68375N10 BW   Additional Phase 3 Data Supporting OPKO’s Rayaldee as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015, 1/15/2010 46222210    BW,#N/A, 4/20/2018 ALXN-US  BW   Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab),#N/A,10/02/2018 4502-JP     BW   Seattle Genetics y Takeda anuncian resultados positivos del ensayo clínico de fase 3 ECHELON-2 que estudia el tratamiento de primera línea con ADCETRIS® (brentuximab vedotina) en el linfoma periférico de células T con...,#N/A, 5/18/2017 BIIB-US     BW   Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™, 5/30/2017 SAN-FR   BW   ImmunoGen and Sanofi Amend License Agreements, 5/03/2011 09058V10 BW   BioCryst to Present at Bank of America Merrill Lynch Healthcare Conference, 4/12/2019 GILD-US      BW   Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH,#N/A,#N/A, 5/27/2013 M2572210 BW   Compugen to Present at Jefferies 2013 Global Healthcare Conference,10/24/2012 00972810  BW   Akorn Announces the Approval and Launch of Generic Prometrium®, 1/08/2013 RBCC-US      BW   RBCC Seeks Out New Breakthroughs at Biotech Showcase 2013,#N/A,#N/A,#N/A,#N/A, 9/05/2017 05156V10 BW   Aurinia to Webcast at Upcoming Investor Conferences,#N/A,#N/A,#N/A,12/08/2010 37416310     BW   Geron Corporation Announces Full Exercise of Over-Allotment Option," 4/12/2018 UCB-BE     BW   Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™",#N/A,"10/09/2018 INCY-US  BW   Incyte kondigt gegevens aan voor pemigatinib, haar selectieve FGFR-remmer, die zullen worden vermeld op het ESMO 2018-congres",#N/A, 8/21/2015 AVII-US  BW   Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the Potential Treatment of Duchenne Muscular Dystrophy,11/03/2016 ALKS-US  BW   ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use Disorders, 6/21/2017 CERS-US  BW   INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)," 7/20/2011 00163U10 BW   The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of Allos Therapeutics, Inc."," 4/17/2018 ARQL-US  BW   ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China",#N/A,#N/A, 2/06/2018 EXEL-US  BW   Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14," 9/15/2016 0GBP93-E  BW   Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzyme’s Aubagio® (teriflunomide) in Patients with Relapsing Multiple Sclerosis Demonstrate High Levels of Treatment Satisfaction", 7/27/2018 VRTX-US   BW   Vertex reçoit un avis favorable du CHMP pour le SYMKEVI® (tezacaftor/ivacaftor) pour les personnes atteintes d'une fibrose kystique âgées de 12 ans et plus avec certaines mutations du gène CFTR,#N/A,#N/A, 4/18/2018 BLUE-US  BW   bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia, 4/27/2018 ACAD-US  BW   ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting,#N/A,#N/A,#N/A,11/03/2017 TXMD-US  BW   TherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6,#N/A,#N/A, 1/22/2018 OMER-US  BW   European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy,"12/05/2017 76133010 BW   Revance’s RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines",#N/A,10/30/2017 IRWD-US  BW   Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting,#N/A,#N/A,#N/A, 7/28/2011 065C1X-E    BW   NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction,#N/A,10/20/2017 SYRS-US  BW   Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress,#N/A,#N/A," 5/04/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at JMP Securities Research Conference", 2/02/2017 ENTA-US    BW   Enanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6),11/21/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming Investor Conferences,#N/A,#N/A,#N/A, 8/01/2013 69512710 BW   EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint,"11/14/2013 RTRX-US  BW   Jeffrey Paley, MD, Joins Retrophin Inc.’s Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 4/23/2018 SAGE-US     BW   Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2013 INVA-US     BW,#N/A,#N/A,#N/A, 9/23/2011 56400P70 BW   MannKind Announces Proposed Offering of Senior Secured Discount Notes Due 2017,#N/A,#N/A,#N/A, 8/25/2011 03236M20 BW   Amyris Lança a Linha de Lubrificantes Industriais EvoShieldTM,#N/A,#N/A,#N/A,#N/A," 5/10/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference",#N/A,#N/A,#N/A, 6/29/2015 29428V10 BW   Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2018 VCYT-US  BW   Veracyte Announces First Quarter 2018 Financial Results, 3/09/2018 DRNA-US  BW   Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium, 9/05/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 9/20/2012 00BBFF-E BW   New Publications from Agios Scientists and Collaborators Reveal Unexpected Regulation of Metabolic Pathways in Cancer,#N/A,#N/A, 1/31/2018 XLRN-US  BW   Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference,#N/A,"10/10/2018 HZNP-US  BW   Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018", 7/28/2016 06PNP8-E  BW   Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting,#N/A,#N/A, 2/28/2017 GLYC-US  BW   GlycoMimetics to Present at Cowen 37th Annual Health Care Conference,#N/A,#N/A,#N/A,11/22/2017 G6674U10 BW   Novocure to Present at Two Upcoming Investor Conferences in December,#N/A,#N/A,#N/A, 4/01/2015 77313F10 BW   Inotek Pharmaceuticals Corporation Reports 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2018 74587V10 BW   Puma Biotechnology to Present at Jefferies Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 8/05/2016 MCRB-US  BW   Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016", 8/29/2018 00900T10 BW   Aimmune Therapeutics to Present at Three Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/29/2016 RARX-US  BW   Ra Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2017 009FRV-E BW   Quanterix Launches the First Comprehensive Multiplex Panel to Study Traumatic Brain Injury Severity,#N/A,#N/A,#N/A, 4/04/2013 30233G10 BW   pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company,#N/A,#N/A,11/19/2018 AXNX-US  BW   Axonics® kündigt vollständige Ausübung des Optionsrechts der Emissionsbanken zum Kauf zusätzlicher Aktien an,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/23/2015 00DD8T-E BW   Personalis to Present Diagnostic Enhancements Achieved With Its ACE Clinical Exome Test at ACMG 2015 Meeting,#N/A,#N/A,#N/A,#N/A,#N/A
 6/20/2017 RIBX-US   BW   Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI),#N/A,11/29/2017 45232710    BW   Illumina ouvre son premier « Solution Center » en France,10/17/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan,#N/A, 5/01/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,10/22/2015 OPK-US   BW   OPKO Health Expands Portfolio of Tests for Inherited Forms of Cancer,#N/A,#N/A," 4/12/2018 ALXN-US  BW   Alexion to Report First Quarter 2018 Results on Thursday, April 26, 2018",#N/A,10/01/2018 4502-JP     BW   Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma,#N/A, 5/17/2017 09062X10    BW   Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference, 5/24/2017 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference," 4/25/2011 09058V10 BW   BioCryst Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011", 4/11/2019 GILD-US      BW   Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019,#N/A,#N/A, 4/25/2013 M2572210 BW   Compugen Ltd. Reports First Quarter 2013 Financial Results, 9/24/2012 00972810  BW   Akorn’s Chairman Adopts 10b5-1 Trading Plan, 1/03/2013 AMGN-US      BW   Hagens Berman: Whistleblower Helps to Expose Alleged Illegal Amgen Marketing Scheme,#N/A,#N/A,#N/A,#N/A," 8/10/2017 05156V10 BW   Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights",#N/A,#N/A,#N/A,12/07/2010 MKTSQ.XX1-US BW   Rodman & Renshaw Acts as Co-Manager to Geron Corporation on the Pricing of Its Public Offering of Common Stock, 3/21/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference,#N/A,"10/09/2018 INCY-US  BW   Incyte annuncia i dati di Pemigatinib, il suo inibitore selettivo dell'FGFR, che sarà presentato al Congresso ESMO 2018",#N/A, 8/12/2015 SRPT-US  BW   Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board,11/02/2016 ALKS-US  BW   Alkermes plc Reports Third Quarter 2016 Financial Results, 6/07/2017 CERS-US  BW   Cerus Provides Update on U.S. Platelet Additive Solution (PAS) Supply," 7/20/2011 AMAG-US  BW   Robbins Umeda LLP Announces an Investigation of Allos Therapeutics, Inc."," 3/20/2018 04269E10 BW   ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018",#N/A,#N/A, 1/20/2018 EXEL-US  BW   Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 9/07/2016 0GBP93-E  BW   More than 35 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS, 7/27/2018 06QNN6-E  BW   Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene,#N/A,#N/A, 4/16/2018 BLUE-US  BW   bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day, 4/23/2018 ACAD-US  BW   PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease,#N/A,#N/A,#N/A,10/05/2017 TXMD-US  BW   TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017,#N/A,#N/A, 1/03/2018 OMER-US  BW   Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy,11/29/2017 76133010 BW   Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia,#N/A,10/19/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call,#N/A,#N/A,#N/A, 6/03/2011 065C1X-E    BW   Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to Be Presented at ASCO,#N/A,"10/16/2017 SYRS-US  BW   Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference",#N/A,#N/A," 4/27/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Annual Health Care Conference"," 1/24/2017 ENTA-US    BW   Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C","11/09/2018 ALNY-US   BW   Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria",#N/A,#N/A,#N/A," 7/30/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call",11/04/2013 RTRX-US  BW   Retrophin to Fund Research Program at The Hospital for Sick Children (“SickKids®”),#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2018 AKBA-US  BW   Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 4/17/2018 SAGE-US     BW   Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2012 060RWY-E    BW,#N/A,#N/A,#N/A, 9/22/2011 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A,#N/A, 8/25/2011 03236M20 BW   Amyris Introduces EvoShieldTM Line of Industrial Lubricants,#N/A,#N/A,#N/A,#N/A," 5/08/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results",#N/A,#N/A,#N/A, 6/20/2015 29428V10 BW   Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A," 4/17/2018 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018", 3/08/2018 DRNA-US  BW   Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update, 9/05/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 9/13/2012 00BBFF-E BW   Agios Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,#N/A, 1/08/2018 XLRN-US  BW   Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy,#N/A,10/04/2018 HZNP-US  BW   Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab, 7/11/2016 00BJ80-E  BW   Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion,#N/A,#N/A,"12/05/2016 06QBQ2-E BW   GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML",#N/A,#N/A,#N/A,11/17/2017 G6674U10 BW   Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent,#N/A,#N/A,#N/A, 2/23/2015 77313F10 BW   Inotek Pharmaceuticals Corporation Announces Closing of Initial Public Offering and Convertible Senior Notes Offering,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2018 74587V10 BW   Puma Biotechnology Reports First Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A," 8/01/2016 MCRB-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seres Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm", 8/08/2018 00900T10 BW   Aimmune Therapeutics Announces Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2016 071VWR-E BW   Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2017 009FRV-E BW   Quanterix to Participate in Second Annual Brain Trust: Pathways to Innovation,#N/A,#N/A,#N/A, 4/01/2013 30233G10 BW   pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema,#N/A,#N/A,11/19/2018 AXNX-US  BW   Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/19/2015 00DD8T-E BW   Personalis Awarded US Department of Veterans Affairs Contract for Clinical Cancer Genomic Testing and Research Analysis,#N/A,#N/A,#N/A,#N/A,#N/A
 6/01/2017 LGND-US   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology,#N/A,11/22/2017 45232710    BW   Illumina to Webcast Upcoming Investor Conference Presentation,10/10/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash,#N/A, 4/24/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results,#N/A,#N/A,#N/A,#N/A,10/21/2015 OPK-US   BW   OPKO Health’s GeneDx business Presenting at National Society of Genetic Counselors Annual Meeting,#N/A,#N/A, 4/11/2018 ALXN-US  BW   Alexion übernimmt Wilson Therapeutics,#N/A, 9/21/2018 4502-JP     BW   Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma,#N/A, 5/15/2017 09062X10    BW   Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke, 5/23/2017 IMGN-US  BW   Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen, 4/22/2011 09058V10 BW   BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology, 4/11/2019 GILD-US      BW   Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019,#N/A,#N/A, 4/23/2013 M2572210 BW   Compugen to Present at the 12th Annual Needham Healthcare Conference, 8/07/2012 AKRX-US   BW   Akorn Reports Preliminary Second Quarter 2012 Financial Results, 1/02/2013 NPSP-US      BW   NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome,#N/A,#N/A,#N/A,#N/A, 7/12/2017 05156V10 BW   Aurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition Rule,#N/A,#N/A,#N/A,12/07/2010 37416310     BW   Geron Corporation Announces the Pricing of Its Public Offering of Common Stock, 3/14/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference,#N/A,"10/09/2018 INCY-US  BW   Incyte annonce que des données relatives au Pemigatinib, son inhibiteur sélectif de FGFR, seront présentées lors du congrès de l'ESMO 2018",#N/A, 8/06/2015 SRPT-US  BW   Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments,11/01/2016 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare Conference, 5/23/2017 CERS-US  BW   Cerus Provides U.S. Business Update," 7/20/2011 AMAG-US  BW   Law Office of Brodsky & Smith, LLC Announces Investigation of Allos Therapeutics, Inc.", 3/15/2018 04269E10 BW   ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting,#N/A,#N/A, 1/16/2018 EXEL-US  BW   Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma, 7/06/2016 80105N10  BW   Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency, 7/25/2018 VRTX-US   BW   Vertex Reports Second-Quarter 2018 Financial Results,#N/A,#N/A, 3/28/2018 BLUE-US  BW   bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States," 3/20/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018",#N/A,#N/A,#N/A, 9/28/2017 TXMD-US  BW   TherapeuticsMD Announces Closing of Common Stock Offering,#N/A,#N/A,12/12/2017 OMER-US  BW   Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients,11/20/2017 76133010 BW   Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia,#N/A,10/16/2017 IRWD-US  BW   Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017,#N/A,#N/A,#N/A, 2/22/2011 065C1X-E    BW   NanoString Technologies Introduces Multiplexed Assay Kit for Human Molecular Karyotyping,#N/A,10/05/2017 SYRS-US  BW   Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML,#N/A,#N/A, 4/18/2011 00182C10     BW   BioSante Pharmaceuticals Announces Pancreatic and Prostate Cancer Vaccine License," 1/23/2017 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016",11/07/2018 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A," 7/18/2013 69512710 BW   New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen"," 9/26/2013 RTRX-US  BW   Cornelius E. Golding Joins Retrophin, Inc.’s Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2018 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 4/04/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2011 061NC9-E    BW,#N/A,#N/A,#N/A, 9/06/2011 56400P70 BW   MannKind to Present at Rodman & Renshaw Annual Global Investment Conference,#N/A,#N/A,#N/A, 8/19/2011 03236M20 BW   Amyris Signs Multi-Year Contract to Supply Renewable Squalane to Nikko Chemicals,#N/A,#N/A,#N/A,#N/A," 4/25/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017",#N/A,#N/A,#N/A," 6/15/2015 29428V10 BW   Epizyme, Inc. to Present at Upcoming Events in June",#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2018 VCYT-US  BW   Veracyte Announces Precision Medicine Collaboration With Loxo Oncology, 3/05/2018 DRNA-US  BW   Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference, 8/22/2018 CLXT-US  BW   Cellectis: Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO,#N/A,#N/A,#N/A," 8/31/2012 05H9RB-E BW   Agios Pharmaceuticals, Inc. and the University of Pennsylvania Announce New Collaboration",#N/A,#N/A," 1/03/2018 CELG-US  BW   Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman",#N/A, 9/27/2018 HZNP-US  BW   The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry, 6/06/2016 00BJ80-E  BW   Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016,#N/A,#N/A,11/10/2016 GLYC-US  BW   GlycoMimetics to Present at Upcoming Healthcare Investor Conferences,#N/A,#N/A,#N/A,11/13/2017 G6674U10 BW   Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A," 2/18/2015 77313F10 BW   Inotek Pharmaceuticals Corporation Announces Pricing of Initial Public Offering of 6,667,000 Shares of Common Stock and 5.0% Convertible Senior Notes due 2020",#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2018 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018,#N/A,#N/A,#N/A,#N/A,#N/A," 8/01/2016 MCRB-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc."," 8/07/2018 00900T10 BW   Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2016 RARX-US  BW   Ra Pharmaceuticals Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2017 009FRV-E BW   Smithers Avanza Adds Quanterix’ Simoa Technology to Bioanalytical Laboratory,#N/A,#N/A,#N/A, 3/22/2013 30233G10 BW   pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European Launch,#N/A,#N/A,11/16/2018 AXNX-US  BW   Axonics® erhält sieben US-amerikanische Gebrauchsmuster für seine implantierbare sakrale Neuromodulationstechnologie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2015 00DD8T-E BW   Personalis Raises $33M in Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A
 5/31/2017 LGND-US   BW   Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix,#N/A,"11/21/2017 NIPT-GB     BW   Illumina Wins Infringement Suit Against Premaitha Health plc and Ariosa Diagnostics, Inc.", 9/29/2017 84763A10  BW   Spectrum Pharmaceuticals Provides Update on At-The-Market Facility,#N/A, 4/11/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A,10/13/2015 OPK-US   BW   Vanderbilt University School of Medicine and OPKO Health Collaborate on Genomics,#N/A,#N/A, 4/11/2018 WTX-SE   BW   Alexion va racheter Wilson Therapeutics,#N/A, 9/04/2018 SGEN-US     BW   Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference,#N/A, 5/02/2017 VSTM-US     BW   Verastem Appoints Eric K. Rowinsky to the Board of Directors, 5/17/2017 IMGN-US  BW   ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting, 3/09/2011 09058V10 BW   BioCryst Announces Close of $30 Million Financing Transaction Related to Future RAPIACTA® Payments, 4/09/2019 GILD-US      BW   Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases,#N/A,#N/A," 4/18/2013 M2572210 BW   Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EDT", 8/07/2012 00972810  BW   Akorn Announces New Management Appointments,"12/19/2012 06680H-E     BW   In the Psoriatic Arthritis Drug Market, Abbott/Eisai’s Humira Will Displace Amgen/Pfizer/Takeda’s Enbrel as the Sales Leader in 2012",#N/A,#N/A,#N/A,#N/A, 6/22/2017 05156V10 BW   Aurinia Announces Results of Annual General Meeting,#N/A,#N/A,#N/A,12/06/2010 37416310     BW   Geron Corporation Announces Proposed Public Offering of Common Stock, 3/07/2018 AERI-US    BW   Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference,#N/A,"10/09/2018 INCY-US  BW   Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress",#N/A, 8/03/2015 06X6HB-E BW   Critical Path Institute Launches New Consortium Dedicated to Duchenne Muscular Dystrophy,10/26/2016 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results, 5/15/2017 CERS-US  BW   First Patient Transfused in Cerus’ Phase III RedeS Study Evaluating Safety and Efficacy of the INTERCEPT Red Blood Cell System," 7/20/2011 AMAG-US  BW   The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Allos Therapeutics, Inc.", 3/05/2018 04269E10 BW   ArQule Reports Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A, 1/09/2018 EXEL-US  BW   Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 6/09/2016 064095-E  BW   Joslin Diabetes Center Announces Extended Collaboration with Sanofi for the Development of Novel Treatments for Diabetes Complications, 7/12/2018 VRTX-US   BW   Vertex to Announce Second Quarter 2018 Financial Results on July 25,#N/A,#N/A, 3/07/2018 BLUE-US  BW   bluebird bio to Present at Investor Conferences in March," 3/06/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018",#N/A,#N/A,#N/A, 9/25/2017 TXMD-US  BW   TherapeuticsMD Announces Pricing of Common Stock Offering,#N/A,#N/A,11/09/2017 OMER-US  BW   Omeros Corporation Reports Third Quarter 2017 Financial Results,11/02/2017 76133010 BW   Revance Releases Third Quarter 2017 Results,#N/A, 9/06/2017 IRWD-US  BW   Ironwood Pharmaceuticals Announces Leadership Change,#N/A,#N/A,#N/A," 2/15/2011 065C1X-E    BW   NanoString Rounds Out Commercial Management Team with New Vice Presidents of Sales, Marketing",#N/A, 9/29/2017 SYRS-US  BW   Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML,#N/A,#N/A, 4/18/2011 ANIP-US      BW   Aduro BioTech Licenses GVAX Pancreas from BioSante Pharmaceuticals to Develop a Therapeutic Vaccine in Conjunction with CRS-207 for Pancreatic Cancer," 1/09/2017 00DYYX-E   BW   Enanta Announces High SVR12 Rates Achieved in Genotype 1 Chronic HCV Infected Japanese Patients with Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)",11/06/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 5/29/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty", 9/18/2013 RTRX-US  BW   Retrophin Proposes Acquisition of Transcept for $4.00 Per Share,#N/A,#N/A,#N/A,#N/A,#N/A,12/01/2017 AKBA-US  BW   Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 3/05/2018 SAGE.XX1-US BW   Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2011 06NG14-E    BW,#N/A,#N/A,#N/A, 8/11/2011 56400P70 BW   MannKind Confirms Design of Pivotal Studies,#N/A,#N/A,#N/A, 8/17/2011 0BXG86-E BW,#N/A,#N/A,#N/A,#N/A," 4/24/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference",#N/A,#N/A,#N/A," 5/28/2015 0DY59V-E BW   Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board",#N/A,#N/A,#N/A,#N/A,#N/A, 3/19/2018 VCYT-US  BW   Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018," 3/01/2018 DRNA-US  BW   Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018"," 8/22/2018 CLXT-US  BW   Cellectis : Calyxt nomme Dr Yves Ribeill, expert chevronné de l’industrie des biotechnologies et membre du conseil d'administration, au poste de directeur général par intérim",#N/A,#N/A,#N/A," 8/31/2012 05H9RB-E BW   The University of Pennsylvania, The Abramson Family Cancer Research Institute at the Abramson Cancer Center of UPenn, Craig Thompson, M.D., Agios Pharmaceuticals and Celgene Corporation Announce Resolution of Lawsuits",#N/A,#N/A, 1/02/2018 XLRN-US  BW   Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference,#N/A, 9/27/2018 HZNP-US  BW   Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout, 5/19/2016 06N2PB-E  BW   Castle Biosciences Announces New Clinical Data to be Presented at ASCO 2016 Confirming Performance of DecisionDx-UM Gene Expression Profile (GEP) Test in Uveal Melanoma,#N/A,#N/A,11/08/2016 GLYC-US  BW   GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting,#N/A,#N/A,#N/A,11/09/2017 G6674U10 BW   Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2018 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 7/29/2016 MCRB-US  BW   Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection, 6/11/2018 00900T10 BW   Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2016 00CFZL-E BW   Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2017 009FRV-E BW   Quanterix to Discuss Precision Cardiovascular Medicine at World Medical Innovation Forum,#N/A,#N/A,#N/A, 3/20/2013 EYPT-US  BW   pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference,#N/A,#N/A,11/15/2018 AXNX-US  BW   Axonics® se voit accorder sept brevets publics américains pour sa technologie de neuromodulation sacrée implantable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/20/2014 00DD8T-E BW   Personalis and the Garvan Institute Announce Commercial Partnership for Whole Human Genome Sequencing, Analysis and Interpretation",#N/A,#N/A,#N/A,#N/A,#N/A
 5/30/2017 LGND-US   BW   Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences,#N/A,11/15/2017 45232710    BW   Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq™ 550Dx System and Expanded Use of MiSeq™Dx System," 9/28/2017 065BPX-E  BW   Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017",#N/A, 3/28/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A,10/08/2015 68375N10 BW   OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology,#N/A,#N/A, 4/11/2018 ALXN-US  BW   Alexion to Acquire Wilson Therapeutics,#N/A, 7/26/2018 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2018 Financial Results,#N/A, 4/25/2017 09062X10    BW   Biogen Reports First Quarter 2017 Revenues of $2.8 Billion, 5/05/2017 IMGN-US  BW   ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results, 2/28/2011 09058V10 BW   BioCryst to Present at Two Upcoming Investor Conferences, 4/05/2019 GILD-US      BW   Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis,#N/A,#N/A, 4/17/2013 M2572210 BW   Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy," 8/07/2012 524500-IN BW   Akorn to File Amended Unaudited Financial Statements for the Quarter Ended March 31, 2012",12/19/2012 IMGN-US      BW   Amgen Takes Third License for Rights to Use ImmunoGen’s TAP Technology,#N/A,#N/A,#N/A,#N/A," 6/21/2017 05156V10 BW   Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC",#N/A,#N/A,#N/A,12/06/2010 37416310     BW   Geron Expands Clinical Oncology Pipeline with License and Collaboration Agreements with Angiochem, 2/28/2018 AERI-US    BW   Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance,#N/A, 9/14/2018 INCY-US  BW   Incyte anuncia datos positivos del ensayo de fase 2b del ruxolitinib en crema en pacientes con dermatitis atópica,#N/A, 7/31/2015 SRPT-US  BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/20/2016 ALKS-IE  BW   Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder, 5/09/2017 CERS-US  BW   Cerus Announces Exercise of Additional BARDA Contract Options Totaling $46.6 million to Support INTERCEPT Red Blood Cell System Development," 7/20/2011 07W3XW-E BW   Harwood Feffer LLP Announces Investigation of Allos Therapeutics, Inc."," 3/05/2018 04269E10 BW   ArQule to Present at the 30th Annual Roth Conference on March 12, 2018",#N/A,#N/A, 1/08/2018 EXEL-US  BW   Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies, 5/27/2016 SNY-FR    BW   Medivation Files Preliminary Consent Revocation Statement, 7/09/2018 00GDBT-E  BW   Syntimmune Strengthens Leadership Team with Appointment of Chief Medical Officer,#N/A,#N/A, 2/21/2018 BLUE-US  BW   bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress, 2/27/2018 ACAD-US  BW   ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A, 9/25/2017 TXMD-US  BW   TherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common Stock,#N/A,#N/A,11/06/2017 OMER-US  BW   Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting,"10/18/2017 76133010 BW   Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017",#N/A, 8/31/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences,#N/A,#N/A,#N/A," 2/01/2011 065C1X-E    BW   NanoString Technologies Names J. Wayne Cowens, M.D. Chief Medical Officer",#N/A," 9/11/2017 SYRS-US  BW   Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients",#N/A,#N/A, 4/13/2011 00182C10     BW   BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel™, 1/06/2017 JPM-US     BW   Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference,10/30/2018 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results,#N/A,#N/A,#N/A," 5/28/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare Conference", 9/03/2013 RTRX-US  BW   Retrophin to Present at the Stifel Healthcare Conference 2013,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2017 AKBA-US  BW   Akebia Therapeutics to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 3/05/2018 SAGE.XX1-US BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2011 06V7M6-E    BW,#N/A,#N/A,#N/A, 8/04/2011 56400P70 BW   MannKind Corporation Reports 2011 Second Quarter Financial Results,#N/A,#N/A,#N/A, 8/15/2011 03236M20 BW   Amyris Commissions Commercial Production Facility at Tate & Lyle,#N/A,#N/A,#N/A,#N/A, 3/27/2017 EGRX-US  BW   FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke,#N/A,#N/A,#N/A, 4/30/2015 29428V10 BW   Epizyme to Present at Upcoming Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A, 3/19/2018 VCYT-US  BW   Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery, 2/06/2018 DRNA-US  BW   Dicerna to Participate in Upcoming Investor Conferences, 8/07/2018 15117K10 BW   Cellectis: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 7/05/2012 00BBFF-E BW   Nature Publication from Agios Scientists and Co-founder Reinforces Link Between Key Metabolic Enzyme IDH and Cancer,#N/A,#N/A,12/10/2017 XLRN-US  BW   Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology,#N/A, 9/25/2018 HZNP-US  BW   Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association, 5/19/2016 06N2PB-E  BW   Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma,#N/A,#N/A,11/04/2016 GLYC-US  BW   GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development,#N/A,#N/A,#N/A,11/08/2017 G6674U10 BW   Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/03/2018 74587V10 BW   Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America,#N/A,#N/A,#N/A,#N/A,#N/A, 7/12/2016 MCRB-US  BW   Seres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions, 5/30/2018 06CCT5-E BW   Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2016 00CFZL-E BW   Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2017 009FRV-E BW   Quanterix to Participate in Fourth Annual Super Bowl Brain Health Summit,#N/A,#N/A,#N/A, 2/06/2013 30233G10 BW   pSivida Corp. Reports Second Quarter Fiscal Year 2013 Results,#N/A,#N/A,11/15/2018 AXNX-US  BW   Axonics® Granted Seven U.S. Utility Patents Related to its Implantable Sacral Neuromodulation Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2014 00DD8T-E BW   Personalis Introduces New Services for Cancer Research and Clinical Trials,#N/A,#N/A,#N/A,#N/A,#N/A
 5/22/2017 LGND-US   BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A,"11/08/2017 45232710    BW   Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare", 9/05/2017 84763A10  BW   Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September,#N/A, 3/27/2018 ARWR-US  BW   Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A,10/07/2015 68375N10 BW   OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE),#N/A,#N/A, 3/15/2018 ALXN-US  BW   Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 7/12/2018 GMAB-DK     BW   Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors,#N/A, 4/24/2017 BIIB-US     BW   Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy, 5/01/2017 IMGN-US  BW   ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer, 2/24/2011 09058V10 BW   BioCryst Awarded Additional $55.0 Million by the U.S. Department of Health & Human Services to Complete Peramivir Phase 3 Program, 3/28/2019 GILD-US      BW   Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients,#N/A,#N/A, 4/02/2013 M2572210 BW   Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy, 5/08/2012 AKRX-US   BW   Akorn Reports Record First Quarter 2012 Financial Results,12/19/2012 0C8BZH-E     BW   RBCC’s Pending JV Partner Amarantus Licenses Alzheimer’s Blood Test Breakthrough,#N/A,#N/A,#N/A,#N/A, 6/16/2017 05156V10 BW   Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017,#N/A,#N/A,#N/A,12/06/2010 37416310     BW   Geron Presents Clinical Data on Its Telomerase Vaccine at the 2010 American Society of Hematology Meeting," 2/21/2018 AERI-US    BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018",#N/A, 9/14/2018 INCY-US  BW   Incyte kondigt positieve gegevens aan van fase 2b-onderzoek van ruxolitinib-crème bij patiënten met atopische dermatitis,#N/A," 7/30/2015 SRPT-US  BW   Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate Developments on August 6, 2015",10/03/2016 ALKS-US  BW   Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia, 5/03/2017 CERS-US  BW   Cerus Corporation Reports First Quarter 2017 Results," 7/20/2011 0B17BB-E BW   Kendall Law Group Investigates Allos Therapeutics, Inc."," 2/20/2018 04269E10 BW   ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018",#N/A,#N/A, 1/04/2018 EXEL-US  BW   Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors, 5/25/2016 SNY-FR    BW   Medivation Urges Stockholders to Reject Sanofi’s Attempt to Replace Medivation Board of Directors, 6/28/2018 VRTX-US   BW   Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene,#N/A,#N/A, 2/14/2018 BLUE-US  BW   bluebird bio Appoints Alison Finger as Chief Commercial Officer," 2/20/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018",#N/A,#N/A,#N/A, 9/25/2017 TXMD-US  BW   TherapeuticsMD Announces Move to Nasdaq Global Select Market,#N/A,#N/A,"11/06/2017 OMER-US  BW   Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017",10/18/2017 76133010 BW   Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis,#N/A, 8/21/2017 IRWD-US  BW   Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout,#N/A,#N/A,#N/A, 1/25/2011 065C1X-E    BW   NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis,#N/A, 9/05/2017 SYRS-US  BW   Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference,#N/A,#N/A," 4/11/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Future Leaders in the Biotech Industry Conference"," 1/04/2017 06CR5C-E   BW   FDA Grants Fast Track Designation to Enanta’s FXR Agonist Candidate, EDP-305, for the treatment of NASH with Liver Fibrosis",10/29/2018 ALNY-US   BW   Hochschulmedizin Zurich et Alnylam organisent une conférence concernant une médecine innovante sur la découverte et les applications cliniques de l'ARN interférence (ARNi),#N/A,#N/A,#N/A," 5/08/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference"," 8/16/2013 RTRX-US  BW   CORRECTING and REPLACING Retrophin, Inc. Raises $25 Million in Private Placement Financing",#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2017 AKBA-US  BW   Akebia Therapeutics Announces Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A, 2/22/2018 SAGE-US     BW   Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update,#N/A,#N/A,#N/A,#N/A,#N/A,12/30/2010 06CR5C-E    BW,#N/A,#N/A,#N/A," 7/28/2011 56400P70 BW   MannKind Corporation to Hold 2011 Second Quarter Financial Results Conference Call on August 4, 2011",#N/A,#N/A,#N/A, 8/15/2011 03236M20 BW   Amyris pronta para produção comercial na Tate & Lyle nos Estados Unidos,#N/A,#N/A,#N/A,#N/A, 3/21/2017 EGRX-US  BW   Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka,#N/A,#N/A,#N/A, 4/28/2015 29428V10 BW   Epizyme Announces First Quarter 2015 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2018 0786F6-E BW   Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma GSC To Be Presented at ENDO 2018, 1/23/2018 DRNA-US  BW   Dicerna to Present at Noble Capital Markets’ NobleCon14, 8/07/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 5/30/2012 0C8MHH-E BW   Ember Therapeutics Expands Scientific Leadership to Advance Metabolic Pipeline,#N/A,#N/A,12/05/2017 XLRN-US  BW   Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition,#N/A, 9/04/2018 HZNP-US  BW   Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference, 5/09/2016 00BJ80-E  BW   Castle Biosciences Announces the Appointment of Bernhard E. Spiess as Chief Operating Officer,#N/A,#N/A,11/03/2016 06QBQ2-E BW   Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of Hematology (ASH) Meeting,#N/A,#N/A,#N/A,11/06/2017 G6674U10 BW   Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2018 74587V10 BW   NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2016 MCRB-US  BW   Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection, 5/29/2018 00900T10 BW   Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2016 00CFZL-E BW   Ra Pharmaceuticals to Present at the Jefferies 2016 Complement Therapeutics Summit,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2017 009FRV-E BW   Quanterix’ Momentum Fuels Vision for the Future of Precision Health,#N/A,#N/A,#N/A, 2/04/2013 EYPT-US  BW   pSivida CEO to Present at 15th Annual BioCEO & Investor Conference February 12,#N/A,#N/A,11/07/2018 AXNX-US  BW   Axonics® erhält Zulassung von Health Canada für sein externes Versuchssystem für sakrale Neuromodulation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/17/2014 00DD8T-E BW   Personalis Launches Third Generation ACE Clinical ExomeTM Test,#N/A,#N/A,#N/A,#N/A,#N/A
 5/09/2017 LGND-US   BW   Ligand Reports First Quarter 2017 Financial Results,#N/A,10/24/2017 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017," 8/17/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th",#N/A, 3/20/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,10/01/2015 68375N10 BW   Conversion Right Extended on OPKO 3.0% Convertible Senior Notes,#N/A,#N/A, 3/07/2018 ALXN-US  BW   Alexion to Present at the Cowen and Company 38th Annual Health Care Conference,#N/A, 7/11/2018 SGEN-US     BW   CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer,#N/A, 4/24/2017 09062X10    BW   TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment, 4/21/2017 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results, 2/10/2011 09058V10 BW   BioCryst Provides Corporate Update and Reports Fourth Quarter and Full Year 2010 Financial Results, 3/28/2019 GILD-US      BW   Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study,#N/A,#N/A, 2/20/2013 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2012 Financial Results, 4/10/2012 AKRX-US   BW   Akorn Announces the Approval and Launch of Generic Vancocin®,"12/17/2012 060RWY-E     BW   Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch in Rheumatoid Arthritis, It Remains a Second-Line Therapy after TNF Inhibitors According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A," 6/05/2017 05156V10 BW   Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks",#N/A,#N/A,#N/A,12/02/2010 37416310     BW   Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer, 2/20/2018 EGRX-US    BW   Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel,#N/A, 9/14/2018 INCY-US  BW   Incyte gibt positive Ergebnisse seiner Phase-2b-Studie zu Ruxolitinib-Creme bei Patienten mit Neurodermitis bekannt,#N/A," 7/22/2015 SRPT-US  BW   Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform"," 9/19/2016 ALKS-US  BW   Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016"," 4/19/2017 CERS-US  BW   Cerus to Release First Quarter 2017 Results on May 3, 2017"," 7/20/2011 AMAG-US  BW   Faruqi & Faruqi, LLP Announces Investigation of Allos Therapeutics, Inc."," 2/08/2018 04269E10 BW   ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018",#N/A,#N/A,12/19/2017 EXEL-US  BW   Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma, 5/25/2016 003ZHQ-E  BW   8ème Journée Mondiale de la Sclérose en Plaques, 6/21/2018 VRTX-US   BW   Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis,#N/A,#N/A, 2/02/2018 BLUE-US  BW   bluebird bio to Present at LEERINK Partners Global Healthcare Conference," 1/02/2018 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018",#N/A,#N/A,#N/A, 9/14/2017 TXMD-US  BW   TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR,#N/A,#N/A,11/01/2017 OMER-US  BW   Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting, 9/19/2017 76133010 BW   Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference,#N/A, 8/03/2017 IRWD-US  BW   Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update,#N/A,#N/A,#N/A,12/06/2010 065C1X-E    BW   NanoString Exclusively Licenses Worldwide Rights to Intrinsic Subtyping Gene Signature for Breast Cancer,#N/A, 8/31/2017 SYRS-US  BW   Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress,#N/A,#N/A, 4/04/2011 00182C10     BW   BioSante Pharmaceuticals to Host LibiGel® R&D Event in New York City,12/22/2016 JPMC66*-US BW   Enanta Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference,10/29/2018 ALNY-US   BW   Hochschulmedizin Zürich und Alnylan veranstalten innovative medizinische Vorlesungsreihe zur Entdeckung und klinischen Anwendung von RNA-Interferenz (RNAi),#N/A,#N/A,#N/A," 5/08/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results", 8/16/2013 RTRX-US  BW   Retrophin Signs Exclusivity Agreement with a Major Pharmaceutical Company to Negotiate a License to a Product to be Developed for Autism and Schizophrenia,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2017 AKBA-US  BW   Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually,#N/A,#N/A,#N/A,#N/A," 2/13/2018 SAGE-US     BW   Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018",#N/A,#N/A,#N/A,#N/A,#N/A,12/01/2010 VAR-US      BW,#N/A,#N/A,#N/A, 6/24/2011 56400P70 BW   Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA®,#N/A,#N/A,#N/A, 8/02/2011 03236M20 BW   Amyris Reports Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 3/16/2017 EGRX-US  BW   Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors,#N/A,#N/A,#N/A," 4/21/2015 29428V10 BW   Epizyme to Report First Quarter 2015 Financial Results and Provide Corporate Update on April 28, 2015",#N/A,#N/A,#N/A,#N/A,#N/A," 2/27/2018 VCYT-US  BW   Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook",12/14/2017 DRNA-US  BW   Dicerna Announces Pricing of Follow-On Public Offering of Common Stock," 8/02/2018 15117K10 BW   Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer",#N/A,#N/A,#N/A, 5/29/2012 00BBFF-E BW   Agios Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference,#N/A,#N/A,11/15/2017 XLRN-US  BW   Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire,#N/A, 9/04/2018 HZNP-US  BW   Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule, 5/02/2016 00BJ80-E  BW   Independent Study Verifies the Performance of Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test for Predicting Risk of Metastasis,#N/A,#N/A, 9/14/2016 GLYC-US  BW   GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma,#N/A,#N/A,#N/A,10/26/2017 G6674U10 BW   Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/28/2018 05YSWP-E BW   Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation",#N/A,#N/A,#N/A,#N/A,#N/A, 6/22/2016 05LKPZ-E BW   Seres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome, 5/28/2018 00900T10 BW   Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/06/2016 00CFZL-E BW   Ra Pharmaceuticals Appoints Chief Scientific Officer and Expands Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2017 009FRV-E BW   Quanterix Announces Significant Advancements to Strategic Partnership with bioMérieux,#N/A,#N/A,#N/A, 1/30/2013 30233G10 BW   pSivida Corp. Announces Second Quarter 2013 Financial Results Release Date and Conference Call Information,#N/A,#N/A,11/07/2018 AXNX-US  BW   Axonics® reçoit l’approbation de Health Canada pour son Système d’essai externe de neuromodulation des racines sacrées,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2014 00DD8T-E BW   Personalis to Showcase New Products for Cancer Research and Inherited Disease Testing at ASHG Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A
 4/13/2017 LGND-US   BW   Ligand to Report First Quarter 2017 Results on May 9th,#N/A,10/17/2017 0F0WRJ-E    BW   Jay Flatley and John Martin to be Named Recipients of Life Sciences Leadership Award at California Life Sciences Association’s 2017 Pantheon DiNA™ Awards, 8/14/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC),#N/A, 3/12/2018 ARWR-US  BW   Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A, 9/28/2015 AGEN-US  BW   Wall St. Analyst Announces Investment Opinion: Biotech Stocks Coverage,#N/A,#N/A, 2/27/2018 ALXN-US  BW   The Manton Center at Boston Children’s Hospital and Alexion Pharmaceuticals Partner in Artificial Intelligence Approaches to Rare Disease Diagnosis,#N/A, 7/09/2018 SGEN-US     BW   Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program,#N/A, 4/21/2017 BIIB-US     BW   Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy, 3/12/2017 IMGN-US  BW   ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting," 2/02/2011 09058V10 BW   BioCryst Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on February 10, 2011", 3/28/2019 GILD-US      BW   Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA),#N/A,#N/A," 2/12/2013 M2572210 BW   CORRECTING and REPLACING Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM EST", 3/06/2012 00972810  BW   Akorn Reports 2011 Fourth Quarter and Year-End Financial Results,"12/12/2012 06680H-E     BW   In 2021, Sales of Cancer Pain Therapies Will Increase to $5.2 Billion in the G7",#N/A,#N/A,#N/A,#N/A, 5/30/2017 05156V10 BW   Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences,#N/A,#N/A,#N/A,11/11/2010 37416310     BW   Geron Announces Two Publications Demonstrating That Its Telomerase Inhibitor Drug Targets Cancer Stem Cells, 2/12/2018 AGN-US     BW   Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region,#N/A, 9/13/2018 INCY-US  BW   Incyte annuncia dati positivi dallo studio di fase 2b su ruxolitinib in crema nei pazienti affetti da dermatite atopica,#N/A, 7/01/2015 80360710 BW   Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company, 9/12/2016 ALKS-US  BW   Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders, 4/06/2017 CERS-US  BW   Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 7/20/2011 00163U10 BW   AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies, 2/07/2018 ARQL-US  BW   Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China,#N/A,#N/A,11/21/2017 EXEL-US  BW   Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations, 5/25/2016 80105N10  BW   Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis, 6/18/2018 VRTX-US   BW   Vertex Opens Expanded Research Site in San Diego,#N/A,#N/A, 1/08/2018 BLUE-US  BW   bluebird bio Announces Closing of Over-Allotment Option in Public Offering,"12/13/2017 ACAD-US  BW   ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development",#N/A,#N/A,#N/A, 9/06/2017 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A,10/20/2017 OMER-US  BW   Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting, 9/06/2017 76133010 BW   Revance Appoints Mark Foley to its Board of Directors,#N/A, 7/20/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call,#N/A,#N/A,#N/A,11/02/2010 065C1X-E    BW   NanoString Launches First Simple and Precise Approach to Detect Hundreds of Genetic Copy Variants in a Single Multiplexed Reaction,#N/A, 8/21/2017 SYRS-US  BW   Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML,#N/A,#N/A, 3/30/2011 00182C10     BW   BioSante Pharmaceuticals Completes Enrollment in Both Pivotal LibiGel® Phase III Efficacy Trials,"12/19/2016 06CR5C-E   BW   Enanta Pharmaceuticals Announces AbbVie’s Submission of NDA for Investigational, Pan-Genotypic HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Genotypes 1 through 6 of Chronic Hepatitis C Virus (HCV)",10/29/2018 ALNY-US   BW   Hochschulmedizin Zurich and Alnylam Host Innovative Medicine Lecture on the Discovery and Clinical Applications of RNA interference (RNAi),#N/A,#N/A,#N/A, 5/06/2013 69512710 BW   Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control, 8/16/2013 RTRX-US  BW   Retrophin Reports Positive Survival Data from Preclinical Trial of RE-024 for the Treatment of the Ultra-Orphan Disease Pantothenate Kinase-Associated Neurodegeneration (PKAN),#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/12/2018 SAGE-US     BW   Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2011 064095-E BW   Type 1 Diabetes Patients Using AFREZZA Have More Positive View of Therapy Compared to Standard Insulin Therapy,#N/A,#N/A,#N/A, 8/01/2011 3405-JP  BW   Amyris Partners with Kuraray to Develop Renewable Polymers,#N/A,#N/A,#N/A,#N/A," 3/01/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results",#N/A,#N/A,#N/A, 4/20/2015 29428V10 BW   Epizyme Presents Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets,#N/A,#N/A,#N/A,#N/A,#N/A," 2/12/2018 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018",12/13/2017 DRNA-US  BW   Dicerna Announces Proposed Public Offering of Common Stock," 8/02/2018 064VBM-E BW   Cellectis nomme Stefan Scherer, M.D., Ph.D., Vice-Président senior du Développement Clinique et Directeur médical adjoint",#N/A,#N/A,#N/A, 5/03/2012 00BBFF-E BW   Agios Strengthens Team with Key Appointments and Promotion,#N/A,#N/A,11/14/2017 XLRN-US  BW   Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions,#N/A, 8/08/2018 HZNP-US  BW   Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases, 3/14/2016 00BJ80-E  BW   Castle Biosciences Expands Credit Facility from Silicon Valley Bank,#N/A,#N/A, 9/06/2016 GLYC-US  BW   GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359,#N/A,#N/A,#N/A,10/16/2017 G6674U10 BW   Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2018 74587V10 BW   Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 6/20/2016 06TW1B-E BW   Seres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile Infection", 5/15/2018 00900T10 BW   Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2016 00CFZL-E BW   Ra Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2017 009FRV-E BW   Quanterix to Present at The 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 1/23/2013 30233G10 BW   Psivida Corp. Announces Final Published Guidance from U.K.’s Nice and Pursuit of Patient Access Scheme for Iluvien® for DME,#N/A,#N/A,11/07/2018 AXNX-US  BW   Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/14/2014 00DD8T-E BW   Personalis Awarded US Department of Veterans Affairs Contract for Clinical Exome Testing Services for Genetic Disorders,#N/A,#N/A,#N/A,#N/A,#N/A
 4/05/2017 LGND-US   BW   Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone,#N/A,10/16/2017 45232710    BW   Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow, 8/03/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update,#N/A, 3/06/2018 ARWR-US  BW   Arrowhead to Present at Barclays Global Healthcare Conference 2018,#N/A,#N/A,#N/A,#N/A, 9/22/2015 OPK-US   BW   OPKO Health to Present at the Ladenburg Thalmann 2015 Healthcare Conference,#N/A,#N/A, 2/08/2018 ALXN-US  BW   Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018,#N/A," 6/28/2018 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018",#N/A, 4/18/2017 09062X10    BW   Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress, 3/01/2017 IMGN-US  BW   ImmunoGen Announces Presentations at AACR Annual Meeting, 1/13/2011 09058V10 BW   BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results and Provides a Clinical Program Update, 3/28/2019 GILD-US      BW   Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia,#N/A,#N/A, 2/05/2013 M2572210 BW   Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San Francisco," 3/05/2012 00972810  BW   Akorn Announces the Appointment of Dr. Adrienne Graves, Ph.D. to its Board of Directors","12/06/2012 060RWY-E     BW   Biologic Agents are Being Used Earlier and More Often to Treat Rheumatoid Arthritis in the EU5, According to Two Recent Reports from BioTrends",#N/A,#N/A,#N/A,#N/A, 5/17/2017 05156V10 BW   Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis,#N/A,#N/A,#N/A,11/04/2010 GERN-US      BW   Life Technologies Convenes Leadership Summit to Highlight Commercial Achievements in Cell Therapy, 2/08/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department,#N/A, 9/13/2018 INCY-US  BW   Incyte publie des données positives d'un essai de Phase 2b sur une crème au ruxolitinib chez les patients atteints d'une dermatite atopique,#N/A, 6/30/2015 80360710 BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 9/06/2016 ALKS-US  BW   Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference, 3/07/2017 CERS-US  BW   Cerus Corporation Reports Fourth Quarter and Year End 2016 Results, 6/21/2011 00163U10 BW   AMAG Pharmaceuticals Announces Update to Feraheme® Label,"11/21/2017 04269E10 BW   ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma",#N/A,#N/A,11/21/2017 EXEL-US  BW   Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium, 5/23/2016 003ZHQ-E  BW   SANOFI GENZYME FELICITE LE SKIPPER THIBAUT VAUCHEL-CAMUS, 6/18/2018 VRTX-US   BW   Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor),#N/A,#N/A,12/21/2017 BLUE-US  BW   bluebird bio to Present at Investor Conferences in January,"11/21/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017",#N/A,#N/A,#N/A, 8/16/2017 TXMD-US  BW   TherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women,#N/A,#N/A,10/16/2017 OMER-US  BW   Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation, 8/30/2017 76133010 BW   Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference,#N/A, 7/20/2017 IRWD-US  BW   Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease,#N/A,#N/A,#N/A,"10/06/2010 065C1X-E    BW   NanoString Technologies Appoints Industry Veteran Barney Saunders, Ph.D., as Chief Commercial Officer",#N/A, 8/10/2017 SYRS-US  BW   Syros Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference,#N/A,#N/A, 3/16/2011 00182C10     BW   BioSante Pharmaceuticals Reports Financial Results for 2010 and Clinical Development and Business Highlights,11/22/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces the Appointment of Dr. Lesley Russell to Its Board of Directors,10/25/2018 ALNY-US   BW   Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran,#N/A,#N/A,#N/A," 5/01/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call"," 8/07/2013 RTRX-US  BW   Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management",#N/A,#N/A,#N/A,#N/A,#N/A,10/04/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/08/2018 SAGE-US     BW   Sage Therapeutics Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/16/2011 56400P70 BW   MannKind to Present at the Wells Fargo Securities 2011 Healthcare Conference,#N/A,#N/A,#N/A, 7/26/2011 03236M20 BW   Amyris to Supply Rio de Janeiro Buses with Renewable Diesel from Sugarcane,#N/A,#N/A,#N/A,#N/A, 2/28/2017 EGRX-US  BW   Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA,#N/A,#N/A,#N/A, 4/20/2015 29428V10 BW   Epizyme to Present Updated Data from Ongoing Phase 1 Dose Escalation Trial of EZH2 Inhibitor EPZ-6438 at International Conference on Malignant Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2018 VCYT-US  BW   Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference,12/07/2017 DRNA-US  BW   Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria, 8/01/2018 15117K10 BW   Cellectis publie ses résultats financiers du deuxième trimestre 2018 et des six premiers mois de l’année 2018,#N/A,#N/A,#N/A, 4/03/2012 00BBFF-E BW   Agios Research in Cancer Metabolism Highlighted at AACR Annual Meeting 2012,#N/A,#N/A,11/07/2017 XLRN-US  BW   Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results,#N/A, 7/25/2018 HZNP-US  BW   PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List,11/25/2015 00BJ80-E  BW   Castle Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A, 8/16/2016 GLYC-US  BW   GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack,#N/A,#N/A,#N/A,10/02/2017 G6674U10 BW   Novocure to Report Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2018 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A," 6/06/2016 MCRB-US  BW   Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases", 5/09/2018 00900T10 BW   Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2016 00CFZL-E BW   Ra Pharmaceuticals Strengthens Senior Management Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2016 009FRV-E BW   Quanterix to Unveil Groundbreaking Neurodegenerative Disease Research and Strategic Partnership at Neuroscience 2016,#N/A,#N/A,#N/A, 1/17/2013 EYPT-US  BW   pSivida Corp. Announces Spain Grants ILUVIEN® Marketing Approval for Chronic Diabetic Macular Edema,#N/A,#N/A,11/05/2018 AXNX-US  BW   Axonics® annonce la clôture du premier appel public à l’épargne relatif aux actions ordinaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2014 00DD8T-E BW   Personalis to Highlight Advances in Clinical-Exome Sequencing at the 2014 National Society of Genetic Counselors Meeting,#N/A,#N/A,#N/A,#N/A,#N/A
 3/28/2017 LGND-US   BW   Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology,#N/A,"10/10/2017 45232710    BW   Illumina to Announce Third Quarter 2017 Financial Results on Tuesday, October 24, 2017"," 8/01/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF",#N/A, 2/22/2018 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease,#N/A,#N/A,#N/A,#N/A, 9/09/2015 OPK-US   BW   OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials,#N/A,#N/A, 2/06/2018 ALXN-US  BW   Data Presented at WORLDSymposium™ 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma® (sebelipase alfa),#N/A, 6/13/2018 GMAB-DK     BW   Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer,#N/A, 4/13/2017 09062X10    BW   Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb," 2/17/2017 IMGN-US  BW   ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016", 1/10/2011 VRTX-US  BW, 3/27/2019 GILD-US      BW   Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019,#N/A,#N/A,12/04/2012 CGEN-IL  BW   Compugen Presents at American Association of Cancer Research Special Conference on Tumor Immunology, 2/28/2012 00972810  BW   Akorn Completes the Acquisition of Certain Assets of Kilitch Drugs in India,"12/05/2012 0CPNB1-E     BW   By Year-End 2015, Surveyed European Rheumatologists Anticipate That the Launches of Biosimilar Etanercept and Infliximab Will Sustain Total Patient Shares of These Molecules at the Expense of Humira in the Rheumatoid Arthritis Drug Market",#N/A,#N/A,#N/A,#N/A," 5/15/2017 05156V10 BW   Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights",#N/A,#N/A,#N/A,11/02/2010 37416310     BW   Geron Awarded Grants Under Qualifying Therapeutic Discovery Project Program, 2/01/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications,#N/A," 9/13/2018 INCY-US  BW   In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)",#N/A, 6/29/2015 AVII-US  BW   Sarepta Therapeutics Secures $40 Million in Debt Financing, 8/08/2016 ALKS-IE  BW   Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia," 3/02/2017 CERS-US  BW   Cerus to Present at the Cowen and Company 37th Annual Health Care Conference on March 8, 2017", 6/14/2011 AMAG-US  BW   Mascoma Appoints David Arkowitz as Chief Financial Officer,11/09/2017 04269E10 BW   ArQule Reports Third Quarter 2017 Financial Results,#N/A,#N/A,11/07/2017 EXEL-US  BW   Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14th, 5/16/2016 003ZHQ-E  BW   Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine, 6/14/2018 VRTX-US   BW   The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program,#N/A,#N/A,12/12/2017 BLUE-US  BW   bluebird bio Announces Pricing of Public Offering of Common Stock,11/07/2017 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A, 8/10/2017 TXMD-US  BW   TherapeuticsMD Provides TX-004HR Regulatory Update,#N/A,#N/A,10/05/2017 0650LH-E BW   Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par, 8/03/2017 76133010 BW   Revance Releases Second Quarter 2017 Results,#N/A, 6/08/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference,#N/A,#N/A,#N/A, 7/14/2010 065C1X-E    BW   NanoString Technologies Increases Multiplexing Capacity for Gene Expression Analysis,#N/A, 8/09/2017 SYRS-US  BW   Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones,#N/A,#N/A," 3/10/2011 05GSQ9-E     BW   BioSante Pharmaceuticals, Inc. to Present at Roth Annual Growth Stock Conference","11/21/2016 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016",10/24/2018 ALNY-US   BW   Alnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community,#N/A,#N/A,#N/A," 4/25/2013 69512710 BW   New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality", 5/08/2013 RTRX-US  BW   Retrophin Names Marc L. Panoff as Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2017 AKBA-US  BW   Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 2/07/2018 SAGE.XX1-US BW   Sage Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2011 56400P70 BW   MannKind to Present at the Jefferies 2011 Global Healthcare Conference,#N/A,#N/A,#N/A, 7/26/2011 03236M20 BW   Amyris Fornecerá Diesel de Cana para Ônibus no Rio de Janeiro,#N/A,#N/A,#N/A,#N/A, 2/28/2017 EGRX-US  BW   Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka,#N/A,#N/A,#N/A, 4/17/2015 29428V10 BW   Epizyme Announces Closing of Common Stock Offering,#N/A,#N/A,#N/A,#N/A,#N/A," 1/25/2018 VCYT-US  BW   Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis",11/21/2017 DRNA-US  BW   Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference, 8/01/2018 15117K10 BW   Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018,#N/A,#N/A,#N/A, 2/29/2012 00BBFF-E BW   Agios Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference,#N/A,#N/A,11/01/2017 XLRN-US  BW   Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition,#N/A, 7/16/2018 HZNP-US  BW   Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid,11/16/2015 00BJ80-E  BW   Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer,#N/A,#N/A, 8/08/2016 GLYC-US  BW   GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference,#N/A,#N/A,#N/A, 9/24/2017 G6674U10 BW   Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2018 74587V10 BW   Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2016 MCRB-US  BW   Seres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference, 5/08/2018 00900T10 BW   Aimmune Therapeutics Announces First Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 00CFZL-E BW   Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2016 009FRV-E BW   Quanterix Kicks Off West Coast Seminar Series in San Francisco,#N/A,#N/A,#N/A,11/29/2012 EYPT-US  BW   pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.’s NICE for ILUVIEN® for DME,#N/A,#N/A,11/02/2018 AXNX-US  BW   Axonics® gibt Abschluss der Erstemission von Stammaktien bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/23/2014 00DD8T-E BW   Personalis, Inc. Receives Accreditation from College of American Pathologists (CAP)",#N/A,#N/A,#N/A,#N/A,#N/A
 3/09/2017 LGND-US   BW   Ligand to Participate in Upcoming Investor Conference,#N/A, 9/07/2017 45232710    BW   Illumina Files New Patent Infringement Suit Against Premaitha Health plc, 7/27/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast,#N/A, 2/15/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT,#N/A,#N/A,#N/A,#N/A, 9/02/2015 OPK-US   BW   OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant),#N/A,#N/A," 2/05/2018 ALXN-US  BW   Alexion Appoints Judith A. Reinsdorf, J.D., to its Board of Directors",#N/A, 6/06/2018 SGEN-US     BW   Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference,#N/A, 3/28/2017 09062X10    BW   Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases, 2/02/2017 IMGN-US  BW   ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences, 1/10/2011 RICHT-HU BW," 3/26/2019 0HZGD8-E     BW   Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection",#N/A,#N/A,11/19/2012 09M5MF-E BW   Compugen Announces $15 Million Funding Agreement for Its Keddem Subsidiary, 1/17/2012 LUN-DK    BW   Akorn Provides Financial Guidance for 2012,12/05/2012 0C8BZH-E     BW   RBCC Target Amarantus Wins MANF Patent Challenge in Europe,#N/A,#N/A,#N/A,#N/A, 5/09/2017 05156V10 BW   Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors,#N/A,#N/A,#N/A,10/28/2010 37416310     BW   Geron Corporation Reports 2010 Third Quarter Financial Results and Events, 1/24/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Pricing of Public Offering of Common Stock,#N/A, 9/13/2018 INCY-US  BW   Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis,#N/A, 6/29/2015 AVII-US  BW   Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping, 7/28/2016 ALKS-US  BW   Alkermes plc Reports Second Quarter 2016 Financial Results," 2/21/2017 CERS-US  BW   Cerus to Release Fourth Quarter and Year End 2016 Results on March 7, 2017", 5/25/2011 00163U10 BW   AMAG Pharmaceuticals Announces Resignation of Chief Financial Officer,11/08/2017 04269E10 BW   ArQule Announces $9.5 Million Private Placement of Preferred Stock,#N/A,#N/A,11/01/2017 EXEL-US  BW   Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update, 5/11/2016 NBIX-US   BW   OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs, 6/07/2018 VRTX-US   BW   Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF,#N/A,#N/A,12/11/2017 BLUE-US  BW   bluebird bio Announces Proposed Public Offering of Common Stock,11/03/2017 ACAD-US  BW   ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting,#N/A,#N/A,#N/A, 8/03/2017 TXMD-US  BW   TherapeuticsMD Announces Second Quarter 2017 Financial Results,#N/A,#N/A, 8/23/2017 OMER-US  BW   Omeros Responds to Statnews.com Story," 8/01/2017 76133010 BW   Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics",#N/A, 6/01/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference,#N/A,#N/A,#N/A, 6/29/2010 065C1X-E    BW   NanoString Technologies Announces Key Executive Management Appointments,#N/A, 7/21/2017 SYRS-US  BW   Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients,#N/A,#N/A, 3/09/2011 00182C10     BW   BioSante Pharmaceuticals Closes $25.1 Million Registered Direct Offering,"11/15/2016 06VHPT-E   BW   Enanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease","10/22/2018 ALNY-US   BW   LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm",#N/A,#N/A,#N/A, 4/12/2013 69512710 BW   New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures," 4/25/2013 0D0JWQ-E BW   Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 2/07/2018 SAGE-US     BW   Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2011 56400P70 BW   MannKind Corporation Reports 2011 First Quarter Financial Results,#N/A,#N/A,#N/A, 7/25/2011 06VMDL-E BW   Amyris Commissions Commercial Production Operations at Antibióticos,#N/A,#N/A,#N/A,#N/A, 2/21/2017 EGRX-US  BW   Eagle Pharmaceuticals Announces New Patents Issued for Bendeka,#N/A,#N/A,#N/A, 3/18/2015 29428V10 BW   Epizyme to Present Data on Preclinical Pipeline at the American Association for Cancer Research (AACR) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 1/19/2018 VCYT-US  BW   Veracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World Conference,11/08/2017 DRNA-US  BW   Dicerna to Present at the Stifel 2017 Healthcare Conference, 7/06/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 2/09/2012 00BBFF-E BW   Agios Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference,#N/A,#N/A,"10/26/2017 XLRN-US  BW   Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017",#N/A," 7/09/2018 HZNP-US  BW   Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018",11/13/2015 00BJ80-E  BW   Castle Biosciences to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum,#N/A,#N/A, 8/04/2016 GLYC-US  BW   GlycoMimetics Reports Second Quarter 2016 Results,#N/A,#N/A,#N/A, 9/22/2017 G6674U10 BW   Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2018 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2016 MCRB-US  BW   Seres Therapeutics to Present at the 2016 UBS Healthcare Conference, 3/12/2018 00900T10 BW   Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2015 00CFZL-E BW   Ra Pharmaceuticals Announces $58.5M Series B Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/18/2016 009FRV-E BW   Quanterix CEO to Speak at 2016 BIO Investor Forum Following Buzz of BIO Award Win,#N/A,#N/A,#N/A,11/08/2012 EYPT-US  BW   pSivida Corp. Reports First Quarter Fiscal Year 2013 Results,#N/A,#N/A,11/02/2018 AXNX-US  BW   Axonics® Announces Closing of Initial Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/27/2014 00DD8T-E BW   Inova and Personalis Announce Partnership to Advance Genomic Medicine,#N/A,#N/A,#N/A,#N/A,#N/A
 2/28/2017 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A," 8/24/2017 06QT6N-E    BW   Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market", 6/19/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting,#N/A, 2/15/2018 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B,#N/A,#N/A,#N/A,#N/A, 8/26/2015 68375N10 BW   OPKO Letter to Shareholders,#N/A,#N/A, 1/31/2018 ALXN-US  BW   Alexion to Present at the Leerink Partners 7th Annual Global Healthcare Conference,#N/A, 6/04/2018 4502-JP     BW   Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting,#N/A," 3/27/2017 09062X10    BW   Biogen to Report First Quarter 2017 Financial Results on April 25, 2017", 1/26/2017 IMGN-US  BW   ImmunoGen Announces First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, 1/05/2011 WLA-US   BW   Maven Semantic: Weight Loss Research Database," 3/07/2019 GILD-US      BW   Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies",#N/A,#N/A,11/14/2012 CGEN-IL  BW   Compugen to Present at Jefferies 2012 Global Healthcare Conference,12/22/2011 LUN-DK    BW   Akorn Acquires Three Hospital-Based Branded Injectables from Lundbeck,11/29/2012 060RWY-E     BW   Surveyed Dermatologists Estimate that Half of Psoriasis Patients Who are Treated with Janssen Biotech/Janssen-Cilag's Stelara Have Previously Failed Treatment with at Least One TNF-Alpha Inhibitor,#N/A,#N/A,#N/A,#N/A, 4/26/2017 05156V10 BW   Aurinia to Present at Bloom Burton & Co. Healthcare Conference,#N/A,#N/A,#N/A,10/25/2010 37416310     BW   Geron Announces Conference Call to Discuss Financial Results for the 2010 Third Quarter, 1/23/2018 AERI-US    BW   Aerie Pharmaceuticals Announces Public Offering of Common Stock,#N/A," 9/11/2018 FMI-US   BW   Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma",#N/A, 5/29/2015 80360710 BW   Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), 7/21/2016 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Second Quarter 2016 Financial Results, 1/04/2017 CERS-US  BW   Cerus Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)," 5/03/2011 00163U10 BW   AMAG Announces Financial Results for the First Quarter Ended March 31, 2011",11/01/2017 04269E10 BW   FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome,#N/A,#N/A,10/26/2017 EXEL-US  BW   Exelixis to Present at the Credit Suisse 26th Annual Healthcare Conference on November 7th," 4/25/2016 0880D9-E  BW   Mirna Therapeutics Appoints Vincent J. O’Neill, M.D., as Chief Medical Officer", 6/06/2018 VRTX-US   BW   Vertex to Present at the Goldman Sachs Healthcare Conference on June 13,#N/A,#N/A,12/11/2017 BLUE-US  BW   bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting,"10/31/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017",#N/A,#N/A,#N/A, 7/20/2017 TXMD-US  BW   TherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3,#N/A,#N/A, 8/21/2017 OMER-US  BW   Omeros Closes $68.3 Million Public Offering of Common Stock," 7/24/2017 76133010 BW   Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017",#N/A, 5/10/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference,#N/A,#N/A,#N/A, 6/10/2010 065C1X-E    BW   NanoString Technologies Launches Early Access Program for New Copy Number Variation Analysis Solution,#N/A," 6/23/2017 SYRS-US  BW   Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients",#N/A,#N/A, 3/04/2011 00182C10     BW   BioSante Pharmaceuticals to Raise $25.1 Million in Registered Direct Offering,"11/11/2016 00DYYX-E   BW   Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C",10/15/2018 ALNY-US   BW   Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran,#N/A,#N/A,#N/A," 4/05/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013", 4/08/2013 RTRX-US  BW   Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 9/05/2017 AKBA-US  BW   Akebia to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 2/02/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2011 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A,#N/A, 7/25/2011 05M7CK-E BW   Amyris and Firmenich Announce Expansion of Collaboration,#N/A,#N/A,#N/A,#N/A," 2/16/2017 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017",#N/A,#N/A,#N/A, 3/17/2015 29428V10 BW   Epizyme Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 1/18/2018 0BSW7D-E BW   Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease,11/02/2017 DRNA-US  BW   Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update, 7/06/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 1/03/2012 00BBFF-E BW   Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,10/05/2017 XLRN-US  BW   Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares,#N/A,10/26/2017 HZNP-US  BW   Horizon Pharma plc to Leverage Medidata Clinical Cloud® and eTMF Solutions to Support its Business Transformation,11/05/2015 00BJ80-E  BW   Castle Biosciences Presents Data on Unique Genetic Test for Predicting Cancer Recurrence in Soft Tissue Sarcoma,#N/A,#N/A, 6/28/2016 GLYC-US  BW   GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia,#N/A,#N/A,#N/A, 9/08/2017 G6674U10 BW   Der Gemeinsame Bundesausschuss beschließt die Einleitung des Beratungsverfahrens für eine Erprobungs-Richtlinie zum Einsatz von Optune® in der Behandlung des neu diagnostizierten Glioblastoms,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2018 74587V10 BW   Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2016 MCRB-US  BW   Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update, 3/07/2018 00900T10 BW   Aimmune Therapeutics to Participate in Four Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2014 00CFZL-E BW   Ra Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Complement C5 Inhibitor at 2014 ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/28/2016 009FRV-E BW   Quanterix and ImmunArray Teaming Up to Address Neurodegenerative Disease,#N/A,#N/A,#N/A,11/01/2012 30233G10 BW   pSivida Corp Announces First Quarter 2013 Financial Results Release Date and Conference Call Information,#N/A,#N/A,"10/31/2018 AXNX-US  BW   Axonics Modulation Technologies, Inc. gibt Preisangaben für Börseneinführung von Stammaktien bekannt",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2014 00DD8T-E BW   Personalis Announces Expansion of Scientific and Clinical Team: Deanna Church and Robert Nussbaum,#N/A,#N/A,#N/A,#N/A,#N/A
 2/28/2017 LGND-US   BW   Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene,#N/A, 8/01/2017 45232710    BW   Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017," 6/02/2017 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017",#N/A, 2/09/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 8/25/2015 68375N10 BW   OPKO Health to Be Present at the Barrington Research Fall Investment Conference,#N/A,#N/A," 1/22/2018 ALXN-US  BW   Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors",#N/A, 6/03/2018 4503-JP     BW   Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy,#N/A," 3/16/2017 09062X10    BW   Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development", 1/25/2017 IMGN-US  BW   ImmunoGen Announces Conference Call to Discuss its Results for Six-Month Period and Quarter Ended December 31, 1/04/2011 09058V10 BW   BioCryst to Present at J.P. Morgan Healthcare Conference," 3/06/2019 GILD-US      BW   Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance",#N/A,#N/A,11/05/2012 CGEN-IL  BW   Compugen Ltd. Reports Third Quarter 2012 Financial Results,11/01/2011 00972810  BW   Akorn Reports Record Third Quarter 2011 Financial Results,11/29/2012 AMBS-US      BW   RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit,#N/A,#N/A,#N/A,#N/A, 4/20/2017 05156V10 BW   Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings,#N/A,#N/A,#N/A,10/11/2010 37416310     BW   Geron Initiates Clinical Trial of Human Embryonic Stem Cell-Based Therapy in Patients with Spinal Cord Injury, 1/16/2018 AGN.XX2-US BW   Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations,#N/A, 9/06/2018 INCY-US  BW   Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018,#N/A, 5/19/2015 80360710 BW   Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA, 6/01/2016 ALKS-US  BW   Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference,"12/19/2016 06CR5C-E BW   Cerus Announces Exercise of Additional BARDA Contract Options Totaling $10,825,555 for Activities Related to Its Planned Phase III Trial of the INTERCEPT Red Blood Cell System"," 4/22/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on May 3, 2011 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2011","10/26/2017 04269E10 BW   ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017",#N/A,#N/A,"10/18/2017 EXEL-US  BW   Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017", 4/18/2016 SNY-FR    BW   New Data Suggesting Positive Effects of Sanofi Genzyme’s Lemtrada® (alemtuzumab) on Brain Volume Loss and Retinal Nerve Fibers to be Presented at AAN," 5/01/2018 VRTX-US   BW   Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members",#N/A,#N/A,12/10/2017 BLUE-US  BW   bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting,10/04/2017 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis,#N/A,#N/A,#N/A, 7/17/2017 TXMD-US  BW   TherapeuticsMD Provides TX-004HR Regulatory Update,#N/A,#N/A, 8/15/2017 OMER-US  BW   Omeros Announces Pricing of Public Offering of Common Stock, 6/15/2017 76133010 BW   Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery,#N/A, 5/09/2017 IRWD-US  BW   Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017,#N/A,#N/A,#N/A, 5/06/2010 065C1X-E    BW   NanoString Technologies Achieves Significant Milestone with ISO 13485:2003 Certification,#N/A, 6/19/2017 SYRS-US  BW   Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting,#N/A,#N/A, 3/03/2011 00182C10     BW   BioSante’s Pancreas Cancer Vaccine Shows Survival Increase in Newly Published Study,11/11/2016 06VHPT-E   BW   Enanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2016,10/10/2018 ALNY-US   BW   Alnylam Appoints Dr. Margaret Hamburg to Board of Directors,#N/A,#N/A,#N/A," 3/27/2013 69512710 BW   Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission", 3/11/2013 76129910 BW   Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2017 AKBA-US  BW   Akebia Announces Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A, 1/31/2018 SAGE-US     BW   Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/19/2011 56400P70 BW   MannKind Corporation to Hold 2011 First Quarter Financial Results Conference Call on May 9, 2011",#N/A,#N/A,#N/A," 7/19/2011 03236M20 BW   Amyris to Announce 2011 Second Quarter Financial Results on Tuesday, August 2, 2011",#N/A,#N/A,#N/A,#N/A, 2/13/2017 EGRX-US  BW   Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference,#N/A,#N/A,#N/A, 3/16/2015 29428V10 BW   Epizyme Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2018 VCYT-US  BW   Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth,11/02/2017 DRNA-US  BW   Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH), 6/27/2018 15117K10 BW   Résultats de l’Assemblée Générale Mixte des actionnaires de Cellectis S.A. du 26 juin 2018,#N/A,#N/A,#N/A,11/17/2011 00BBFF-E BW   Agios Secures $78 Million in Oversubscribed Series C Financing,#N/A,#N/A, 9/20/2017 XLRN-US  BW   Acceleron Announces Pricing of Public Offering of Common Stock,#N/A, 5/06/2016 HZNP-US  BW   Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming May 9 Deadline in the Securities Class Action Against Horizon Pharma plc and Encourages Investors to Contact the Firm,"11/03/2015 00BJ80-E  BW   Castle Biosciences Announces the Appointment of Federico Monzon, M.D., FCAP as Chief Medical Officer",#N/A,#N/A, 6/17/2016 GLYC-US  BW   GlycoMimetics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A, 9/08/2017 G6674U10 BW   Novocure kündigt Datenpräsentationen für den ESMO-Kongress 2017 an,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2018 PBYI-US  BW   Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2016 MCRB-US  BW   Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President," 3/04/2018 00900T10 BW   Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/30/2013 00CFZL-E BW   Ra Pharmaceuticals Appoints Pamela Esposito, Ph.D., as Chief Business Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2016 009FRV-E BW   Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016,#N/A,#N/A,#N/A,10/15/2012 EYPT-US  BW   pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Upcoming Massachusetts Biotechnology Council Meeting,#N/A,#N/A,"10/31/2018 AXNX-US  BW   Axonics Modulation Technologies, Inc. annonce l'introduction en bourse de ses actions ordinaires",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2013 00DD8T-E BW   Personalis Launches the ACE Clinical Exome™,#N/A,#N/A,#N/A,#N/A,#N/A
 2/27/2017 LGND-US   BW   Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes,#N/A," 7/11/2017 45232710    BW   Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017", 5/30/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th,#N/A, 2/02/2018 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 8/20/2015 68375N10 BW   OPKO Completes Acquisition of Bio-Reference Laboratories,#N/A,#N/A," 1/18/2018 ALXN-US  BW   Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018",#N/A," 5/17/2018 SGEN-US     BW   Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer",#N/A, 3/03/2017 BIIB-US     BW   ACHTUNG - KORREKTUR : Volltext der Pressemitteilung folgt: BIOCAD: Erstes Biosimilar von Interferon beta-1a erhält Zulassung in Russland, 1/23/2017 IMGN-US  BW   ImmunoGen Announces Departure of Sandra Poole,12/22/2010 09058V10 BW   BioCryst Initiates a Phase 2b Study of BCX4208 as Add-on Therapy in Gout Patients Not Responding to Allopurinol Alone," 3/06/2019 GILD-US      BW   Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women",#N/A,#N/A,10/31/2012 EVGN-IL  BW   Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy,10/06/2011 524500-IN BW   Akorn Enters Into an Agreement to Acquire Certain Assets of Kilitch Drugs in India,"11/28/2012 060RWY-E     BW   Surveyed U.S. Rheumatologists Report Enbrel is Their Preferred First-Line Biologic for Peripheral Predominant Psoriatic Arthritis and Ankylosing Spondylitis, Followed Closely By Humira",#N/A,#N/A,#N/A,#N/A, 4/17/2017 05156V10 BW   Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome,#N/A,#N/A,#N/A,10/05/2010 37416310     BW   Geron Announces Launch of GE Healthcare’s Human Cardiomyocyte Product for Drug Discovery and Toxicity Screening, 1/02/2018 0BMMPF-E   BW   Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs,#N/A, 8/28/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A, 5/12/2015 80360710 BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)," 5/26/2016 ALKS-IE  BW   Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors",12/19/2016 09BTYY-E BW   Cerus Provides an Update on the Timeline for the INTERCEPT Blood System for Red Blood Cells in Europe, 3/09/2011 992-HK   BW   Virtual Computer and Lenovo Collaborate to Optimize Client Virtualization,10/16/2017 ARQL-US  BW   ArQule Announces $15.7 Million Private Placement of Common Stock,#N/A,#N/A,10/16/2017 EXEL-US  BW   Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma," 3/08/2016 MRK-US    BW   Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies", 4/26/2018 VRTX-US   BW   Vertex Reports First-Quarter 2018 Financial Results,#N/A,#N/A,12/10/2017 BLUE-US  BW   bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting," 9/19/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017",#N/A,#N/A,#N/A," 6/09/2017 TXMD-US  BW   June 19 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against TherapeuticsMD, Inc.",#N/A,#N/A, 8/14/2017 OMER-US  BW   Omeros Announces Public Offering of Common Stock, 6/05/2017 76133010 BW   Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial,#N/A, 5/08/2017 IRWD-US  BW   Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update,#N/A,#N/A,#N/A, 4/19/2010 065C1X-E    BW   NanoString Technologies Introduces Novel Solution for microRNA Research,#N/A, 6/13/2017 SYRS-US  BW   Syros to Participate in JMP Securities Life Sciences Conference,#N/A,#N/A, 2/24/2011 00182C10     BW   BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Efficacy Trial,"11/01/2016 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016","10/08/2018 ALNY-US   BW   Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders in Recently Filed Class Action",#N/A,#N/A,#N/A," 3/07/2013 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results", 2/12/2013 76129910 BW   Retrophin Raises $10.0 Million in Private Placement,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 1/08/2018 00BBB0-E    BW   Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2011 56400P70 BW   MannKind’s End-of-Review Meeting with FDA Rescheduled,#N/A,#N/A,#N/A, 7/19/2011 09K18M-E BW   Amyris to Supply São Paulo City Buses with Renewable Diesel from Sugarcane,#N/A,#N/A,#N/A,#N/A, 1/23/2017 06CR5C-E BW   Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA,#N/A,#N/A,#N/A, 3/12/2015 29428V10 BW   Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2017 VCYT-US  BW   Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis,"10/26/2017 DRNA-US  BW   Dicerna to Report Third Quarter 2017 Financial Results and Host Conference Call on November 2, 2017"," 6/27/2018 15117K10 BW   Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018",#N/A,#N/A,#N/A,10/05/2011 00BBFF-E BW   Celgene and Agios Extend Cancer Metabolism Collaboration,#N/A,#N/A, 9/19/2017 XLRN-US  BW   Acceleron Announces Proposed Public Offering of Common Stock,#N/A, 5/03/2016 HZNP-US  BW   GPM Reminds Investors of the May 9 Deadline in the Class Action Lawsuit Against Horizon Pharma plc and Encourages Investors to Contact the Firm, 7/27/2015 00BJ80-E  BW   Castle Biosciences Closes $11.7 Million Tranche of $20 Million Financing,#N/A,#N/A, 6/16/2016 GLYC-US  BW   GlycoMimetics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 9/06/2017 NVCR-US  BW   Novocure Announces Data Presentations at the ESMO 2017 Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2018 74587V10 BW   Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2016 MCRB-US  BW   Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease, 3/02/2018 00900T10 BW   Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/01/2013 00CFZL-E BW   Ra Pharmaceuticals Announces Broad Collaboration with Merck to Develop Cyclomimetics™,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2016 009FRV-E BW   Quanterix and Banyan Biomarkers Join Together to Address Traumatic Brain Injury Head On,#N/A,#N/A,#N/A, 9/24/2012 EYPT-US  BW   pSivida Corp. Reports Fourth Quarter and Fiscal Year 2012 Results,#N/A,#N/A,"10/30/2018 AXNX-US  BW   Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/07/2013 00DD8T-E BW   Personalis Closes $22M Series B Financing,#N/A,#N/A,#N/A,#N/A,#N/A
 2/23/2017 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2016 Financial Results,#N/A, 6/29/2017 45232710    BW   Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit, 5/16/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17,#N/A, 1/22/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million,#N/A,#N/A,#N/A,#N/A, 8/19/2015 68375N10 BW   OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test,#N/A,#N/A, 1/02/2018 066LTV-E BW   Alexion and Elliott Agree to Collaborate on Identifying a New Board Member,#N/A, 5/17/2018 SGEN-US     BW   Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting,#N/A, 3/03/2017 BIIB-US     BW   CORRECTING and REPLACING BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia,12/28/2016 IMGN-US  BW   ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results in Platinum-Resistant Ovarian Cancer Published in the Journal of Clinical Oncology,12/04/2010 09058V10 BW   BioCryst Reports New Data from Its Phase 2 Forodesine Study in Patients with Chronic Lymphocytic Leukemia at the 52nd Annual American Society of Hematology Meeting, 3/06/2019 GILD-US      BW   Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection,#N/A,#N/A,"10/29/2012 CGEN-IL  BW   Compugen Postpones Issuance of Third Quarter 2012 Report and Associated Conference Call to November 5, 2012, Due to Expected Severe Weather Conditions", 8/02/2011 00972810  BW   Akorn to Acquire a Minority Stake in Aciex Therapeutics,11/27/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference,#N/A,#N/A,#N/A,#N/A," 4/10/2017 05156V10 BW   Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL",#N/A,#N/A,#N/A, 9/13/2010 37416310     BW   Geron Announces Collaboration With University Campus Suffolk to Develop Human Embryonic Stem Cell-Derived Chondrocytes for Cartilage Repair,12/18/2017 AERI-US    BW   Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension,#N/A, 7/31/2018 INCY-US  BW   Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs,#N/A, 5/07/2015 80360710 BW   Sarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments, 5/25/2016 ALKS-US  BW   Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230,11/03/2016 06CR5C-E BW   Cerus Corporation Reports Third Quarter 2016 Results, 2/25/2011 00163U10 BW   AMAG Announces Fourth Quarter and Year End 2010 Financial Results," 9/19/2017 04269E10 BW   ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017",#N/A,#N/A,10/16/2017 EXEL-US  BW   Ipsen annonce que l'étude de phase 3 CELESTIAL avec le cabozantinib atteint son critère d'évaluation principal de survie globale chez des patients atteints de carcinome hépatocellulaire avancé, 3/03/2016 003ZHQ-E  BW   Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease," 4/26/2018 VRTX-US   BW   Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis",#N/A,#N/A,12/10/2017 BLUE-US  BW   Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting, 8/08/2017 ACAD-US  BW   ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A," 6/05/2017 TXMD-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A, 8/14/2017 OMER-US  BW   Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721, 6/01/2017 76133010 BW   Revance to Participate in Upcoming Investor Conferences,#N/A," 5/01/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017",#N/A,#N/A,#N/A, 2/03/2010 065C1X-E    BW   William D. Young Joins NanoString Technologies as Executive Chairman of the Board,#N/A, 6/12/2017 SYRS-US  BW   Syros Appoints Srinivas Akkaraju to Its Board of Directors,#N/A,#N/A," 2/22/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at Citi Global Health Care Conference",10/26/2016 CS-CH      BW   Enanta Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference,"10/06/2018 ALNY-US   BW   ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – ALNY",#N/A,#N/A,#N/A," 3/06/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference", 2/04/2013 76129910 BW   Retrophin to Present at the 15th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2017 AKBA-US  BW   Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters,#N/A,#N/A,#N/A,#N/A, 1/03/2018 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2011 56400P70 BW   MannKind Provides Regulatory Update,#N/A,#N/A,#N/A," 6/17/2011 03236M20 BW   Amyris anuncia planos de expansão na Ásia e na área de surfactantes globais em colaboração com a Wilmar, um dos maiores grupos globais do agronegócio",#N/A,#N/A,#N/A,#N/A, 1/04/2017 EGRX-US  BW   Eagle Pharmaceuticals to Present at J.P. Morgan 35th Annual Healthcare Conference,#N/A,#N/A,#N/A, 3/12/2015 29428V10 BW   Epizyme Announces 2014 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2017 VCYT-US  BW   Veracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference,"10/16/2017 DRNA-US  BW   Dicerna Files Clinical Trial Application for DCR-PHXC, the Company’s Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)", 6/12/2018 15117K10 BW   Cellectis publie dans Scientific Reports de nouvelles techniques pour améliorer l’utilisation clinique des thérapies fondées sur les cellules CAR-T,#N/A,#N/A,#N/A," 9/20/2011 00BBFF-E BW   Marc Tessier-Lavigne, Ph.D., President of The Rockefeller University, Joins Agios Board of Directors",#N/A,#N/A, 9/19/2017 XLRN-US  BW   Acceleron Showcases Vision and Strategy at 2017 R&D Day,#N/A," 4/25/2016 HZNP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Horizon Pharma plc of Class Action Lawsuit and a Lead Plaintiff Deadline of May 9, 2016", 6/29/2015 00BJ80-E  BW   Castle Biosciences Announces the Appointment of Veracyte CEO Bonnie H. Anderson to its Board of Directors,#N/A,#N/A, 6/13/2016 06CR5C-E BW   GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia,#N/A,#N/A,#N/A, 9/05/2017 G6674U10 BW   German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2018 74587V10 BW   Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2016 063Y8S-E BW   Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment," 2/27/2018 00900T10 BW   Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2012 00CFZL-E BW   Ra Pharmaceuticals Unveils Hereditary Angioedema as Lead Program Leveraging Its Cyclomimetic Discovery Platform,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2016 009FRV-E BW   Frontage Laboratories Announces Partnership with Quanterix and Validation of Simoa HD-1 Analyzer and Software to Support Biomarker Analysis,#N/A,#N/A,#N/A, 9/17/2012 EYPT-US  BW   pSivida Corp. Announces Fourth Quarter and Fiscal Year 2012 Financial Results Release Date and Conference Call Information,#N/A,#N/A,10/09/2018 0DM9XX-E BW   Axonics® gibt Einreichung eines Antrags auf Börsenzulassung bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2013 00DD8T-E BW   Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales,#N/A,#N/A,#N/A,#N/A,#N/A
" 2/14/2017 LGND-US   BW   Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform",#N/A, 6/27/2017 45232710    BW   Genomics England adopte le logiciel BaseSpace d’Illumina pour le cancer, 5/02/2017 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update,#N/A, 1/18/2018 05NBLJ-E BW   Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 8/05/2015 68375N10 BW   OPKO Announces Second Quarter Operating and Financial Results,#N/A,#N/A, 1/02/2018 ALXN-US  BW   Alexion to Present at the 36th Annual J.P. Morgan Healthcare Conference,#N/A, 5/02/2018 SGEN-US     BW   Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018,#N/A, 2/28/2017 09062X10    BW   Biogen to Present at the Cowen & Company 37th Annual Health Care Conference,12/28/2016 IMGN-US  BW   ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference,11/08/2010 09058V10 BW   BioCryst to Present New Data for BCX4208 Monotherapy at the 74th Annual American College of Rheumatology (ACR) Scientific Meeting, 3/05/2019 GILD-US      BW   Gilead Announces Senior Management Change,#N/A,#N/A,"10/23/2012 CGEN-IL  BW   Compugen Third Quarter 2012 Conference Call Scheduled for Tuesday, October 30, 2012 at 10:00 AM EDT", 8/02/2011 009PVH-E  BW   Akorn Reports Second Quarter 2011 Financial Results,"11/27/2012 060RWY-E     BW   Sensipar, Fosrenol and Renagel/Renvela are Likely to be Negatively Impacted in 2014 When Oral Medications Become Included in the Dialysis Bundle, According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A, 4/06/2017 05156V10 BW   Aurinia Announces Development Plans for Voclosporin in Europe and Japan,#N/A,#N/A,#N/A, 9/13/2010 37416310     BW   Geron Obtains Exclusive License for Deriving Cartilage from Human Embryonic Stem Cells from University of Edinburgh,12/04/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region,#N/A, 7/12/2018 INCY-US  BW   Incyte to Report Second Quarter Financial Results,#N/A, 5/01/2015 80360710 BW   Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), 5/24/2016 ALKS-IE  BW   Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting,"11/01/2016 CERS-US  BW   Cerus to Present at the Stephens 2016 Fall Investment Conference on November 8, 2016"," 2/24/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 8/04/2017 04269E10 BW   ArQule Reports Second Quarter 2017 Financial Results,#N/A,#N/A,10/16/2017 EXEL-US  BW   Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma, 3/02/2016 003ZHQ-E  BW   Actress Madeleine Stowe and Sanofi Genzyme Launch New Phase of Take Action on MS with Dynamic Webisode Series, 4/17/2018 VRTX-US   BW   Vertex to Announce First Quarter 2018 Financial Results on April 26,#N/A,#N/A,12/07/2017 BLUE-US  BW   bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy," 8/01/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017",#N/A,#N/A,#N/A," 6/02/2017 TXMD-US  BW   The Klein Law Firm Announces a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A, 8/10/2017 OMER-US  BW   Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference, 5/18/2017 76133010 BW   Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial,#N/A, 4/24/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2017 SYRS-US  BW   Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients,#N/A,#N/A, 2/15/2011 00182C10     BW   BioSante Presents Data Showing Female Sexual Dysfunction is a Significant Unmet Medical Need,10/03/2016 00DYYX-E   BW   Enanta Pharmaceuticals Announces New Data Presentations at The Liver Meeting® 2016,10/04/2018 ALNY-US   BW   Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1,#N/A,#N/A,#N/A," 2/28/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/28/2017 AKBA-US  BW   Akebia Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,12/07/2017 SAGE.XX1-US BW   Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 56400P70 BW   MannKind Posters Win Awards from International Pharmaceutical Aerosol Consortium on Regulation and Science,#N/A,#N/A,#N/A," 6/16/2011 F34-SG   BW   Amyris Announces Plans to Expand into Asia and Global Surfactants Though Collaboration with Wilmar, One of World’s Leading Agribusiness Groups",#N/A,#N/A,#N/A,#N/A, 1/03/2017 06CR5C-E BW   Eagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review,#N/A,#N/A,#N/A," 3/05/2015 29428V10 BW   Epizyme to Report Fourth Quarter 2014 Financial Results and Provide Corporate Update on March 12, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2017 VCYT-US  BW   Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology, 9/20/2017 DRNA-US  BW   Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series, 6/12/2018 15117K10 BW   Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports,#N/A,#N/A,#N/A, 8/02/2011 00BBFF-E BW   Agios Founder and Advisor Publish In Nature Genetics On Further Links Between Serine Metabolic Pathway and Cancer,#N/A,#N/A, 9/19/2017 XLRN-US  BW   Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension,#N/A, 4/22/2016 HZNP-IE  BW   HZNP INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Horizon Pharma PLC," 6/15/2015 00BJ80-E  BW   Castle Biosciences Announces National Payer Agreements with MultiPlan, FedMed and Preferred Medical Claim Solutions",#N/A,#N/A, 6/10/2016 GLYC-US  BW   GlycoMimetics’ GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML,#N/A,#N/A,#N/A, 8/24/2017 G6674U10 BW   Novocure to Present at Two Upcoming Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2018 06V2PS-E BW   Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel,#N/A,#N/A,#N/A,#N/A,#N/A," 5/09/2016 MCRB-US  BW   Seres Therapeutics to Host First Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on May 16, 2016", 2/26/2018 00900T10 BW   Aimmune Therapeutics Announces Closing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/24/2016 009FRV-E BW   Quanterix to Present at 5th Annual One Mind Summit,#N/A,#N/A,#N/A, 9/05/2012 EYPT-US  BW   pSivida Corp. Reports U.K. National Institute for Health and Clinical Evidence Accepts ILUVIEN® Subgroup Data for Review,#N/A,#N/A,10/09/2018 0DM9XX-E BW   Axonics® annonce le dépôt d'une déclaration d'enregistrement pour une proposition d'offre publique initiale,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/20/2013 00DD8T-E BW   Personalis Co-Founder Dr. Atul Butte MD, Stanford University, Recognized at the White House",#N/A,#N/A,#N/A,#N/A,#N/A
 2/13/2017 LGND-US   BW   Reminder: Ligand to Host Analyst Day on February 28th in New York City,#N/A, 6/27/2017 45232710    BW   Genomics England übernimmt BaseSpace Variant Interpreter für Krebs von Illumina, 4/27/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4,#N/A, 1/17/2018 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 8/05/2015 68375N10 BW   Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE conference),#N/A,#N/A,12/26/2017 ALXN-US  BW   Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG),#N/A, 4/26/2018 SGEN-US     BW   Seattle Genetics Reports First Quarter 2018 Financial Results,#N/A, 2/15/2017 09062X10    BW   Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference,"12/05/2016 IMGN-US  BW   Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting",11/02/2010 09058V10 BW   BioCryst Awarded $1.1 Million in Grants for Qualifying Therapeutic Development Projects," 3/05/2019 GILD-US      BW   Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12",#N/A,#N/A, 9/10/2012 CGEN-IL  BW   Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance, 6/01/2011 00972810  BW   Akorn Announces Closing of $120 Million of Convertible Senior Notes Due 2016,11/26/2012 0C8BZH-E     BW   RBCC JV Target Amarantus Explores Orphan Drug Designation for MANF,#N/A,#N/A,#N/A,#N/A, 3/27/2017 05156V10 BW   Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017),#N/A,#N/A,#N/A, 9/09/2010 37416310     BW   Geron Corporation to Present at Three Upcoming Investor Conferences,12/01/2017 089F0V-E   BW   Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources,#N/A, 6/21/2018 INCY-US  BW   Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event,#N/A," 4/30/2015 80360710 BW   Sarepta Therapeutics to Announce First Quarter 2015 Financial Results and Recent Corporate Developments on May 7, 2015", 4/28/2016 ALKS-US  BW   Alkermes plc Reports First Quarter 2016 Financial Results,"10/20/2016 CERS-US  BW   Cerus to Release Third Quarter 2016 Results on November 3, 2016"," 2/18/2011 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on February 25, 2011 at 8:00 a.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2010"," 7/21/2017 04269E10 BW   ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017",#N/A,#N/A,10/16/2017 EXEL-US  BW   Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma, 3/02/2016 SNY-FR    BW   ATTENTION - RECTIFICATION : Revoici la dépêche corrigée: Les Grands Groupes Français du CAC 40 choisissent Trintech qu'ils considèrent comme la solution la plus fiable pour l'automatisation de leur processus Record to Report, 4/04/2018 0FK70W-E  BW   Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration,#N/A,#N/A,11/29/2017 BLUE-US  BW   bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients, 7/25/2017 ACAD-US  BW   ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies,#N/A,#N/A,#N/A," 5/30/2017 TXMD-US  BW   TXMD INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A, 8/08/2017 OMER-US  BW   Omeros Corporation Reports Second Quarter 2017 Financial Results, 5/09/2017 76133010 BW   Revance Releases First Quarter 2017 Results,#N/A, 4/06/2017 IRWD-US  BW   Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2017 SYRS-US  BW   Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones,#N/A,#N/A, 2/14/2011 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program, 9/30/2016 06CR5C-E   BW   Enanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation,"10/03/2018 ALNY-US   BW   Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)",#N/A,#N/A,#N/A," 2/25/2013 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/28/2017 AKBA-US  BW   Akebia Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,12/07/2017 SAGE-US     BW   Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2011 56400P70 BW   MannKind to Present at the Citi 2011 Global Healthcare Conference,#N/A,#N/A,#N/A, 6/13/2011 03236M20 BW   Amyris e Cosan formam Novvi S.A. para Produção e Comercialização Globais de Óleos de Base Renovável,#N/A,#N/A,#N/A,#N/A,12/19/2016 06CR5C-E BW   Eagle Pharmaceuticals Announces David Pernock as President and Chief Commercial Officer,#N/A,#N/A,#N/A, 3/03/2015 29428V10 BW   Epizyme Announces Presentation of Data from Phase 1 Study of EZH2 Inhibitor EPZ-6438 (E7438),#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2017 VCYT-US  BW   Veracyte Announces Third Quarter 2017 Financial Results, 9/05/2017 DRNA-US  BW   Dicerna to Present at Rodman & Renshaw 19th Annual Global Investment Conference, 6/08/2018 15117K10 BW   Cellectis : Assemblée Générale Mixte du 26 juin 2018,#N/A,#N/A,#N/A, 7/14/2011 06471L-E BW   Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer,#N/A,#N/A," 9/12/2017 XLRN-US  BW   Acceleron to Host Research and Development Day on September 19, 2017",#N/A," 4/15/2016 HZNP-IE  BW   INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Horizon Pharma plc and a Lead Plaintiff Deadline of May 9, 2016", 6/01/2015 00BJ80-E  BW   Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification of High Risk Disease in Tumors of Intermediate T2/T3 Thickness,#N/A,#N/A, 6/06/2016 GLYC-US  BW   GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia,#N/A,#N/A,#N/A, 8/10/2017 G6674U10 BW   Novocure™ kündigt landesweite Kostenerstattung für Optune® in Österreich an,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2018 74587V10 BW   Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2016 0B0VJP-E BW   Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease, 2/21/2018 00900T10 BW   Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2016 009FRV-E BW   Quanterix Named a Recipient of the Massachusetts Life Sciences Center’s Tax Incentive Program for Third Year,#N/A,#N/A,#N/A, 8/29/2012 EYPT-US  BW   pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Drug Delivery Technologies & Formulation Conference in Switzerland,#N/A,#N/A,10/09/2018 0DM9XX-E BW   Axonics® Announces Filing of Registration Statement for Proposed Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2013 00DD8T-E BW   Personalis Announces Participation in the European Society of Human Genetics Conference,#N/A,#N/A,#N/A,#N/A,#N/A
 1/24/2017 LGND-US   BW   Ligand to Host Analyst Day on February 28th in New York City,#N/A, 6/26/2017 45232710    BW   Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer, 4/25/2017 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast,#N/A,12/27/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors,#N/A,#N/A,#N/A,#N/A, 7/31/2015 ULTI-US  BW   Ultimate Software Ranked #7 on Forbes List of 100 Most Innovative Growth Companies,#N/A,#N/A,12/20/2017 ALXN-US  BW   Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference,#N/A, 4/12/2018 06P9WL-E    BW   Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 2/07/2017 09062X10    BW   Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference,11/11/2016 IMGN-US  BW   ImmunoGen to Present Preclinical Data Highlighting Potential of Combining Mirvetuximab Soravtansine with an Immune Checkpoint Inhibitor at SITC 2016 Annual Meeting,10/28/2010 09058V10 BW   BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update, 2/26/2019 GILD-US      BW   Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV,#N/A,#N/A, 8/07/2012 CGEN-IL  BW   Compugen Ltd. Reports Second Quarter 2012 Financial Results, 5/26/2011 00972810  BW   Akorn Announces Pricing of $100 Million of Convertible Senior Notes Due 2016,11/19/2012 0C8BZH-E     BW   RBCC: Short R&D Timeline Could Lead to Larger Profits,#N/A,#N/A,#N/A,#N/A, 3/20/2017 05156V10 BW   Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares,#N/A,#N/A,#N/A, 7/30/2010 37416310     BW   Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy,11/27/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics,#N/A, 6/21/2018 INCY-US  BW   Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease,#N/A," 3/31/2015 80360710 BW   Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs", 4/28/2016 ALKS-US  BW   Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results,10/13/2016 06CR5C-E BW   Cerus Announces First U.S. Blood Center Customer Submits Biologics License Application to the FDA to Allow for Interstate Export of INTERCEPT Platelet Components, 2/08/2011 AMAG-US  BW   AMAG Pharmaceuticals Provides Update on Canadian New Drug Submission," 7/11/2017 04269E10 BW   ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies",#N/A,#N/A,10/04/2017 EXEL-US  BW   Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORγt Inverse Agonist Program, 2/29/2016 07JQ3W-E  BW   Sanofi Genzyme Recognizes Rare Disease Day 2016 with Program of Events around the World, 3/29/2018 VRTX-US   BW   Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer,#N/A,#N/A,11/16/2017 BLUE-US  BW   Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma, 5/09/2017 ACAD-US  BW   ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results,#N/A,#N/A,#N/A," 5/26/2017 TXMD-US  BW   EQUITY ALERT: Levi & Korsinsky, LLP N Shareholders of a Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc.",#N/A,#N/A, 8/04/2017 OMER-US  BW   FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy, 5/01/2017 76133010 BW   Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis,#N/A, 3/10/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 5/15/2017 SYRS-US  BW   Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors",#N/A,#N/A," 2/14/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update at BIO CEO & Investor Conference", 9/29/2016 ENTA-US    BW   Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference,"10/02/2018 ALNY-US   BW   Alnylam Launches ONPATTRO™ (patisiran), the First-Ever RNAi Therapeutic, in Germany",#N/A,#N/A,#N/A," 1/17/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/20/2017 AKBA-US  BW   Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017",#N/A,#N/A,#N/A,#N/A,12/04/2017 SAGE.XX1-US BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/17/2011 56400P70 BW   Lieff, Cabraser, Heimann & Bernstein, LLP Announces Class Action Lawsuits Against MannKind Corporation (Nasdaq: MNKD)",#N/A,#N/A,#N/A, 6/13/2011 CSAN3-BR BW   Cosan and Amyris Forming Novvi S.A. for Global Production and Commercialization of Renewable Base Oils,#N/A,#N/A,#N/A,#N/A,12/13/2016 EGRX-US  BW   Eagle Pharmaceuticals Reports Positive Results from Pivotal Animal Study Supporting the Efficacy of RYANODEX for Exertional Heat Stroke,#N/A,#N/A,#N/A, 2/27/2015 29428V10 BW   Epizyme to Present at Cowen and Company 35th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2017 VCYT-US  BW   Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum, 8/10/2017 DRNA-US  BW   Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update," 6/08/2018 15117K10 BW   Cellectis: Shareholders’ General Meeting of June 26, 2018",#N/A,#N/A,#N/A, 6/01/2011 09LL8W-E BW   Tripos Announces Agios Pharmaceuticals’ Choice of D360 Software,#N/A,#N/A, 9/05/2017 XLRN-US  BW   Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology,#N/A," 4/06/2016 HZNP-IE  BW   INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Horizon Pharma plc and a Lead Plaintiff Deadline of May 9, 2016"," 5/28/2015 00BJ80-E  BW   Castle Biosciences Expands Sales Force and Appoints Patrick Hall as Executive Director of Medical Affairs, Promotes Robert W. Cook to Executive Director, R&D",#N/A,#N/A, 6/02/2016 GLYC-US  BW   GlycoMimetics to Present at Jefferies 2016 Healthcare Conference,#N/A,#N/A,#N/A, 8/08/2017 G6674U10 BW   Novocure™ Announces National Reimbursement for Optune® in Austria,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2018 74587V10 BW   Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2016 MCRB-US  BW   Seres Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference, 2/20/2018 00900T10 BW   Aimmune Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2016 009FRV-E BW   Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology,#N/A,#N/A,#N/A, 8/28/2012 EYPT-US  BW   pSivida to Present at Two Investment Conferences in September,#N/A,#N/A, 9/27/2018 0DM9XX-E BW   Axonics® reçoit de Medtech Insight le prix de l’innovation technologique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2013 00DD8T-E BW   Michael Fitzpatrick Joins Personalis as Vice President Worldwide Sales,#N/A,#N/A,#N/A,#N/A,#N/A
 1/23/2017 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd,#N/A," 6/08/2017 ILMN-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files Amended Complaint Against Illumina, Inc. and Senior Officers", 4/04/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting,#N/A,12/22/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV,#N/A,#N/A,#N/A,#N/A," 7/30/2015 68375N10 BW   OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015",#N/A,#N/A,12/11/2017 ALXN-US  BW   Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting,#N/A," 4/05/2018 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018",#N/A," 2/01/2017 BIVV-US     BW   Biogen Completes Separation of Global Hemophilia Business, Bioverativ",11/03/2016 06QBQ2-E BW   ImmunoGen Announces Preclinical Data Presentations for Two ADCs With Novel IGN Payloads at Upcoming 58th ASH Annual Meeting,10/27/2010 09058V10 BW   BioCryst’s Partner Shionogi Receives Approval for Pediatric Use Of Peramivir in Japan, 2/11/2019 GILD-US      BW   Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH),#N/A,#N/A," 7/30/2012 CGEN-IL  BW   Compugen Second Quarter 2012 Conference Call Scheduled for Tuesday, August 7, 2012 at 10:00 AM EDT", 5/25/2011 00972810  BW   Akorn Announces Proposed Offering of $100 Million of Convertible Senior Notes Due 2016,11/15/2012 0C8BZH-E     BW   RBCC JV Target Amarantus Secures $1.1 Million in Financing,#N/A,#N/A,#N/A,#N/A, 3/16/2017 05156V10 BW   Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017),#N/A,#N/A,#N/A, 7/29/2010 37416310     BW   Geron Corporation Reports 2010 Second Quarter Financial Results and Events,11/16/2017 AERI-US    BW   Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan,#N/A, 5/24/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A, 2/26/2015 80360710 BW   Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments, 4/21/2016 ALKS-US  BW   Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results,10/10/2016 CERS-US  BW   Cerus Announces that Hemolife Fundación Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System, 1/09/2011 4502-JP  BW   AMAG Pharmaceuticals Provides Business Update," 6/23/2017 04269E10 BW   ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)",#N/A,#N/A," 9/24/2017 EXEL-US  BW   Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study", 2/26/2016 003ZHQ-E  BW   Sanofi Genzyme Leadership in Rare Diseases Highlighted at WORLDSymposium 2016, 3/12/2018 VRTX-US   BW   Vertex to Present at the Cowen Healthcare Conference on March 13,#N/A,#N/A,"11/16/2017 BLUE-US  BW   bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype"," 5/08/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017",#N/A,#N/A,#N/A, 5/23/2017 TXMD-US  BW   TherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8,#N/A,#N/A," 8/02/2017 OMER-US  BW   Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017"," 4/25/2017 76133010 BW   Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017",#N/A, 3/09/2017 IRWD-US  BW   Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines to Patients and Building a Top-Performing Commercial Biotech at R&D Day 2017,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2017 SYRS-US  BW   Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting,#N/A,#N/A, 2/12/2011 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program," 9/28/2016 ENTA-US    BW   Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)",10/02/2018 ALNY-US   BW   Alnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting,#N/A,#N/A,#N/A," 1/15/2013 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Notes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2017 AKBA-US  BW   Akebia Prevails in Two Additional European Patent Disputes,#N/A,#N/A,#N/A,#N/A,"11/17/2017 SAGE-US     BW   Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/11/2011 56400P70 BW   49 Days Left - Kahn Swick & Foti, LLC and Former Louisiana Attorney General Remind Investors With Large Financial Interests (Over $100,000) of Lead Plaintiff Deadline in Lawsuit Against MannKind Corp. - MNKD",#N/A,#N/A,#N/A, 5/17/2011 AMRS-US  BW   Amyris Names Schwartz Communications Public Relations Agency of Record,#N/A,#N/A,#N/A,#N/A,11/21/2016 EGRX-US  BW   Eagle Pharmaceuticals to Present at Piper Jaffray 28th Annual Healthcare Conference,#N/A,#N/A,#N/A," 2/05/2015 29428V10 BW   Epizyme, Inc. to Present at Upcoming Conferences in February",#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2017 VCYT-US  BW   CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis," 8/03/2017 DRNA-US  BW   Dicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017", 6/07/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A, 3/01/2011 00BBFF-E BW   Agios Pharmaceuticals to Present at 31st Annual Cowen Healthcare Conference,#N/A,#N/A, 8/03/2017 XLRN-US  BW   Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results,#N/A," 4/06/2016 HZNP-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Horizon Pharma plc of Class Action Lawsuit and a Lead Plaintiff Deadline of May 9, 2016 - HZNP", 4/21/2015 00BJ80-E  BW   Castle Biosciences Hires Vice President of Marketing,#N/A,#N/A, 5/25/2016 GLYC-US  BW   GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine,#N/A,#N/A,#N/A, 8/02/2017 G6674U10 BW   Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2017 74587V10 BW   Puma Biotechnology Added to NASDAQ Biotechnology Index,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2016 06CR5C-E BW   Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection, 2/20/2018 00900T10 BW   Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/23/2016 009FRV-E BW   Quanterix Raises $46 Million in Series D Financing,#N/A,#N/A,#N/A, 8/08/2012 EYPT-US  BW   pSivida Corp. Announces Closing of $5.36 Million Registered Direct Financing,#N/A,#N/A, 9/27/2018 0DM9XX-E BW   Axonics® erhält Technology Innovation Award von Medtech Insight,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/12/2013 00DD8T-E BW   Personalis Awarded Contract From VA Million Veteran Program – Whole Genome Sequencing and Data Analysis for Over 1,000 Individuals",#N/A,#N/A,#N/A,#N/A,#N/A
" 1/13/2017 LGND-US   BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A, 5/31/2017 ILMN-US     BW   FitnessGenes™ Secures $5 Million Series A Funding," 3/31/2017 84763A10  BW   Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017",#N/A,12/20/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT,#N/A,#N/A,#N/A,#N/A, 7/28/2015 OPK-US   BW   FDA Accepts OPKO’s New Drug Application for Rayaldee™,#N/A,#N/A,12/07/2017 ALXN-US  BW   Alexion and Halozyme Enter License Agreement for ENHANZE Technology,#N/A, 3/26/2018 4503-JP     BW   Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer,#N/A, 1/26/2017 09062X10    BW   Biogen Reports 2016 Revenues of $11.4 Billion,10/28/2016 IMGN-US  BW   ImmunoGen Reports Financial Results for Quarter Ended September 30 and Reviews Business Highlights,10/25/2010 09058V10 BW   BioCryst to Present at Oppenheimer Healthcare Conference, 2/04/2019 GILD-US      BW   Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend,#N/A,#N/A, 7/02/2012 CGEN-IL  BW   Compugen Announces Development of NexGen Infrastructure Platform for Analysis of Next Generation Sequencing Data, 5/03/2011 00972810  BW   Akorn Reports First Quarter 2011 Financial Results,11/14/2012 RBCC-US      BW   RBCC Scouts New Biotech Innovations at NIBA Investment Conference,#N/A,#N/A,#N/A,#N/A, 3/14/2017 05156V10 BW   Aurinia Prices US$150.5 Million Public Offering of Common Shares,#N/A,#N/A,#N/A, 7/26/2010 37416310     BW   Geron Announces Conference Call to Discuss Financial Results for the 2010 Second Quarter,11/08/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update,#N/A, 5/01/2018 INCY-US  BW   Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs,#N/A, 2/24/2015 80360710 BW   Sarepta Therapeutics to Present Company Overview at Upcoming Conferences, 3/31/2016 ALKS-IE  BW   Study on Extended-Release Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice System Published in the New England Journal of Medicine,10/05/2016 CERS-US  BW   Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)," 1/05/2011 AMAG-US  BW   AMAG Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference"," 6/07/2017 04269E10 BW   ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases",#N/A,#N/A, 9/19/2017 EXEL-US  BW   Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25, 2/26/2016 003ZHQ-E  BW   Sanofi Genzyme s’engage pour la Journée internationale des Maladies Rares pour porter l’espoir auprès des malades," 3/01/2018 VRTX-US   BW   Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation",#N/A,#N/A,11/01/2017 BLUE-US  BW   bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress," 5/02/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017",#N/A,#N/A,#N/A," 5/17/2017 TXMD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc.",#N/A,#N/A, 6/29/2017 OMER-US  BW   Omeros Releases Statement in Response to Recent False Report, 3/07/2017 76133010 BW   Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines,#N/A, 2/28/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2017 SYRS-US  BW   Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference",#N/A,#N/A," 2/02/2011 00182C10     BW   BioSante Pharmaceuticals, Inc. To Provide Update on LibiGel® Safety Study at International Society for the Study of Women’s Sexual Health Meeting", 9/23/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C,"10/01/2018 ALNY-US   BW   IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",#N/A,#N/A,#N/A,12/18/2012 PCRX-US  BW   New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/25/2017 AKBA-US  BW   Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,11/14/2017 PGLC-US     BW   Sage Therapeutics Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/11/2011 56400P70 BW   Abraham, Fruchter & Twersky, LLP Announces Filing of Class Action Lawsuit against Mannkind Corporation",#N/A,#N/A,#N/A, 5/17/2011 03236M20 BW   Amyris to Present to Investment Community,#N/A,#N/A,#N/A,#N/A,11/11/2016 EGRX-US  BW   Eagle Pharmaceuticals Signs Definitive Agreement to Acquire Arsia Therapeutics Marking Entry into Biosimilar Market,#N/A,#N/A,#N/A, 2/03/2015 29428V10 BW   Epizyme Appoints Andrew Singer as Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,"10/26/2017 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017", 7/17/2017 DRNA-US  BW   Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC, 6/07/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A, 1/06/2011 00BBFF-E BW   Agios Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 8/01/2017 XLRN-US  BW   Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease,#N/A, 4/04/2016 HZNP-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Horizon Pharma plc Investors and Encourages Investors to Contact the Firm, 4/14/2015 00BJ80-E  BW   Castle Biosciences Secures $6 Million Credit Facility from Silicon Valley Bank,#N/A,#N/A, 5/19/2016 07G766-E BW   Initial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress,#N/A,#N/A,#N/A, 7/27/2017 G6674U10 BW   Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/13/2017 74587V10 BW   Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2016 BCS-GB   BW   Seres Therapeutics to Present at the Barclays Global Healthcare Conference," 2/14/2018 080VNJ-E BW   Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/08/2016 009FRV-E BW   Quanterix to Present at Cowen and Company 36th Annual Health Care Conference,#N/A,#N/A,#N/A, 8/02/2012 EYPT-US  BW   pSivida Corp. Announces $5.36 Million Registered Direct Financing,#N/A,#N/A, 9/27/2018 0DM9XX-E BW   Axonics® Receives Technology Innovation Award from Medtech Insight,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2013 00DD8T-E BW   Personalis Introduces Genome Services for Research – High Accuracy Sequencing and Interpretation of Human Genomes,#N/A,#N/A,#N/A,#N/A,#N/A
" 1/07/2017 LGND-US   BW   DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm",#N/A, 5/30/2017 45232710    BW   Illumina to Webcast Live Presentation at the Goldman Sachs Global Healthcare Conference, 3/30/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations,#N/A,12/18/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4),#N/A,#N/A,#N/A,#N/A, 7/10/2015 68375N10 BW   OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults,#N/A,#N/A,11/27/2017 ALXN-US  BW   Alexion to Present at the Citi 2017 Global Healthcare Conference,#N/A, 3/20/2018 SGEN-US     BW   Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma,#N/A," 1/17/2017 09062X10    BW   Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017","10/14/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Financial Results for Quarter Ended September 30",10/21/2010 09058V10 BW   BioCryst to Present New Clinical & Virologic Data for I.V. Peramivir at the 48th Annual IDSA Meeting, 2/04/2019 GILD-US      BW   Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results,#N/A,#N/A, 6/27/2012 CGEN-IL  BW   Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy, 5/03/2011 00972810  BW   Akorn Enters Into an Agreement to Acquire Advanced Vision Research,11/12/2012 06W76T-E     BW   First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University,#N/A,#N/A,#N/A,#N/A, 3/13/2017 05156V10 BW   Aurinia Announces Public Offering of Common Shares,#N/A,#N/A,#N/A, 7/19/2010 37416310     BW   Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer,11/07/2017 AERI-US    BW   Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference,#N/A, 4/26/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A," 2/19/2015 80360710 BW   Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015", 3/28/2016 ALKS-US  BW   Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference, 9/07/2016 CERS-US  BW   Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),11/29/2010 00163U10 BW   AMAG Pharmaceuticals Announces Update to Feraheme® Label, 6/03/2017 04269E10 BW   ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,#N/A, 9/09/2017 EXEL-US  BW   Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017, 1/11/2016 SNY-FR    BW   Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms," 2/26/2018 VRTX-US   BW   Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer",#N/A,#N/A,11/01/2017 BLUE-US  BW   bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting," 3/30/2017 ACAD-US  BW   ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer",#N/A,#N/A,#N/A, 5/10/2017 TXMD-US  BW   TherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16,#N/A,#N/A, 6/13/2017 OMER-US  BW   FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy, 3/03/2017 76133010 BW   Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting,#N/A," 2/23/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017",#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2017 SYRS-US  BW   Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer,#N/A,#N/A, 1/25/2011 06CR5C-E     BW   BioSante Announces FDA Orphan Drug Designation for its Melanoma Cancer Vaccine, 8/29/2016 MS-US      BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 9/28/2018 ALNY-US   BW   Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO™ (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis,#N/A,#N/A,#N/A,"12/06/2012 69512710 BW   Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/24/2017 AKBA-US  BW   Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents,#N/A,#N/A,#N/A,#N/A,11/13/2017 PGLC-US     BW   Sage Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2011 56400P70 BW   MannKind Corporation Reports 2010 Fourth Quarter and Full Year Financial Results,#N/A,#N/A,#N/A, 5/05/2011 03236M20 BW   Amyris Reports First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,11/11/2016 06CR5C-E BW   Eagle Pharmaceuticals Initiates Rolling Submission of NDA for Ryanodex in Exertional Heat Stroke,#N/A,#N/A,#N/A," 1/29/2015 29428V10 BW   Epizyme Appoints Robert A. Copeland, Ph.D., as President of Research",#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2017 VCYT-US  BW   Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA," 6/15/2017 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", 6/04/2018 15117K10 BW   FDA Grants Cellectis IND Approval for UCART22 in B-ALL,#N/A,#N/A,#N/A,12/14/2010 00BBFF-E BW   Agios Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics,#N/A,#N/A," 7/27/2017 XLRN-US  BW   Acceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017",#N/A, 3/28/2016 HZNP-IE  BW   HZNP INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Horizon Pharma PLC, 4/02/2015 00BJ80-E  BW   New Gene Expression Profile Test Used in Combination with Sentinel Lymph Node Biopsy Improves Prediction of Metastasis and Death in Patients with Head and Neck Melanoma,#N/A,#N/A, 5/04/2016 06CR5C-E BW   GlycoMimetics Reports First Quarter 2016 Results,#N/A,#N/A,#N/A, 7/24/2017 G6674U10 BW   Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2017 74587V10 BW   Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2016 MCRB-US  BW   Seres Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference, 2/12/2018 00900T10 BW   Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 009FRV-E BW   Quanterix’s Single Molecule Array Technology Unlocks New Biomarker Fueling Advancements in Neurological Research,#N/A,#N/A,#N/A, 8/01/2012 EYPT-US  BW   pSivida Corp. Reports Alimera’s Intention to Resubmit Application to FDA for ILUVIEN® in DME Using Data from Completed Trials,#N/A,#N/A, 7/09/2018 0DM9XX-E BW   Axonics® reçoit le marquage CE pour son système d'essai externe de neuromodulation sacrée,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2011 06FQWK-E BW,#N/A,#N/A,#N/A,#N/A,#N/A
" 1/04/2017 LGND-US   BW   Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the Lead Plaintiff Deadline of January 17, 2017",#N/A," 5/22/2017 45232710    BW   Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role", 3/08/2017 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update,#N/A,12/12/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results,#N/A,#N/A,#N/A,#N/A, 7/10/2015 OPK-US   BW   OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources,#N/A,#N/A,11/09/2017 ALXN-US  BW   Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service,#N/A, 3/15/2018 SGEN-US     BW   Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors,#N/A, 1/17/2017 SIEGY-DE    BW   Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis, 9/29/2016 IMGN-US  BW   ImmunoGen Completes Strategic Review to Strengthen the Organization and Drive Long-Term Growth,10/20/2010 09058V10 BW   BioCryst Ranked Number Five in Deloitte’s 2010 Technology Fast 500™ Program for Fastest Growing Companies in North America," 1/22/2019 GILD-US      BW   Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019",#N/A,#N/A, 6/25/2012 0BNZGT-E BW   Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd., 3/01/2011 00972810  BW   Akorn Reports 2010 Fourth Quarter and Year-End Financial Results,11/12/2012 0C8BZH-E     BW   RBCC Joint Venture’s Technology Could Lead to Cancer-Fighting Breakthrough,#N/A,#N/A,#N/A,#N/A, 3/09/2017 05156V10 BW   Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A, 7/15/2010 37416310     BW   Geron Provides Update on Telomerase Activation Program,"11/01/2017 AERI-US    BW   Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017",#N/A, 4/25/2018 INCY-US  BW   Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting,#N/A, 2/04/2015 80360710 BW   Sarepta Therapeutics to Present Company Overview at Upcoming Conferences," 3/17/2016 ALKS-IE  BW   Reset Therapeutics, Inc. lance un partenariat de recherche avec Alkermes en vue de la découverte et du développement de nouveaux modulateurs de l'orexine"," 9/07/2016 000FKS-E BW   Cerus to Present at the Morgan Stanley Global Healthcare Conference on September 14, 2016","11/26/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call on Monday, November 29, 2010 at 8:00 a.m. ET to Provide an Update on Feraheme Label Discussions"," 5/18/2017 04269E10 BW   ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)",#N/A,#N/A, 9/07/2017 EXEL-US  BW   Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy, 1/06/2016 0C6ZGM-E  BW   X-Chem Collaborates with Sanofi on the Discovery of Lead Molecules against Multiple Challenging Targets," 2/21/2018 VRTX-US   BW   Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis",#N/A,#N/A,10/31/2017 BLUE-US  BW   bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November," 3/29/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017",#N/A,#N/A,#N/A," 5/08/2017 TXMD-US  BW   Law Offices of Howard G. Smith Reminds TherapeuticsMD, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm",#N/A,#N/A, 6/01/2017 OMER-US  BW   Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress, 2/27/2017 76133010 BW   Revance Releases Fourth Quarter and Full Year 2016 Results,#N/A, 2/21/2017 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2017 SYRS-US  BW   Syros Participates in International Symposium to Support MDS Foundation’s Efforts to Raise Awareness of Novel Therapies in Development for MDS,#N/A,#N/A, 1/10/2011 063W0W-E     BW   BioSante Pharmaceuticals Confirms Female Sexual Dysfunction as an Unmet Medical Need," 8/08/2016 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2016"," 9/27/2018 ALNY-US   BW   Glancy Prongay & Murray LLP Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY)",#N/A,#N/A,#N/A,"11/20/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2017 AKBA-US  BW   Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval,#N/A,#N/A,#N/A,#N/A,11/09/2017 PGLC-US     BW   Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/08/2011 56400P70 BW   Glancy Binkow & Goldberg LLP, Representing Investors of MannKind Corporation, Announces Class Action Lawsuit and Seeks to Recover Losses",#N/A,#N/A,#N/A, 4/29/2011 03236M20 BW   Amyris finaliza sua primeira unidade de produção comercial,#N/A,#N/A,#N/A,#N/A,11/09/2016 EGRX-US  BW   Eagle Pharmaceuticals to Present at Jefferies 2016 London Healthcare Conference,#N/A,#N/A,#N/A,12/12/2014 29428V10 BW   Epizyme Elects Kenneth Bate to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2017 VCYT-US  BW   Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting," 6/08/2017 DRNA-US  BW   Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer", 6/04/2018 15117K10 BW   La FDA autorise l’essai clinique pour UCART22 en leucémie lymphoblastique aiguë à cellules B,#N/A,#N/A,#N/A,11/04/2010 00BBFF-E BW   Agios Awarded Two Federal Grants to Advance Cancer Metabolism Focused Therapeutics,#N/A,#N/A, 6/23/2017 XLRN-US  BW   Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association,#N/A," 3/28/2016 HZNP-IE  BW   INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Horizon Pharma plc and a Lead Plaintiff Deadline of May 9, 2016", 3/20/2015 00BJ80-E  BW   Study Demonstrates New Noninvasive Gene Expression Profile Test Predicts Melanoma Risk More Accurately Than AJCC Online Predictor Tool,#N/A,#N/A, 4/25/2016 GLYC-US  BW   GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at “Digestive Disease Week” Conference,#N/A,#N/A,#N/A, 7/12/2017 G6674U10 BW   Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2017 05HW8Z-E BW   Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2016 MCRB-US  BW   Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update, 1/10/2018 AIMT-US  BW   Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2016 009FRV-E BW   Quanterix Named One of the World’s Most Innovative Companies in 2016 by Fast Company,#N/A,#N/A,#N/A, 7/30/2012 30233G10 BW   pSivida Corp. Announces Tech Evaluation Agreement for Tethadur™ Protein/Antibody Delivery System with Leading Biopharmaceutical Company,#N/A,#N/A, 7/09/2018 0DM9XX-E BW   Axonics® erhält CE-Zeichen für sein externes Versuchssystem für sakrale Neuromodulation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/27/2016 LGND-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A, 5/04/2017 45232710    BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference, 3/01/2017 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast,#N/A,12/06/2017 ARWR-US  BW   Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy,#N/A,#N/A,#N/A,#N/A, 7/02/2015 68375N10 BW   OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition,#N/A,#N/A,11/09/2017 ALXN-US  BW   Alexion y sus empleados voluntarios colaboran en el segundo Día Mundial del Servicio para mejorar sus comunidades locales,#N/A, 3/13/2018 SGEN-US     BW   Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018,#N/A, 1/17/2017 FWP-DK      BW   Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement, 8/09/2016 IMGN-US  BW   ImmunoGen Announces Departure of Chief Development Officer,"10/18/2010 09058V10 BW   BioCryst Pharmaceuticals to Announce Third Quarter 2010 Financial Results on October 28, 2010"," 1/08/2019 GILD-US      BW   Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)",#N/A,#N/A, 5/01/2012 M2572210 BW   Compugen Ltd. Reports First Quarter 2012 Financial Results,"12/29/2010 00972810  BW   Akorn Announces the Sale of the Akorn-Strides Joint Venture Product Portfolio to Pfizer, Inc.",11/07/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences,#N/A,#N/A,#N/A,#N/A, 3/06/2017 05156V10 BW   Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings,#N/A,#N/A,#N/A, 6/07/2010 37416310     BW   Geron Presents Clinical Data on Its Telomerase Inhibitor Drug in Breast Cancer at ASCO,"10/30/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs",#N/A, 4/13/2018 INCY-US  BW   Incyte to Report First Quarter Financial Results,#N/A," 1/30/2015 80360710 BW   INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith"," 3/17/2016 ALKS-IE  BW   Reset Therapeutics, Inc. Establishes Research Collaboration With Alkermes for Discovery and Development of Novel Orexin Modulators"," 9/01/2016 06SHTG-E BW   Cerus to Present at the Baird 2016 Healthcare Conference on September 8, 2016",11/22/2010 00163U10 BW   Palo Alto Investors Calls on Board of AMAG Pharmaceuticals to Use Excess Cash to Repurchase Stock and Increase Stockholder Value, 5/17/2017 04269E10 BW   ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,#N/A, 9/06/2017 EXEL-US  BW   Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress, 1/06/2016 SNY-FR    BW   Sanofi Genzyme Announces Recipients of Patient Advocacy Leadership (PAL) Awards, 2/14/2018 VRTX-US   BW   Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study,#N/A,#N/A,10/06/2017 BLUE-US  BW   bluebird bio to Present at Chardan Gene Therapy Conference," 2/28/2017 ACAD-US  BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016",#N/A,#N/A,#N/A," 5/08/2017 TXMD-US  BW   TXMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017",#N/A,#N/A, 5/18/2017 LLY-US   BW   Nativis Expands C-Suite with the Addition of Dr. Kenneth Ferguson as Chief Scientific Officer, 2/22/2017 76133010 BW   Revance to Participate in Upcoming Investor Conferences,#N/A, 2/07/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2017 SYRS-US  BW   Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference,#N/A,#N/A,12/31/2010 00182C10     BW   BioSante Pharmaceuticals Closes $18 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunction," 7/25/2016 06CR5C-E   BW   Enanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus", 9/27/2018 ALNY-US   BW   Alnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria,#N/A,#N/A,#N/A,"11/20/2012 69512710 BW   New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2017 AKBA-US  BW   Akebia Announces First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,"11/08/2017 PGLC-US     BW   Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2011 56400P70 BW   MannKind to Present at the 13th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A, 4/29/2011 03236M20 BW   Amyris's First Commercial Production Facility Complete and Operational,#N/A,#N/A,#N/A,#N/A,"11/09/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results",#N/A,#N/A,#N/A,12/08/2014 29428V10 BW   Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro and In Vivo Activity in Models of Mantle Cell Lymphoma,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2017 VCYT-US  BW   Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017, 6/01/2017 DRNA-US  BW   Dicerna to Present at Jefferies 2017 Global Healthcare Conference, 5/22/2018 15117K10 BW   INSERTION ET REMPLACE : Accélération du développement clinique d’UCART123 en LAM suite à l’approbation d’un protocole modifié,#N/A,#N/A,#N/A," 9/20/2010 00BBFF-E BW   Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer",#N/A,#N/A, 6/23/2017 XLRN-US  BW   Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association,#N/A, 3/24/2016 HZNP-IE  BW   STOCK ALERT: Rosen Law Firm Reminds Horizon Pharma plc Investors of Important Deadline in Class Action – HZNP, 3/18/2015 00BJ80-E  BW   Survey of Thoracic Surgeons Reveals Willingness to Change Treatment Approaches to Esophageal Cancer Based on Castle Biosciences’ New Predictive Test,#N/A,#N/A, 3/21/2016 IDXX-US  BW   GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors,#N/A,#N/A,#N/A, 7/11/2017 G6674U10 BW   Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2017 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A," 2/16/2016 MCRB-US  BW   Seres Therapeutics to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on February 25, 2016"," 1/08/2018 AIMT-US  BW   Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2016 009FRV-E BW   Quanterix Names Frontage Laboratories as a Preferred Partner in Biomarker Assay Development and Testing Services in the Regulated Space,#N/A,#N/A,#N/A, 7/26/2012 30233G10 BW   pSivida Corp. Announces Germany Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 7/09/2018 0DM9XX-E BW   Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/22/2016 NOVN-CH   BW   Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib,#N/A, 4/25/2017 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2017, 2/16/2017 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd,#N/A,12/05/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results,#N/A,#N/A,#N/A,#N/A, 7/01/2015 OPK-US   BW   Conversion Right Extended on OPKO 3.0% Convertible Senior Notes,#N/A,#N/A,11/09/2017 ALXN-US  BW   Deuxième Journée mondiale annuelle des services d’Alexion : les employés contribuent à améliorer leurs communautés locales avec du bénévolat,#N/A, 3/09/2018 CASC-US     BW   Seattle Genetics Completes Acquisition of Cascadian Therapeutics,#N/A, 1/13/2017 BIIB-US     BW   New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy," 8/05/2016 MS-US    BW   ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences", 9/21/2010 09058V10 BW   BioCryst to Present At JMP Securities Healthcare Conference, 1/06/2019 000100-KR    BW   Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis,#N/A,#N/A, 4/24/2012 CGEN-IL  BW   Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001,11/01/2010 00972810  BW   Akorn Reports Third Quarter 2010 Results,11/01/2012 AMGN-US      BW   Fitch Affirms Amgen's IDR at 'BBB'; Outlook Stable,#N/A,#N/A,#N/A,#N/A, 3/02/2017 COWN-US  BW   Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference,#N/A,#N/A,#N/A, 5/20/2010 37416310     BW   Geron Appoints Hoyoung Huh and Robert Spiegel to Its Board of Directors,10/13/2017 AERI-US    BW   Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%,#N/A, 4/06/2018 INCY-US  BW   Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma,#N/A," 1/20/2015 80360710 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc.", 3/09/2016 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference, 8/29/2016 06CR5C-E BW   FDA's New Recommendation for Universal Zika Risk Reduction of Blood Components Includes Use of Pathogen Reduction,"10/28/2010 00163U10 BW   AMAG Pharmaceuticals Announces Financial Results for the Third Quarter Ended September 30, 2010 and a Restructuring Plan to Reduce Operating Expenses", 5/03/2017 04269E10 BW   Arqule Reports First Quarter 2017 Financial Results,#N/A,#N/A, 8/29/2017 EXEL-US  BW   Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13," 1/06/2016 0015KG-E  BW   X-Chem Established as Independent, Privately Owned Biotechnology Company", 2/12/2018 VRTX-US   BW   FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene,#N/A,#N/A,10/04/2017 BLUE-US  BW   bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine," 2/27/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017",#N/A,#N/A,#N/A, 5/08/2017 TXMD-US  BW   TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application,#N/A,#N/A, 5/17/2017 OMER-US  BW   Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial," 2/16/2017 76133010 BW   Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017",#N/A, 1/29/2017 4503-JP  BW   Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2017 SYRS-US  BW   Syros Closes $35 Million Private Financing,#N/A,#N/A,"12/28/2010 MKTSQ.XX1-US BW   Rodman & Renshaw Acts as Exclusive Placement Agent to BioSante Pharmaceuticals, Inc. on $18.0 Million Registered Direct Offering"," 7/18/2016 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016", 9/26/2018 ALNY-US   BW   Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference,#N/A,#N/A,#N/A,11/13/2012 PCRX-US  BW   New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,11/03/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/03/2011 56400P70 BW   Holzer Holzer & Fistel, LLC Announces That It Has Filed a Class Action Lawsuit on Behalf of Investors in Mannkind Corporation",#N/A,#N/A,#N/A," 4/21/2011 03236M20 BW   Amyris to Announce 2011 First Quarter Financial Results on Thursday, May 5, 2011",#N/A,#N/A,#N/A,#N/A,11/02/2016 EGRX-US  BW   CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection,#N/A,#N/A,#N/A,12/08/2014 29428V10 BW   Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2017 VCYT-US  BW   Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting, 5/08/2017 DRNA-US  BW   Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update, 5/22/2018 15117K10 BW   INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development,#N/A,#N/A,#N/A," 7/29/2010 00BBFF-E BW   Agios Creates Expanded Scientific Advisory Role for Lewis Cantley, Ph.D.",#N/A,#N/A, 6/12/2017 XLRN-US  BW   Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma,#N/A," 3/17/2016 HZNP-US  BW   Glancy, Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Horizon Pharma plc Investors and Encourages Investors to Contact the Firm", 3/05/2015 00BJ80-E  BW   Study Shows Castle Biosciences’ Noninvasive Skin Melanoma Gene Test Improves Accuracy of Sentinel Lymph Node Biopsy in Predicting Metastasis,#N/A,#N/A, 3/17/2016 GLYC-US  BW   GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016,#N/A,#N/A,#N/A, 6/30/2017 G6674U10 BW   Novocure to Report Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/22/2017 0H44P1-E BW   Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia",#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2016 MCRB-US  BW   Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases, 1/03/2018 00900T10 BW   Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2016 009FRV-E BW   Quanterix’s Simoa Technology Demonstrates Ability to Analyze Single Cancer Cells,#N/A,#N/A,#N/A, 7/19/2012 EYPT-US  BW   pSivida Corp. Receives FDA Clearance for Pivotal Trials for Injectable Sustained-Release Micro-Insert to Treat Uveitis,#N/A,#N/A, 6/27/2018 0DM9XX-E BW   Axonics® termine le recrutement de l'étude pivot de la FDA américaine sur son système de neuromodulation sacrée,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/22/2016 4528-JP   BW   Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.",#N/A," 4/11/2017 45232710    BW   Illumina to Announce First Quarter 2017 Financial Results on Tuesday, April 25, 2017",12/08/2016 07LCB1-E  BW   Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer,#N/A,11/14/2017 ARWR-US  BW   Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 6/26/2015 68375N10 BW   OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection,#N/A,#N/A,11/09/2017 ALXN-US  BW   Funcionários da Alexion se apresentam como voluntários para melhorar suas comunidades durante o Segundo Dia de Serviço Mundial,#N/A, 3/09/2018 CASC-US     BW   Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics,#N/A, 1/12/2017 BIIB-US     BW   Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock, 8/04/2016 IMGN-US  BW   ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update, 9/16/2010 09058V10 BW   BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout," 1/02/2019 GILD-US      BW   Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7",#N/A,#N/A," 4/23/2012 061PXR-E BW   Dr. Mary Haak-Frendscho, Chairperson of Compugen’s US Subsidiary, to Give Keynote Address at China Pharmaceutical R&D Summit", 9/16/2010 00972810  BW   Akorn Announces Launch of Erythromycin Ophthalmic Ointment USP 1 g,10/31/2012 RBCC-US      BW   RBCC: Mobile Technology May Help Reduce Athletes’ Risk of Brain Injury,#N/A,#N/A,#N/A,#N/A," 3/01/2017 05156V10 BW   Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study",#N/A,#N/A,#N/A, 5/19/2010 37416310     BW   Geron Announces Positive Data on Its Small Molecule Telomerase Activator in Model of Idiopathic Pulmonary Fibrosis,10/13/2017 AERI-US    BW   Aerie Pharmaceuticals Stock Trading Halted Today,#N/A, 3/15/2018 INCY-US  BW   Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018,#N/A, 1/14/2015 80360710 BW   Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients, 3/01/2016 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 36th Annual Health Care Conference, 8/09/2016 CERS-US  BW   Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer,"10/22/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Third Quarter on October 28, 2010 at 5:30 p.m. ET"," 4/26/2017 04269E10 BW   ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531",#N/A,#N/A, 8/16/2017 EXEL-US  BW   Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer,12/15/2015 001G3L-E  BW   Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap," 2/01/2018 VRTX-US   BW   Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis",#N/A,#N/A,10/04/2017 0B6G4F-E BW   bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine," 2/21/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017",#N/A,#N/A,#N/A, 5/02/2017 TXMD-US  BW   TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8,#N/A,#N/A, 5/10/2017 OMER-US  BW   Omeros Corporation Reports First Quarter 2017 Financial Results, 1/26/2017 76133010 BW   BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017,#N/A, 1/08/2017 IRWD-US  BW   Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2017 SYRS-US  BW   Syros Announces $35 Million Private Placement,#N/A,#N/A,12/27/2010 00182C10     BW   BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering, 6/20/2016 ENTA-US    BW   Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus, 9/14/2018 ALNY-US   BW   Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran,#N/A,#N/A,#N/A,"11/08/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/25/2017 4578-JP  BW   Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories",#N/A,#N/A,#N/A,#N/A,11/02/2017 SAGE-US     BW   Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2011 56400P70 BW   Law Offices of Howard G. Smith Announces Class Action Lawsuit Against MannKind Corporation,#N/A,#N/A,#N/A, 3/22/2011 03236M20 BW   Amyris aumenta sua capacidade de produção através de acordo com a Paraíso Bioenergia,#N/A,#N/A,#N/A,#N/A,11/01/2016 EGRX-US  BW   Final Reminder: Eagle Pharmaceuticals to Host 2016 Investor Day in New York City,#N/A,#N/A,#N/A,"12/03/2014 29428V10 BW   Epizyme to Webcast Company Presentation at American Society of Hematology (ASH) Annual Meeting on December 8, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,10/05/2017 VCYT-US  BW   Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting," 5/01/2017 DRNA-US  BW   Dicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017", 5/22/2018 15117K10 BW   Cellectis : Accélération du développement clinique d’UCART123 en LAM suite à l’approbation d’un protocole modifié,#N/A,#N/A,#N/A," 6/24/2010 00BBFF-E BW   Agios Appoints John Maraganore, Ph.D., to Board of Directors",#N/A,#N/A, 6/01/2017 CELG-US  BW   Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia,#N/A, 3/17/2016 HZNP-US  BW   SHAREHOLDER REMINDER: Goldberg Law PC Announces Securities Class Action Lawsuit against Horizon Pharma plc and Encourages Investors with Losses to Contact the Firm, 2/24/2015 00BJ80-E  BW   Castle Biosciences Announces New Director Appointment and CFO Hire,#N/A,#N/A, 3/02/2016 GLYC-US  BW   GlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients,#N/A,#N/A,#N/A, 6/28/2017 G6674U10 BW   Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2017 74587V10 BW   Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2016 MCRB-US  BW   Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences,12/07/2017 00900T10 BW   Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2016 009FRV-E BW   Quanterix Presented Ultrasensitive Technology at NFL Health and Safety Update & Interactive Head Health Showcase,#N/A,#N/A,#N/A, 7/18/2012 EYPT-US  BW   pSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 6/27/2018 0DM9XX-E BW   Axonics® schließt Teilnehmerrekrutierung für FDA-Zulassungsstudie für sakrales Neuromodulationssystem ab,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/05/2016 LGND-US   BW   LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important Deadline in Class Action Filed by Firm - LGND,#N/A, 4/10/2017 45232710    BW   Illumina lanciert VeriSeq™ NIPT-Lösung in Europa,12/06/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology (ASH),#N/A,10/23/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/09/2015 OPK-US   BW   OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress on Its Long-Acting Clotting Factor VIIa,#N/A,#N/A,11/09/2017 ALXN-US  BW   Alexion-Mitarbeiter engagieren sich ehrenamtlich für ihre lokalen Gemeinschaften beim zweiten jährlichen „Global Day of Service“,#N/A, 3/07/2018 SGEN-US     BW   Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma,#N/A, 1/11/2017 NVS-CH      BW   Centron Hires Industry Veteran Celine Vita as President of Centron Advertising," 7/21/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016 Financial Results", 9/15/2010 09058V10 BW   BioCryst to Present Peramivir Data at the 50th Annual ICAAC Meeting, 1/02/2019 GILD-US      BW   HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead,#N/A,#N/A," 4/23/2012 CGEN-IL  BW   Compugen First Quarter 2012 Conference Call Scheduled for Tuesday, May 1, 2012 at 10:00 AM EST", 8/03/2010 00972810  BW   Akorn Reports Second Quarter 2010 Results,"10/29/2012 SPPI-US      BW   Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations",#N/A,#N/A,#N/A,#N/A, 2/14/2017 05156V10 BW   Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin,#N/A,#N/A,#N/A, 5/14/2010 37416310     BW   Geron to Present at the Rodman & Renshaw Annual Global Healthcare Conference,10/09/2017 0DFDSP-E   BW   Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team,#N/A, 3/12/2018 SYRS-US  BW   Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones,#N/A, 1/12/2015 80360710 BW   Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy," 2/25/2016 ALKS-US  BW   Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016", 8/04/2016 06CR5C-E BW   Cerus Corporation Reports Second Quarter 2016 Results,"10/21/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. Announces Data Presentations at the American Society of Nephrology (ASN) Renal Week Meeting"," 4/19/2017 04269E10 BW   ArQule To Report First Quarter 2017 Financial Results On May 3, 2017",#N/A,#N/A, 8/02/2017 EXEL-US  BW   Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update,10/08/2015 SNY-FR    BW   Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials, 1/31/2018 VRTX-US   BW   Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results,#N/A,#N/A, 9/28/2017 BLUE-US  BW   bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma," 1/03/2017 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017",#N/A,#N/A,#N/A, 5/02/2017 TXMD-US  BW   TherapeuticsMD Announces First Quarter 2017 Financial Results,#N/A,#N/A," 5/03/2017 OMER-US  BW   Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017", 1/18/2017 76133010 BW   Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017,#N/A, 1/04/2017 IRWD-US  BW   Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A," 4/18/2017 SYRS-US  BW   Syros to Present on SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference",#N/A,#N/A,"11/17/2010 00182C10     BW   BioSante Pharmaceuticals Sells Oncolytic Virus Technology to Cold Genesys, Inc.", 6/01/2016 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 8/30/2018 ALNY-US   BW   Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe,#N/A,#N/A,#N/A,"11/01/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/25/2017 AKBA-US  BW   Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories",#N/A,#N/A,#N/A,#N/A,"10/24/2017 SAGE-US     BW   Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2011 56400P70 BW   The Law Office of Robbins Umeda LLP Announces an Investigation of MannKind Corporation,#N/A,#N/A,#N/A, 3/22/2011 03236M20 BW   Amyris Adds Additional Production Capacity Through Agreement With Paraíso Bioenergia,#N/A,#N/A,#N/A,#N/A,10/31/2016 06HCNQ-E BW   Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA (Ecstasy) Induced Hyperthermia Conducted at the National Institutes of Health,#N/A,#N/A,#N/A,11/19/2014 29428V10 BW   Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2017 VCYT-US  BW   Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA, 4/12/2017 DRNA-US  BW   Dicerna Announces Closing of $70 Million Convertible Preferred Stock Financing, 5/22/2018 15117K10 BW   Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development,#N/A,#N/A,#N/A, 4/21/2010 00BBFF-E BW   Agios Scientists Present IDH1 Data at 2010 AACR Meeting,#N/A,#N/A, 6/01/2017 XLRN-US  BW   Acceleron to Participate in Two Healthcare Investor Conferences in June,#N/A, 3/15/2016 HZNP-US  BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Horizon Pharma plc And Encourages Investors With Losses To Contact the Firm, 2/23/2015 00BJ80-E  BW   Study of Castle Biosciences’ Multi-Analyte Test for Esophageal Cancer Published in Gastrointestinal Cancer: Targets and Therapy,#N/A,#N/A, 3/01/2016 GLYC-US  BW   GlycoMimetics to Present at Cowen and Company’s 36th Annual Health Care Conference,#N/A,#N/A,#N/A, 6/13/2017 G6674U10 BW   Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2017 74587V10 BW   Puma Biotechnology Reports Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 MCRB-US  BW   Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science for Microbiome-Based Clostridium difficile and Inflammatory Bowel Disease Therapies in Markets Outside of North America,"11/20/2017 00900T10 BW   Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/27/2016 009FRV-E BW   Quanterix Announces Expansion into Asia Pacific,#N/A,#N/A,#N/A, 7/18/2012 EYPT-US  BW   pSivida’s Partner Alimera Sciences Announces an Agreement to Raise Capital to Fund the Development and Commercialization of ILUVIEN®,#N/A,#N/A, 6/27/2018 0DM9XX-E BW   Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/21/2016 06CR5C-E  BW   Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016,#N/A, 4/10/2017 45232710    BW   Illumina lanceert de VeriSeq™ NIPT-oplossing in Europa,"12/05/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016",#N/A,10/23/2017 ARWR-US  BW   Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017,#N/A,#N/A,#N/A,#N/A, 6/08/2015 68375N10 BW   OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger,#N/A,#N/A,"11/08/2017 ALXN-US  BW   Alexion Appoints Francois Nader, M.D. to its Board of Directors",#N/A, 2/27/2018 SGEN-US     BW   Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference,#N/A,"12/23/2016 09062X10    BW   U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy", 6/15/2016 IMGN-US  BW   ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021, 9/15/2010 09058V10 BW   BioCryst Reports Results from Two Forodesine Oncology Studies,12/20/2018 AGEN-US      BW   Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies,#N/A,#N/A, 3/28/2012 061PXR-E BW   Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates, 5/03/2010 00972810  BW   Akorn Reports First Quarter 2010 Financial Results,10/22/2012 INCY-US      BW   Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A," 2/10/2017 05156V10 BW   Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference",#N/A,#N/A,#N/A, 5/13/2010 37416310     BW   Geron Announces Positive Study Data on GRNCM1,10/05/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Further Advance Its Retinal Disease Program,#N/A, 2/28/2018 06TVH6-E BW   Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018,#N/A," 1/07/2015 80360710 BW   Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors", 2/25/2016 ALKS-US  BW   Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia," 7/21/2016 CERS-US  BW   Cerus to Release Second Quarter 2016 Results on August 4, 2016"," 9/07/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences"," 4/11/2017 04269E10 BW   ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531",#N/A,#N/A, 8/01/2017 EXEL-US  BW   Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress,10/07/2015 SNY-FR    BW   New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis," 1/31/2018 VRTX-US   BW   Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis",#N/A,#N/A," 9/20/2017 BLUE-US  BW   bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors",12/20/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis,#N/A,#N/A,#N/A," 5/01/2017 TXMD-US  BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A, 4/03/2017 OMER-US  BW   Omeros to Present at the Needham Healthcare Conference, 1/05/2017 76133010 BW   Revance Provides Clinical Milestones and Financial Outlook for 2017,#N/A, 1/04/2017 06CR5C-E BW   Ironwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review,#N/A,#N/A,#N/A,#N/A,#N/A," 4/10/2017 SYRS-US  BW   Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors",#N/A,#N/A,11/12/2010 00182C10     BW   BioSante Pharmaceuticals Reports Third Quarter 2010 Financial Results," 5/09/2016 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016", 8/29/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming September Investor Conferences,#N/A,#N/A,#N/A,"10/25/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2017 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 9/22/2017 SAGE-US     BW   Sage Therapeutics to Participate in Leerink Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2011 56400P70 BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against MannKind Corporation,#N/A,#N/A,#N/A, 3/21/2011 03236M20 BW   Amyris e U.S. Venture anunciam planos de formar joint venture de desenvolvimento de lubrificantes renováveis,#N/A,#N/A,#N/A,#N/A,"10/26/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2016 Financial Results on November 9, 2016",#N/A,#N/A,#N/A,11/06/2014 29428V10 BW   Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2017 VCYT-US  BW   Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer, 3/30/2017 DRNA-US  BW   Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results, 5/22/2018 CLXT-US  BW   Cellectis S.A. : Calyxt Announces Successful Closing of $60.9 Million Public Offering,#N/A,#N/A,#N/A, 4/15/2010 CELG-US  BW   Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism,#N/A,#N/A, 5/18/2017 CELG-US  BW   Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association,#N/A, 3/14/2016 HZNP-IE  BW   Robbins Arroyo LLP: Horizon Pharma plc (HZNP) Misled Shareholders According to a Recently Filed Class Action, 1/06/2015 00BJ80-E  BW   Study of Castle Biosciences’ Skin Melanoma Gene Test Published in Clinical Cancer Research,#N/A,#N/A, 2/29/2016 GLYC-US  BW   GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results,#N/A,#N/A,#N/A, 6/08/2017 G6674U10 BW   First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2017 74587V10 BW   Puma Biotechnology to Present at Stifel Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2016 MCRB-US  BW   Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer,11/06/2017 00900T10 BW   Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/14/2016 06XTFS-E BW   ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary",#N/A,#N/A,#N/A, 6/28/2012 EYPT-US  BW   pSivida Corp. Announces Enrollment of First Patient in Uveitis Trial,#N/A,#N/A, 4/03/2018 0DM9XX-E BW   Axonics® annonce un financement de 40 millions USD,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/18/2016 LGND-US   BW   INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A, 4/10/2017 45232710    BW   Illumina lancia la soluzione VeriSeq™ NIPT in Europa,"12/02/2016 06QBQ2-E  BW   Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 3-6, 2016",#N/A,10/10/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®,#N/A,#N/A,#N/A,#N/A, 6/04/2015 68375N10 BW   OPKO Health to Acquire Bio-Reference Laboratories,#N/A,#N/A,"11/06/2017 ALXN-US  BW   Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio",#N/A, 2/16/2018 CASC-US     BW   Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period,#N/A,"12/23/2016 09062X10    BW   U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy", 6/13/2016 IMGN-US  BW   ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021," 9/08/2010 09058V10 BW   BioCryst to Host & Webcast Investor Day on September 16, 2010",12/19/2018 GILD-US      BW   Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases,#N/A,#N/A, 2/27/2012 M2572210 BW   Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference, 4/30/2010 00972810  BW   Akorn Announces Changes to the Company’s Board of Directors,10/22/2012 NPSP-US      BW   NPS Pharmaceuticals Reports Characteristics of Patients Who Achieved Independence from Parenteral Support in STEPS 2 Study of Gattex® (teduglutide) in Adult Short Bowel Syndrome,#N/A,#N/A,#N/A,#N/A," 2/06/2017 05156V10 BW   Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer",#N/A,#N/A,#N/A, 4/30/2010 37416310     BW   Geron Comments on Decision by U.S. PTO on WARF Patent,10/02/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Ann Keevans as Director of Human Resources - Europe,#N/A, 2/20/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A, 1/05/2015 80360710 BW   Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference, 2/18/2016 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results, 7/11/2016 07P2BQ-E BW   Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma," 8/03/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Canaccord Genuity 30th Annual Global Growth Conference"," 3/28/2017 04269E10 BW   ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017",#N/A,#N/A, 7/20/2017 DNA-US   BW   Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib,"10/05/2015 SNY-FR    BW   Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care", 1/10/2018 VRTX-US   BW   Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation,#N/A,#N/A," 9/13/2017 BLUE-US  BW   bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121",12/01/2016 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder,#N/A,#N/A,#N/A," 4/28/2017 TXMD-US  BW   SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In TherapeuticsMD, Inc. To Contact The Firm",#N/A,#N/A, 3/30/2017 OMER-US  BW   Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases,12/12/2016 76133010 BW   Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial,#N/A, 1/03/2017 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 4/04/2017 SYRS-US  BW   Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARα Agonist, for Genomically Defined AML and MDS Patients",#N/A,#N/A,"10/26/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences"," 4/27/2016 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2016"," 8/21/2018 ALNY-US   BW   Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)",#N/A,#N/A,#N/A,"10/18/2012 69512710 BW   Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/29/2017 AKBA-US  BW   Akebia to Present at the 16th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 9/12/2017 SAGE-US     BW   Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/27/2011 56400P70 BW   MannKind Corporation to Hold 2010 Fourth Quarter and Full Year Financial Results Conference Call on February 10, 2011",#N/A,#N/A,#N/A, 3/21/2011 0BN6J8-E BW   Amyris and U.S. Venture Announce Plans for Joint Venture in Development of Renewable Lubricants,#N/A,#N/A,#N/A,#N/A, 9/27/2016 EGRX-US  BW   Eagle Pharmaceuticals Announces “Save the Date” for 2016 Investor Day,#N/A,#N/A,#N/A,11/06/2014 29428V10 BW   Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2017 VCYT-US  BW   Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference, 3/30/2017 DRNA-US  BW   Dicerna Secures $70 Million in Convertible Preferred Stock Financing," 5/22/2018 CLXT-US  BW   Cellectis S.A. : Calyxt annonce la réalisation de son offre secondaire d’actions pour un total de 60,9 millions de dollars",#N/A,#N/A,#N/A," 3/11/2010 00BBFF-E BW   Agios Pharmaceuticals Appoints William Kaelin Jr., M.D. to Scientific Advisory Board",#N/A,#N/A, 5/08/2017 XLRN-US  BW   Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results,#N/A, 3/10/2016 HZNP-IE  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Horizon Pharma plc – HZNP,12/09/2014 00BJ80-E  BW   Vast Majority of Ophthalmologists Treating Uveal Melanoma Use Molecular Testing to Guide Patient Care,#N/A,#N/A, 2/01/2016 GLYC-US  BW   GlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A, 6/05/2017 G6674U10 BW   Health Care Service Corporation Issues Positive Coverage Decision for Optune,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2017 74587V10 BW   Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2016 MCRB-US  BW   Seres Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference,11/01/2017 00900T10 BW   Aimmune Therapeutics to Participate in Four Investor Conferences in November,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 009FRV-E BW   CORRECTING and REPLACING Quanterix to Present at The 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A, 6/06/2012 30233G10 BW   pSivida Corp. Announces Issuance of US Patent for Inserter to Be Used in Planned Phase III Uveitis Trials,#N/A,#N/A, 4/03/2018 0DM9XX-E BW   Axonics® gibt Finanzierung in Höhe von 40 Millionen US-Dollar bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"11/18/2016 LGND-US   BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Encourages Investors to Contact the Firm",#N/A, 4/10/2017 45232710    BW   Illumina lanza la solución VeriSeq™ NIPT en Europa,"11/17/2016 07LCB1-E  BW   Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016",#N/A,10/03/2017 ARWR-US  BW   Arrowhead to Present at Chardan Gene Therapy Conference,#N/A,#N/A,#N/A,#N/A, 5/29/2015 68375N10 BW   OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration,#N/A,#N/A,11/03/2017 ALXN-US  BW   New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa),#N/A, 2/09/2018 PIRS-US     BW   Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration,#N/A,12/22/2016 BIIB-US     BW   Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement, 5/18/2016 IMGN-US  BW   ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer, 8/16/2010 09058V10 BW   BioCryst’s Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea,12/10/2018 GILD-US      BW   Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer,#N/A,#N/A, 2/07/2012 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results, 4/21/2010 00972810  BW   Akorn Announces FDA Approval to Re-Launch Erythromycin Ophthalmic Ointment USP 3.5 g,10/16/2012 NPSP-US      BW   NPS Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Gattex® New Drug Application for the Treatment of Adults with Short Bowel Syndrome,#N/A,#N/A,#N/A,#N/A, 1/27/2017 05156V10 BW   Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial,#N/A,#N/A,#N/A, 4/28/2010 37416310     BW   Geron Corporation Reports 2010 First Quarter Financial Results and Highlights, 9/29/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team,#N/A," 2/15/2018 INCY-US  BW   Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs",#N/A," 1/02/2015 80360710 BW   SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015", 2/10/2016 ALKS-US  BW   Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia," 7/07/2016 CERS-US  BW   A Cerus e a CEI anunciam a doação de kits para Sistema Sanguíneo INTERCEPT ao HEMORIO, preparando-se para emergências antes dos jogos olímpicos de verão no Rio de Janeiro"," 7/28/2010 00163U10 BW   AMAG Pharmaceuticals Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2010", 3/27/2017 ARQL-US  BW   ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan,#N/A,#N/A," 7/17/2017 EXEL-US  BW   Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017",10/01/2015 ALNY-US   BW   Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe, 1/03/2018 VRTX-US   BW   Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results,#N/A,#N/A, 9/06/2017 BLUE-US  BW   bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting,11/15/2016 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia,#N/A,#N/A,#N/A," 4/26/2017 TXMD-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A, 3/28/2017 OMER-US  BW   Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation,12/07/2016 76133010 BW   Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines,#N/A,12/22/2016 06CR5C-E BW   Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS,#N/A,#N/A,#N/A,#N/A,#N/A," 4/03/2017 SYRS-US  BW   Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors",#N/A,#N/A,10/25/2010 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation," 4/26/2016 DB-DE      BW   Enanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4, 2016 at 8:00 A.M. ET", 8/13/2018 ALNY-US   BW   US Bioservices Selected by Alnylam Pharmaceuticals as a Specialty Pharmacy Partner for ONPATTRO™ (patisiran),#N/A,#N/A,#N/A,"10/08/2012 PCRX-US  BW   EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/28/2017 AKBA-US  BW   Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 9/07/2017 SAGE-US     BW   Sage Therapeutics to Present at Morgan Stanley Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/27/2011 56400P70 BW   Holzer Holzer & Fistel, LLC is Investigating Potential Violations of Federal Securities Laws by MannKind Corporation",#N/A,#N/A,#N/A, 3/04/2011 03236M20 BW   Amyris to Webcast Management Presentation,#N/A,#N/A,#N/A,#N/A," 8/09/2016 06CR5C-E BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results",#N/A,#N/A,#N/A,"10/30/2014 29428V10 BW   Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014",#N/A,#N/A,#N/A,#N/A,#N/A, 8/24/2017 VCYT-US  BW   Veracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference, 3/27/2017 DRNA-US  BW   Dicerna Pharmaceuticals to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference, 5/21/2018 15117K10 BW   Cellectis S.A. : Calyxt annonce l’exercice intégral de l’option de surallocation consentie aux banques en charge du placement,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2017 CELG-US  BW   Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes,#N/A, 3/01/2016 HZNP-US  BW   Glancy Prongay & Murray Commences Investigation on Behalf of Horizon Pharma plc Investors,10/23/2014 00BJ80-E  BW   Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant to Standard Treatment of Chemoradiation Therapy,#N/A,#N/A,12/07/2015 GLYC-US  BW   GlycoMimetics Highlights Preclinical Data in Oral Presentation at ASH Meeting Demonstrating Impact of GMI-1271 on T Memory Stem Cells,#N/A,#N/A,#N/A, 6/02/2017 G6674U10 BW   Novocure to Present at the JMP Securities 2017 Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2017 74587V10 BW   Puma Biotechnology to Present at Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2015 MCRB-US  BW   Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis,10/31/2017 00900T10 BW   Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/02/2015 009FRV-E BW   Quanterix Teams Up with Global Leaders to Establish a Groundbreaking Vision for Early Disease Detection, Prevention and Precision Drug Development to Revolutionize Healthcare",#N/A,#N/A,#N/A, 6/05/2012 30233G10 BW   pSivida Corp. Announces Portugal Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 4/03/2018 0DM9XX-E BW   Axonics® Announces $40 Million Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/17/2016 LGND-US   BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A, 4/10/2017 45232710    BW   Illumina lance la solution de dépistage anténatal non invasif VeriSeq™ en Europe,"11/14/2016 SPPI-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 21, 2016",#N/A, 9/27/2017 ARWR-US  BW   Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment,#N/A,#N/A,#N/A,#N/A, 5/27/2015 OPK-US   BW   OPKO Health to Present at the Jefferies 2015 Healthcare Conference,#N/A,#N/A,11/01/2017 ALXN-US  BW   New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting,#N/A," 2/08/2018 CASC-US     BW   Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.",#N/A,"12/22/2016 BIIB-US     BW   Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017"," 5/11/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences", 8/05/2010 09058V10 BW   BioCryst Reports Second Quarter 2010 Financial Results and Provides Corporate Update,"12/04/2018 GILD-US      BW   China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection",#N/A,#N/A, 2/06/2012 M2572210 BW   Compugen to Present at the BIO CEO & Investor Conference 2012," 4/15/2010 00972810  BW   Akorn, Inc. Announces FDA Approval for Hydromorphone Hydrochloride Injection 10mg/ml in 1ml, 5ml and 50ml Doses",10/16/2012 0C8BZH-E     BW   RBCC: Could Stem Cells Be Key to Promising Autism Therapy?,#N/A,#N/A,#N/A,#N/A, 1/26/2017 05156V10 BW   Aurinia Pharmaceuticals to Participate in Upcoming Conferences,#N/A,#N/A,#N/A, 4/26/2010 37416310     BW   Geron Announces Conference Call to Discuss Financial Results for the 2010 First Quarter," 9/25/2017 OXUR-BE    BW   Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons",#N/A, 2/06/2018 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A,"12/08/2014 80360710 BW   INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP", 2/02/2016 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences, 7/06/2016 07R52H-E BW   Cerus and CEI Announce Donation of INTERCEPT Blood System Kits to HEMORIO for Emergency Preparedness Ahead of the Summer Olympic Games in Rio de Janeiro," 7/21/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Second Quarter on July 28, 2010 at 4:30 p.m. ET", 3/07/2017 04269E10 BW   ArQule Reports Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A," 7/10/2017 BMY-US   BW   Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma", 9/23/2015 SNY-FR    BW   More Than 50 Presentations of New Data from Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS,12/12/2017 CRSP-US   BW   Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia,#N/A,#N/A, 9/01/2017 BLUE-US  BW   bluebird bio to Present at Investor Conferences in September,11/07/2016 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A," 4/26/2017 TXMD-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A, 3/27/2017 OMER-US  BW   Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology,11/17/2016 008ZWN-E BW   Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference,#N/A,12/22/2016 06CR5C-E BW   Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2017 SYRS-US  BW   Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones,#N/A,#N/A,10/18/2010 00182C10     BW   BioSante Pharmaceuticals Reaches Key LibiGel® Safety Study Enrollment Target, 4/25/2016 06CR5C-E   BW   Enanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis, 8/10/2018 ALNY-US   BW   Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO™ (patisiran),#N/A,#N/A,#N/A," 9/25/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2017 AKBA-US  BW   Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/06/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/27/2011 56400P70 BW   Bronstein, Gewirtz & Grossman, LLC Investigating Possible Securities Law Violations at MannKind Corporation",#N/A,#N/A,#N/A," 3/03/2011 03236M20 BW   Amyris entra em acordo para a fabricação do Biofene™ com a Antibióticos, S.A.",#N/A,#N/A,#N/A,#N/A, 8/09/2016 06CR5C-E BW   Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission,#N/A,#N/A,#N/A,"10/27/2014 29428V10 BW   Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D.",#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2017 VCYT-US  BW   Veracyte Announces Second Quarter 2017 Financial Results," 3/23/2017 DRNA-US  BW   Dicerna to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 30, 2017", 5/21/2018 15117K10 BW   Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2017 XLRN-US  BW   Acceleron Announces Management Change,#N/A," 2/10/2016 HZNP-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors", 8/13/2014 00BJ80-E  BW   Castle Biosciences Announces $11.8 Million Financing,#N/A,#N/A,12/07/2015 GLYC-US  BW   GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model,#N/A,#N/A,#N/A, 5/15/2017 G6674U10 BW   Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2017 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2015 MCRB-US  BW   Seres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update,10/19/2017 00900T10 BW   Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2015 009FRV-E BW   Quanterix’s Ultrasensitive Single Molecule Measurement Technology Featured in Clinical Chemistry,#N/A,#N/A,#N/A, 5/17/2012 EYPT-US  BW   pSivida Corp. Announces Expiration of 2.7 Million Warrants,#N/A,#N/A, 2/20/2018 0DM9XX-E BW   Axonics® gibt Veröffentlichung klinischer Beiträge über sein Sacral Neuromodulation-System im Journal of Neurourology and Urodynamics bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/17/2016 LGND-US   BW   EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND,#N/A, 4/10/2017 45232710    BW   Illumina Launches the VeriSeq™ NIPT Solution in Europe,11/14/2016 84763A10  BW   Spectrum Pharmaceuticals Provides Third Quarter Financial Update,#N/A, 9/14/2017 ARWR-US  BW   Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates,#N/A,#N/A,#N/A,#N/A, 5/18/2015 68375N10 BW   OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting,#N/A,#N/A,10/30/2017 ALXN-US  BW   Alexion to Present at the 26th Annual Credit Suisse Healthcare Conference,#N/A, 2/06/2018 SGEN-US     BW   Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results,#N/A,12/21/2016 GS-US       BW   Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference, 4/29/2016 IMGN-US  BW   ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update," 7/27/2010 09058V10 BW   BioCryst Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010",12/04/2018 GILD-US      BW   China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6,#N/A,#N/A, 2/02/2012 M2572210 BW   Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy, 3/15/2010 00972810  BW   Akorn Reports 2009 Fourth Quarter and Year-End Financial Results,10/15/2012 NPSP-US      BW   New Data From REPLACE Study Show Initiation of Bone Remodeling for Natpara®-Treated Patients with Hypoparathyroidism,#N/A,#N/A,#N/A,#N/A,12/28/2016 05156V10 BW   Aurinia Closes US$28 Million Financing,#N/A,#N/A,#N/A, 4/22/2010 37416310     BW   Geron Gives Five Presentations on Telomerase Inhibitor Imetelstat at the AACR Annual Meeting, 9/20/2017 AERI-US    BW   Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,#N/A, 1/31/2018 INCY-US  BW   Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results,#N/A,"11/24/2014 80360710 BW   Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014", 1/25/2016 ALKS-US  BW   Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119," 7/05/2016 CERS-US  BW   CORRECTING and REPLACING Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13, 2016", 6/29/2010 00163U10 BW   AMAG Pharmaceuticals and Takeda Announce Acceptance of Submission of Feraheme® Marketing Authorization Application to the European Medicines Agency," 2/24/2017 04269E10 BW   ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017",#N/A,#N/A," 6/29/2017 EXEL-US  BW   Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness", 9/14/2015 4587-JP   BW   PeptiDream Announces Peptide Discovery Collaboration Agreement with Sanofi,12/07/2017 VRTX-US   BW   Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years,#N/A,#N/A, 8/09/2017 BLUE-US  BW   bluebird bio to Present at Wedbush PacGrow Healthcare Conference,11/03/2016 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia,#N/A,#N/A,#N/A," 4/26/2017 TXMD-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A, 3/16/2017 OMER-US  BW   Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results,11/07/2016 RVNC-US  BW   Revance to Participate in the Jefferies 2016 London Healthcare Conference,#N/A,12/19/2016 IRWD-US  BW   Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C,#N/A,#N/A,#N/A,#N/A,#N/A," 3/01/2017 SYRS-US  BW   Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting",#N/A,#N/A,"10/14/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at Cancer Immunotherapy Conference", 4/16/2016 00DYYX-E   BW   Enanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus," 8/10/2018 ALNY-US   BW   Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults",#N/A,#N/A,#N/A," 9/12/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 AKBA-US  BW   Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights,#N/A,#N/A,#N/A,#N/A, 8/03/2017 SAGE.XX1-US BW   Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/19/2011 56400P70 BW   MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA®,#N/A,#N/A,#N/A," 3/03/2011 08J3M2-E BW   Amyris Contracts for Biofene™ Manufacture with Antibióticos, S.A.",#N/A,#N/A,#N/A,#N/A," 7/25/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2016 Financial Results on August 9, 2016",#N/A,#N/A,#N/A,10/23/2014 29428V10 BW   Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2017 VCYT-US  BW   Veracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer, 3/01/2017 DRNA-US  BW   Dicerna to Present at Cowen and Company 37th Annual Health Care Conference, 5/18/2018 15117K10 BW   Cellectis S.A. : Calyxt annonce l’augmentation du nombre d’actions émises et la fixation du prix de l’offre réalisée dans le cadre de son offre secondaire d’actions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2017 XLRN-US  BW   Acceleron to Participate in Two Healthcare Investor Conferences in May,#N/A,12/16/2015 071YWR-E BW   Illinois Biotechnology Industry Organization Announces Horizon Pharma Chairman and CEO Timothy P. Walbert as New Chairman, 6/02/2014 00BJ80-E  BW   Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease in a Cohort of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy,#N/A,#N/A,"12/05/2015 GLYC-US  BW   GlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271",#N/A,#N/A,#N/A, 5/11/2017 G6674U10 BW   Martin J. Madden Joins Novocure Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/18/2017 74587V10 BW   Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2015 MCRB-US  BW   Seres Therapeutics Appoints Kurt Graves to Board of Directors,10/16/2017 AIMT-US  BW   Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2015 009FRV-E BW   Quanterix Launches Next Generation Simoa 2.0 Ultrasensitive Immunoassay Platform,#N/A,#N/A,#N/A," 5/09/2012 30233G10 BW   pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012",#N/A,#N/A, 2/20/2018 0DM9XX-E BW   Axonics®annonce la publication d'articles cliniques relatifs à son système de neuromodulation sacrée dans le Journal of Neurourology and Urodynamics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/15/2016 LGND-US   BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm,#N/A, 4/06/2017 ILMN-US     BW   Lucigen to Distribute Entire Epicentre Product Line,"11/09/2016 SPPI-US   BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 9/11/2017 ARWR-US  BW   Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 5/15/2015 68375N10 BW   OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large Community-Based Referral Cohort,#N/A,#N/A,10/26/2017 ALXN-US  BW   Alexion Reports Third Quarter 2017 Results,#N/A, 2/02/2018 SGEN-US     BW   Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,"12/21/2016 09062X10    BW   Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017", 4/26/2016 IMGN-US  BW   ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer, 6/01/2010 09058V10 BW   BioCryst Initiates a Phase 2 Study of BCX4208 Alone and in Combination with Allopurinol in Patients with Gout,12/03/2018 GILD-US      BW   Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,#N/A,#N/A," 1/31/2012 M2572210 BW   Compugen Fourth Quarter 2011 Conference Call Scheduled for Tuesday, February 7, 2012 at 10:00 AM EST"," 3/11/2010 00972810  BW   Akorn, Inc. Enters into an Agreement to Sell Common Stock and Warrants",10/12/2012 NPSP-US      BW   FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Gattex® (teduglutide) for Adult Short Bowel Syndrome,#N/A,#N/A,#N/A,#N/A,12/22/2016 002ZVF-E BW   Aurinia Announces US$25.0 Million Bought Deal Financing,#N/A,#N/A,#N/A, 3/26/2010 37416310     BW   Geron Appoints Thomas Hofstaetter to Board of Directors and Announces Retirement of Patrick Zenner," 9/19/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development",#N/A, 1/24/2018 INCY-US  BW   Incyte to Report Fourth Quarter and Year-End Financial Results,#N/A,11/24/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at Upcoming Conferences," 1/21/2016 ALKS-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Alkermes plc"," 6/30/2016 CERS-US  BW   Cerus Corporation, the Transfusion Service of the Swiss Red Cross, and the University Hospital of Basel Receive a Grant of 2 Million Swiss Francs From the Swiss Red Cross Humanitarian Foundation for Whole Blood Pathogen Inactivation for Africa"," 6/04/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences", 2/17/2017 ARQL-US  BW   Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma,#N/A,#N/A, 6/19/2017 IPN-FR   BW   Ipsen et son partenaire Exelixis annoncent que l’évaluation par un comité radiologique indépendant confirme les résultats de l'étude de phase 2 CABOSUN comparant le cabozantinib au sunitinib chez des patients atteints de carcinome avancé du rein ..., 8/25/2015 008P4S-E  BW   Pfizer’s Stephen Baker Joins Innovive Inc,11/10/2017 VRTX-US   BW   Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union,#N/A,#N/A, 8/02/2017 BLUE-US  BW   bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress,"11/01/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016",#N/A,#N/A,#N/A," 4/25/2017 TXMD-US  BW   INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit Against TherapeuticsMD, Inc.",#N/A,#N/A," 3/10/2017 OMER-US  BW   Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017",11/03/2016 RVNC-US  BW   Revance Releases Third Quarter 2016 Results,#N/A,11/13/2016 IRWD-US  BW   Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 SYRS-US  BW   Syros Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,"10/11/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. Presents LibiGel® Clinical Study Update at North American Menopause Society Meeting"," 4/15/2016 ENTA-US    BW   Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals", 8/03/2018 ALNY-US   BW   Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran,#N/A,#N/A,#N/A," 9/05/2012 PCRX-US  BW   Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2017 AKBA-US  BW   Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation,#N/A,#N/A,#N/A,#N/A," 7/20/2017 SAGE.XX1-US BW   Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2011 MNKD-US  BW   MannKind to Present at the JP Morgan 29th Annual Healthcare Conference,#N/A,#N/A,#N/A, 2/28/2011 03236M20 BW   Amyris Reports Fourth Quarter and 2010 Year-End Results,#N/A,#N/A,#N/A,#N/A," 7/18/2016 EGRX-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016",#N/A,#N/A,#N/A,10/17/2014 29428V10 BW   Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma,#N/A,#N/A,#N/A,#N/A,#N/A, 7/26/2017 VCYT-US  BW   Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer, 2/08/2017 DRNA-US  BW   Dicerna to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference, 5/18/2018 CLXT-US  BW   Calyxt Announces Upsizing and Pricing of Follow-On Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2017 CELG-US  BW   Acceleron Provides Clinical Development Updates on Luspatercept Program,#N/A,11/11/2015 HZNP-IE  BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Horizon Pharma plc,#N/A,#N/A,#N/A,12/05/2015 GLYC-US  BW   GlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models,#N/A,#N/A,#N/A," 5/08/2017 G6674U10 BW   Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2017 74587V10 BW   Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress,#N/A,#N/A,#N/A,#N/A,#N/A,"11/04/2015 MCRB-US  BW   Seres Therapeutics to Host Third Quarter 2015 Financial Results Conference Call and Webcast on Nov. 10, 2015", 9/06/2017 00900T10 BW   Aimmune Therapeutics to Participate in Three Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/20/2015 009FRV-E BW   Quanterix Announces Second Bi-Annual Conference, “Proteins Powering NexGen Healthcare: San Francisco”",#N/A,#N/A,#N/A, 5/07/2012 EYPT-US  BW   pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 2/20/2018 0DM9XX-E BW   Axonics® Announces Publication of Clinical Articles about Its Sacral Neuromodulation System in the Journal of Neurourology and Urodynamics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"11/15/2016 LGND-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ligand Pharmaceuticals, Inc.",#N/A," 4/03/2017 45232710    BW   Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC","11/09/2016 SPPI-US   BW   SPPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Spectrum Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 21, 2016",#N/A, 9/01/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies,#N/A,#N/A,#N/A,#N/A, 5/11/2015 68375N10 BW   OPKO Announces First Quarter Operating and Financial Results,#N/A,#N/A,10/23/2017 ALXN-US  BW   FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG),#N/A, 2/01/2018 SGEN-US     BW   Seattle Genetics Announces Pricing of Public Offering of Common Stock,#N/A,12/20/2016 BIIB-US     BW   Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock, 4/18/2016 IMGN-US  BW   ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia, 5/27/2010 09058V10 BW   BioCryst to Present at Jefferies 2010 Global Life Sciences Conference,12/02/2018 GILD-US      BW   Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma,#N/A,#N/A, 1/30/2012 CGEN-IL  BW   Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring Conference,#N/A,10/11/2012 0C8BZH-E     BW   RBCC: Nobel Prize Could Bring Big Investments in Stem Cell Research,#N/A,#N/A,#N/A,#N/A,12/19/2016 LONN-CH  BW   Aurinia Announces Long-Term Manufacturing Collaboration Agreement with Lonza for Clinical and Commercial Supply of Voclosporin,#N/A,#N/A,#N/A, 3/03/2010 37416310     BW   Geron Highlights Product Launch from Collaboration with Corning – the Synthemax™ Surface for Scalable Growth of Human Embryonic Stem Cells, 9/06/2017 AERI-US    BW   Aerie Pharmaceuticals to Present at Two Investor Conferences in September,#N/A, 1/23/2018 INCY-US  BW   Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation,#N/A,11/18/2014 80360710 BW   Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy," 1/21/2016 ALKS-US  BW   Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder", 6/19/2016 06CR5C-E BW   Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program," 5/20/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the 2010 Citi Investment Research Global Healthcare Conference"," 2/08/2017 04269E10 BW   ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017",#N/A,#N/A," 6/19/2017 EXEL-US  BW   Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma", 8/18/2015 OXBT-US   BW   Tenax Therapeutics Announces Nomination of James Mitchum to Board of Directors,11/09/2017 DHC-US    BW   Senior Housing Properties Trust Announces Third Quarter 2017 Results,#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio présente de nouvelles données de l'étude HGB-205 sur le produit LentiGlobin™ chez les patients atteints de bêta-thalassémie transfusion- dépendants (TDT) et de drépanocytose sévère...,10/31/2016 ACAD-US  BW   ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation,#N/A,#N/A,#N/A," 4/24/2017 TXMD-US  BW   SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A, 3/02/2017 OMER-US  BW   Omeros to Present at the Cowen and Company Annual Health Care Conference,11/03/2016 RVNC-US  BW   Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis,#N/A,11/10/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2017 SYRS-US  BW   Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference,#N/A,#N/A,"10/04/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present LibiGel® Clinical Trial Update at North American Menopause Society Meeting", 4/14/2016 00DYYX-E   BW   Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients, 8/02/2018 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A," 8/09/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2017 AKBA-US  BW   Akebia to Present at the 19th BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A, 7/10/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/28/2010 56400P70 BW   MannKind Updates Status of New Drug Application for AFREZZA®,#N/A,#N/A,#N/A, 2/28/2011 03236M20 BW   Amyris Sells First Renewable Product,#N/A,#N/A,#N/A,#N/A, 7/14/2016 EGRX-US  BW   IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm,#N/A,#N/A,#N/A,10/10/2014 29428V10 BW   Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A," 7/18/2017 VCYT-US  BW   Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017"," 2/02/2017 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", 5/15/2018 15117K10 BW   Calyxt Announces Launch of Proposed Follow-On Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/26/2017 XLRN-US  BW   Acceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017",#N/A,"10/20/2015 HZNP-US  BW   HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors",#N/A,#N/A,#N/A,12/02/2015 GLYC-US  BW   Biotech Leader Provides Testimony Before House Capital Markets Subcommittee,#N/A,#N/A,#N/A, 5/04/2017 G6674U10 BW   Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2017 74587V10 BW   Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2015 MCRB-US  BW   Seres Therapeutics to Participate in November Investor Conferences," 8/09/2017 00900T10 BW   Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 009FRV-E BW   Kevin Hrusovsky Keynotes at Meeting on Concussion Management and Co-Authors Whitepaper,#N/A,#N/A,#N/A, 5/03/2012 30233G10 BW   pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 1/08/2018 0DM9XX-E BW   Le système de neuromodulation sacrée Axonics® reçoit l’autorisation de mise sur le marché en Australie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/15/2016 LGND-US   BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm,#N/A," 3/21/2017 ILMN-US     BW   Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research",11/03/2016 84763A10  BW   Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update,#N/A, 8/03/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 Third Quarter Results,#N/A,#N/A,#N/A,#N/A," 5/07/2015 68375N10 BW   CORRECTING and REPLACING OPKO To Announce First Quarter Financial Results on May 11, 2015",#N/A,#N/A,"10/13/2017 ALXN-US  BW   ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. – (ALXN)",#N/A," 1/31/2018 CASC-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to Shareholders",#N/A,12/20/2016 BIIB-US     BW   Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference," 4/11/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results", 5/03/2010 09058V10 BW   BioCryst To Present at Two Upcoming Investor Conferences,11/18/2018 GILD-US      BW   China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection,#N/A,#N/A,12/20/2011 M2572210 BW   Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology,#N/A,"10/04/2012 00B8PL-E     BW   Rheumatologists Continue to Prefer Enbrel and Humira as Both Their First and Second Line Biologic Agents and the Combined Formulations of Orencia as the Dominant Third Line Agent, According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A,12/13/2016 06CR5C-E BW   Aurinia Confirms Receipt of FDA End of Phase 2 Meeting Minutes,#N/A,#N/A,#N/A, 3/03/2010 37416310     BW   Corning Incorporated Introduces New Synthemax™ Synthetic Surface to Enhance and Support Stem Cell Growth, 9/06/2017 AERI-US    BW   Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,#N/A, 1/08/2018 INCY-US  BW   Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms,#N/A,11/12/2014 80360710 BW   Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy, 1/05/2016 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare Conference, 5/23/2016 06X1SR-E BW   Health Canada Approves INTERCEPT Blood System for Plasma," 5/03/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference","12/04/2016 04269E10 BW   Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting",#N/A,#N/A, 6/12/2017 EXEL-US  BW   Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors, 7/30/2015 LGNZZ-US  BW   Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844,11/03/2017 VRTX-US   BW   Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio gibt auf der Jahrestagung der European Hematology Association (EHA) erste Daten aus der Phase-3-Studie Northstar-2 (HGB-207) zur Gentherapie LentiGlobinTM bekannt,10/11/2016 ACAD-US  BW   ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™,#N/A,#N/A,#N/A," 4/21/2017 TXMD-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A, 3/01/2017 OMER-US  BW   Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy,"10/24/2016 RVNC-US  BW   Revance Therapeutics to Release Third Quarter 2016 Financial Results Thursday, November 3, 2016",#N/A,11/03/2016 CRM-US   BW   Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2017 SYRS-US  BW   Syros’ Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium,#N/A,#N/A, 9/30/2010 00182C10     BW   BioSante Pharmaceuticals to Present at the Bio Investor Forum, 3/30/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress™ 2016, 7/27/2018 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results,#N/A,#N/A,#N/A," 8/07/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/20/2016 AKBA-US  BW   Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.,#N/A,#N/A,#N/A,#N/A, 6/12/2017 SAGE-US     BW   Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2010 MNKD-US  BW   Maven Semantic: Flow Cytometry Research Database,#N/A,#N/A,#N/A, 2/28/2011 03236M20 BW   Amyris comercializa seu primeiro produto renovável,#N/A,#N/A,#N/A,#N/A, 7/07/2016 EGRX-US  BW   IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm,#N/A,#N/A,#N/A,10/01/2014 29428V10 BW   Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2015 00BJ80-E BW   Castle Biosciences Announces the Appointment of Veracyte CEO Bonnie H. Anderson to its Board of Directors,11/09/2016 DRNA-US  BW   Dicerna to Present at the Stifel 2016 Healthcare Conference, 5/15/2018 15117K10 BW   Calyxt annonce le lancement d’une offre secondaire d’actions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/06/2017 XLRN-US  BW   Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes,#N/A, 9/09/2015 ACN-IE   BW   Accenture Selected to Help Transform Horizon Pharma’s Business Operations,#N/A,#N/A,#N/A,11/12/2015 GLYC-US  BW   GlycoMimetics to Present at Two Investor Conferences in November,#N/A,#N/A,#N/A," 5/02/2017 G6674U10 BW   Novocure™ kündigt Präsentation von Daten auf der 5. Versammlung der World Federation of Neuro-Oncology Societies an, die alle vier Jahre stattfindet",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2017 74587V10 BW   Puma Biotechnology Announces Publication of Abstracts for ESMO 2017,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2015 MCRB-US  BW   Seres Therapeutics to Present at 22nd Annual BioCentury NewsMakers Conference, 8/08/2017 00900T10 BW   Aimmune Therapeutics Announces Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2015 009FRV-E BW   Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes,#N/A,#N/A,#N/A, 4/24/2012 30233G10 BW   pSivida Corp. Announces ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 1/08/2018 0DM9XX-E BW   Sakrales Neuromodulationssystem von Axonics® erhält Marktzulassung in Australien,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/03/2016 LGND-US   BW   Ligand Reports Third Quarter 2016 Financial Results,#N/A, 3/08/2017 ILMN-US     BW   MLL Münchner Leukämielabor wählt IBM Watson und Illumina für Forschungszusammenarbeit zur Vervollkommnung der Diagnostik und Entwicklung personalisierter Behandlungsinstrumente bei Leukämie und Lymphomen,"10/31/2016 SPPI-US   BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 7/27/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 5/05/2015 OPK-US   BW   OPKO Health Acquires EirGen Pharma,#N/A,#N/A,"10/10/2017 ALXN-US  BW   Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017",#N/A, 1/31/2018 SGEN-US     BW   Seattle Genetics Announces Proposed Public Offering of Common Stock,#N/A,"12/20/2016 05G4B5-E    BW   PixarBio Corporation Names Steve Chartier Chief Operating Officer, To Lead Regulatory Affairs, CMC, and Clinical Studies for NeuroRelease™ a Morphine Replacement, Non Addictive Pain Treatment"," 4/05/2016 IMGN-US  BW   Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.", 4/28/2010 09058V10 BW   BioCryst Reports First Quarter 2010 Financial Results and Provides Corporate Update,11/14/2018 HEMA-US      BW   HemaCare Provides Starting Material for Three FDA Approved Cellular Therapies,#N/A,#N/A,12/13/2011 M2572210 BW   BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen,#N/A,10/04/2012 0C8BZH-E     BW   RBCC: NASA Bioreactor Could Speed Parkinson’s Research,#N/A,#N/A,#N/A,#N/A,12/12/2016 05156V10 BW   Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee,#N/A,#N/A,#N/A, 3/02/2010 37416310     BW   Presentations on Geron’s Telomerase Inhibitor At AACR Special Conference, 8/28/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director,#N/A,12/14/2017 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A,"11/11/2014 80360710 BW   INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP",12/16/2015 ALKS-US  BW   Alkermes Announces Achievement of Milestones for CNS Medicines in Proprietary Product and Pipeline Portfolio, 5/03/2016 CERS-US  BW   Cerus Corporation Reports First Quarter 2016 Results, 4/27/2010 00163U10 BW   AMAG Pharmaceuticals Announces First Quarter 2010 Financial Results,"12/03/2016 04269E10 BW   Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting",#N/A,#N/A, 6/08/2017 EXEL-US  BW   Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13, 7/29/2015 SNY-FR    BW   Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program,11/03/2017 VRTX-US   BW   Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine,#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio präsentiert neue Daten der HGB-205-Studie für die Therapie mit LentiGlobin™ zur Behandlung von transfusionsabhängiger β-Thalassämie (TDT) und schwerer Sichelzellenanämie (SCD) ...," 9/20/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016",#N/A,#N/A,#N/A," 4/20/2017 TXMD-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against TherapeuticsMD, Inc.",#N/A,#N/A,12/07/2016 06W5GZ-E BW   Data from Omeros’ OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference, 8/30/2016 008ZWN-E BW   Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference,#N/A,11/01/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2017 SYRS-US  BW   Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer,#N/A,#N/A," 9/22/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at the JMP Healthcare Conference", 3/10/2016 BCS-GB     BW   Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference, 7/27/2018 ALNY-US   BW   Alnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy,#N/A,#N/A,#N/A," 7/31/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2016 AKBA-US  BW   Akebia Prevails in Additional European Patent Dispute,#N/A,#N/A,#N/A,#N/A, 6/08/2017 SAGE-US     BW   Sage Therapeutics to Present at Goldman Sachs Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2010 56400P70 BW   Presentation at American Society of Hematology Annual Meeting Confirms Inhibiting Unfolded Protein Response is Promising Treatment for Multiple Myeloma,#N/A,#N/A,#N/A," 2/25/2011 03236M20 BW   Paulo Diniz Joins Amyris as CEO, Amyris Brasil",#N/A,#N/A,#N/A,#N/A," 7/05/2016 EGRX-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016",#N/A,#N/A,#N/A," 9/25/2014 29428V10 BW   Epizyme, Inc. to Present at Upcoming Events in October",#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2012 SAN-FR   BW   Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis,11/07/2016 DRNA-US  BW   Dicerna Reports Third Quarter 2016 Financial and Operational Results, 5/10/2018 15117K10 BW   Cellectis présentera des données à la conférence annuelle de l’American Society of Gene & Cell Therapy (ASGCT),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2017 XLRN-US  BW   Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2015 GLYC-US  BW   GlycoMimetics Reports Third Quarter 2015 Results,#N/A,#N/A,#N/A, 5/01/2017 G6674U10 BW   Novocure to Present at Three Upcoming Investor Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/25/2017 74587V10 BW   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A," 8/21/2015 MCRB-US  BW   Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults", 8/08/2017 00900T10 BW   Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 009FRV-E BW   Quanterix and Beth Israel Deaconess Medical Center Publish Study on the Development and Validation of Digital ELISAs for Ultrasensitive Detection and Quantification of C. difficile toxins in Stool,#N/A,#N/A,#N/A, 3/13/2012 30233G10 BW   pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology,#N/A,#N/A, 1/08/2018 0DM9XX-E BW   Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/24/2016 06CR5C-E  BW   Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections,#N/A, 3/08/2017 ILMN-US     BW   Le Munich Leukemia Laboratory lance avec IBM Watson et Illumina une recherche collaborative visant à améliorer les diagnostics et à mettre au point des traitements personnalisés contre la leucémie et le lymphome,"10/31/2016 SPPI-US   BW   GPM Reminds Investors of the November 21st Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm",#N/A, 6/09/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 4/21/2015 68375N10 BW   OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test,#N/A,#N/A," 9/29/2017 ALXN-US  BW   ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. – (ALXN)",#N/A," 1/31/2018 CASC-US     BW   Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline",#N/A,12/19/2016 09062X10    BW   Biogen Names Michel Vounatsos Chief Executive Officer," 3/29/2016 06P9WL-E BW   ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting", 4/28/2010 09058V10 BW   BioCryst Reports Positive Results from Part One of Its Phase 2a Study of BCX4208 in Patients with Gout,"11/12/2018 GILD-US      BW   Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27",#N/A,#N/A,11/30/2011 M2572210 BW   Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference,#N/A,10/03/2012 0C8BZH-E     BW   RBCC Looks to China for Stem Cell Research,#N/A,#N/A,#N/A,#N/A,11/21/2016 06QBQ8-E BW   Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016,#N/A,#N/A,#N/A, 2/25/2010 37416310     BW   Geron Corporation Reports Fourth Quarter and Annual 2009 Financial Results and Highlights," 8/14/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons",#N/A,12/10/2017 INCY-US  BW   Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera,#N/A,"11/10/2014 80360710 BW   SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith",11/11/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 London Healthcare Conference, 5/03/2016 CERS-US  BW   Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System," 4/27/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. Appoints Gary J. Zieziula as Executive Vice President and Chief Commercial Officer",11/07/2016 04269E10 BW   ArQule Reports Third Quarter 2016 Financial Results,#N/A,#N/A, 5/03/2017 EXEL-US  BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 7/27/2015 SNY-FR    BW   Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca,11/02/2017 VRTX-US   BW   Vertex to Present at the Credit Suisse Healthcare Conference on November 7,#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio annuncia al Congresso annuale dell'Associazione Europea di Ematologia (EHA) i risultati preliminari dello studio di fase 3 Northstar-2 (HGB-207) con LentiGlobin™, 9/19/2016 ACAD-US  BW   ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit,#N/A,#N/A,#N/A, 4/19/2017 TXMD-US  BW   TherapeuticsMD Provides Additional Information on TX-004HR Regulatory Update,#N/A,#N/A,12/06/2016 OMER-US  BW   Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment, 8/04/2016 RVNC-US  BW   Revance Releases Second Quarter 2016 Results,#N/A,10/25/2016 IRWD-US  BW   Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2017 SYRS-US  BW   Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference,#N/A,#N/A," 9/07/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Healthcare Conference", 2/26/2016 080RQG-E   BW   Enanta Pharmaceuticals Announces CHMP Positive Opinion for AbbVie’s VIEKIRAX® + EXVIERA® Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis, 7/23/2018 ALNY-US   BW   Alnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting,#N/A,#N/A,#N/A, 6/05/2012 69512710 BW   New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2016 AKBA-US  BW   Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/05/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/01/2010 56400P70 BW   MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference",#N/A,#N/A,#N/A, 2/25/2011 03236M20 BW   Paulo Diniz Assume a Presidência da Amyris Brasil,#N/A,#N/A,#N/A,#N/A," 7/05/2016 EGRX-US  BW   Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director, Michael Graves Appointed Chairman",#N/A,#N/A,#N/A," 9/15/2014 29428V10 BW   Epizyme Appoints Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D., as Vice President, Business Development",#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2012 SAN-FR   BW   Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients,"10/31/2016 DRNA-US  BW   Dicerna to Report Third Quarter 2016 Financial Results and Host Conference Call on November 7, 2016", 5/10/2018 15117K10 BW   Cellectis to Present Data at the 2018 ASGCT Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 XLRN-US  BW   Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2015 GLYC-US  BW   GlycoMimetics E-selectin and Blood Cancer Data to Be Highlighted at 57th Annual ASH Meeting,#N/A,#N/A,#N/A, 5/01/2017 G6674U10 BW   Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/11/2017 PBYI-US  BW   PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 MCRB-US  BW   Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update, 7/05/2017 00900T10 BW   Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2015 009FRV-E BW   National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury,#N/A,#N/A,#N/A, 3/06/2012 30233G10 BW   pSivida Corp. Names Douglas Godshall to Board of Directors,#N/A,#N/A, 1/03/2018 0DM9XX-E BW   Premiers patients ayant subi l’implantation du système de neuromodulation sacrée Axonics® dans le cadre d'une étude pivot de la FDA américaine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/13/2016 LGND-US   BW   Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference,#N/A, 3/08/2017 ILMN-US     BW   CORRECTING and REPLACING Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma,10/27/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference and Webcast,#N/A, 5/03/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 Second Quarter Results,#N/A,#N/A,#N/A,#N/A, 4/01/2015 68375N10 BW   Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes,#N/A,#N/A," 9/26/2017 0FKPTT-E BW   Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Lawsuit",#N/A, 1/22/2018 4502-JP     BW   Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy,#N/A,"12/12/2016 BIIB-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016", 3/21/2016 IDXX-US  BW   GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors, 4/23/2010 BCRX-US  BW   Company Profile for BioCryst Pharmaceuticals,11/09/2018 GILD-US      BW   Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018,#N/A,#N/A,11/29/2011 M2572210 BW   Compugen and DiscoveRx® Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets,#N/A,10/01/2012 0C8BZH-E     BW   RBCC: Could Stem Cells Hold the Key to Treating Traumatic Brain Injuries?,#N/A,#N/A,#N/A,#N/A,11/16/2016 0793RM-E BW   Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting,#N/A,#N/A,#N/A, 2/23/2010 37416310     BW   Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2009 Financial Results and Highlights, 8/08/2017 AERI-US    BW   Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer,#N/A,11/15/2017 INCY-US  BW   Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia,#N/A,11/06/2014 80360710 BW   Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments,11/03/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to Be Webcast at the Credit Suisse 24Th Annual Healthcare Conference," 4/28/2016 DB-DE    BW   Cerus to Present at the Deutsche Bank 41st Annual Health Care Conference on May 5, 2016"," 4/21/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended March 31, 2010",11/03/2016 ARQL-US  BW   Advancements in ArQule’s Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting,#N/A,#N/A, 5/01/2017 EXEL-US  BW   Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update," 7/13/2015 06M48D-E  BW   Distinguished Pharma Leaders and Experienced Investors Join Together in Nuvelution Pharma, Inc.","11/01/2017 VRTX-US   BW   Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers",#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio presenta nuovi dati dello studio clinico HGB-205 su LentiGlobin™ nei pazienti affetti da beta-talassemia trasfusione dipendente (TDT) e anemia falciforme (AF) grave al convegno annuale della European Hematology Association (EHA)," 9/06/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016",#N/A,#N/A,#N/A," 4/18/2017 TXMD-US  BW   Robbins Arroyo LLP: TherapeuticsMD, Inc. (TXMD) Misled Shareholders According to a Recently Filed Class Action",#N/A,#N/A,12/05/2016 OMER-US  BW   Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy," 7/21/2016 RVNC-US  BW   Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016",#N/A,10/20/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2017 SYRS-US  BW   Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors,#N/A,#N/A, 8/12/2010 00182C10     BW   BioSante Pharmaceuticals Reports Second Quarter 2010 Financial Results," 2/08/2016 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015", 7/04/2018 ALNY-US   BW   Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine,#N/A,#N/A,#N/A," 5/29/2012 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2016 AKBA-US  BW   Akebia Announces Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A, 5/18/2017 SAGE-US     BW   Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/15/2010 56400P70 BW   New Findings Show Bioequivalence, Ease-of-Use and Efficiency of MannKind’s Drug Delivery Platform",#N/A,#N/A,#N/A, 2/24/2011 03236M20 BW   Amyris faz parceria com a Givaudan para desenvolver importante ingrediente de perfumaria a partir do Biofene,#N/A,#N/A,#N/A,#N/A, 7/01/2016 EGRX-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm,#N/A,#N/A,#N/A, 9/02/2014 29428V10 BW   Epizyme Announces Resignation of President and Chief Financial Officer Jason Rhodes,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2010 008W47-E BW   Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product, 9/26/2016 DRNA-US  BW   Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates, 5/07/2018 CLXT-US  BW   Calyxt Reports Financial Results for First Quarter 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2017 XLRN-US  BW   Acceleron to Participate in Two Healthcare Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,"10/29/2015 GLYC-US  BW   GlycoMimetics, Inc. Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel",#N/A,#N/A,#N/A, 4/27/2017 G6674U10 BW   Novocure Reports First Quarter 2017 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2017 74587V10 BW   Puma Biotechnology Reports Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 MCRB-US  BW   Seres Therapeutics to Present at Canaccord Genuity 35th Annual Growth Conference, 6/20/2017 00900T10 BW   Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2015 009FRV-E BW   Quanterix Named Final Winner of NFL and GE Head Health Challenge I,#N/A,#N/A,#N/A, 2/28/2012 30233G10 BW   pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN® for the Treatment of Chronic Diabetic Macular Edema,#N/A,#N/A, 1/03/2018 0DM9XX-E BW   Erste Implantationen des sakralen Neuromodulationssystems Axonics® bei Patienten in Pivotstudie der US-amerikanischen FDA,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/07/2016 LGND-US   BW   Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types,#N/A," 2/28/2017 45232710    BW   Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program","10/18/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of Luigi Lenaz, M.D., as Lead Director",#N/A, 4/26/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results,#N/A,#N/A,#N/A,#N/A, 3/27/2015 68375N10 BW   Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings,#N/A,#N/A," 9/14/2017 ALXN-US  BW   Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors",#N/A," 1/18/2018 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018",#N/A,12/08/2016 09062X10    BW   Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting, 2/04/2016 IMGN-US  BW   ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® (pembrolizumab) for the Treatment of Ovarian Cancer," 4/21/2010 09058V10 BW   BioCryst Pharmaceuticals to Announce First Quarter 2010 Financial Results on April 28, 2010",11/09/2018 GILD-US      BW   Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018,#N/A,#N/A,11/08/2011 M2572210 BW   Compugen Reports Third Quarter 2011 Financial Results,#N/A, 9/27/2012 0C8BZH-E     BW   RBCC: Stem Cell Market Poised for Billion-Dollar Growth,#N/A,#N/A,#N/A,#N/A,11/10/2016 SF-US    BW   Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference,#N/A,#N/A,#N/A, 2/08/2010 37416310     BW   Geron to Present at the BIO CEO & Investor Conference, 8/02/2017 AERI-US    BW   Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,#N/A,11/01/2017 INCY-US  BW   More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting,#N/A,11/04/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at Upcoming Conferences,10/29/2015 ALKS-US  BW   Alkermes plc Reports Third Quarter 2015 Financial Results," 4/19/2016 CERS-US  BW   Cerus to Release First Quarter 2016 Results on May 3, 2016", 4/01/2010 00163U10 BW   AMAG Pharmaceuticals to Host Conference Call to Discuss Strategic Collaboration with Takeda Pharmaceutical Company for Feraheme® in Select Ex-US Territories,"10/24/2016 04269E10 BW   ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016",#N/A,#N/A, 4/24/2017 EXEL-US  BW   Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3, 7/06/2015 RTRX-US   BW   Retrophin Closes Sale of Priority Review Voucher,10/31/2017 CNCE-US   BW   Flex Pharma Names Dr. Roger Tung to Its Board of Directors,#N/A,#N/A, 6/28/2017 BLUE-US  BW   bluebird bio annonce la présentation de données préliminaires de l'étude de Phase 3 Northstar-2 (HGB-207) portant sur le produit LentiGlobinTM lors du congrès annuel de l'Association européenne d'hématologie (EHA)," 8/24/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer",#N/A,#N/A,#N/A," 4/10/2017 TXMD-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving TherapeuticsMD, Inc.",#N/A,#N/A,11/30/2016 OMER-US  BW   International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury, 7/14/2016 06CR5C-E BW   Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines,#N/A,"10/03/2016 IRWD-US  BW   Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows",#N/A,#N/A,#N/A,#N/A,#N/A, 1/10/2017 SYRS-US  BW   Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 7/13/2010 00182C10     BW   BioSante Pharmaceuticals Announces Initiation of LibiGel® Study to Evaluate its Effect on Cognitive Function in Women, 2/01/2016 ENTA-US    BW   Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference, 6/21/2018 ALNY-US   BW   Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series,#N/A,#N/A,#N/A," 5/21/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 AKBA-US  BW   Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 5/09/2017 SAGE-US     BW   Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2010 56400P70 BW   MannKind to Present at the Lazard Capital Markets 7th Annual Healthcare Conference,#N/A,#N/A,#N/A, 2/24/2011 03236M20 BW   Amyris Partners with Givaudan to Develop Key Fragrance Ingredient from Biofene,#N/A,#N/A,#N/A,#N/A," 6/27/2016 002PSJ-E BW   Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year® 2016 New Jersey Region",#N/A,#N/A,#N/A, 8/26/2014 29428V10 BW   Epizyme to Present at Upcoming Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2016 DRNA-US  BW   Dicerna to Present at September Investor Conferences, 5/07/2018 15117K10 BW   Cellectis publie ses résultats financiers du premier trimestre 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/22/2017 XLRN-US  BW   Acceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017",#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2015 GLYC-US  BW   GlycoMimetics Announces Issuance of U.S. Composition of Matter Patent for Drug Candidate GMI-1271,#N/A,#N/A,#N/A, 4/19/2017 G6674U10 BW   Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2017 74587V10 BW   Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP),#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2015 81750R10 BW   Seres Therapeutics Announces Closing of Initial Public Offering, 6/15/2017 00900T10 BW   Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/17/2015 009FRV-E BW   Quanterix to Showcase Expertise at Leading Industry Conferences,#N/A,#N/A,#N/A," 2/08/2012 30233G10 BW   pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011",#N/A,#N/A, 1/03/2018 0DM9XX-E BW   First Patients Implanted with Axonics® Sacral Neuromodulation System in U.S. FDA Pivotal Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/22/2016 LGND-US   BW   Ligand Licenses Four Programs to Seelos Therapeutics,#N/A, 2/21/2017 ILMN-US     BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference,"10/11/2016 SPPI-US   BW   SPPI LOSS NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action Filed by Firm - SPPI",#N/A, 4/24/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A, 3/23/2015 68375N10 BW   OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources,#N/A,#N/A, 9/13/2017 ALXN-US  BW   Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis,#N/A, 1/08/2018 SGEN-US     BW   Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference,#N/A,12/03/2016 09062X10    BW   Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting," 2/03/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences",#N/A,11/09/2018 GILD-US      BW   Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018,#N/A,#N/A,10/25/2011 M2572210 BW   Compugen's CGEN-15001 Pre-Clinical Data Presented at International Conference on Immune Tolerance,#N/A, 9/19/2012 06W76T-E     BW   Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product NiCord® for Hematological Malignancies,#N/A,#N/A,#N/A,#N/A,11/09/2016 05156V10 BW   Aurinia Establishes At-The-Market Facility,#N/A,#N/A,#N/A, 1/26/2010 37416310     BW   Geron Forms Collaboration to Investigate GRNOPC1 in Alzheimer’s Disease Models, 8/01/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update,#N/A,10/31/2017 INCY-US  BW   Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs,#N/A,"10/31/2014 80360710 BW   Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014",10/29/2015 ALKS-US  BW   Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS 8700 for Treatment of Multiple Sclerosis, 3/16/2016 06CR5C-E BW   Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma," 4/01/2010 00163U10 BW   AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme® in All Therapeutic Indications in Select Ex-US Territories, Including Europe"," 9/21/2016 ARQL-US  BW   ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016",#N/A,#N/A," 4/18/2017 EXEL-US  BW   Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017", 6/15/2015 SNY-FR    BW   Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients,10/25/2017 VRTX-US   BW   Vertex Reports Third-Quarter 2017 Financial Results,#N/A,#N/A, 6/27/2017 BLUE-US  BW   bluebird bio Announces Pricing of Public Offering of Common Stock, 8/23/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 4/10/2017 TXMD-US  BW   TherapeuticsMD Provides TX-004HR Regulatory Update,#N/A,#N/A,11/21/2016 06CR5C-E BW   Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial, 7/05/2016 RVNC-US  BW   Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors,#N/A,10/03/2016 IRWD-US  BW   Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2017 SYRS-US  BW   Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals,#N/A,#N/A, 6/30/2010 00182C10     BW   BioSante Pharmaceuticals Announces Positive Clinical Results in Pill-Plus™ Oral Contraceptive Study," 1/28/2016 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015", 6/20/2018 ALNY-US   BW   Alnylam Expands Senior Leadership Team with Two Key Appointments,#N/A,#N/A,#N/A," 5/10/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/17/2016 AKBA-US  BW   Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2016 Annual Meeting,#N/A,#N/A,#N/A,#N/A, 5/04/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 56400P70 BW   Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of MannKind Corporation,#N/A,#N/A,#N/A, 2/22/2011 03236M20 BW   Amyris Technology Performs Successfully at Industrial Scale,#N/A,#N/A,#N/A,#N/A," 6/23/2016 EGRX-US  BW   SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A, 8/13/2014 29428V10 BW   Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2016 DRNA-US  BW   Dicerna Reports Second Quarter 2016 Financial and Operational Results, 5/07/2018 15117K10 BW   Cellectis Reports 1st Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2017 XLRN-US  BW   Acceleron to Participate in Two Healthcare Investor Conferences in February,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2015 GLYC-US  BW   GlycoMimetics to Present at the Canaccord Genuity Growth Conference,#N/A,#N/A,#N/A, 4/17/2017 G6674U10 BW   CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2017 74587V10 BW   Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States,#N/A,#N/A,#N/A,#N/A,#N/A," 6/25/2015 81750R10 BW   Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering", 6/12/2017 00900T10 BW   Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2015 00F34P-E BW   908 Devices Accelerates Entry into Life Science Market with Backing from Leading Industry Players,#N/A,#N/A,#N/A, 2/06/2012 30233G10 BW   pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14,#N/A,#N/A,12/04/2017 0DM9XX-E BW   Axonics® erhält sieben neue US-amerikanische Patente für seine implantierbare sakrale Neuromodulationstechnologie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 9/16/2016 LGND-US   BW   Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.",#N/A," 2/20/2017 UPS-US      BW   Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina"," 9/23/2016 SPPI-US   BW   INVESTOR ALERT: Investigation of Spectrum Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith",#N/A, 4/20/2017 ARWR-US  BW   Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A, 3/18/2015 68375N10 BW   OPKO Lab Receives Accreditation From College of American Pathologists,#N/A,#N/A, 9/12/2017 ALXN-US  BW   Alexion Announces Restructuring to Advance Corporate Strategy,#N/A, 1/02/2018 SGEN-US     BW   FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma,#N/A,"11/25/2016 BIIB-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016", 1/29/2016 IMGN-US  BW   ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update,#N/A,11/01/2018 GILD-US      BW   Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018,#N/A,#N/A,"10/24/2011 M2572210 BW   Compugen Third Quarter 2011 Conference Call Scheduled for Tuesday, November 8, 2011 at 10:00 AM EST",#N/A, 9/19/2012 0C8BZH-E     BW   RBCC Initiates Talks to Acquire License for NASA Bioreactor Technology,#N/A,#N/A,#N/A,#N/A,11/04/2016 06CR5C-E BW   Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights,#N/A,#N/A,#N/A, 1/15/2010 37416310     BW   Geron Corporation Announces Warrant Exchange, 7/31/2017 DSM-NL     BW   Aerie Pharmaceuticals Enters into Collaboration Agreement with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases such as Wet AMD,#N/A,10/31/2017 AZN-GB   BW   Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer,#N/A,10/27/2014 80360710 BW   Sarepta Therapeutics Announces Regulatory Update on Eteplirsen,10/22/2015 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Third Quarter 2015 Financial Results, 3/15/2016 06CR5C-E BW   Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets," 3/25/2010 00163U10 BW   Abraham, Fruchter & Twersky, LLP Warns Investors That It is the Only Law Firm That Has Filed a Class Action Lawsuit Against AMAG Pharmaceuticals, Inc."," 9/15/2016 04269E10 BW   ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal",#N/A,#N/A, 4/04/2017 EXEL-US  BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 6/04/2015 80105N10  BW   FDA Grants Breakthrough Therapy Designation for Genzyme’s Olipudase Alfa,10/23/2017 VRTX-US   BW   Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families,#N/A,#N/A, 6/26/2017 BLUE-US  BW   bluebird bio Announces Proposed Public Offering of Common Stock, 8/09/2016 ACAD-US  BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A, 4/03/2017 TXMD-US  BW   TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017,#N/A,#N/A,11/10/2016 OMER-US  BW   Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway," 6/11/2015 76133010 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Laws Violations by the Board of Revance Therapeutics, Inc.",#N/A, 9/26/2016 IRWD-US  BW   Ironwood Closes $150 Million Debt Refinancing,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2016 SYRS-US  BW   Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARα Agonist in Genomically Defined Subsets of Breast Cancer,#N/A,#N/A, 6/28/2010 00182C10     BW   BioSante Pharmaceuticals Added to Russell 3000® Index, 1/11/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference, 6/15/2018 ALNY-US   BW   Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology,#N/A,#N/A,#N/A," 5/09/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2016 AKBA-US  BW   Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia,#N/A,#N/A,#N/A,#N/A, 4/27/2017 SAGE-US     BW   Sage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 56400P70 BW   MannKind Corporation Issues Statement on Lawsuit,#N/A,#N/A,#N/A," 2/16/2011 03236M20 BW   Amyris to Announce 2010 Fourth Quarter and Year End Financial Results on Monday, February 28, 2011",#N/A,#N/A,#N/A,#N/A, 6/06/2016 EGRX-US  BW   INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm,#N/A,#N/A,#N/A, 8/12/2014 29428V10 BW   Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/28/2016 DRNA-US  BW   Dicerna to Report Second Quarter 2016 Financial Results and Host Conference Call on August 4, 2016", 5/04/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2017 XLRN-US  BW   Acceleron Outlines Corporate Goals and Priorities for 2017,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 GLYC-US  BW   GlycoMimetics Reports Second Quarter 2015 Results,#N/A,#N/A,#N/A," 4/02/2017 G6674U10 BW   Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/28/2017 PBYI-US  BW   PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",#N/A,#N/A,#N/A,#N/A,#N/A," 6/12/2015 0CT325-E BW   Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109"," 6/08/2017 00900T10 BW   Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2015 009FRV-E BW   Quanterix Names PBL Assay Science as a Preferred Partner in Assay Development and Testing Services,#N/A,#N/A,#N/A, 2/02/2012 30233G10 BW   pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3,#N/A,#N/A,12/04/2017 0DM9XX-E BW   Axonics®se voit accorder sept nouveaux brevets américains pour sa technologie de neuromodulation sacrée implantable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/13/2016 LGND-US   BW   Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes,#N/A," 2/03/2017 ILMN-US     BW   ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina, Inc. and a Lead Plaintiff Deadline of February 14, 2017"," 9/21/2016 SPPI-US   BW   SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Spectrum Pharmaceuticals, Inc. To Contact The Firm",#N/A, 4/05/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™,#N/A,#N/A,#N/A,#N/A, 3/06/2015 68375N10 BW   Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference,#N/A,#N/A," 9/11/2017 ALXN-US  BW   Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017",#N/A,12/19/2017 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A,11/15/2016 BIIB-US     BW   Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ, 1/26/2016 IMGN-US  BW   ImmunoGen Earns Milestone with Bayer’s Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration,#N/A,10/31/2018 0GYDTX-E     BW   Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies,#N/A,#N/A,10/12/2011 M2572210 BW   Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate,#N/A, 9/18/2012 0C8BZH-E     BW   RBCC Explores NASA Technology in Stem Cell Search,#N/A,#N/A,#N/A,#N/A,11/02/2016 05156V10 BW   Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA,#N/A,#N/A,#N/A,#N/A," 7/26/2017 AERI-US    BW   Aerie Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017",#N/A,10/30/2017 INCY-US  BW   Incyte Names New Member to Its Board of Directors,#N/A,10/16/2014 80360710 BW   Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy,"10/07/2015 ALKS-US  BW   Early Warning Signs of Schizophrenia Are Not Acted on Soon Enough, According to New Survey of Psychiatrists and Caregivers", 3/09/2016 CERS-US  BW   Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology," 3/24/2010 00163U10 BW   AMAG Pharmaceuticals under Investigation for Potentially Defrauding Shareholders, Says Hagens Berman", 8/03/2016 04269E10 BW   ArQule Reports Second Quarter 2016 Financial Results,#N/A,#N/A, 3/29/2017 EXEL-US  BW   Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan, 5/27/2015 0D0JWQ-E  BW   Retrophin Agrees to Sell Priority Review Voucher to Sanofi,"10/17/2017 VRTX-US   BW   Vertex Announces 10-Year, $500 Million Corporate Giving Commitment",#N/A,#N/A, 6/26/2017 BLUE-US  BW   bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD), 8/08/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 3/16/2017 TXMD-US  BW   TherapeuticsMD Announces Presentation at the Oppenheimer 27th Annual Healthcare Conference on March 22,#N/A,#N/A,11/09/2016 OMER-US  BW   Omeros Corporation Reports Third Quarter 2016 Financial Results, 4/02/2013 008ZWN-E BW   Revance Therapeutics Announces $33 Million Series E Financing,#N/A, 9/07/2016 MS-US    BW   Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2016 SYRS-US  BW   Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARα Agonist for Genomically Defined Subsets of AML and MDS Patients,#N/A,#N/A, 6/23/2010 00182C10     BW   BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunction," 1/11/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces That AbbVie Has Initiated Enrollment of Six Global Phase 3 Clinical Studies of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment", 6/12/2018 ALNY-US   BW   Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day,#N/A,#N/A,#N/A," 5/03/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2016 AKBA-US  BW   Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A," 4/25/2017 SAGE-US     BW   Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 56400P70 BW   Berman DeValerio Announces Investigation Into MannKind Corp.,#N/A,#N/A,#N/A, 2/16/2011 03236M20 BW   Amyris to Participate in Investor Conferences,#N/A,#N/A,#N/A,#N/A," 6/06/2016 EGRX-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc.",#N/A,#N/A,#N/A," 7/28/2014 29428V10 BW   Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2016 DRNA-US  BW   New Preclinical Data Show Potential of Dicerna GalXC™ Subcutaneous Delivery Platform as RNAi Drug Discovery Engine, 5/04/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2017 JPM-US   BW   Acceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2015 062RZ9-E BW   GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel,#N/A,#N/A,#N/A, 4/02/2017 G6674U10 BW   Optune™ bietet in Kombination mit der Standard-Chemotherapie mit Temozolomid entscheidende Fünf-Jahres-Überlebensrate bei neu diagnostizierten Glioblastom-Patienten,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2017 PBYI-US  BW   NERLYNX™(neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting,#N/A,#N/A,#N/A,#N/A,#N/A," 6/11/2015 0CT325-E BW   Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors", 6/07/2017 00900T10 BW   Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2015 009FRV-E BW   Quanterix Announces the Commercial Availability of Multiplex Assays and Homebrew Kits for Biomarker Discovery and Validation,#N/A,#N/A,#N/A, 2/01/2012 30233G10 BW   pSivida Corp Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information,#N/A,#N/A,12/04/2017 0DM9XX-E BW   Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/07/2016 LGND-US   BW   Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis,#N/A," 2/01/2017 ILMN-US     BW   Investor Alert: GPM Reminds Investors of the February 14 Deadline in the Class Action Lawsuit Against Illumina, Inc."," 9/20/2016 SPPI-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spectrum Pharmaceuticals, Inc.",#N/A, 3/23/2017 ARWR-US  BW   Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement,#N/A,#N/A,#N/A,#N/A, 3/03/2015 68375N10 BW   Twelve Months Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at ENDO 2015 Conference,#N/A,#N/A, 9/05/2017 ALXN-US  BW   Alexion to Present at Upcoming Investor Conferences,#N/A,12/13/2017 4502-JP     BW   Takeda e Seattle Genetics Apresentam Dados Positivos do Teste Clínico do ECHELON-1 Fase 3 Avaliando o ADCETRIS® (brentuximab vedotin) no Linfoma de Hodgkin Avançado em Linha de Frente,#N/A,11/07/2016 09062X10    BW   Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy," 1/20/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2016 Financial Results",#N/A,"10/30/2018 GILD-US      BW   Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy",#N/A,#N/A, 9/13/2011 M2572210 BW   Compugen Announces Validation of Two Immune System Modulating Drug Candidates,#N/A, 9/17/2012 0C8BZH-E     BW   RBCC Expands Cell Culturing Focus to Include Adult Stem Cells,#N/A,#N/A,#N/A,#N/A,10/24/2016 05156V10 BW   Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings,#N/A,#N/A,#N/A,#N/A, 7/25/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Richard A. Halprin as Director of Professional Affairs,#N/A,10/25/2017 INCY-US  BW   Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012,#N/A,10/08/2014 80360710 BW   Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society,10/05/2015 ALKS-IE  BW   ADDING MULTIMEDIA FDA Approves ARISTADA™ for Treatment of Schizophrenia, 3/08/2016 CERS-US  BW   Cerus Corporation Reports Fourth Quarter and Year End 2015 Results," 3/16/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. Announces Data Presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting"," 7/29/2015 04269E10 BW   ArQule to Report Second Quarter 2015 Financial Results on August 5, 2015",#N/A,#N/A, 3/27/2017 EXEL-US  BW   Exelixis to Present at the Needham & Company Healthcare Conference on April 4, 5/27/2015 SNY-FR    BW   Genzyme Commemorates World MS Day with Awareness and Educational Events Globally,10/16/2017 VRTX-US   BW   Vertex to Announce Third Quarter 2017 Financial Results on October 25,#N/A,#N/A, 6/23/2017 BLUE-US  BW   bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting, 8/04/2016 ACAD-US  BW   ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A, 3/03/2017 TXMD-US  BW   TherapeuticsMD Announces Presentation at Cowen and Company 37th Annual Healthcare Conference on March 7,#N/A,#N/A,"11/07/2016 OMER-US  BW   Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016", 3/25/2013 008ZWN-E BW   Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer,#N/A, 9/01/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2016 SYRS-US  BW   Syros Pharmaceuticals Announces Late-Breaking Presentation on SY-1425 at San Antonio Breast Cancer Symposium,#N/A,#N/A, 6/21/2010 00182C10     BW   BioSante Pharmaceuticals to Raise $15 Million in Registered Direct Offering, 1/07/2016 ENTA-US    BW   Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie’s Supplemental New Drug Application for VIEKIRA PAK® Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis, 6/08/2018 ALNY-US   BW   Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1),#N/A,#N/A,#N/A," 5/02/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2016 AKBA-US  BW   Akebia to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 4/24/2017 SAGE-US     BW   Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2010 56400P70 BW   MannKind Corporation Reports 2010 Third Quarter Financial Results,#N/A,#N/A,#N/A, 2/09/2011 AMRS-US  BW   BIO Joins California’s Low Carbon Fuel Standard Advisory Panel,#N/A,#N/A,#N/A,#N/A," 6/03/2016 EGRX-US  BW   Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. (EGRX) and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A," 9/05/2012 07CMVM-E BW   Epizyme Initiates Phase 1 Trial of EPZ-5676, a DOT1L Inhibitor",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/15/2016 DRNA-US  BW   Dicerna Appoints Martin Freed, M.D., to Board of Directors", 5/02/2018 15117K10 BW   Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/22/2016 XLRN-US  BW   Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2015 38000Q10 BW   GlycoMimetics to Present at the Jefferies 2015 Healthcare Conference,#N/A,#N/A,#N/A," 3/31/2017 G6674U10 BW   Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/17/2017 74587V10 BW   U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A," 5/28/2015 0CT325-E BW   Seres Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults"," 5/11/2017 00900T10 BW   Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2015 009FRV-E BW   Quanterix Introduces “Proteins Powering NexGen Healthcare” Conference Series,#N/A,#N/A,#N/A,11/22/2011 30233G10 BW   pSivida Announces Tech Evaluation Agreement with Leading Pharmaceutical Company,#N/A,#N/A,11/07/2017 0DM9XX-E BW   Axonics® erhält von der US-amerikanischen FDA Forschungsausnahmegenehmigung (IDE) für die Pivotstudie seines Sakral-Neuromodulationssystems zur Behandlung von Funktionsstörungen des Harntrakts,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/02/2016 MS-US     BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A, 1/31/2017 45232710    BW   Illumina Reports Full Financial Results for Fourth Quarter and Fiscal Year 2016," 9/19/2016 SPPI-US   BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A, 2/06/2017 ARWR-US  BW   Arrowhead Reports Fiscal 2017 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 2/27/2015 68375N10 BW   OPKO Announces Fourth Quarter Operating and Financial Results,#N/A,#N/A," 8/21/2017 ALXN-US  BW   Europäische Kommission genehmigt neue Indikation für Soliris® (Eculizumab) zur Behandlung von Patienten mit refraktärer, generalisierter Myasthenia gravis (gMG)",#N/A,12/12/2017 4502-JP     BW   Takeda y Seattle Genetics presentan datos positivos del ensayo clínico de fase 3 ECHELON-1 que estudia el uso de ADCETRIS® (brentuximab vedotina) para el tratamiento de primera línea del linfoma de Hodgkin avanzado,#N/A,"10/28/2016 BIIB-US     BW   SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm", 1/10/2016 IMGN-US  BW   ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference,#N/A,10/25/2018 GILD-US      BW   Gilead Sciences Announces Fourth Quarter 2018 Dividend,#N/A,#N/A, 8/02/2011 M2572210 BW   Compugen Reports Second Quarter 2011 Financial Results,#N/A, 9/13/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,"10/11/2016 05156V10 BW   Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016",#N/A,#N/A,#N/A,#N/A, 7/19/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results,#N/A,10/24/2017 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A, 9/30/2014 80360710 BW   Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate, 9/10/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to Be Webcast at the Morgan Stanley Global Healthcare Conference, 3/03/2016 CERS-US  BW   Cerus Celebra Acuerdo con Banco de Sangre de Servicios Mutuos para el Uso de Plaquetas y Plasma de INTERCEPT en Puerto Rico con el Objetivo de Mantener el Suministro de Sangre Durante la Epidemia de Zika," 3/02/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 30th Annual Healthcare Conference"," 7/06/2015 ARQL-US  BW   ArQule Announces Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in Patients with MET-High, KRAS Wild Type Colorectal Cancer Presented at ESMO World Congress on Gastrointestinal Cancer 2015",#N/A,#N/A, 3/06/2017 EXEL-US  BW   Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma, 5/26/2015 SNY-FR    BW   Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC, 9/21/2017 VRTX-US   BW   Vertex to Present at the Leerink Partners Roundtable Series on September 27,#N/A,#N/A, 6/23/2017 BLUE-US  BW   bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting," 7/29/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016",#N/A,#N/A,#N/A, 2/23/2017 TXMD-US  BW   TherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results,#N/A,#N/A,11/04/2016 OMER-US  BW   Omeros Announces Completion of Initial Funding under $125 Million Credit Facility,10/08/2012 MRX-US   BW   Revance Therapeutics Regains All Worldwide Rights to Its Botulinum Toxin Products,#N/A, 8/04/2016 IRWD-US  BW   Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2016 SYRS-US  BW   Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update,#N/A,#N/A, 6/21/2010 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Clinical Program," 1/04/2016 ENTA-US    BW   Enanta Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference Presentation to be Webcast on January 13, 2016 at 11:00 A.M. PT"," 6/04/2018 ALNY-US   BW   Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis",#N/A,#N/A,#N/A," 4/25/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/22/2016 AKBA-US  BW   Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients,#N/A,#N/A,#N/A,#N/A, 4/19/2017 SAGE-US     BW   Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/22/2010 56400P70 BW   MannKind Corporation to Hold 2010 Third Quarter Financial Results Conference Call on October 29, 2010",#N/A,#N/A,#N/A, 2/03/2011 03236M20 BW   Jim Richardson é o novo vice-presidente sênior de mercados verticais e operações de vendas da Amyris,#N/A,#N/A,#N/A,#N/A, 6/02/2016 EGRX-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm,#N/A,#N/A,#N/A, 9/04/2012 07CMVM-E BW   Epizyme to Participate in Upcoming Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2016 DRNA-US  BW   Dicerna to Present at the Jefferies 2016 Healthcare Conference, 5/02/2018 15117K10 BW   Cellectis a soumis une demande d’essai clinique pour UCART22 en leucémie lymphoblastique aiguë à cellules B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2016 CELG-US  BW   Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2015 38000Q10 BW   GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy,#N/A,#N/A,#N/A, 3/31/2017 G6674U10 BW   Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2017 74587V10 BW   Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/09/2017 00900T10 BW   Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2015 009FRV-E BW   Simoa’s Multiplexing Capabilities Featured in The Journal of Immunological Methods Highlights the Technology’s Remarkably Sensitive and Precise Single Molecule Measurement,#N/A,#N/A,#N/A,11/11/2011 30233G10 BW   pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida’s Product Pipeline,#N/A,#N/A,11/07/2017 0DM9XX-E BW   Axonics® obtient l'autorisation IDE de la U.S. FDA pour mener une étude pivot de son système de neuromodulation sacrée pour le traitement de la dysfonction urinaire,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/01/2016 NTEC-IL   BW   Intec Pharma Reports First Half 2016 Financial Results,#N/A," 1/30/2017 45232710    BW   Illumina lance le logiciel d'analyse VeriSeq™ (48 échantillons), avec analyse optimisée des données pour tests prénataux non invasifs"," 9/19/2016 SPPI-US   BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Spectrum Pharmaceuticals, Inc.",#N/A, 1/30/2017 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results,#N/A,#N/A,#N/A,#N/A," 2/26/2015 68375N10 BW   OPKO to Announce Fourth Quarter and Full Year 2014 Financial Results on February 27, 2015",#N/A,#N/A, 8/21/2017 ALXN-US  BW   Approbation par la Commission européenne d’une nouvelle indication pour Soliris® (éculizumab) pour le traitement des patients atteints de myasthénie grave (MG) généralisée réfractaire,#N/A,12/11/2017 4502-JP     BW   Takeda und Seattle Genetics präsentieren positive Daten aus klinischer Phase-3-Studie ECHELON-1 zur Prüfung von ADCETRIS® (Brentuximab Vedotin) als Erstlinientherapie bei fortgeschrittenem Hodgkin-Lymphom,#N/A,10/28/2016 09062X10    BW   Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA," 1/04/2016 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentation and Q&A at the 34th Annual J. P. Morgan Healthcare Conference",#N/A,10/25/2018 GILD-US      BW   Gilead Sciences Announces Third Quarter 2018 Financial Results,#N/A,#N/A," 7/27/2011 M2572210 BW   Compugen Second Quarter 2011 Conference Call Scheduled for Tuesday, August 2, 2011 at 10:00 AM EDT",#N/A," 9/11/2012 05NT8H-E     BW   ISR Adds Biosimilar Recruitment to Growing Library of Biosimilar, Recruitment Reports",#N/A,#N/A,#N/A,#N/A,10/06/2016 05156V10 BW   Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis,#N/A,#N/A,#N/A,#N/A, 6/01/2017 AERI-US    BW   Aerie Pharmaceuticals to Present at Two Investor Conferences in June,#N/A,10/12/2017 INCY-US  BW   Incyte to Report Third Quarter Financial Results,#N/A, 9/24/2014 80360710 BW   Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable, 8/21/2015 ALKS-IE  BW   Alkermes Provides Update on FDA Review of ARISTADA™ for the Treatment of Schizophrenia, 3/03/2016 CERS-US  BW   Cerus Enters Into Agreement With Banco de Sangre de Servicios Mutuos for the Use of INTERCEPT Platelets and Plasma in Puerto Rico to Sustain Blood Supply During Zika Epidemic, 3/01/2010 00163U10 BW   AMAG Pharmaceuticals Announces Fourth Quarter and Year End 2009 Financial Results, 6/01/2015 04269E10 BW   ArQule Appoints Robert J. Weiskopf as Chief Financial Officer,#N/A,#N/A, 3/01/2017 EXEL-US  BW   Exelixis Announces Webcasts of Investor Conference Presentations in March, 5/26/2015 NVP-SE    BW   NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion® in South Korea, 9/19/2017 FOLD-US   BW   Orphan Technologies Applauds Margaret McGlynn for Trailblazer Lifetime Achievement Award,#N/A,#N/A," 6/08/2017 BLUE-US  BW   bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors", 6/27/2016 ACAD-US  BW   ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index,#N/A,#N/A,#N/A, 2/15/2017 TXMD-US  BW   TherapeuticsMD Announces Webcast of Investor Day on March 1,#N/A,#N/A,11/03/2016 06CR5C-E BW   Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy, 6/10/2011 05GLRV-E BW   Revance Announces $45 Million Financing,#N/A, 7/21/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2016 SYRS-US  BW   Syros Pharmaceuticals to Participate in Upcoming Investor Conferences,#N/A,#N/A, 6/21/2010 00182C10     BW   BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin has No Impact on LibiGel®,"12/14/2015 ENTA-US    BW   Enanta Pharmaceuticals Announces the Election of Bruce L.A. Carter, Ph.D. as Non-Executive Chairman of the Board of Directors", 5/29/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming June Investor Conferences,#N/A,#N/A,#N/A," 4/12/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2016 AKBA-US  BW   Akebia Announces Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A, 4/05/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2010 56400P70 BW   MannKind Announces Initiation of Phase 2 Trial of Cancer Vaccine for Advanced Melanoma,#N/A,#N/A,#N/A," 2/03/2011 03236M20 BW   Jim Richardson Joins Amyris as Senior Vice President, Vertical Markets and Sales Operations",#N/A,#N/A,#N/A,#N/A, 6/02/2016 EGRX-US  BW   Glancy Prongay & Murray Commences Investigation on Behalf of Eagle Pharmaceuticals Inc. Investors,#N/A,#N/A,#N/A, 8/01/2012 07CMVM-E BW   Epizyme to Participate in Wedbush 2012 Life Sciences: Management Access Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2016 DRNA-US  BW   Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1), 5/01/2018 15117K10 BW   Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2016 CELG-US  BW   Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2015 38000Q10 BW   FDA Grants Orphan Drug Designation To GlycoMimetics’ GMI-1271 For Treatment of Acute Myleogenous Leukemia (AML),#N/A,#N/A,#N/A, 3/31/2017 G6674U10 BW   Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/29/2017 PBYI-US  BW   PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2017 00900T10 BW   Aimmune Therapeutics Announces First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/04/2015 009FRV-E BW   With Record Growth of its Simoa Accelerator Lab, Quanterix Invites Academics, Clinical Researchers and Scientists to Apply for a Grant to Further Biomarker Research",#N/A,#N/A,#N/A,11/11/2011 EYPT-US  BW   pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN® for DME,#N/A,#N/A,11/07/2017 0DM9XX-E BW   Axonics® Receives IDE Clearance from U.S. FDA to Conduct a Pivotal Study with its Sacral Neuromodulation System for the Treatment of Urinary Dysfunction,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 8/15/2016 LGND-US   BW   Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism",#N/A," 1/30/2017 45232710    BW   Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized Data Analysis for Noninvasive Prenatal Testing"," 9/16/2016 SPPI-US   BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc.",#N/A," 1/20/2017 ARWR-US  BW   Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action",#N/A,#N/A,#N/A,#N/A, 2/20/2015 68375N10 BW   OPKO Announces Publication of 20 Year Outcome Study for Lethal Prostate Cancer Using Kallikrein Biomarkers in 4Kscore Test,#N/A,#N/A, 8/21/2017 ALXN-US  BW   European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG),#N/A,12/11/2017 4502-JP     BW   Takeda et Seattle Genetics présenteront des données positives de l’essai clinique ECHELON-1 de Phase 3 pour l’évaluation de l’ADCETRIS® (brentuximab vedotin) dans le cadre d’un traitement de première intention contre le lymphome…,#N/A,10/27/2016 09062X10    BW   Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference,"12/02/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Oppenheimer 26th Annual Healthcare Conference Webcast",#N/A,10/22/2018 GILD-US      BW   Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet,#N/A,#N/A, 6/21/2011 M2572210 BW   Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate,#N/A," 9/11/2012 SPPI-US      BW   Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer",#N/A,#N/A,#N/A,#N/A, 9/29/2016 05156V10 BW   Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN),#N/A,#N/A,#N/A,#N/A, 5/26/2017 AERI-US    BW   Aerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering,#N/A,10/06/2017 INCY-US  BW   Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware,#N/A, 8/28/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at Upcoming Conferences, 7/30/2015 ALKS-US  BW   Alkermes plc Reports Second Quarter 2015 Financial Results," 3/03/2016 CERS-US  BW   Cerus firma acordo com o Banco de Sangre de Servicios Mutuos para o uso de plaquetas e Plasma INTERCEPT em Porto Rico, para manter a oferta de sangue durante a epidemia de Zika"," 2/22/2010 00163U10 BW   AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2009", 5/29/2015 04269E10 BW   ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015,#N/A,#N/A, 2/28/2017 EXEL-US  BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 5/20/2015 SNY-FR    BW   Genzyme’s Announces Launch of Expression of Hope III Art Exhibit, 9/19/2017 VRTX-US   BW   Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference,#N/A,#N/A, 6/05/2017 BLUE-US  BW   bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting," 6/16/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016",#N/A,#N/A,#N/A, 2/09/2017 TXMD-US  BW   TherapeuticsMD to Host Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast on February 23,#N/A,#N/A,11/02/2016 OMER-US  BW   Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone,10/22/2010 008ZWN-E BW   Revance Therapeutics Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society of Dermatologic Surgery,#N/A, 6/06/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,"11/03/2016 06QBQ2-E BW   Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RARα Agonist, at the ASH Annual Meeting",#N/A,#N/A," 6/18/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Update at ENDO Annual Meeting",12/02/2015 ENTA-US    BW   Enanta Pharmaceuticals Announces FDA Acceptance of AbbVie’s New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® for the Treatment of Genotype 1 Chronic Hepatitis C Virus Infection, 5/15/2018 063Z5S-E  BW   Alnylam Appoints Colleen Reitan to the Board of Directors,#N/A,#N/A,#N/A," 4/11/2012 PCRX-US  BW   Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2016 AKBA-US  BW   Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 3/02/2017 SAGE-US     BW   Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2010 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A,#N/A, 1/07/2011 03236M20 BW   Joel Velasco Joins Amyris as Senior Vice President,#N/A,#N/A,#N/A,#N/A," 6/01/2016 EGRX-US  BW   Kirby McInerney LLP Announces Class Action on Behalf of Eagle Pharmaceuticals, Inc. Investors",#N/A,#N/A,#N/A, 7/16/2012 07CMVM-E BW   Epizyme to Participate in Upcoming Conferences in July,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2016 DRNA-US  BW   Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates, 5/01/2018 05G05Z-E BW   L'Institut Wyss de Harvard s'associe à Cellectis pour réécrire le génome humain,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2016 CELG-US  BW   Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2015 38000Q10 BW   GlycoMimetics Reports First Quarter 2015 Results,#N/A,#N/A,#N/A, 3/28/2017 G6674U10 BW   Novocure to Report First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/13/2017 PBYI-US  BW   The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/13/2017 00900T10 BW   Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/31/2015 009FRV-E BW   Quanterix’ Simoa Technology to Broaden RayBiotech Immunoassay Services,#N/A,#N/A,#N/A,"11/07/2011 30233G10 BW   pSivida Corp. Reports Results for the First Quarter Ended September 30, 2011",#N/A,#N/A, 9/13/2017 0DM9XX-E BW   Présentation des résultats positifs de l’étude clinique RELAX-OAB d’Axonics® lors du Congrès de la Société internationale de la Continence,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/04/2016 LGND-US   BW   Ligand Reports Second Quarter 2016 Financial Results,#N/A," 1/30/2017 45232710    BW   Illumina präsentiert Analysesoftware VeriSeq™ (48 Proben), optimierte Datenanalyse für nicht-invasive pränatale Diagnostik", 9/14/2016 06CR5C-E  BW   FDA Advisory Committee Votes that Qapzola™ (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo,#N/A," 1/09/2017 ARWR-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR",#N/A,#N/A,#N/A,#N/A, 2/13/2015 68375N10 BW   OPKO Health to Present at the 2015 RBC Capital Markets’ Healthcare Conference,#N/A,#N/A," 8/15/2017 ALXN-US  BW   Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027",#N/A,12/11/2017 BMY-US      BW   Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma,#N/A,10/26/2016 09062X10    BW   Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion,"12/01/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition",#N/A,10/20/2018 GILD-US      BW   Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting,#N/A,#N/A, 5/19/2011 M2572210 BW   Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations,#N/A, 9/10/2012 AMGN-US      BW   Fitch Rates Amgen's Senior Notes 'BBB',#N/A,#N/A,#N/A,#N/A," 9/22/2016 05LK9B-E BW   Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016",#N/A,#N/A,#N/A,#N/A, 5/25/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Public Offering of Common Stock,#N/A, 9/12/2017 MRK-US   BW   Los datos de supervivencia sin progresión del ensayo ECHO-202 de epacadostat de Incyte en combinación KEYTRUDA® (pembrolizumab) destacan la durabilidad de la respuesta en pacientes con melanoma avanzado,#N/A," 8/21/2014 80360710 BW   Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy", 7/23/2015 ALKS-US  BW   Alkermes to Host Conference Call to Discuss Second Quarter 2015 Financial Results," 3/02/2016 0024VM-E BW   Cerus to Present at the Cowen and Company 36th Annual Health Care Conference on March 9, 2016", 2/05/2010 00163U10 BW   AMAG Pharmaceuticals Provides Feraheme® Safety Update," 5/27/2015 ARQL-US  BW   ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference",#N/A,#N/A, 2/27/2017 EXEL-US  BW   Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update, 5/13/2015 80105N10  BW   Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology, 9/07/2017 VRTX-US   BW   Vertex to Present at the Morgan Stanley Healthcare Conference on September 11,#N/A,#N/A, 6/01/2017 BLUE-US  BW   bluebird bio to Present at Two Investor Conferences in June," 6/01/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016",#N/A,#N/A,#N/A, 1/19/2017 TXMD-US  BW   TherapeuticsMD Announces Investor Day on March 1,#N/A,#N/A,10/31/2016 06CR5C-E BW   Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy,#N/A,#N/A, 6/03/2016 IRWD-US  BW   Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad,#N/A,#N/A,#N/A,#N/A,#N/A,10/11/2016 SYRS-US  BW   Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers,#N/A,#N/A, 6/07/2010 00182C10     BW   BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine,"11/23/2015 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015", 5/08/2018 ALNY-US   BW   Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics,#N/A,#N/A,#N/A," 4/09/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL®",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2016 AKBA-US  BW   Akebia Therapeutics Appoints Scott A. Canute to its Board of Directors,#N/A,#N/A,#N/A,#N/A, 2/23/2017 SAGE-US     BW   Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/23/2010 56400P70 BW   MannKind Corporation Providing AFREZZA™ to Juvenile Diabetes Research Foundation for Artificial Pancreas Project,#N/A,#N/A,#N/A, 1/07/2011 03236M20 BW   Joel Velasco junta-se à Amyris como Vice Presidente Sênior,#N/A,#N/A,#N/A,#N/A," 6/01/2016 EGRX-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Eagle Pharmaceuticals Inc.",#N/A,#N/A,#N/A, 6/07/2012 07CMVM-E BW   Epizyme to Participate in Upcoming Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2016 DRNA-US  BW   Dicerna Reports First Quarter 2016 Financial and Operational Results, 4/11/2018 15117K10 BW   Cellectis présentera des données à la conférence annuelle de l’American Association for Cancer Research (AACR),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2016 06QBQ2-E BW   Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2015 062RZ9-E BW   GlycoMimetics Provides Update on Pfizer’s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015,#N/A,#N/A,#N/A, 3/28/2017 G6674U10 BW   Novocure to Present at the 16th Annual Needham & Company Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/12/2017 PBYI-US  BW   The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/15/2017 00900T10 BW   Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/17/2015 009FRV-E BW   Quanterix Appoints SCRUM Inc. for Simoa Distribution in Japan,#N/A,#N/A,#N/A,10/31/2011 30233G10 BW   pSivida Corp. Announces First Quarter 2012 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 9/13/2017 0DM9XX-E BW   Positive Ergebnisse der klinischen Studie RELAX-OAB von Axonics® auf Kongress der Internationalen Kontinenzgesellschaft präsentiert,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/29/2016 LGND-US   BW   Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals,#N/A," 1/27/2017 45232710    BW   Illumina Names Caroline Dorsa to Its Board of Directors, Adding Over 30 Years of Leadership Experience in the Healthcare, Telecommunications and Energy Industries", 8/09/2016 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update,#N/A, 1/09/2017 ARWR-US  BW   Arrowhead Provides Response to New Minority Shareholder Announcement,#N/A,#N/A,#N/A,#N/A, 1/30/2015 68375N10 BW   OPKO Submits Investigational New Drug Application to Initiate a Phase 2a Trial for its Long-Acting Coagulation Factor VIIa-CTP to Treat Hemophilia,#N/A,#N/A, 8/10/2017 ALXN-US  BW   Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology,#N/A,12/10/2017 SGEN-US     BW   Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting,#N/A,10/08/2016 09062X10    BW   New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy,11/13/2015 IMGN-US  BW   ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year,#N/A,"10/11/2018 GILD-US      BW   Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018",#N/A,#N/A, 5/11/2011 M2572210 BW   Compugen Reports First Quarter 2011 Financial Results,#N/A, 9/10/2012 GSK-GB       BW   Biogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund,#N/A,#N/A,#N/A,#N/A, 9/21/2016 05156V10 BW   Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York,#N/A,#N/A,#N/A,#N/A, 5/24/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results,#N/A, 9/10/2017 INCY-US  BW   Daten aus der ECHO-202-Studie zum progressionsfreien Überleben mit Epacadostat in Kombination mit KEYTRUDA® (Pembrolizumab) von Incyte bestätigen die Dauer des Ansprechens bei Patienten mit fortgeschrittenem Melanom,#N/A, 8/07/2014 80360710 BW   Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments, 6/16/2015 ALKS-IE  BW   Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting," 2/23/2016 CERS-US  BW   Cerus to Release Fourth Quarter and Year End 2015 Results on March 8, 2016"," 1/20/2010 00163U10 BW   AMAG Pharmaceuticals Announces Pricing of Public Offering of 3,600,000 Shares of Common Stock", 5/06/2015 04269E10 BW   ArQule Reports First Quarter 2015 Financial Results,#N/A,#N/A, 2/27/2017 EXEL-US  BW   Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors, 4/28/2015 SNY-FR    BW   FDA Grants Fast Track Designation to Genzyme’s Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease, 9/06/2017 VRTX-US   BW   Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer,#N/A,#N/A," 5/23/2017 BLUE-US  BW   bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy", 5/31/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 1/11/2017 TXMD-US  BW   TherapeuticsMD Announces Publication of Two Manuscripts on the Rejoice Trial for TX-004HR in Leading Peer-Reviewed Medical Journal,#N/A,#N/A,10/27/2016 OMER-US  BW   Omeros Announces $125 Million New Credit Facility,#N/A,#N/A, 6/01/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2016 SYRS-US  BW   Syros Announces Appointment of Gerald E. Quirk as Chief Legal Officer,#N/A,#N/A," 6/07/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present at the Annual Needham Healthcare Conference",11/16/2015 ENTA-US    BW   Enanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s Next-Generation Protease Inhibitor ABT-493 Demonstrates High Sustained Virologic Response Rates in Phase 2 Studies in Patients with Chronic Hepatitis C, 5/03/2018 ALNY-US   BW   Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A," 3/27/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/05/2016 AKBA-US  BW   Akebia to Present at the Cantor Fitzgerald Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A," 2/17/2017 SAGE-US     BW   Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/19/2010 56400P70 BW   MannKind Announces Entry into Stock Lending Agreement,#N/A,#N/A,#N/A, 1/04/2011 06SRRY-E BW   Amyris Expands Farnesene Processing and Finishing Production Capabilities by Signing Definitive Agreements with Glycotech,#N/A,#N/A,#N/A,#N/A, 5/31/2016 EGRX-US  BW   Eagle Pharmaceuticals to Present at Upcoming June Conferences,#N/A,#N/A,#N/A," 6/01/2012 07CMVM-E BW   Epizyme Ranked #2 Worldwide in The Scientist's 10th Annual “Best Places to Work in Industry"" Survey",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2016 DRNA-US  BW   Dicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016", 4/11/2018 15117K10 BW   Cellectis to Present Data at the 2018 AACR Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2016 XLRN-US  BW   Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A, 3/19/2015 38000Q10 BW   GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015,#N/A,#N/A,#N/A, 3/20/2017 G6674U10 BW   Novocure Receives MHLW Approval for Second Generation Optune® in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/08/2017 PBYI-US  BW   PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/08/2017 00900T10 BW   Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2015 009FRV-E BW   Quanterix’ Simoa Technology to Support Myriad RBM’s New Immunoassay Services,#N/A,#N/A,#N/A,10/20/2011 30233G10 BW   pSivida Ranked 59th Fastest Growing Company in North America on Deloitte’s 2011 Technology Fast 500™,#N/A,#N/A, 9/13/2017 0DM9XX-E BW   Positive Results for the Axonics® RELAX-OAB Clinical Study Presented at the International Continence Society Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/14/2016 LGND-US   BW   Ligand to Report Second Quarter Results on August 4th,#N/A," 1/26/2017 ILMN-US     BW   February 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Illumina, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm", 8/02/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference and Webcast,#N/A," 1/07/2017 ARWR-US  BW   DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm",#N/A,#N/A,#N/A,#N/A, 1/28/2015 68375N10 BW   OPKO Launches the 4Kscore Test in Mexico,#N/A,#N/A, 7/27/2017 ALXN-US  BW   Alexion Reports Second Quarter 2017 Results,#N/A,12/10/2017 4502-JP     BW   Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma,#N/A, 9/26/2016 09062X10    BW   Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy,11/08/2015 IMGN-US  BW   Treatment Response to ImmunoGen’s Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha,#N/A,10/11/2018 GILD-US      BW   Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018,#N/A,#N/A," 5/03/2011 M2572210 BW   Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11, 2011 at 10:00 AM EDT",#N/A, 9/10/2012 06MYFH-E     BW   Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner,#N/A,#N/A,#N/A,#N/A, 9/07/2016 RRSHQ-US BW   Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A, 5/16/2017 AERI-US    BW   Aerie Pharmaceuticals Announces New Hires,#N/A, 9/09/2017 INCY-US  BW   Progressievrije overlevingsgegevens van ECHO-202-studie van Incyte's epacadostat in combinatie met KEYTRUDA® (pembrolizumab) onderstrepen duurzaamheid van respons bij patiënten met gevorderd melanoom,#N/A, 7/31/2014 80360710 BW   Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman, 6/09/2015 G0176710 BW   Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical Psychiatry, 2/17/2016 CERS-US  BW   FDA’s Zika Guidance Document Allows Use of Pathogen Reduction to Reduce Transfusion Risk and Maintain Local Blood Availability," 1/19/2010 00163U10 BW   AMAG Pharmaceuticals Announces Proposed Offering of 3,000,000 Shares of Common Stock", 5/05/2015 04269E10 BW   ArQule and Beryllium Announce Collaborative Research and Development Agreement,#N/A,#N/A, 2/27/2017 BMY-US   BW   Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma, 4/27/2015 MOB-SE    BW   Moberg Pharma Acquires U.S OTC Brand Balmex®, 8/24/2017 VRTX-US   BW   Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA,#N/A,#N/A, 5/18/2017 BLUE-US  BW   bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting, 5/05/2016 ACAD-US  BW   ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results,#N/A,#N/A,#N/A, 1/03/2017 TXMD-US  BW   TherapeuticsMD to Present at 35th Annual J.P. Morgan Healthcare Conference on January 11,#N/A,#N/A,10/20/2016 OMER-US  BW   Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy,#N/A,#N/A, 5/18/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 9/22/2016 SYRS-US  BW   Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome,#N/A,#N/A," 6/04/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at the Annual Needham Healthcare Conference","11/14/2015 ENTA-US    BW   Enanta Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis"," 5/03/2018 ALNY-US   BW   Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A," 3/21/2012 PCRX-US  BW   Boomerang Pharmaceutical Communications Named Digital Agency of Record For Pacira Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2016 AKBA-US  BW   Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction,#N/A,#N/A,#N/A,#N/A, 2/16/2017 SAGE-US     BW   Sage Therapeutics Not in M&A Discussions: STATEMENT,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/19/2010 56400P70 BW   MannKind Announces Pricing of $100 Million Senior Convertible Notes,#N/A,#N/A,#N/A,12/21/2010 03236M20 BW   Amyris and São Martinho Announce Construction Manager Selection and Start of Site Preparation for Joint Venture Industrial Plant,#N/A,#N/A,#N/A,#N/A," 5/09/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share",#N/A,#N/A,#N/A," 5/16/2012 07CMVM-E BW   Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2016 DRNA-US  BW   Dicerna Announces Appointment of John “Jack” Green as Chief Financial Officer, 4/10/2018 15117K10 BW   Cellectis annonce la réalisation de son offre d’ADS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2016 06QBQ2-E BW   Acceleron Announces New Data Presentations at the 58th American Society of Hematology Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2015 38000Q10 BW   GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results,#N/A,#N/A,#N/A, 3/01/2017 G6674U10 BW   Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2017 PBYI-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/06/2017 00900T10 BW   Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2015 009FRV-E BW   CORRECTING and REPLACING PHOTO Quanterix Expands Kevin Hrusovsky’s Role to CEO,#N/A,#N/A,#N/A, 9/12/2011 30233G10 BW   pSivida Corp. Reports Fourth Quarter and Fiscal Year 2011 Results,#N/A,#N/A, 9/06/2017 0DM9XX-E BW   Axonics® ernennt Dr. Karen L. Noblett zum medizinischen Vorstand (Chief Medical Officer),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/08/2016 LGND-US   BW   Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences,#N/A," 1/23/2017 ILMN-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017", 7/27/2016 SPPI-US   BW   Onxeo signe un accord de licence exclusive avec Pint Pharma pour la commercialisation de Beleodaq® en Amérique du Sud dans le domaine du PTCL,#N/A,"12/21/2016 ARWR-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A,#N/A,#N/A,#N/A, 1/13/2015 68375N10 BW   OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant,#N/A,#N/A," 7/19/2017 ALXN-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders",#N/A,12/09/2017 SGEN-US     BW   Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting,#N/A, 9/15/2016 09062X10    BW   New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile,10/27/2015 IMGN-US  BW   ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update,#N/A,"10/03/2018 GILD-US      BW   Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy",#N/A,#N/A, 4/27/2011 M2572210 BW   Compugen Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy,#N/A, 9/06/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A, 8/15/2016 05156V10 BW   Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis,#N/A,#N/A,#N/A,#N/A, 5/15/2017 AERI-US    BW   Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,#N/A, 9/09/2017 INCY-US  BW   I dati sulla sopravvivenza libera da progressione dello studio clinico ECHO-202 su epacadostat di Incyte in combinazione con KEYTRUDA® (pembrolizumab) sottolineano la durata della risposta nei pazienti affetti da melanoma avanzato,#N/A, 7/31/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference, 6/02/2015 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare Conference, 2/09/2016 CERS-US  BW   Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma,#N/A," 4/29/2015 04269E10 BW   ArQule to Report First Quarter 2015 Financial Results on May 6, 2015",#N/A,#N/A, 2/17/2017 EXEL-US  BW   Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors, 4/23/2015 80105N10  BW   Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years, 8/01/2017 VRTX-US   BW   FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations,#N/A,#N/A, 5/17/2017 BLUE-US  BW   bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting," 5/04/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016",#N/A,#N/A,#N/A,12/12/2016 TXMD-US  BW   TherapeuticsMD Announces Participation in 2016 BioFlorida Conference,#N/A,#N/A,10/19/2016 0F21DT-E BW   Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse,#N/A,#N/A, 5/17/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week® 2016,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2016 MS-US    BW   Syros Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference,#N/A,#N/A, 5/20/2010 00182C10     BW   BioSante Pharmaceuticals Announces Novartis’ Successful Use of 2A/Furin Technology in Their Antibody Development Platform,"11/13/2015 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015", 5/01/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming May Investor Conferences,#N/A,#N/A,#N/A," 3/20/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Announces Timing for 2011 Financial Results Webcast and Conference Call",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2016 AKBA-US  BW   Akebia to Present at the 2016 UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 2/13/2017 SAGE-US     BW   Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/16/2010 56400P70 BW   MannKind Announces Proposed Offering of Common Stock and Related Share Lending Arrangement,#N/A,#N/A,#N/A,12/16/2010 03236M20 BW   Amyris e Cosan estão estabelecendo uma joint venture para produção e comercialização de óleos base renováveis,#N/A,#N/A,#N/A,#N/A, 4/26/2016 EGRX-US  BW   Eagle Pharmaceuticals to Present at May Conferences,#N/A,#N/A,#N/A, 5/01/2012 07CMVM-E BW   Epizyme to Participate in Upcoming Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2016 DRNA-US  BW   Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results, 4/10/2018 15117K10 BW   Cellectis Announces Closing of Follow-On Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/02/2016 XLRN-US  BW   Acceleron to Present at Credit Suisse Healthcare Conference Monday, November 7, 2016",#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2015 38000Q10 BW   GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease,#N/A,#N/A,#N/A, 2/23/2017 G6674U10 BW   Novocure Announces Departure of Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2017 74587V10 BW   Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 BARC-GB  BW   Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2015 009FRV-E BW   Quanterix leads discussion at 4th Annual SLAS Conference and Exhibition,#N/A,#N/A,#N/A," 9/12/2011 30233G10 BW   pSivida Announces Opening of Investigator-Sponsored Trial for Injectable, Sustained Release FAc Insert for Posterior Uveitis",#N/A,#N/A, 9/06/2017 0DM9XX-E BW   Axonics® nomme Dr. Karen L. Noblett au poste de directrice médicale,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/30/2016 0DF0L8-E  BW   Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements,#N/A," 1/17/2017 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on Tuesday, January 31, 2017", 7/13/2016 SPPI-US   BW   Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation,#N/A,12/14/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Year End Results,#N/A,#N/A,#N/A,#N/A, 1/05/2015 68375N10 BW   OPKO Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A," 7/11/2017 ALXN-US  BW   Alexion to Report Second Quarter 2017 Results and Strategic Update on Thursday, July 27, 2017",#N/A,12/07/2017 SGEN-US     BW   Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium,#N/A," 9/14/2016 09062X10    BW   Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016","10/13/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results",#N/A,10/02/2018 GILD-US      BW   Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer,#N/A,#N/A, 3/07/2011 M2572210 BW   Compugen Announces Positive Animal Model Results for Novel Peptide Predicted to Block Protein-Protein Interaction,#N/A, 9/05/2012 00CX09-E     BW   HzO Among 2012’s Top Nanotech Innovators,#N/A,#N/A,#N/A,#N/A, 8/05/2016 05156V10 BW   Aurinia Reports Second Quarter 2016 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A, 5/02/2017 AERI-US    BW   Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update,#N/A, 9/09/2017 INCY-US  BW   Les données de survie sans progression de l'essai ECHO-202 sur l'épacadostat d'Incyte en combinaison avec le KEYTRUDA® (pembrolizumab) mettent en avant la durabilité de la réponse chez les patients atteints de mélanome avancé,#N/A," 7/31/2014 80360710 BW   Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on August 7, 2014", 5/29/2015 G0176710 BW   Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers, 1/14/2016 CERS-US  BW   AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease,#N/A," 4/21/2015 04269E10 BW   ArQule Announces Data Presentations with ARQ 087, Inhibitor of FGFR, at AACR",#N/A,#N/A, 2/07/2017 EXEL-US  BW   Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15, 4/21/2015 SNY-FR    BW   Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease, 7/26/2017 VRTX-US   BW   Vertex Reports Second-Quarter 2017 Financial Results,#N/A,#N/A, 5/03/2017 BLUE-US  BW   bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress," 5/02/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016",#N/A,#N/A,#N/A,12/05/2016 TXMD-US  BW   TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR,#N/A,#N/A,10/17/2016 06CR5C-E BW   Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases,#N/A,#N/A, 5/09/2016 IRWD-US  BW   Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A, 8/29/2016 SYRS-US  BW   Syros’ Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer,#N/A,#N/A," 5/17/2010 00182C10     BW   BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies",11/02/2015 ENTA-US    BW   Enanta Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference, 4/26/2018 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results,#N/A,#N/A,#N/A," 3/07/2012 69512710 BW   Pacira Pharmaceuticals, Inc. to Present at Barclays Capital Global Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2016 AKBA-US  BW   Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A, 2/07/2017 SAGE-US     BW   Sage Therapeutics to Participate in Upcoming February Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/16/2010 56400P70 BW   MannKind Announces Proposed Offering of $100 Million Senior Convertible Notes,#N/A,#N/A,#N/A,12/16/2010 03236M20 BW   Amyris y Cosan Establishing JV se dedicarán a la producción y comercialización de lubricantes base renovables,#N/A,#N/A,#N/A,#N/A," 4/25/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2016 Financial Results on May 9, 2016",#N/A,#N/A,#N/A," 4/26/2012 CELG-US  BW   Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/04/2016 DRNA-US  BW   Dicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016", 4/05/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/27/2016 XLRN-US  BW   Acceleron Pharma to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016",#N/A,#N/A,#N/A,#N/A,#N/A, 2/26/2015 38000Q10 BW   GlycoMimetics to Present at Two Investor Conferences in March,#N/A,#N/A,#N/A, 2/23/2017 G6674U10 BW   Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/02/2017 PBYI-US  BW   PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/27/2017 00900T10 BW   Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/16/2014 009FRV-E BW   Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development",#N/A,#N/A,#N/A, 9/09/2011 30233G10 BW   pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference,#N/A,#N/A, 9/06/2017 0DM9XX-E BW   Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/04/2016 LGND-US   BW   Ligand Reports First Quarter 2016 Financial Results,#N/A," 1/12/2017 08JRVQ-E    BW   Illumina, NRGene Collaborate to Accelerate Development of New Molecular Breeding Tools for Cattle to Support Global Food Production", 7/06/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13th,#N/A,"12/08/2016 ARWR-US  BW   ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR",#N/A,#N/A,#N/A,#N/A,"12/15/2014 FLNT-US  BW   Tiger Media Announces Agreement to Acquire Interactive Data, LLC",#N/A,#N/A, 7/05/2017 ALXN-US  BW   Alexion parvient à une entente de financement avec NICE et NHS England portant sur Strensiq® (asfotase alfa) destiné aux patients atteints d'hypophosphatasie apparue dans l'enfance,#N/A,12/04/2017 SGEN-US     BW   Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,#N/A, 9/14/2016 09062X10    BW   New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting," 9/17/2015 IMGN-US  BW   Webcast of the ImmunoGen, Inc. Analyst & Investor Event on September 18, 2015",#N/A, 9/24/2018 GILD-US      BW   Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C,#N/A,#N/A, 2/15/2011 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2010 Financial Results,#N/A," 9/04/2012 IMGN-US      BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A,#N/A,#N/A,#N/A, 7/28/2016 05156V10 BW   Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York,#N/A,#N/A,#N/A,#N/A," 4/25/2017 AERI-US    BW   Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017",#N/A, 9/09/2017 INCY-US  BW   Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma,#N/A, 7/10/2014 80360710 BW   Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy, 5/26/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 Global Healthcare Conference," 1/11/2016 CERS-US  BW   Cerus Appoints New Leadership for Europe, Middle East and Africa Region",#N/A," 4/07/2015 ARQL-US  BW   ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference",#N/A,#N/A," 2/02/2017 EXEL-US  BW   Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017", 4/21/2015 0DNDQN-E  BW   National Access Project for Cancer Testing Gains Momentum, 7/25/2017 CNCE-US   BW   Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656,#N/A,#N/A, 5/02/2017 BLUE-US  BW   bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies, 4/29/2016 ACAD-US  BW   FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A,11/08/2016 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A, 9/08/2016 OMER-US  BW   Omeros’ MASP-2 Antibody Preserves Brain Tissue and Function in Stroke Models,#N/A,#N/A, 5/03/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2016 0C5BX7-E BW   Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference,#N/A,#N/A, 5/14/2010 00182C10     BW   BioSante Pharmaceuticals Reports Recent Developments and First Quarter Financial Results,10/01/2015 ENTA-US    BW   CORRECTING and REPLACING Enanta Pharmaceuticals Announces Data Presentations at The Liver Meeting® 2015, 4/24/2018 ALNY-US   BW   Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting,#N/A,#N/A,#N/A," 2/21/2012 69512710 BW   Pacira Pharmaceuticals, Inc. to Participate in RBC Capital Markets Global Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2016 AKBA-US  BW   Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings,#N/A,#N/A,#N/A,#N/A," 1/03/2017 SAGE-US     BW   Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/11/2010 56400P70 BW   MannKind Receives Commitment from The Mann Group to Reduce Indebtedness in Return for Up to 18,200,000 Shares of Common Stock",#N/A,#N/A,#N/A,12/15/2010 03236M20 BW   Amyris and Cosan Establishing JV for Production and Commercialization of Renewable Base Oils,#N/A,#N/A,#N/A,#N/A, 4/20/2016 EGRX-US  BW   CMS Determines that Existing J-Code J9033 Adequately Describes BENDEKA (bendamustine hydrochloride) Injection,#N/A,#N/A,#N/A, 4/10/2012 07CMVM-E BW   Epizyme to Participate in Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2016 DRNA-US  BW   Dicerna to Present at Two March Conferences, 4/05/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2016 XLRN-US  BW   Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2015 38000Q10 BW   GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A, 2/15/2017 G6674U10 BW   First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2017 74587V10 BW   Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/16/2017 00900T10 BW   Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2014 009FRV-E BW   Simoa Technology Highlighted in a Nature Publication for Effectively Measuring Brain Biomarkers in Blood for Traumatic Brain Injury,#N/A,#N/A,#N/A, 9/06/2011 30233G10 BW   pSivida Corp Announces Fourth Quarter and Fiscal Year 2011 Financial Results Release Date and Conference Call Information,#N/A,#N/A," 7/06/2017 0DM9XX-E BW   Axonics gibt den Abschluss seiner zweiten Series-C-Finanzierungsrunde in Höhe von 20,5 Millionen US-Dollar bekannt.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/04/2016 00B680-E  BW   Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million,#N/A," 1/09/2017 ILMN-US     BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm", 6/01/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th,#N/A,12/07/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results,#N/A,#N/A,#N/A,#N/A,12/15/2014 68375N10 BW   OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP),#N/A,#N/A, 7/05/2017 ALXN-US  BW   Alexion trifft Finanzierungsvereinbarung mit NICE und NHS England zu Strensiq® (Asfotase Alfa) für Patienten mit der pädiatrischen Form der Hypophosphatasie (HPP),#N/A,11/09/2017 SGEN-US     BW   Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF),#N/A, 9/08/2016 09062X10    BW   Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio," 9/10/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast",#N/A, 9/12/2018 GILD-US      BW   Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing,#N/A,#N/A," 2/08/2011 M2572210 BW   Compugen Ltd. to Review Fourth Quarter and Year-End 2010 Financial Results on Tuesday, February 15, 2011",#N/A," 8/30/2012 060RWY-E     BW   Surveyed Rheumatoid Arthritis Patients on Biologic Therapy Believe That the Benefits Outweigh the Risks for Available Biologics, with Enbrel Rating the Highest, According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A, 7/22/2016 05156V10 BW   Aurinia Establishes At-The-Market Facility,#N/A,#N/A,#N/A,#N/A, 4/24/2017 AVNR-US    BW   Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance,#N/A, 9/09/2017 INCY-US  BW   Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma,#N/A, 6/18/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24, 5/11/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare Conference, 1/07/2016 CERS-US  BW   Cerus and LifeShare Blood Centers Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A, 3/04/2015 04269E10 BW   ArQule Reports Fiscal 2014 Year End and Fourth Quarter Results,#N/A,#N/A," 2/02/2017 4502-JP  BW   Exelixis e Takeda firmam acordo de licenciamento exclusivo para comercializar e desenvolver um novo tratamento contra o câncer, o Cabozantinibe no Japão", 4/16/2015 064Q9G-E  BW   Cystic Fibrosis Foundation Therapeutics Announces $14 Million Research Expansion with Genzyme, 7/24/2017 CNCE-US   BW   Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex,#N/A,#N/A, 5/02/2017 BLUE-US  BW   bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies," 4/06/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016",#N/A,#N/A,#N/A,11/03/2016 TXMD-US  BW   TherapeuticsMD Expands Commercial and Business Development Leadership,#N/A,#N/A, 8/12/2016 OMER-US  BW   Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference,#N/A,#N/A, 4/26/2016 06CR5C-E BW   Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad,#N/A,#N/A,#N/A,#N/A,#N/A, 8/15/2016 06CR5C-E BW   Syros Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update,#N/A,#N/A," 5/12/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference", 9/28/2015 ENTA-US    BW   Enanta Announces Approval of VIEKIRAX®(ombitasvir/paritaprevir/ritonavir tablets) in Japan for the Treatment of Genotype 1 Chronic Hepatitis C," 4/23/2018 ALNY-US   BW   Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis",#N/A,#N/A,#N/A," 1/09/2012 69512710 BW   Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2016 AKBA-US  BW   Akebia to Present at the 15th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,12/29/2016 GS-US       BW   Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/11/2010 56400P70 BW   MannKind Receives Commitment to Purchase Up to 18,200,000 Shares of Common Stock for Cash",#N/A,#N/A,#N/A,12/09/2010 03236M20 BW   Philippe Boisseau Joins Amyris Board of Directors,#N/A,#N/A,#N/A,#N/A, 3/28/2016 06HCNQ-E BW   Eagle Pharmaceuticals and the National Institutes of Health (NIH/NIDA) Enter into Agreement to Explore Use of Ryanodex in MDMA (Ecstasy) and Methamphetamine Intoxication,#N/A,#N/A,#N/A, 3/13/2012 065B9K-E BW   The Leukemia & Lymphoma Society and Epizyme Announce Achievement of Pre-clinical Milestone in DOT1L Personalized Therapeutic Partnership,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2016 DRNA-US  BW   Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates, 4/04/2018 15117K10 BW   Cellectis Announces Pricing of Follow-On Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2016 XLRN-US  BW   Acceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2014 38000Q10 BW   GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting,#N/A,#N/A,#N/A, 2/07/2017 G6674U10 BW   Novocure to Participate in the BIO 2017 CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/30/2017 PBYI-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2017 AIMT-US  BW   Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2014 009FRV-E BW   Dr. Mark Roskey Joins Quanterix Leadership Team,#N/A,#N/A,#N/A, 8/16/2011 064QLY-E BW   pSivida Announces an Evaluation Agreement with Hospital for Special Surgery To Investigate Bioerodible Sustained Release Systems in Orthopedic Surgery,#N/A,#N/A," 7/06/2017 0DM9XX-E BW   Axonics annonce la deuxième clôture de son financement de Série C à hauteur de 20,5 millions USD",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/22/2016 LGND-US   BW   Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences,#N/A, 1/09/2017 45232710    BW   Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases," 5/06/2016 84763A10  BW   Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research Inc. (AUA) in San Diego, California, May 6-10, 2016",#N/A,"11/30/2016 ARWR-US  BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,#N/A,#N/A,#N/A,12/03/2014 68375N10 BW   OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference,#N/A,#N/A, 7/05/2017 ALXN-US  BW   Alexion Reaches Funding Agreement with NICE and NHS England for Strensiq® (asfotase alfa) for Patients with Pediatric-onset Hypophosphatasia (HPP),#N/A,11/08/2017 4503-JP     BW   Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer,#N/A, 9/01/2016 MS-US       BW   Biogen to Present at the Morgan Stanley Global Healthcare Conference," 8/20/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015",#N/A, 9/11/2018 GILD-US      BW   Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis,#N/A,#N/A,12/30/2010 M2572210 BW   Compugen Signs $5 Million R&D Funding Agreement in Support of its Pipeline Program,#N/A, 8/22/2012 07G69B-E     BW   Research and Markets: Erythropoietin Market Forecast to 2015,#N/A,#N/A,#N/A,#N/A, 7/11/2016 05156V10 BW   Aurinia Announces Appointment of Head of Communications & Advocacy,#N/A,#N/A,#N/A,#N/A, 4/12/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%,#N/A," 9/08/2017 INCY-US  BW   Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock",#N/A," 6/02/2014 80360710 BW   Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass.", 4/30/2015 G0176710 BW   Alkermes plc Reports First Quarter 2015 Financial Results," 1/05/2016 CERS-US  BW   Cerus Announces Agreement with Blood Systems, Inc. for the Use of INTERCEPT Platelets and Plasma",#N/A," 2/25/2015 04269E10 BW   ArQule to Report Fiscal 2014 Financial Results on March 4, 2015",#N/A,#N/A," 2/02/2017 4502-JP  BW   Exelixis et Takeda concluent un contrat de licence exclusive relatif à la commercialisation et au développement du cabozantinib, nouvelle thérapie contre le cancer, au Japon", 4/13/2015 SNY-FR    BW   Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN, 7/18/2017 VRTX-US   BW   Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min),#N/A,#N/A, 4/26/2017 BLUE-US  BW   bluebird bio to Present at Upcoming Investor Conferences, 3/29/2016 ACAD-US  BW   FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks,#N/A,#N/A,#N/A,11/03/2016 TXMD-US  BW   TherapeuticsMD Announces Third Quarter 2016 Financial Results,#N/A,#N/A, 8/10/2016 OMER-US  BW   Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model,#N/A,#N/A, 4/25/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2016 SYRS-US  BW   Syros Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference,#N/A,#N/A, 5/03/2010 00182C10     BW   BioSante Pharmaceuticals Announces Reinitiation of Prostate Cancer Vaccine Development, 9/02/2015 ENTA-US    BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences, 4/20/2018 DRNA-US   BW   Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation,#N/A,#N/A,#N/A," 5/11/2010 PCRX-US  BW   GE Capital Provides $11.25 Million Credit Facility to Pacira Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2016 AKBA-US  BW   Akebia Announces Fourth Quarter and Full-Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,12/19/2016 SAGE-US     BW   Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2010 56400P70 BW   MannKind to Present at the 30th Annual Canaccord Genuity Growth Conference,#N/A,#N/A,#N/A,11/10/2010 03236M20 BW   Amyris Enters Into Collaboration and Joint Development Agreement with Firmenich,#N/A,#N/A,#N/A,#N/A, 3/28/2016 06CR5C-E BW   FDA Does Not Grant Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection),#N/A,#N/A,#N/A, 2/10/2012 07CMVM-E BW   Epizyme to Participate in Three Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2016 DRNA-US  BW   Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference, 4/04/2018 15117K10 BW   Cellectis annonce les modalités définitives de son offre d’ADS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2016 MS-US    BW   Acceleron to Participate in Three Healthcare Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2014 38000Q10 BW   University of Michigan to Study GlycoMimetics’ GMI-1271 as Potential Treatment for Serious Blood-Clotting Disorder,#N/A,#N/A,#N/A, 1/24/2017 G6674U10 BW   Novocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/24/2017 74587V10 BW   Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/01/2016 00900T10 BW   Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2014 009FRV-E BW   Quanterix Appoints Kevin Hrusovsky as Executive Chairman,#N/A,#N/A,#N/A, 6/15/2011 30233G10 BW   pSivida CEO to Present on Company Technologies at Three Conferences in June,#N/A,#N/A, 7/06/2017 0DM9XX-E BW   Axonics Announces $20.5 Million Second Closing of its Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/07/2016 071VWR-E  BW   Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP,#N/A, 1/09/2017 45232710    BW   Illumina Introduces the NovaSeq Series—a New Architecture Designed to Usher in the $100 Genome, 5/05/2016 84763A10  BW   Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update,#N/A,11/29/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,11/13/2014 68375N10 BW   OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference,#N/A,#N/A, 6/23/2017 ALXN-US  BW   Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union,#N/A,11/02/2017 SGEN-US     BW   Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma,#N/A, 9/01/2016 06CR5C-E    BW   Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation," 8/10/2015 IMGN-US  BW   ImmunoGen, Inc. Announces Canaccord Genuity Growth Conference Webcast",#N/A, 9/06/2018 GILD-US      BW   Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint,#N/A,#N/A,12/14/2010 M2572210 BW   Compugen Announces Positive Therapeutic Effect of CGEN-15001 in Animal Model of Rheumatoid Arthritis,#N/A, 8/21/2012 NPSP-US      BW   NPS Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Gattex® (teduglutide),#N/A,#N/A,#N/A,#N/A, 6/28/2016 05156V10 BW   Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN),#N/A,#N/A,#N/A,#N/A, 4/10/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Expansion of Commercialization Team,#N/A," 9/07/2017 INCY-US  BW   Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock",#N/A, 5/22/2014 80360710 BW   Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts, 4/23/2015 G0176710 BW   Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results,12/23/2015 CERS-US  BW   Cerus Announces Rhode Island Blood Center Enters into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A," 2/17/2015 04269E10 BW   ArQule, Inc. to Present at 2015 RBC Capital Markets’ Global Healthcare Conference",#N/A,#N/A, 2/02/2017 4502-JP  BW   Exelixis y Takeda Suscriben Acuerdo de Licencia Exclusiva para Comercializar y Desarrollar Nuevas Terapias contra el Cáncer con Cabozantinib en Japón, 3/30/2015 80105N10  BW   Genzyme’s Cerdelga® (eliglustat) Capsules Approved in Japan, 7/17/2017 VRTX-US   BW   Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts,#N/A,#N/A, 3/20/2017 BLUE-US  BW   bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives, 3/29/2016 ACAD-US  BW   ACADIA Pharmaceuticals Stock Trading Halted Today,#N/A,#N/A,#N/A,10/20/2016 TXMD-US  BW   TherapeuticsMD to Host Third Quarter Financial Results Conference Call and Webcast on November 3,#N/A,#N/A, 8/09/2016 OMER-US  BW   Omeros Corporation Reports Second Quarter 2016 Financial Results,#N/A,#N/A, 4/07/2016 IRWD-US  BW   Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A," 7/06/2016 SYRS-US  BW   Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares",#N/A,#N/A," 4/30/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. to Present Cancer Vaccine Portfolio Update at the BIO International Convention"," 8/06/2015 ENTA-US    BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2015", 4/20/2018 DRNA-US   BW   Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2016 AKBA-US  BW   Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat,#N/A,#N/A,#N/A,#N/A,12/13/2016 SAGE-US     BW   Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Movement Disorders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2010 56400P70 BW   MannKind’s Chairman and CEO Recognized as One of PharmaVOICE’s “100 Most Inspiring People in the Life Sciences”,#N/A,#N/A,#N/A,11/05/2010 03236M20 BW   Amyris to Present at Stifel Nicolaus Cleantech Conference and RW Baird Clean Technology Conference,#N/A,#N/A,#N/A,#N/A, 3/18/2016 06CR5C-E BW   Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application,#N/A,#N/A,#N/A, 1/10/2012 07CMVM-E BW   Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/31/2015 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", 4/03/2018 15117K10 BW   Cellectis annonce le lancement d’une nouvelle offre d’ADS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2016 XLRN-US  BW   Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2014 38000Q10 BW   GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers,#N/A,#N/A,#N/A, 1/19/2017 06CR5C-E BW   Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/22/2017 74587V10 BW   Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2016 00900T10 BW   Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2014 009FRV-E BW   CORRECTING and REPLACING Kevin Hrusovsky Joins Quanterix as Executive Chairman,#N/A,#N/A,#N/A," 6/14/2011 30233G10 BW   pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma",#N/A,#N/A, 5/31/2017 0DM9XX-E BW   Présentation des résultats initiaux positifs de l'étude clinique RELAX-OAB d'Axonics® lors du Congrès mondial de la Société internationale de neuromodulation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/28/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics,#N/A, 1/05/2017 45232710    BW   GRAIL Plans to Raise in Excess of $1B in Series B Funding, 5/03/2016 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016 Healthcare Conference on May 10th,#N/A,"11/25/2016 ARWR-US  BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A,"11/10/2014 68375N10 BW   OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore™ Test for High Grade Prostate Cancer in the United States",#N/A,#N/A, 6/13/2017 ALXN-US  BW   Alexion Names Paul Clancy Chief Financial Officer,#N/A,11/01/2017 SGEN-US     BW   Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017,#N/A, 8/31/2016 09062X10    BW   Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab," 7/31/2015 IMGN-US  BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results",#N/A, 9/04/2018 GILD-US      BW   Gilead Enters Licensing Agreement With Trianni for Use of Trianni Transgenic Human Monoclonal Antibody Discovery Platform,#N/A,#N/A,12/06/2010 M2572210 BW   New Studies Support Therapeutic Potential of Compugen Discovered Target for Multiple Myeloma Treatment,#N/A, 8/10/2012 07G69B-E     BW   Research and Markets: Market and Product Forecasts: Targeted Cancer Therapies 2011-21 - Eurozone price cuts impact targeted cancer therapies market,#N/A,#N/A,#N/A,#N/A, 6/22/2016 05156V10 BW   Aurinia Announces Closing of US$7 Million Private Placement,#N/A,#N/A,#N/A,#N/A, 3/28/2017 AERI-US    BW   Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference,#N/A, 9/01/2017 INCY-US  BW   Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month,#N/A, 5/16/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the UBS Global Healthcare Conference on May 20, 4/13/2015 G0176710 BW   Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™) Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting,12/10/2015 CERS-US  BW   Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma,#N/A," 2/04/2015 04269E10 BW   ArQule, Inc. to Present at Leerink Global Healthcare Conference",#N/A,#N/A, 2/01/2017 TKPYY-JP BW   Exelixis und Takeda schließen exklusiven Lizenzvertrag zur Kommerzialisierung und Entwicklung der neuartigen Krebstherapie Cabozantinib in Japan ab, 2/27/2015 SAN-FR    BW   Genzyme Recognizes International Rare Disease Day with Global Education and Fund-Raising Events; Announces Founding Partnership of Give RARE, 7/13/2017 VRTX-US   BW   Vertex to Announce Second Quarter 2017 Financial Results on July 26,#N/A,#N/A, 3/01/2017 BLUE-US  BW   bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine," 3/01/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016",#N/A,#N/A,#N/A, 9/22/2016 TXMD-US  BW   TherapeuticsMD Announces Multiple Presentations Related to Yuvvexy™ (TX-004HR) at Two Upcoming Medical Conferences,#N/A,#N/A," 8/04/2016 OMER-US  BW   Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016",#N/A,#N/A, 4/05/2016 IRWD-US  BW   Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2016 SYRS-US  BW   Syros Pharmaceuticals Announces Pricing of Initial Public Offering,#N/A,#N/A," 4/28/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Healthcare Conference"," 7/30/2015 ENTA-US    BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Third Quarter and Nine-Months Ended June 30, 2015"," 4/14/2018 ALNY-US   BW   Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/08/2016 AKBA-US  BW   Akebia to Host Conference Call on March 14th to Discuss Full-Year 2015 Financial Results and Corporate Highlights,#N/A,#N/A,#N/A,#N/A,"12/07/2016 SAGE-US     BW   Sage Therapeutics to Webcast R&D Day on December 13, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2010 56400P70 BW   MannKind Corporation Reports 2010 Second Quarter Financial Results,#N/A,#N/A,#N/A,11/04/2010 03236M20 BW   Amyris Signs Contract Manufacturing Agreement with Tate & Lyle,#N/A,#N/A,#N/A,#N/A," 2/25/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Results",#N/A,#N/A,#N/A,11/30/2011 07CMVM-E BW   Epizyme to Present at World Epigenetics Summit and Convergence Forum West,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/21/2015 DRNA-US  BW   Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers, 4/03/2018 15117K10 BW   Cellectis Announces Launch of Follow-On Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/28/2016 XLRN-US  BW   Acceleron Pharma to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2014 38000Q10 BW   GlycoMimetics to Present at Stifel Healthcare Conference 2014,#N/A,#N/A,#N/A, 1/10/2017 G6674U10 BW   Novocure to Report Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2017 74587V10 BW   Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2016 AIMT-US  BW   Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 009FRV-E BW   Quanterix Selected as a Red Herring Top 100 North America Winner,#N/A,#N/A,#N/A, 6/14/2011 30233G10 BW   pSivida and Pfizer Amend Agreement to Focus Solely on Development of Sustained-Release Implant to Deliver Latanoprost for Ocular Hypertension and Glaucoma,#N/A,#N/A, 5/31/2017 0DM9XX-E BW   Positive erste Ergebnisse der klinischen Studie RELAX-OAB von Axonics® auf Weltkongress der International Neuromodulation Society präsentiert,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/15/2016 06CR5C-E  BW   Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection,#N/A," 1/03/2017 45232710    BW   Illumina Taps Garret Hampton, One of the World’s Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit", 4/28/2016 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast,#N/A,11/21/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen,#N/A,#N/A,#N/A,#N/A,"11/07/2014 68375N10 BW   OPKO To Hold Conference Call on November 10, 2014",#N/A,#N/A, 6/01/2017 ALXN-US  BW   Alexion Announces Additions to Executive Leadership Team,#N/A,10/26/2017 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2017 Financial Results,#N/A," 8/30/2016 05J8D9-E    BW   State Street Global Advisors Announces Annual Rebalancing of the SSGA Gender Diversity Index, Adds 88 New Companies to Index"," 7/15/2015 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results",#N/A," 8/30/2018 GILD-US      BW   Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12",#N/A,#N/A,11/22/2010 M2572210 BW   Compugen Announces Discovery Platform for New Members of Protein Families with Known Therapeutic Applications,#N/A, 8/09/2012 0C8BZH-E     BW   RBCC Partner n3D Courts ‘MAD’ Scientists With Cell Culturing Contest,#N/A,#N/A,#N/A,#N/A, 6/15/2016 05156V10 BW   Aurinia Announces Private Placement,#N/A,#N/A,#N/A,#N/A, 3/07/2017 AERI-US    BW   Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update,#N/A, 8/31/2017 INCY-US  BW   Nuovi dati relativi a Epacadostat in combinazione con KEYTRUDA® (pembrolizumab) dimostrano risposte durevoli in pazienti affetti da melanoma avanzato,#N/A, 5/08/2014 80360710 BW   Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments, 4/06/2015 G0176710 BW   Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia,12/09/2015 CERS-US  BW   Cerus Announces Agência Nacional de Vigilância Sanitária Approval of the INTERCEPT Blood System for Platelets and Plasma in Brazil,#N/A,11/13/2014 04269E10 BW   ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium,#N/A,#N/A, 1/31/2017 EXEL-US  BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 2/17/2015 003ZHQ-E  BW   ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association," 7/13/2017 VRTX-US   BW   Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",#N/A,#N/A, 2/28/2017 BARC-GB  BW   bluebird bio to Present at Two Investor Conferences in March," 2/29/2016 ACAD-US  BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015",#N/A,#N/A,#N/A, 9/19/2016 TXMD-US  BW   TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy™ (TX-004HR),#N/A,#N/A, 8/04/2016 OMER-US  BW   Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System,#N/A,#N/A, 3/30/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present Clinical and Preclinical Data on sGC Stimulators at Upcoming Scientific Conferences,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2016 07G766-E BW   Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidates at 21st Congress of the European Hematology Association,#N/A,#N/A, 4/26/2010 00182C10     BW   BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression Technology," 7/24/2015 ENTA-US    BW   Enanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets", 3/28/2018 ALNY-US   BW   Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2016 AKBA-US  BW   Akebia to Present at the 18th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,12/06/2016 SAGE-US     BW   Sage Announces Expedited Development Plan for SAGE-547 in the Treatment of Postpartum Depression based on FDA Breakthrough Therapy Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/26/2010 56400P70 BW   MannKind Corporation to Hold 2010 Second Quarter Financial Results,#N/A,#N/A,#N/A,11/04/2010 03236M20 BW   Amyris Reports Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 2/23/2016 EGRX-US  BW   Eagle Pharmaceuticals Receives Sixth Patent for Bendamustine,#N/A,#N/A,#N/A,11/09/2011 07CMVM-E BW   Epizyme to Present at Lazard Capital Markets Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/21/2015 DRNA-US  BW   Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors, 4/03/2018 15117K10 BW   Cellectis et Allogene Therapeutics entendent poursuivre la collaboration stratégique initiée avec Pfizer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/25/2016 XLRN-US  BW   Acceleron Pharma Appoints Thomas McCourt to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2014 38000Q10 BW   GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting,#N/A,#N/A,#N/A, 1/10/2017 NVCR-GB  BW   Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/10/2017 PBYI-US  BW   Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Misled Shareholders According to a Recently Filed Class Action",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2016 00900T10 BW   Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2014 009FRV-E BW   Quanterix is a Finalist for the 2014 Red Herring Top 100 North America Award,#N/A,#N/A,#N/A, 5/13/2011 30233G10 BW   pSivida Announces Resubmission of New Drug Application for ILUVIEN®,#N/A,#N/A, 5/30/2017 0DM9XX-E BW   Positive Initial Results of the Axonics® RELAX-OAB Clinical Study Presented at the International Neuromodulation Society World Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/10/2016 LGND-US   BW   Ligand Reports Fourth Quarter and Full Year 2015 Financial Results,#N/A,"12/28/2016 ILMN-US     BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Illumina, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit"," 4/20/2016 06CR5C-E  BW   FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma",#N/A,"11/19/2016 ARWR-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A,11/07/2014 68375N10 BW   OPKO Announces Third Quarter Operating and Financial Results,#N/A,#N/A, 5/30/2017 ALXN-US  BW   Alexion to Present at Upcoming Investor Conferences,#N/A,10/11/2017 SGEN-US     BW   Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer,#N/A, 8/09/2016 09062X10    BW   Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company, 6/17/2015 45253H10 BW   ImmunoGen’s IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma,#N/A," 8/28/2018 GILD-US      BW   Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations",#N/A,#N/A,10/29/2010 M2572210 BW   Compugen Licenses Novel Oncology Target to Seattle Genetics,#N/A," 8/06/2012 06680H-E     BW   For the Treatment of Psoriasis, Abbott/Eisai’s Humira Has Emerged as the Leading Agent with Major-Market Sales of More Than $1.4 Billion in 2011",#N/A,#N/A,#N/A,#N/A, 6/09/2016 05156V10 BW   Aurinia Announces Results of Annual General Meeting,#N/A,#N/A,#N/A,#N/A, 3/02/2017 OPY-US     BW   Aerie Pharmaceuticals to Present at Three Investor Conferences in March,#N/A, 8/31/2017 MRK-US   BW   Nuevos datos de epacadostat en combinación con KEYTRUDA® (pembrolizumab) demuestran respuestas duraderas en pacientes con melanoma avanzado,#N/A, 5/06/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the 2014 Bank of America Merrill Lynch Healthcare Conference, 3/23/2015 G0176710 BW   Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research,12/08/2015 CERS-US  BW   First Patient Enrolled in Cerus’ Phase IV PIPER Study,#N/A,11/11/2014 04269E10 BW   ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome,#N/A,#N/A, 1/30/2017 4502-JP  BW   Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan, 2/12/2015 80105N10  BW   Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposium 2015, 6/09/2017 VRTX-US   BW   Vertex to Present at the Goldman Sachs Healthcare Conference on June 13,#N/A,#N/A, 2/22/2017 BLUE-US  BW   bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress," 2/23/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016",#N/A,#N/A,#N/A, 8/04/2016 TXMD-US  BW   TherapeuticsMD Announces Second Quarter 2016 Financial Results,#N/A,#N/A, 7/07/2016 OMER-US  BW   Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference,#N/A,#N/A, 3/23/2016 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2016 0D059L-E BW   Syros Pharmaceuticals Appoints Industry Leader Sanj K. Patel to its Board of Directors,#N/A,#N/A," 4/19/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present and Participate in Cancer Immunotherapy Panel at the World Vaccine Congress"," 6/30/2015 29251M10   BW   CORRECTING and REPLACING Enanta Pharmaceuticals Announces the Appointment of Nathalie Adda, M.D. as Chief Medical Officer", 3/28/2018 ALNY-US   BW   Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2016 AKBA-US  BW   Akebia Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,12/01/2016 SAGE-US     BW   Sage Therapeutics to Present at American Epilepsy Society 70th Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/20/2010 56400P70 BW   FDA Accepts AFREZZA Complete Response Resubmission and Sets Target Action Date,#N/A,#N/A,#N/A,11/01/2010 03236M20 BW   Amyris No Compromise® Renewable Diesel Receives Highest EPA Blending Registration for Renewable Fuel,#N/A,#N/A,#N/A,#N/A, 2/10/2016 EGRX-US  BW   Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference,#N/A,#N/A,#N/A,10/14/2011 07CMVM-E BW   Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2015 DRNA-US  BW   Dicerna Announces Addition to NASDAQ Biotechnology Index, 4/03/2018 PFE-US   BW   Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2016 XLRN-US  BW   Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2014 38000Q10 BW   GlycoMimetics Reports Third Quarter 2014 Results,#N/A,#N/A,#N/A,12/22/2016 NVCR-US  BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Novocure Limited. and Encourages Investors to Contact the Firm,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2017 74587V10 BW   Puma Biotechnology Reports First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2016 00900T10 BW   Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2014 009FRV-E BW   Quanterix’s Simoa Technology to Detect Blood Biomarker for Concussion in Hockey Players,#N/A,#N/A,#N/A," 5/10/2011 30233G10 BW   pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2011",#N/A,#N/A," 5/02/2017 0DM9XX-E BW   Axonics® gibt den Abschluss seiner ersten Series-C-Finanzierungsrunde in Höhe von 14,5 Millionen USD bekannt",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/02/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics,#N/A,12/27/2016 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference  , 3/15/2016 06CR5C-E  BW   Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection,#N/A,"11/18/2016 ARWR-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A,"10/09/2014 68375N10 BW   Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve",#N/A,#N/A, 5/23/2017 ALXN-US  BW   Alexion Announces Executive Leadership Changes,#N/A,10/10/2017 4503-JP     BW   Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer,#N/A, 8/01/2016 09062X10    BW   Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy," 6/15/2015 008SHY-E BW   BIO Elects New Chair, Officers, and Board Members",#N/A," 8/27/2018 KITE-US      BW   Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy",#N/A,#N/A,10/26/2010 M2572210 BW   Compugen Reports Third Quarter 2010 Financial Results,#N/A," 8/06/2012 NPSP-US      BW   NPS Pharmaceuticals Joins the Oley Foundation in Recognizing HPN Awareness Week, August 5-11",#N/A,#N/A,#N/A,#N/A, 5/12/2016 05156V10 BW   Aurinia Announces Presentations at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Meeting,#N/A,#N/A,#N/A,#N/A, 3/01/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%,#N/A, 8/31/2017 INCY-US  BW   De nouvelles données pour l'épacadostat en combinaison avec le KEYTRUDA® (pembrolizumab) font état de réponses durables chez les patients atteints de mélanome avancé,#N/A, 4/29/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the 2014 39th Annual Deutsche Bank Healthcare Conference," 3/09/2015 ALKS-IE  BW   Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc.",12/07/2015 CERS-US  BW   Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A,11/10/2014 04269E10 BW   ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer,#N/A,#N/A," 1/09/2017 000KXY-E BW   Update on Dispute between Exelixis and Genentech, a Member of the Roche Group", 2/12/2015 80105N10  BW   Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORLD Symposium 2015, 6/09/2017 VRTX-US   BW   Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference,#N/A,#N/A, 2/03/2017 BLUE-US  BW   bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease," 2/03/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016",#N/A,#N/A,#N/A, 7/20/2016 TXMD-US  BW   TherapeuticsMD to Host Second Quarter Financial Results,#N/A,#N/A, 6/29/2016 06CR5C-E BW   Omeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA®,#N/A,#N/A, 3/09/2016 BCS-GB   BW   Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2016 06CR5C-E BW   Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 Into Phase 2 Clinical Trial,#N/A,#N/A," 3/31/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. Discusses LibiGel® and its Cancer Vaccines in Fireside Chat with Research Analyst", 6/16/2015 062WH0-E   BW   Enanta Pharmaceuticals to Present at the JMP Securities Life Sciences Conference," 3/26/2018 ALNY-US   BW   Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 AKBA-US  BW   Akebia Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,11/16/2016 06CR5C-E    BW   SAGE-547 Granted PRIME Designation by EMA for the Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/28/2010 56400P70 BW   AFREZZA™ Demonstrates Long-Term Efficacy in Controlling Blood Sugar Levels in Patients with Type 2 Diabetes,#N/A,#N/A,#N/A,"10/25/2010 03236M20 BW   Amyris to Announce 2010 Third Quarter Financial Results on Thursday, November 4, 2010",#N/A,#N/A,#N/A,#N/A," 2/05/2016 EGRX-US  BW   Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016",#N/A,#N/A,#N/A," 9/06/2011 06S6MV-E BW   Epizyme, Inc. Named a “Fierce 15” Biotech Company for 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 DRNA-US  BW   Dicerna Pharmaceuticals Appoints John “Jack” Green Interim Chief Financial Officer," 3/13/2018 15117K10 BW   Départ à la retraite de Mathieu Simon, Directeur des Opérations ; Elsy Boglioli est nommée Directrice des Opérations",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2016 XLRN-US  BW   Acceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2014 38000Q10 BW   GlycoMimetics to Present at 34th Annual Canaccord Genuity Global Growth Conference,#N/A,#N/A,#N/A,12/22/2016 NVCR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of NovoCure Limited Investors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2017 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/04/2016 AIMT-US  BW   Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2014 009FRV-E BW   Quanterix One of 33 Recipients of Massachusetts Life Sciences Center Tax Incentive Award,#N/A,#N/A,#N/A, 5/03/2011 30233G10 BW   pSivida Corp. Announces Third Quarter 2011 Financial Results Release Date and Conference Call Information,#N/A,#N/A," 5/02/2017 0DM9XX-E BW   Axonics® annonce la première clôture d'un financement de Série C à hauteur de 14,5 millions USD",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/22/2016 LGND-US   BW   Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th,#N/A,"12/20/2016 45232710    BW   Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team", 3/15/2016 06CR5C-E  BW   FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection,#N/A,"11/16/2016 ARWR-US  BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A, 9/29/2014 68375N10 BW   OPKO Health Supports National Prostate Cancer Council Legislation,#N/A,#N/A," 5/18/2017 ALXN-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors",#N/A,10/10/2017 GMAB-DK     BW   Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer,#N/A, 7/25/2016 MRK-DE      BW   Enigma Biomedical Group Inc Signs Research Agreement with Biogen and Merck for Novel Tau Imaging Agent, 5/30/2015 45253H10 BW   ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer,#N/A, 8/14/2018 GILD-US      BW   Gilead Sciences Announces Executive Promotions,#N/A,#N/A,"10/19/2010 M2572210 BW   Compugen Ltd. to Review Third Quarter 2010 Financial Results on Tuesday, October 26, 2010",#N/A, 7/27/2012 NPSP-US      BW   NPS Pharmaceuticals to Report Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A, 5/11/2016 05156V10 BW   Aurinia Reports First Quarter 2016 Financial Results and Operational Highlights,#N/A,#N/A,#N/A,#N/A," 2/27/2017 AERI-US    BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017",#N/A, 8/31/2017 INCY-US  BW   Neue Ergebnisse zu Epacadostat in Kombination mit KEYTRUDA® (Pembrolizumab) zeigen dauerhaftes Ansprechen bei Patienten mit fortgeschrittenem Melanom,#N/A," 4/29/2014 80360710 BW   Sarepta Therapeutics to Announce First Quarter 2014 Financial Results and Corporate Update on May 8, 2014", 3/03/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference,12/04/2015 CERS-US  BW   Cerus Announces Mississippi Valley Regional Blood Center Enters Into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A,11/10/2014 04269E10 BW   ArQule Announces Third Quarter Fiscal 2014 Results,#N/A,#N/A, 1/03/2017 EXEL-US  BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 1/20/2015 80105N10  BW   INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Law Offices of Howard G. Smith," 6/08/2017 VRTX-US   BW   Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors",#N/A,#N/A, 1/04/2017 JPM-US   BW   bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference, 1/29/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 7/07/2016 TXMD-US  BW   TherapeuticsMD Announces New Drug Application Submission for Yuvvexy™ (TX-004HR),#N/A,#N/A, 5/17/2016 OMER-US  BW   Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds,#N/A,#N/A, 3/01/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 5/19/2016 07G766-E BW   Syros Pharmaceuticals to Present on its Two Lead Programs, SY-1425 and SY-1365, at 21st Congress of the European Hematology Association",#N/A,#N/A," 3/30/2010 00182C10     BW   BioSante Pharmaceuticals Reports Receipt of $2.16 Million in Elestrin™ Royalty Buydown, and Financial Results for 2009"," 5/26/2015 062WH0-E   BW   Enanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hepatitis C Virus1", 3/21/2018 ALNY-US   BW   Alnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 AKBA-US  BW   Akebia Initiates Phase 3 PRO2TECT™ Program,#N/A,#N/A,#N/A,#N/A,11/10/2016 SAGE-US     BW   Sage Therapeutics to Present at Society for Neuroscience 2016 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/26/2010 56400P70 BW   AFREZZA™ Suppresses Endogenous Glucose Production More Rapidly Than Currently Available Insulin Therapy,#N/A,#N/A,#N/A,10/08/2010 03236M20 BW   Amyris to Present at GoingGreen Silicon Valley 2010,#N/A,#N/A,#N/A,#N/A, 2/04/2016 EGRX-US  BW   Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales,#N/A,#N/A,#N/A, 8/31/2011 07CMVM-E BW   Epizyme to Participate in Three Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2015 DRNA-US  BW   Dicerna to Present at Two November Conferences, 3/13/2018 15117K10 BW   Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2016 CELG-US  BW   Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2014 38000Q10 BW   GlycoMimetics Reports Second Quarter 2014 Results,#N/A,#N/A,#N/A,12/19/2016 NVCR-GB  BW   Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2017 PBYI-US  BW   PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 00900T10 BW   Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2014 009FRV-E BW   Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge,#N/A,#N/A,#N/A, 5/03/2011 30233G10 BW   pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN® in Diabetic Macular Edema,#N/A,#N/A, 5/02/2017 0DM9XX-E BW   Axonics® Announces $14.5 Million First Close of Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/13/2016 LGND-US   BW   Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions,#N/A,"12/17/2016 ILMN-US     BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm", 3/09/2016 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update,#N/A,11/14/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle,#N/A,#N/A,#N/A,#N/A, 9/23/2014 68375N10 BW   OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints,#N/A,#N/A, 5/16/2017 ALXN-US  BW   Rady Children’s Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns,#N/A,"10/05/2017 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017",#N/A, 7/22/2016 BIIB-US     BW   Medidata Cloud Technology Selected to Support Biogen Clinical Trials," 5/13/2015 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting",#N/A," 8/06/2018 GILD-US      BW   China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection",#N/A,#N/A, 7/27/2010 M2572210 BW   Compugen Reports Second Quarter 2010 Financial Results,#N/A, 7/26/2012 LIFE.XX5-US  BW   Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry,#N/A,#N/A,#N/A,#N/A, 5/09/2016 05156V10 BW   Aurinia Initiates First Clinical Study of Voclosporin for Japan,#N/A,#N/A,#N/A,#N/A, 2/15/2017 061XBV-E   BW   Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference,#N/A, 8/30/2017 INCY-US  BW   Nieuwe gegevens voor Epacadostat in combinatie met KEYTRUDA® (pembrolizumab) tonen duurzame reacties bij patiënten met gevorderd melanoom,#N/A," 4/28/2014 80360710 BW   Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014"," 3/02/2015 G0176710 BW   Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation, Depression and Other CNS Diseases",12/02/2015 CERS-US  BW   Cerus Announces Collaboration Agreement With Haemonetics for the Use of Acrodose Platelet Kits With the INTERCEPT Blood System for Platelets,#N/A,"11/03/2014 04269E10 BW   ArQule to Report Third Quarter 2014 Financial Results on November 10, 2014",#N/A,#N/A,12/21/2016 IPSEY-FR BW   Exelixis et Ipsen étendent leur accord exclusif de licence pour la commercialisation et le développement du cabozantinib au Canada," 1/19/2015 80105N10  BW   UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015"," 6/01/2017 VRTX-US   BW   Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI® (lumacaftor/ivacaftor), KALYDECO® (ivacaftor) and Future Cystic Fibrosis Medicines",#N/A,#N/A,12/15/2016 0FTLW8-E BW   bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement," 1/25/2016 ACAD-US  BW   ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer",#N/A,#N/A,#N/A, 6/29/2016 TXMD-US  BW   TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application,#N/A,#N/A, 5/10/2016 OMER-US  BW   Omeros Corporation Reports First Quarter 2016 Financial Results,#N/A,#N/A, 2/29/2016 IRWD-US  BW   Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS® (linaclotide),#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2016 0D059L-E BW   Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia,#N/A,#N/A, 3/23/2010 00182C10     BW   BioSante Announces Additional Positive Leukemia Vaccine Results and Second FDA Orphan Drug Designation," 5/07/2015 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2015", 3/14/2018 ALNY-US   BW   Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2015 AKBA-US  BW   Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia,#N/A,#N/A,#N/A,#N/A,11/09/2016 SAGE-US     BW   Sage Therapeutics to Present at the Stifel 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2010 56400P70 BW   American Diabetes Association/The Lancet Symposium Will Highlight Study Showing AFREZZA™ Provides Comparable Glycemic Control with Less Weight Gain and Hypoglycemia than Standard of Care,#N/A,#N/A,#N/A, 9/28/2010 03236M20 BW   Amyris Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A," 2/02/2016 EGRX-US  BW   Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula",#N/A,#N/A,#N/A, 7/11/2011 07CMVM-E BW   Epizyme and Collaborators Publish Paper in Cancer Cell Supporting Use of DOT1L Histone Methyltransferase Inhibitors as Personalized Therapeutics for Genetically-Defined MLL-rearranged Leukemia Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2015 DRNA-US  BW   Dicerna Announces Third Quarter 2015 Financial and Operational Results, 3/12/2018 15117K10 BW   Cellectis Reports 4th Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2016 CELG-US  BW   Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A," 7/10/2014 38000Q10 BW   GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors",#N/A,#N/A,#N/A,12/15/2016 NVCR-GB  BW   Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2017 PBYI-US  BW   PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/11/2016 00900T10 BW   Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2013 009FRV-E BW   Quanterix to Present Poster Session on Blood-based Brain Biomarker Measurements of Sports Related Brain Injury at Neuroscience,#N/A,#N/A,#N/A," 2/09/2011 30233G10 BW   pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2010",#N/A,#N/A, 4/18/2017 0DM9XX-E BW   Axonics® wird Ergebnisse der klinischen Studie RELAX-OAB auf Weltkongress der International Neuromodulation Society präsentieren,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/17/2015 LGND-US   BW   Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock",#N/A,"12/16/2016 ILMN-US     BW   Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Illumina, Inc."," 3/07/2016 84763A10  BW   Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor",#N/A,11/14/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents New Data on ARC-AAT,#N/A,#N/A,#N/A,#N/A, 9/15/2014 68375N10 BW   OPKO Launches the 4Kscore Test in Europe,#N/A,#N/A, 5/15/2017 ALXN-US  BW   Long-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years,#N/A,10/03/2017 4502-JP     BW   Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,#N/A, 7/21/2016 09062X10    BW   Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion," 5/04/2015 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A, 7/25/2018 GILD-US      BW   Gilead Sciences Announces Third Quarter 2018 Dividend,#N/A,#N/A," 7/20/2010 M2572210 BW   Compugen Second Quarter 2010 Webcast and Conference Call Scheduled for Tuesday, July 27, 2010 at 10:00 AM EDT",#N/A," 7/25/2012 AMGN-US      BW   Securities Class Action Filings Are Down in the First Half of 2012, According to Mid-Year Report by Stanford Law School and Cornerstone Research",#N/A,#N/A,#N/A,#N/A, 4/28/2016 05156V10 BW   Aurinia Pharmaceuticals to Present at the 2016 Bloom Burton & Co. Healthcare Investor Conference,#N/A,#N/A,#N/A,#N/A," 2/06/2017 064T7Q-E   BW   Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety",#N/A, 8/30/2017 INCY-US  BW   New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma,#N/A, 4/23/2014 80360710 BW   Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of Common Stock, 2/24/2015 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care Conference,12/01/2015 CERS-US  BW   Cerus and The Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A, 8/05/2014 04269E10 BW   ArQule Reports Second Quarter 2014 Financial Results,#N/A,#N/A,12/21/2016 05MYKN-E BW   Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada," 1/16/2015 80105N10  BW   Sanofi Shareholder Alert by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi"," 5/30/2017 CNCE-US   BW   Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws",#N/A,#N/A,12/14/2016 BLUE-US  BW   bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia, 1/11/2016 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors,#N/A,#N/A,#N/A, 6/06/2016 TXMD-US  BW   TherapeuticsMD Announces New Innovation in Compliance Packaging for Prenatal Vitamins,#N/A,#N/A, 5/10/2016 OMER-US  BW   Leonard M. Blum Joins Omeros to Lead Business and Commercial Activities,#N/A,#N/A, 2/24/2016 IRWD-US  BW   Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2016 0D059L-E BW   Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia,#N/A,#N/A," 3/18/2010 00182C10     BW   Rodman & Renshaw and BioSante Pharmaceuticals, Inc. Announce Fireside Chat on Women's Health", 4/27/2015 29251M10   BW   Enanta Pharmaceuticals to Present at the Deutsche Bank 40th Annual Healthcare Conference, 3/13/2018 ALNY-US   BW   Alnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 AKBA-US  BW   Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program,#N/A,#N/A,#N/A,#N/A,11/03/2016 SAGE-US     BW   CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2010 56400P70 BW   AFREZZA Demonstrates Non-Inferiority Compared to Standard Therapy in Controlling Blood Sugar Levels in Type 1 Diabetes Patients,#N/A,#N/A,#N/A, 6/25/2010 AMRS-US  BW   Amyris Enters Into Off-Take Agreement With Shell,#N/A,#N/A,#N/A,#N/A," 2/01/2016 EGRX-US  BW   FDA Grants Fast Track Designation to RYANODEX for Treatment of Exertional Heat Stroke; Fast Track Designation Highlights Serious, Unmet Medical Need that Exists for Patients with EHS",#N/A,#N/A,#N/A, 6/23/2011 065B9K-E BW   The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/03/2015 DRNA-US  BW   Dicerna to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 10, 2015", 3/12/2018 15117K10 BW   Cellectis publie ses résultats financiers du quatrième trimestre 2017 et de l’exercice 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2016 XLRN-US  BW   Acceleron Pharma to Host Conference Call and Webcast to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2014 38000Q10 BW   GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070),#N/A,#N/A,#N/A,12/12/2016 G6674U10 BW   Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2017 74587V10 BW   Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2016 00900T10 BW   Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2013 009FRV-E BW   Quanterix Announces Key Patents Issued for Simoa Platform,#N/A,#N/A,#N/A, 2/03/2011 30233G10 BW   pSivida Announces Positive Results from the 36 Month Readout of Completed Phase 3 FAME™ Study of ILUVIEN® in Patients with Diabetic Macular Edema,#N/A,#N/A, 4/18/2017 0DM9XX-E BW   Axonics® s'apprête à présenter les résultats de l'étude clinique RELAX-OAB lors du Congrès mondial de la Société internationale de neuromodulation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/08/2015 LGND-US   BW   RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs,#N/A,"12/07/2016 45232710    BW   Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer", 3/02/2016 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast,#N/A,"11/09/2016 ARWR-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Arrowhead Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A, 9/11/2014 68375N10 BW   Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference,#N/A,#N/A, 5/11/2017 ALXN-US  BW   Alexion Global Headquarters Earns Highest LEED® Green Building Certification,#N/A,10/02/2017 SGEN-US     BW   Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma,#N/A, 7/18/2016 080RQG-E    BW   Requerimento de autorização de marketing da Samsung Bioepis para candidato biossimilar de adalimumabe SB5 aceito para revisão por parte da agência europeia de medicamentos," 4/24/2015 45253H10 BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results",#N/A, 7/25/2018 GILD-US      BW   Gilead Sciences Announces Second Quarter 2018 Financial Results,#N/A,#N/A, 7/01/2010 M2572210 BW   Compugen Discovered Protein Shown to Abolish Recurring Relapses in Multiple Sclerosis Animal Model,#N/A, 7/18/2012 08GMCC-E     BW   Research and Markets: Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings,#N/A,#N/A,#N/A,#N/A, 4/11/2016 05156V10 BW   Aurinia Announces Appointment of New Chief Executive Officer,#N/A,#N/A,#N/A,#N/A, 2/03/2017 AERI-US    BW   Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland,#N/A, 8/10/2017 INCY-US  BW   Forbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year,#N/A, 4/22/2014 80360710 BW   Sarepta Therapeutics Announces Proposed Public Offering of Common Stock," 2/24/2015 G0176710 BW   Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015",11/05/2015 CERS-US  BW   Cerus Corporation Reports Third Quarter 2015 Results,#N/A," 7/29/2014 04269E10 BW   ArQule to Report Second Quarter 2014 Financial Results on August 5, 2014",#N/A,#N/A,12/21/2016 EXEL-US  BW   Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada, 1/14/2015 80105N10  BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sanofi, 5/24/2017 CNCE-US   BW   Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals,#N/A,#N/A,12/06/2016 BLUE-US  BW   bluebird bio Announces Pricing of Public Offering of Common Stock," 1/07/2016 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016",#N/A,#N/A,#N/A, 6/03/2016 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A, 5/10/2016 OMER-US  BW   Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®,#N/A,#N/A, 2/18/2016 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A, 4/06/2016 05KDBG-E BW   Syros Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference,#N/A,#N/A, 3/15/2010 00182C10     BW   BioSante Announces FDA Orphan Drug Designation for GVAX Pancreatic Cancer Vaccine," 4/27/2015 29251M10   BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six-Months Ended March 31, 2015"," 3/12/2018 ALNY-US   BW   Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2015 AKBA-US  BW   Akebia to Present at the 2015 Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,"10/27/2016 SAGE-US     BW   Sage Therapeutics to Report Third Quarter 2016 Financial Results on Thursday, November 3, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2010 56400P70 BW   MannKind to Present at Upcoming Conferences and Annual Stockholders Meeting,#N/A,#N/A,#N/A, 6/24/2010 PG-US    BW   Amyris Enters Into Multi-Products Collaboration and Off-Take Agreements With P&G,#N/A,#N/A,#N/A,#N/A, 1/28/2016 TEVVF-IL BW   Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine hydrochloride) Injection,#N/A,#N/A,#N/A, 6/16/2011 07CMVM-E BW   Epizyme Announces Participation in Boston Biotech CEO Conference and BIO International Convention,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/30/2015 DRNA-US  BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", 3/09/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2016 XLRN-US  BW   Acceleron Pharma to Participate in Two Healthcare Investor Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2014 GLYC-US  BW   BIO Elects New Board Members and Officers for the 2014-2015 Term,#N/A,#N/A,#N/A,12/12/2016 G6674U10 BW   Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2017 PBYI-US  BW   Caligor to Support Puma Biotechnology’s Expanded Access Program for PB272 (Neratinib) in the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/18/2016 00900T10 BW   Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/17/2013 009FRV-E BW   Quanterix Launches Multiplexed Single Molecule Immunoassay Technology to Improve Diagnosis and Potential Treatment of Complex Diseases,#N/A,#N/A,#N/A, 2/02/2011 30233G10 BW   pSivida Corp. Announces Second Quarter 2011 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 4/18/2017 0DM9XX-E BW   Axonics® to Present Results of the RELAX-OAB Clinical Study at the International Neuromodulation Society World Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/18/2015 LGND-US   BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A,12/01/2016 45232710    BW   Illumina Launches iHope Program to Identify Causes of Undiagnosed Genetic Diseases in Children, 2/22/2016 RY-CA     BW   Spectrum Pharmaceuticals to Present Corporate Update at 2016 RBC Capital Markets' Global Healthcare Conference on February 24,#N/A,"11/09/2016 ARWR-US  BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Arrowhead Pharmaceuticals, Inc. Investors",#N/A,#N/A,#N/A,#N/A, 9/08/2014 68375N10 BW   OPKO Licensee TESARO Submits New Drug Application for Rolapitant,#N/A,#N/A, 5/09/2017 ALXN-US  BW   Alexion to Present at the Bank of America Merrill Lynch 2017 Health Care Conference,#N/A, 9/08/2017 GMAB-DK     BW   Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress,#N/A, 7/18/2016 0085TV-E    BW   Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress," 4/14/2015 05FYVH-E BW   Mintz Levin Represents ImmunoGen, Inc. in $200 Million Transaction",#N/A, 7/25/2018 GILD-US      BW   Gilead Sciences Announces CEO John F. Milligan to Step Down,#N/A,#N/A, 5/11/2010 M2572210 BW   Compugen Discovers Drug Target for Treatment of Multiple Myeloma,#N/A, 7/12/2012 073NT1-E     BW   Lab21 among First to Offer FDA Approved Companion Diagnostic in the US,#N/A,#N/A,#N/A,#N/A, 3/29/2016 05156V10 BW   Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned,#N/A,#N/A,#N/A,#N/A," 1/23/2017 UGNEQ-US   BW   Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research",#N/A, 8/01/2017 INCY-US  BW   Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs,#N/A, 4/21/2014 80360710 BW   Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014, 2/24/2015 G0176710 BW   Alkermes Announces Results From Phase 1 Study of ALKS 7106,11/05/2015 CERS-US  BW   Cerus and OneBlood Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A, 5/30/2014 04269E10 BW   ArQule Announces Data Presentations with Tivantinib to Be Featured at ASCO 2014,#N/A,#N/A,12/07/2016 EXEL-US  BW   Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline," 1/14/2015 80105N10  BW   SNY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015"," 5/23/2017 VRTX-US   BW   BioAxone BioSciences CEO Lisa McKerracher Invited Speaker at the 12th Annual Neurotech Investing and Partnering Conference, Orphan Disease Panel",#N/A,#N/A,12/06/2016 BLUE-US  BW   bluebird bio Announces Proposed Public Offering of Common Stock, 1/06/2016 ACAD-US  BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A, 5/14/2016 TXMD-US  BW   TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial,#N/A,#N/A," 5/04/2016 OMER-US  BW   Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016",#N/A,#N/A, 2/18/2016 IRWD-US  BW   Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2016 0D059L-E BW   Syros Pharmaceuticals to Present Preclinical Data on SY-1425 and CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting,#N/A,#N/A, 3/11/2010 00182C10     BW   BioSante Announces Positive Leukemia Vaccine Results, 4/25/2015 29251M10   BW   Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress™ 2015, 3/06/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming March Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2015 AKBA-US  BW   Akebia Therapeutics Announces Additions to its Management Team,#N/A,#N/A,#N/A,#N/A,10/20/2016 SAGE-US     BW   Sage Therapeutics and Collaborators Publish New Pre-clinical Data in Neuropharmacology Demonstrating a Novel Metabotropic Mechanism of Sage Compounds Resulting in Enhanced Effects,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2010 56400P70 BW   MannKind Corporation Reports 2010 First Quarter Financial Results,#N/A,#N/A,#N/A, 6/24/2010 AMRS-US  BW   Amyris and M&G Finanziaria Enter Into Off-Take Agreement,#N/A,#N/A,#N/A,#N/A, 1/11/2016 EGRX-US  BW   Industry Veteran Sherry Korczynski Joins Eagle Pharmaceuticals as Senior Vice President of Marketing,#N/A,#N/A,#N/A," 4/27/2011 07CMVM-E BW   Epizyme Named #1 Nationwide in The Scientist's ""Best Places to Work – Industry 2011"" Survey",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2015 DRNA-US  BW   Dicerna to Present Advances in Conjugate Delivery Technology at Leerink Partners Rare Disease Roundtable, 3/09/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2016 XLRN-US  BW   Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A, 6/19/2014 38000Q10 BW   GlycoMimetics Initiates First Clinical Trial of GMI-1271 as Potential Treatment for Blood-Related Cancers,#N/A,#N/A,#N/A,"12/08/2016 G6674U10 BW   Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2017 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2016 00900T10 BW   Aimmune Therapeutics Announces Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/15/2013 009FRV-E BW   Paul Meister Joins Quanterix Board of Directors,#N/A,#N/A,#N/A, 1/24/2011 30233G10 BW   pSivida Completes Previously Announced Registered Direct Financing,#N/A,#N/A, 2/23/2017 0DM9XX-E BW   Axonics se voit accorder quatre brevets américains liés à sa technologie de neuromodulation sacrée implantable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/09/2015 LGND-US   BW   Ligand Reports Third Quarter 2015 Financial Results,#N/A,11/30/2016 YELP-US     BW   Splunk Customers Demonstrate Success on the AWS Cloud, 2/19/2016 SPPI-US   BW   Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation),#N/A,"11/09/2016 ARWR-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Arrowhead Pharmaceuticals, Inc. -- ARWR",#N/A,#N/A,#N/A,#N/A, 8/11/2014 68375N10 BW   OPKO Announces Second Quarter Operating and Financial Results,#N/A,#N/A, 4/27/2017 ALXN-US  BW   Alexion Reports First Quarter 2017 Results,#N/A, 9/06/2017 SGEN-US     BW   Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference,#N/A," 7/17/2016 080RQG-E    BW   SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency"," 4/09/2015 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2015 Financial Results",#N/A, 7/24/2018 GILD-US      BW   Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States,#N/A,#N/A," 5/03/2010 M2572210 BW   Compugen to Host Q&A Conference Call on Wednesday, May 5, 2010 at 10:00 AM EDT",#N/A, 7/03/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 3/18/2016 05156V10 BW   Aurinia Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Highlights,#N/A,#N/A,#N/A,#N/A, 1/09/2017 AERI-US    BW   Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland,#N/A, 7/20/2017 INCY-US  BW   Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease,#N/A," 3/26/2014 80360710 BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014"," 2/23/2015 ALKS-IE  BW   Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015","11/03/2015 CERS-US  BW   Cerus to Present at the Stephens 2015 Fall Investment Conference on November 10, 2015",#N/A, 5/29/2014 04269E10 BW   ArQule to Present at Jefferies Global Healthcare Conference,#N/A,#N/A,11/30/2016 EXEL-US  BW   Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14, 1/12/2015 80105N10  BW   Lieff Cabraser Reminds Sanofi Investors of Upcoming Deadline in Class Action Litigation - SNY, 5/22/2017 CNCE-US   BW   Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act,#N/A,#N/A,12/05/2016 BLUE-US  BW   bluebird bio Provides Updates on HSC Gene Therapy Programs, 1/05/2016 ACAD-US  BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 5/04/2016 TXMD-US  BW   TherapeuticsMD to Present at Two Upcoming Investor Conferences,#N/A,#N/A, 4/26/2016 OMER-US  BW   Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming Ophthalmology Congresses,#N/A,#N/A, 2/17/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 0D059L-E BW   Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer,#N/A,#N/A, 3/09/2010 00182C10     BW   BioSante Pharmaceuticals Closes $18 Million in Registered Direct Offering," 4/23/2015 062WH0-E   BW   Enanta Announces U.S. FDA Grants Priority Review for AbbVie’s Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection", 2/08/2018 SAN-FR    BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 AKBA-US  BW   Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 9/27/2016 06CR5C-E    BW   Sage Reports Additional Positive Data on Secondary Endpoints from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression at the Marcé Society for Perinatal Mental Health Biennial Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2010 56400P70 BW   MannKind to Present at Upcoming Conferences,#N/A,#N/A,#N/A, 6/22/2010 AMRS-US  BW   Amyris and Soliance Partner to Commercialize Renewable Bio-Sourced Cosmetics,#N/A,#N/A,#N/A,#N/A," 1/11/2016 EGRX-US  BW   Eagle Pharmaceuticals and AMRI Announce Agreement to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products",#N/A,#N/A,#N/A, 4/12/2011 07CMVM-E BW   Epizyme to Participate in Two Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2015 DRNA-US  BW   Dicerna to Present at the Leerink Partners Rare Disease Roundtable, 3/08/2018 15117K10 BW   Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2016 XLRN-US  BW   Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2014 38000Q10 BW   GlycoMimetics to Present at Jefferies Healthcare Conference,#N/A,#N/A,#N/A,11/18/2016 NVCR-GB  BW   Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2017 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2016 00900T10 BW   Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2013 06H8CC-E BW   Sony DADC Develops Smart Consumables for Quanterix Simoa HD-1 Analyzer,#N/A,#N/A,#N/A, 1/19/2011 30233G10 BW   pSivida Announces $10.75 Million Registered Direct Financing,#N/A,#N/A, 2/23/2017 0DM9XX-E BW   Axonics erhält vier amerikanische Patente für seine implantierbare sakrale Neuromodulationstechnologie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/20/2015 LGND-US   BW   Ligand to Report Third Quarter Results on November 9th,#N/A,11/28/2016 C-US        BW   Illumina to Webcast Live Presentation at the Citi Global Healthcare Conference, 2/04/2016 EGRX-US   BW   Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales,#N/A,11/08/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study,#N/A,#N/A,#N/A,#N/A, 8/11/2014 68375N10 BW   Rayaldee Phase 3 Trial Meets Primary Endpoints,#N/A,#N/A," 4/06/2017 ALXN-US  BW   Alexion to Report First Quarter 2017 Results on Thursday, April 27, 2017",#N/A, 8/29/2017 GMAB-DK     BW   Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors,#N/A, 7/05/2016 09062X10    BW   Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis," 4/01/2015 45253H10 BW   ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer",#N/A, 7/19/2018 0G47R8-E     BW   Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors,#N/A,#N/A, 4/27/2010 M2572210 BW   Compugen Reports First Quarter 2010 Financial Results,#N/A, 7/02/2012 NPSP-US      BW   NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen,#N/A,#N/A,#N/A,#N/A, 3/02/2016 06CR5C-E BW   Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis,#N/A,#N/A,#N/A,#N/A,12/23/2016 AERI-US    BW   Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%,#N/A, 7/11/2017 INCY-US  BW   Incyte to Report Second Quarter Financial Results,#N/A, 3/26/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference," 2/23/2015 G0176710 BW   Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development",11/02/2015 CERS-US  BW   Cerus Corporation Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma,#N/A, 5/07/2014 04269E10 BW   ArQule Reports First Quarter 2014 Financial Results,#N/A,#N/A,11/21/2016 PIPR-US  BW   Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29," 1/09/2015 80105N10  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sanofi To Contact Brower Piven Before The February 2, 2015 Lead Plaintiff Deadline In Class Action Lawsuit"," 5/19/2017 VRTX-US   BW   Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members",#N/A,#N/A,12/03/2016 BLUE-US  BW   bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting,12/15/2015 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors,#N/A,#N/A,#N/A, 5/03/2016 TXMD-US  BW   TherapeuticsMD Announces First Quarter 2016 Financial Results,#N/A,#N/A, 4/20/2016 OMER-US  BW   Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases,#N/A,#N/A, 2/04/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2015 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 0D059L-E BW   Syros Pharmaceuticals to Participate in Two Upcoming Conferences,#N/A,#N/A, 3/04/2010 00182C10     BW   BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering, 4/15/2015 29251M10   BW   Enanta Pharmaceuticals Announces AbbVie’s Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan, 2/05/2018 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming February Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/12/2015 AKBA-US  BW   AKBA SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Securities Laws by Akebia Thereapeutics, Inc.",#N/A,#N/A,#N/A,#N/A, 9/21/2016 SAGE-US     BW   Sage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/23/2010 56400P70 BW   MannKind Corporation to Hold 2010 First Quarter Financial Results Conference Call on April 30, 2010",#N/A,#N/A,#N/A, 6/22/2010 CSAN3-BR BW   Amyris and Cosan Creating Joint Venture for Production and Commercialization of Cane Based Renewable Chemicals,#N/A,#N/A,#N/A,#N/A,12/29/2015 EGRX-US  BW   Eagle Pharmaceuticals to Present at J.P. Morgan 34th Annual Healthcare Conference,#N/A,#N/A,#N/A, 3/17/2011 07CMVM-E BW   Epizyme to Present at MassBio Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/02/2015 DRNA-US  BW   Dicerna Pharmaceuticals Submits Investigational New Drug (IND) Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)", 3/08/2018 15117K10 BW   Cellectis : Servier et Pfizer présenteront les résultats des études chez l’homme d’UCART19 lors du 44e congrès annuel de l’EBMT (European Society for Blood and Marrow Transplantation),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/28/2016 XLRN-US  BW   Acceleron Pharma to Host First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2014 38000Q10 BW   GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial,#N/A,#N/A,#N/A,11/17/2016 NVCR-GB  BW   Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/02/2017 74587V10 BW   Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/05/2016 00900T10 BW   Aimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2013 009FRV-E BW   Quanterix Announces Commercial Availability of Its Simoa Single Molecule Array Technology,#N/A,#N/A,#N/A,12/23/2010 30233G10 BW   FDA Issues Complete Response Letter Regarding New Drug Application for ILUVIEN®,#N/A,#N/A, 2/23/2017 0DM9XX-E BW   Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/12/2015 LGND-US   BW   Ligand to Host Analyst Day on November 18th in New York City,#N/A,11/10/2016 063VST-E    BW   Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing," 1/29/2016 84763A10  BW   Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer",#N/A,11/01/2016 CS-CH    BW   Arrowhead Pharmaceuticals to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A, 8/07/2014 68375N10 BW   OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy,#N/A,#N/A," 3/27/2017 BXLT-US  BW   Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer",#N/A, 8/16/2017 SGEN-US     BW   FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma,#N/A," 6/21/2016 09062X10    BW   Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology"," 3/30/2015 45253H10 BW   ImmunoGen, Inc. Announces $200 Million Non-Dilutive Royalty Transaction",#N/A," 7/13/2018 GILD-US      BW   Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018",#N/A,#N/A, 4/22/2010 M2572210 BW   Compugen Announces New Drug Discovery Platform to Predict Peptides that Block Protein – Protein Interactions,#N/A, 6/26/2012 NPSP-US      BW   NPS Pharmaceuticals Launches Educational Website on Hypoparathyroidism,#N/A,#N/A,#N/A,#N/A, 2/29/2016 AUP-CA   BW   Aurinia Pharmaceuticals to Present at the 36th Annual Cowan Health Care Conference,#N/A,#N/A,#N/A,#N/A,12/19/2016 NOVN-CH    BW   Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer,#N/A, 6/07/2017 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A," 3/19/2014 80360710 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014", 2/17/2015 ALKS-IE  BW   Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results,"10/26/2015 CERS-US  BW   Cerus to Release Third Quarter 2015 Results on November 5, 2015",#N/A," 4/30/2014 04269E10 BW   ArQule to Report First Quarter 2014 Financial Results on May 7, 2014",#N/A,#N/A,11/07/2016 EXEL-US  BW   Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15, 1/09/2015 80105N10  BW   INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Glancy Binkow & Goldberg LLP, 5/18/2017 VRTX-US   BW   Vertex to Present at the UBS Healthcare Conference on May 23,#N/A,#N/A,12/02/2016 BLUE-US  BW   bluebird bio Announces Management Appointments,"11/30/2015 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development",#N/A,#N/A,#N/A, 4/19/2016 TXMD-US  BW   TherapeuticsMD to Host First Quarter 2016 Financial Results Conference Call and Webcast May 3,#N/A,#N/A, 4/07/2016 05KDBG-E BW   Omeros to Present at the 15th Annual Needham Healthcare Conference,#N/A,#N/A, 1/11/2016 IRWD-US  BW   Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2016 0D059L-E BW   Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing,#N/A,#N/A," 3/01/2010 00182C10     BW   BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies", 4/08/2015 29251M10   BW   Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015," 2/01/2018 ALNY-US   BW   Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2015 AKBA-US  BW   Akebia Announces Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/16/2016 SAGE-US     BW   Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/23/2010 56400P70 BW   Study Shows AFREZZA™ Controls Blood Sugar Levels in Type 1 Diabetes, Results in Weight Loss, Less Hypoglycemia Than Usual Care",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/24/2015 EGRX-US  BW   Eagle Pharmaceuticals Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula",#N/A,#N/A,#N/A, 3/10/2011 4523-JP  BW   Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/01/2015 00FQTC-E BW   Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board", 2/13/2018 15117K10 BW   Cellectis obtient deux brevets américains couvrant l’utilisation de CRISPR dans les cellules T,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2016 XLRN-US  BW   Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2014 38000Q10 BW   GlycoMimetics Announces Presentation of Rivipansel Data in Pediatric Patients at American Society of Pediatric Hematology Oncology 27th Annual Meeting,#N/A,#N/A,#N/A,11/14/2016 G6674U10 BW   Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2017 74587V10 BW   Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/21/2016 00900T10 BW   Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/29/2013 009FRV-E BW   Quanterix to Present Multiple Sessions at AACC Annual Meeting and Clinical Lab Expo,#N/A,#N/A,#N/A,11/16/2010 30233G10 BW   pSivida Corp. to Present at the Maxim Group Growth Conference,#N/A,#N/A, 1/05/2017 0DM9XX-E BW   Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/29/2015 LGND-US   BW   Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689,#N/A,11/07/2016 45232710    BW   Illumina Launches TruSight Tumor 170, 1/11/2016 84763A10  BW   Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada,#N/A,10/20/2016 06VHPT-E BW   Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®,#N/A,#N/A,#N/A,#N/A," 8/07/2014 68375N10 BW   OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014",#N/A,#N/A, 3/22/2017 ALXN-US  BW   Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG),#N/A, 8/01/2017 SGEN-US     BW   Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb,#N/A," 6/20/2016 09062X10    BW   Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016"," 3/23/2015 45253H10 BW   Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology",#N/A," 7/12/2018 0HZG24-E     BW   Gilead Receives Approval in Canada for BIKTARVY™ (bictegravir, emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection",#N/A,#N/A," 4/19/2010 M2572210 BW   Compugen First Quarter 2010 Webcast and Conference Call Scheduled for Tuesday, April 27, 2010 at 10:00 AM EDT",#N/A," 6/25/2012 07HG7X-E     BW   RMi’s IntelliScore™ Tracks Physician Response to Pharma Marketing Real-Time, Across All Channels",#N/A,#N/A,#N/A,#N/A, 2/11/2016 05156V10 BW   Aurinia to Host Conference Call & Webcast to Review Results from the AURION Study,#N/A,#N/A,#N/A,#N/A,12/07/2016 AERI-US    BW   Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,#N/A, 6/07/2017 BMY-US   BW   Les données provenant de l'essai clinique portant sur la combinaison d'Epacadostat et d' Opdivo® (nivolumab) démontrent des réponses cliniques durables chez les patients atteints d'un mélanome et d'un cancer...,#N/A, 2/27/2014 80360710 BW   Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments, 2/09/2015 G0176710 BW   Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis,10/21/2015 CERS-US  BW   Cerus Corporation Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits,#N/A," 4/02/2014 04269E10 BW   ArQule, Inc. to Present at Needham 13th Annual Healthcare Conference",#N/A,#N/A,11/07/2016 EXEL-US  BW   Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials, 1/06/2015 80105N10  BW   SHAREHOLDER ALERT: Investigation on Behalf of Investors of Sanofi Announced by Law Offices of Howard G. Smith, 5/17/2017 VRTX-US   BW   FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations,#N/A,#N/A,11/30/2016 BLUE-US  BW   bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma,"11/30/2015 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors",#N/A,#N/A,#N/A, 4/02/2016 TXMD-US  BW   TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) at ENDO 2016,#N/A,#N/A, 3/08/2016 06CR5C-E BW   Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA,#N/A,#N/A, 1/04/2016 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,"12/07/2015 0D059L-E BW   Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer",#N/A,#N/A, 2/22/2010 00182C10     BW   BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program, 3/03/2015 29251M10   BW   Enanta Pharmaceuticals to Present at Barclays Global Healthcare Conference, 2/01/2018 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/16/2015 06TNW4-E BW   Akebia to Present at the 2015 JMP Securities Life Sciences Conference ,#N/A,#N/A,#N/A,#N/A, 9/08/2016 SAGE-US     BW   Sage Therapeutics Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2010 56400P70 BW   Follow-up Safety Data Show AFREZZA™ Comparable to Standard Antidiabetic Therapy in Lung Function Tests,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2015 EGRX-US  BW   Eagle Pharmaceuticals Reports Successful Outcomes from Safety and Efficacy Study of RYANODEX for Exertional Heat Stroke,#N/A,#N/A,#N/A, 1/10/2011 07CMVM-E BW   Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 DRNA-US  BW   Dicerna Announces Second Quarter 2015 Financial and Operational Results, 2/13/2018 15117K10 BW   Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2016 XLRN-US  BW   Acceleron Pharma to Participate in Four Healthcare Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2014 38000Q10 BW   GlycoMimetics Reports First Quarter 2014 Results,#N/A,#N/A,#N/A,11/07/2016 G6674U10 BW   Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2017 74587V10 BW   Puma Biotechnology to Present at Cowen’s Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/13/2016 00900T10 BW   Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/13/2013 BIM-FR   BW   bioMérieux - Résultats annuels 2012,#N/A,#N/A,#N/A,"11/05/2010 30233G10 BW   pSivida Corp. Reports Results for the First Quarter Ended September 30, 2010",#N/A,#N/A,12/06/2016 0DM9XX-E BW   Axonics Announces First Fecal Incontinence Patients Implanted with Its Miniaturized Rechargeable Sacral Neuromodulation System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/02/2015 LGND-US   BW   Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia,#N/A,11/01/2016 45232710    BW   Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016,"12/16/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer",#N/A,10/06/2016 SBPH-US  BW   Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A, 7/22/2014 68375N10 BW   OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE,#N/A,#N/A, 3/08/2017 ALXN-US  BW   FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG),#N/A, 7/27/2017 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2017 Financial Results,#N/A, 6/09/2016 09062X10    BW   New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio," 3/19/2015 45253H10 BW   ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting 2015",#N/A," 7/09/2018 GILD-US      BW   Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy",#N/A,#N/A, 3/16/2010 M2572210 BW   Compugen Announces Discovery Platform to Predict Cell Penetrating Peptides for Drug Delivery,#N/A, 6/22/2012 4502-JP      BW   Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome,#N/A,#N/A,#N/A,#N/A, 2/08/2016 05156V10 BW   Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis,#N/A,#N/A,#N/A,#N/A,12/01/2016 C-US       BW   Aerie Pharmaceuticals to Participate in Two Investor Conferences in December,#N/A, 6/06/2017 BMY-US   BW   Daten aus klinischen Studien zu einer Kombination aus Epacadostat und Opdivo® (Nivolumab) belegen langlebige klinische Reaktionen bei Patienten mit Melanom und Kopf-Hals-Karzinom,#N/A, 2/20/2014 80360710 BW   Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare Conference, 2/03/2015 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences,10/06/2015 CERS-US  BW   Cerus and the Community Blood Center of the Carolinas Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A, 3/05/2014 04269E10 BW   ArQule Reports Fiscal 2013 Year End and Fourth Quarter Results,#N/A,#N/A,11/03/2016 EXEL-US  BW   Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update," 1/02/2015 80105N10  BW   SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Sanofi", 5/16/2017 VRTX-US   BW   X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration,#N/A,#N/A,11/14/2016 BLUE-US  BW   bluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium,11/05/2015 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A, 3/02/2016 TXMD-US  BW   TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences,#N/A,#N/A, 3/07/2016 OMER-US  BW   Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results,#N/A,#N/A,11/30/2015 4503-JP  BW   Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2015 0D059L-E BW   Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of First-in-Class Selective CDK7 Inhibitor in Models of Acute Leukemias,#N/A,#N/A," 2/18/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present LibiGel® Clinical Update at ISSWSH Conference"," 2/23/2015 29251M10   BW   Enanta Announces JAMA Publication of Results from AbbVie’s Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I)", 1/25/2018 ALNY-US   BW   Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2015 00972D10 BW   Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease at the 52nd ERA-EDTA Congress,#N/A,#N/A,#N/A,#N/A, 9/07/2016 SAGE-US     BW   Sage Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/29/2010 56400P70 BW   MannKind Corporation Achieves All Milestones of Research Agreement with Multiple Myeloma Research Foundation to Develop New Therapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2015 EGRX-US  BW   Eagle Pharmaceuticals Achieves Milestone to Receive $15 Million Payment for Approval of BENDEKA,#N/A,#N/A,#N/A, 1/06/2011 0844XQ-E BW   Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation Treatments,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/06/2015 DRNA-US  BW   EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)", 2/06/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2016 XLRN-US  BW   Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights,#N/A,#N/A,#N/A,#N/A,#N/A," 4/23/2014 38000Q10 BW   GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President, Corporate Development",#N/A,#N/A,#N/A,11/03/2016 06CR5C-E BW   United Healthcare Issues Positive Coverage Decision for Optune,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 74587V10 BW   Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2016 00900T10 BW   Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/22/2013 009FRV-E BW   Quanterix’s Ultrasensitive Simoa™ Technology Forges New Ground with Direct Detection of Genomic DNA in Human Blood and River Water,#N/A,#N/A,#N/A,"11/03/2010 30233G10 BW   pSivida Corp Awarded Two Therapeutic Discovery Project Grants Totaling $489,000",#N/A,#N/A, 9/26/2016 0DM9XX-E BW   Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/24/2015 LGND-US   BW   FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia,#N/A,10/28/2016 ILMN-US     BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm,"12/15/2015 SPPI-US   BW   TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers",#N/A, 9/07/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521,#N/A,#N/A,#N/A,#N/A, 7/09/2014 68375N10 BW   OPKO's Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe,#N/A,#N/A," 3/02/2017 ALXN-US  BW   Leonard Bell, M.D., Alexion’s Founder, Announces Plans to Retire as Chairman and Board Member",#N/A, 7/25/2017 SGEN-US     BW   Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression,#N/A, 6/07/2016 09062X10    BW   Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis," 2/24/2015 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference",#N/A," 6/29/2018 KITE-US      BW   European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy",#N/A,#N/A, 3/02/2010 M2572210 BW   Compugen Appoints Dr. Anat Cohen-Dayag as President and CEO Martin Gerstel to Reassume Chairman Post,#N/A," 6/20/2012 07G69B-E     BW   Research and Markets: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar",#N/A,#N/A,#N/A,#N/A, 2/04/2016 AUP-CA   BW   Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,11/03/2016 0CC2Z1-E   BW   Aerie Pharmaceuticals to Participate in Three Investor Conferences in November,#N/A, 6/05/2017 INCY-US  BW   La combinación de Epacadostat y Keytruda® (pembrolizumab) demuestra actividad en ensayo clínico de pacientes con cáncer de pulmón avanzado de células no pequeñas (NSCLC).,#N/A," 2/13/2014 80360710 BW   Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update on February 27, 2014", 1/07/2015 G0176710 BW   Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia," 9/10/2015 CERS-US  BW   Cerus to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 17, 2015",#N/A," 2/26/2014 04269E10 BW   ArQule to Report Fiscal 2013 Financial Results on March 5, 2014",#N/A,#N/A,"10/20/2016 EXEL-US  BW   Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016",12/30/2014 80105N10  BW   INVESTOR ALERT: Investigation on Behalf of Investors of Sanofi Announced by Glancy Binkow & Goldberg LLP, 5/04/2017 VRTX-US   BW   Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis,#N/A,#N/A,11/03/2016 06QBQ2-E BW   bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting,"11/04/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015",#N/A,#N/A,#N/A, 2/25/2016 TXMD-US  BW   TherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A, 3/03/2016 OMER-US  BW   Omeros to Present at the Cowen and Company 36th Annual Health Care Conference,#N/A,#N/A,11/30/2015 IRWD-US  BW   Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2015 0D059L-E BW   Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform,#N/A,#N/A, 2/16/2010 00182C10     BW   BioSante Pharmaceuticals Rated Among Top 15 Companies on The Biotechnology Patent Scorecard™ as published in The Wall Street Journal," 2/12/2015 29251M10   BW   Enanta Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C", 1/07/2018 ALNY-US   BW   Alnylam Announces 2018 Corporate Goals,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/26/2015 06TNW4-E BW   Akebia to Present at the Jefferies 2015 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 9/06/2016 06CR5C-E    BW   Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/24/2010 56400P70 BW   MannKind Corporation Wins Prestigious Frost & Sullivan Entrepreneurial Company of the Year Award,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2015 EGRX-US  BW   Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (bendamustine hydrochloride) Injection,#N/A,#N/A,#N/A,"11/23/2010 07CMVM-E BW   Epizyme Announces Oral Presentations at 52nd ASH Annual Meeting and Exposition in Orlando, Florida",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2015 DRNA-US  BW   Dicerna to Announce Second Quarter 2015 Financial Results and Host Conference Call on August 6, 2015", 2/06/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2016 XLRN-US  BW   Acceleron Pharma to Host Fourth Quarter and Year Ended 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2014 38000Q10 BW   GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease,#N/A,#N/A,#N/A,11/02/2016 G6674U10 BW   Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 74587V10 BW   Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2016 00900T10 BW   Aimmune Therapeutics to Present at Upcoming June Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2012 009FRV-E BW   Quanterix Issued Key Patent for Simoa™ Technology,#N/A,#N/A,#N/A,10/28/2010 30233G10 BW   pSivida Corp Announces First Quarter 2011 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 7/28/2016 0DM9XX-E BW   Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/04/2015 LGND-US   BW   Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer,#N/A,10/24/2016 45232710    BW   German Court Issues Preliminary Injunction Against amedes Fetalis® Test for Infringement of Non-Invasive Prenatal Screening Patent,"12/09/2015 SPPI-US   BW   Spectrum Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors",#N/A, 9/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT,#N/A,#N/A,#N/A,#N/A, 6/27/2014 68375N10 BW   OPKO Granted Patent from European Patent Office for Lagova™,#N/A,#N/A, 2/27/2017 RJF-US   BW   Alexion to Present at Upcoming Investor Conferences,#N/A, 7/24/2017 SGEN-US     BW   Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer,#N/A, 6/01/2016 080RQG-E    BW   Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program," 2/04/2015 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 6/25/2018 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection",#N/A,#N/A, 2/09/2010 M2572210 BW   Compugen Ltd. Reports Fourth Quarter and Calendar 2009 Financial Results,#N/A, 6/01/2012 NPSP-US      BW   NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day,#N/A,#N/A,#N/A,#N/A, 2/02/2016 05156V10 BW   Aurinia Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,11/02/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update,#N/A, 6/05/2017 INCY-US  BW   Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017,#N/A, 2/10/2014 80360710 BW   Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate, 1/06/2015 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference," 9/02/2015 CERS-US  BW   Cerus to Present at the Baird 2015 Healthcare Conference on September 9, 2015",#N/A," 2/18/2014 04269E10 BW   ArQule, Inc. to Present at RBC Capital Markets Healthcare Conference",#N/A,#N/A,10/10/2016 078V1F-E BW   Ipsen & Exelixis: résultats positifs ph2 CABOSUN cabozantinib vs sunitinib carcinome avancé du rein à l'ESMO 2016,12/22/2014 80105N10  BW   Lieff Cabraser Announces Class Action Litigation Against Sanofi – SNY, 4/27/2017 VRTX-US   BW   Vertex Reports First-Quarter 2017 Financial Results,#N/A,#N/A,11/02/2016 BLUE-US  BW   bluebird bio Reports Third Quarter 2016 Financial Results and Recent Operational Progress,11/02/2015 ACAD-US  BW   ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 2/18/2016 TXMD-US  BW   TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting,#N/A,#N/A," 3/02/2016 OMER-US  BW   Omeros Corporation to Announce Fourth Quarter and Year-End 2015 Financial Results on March 8, 2016",#N/A,#N/A,11/04/2015 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 0D059L-E BW   Syros Pharmaceuticals to Present Preclinical Data on First-in-Class Selective CDK7 Inhibitor Program at American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A," 2/09/2010 00182C10     BW   BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs", 2/05/2015 29251M10   BW   Enanta Pharmaceuticals to Present at 2015 Leerink Global Healthcare Conference, 1/07/2018 ALNY-US   BW   Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/26/2015 00972D10 BW   Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress,#N/A,#N/A,#N/A,#N/A, 8/30/2016 SAGE-US     BW   Sage Therapeutics and Collaborators Announce Publication Highlighting Epidemiology and Burden of Illness for Super-Refractory Status Epilepticus in Journal of Medical Economics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/15/2010 56400P70 BW   FDA Requests Additional Information Regarding AFREZZA™ in Complete Response Letter to MannKind,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/23/2015 EGRX-US  BW   Eagle Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference,#N/A,#N/A,#N/A,11/15/2010 07CMVM-E BW   Epizyme Publication Identifies Novel Opportunity for Treatment of Genetically-Defined Human B-cell Lymphomas,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/01/2015 25303110 BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", 1/08/2018 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2016 XLRN-US  BW   Acceleron Pharma to Participate in Two Healthcare Investor Conferences in February,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2014 38000Q10 BW   GlycoMimetics Presents Data on Its E-Selectin Antagonist at American Association for Cancer Research Annual Meeting 2014,#N/A,#N/A,#N/A,11/01/2016 G6674U10 BW   Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2017 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2016 00900T10 BW   Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/20/2010 30233G10 BW   pSivida Ranked 15th on 2010 Technology Fast 500™, Deloitte’s Ranking of Fastest Growing Companies in North America",#N/A,#N/A, 6/20/2016 0DM9XX-E BW   Axonics Announces First Patients Treated in Sacral Neuromodulation Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/04/2015 LGND-US   BW   Ligand Reports Second Quarter 2015 Financial Results,#N/A,10/24/2016 IQV-US      BW   Q2 Solutions Enhances Companion Diagnostics Capabilities in Collaboration with Illumina,12/08/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Four Abstracts on SPI-2012 and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS),#N/A, 9/01/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming September Conferences,#N/A,#N/A,#N/A,#N/A, 6/25/2014 68375N10 BW   Strong Data from Lagova™ Phase II Clinical Study Presented during Webcast,#N/A,#N/A, 2/16/2017 ALXN-US  BW   Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017,#N/A," 7/06/2017 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017",#N/A, 5/31/2016 080RQG-E    BW   Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy," 1/30/2015 45253H10 BW   ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results",#N/A, 6/11/2018 GILD-US      BW   Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia,#N/A,#N/A, 2/02/2010 M2572210 BW   Compugen Discovers Novel Protein for Treatment of Autoimmune Diseases,#N/A, 5/31/2012 0C8BZH-E     BW   RBCC Anticipates Favorable Test Results of New Brain Injury Treatment,#N/A,#N/A,#N/A,#N/A, 1/29/2016 05156V10 BW   Aurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day,#N/A,#N/A,#N/A,#N/A,10/27/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of RhopressaTM (netarsudil ophthalmic solution) 0.02%,#N/A, 6/05/2017 BMY-US   BW   Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer,#N/A, 2/05/2014 80360710 BW   Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy, 1/06/2015 G0176710 BW   Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder, 8/06/2015 CERS-US  BW   Cerus Corporation Reports Second Quarter 2015 Results,#N/A," 2/05/2014 04269E10 BW   ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference",#N/A,#N/A,10/10/2016 IPSEY-FR BW   Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Society for Medical Oncology (ESMO) 2016 Congress,"12/16/2014 80105N10  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sanofi To Contact Brower Piven Before The February 2, 2015 Lead Plaintiff Deadline In Class Action Lawsuit", 4/12/2017 VRTX-US   BW   Vertex to Announce First Quarter 2017 Financial Results on April 27,#N/A,#N/A,11/01/2016 BLUE-US  BW   bluebird bio to Present at Two Investor Conferences in November,"10/29/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015",#N/A,#N/A,#N/A, 2/11/2016 TXMD-US  BW   TherapeuticsMD to Host Fourth Quarter and Year End 2015 Financial Results,#N/A,#N/A, 2/24/2016 OMER-US  BW   Physicians Increasingly Seek Access to OMS721 Compassionate Use Program,#N/A,#N/A,11/03/2015 IRWD-US  BW   Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2015 0D059L-E BW   Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors,#N/A,#N/A," 2/03/2010 00182C10     BW   BioSante Pharmaceuticals, Inc. To Present At BIO CEO & Investor Conference"," 2/05/2015 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2014", 1/04/2018 ALNY-US   BW   Alnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2015 06TNW4-E BW   Akebia to Present at the 2015 UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 8/09/2016 SAGE-US     BW   Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2010 56400P70 BW   MannKind Elects James S. Shannon to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2015 EGRX-US  BW   Eagle Pharmaceuticals to Present at November Conferences,#N/A,#N/A,#N/A,"11/03/2010 07CMVM-E BW   Epizyme Awarded $733,000 Grant under Qualified Therapeutic Discovery Project Program",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/19/2015 0098J6-E BW   Dicerna to Present at the JMP Securities Life Sciences Conference 2015, 1/08/2018 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2016 XLRN-US  BW   Acceleron Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 4/01/2014 38000Q10 BW   GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair,#N/A,#N/A,#N/A, 9/19/2016 G6674U10 BW   CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2017 74587V10 BW   Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2016 AIMT-US  BW   Aimmune Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/22/2010 30233G10 BW   pSivida Corp. Reports Fourth Quarter and Fiscal Year 2010 Financial Results,#N/A,#N/A, 6/06/2016 0DM9XX-E BW   Axonics Receives CE Mark for its Sacral Neuromodulation System for the Treatment of Urinary and Fecal Dysfunction,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/30/2015 LGNZZ-US  BW   Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844,#N/A,10/21/2016 ILMN-US     BW   IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Illumina Inc. and Encourages Investors with Losses to Contact the Firm,12/06/2015 SPPI-US   BW   Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq®) and Standard CHOP,#N/A, 8/12/2016 0677K4-E BW   Arrowhead Pharmaceuticals Closes $45 Million Private Offering,#N/A,#N/A,#N/A,#N/A, 6/23/2014 68375N10 BW   OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder,#N/A,#N/A," 1/26/2017 ALXN-US  BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results on Thursday, February 16, 2017",#N/A, 6/28/2017 4502-JP     BW   A Takeda e a Seattle Genetics anunciam resultados positivos obtidos do ensaio clínico de Fase 3 do ECHELON-1 que analisa o ADCETRIS® (brentuximabe vedotina) no tratamento de primeira linha com linfoma de Hodgkin (LH) avançado,#N/A," 5/30/2016 071VWR-E    BW   FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union"," 1/21/2015 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2015 Financial Results",#N/A, 6/04/2018 GILD-US      BW   Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy,#N/A,#N/A," 2/02/2010 M2572210 BW   Compugen Ltd. to Review Fourth Quarter and Year-End 2009 Financial Results on Tuesday, February 9, 2010",#N/A," 5/30/2012 00B8PL-E     BW   Six Months Post-Launch, Trial and Usage of Orencia SC is Continuing to Increase, Yet It is Still Viewed as a Second-Line Therapy After Anti-TNF Agents for Rheumatoid Arthritis Based on a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A, 1/19/2016 05156V10 BW   Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis,#N/A,#N/A,#N/A,#N/A,"10/25/2016 AERI-US    BW   Aerie Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016",#N/A, 6/05/2017 INCY-US  BW   Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types,#N/A," 1/30/2014 80360710 BW   Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc.,",12/15/2014 G0176710 BW   Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia," 8/04/2015 CERS-US  BW   Cerus to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 11, 2015",#N/A, 2/04/2014 04269E10 BW   ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan,#N/A,#N/A,10/10/2016 EXEL-US  BW   Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016,"12/08/2014 80105N10  BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Sanofi", 4/06/2017 IRWD-US   BW   Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer,#N/A,#N/A,10/13/2016 BLUE-US  BW   bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day," 9/22/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015",#N/A,#N/A,#N/A," 1/25/2016 TXMD-US  BW   VitaMedMD Launches VitaTrue™, the First Certified Vegan and Kosher Prescription Prenatal Multivitamin",#N/A,#N/A, 1/15/2016 OMER-US  BW   Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference,#N/A,#N/A,11/03/2015 IRWD-US  BW   Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2015 0D059L-E BW   FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015,#N/A,#N/A,#N/A, 2/02/2015 29251M10   BW   Enanta Announces 95 percent SVR12 rate in AbbVie’s Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients, 1/02/2018 ALNY-US   BW   Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2015 00972D10 BW   Akebia Announces First Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A, 8/03/2016 SAGE-US     BW   Sage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2010 56400P70 BW   MannKind to Present at the 12th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/11/2015 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results",#N/A,#N/A,#N/A, 7/16/2010 07CMVM-E BW   Epizyme Scientists Detail Epigenetic Approaches to Cancer Therapy in Drug Discovery Today: Therapeutic Strategies and Current Opinion in Chemical Biology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2015 0098J6-E BW   Dicerna Responds to Alnylam Complaint, 1/03/2018 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 XLRN-US  BW   Acceleron Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 3/31/2014 38000Q10 BW   GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results,#N/A,#N/A,#N/A, 9/15/2016 G6674U10 BW   Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2017 74587V10 BW   Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2016 00900T10 BW   Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2010 30233G10 BW   pSivida Corp Announces Fourth Quarter and Fiscal Year 2010 Financial Results Release Date and Conference Call Information,#N/A,#N/A, 5/09/2016 0DM9XX-E BW   Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 7/24/2015 LGND-US   BW   Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder",#N/A,"10/21/2016 ILMN-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Illumina Inc.","12/04/2015 SPPI-US   BW   Spectrum Pharmaceuticals Highlights 18 Abstracts at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015",#N/A, 8/09/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 6/19/2014 68375N10 BW   OPKO to Hold Conference Call to Discuss Six Month Data from Phase 2 hGH-CTP Trial,#N/A,#N/A," 1/13/2017 ALXN-US  BW   ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Alexion Pharmaceuticals, Inc. – (ALXN)",#N/A, 6/28/2017 4502-JP     BW   Takeda y Seattle Genetics anuncian resultados positivos del ensayo clínico de fase 3 ECHELON-1 que estudia el tratamiento de primera línea con ADCETRIS® (brentuximab vedotina) en pacientes con linfoma de Hodgkin avanzado,#N/A, 5/27/2016 09062X10    BW   Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis," 1/11/2015 45253H10 BW   ImmunoGen, Inc. Announces 2015 Outlook for Product Pipeline",#N/A, 6/04/2018 KITE-US      BW   Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors,#N/A,#N/A,#N/A,#N/A, 5/29/2012 0C8BZH-E     BW   RBCC: Cure for Traumatic Brain Injury May be in Sight,#N/A,#N/A,#N/A,#N/A,11/24/2015 AUP-CA   BW   Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned,#N/A,#N/A,#N/A,#N/A," 9/28/2016 AERI-US    BW   Aerie Pharmaceuticals to Host Investor Day on October 5, 2016",#N/A, 6/04/2017 INCY-US  BW   Kombination aus Epacadostat plus Keytruda® (Pembrolizumab) zeigt Aktivität in klinischer Studie mit Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkrebs (NSCLC),#N/A, 1/15/2014 80360710 BW   Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy,11/25/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at The NASDAQ OMX 31st Investor Program, 7/21/2015 CERS-US  BW   Cerus and Unyts Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A, 1/16/2014 04269E10 BW   ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib,#N/A,#N/A,"10/07/2016 000KXY-E BW   Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress",12/03/2014 80105N10  BW   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi – SNY, 3/28/2017 VRTX-US   BW   Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis,#N/A,#N/A,"10/06/2016 BLUE-US  BW   bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation", 9/03/2015 ACAD-US  BW   ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer,#N/A,#N/A,#N/A, 1/13/2016 TXMD-US  BW   TherapeuticsMD to Present at Noble Financial Capital Markets’ NobleCon12,#N/A,#N/A, 1/06/2016 OMER-US  BW   Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team,#N/A,#N/A,11/02/2015 IRWD-US  BW   Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2015 0D059L-E BW   Syros Pharmaceuticals Announces New Publication Highlighting the Strong Potential of CDK7 Inhibition in Difficult-to-Treat Cancer,#N/A,#N/A,#N/A, 1/16/2015 29251M10   BW   Enanta Announces European Commission Grants Marketing Authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)...,12/28/2017 ALNY-US   BW   Alnylam to Webcast Presentation at Goldman Sachs Healthcare CEOs Unscripted Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/22/2015 00972D10 BW   Akebia Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A," 8/02/2016 SAGE-US     BW   Sage Therapeutics to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2010 56400P70 BW   MannKind Corporation Reports 2009 Fourth Quarter and Full Year Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2015 EGRX-US  BW   Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement,#N/A,#N/A,#N/A," 5/14/2010 07CMVM-E BW   Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2015 25303110 BW   Dicerna Presents Preliminary Safety and Efficacy Data from DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting, 1/02/2018 15117K10 BW   Cellectis participera à la 36e conférence annuelle healthcare de J.P. Morgan avec une présentation le 8 janvier 2018,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2015 CELG-US  BW   Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2014 38000Q10 BW   GlycoMimetics Announces Sudden Passing of Board Director and Audit Committee Member William Gust,#N/A,#N/A,#N/A, 9/14/2016 G6674U10 BW   Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/09/2017 PBYI-US  BW   Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2016 00900T10 BW   Aimmune Therapeutics Appoints Douglas Sheehy as General Counsel and Secretary,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2010 30233G10 BW   pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference,#N/A,#N/A,12/21/2015 0DM9XX-E BW   Axonics Modulation Technologies Announces $38.5 Million Series B Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/16/2015 LGND-US   BW   Ligand to Report Second Quarter Results on August 4th,#N/A,10/20/2016 ILMN-US     BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm,11/20/2015 SPPI-US   BW   Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug (IND) Application for Poziotinib,#N/A, 8/09/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Prices $45 Million Private Offering,#N/A,#N/A,#N/A,#N/A, 5/28/2014 68375N10 BW   OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference,#N/A,#N/A, 1/09/2017 06CR5C-E BW   Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG),#N/A, 6/27/2017 4502-JP     BW   Takeda und Seattle Genetics geben positive Ergebnisse aus der klinischen Echelon-1-Studie der Phase 3 zur Evaluierung von ADCETRIS® (Brentuximab Vedotin) zur Erstbehandlung des fortgeschrittenen Hodgkin-Lymphoms bekannt,#N/A, 5/27/2016 09062X10    BW   Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis,"12/22/2014 45253H10 BW   ImmunoGen, Inc. Appoints Richard J. Gregory, Ph.D. as EVP, Chief Scientific Officer; John M. Lambert, Ph.D. Named EVP, Distinguished Research Fellow",#N/A, 6/04/2018 KITE-US      BW   Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting,#N/A,#N/A,#N/A,#N/A, 5/23/2012 061NC9-E     BW   The Avoca Group Holds Quality Summit to Debate Adoption of Quality Standards,#N/A,#N/A,#N/A,#N/A,11/13/2015 05156V10 BW   Aurinia Reports Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/16/2016 0032QC-E   BW   Aerie Pharmaceuticals Raises $125 Million in Public Offerings,#N/A, 6/04/2017 INCY-US  BW   Combinatie van epacadostat plus Keytruda® (pembrolizumab) demonstreert activiteit bij klinische proef van patiënten met gevorderde niet-kleincellige longkanker (NSCLC),#N/A," 1/09/2014 80360710 BW   Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer",11/04/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference, 7/13/2015 CERS-US  BW   Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A,11/07/2013 04269E10 BW   ArQule Announces Third Quarter Fiscal 2013 Results,#N/A,#N/A,10/07/2016 EXEL-US  BW   Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors,12/03/2014 003ZHQ-E  BW   First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval, 3/06/2017 VRTX-US   BW   Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis,#N/A,#N/A, 9/29/2016 BLUE-US  BW   bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy, 9/03/2015 ACAD-US  BW   ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 1/12/2016 TXMD-US  BW   TherapeuticsMD Announces Closing of Common Stock Offering,#N/A,#N/A,"11/08/2012 05MTSP-E BW   The Law Firm of Davis Wright Tremaine Announces That Richard Klein, Former CFO of Seattle Biopharmaceutical Company Omeros Corp., Receives $3.9 Million to Settle Whistleblower Suit",#N/A,#N/A,10/19/2015 IRWD-US  BW   Ironwood Highlights Refractory GERD and Constipation Research at the American College of Gastroenterology 2015 Annual Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2015 0D059L-E BW   Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform,#N/A,#N/A,#N/A, 1/07/2015 29251M10   BW   Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference,12/18/2017 SAN-FR    BW   Alnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2015 00972D10 BW   Akebia Therapeutics Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 7/26/2016 SAGE-US     BW   Gupshup Partners with Sage to Launch Spreadsheet-Killing Accounting Bot,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/25/2010 56400P70 BW   MannKind Corporation to Hold 2009 Fourth Quarter and Full Year Financial Results Conference Call on February 1, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/29/2015 EGRX-US  BW   Eagle Pharmaceuticals to Discuss Third Quarter 2015 Financial Results on November 11, 2015",#N/A,#N/A,#N/A," 3/24/2010 07CMVM-E BW   Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2015 25303110 BW   Dicerna to Present at the Jefferies 2015 Healthcare Conference," 1/02/2018 15117K10 BW   Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2015 CELG-US  BW   FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2014 38000Q10 BW   GlycoMimetics to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A, 9/12/2016 NVCR-GB  BW   Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2017 74587V10 BW   Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2016 00900T10 BW   Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2010 30233G10 BW   pSivida Announces Iluvien® Receives FDA Priority Review for Treatment of Diabetic Macular Edema,#N/A,#N/A,12/02/2015 0DM9XX-E BW   Axonics Announces Presentation of Study on Cost Savings Associated with Rechargeable Neuromodulation Devices for the Treatment of Overactive Bladder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/17/2015 53220K50  BW   Ligand to Participate in Four Upcoming Investor Conferences,#N/A,10/20/2016 09WJ1Y-E    BW   Illumina Contributes to ClinVar Database,11/18/2015 84763A10  BW   Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma,#N/A, 8/01/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 5/22/2014 68375N10 BW   OPKO Completes Acquisition of Inspiro Medical Ltd.,#N/A,#N/A," 1/07/2017 ALXN-US  BW   DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm",#N/A, 6/27/2017 4502-JP     BW   Takeda et Seattle Genetics annoncent les résultats positifs de l'étude clinique ECHELON-1 de Phase 3 d'évaluation d'ADCETRIS® (brentuximab vedotin) dans le traitement de première ligne du lymphome hodgkinien avancé,#N/A," 5/27/2016 BIIB-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Biogen Inc.",12/19/2014 45253H10 BW   ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial,#N/A, 5/30/2018 GILD-US      BW   Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis,#N/A,#N/A,#N/A,#N/A," 5/23/2012 060RWY-E     BW   Since the Dialysis Bundle Legislation Was Implemented in January 2011, Bundling Appears to Have Limited Impact on Medications Used for Dialysis Patients According to a Recent BioTrends Chart Study",#N/A,#N/A,#N/A,#N/A,10/19/2015 05156V10 BW   Aurinia Pharmaceuticals to Present at the 14th Annual BIO Investor Forum,#N/A,#N/A,#N/A,#N/A, 9/15/2016 AERI-US    BW   Aerie Pharmaceuticals Announces Public Offering of Common Stock,#N/A, 6/03/2017 INCY-US  BW   Une combinaison d'epacadostat et de Keytruda® (pembrolizumab) fait état d'une activité dans un essai clinique pour les patients atteints de cancer du poumon non à petites cellules avancé (CPNPC),#N/A, 2/05/2013 80360710 BW,10/29/2014 G0176710 BW   Alkermes plc Reports Third Quarter 2014 Financial Results," 7/06/2015 15708510 BW   Cerus to Release Second Quarter 2015 Results on August 6, 2015",#N/A,"10/31/2013 04269E10 BW   ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013",#N/A,#N/A,"10/05/2016 00CLKM-E BW   CABOMETYXTM (Cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, Available at Biologics, Inc.",11/21/2014 003ZHQ-E  BW   European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules, 3/02/2017 VRTX-US   BW   Vertex to Present at the Cowen Healthcare Conference on March 6,#N/A,#N/A, 9/21/2016 080RQG-E BW   LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program, 8/06/2015 ACAD-US  BW   ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A, 1/07/2016 TXMD-US  BW   TherapeuticsMD Announces Pricing of $125 Million Common Stock Offering,#N/A,#N/A," 3/28/2012 06T0MQ-E BW   Accelerator Corporation Names David McElligott, Ph.D. as Chief Scientific Officer",#N/A,#N/A,10/14/2015 IRWD-US  BW   Ironwood Pharmaceuticals to Host Third Quarter 2015 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2015 0D059L-E BW   Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer,#N/A,#N/A,#N/A,12/19/2014 29251M10   BW   Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus,12/15/2017 0721RM-E  BW   FDA Lifts Clinical Hold on Fitusiran,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2015 06TNW4-E BW   Akebia Therapeutics Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A, 7/19/2016 SAGE-US     BW   Sage Appoints Geno Germano to Company's Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 EGRX-US  BW   Eagle Pharmaceuticals Successfully Completes Clinical Treatment Portion of Its Safety and Efficacy Study of Ryanodex for Exertional Heat Stroke,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2015 25303110 BW   Dicerna Announces Pricing of Follow-On Offering of Common Stock,12/12/2017 15117K10 BW   Servier et Pfizer publient des résultats préliminaires de deux essais cliniques de Phase I indiquant un taux élevé de rémission complète obtenus avec UCART19 dans le traitement de la leucémie aigue lymphoblastique de l’adulte et de l’enfant,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2015 CELG-US  BW   Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2014 38000Q10 BW   GlycoMimetics to Present GMI-1271 Research Findings at AACR Annual Meeting 2014,#N/A,#N/A,#N/A, 9/01/2016 G6674U10 BW   International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2017 JPM-US   BW   Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 00900T10 BW   Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2010 30233G10 BW   pSivida Added to Russell Microcap Index,#N/A,#N/A, 5/20/2015 0DM9XX-E BW   Axonics to Present its Sacral Neuromodulation System at the International Neuromodulation Society 12th World Congress in Montreal,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/12/2015 LGND-US   BW   FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication,#N/A,10/10/2016 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016,"11/04/2015 SPPI-US   BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Strongly Encourages Shareholders to Contact the Firm",#N/A, 7/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 5/20/2014 68375N10 BW   Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at the 2014 ICE/ENDO Meeting,#N/A,#N/A, 1/06/2017 06CR5C-E BW   FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 6/26/2017 4502-JP     BW   Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma,#N/A, 5/19/2016 09062X10    BW   Biogen Announces Webcast of Virtual Annual Meeting of Stockholders,"12/15/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare Conference",#N/A," 5/30/2018 GILD-US      BW   Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13",#N/A,#N/A,#N/A,#N/A, 5/21/2012 09LDY4-E     BW   Early and Late Stage Innovators and Investors Meet at C21 BioVentures in Napa Valley,#N/A,#N/A,#N/A,#N/A, 9/17/2015 05156V10 BW   Aurinia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus,#N/A,#N/A,#N/A,#N/A, 9/14/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results,#N/A, 6/03/2017 INCY-US  BW   Dimostrata l'attività della combinazione di epacadostat più Keytruda® (pembrolizumab) in uno studio clinico su pazienti con carcinoma polmonare non a piccole cellule (NSCLC) in fase avanzata,#N/A,10/03/2012 0731W3-E BW   Duchenne Muscular Dystrophy Is Closer to a Treatment With New Results From Sarepta Therapeutics; Cure Duchenne Early Supporter of Study,10/22/2014 ALKS-IE  BW   Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results," 7/01/2015 CERS-US  BW   Cerus to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference on July 8, 2015",#N/A, 7/30/2013 04269E10 BW   ArQule Reports Second Quarter 2013 Financial Results,#N/A,#N/A,10/03/2016 EXEL-US  BW   Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress,11/18/2014 80105N10  BW   Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association, 1/25/2017 VRTX-US   BW   Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results,#N/A,#N/A, 9/09/2016 BLUE-US  BW   bluebird bio Announces Webcast of Gene Therapy Day, 8/06/2015 ACAD-US  BW   ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association,#N/A,#N/A,#N/A, 1/05/2016 TXMD-US  BW   TherapeuticsMD Announces $125 Million Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2015 IRWD-US  BW   Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 0D059L-E BW   Syros Pharmaceuticals to Participate in September Investor Conferences,#N/A,#N/A,#N/A,12/15/2014 29251M10   BW   Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index,12/12/2017 ALNY-US   BW   Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2015 00972D10 BW   Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease at the International Society of Nephrology’s World Congress of Nephrology,#N/A,#N/A,#N/A,#N/A, 7/12/2016 SAGE-US     BW   Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2015 EGRX-US  BW   Eagle Pharmaceuticals Receives New Patent for Bendamustine Rapid Infusion Product,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2015 25303110 BW   Dicerna Announces Follow-On Public Offering of Common Stock,12/12/2017 15117K10 BW   Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/01/2015 XLRN-US  BW   Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting",#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2014 38000Q10 BW   GlycoMimetics to Present at BIO CEO & Investor Conference,#N/A,#N/A,#N/A, 8/16/2016 G6674U10 BW   Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2016 74587V10 BW   Puma Biotechnology to Move Stock Exchange Listing to Nasdaq,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2016 BCS-GB   BW   Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2010 30233G10 BW   pSivida Announces Submission of Marketing Authorization Application for an Ophthalmic Product for Diabetic Macular Edema In Certain European Union Countries,#N/A,#N/A, 3/25/2014 0DM9XX-E BW   Axonics Modulation Technologies Announces $32.6 Million Series A Financing Led by Edmond De Rothschild Investment Partners,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/07/2015 LGND-US   BW   Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial,#N/A, 9/21/2016 009FRV-E    BW   Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016,11/04/2015 EGRX-US   BW   Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement,#N/A, 6/09/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521,#N/A,#N/A,#N/A,#N/A, 5/19/2014 68375N10 BW   OPKO Presents 4Kscore™ Test Clinical Study at the American Urological Association Plenary Session,#N/A,#N/A, 1/05/2017 ALXN-US  BW   Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference,#N/A, 6/20/2017 SGEN-US     BW   Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma,#N/A, 5/16/2016 05H9RB-E    BW   Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs,"12/06/2014 45253H10 BW   ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition",#N/A, 5/30/2018 PFE-US       BW   Allogene Therapeutics Announces Board of Directors,#N/A,#N/A,#N/A,#N/A," 5/21/2012 060RWY-E     BW   For Moderate to Severe Psoriasis, Surveyed U.S. Dermatologists Would Accept a Substantial Decrease in Efficacy Compared with Enbrel in Order to Have an Oral Therapy with a Lower Rate of Serious Infection and Comparable Safety Profile",#N/A,#N/A,#N/A,#N/A, 9/02/2015 05156V10 BW   Aurinia Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A, 9/06/2016 06CR5C-E   BW   Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,#N/A, 6/03/2017 INCY-US  BW   Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC),#N/A,10/01/2012 GRST-CA  BW   GreeneStone Muskoka Once Again Featured on Intervention Canada,10/22/2014 G0176710 BW   Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA, 6/29/2015 15708510 BW   First INTERCEPT Pathogen Reduced Platelet Units Produced in the Continental US,#N/A," 7/23/2013 04269E10 BW   ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013",#N/A,#N/A, 9/26/2016 EXEL-US  BW   Exelixis Elects Julie Anne Smith to Its Board of Directors,11/14/2014 003ZHQ-E  BW   Genzyme’s Lemtrada Approved by the FDA," 1/11/2017 MRK-DE    BW   Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex",#N/A,#N/A, 9/08/2016 BLUE-US  BW   bluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia," 8/05/2015 ACAD-US  BW   ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development",#N/A,#N/A,#N/A,"12/07/2015 TXMD-US  BW   TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR",#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2015 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 0D059L-E BW   Syros Pharmaceuticals to Participate in August Investor Conferences,#N/A,#N/A,#N/A,"11/24/2014 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2014",12/11/2017 ALNY-US   BW   Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/11/2015 00972D10 BW   Akebia to Host Conference Call and Slide Webcast Following Presentation of AKB-6548 Phase 2b Study Results at International Society of Nephrology’s World Congress of Nephrology,#N/A,#N/A,#N/A,#N/A, 6/07/2016 SAGE-US     BW   Sage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-217,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/11/2015 EGRX-US  BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2015 Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2015 25303110 BW   Dicerna Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs),"12/04/2017 15117K10 BW   Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2015 XLRN-US  BW   Acceleron Pharma to Present at Piper Jaffray 27th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 1/15/2014 38000Q10 BW   GlycoMimetics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A, 8/08/2016 NVCR-GB  BW   Novocure to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2016 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/25/2016 00900T10 BW   Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2010 30233G10 BW   pSivida Announces Submission of NDA to FDA for an Ophthalmic Product for Diabetic Macular Edema,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/05/2015 53220K50  BW   Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions,#N/A, 8/30/2016 MS-US       BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference,11/04/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Pipeline Update,#N/A, 6/03/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference,#N/A,#N/A,#N/A,#N/A," 5/19/2014 68375N10 BW   Senesco Completes Acquisition of Fabrus, An OPKO Portfolio Company",#N/A,#N/A, 1/04/2017 ALXN-US  BW   Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016,#N/A, 6/19/2017 SGEN-US     BW   Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia,#N/A, 5/13/2016 071VWR-E    BW   Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B,"11/24/2014 45253H10 BW   ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition",#N/A," 5/30/2018 GILD-US      BW   China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection",#N/A,#N/A,#N/A,#N/A, 5/18/2012 EMC-US       BW   Reveille Software Announces Support for EMC Documentum D2 and EMC Documentum Mobile,#N/A,#N/A,#N/A,#N/A, 8/11/2015 05156V10 BW   Aurinia Reports Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A, 8/04/2016 09QXDQ-E   BW   Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,#N/A, 6/03/2017 INCY-US  BW   Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC),#N/A, 7/24/2012 0731W3-E BW   Cure Duchenne Supported Sarepta Therapeutics Research Study for the Treatment of Duchenne Muscular Dystrophy," 9/03/2014 G0176710 BW   Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic"," 6/08/2015 CERS-US  BW   Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer",#N/A," 7/03/2013 04269E10 BW   ArQule, Inc. to Present at JMP Securities Annual Healthcare Conference",#N/A,#N/A," 9/26/2016 EXEL-US  BW   Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist",11/04/2014 003ZHQ-E  BW   Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis, 1/08/2017 VRTX-US   BW   Vertex Provides Update on Business and Financial Performance and Research and Development Programs,#N/A,#N/A, 8/30/2016 MS-US    BW   bluebird bio to Present at Four Upcoming Conferences," 7/30/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015",#N/A,#N/A,#N/A,11/11/2015 TXMD-US  BW   TherapeuticsMD to Present at Stifel 2015 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 IRWD-US  BW   Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2015 0D059L-E BW   Syros Pharmaceuticals Announces Appointment of CEO Nancy Simonian to BIO Board,#N/A,#N/A,#N/A,11/21/2014 29251M10   BW   Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST,12/07/2017 ALNY-US   BW   Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2015 00972D10 BW   Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 6/01/2016 SAGE-US     BW   Sage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/31/2015 EGRX-US  BW   Eagle Pharmaceuticals to Discuss Second Quarter 2015 Financial Results on August 11, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 25303110 BW   Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting,12/04/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 XLRN-US  BW   Acceleron Announces New Data Presentations at the 2015 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2014 GLYC-US  BW   GlycoMimetics Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A, 7/28/2016 G6674U10 BW   Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2016 74587V10 BW   Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/10/2016 AIMT-US  BW   Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2010 30233G10 BW   pSivida CEO to Speak at Glaucoma & Retinopathies 2010 Conference in London,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 6/02/2015 53220K50  BW   Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance",#N/A," 8/10/2016 45232710    BW   Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics",11/02/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 5/10/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 Second Quarter Results,#N/A,#N/A,#N/A,#N/A, 5/12/2014 68375N10 BW   OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant,#N/A,#N/A," 1/04/2017 ALXN-US  BW   Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action",#N/A, 6/15/2017 BMY-US      BW   Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma,#N/A, 5/03/2016 09062X10    BW   Biogen Announces Intent to Spin off Its Hemophilia Business,"11/13/2014 45253H10 BW   ImmunoGen, Inc. Again Named One of The Boston Globe’s Top Places to Work",#N/A," 5/23/2018 GILD-US      BW   Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6",#N/A,#N/A,#N/A,#N/A, 5/17/2012 07G69B-E     BW   Research and Markets: Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential Despite Moderate Scope of Current Late Stage Molecules,#N/A,#N/A,#N/A,#N/A, 8/06/2015 05156V10 BW   Aurinia Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A, 8/03/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update,#N/A, 5/22/2017 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A, 6/07/2012 066807-E BW   Experts Agree That a Disease-Modifying Therapy is the Greatest Unmet Need in the Treatment of Duchenne Muscular Dystrophy, 9/02/2014 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference, 5/05/2015 15708510 BW   Cerus Corporation Reports First Quarter 2015 Results,#N/A, 6/01/2013 04269E10 BW   Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at ASCO 2013,#N/A,#N/A, 9/20/2016 078V1F-E BW   Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress,10/20/2014 003ZHQ-E  BW   Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio, 1/04/2017 VRTX-US   BW   Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A, 8/04/2016 002DGD-E BW   bluebird bio to Present at Wedbush PacGrow Healthcare Conference," 6/17/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015",#N/A,#N/A,#N/A,11/04/2015 TXMD-US  BW   TherapeuticsMD Announces Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 IRWD-US  BW   Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2015 0D059L-E BW   Syros Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference,#N/A,#N/A,#N/A,11/21/2014 29251M10   BW   Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe,11/20/2017 ALNY-US   BW   U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2015 00972D10 BW   Akebia to Present at the 27th Annual ROTH Conference,#N/A,#N/A,#N/A,#N/A, 5/26/2016 SAGE-US     BW   Sage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe Postpartum Depression,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2015 EGRX-US  BW   Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2015 25303110 BW   Dicerna Announces First Quarter 2015 Financial and Operational Results,12/04/2017 15117K10 BW   Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2015 XLRN-US  BW   Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2013 GLYC-US  BW   GlycoMimetics Shares Progress with Novel E-Selectin Antagonist Drug Candidate at 2013 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A," 7/28/2016 G6674U10 BW   Novocure to Host Research and Development Day on Dec. 12, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/07/2016 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2016 00900T10 BW   Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2010 30233G10 BW   pSivida Corp. Reports Third Quarter Fiscal Year 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/11/2015 53220K50  BW   Ligand Reports First Quarter 2015 Financial Results,#N/A, 7/28/2016 ILMN-US     BW   Illumina Names Philip W. Schiller to its Board of Directors,10/26/2015 84763A10  BW   Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement,#N/A, 5/06/2016 ARWR-US  BW   Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration,#N/A,#N/A,#N/A,#N/A, 5/09/2014 68375N10 BW   OPKO Announces First Quarter Operating Results,#N/A,#N/A,"12/27/2016 ALXN-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017",#N/A, 6/07/2017 4502-JP     BW   Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma,#N/A, 4/29/2016 09062X10    BW   Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis,"10/24/2014 45253H10 BW   ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results",#N/A, 5/15/2018 GILD-US      BW   U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents,#N/A,#N/A,#N/A,#N/A, 5/10/2012 AMGN-US      BW   Fitch Rates Amgen's Senior Notes 'BBB',#N/A,#N/A,#N/A,#N/A, 5/27/2015 05156V10 BW   Aurinia Announces Results of Annual General Meeting,#N/A,#N/A,#N/A,#N/A," 7/27/2016 AERI-US    BW   Aerie Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016",#N/A, 5/17/2017 INCY-US  BW   First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017,#N/A, 6/01/2012 07G69B-E BW   Research and Markets: Orphan Disease Therapeutic Disorders to 2018 - Emerging utics in GenAgents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity, 8/26/2014 G0176710 BW   Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain, 4/27/2015 15708510 BW   Cerus to Present at AABB Symposium on Pathogen-Reduced Components,#N/A," 5/30/2013 04269E10 BW   ArQule, Inc. to Present at Jefferies 2013 Global Healthcare Conference",#N/A,#N/A, 9/14/2016 EXEL-US  BW   European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy,10/20/2014 MRK-US    BW   US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine,"12/19/2016 VRTX-US   BW   Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",#N/A,#N/A, 8/03/2016 BLUE-US  BW   bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress, 6/16/2015 00422510 BW   ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders,#N/A,#N/A,#N/A,10/27/2015 TXMD-US  BW   TherapeuticsMD to Host Third Quarter 2015 Financial Results Conference Call and Webcast November 4,#N/A,#N/A,#N/A,#N/A,#N/A, 7/22/2015 IRWD-US  BW   Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2015 0D059L-E BW   Syros Pharmaceuticals Augments Senior Leadership Team,#N/A,#N/A,#N/A,"11/17/2014 29251M10   BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2014",11/16/2017 ALNY-US   BW   Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2015 00972D10 BW   Akebia Announces Fourth Quarter and Full-Year 2014 Financial Results,#N/A,#N/A,#N/A,#N/A, 5/05/2016 SAGE-US     BW   Sage Therapeutics Announces First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/30/2015 00930K-E BW   Eagle Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/06/2015 25303110 BW   Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1)",12/04/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2015 XLRN-US  BW   Acceleron Pharma to Present at Upcoming Investor Conferences in November,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2013 GLYC-US  BW   GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A, 7/26/2016 NVCR-GB  BW   NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2016 74587V10 BW   CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 00900T10 BW   Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2010 30233G10 BW   pSivida Corp Announces Third Quarter 2010 Financial Results Release Date and Conference Call Information,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/11/2015 LGND-US   BW   Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA,#N/A, 7/26/2016 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016,"10/23/2015 SPPI-US   BW   SHAREHOLDER ALERT: L & K Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spectrum Pharmaceuticals, Inc. and Certain Officers and Directors",#N/A, 5/03/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results,#N/A,#N/A,#N/A,#N/A," 5/08/2014 68375N10 BW   OPKO Announces Dismissal of PROLOR Biotech, Inc. Class Action Lawsuit",#N/A,#N/A,12/21/2016 ALXN-US  BW   Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation,#N/A, 6/05/2017 SGEN-US     BW   Seattle Genetics and Astellas Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting,#N/A," 4/27/2016 09062X10    BW   Biogen Appoints Michael Ehlers Executive Vice President, Research and Development","10/10/2014 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2015 Financial Results",#N/A, 5/15/2018 KITE-US      BW   Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline,#N/A,#N/A,#N/A,#N/A, 5/04/2012 0C90HB-E     BW   RBCC Target’s Brain Injury Treatment Awareness Campaign Reaches Milestone,#N/A,#N/A,#N/A,#N/A, 5/19/2015 0DDLD3-E BW   Aurinia Pharmaceuticals to Present at the 2015 UBS Global Health Care Conference,#N/A,#N/A,#N/A,#N/A, 7/06/2016 06P5F0-E   BW   Aerie Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference,#N/A, 5/17/2017 INCY-US  BW   New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab),#N/A," 7/29/2011 07G69B-E BW   Research and Markets: West Nile Virus Global Clinical Trials Review, Q1, 2011 - Examine Trial Performance, Success Rates & Clinical Trial Status Globally", 8/25/2014 G0176710 BW   Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia," 4/22/2015 15708510 BW   Cerus to Release First Quarter 2015 Results on May 5, 2015",#N/A, 5/08/2013 04269E10 BW   ArQule Reports First Quarter 2013 Financial Results,#N/A,#N/A, 9/06/2016 EXEL-US  BW   Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma,10/01/2014 80105N10  BW   Genzyme Announces Winners of Patient Advocacy Leadership (PAL) Awards,11/07/2016 VRTX-US   BW   Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017,#N/A,#N/A, 7/18/2016 06QBQ2-E BW   bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing," 5/26/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015",#N/A,#N/A,#N/A,10/13/2015 TXMD-US  BW   TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate,#N/A,#N/A,#N/A,#N/A,#N/A, 7/15/2015 46333X10 BW   Ironwood Pharmaceuticals to Host Second Quarter 2015 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2015 0D059L-E BW   Syros Pharmaceuticals to Present New Data from its Gene Control Platform in AML and Breast Cancer at AACR Annual Meeting 2015,#N/A,#N/A,#N/A,11/11/2014 29251M10   BW   Enanta Announces Results from TURQUOISE-I Study in Chronic Hepatitis C Patients with HIV-1 Co-infection and from the CORAL-I Study In Liver Transplant Recipients at The Liver Meeting 2014®,11/16/2017 ALNY-US   BW   Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2015 00972D10 BW   Akebia to Present at the 17th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A," 4/28/2016 SAGE-US     BW   Sage Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2015 26979610 BW   Eagle Pharmaceuticals Added to Russell 2000 Index,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2015 25303110 BW   Dicerna to Present at the 17th Annual TIDES: Oligonucleotide and Peptide® Therapeutics From Research through Commercialization Conference,"12/04/2017 15117K10 BW   Cellectis nomme Stéphane Depil, un expert en immuno-oncologie, au poste de Vice-président senior de la Recherche et du Développement et Directeur médical",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/29/2015 XLRN-US  BW   Acceleron Pharma to Host Third Quarter 2015 Financial Results Conference Call and Webcast on November 4, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,10/07/2013 062RZ9-E BW   GlycoMimetics Files Registration Statement for Proposed Initial Public Offering,#N/A,#N/A,#N/A, 7/13/2016 06CR5C-E BW   Novocure Receives FDA Approval for Second Generation Optune System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/15/2016 PBYI-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2016 AIMT-US  BW   Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2010 30233G10 BW   Results of Studies Using pSivida Technologies in Glaucoma and Degenerative Eye Diseases to be Presented at Upcoming ARVO Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/07/2015 53220K50  BW   Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th Scientific Sessions on June 7th and Host Investor Presentation,#N/A," 7/12/2016 45232710    BW   Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016",10/23/2015 84763A10  BW   Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA™ (melphalan) for Injection,#N/A, 4/29/2016 ARWR-US  BW   Arrowhead Pharmaceuticals to Present at Upcoming May Conferences,#N/A,#N/A,#N/A,#N/A, 5/07/2014 68375N10 BW   OPKO Creates Global Supply Chain Structure,#N/A,#N/A,"12/16/2016 ALXN-US  BW   Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders",#N/A, 6/02/2017 BMY-US      BW   Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma,#N/A, 4/21/2016 09062X10    BW   Biogen Reports First Quarter 2016 Revenues of $2.7 Billion," 9/15/2014 45253H10 BW   ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations",#N/A, 5/09/2018 GILD-US      BW   Harish Manwani Joins Gilead Sciences’ Board of Directors,#N/A,#N/A,#N/A,#N/A," 4/27/2012 IMGN-US      BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update",#N/A,#N/A,#N/A,#N/A, 5/15/2015 05156V10 BW   Aurinia Reports First Quarter 2015 Financial Results and Restatement of 2014 Financial Statements,#N/A,#N/A,#N/A,#N/A, 6/16/2016 AERI-US    BW   Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of RhopressaTM (netarsudil ophthalmic solution) 0.02%,#N/A, 5/04/2017 INCY-US  BW   Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs,#N/A,#N/A, 7/31/2014 G0176710 BW   Alkermes plc Reports Second Quarter 2014 Financial Results, 3/16/2015 15708510 BW   First Patient Enrolled in Cerus' TRUE Study With the American Red Cross to Address Chikungunya and Dengue Blood Safety Risks With Pathogen Reduced Platelets,#N/A," 5/01/2013 04269E10 BW   ArQule to Report First Quarter 2013 Financial Results on May 8, 2013",#N/A,#N/A, 8/31/2016 EXEL-US  BW   Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13, 9/24/2014 003ZHQ-E  BW   Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood Blindness,11/02/2016 CS-CH     BW   Vertex to Present at the Credit Suisse Healthcare Conference on November 8,#N/A,#N/A, 5/23/2016 GS-US    BW   bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference, 5/07/2015 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results,#N/A,#N/A,#N/A, 9/30/2015 TXMD-US  BW   Menopausal Women Experiencing Distressing Pain During Sex Suffer Due to Misperceptions,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2015 IRWD-US  BW   AstraZeneca and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2015 0D059L-E BW   Syros Pharmaceuticals Announces New Research Published on Role of Cell Signaling Pathways in Gene Control,#N/A,#N/A,#N/A,11/11/2014 29251M10   BW   Enanta Announces Results from Phase 2b PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting 2014®,11/13/2017 ALNY-US   BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2015 00972D10 BW   Akebia Completes Enrollment in the Two Planned Cohorts of its Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis,#N/A,#N/A,#N/A,#N/A," 4/17/2016 SAGE-US     BW   Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2015 26979610 BW   Eagle Pharmaceuticals to Present at Two Investor Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2015 25303110 BW   Dicerna to Present at the Deutsche Bank 40th Annual Health Care Conference,"12/04/2017 15117K10 BW   Cellectis nomme Elsy Boglioli au poste de Vice-présidente exécutive, Stratégie et Développement Corporate",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/23/2015 XLRN-US  BW   Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event",#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2013 080RQG-E BW   GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease,#N/A,#N/A,#N/A, 6/30/2016 0CX9J5-E BW   Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2016 74587V10 BW   Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2015 00900T10 BW   Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/28/2010 30233G10 BW   pSivida Receives $15 million payment from Alimera Sciences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/05/2015 53220K50  BW   Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering,#N/A, 7/07/2016 06CR5C-E    BW   Illumina Applauds FDA’s Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing, 9/03/2015 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th,#N/A, 4/28/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521,#N/A,#N/A,#N/A,#N/A, 5/06/2014 68375N10 BW   OPKO Completes Patient Enrollment in Third Phase 3 Trial of RAYALDEE™,#N/A,#N/A,"12/13/2016 ALXN-US  BW   Alexion Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors",#N/A, 5/09/2017 SGEN-US     BW   Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference,#N/A, 4/20/2016 09062X10    BW   Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action," 9/02/2014 45253H10 BW   ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast",#N/A, 5/09/2018 0056YC-E     BW   Gilead Lawsuits: California HIV Patients File Class Action and Personal Injury Cases Over Key HIV Drug,#N/A,#N/A,#N/A,#N/A, 4/26/2012 NPSP-US      BW   NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey,#N/A,#N/A,#N/A,#N/A, 4/23/2015 05156V10 BW   Aurinia Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting and Webcast on May 5 in New York,#N/A,#N/A,#N/A,#N/A, 6/02/2016 AERI-US    BW   Aerie Pharmaceuticals to Participate in Two Investor Conferences in June,#N/A, 4/25/2017 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 7/30/2014 G0176710 BW   Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder, 2/27/2015 15708510 BW   Cerus Signs INTERCEPT Platelet Agreement With Sweden’s Largest Blood Product Supplier,#N/A," 4/23/2013 04269E10 BW   ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference",#N/A,#N/A, 8/31/2016 078V1F-E BW   Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress," 9/11/2014 003ZHQ-E  BW   At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies",10/27/2016 VRTX-US   BW   Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF,#N/A,#N/A, 5/09/2016 0F9D18-E BW   bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting," 5/06/2015 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015",#N/A,#N/A,#N/A, 9/09/2015 TXMD-US  BW   TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2015 46333X10 BW   Ironwood Pharmaceuticals Prices $300 Million of Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2015 0D059L-E BW   Syros Pharmaceuticals to Present at Leading Investor Conferences,#N/A,#N/A,#N/A,11/05/2014 29251M10   BW   Enanta Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference,11/13/2017 ALNY-US   BW   European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/15/2014 00972D10 BW   Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index",#N/A,#N/A,#N/A,#N/A," 3/23/2016 SAGE-US     BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sage Therapeutics, Inc. - SAGE",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2015 26979610 BW   Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/29/2015 25303110 BW   Dicerna to Announce First Quarter 2015 Financial Results and Host Conference Call on May 11, 2015",11/20/2017 15117K10 BW   Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2015 XLRN-US  BW   Acceleron to Host Research and Development Day on October 23,#N/A,#N/A,#N/A,#N/A,#N/A," 8/22/2013 062RZ9-E BW   GlycoMimetics, Inc. Presents on Clinical Trial Implementation at National Institutes of Health Workshop on Sickle Cell Disease Treatments",#N/A,#N/A,#N/A, 6/30/2016 G6674U10 BW   Novocure to Report Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2016 74587V10 BW   Puma Biotechnology Reports Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2015 AIMT-US  BW   Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2010 30233G10 BW   Newly-Published Peer-Reviewed Paper shows Durasert device was neuroprotectant in Retinitis Pigmentosa Model,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/29/2015 LGND-US   BW   Ligand Partner Viking Therapeutics Announces Pricing of Initial Public Offering,#N/A," 7/07/2016 ENZ-US      BW   Enzo Biochem’s Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.", 9/02/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Publication of Pivotal EVOMELA™ (melphalan hydrochloride) for Injection Data in the Biology of Blood and Marrow Transplantation Journal,#N/A, 4/18/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016,#N/A,#N/A,#N/A,#N/A, 4/22/2014 68375N10 BW   OPKO Announces Presentation of Data on Long-Acting Oxyntomodulin at Diabetes Conference,#N/A,#N/A,"12/12/2016 ALXN-US  BW   ALEXION SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – (ALXN)",#N/A," 5/05/2017 IMMU-US     BW   Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value",#N/A, 4/18/2016 BIIB-US     BW   TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness," 8/04/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 5/08/2018 GILD-US      BW   Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16",#N/A,#N/A,#N/A,#N/A, 4/13/2012 005D7X-E     BW   Research and Markets: Global Rheumatoid Arthritis Drugs Market 2011-2015 - The Global Rheumatoid Arthritis Drugs Market to Grow At A CAGR Of 12.1 Percent over the Period 2011-2015,#N/A,#N/A,#N/A,#N/A, 3/30/2015 05156V10 BW   Aurinia Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers,#N/A,#N/A,#N/A,#N/A, 5/05/2016 AERI-US    BW   Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,#N/A, 4/20/2017 INCY-US  BW   Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting,#N/A,#N/A, 7/24/2014 ALKS-IE  BW   Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results, 2/26/2015 15708510 BW   Cerus Corporation Reports Fourth Quarter and Year-End 2014 Results,#N/A," 4/09/2013 04269E10 BW   ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Trial",#N/A,#N/A, 8/24/2016 EXEL-US  BW   Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019, 9/10/2014 003ZHQ-E  BW   Genzyme Announces Launch of “Expression of Hope III” Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art,10/25/2016 VRTX-US   BW   Vertex Reports Third Quarter 2016 Financial Results,#N/A,#N/A, 5/04/2016 06W0Z6-E BW   bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress," 4/30/2015 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015",#N/A,#N/A,#N/A, 8/06/2015 TXMD-US  BW   TherapeuticsMD Announces Second Quarter 2015 Financial Results  ,#N/A,#N/A,#N/A,#N/A,#N/A, 6/08/2015 46333X10 BW   Ironwood Pharmaceuticals Announces Proposed Offering of $300 Million of Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2015 0D059L-E BW   Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response,#N/A,#N/A,#N/A,10/20/2014 29251M10   BW   Enanta Pharmaceuticals Provides Update on its Collaboration Agreement with AbbVie,"11/13/2017 ALNY-US   BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2014 00972D10 BW   Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,12/02/2015 SAGE-US     BW   SAGE to Present Three Poster Presentations at the American Epilepsy Society 69th Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2015 26979610 BW   New Patent Issued for Eagle Pharmaceuticals’ Bendamustine Rapid Infusion Product,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/23/2015 25303110 BW   FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna’s Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",11/20/2017 15117K10 BW   Cellectis a démontré comment la spécificité de l’édition du génome ciblée avec la technologie TALEN® peut être affinée pour améliorer l’immunothérapie par transfert adoptif de lymphocytes T,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2015 XLRN-US  BW   Acceleron Announces Presentation of Sotatercept Data at the American Society of Nephrology Kidney Week 2015,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2013 062RZ9-E BW   Tech Council of Maryland Names GlycoMimetics CEO Rachel King as 2013 Executive of the Year,#N/A,#N/A,#N/A, 6/08/2016 NVCR-GB  BW   Novocure to Present at JMP Securities 2016 Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 74587V10 BW   Puma Biotechnology to Present at Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2015 00900T10 BW   Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2010 30233G10 BW   pSivida to Present at Cowen and Company Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/24/2015 53220K50  BW   Ligand to Participate in Two Upcoming Investor Conferences,#N/A, 6/16/2016 07B3VF-E    BW   Illumina Announces Initial Customer Orders for the Global Screening Array, 8/17/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC),#N/A, 4/13/2016 ARWR-US  BW   Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress™ 2016,#N/A,#N/A,#N/A,#N/A, 4/17/2014 68375N10 BW   OPKO Acquires Next Generation Dry Powder Inhaler to Treat Respiratory Disorders,#N/A,#N/A,12/12/2016 AZN-GB   BW   Alexion’s Board of Directors Announces New Leadership Appointments,#N/A, 5/05/2017 SGEN-US     BW   Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132),#N/A, 4/14/2016 0085TV-E    BW   Biogen Joins in Celebration of World Hemophilia Day," 8/01/2014 45253H10 BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results",#N/A, 5/01/2018 GILD-US      BW   Gilead Sciences Announces Second Quarter 2018 Dividend,#N/A,#N/A,#N/A,#N/A, 4/12/2012 0C8BZM-E     BW   RBCC: New N3D Prototype Could be the Beginning of Something Big,#N/A,#N/A,#N/A,#N/A, 3/06/2015 05156V10 BW   Aurinia Announces Change to Its Board of Directors,#N/A,#N/A,#N/A,#N/A, 5/04/2016 07MDY1-E   BW   Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,#N/A, 4/18/2017 INCY-US  BW   Incyte to Report First Quarter Financial Results,#N/A,#N/A, 7/17/2014 G0176710 BW   Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis," 2/24/2015 15708510 BW   Cerus to Present at the Cowen and Company 35th Annual Health Care Conference on March 3, 2015",#N/A, 4/01/2013 04269E10 BW   ArQule Regains Worldwide Rights to AKT Program,#N/A,#N/A, 8/03/2016 EXEL-US  BW   Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update, 9/08/2014 003ZHQ-E  BW   Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS,10/25/2016 VRTX-US   BW   Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis,#N/A,#N/A, 4/27/2016 DB-DE    BW   bluebird bio to Present at Two Upcoming Investor Conferences," 4/15/2015 00422510 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2015",#N/A,#N/A,#N/A, 8/05/2015 TXMD-US  BW   TherapeuticsMD Receives Patent Allowance for VVA Candidate TX-004HR,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2015 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2015 0D059L-E BW   Syros Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,10/01/2014 29251M10   BW   Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing ABT-450 or ABT-493 to be Presented at the American Association for the Study of Liver Diseases (AASLD),11/09/2017 ALNY-US   BW   Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2014 00972D10 BW   Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan,#N/A,#N/A,#N/A,#N/A, 9/29/2015 LGND-US     BW   Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/12/2015 26979610 BW   Eagle Pharmaceuticals, Inc. Reports First Quarter 2015 Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2015 25303110 BW   Dicerna Presents New β-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory,11/13/2017 15117K10 BW   Cellectis publie ses résultats financiers du troisième trimestre 2017 et des neuf premiers mois de l’année 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2015 XLRN-US  BW   Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2013 PFE-US   BW   GlycoMimetics Announces Top Line Results from Phase 2 Trial with GMI-1070 in Sickle Cell Disease,#N/A,#N/A,#N/A, 5/31/2016 06CR5C-E BW   Novocure Receives IDE Approval to Initiate METIS Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/28/2016 PBYI-US  BW   PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2015 00900T10 BW   Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2010 30233G10 BW   pSivida Reports Presentation of Additional Positive 24-Month Data from Iluvien® Phase 3 FAME™ Study for Diabetic Macular Edema at Angiogenesis 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/23/2015 53220K50  BW   Ligand to Report First Quarter Results on May 11th,#N/A, 6/13/2016 ILMN-US     BW   Xcell Biosciences to Present Data From its Avatar System at ISSCR Annual Meeting, 8/06/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results and Pipeline Update,#N/A, 4/06/2016 ARWR-US  BW   Arrowhead Research Changes Name to Arrowhead Pharmaceuticals,#N/A,#N/A,#N/A,#N/A, 4/03/2014 68375N10 BW   OPKO Health Announces Key Executive Appointments for Renal Division,#N/A,#N/A,12/04/2016 06QBQ2-E BW   New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 4/27/2017 SGEN-US     BW   Seattle Genetics Reports First Quarter 2017 Financial Results,#N/A, 4/12/2016 BIIB-US     BW   Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients," 7/18/2014 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014 Financial Results",#N/A, 5/01/2018 GILD-US      BW   Gilead Sciences Announces First Quarter 2018 Financial Results,#N/A,#N/A,#N/A,#N/A," 4/04/2012 066807-E     BW   Patient Access to Premium-Priced Targeted Cancer Treatments in Brazil and Mexico is Improving, Creating an Opportunity for Developers of EGFR Inhibitors",#N/A,#N/A,#N/A,#N/A, 2/26/2015 05156V10 BW   Aurinia Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A, 5/02/2016 AERI-US    BW   Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update,#N/A, 4/14/2017 INCY-US  BW   U.S. FDA Issues Complete Response Letter for Baricitinib,#N/A,#N/A, 7/09/2014 G0176710 BW   Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates," 2/13/2015 15708510 BW   Cerus to Release Fourth Quarter 2014 Results on February 26, 2015",#N/A, 3/14/2013 04269E10 BW   ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results,#N/A,#N/A, 7/22/2016 071VWR-E BW   Ipsen et son partenaire Exelixis reçoivent un avis favorable du CHMP pour le Cabometyx™ dans le traitement du cancer du rein avancé de l'adulte ayant reçu au préalable une thérapie ciblant le VEGF," 9/02/2014 SAN-FR    BW   Sanofi Diabetes is on a Mission to Support Children, Parents and Carers of Children with Type 1 Diabetes through Gaming",10/07/2016 VRTX-US   BW   Vertex to Announce Third Quarter 2016 Financial Results on October 25,#N/A,#N/A, 4/20/2016 BLUE-US  BW   bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D™ at AAN 2016 Annual Meeting," 4/07/2015 00422510 BW   ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015",#N/A,#N/A,#N/A, 7/27/2015 TXMD-US  BW   TherapeuticsMD to Host Second Quarter 2015 Financial Results Conference Call and Webcast August 6,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 46333X10 BW   Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2015 0D059L-E BW   Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference,#N/A,#N/A,#N/A,10/01/2014 29251M10   BW   Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis,11/07/2017 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2014 00972D10 BW   Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting,#N/A,#N/A,#N/A,#N/A, 4/22/2015 LGND-US     BW   Ligand Earns Milestone from SAGE Therapeutics for SAGE-547,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2015 26979610 BW   Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2015 Financial Results on May 12, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/31/2015 25303110 BW   Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",11/13/2017 15117K10 BW   Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2015 XLRN-US  BW   Acceleron Pharma to Present at Upcoming Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A, 1/17/2013 PFE-US   BW   GlycoMimetics Completes Enrollment in Phase 2 Sickle Cell Disease Study with Lead Drug Candidate GMI-1070,#N/A,#N/A,#N/A, 5/23/2016 G6674U10 BW   Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2016 74587V10 BW   Puma Biotechnology Closes $172 Million Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2015 AIMT-US  BW   Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/11/2010 30233G10 BW   pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2009",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/23/2015 53220K50  BW   Ligand Names Melanie J. Herman Interim Chief Financial Officer,#N/A, 6/07/2016 45232710    BW   Illumina Announces Donald Danforth Plant Science Center to Receive Agricultural Greater Good Initiative Grant to Improve Food Security in Sub-Saharan Africa, 7/30/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 3/30/2016 ARWR-US  BW   Arrowhead to Present at Upcoming April Conferences,#N/A,#N/A,#N/A,#N/A, 4/01/2014 68375N10 BW   OPKO Health Announces Executive Appointments,#N/A,#N/A,11/29/2016 C-US     BW   Alexion to Present at the Citi 2016 Global Healthcare Conference,#N/A," 4/06/2017 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017",#N/A," 4/01/2016 09062X10    BW   FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion"," 6/16/2014 45253H10 BW   CORRECTING and REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia",#N/A, 4/30/2018 0FYFQF-E     BW   Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases,#N/A,#N/A,#N/A,#N/A, 3/27/2012 NPSP-US      BW   NPS Pharmaceuticals to Present at Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 2/09/2015 05156V10 BW   Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers,#N/A,#N/A,#N/A,#N/A," 4/25/2016 AERI-US    BW   Aerie Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Monday, May 2, 2016",#N/A, 4/02/2017 BMY-US   BW   Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials,#N/A,#N/A, 6/18/2014 G0176710 BW   Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting, 2/05/2015 15708510 BW   Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A," 3/07/2013 04269E10 BW   ArQule to Report Fiscal 2012 Financial Results on March 14, 2013",#N/A,#N/A, 7/22/2016 080RQG-E BW   Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy, 8/19/2014 003ZHQ-E  BW   FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules, 9/28/2016 VRTX-US   BW   U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation,#N/A,#N/A, 4/18/2016 BLUE-US  BW   bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting, 3/26/2015 00422510 BW   ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors,#N/A,#N/A,#N/A, 7/09/2015 88338N10 BW   TherapeuticsMD Announces Pricing of Common Stock Offering,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 IRWD-US  BW   Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2014 0D059L-E BW   Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences,#N/A,#N/A,#N/A, 9/10/2014 29251M10   BW   Enanta Pharmaceuticals Announces the Initiation of Phase 2b Clinical Trial with Regimen Containing HCV Protease Inhibitor ABT-493,"11/07/2017 ALNY-US   BW   Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2014 00972D10 BW   Akebia Announces Third Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/02/2014 78667J10    BW   SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/22/2015 26979610 BW   Eagle Pharmaceuticals to Present at Deutsche Bank 40th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2015 25303110 BW   Dicerna Announces Fourth Quarter and Full Year 2014 Financial and Operational Results,11/08/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 XLRN-US  BW   Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2012 062RZ9-E BW   GlycoMimetics Announces Progress from Its Novel Compounds as Presented at 2012 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A, 5/19/2016 G6674U10 BW   Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2016 74587V10 BW   Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2015 00900T10 BW   Aimmune Therapeutics Announces COO Transition,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2010 30233G10 BW   pSivida Corp Announces Second Quarter 2010 Financial Results Release Date and Conference Call Information,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/22/2015 LGND-US   BW   Ligand Earns Milestone from SAGE Therapeutics for SAGE-547,#N/A, 6/06/2016 0DBFR7-E    BW   ArcherDX Partners with Illumina to Bring Leading Fusion Oncology Assays to Global Markets, 6/24/2015 SPPI-US   BW   Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication in the Journal of Clinical Oncology,#N/A, 3/07/2016 ARWR-US  BW   Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016,#N/A,#N/A,#N/A,#N/A, 3/31/2014 68375N10 BW   OPKO Announces Launch of 4Kscore Test for Prostate Cancer,#N/A,#N/A,"11/22/2016 ALXN-US  BW   Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action",#N/A, 4/03/2017 SGEN-US     BW   Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,#N/A," 3/30/2016 09062X10    BW   Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer"," 6/01/2014 45253H10 BW   ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data with Sanofi’s SAR3419 in Diffuse Large B-Cell Lymphoma",#N/A," 4/27/2018 GILD-US      BW   European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)",#N/A,#N/A,#N/A,#N/A, 3/27/2012 09QXDQ-E     BW,#N/A,#N/A,#N/A,#N/A, 2/06/2015 05156V10 BW   Company Profile for Aurinia Pharmaceuticals Inc.,#N/A,#N/A,#N/A,#N/A, 4/05/2016 05KDBG-E   BW   Aerie Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference,#N/A, 3/31/2017 INCY-US  BW   Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab),#N/A,#N/A, 6/10/2014 G0176710 BW   Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder, 2/04/2015 15708510 BW   Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma,#N/A," 2/27/2013 04269E10 BW   ArQule, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference",#N/A,#N/A," 7/12/2016 EXEL-US  BW   Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016", 8/01/2014 003ZHQ-E  BW   Genzyme Receives Label Expansion for Lumizyme® (alglucosidase alfa) in the United States for the treatment of Pompe Disease, 9/09/2016 VRTX-US   BW   Vertex to Present at Upcoming Investor Conferences,#N/A,#N/A, 3/23/2016 BLUE-US  BW   Synlogic Appoints an Industry Leader Nick Leschly to Its Board of Directors," 3/25/2015 00422510 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A," 6/09/2015 88338N10 BW   TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCapTM)",#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2015 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2014 0D059L-E BW   Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers,#N/A,#N/A,#N/A, 8/27/2014 29251M10   BW   Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences,11/06/2017 ALNY-US   BW   The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2014 00972D10 BW   Akebia to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 8/14/2014 78667J10    BW   SAGE Therapeutics Reports Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2015 26979610 BW   Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/09/2015 25303110 BW   Dicerna to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 12, 2015",11/08/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2015 XLRN-US  BW   Acceleron Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast on August 6, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2012 062RZ9-E BW   GlycoMimetics Announces Publication in Nature Medicine of Preclinical Data for Its GMI-1070 Drug Candidate,#N/A,#N/A,#N/A, 5/18/2016 G6674U10 BW   Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2016 74587V10 BW   Puma Biotechnology Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/07/2015 00900T10 BW   Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2010 30233G10 BW   pSivida CEO To Discuss Ocular Drug Delivery in Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 in London,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/20/2015 53220K50  BW   Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting,#N/A," 6/02/2016 45232710    BW   Illumina ernennt Paula Dowdy als Senior Vice President und General Manager of Commercial Operations für Europa, den Nahen Osten und Afrika"," 5/29/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29-June 2, 2015",#N/A, 3/01/2016 BCS-GB   BW   Arrowhead to Present at Upcoming March Conferences,#N/A,#N/A,#N/A,#N/A, 3/25/2014 68375N10 BW   American Urological Association (AUA) Accepts 4Kscore Test Clinical Study for Plenary Presentation at 2014 Annual Meeting,#N/A,#N/A,"11/18/2016 ALXN-US  BW   IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm",#N/A, 3/30/2017 SGEN-US     BW   Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 3/28/2016 GS-US       BW   Biogen to Present at the Goldman Sachs Alzheimer’s Symposium," 5/14/2014 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO",#N/A," 4/25/2018 00GDBT-E     BW   Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise",#N/A,#N/A,#N/A,#N/A, 3/23/2012 0C8BZH-E     BW   RBCC Prepares to Join the $3 Billion Fight Against Parkinson’s Disease,#N/A,#N/A,#N/A,#N/A, 2/03/2015 05156V10 BW   Aurinia Pharmaceuticals Announces Recently Granted Nanomicellar Formulation Patents in Japan and China for Topical Ophthalmic Administration of voclosporin,#N/A,#N/A,#N/A,#N/A, 3/28/2016 AERI-US    BW   Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,#N/A, 3/02/2017 INCY-US  BW   Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017,#N/A,#N/A, 6/03/2014 G0176710 BW   Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting, 1/07/2015 15708510 BW   Cerus Prices $70.0 Million Public Offering of Common Stock,#N/A," 2/19/2013 04269E10 BW   ArQule, Inc. to Present at RBC Capital Markets Global Healthcare Conference",#N/A,#N/A," 6/06/2016 06N2PB-E BW   Exelixis et son partenaire Ipsen présentent les résultats positifs de survie globale issus de l'analyse des sous-groupes de l'essai de phase 3 avec CABOMETYX™ (comprimés de cabozantinib), lors de la réunion annuelle 2016 de l'ASCO", 7/28/2014 INWK-US   BW   Sanofi and InnerWorkings Sign Global Marketing Partnership, 8/15/2016 VRTX-US   BW   Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis,#N/A,#N/A, 3/03/2016 06W0Z6-E BW   bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting, 3/16/2015 00422510 BW   INVESTOR ALERT: Investigation of ACADIA Pharmaceuticals Inc. Announced by Glancy Binkow & Goldberg LLP,#N/A,#N/A,#N/A," 5/26/2015 88338N10 BW   TherapeuticsMD, Inc. to Participate in Upcoming Investor Conferences",#N/A,#N/A,#N/A,#N/A,#N/A," 4/16/2015 IRWD-US  BW   Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2014 0D059L-E BW   Syros Pharmaceuticals Closes $53 Million Series B Financing,#N/A,#N/A,#N/A," 8/11/2014 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2014",11/03/2017 ALNY-US   BW   Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2014 00972D10 BW   Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease,#N/A,#N/A,#N/A,#N/A, 8/07/2014 78667J10    BW   SAGE Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/13/2015 26979610 BW   Eagle Pharmaceuticals Appoints David M. Pernock to Its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/26/2015 25303110 BW   Dicerna Pharmaceuticals Announces Move to Larger Office and Lab Space in Cambridge, Massachusetts",11/06/2017 15117K10 BW   La Food and Drug Administration (FDA) aux États-Unis a levé l’avis de suspension pour les deux essais cliniques de Phase I du produit candidat UCART123 ciblant la LAM et la LpDC,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2015 0068K6-E BW   Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A," 9/24/2012 062RZ9-E BW   GlycoMimetics, Inc. Announces Presentation at National Sickle Cell Conference",#N/A,#N/A,#N/A, 5/13/2016 G6674U10 BW   Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/18/2016 74587V10 BW   Puma Biotechnology Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2015 AIMT-US  BW   Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/14/2015 LGND-US   BW   Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors,#N/A," 6/02/2016 45232710    BW   Illumina nomme Paula Dowdy au poste de vice-présidente principale et directrice générale des opérations commerciales pour la région Europe, Moyen-Orient et Afrique", 5/28/2015 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd,#N/A, 2/16/2016 ARWR-US  BW   Arrowhead to Present at Upcoming February Conferences,#N/A,#N/A,#N/A,#N/A, 3/10/2014 68375N10 BW   Sony DADC and OPKO Diagnostics Announce Manufacturing Partnership,#N/A,#N/A,"11/17/2016 ALXN-US  BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A," 3/10/2017 SGEN-US     BW   March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm",#N/A," 3/21/2016 09062X10    BW   Biogen to Report First Quarter 2016 Financial Results on April 21, 2016"," 5/06/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 4/17/2018 GILD-US      BW   Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018",#N/A,#N/A,#N/A,#N/A, 3/15/2012 0087HF-E     BW   TetraLogic Pharmaceuticals Appoints C. Glenn Begley as Senior Vice President Research and Development,#N/A,#N/A,#N/A,#N/A, 1/29/2015 05156V10 BW   Aurinia Pharmaceuticals to Present at the BIO CEO Investor Conference,#N/A,#N/A,#N/A,#N/A, 3/17/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Update on Positive Safety Results for RhopressaTM QD (netarsudil ophthalmic solution) 0.02%,#N/A, 2/28/2017 INCY-US  BW   Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017,#N/A,#N/A," 6/02/2014 G0176710 BW   Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic", 1/05/2015 15708510 BW   Cerus Announces Proposed Public Offering of Common Stock,#N/A," 2/07/2013 04269E10 BW   ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference",#N/A,#N/A, 6/06/2016 EXEL-US  BW   Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting, 6/30/2014 SNY-FR    BW   Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis," 8/02/2016 002PSJ-E  BW   Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors",#N/A,#N/A, 3/02/2016 05GSQ9-E BW   bluebird bio to Present at Three Upcoming Investor Conferences, 3/13/2015 00422510 BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against ACADIA Pharmaceuticals Inc.,#N/A,#N/A,#N/A, 5/21/2015 88338N10 BW   TherapeuticsMD featured at the 10th European Congress on Menopause and Andropause,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2015 46333X10 BW   Ironwood Pharmaceuticals to Host First Quarter 2015 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2014 0D059L-E BW   Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid Leukemia at AACR Hematologic Malignancies Meeting,#N/A,#N/A,#N/A, 8/07/2014 29251M10   BW   Enanta Pharmaceuticals’ HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025),11/02/2017 SAN-FR    BW   Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2014 00972D10 BW   Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis,#N/A,#N/A,#N/A,#N/A, 7/23/2014 78667J10    BW   SAGE Therapeutics Announces Closing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2015 00930K-E BW   Eagle Pharmaceuticals Announces New Patent for Low-Sodium Bendamustine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2015 25303110 BW   Dicerna to Present at the 2015 Leerink Global Healthcare Conference,11/06/2017 15117K10 BW   FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2015 0068K6-E BW   Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A," 9/21/2012 062RZ9-E BW   William E. Proudford Sickle Cell Fund Honors GlycoMimetics, Inc. with “Unsung Hero” Award",#N/A,#N/A,#N/A, 5/11/2016 G6674U10 BW   Novocure Enters into Employment Agreement with William Doyle,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/14/2016 PBYI-US  BW   PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2015 00900T10 BW   Aimmune Therapeutics Reports Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/03/2015 53220K50  BW   Ligand to Present at the 27th Annual Roth Conference on March 9th,#N/A," 6/02/2016 45232710    BW   Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa", 5/14/2015 SPPI-US   BW   Spectrum Pharmaceuticals Commits to Review Shareholder Proposal,#N/A, 2/09/2016 ARWR-US  BW   Arrowhead Reports Fiscal 2016 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 3/03/2014 68375N10 BW   OPKO Announces Fourth Quarter and Full Year 2013 Results,#N/A,#N/A,"11/17/2016 ALXN-US  BW   IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm",#N/A," 3/09/2017 SGEN-US     BW   Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against Seattle Genetics, Inc.",#N/A, 2/29/2016 0024VM-E    BW   Biogen to Present at the Cowen and Company 36th Annual Health Care Conference," 4/25/2014 45253H10 BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update −Quarterly Conference Call Today at 8:00 am ET−",#N/A, 4/13/2018 GILD-US      BW   Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018,#N/A,#N/A,#N/A,#N/A, 3/14/2012 0C8BZH-E     BW   RBCC: Promising New Parkinson’s Therapies May Also Treat Brain Injuries,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 AERI-US    BW   Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting,#N/A, 2/23/2017 INCY-US  BW   Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania,#N/A,#N/A, 5/27/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences, 1/05/2015 15708510 BW   Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint,#N/A, 1/31/2013 04269E10 BW   Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib,#N/A,#N/A, 6/06/2016 EXEL-US  BW   Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting, 5/30/2014 80105N10  BW   Genzyme’s Lemtrada Resubmission Accepted for Review by FDA, 7/27/2016 VRTX-US   BW   Vertex Reports Second Quarter 2016 Financial Results,#N/A,#N/A, 2/25/2016 BLUE-US  BW   bluebird bio Announces Transition of Chief Financial Officer," 3/11/2015 00422510 BW   ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer",#N/A,#N/A,#N/A, 5/06/2015 88338N10 BW   TherapeuticsMD Inc. to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2015 IRWD-US  BW   Video Alert: Updated Direct-to-Consumer Awareness Campaign Available for LINZESS® (linaclotide),#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2014 0D059L-E BW   Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature,#N/A,#N/A,#N/A," 6/17/2014 29251M10   BW   Enanta Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Applications for AbbVie’s Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C",10/31/2017 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming November Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2014 00972D10 BW   Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors,#N/A,#N/A,#N/A,#N/A, 7/22/2014 0C58C1-E    BW   Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2015 00930K-E BW   Eagle Pharmaceuticals to Present at Needham & Company’s 14th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/02/2015 25303110 BW   Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma",11/01/2017 15117K10 BW   Servier et Pfizer annoncent que les résultats préliminaires des premières études d'UCART19 chez l’homme seront présentés lors du 59è congrès annuel de l'American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2015 00434H10 BW   Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A," 5/09/2012 008TL8-E BW   IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate",#N/A,#N/A,#N/A, 5/09/2016 G6674U10 BW   Novocure Reports First Quarter 2016 Financial Results and Provides Company Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2016 74587V10 BW   Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2015 00900T10 BW   Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/09/2015 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2014 Financial Results,#N/A, 5/31/2016 0DBFR7-E    BW   ArcherDX to Collaborate with Illumina on Next-Generation Sequencing-Based In Vitro Diagnostics Development," 5/07/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Continued Advancement of Robust, Late-Stage Pipeline and First Quarter 2015 Financial Results",#N/A, 2/02/2016 ARWR-US  BW   Arrowhead to Webcast Fiscal 2016 First Quarter Results,#N/A,#N/A,#N/A,#N/A, 2/28/2014 68375N10 BW   OPKO's Longer-Acting Clotting Factor VIIa-CTP Receives Orphan Drug Designation in the U.S.,#N/A,#N/A,"11/17/2016 ALXN-US  BW   EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – ALXN",#N/A, 3/06/2017 SGEN-US     BW   FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine,#N/A, 2/26/2016 080RQG-E    BW   Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B," 4/17/2014 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results",#N/A," 3/12/2018 GILD-US      BW   Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer",#N/A,#N/A,#N/A,#N/A, 3/13/2012 AMGN-US      BW   Research and Markets: Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Year End 2015 Financial Results and Provides Business Update,#N/A, 2/21/2017 BCS-GB   BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/12/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare Conference,12/22/2014 15708510 BW   Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint,#N/A, 1/11/2013 4568-JP  BW   Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer,#N/A,#N/A, 6/05/2016 IPN-FR   BW   Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO, 5/28/2014 80105N10  BW   Genzyme Recognizes Sixth Annual World MS Day, 7/18/2016 DHCNI-US  BW   Senior Housing Properties Trust Announces $620 Million Mortgage Financing on Boston Seaport Buildings,#N/A,#N/A, 2/24/2016 BLUE-US  BW   bluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress, 3/11/2015 00422510 BW   ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZIDTM NDA Submission,#N/A,#N/A,#N/A, 5/05/2015 88338N10 BW   TherapeuticsMD Announces First Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2015 IRWD-US  BW   Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard®,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2014 0D059L-E BW   Syros Pharmaceuticals Appoints Genomics Entrepreneur Jorge Conde to Dual Role as Chief Financial Officer and Chief Product Officer,#N/A,#N/A,#N/A," 6/13/2014 29251M10   BW   Enanta Pharmaceuticals Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C",10/30/2017 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/27/2014 00972D10 BW   Akebia to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 7/22/2014 78667J10    BW   SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/17/2015 26979610 BW   Eagle Pharmaceuticals Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2015 25303110 BW   Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads,11/01/2017 15117K10 BW   Cellectis annonce deux présentations orales et un poster lors du congrès annuel de l’American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2015 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2012 062RZ9-E BW   Tech Council of Maryland Names GlycoMimetics as 2012 Life Sciences Company of the Year,#N/A,#N/A,#N/A, 5/06/2016 G6674U10 BW   Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/22/2016 74587V10 BW   Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 00900T10 BW   Aimmune Therapeutics Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/06/2015 53220K50  BW   Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®,#N/A, 5/25/2016 GS-US       BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June, 4/30/2015 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference and Webcast,#N/A, 1/19/2016 ARWR-US  BW   Arrowhead’s ARC-AAT Granted EMA Orphan Drug Designation,#N/A,#N/A,#N/A,#N/A, 2/13/2014 68375N10 BW   OPKO Announces Successful Confirmation of 4Kscore™ Algorithm in the United States,#N/A,#N/A,11/17/2016 ALXN-US  BW   New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris® (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant,#N/A, 3/01/2017 BARC-GB     BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 2/08/2016 BIIB-US     BW   Biogen Joins Pioneering Target Validation Collaboration," 4/08/2014 45253H10 BW   ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853",#N/A," 3/05/2018 GILD-US      BW   Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen",#N/A,#N/A,#N/A,#N/A, 3/12/2012 0C8BZH-E     BW   RBCC Identifies Promising New Business Targets at Texas’ Premiere Life Sciences Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2016 AERI-US    BW   Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week,#N/A, 2/14/2017 AGEN-US  BW   Incyte and Agenus Amend Collaboration Agreement,#N/A,#N/A, 4/30/2014 G0176710 BW   Alkermes plc Reports First Quarter 2014 Financial Results,12/18/2014 15708510 BW   FDA Approves INTERCEPT Blood System for Platelets,#N/A,"12/13/2012 04269E10 BW   ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087, an FGFR Inhibitor",#N/A,#N/A, 6/05/2016 EXEL-US  BW   Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting, 5/27/2014 80105N10  BW   Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE), 7/14/2016 VRTX-US   BW   Vertex to Announce Second Quarter 2016 Financial Results on July 27,#N/A,#N/A, 2/17/2016 BLUE-US  BW   bluebird bio Announces First Patient Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma," 2/26/2015 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014",#N/A,#N/A,#N/A, 5/04/2015 88338N10 BW   CORRECTING AND REPLACING New Data on Compounded Prescription Practices Show Differences among Medical Specialties,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2015 46333X10 BW   Ironwood Pharmaceuticals Initiates Phase I Clinical Study of Sgc Stimulator IW-1973,#N/A,#N/A,#N/A,#N/A,#N/A," 4/02/2014 0D059L-E BW   Richard A. Young, Syros Pharmaceuticals Scientific Founder, to Open AACR Annual Meeting 2014 with Address Highlighting His Pioneering Gene Control Research",#N/A,#N/A,#N/A, 6/10/2014 29251M10   BW   Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences,10/20/2017 ALNY-US   BW   Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2014 00972D10 BW   Akebia Announces Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A, 7/21/2014 78667J10    BW   SAGE Therapeutics Announces Full Exercise of Over-Allotment Option,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2015 26979610 BW   Eagle Pharmaceuticals Announces Commencement of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2015 25303110 BW   Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and β-Catenin at AACR MYC: From Biology to Therapy Meeting,11/01/2017 15117K10 BW   Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2015 00434H10 BW   Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A," 4/17/2012 07TN9C-E BW   Leaders in Science, Advocacy to Judge 2012 Biotech Humanitarian Award",#N/A,#N/A,#N/A, 5/05/2016 G6674U10 BW   Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2016 74587V10 BW   Puma Biotechnology Reports Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2015 0DFTQ2-E BW   Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/03/2015 53220K50  BW   Ligand Signs License Agreement with Sermonix for Lasofoxifene,#N/A, 5/09/2016 45232710    BW   Illumina Registers MiSeqDx System in South Korea, 4/29/2015 SPPI-US   BW   Spectrum Pharmaceuticals Selects DSG for Blended SaaS and Tech Transfer EDC,#N/A, 1/07/2016 ARWR-US  BW   Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A, 2/06/2014 68375N10 BW   OPKO Health Announces the Appointment of Greg Stanley as Vice President of Sales and Marketing for its Global Diagnostics Business Unit,#N/A,#N/A,11/16/2016 ALXN-US  BW   Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q,#N/A," 2/27/2017 SGEN-US     BW   SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017",#N/A, 2/04/2016 BIIB-US     BW   Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference," 3/17/2014 45253H10 BW   ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting",#N/A," 3/05/2018 GILD-US      BW   Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine",#N/A,#N/A,#N/A,#N/A, 2/17/2012 0C8BZM-E     BW   RBCC Sets Sights on Top Emerging Biotech Innovations,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/22/2016 AERI-US    BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2015 Financial Results and Host Conference Call on Tuesday, March 1, 2016",#N/A," 2/14/2017 INCY-US  BW   Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs",#N/A,#N/A, 4/23/2014 G0176710 BW   Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results,12/16/2014 15708510 BW   FDA Approves INTERCEPT Blood System for Plasma,#N/A,"12/05/2012 ARQL-US  BW   ArQule, Inc. to Present at Oppenheimer Healthcare Conference",#N/A,#N/A, 5/23/2016 IPSEY-FR BW   Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma, 5/09/2014 AMGN-US   BW   BayBio Names Henry M. Gunn High School Senior Amgen Bay Area BioGENEius Finalist, 7/06/2016 0B36V1-E  BW   Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis,#N/A,#N/A, 1/05/2016 BLUE-US  BW   bluebird bio to Present at the 34th Annual J.P. Morgan Healthcare Conference, 2/24/2015 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A, 4/22/2015 88338N10 BW   TherapeuticsMD to Host First Quarter 2015 Financial Results Conference Call and Webcast May 5,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2015 46333X10 BW   Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2013 0D059L-E BW   Syros Pharmaceuticals Announces Publication of Important Scientific Studies Related to Company's Industry-Leading Gene Control Platform,#N/A,#N/A,#N/A, 5/22/2014 29251M10   BW   Enanta Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference,10/18/2017 ALNY-US   BW   Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2014 00972D10 BW   Akebia Therapeutics Announces Expansion of Management Team,#N/A,#N/A,#N/A,#N/A, 7/17/2014 78667J10    BW   SAGE Therapeutics Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2015 26979610 BW   Az FDA hétéves kizárólagos jogot biztosít az Eagle Pharmaceuticals számára a malignus hyperthermia kezelésére szolgáló Ryanodex forgalmazására,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/17/2014 25303110 BW   Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)",11/01/2017 15117K10 BW   Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2015 00434H10 BW   FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2012 062RZ9-E BW   GlycoMimetics Announces Two Key Leadership Promotions,#N/A,#N/A,#N/A, 5/04/2016 NVCR-GB  BW   Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2016 74587V10 BW   Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2015 0DFTQ2-E BW   Allergen Research Corporation Renamed Aimmune Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/02/2015 53220K50  BW   Ligand Promotes Matthew W. Foehr to President,#N/A, 5/09/2016 45232710    BW   Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders," 3/30/2015 84763A10  BW   Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the American Pharmacists Association (APhA) in San Diego, Highlighting Stability",#N/A,12/14/2015 ARWR-US  BW   Arrowhead Reports Fiscal 2015 Year End Results,#N/A,#N/A,#N/A,#N/A," 2/03/2014 68375N10 BW   Neovasc, an OPKO Investee, Reports Successful First Human Implant of Tiara™ Transcatheter Mitral Valve",#N/A,#N/A,11/11/2016 06VHPT-E BW   New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa),#N/A," 2/14/2017 SGEN-US     BW   DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm",#N/A, 1/27/2016 09062X10    BW   Biogen 2015 Revenues Increase 11% to $10.8 Billion," 2/27/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 3/04/2018 GILD-US      BW   Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys",#N/A,#N/A,#N/A,#N/A," 2/13/2012 06W76T-E     BW   The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2016 AERI-US    BW   Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2,#N/A," 1/30/2017 CALA-US  BW   Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor",#N/A,#N/A, 4/08/2014 G0176710 BW   Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia,11/21/2014 15708510 BW   FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma,#N/A,11/27/2012 4151-JP  BW   Edison expands oncology sector presence with launch of coverage of ArQule,#N/A,#N/A, 5/23/2016 EXEL-US  BW   Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma, 5/08/2014 SNY-FR    BW   Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®, 6/24/2016 0DP3CK-E  BW   CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing,#N/A,#N/A,12/06/2015 BLUE-US  BW   bluebird bio Presents Pre-Clinical and Manufacturing Data from CAR T Oncology Programs at ASH Annual Meeting," 2/19/2015 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015",#N/A,#N/A,#N/A, 3/18/2015 88338N10 BW   TherapeuticsMD Appoints Biopharmaceutical Senior Executives Angus C. Russell and J. Martin Carroll as Independent Directors,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 46333X10 BW   Ironwood Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2013 0D059L-E BW   Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors,#N/A,#N/A,#N/A," 5/12/2014 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014", 9/26/2017 ALNY-US   BW   Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/17/2014 00972D10 BW   Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors",#N/A,#N/A,#N/A,#N/A, 6/10/2014 0C58C1-E    BW   SAGE Therapeutics Appoints James M. Frates to the Company’s Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2015 26979610 BW   Amerykańska Agencja ds. Żywności i Leków przyznaje spółce Eagle Pharmaceuticals siedmioletni okres wyłączności na produkcję leku Ryanodex do leczenia hipertermii złośliwej,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2014 25303110 BW   Dicerna R&D Update Webcast Reminder,"10/04/2017 15117K10 BW   Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 0068K6-E BW   Acceleron to Present Dalantercept Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,12/13/2011 062RZ9-E BW   Progress of GlycoMimetics’ Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology,#N/A,#N/A,#N/A, 4/26/2016 G6674U10 BW   Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2016 74587V10 BW   Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2015 0DFTQ2-E BW   Allergen Research Corporation Names Mark McDade as Chairman and Mark Iwicki as Member of the Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/28/2015 53220K50  BW   Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February,#N/A, 5/03/2016 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2016, 3/13/2015 84763A10  BW   Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results,#N/A,12/14/2015 ARWR-US  BW   Arrowhead Added to NASDAQ Biotechnology Index®,#N/A,#N/A,#N/A,#N/A, 1/09/2014 68375N10 BW   OPKO Health to Present at the 32nd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,"11/10/2016 ALXN-US  BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A, 2/14/2017 0BWYJ5-E    BW   venBio Takes Steps to Protect Rights of Immunomedics Stockholders,#N/A," 1/16/2016 BIIB-US     BW   BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union"," 2/20/2014 45253H10 BW   ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer",#N/A, 2/22/2018 GILD-US      BW   Gilead Sciences Announces Senior Management Change,#N/A,#N/A,#N/A,#N/A," 2/08/2012 06Z0F5-E     BW   Lance Berman, M.D. Joins Relypsa as Senior Vice President, Commercial Strategy & Medical Affairs",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/16/2016 AERI-US    BW   Aerie Pharmaceuticals to Present at the RBC Capital Markets 2016 Healthcare Conference,#N/A, 1/24/2017 INCY-US  BW   Incyte to Report Fourth Quarter and Year-End Financial Results,#N/A,#N/A, 3/06/2014 G0176710 BW   Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder,11/04/2014 15708510 BW   Cerus Corporation Reports Third Quarter 2014 Results,#N/A,"11/07/2012 04269E10 BW   ArQule, Inc. to Present at Lazard Healthcare Conference",#N/A,#N/A, 5/05/2016 07MDY1-E BW   Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 4/30/2014 80105N10  BW   Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center, 6/10/2016 0B25H7-E  BW   Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference,#N/A,#N/A,12/06/2015 BLUE-US  BW   bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 and HGB-206 Studies of LentiGlobin® at ASH Annual Meeting," 1/06/2015 00422510 BW   ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015",#N/A,#N/A,#N/A, 3/10/2015 88338N10 BW   TherapeuticsMD Announces Fourth Quarter and Full-Year 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2015 46333X10 BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,10/10/2013 0D059L-E BW   Syros Pharmaceuticals Announces New Findings on Central Role of Super-Enhancers in Controlling Cell Biology and Disease,#N/A,#N/A,#N/A," 5/12/2014 29251M10   BW   Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel"," 9/25/2017 ALNY-US   BW   Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on ""Enhanced Stabilization Chemistry Plus"" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/30/2014 00972D10 BW   Akebia Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes",#N/A,#N/A,#N/A,#N/A, 6/05/2014 0C58C1-E    BW   SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2015 26979610 BW   FDA (americký Úřad pro potraviny a léčiva) zaručuje sedmiletou exkluzivitu na trhu pro lék Ryanodex společnosti Eagle Pharmaceuticals určený k léčbě maligní hypertermie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2014 25303110 BW   Dicerna to Present at the 2014 Deutsche Bank BioFEST,"10/04/2017 15117K10 BW   Mathieu Simon, M.D., Vice-président exécutif et directeur des opérations de Cellectis occupe les fonctions de directeur médical par intérim",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 00434H10 BW   Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,10/11/2011 PFE-US   BW   GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease,#N/A,#N/A,#N/A, 4/25/2016 06CR5C-E BW   FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2016 74587V10 BW   Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2015 0DFTQ2-E BW   Allergen Research Corporation Announces New CFO Warren DeSouza and Board of Directors Audit Committee Chair Kate Falberg,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/27/2015 53220K50  BW   Ligand to Report Fourth Quarter Results on February 9th,#N/A, 4/27/2016 45232710    BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference," 3/11/2015 84763A10  BW   Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals’ Analyst Day on Friday, March 13th",#N/A,12/07/2015 ARWR-US  BW   Arrowhead to Webcast Fiscal 2015 Year End Results,#N/A,#N/A,#N/A,#N/A, 1/08/2014 0DHCLH-E BW   OPKO Health Completes Acquisition of Laboratorio Arama de Uruguay Limitada,#N/A,#N/A,"11/10/2016 ALXN-US  BW   Bragar Eagel & Squire, P.C. Is Investigating Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Stockholders and Encourages Investors to Contact the Firm",#N/A, 2/13/2017 0DY7WH-E    BW   Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference,#N/A,"12/21/2015 09062X10    BW   Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016"," 2/06/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 2/22/2018 SGMO-US      BW   Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer",#N/A,#N/A,#N/A,#N/A," 1/31/2012 128940-KR    BW   Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 AERI-US    BW   Aerie Pharmaceuticals to Participate in Several Conferences in November,#N/A, 1/09/2017 INCY-US  BW   Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab),#N/A,#N/A," 2/27/2014 G0176710 BW   Alkermes plc Reports Financial Results for the Periods Ended Dec. 31, 2013 and Provides Financial Expectations for 2014",10/29/2014 15708510 BW   Cerus Announces Agreement With Kawasumi Laboratories for the Development of INTERCEPT Platelets Kits in Japan,#N/A,11/01/2012 04269E10 BW   ArQule Announces Third Quarter Fiscal 2012 Results,#N/A,#N/A, 5/04/2016 06CR5C-E BW   Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update, 4/30/2014 80105N10  BW   Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s LemtradaTM, 5/31/2016 GS-US     BW   Vertex to Present at the Goldman Sachs Healthcare Conference on June 7,#N/A,#N/A,12/05/2015 BLUE-US  BW   bluebird bio Reports New Beta-thalassemia Major Data from Northstar Study of LentiGlobin® at ASH Annual Meeting,12/08/2014 00422510 BW   ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders,#N/A,#N/A,#N/A, 3/09/2015 88338N10 BW   Physicians’ Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2015 46333X10 BW   Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease,#N/A,#N/A,#N/A,#N/A,#N/A," 9/05/2013 0D059L-E BW   Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors",#N/A,#N/A,#N/A," 5/08/2014 29251M10   BW   Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450", 9/20/2017 SAN-FR    BW   Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 00972D10 BW   Akebia Therapeutics anuncia próxima presentación en el 51º Congreso Anual ERA-EDTA,#N/A,#N/A,#N/A,#N/A, 5/05/2014 0C58C1-E    BW   SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   La FDA accorda sette anni di esclusività sul mercato a Ryanodex di Eagle Pharmaceuticals per il trattamento dell'ipertermia maligna,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2014 25303110 BW   Dicerna Reports on Progress of Development Programs,10/04/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2015 00434H10 BW   Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2010 062RZ9-E BW   GlycoMimetics Announces Data Presentations on Lead Compound at American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A, 4/07/2016 NVCR-GB  BW   Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2016 080RQG-E BW   Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2015 0DFTQ2-E BW   Allergen Research Corporation Expands Management with New VP Functions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/09/2015 53220K50  BW   Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan,#N/A, 4/21/2016 06YV06-E    BW   Illumina Files Patent Infringement Suit in Switzerland against Genoma SA for Infringement of NIPT Patents, 3/09/2015 84763A10  BW   Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan,#N/A,12/07/2015 ARWR-US  BW   Arrowhead’s ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A,12/19/2013 68375N10 BW   OPKO Records Highly Successful Exit of Investment in Sorrento Therapeutics,#N/A,#N/A,"11/10/2016 ALXN-US  BW   INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A," 2/10/2017 SGEN-US     BW   Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors",#N/A,12/18/2015 BIIB-US     BW   Biogen to Present at the 34th Annual J.P. Morgan Healthcare Conference," 1/31/2014 45253H10 BW   ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management",#N/A," 2/08/2018 GILD-US      BW   Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21",#N/A,#N/A,#N/A,#N/A," 1/30/2012 0C17GS-E     BW   Robert F. Baltera, Jr. Joins PBS Biotech Advisory Board",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/04/2015 AERI-US    BW   Aerie Pharmaceuticals to Host Investor and Media Briefing During the 2015 American Academy of Ophthalmology Annual Meeting on November 13, 2015",#N/A,12/30/2016 INCY-US  BW   Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease,#N/A,#N/A, 2/24/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 34Th Annual Health Care Conference,10/23/2014 15708510 BW   American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks,#N/A,"10/25/2012 04269E10 BW   ArQule to Report Third Quarter 2012 Financial Results on November 1, 2012",#N/A,#N/A," 4/26/2016 EXEL-US  BW   Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016", 4/22/2014 80105N10  BW   Data from Genzyme’s Multiple Sclerosis Franchise Featured at AAN, 5/31/2016 06CR5C-E  BW   U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation,#N/A,#N/A,12/03/2015 BLUE-US  BW   bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy,11/25/2014 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 2/24/2015 88338N10 BW   TherapeuticsMD to Host Fourth Quarter, Full-Year 2014 Financial Results Conference Call and Webcast",#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2015 46333X10 BW   Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A," 5/22/2013 0D059L-E BW   Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer",#N/A,#N/A,#N/A, 4/30/2014 29251M10   BW   Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference," 9/08/2017 ALNY-US   BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 00972D10 BW   Akebia Therapeutics kondigt presentatie aan tijdens 51e jaarlijkse ERA-EDTA-congres,#N/A,#N/A,#N/A,#N/A, 5/01/2014 0C58C1-E    BW   SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   La FDA otorga siete años de exclusividad de mercado a Ryanodex de Eagle Pharmaceuticals para el tratamiento de la hipertermia maligna,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2014 0098J6-E BW   Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program,10/04/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2015 0068K6-E BW   Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A," 9/28/2010 062RZ9-E BW   Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model",#N/A,#N/A,#N/A, 4/05/2016 G6674U10 BW   Novocure to Report First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2016 74587V10 BW   Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2015 0DFTQ2-E BW   Allergen Research Corporation Completes $80 Million Series B Financing to Advance Drug Development Portfolio for Food Allergy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/08/2015 53220K50  BW   Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV,#N/A, 4/18/2016 45232710    BW   Illumina Announces Preliminary Revenue for First Quarter of Fiscal Year 2016," 3/04/2015 84763A10  BW   Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals",#N/A,11/16/2015 ARWR-US  BW   Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA,#N/A,#N/A,#N/A,#N/A,12/19/2013 68375N10 BW   OPKO Completes Patient Recruitment in Second Phase 3 Trial of RayaldyTM,#N/A,#N/A,"11/10/2016 ALXN-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc.-- ALXN",#N/A, 2/09/2017 SGEN-US     BW   Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results,#N/A,12/16/2015 0F9W1R-E    BW   Arsia Therapeutics Inc. and Biogen Sign a Research Collaboration for the Development of Subcutaneous Biologics," 1/31/2014 45253H10 BW   ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update",#N/A," 2/07/2018 GILD-US      BW   U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection",#N/A,#N/A,#N/A,#N/A," 1/28/2012 MITI-US      BW   Faruqi & Faruqi, LLP Announces Investigation of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2015 AERI-US    BW   Aerie Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update,#N/A,12/21/2016 INCY-US  BW   Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies,#N/A,#N/A," 2/20/2014 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Periods Ended Dec. 31, 2013","10/22/2014 15708510 BW   Cerus to Release Third Quarter 2014 Results on November 4, 2014",#N/A,10/16/2012 4568-JP  BW   ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma,#N/A,#N/A, 4/25/2016 06CR5C-E BW   Ipsen est heureux d’annoncer que son partenaire Exelixis a reçu l’autorisation de mise sur le marché des autorités réglementaires américaines (FDA) pour CABOMETYX™ (cabozantinib) comprimés ..., 4/15/2014 80105N10  BW   Sanofi Launches Probi Digestis® in Korea, 4/27/2016 VRTX-US   BW   Vertex Reports First Quarter 2016 Financial Results,#N/A,#N/A,11/25/2015 BLUE-US  BW   bluebird bio Announces Participation in 27th Annual Piper Jaffray Healthcare Conference,"11/13/2014 00422510 BW   ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014",#N/A,#N/A,#N/A, 2/11/2015 88338N10 BW   TherapeuticsMD Announces Pricing of Common Stock Offering,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2015 46333X10 BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2013 0057B5-E BW   Syros Pharmaceuticals Launches with $30 Million Series A Financing,#N/A,#N/A,#N/A," 4/28/2014 29251M10   BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six Months Ended March 31, 2014"," 9/07/2017 ALNY-US   BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 00972D10 BW   Akebia Therapeutics Announces Upcoming Presentation at 51st ERA-EDTA Annual Congress,#N/A,#N/A,#N/A,#N/A, 4/01/2014 0C58C1-E    BW   SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   FDA gewährt Eagle Pharmaceuticals-Medikament Ryanodex zur Behandlung der malignen Hyperthermie siebenjährige Marktexklusivität,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2014 25303110 BW   Dicerna to Present at Two Upcoming Investor Conferences, 9/08/2017 070P8N-E BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2015 00434H10 BW   Acceleron Pharma to Host First Quarter 2015 Financial Results Conference Call and Webcast on May 7, 2015",#N/A,#N/A,#N/A,#N/A,#N/A, 7/14/2010 062RZ9-E BW   Key GlycoMimetics Patents Issue in the U.S.,#N/A,#N/A,#N/A, 4/04/2016 G6674U10 BW   Novocure und führendes Krebs-Zentrum leiten präklinische Forschungskooperation zur Untersuchung von TTFields ein,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2016 74587V10 BW   Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2014 0DFTQ2-E BW   Allergen Research Corporation Initiates Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy (OIT),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/26/2014 53220K50  BW   Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan,#N/A, 4/14/2016 45232710    BW   Illumina Invests In New Venture Fund, 2/20/2015 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24th,#N/A,11/15/2015 ARWR-US  BW   Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees,#N/A,#N/A,#N/A,#N/A,12/16/2013 68375N10 BW   OPKO Announces Investor Conference Call Details,#N/A,#N/A,"11/09/2016 ALXN-US  BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A," 2/01/2017 SGEN-US     BW   The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Seattle Genetics, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,12/08/2015 BIIB-US     BW   New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B," 1/24/2014 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results",#N/A, 2/06/2018 GILD-US      BW   Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend,#N/A,#N/A,#N/A,#N/A, 1/27/2012 MITI-US      BW   Harwood Feffer LLP Announces Investigation of Micromet Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/20/2015 AERI-US    BW   Aerie Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Tuesday, November 3, 2015",#N/A,12/13/2016 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A,#N/A, 2/03/2014 G0176710 BW   Alkermes to Present at Two Upcoming Investor Conferences,10/20/2014 15708510 BW   Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma,#N/A,10/02/2012 04269E10 BW   ArQule and Daiichi Sankyo Announce Discontinuation of Phase 3 MARQUEE Clinical Trial in Non-Small Cell Lung Cancer,#N/A,#N/A, 4/25/2016 06CR5C-E BW   Ipsen is Pleased to Announce That Its Partner Exelixis Obtained FDA Approval of CABOMETYX™ (cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy, 4/07/2014 80105N10  BW   Genzyme to Resubmit LemtradaTM Application for FDA Review, 4/15/2016 VRTX-US   BW   Vertex to Announce First Quarter 2016 Financial Results on April 27,#N/A,#N/A,11/05/2015 BLUE-US  BW   bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology,11/10/2014 00422510 BW   ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission,#N/A,#N/A,#N/A, 2/10/2015 88338N10 BW   TherapeuticsMD Announces Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2014 46333X10 BW   Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2013 0D059L-E BW   Syros Pharmaceuticals Announces Publications in Cell Related to Key Gene Control Discovery,#N/A,#N/A,#N/A," 4/22/2014 29251M10   BW   Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen"," 9/07/2017 ALNY-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alnylam Pharmaceuticals, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 00972D10 BW   Akebia Therapeutics annuncia imminente presentazione al 51o congresso annuale ERA-EDTA,#N/A,#N/A,#N/A,#N/A, 3/27/2014 0C58C1-E    BW   SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   FDA verleent zevenjarige marktexclusiviteit aan Ryanodex van Eagle Pharmaceuticals voor de behandeling van maligne hyperthermie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2014 25303110 BW   Dicerna Announces Third Quarter 2014 Financial and Operational Results, 9/07/2017 15117K10 BW   Cellectis: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2015 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2010 062RZ9-E BW   GlycoMimetics Initiates Phase 2 Clinical Trial of Lead Candidate GMI-1070 in Sickle Cell Patients,#N/A,#N/A,#N/A, 3/30/2016 G6674U10 BW   Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2016 UBS-CH   BW   Puma Biotechnology to Present at UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/22/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta®,#N/A, 4/05/2016 45232710    BW   Illumina Introduces BaseSpace® Informatics Suite to Accelerate Genomic Data Analysis for Sequence Labs, 2/17/2015 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results and Analyst Day,#N/A,11/11/2015 ARWR-US  BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,12/16/2013 0CZTNZ-E BW   OPKO Health to Expand Latin American Presence with Acquisition of Uruguayan Pharmaceutical Company,#N/A,#N/A,"11/09/2016 ALXN-US  BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors",#N/A," 1/27/2017 SGEN-US     BW   IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm",#N/A,11/24/2015 BIIB-US     BW   Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A," 1/09/2014 077JML-E BW   CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets",#N/A, 2/06/2018 GILD-US      BW   Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results,#N/A,#N/A,#N/A,#N/A," 1/27/2012 MITI-US      BW   Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2015 AERI-US    BW   Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of RhopressaTM,#N/A,12/04/2016 INCY-US  BW   Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib),#N/A,#N/A, 1/13/2014 G0176710 BW   Invesco Perpetual Funds to Make $250 Million Direct Investment in Alkermes’ Ordinary Shares,10/07/2014 15708510 BW   U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks,#N/A," 9/12/2012 ARQL-US  BW   ArQule, Inc. to Present at UBS Global Life Sciences Conference",#N/A,#N/A, 4/25/2016 EXEL-US  BW   ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy," 4/04/2014 80105N10  BW   At the Forefront of 4K: Intelsat, BT, Ericsson, Newtec and Sony Demonstrate Next Steps to Make True 4K UHDTV a Commercial Reality", 3/10/2016 BCS-GB    BW   Vertex to Present at the Barclays Healthcare Conference on March 15,#N/A,#N/A,11/04/2015 BLUE-US  BW   bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress,"11/03/2014 00422510 BW   ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014",#N/A,#N/A,#N/A,"12/15/2014 88338N10 BW   TherapeuticsMD Receives Five New Patent Allowances, Further Strengthens IP Assets",#N/A,#N/A,#N/A,#N/A,#N/A,11/20/2014 46333X10 BW   Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2014 29251M10   BW   Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting, 9/07/2017 ALNY-US   BW   Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 00972D10 BW   Akebia to Present at the Annual UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 3/13/2014 0C58C1-E    BW   SAGE Therapeutics Closes $38M Oversubscribed Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   FDA concede sete anos de exclusividade de mercado ao Ryanodex da Eagle Pharmaceuticals para o tratamento de hipertermia maligna,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/24/2014 25303110 BW   Dicerna to Announce Third-Quarter 2014 Financial Results and Host Conference Call on November 6, 2014", 9/07/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2015 00434H10 BW   Acceleron Announces Oral Presentations of Luspatercept and Sotatercept Data at the 13th International Symposium on Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2016 G6674U10 BW   Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2016 74587V10 BW   Puma Biotechnology Reports First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/19/2014 53220K50  BW   Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus,#N/A, 3/07/2016 45232710    BW   Jay Flatley to Assume Role of Executive Chairman of the Board of Directors of Illumina; Francis deSouza Appointed President and CEO, 2/12/2015 84763A10  BW   Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting,#N/A,10/20/2015 ARWR-US  BW   Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A,12/13/2013 68375N10 BW   OPKO To Hold Investor Conference,#N/A,#N/A,11/09/2016 ALXN-US  BW   Alexion Provides Update on Form 10-Q Filing,#N/A," 1/27/2017 SGEN-US     BW   Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Seattle Genetics, Inc. Investors and Encourages Investors to Contact the Firm",#N/A,11/20/2015 BIIB-US     BW   Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP," 1/06/2014 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the 32nd Annual J.P. Morgan Healthcare Conference",#N/A," 2/01/2018 GILD-US      BW   Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors",#N/A,#N/A,#N/A,#N/A," 1/27/2012 MITI-US      BW   Robbins Umeda LLP Announces an Investigation of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2015 AERI-US    BW   Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of RoclatanTM,#N/A,11/03/2016 06QBQ2-E BW   More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting,#N/A,#N/A, 1/08/2014 G0176710 BW   Alkermes Announces Advances With Its Late-Stage CNS Pipeline, 9/11/2014 15708510 BW   Cerus and Biomedica Foscama Group S.p.A. Enter Distribution Agreement for the INTERCEPT Blood System in Italy,#N/A," 8/30/2012 ARQL-US  BW   ArQule, Inc. to Present at Upcoming Investment Conferences",#N/A,#N/A, 4/20/2016 06N2PB-E BW   Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting, 3/26/2014 80105N10  BW   U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients," 3/08/2016 0BJDF0-E  BW   Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",#N/A,#N/A,11/04/2015 BLUE-US  BW   bluebird bio Announces Participation in 24th Annual Credit Suisse Healthcare Conference, 9/09/2014 00422510 BW   ACADIA Pharmaceuticals reçoit la désignation de thérapie novatrice de la part de la FDA pour le NUPLAZID™ (Pimavanserin) destiné au traitement des troubles psychotiques liés à la maladie de Parkinson,#N/A,#N/A,#N/A,11/14/2014 88338N10 BW   TherapeuticsMD Inc. to present at the Stifel Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2014 29251M10   BW   Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting, 9/05/2017 ALNY-US   BW   Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 00972D10 BW   Akebia Announces First Quarter 2014 Financial Results and Recent Corporate Highlights,#N/A,#N/A,#N/A,#N/A, 2/05/2014 0C58C1-E    BW   SAGE Therapeutics to Present at the 2014 Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/23/2015 26979610 BW   La FDA accorde à Eagle Pharmaceuticals une exclusivité commerciale de sept ans pour le Ryanodex, un médicament pour le traitement de l’hyperthermie maligne",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/14/2014 25303110 BW   Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society," 9/07/2017 CLLS-US  BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/06/2015 00434H10 BW   Acceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2016 G6674U10 BW   Humana Issues Positive Coverage Decision For Optune,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2016 07MDY1-E BW   Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/18/2014 53220K50  BW   Ligand Provides Highlights from Today’s Analyst Day Event,#N/A, 2/24/2016 ILMN-US     BW   Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software,12/26/2014 LGND-US   BW   Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan,#N/A,10/14/2015 ARWR-US  BW   Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format,#N/A,#N/A,#N/A,#N/A,12/04/2013 68375N10 BW   OPKO Health to Present at the Oppenheimer 24th Annual Healthcare Conference,#N/A,#N/A,11/03/2016 06QBQ2-E BW   Researchers to Present New Phase 1/2 Data on ALXN1210 in Patients with PNH at ASH 2016 Annual Meeting,#N/A," 1/24/2017 SGEN-US     BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",#N/A,11/03/2015 000N8F-E    BW   Solid GT Raises $42.5 Million in Series B Financing,"12/30/2013 45253H10 BW   ImmunoGen, Inc. Appoints David Johnston as Chief Financial Officer",#N/A," 1/23/2018 GILD-US      BW   Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018",#N/A,#N/A,#N/A,#N/A," 1/26/2012 MITI-US      BW   Ryan & Maniskas, LLP Announces Investigation of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2015 AERI-US    BW   Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results,#N/A,11/02/2016 INCY-US  BW   Incyte to Present at Upcoming Investor Conference,#N/A,#N/A, 1/07/2014 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the 32nd Annual J.P. Morgan Healthcare Conference, 9/10/2014 15708510 BW   Cerus Submits IDE Supplement to Make INTERCEPT Platelets Available Pre-Approval in U.S. Areas at Risk from Outbreaks of Chikungunya and Dengue,#N/A, 8/02/2012 04269E10 BW   ArQule Reports Second Quarter 2012 Financial Results,#N/A,#N/A, 3/03/2016 EXEL-US  BW   Exelixis to Present at Two Investor Conferences in March, 3/21/2014 80105N10  BW   Genzyme’s Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis, 2/24/2016 VRTX-US   BW   Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis,#N/A,#N/A,10/19/2015 BLUE-US  BW   bluebird bio Announces Presentation at Cooley’s Anemia Foundation Symposium, 9/02/2014 00422510 BW   ACADIA Pharmaceuticals erhält FDA-Bezeichnung „Breakthrough Therapy“ für NUPLAZID™ (Pimavanserin) für Parkinson-Psychosen,#N/A,#N/A,#N/A,11/06/2014 88338N10 BW   TherapeuticsMD Announces Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2014 46333X10 BW   Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/24/2014 29251M10   BW   Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting," 8/28/2017 ALNY-US   BW   New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2014 00972D10 BW   Akebia Therapeutics Announces Completion of Enrollment in its Phase 2b Clinical Study of AKB-6548,#N/A,#N/A,#N/A,#N/A, 1/06/2014 0C58C1-E    BW   SAGE Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 26979610 BW   FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2014 25303110 BW   Dicerna to Present at Three Upcoming Investor Conferences, 9/05/2017 ALCLS-FR BW   SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2015 00434H10 BW   Acceleron Pharma Announces Executive Appointments and Promotions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/29/2016 06CR5C-E BW   Novocure Reports 2015 Operating Statistics and Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2016 06P9WL-E BW   Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/12/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag),#N/A, 2/23/2016 45232710    BW   Illumina Sues Oxford Nanopore for Patent Infringement,12/26/2014 84763A10  BW   Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan,#N/A,10/05/2015 ARWR-US  BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,11/15/2013 68375N10 BW   OPKO Completes Patient Recruitment in First Phase 3 Trial of RayaldyTM,#N/A,#N/A,10/27/2016 ALXN-US  BW   Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS),#N/A," 1/20/2017 SGEN-US     BW   Robbins Arroyo LLP: Seattle Genetics, Inc. (SGEN) Misled Shareholders According to a Recently Filed Class Action",#N/A,10/21/2015 09062X10    BW   Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS,"12/09/2013 45253H10 BW   ImmunoGen, Inc. Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population",#N/A, 1/18/2018 PFE-US       BW   Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma,#N/A,#N/A,#N/A,#N/A," 1/26/2012 MITI-US      BW   Finkelstein Thompson LLP Announces Investigation of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/09/2015 AERI-US    BW   Aerie Pharmaceuticals Announces that Richard A. Lewis, M.D., Has Joined as Chief Medical Officer",#N/A,11/01/2016 NOVN-CH  BW   Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs,#N/A,#N/A, 1/06/2014 G0176710 BW   Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis," 9/04/2014 15708510 BW   Cerus to Present at the Morgan Stanley 2014 Global Health Care Conference on September 10, 2014",#N/A," 7/26/2012 04269E10 BW   ArQule to Report Second Quarter 2012 Financial Results on August 2, 2012",#N/A,#N/A," 3/01/2016 IPSEY-FR BW   Exelixis et Ipsen concluent un accord exclusif de licence pour le développement et la commercialisation du Cabozantinib, un traitement innovant dans le cancer, pour les territoires hors Etats-Unis, Canada et Japon", 2/28/2014 80105N10  BW   Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Fourth Annual Patient Advocacy Leadership (PAL) Awards, 2/09/2016 VRTX-US   BW   Vertex to Present at Upcoming Investor Conferences,#N/A,#N/A, 9/24/2015 BLUE-US  BW   bluebird bio Announces Participation in Leerink Partners Immuno-Oncology Roundtable, 9/02/2014 00422510 BW   ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A,10/23/2014 88338N10 BW   TherapeuticsMD to Host Third Quarter 2014 Financial Results Conference Call and Webcast November 6,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2014 46333X10 BW   Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2014 29251M10   BW   Enanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), 8/09/2017 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/26/2014 00972D10 BW   Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,12/19/2013 0C58C1-E    BW   SAGE Therapeutics Announces Collaboration with Washington University to Develop Novel GABA Receptor Small Molecules,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/17/2015 26979610 BW   Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2014 25303110 BW   Dicerna Announces Appointment of Biotech Industry Leader Bruce Peacock to its Board of Directors and Audit Committee," 9/05/2017 CLLS-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2015 00434H10 BW   Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2016 NVCR-GB  BW   Novocure to Present at Cowen and Company 36th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2016 74587V10 BW   Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/27/2014 53220K50  BW   Ligand Reports Third Quarter 2014 Financial Results,#N/A, 2/23/2016 0024VM-E    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference,"12/05/2014 84763A10  BW   Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014",#N/A, 9/24/2015 ARWR-US  BW   Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study,#N/A,#N/A,#N/A,#N/A,11/11/2013 68375N10 BW   OPKO Announces Third Quarter 2013 Financial and Operating Highlights,#N/A,#N/A,10/27/2016 ALXN-US  BW   Alexion Reports Third Quarter 2016 Results,#N/A," 1/20/2017 SGEN-US     BW   INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,10/21/2015 09062X10    BW   Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance,"12/09/2013 45253H10 BW   ImmunoGen, Inc. Announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR650984",#N/A, 1/08/2018 0056YC-E     BW   AHF: “Shameless” Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration,#N/A,#N/A,#N/A,#N/A," 1/26/2012 MITI-US      BW   Pomerantz Law Firm Investigates Claims on Behalf of Investors of Micromet, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 AERI-US    BW   Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration,#N/A,10/14/2016 INCY-US  BW   Incyte to Report Third Quarter Financial Results,#N/A,#N/A,"12/09/2013 G0176710 BW   Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP Meeting"," 8/28/2014 15708510 BW   Cerus to Present at the Baird 2014 Health Care Conference on September 3, 2014",#N/A," 7/06/2012 ARQL-US  BW   ArQule, Inc. to Present at JMP Securities Annual Healthcare Conference",#N/A,#N/A," 3/01/2016 EXEL-US  BW   Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan", 2/06/2014 80105N10  BW   Sanofi RN 2013 - Interview du Directeur Général Chris Viehbacher, 2/05/2016 VRTX-US   BW   Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations,#N/A,#N/A, 9/11/2015 BLUE-US  BW   bluebird bio Announces Participation at Morgan Stanley Global Healthcare Conference, 8/28/2014 00422510 BW   ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin,#N/A,#N/A,#N/A,10/15/2014 88338N10 BW   TherapeuticsMD Announces Oral Presentation of Positive Phase 2 and Bioavailability Data on TX-004HR (VagiCapTM),#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2014 46333X10 BW   Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2014 29251M10   BW   PEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), 8/01/2017 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2014 00972D10 BW   Akebia Therapeutics Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,"12/09/2013 0C58C1-E    BW   SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds and Novel Approach for the Treatment of Chronic Epilepsies",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2015 00930K-E BW   Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle’s Rapid Infusion Bendamustine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2014 25303110 BW   Dicerna to Present at the Baird 2014 Health Care Conference, 9/04/2017 15117K10 BW   Cellectis to Participate in Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2015 00434H10 BW   Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2016 G6674U10 BW   Ergebnisse der Phase-3-Studie von Novocure beim neu diagnostizierten Glioblastom erscheinen im ASCO-Bericht 2016 zu Fortschritten in der Krebsmedizin,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/28/2016 06CR5C-E BW   Puma Biotechnology Updates Timeline for Filing New Drug Application,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/16/2014 53220K50  BW   Ligand to Host Analyst Day on November 18th in New York City,#N/A, 2/11/2016 ILMN-US     BW   Genomics England Enters Bioinformatics Partnership with Illumina,11/12/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare Conference on November 19th,#N/A, 9/11/2015 ARWR-US  BW   Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System,#N/A,#N/A,#N/A,#N/A,"11/06/2013 68375N10 BW   Neovasc, an OPKO Supported Company, Reports That Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina",#N/A,#N/A,10/19/2016 06CR5C-E BW   FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD),#N/A," 1/20/2017 SGEN-US     BW   Glancy Prongay & Murray LLP Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",#N/A,"10/12/2015 BIIB-US     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 – BIIB","12/03/2013 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 55th ASH Annual Meeting and Exposition",#N/A,"12/21/2017 GILD-US      BW   Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8",#N/A,#N/A,#N/A,#N/A," 1/26/2012 0BGL4K-E     BW   The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Micromet, Inc. in Connection with the Sale of the Company to Amgen Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 AERI-US    BW   Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,#N/A,10/07/2016 INCY-US  BW   Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab),#N/A,#N/A,11/05/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2013 Healthcare Conference," 8/07/2014 15708510 BW   Cerus to Present at the Wedbush 2014 Life Sciences Management Access Conference on August 12, 2014",#N/A, 6/02/2012 4568-JP  BW   Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to Be Presented at ASCO,#N/A,#N/A, 2/29/2016 EXEL-US  BW   Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update, 2/06/2014 80105N10  BW   Sanofi FY 2013 - Interview with CEO Chris Viehbacher, 1/27/2016 VRTX-US   BW   Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results,#N/A,#N/A, 8/06/2015 BLUE-US  BW   bluebird bio Reports Second Quarter 2015 Financial Results and Recent Operational Progress, 8/05/2014 00422510 BW   ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,10/02/2014 88338N10 BW   TherapeuticsMD Inc. to Present at the 13th Annual Bio Investor Forum,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2014 46333X10 BW   Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2014 29251M10   BW   Enanta Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference, 7/27/2017 ALNY-US   BW   Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2014 06TNW4-E BW   Akebia Therapeutics Appoints Michael Wyzga to its Board of Directors,#N/A,#N/A,#N/A,#N/A,11/18/2013 0C58C1-E    BW   SAGE’s Novel Approach to Treatment of CNS Disorders to be Highlighted at Leading Industry and Scientific Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/20/2015 26979610 BW   Eagle Pharmaceuticals, Inc. Announces Change in Fiscal Year End",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/21/2014 25303110 BW   Dicerna Announces the Issuance of Multiple Patents Covering Claims for Dicer Substrate siRNAs, 9/04/2017 15117K10 BW   Cellectis annonce la suspension des études cliniques de UCART123,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/26/2015 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2016 NVCR-GB  BW   Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/18/2016 74587V10 BW   Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/08/2014 53220K50  BW   Ligand Reports Third Quarter Revenues and Expected Diluted EPS,#N/A, 2/10/2016 0DLLD6-E    BW   GRAIL Hires Google Executive Jeff Huber as CEO to Lead Development for Early Cancer Detection,11/06/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year,#N/A, 9/10/2015 ARWR-US  BW   Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A,11/04/2013 68375N10 BW   OPKO Commences Pivotal Clinical Validation Study for 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy,#N/A,#N/A,"10/10/2016 ALXN-US  BW   Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016",#N/A," 1/19/2017 SGEN-US     BW   INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Seattle Genetics, Inc. Investors",#N/A,10/12/2015 BIIB-US     BW   Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World,"11/20/2013 45253H10 BW   ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla® in the European Union",#N/A,"12/14/2017 GILD-US      BW   Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors",#N/A,#N/A,#N/A,#N/A, 1/25/2012 0C8BZH-E     BW   RBCC Seeks Out the Next Big Bioscience Breakthrough,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 AERI-US    BW   Aerie Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update,#N/A, 9/28/2016 INCY-US  BW   Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab),#N/A,#N/A,"10/31/2013 G0176710 BW   Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013", 7/31/2014 15708510 BW   Cerus Corporation Reports Second Quarter 2014 Results,#N/A," 5/31/2012 04269E10 BW   ArQule, Inc. to Present at Jefferies 2012 Global Healthcare Conferences",#N/A,#N/A," 2/29/2016 EXEL-US  BW   Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan", 2/04/2014 SAN-FR    BW   Glancy Binkow & Goldberg Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit on Behalf of Investors of Sanofi Contingent Value Rights, 1/26/2016 VRTX-US   BW   Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation,#N/A,#N/A, 8/05/2015 BLUE-US  BW   bluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference," 7/29/2014 00422510 BW   ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014",#N/A,#N/A,#N/A, 9/30/2014 88338N10 BW   TherapeuticsMD Inc. Granted Two New Patents,#N/A,#N/A,#N/A,#N/A,#N/A,10/14/2014 46333X10 BW   Ironwood Pharmaceuticals to Host Third Quarter 2014 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/13/2014 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2013", 7/10/2017 ALNY-US   BW   Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 06TNW4-E BW   Akebia Therapeutics Strengthens Its Leadership Team with Key Additions,#N/A,#N/A,#N/A,#N/A,11/12/2013 0C58C1-E    BW   SAGE Presents New Mechanistic Insights On Novel Approach to NMDA Receptor Modulation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/17/2014 26979610 BW   Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2014 25303110 BW   Dicerna Provides Operational Update and Reports Second Quarter 2014 Financial Results, 9/04/2017 15117K10 BW   Cellectis Reports Clinical Hold of UCART123 Studies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/24/2015 00434H10 BW   Acceleron Pharma to Host Fourth Quarter and Year Ended 2014 Financial Results Conference Call and Webcast on March 2, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2016 NVCR-GB  BW   Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2016 0024VM-E BW   Puma Biotechnology to Present at Cowen’s Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/26/2014 53220K50  BW   Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion,#N/A, 2/10/2016 45232710    BW   Illumina Building Long Read Application Partnerships,10/30/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 8/05/2015 ARWR-US  BW   Arrowhead to Present at Jefferies 2015 Hepatitis B Summit,#N/A,#N/A,#N/A,#N/A,10/21/2013 OPK-US   BW   OPKO Obtains Final Marketing Authorization for Citicoline in Spain,#N/A,#N/A,10/06/2016 ALXN-US  BW   New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa),#N/A," 1/19/2017 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017",#N/A,10/09/2015 09062X10    BW   Biogen Announces Departure of Tony Kingsley,"11/11/2013 45253H10 BW   ImmunoGen, Inc. Announces Fifth New License Agreement in 2013",#N/A,12/11/2017 GILD-US      BW   Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia,#N/A,#N/A,#N/A,#N/A, 1/17/2012 09R1H5-E     BW   Research and Markets: Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 AERI-US    BW   Aerie Pharmaceuticals and GrayBug Announce Research Collaboration,#N/A, 9/27/2016 06CR5C-E BW   NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis,#N/A,#N/A,"10/24/2013 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013", 7/17/2014 15708510 BW   Cerus Submits Final Module in Premarket Approval (PMA) Application Process for INTERCEPT Platelets,#N/A, 5/18/2012 04269E10 BW   ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer,#N/A,#N/A," 2/15/2016 EXEL-US  BW   Exelixis to Release Fourth Quarter and Full Year 2015 Financial Results on Monday, February 29, 2016", 2/04/2014 80105N10  BW   Genzyme’s Lemtrada® Approved in Mexico for Treatment of Multiple Sclerosis, 1/10/2016 VRTX-US   BW   Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases,#N/A,#N/A, 6/23/2015 09609G10 BW   bluebird bio Announces Pricing of Public Offering of Common Stock," 7/15/2014 00422510 BW   ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer",#N/A,#N/A,#N/A," 9/29/2014 88338N10 BW   TherapeuticsMD Begins Phase 3 Clinical Trial of TX-004HR (VagiCapTM) for the Treatment of Painful Intercourse, a Symptom of VVA, Due to Menopause",#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2014 46333X10 BW   Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/11/2014 29251M10   BW   Enanta Pharmaceuticals Announces the Appointment of George S. Golumbeski, Ph.D. to Board of Directors", 7/07/2017 SAN-FR    BW   Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/16/2013 06TNW4-E BW   Akebia Appoints Jason A. Amello as Senior Vice President, Chief Financial Officer and Treasurer",#N/A,#N/A,#N/A,#N/A,10/30/2013 0C58C1-E    BW   SAGE’s Discovery of Novel Allosteric Therapeutic Approach for a Broad Range of CNS Disorders Published in Journal of Neuroscience,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/04/2014 26979610 BW   Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/25/2014 25303110 BW   Dicerna to Announce Second-Quarter 2014 Financial Results and Host Conference Call on August 7, 2014", 8/17/2017 15117K10 BW   Cellectis annonce la première administration de UCART123 chez un patient atteint de leucémie à cellules dendritiques plasmacytoïdes dans le cadre de son étude clinique de Phase I menée au MD Anderson Cancer Center,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/19/2015 00434H10 BW   Acceleron to Present New Dalantercept Clinical Data at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/01/2016 G6674U10 BW   Novocure to Report Fourth Quarter, Year-End Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/29/2016 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 9/09/2014 LGND-US   BW   Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc.",#N/A, 2/02/2016 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015, 9/18/2014 84763A10  BW   Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs,#N/A, 8/04/2015 ARWR-US  BW   Arrowhead Reports Fiscal 2015 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,10/10/2013 OPK-US   BW   OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies,#N/A,#N/A, 9/23/2016 ALXN-US  BW   Alexion Employees Volunteer Together in Company’s First Global Day of Service,#N/A, 1/18/2017 SGEN-US     BW   SGEN LOSS NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action,#N/A,10/08/2015 09062X10    BW   Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS,"11/08/2013 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A,12/10/2017 GILD-US      BW   Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma,#N/A,#N/A,#N/A,#N/A, 1/17/2012 0C8BZH-E     BW   RBCC: Biotech Growing Faster than any Other Sector in Houston,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/22/2015 AERI-US    BW   Aerie Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Wednesday, August 5, 2015",#N/A, 9/08/2016 INCY-US  BW   Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month,#N/A,#N/A,10/10/2013 G0176710 BW   Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder," 7/17/2014 15708510 BW   Cerus to Release Second Quarter 2014 Results on July 31, 2014",#N/A, 5/17/2012 04269E10 BW   Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology,#N/A,#N/A, 2/04/2016 EXEL-US  BW   Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10, 1/29/2014 SAN-FR    BW   Sanofi and Transgene Launch Construction Phase of New State-of-the-art Bioproduction Platform, 1/05/2016 VRTX-US   BW   Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A, 6/23/2015 09609G10 BW   bluebird bio Announces Proposed Public Offering of Common Stock," 6/17/2014 00422510 BW   ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014",#N/A,#N/A,#N/A, 8/06/2014 88338N10 BW   TherapeuticsMD Announces Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/06/2014 29251M10   BW   Enanta Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference Presentation to be Webcast on February 13, 2014 at 2:15 P.M. ET", 6/26/2017 ALNY-US   BW   Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2013 06TNW4-E BW   Akebia Appoints Renal Industry Veteran John P. Butler as President and CEO,#N/A,#N/A,#N/A,#N/A,10/16/2013 0C58C1-E    BW   SAGE Therapeutics Secures $20M Series B Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/20/2014 26979610 BW   Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2014 25303110 BW   Dicerna to Ring the NASDAQ Stock Market Closing Bell July 15th, 8/17/2017 15117K10 BW   Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/28/2015 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in February,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2016 G6674U10 BW   Novocure präsentiert die Ergebnisse der Phase-II-PANOVA-Studie im Rahmen des ASCO GI Symposiums - Tumor Treating Fields Therapie plus Chemotherapie mit gleichwertigem Sicherheitsprofil wie Erstlinientherapie...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2016 PBYI-US  BW   Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/27/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia,#N/A, 2/01/2016 ILMN-US     BW   Illumina Signs Multiple Biobank Deals, 9/16/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq™ (belinostat) for Injection with Patent Term Adjustment till 2027,#N/A, 7/28/2015 ARWR-US  BW   Arrowhead to Report Fiscal 2015 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 8/30/2013 68375N10 BW   Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes,#N/A,#N/A, 9/23/2016 ALXN-US  BW   Les employés d'Alexion font du bénévolat ensemble pour la première Journée mondiale de service célébrée par l'entreprise,#N/A," 1/17/2017 SGEN-US     BW   IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Seattle Genetics, Inc. and Advises Investors With Losses to Contact the Firm",#N/A,"10/07/2015 09062X10    BW   New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients","11/05/2013 45253H10 BW   ImmunoGen, Inc. Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC)",#N/A,12/07/2017 GILD-US      BW   Gilead Sciences and Kite to Acquire Cell Design Labs,#N/A,#N/A,#N/A,#N/A," 1/12/2012 06Q0C1-E     BW   Mitsui Fudosan America, Inc. Acquires The Homer Building in Washington, D.C.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2015 007KSQ-E   BW   Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference,#N/A, 8/30/2016 MS-US    BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,10/09/2013 G0176710 BW   Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder, 7/01/2014 CERS-US  BW   Cerus Corporation Secures $30 Million Growth Capital Credit Facility From Oxford Finance,#N/A, 5/03/2012 04269E10 BW   ArQule Reports First Quarter 2012 Financial Results,#N/A,#N/A," 2/01/2016 EXEL-US  BW   Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma", 1/28/2014 SAN-FR    BW   SANOFI CONTINGENT VALUE RIGHTS SHAREHOLDERS: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline in Class Action Lawsuit Filed on Behalf of Sanofi Contingent Value Rights Investors,11/23/2015 VRTX-US   BW   Vertex to Present at the Piper Jaffray Healthcare Conference on December 1,#N/A,#N/A," 6/15/2015 09609G10 BW   Philip Gregory, D. Phil., Joins bluebird bio as Chief Scientific Officer"," 5/27/2014 00422510 BW   ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014",#N/A,#N/A,#N/A, 8/01/2014 88338N10 BW   TherapeuticsMD to Hold Second Quarter 2014 Financial Results Conference Call and Webcast on August 6,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2014 46333X10 BW   Ironwood Appoints Two New Senior Executives to Support Continued Growth as a Leader in Gastroenterology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/03/2014 29251M10   BW   Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development"," 6/26/2017 ALNY-US   BW   Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2013 06TNW4-E BW   Akebia Therapeutics Announces Initiation of Phase 2b Trial of Oral Anemia Candidate,#N/A,#N/A,#N/A,#N/A, 8/14/2013 0C58C1-E    BW   CORRECTING and REPLACING SAGE Therapeutics Appoints Biotech Industry Veteran Dr. Jeffrey Jonas to Chief Executive Officer; Expands Leadership Team with Two Key Appointments,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/10/2014 26979610 BW   Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/30/2014 25303110 BW   Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 (PH1), 8/02/2017 15117K10 BW   Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2015 00434H10 BW   Acceleron Pharma Outlines Corporate Objectives for 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/20/2016 G6674U10 BW   Novocure presenta resultados de su ensayo clínico de Fase 2 PANOVA en ASCO GI, que sugieren que la terapia de los campos de tumores más quimioterapia podría ser segura como tratamiento de primera línea y mejorar la supervivencia de los pacientes...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/16/2016 74587V10 BW   Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/14/2014 53220K50  BW   Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals,#N/A, 1/28/2016 45232710    BW   Illumina Appoints Dr. Frances Arnold to Its Board of Directors," 9/09/2014 84763A10  BW   Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.",#N/A, 7/08/2015 04280A10 BW   Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand,#N/A,#N/A,#N/A,#N/A, 8/28/2013 68375N10 BW   OPKO Health Announces Listing in Major Indices on Tel Aviv Stock Exchange,#N/A,#N/A, 9/23/2016 ALXN-US  BW   Funcionários da Alexion se apresentam como voluntários no primeiro Dia de Serviço Global da empresa,#N/A, 1/05/2017 SGEN-US     BW   Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma,#N/A,10/05/2015 09062X10    BW   Biogen Announces Webcast of Investor R&D Day,"11/05/2013 45253H10 BW   ImmunoGen, Inc. Initiates Phase I Testing of Its EGFR-Targeting ADC, IMGN289",#N/A,"12/04/2017 GILD-US      BW   Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States",#N/A,#N/A,#N/A,#N/A, 1/09/2012 0C17GS-E     BW   George J. Morrow Joins PBS Biotech Advisory Board,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2015 00771V10   BW   Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors,#N/A, 8/25/2016 0B071P-E BW   Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year,#N/A,#N/A,10/08/2013 G0176710 BW   Alkermes Announces Completion of Patient Enrollment in Pivotal Phase 3 Study of Aripiprazole Lauroxil, 5/29/2014 15708510 BW   Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the INTERCEPT Blood System for Platelets,#N/A," 4/26/2012 04269E10 BW   ArQule to Report First Quarter 2012 Financial Results on May 3, 2012",#N/A,#N/A, 1/28/2016 EXEL-US  BW   Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma, 1/17/2014 SAN-FR    BW   Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of Investors of Sanofi Contingent Value Rights,11/23/2015 VRTX-US   BW   Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer,#N/A,#N/A, 6/13/2015 09609G10 BW   bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA, 5/06/2014 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results,#N/A,#N/A,#N/A, 7/30/2014 88338N10 BW   TherapeuticsMD Announces Pricing of Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2014 46333X10 BW   Ironwood Pharmaceuticals Provides Second Quarter 2014 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/31/2014 29251M10   BW   Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection"," 6/19/2017 ALNY-US   BW   Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2013 06TNW4-E BW   Akebia Closes $41 Million Series C,#N/A,#N/A,#N/A,#N/A, 7/31/2013 0C58C1-E    BW   SAGE Therapeutics Awarded Collaborative NIH Grant to Accelerate Development of New Treatment for Fragile X Syndrome,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2014 26979610 BW   Eagle Pharmaceuticals to Present at Stifel 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/19/2014 25303110 BW   Dicerna to Present at the 9th Annual JMP Securities Healthcare Conference, 8/02/2017 15117K10 BW   Cellectis publie ses résultats financiers du deuxième trimestre 2017 et des six premiers mois de l’année 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2014 00434H10 BW   Acceleron Pharma Added to NASDAQ Biotechnology Index,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/19/2016 G6674U10 BW   Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2016 74587V10 BW   Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/13/2014 53220K50  BW   Ligand Prices Offering of $225 Million of Convertible Senior Notes,#N/A," 1/19/2016 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2015 Financial Results on Tuesday, February 2, 2016", 9/02/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Conference in New York City on September 9th,#N/A, 7/02/2015 ARWR-US  BW   Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A, 8/19/2013 68375N10 BW   OPKO Health Announces New Listing on Tel Aviv Stock Exchange,#N/A,#N/A, 9/23/2016 ALXN-US  BW   Alexion-Mitarbeiter leisten Freiwilligeneinsatz beim ersten unternehmensweiten „Global Day of Service‟,#N/A,"12/28/2016 SGEN-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Seattle Genetics, Inc. and Certain Officers and Directors",#N/A,"10/01/2015 09062X10    BW   Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment","10/25/2013 45253H10 BW   ImmunoGen, Inc. Reports First Quarter Fiscal Year 2014 Financial Results and Provides Quarterly Update",#N/A,"11/22/2017 GILD-US      BW   Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6",#N/A,#N/A,#N/A,#N/A," 1/05/2012 009D1Z-E     BW   Zymeworks Announces the Formation of its Therapeutics Advisory Team, and Appointment of VP, Preclinical R&D to Advance its Strategic Therapeutics Initiative",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/18/2015 00771V10   BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Aerie Pharmaceuticals, Inc. Of Upcoming Deadline",#N/A, 8/09/2016 INCY-US  BW   Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs,#N/A,#N/A, 9/30/2013 G0176710 BW   Alkermes Expands Senior Management Team, 5/01/2014 15708510 BW   Cerus Corporation Reports First Quarter 2014 Results,#N/A, 4/16/2012 04269E10 BW   ArQule Announces Completion of Common Stock Offering with Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A, 1/28/2016 EXEL-US  BW   Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma, 1/13/2014 ALNY-US   BW   Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines,"11/20/2015 VRTX-US   BW   Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",#N/A,#N/A, 6/09/2015 09609G10 BW   bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol, 5/01/2014 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A, 7/29/2014 88338N10 BW   TherapeuticsMD Announces $40 Million Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2014 46333X10 BW   Ironwood Pharmaceuticals to Host Second Quarter 2014 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 29251M10   BW   Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788, 6/12/2017 ALNY-US   BW   Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/23/2012 00B8PL-E BW   U.S. Nephrologists Continue to Report a Decreasing Treatment Prevalence for ESAs and an Increasing Treatment Prevalence Trend for IV Iron, According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A, 4/04/2013 0C58C1-E    BW   SAGE Therapeutics’ Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2014 26979610 BW   Eagle Pharmaceuticals to Present at 21st Annual NewsMakers in the Biotechnology Industry Investment Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2014 25303110 BW   Dicerna to Present at Upcoming Conferences, 8/02/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2014 00434H10 BW   Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 NVCR-GB  BW   Novocure Announces Preliminary 2015 Operating Statistics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2016 PBYI-US  BW   Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/11/2014 53220K50  BW   Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes and Announces $200 Million Share Repurchase Program,#N/A, 1/11/2016 ILMN-US     BW   Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics," 8/07/2014 84763A10  BW   Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster",#N/A, 6/17/2015 ARWR-US  BW   Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A, 8/15/2013 68375N10 BW   OPKO Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldy™,#N/A,#N/A, 9/23/2016 ALXN-US  BW   Alexion y sus empleados voluntarios colaboran en el primer Día Mundial del Servicio,#N/A,12/27/2016 06CR5C-E    BW   Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A),#N/A," 9/25/2015 BIIB-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015","10/22/2013 45253H10 BW   ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at AACR-NCI-EORTC Conference",#N/A,10/26/2017 GILD-US      BW   Gilead Sciences Announces Fourth Quarter 2017 Dividend,#N/A,#N/A,#N/A,#N/A, 1/04/2012 05MW68-E     BW   Design the 2012 Amgen Tour of California Breakaway from Cancer® Most Courageous Rider Jersey and Win a Trip to the Race,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2015 007KSQ-E   BW   Aerie Pharmaceuticals Receives Positive Feedback from FDA,#N/A," 7/19/2016 INCY-US  BW   Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016",#N/A,#N/A, 9/03/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference, 4/29/2014 15708510 BW   Cerus Announces Collaboration Agreement With Nipro for Innovative INTERCEPT Red Blood Cell System Component,#N/A, 4/11/2012 ARQL-US  BW   ArQule Prices Public Offering of Common Stock,#N/A,#N/A, 1/11/2016 EXEL-US  BW   Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma, 1/13/2014 ALNY-US   BW   Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases,11/18/2015 VRTX-US   BW   Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis,#N/A,#N/A, 6/03/2015 05N2D8-E BW   Celgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA," 4/29/2014 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014",#N/A,#N/A,#N/A, 6/17/2014 88338N10 BW   TherapeuticsMD to Present at 9th Annual JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2014 29251M10   BW   Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference, 6/07/2017 ALNY-US   BW   Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18 Organizations,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/05/2012 06TNW4-E BW   Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548",#N/A,#N/A,#N/A,#N/A,"11/30/2011 0C58C1-E    BW   SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/17/2014 26979610 BW   Eagle Pharmaceuticals Announces That Teva Requests a Motion to Dismiss with Prejudice in Its Bendamustine Patent Infringement Lawsuit,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2014 25303110 BW   Dicerna Announces First Quarter 2014 Financial and Operational Results, 8/02/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2014 00434H10 BW   Luspatercept Data on Myelodysplastic Syndromes Selected for “Best of ASH” by the American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2016 NVCR-GB  BW   Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2016 74587V10 BW   Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/04/2014 53220K50  BW   Ligand Reports Second Quarter 2014 Financial Results,#N/A, 1/11/2016 45232710    BW   Illumina Extends Genomics Portfolio, 7/31/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 6/10/2015 ARWR-US  BW   Arrowhead Receives Orphan Drug Designation for ARC-AAT,#N/A,#N/A,#N/A,#N/A, 8/09/2013 68375N10 BW   OPKO Announces Second Quarter 2013 Operating and Financial Highlights,#N/A,#N/A, 9/13/2016 ALXN-US  BW   Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases,#N/A,12/20/2016 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A, 9/25/2015 BIIB-US     BW   Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A,"10/20/2013 45253H10 BW   ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference",#N/A,10/26/2017 GILD-US      BW   Gilead Sciences Announces Third Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,12/20/2011 0C8BZH-E     BW   RBCC: N3D’s Bio-Assembler Makes Cell Research Simple,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/12/2015 00771V10   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Aerie Pharmaceuticals, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of June 29, 2015",#N/A, 7/14/2016 INCY-US  BW   Incyte to Report Second Quarter Financial Results,#N/A,#N/A," 7/25/2013 G0176710 BW   Alkermes plc Reports Financial Results for Quarter Ended June 30, 2013"," 4/21/2014 15708510 BW   Cerus to Release First Quarter 2014 Results on May 1, 2014",#N/A, 4/10/2012 ARQL-US  BW   ArQule Announces Proposed Public Offering,#N/A,#N/A, 1/04/2016 EXEL-US  BW   Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium,12/30/2013 SNY-FR    BW   Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) Application,11/04/2015 VRTX-US   BW   Vertex to Present at the Credit Suisse Healthcare Conference on November 10,#N/A,#N/A, 5/22/2015 09609G10 BW   bluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference," 4/01/2014 00422510 BW   ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014",#N/A,#N/A,#N/A," 6/10/2014 88338N10 BW   TherapeuticsMD Announces Webcast for Investor Day on June 16, 2014",#N/A,#N/A,#N/A,#N/A,#N/A," 6/04/2014 46333X10 BW   Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2013 29251M10   BW   Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study, 5/31/2017 ALNY-US   BW   FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2012 06TNW4-E BW   Akebia Draws Down $4.1 Million Series B Financing Tranche,#N/A,#N/A,#N/A,#N/A,10/19/2011 LGND-US     BW   Ligand Enters into Platform Captisol® License Agreement with SAGE Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/11/2014 26979610 BW   Eagle Pharmaceuticals, Inc. Reports Third Quarter 2014 Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2014 25303110 BW   Dicerna to Announce First Quarter 2014 Financial Results and Host Conference Call on May 13, 2014", 7/25/2017 15117K10 BW   Cellectis S.A. : Calyxt annonce l’exercice en totalité de l’option de surallocation et la réalisation définitive de son introduction en bourse,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2014 00434H10 BW   New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2016 G6674U10 BW   Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 PBYI-US  BW   Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/23/2014 GSK-GB    BW   Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million,#N/A, 1/10/2016 45232710    BW   Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening, 7/07/2014 84763A10  BW   FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection,#N/A, 5/27/2015 ARWR-US  BW   Arrowhead to Present at Jefferies 2015 Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 7/24/2013 68375N10 BW   OPKO’s Citicoline Products Approved for Commercialization in Spain,#N/A,#N/A, 9/06/2016 MS-US    BW   Alexion to Present at Upcoming Investor Conferences,#N/A,12/10/2016 SGEN-US     BW   Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium,#N/A," 9/22/2015 09062X10    BW   Biogen to Report Third Quarter 2015 Financial Results on October 21, 2015","10/18/2013 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results",#N/A,"10/24/2017 GILD-US      BW   Gilead Sciences to Present at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7",#N/A,#N/A,#N/A,#N/A,"12/16/2011 0C8BZM-E     BW   RBCC Plans to Make the Impossible, Possible with n3D Nanoparticle Technology",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/12/2015 00771V10   BW   AERI Investor Alert: Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on Behalf of Aerie Pharmaceuticals, Inc. Investors",#N/A, 6/23/2016 06CR5C-E BW   FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD),#N/A,#N/A," 7/18/2013 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013", 4/07/2014 15708510 BW   Cerus Submits the Medical Device License Application to Health Canada for INTERCEPT Plasma,#N/A, 3/29/2012 ARQL-US  BW   ArQule Announces Presentations at AACR 102nd Annual Meeting,#N/A,#N/A,12/23/2015 EXEL-US  BW   Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma,12/19/2013 SNY-FR    BW   Genzyme’s Lemtrada™ Approved in Australia for Treatment of Multiple Sclerosis,10/28/2015 VRTX-US   BW   Vertex Reports Third Quarter 2015 Financial Results,#N/A,#N/A, 5/21/2015 05N2D8-E BW   bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association, 3/05/2014 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 5/28/2014 88338N10 BW   TherapeuticsMD, Inc. Launches the First Daily Chewable Prescription Prenatal Vitamins with FOLMAX",#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2013 29251M10   BW   Enanta Pharmaceuticals to Present at the Deutsche Bank 2013 BioFest, 5/30/2017 ALNY-US   BW   Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2011 06TNW4-E BW   Akebia Initiates Phase 1 Study of First-In-Class HPTPβ Inhibitor for Diabetic Macular Edema,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2014 26979610 BW   Eagle Pharmaceuticals Schedules Third Quarter Earnings Release and Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/18/2014 25303110 BW   Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), 7/25/2017 15117K10 BW   Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2014 00434H10 BW   New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 NVCR-GB  BW   Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/30/2015 74587V10 BW   Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/22/2014 0C58C1-E  BW   Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus,#N/A," 1/08/2016 45232710    BW   Illumina to Host Investor Call on Sunday, January 10, 2016", 5/30/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd,#N/A, 5/11/2015 04280A10 BW   Arrowhead Reports Fiscal 2015 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A," 7/16/2013 68375N10 BW   OPKO Health Announces Appointment of David Okrongly, Ph.D. as President of its Diagnostics Business Unit",#N/A,#N/A, 8/30/2016 ALXN-US  BW   La Commission européenne accorde la désignation de médicament orphelin à l'ALXN1007 pour le traitement de patients atteints de la réaction du greffon contre l'hôte (GVHD),#N/A,12/05/2016 BMY-US      BW   Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting,#N/A, 9/11/2015 09062X10    BW   Biogen Named the Global Biotechnology Industry Leader on Dow Jones Sustainability World Index for Second Consecutive Year,"10/15/2013 45253H10 BW   ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference",#N/A,10/24/2017 GILD-US      BW   Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH),#N/A,#N/A,#N/A,#N/A,12/13/2011 0731W3-E     BW   Cure Duchenne Appoints Michael Kelly as Chief Scientific Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/08/2015 00771V10   BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Aerie Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit",#N/A, 6/22/2016 INCY-US  BW   Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study,#N/A,#N/A, 7/17/2013 G0176710 BW   Alkermes Unveils Three New Drug Candidates Demonstrating Productivity of Its R&D Capabilities, 3/26/2014 15708510 BW   Partnership to Initiate Development of Whole Blood Pathogen Inactivation for Sub-Saharan Africa,#N/A," 3/28/2012 ARQL-US  BW   ArQule, Inc. to Present at 11th Annual Needham Healthcare Conference",#N/A,#N/A,11/25/2015 EXEL-US  BW   Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma,12/16/2013 SNY-FR    BW   Genzyme and NORD Establish Program to Help Undiagnosed Patients with Rare Diseases,10/26/2015 VRTX-US   BW   Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases,#N/A,#N/A, 5/19/2015 09609G10 BW   bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major, 3/04/2014 00422510 BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A, 5/27/2014 88338N10 BW   TherapeuticsMD Announces 2014 Investor Day,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2014 46333X10 BW   Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/25/2013 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013", 5/24/2017 ALNY-US   BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2011 06TNW4-E BW   Akebia Therapeutics Announces Presentation of Clinical Data at Kidney Week 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2014 26979610 BW   FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2014 25303110 BW   Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies, 7/24/2017 15117K10 BW   Cellectis obtient un brevet couvrant l’utilisation de la technologie CRISPR dans les cellules T,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2014 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in December,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2015 G6674U10 BW   El Journal of the American Medical Association  (JAMA) publica datos esenciales de fase 3 sobre Optune más temozolomida para tratar el glioblastoma de reciente diagnóstico,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/29/2015 PBYI-US  BW   Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/17/2014 53220K50  BW   Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program,#N/A, 1/07/2016 ILMN-US     BW   Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT, 5/28/2014 84763A10  BW   Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) to Treat Chemotherapy-induced Neutropenia,#N/A, 5/06/2015 04280A10 BW   Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases,#N/A,#N/A,#N/A,#N/A, 5/30/2013 OPK-US   BW   OPKO Health to Present at the Jefferies 2013 Global Healthcare Conference,#N/A,#N/A, 8/29/2016 ALXN-US  BW   Europäische Kommission verleiht ALXN1007 für die Behandlung von Patienten mit Graft-versus-Host-Reaktion (GvHR) den Status eines Arzneimittels für seltene Krankheiten,#N/A,12/05/2016 06QBQ2-E    BW   Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting,#N/A, 9/11/2015 09062X10    BW   Biogen Prices $6.0 Billion of Senior Unsecured Notes,"10/11/2013 NVS-CH   BW   ImmunoGen, Inc. Announces New License Agreement",#N/A,10/23/2017 KITE-US      BW   Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs,#N/A,#N/A,#N/A,#N/A,12/05/2011 MITI-US      BW   Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2015 00771V10   BW   Aerie Pharmaceuticals to Participate in Two Investor Conferences in June,#N/A, 6/22/2016 AGEN-US  BW   Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors,#N/A,#N/A," 7/17/2013 G0176710 BW   Alkermes Announces Initiation of Phase 2 Clinical Study of ALKS 3831, Designed to Be a Broad Spectrum Oral Antipsychotic for the Treatment of Schizophrenia", 3/25/2014 15708510 BW   Frank Witney Joins Cerus Board of Directors,#N/A," 3/02/2012 04269E10 BW   ArQule, Inc. to Present at Cowen and Company 32nd Annual Healthcare Conference",#N/A,#N/A,11/21/2015 EXEL-US  BW   Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC™ in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress,12/13/2013 SNY-FR    BW   Genzyme’s Lemtrada™ Approved in Canada for Treatment of Multiple Sclerosis,10/09/2015 VRTX-US   BW   Vertex to Announce Third Quarter 2015 Financial Results on October 28,#N/A,#N/A, 5/06/2015 09609G10 BW   bluebird bio Reports First Quarter 2015 Financial Results and Business Updates, 3/03/2014 00422510 BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A, 5/22/2014 88338N10 BW   TherapeuticsMD to Present at Jefferies 2014 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2014 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/25/2013 29251M10   BW   Enanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors", 5/23/2017 ALNY-US   BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/08/2014 26979610 BW   Eagle Pharmaceuticals Receives Orphan Drug Designation for Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product for Chronic Lymphocytic Leukemia and Indolent B-Cell Non-Hodgkin’s Lymphoma",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2014 25303110 BW   Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical Officer, 7/24/2017 15117K10 BW   Cellectis Granted Patent for CRISPR Use in T-Cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2014 00434H10 BW   Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 NVCR-GB  BW   Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/23/2015 PBYI-US  BW   ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/25/2014 53220K50  BW   Ligand Partner GSK Announces the Start of a Phase 3 Study with Eltrombopag in Patients with Myelodysplastic Syndromes,#N/A,12/28/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference, 5/09/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 13th,#N/A, 5/05/2015 04280A10 BW   Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT,#N/A,#N/A,#N/A,#N/A, 5/23/2013 OPK-US   BW   OPKO Surpasses 50% Enrollment in First Phase 3 Trial of RayaldyTM (CTAP101 Capsules),#N/A,#N/A, 8/29/2016 071VWR-E BW   European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD),#N/A,"12/05/2016 06QBQ2-E    BW   Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting",#N/A, 9/10/2015 BIIB-US     BW   CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London," 9/28/2013 45253H10 BW   ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress",#N/A,10/20/2017 GILD-US      BW   Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®,#N/A,#N/A,#N/A,#N/A,11/14/2011 AMGN-US      BW   Fitch Rates Amgen's Senior Notes 'BBB',#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 00771V10   BW   Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Business and Strategic Update,#N/A, 6/10/2016 INCY-US  BW   New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV),#N/A,#N/A," 7/10/2013 G0176710 BW   Alkermes Announces Webcast of R&D Day on July 17, 2013"," 2/27/2014 15708510 BW   Cerus to Present at the Cowen and Company 34th Annual Health Care Conference, on March 4, 2014",#N/A, 3/01/2012 04269E10 BW   ArQule Reports Fiscal 2011 Year End and Fourth Quarter Results,#N/A,#N/A,"11/12/2015 EXEL-US  BW   Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17","12/11/2013 SNY-FR    BW   FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease","10/08/2015 VRTX-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Vertex Pharmaceuticals Incorporated -- VRTX",#N/A,#N/A, 4/30/2015 09609G10 BW   bluebird bio Announces Participation at Two Upcoming Health Care Conferences," 2/27/2014 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013",#N/A,#N/A,#N/A, 5/05/2014 88338N10 BW   TherapeuticsMD Reports First Quarter 2014 Results,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2014 46333X10 BW   Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS®,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/18/2013 29251M10   BW   Enanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I Study," 5/12/2017 ALNY-US   BW   Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/02/2014 26979610 BW   Eagle Pharmaceuticals Receives Tentative Approval for Patented, Ready-to-Dilute Bendamustine Hydrochloride Injection NDA",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/27/2014 25303110 BW   Dicerna Announces Fourth Quarter and Full Year 2013 Financial and Operational Results, 7/19/2017 15117K10 BW   Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2014 00434H10 BW   Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 G6674U10 BW   Journal of the American Medical Association (JAMA) veröffentlicht Daten aus zulassungsrelevanter Phase-3-Studie zu Optune plus Temozolomid bei der Behandlung von neu diagnostiziertem Glioblastom,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2015 74587V10 BW   Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/24/2014 53220K50  BW   Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program,#N/A,"12/14/2015 BIM-FR      BW   bioMérieux and Illumina announce the launch of bioMérieux EpiSeq™, a revolutionary Next-Generation Sequencing service for epidemiological monitoring of bacterial infections", 5/08/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014,#N/A, 5/04/2015 04280A10 BW   Arrowhead to Report Fiscal 2015 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 5/09/2013 OPK-US   BW   OPKO Announces First Quarter 2013 Operating and Financial Highlights,#N/A,#N/A, 7/28/2016 ALXN-US  BW   Alexion Reports Second Quarter 2016 Results,#N/A,12/03/2016 4502-JP     BW   Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma,#N/A, 9/09/2015 BIIB-US     BW   Biogen Licenses Mitsubishi Tanabe Pharma’s Phase 2 Molecule for Autoimmune Diseases," 9/20/2013 45253H10 BW   ImmunoGen, Inc. Announces Positive Regulatory Decisions for Roche’s Kadcyla® in the European Union and Japan",#N/A,10/18/2017 GILD-US      BW   Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy,#N/A,#N/A,#N/A,#N/A,11/08/2011 DNDNQ-US     BW   Dendreon Announces Election of Dennis M. Fenton to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 00771V10   BW   Aerie Pharmaceuticals Elects Richard Croarkin to the Company’s Board of Directors,#N/A, 6/06/2016 INCY-US  BW   Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF),#N/A,#N/A, 5/31/2013 G0176710 BW   Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting, 2/25/2014 15708510 BW   Cerus Corporation Reports Fourth Quarter and Year-End 2013 Results,#N/A," 2/23/2012 04269E10 BW   ArQule to Report Fiscal 2011 Financial Results on March 1, 2012",#N/A,#N/A,11/10/2015 EXEL-US  BW   Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update,"12/02/2013 80105N10  BW   Hagens Berman: Statement of Steve W. Berman, lead attorney in US-Based Thalidomide Cases, in Response to Recent $81 million settlement for Australian victims",10/08/2015 VRTX-US   BW   Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease,#N/A,#N/A, 3/18/2015 09609G10 BW   bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day," 2/20/2014 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014",#N/A,#N/A,#N/A, 5/01/2014 88338N10 BW   TherapeuticsMD to Present the Design of Its REPLENISH Trial at the International Menopause Society's 14th World Congress,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2014 46333X10 BW   Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/15/2013 29251M10   BW   Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013", 5/10/2017 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming May Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/22/2014 26979610 BW   Eagle Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/25/2014 25303110 BW   Dicerna to Present at Future Leaders in the Biotech Industry Conference on March 28, 2014"," 7/19/2017 15117K10 BW   Cellectis S.A. : Calyxt annonce la fixation du prix de l’offre réalisée dans le cadre de son introduction en bourse, d’un montant total de 56 millions de dollars",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2014 00434H10 BW   Acceleron Announces New Clinical Data Presentations at the 2014 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 G6674U10 BW   Il Journal of the American Medical Association (JAMA) pubblica i dati dello studio clinico registrativo di fase 3 su Optune in combinazione con temozolomide per il trattamento del glioblastoma di prima diagnosi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2015 74587V10 BW   Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/23/2014 53220K50  BW   Ligand to Participate in ROTH Capital Partners’ Healthcare Corporate Access Day in London,#N/A,"12/14/2015 BIM-FR      BW   bioMérieux et Illumina annoncent le lancement de bioMérieux EpiSeq™, un service d’avant-garde en Séquençage Nouvelle Génération pour le suivi épidémiologique des infections bactériennes", 5/01/2014 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference and Webcast,#N/A, 4/30/2015 04280A10 BW   Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery,#N/A,#N/A,#N/A,#N/A," 4/26/2013 PBTH-US  BW   PROLOR Biotech, Inc. Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Acquisition Agreement",#N/A,#N/A, 7/14/2016 ALXN-US  BW   Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB),#N/A,12/03/2016 SGEN-US     BW   Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting,#N/A," 9/08/2015 BIIB-US     BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Biogen Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit"," 9/04/2013 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A,10/17/2017 0F0WRJ-E     BW   Jay Flatley and John Martin to be Named Recipients of Life Sciences Leadership Award at California Life Sciences Association’s 2017 Pantheon DiNA™ Awards,#N/A,#N/A,#N/A,#N/A,11/07/2011 AMGN-US      BW   Fitch Downgrades Amgen's IDR to 'BBB'; Outlook Stable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/29/2015 00771V10   BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Aerie Pharmaceuticals, Inc.",#N/A, 6/01/2016 INCY-US  BW   Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance,#N/A,#N/A, 5/29/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences," 2/11/2014 15708510 BW   Cerus to Release Fourth Quarter and Year End 2013 Results on February 25, 2014",#N/A," 2/21/2012 04269E10 BW   ArQule, Inc. to Present at RBC Capital Markets and Citi Conferences",#N/A,#N/A,11/10/2015 EXEL-US  BW   FDA Approves COTELLIC™ (Cobimetinib) for use in Combination with Vemurafenib to Treat Advanced Melanoma,"11/25/2013 ALNY-US   BW   Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",10/07/2015 VRTX-US   BW   Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA,#N/A,#N/A, 2/25/2015 09609G10 BW   bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress,11/26/2013 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A, 4/29/2014 88338N10 BW   TherapeuticsMD to Present at Bank of America Merrill Lynch 2014 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/18/2014 46333X10 BW   Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2013 29251M10   BW   Enanta Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference, 5/09/2017 ALNY-US   BW   Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/14/2014 26979610 BW   Eagle Pharmaceuticals, Inc. Reports Second Quarter 2014 Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/24/2014 25303110 BW   Dicerna to Announce Fourth Quarter 2013 Financial Results and Host Conference Call on March 27, 2014", 7/10/2017 15117K10 BW   Cellectis : Calyxt annonce le lancement de son introduction en bourse sur le NASDAQ pour un montant total d’environ 100 millions de dollars,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/30/2014 00434H10 BW   Acceleron Pharma to Host Third Quarter 2014 Financial Results Conference Call and Webcast on November 7, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 NVCR-GB  BW   Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2015 PBYI-US  BW   Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/23/2014 53220K50  BW   Ligand Announces Presentation of Positive Data from a Phase 1 Study on the Effect of the SERM Lasofoxifene to Increase Testosterone Levels in Men,#N/A,"12/14/2015 ILMN-US     BW   bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™, a Revolutionary Next-Generation Sequencing Service for Epidemiological Monitoring of Bacterial Infections", 4/23/2014 LGND-US   BW   Ligand’s Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial,#N/A, 4/28/2015 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A," 4/26/2013 OPK-US   BW   Law Firm Brower Piven Announces Investigation of PROLOR Biotech, Inc. Proposed Buyout",#N/A,#N/A," 7/11/2016 ALXN-US  BW   Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016",#N/A,12/03/2016 SGEN-US     BW   Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting,#N/A, 9/08/2015 BIIB-US     BW   Biogen to Present at the Morgan Stanley Global Healthcare Conference," 8/27/2013 45253H10 BW   ImmunoGen, Inc. Announces Executive Change",#N/A,"10/17/2017 GILD-US      BW   Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics",#N/A,#N/A,#N/A,#N/A,11/03/2011 009RZP-E     BW   Thirteen Host Cities Announced for 2012 Amgen Tour of California,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2015 00771V10   BW   Aerie Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Thursday, May 7, 2015",#N/A, 5/31/2016 INCY-US  BW   Incyte Announces the Launch of the Incyte Charitable Giving Foundation,#N/A,#N/A, 5/28/2013 G0176710 BW   Alkermes Presents Positive Results from Phase 1 Study of ALKS 3831 as a Broad Spectrum Treatment for Schizophrenia,12/11/2013 15708510 BW   Cerus Appoints North American Sales Team Leadership,#N/A," 2/09/2012 04269E10 BW   ArQule, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference",#N/A,#N/A,10/22/2015 EXEL-US  BW   Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer,11/21/2013 SNY-FR    BW   Genzyme Convenes 5th Annual Gaucher Leadership Forum in Madrid, 9/25/2015 VRTX-US   BW   Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union,#N/A,#N/A, 2/24/2015 09609G10 BW   bluebird bio Announces Participation in Upcoming Investor Conferences,11/14/2013 00422510 BW   ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis,#N/A,#N/A,#N/A," 4/25/2014 88338N10 BW   TherapeuticsMD to Host Conference Call and Live Audio Webcast to Disclose Financial Results for Quarter Ended March 31, 2014",#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2013 29251M10   BW   New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting, 5/05/2017 ALNY-US   BW   Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2014 26979610 BW   Eagle Pharmaceuticals Schedules Second Quarter Earning Release and Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2014 25303110 BW   Dicerna to Present at Two Upcoming Conferences, 7/10/2017 15117K10 BW   Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2014 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in November,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 G6674U10 BW   Journal of the American Medical Association (JAMA) publiceert cruciale fase 3-gegevens voor Optune plus Temozolomide ter behandeling van nieuwe gevallen van glioblastoom,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/10/2015 74587V10 BW   Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/16/2014 53220K50  BW   Ligand Announces Successful First-in-Human Trial Results for Glucagon Program,#N/A,12/14/2015 ILMN-US     BW   Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications, 4/23/2014 84763A10  BW   Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint,#N/A, 4/13/2015 04280A10 BW   Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520,#N/A,#N/A,#N/A,#N/A," 4/25/2013 OPK-US   BW   Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of PROLOR Biotech, Inc. Shareholders",#N/A,#N/A, 7/07/2016 ALXN-US  BW   New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress,#N/A,11/29/2016 SGEN-US     BW   Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,#N/A, 9/08/2015 09062X10    BW   Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer’s Disease," 8/02/2013 45253H10 BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update",#N/A,10/16/2017 GILD-US      BW   Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research,#N/A,#N/A,#N/A,#N/A,10/10/2011 MAXY-US      BW   Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/24/2015 00771V10   BW   EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against Aerie Pharmaceuticals, Inc.",#N/A, 5/19/2016 07G766-E BW   Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings,#N/A,#N/A, 5/23/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference,12/04/2013 15708510 BW   Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma,#N/A," 1/17/2012 4568-JP  BW   ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma",#N/A,#N/A,"10/20/2015 EXEL-US  BW   Exelixis to Release Third Quarter 2015 Financial Results on Tuesday, November 10, 2015",10/30/2013 80105N10  BW   Sanofi Q3 2013 - Interview with CFO Jérôme Contamine, 9/08/2015 VRTX-US   BW   Vertex to Present at the Morgan Stanley Healthcare Conference on September 16,#N/A,#N/A, 2/05/2015 09609G10 BW   bluebird bio to Present at the Leerink Global Healthcare Conference,11/06/2013 00422510 BW   ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A, 4/07/2014 88338N10 BW   TherapeuticsMD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap™ (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA),#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2014 46333X10 BW   Ironwood Pharmaceuticals Announces Exercise of Underwriters’ Option in Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2013 29251M10   BW   Enanta Announces New Data on ABT-450 Regimens to be Presented at The Liver Meeting (AASLD), 4/27/2017 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2014 26979610 BW   Eagle Pharmaceuticals to Present at 39th Annual Deutsche Bank Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2014 25303110 BW   Dicerna to Present at 2014 AsiaTIDES Conference, 7/07/2017 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2014 00434H10 BW   Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2015 G6674U10 BW   Journal of the American Medical Association (JAMA) Publication des données d’un essai pivot de phase 3 sur Optune combiné au témozolomide pour le traitement des cas de glioblastome nouvellement diagnostiqués,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2015 74587V10 BW   Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/13/2014 53220K50  BW   Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta™/Revolade™) in Pediatric Patients with Chronic Immune Thrombocytopenia,#N/A,12/09/2015 45232710    BW   Illumina Accelerator Announces Third Funding Cycle of Genomics Startups, 4/21/2014 84763A10  BW   Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer,#N/A, 3/05/2015 04280A10 BW   Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio,#N/A,#N/A,#N/A,#N/A," 4/24/2013 0BKJXM-E BW   Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of PROLOR Biotech, Inc.",#N/A,#N/A," 6/17/2016 ALXN-US  BW   SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,11/10/2016 06CR5C-E    BW   Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma,#N/A, 8/26/2015 BIIB-US     BW   Biogen Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors," 8/01/2013 45253H10 BW   ImmunoGen, Inc. Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289",#N/A,"10/12/2017 GILD-US      BW   Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017",#N/A,#N/A,#N/A,#N/A,10/04/2011 ATRX-US      BW   BioTime Announces Appointment of Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2015 00771V10   BW   Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results,#N/A, 5/18/2016 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/23/2013 G0176710 BW   Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial Expectations,11/20/2013 15708510 BW   Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus,#N/A,12/14/2011 4151-JP  BW   Russia’s Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015,#N/A,#N/A,10/06/2015 EXEL-US  BW   Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma,10/30/2013 80105N10  BW   Sanofi T3 2013 - Interview du Directeur Financier Jérôme Contamine, 8/19/2015 VRTX-US   BW   Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts,#N/A,#N/A, 2/02/2015 09609G10 BW   FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major,10/31/2013 00422510 BW   ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin,#N/A,#N/A,#N/A," 4/07/2014 88338N10 BW   BocaGreenMD Launches Prena1 Pearl™, the Only Generic Version of vitaMedMD’s vitaPearl™",#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2014 46333X10 BW   Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2013 29251M10   BW   Enanta Pharmaceuticals Announces National Institute of Allergy and Infectious Diseases (NIAID) Will Fund Further Development of a Novel Bicyclolide," 4/26/2017 ALNY-US   BW   Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/01/2014 26979610 BW   Eagle Pharmaceuticals’ Exclusive Licensor Granted U.S. Patent for Dantrolene in the Treatment of Heat Stroke,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2014 25303110 BW   Dicerna to Present at 2014 Leerink Global Healthcare Conference on February 13th, 7/07/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2014 00434H10 BW   Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2015 G6674U10 BW   New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/07/2015 PBYI-US  BW   Dr. Fredric N. Eshelman Announces Intent to Set Consent Solicitation Record Date December 17, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/22/2014 53220K50  BW   Ligand Licenses Five Programs to Viking Therapeutics,#N/A,12/09/2015 ILMN-US     BW   Desktop Genetics Receives Strategic Investment from Illumina to Advance Genome Editing Software Platform," 4/08/2014 84763A10  BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Spectrum Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty",#N/A, 3/04/2015 04280A10 BW   Arrowhead to Present at 2015 Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A," 4/24/2013 OPK-US   BW   The Law Firm of Wohl & Fruchter Commences Investigation into the Acquisition of PROLOR Biotech, Inc. by OPKO Health, Inc.",#N/A,#N/A, 6/11/2016 ALXN-US  BW   Présentation de données de dernière minute au congrès de l’AEH : Tous les patients atteints de HPN traités avec une dose d’ALXN1210 administrée mensuellement dans le cadre d’une étude de phase 1/2 affichent des réductions rapides et soutenues de la LDH,#N/A,11/08/2016 4502-JP     BW   Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma,#N/A," 8/18/2015 BIIB-US     BW   Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS"," 7/23/2013 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2013 Financial Results",#N/A,"10/04/2017 GILD-US      BW   Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens",#N/A,#N/A,#N/A,#N/A, 9/30/2011 0C32HM-E     BW   Concentric Pharma Advertising Joins MDC Partners,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2015 00771V10   BW   Aerie Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference,#N/A, 5/10/2016 ARIA-US  BW   Incyte y ARIAD anuncian un acuerdo según el cual Incyte adquiere los derechos de licencia de Iclusig® (ponatinib) y las operaciones de ARIAD en Europa,#N/A,#N/A, 5/22/2013 G0176710 BW   Alkermes Announces Data on ALKS 5461 and ALKS 3831 to Be Presented at 53rd Annual NCDEU Meeting,11/06/2013 15708510 BW   Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma,#N/A,"12/06/2011 04269E10 BW   ArQule, Inc. to Present at Oppenheimer 22nd Annual Healthcare Conference",#N/A,#N/A, 9/25/2015 EXEL-US  BW   Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015,"10/15/2013 SNY-FR    BW   Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme®", 7/29/2015 VRTX-US   BW   Vertex Reports Second Quarter 2015 Financial Results,#N/A,#N/A, 1/29/2015 09609G10 BW   bluebird bio Announces Transition of Chief Scientific Officer,"10/30/2013 00422510 BW   ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013",#N/A,#N/A,#N/A, 3/20/2014 88338N10 BW   TherapeuticsMD Announces Pricing of Secondary Offering,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2014 46333X10 BW   Ironwood Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2013 29251M10   BW   Enanta Pharmaceuticals to Present at Upcoming Investor Conferences, 4/26/2017 ALNY-US   BW   The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/20/2014 26979610 BW   NDA for Eagle Pharmaceuticals’ Orphan Drug Ryanodex® for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2014 25303110 BW   Dicerna Announces Participation in Panel on RNAi Therapeutics at 16th Annual BIO CEO and Investor Conference on February 10th, 7/07/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/14/2014 00434H10 BW   Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2015 G6674U10 BW   Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2015 PBYI-US  BW   Puma Biotechnology Provides Update from Meeting with European Medicines Agency,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/14/2014 53220K50  BW   Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases,#N/A,11/02/2015 45232710    BW   Illumina Announces New $250 Million Share Repurchase Authorization, 3/07/2014 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 26th Annual ROTH Conference in Laguna Niguel on March 11th,#N/A, 2/23/2015 04280A10 BW   Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency,#N/A,#N/A,#N/A,#N/A, 4/18/2013 68375N10 BW   OPKO Health Acquires Interest in Growing Russian Pharmaceutical Company,#N/A,#N/A," 6/10/2016 07G766-E BW   Hochaktuelle Daten auf der EHA-Tagung vorgelegt: Alle PNH-Patienten, die in einer Phase-1/2-Studie einmal monatlich mit einer Dosis ALXN1210 behandelt wurden, zeigten rapide und anhaltende Verringerungen der LDH-Werte",#N/A,11/03/2016 06QBQ2-E    BW   Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company’s Expanding Global Leadership in the Development of Innovative Antibody-Drug Conjugates,#N/A, 8/17/2015 09062X10    BW   Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B," 6/03/2013 45253H10 BW   First Clinical Data Presented with IMGN853, ImmunoGen, Inc.’s Potential New Therapy for Ovarian and Other Cancers",#N/A,10/04/2017 GILD-US      BW   Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir,#N/A,#N/A,#N/A,#N/A, 9/26/2011 ARAY-US      BW   NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/24/2015 00771V10   BW   Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial (“Rocket 2”) of Rhopressa™, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma",#N/A, 5/10/2016 ARIA-US  BW   ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review,#N/A,#N/A, 5/16/2013 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013,10/31/2013 15708510 BW   Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets,#N/A,"12/05/2011 066807-E BW   Despite the Generic Erosion of Key Agents, the Non-Small-Cell Lung Cancer Drug Market Will Increase 2.5 Percent Annually Between 2010 and 2020",#N/A,#N/A, 9/25/2015 EXEL-US  BW   European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma, 9/26/2013 SNY-FR    BW   Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS, 7/14/2015 92532F10  BW   Vertex to Announce Second Quarter 2015 Financial Results on July 29,#N/A,#N/A, 1/06/2015 09609G10 BW   bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference, 9/03/2013 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 3/19/2014 88338N10 BW   vitaMedMD Launches vitaPearl™, The Smallest Complete Prescription Prenatal Multivitamin With FOLMAX™, FePlus™, and pur-DHA™",#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2014 46333X10 BW   Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/12/2013 29251M10   BW   Enanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013", 3/28/2017 ALNY-US   BW   Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2014 26979610 BW   Eagle Pharmaceuticals Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2014 25303110 BW   Dicerna Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares," 6/28/2017 15117K10 BW   Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2014 00434H10 BW   Acceleron to Host Educational Webcast on Beta-thalassemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2015 G6674U10 BW   Los datos preliminares de la fase dos del tratamiento Tumor Treating Fields demuestran que es seguro para pacientes con metástasis cerebral originada por cáncer pulmonar de células no pequeñas,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2015 74587V10 BW   Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/12/2014 53220K50  BW   Ligand Earns Milestone from SAGE Therapeutics for SAGE-547,#N/A,10/20/2015 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2015, 3/06/2014 84763A10  BW   Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results,#N/A, 2/17/2015 04280A10 BW   Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 4/05/2013 68375N10 BW   OPKO Health Announces Publication of Study Detecting Antibodies in NMO Patients Using OPKO Screening Technology,#N/A,#N/A, 6/10/2016 ALXN-US  BW   Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH,#N/A,11/01/2016 SGEN-US     BW   Seattle Genetics to Present at Credit Suisse 25th Annual Healthcare Conference,#N/A, 8/10/2015 09062X10    BW   Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia," 5/30/2013 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A,"10/03/2017 GILD-US      BW   Gilead Sciences Completes Acquisition of Kite Pharma, Inc.",#N/A,#N/A,#N/A,#N/A," 9/22/2011 09JWQ9-E     BW   Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2015 00771V10   BW   Aerie Pharmaceuticals to Participate in Two Investor Conferences in March,#N/A, 5/10/2016 ARIA-US  BW   Incyte et ARIAD annoncent un accord dans le cadre duquel Incyte rachètera les opérations européennes d'ARIAD et vendra sous licence Iclusig® (ponatinib) en Europe,#N/A,#N/A, 5/16/2013 G0176710 BW   Alkermes Elects Nancy Wysenski to Board of Directors,10/29/2013 15708510 BW   Cerus Corporation Reports Third Quarter 2013 Results,#N/A,11/10/2011 04269E10 BW   ArQule Announces Third Quarter Fiscal 2011 Results,#N/A,#N/A," 9/24/2015 EXEL-US  BW   Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib", 9/19/2013 SNY-FR    BW   Sanofi Forms Partnership with UMass Boston with $1 Million Support of Student Success Program for STEM Education, 7/02/2015 92532F10  BW   ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation,#N/A,#N/A,"12/23/2014 09609G10 BW   INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into bluebird bio, Inc. Regarding Possible Breaches of Fiduciary Duty", 8/19/2013 00422510 BW   ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer,#N/A,#N/A,#N/A, 3/18/2014 88338N10 BW   TherapeuticsMD Announces Launch of Secondary Offering,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2014 46333X10 BW   Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS® Patent Protection Through 2031,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2013 29251M10   BW   Enanta Pharmaceuticals Added to the Russell 3000® and Russell 2000® Indexes, 3/17/2017 ALNY-US   BW   The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2011 AVDL-US  BW   Eagle Pharmaceuticals and Flamel Technologies Announce Eagle to License Medusa Technology for Extended-Release of Tigecycline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2014 25303110 BW   Dicerna Announces Pricing of Initial Public Offering," 6/28/2017 15117K10 BW   Cellectis annonce la nomination de Rainer Boehm, M.D. et Hervé Hoppenot à son conseil d’administration",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2014 00434H10 BW   Acceleron to Webcast Presentation at Leerink Partners Rare Disease Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/03/2015 G6674U10 BW   Vorläufige Daten aus Phase-2-Studie belegen Sicherheit der TTFields-Therapie bei Patienten mit Hirnmetastasen, bedingt durch nicht-kleinzelliges Lungenkarzinom",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2015 74587V10 BW   Puma Biotechnology Reports Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/07/2014 53220K50  BW   Ligand Reports First Quarter 2014 Financial Results,#N/A,10/07/2015 ILMN-US     BW   Illumina Introduces Genomics Solutions to Advance Clinical Research, 2/27/2014 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast,#N/A, 2/09/2015 04280A10 BW   Arrowhead Reports Fiscal 2015 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 3/29/2013 PHIO-US  BW   RXi Pharmaceuticals Reports Full Year 2012 Financial Results,#N/A,#N/A," 6/07/2016 ALXN-US  BW   IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm",#N/A,10/27/2016 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2016 Financial Results,#N/A, 7/27/2015 09062X10    BW   Biogen Enters Collaboration with the Parkinson’s Institute and Clinical Center," 5/03/2013 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference",#N/A,"10/03/2017 GILD-US      BW   Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.",#N/A,#N/A,#N/A,#N/A, 8/15/2011 NPSP-US      BW   NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2015 00771V10   BW   Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business and Product Development Update,#N/A, 5/09/2016 ARIA-US  BW   Incyte en ARIAD akkoord over overname Europese ARIAD-onderdelen door Incyte en licentiëring Iclusig (ponatinib),#N/A,#N/A, 5/01/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Bank of America Merrill Lynch 2013 Smid Cap Conference,10/21/2013 15708510 BW   Cerus Announces Appointment of Daniel Swisher as New Chair of Board of Directors,#N/A,"11/10/2011 04269E10 BW   Daiichi Sankyo To License ARQ 092 from ArQule, the First New Compound Resulting from the Companies’ Joint AKIP Research Collaboration",#N/A,#N/A, 9/22/2015 EXEL-US  BW   Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015, 9/17/2013 SNY-FR    BW   European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)," 6/18/2015 92532F10  BW   Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors",#N/A,#N/A,12/15/2014 09609G10 BW   bluebird bio Announces Pricing of Public Offering of Common Stock, 8/06/2013 00422510 BW   ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results,#N/A,#N/A,#N/A, 3/03/2014 88338N10 BW   TherapeuticsMD Reports Fourth Quarter and Full-Year 2013 Results,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2013 29251M10   BW   Enanta Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference," 3/01/2017 ALNY-US   BW   Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2013 0098J6-E BW   Dicerna Announces Publication of Data Demonstrating Tumor Growth Inhibition from Knockdown of Key Oncogene Using Dicer Substrate RNAi Compounds, 6/27/2017 15117K10 BW   Cellectis annonce la première administration de UCART123 chez l’homme dans le cadre de son étude clinique de Phase I menée au Weill Cornell Medicine – NewYork-Presbyterian Hospital ciblant la leucémie aiguë myeloblastique (LAM),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2014 00434H10 BW   Acceleron Provides Update on Externally Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 G6674U10 BW   Des résultats préliminaires de phase 2 démontrent que le traitement des tumeurs par champs électriques est sûr pour les patients ayant des métastases au cerveau provenant d’un cancer du poumon non à petites cellules,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2015 74587V10 BW   Puma Biotechnology to Present at Credit Suisse Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/30/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic Anemia,#N/A,10/06/2015 45232710    BW   Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species," 2/06/2014 84763A10  BW   Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq™ (belinostat) for Injection, a novel pan-HDAC inhibitor",#N/A, 2/02/2015 04280A10 BW   Arrowhead to Report Fiscal 2015 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 3/07/2013 68375N10 BW,#N/A,#N/A," 6/07/2016 ALXN-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN",#N/A,10/20/2016 SGEN-US     BW   Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016,#N/A," 7/24/2015 BIIB-US     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws"," 4/26/2013 45253H10 BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update",#N/A," 9/27/2017 GILD-US      BW   Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire",#N/A,#N/A,#N/A,#N/A, 8/02/2011 GSK-GB       BW   NPS Pharmaceuticals Announces New Calcilytics Agreement with GSK,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2015 00771V10   BW   Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research,#N/A, 5/09/2016 ARIA-US  BW   Incyte und ARIAD geben Vereinbarung zur Übernahme des europäischen Geschäfts von ARIAD durch Incyte und die Einlizenzierung von Iclusig® (Ponatinib) in Europa bekannt,#N/A,#N/A, 4/17/2013 G0176710 BW   Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive Disorder,"10/18/2013 15708510 BW   Cerus to Release Third Quarter 2013 Results on October 29, 2013",#N/A,"11/08/2011 04269E10 BW   ArQule, Inc. to Present at Lazard Capital Markets 8th Annual Healthcare Conference",#N/A,#N/A, 8/27/2015 EXEL-US  BW   Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland," 9/04/2013 06QYMX-E  BW   Global Green, Inc. Signs Agreement with Merial for Evaluation of Salmonella Vaccine and License Option", 6/11/2015 VRTX-US   BW   Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference,#N/A,#N/A,12/15/2014 09609G10 BW   bluebird bio Announces Proposed Public Offering of Common Stock," 7/30/2013 00422510 BW   ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013",#N/A,#N/A,#N/A, 2/25/2014 88338N10 BW   TherapeuticsMD to Present at the Cowen and Company 34th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 1/21/2014 46333X10 BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/14/2013 29251M10   BW   Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference, 2/28/2017 ALNY-US   BW   Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2013 0098J6-E BW   Dicerna Secures $60 Million in Oversubscribed Series C Financing," 6/27/2017 15117K10 BW   First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2014 00434H10 BW   Acceleron to Host Educational Webcast Series with Clinical Thought Leaders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 G6674U10 BW   Voorlopige gegevens uit fase 2-onderzoek duiden erop dat gebruik van tumorbehandelende velden veilig is bij patiënten met hersenmetastasen veroorzaakt door niet-kleincellig longcarcinoom,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2015 PBYI-US  BW   Dr. Fredric N. Eshelman Files Preliminary Written Consent Statement in Connection with Puma Biotechnology Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/23/2014 53220K50  BW   Ligand’s Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial,#N/A,10/05/2015 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2015, 1/09/2014 84763A10  BW   Spectrum Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 16th,#N/A, 1/12/2015 04280A10 BW   Arrowhead Provides Update on IND for ARC-520 Phase 2b Study,#N/A,#N/A,#N/A,#N/A, 3/07/2013 68375N10 BW,#N/A,#N/A, 6/06/2016 ALXN-US  BW   Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG),#N/A,"10/07/2016 078V1F-E    BW   Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress",#N/A, 7/24/2015 09062X10    BW   Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion," 4/18/2013 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Results",#N/A, 9/26/2017 GILD-US      BW   Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period,#N/A,#N/A,#N/A,#N/A, 7/20/2011 BMY-US       BW   Research and Markets: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2015 00771V10   BW   Aerie Pharmaceuticals Announces Rhopressa™ Presentation at 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics,#N/A, 5/09/2016 INCY-US  BW   Incyte First Quarter Financial Results Conference Call and Webcast,#N/A,#N/A, 2/19/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Three Upcoming Conferences,10/01/2013 15708510 BW   Cerus Submits the First of Three Modules in the Premarket Approval (PMA) Application Process for INTERCEPT Platelets,#N/A,"11/03/2011 04269E10 BW   ArQule to Report Third Quarter 2011 Financial Results on November 10, 2011",#N/A,#N/A, 8/24/2015 EXEL-US  BW   Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015," 8/30/2013 SNY-FR    BW   European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)", 6/04/2015 VRTX-US   BW   Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases,#N/A,#N/A,12/08/2014 09609G10 BW   bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free," 7/02/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013",#N/A,#N/A,#N/A," 2/25/2014 88338N10 BW   TherapeuticsMD To Host Conference Call and Live Audio Webcast to Disclose Financial Results for Quarter and Year Ended December 31, 2013",#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2014 46333X10 BW   Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2013 29251M10   BW   Enanta Pharmaceuticals to Present at Upcoming Investor Conferences, 2/27/2017 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming March Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/01/2013 0098J6-E BW   Dicerna Announces Additional Patent Claims Allowed, Broadening Coverage of Extended Dicer Substrate Therapeutic Structures", 6/26/2017 15117K10 BW   Résultats de l’Assemblée Générale Mixte des actionnaires de Cellectis S.A. du 26 juin 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/27/2014 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 G6674U10 BW   Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2015 PBYI-US  BW   Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/23/2014 53220K50  BW   Ligand to Participate in Three Upcoming Investor Conferences,#N/A,10/01/2015 45232710    BW   Illumina Expands World’s Largest Genomics Analysis Platform and Adds to Open Source Initiative,12/18/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Pricing of $100 Million Convertible Notes Offering,#N/A,12/15/2014 04280A10 BW   Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients,#N/A,#N/A,#N/A,#N/A, 3/07/2013 68375N10 BW,#N/A,#N/A, 6/02/2016 ALXN-US  BW   La Commission européenne accorde la désignation de médicament orphelin au ALXN1210 pour le traitement des patients atteints d'hémoglobinurie paroxystique nocturne (HPN).,#N/A,"10/06/2016 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016",#N/A, 7/22/2015 09062X10    BW   Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015," 4/11/2013 45253H10 BW   Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013",#N/A, 9/25/2017 GILD-US      BW   China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection,#N/A,#N/A,#N/A,#N/A," 7/12/2011 06W76T-E     BW   The Gamida Cell-Teva Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/17/2015 00771V10   BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2, 2015",#N/A, 5/09/2016 INCY-US  BW   Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 2/05/2013 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences," 9/04/2013 15708510 BW   Cerus to Present at the Baird's 2013 Health Care Conference on September 10, 2013",#N/A," 9/12/2011 04269E10 BW   ArQule, Inc. to Present at UBS Global Life Sciences Conference",#N/A,#N/A, 8/24/2015 EXEL-US  BW   FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy, 8/12/2013 80105N10  BW   Hagens Berman Adds Five Cases to Thalidomide Litigation, 6/03/2015 VRTX-US   BW   Vertex to Present at the Goldman Sachs Healthcare Conference on June 11,#N/A,#N/A,11/12/2014 09609G10 BW   bluebird bio Reports Fiscal Third Quarter 2014 Financial Results, 7/01/2013 00422510 BW   ACADIA Pharmaceuticals Added to Russell 2000 Index,#N/A,#N/A,#N/A, 1/28/2014 88338N10 BW   TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap™ (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA),#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2014 46333X10 BW   Ironwood Pharmaceuticals to Host Fourth Quarter 2013 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2013 062WH0-E   BW   Enanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013"," 2/10/2017 ALNY-US   BW   Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2013 0098J6-E BW   Dicerna Announces First Patent Grant in Japan to Dicer Substrate siRNA Molecules," 6/26/2017 15117K10 BW   Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/12/2014 00434H10 BW   Acceleron Pharma Reports Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 G6674U10 BW   I dati preliminari di fase 2 dimostrano che il trattamento con Tumor Treating Fields è sicuro nei pazienti con metastasi cerebrali generate da carcinoma polmonare non a piccole cellule,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2015 74587V10 BW   Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/22/2014 53220K50  BW   Ligand to Report First Quarter Results on May 7th,#N/A, 9/30/2015 ILMN-US     BW   Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China,12/16/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Offering of $100 Million of Convertible Notes,#N/A,12/04/2014 04280A10 BW   CORRECTING and REPLACING Arrowhead Appoints Patrick O’Brien as General Counsel,#N/A,#N/A,#N/A,#N/A, 3/04/2013 68375N10 BW   OPKO Health Completes Acquisition of Two Phase 3 Products,#N/A,#N/A, 6/02/2016 ALXN-US  BW   Europäische Kommission erteilt ALXN1210 den Orphan-Arzneimittel-Status zur Behandlung von Patienten mit paroxysmaler nächtlicher Hämoglobinurie (PNH),#N/A,10/04/2016 SGEN-US     BW   Seattle Genetics Announces Executive Promotions and Leadership Appointment,#N/A, 7/10/2015 09062X10    BW   Douglas Williams to Leave Biogen for Biotechnology Start-Up," 4/10/2013 45253H10 BW   ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers",#N/A, 9/14/2017 GILD-US      BW   Gilead Prices $3 Billion of Senior Unsecured Notes,#N/A,#N/A,#N/A,#N/A, 7/11/2011 MITI-US      BW   Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2015 00771V10   BW   Aerie Pharmaceuticals to Participate in Two Investor Conferences in February,#N/A, 5/09/2016 ARIA-US  BW   Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe,#N/A,#N/A, 1/31/2013 G0176710 BW   Alkermes plc Reports Third Quarter Fiscal 2013 Financial Results," 8/07/2013 15708510 BW   Cerus to Present at the Wedbush 2013 Life Sciences Management Access Conference on August 14, 2013",#N/A," 9/01/2011 04269E10 BW   ArQule, Inc. to Present at Stifel Nicolaus 2011 Global Healthcare Conference",#N/A,#N/A, 8/11/2015 EXEL-US  BW   Exelixis Announces Second Quarter 2015 Financial Results and Provides Corporate Update, 8/01/2013 80105N10  BW   Sanofi Q2 2013 - Interview with CEO Chris Viehbacher, 5/17/2015 92532F10  BW   New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation,#N/A,#N/A,11/10/2014 09609G10 BW   James M. DeTore joins bluebird bio as Chief Financial Officer, 6/18/2013 00422510 BW   ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders,#N/A,#N/A,#N/A, 1/24/2014 88338N10 BW   TherapeuticsMD Initiates Phase 3 Clinical Trial of Its Progesterone Candidate (TX 12-002-HR) for Treatment of Secondary Amenorrhea,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2014 46333X10 BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2013 29251M10   BW   Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450, 2/08/2017 ALNY-US   BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/19/2013 4151-JP  BW   Dicerna Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator", 6/23/2017 15117K10 BW   Calyxt Files Registration Statement for Proposed Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2014 00434H10 BW   Acceleron Pharma to Host Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/20/2015 G6674U10 BW   New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2015 74587V10 BW   Puma Biotechnology Reports Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 3/17/2014 53220K50  BW   Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL® (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation",#N/A, 9/29/2015 ILMN-US     BW   Illumina Launches TruSight® Tumor OncoPanel,12/11/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN® and MARQIBO® Clinical Data Presented at the 55th Annual Meeting of the American Society of Hematology (ASH),#N/A,12/01/2014 04280A10 BW   INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced by Law Offices of Howard G. Smith,#N/A,#N/A,#N/A,#N/A, 3/01/2013 OPK-US   BW   OPKO Point-of-Care Technology Demonstrated on Mobile Device with Cloud Connectivity to Diagnose and Track Disease in Africa,#N/A,#N/A, 6/01/2016 ALXN-US  BW   European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A, 9/19/2016 SGEN-US     BW   Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia,#N/A," 7/06/2015 09062X10    BW   Biogen to Report Second Quarter 2015 Financial Results on July 24, 2015"," 3/12/2013 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013",#N/A," 9/05/2017 GILD-US      BW   Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11",#N/A,#N/A,#N/A,#N/A," 7/06/2011 CLDX-US      BW   Celldex Expands Senior Management Team with Appointment of Dr. Ronald A. Pepin, Senior Vice President and Chief Business Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2015 00771V10   BW   Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial (“Rocket 1”) of RhopressaTM,#N/A, 4/28/2016 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 1/24/2013 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2013, 7/30/2013 15708510 BW   Cerus Corporation Reports Second Quarter 2013 Results,#N/A, 8/04/2011 04269E10 BW   ArQule Reports Second Quarter 2011 Financial Results,#N/A,#N/A," 7/28/2015 EXEL-US  BW   Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015", 8/01/2013 80105N10  BW   Sanofi T2 2013 - Interview du Directeur Général Chris Viehbacher, 5/13/2015 VRTX-US   BW   Vertex to Present at the UBS Healthcare Conference on May 19,#N/A,#N/A,11/07/2014 05N2D8-E BW   bluebird bio to Present at Three Upcoming Health Care Conferences, 6/03/2013 00422510 BW   ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development,#N/A,#N/A,#N/A," 1/22/2014 88338N10 BW   TherapeuticsMD Announces Issuance of U.S. Patent Covering Natural Combination Hormone Replacement Formulations and Therapies, Including TX 12-001-HR",#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2013 46333X10 BW   Ironwood Pharmaceuticals Details Strategy to Establish Leading Gastrointestinal Therapeutics Company,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2013 29251M10   BW   Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL, 2/07/2017 ALNY-US   BW   Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/03/2013 4151-JP  BW   Dicerna Announces That Kyowa Hakko Kirin Has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment", 6/23/2017 15117K10 BW   Calyxt a déposé un document d’enregistrement en vue de son projet d’introduction en bourse,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/14/2014 00434H10 BW   Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/19/2015 G6674U10 BW   Novocure kündigt 18 Präsentationen zur TTFields-Therapie auf dem SNO-Kongress 2015 an, darunter neue Analysen von Daten der EF-14 Studie bei neu diagnostiziertem Glioblastom",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/31/2015 PBYI-US  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 3, 2015 – PBYI",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/11/2014 53220K50  BW   Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference,#N/A, 9/23/2015 45232710    BW   Illumina Joins WIN Consortium in Personalized Cancer Medicine,"12/10/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Submission of New Drug Application for Belinostat, a novel pan-HDAC inhibitor",#N/A,"11/28/2014 04280A10 BW   ARROWHEAD RESEARCH CORP. SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Arrowhead Research Corp.",#N/A,#N/A,#N/A,#N/A, 2/15/2013 0CXR0W-E BW   OPKO Health Completes Acquisition of Brazilian Pharmaceutical Company,#N/A,#N/A, 5/31/2016 GS-US    BW   Alexion to Present at Upcoming Investor Conferences,#N/A, 9/06/2016 MS-US       BW   Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference,#N/A, 7/02/2015 09062X10    BW   Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology," 2/22/2013 IMGN-US  BW   ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1)",#N/A," 9/01/2017 GILD-US      BW   Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6",#N/A,#N/A,#N/A,#N/A, 6/27/2011 AMGN-US      BW   Fitch Rates Amgen's Senior Notes 'A-',#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2014 00771V10   BW   Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI),#N/A, 4/15/2016 06P9WL-E BW   Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio,#N/A,#N/A, 1/03/2013 0068K6-E BW   Acceleron Pharma to Present at the 31st Annual J.P. Morgan Healthcare Conference," 7/09/2013 15708510 BW   Cerus to Release Second Quarter 2013 Results on July 30, 2013",#N/A," 7/28/2011 04269E10 BW   ArQule to Report Second Quarter 2011 Financial Results on August 4, 2011",#N/A,#N/A, 7/23/2015 EXEL-US  BW   Exelixis Prices Public Offering of Common Stock, 7/30/2013 083KNS-E  BW   Edimer Secures $18M Series B Financing Led by New Enterprise Associates, 5/12/2015 92532F10  BW   Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation,#N/A,#N/A,11/06/2014 09609G10 BW   bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference," 5/29/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013",#N/A,#N/A,#N/A, 1/06/2014 88338N10 BW   TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection,#N/A,#N/A,#N/A,#N/A,#N/A,"11/21/2013 46333X10 BW   Ironwood Pharmaceuticals to Host Investor Day on December 12, 2013",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/26/2013 29251M10   BW   Enanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option, 2/02/2017 ALNY-US   BW   Alnylam Presents New Data on Fitusiran at EAHAD,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2012 0098J6-E BW   Dicerna Announces Allowance of Patent Claims Covering Extended Dicer Substrate Therapeutic Structures, 6/09/2017 15117K10 BW   Cellectis : Assemblée Générale Mixte du 26 juin 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/19/2014 00434H10 BW   Acceleron Pharma to Present at JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2015 G6674U10 BW   Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/26/2015 74587V10 BW   IMPORTANT INVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses Greater Than $100,000 In Puma Biotechnology, Inc. Of The August 3, 2015 Deadline",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/10/2014 53220K50  BW   Captisol® Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV,#N/A, 9/16/2015 ILMN-US     BW   Memorial Sloan Kettering Cancer Center and Illumina Launch Comprehensive Circulating Tumor DNA Program,"12/06/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights 13 Abstracts at the 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013",#N/A,11/26/2014 04280A10 BW   INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Arrowhead Research Corporation,#N/A,#N/A,#N/A,#N/A, 2/08/2013 68375N10 BW   Clarification Regarding Exercise and Sale of Common Stock Options by OPKO Health Company Officer,#N/A,#N/A, 5/19/2016 ALXN-US  BW   Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress,#N/A, 8/02/2016 06CR5C-E    BW   Takeda e Seattle Genetics anunciam dados positivos do estudo clínico de Fase 3 ALCANZA do ADCETRIS® (brentuximabe vedotina) para linfoma cutâneo de células T que expressam CD30,#N/A, 6/26/2015 09062X10    BW   Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX® (rFIXFc) Marketing Authorization Application," 2/12/2013 IMGN-US  BW   ImmunoGen, Inc. Attains Patient Enrollment Milestone in IMGN901 NORTH Trial",#N/A," 8/30/2017 0BGL4K-E     BW   INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholders",#N/A,#N/A,#N/A,#N/A," 6/14/2011 06SG07-E     BW   ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/02/2014 00771V10   BW   Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial (“Rocket 1”) of Rhopressa™, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma",#N/A, 4/14/2016 INCY-US  BW   Incyte to Report First Quarter Financial Results,#N/A,#N/A," 1/03/2013 G0176710 BW   Alkermes Announces Notice of Allowance of Key U.S. Patent for Aripiprazole Lauroxil, a New Schizophrenia Drug Candidate", 6/11/2013 15708510 BW   Cerus Initiates Patient Enrollment in European Phase III Clinical Trials for INTERCEPT Red Blood Cells for Acute and Chronic Anemia,#N/A," 6/03/2011 04269E10 BW   ArQule, Inc. to Present at Jefferies 2011 Global Healthcare Conference",#N/A,#N/A, 7/21/2015 EXEL-US  BW   Exelixis Launches Proposed Public Offering of Common Stock, 7/16/2013 00804Y-E  BW   Asklepios Enters Cross-License Agreement with Genzyme, 4/29/2015 92532F10  BW   Vertex Reports First Quarter 2015 Financial Results,#N/A,#N/A,10/14/2014 09609G10 BW   bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy, 5/20/2013 00422510 BW   ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock,#N/A,#N/A,#N/A,12/18/2013 88338N10 BW   TherapeuticsMD Names Randall S. Stanicky to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2013 46333X10 BW   Ironwood Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2013 29251M10   BW   Enanta Pharmaceuticals Announces Pricing of Initial Public Offering, 2/01/2017 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/17/2012 0098J6-E BW   Dicerna Presents Data on RNAi Therapeutic Programs at the International Liver Cancer Association (ILCA) Sixth Annual Conference," 6/09/2017 15117K10 BW   Cellectis: Annual General Meeting of June 26, 2017",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/14/2014 00434H10 BW   Studienergebnisse im Rahmen der 19. Jahresversammlung der European Hematology Association (EHA) zur Evaluierung der „Activin Receptor Ligand Trap"" Programme zur Behandlung von Beta-Thalassämie vorgestellt",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2015 G6674U10 BW   Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/19/2015 74587V10 BW   INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Puma Biotechnology, Inc. And Advises Shareholders With Losses Exceeding $100,000 To Contact Goldberg Law PC Prior To The Lead Plaintiff Deadline",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/28/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia,#N/A, 9/09/2015 008541-E    BW   Asuragen to Collaborate with Illumina on Companion Diagnostics Development,11/12/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for Third Quarter 2013,#N/A,11/25/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Year End Financial Results,#N/A,#N/A,#N/A,#N/A, 1/31/2013 68375N10 BW   OPKO Closes Offering of $175 Million of 3.00% Convertible Senior Notes Due 2033,#N/A,#N/A, 5/04/2016 07MDY1-E BW   Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,#N/A," 8/02/2016 4502-JP     BW   Takeda y Seattle Genetics anuncian datos positivos del ensayo clínico de fase 3 ALCANZA, que estudia ADCETRIS® (brentuximab vedotina) en el linfoma cutáneo de células T con expresión de CD30",#N/A, 6/23/2015 09062X10    BW   Biogen Achieves Carbon Neutrality," 2/05/2013 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 8/29/2017 0BGL4K-E     BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences, Inc. is Fair to Shareholders",#N/A,#N/A,#N/A,#N/A," 6/13/2011 06NPWM-E     BW   VLST Corporation Appoints Brian Blackman as Vice President, Finance & Administration",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference,#N/A, 4/06/2016 LLY-US   BW   Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD),#N/A,#N/A," 1/03/2013 G0176710 BW   Alkermes Expands CNS Pipeline and Announces Positive Results from Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of Schizophrenia", 5/28/2013 15708510 BW   First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus,#N/A, 5/31/2011 04269E10 BW   ArQule Comments on Presentations at ASCO 2011,#N/A,#N/A," 7/20/2015 EXEL-US  BW   Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma", 7/01/2013 80105N10  BW   Genzyme Convenes 1st International Gaucher Conference on Bone Disease, 4/09/2015 92532F10  BW   Vertex to Announce First Quarter 2015 Financial Results on April 29,#N/A,#N/A, 9/02/2014 09609G10 BW   bluebird bio to Present at Morgan Stanley Global Health Care Conference, 5/20/2013 00422510 BW   ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index,#N/A,#N/A,#N/A,12/09/2013 88338N10 BW   TherapeuticsMD Receives Notice of Allowance for Patent Covering Platform Technology of Oral Combination Bioidentical 17β-Estradiol and Progesterone,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2013 46333X10 BW   Ironwood Pharmaceuticals Provides Third Quarter 2013 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2017 ALNY-US   BW   Alnylam Announces Management Change and Key Promotion,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/08/2012 4151-JP  BW   Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone"," 6/07/2017 15117K10 BW   Calyxt Names Joseph B. Saluri as General Counsel & EVP, Corporate Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/14/2014 00434H10 BW   Présentation, à l’occasion du 19ème congrès annuel de l’Association européenne d'hématologie, d’études évaluant des programmes de pièges à ligands pour le récepteur de l’activine visant à traiter la bêta-thalassémie",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2015 G6674U10 BW   Novocure Reports Third Quarter 2015 Operating and Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2015 74587V10 BW   PBYI INVESTORS: Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Puma Biotechnology, Inc. Investors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/26/2014 53220K50  BW   Ligand to Present at the 26th Annual Roth Conference on March 11,#N/A, 9/03/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference,11/11/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Credit Suisse 2013 Healthcare Conference in Arizona on November 13th,#N/A,"11/24/2014 04280A10 BW   UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014",#N/A,#N/A,#N/A,#N/A, 1/25/2013 68375N10 BW   OPKO Prices Offering of $175 Million of 3.00% Convertible Senior Notes Due 2033,#N/A,#N/A, 4/28/2016 ALXN-US  BW   Alexion Reports First Quarter 2016 Results,#N/A, 8/01/2016 4502-JP     BW   Takeda und Seattle Genetics melden positive Ergebnisse der klinischen Phase-3-Studie ALCANZA zu ADCETRIS® (Brentuximab Vedotin) bei CD30-exprimierendem kutanem T-Zell-Lymphom,#N/A, 6/18/2015 BIIB-US     BW   New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use," 1/25/2013 IMGN-US  BW   ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update",#N/A," 8/28/2017 KITE-US      BW   ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kite Pharma, Inc.",#N/A,#N/A,#N/A,#N/A, 5/03/2011 AMGN-US      BW   Fitch Downgrades Amgen's IDR to 'A-'; Outlook Stable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference,#N/A, 3/16/2016 06P9WL-E BW   Incyte’s Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016,#N/A,#N/A, 1/02/2013 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at the 31st Annual J.P. Morgan Healthcare Conference, 4/30/2013 15708510 BW   Cerus Corporation Reports First Quarter 2013 Results,#N/A, 5/05/2011 04269E10 BW   ArQule Reports First Quarter 2011 Financial Results,#N/A,#N/A, 7/15/2015 30161Q10 BW   Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer, 6/28/2013 SNY-FR    BW   Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe, 3/23/2015 92532F10  BW   Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A, 8/12/2014 09609G10 BW   bluebird bio Reports Fiscal Second Quarter 2014 Financial Results, 5/15/2013 00422510 BW   ACADIA Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,"12/04/2013 88338N10 BW   TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer",#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2013 46333X10 BW   Ironwood Pharmaceuticals to Host Third Quarter 2013 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2017 ALNY-US   BW   Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2012 0098J6-E BW   Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer, 6/05/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/14/2014 00434H10 BW   Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/19/2015 G6674U10 BW   NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2015 74587V10 BW   Puma Biotechnology Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/11/2014 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2013 Financial Results,#N/A, 9/01/2015 45232710    BW   Illumina Completes Acquisition of GenoLogics,11/08/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2013 Financial Results Teleconference and Webcast,#N/A,11/21/2014 04280A10 BW   SHAREHOLDER ALERT: Investigation on Behalf of Arrowhead Research Corporation Investors Announced by Law Offices of Howard G. Smith,#N/A,#N/A,#N/A,#N/A, 1/23/2013 68375N10 BW   OPKO Announces Proposed Private Offering of $150 Million Convertible Senior Notes Due 2033,#N/A,#N/A," 4/12/2016 ALXN-US  BW   Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016",#N/A, 8/01/2016 4502-JP     BW   Takeda et Seattle Genetics annoncent des données positives de l’essai clinique de phase 3 ALCANZA® portant sur ADCETRIS (brentuximab védotine) pour le traitement du lymphome cutané à cellules T exprimant l’antigène...,#N/A," 6/15/2015 00G87M-E    BW   Alfred Sandrock, Jr., M.D., Ph.D., Chief Medical Officer of Biogen, Joins Flex Pharma’s Scientific Advisory Board"," 1/18/2013 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2013 Financial Results",#N/A, 8/28/2017 GILD-US      BW   Gilead Sciences to Acquire Kite Pharma for $11.9 Billion,#N/A,#N/A,#N/A,#N/A, 5/02/2011 AMRX-US      BW   Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2014 00771V10   BW   Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update,#N/A, 2/29/2016 06TVH6-E BW   Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard,#N/A,#N/A,12/03/2012 ALKS-IE  BW   Alkermes and Collaborators to Present Data from Three Ongoing Clinical Development Programs at Two Major Medical Meetings, 4/24/2013 15708510 BW   Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets,#N/A," 4/28/2011 04269E10 BW   ArQule to Report First Quarter 2011 Financial Results on May 5, 2011",#N/A,#N/A, 7/13/2015 30161Q10 BW   Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors, 6/12/2013 80105N10  BW   Genzyme Convenes 14th Annual North American Lysosomal Storage Disorder Registries Meeting, 3/18/2015 92532F10  BW   Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene,#N/A,#N/A, 8/05/2014 09609G10 BW   bluebird bio to Present at Two Upcoming Health Care Conferences, 5/14/2013 00422510 BW   ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,11/22/2013 88338N10 BW   TherapeuticsMD To Present At 25th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2013 0BGDM3-E BW   Ironwood and AstraZeneca Initiate Linaclotide Phase III Trial in China for Adults with IBS-C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2016 ALNY-US   BW   Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/15/2011 0098J6-E BW   Dicerna Pharmaceuticals Announces First DsiRNA Therapeutic Candidate Selected for Development, Triggering $5 Million Milestone Payment", 6/05/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 00434H10 BW   Acceleron Pharma to Present at Upcoming Investor and Medical Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2015 G6674U10 BW   Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2015 PBYI-US  BW   Puma Biotechnology to Present at Goldman Sachs Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/10/2014 53220K50  BW   Ligand to Receive $1 Million Kyprolis® Commercial Milestone Payment from Onyx Pharmaceuticals,#N/A, 8/24/2015 45232710    BW   Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology,"10/30/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Completion of Enrollment, in Pivotal Trial of Captisol-Enabled® (Propylene Glycol-Free) Melphalan",#N/A,"11/19/2014 04280A10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A, 1/14/2013 68375N10 BW   OPKO Health Expands Collaboration with Bristol-Myers Squibb,#N/A,#N/A," 4/04/2016 0786F6-E BW   Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq® (asfotase alfa)",#N/A, 8/01/2016 06CR5C-E    BW   Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma,#N/A, 6/10/2015 09062X10    BW   Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress," 1/02/2013 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference",#N/A," 8/10/2017 GILD-US      BW   Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV",#N/A,#N/A,#N/A,#N/A," 4/18/2011 SGEN-US      BW   Seattle Genetics Appoints Vice President, Corporate Development and Announces Management Promotion",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/28/2014 00771V10   BW   Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014",#N/A, 2/16/2016 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,11/07/2012 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences," 4/17/2013 CERS-US  BW   Cerus to Release First Quarter 2013 Results on April 30, 2013",#N/A," 4/28/2011 04269E10 BW   ArQule, Inc. Announces Appointment of Dr. Susan Kelley to Board of Directors",#N/A,#N/A," 7/01/2015 EXEL-US  BW   Exelixis Provides Update on Genentech’s Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound", 5/29/2013 80105N10  BW   Genzyme Celebrates Fifth Annual World MS Day, 2/11/2015 92532F10  BW   Vertex to Present at Upcoming Investor Conferences,#N/A,#N/A, 7/16/2014 09609G10 BW   bluebird bio Appoints Mark Vachon to its Board of Directors," 5/10/2013 00422510 BW   Faruqi & Faruqi, LLP Launches An Investigation Against ACADIA Pharmaceuticals Inc. (ACAD) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors",#N/A,#N/A,#N/A,11/19/2013 88338N10 BW   TherapeuticsMD Applauds Congressional Leadership on Passage of Drug Quality and Security Act,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2013 46333X10 BW   Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2016 ALNY-US   BW   Alnylam to Webcast R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2011 0098J6-E BW   Dicerna Pharmaceuticals Awarded Notice of Allowance by U.S. Patent and Trademark Office for Patent Claims Broadly Covering Dicer Substrate siRNA Molecules, 5/10/2017 15117K10 BW   Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2014 00434H10 BW   Acceleron Announces New Interim Phase 2 Data on Sotatercept and ACE-536 to be Reported at Three Oral Presentations at the 19th Annual Congress of the European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/16/2015 G6674U10 BW   Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2015 PBYI-US  BW   Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/03/2014 53220K50  BW   Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia,#N/A," 8/18/2015 ILMN-US     BW   Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix to Accelerate Consumer Adoption of Genomics", 9/04/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Conference in New York City on September 11th,#N/A,11/18/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Fourth Quarter and Year End Financial Results,#N/A,#N/A,#N/A,#N/A, 1/08/2013 OPK-US   BW   OPKO Health to Acquire Two Phase 3 Products,#N/A,#N/A, 3/28/2016 0B0XYS-E BW   Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D),#N/A, 7/26/2016 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2016 Financial Results,#N/A, 5/28/2015 09062X10    BW   Biogen 2015 Annual Shareholder Meeting Webcast,12/19/2012 IMGN-US  BW   Amgen Takes Third License for Rights to Use ImmunoGen’s TAP Technology,#N/A, 8/01/2017 GILD-US      BW   U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV,#N/A,#N/A,#N/A,#N/A, 3/28/2011 060RWY-E     BW   More Rheumatologists Prefer Switching to a Biologic with an Alternative Mechanism of Action Following an Initial TNF-Alpha Inhibitor Failure Compared to Six Months Ago,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/06/2014 00771V10   BW   Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors",#N/A," 2/11/2016 INCY-US  BW   Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs",#N/A,#N/A,11/01/2012 ALKS-IE  BW   Alkermes plc Reports Second Quarter Fiscal 2013 Financial Results, 4/03/2013 15708510 BW   Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet Components,#N/A," 4/11/2011 04269E10 BW   ArQule, Inc. to Present at Future Leaders in the Biotech Industry Conference",#N/A,#N/A, 5/31/2015 30161Q10 BW   Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers, 5/21/2013 BIM-FR    BW   Nicolas Cartier est nommé Directeur de l’Unité Microbiologie Industrielle de bioMérieux, 1/28/2015 92532F10  BW   Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015,#N/A,#N/A, 7/08/2014 09609G10 BW   bluebird bio Announces Pricing of Public Offering of Common Stock, 5/07/2013 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results,#N/A,#N/A,#N/A,11/04/2013 88338N10 BW   TherapeuticsMD Reports Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 8/21/2013 46333X10 BW   Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical Development,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2016 06QBQ2-E  BW   Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2011 06QPQV-E BW," 5/10/2017 15117K10 BW   Un brevet couvrant largement les technologies d’édition du génome, dont Cellectis a une licence exclusive, a été maintenu par l’USPTO au terme d’un réexamen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2014 00434H10 BW   Acceleron Pharma Reports First Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2015 G6674U10 BW   Úřad FDA schválil Optune v kombinaci s temozolomidem pro léčbu nově diagnostikovaných glioblastomů,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2015 74587V10 BW   Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/29/2014 53220K50  BW   Ligand to Report Fourth Quarter Results on February 11th,#N/A, 8/05/2015 45232710    BW   Illumina Accelerator Invests in Second Class of Genomics Startups from US and Europe, 9/03/2013 84763A10  BW   Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders,#N/A,11/18/2014 04280A10 BW   Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT,#N/A,#N/A,#N/A,#N/A, 1/04/2013 OPK-US   BW   OPKO Health to Present at the 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 3/03/2016 ALXN-US  BW   New Data Presented at WORLDSymposium™ 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma™ (sebelipase alfa),#N/A, 7/20/2016 4502-JP     BW   Seattle Genetics und Takeda melden Veröffentlichung der endgültigen Ergebnisse der zulassungsrelevanten klinischen Phase-2-Studie zu ADCETRIS® (Brentuximab Vedotin) als Monotherapie bei rezidiviertem oder refraktärem...,#N/A, 5/20/2015 09062X10    BW   Biogen to Present at Bernstein’s 31st Annual Strategic Decisions Conference,"12/10/2012 IMGN-US  BW   ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH",#N/A, 7/28/2017 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C,#N/A,#N/A,#N/A,#N/A, 3/17/2011 005YZ9-E     BW   KaloBios Announces Two Significant Additions to Its Management Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2014 00771V10   BW   Aerie Announces Closing of $125 Million Convertible Notes Financing,#N/A, 2/11/2016 INCY-US  BW   Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer,#N/A,#N/A,10/25/2012 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2013, 3/15/2013 15708510 BW   Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria,#N/A, 3/31/2011 04269E10 BW   ArQule Announces Presentations at AACR 102nd Annual Meeting,#N/A,#N/A, 5/31/2015 30161Q10 BW   Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer, 5/21/2013 80105N10  BW   Sanofi konsolidiert IT-Infrastruktur und verringert Betriebskosten dank Axway," 1/11/2015 92532F10  BW   Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis",#N/A,#N/A, 7/07/2014 09609G10 BW   bluebird bio Announces Proposed Public Offering of Common Stock," 4/30/2013 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013",#N/A,#N/A,#N/A,"10/23/2013 88338N10 BW   TherapeuticsMD Appoints Sebastian Mirkin, M.D. as Chief Medical Officer",#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2013 46333X10 BW   Ironwood Pharmaceuticals Provides Second Quarter 2013 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2016 06QBQ2-E  BW   Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2011 0098J6-E BW   Dicerna Pharmaceuticals to Present at Upcoming Conferences, 5/09/2017 15117K10 BW   Cellectis Reports 1st Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2014 00434H10 BW   Acceleron to Report New Encouraging Interim Clinical Data from Phase 2 Trial of Dalantercept in Renal Cell Carcinoma at the 50th Annual Meeting of the American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/07/2015 G6674U10 BW   NovoCure Limited Announces Closing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 74587V10 BW   Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/09/2013 53220K50  BW   Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology,#N/A," 8/04/2015 ILMN-US     BW   Illumina Signs Agreement to Acquire GenoLogics, Leader in Genomics Laboratory Information Management System Market", 8/07/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for Second Quarter 2013,#N/A,11/14/2014 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,12/26/2012 68375N10 BW   OPKO Health to Expand Latin American Presence with Acquisition of Brazilian Pharmaceutical Company,#N/A,#N/A, 3/03/2016 ALXN-US  BW   Ensemble Therapeutics Achieves Milestone,#N/A, 7/20/2016 4502-JP     BW   Seattle Genetics et Takeda annoncent la publication des données finales de l’essai clinique pivot en monothérapie de phase 2 d'ADCETRIS® ® (Brentuximab védotine) pour le traitement du lymphome hodgkinien récidivant ou ...,#N/A, 5/13/2015 09062X10    BW   Biogen to Present at the 2015 UBS Global Healthcare Conference,"12/06/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference",#N/A, 7/26/2017 GILD-US      BW   Gilead Sciences Announces Third Quarter 2017 Dividend,#N/A,#N/A,#N/A,#N/A, 3/01/2011 05M7WL-E     BW   Fitch Affirms Amgen's IDR at 'A'; Outlook Stable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2014 0016FP-E   BW   Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals,#N/A, 1/27/2016 INCY-US  BW   Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP,#N/A,#N/A,10/16/2012 ACOR-US  BW   Acorda Therapeutics Announces Hatch-Waxman Extension of AMPYRA® (dalfampridine) Sustained-Release Formulation Patent, 3/14/2013 CERS-US  BW   Cerus Prices Public Offering of Common Stock,#N/A," 3/30/2011 04269E10 BW   ArQule, Inc. to Present at Needham and Leerink Swann Conferences",#N/A,#N/A, 5/30/2015 30161Q10 BW   Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting, 5/21/2013 AXW-FR    BW   Sanofi fait confiance à Axway pour pérenniser son infrastructure et réduire ses coûts d’exploitation, 1/06/2015 92532F10  BW   Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results,#N/A,#N/A," 6/30/2014 0D1XX5-E BW   bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company"," 4/25/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013",#N/A,#N/A,#N/A,10/22/2013 88338N10 BW   TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy (VVA),#N/A,#N/A,#N/A,#N/A,#N/A, 7/09/2013 46333X10 BW   Ironwood Pharmaceuticals to Host Second Quarter 2013 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2016 ALNY-US   BW   Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/08/2011 0098J6-E BW   Dicerna Pharmaceuticals to Present at Upcoming Conferences, 5/09/2017 15117K10 BW   Cellectis publie ses résultats financiers du premier trimestre 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 00434H10 BW   Acceleron to Present at 2014 UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/07/2015 G6674U10 BW   Az FDA jóváhagyta az újonnan diagnosztizált glioblastomás betegek kombinált, Temozolomide adása mellett Optune-nal végzett kezelését",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2015 74587V10 BW   Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/04/2013 53220K50  BW   Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast,#N/A, 7/21/2015 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2015, 8/01/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2013 Financial Results Teleconference and Webcast,#N/A,11/10/2014 04280A10 BW   Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD The Liver Meeting® 2014,#N/A,#N/A,#N/A,#N/A,12/18/2012 07S951-E BW   OPKO Health Completes Acquisition of CLIA Laboratory,#N/A,#N/A, 3/01/2016 ALXN-US  BW   SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Dose Studied in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) in Phase 1/2 Study at Six Months,#N/A, 7/19/2016 4502-JP     BW   Seattle Genetics y Takeda anuncian la publicación de los datos finales de ADCETRIS® Publicación del estudio clínico central de fase 2 de agente único (Brentuximab Vedotin) en linfoma Hodgkin clásico ...,#N/A, 5/13/2015 09062X10    BW   Biogen Names Matt Griffiths as Chief Information Officer,"12/03/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition",#N/A, 7/26/2017 GILD-US      BW   Gilead Sciences Announces Second Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A, 2/15/2011 AMGN-US      BW   Research and Markets: Amgen Inc. - Detailed Product Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2014 00771V10   BW   Aerie Announces $125 Million Convertible Notes,#N/A, 1/21/2016 INCY-US  BW   Incyte to Report Fourth Quarter/Year-End Financial Results,#N/A,#N/A,"10/15/2012 0BCZ6T-E BW   Civitas Therapeutics to Present Positive Clinical Study Results for CVT-301 at Sixth Annual Parkinson’s Disease Therapeutics Conference, Sponsored by The Michael J. Fox Foundation for Parkinson’s Research", 3/13/2013 CERS-US  BW   Cerus Announces Proposed Public Offering of Common Stock,#N/A, 3/01/2011 04269E10 BW   ArQule Reports Fiscal 2010 Year End and Fourth Quarter Results,#N/A,#N/A, 5/04/2015 30161Q10 BW   Exelixis to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 12, 5/21/2013 80105N10  BW   Sanofi si affida ad Axway per creare un'infrastruttura a prova di futuro e ridurre i costi operativi attraverso il consolidamento globale,12/29/2014 92532F10  BW   U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation,#N/A,#N/A, 6/14/2014 09609G10 BW   bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate, 4/11/2013 00422510 BW   ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA,#N/A,#N/A,#N/A,10/21/2013 88338N10 BW   TherapeuticsMD to Host Third Quarter 2013 Earnings Call,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2013 46333X10 BW   Ironwood Pharmaceuticals Announces Partial Exercise of Underwriters’ Option in Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/03/2016 ALNY-US   BW   Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2011 0098J6-E BW   Dicerna Pharmaceuticals to Present at Upcoming Conferences, 5/03/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/08/2014 00434H10 BW   Acceleron Pharma to Host First Quarter 2014 Financial Results Conference Call and Webcast on May 15, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   Amerykańska Agencja ds. Żywności i Leków zatwierdza terapię Optune w skojarzeniu z temozolomidem do leczenia nowo zdiagnozowanych glejaków,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2015 74587V10 BW   Puma Biotechnology Reports First Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/14/2013 53220K50  BW   Ligand Announces Highlights from Today’s Analyst Day Event,#N/A, 7/20/2015 45232710    BW   Illumina Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics," 7/17/2013 84763A10  BW   Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.",#N/A,"10/22/2014 04280A10 BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,#N/A,#N/A,11/29/2012 OPK-US   BW   OPKO Health Announces Research Grants from Mexican Technology and Science Council,#N/A,#N/A, 2/29/2016 ALXN-US  BW   Funcionários da Alexion em todo o Mundo se Reúnem para Apoiar o Dia contra Doenças Raras de 2016,#N/A, 7/18/2016 4502-JP     BW   Seattle Genetics e Takeda anunciam publicação dos dados finais do estudo clínico de referência de fase II da monoterapia com ADCETRIS® (brentuximabe vedotina) em linfoma de Hodgkin clássico reincidente ou refratário no periódico científico Blood,#N/A, 5/07/2015 09062X10    BW   Biogen Announces $5 Billion Share Repurchase Program,"11/26/2012 ALTH-US  BW   ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer",#N/A," 7/24/2017 GILD-US      BW   Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV",#N/A,#N/A,#N/A,#N/A, 1/27/2011 05ZNHJ-E     BW   Russell Armstrong of Crescent Financial Partners Announces Marjorie DeHey Daleo as Director,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/04/2014 00771V10   BW   Aerie Pharmaceuticals to Host Investor Day on September 10, 2014",#N/A, 1/21/2016 AGEN-US  BW   Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and anti-GITR Antibodies,#N/A,#N/A," 9/25/2012 G0176710 BW   Alkermes plc Closes Debt Refinancing, Lowering Interest Rate and Reducing Principal Amount", 2/28/2013 15708510 BW   Cerus Corporation Reports Fourth Quarter and Year-End 2012 Results,#N/A," 2/28/2011 04269E10 BW   ArQule, Inc. Announces Departure of Board Member",#N/A,#N/A, 4/30/2015 EXEL-US  BW   Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting, 5/21/2013 80105N10  BW   Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global Consolidation,"12/15/2014 92532F10  BW   David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer",#N/A,#N/A, 6/09/2014 09609G10 BW   bluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects, 3/20/2013 00422510 BW   ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting,#N/A,#N/A,#N/A,10/09/2013 88338N10 BW   Phase 1 Data Presented on First Oral Combination 17β-Estradiol and Progesterone Capsule to Treat Menopausal Symptoms Being Developed for FDA Review,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2013 46333X10 BW   Ironwood Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2016 ALNY-US   BW   The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2010 4151-JP  BW   Dicerna Pharmaceuticals and Kyowa Hakko Kirin Expand Dicer Substrate Technology Partnership into Immunologic and Inflammatory Diseases, 5/03/2017 15117K10 BW   Cellectis: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2014 00434H10 BW   Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   FDA erteilt Zulassung für Optune in Kombination mit Temozolomid für die Behandlung von neu diagnostizierten Glioblastomen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2015 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/12/2013 53220K50  BW   Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes,#N/A, 7/16/2015 45232710    BW   Illumina Introduces Illumina SeqLab, 7/02/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 8th Annual JMP Securities Healthcare Conference in New York City on July 9th,#N/A,10/14/2014 04280A10 BW   SHAREHOLDER ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Filed By Glancy Binkow & Goldberg LLP,#N/A,#N/A,#N/A,#N/A,"11/14/2012 09JZL6-E BW   Oragenics Announces New Strategic Partnership with Mexico-Based Company, Pharmacos Exakta, S.A. de C.V.",#N/A,#N/A, 2/29/2016 ALXN-US  BW   Alexion to Present at Upcoming Investor Conferences,#N/A, 7/18/2016 4502-JP     BW   Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood,#N/A, 5/07/2015 BIIB-US     BW   Biogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference,"11/06/2012 45253H10 BW   ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application",#N/A, 7/18/2017 GILD-US      BW   U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus,#N/A,#N/A,#N/A,#N/A, 1/27/2011 008XMD-E     BW   PhysioSonics Completes Series B Funding,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2014 00771V10   BW   Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of RhopressaTM in Patients with Glaucoma,#N/A, 1/11/2016 INCY-US  BW   Incyte Presents Significant Progress in its Development Portfolio,#N/A,#N/A, 9/19/2012 ALKS-IE  BW   Alkermes plc Announces Pricing of New Term Loans," 2/27/2013 CERS-US  BW   Cerus to Present at the Cowen and Company 33rd Annual Health Care Conference on March 6, 2013",#N/A," 2/23/2011 04269E10 BW   ArQule, Inc. to Present at Citi and Cowen Investment Conferences",#N/A,#N/A, 4/30/2015 30161Q10 BW   Exelixis Announces First Quarter 2015 Financial Results and Provides Corporate Update, 5/20/2013 07G69B-E  BW   Research and Markets: Travel Vaccines Market to 2019 Report,11/20/2014 92532F10  BW   Vertex to Present at Deutsche Bank BioFEST on December 2,#N/A,#N/A, 5/21/2014 09609G10 BW   bluebird bio to present initial clinical data from its HGB-205 Study in beta-thalassemia major patients at the 19th European Hematology Association Congress," 3/13/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013",#N/A,#N/A,#N/A,10/04/2013 88338N10 BW   TherapeuticsMD to Present at 12th Annual Bio Investor Forum,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2013 46333X10 BW   Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2016 06QBQ2-E  BW   Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision for Co-Development and Co-Commercialization of Fitusiran in Hemophilia and Rare Bleeding Disorders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/03/2010 0098J6-E BW   Dicerna Pharmaceuticals Awarded $488,958 in Federal Grant Funding for Qualifying Therapeutic Discovery Project", 4/27/2017 15117K10 BW   Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/24/2014 00434H10 BW   Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   FDA verleent goedkeuring voor Optune in combinatie met temozolomide voor de behandeling van glioblastoom met een recente diagnose,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2015 74587V10 BW   Puma Biotechnology to Present at Deutsche Bank Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/07/2013 53220K50  BW   Reminder: Ligand to Host Analyst Day on November 14th in Chicago,#N/A," 7/13/2015 45232710    BW   Study of Illumina’s Non-Invasive verifi® Prenatal Test Suggests that Test Results, When Discordant from Fetal Karyotyping, May Reflect Presence of Maternal Cancer", 7/01/2013 84763A10  BW   Spectrum Pharmaceuticals Elects Two New Healthcare Industry Veterans to the Board of Directors,#N/A,10/14/2014 04280A10 BW   Arrowhead Research Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,#N/A,#N/A,#N/A,#N/A,11/07/2012 OPK-US   BW   OPKO Health Announces Grant to Develop Tuberculosis Diagnostics Technology,#N/A,#N/A, 2/29/2016 ALXN-US  BW   Empleados de Alexion alrededor del mundo se unen para apoyar el Día de las Enfermedades Raras 2016,#N/A," 7/13/2016 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016",#N/A, 4/29/2015 09062X10    BW   FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS,"11/05/2012 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 7/13/2017 GILD-US      BW   European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV",#N/A,#N/A,#N/A,#N/A, 1/27/2011 AMGN-US      BW   EHSI Examines Biotech Firm OceanBASIS’ Stem Cell Project,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference,#N/A, 1/11/2016 INCY-US  BW   Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration,#N/A,#N/A, 8/30/2012 ALKS-IE  BW   Alkermes’ Corporate Presentation to Be Webcast at Two Upcoming Conferences," 2/14/2013 15708510 BW   Cerus to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013",#N/A," 2/22/2011 04269E10 BW   ArQule to Report Fiscal 2010 Financial Results on March 1, 2011",#N/A,#N/A, 4/13/2015 00BF53-E BW   Kolltan Pharmaceuticals Appoints Industry Veteran Frank Karbe to Its Board of Directors, 5/16/2013 07G69B-E  BW   Research and Markets: PharmaPoint Analysis: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022,11/05/2014 92532F10  BW   Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A, 5/13/2014 09609G10 BW   bluebird bio Reports Fiscal First Quarter 2014 Financial Results," 3/12/2013 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012",#N/A,#N/A,#N/A, 9/25/2013 88338N10 BW   TherapeuticsMD Announces Pricing of Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2013 46333X10 BW   Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2016 ALNY-US   BW   Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2010 0098J6-E BW   Dicerna Pharmaceuticals to Present at Upcoming Conferences in November, 4/25/2017 15117K10 BW   CORRECTING and REPLACING: Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/20/2014 00434H10 BW   Acceleron to Present at the 21st Annual Future Leaders in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   La FDA approva Optune in combinazione con temozolomide per il trattamento del glioblastoma di prima diagnosi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2015 74587V10 BW   Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/30/2013 53220K50  BW   Ligand Reports Third Quarter Financial Results,#N/A," 7/07/2015 45232710    BW   Illumina to Announce Second Quarter 2015 Financial Results on Tuesday, July 21, 2015", 6/06/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Goldman Sachs 34th Annual Global Healthcare Conference in Rancho Palos Verdes on June 11th,#N/A,"10/13/2014 04280A10 BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Arrowhead Research Corp. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2014",#N/A,#N/A,#N/A,#N/A,"10/19/2012 07S951-E BW   OPKO Health to Acquire Prost-Data (OURLab), a Profitable CLIA Laboratory with Strong U.S. Presence in Urologic Pathology",#N/A,#N/A, 2/29/2016 ALXN-US  BW   Les employés d’Alexion à travers le monde s’unissent pour soutenir la Journée des maladies rares 2016,#N/A, 7/06/2016 SGEN-US     BW   Seattle Genetics Announces European Commission Approval of ADCETRIS® (Brentuximab Vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma,#N/A, 4/28/2015 09062X10    BW   Biogen to Present at the 40th Annual Deutsche Bank Health Care Conference,"10/26/2012 IMGN-US  BW   ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update",#N/A," 7/12/2017 GILD-US      BW   Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017",#N/A,#N/A,#N/A,#N/A, 1/25/2011 0B31SR-E     BW   Maven Semantic: Colorectal Cancer Research Database Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2014 00771V10   BW   Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update,#N/A,12/14/2015 INCY-US  BW   Incyte to Present at the 34th Annual J. P. Morgan Healthcare Conference,#N/A,#N/A, 8/13/2012 ACOR-US  BW   Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine-ER,12/13/2012 15708510 BW   Cerus Announces FDA Agreement on Modular Premarket Approval Application (PMA) Submission Process for INTERCEPT Plasma,#N/A," 2/07/2011 04269E10 BW   ArQule, Inc. to Present at 13th Annual BIO CEO and Investor Conference",#N/A,#N/A," 4/09/2015 30161Q10 BW   Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015", 5/15/2013 07GVF3-E  BW   Research and Markets: Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022,10/30/2014 92532F10  BW   Vertex to Present at the Credit Suisse Healthcare Conference on November 11,#N/A,#N/A, 5/01/2014 09609G10 BW   bluebird bio to Present at Three Upcoming Health Care Conferences," 3/05/2013 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013",#N/A,#N/A,#N/A, 9/05/2013 88338N10 BW   TherapeuticsMD Begins Patient Enrollment in Pivotal Phase 3 Clinical Trial of TX 12-001-HR to Treat Symptoms of Menopause and Provide Endometrial Protection,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2013 46333X10 BW   Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2016 06QBQ2-E  BW   Alnylam to Present New Clinical Results at 58th Annual Meeting of the American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2010 0098J6-E BW   Dicerna Pharmaceuticals Announces Second Close of Series B Financing, 4/25/2017 15117K10 BW   Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/17/2014 00434H10 BW   Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   La FDA aprueba Optune en combinación con temozolomida para el tratamiento del glioblastoma recientemente diagnosticado,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2015 74587V10 BW   Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/14/2013 53220K50  BW   Ligand to Host Analyst Day on November 14th in Chicago,#N/A, 7/01/2015 00F34P-E    BW   908 Devices Accelerates Entry into Life Science Market with Backing from Leading Industry Players," 6/05/2013 84763A10  BW   Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer",#N/A,10/09/2014 04280A10 BW   Arrowhead Issues Open Letter to Shareholders,#N/A,#N/A,#N/A,#N/A,10/01/2012 68375N10 BW   OPKO Health Announces Launch of 4Kscore™ in Europe,#N/A,#N/A, 2/29/2016 ALXN-US  BW   Mitarbeiter von Alexion in aller Welt unterstützen gemeinsam den Tag der Seltenen Erkrankungen 2016,#N/A, 6/06/2016 ALPMY-JP    BW   Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting,#N/A, 4/24/2015 09062X10    BW   Biogen Reports First Quarter 2015 Revenues of $2.6 Billion,"10/19/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results",#N/A, 6/23/2017 GILD-US      BW   European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes,#N/A,#N/A,#N/A,#N/A, 1/25/2011 WAT-US       BW   Maven Semantic: Analytical Chemistry Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/24/2014 00771V10   BW   Aerie Pharmaceuticals, Inc. Receives Health Canada “No Objection Letter” to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada",#N/A,12/05/2015 INCY-US  BW   Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint,#N/A,#N/A, 7/26/2012 0C2G14-E BW   Alkermes plc Reports First Quarter Fiscal 2013 Financial Results,12/04/2012 07ZY29-E BW   Cerus Signs Agreement With Swiss Red Cross for Initial Deployment of the INTERCEPT Blood System for Plasma,#N/A, 1/25/2011 04269E10 BW   ArQule Announces Completion of Common Stock Offering with Full Exercise of Overallotment Option,#N/A,#N/A, 4/09/2015 30161Q10 BW   Exelixis’ Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma, 5/15/2013 07G69B-E  BW   Research and Markets: Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022,10/28/2014 92532F10  BW   Vertex Reports Third Quarter 2014 Financial Results,#N/A,#N/A, 3/27/2014 09609G10 BW   bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia," 2/25/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013",#N/A,#N/A,#N/A, 8/29/2013 88338N10 BW   TherapeuticsMD to Present at Stifel Nicolaus 2013 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2013 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2016 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2010 0098J6-E BW   Dicerna Pharmaceuticals to Present at Upcoming Conferences in October," 4/12/2017 15117K10 BW   Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2014 00434H10 BW   Acceleron to Present at Cowen and Company 34th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   FDA aprova o Optune em combinação com temozolomida para o tratamento do glioblastoma recém-diagnosticado,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2015 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/09/2013 53220K50  BW   Ligand to Report Third Quarter Results on October 30th,#N/A, 6/10/2015 45232710    BW   Annoroad and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health, 6/03/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Positive Data from the BELIEF Trial Presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A,10/09/2014 04280A10 BW   EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Arrowhead Research Corp. - ARWR,#N/A,#N/A,#N/A,#N/A, 8/22/2012 68375N10 BW   OPKO Health Awarded NASA Contract,#N/A,#N/A, 2/29/2016 ALXN-US  BW   Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016,#N/A, 5/25/2016 SGEN-US     BW   Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML),#N/A, 4/21/2015 BIIB-US     BW   PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients,10/01/2012 05RBVG-E BW   Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer,#N/A," 6/12/2017 GILD-US      BW   Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment",#N/A,#N/A,#N/A,#N/A, 1/24/2011 TAKDF.XX1-US BW   Maven Semantic: Biotechnology Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/23/2014 00771V10   BW   Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014",#N/A,12/05/2015 INCY-US  BW   Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi® (ruxolitinib) in Patients with Myeloproliferative Neoplasms (MPNs),#N/A,#N/A, 7/19/2012 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2013,"11/21/2012 15708510 BW   Cerus to Present at the Piper Jaffray Healthcare Conference on November 28, 2012",#N/A, 1/24/2011 04269E10 BW   Phase 1 Results of ARQ 197 c-MET Inhibitor in Colorectal Cancer Presented at ASCO 2011 Gastrointestinal Cancers Symposium,#N/A,#N/A," 2/26/2015 30161Q10 BW   Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3", 5/14/2013 0BDC8M-E  BW   Research and Markets: Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022,10/21/2014 92532F10  BW   FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation,#N/A,#N/A, 3/05/2014 09609G10 BW   bluebird bio Reports Fiscal Year End 2013 Financial Results," 2/05/2013 00422510 BW   ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013",#N/A,#N/A,#N/A, 8/12/2013 88338N10 BW   TherapeuticsMD Initiates Phase I Study of Estradiol VagiCap™ for VVA,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2013 46333X10 BW   Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 CS-CH     BW   Alnylam to Webcast Presentations at Upcoming November Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2010 0098J6-E BW   Dicerna Pharmaceuticals Named One of the “Fierce 15” Leading Biotech Companies of 2010," 4/12/2017 15117K10 BW   Cellectis S.A. envisage une potentielle introduction en bourse pour Calyxt, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/26/2014 00434H10 BW   Acceleron Pharma Reports Fourth Quarter and Year Ended 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2015 G6674U10 BW   La FDA approuve Optune en combinaison avec le témozolomide pour le traitement des cas de glioblastome nouvellement diagnostiqués,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2015 74587V10 BW   Puma Biotechnology to Present at Cowen Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/07/2013 53220K50  BW   Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program,#N/A," 6/08/2015 ILMN-US     BW   Illumina, Merck KGaA, Darmstadt, Germany, and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment"," 5/31/2013 84763A10  BW   Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 31 – June 4, 2013",#N/A,10/08/2014 04280A10 BW   Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting® 2014,#N/A,#N/A,#N/A,#N/A, 8/03/2012 68375N10 BW   OPKO Health Announces Acquisition of Growing European Healthcare Company,#N/A,#N/A, 2/04/2016 ALXN-US  BW   Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference,#N/A, 5/04/2016 SGEN-US     BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A," 4/20/2015 BIIB-US     BW   TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients","10/01/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial",#N/A," 6/01/2017 GILD-US      BW   Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15",#N/A,#N/A,#N/A,#N/A, 1/20/2011 PFE-US       BW   Maven Semantic: Neurology Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/14/2014 00771V10   BW   Aerie Pharmaceuticals Initiates Phase 3 Registration Trials of RhopressaTM, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma",#N/A,11/30/2015 INCY-US  BW   Incyte’s Jakafi® (ruxolitinib) to be Featured in over 60 Abstracts at ASH Annual Meeting,#N/A,#N/A," 6/15/2012 0BCZ6T-E BW   Civitas Therapeutics Initiates Phase 2a Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson’s Disease","11/08/2012 15708510 BW   Cerus to Present at the Stephens Fall Investment Conference on November 14, 2012",#N/A, 1/20/2011 04269E10 BW   ArQule Prices Public Offering of Common Stock,#N/A,#N/A, 2/24/2015 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update, 5/08/2013 077VL7-E  BW   Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi,10/14/2014 92532F10  BW   Vertex to Announce Third Quarter 2014 Financial Results on October 28,#N/A,#N/A, 2/26/2014 09609G10 BW   bluebird bio to Present at the Cowen and Company Health Care Conference, 1/22/2013 00422510 BW   ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors,#N/A,#N/A,#N/A, 8/06/2013 88338N10 BW   TherapeuticsMD Reports Second Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2013 46333X10 BW   Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2016 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2010 0098J6-E BW   Dicerna Pharmaceuticals Management and Scientific Co-Founders to Present at Upcoming Conferences, 4/05/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/19/2014 00434H10 BW   Acceleron Pharma to Host Fourth Quarter and Year Ended 2013 Financial Results Conference Call and Webcast on February 26, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/05/2015 G6674U10 BW   ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2015 74587V10 BW   Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/03/2013 LGND-US   BW   Ligand Partner Pfizer Receives FDA Approval for DUAVEETM for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis,#N/A, 5/21/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June, 5/29/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2013 Global Healthcare Conference in New York City on June 5th,#N/A,10/07/2014 04280A10 BW   Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society,#N/A,#N/A,#N/A,#N/A," 7/30/2012 TRXC-US  BW   SafeStitch Medical®, Inc. Agrees with Herniamesh® Srl to Distribute Mesh",#N/A,#N/A, 2/03/2016 ALXN-US  BW   Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016,#N/A, 4/28/2016 SGEN-US     BW   Seattle Genetics Reports First Quarter 2016 Financial Results,#N/A, 4/15/2015 CELG-US     BW   Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors," 9/06/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical Data",#N/A," 5/30/2017 GILD-US      BW   Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13",#N/A,#N/A,#N/A,#N/A, 1/20/2011 0B31SR-E     BW   Maven Semantic: Nucleic Acid Structure and Function Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/07/2014 00771V10   BW   Aerie Pharmaceuticals Expands Management Team, Names Michael McCleerey as Vice President, Marketing",#N/A,11/03/2015 INCY-US  BW   Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers,#N/A,#N/A, 6/12/2012 ALKS-IE  BW   INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for Schizophrenia,"11/08/2012 CERS-US  BW   Cerus to Present at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012",#N/A, 1/19/2011 04269E10 BW   ArQule Announces Proposed Public Offering,#N/A,#N/A, 2/19/2015 30161Q10 BW   Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma," 5/03/2013 07G69B-E  BW   Research and Markets: The Global Pharmaceutical Industry Is Expected To Reach $1,241 Billion By 2016, Growing At A CAGR Of 5.7%.",10/09/2014 92532F10  BW   Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis,#N/A,#N/A, 2/05/2014 09609G10 BW   bluebird bio to Present at the Leerink Global Healthcare Conference,12/20/2012 065MX1-E BW   ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program,#N/A,#N/A,#N/A, 7/01/2013 88338N10 BW   TherapeuticsMD Added to 2013 Russell Indexes,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2013 46333X10 BW   Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/10/2016 ALNY-US   BW   Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2010 0098J6-E BW   Dicerna Closes $25 Million Series B Financing, 4/05/2017 15117K10 BW   Cellectis: Monthly Information on Share Capital and Company Voting Rights,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2014 00434H10 BW   Acceleron to Present at 2014 Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/05/2015 G6674U10 BW   Novocure meldet CE-Kennzeichnung und ersten Patienteneinsatz der zweiten Generation des Optune-Systems,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2015 74587V10 BW   Puma Biotechnology to Present at Leerink Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/24/2013 53220K50  BW   Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia,#N/A," 5/18/2015 ILMN-US     BW   Illumina Files New Patent Infringement Suit Against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.", 5/23/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th,#N/A, 9/30/2014 04280A10 BW   Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs,#N/A,#N/A,#N/A,#N/A, 7/18/2012 68375N10 BW   OPKO Health Announces License for Topically Active Formulation of Ranibizumab,#N/A,#N/A," 1/20/2016 ALXN-US  BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016",#N/A, 4/18/2016 06P9WL-E    BW   Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 4/14/2015 09062X10    BW   Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair," 9/04/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 5/30/2017 GILD-US      BW   Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies",#N/A,#N/A,#N/A,#N/A, 1/20/2011 LLY-US       BW   Maven Semantic: Molecular Assembly Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/25/2014 00771V10   BW   Aerie Pharmaceuticals Reports RoclatanTM Phase 2b Results Achieve All Clinical Endpoints,#N/A,11/03/2015 INCY-US  BW   Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A," 6/09/2012 G0176710 BW   BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes",11/07/2012 15708510 BW   Cerus Corporation Reports Third Quarter 2012 Results,#N/A," 1/12/2011 MDVN-US  BW   Thirteenth Annual BIO CEO & Investor Conference Therapeutic Sessions to Focus on Oncology, Rheumatoid Arthritis, and Psychiatry",#N/A,#N/A," 2/02/2015 30161Q10 BW   Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015", 5/02/2013 80105N10  BW   Sanofi Q1 2013 - Interview with CFO Jérôme Contamine," 9/08/2014 92532F10  BW   Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014",#N/A,#N/A, 1/09/2014 09609G10 BW   bluebird bio Appoints Dr James Mandell to its Board of Directors,"12/12/2012 00422510 BW   ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012",#N/A,#N/A,#N/A, 6/26/2013 88338N10 BW   TherapeuticsMD to Present at JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A," 2/11/2013 46333X10 BW   Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/06/2016 ALNY-US   BW   INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2010 0098J6-E BW   Dicerna Selected as Top Biotech to Watch for Windhover’s 2010 Euro-Biotech Forum, 3/29/2017 15117K10 BW   Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/28/2014 00434H10 BW   Acceleron Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/05/2015 NVCR-GB  BW   Novocure Announces CE Mark and First Patient Use of Second Generation Optune System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/27/2015 74587V10 BW   Puma Biotechnology Closes $218 Million Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 8/14/2013 53220K50  BW   Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection",#N/A, 4/29/2015 ILMN-US     BW   Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference, 5/13/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th,#N/A, 9/19/2014 04280A10 BW   Arrowhead to Present at BioCentury’s NewsMakers in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A, 7/17/2012 OPK-US   BW   OPKO Scientist Reports Results at Alzheimer’s Association International Conference,#N/A,#N/A," 1/15/2016 ALXN-US  BW   Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq® (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP)",#N/A, 4/17/2016 06P9WL-E    BW   Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 4/07/2015 09062X10    BW   Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology," 8/27/2012 RO-CH    BW   ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial",#N/A," 5/04/2017 GILD-US      BW   Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18",#N/A,#N/A,#N/A,#N/A," 1/20/2011 05RBVG-E     BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/16/2014 00771V10   BW   Aerie Pharmaceuticals Names Craig R. Skenes as Vice President, Business Development",#N/A,10/13/2015 INCY-US  BW   Incyte to Report Third Quarter Financial Results,#N/A,#N/A, 6/09/2012 G0176710 BW   BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four Years,10/29/2012 15708510 BW   Cerus to Postpone Third Quarter 2012 Conference Call and Earnings Release Due to Expectation of Severe Weather,#N/A, 1/12/2011 04269E10 BW   Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient into Global Phase 3 Trial for ARQ 197,#N/A,#N/A," 1/29/2015 30161Q10 BW   Exelixis to Present at the Leerink Global Healthcare Conference on Wednesday, February 11", 5/02/2013 80105N10  BW   Sanofi T1 2013 - Interview du Directeur Financier Jérôme Contamine, 9/02/2014 92532F10  BW   Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10,#N/A,#N/A, 1/08/2014 09609G10 BW   bluebird bio to Present at the J.P.Morgan Healthcare Conference,12/12/2012 ACAD-US  BW   ACADIA Pharmaceuticals Announces $86 Million Equity Financing,#N/A,#N/A,#N/A, 6/14/2013 88338N10 BW   TherapeuticsMD Investigational New Drug Filing Accepted By FDA,#N/A,#N/A,#N/A,#N/A,#N/A, 1/15/2013 IRWD-US  BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/06/2016 ALNY-US   BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc. and Certain Officers and Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2010 0098J6-E BW   Dicerna Names Douglas Fambrough as Chief Executive Officer, 3/09/2017 15117K10 BW   Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/22/2014 00434H10 BW   Acceleron Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2015 G6674U10 BW   NovoCure Limited Announces Launch of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/22/2015 74587V10 BW   Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/01/2013 53220K50  BW   Ligand Reports Second Quarter Financial Results,#N/A, 4/21/2015 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2015, 5/10/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th,#N/A, 8/12/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520,#N/A,#N/A,#N/A,#N/A, 7/16/2012 OPK-US   BW   OPKO Health Announces Appointment of Juan F. Rodriguez as Chief Financial Officer,#N/A,#N/A, 1/04/2016 ALXN-US  BW   Alexion to Present at the 34th Annual J.P. Morgan Healthcare Conference,#N/A," 4/07/2016 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on April 28, 2016",#N/A," 4/01/2015 09062X10    BW   Biogen to Report First Quarter 2015 Financial Results on April 24, 2015"," 8/03/2012 IMGN-US  BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2012 Financial Results and Provides Corporate Update and Fiscal Year 2013 Guidance",#N/A, 5/02/2017 GILD-US      BW   Gilead Sciences Announces Second Quarter 2017 Dividend,#N/A,#N/A,#N/A,#N/A, 1/19/2011 REGN-US      BW   Maven Semantic: Immunohistochemistry Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2014 00771V10   BW   Aerie Pharmaceuticals Elects James Mazzo to the Company’s Board of Directors,#N/A,10/13/2015 INCY-US  BW   Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma,#N/A,#N/A," 6/09/2012 G0176710 BW   Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 Diabetes",10/25/2012 15708510 BW   Cerus Appoints Chrystal Menard as Chief Legal Officer,#N/A,"12/06/2010 04269E10 BW   ArQule Enrolls First Patient in Phase 1 Trial of ARQ 736, Its Pan-RAF Inhibitor",#N/A,#N/A, 1/07/2015 30161Q10 BW   Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer, 4/29/2013 078WL3-E  BW   Transgene a présenté à l’EASL des données précliniques prometteuses qui confirment le potentiel du produit d’immunothérapie TG1050 dans l’hépatite B chronique, 7/31/2014 92532F10  BW   Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations,#N/A,#N/A,12/26/2013 09609G10 BW   bluebird bio Joins the NASDAQ Biotechnology Index,11/27/2012 00422510 BW   ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial,#N/A,#N/A,#N/A, 6/12/2013 88338N10 BW   TherapeuticsMD to Ring Opening Bell at NYSE,#N/A,#N/A,#N/A,#N/A,#N/A, 1/10/2013 46333X10 BW   Ironwood Pharmaceuticals to Host Fourth Quarter 2012 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/05/2016 ALNY-US   BW   Alnylam Pharmaceuticals Discontinues Revusiran Development,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2010 0098J6-E BW   Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology, 3/09/2017 15117K10 BW   Servier et Pfizer annoncent l’obtention de la part de la FDA de l’autorisation de mener aux Etats-Unis le développement clinique précoce de UCART 19 dans le traitement des leucémies lymphoblastiques aiguës en rechute ou réfractaires chez l’adulte,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/21/2014 00434H10 BW   Acceleron Commences Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2015 079TK4-E BW   NovoCure Limited meldet Start des Börsengangs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/21/2015 74587V10 BW   Puma Biotechnology Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/26/2013 080RQG-E  BW   Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection,#N/A," 4/07/2015 45232710    BW   Illumina to Announce First Quarter 2015 Financial Results on Tuesday, April 21, 2015", 5/09/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013,#N/A, 7/31/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 6/05/2012 OPK-US   BW   OPKO Health To Acquire Stake in Israeli Hepatitis B Vaccine Manufacturer,#N/A,#N/A,12/10/2015 ALXN-US  BW   Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting,#N/A, 3/01/2016 0024VM-E    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A," 3/30/2015 09062X10    BW   Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab"," 7/26/2012 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2012 Financial Results",#N/A, 5/02/2017 GILD-US      BW   Gilead Sciences Announces First Quarter 2017 Financial Results,#N/A,#N/A,#N/A,#N/A, 1/18/2011 WLA-US       BW   Maven Semantic: Parkinsons Disease Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2014 00771V10   BW   Aerie Pharmaceuticals Announces Voting Results of 2014 Annual Meeting of Stockholders,#N/A,10/02/2015 INCY-US  BW   Data at SITC Annual Meeting to Highlight Progress of Incyte’s Immuno-oncology Portfolio,#N/A,#N/A, 5/31/2012 ALKS-IE  BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences,"10/16/2012 15708510 BW   Cerus to Release Third Quarter Results on October 30, 2012",#N/A,"11/10/2010 04269E10 BW   ArQule, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference",#N/A,#N/A,12/15/2014 30161Q10 BW   Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma, 4/26/2013 07G69B-E  BW   Research and Markets: Clopidogrel - Comprehensive Patent Search, 7/29/2014 92532F10  BW   Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs,#N/A,#N/A,12/02/2013 09609G10 BW   bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia,"11/26/2012 00422510 BW   ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial",#N/A,#N/A,#N/A, 5/28/2013 88338N10 BW   TherapeuticsMD to Present at Jefferies 2013 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2013 46333X10 BW   Ironwood Completes $175 Million Debt Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/03/2016 ALNY-US   BW   Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2010 0098J6-E BW   Dicerna to Present New Data on Dicer Substrate siRNA Molecules at Cambridge Healthtech Institute’s Second Annual RNA Interference: From Tools to Therapies Conference, 3/07/2017 15117K10 BW   Cinq éminents experts rejoignent le Conseil Scientifique de Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2014 00434H10 BW   Acceleron Files Registration Statement for Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2015 079TK4-E BW   NovoCure Limited Announces Launch of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2015 74587V10 BW   Puma Biotechnology Announces Proposed Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/26/2013 53220K50  BW   Ligand Receives Orphan Designation for Captisol-EnabledTM Topiramate Injection,#N/A, 3/31/2015 ILMN-US     BW   Berry Genomics NextSeq CN500 Instrument and Non-Invasive Prenatal Testing Reagent Kit Receives Chinese FDA Premarket Clearance, 5/02/2013 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast,#N/A, 6/19/2014 04280A10 BW   Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease,#N/A,#N/A,#N/A,#N/A, 5/31/2012 OPK-US   BW   OPKO Health to Present at the Jefferies 2012 Global Healthcare Conference,#N/A,#N/A,12/10/2015 ALXN-US  BW   Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting,#N/A, 2/25/2016 SGEN-US     BW   Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma,#N/A, 3/27/2015 09062X10    BW   European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS," 7/12/2012 IMGN-US  BW   ImmunoGen, Inc. Prices Public Offering of Common Stock",#N/A, 4/21/2017 GILD-US      BW   Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection,#N/A,#N/A,#N/A,#N/A, 1/18/2011 PFE-US       BW   Maven Semantic: Pain Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference,#N/A, 9/15/2015 INCY-US  BW   Incyte to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference,#N/A,#N/A, 5/30/2012 G0176710 BW   Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation, 9/11/2012 05KRQK-E BW   Cerus to Partner with American Red Cross and Blood Systems Incorporated to Commercialize INTERCEPT Plasma for Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication,#N/A,11/09/2010 04269E10 BW   ArQule Announces Third Quarter Fiscal 2010 Results,#N/A,#N/A,12/01/2014 30161Q10 BW   Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer, 4/25/2013 80105N10  BW   Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study," 7/25/2014 92532F10  BW   MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX",#N/A,#N/A,11/27/2013 09609G10 BW   bluebird bio to Present at Deutsche Bank BioFEST Conference,11/05/2012 ACAD-US  BW   ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results,#N/A,#N/A,#N/A, 5/16/2013 88338N10 BW   TherapeuticsMD Elects Jules A. Musing to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2013 IRWD-US  BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/28/2016 ALNY-US   BW   Alnylam Presents Clinical and Non-Clinical Data Demonstrating Continued RNAi Platform Optimization and Leadership in the Development of RNA-Based Therapeutics at 12th Annual Meeting of the Oligonucleotide Therapeutics Society,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2017 15117K10 BW   Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/20/2013 00434H10 BW   Acceleron Pharma to Be Added to Russell 2000® Index,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2015 079TK4-E BW   Novocure präsentiert die jüngsten Daten aus der klinischen Studie EF-14 zu neu diagnostiziertem Glioblastom (GBM) auf dem 15. Interim Meeting of the World Federation of Neurosurgical Societies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2015 74587V10 BW   Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/24/2013 53220K50  BW   Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene,#N/A, 3/16/2015 45232710    BW   Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents," 4/30/2013 84763A10  BW   DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Upcoming Deadline",#N/A, 6/16/2014 04280A10 BW   Arrowhead Research Set to Join Russell 3000 Index,#N/A,#N/A,#N/A,#N/A, 5/31/2012 68375N10 BW   OPKO Health Receives Core Technology U.S. Patent Allowance,#N/A,#N/A,12/08/2015 ALXN-US  BW   ADDING MULTIMEDIA FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D),#N/A, 2/22/2016 SGEN-US     BW   Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine (SGN-CD33A) Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (MDS),#N/A, 3/23/2015 09062X10    BW   Biogen Idec Becomes Biogen," 7/11/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock",#N/A, 4/21/2017 GILD-US      BW   Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017,#N/A,#N/A,#N/A,#N/A, 1/18/2011 PGNX-US      BW   Maven Semantic: Protein Structure and Function Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the UBS Global Healthcare Conference,#N/A," 9/10/2015 INCY-US  BW   MPN Awareness Day Raises Awareness and Support for the Nearly 300,000 People in the United States Affected by Rare Blood Cancers",#N/A,#N/A, 5/29/2012 G0176710 BW   Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting, 9/04/2012 CERS-US  BW   Cerus Announces INTERCEPT Blood System for Platelets Regulatory Submission for Approval in South Africa,#N/A,"11/03/2010 04269E10 BW   ArQule to Report Third Quarter 2010 Financial Results on November 9, 2010",#N/A,#N/A,"11/25/2014 30161Q10 BW   Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2", 4/23/2013 0CN75T-E  BW   Bay Area High School Student Wins BioGENEius Challenge, 7/14/2014 92532F10  BW   Vertex to Announce Second Quarter 2014 Financial Results on July 29,#N/A,#N/A,11/14/2013 09609G10 BW   bluebird bio Reports Fiscal Third Quarter 2013 Financial Results,"10/29/2012 00422510 BW   ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012",#N/A,#N/A,#N/A, 5/08/2013 88338N10 BW   TherapeuticsMD Reports First Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2012 060RWY-E BW   Constella/Linzess Will Achieve Blockbuster Sales of $1.2 Billion in 2021 in the Irritable Bowel Syndrome Drug Market,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/24/2016 ALNY-US   BW   Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2017 15117K10 BW   Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2013 0068K6-E BW   Acceleron Earns $7 Million Milestone Payment for Celgene’s Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2015 079TK4-E BW   Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/30/2014 PBYI-US  BW   SHAREHOLDER ALERT: Investigation on Behalf of Investors of Roka Bioscience, Inc. Announced by Law Offices of Howard G. Smith",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/22/2013 53220K50  BW   Ligand Signs Global License Agreement with Azure for Lasofoxifene,#N/A, 3/10/2015 45232710    BW   Illumina Announces Strategic Collaboration with Merck Serono to Expand Companion Diagnostics for Oncology," 4/28/2013 84763A10  BW   Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 6/13/2014 04280A10 BW   Arrowhead Issues a Statement on Intellectual Property Protection for ARC-520,#N/A,#N/A,#N/A,#N/A, 5/14/2012 68375N10 BW   OPKO Health Receives Important U.S. Patent Allowance,#N/A,#N/A,12/07/2015 ALXN-US  BW   Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris® (eculizumab) Treatment,#N/A, 2/09/2016 SGEN-US     BW   Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results,#N/A, 3/20/2015 09062X10    BW   Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference," 7/11/2012 IMGN-US  BW   ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target",#N/A," 4/20/2017 GILD-US      BW   Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread",#N/A,#N/A,#N/A,#N/A, 1/18/2011 TLRK-US      BW   Maven Semantic: Signal Transduction Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 00771V10   BW   Aerie Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Business and Product Development Update,#N/A, 9/01/2015 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/17/2012 0C2G14-E BW   Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013," 8/30/2012 CERS-US  BW   Cerus to Present at the Baird Healthcare Conference on September 6, 2012",#N/A,"11/02/2010 04269E10 BW   ArQule Awarded $978,000 in Grants under the Patient Protection and Affordable Care Act",#N/A,#N/A,11/16/2014 30161Q10 BW   Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib, 4/18/2013 80105N10  BW   Genzyme Convenes 13th European Fabry Disease Roundtable," 7/10/2014 92532F10  BW   Vertex Announces Retirement of Peter Mueller, Ph.D.",#N/A,#N/A,10/28/2013 09609G10 BW   bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD, 9/05/2012 00422510 BW   ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A, 4/22/2013 TXMD-US  BW   TherapeuticsMD Announces Trading of Its Common Stock on the NYSE MKT Under Symbol “TXMD”,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2012 46333X10 BW   Ironwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/21/2016 ALNY-US   BW   Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2017 15117K10 BW   Cellectis Reports 4th Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2013 00434H10 BW   Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 079TK4-E BW   Optune von Novocure nun in mehr als 200 führenden Krebszentren in den USA erhältlich,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/19/2014 74587V10 BW   SHAREHOLDER ALERT: Investigation on Behalf of Investors of Puma Biotechnology, Inc. Announced by Law Offices of Howard G. Smith",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/16/2013 53220K50  BW   Ligand to Report Second Quarter Results on August 1st,#N/A, 3/04/2015 45232710    BW   Illumina Launches TruSight HLA Solution," 4/26/2013 84763A10  BW   SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position",#N/A, 6/11/2014 04280A10 BW   Arrowhead to Host Analyst Day to Discuss New Rare Liver Disease Candidate,#N/A,#N/A,#N/A,#N/A, 5/04/2012 68375N10 BW   OPKO Health Enters into License Agreement with International Health Technology for Next Generation Prostate Cancer Biomarker Panel,#N/A,#N/A,11/19/2015 ALXN-US  BW   Alexion to Highlight Robust Rare Disease Pipeline at Investor Day,#N/A, 2/04/2016 SGEN-US     BW   Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda,#N/A, 2/27/2015 BIIB-US     BW   Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study," 6/04/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419",#N/A, 4/20/2017 GILD-US      BW   Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017,#N/A,#N/A,#N/A,#N/A, 1/18/2011 LLY-US       BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2014 00771V10   BW   Aerie Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014",#N/A, 8/21/2015 INCY-US  BW   Incyte Named 7th Most Innovative Company in the World by Forbes Magazine,#N/A,#N/A, 5/10/2012 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2012," 8/29/2012 CERS-US  BW   Cerus to Present at the Stifel Nicolaus Weisel Healthcare Conference on September 5, 2012",#N/A,"10/26/2010 04269E10 BW   ArQule, Inc. to Present at Oppenheimer 21st Annual Healthcare Conference",#N/A,#N/A,"11/11/2014 30161Q10 BW   Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18", 4/10/2013 ALMDT-FR  BW   MEDIAN TECHNOLOGIES : 2012 : ANNEE DE STRUCTURATION COMMERCIALE," 7/07/2014 92532F10  BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014",#N/A,#N/A,10/01/2013 09609G10 BW   bluebird bio Joins the Russell 2000® Index, 8/29/2012 ACAD-US  BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A, 3/15/2013 88338N10 BW   TherapeuticsMD Announces Pricing of Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2012 46333X10 BW   Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/20/2016 ALNY-US   BW   Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2017 15117K10 BW   Cellectis publie ses résultats financiers du quatrième trimestre 2016 et de l’exercice 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2013 00434H10 BW   Acceleron Pharma Provides Update on Clinical Pipeline at Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 079TK4-E BW   Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2014 74587V10 BW   Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/24/2013 53220K50  BW   Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes,#N/A, 2/26/2015 45232710    BW   Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates," 4/23/2013 84763A10  BW   21 Days Remain before May 13, 2013, Lead Plaintiff Deadline in Investor Lawsuit against Spectrum Pharmaceuticals, Inc.",#N/A, 6/10/2014 04280A10 BW   Arrowhead to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A, 4/25/2012 68375N10 BW   OPKO Health Receives Important U.S. Patent Allowance,#N/A,#N/A,11/07/2015 ALXN-US  BW   Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic Microangiopathy (TMA) Events in Patients with Atypical Hemolytic Uremic Syndrome (aHUS),#N/A," 1/20/2016 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016",#N/A, 2/23/2015 09062X10    BW   Biogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference," 6/03/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer",#N/A," 4/18/2017 GILD-US      BW   Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017",#N/A,#N/A,#N/A,#N/A, 1/14/2011 PFE-US       BW   Maven Semantic: Single Cell Analysis Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference,#N/A, 8/04/2015 INCY-US  BW   Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 5/03/2012 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the R.W. Baird Growth Stock Conference, 8/08/2012 15708510 BW   Cerus to Present at the Wedbush 2012 Life Sciences Management Access Conference on August 14,#N/A,10/12/2010 04269E10 BW   ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology,#N/A,#N/A,11/06/2014 30161Q10 BW   Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma, 4/10/2013 SAN-FR    BW   Pieris and Sanofi Broaden Existing Collaboration, 7/01/2014 92532F10  BW   INVESTOR ALERT: Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated Announced by Glancy Binkow & Goldberg LLP,#N/A,#N/A,"10/01/2013 09609G10 BW   Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy", 8/08/2012 00422510 BW   ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A," 3/07/2013 88338N10 BW   TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common Stock",#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2012 ALM-ES   BW   Constella® (linaclotide) Approved in Europe for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2016 ALNY-US   BW   Alnylam Expands and Strengthens Management Team as it Plans for Commercialization,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2017 15117K10 BW   Cellectis participera à la 6ème conférence annuelle Global Healthcare de LEERINK Partners avec une présentation le 16 février 2017 à 13h30 à New-York,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2013 00434H10 BW   Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia to be Presented at 2013 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2015 079TK4-E BW   Novocure präsentiert Konzepte klinischer Studien und vorklinische Daten zu Tumor Treating Fields bei der 16. World Conference on Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/10/2014 74587V10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Puma Biotechnology, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/20/2013 53220K50  BW   Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding,#N/A, 2/23/2015 45232710    BW   Illumina Launches the NeoPrep Library Prep System," 4/19/2013 0BGL4K-E  BW   SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position",#N/A, 5/29/2014 04280A10 BW   Arrowhead to Present at the Jefferies 2014 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 4/12/2012 68375N10 BW   OPKO Health Announces the Start of Phase 3 Clinical Trials of Rolapitant for the Prevention of CINV,#N/A,#N/A,11/05/2015 ALXN-US  BW   Researchers to Present Data on Enhancing the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2015 Annual Meeting,#N/A, 1/05/2016 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A," 2/19/2015 BIIB-US     BW   Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways"," 6/03/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial",#N/A, 4/17/2017 GILD-US      BW   Robin L. Washington Named “Financial Woman of the Year”,#N/A,#N/A,#N/A,#N/A, 1/11/2011 PFE-US       BW   Maven Semantic: Cell Biology Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/25/2014 00771V10   BW   Aerie Pharmaceuticals Names Richard A. Lewis, M.D., as Chair of Scientific Advisory Board",#N/A, 7/14/2015 45337C10 BW   Incyte to Report Second Quarter Financial Results on August 4,#N/A,#N/A, 5/03/2012 G0176710 BW   VIVITROL® Data to be Presented at Upcoming American Psychiatric Association Annual Meeting, 8/07/2012 09PB0Z-E BW   Cerus Announces First INTERCEPT Blood System Customer in Turkey,#N/A,10/11/2010 04269E10 BW   ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment,#N/A,#N/A,11/04/2014 30161Q10 BW   Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer, 4/08/2013 80105N10  BW   AUBAGIO® (teriflunomida) oral para administração uma vez por dia aprovado na Argentina para o tratamento de esclerose múltipla reincidente, 6/30/2014 92532F10  BW   Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation,#N/A,#N/A, 9/04/2013 09609G10 BW   bluebird bio to Present at Morgan Stanley Global Healthcare Conference," 8/01/2012 00422510 BW   ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012",#N/A,#N/A,#N/A,"11/01/2012 88338N10 BW   BocaGreenMD, Inc. Launches Line of Generic Prescription Prenatal Multivitamins",#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2012 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/07/2016 ALNY-US   BW   Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/07/2017 15117K10 BW   Cellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30 p.m. ET in New York",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2013 00434H10 BW   Acceleron to Present at Piper Jaffray Healthcare Conference in December,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2015 NVCR-GB  BW   Novocure to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/09/2014 74587V10 BW   INVESTOR ALERT: Investigation of Puma Biotechnology, Inc. Announced by Glancy Binkow & Goldberg LLP",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/29/2013 LGND-US   BW   Ligand Provides New Corporate Presentation at Investor Conference,#N/A, 2/18/2015 45232710    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference," 4/12/2013 84763A10  BW   Law Offices of Todd M. Garber Announces Investigation of Spectrum Pharmaceuticals, Inc.",#N/A, 5/06/2014 04280A10 BW   Arrowhead to Present at Upcoming Scientific Conferences,#N/A,#N/A,#N/A,#N/A, 4/04/2012 0CBJRM-E BW   OPKO Health Acquires Chilean Pharmaceutical Company,#N/A,#N/A,10/29/2015 ALXN-US  BW   Alexion Reports Third Quarter 2015 Results,#N/A,12/23/2015 SGEN-US     BW   Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma,#N/A, 2/17/2015 09062X10    BW   Biogen Idec to Present at the 2015 RBC Capital Markets’ Global Healthcare Conference," 5/16/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company’s TAP Technology",#N/A, 4/07/2017 GILD-US      BW   U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection,#N/A,#N/A,#N/A,#N/A, 1/11/2011 PFE-US       BW   Maven Semantic: Cell Adhesion Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/18/2014 00771V10   BW   Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business and Product Development Update,#N/A, 7/07/2015 INCY-US  BW   Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance,#N/A,#N/A, 3/13/2012 0C2G14-E BW   Elan Raises $381 Million in Sale of 76% of Alkermes Holding, 8/02/2012 15708510 BW   Cerus Corporation Reports Second Quarter 2012 Results,#N/A,10/11/2010 04269E10 BW   Presentation at ESMO Highlights Anti-Metastatic Effects of ARQ 197 c-MET Inhibitor in Non-Small Cell Lung Cancer,#N/A,#N/A,11/04/2014 30161Q10 BW   Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update," 4/08/2013 80105N10  BW   AUBAGIO® (teriflunomida) una vez al día por vía oral, de Genzyme, autorizado en Argentina para el tratamiento de la esclerosis múltiple recurrente", 6/27/2014 92532F10  BW   Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations,#N/A,#N/A, 8/27/2013 09609G10 BW   bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum, 7/09/2012 ACAD-US  BW   ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis,#N/A,#N/A,#N/A," 9/26/2012 TXMD-US  BW   TherapeuticsMD, Inc. Announces $8.5 Million Private Placement",#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2012 46333X10 BW   Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS™ (Linaclotide),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2016 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming September Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/06/2017 15117K10 BW   La FDA autorise l'entrée en développement clinique d'UCART123, le candidat médicament CAR-T allogénique « sur étagère » de Cellectis ciblant des tumeurs hématologiques (LAM et LpDC)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2013 00434H10 BW   Acceleron Pharma Reports Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2015 079TK4-E BW   Daten zu Tumor Treating Fields werden bei der 37. Jahrestagung der IEEE Engineering in Medicine and Biology Society präsentiert,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2014 74587V10 BW   Puma Biotechnology Updates Timeline for Filing New Drug Application,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/23/2013 53220K50  BW   Ligand to Present at Upcoming Investor Conferences,#N/A, 1/27/2015 45232710    BW   Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2014," 4/08/2013 84763A10  BW   Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia",#N/A, 5/06/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 4/03/2012 68375N10 BW   OPKO Health Announces License Agreement for OPKO’s Alzheimer’s Diagnostic Technology,#N/A,#N/A,"10/23/2015 ALXN-US  BW   FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)",#N/A,12/10/2015 SGEN-US     BW   Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium,#N/A, 1/29/2015 09062X10    BW   Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion," 5/08/2012 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 2/28/2017 GILD-US      BW   Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14",#N/A,#N/A,#N/A,#N/A, 1/10/2011 XGEN.XX1-US  BW   Maven Semantic: Prostate Cancer Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/06/2014 00771V10   BW   Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014",#N/A, 6/19/2015 45337C10 BW   Incyte Announces Organizational and Management Changes to Drive Future Global Expansion,#N/A,#N/A," 3/13/2012 ALKS-IE  BW   Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by Elan"," 7/19/2012 15708510 BW   Cerus to Release Second Quarter 2012 Results on August 2, 2012",#N/A," 9/10/2010 04269E10 BW   ArQule, Inc. to Present at Stifel Nicolaus and UBS Conferences",#N/A,#N/A,"10/14/2014 30161Q10 BW   Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014"," 4/08/2013 80105N10  BW   Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis", 6/24/2014 92532F10  BW   Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation,#N/A,#N/A, 8/14/2013 09609G10 BW   bluebird bio Reports Fiscal Second Quarter 2013 Financial Results," 7/09/2012 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012",#N/A,#N/A,#N/A," 7/10/2012 88338N10 BW   TherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur with the Recent Joint Statement from NAMS, ASRM and The Endocrine Society",#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2012 46333X10 BW   Ironwood and AstraZeneca Announce Linaclotide Collaboration for China,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/08/2016 ALNY-US   BW   Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/06/2017 15117K10 BW   FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/05/2013 00434H10 BW   Acceleron Pharma to Ring The NASDAQ Stock Market Closing Bell on November 5, 2013",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2015 079TK4-E BW   Data on Tumor Treating Fields to be Presented at the 37th Annual Conference of the IEEE Engineering in Medicine and Biology Society,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/13/2014 74587V10 BW   Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/14/2013 53220K50  BW   Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV,#N/A, 1/21/2015 45232710    BW   Illumina Announces First Targeted Next-Generation Sequencing Solution for Forensic Genomics," 4/05/2013 84763A10  BW   Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 5/01/2014 04280A10 BW   Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A, 3/19/2012 68375N10 BW   OPKO Health Expands Collaboration with Arctic Partners,#N/A,#N/A,10/12/2015 ALXN-US  BW   Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq™ (asfotase alfa) Sustained for at least Five Years,#N/A,12/07/2015 SGEN-US     BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015,#N/A," 1/29/2015 09062X10    BW   Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia"," 4/27/2012 IMGN-US  BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update",#N/A, 2/14/2017 GILD-US      BW   Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults,#N/A,#N/A,#N/A,#N/A, 1/10/2011 SIGA-US      BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference,#N/A, 5/27/2015 45337C10 BW   Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings,#N/A,#N/A," 3/08/2012 G0176710 BW   Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan", 5/01/2012 15708510 BW   Cerus Corporation Reports First Quarter 2012 Results,#N/A, 8/04/2010 04269E10 BW   ArQule Reports Second Quarter 2010 Financial Results,#N/A,#N/A, 9/29/2014 30161Q10 BW   Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma, 3/25/2013 0CMSYG-E  BW   89 Degrees to Present at Demandware XChange with Clients Fila and Crabtree & Evelyn, 6/18/2014 92532F10  BW   Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza,#N/A,#N/A, 8/06/2013 09609G10 BW   bluebird bio to Present at Two Upcoming Conferences, 6/20/2012 07GVF3-E BW   Research and Markets: Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020,#N/A,#N/A,#N/A," 6/21/2012 TXMD-US  BW   TherapeuticsMD, Inc. Files for Two Additional Patents on Prescription Products for Treatment of Menopausal Symptoms & Related Conditions",#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2012 IRWD-US  BW   Ironwood Pharmaceuticals Provides Third Quarter 2012 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2016 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2017 15117K10 BW   Cellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/30/2013 00434H10 BW   Acceleron Pharma to Host Third Quarter 2013 Financial Results Conference Call and Webcast on November 6, 2013",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 079TK4-E BW   Weltwirtschaftsforum zeichnet Novocure als Technologiepionier aus,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2014 74587V10 BW   Puma Biotechnology to Present at Stifel 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/08/2013 53220K50  BW   Ligand Reports First Quarter Financial Results,#N/A," 1/13/2015 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on Tuesday, January 27, 2015"," 4/03/2013 84763A10  BW   Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit",#N/A, 4/29/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 Second Quarter Financial Results,#N/A,#N/A,#N/A,#N/A, 3/09/2012 OPK-US   BW   OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks Brain Cell Destruction in Parkinson’s Disease,#N/A,#N/A,"10/12/2015 ALXN-US  BW   Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015",#N/A,12/07/2015 SGEN-US     BW   Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015,#N/A, 1/11/2015 09062X10    BW   Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals," 4/18/2012 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results",#N/A," 2/13/2017 GILD-US      BW   Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV",#N/A,#N/A,#N/A,#N/A, 1/10/2011 XGEN.XX1-US  BW   Maven Semantic: Molecular Imaging Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference,#N/A, 4/30/2015 INCY-US  BW   Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A," 3/07/2012 G0176710 BW   Alkermes plc Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan"," 4/30/2012 15708510 BW   Cerus, the University Hospitals of Geneva, and the Transfusion Service of the Swiss Red Cross Intend to Collaborate on Whole Blood Pathogen Inactivation for Africa",#N/A, 8/03/2010 04269E10 BW   REPEAT/ArQule and Daiichi Sankyo Move Forward with Phase 3 Clinical Trial Plan for ARQ 197 in Non-Small Cell Lung Cancer,#N/A,#N/A, 9/17/2014 30161Q10 BW   Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress, 3/25/2013 078WL3-E  BW   Sanofi et Transgene annoncent une collaboration innovante de long terme pour la production de traitements d’immunothérapie, 6/17/2014 92532F10  BW   INVESTOR ALERT: Investigation of Vertex Pharmaceuticals Incorporated Announced By Glancy Binkow & Goldberg LLP,#N/A,#N/A, 6/24/2013 09609G10 BW   bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option, 6/05/2012 ACAD-US  BW   Research and Markets: ACADIA Pharmaceuticals Inc. - Product Pipeline Review - 2012,#N/A,#N/A,#N/A," 5/16/2012 88338N10 BW   Tommy G. Thompson, Former U.S. Secretary of Health and Human Services, Joins TherapeuticsMD, Inc. as Chairman",#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2012 46333X10 BW   Ironwood Pharmaceuticals to Host Third Quarter 2012 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2016 ALNY-US   BW   Jacobs Wins Contract for New Alnylam Biopharmaceutical Manufacturing Facility,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2017 15117K10 BW   Quatre éminents spécialistes intègrent le Conseil Scientifique de Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2013 00434H10 BW   Acceleron Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 079TK4-E BW   Novocure Selected as Technology Pioneer by World Economic Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2014 74587V10 BW   Puma Biotechnology Reports Third Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/30/2013 53220K50  BW   Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA,#N/A, 1/12/2015 ILMN-US     BW   Lockheed Martin and Illumina to Collaborate on Developing Genomics Solutions to Improve Public Health and Wellness," 3/29/2013 84763A10  BW   Glancy Binkow & Goldberg LLP Announces Filing of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 4/01/2014 04280A10 BW   Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A," 2/27/2012 68375N10 BW   OPKO Invests in BioZone Pharmaceuticals, Inc.",#N/A,#N/A,"10/02/2015 ALXN-US  BW   Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)",#N/A,12/07/2015 SGEN-US     BW   Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015,#N/A, 1/09/2015 09062X10    BW   Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research," 4/17/2012 IMGN-US  BW   ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853",#N/A, 2/13/2017 GILD-US      BW   Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors,#N/A,#N/A,#N/A,#N/A, 1/10/2011 VRTX-US      BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2014 00771V10   BW   Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324,#N/A, 4/23/2015 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 3/05/2012 ALKS-IE  BW   Alkermes Appoints Mark Stejbach as Chief Commercial Officer, 4/24/2012 002CD9-E BW   Cerus and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity,#N/A, 8/03/2010 04269E10 BW   ArQule and Daiichi Sankyo Move Forward with Phase 3 Clinical Trial Plan for ARQ 197 in Non-Small Cell Lung Cancer,#N/A,#N/A," 9/08/2014 30161Q10 BW   Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9", 3/25/2013 80105N10  BW   Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments, 6/16/2014 92532F10  BW   Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis,#N/A,#N/A," 5/06/2013 05N2D8-E BW   bluebird bio Appoints Two New Members to Its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D."," 5/15/2012 00422510 BW   ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012",#N/A,#N/A,#N/A," 5/10/2012 88338N10 BW   TherapeuticsMD, Inc. Launches vitaMedMD RediChew RX, the First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic",#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2012 ALM-ES   BW   Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2016 CF.PRA-CA BW   Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2017 15117K10 BW   Cellectis publie une étude portant sur la sécurité d’une nouvelle architecture de CAR permettant de contrôler les fonctions des cellules CAR T,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/18/2013 XLRN-US  BW   Acceleron Announces Pricing of Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/10/2015 079TK4-E BW   Firma Novocure spouští nové webové stránky ke klinickým hodnocením -www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2014 74587V10 BW   Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/26/2013 53220K50  BW   Ligand Presents Preclinical Data on HepDirect™ Liver-Targeting Technology Platform at 2013 International Liver Congress (EASL) Annual Meeting,#N/A, 1/12/2015 45232710    BW   Illumina Expands World’s Most Comprehensive Next-Generation Sequencing Portfolio," 3/26/2013 84763A10  BW   Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 3/24/2014 04280A10 BW   Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients,#N/A,#N/A,#N/A,#N/A, 2/23/2012 68375N10 BW   OPKO Health to Present at the Citi 2012 Global Health Care Conference,#N/A,#N/A," 9/16/2015 ALXN-US  BW   Alexion Announces Presentations at 2015 American Society for Bone and Mineral Research Annual Meeting, Including New Data on Strensiq™ (asfotase alfa) in Children with Hypophosphatasia (HPP) Treated for Five Years",#N/A,12/06/2015 SGEN-US     BW   Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015,#N/A, 1/08/2015 09062X10    BW   Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis," 4/17/2012 IMGN-US  BW   ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin’s Lymphoma with Its Novel IMGN529 Anticancer Compound",#N/A," 2/08/2017 GILD-US      BW   Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22",#N/A,#N/A,#N/A,#N/A, 1/10/2011 RICHT-HU     BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/24/2014 00771V10   BW   Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance",#N/A, 4/17/2015 45337C10 BW   Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting,#N/A,#N/A, 2/27/2012 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen & Company 32nd Annual Health Care Conference, 4/18/2012 15708510 BW   Cerus Announces First INTERCEPT Platelet System Customer in Austria,#N/A, 8/03/2010 04269E10 BW   ArQule und Daiichi Sankyo schreiten mit Plan für klinische Phase-3-Studie über ARQ 197 zur Behandlung von nicht-kleinzelligem Lungenkrebs voran,#N/A,#N/A, 9/01/2014 30161Q10 BW   Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer," 3/22/2013 80105N10  BW   Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis"," 6/12/2014 92532F10  BW   Kirby McInerney LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals, Inc.",#N/A,#N/A, 3/21/2013 CELG-US  BW   bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology, 5/08/2012 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results,#N/A,#N/A,#N/A," 4/09/2012 TXMD-US  BW   TherapeuticsMD, Inc. Launches vitaMedMD One Rx, the First Daily One Pill Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA",#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2012 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2016 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2017 15117K10 BW   Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2013 0068K6-E BW   Acceleron Files Registration Statement for Proposed Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/10/2015 079TK4-E BW   Novocure startet Website für klinische Studien unter www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2014 74587V10 BW   Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/23/2013 53220K50  BW   Ligand to Present at Upcoming Investor Conferences,#N/A, 1/11/2015 45232710    BW   £15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare," 3/22/2013 09Y0ZH-E  BW   CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc.",#N/A, 3/10/2014 04280A10 BW   Arrowhead to Present at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 2/15/2012 68375N10 BW,#N/A,#N/A, 9/09/2015 ALXN-US  BW   New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data on Kanuma™ (sebelipase alfa) in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D),#N/A,12/02/2015 SGEN-US     BW   Seattle Genetics to Present at Oppenheimer Healthcare Conference,#N/A,"12/23/2014 09062X10    BW   CORRECTING AND REPLACING Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 29, 2015"," 3/30/2012 45253H10 BW   ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today’s Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901",#N/A, 2/07/2017 GILD-US      BW   Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend,#N/A,#N/A,#N/A,#N/A, 1/07/2011 002W7F-E     BW   Maven Semantic: Breast Cancer Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/19/2014 00771V10   BW   Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference,#N/A, 4/15/2015 0CGL9F-E BW   Incyte Joins SAFE-BioPharma Association,#N/A,#N/A, 2/16/2012 ALKS-IE  BW   Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder Agreement," 4/12/2012 15708510 BW   Cerus to Release First Quarter 2012 Results on May 1, 2012",#N/A," 7/30/2010 04269E10 BW   ArQule, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference",#N/A,#N/A, 7/31/2014 30161Q10 BW   Exelixis Announces Second Quarter 2014 Financial Results, 3/21/2013 SNY-FR    BW   Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies, 6/12/2014 92532F10  BW   Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference,#N/A,#N/A, 1/03/2013 05N2D8-E BW   bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference," 5/01/2012 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012",#N/A,#N/A,#N/A," 3/02/2012 TXMD-US  BW   TherapeuticsMD, Inc. Elects Four Additional Directors",#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2012 IRWD-US  BW   Ironwood Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/25/2016 0085TV-E  BW   Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2017 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2013 0068K6-E BW   Acceleron Named to the “Best Places to Work” List by The Scientist Magazine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/09/2015 079TK4-E BW   Novocure uruchamia nowy serwis internetowy poświęcony badaniom klinicznym - www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/21/2014 74587V10 BW   PUMA BIOTECHNOLOGY, INC. SHAREHOLDER ALERT – Puma Biotechnology, Inc.: The Law Offices of Vincent Wong Launch an Investigation into Puma Biotechnology, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/22/2013 53220K50  BW   Ligand to Report First Quarter Results on May 8th,#N/A, 1/08/2015 45232710    BW   Illumina Announces African Orphan Crops Consortium to Receive Agricultural Greater Good Initiative Grant," 3/22/2013 84763A10  BW   Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline",#N/A, 3/03/2014 04280A10 BW   Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520,#N/A,#N/A,#N/A,#N/A, 1/23/2012 0CBJRM-E BW   OPKO Health to Acquire Chilean Pharmaceutical Company,#N/A,#N/A, 9/04/2015 ALXN-US  BW   Alexion Receives Notification of PDUFA Date Extension for Kanuma™ (sebelipase alfa),#N/A,12/01/2015 SGEN-US     BW   Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting,#N/A,12/22/2014 09062X10    BW   Biogen Idec to Present at the 33rd Annual J.P. Morgan Healthcare Conference," 3/30/2012 45253H10 BW   ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate",#N/A, 2/07/2017 GILD-US      BW   Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A, 1/07/2011 LLY-US       BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/30/2014 00771V10   BW   Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension",#N/A, 4/14/2015 45337C10 BW   Incyte to Report First Quarter Financial Results on April 30,#N/A,#N/A, 2/09/2012 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare Conference, 4/03/2012 07B66X-E BW   Cerus Announces New Supply Agreement with Largest Blood Service in Saudi Arabia,#N/A," 7/28/2010 04269E10 BW   ArQule to Report Second Quarter 2010 Financial Results on August 4, 2010",#N/A,#N/A," 7/16/2014 30161Q10 BW   Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014", 3/15/2013 07G69B-E  BW   Research and Markets: Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022," 6/06/2014 92532F10  BW   SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit",#N/A,#N/A,10/26/2012 05N2D8-E BW   bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy Clinical Development," 4/13/2012 ACAD-US  BW   ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012",#N/A,#N/A,#N/A," 3/02/2012 TXMD-US  BW   TherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, the First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA",#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2012 46333X10 BW   Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/25/2016 ALNY-US   BW   Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/03/2017 15117K10 BW   Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2013 0068K6-E BW   Acceleron’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/09/2015 079TK4-E BW   Novocure lance un site web dédié aux essais cliniques : www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2014 74587V10 BW   Puma Biotechnology Reports Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/14/2013 53220K50  BW   Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan,#N/A,12/22/2014 45232710    BW   Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference, 3/21/2013 84763A10  BW   Spectrum Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors,#N/A, 2/24/2014 04280A10 BW   Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million,#N/A,#N/A,#N/A,#N/A, 1/23/2012 68375N10 BW   OPKO Health Acquires Next Generation Prostate Cancer Tests,#N/A,#N/A, 9/03/2015 ALXN-US  BW   Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference,#N/A,11/23/2015 SGEN-US     BW   Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia,#N/A,"12/03/2014 09062X10    BW   Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting"," 3/30/2012 45253H10 BW   ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial",#N/A," 1/24/2017 GILD-US      BW   Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017",#N/A,#N/A,#N/A,#N/A," 1/05/2011 06165P-E     BW   Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2014 00771V10   BW   Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals,#N/A," 4/14/2015 45337C10 BW   Incyte to Establish European Headquarters in Geneva, Switzerland",#N/A,#N/A, 2/06/2012 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference, 3/21/2012 15708510 BW   Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study,#N/A, 7/28/2010 04269E10 BW   ArQule Announces Initiation by Kyowa Hakko Kirin of Phase 2 Clinical Trial in Asia with ARQ 197 in Gastric Cancer,#N/A,#N/A, 7/14/2014 30161Q10 BW   Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma, 3/13/2013 80105N10  BW   Genzyme’s Multiple Sclerosis Franchise Featured at AAN, 6/04/2014 92532F10  BW   Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation,#N/A,#N/A, 9/19/2012 05N2D8-E BW   bluebird bio Named One of FierceBiotech’s 2012 Fierce 15," 3/28/2012 00422510 BW   ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012",#N/A,#N/A,#N/A," 2/07/2012 TXMD-US  BW   TherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin on March 1, 2012",#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2012 IRWD-US  BW   ADDING MULTIMEDIA Ironwood and Forest Announce FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/12/2016 ALNY-US   BW   Alnylam to Host Third Annual ""RNAi Roundtable"" Webcast Series",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2017 15117K10 BW   Cellectis participera à la 35e conférence annuelle healthcare de J.P. Morgan avec une présentation le 9 janvier 2017,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2013 SHP-GB   BW   Acceleron and Shire Conclude Collaboration on ACE-031,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/09/2015 079TK4-E BW   Novocure Launches Clinical Trial Website at www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/22/2014 74587V10 BW   Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 2/25/2013 53220K50  BW   Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc.",#N/A,12/03/2014 ILMN-US     BW   Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding Patent Disputes," 3/18/2013 84763A10  BW   Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer",#N/A, 2/21/2014 04280A10 BW   Arrowhead Listing Upgraded to NASDAQ Global Select Market,#N/A,#N/A,#N/A,#N/A, 1/06/2012 68375N10 BW   OPKO Health to Present at the 30th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 9/01/2015 ALXN-US  BW   La Comisión Europea garantiza la autorización de comercialización de Strensiq™(asfotasa alfa) para el tratamiento de pacientes con hipofosfatasia de aparición en la infancia (HF),#N/A,11/05/2015 SGEN-US     BW   Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs,#N/A,11/19/2014 09062X10    BW   Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference," 3/02/2012 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care Conference",#N/A, 1/20/2017 080RQG-E     BW   European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX),#N/A,#N/A,#N/A,#N/A, 1/05/2011 WLA-US       BW   Maven Semantic: Weight Loss Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2013 00771V10   BW   Aerie Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update,#N/A, 3/17/2015 45337C10 BW   Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera,#N/A,#N/A, 2/02/2012 G0176710 BW   Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results," 2/29/2012 15708510 BW   Cerus to Present at the Cowen and Company 32nd Annual Healthcare Conference on March 7, 2012",#N/A," 6/08/2010 04269E10 BW   ArQule, Inc. to Present at Jefferies and Needham Investment Conferences",#N/A,#N/A, 6/03/2014 30161Q10 BW   Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10, 3/08/2013 07GVF3-E  BW   Research and Markets: Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022, 6/03/2014 92532F10  BW   SHAREHOLDER ALERT: Investigation on Behalf of Vertex Pharmaceuticals Incorporated Investors Announced by Law Offices of Howard G. Smith,#N/A,#N/A, 9/13/2012 05N2D8-E BW   bluebird bio to Present at UBS Global Life Sciences Conference, 3/27/2012 00422510 BW   ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease,#N/A,#N/A,#N/A,"10/05/2011 88338N10 BW   TherapeuticsMD, Inc. Acquires VitaMedMD, LLC",#N/A,#N/A,#N/A,#N/A,#N/A, 7/17/2012 IRWD-US  BW   Ironwood Pharmaceuticals Provides Second Quarter 2012 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/07/2016 ALNY-US   BW   Alnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2017 15117K10 BW   Cellectis a soumis une demande d’essais cliniques pour UCART123 un produit allogénique fondé sur des cellules CART ingéniérées ciblant des tumeurs hématologiques (LAM et LpDC),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/26/2013 0068K6-E BW   Acceleron Receives Two FDA Orphan Designations for ACE-536,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/09/2015 079TK4-E BW   Novocure Launches Clinical Trial Website at www.novocuretrials.com,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/22/2014 74587V10 BW   Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/13/2013 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2012 Financial Results,#N/A,"11/19/2014 45232710    BW   USAID, Broad Institute and Illumina Form a Public-Private Partnership Combating the Ebola Epidemic in West Africa"," 3/16/2013 84763A10  BW   Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.",#N/A, 2/20/2014 04280A10 BW   Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,12/29/2011 0C8YFW-E BW   OPKO Completes Acquisition of FineTech Pharmaceutical Ltd.,#N/A,#N/A, 9/01/2015 ALXN-US  BW   Europese Commissie verleent marktgoedkeuring voor Kanuma™ (sebelipase alfa) voor de behandeling van patiënten van alle leeftijden met Lysosomale zure lipase deficiëntie (LAL-D),#N/A,10/29/2015 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2015 Financial Results,#N/A,10/31/2014 09062X10    BW   Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review," 2/07/2012 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 1/11/2017 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection",#N/A,#N/A,#N/A,#N/A, 1/04/2011 PFE-US       BW   Maven Semantic: Lung Disease Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/20/2013 00771V10   BW   Aerie Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, December 4, 2013",#N/A," 3/02/2015 45337C10 BW   Incyte Appoints Steven H. Stein, MD as Chief Medical Officer",#N/A,#N/A, 1/31/2012 G0176710 BW   Alkermes Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence, 2/28/2012 15708510 BW   Cerus Corporation Reports Fourth Quarter and Year-End 2011 Results,#N/A, 6/05/2010 04269E10 BW   ArQule and Daiichi Sankyo Present Final Phase 2 Results for ARQ 197 c-Met Inhibitor in Non-Small Cell Lung Cancer at ASCO,#N/A,#N/A, 5/14/2014 30161Q10 BW   Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting, 3/05/2013 DBV-FR    BW   DBV Technologies conclut un accord stratégique de fabrication avec Sanofi, 6/03/2014 92532F10  BW   Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10,#N/A,#N/A, 9/07/2012 05N2D8-E BW   bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference," 3/06/2012 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011",#N/A,#N/A,#N/A," 9/09/2010 88338N10 BW   AMHN, Inc. Announces Strategic Changes in Revenue/Expense Models",#N/A,#N/A,#N/A,#N/A,#N/A, 7/10/2012 46333X10 BW   Ironwood Pharmaceuticals to Host Second Quarter 2012 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2016 ALNY-US   BW   Alnylam Reports New Results from Investigational RNAi Therapeutic Programs for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN) and Cardiomyopathy (hATTR-CM),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/03/2017 15117K10 BW   Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2013 CELG-US  BW   Acceleron Initiates Phase 2 Study of ACE-536 to Treat Patients with Beta-Thalassemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2015 079TK4-E BW   Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/09/2014 74587V10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Puma Biotechnology, Inc. Regarding Possible Breaches of Fiduciary Duty",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/23/2013 LGND-US   BW   Ligand to Report Fourth Quarter Results on February 13th,#N/A,11/18/2014 45232710    BW   bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections," 3/15/2013 84763A10  BW   Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc.",#N/A, 2/19/2014 04280A10 BW   Arrowhead Announces Pricing of Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,12/21/2011 0751KF-E BW   OPKO Health To Acquire FineTech Pharmaceutical Ltd.,#N/A,#N/A, 9/01/2015 ALXN-US  BW   La Commission européenne autorise la mise sur le marché de KanumaMC (sebelipase alfa) pour le traitement de patients de tout âge souffrant d'un déficit en lipase acide lysosomale (déficit en LAL),#N/A,10/29/2015 SGEN-US     BW   Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),#N/A,10/23/2014 09062X10    BW   Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases," 1/18/2012 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results",#N/A, 1/10/2017 MGNK-DE      BW   MOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod,#N/A,#N/A,#N/A,#N/A, 1/04/2011 XGEN.XX1-US  BW   Maven Semantic: Joint Diseases Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2013 00771V10   BW   Aerie Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option,#N/A," 2/26/2015 45337C10 BW   Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer",#N/A,#N/A, 1/26/2012 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012," 2/06/2012 15708510 BW   Cerus to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012",#N/A, 5/21/2010 04269E10 BW   ArQule Provides Update on ARQ 197 Presentations at ASCO 2010,#N/A,#N/A, 5/07/2014 30161Q10 BW   Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014, 3/04/2013 80105N10  BW   Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation, 5/13/2014 92532F10  BW   Vertex to Present at the UBS Global Healthcare Conference on May 20,#N/A,#N/A, 7/25/2012 05N2D8-E BW   bluebird bio Secures $60 Million in Oversubscribed Financing," 3/05/2012 00422510 BW   ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.",#N/A,#N/A,#N/A," 6/08/2010 88338N10 BW   AMHN, Inc. Signs Letter of Intent to Acquire Spectrum Health Network, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A, 6/14/2012 00938Y-E BW   Rising Number of Small- to Mid-Sized Pharmaceutical Companies Switching to Cloud CRM,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2016 ALNY-US   BW   Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2016 15117K10 BW   Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2013 0068K6-E BW   Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2015 079TK4-E BW   Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2014 74587V10 BW   Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/09/2013 0BVHZK-E  BW   Ligand Receives Equity Milestone Payment from Retrophin,#N/A,11/17/2014 ILMN-US     BW   Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing, 3/15/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 25th Annual ROTH Conference in Laguna Niguel on March 20th,#N/A, 2/18/2014 04280A10 BW   Arrowhead Announces Proposed Underwritten Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,12/20/2011 68375N10 BW   OPKO Health Announces Commencement of U.S. Clinical Trial for Point-of-Care Prostate Specific Antigen Test,#N/A,#N/A, 9/01/2015 ALXN-US  BW   Europäische Kommission erteilt Marktzulassung für Kanuma™ (Sebelipase Alfa) für die Behandlung von Patienten aller Altersgruppen mit Mangel an lysosomaler saurer Lipase (LAL-d).,#N/A,10/28/2015 4502-JP     BW   Seattle Genetics e Takeda alcançam a participação desejada no ensaio clínico de Fase 3 do ECHELON-1 para analisar o ADCETRIS® (brentuximabe vedotina) em pacientes virgens de tratamento com linfoma de Hodgkin (LH) avançado,#N/A,10/22/2014 09062X10    BW   Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion,12/06/2011 072YSW-E BW   ACT Announces Two New Appointments to Board of Directors,#N/A, 1/10/2017 GILD-US      BW   Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research,#N/A,#N/A,#N/A,#N/A,12/23/2010 0B8DCM-E     BW   EHSI: China Emerging as a Stem Cell Leader,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2013 00771V10   BW   Aerie Pharmaceuticals Announces Pricing of Initial Public Offering,#N/A, 2/17/2015 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 1/04/2012 G0176710 BW   Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder," 2/02/2012 15708510 BW   Cerus to Release Fourth Quarter and Year-End 2011 Results on February 28, 2012",#N/A, 5/06/2010 04269E10 BW   ArQule Reports First Quarter 2010 Financial Results,#N/A,#N/A, 5/06/2014 30161Q10 BW   Exelixis to Present at Two Investor Conferences in May, 2/28/2013 80105N10  BW   Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) Awards, 5/07/2014 92532F10  BW   William Young Joins Vertex Board of Directors,#N/A,#N/A, 6/19/2012 05N2D8-E BW   bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy, 2/29/2012 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 4/26/2010 88338N10 BW   AMHN, Inc. Announces Installation Update for America's Minority Health Network",#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2012 46333X10 BW   Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2016 074JNF-E  BW   Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual “Helping Hands” Community Service Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/16/2016 15117K10 BW   Cellectis organise une conférence téléphonique suite à la présentation faite auprès du Comité Consultatif sur l’ADN Recombinant (RAC),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2013 0068K6-E BW   Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2015 079TK4-E BW   Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2014 74587V10 BW   Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/13/2012 LGND-US   BW   U.S. Food and Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention of Osteoporosis",#N/A,10/20/2014 45232710    BW   Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014," 3/14/2013 84763A10  BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Spectrum Pharmaceuticals, Inc.",#N/A, 2/04/2014 04280A10 BW   Arrowhead Reports Fiscal 2014 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,11/08/2011 68375N10 BW   OPKO Health to Present at the Lazard Capital Markets 8th Annual Healthcare Conference,#N/A,#N/A, 9/01/2015 ALXN-US  BW   La Commission européenne autorise la commercialisation de Strensiq™ (asfotase alfa) pour le traitement des patients souffrant d’hypophosphatasie (HPP) depuis l’enfance,#N/A,"10/28/2015 4502-JP     BW   Seattle Genetics y Takeda alcanzan la cantidad de inscripciones deseada en el ensayo clínico de fase 3 ECHELON-1, que evalúa ADCETRIS® (brentuximab vedotina) en pacientes con linfoma de Hodgkin (LH) avanzado que no han recibido...",#N/A,"10/15/2014 09062X10    BW   Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals","10/20/2011 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results",#N/A," 1/03/2017 GILD-US      BW   Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head",#N/A,#N/A,#N/A,#N/A,12/21/2010 TGEN-US      BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/17/2013 00771V10   BW   Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering,#N/A, 2/12/2015 45337C10 BW   Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 1/03/2012 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the 30th Annual J.P. Morgan Healthcare Conference, 2/01/2012 ILX-IL   BW   Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in Israel,#N/A," 4/29/2010 04269E10 BW   ArQule to Report First Quarter 2010 Financial Results on May 6, 2010",#N/A,#N/A, 5/01/2014 30161Q10 BW   Exelixis Announces First Quarter 2014 Financial Results, 2/27/2013 80105N10  BW   Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS), 5/01/2014 92532F10  BW   Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study,#N/A,#N/A," 5/31/2012 05N2D8-E BW   John Maraganore, Ph.D., Joins the bluebird bio Board of Directors"," 2/28/2012 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012",#N/A,#N/A,#N/A," 3/25/2010 88338N10 BW   AMHN, Inc. Files Annual Report",#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2012 46333X10 BW   Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2016 07G766-E  BW   Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2016 15117K10 BW   Recommandation favorable à l’unanimité du Comité Consultatif sur l’ADN Recombinant (RAC) concernant les protocoles d’étude clinique de Phase I des programmes UCART123 ciblant la leucémie aiguë myeloblastique...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2013 0068K6-E BW   Acceleron Pharma to Present at the 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 079TK4-E BW   Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 74587V10 BW   Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/13/2012 LGND-US   BW   U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis",#N/A,10/17/2014 45232710    BW   Illumina Launches New Reagent Kits for HiSeq X Ten and HiSeq 2500 Systems, 3/14/2013 SPPI-US   BW   Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan,#N/A, 2/04/2014 04280A10 BW   Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,10/19/2011 68375N10 BW   OPKO Health Subsidiary Receives Wall Street Journal 2011 Technology Innovation Award,#N/A,#N/A, 9/01/2015 ALXN-US  BW   Europäische Kommission erteilt Marktzulassung für Strensiq™ (Asfotase Alfa) zur Behandlung von Patienten mit ersten Symptomen von Hypophosphatasie (HPP) im Kindesalter,#N/A,10/28/2015 SGEN-US     BW   Seattle Genetics to Present at Credit Suisse Healthcare Conference,#N/A," 9/25/2014 09062X10    BW   CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014"," 8/05/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the Canaccord Genuity 31st Annual Growth Conference",#N/A,"12/26/2016 GILD-US      BW   Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9",#N/A,#N/A,#N/A,#N/A,12/21/2010 ORGG.XX1-US  BW   Maven Semantic: Bioengineering Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/05/2013 007KSQ-E   BW   Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors,#N/A, 1/28/2015 45337C10 BW   Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine,#N/A,#N/A,12/19/2011 G0176710 BW   Alkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia, 1/09/2012 05SVYX-E BW   Cerus Appoints Andrew Gomperts as Chief Business Officer,#N/A, 4/16/2010 04269E10 BW   ArQule Presentations at AACR 101St Annual Meeting Focus on Development of Oncology Pipeline,#N/A,#N/A," 4/21/2014 30161Q10 BW   Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014", 2/18/2013 0CMSYG-E  BW   89 Degrees Introduces ECHO, 5/01/2014 92532F10  BW   Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities,#N/A,#N/A, 2/28/2012 05N2D8-E BW   bluebird bio to Present at Cowen and Company 32nd Annual Health Care Conference," 2/06/2012 00422510 BW   ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012",#N/A,#N/A,#N/A," 3/22/2010 88338N10 BW   America's Minority Health Network, Inc. Names Network President",#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2012 46333X10 BW   Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/09/2016 ALNY-US   BW   Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2016 15117K10 BW   Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2012 0CGR8F-E BW   Acceleron Announces the Initiation of the Gynecologic Oncology Group Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Endometrial Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2015 079TK4-E BW   NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/19/2014 74587V10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Puma Biotechnology, Inc. Regarding Possible Breaches of Fiduciary Duty",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/10/2012 LGND-US   BW   Ligand Initiates Pivotal Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan in Patients with Multiple Myeloma",#N/A,10/15/2014 45232710    BW   Illumina Accelerator Announces Investment in Inaugural Startup Class, 3/14/2013 84763A10  BW   Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan,#N/A, 1/28/2014 04280A10 BW   Arrowhead to Report Fiscal 2014 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,10/17/2011 68375N10 BW   OPKO Health to Share in NIH Grant Award,#N/A,#N/A, 9/01/2015 ALXN-US  BW   Europese Commissie verleent marktgoedkeuring voor Strensiq™ (asfotase alfa) voor de behandeling van patiënten met hypofosfatasie (HPP) met manifestaties in de kinderjaren,#N/A,"10/27/2015 4502-JP     BW   Seattle Genetics et Takeda atteignent leur objectif de recrutement pour l’essai clinique de phase 3 ECHELON-1, qui évalue ADCETRIS® (brentuximab védotine) pour le traitement du lymphome hodgkinien avancé (LH), précédemment non...",#N/A, 9/23/2014 09062X10    BW   Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index," 8/03/2011 45253H10 BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Provides Corporate Update and Fiscal Year 2012 Guidance",#N/A,"12/19/2016 0B0XYS-E     BW   Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for Patients With Chronic Hepatitis B Virus Infection",#N/A,#N/A,#N/A,#N/A,12/20/2010 XGEN.XX1-US  BW   Maven Semantic: Kidney Disease Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/19/2013 007KSQ-E   BW   Aerie Pharmaceuticals Elects Murray Goldberg to the Company’s Board of Directors,#N/A, 1/27/2015 45337C10 BW   Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12,#N/A,#N/A,11/29/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the NASDAQ OMX 27th Investor Program,"12/07/2011 15708510 BW   Cerus to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011",#N/A," 4/05/2010 04269E10 BW   ArQule, Inc. to Present at Future Leaders in the Biotech Industry Conference",#N/A,#N/A, 3/25/2014 30161Q10 BW   Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer, 2/15/2013 SNY-FR    BW   Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease, 4/10/2014 92532F10  BW   Vertex to Announce First Quarter 2014 Financial Results on May 1,#N/A,#N/A," 2/16/2012 05N2D8-E BW   bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer", 1/30/2012 ACAD-US  BW   ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors,#N/A,#N/A,#N/A," 3/17/2010 88338N10 BW   AMHN, Inc. Announces Change in Executive Officers",#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2012 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2012 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2016 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/22/2016 15117K10 BW   Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2012 0068K6-E BW   Acceleron’s ACE-536 Corrects Anemia and Iron Overload in Preclinical Model of Beta-Thalassemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2015 079TK4-E BW   FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2014 74587V10 BW   Puma Biotechnology to Present at UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
"12/04/2012 53220K50  BW   Ligand to Present Growth Prospects, Review Key Portfolio Assets and Introduce Financial Guidance at Analyst Day Event",#N/A,"10/06/2014 45232710    BW   Illumina to Announce Third Quarter 2014 Financial Results on Monday, October 20, 2014", 3/12/2013 84763A10  BW   Spectrum Pharmaceuticals Provides Corporate Update,#N/A,12/18/2013 04280A10 BW   Arrowhead Reports Fiscal 2013 Fourth Quarter and Year-End Financial Results,#N/A,#N/A,#N/A,#N/A,10/13/2011 OPK-US   BW   OPKO Health Announces Acquisition of Claros Diagnostics,#N/A,#N/A, 9/01/2015 ALXN-US  BW   European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D),#N/A,10/27/2015 4502-JP     BW   Seattle Genetics und Takeda erreichen das Rekrutierungsziel für klinische Phase-3-Studie ECHELON-1 zur Beurteilung von ADCETRIS® (Brentuximab Vedotin) bei bislang unbehandeltem fortgeschrittenem Hodgkin-Lymphom (HL),#N/A," 9/23/2014 09062X10    BW   Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy"," 7/28/2011 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2011 Financial Results",#N/A,12/08/2016 06CR5C-E     BW   Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir,#N/A,#N/A,#N/A,#N/A,12/20/2010 MLNM-US      BW   Maven Semantic: Multiple Sclerosis Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2013 007KSQ-E   BW   Aerie Pharmaceuticals Names Thomas Mitro as President and Chief Operating Officer,#N/A, 1/23/2015 45337C10 BW   Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera,#N/A,#N/A,11/29/2011 0BCZ6T-E BW   Civitas Therapeutics Announces Award of Michael J. Fox Foundation Grant and Lead Drug Candidate for Parkinson’s Disease,12/06/2011 15708510 BW   Cerus Announces Contracts for 19 New INTERCEPT Blood System Illuminators in Russia,#N/A, 3/31/2010 04269E10 BW   ArQule Announces Results of Phase 2 Trial with ARQ 197 in Advanced Non-Small Cell Lung Cancer,#N/A,#N/A," 3/25/2014 30161Q10 BW   Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma", 2/13/2013 FP-FR     BW   TOTAL : Résultats du quatrième trimestre et de l’année 2012, 3/06/2014 92532F10  BW   Vertex to Present at the Barclays Global Healthcare Conference on March 11,#N/A,#N/A, 2/09/2012 05N2D8-E BW   bluebird bio to Present at the Leerink Swann 2012 Global Healthcare Conference,"12/07/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011",#N/A,#N/A,#N/A," 3/16/2010 88338N10 BW   AMHN, Inc. Announces Bridge Financing Commitment of $1.5 Million",#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2012 46333X10 BW   Ironwood Pharmaceuticals to Host First Quarter 2012 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2016 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming June Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/22/2016 15117K10 BW   Cellectis publie ses résultats financiers du troisième trimestre 2016 et des neuf premiers mois de l’année 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/11/2012 0068K6-E BW   Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the ""2012 Markers in Cancer"" Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2015 079TK4-E BW   New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2014 74587V10 BW   Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/27/2012 LGND-US   BW   Reminder: Ligand to Host Analyst Day on December 4th in New York City,#N/A,10/02/2014 09JSSJ-E    BW   AB SCIEX and Illumina Collaborate to Create World’s First Multi-omics Cloud-Computing Environment," 2/21/2013 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012",#N/A,12/11/2013 04280A10 BW   Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results,#N/A,#N/A,#N/A,#N/A,10/12/2011 OPK-US   BW   OPKO Completes Sale of Ophthalmic Instrumentation Business,#N/A,#N/A, 9/01/2015 ALXN-US  BW   European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D),#N/A,10/27/2015 4502-JP     BW   Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL),#N/A, 9/12/2014 BIIB-US     BW   Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)," 7/15/2011 ZIOP-US  BW   ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer",#N/A,"11/16/2016 GILD-US      BW   Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations",#N/A,#N/A,#N/A,#N/A,12/20/2010 LLY-US       BW   Maven Semantic: Hormone Replacement Therapy Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/25/2013 007KSQ-E   BW   Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer",#N/A, 1/09/2015 45337C10 BW   Incyte Board Appoints Two New Directors,#N/A,#N/A,11/09/2011 G0176710 BW   New Long-Term Data on VIVITROL® Showed Sustained Efficacy and Safety over 18 Months of Treatment,11/10/2011 08C6CM-E BW   Cerus Announces New Supply Agreement with French National Blood Service,#N/A," 3/04/2010 04269E10 BW   ArQule, Inc. to Present at Cowen and Company Health Care Conference",#N/A,#N/A, 2/26/2014 30161Q10 BW   Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference, 2/13/2013 073CJ0-E  BW   Nanobiotix nomme le Dr. Alain Herrera au sein de son Conseil de Surveillance, 2/21/2014 92532F10  BW   U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis,#N/A,#N/A, 4/20/2011 05N2D8-E BW   bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team,11/09/2011 00422510 BW   ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 46333X10 BW   Ironwood e Forest informam que o FDA ampliou o período de avaliação do linaclotide até setembro de 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2016 ALNY-US   BW   Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/21/2016 CLLS-FR  BW   Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2012 0068K6-E BW   The Wall Street Journal Names Acceleron to “The Next Big Thing” List of Top 50 Start-Ups in the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2015 079TK4-E BW   Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 74587V10 BW   Puma Biotechnology Reports First Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/19/2012 53220K50  BW   Ligand Partner GlaxoSmithKline Receives FDA Approval for New Indication for PROMACTA® (eltrombopag),#N/A, 9/08/2014 45232710    BW   Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions, 2/20/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the RBC Capital Markets Healthcare Conference in New York on February 27th,#N/A,12/09/2013 04280A10 BW   Arrowhead Presents Phase 1 Data on ARC-520 at HepDART 2013,#N/A,#N/A,#N/A,#N/A, 9/22/2011 0895Z3-E BW   OPKO Announces Sale of Ophthalmic Instrumentation Business,#N/A,#N/A, 9/01/2015 ALXN-US  BW   La Commissione europea concede l'autorizzazione alla commercializzazione per Strensiq™ (asfotase alfa) per il trattamento dei pazienti affetti da ipofosfatasia (HPP) con esordio pediatrico,#N/A,10/19/2015 SGEN-US     BW   Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),#N/A, 9/11/2014 09062X10    BW   PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients," 6/14/2011 06SG07-E BW   ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission",#N/A,11/16/2016 GILD-US      BW   Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis,#N/A,#N/A,#N/A,#N/A,12/20/2010 MLNM-US      BW   Maven Semantic: Drug Metabolism Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/04/2013 007KSQ-E   BW   Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board",#N/A, 1/09/2015 AGEN-US  BW   Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m. EST,#N/A,#N/A,11/08/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Lazard Capital Markets 8th Annual Healthcare Conference,"11/09/2011 15708510 BW   Cerus to Present at the Stephens Inc. Fall Conference on November 16, 2011",#N/A, 3/02/2010 04269E10 BW   ArQule Reports Fiscal 2009 Year End and Fourth Quarter Results,#N/A,#N/A, 2/20/2014 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results, 2/07/2013 80105N10  BW   Sanofi FY 2012 - Interview with CEO Chris Viehbacher, 2/20/2014 92532F10  BW   Vertex to Present at the RBC Global Healthcare Conference on February 25,#N/A,#N/A, 3/21/2011 05N2D8-E BW   bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board,11/07/2011 0BNW6D-E BW   ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 46333X10 BW   Ironwood et Forest annoncent le prolongement par la FDA de la période d'examen portant sur le linaclotide à septembre 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2016 ALNY-US   BW   Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2016 15117K10 BW   Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2012 05G05N-E BW   Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 079TK4-E BW   Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and Cisplatin or Carboplatin for the Treatment of Malignant Mesothelioma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2014 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/13/2012 53220K50  BW   Ligand Announces Positive Preclinical Data on HepDirect™ Liver-Targeted Antiviral for the Treatment of Hepatitis C,#N/A, 8/27/2014 45232710    BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference, 2/12/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012 Financial Results Teleconference and Webcast,#N/A,11/26/2013 04280A10 BW   Arrowhead to Present at Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 9/15/2011 68375N10 BW   OPKO Announces Investment by Teva in Cocrystal Discovery Inc.,#N/A,#N/A, 9/01/2015 ALXN-US  BW   European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP),#N/A,"10/08/2015 SGEN-US     BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2015 Financial Results on October 29, 2015",#N/A, 9/11/2014 09062X10    BW   New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients," 6/14/2011 CBIO-US  BW   Mintz Levin Represents ImmunoGen, Inc. and Targacept, Inc. in Public Offerings Totaling Approximately $170 Million",#N/A,"11/15/2016 GILD-US      BW   Gilead Sciences to Present at the Annual Piper Jaffray Healthcare Conference on Tuesday, November 29",#N/A,#N/A,#N/A,#N/A,12/16/2010 PFE-US       BW   Maven Semantic: DNA Sequence Analysis Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2013 007KSQ-E   BW   Aerie Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference,#N/A, 1/09/2015 45337C10 BW   Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies,#N/A,#N/A,11/03/2011 G0176710 BW   Alkermes plc Reports Second Quarter Fiscal 2012 Financial Results,"11/08/2011 15708510 BW   Cerus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on November 15, 2011",#N/A," 2/23/2010 04269E10 BW   ArQule to Report Fiscal 2009 Financial Results on March 2, 2010",#N/A,#N/A, 2/12/2014 30161Q10 BW   Exelixis Appoints Executive Vice President and General Counsel, 2/07/2013 80105N10  BW   Sanofi RN 2012 - Interview avec Directeur Général Chris Viehbacher, 1/29/2014 92532F10  BW   Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014,#N/A,#N/A," 3/17/2011 05N2D8-E BW   bluebird bio Appoints Alexandre P. LeBeaut, M.D., as Chief Medical Officer","11/02/2011 00422510 BW   ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 46333X10 BW   Ironwood y Forest anuncian que la FDA ha prolongado el período de revisión para la linaclotida hasta septiembre de 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2016 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming May Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2016 15117K10 BW   Cellectis annonce avoir réalisé avec succès les campagnes de production de son second produit candidat UCART123 selon les Bonnes Pratiques de Fabrication (BPF),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2012 0C8MHH-E BW   Ember Therapeutics Expands Scientific Leadership to Advance Metabolic Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2015 079TK4-E BW   Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2014 74587V10 BW   Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/05/2012 LGND-US   BW   Ligand Pharmaceuticals Reports Preliminary Third Quarter 2012 Results,#N/A," 8/21/2014 45232710    BW   Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology", 2/07/2013 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the Leerink Swann 2013 Global Healthcare Conference in New York on February 14th,#N/A,11/25/2013 04280A10 BW   Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A, 9/14/2011 68375N10 BW   OPKO Health to Transfer Listing of Common Stock to the New York Stock Exchange,#N/A,#N/A, 7/30/2015 ALXN-US  BW   Alexion Reports Second Quarter 2015 Results,#N/A,10/07/2015 SGEN-US     BW   Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma,#N/A," 9/10/2014 09062X10    BW   New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms"," 6/05/2011 45253H10 BW   ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma",#N/A,11/14/2016 GILD-US      BW   Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016,#N/A,#N/A,#N/A,#N/A,"12/16/2010 SN-GB        BW   EHSI: Possible AIDS Cure, Other Stem Cell Breakthroughs Changing the Face of Medicine",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/02/2012 007KSQ-E   BW   Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma",#N/A,12/23/2014 45337C10 BW   Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference,#N/A,#N/A,11/01/2011 G0176710 BW   Alkermes' Corporate Presentation to be Webcast at 2011 Annual Credit Suisse Health Care Conference,11/01/2011 15708510 BW   Cerus Corporation Reports Third Quarter 2011 Results,#N/A, 2/04/2010 04269E10 BW   ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer,#N/A,#N/A, 2/10/2014 30161Q10 BW   Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call, 1/29/2013 80105N10  BW, 1/12/2014 92532F10  BW   Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 3/16/2011 05N2D8-E BW   bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia," 9/21/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 46333X10 BW   Ironwood und Forest melden Verlängerung des Prüfungszeitraums für Linaclotid durch FDA bis September 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2016 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2016 15117K10 BW   Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/03/2012 0068K6-E BW   Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2015 079TK4-E BW   Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2014 74587V10 BW   Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/05/2012 LGND-US   BW   Ligand Pharmaceuticals to Restate Previous Financial Statements,#N/A, 7/31/2014 45232710    BW   UK to Become World Number One in DNA Testing with Plan to Revolutionise Fight Against Cancer and Rare Diseases," 1/31/2013 84763A10  BW   Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application",#N/A,11/07/2013 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A, 9/06/2011 68375N10 BW   OPKO Health Announces Grant from Penn Center for Orphan Disease Research and Therapy,#N/A,#N/A," 7/13/2015 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015",#N/A, 9/14/2015 SGEN-US     BW   Seattle Genetics Announces Exercise of Over-Allotment Option,#N/A, 9/03/2014 09062X10    BW   Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care," 6/04/2011 45253H10 BW   ImmunoGen, Inc. Announces Presentation of Favorable SAR3419 Interim Clinical Data at ASCO",#N/A,"11/11/2016 080RQG-E     BW   European CHMP Adopts Positive Opinion for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection",#N/A,#N/A,#N/A,#N/A,12/14/2010 LLY-US       BW   Research and Markets: This Global Protein Therapeutics Market Analysis Forecasts the Industry to Grow at a CAGR of 12% during 2011-2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/01/2012 007KSQ-E   BW   Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma",#N/A,12/04/2014 45337C10 BW   FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera,#N/A,#N/A,10/27/2011 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2012,"10/13/2011 15708510 BW   Cerus to Release Third Quarter 2011 Results on November 1, 2011",#N/A,#N/A,#N/A,#N/A, 1/31/2014 30161Q10 BW   Exelixis Announces Webcasts of Investor Conference Presentations in February, 1/28/2013 80105N10  BW   Genzyme’s LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDA, 1/09/2014 92532F10  BW   Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C,#N/A,#N/A,12/14/2010 05N2D8-E BW   bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy," 9/06/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 46333X10 BW   Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/20/2016 ALNY-US   BW   Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 15117K10 BW   Cellectis a organisé le 1er dîner issu de l’édition du génome à New York,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/23/2011 0068K6-E BW   Acceleron Secures $30M Private Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2014 079TK4-E BW   Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2014 74587V10 BW   Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/01/2012 53220K50  BW   Ligand to Host Analyst Day on December 4th in New York City,#N/A," 7/31/2014 ILMN-US     BW   Providence Health, NantHealth and The Chan Soon-Shiong Institute of Molecular Medicine Partner to Create the Country’s First Health Network for Clinical Whole Genomic Sequencing", 1/28/2013 SPPI-US   BW   Spectrum Pharmaceuticals Announces Presentation of Belinostat Safety Profile from BELIEF Registrational Phase 2 Trial at the Fifth Annual T-Cell Lymphoma Forum,#N/A,11/04/2013 04280A10 BW   Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A, 8/17/2011 68375N10 BW   OPKO Invests in Cardiac Device Company,#N/A,#N/A, 7/06/2015 01535110 BW   Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP),#N/A, 9/10/2015 SGEN-US     BW   Seattle Genetics Announces Pricing of Public Offering of Common Stock,#N/A, 9/02/2014 09062X10    BW   Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014," 6/01/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Jefferies 2011 Global Healthcare Conference",#N/A,11/10/2016 06CR5C-E     BW   U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection,#N/A,#N/A,#N/A,#N/A,12/14/2010 LLY-US       BW   Maven Semantic: Cellular Imaging Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/18/2012 007KSQ-E   BW   Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer,#N/A,12/02/2014 45337C10 BW   Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs),#N/A,#N/A,10/03/2011 ALKS-IE  BW   Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation,10/03/2011 07FB92-E BW   Cerus Corporation Obtains Credit Facility,#N/A,#N/A,#N/A,#N/A," 1/23/2014 30161Q10 BW   Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock", 1/18/2013 07GVF3-E  BW   Research and Markets: PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis," 1/08/2014 92532F10  BW   Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development",#N/A,#N/A,11/02/2010 05N2D8-E BW   bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants, 8/10/2011 00422510 BW   ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2012 46333X10 BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2011 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/06/2016 05KDBG-E  BW   Alnylam to Webcast Presentation at 15th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2016 15117K10 BW   Cellectis Hosts World’s First Gene Edited Dinner in NYC,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2011 0068K6-E BW   Acceleron Pharma to Present at Two Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2014 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/22/2012 53220K50  BW   Ligand to Report Third Quarter Results on November 5th,#N/A, 7/31/2014 45232710    BW   Illumina Appoints Jeff Huber to its Board of Directors, 1/17/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Extension of FUSILEV® (levoleucovorin) for Injection Patent Until 2022,#N/A,10/25/2013 04280A10 BW   Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4),#N/A,#N/A,#N/A,#N/A, 6/21/2011 68375N10 BW   OPKO Health Repurchases Approximately 2.4 Million Shares,#N/A,#N/A, 6/27/2015 01535110 BW   Alexion erhält positive CHMP-Stellungnahmen zu Strensiq™ (Asfotase Alfa) und Kanuma™ (Sebelipase Alfa) in der Europäischen Union,#N/A, 9/09/2015 SGEN-US     BW   Seattle Genetics Announces Proposed Public Offering of Common Stock,#N/A, 8/26/2014 09062X10    BW   Biogen Idec in Panel at the Citi 9th Annual Biotech Conference," 5/26/2011 45253H10 BW   ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting",#N/A,11/01/2016 GILD-US      BW   Gilead Sciences Announces Fourth Quarter 2016 Dividend,#N/A,#N/A,#N/A,#N/A,12/14/2010 MNKD-US      BW   Maven Semantic: Flow Cytometry Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2011 073D4G-E   BW   GE Healthcare’s IN Cell Analyzer Image Competition Inspires Through the Beauty of Cells,#N/A,11/17/2014 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 9/21/2011 ALKS-IE  BW   Alkermes to Present at Jefferies 2011 Global Healthcare Conference," 9/22/2011 0790QJ-E BW   Aduro BioTech, Inc. Appoints Thomas Dubensky, Jr. as Chief Scientific Officer",#N/A,#N/A,#N/A,#N/A, 1/22/2014 30161Q10 BW   Exelixis Launches Proposed Overnight Public Offering of Common Stock, 1/17/2013 07GVF3-E  BW   Research and Markets: Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis, 1/07/2014 92532F10  BW   Vertex Announces Upcoming Presentation at J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2013 Financial Results,#N/A,#N/A, 9/15/2010 05N2D8-E BW   NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio’s Phase 1/2 Beta-Thalassemia Study," 8/03/2011 00422510 BW   ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2012 46333X10 BW   Ironwood Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2016 ALNY-US   BW   Alnylam Initiates Fitusiran (ALN-AT3) Dosing in Hemophilia A and B Patients with Inhibitors in Ongoing Phase 1 Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/04/2016 15117K10 BW   Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2011 0068K6-E BW   Acceleron Initiates Phase 1 Study of ACE-536,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2014 74587V10 BW   Puma Biotechnology to Present at Cowen Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/22/2012 LGND-US   BW   Ligand to Receive $2 Million Milestone Payment from Merck Triggered by Initiation of Phase 2b/3 Trial of Dinaciclib,#N/A, 7/23/2014 45232710    BW   Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2014, 1/11/2013 SPPI-US   BW   Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years,#N/A,10/18/2013 04280A10 BW   Arrowhead to Present at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A, 6/07/2011 68375N10 BW   OPKO Health Announces Research Grants from Mexican Technology and Science Council,#N/A,#N/A, 6/27/2015 01535110 BW   Alexion ontvangt positieve beoordeling van CHMP voor Strensiq™ (asfotase alfa) en Kanuma™™ (sebelipase alfa) in de Europese Unie,#N/A, 9/09/2015 SGEN-US     BW   Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL),#N/A, 8/26/2014 09062X10    BW   Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub," 5/20/2011 45253H10 BW   ImmunoGen, Inc. Prices Public Offering of Common Stock",#N/A,11/01/2016 GILD-US      BW   Gilead Sciences Announces Third Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,12/14/2010 WAT-US       BW   Maven Semantic: High Content Analysis Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2014 45337C10 BW   Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 9/19/2011 0BRKZH-E BW   Alkermes plc Launches Corporate Operations in Ireland," 9/21/2011 15708510 BW   Cerus to Present at Jefferies 2011 Global Healthcare Conference on Sept 28, 2011",#N/A,#N/A,#N/A,#N/A,"12/19/2013 30161Q10 BW   COMETRIQ® (cabozantinib) Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma", 1/17/2013 07GVF3-E  BW   Research and Markets: Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis,12/19/2013 92532F10  BW   Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation,#N/A,#N/A, 9/09/2010 05N2D8-E BW   Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer, 5/17/2011 00422510 BW   ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2012 46333X10 BW   Ironwood Pharmaceuticals to Host Fourth Quarter 2011 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/09/2016 ALNY-US   BW   Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/04/2016 CLLS-FR  BW   Cellectis annonce la délivrance par l'USPTO du brevet U.S. 9,458,439 qui s’ajoute au brevet U.S. 8,921,332 délivré en décembre 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2011 0068K6-E BW   Acceleron Pharma to Present at Two September Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2014 74587V10 BW   Puma Biotechnology Closes $138 Million Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/08/2012 LGND-US   BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A, 7/21/2014 45232710    BW   Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and Approval by Chinese Regulatory Agency, 1/07/2013 84763A10  BW   Spectrum Pharmaceuticals Announces Positive RenaZorb® Phase 1 Clinical Data Demonstrating Robust Activity in Easy-to-Swallow Pill Formulation,#N/A,10/14/2013 04280A10 BW   Arrowhead Closes Private Offering with Net Proceeds of $60 Million,#N/A,#N/A,#N/A,#N/A, 6/06/2011 68375N10 BW   OPKO Health Announces Redemption of Series A Preferred Stock,#N/A,#N/A, 6/26/2015 01535110 BW   Alexion reçoit l'avis favorable du CHMP pour Strensiq™ (asfotase alfa) etKanuma™ (sebelipase alfa) dans l'Union européenne,#N/A, 8/17/2015 SGEN-US     BW   Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation,#N/A," 8/21/2014 09062X10    BW   Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions"," 5/19/2011 45253H10 BW   ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock",#N/A,"10/25/2016 GILD-US      BW   Gilead Sciences to Release Third Quarter 2016 Financial Results on Tuesday, November 1, 2016",#N/A,#N/A,#N/A,#N/A,12/14/2010 TAKDF.XX1-US BW   Maven Semantic: Cell Culture Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2014 45337C10 BW   Incyte to Present at the Nomura BioPharma Conference,#N/A,#N/A," 9/16/2011 G0176710 BW   Alkermes plc and Elan Corporation plc Announce Completion of Merger Between Alkermes, Inc. and Elan Drug Technologies"," 9/01/2011 15708510 BW   Cerus to Present at Stifel, Nicolaus & Company’s Annual Healthcare Conference on Sept 8, 2011",#N/A,#N/A,#N/A,#N/A,12/17/2013 30161Q10 BW   Exelixis Announces Webcast of January 15 Presentation at the J.P. Morgan 32nd Annual Healthcare Conference," 1/08/2013 CBST-US   BW   Cubist to Appoint Tom DesRosier as Senior Vice President, Chief Legal Officer and Secretary",11/20/2013 06Y1QQ-E  BW   Vertex Sells INCIVO ® Product Royalty Rights for $152 Million,#N/A,#N/A,#N/A, 5/10/2011 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2012 46333X10 BW   Ironwood Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/29/2016 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming March Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2016 15117K10 BW   Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2011 CELG-US  BW   Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2014 74587V10 BW   Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/25/2012 53220K50  BW   Ligand to Report Second Quarter Results on August 8th,#N/A," 7/16/2014 00FHB8-E    BW   Illumina Acquires Myraqa, a Leading IVD and Companion Diagnostic Consulting Firm", 1/02/2013 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at 31st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9th,#N/A,10/08/2013 04280A10 BW   Arrowhead Prices At-Market Private Offering for $60 Million Net Proceeds,#N/A,#N/A,#N/A,#N/A, 6/03/2011 68375N10 BW   OPKO Health to Present at the Jefferies 2011 Global Healthcare Conference,#N/A,#N/A, 6/26/2015 01535110 BW   Alexion riceve i pareri positivi del CHMP per Strensiq™ (asfotase alfa) e Kanuma™ (sebelipase alfa) nell'Unione Europea,#N/A, 7/30/2015 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2015 Financial Results,#N/A, 8/15/2014 09062X10    BW   Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis," 5/03/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Bank of America Merrill Lynch 2011 Health Care Conference",#N/A,"10/24/2016 GILD-US      BW   Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7",#N/A,#N/A,#N/A,#N/A,12/14/2010 WAT-US       BW   Maven Semantic: Mass Spectrometry Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/17/2014 45337C10 BW   Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer,#N/A,#N/A, 9/12/2011 G0176710 BW   Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011," 8/31/2011 15708510 BW   Cerus to Present at the Baird’s Health Care Conference on September 7, 2011",#N/A,#N/A,#N/A,#N/A,12/02/2013 30161Q10 BW   Exelixis Initiates Randomized Phase 2 Clinical Trial of Cabozantinib Plus Abiraterone in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer,12/18/2012 06680H-E  BW   U.S. Neurologists Report that 30 to 40 Percent of Treated Relapsing and Progressive Multiple Sclerosis Patients are Dissatisfied with Their Current Disease-Modifying Therapy (DMT) and would be Eager to Switch to a New Drug,11/11/2013 92532F10  BW   Vertex To Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A," 5/04/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 46333X10 BW   Ironwood Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2016 ALNY-US   BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2016 15117K10 BW   Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2011 CELG-US  BW   Celgene and Acceleron Initiate Phase 2/3 Study of ACE-011 (sotatercept) to Treat Chemotherapy-Induced Anemia in Patients with Lung Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2014 74587V10 BW   Puma Biotechnology Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/25/2012 53220K50  BW   Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection,#N/A, 7/14/2014 45232710    BW   Illumina Names Tina S. Nova as Senior Vice President and General Manager of Oncology,12/21/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial,#N/A,10/08/2013 04280A10 BW   Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A, 5/09/2011 68375N10 BW   OPKO Health Announces Grant from Dravet Syndrome Foundation,#N/A,#N/A, 6/26/2015 01535110 BW   Alexion recibe opiniones positivas del CHMP para Strensiq™ (asfotasa alfa) y Kanuma™ (sebelipasa alfa) en la Unión Europea,#N/A," 7/09/2015 81257810    BW   Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease",#N/A, 7/23/2014 09062X10    BW   PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis," 4/28/2011 45253H10 BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2011 Financial Results and Provides Quarterly Update",#N/A,10/24/2016 GILD-US      BW   Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens,#N/A,#N/A,#N/A,#N/A,"11/26/2010 TEX-US       BW   Zacks Analyst Blog Highlights: Caterpillar Inc, McDonald, Terex, Johnson & Johnson and Amgen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2014 45337C10 BW   Incyte to Report Third Quarter 2014 Financial Results on October 30,#N/A,#N/A, 9/08/2011 G0176710 BW   Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies, 8/18/2011 15708510 BW   Cerus Awarded $2.1 Million to Advance Development of Pathogen Inactivation for Red Blood Cells,#N/A,#N/A,#N/A,#N/A,11/26/2013 30161Q10 BW   Exelixis Announces Webcast of December 3 Presentation at the 25th Annual Piper Jaffray Healthcare Conference,12/14/2012 80105N10  BW,10/29/2013 92532F10  BW   Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014,#N/A,#N/A,#N/A," 5/03/2011 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2012 46333X10 BW   Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2016 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2016 15117K10 BW   Cellectis publie ses résultats financiers du deuxième trimestre 2016 et du premier semestre 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2011 0068K6-E BW   Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/06/2014 74587V10 BW   Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/20/2012 53220K50  BW   Ligand Licensee Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis™ (carfilzomib) for Injection,#N/A," 7/09/2014 45232710    BW   Illumina to Announce Second Quarter 2014 Financial Results on Wednesday, July 23, 2014","12/13/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Promising ZEVALIN®, FOLOTYN® and Belinostat Clinical Data Presented at the 54th Annual Meeting of the American Society of Hematology",#N/A, 9/19/2013 04280A10 BW   Arrowhead Promotes David Lewis to Chief Scientific Officer,#N/A,#N/A,#N/A,#N/A, 3/18/2011 68375N10 BW   OPKO Health Announces Exercise of Over-Allotment Option,#N/A,#N/A, 6/26/2015 01535110 BW   Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union,#N/A," 7/08/2015 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial Results on July 30, 2015",#N/A, 7/23/2014 09062X10    BW   Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year," 4/21/2011 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2011 Financial Results",#N/A,"10/20/2016 GILD-US      BW   Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients",#N/A,#N/A,#N/A,#N/A,10/14/2010 AMGN-US      BW   Research and Markets: Musculoskeletal Disorders Therapeutics to 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2014 45337C10 BW   Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe,#N/A,#N/A, 9/07/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences," 8/09/2011 15708510 BW   Cerus to Present at the Wedbush 2011 Life Sciences Management Access Conference on August 17, 2011",#N/A,#N/A,#N/A,#N/A,11/04/2013 30161Q10 BW   Exelixis Announces Webcast of November 12 Presentation at the Credit Suisse 2013 Healthcare Conference,12/07/2012 SNY-FR    BW   Genzyme Receives European Label Expansion for Thyrogen,10/29/2013 92532F10  BW   Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK,#N/A,#N/A,#N/A," 4/01/2011 00422510 BW   ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2012 46333X10 BW   Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/01/2016 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming February Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2016 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 0068K6-E BW   Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2013 74587V10 BW   Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/19/2012 LGND-US   BW   Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene/Conjugated Estrogens for the Treatment of Symptoms Associated with Menopause and Osteoporosis,#N/A," 6/30/2014 45232710    BW   Biomnis, Genoma und das Zentrum für Humangenetik und Laboratoriumsdiagnostik in Martinsried schließen Verträge mit Illumina zwecks Verbreitung von nicht invasiven Pränataltests in ganz Europa","12/11/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Year-End, Special Cash Dividend of $0.15 per Share of Common Stock",#N/A, 8/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 3/14/2011 68375N10 BW   OPKO Health Announces Completion of Public Offering of Common Stock,#N/A,#N/A, 6/23/2015 01535110 BW   Alexion Completes Acquisition of Synageva,#N/A, 6/17/2015 81257810    BW   Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma,#N/A, 7/16/2014 09062X10    BW   Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS), 4/07/2011 45253H10 BW   T-DM1 Significantly Improved Progression-Free Survival in Randomized Phase II Trial,#N/A,"10/20/2016 GILD-US      BW   Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)",#N/A,#N/A,#N/A,#N/A,"10/14/2010 TEVA-IL      BW   Zacks Bull and Bear of the Day Highlights: SFLY, BMRN, LLY, AMGN, TEVA",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2014 45337C10 BW   Incyte to Present at the 21st Annual BioCentury NewsMakers Conference,#N/A,#N/A, 8/31/2011 G0176710 BW   Alkermes’ Corporate Presentation to Be Webcast at Baird’s 2011 Health Care Conference, 7/28/2011 15708510 BW   Cerus Corporation Reports Second Quarter 2011 Results,#N/A,#N/A,#N/A,#N/A,10/30/2013 30161Q10 BW   Exelixis Announces Third Quarter 2013 Financial Results,11/28/2012 SAN-FR    BW   Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies for up to Three Allergy Indications Based on Selecta’s Synthetic Vaccine Particle Technology,10/18/2013 92532F10  BW   Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study,#N/A,#N/A,#N/A," 3/29/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2012 07ZR4G-E BW   Synergy Pharmaceuticals Engages The Trout Group for Investor Relations Services,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/01/2016 ALNY-US   BW   Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2016 15117K10 BW   Cellectis Named 2016 Technology Pioneer by the World Economic Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2011 0068K6-E BW   Acceleron Pharma to Present at Two Upcoming Investor Conferences in April,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2013 74587V10 BW   Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/09/2012 LGND-US   BW   Ligand Announces New Presentation Time at the JMP Securities 7th Annual Healthcare Conference,#N/A," 6/30/2014 45232710    BW   Biomnis, Genoma, et le Centre de génétique humaine et de diagnostics de laboratoire Martinsried, signent avec Illumina des accords visant à étendre l'accès au dépistage prénatal non invasif dans toute l’Europe","12/07/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights 19 Abstracts at the 54th Annual Meeting of the American Society of Hematology (ASH), Atlanta, Georgia, December 8-11, 2012",#N/A, 7/31/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 3/09/2011 OPK-US   BW   OPKO Health Announces Pricing of Public Offering of Common Stock,#N/A,#N/A, 6/22/2015 ALXN-US  BW   Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer,#N/A, 6/08/2015 SGEN-US     BW   Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration,#N/A," 6/30/2014 09062X10    BW   Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014"," 4/04/2011 45253H10 BW   ImmunoGen, Inc. Announces First Data for its Novel Therapeutic for Ovarian Cancer and Other Carcinomas",#N/A,10/03/2016 GILD-US      BW   Rover.com Retrieves $40 Million Round of Funding,#N/A,#N/A,#N/A,#N/A, 9/13/2010 AMGN-US      BW   Fitch Rates Amgen's Senior Notes 'A',#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2014 45337C10 BW   Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNs) and Honor MPN Heroes,#N/A,#N/A," 8/10/2011 G0176710 BW   BYDUREON™ FDA Action Date Set for January 28, 2012"," 7/12/2011 15708510 BW   Cerus to Release Second Quarter 2011 Results on July 28, 2011",#N/A,#N/A,#N/A,#N/A,10/15/2013 30161Q10 BW   Exelixis Announces October 30th Webcast of Third Quarter 2013 Financial Results Conference Call,"11/27/2012 060RWY-E  BW   Sensipar, Fosrenol and Renagel/Renvela are Likely to be Negatively Impacted in 2014 When Oral Medications Become Included in the Dialysis Bundle, According to a Recent BioTrends Report",10/17/2013 92532F10  BW   Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis,#N/A,#N/A,#N/A," 3/10/2011 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/04/2012 46333X10 BW   Ironwood Pharmaceuticals and Bionomics Announce Collaboration, Research, and License Agreement",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 ALNY-US   BW   Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2016 15117K10 BW   MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2011 064BG1-E BW   Acceleron Awarded $1.5 Million Grant from Muscular Dystrophy Association to Support ACE-031,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2013 74587V10 BW   Puma Biotechnology Reports Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/27/2012 LGND-US   BW   Ligand to Present at the JMP Securities 7th Annual Healthcare Conference,#N/A," 6/30/2014 0733MF-E    BW   Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, Enter Agreements with Illumina to Expand Access for Non-Invasive Prenatal Testing Across Europe",12/05/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Oppenheimer 23rd Annual Healthcare Conference in New York City on December 12th,#N/A, 7/23/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 3/02/2011 68375N10 BW   OPKO Health Announces Proposed Offering of Common Stock,#N/A,#N/A, 6/02/2015 01535110 BW   Alexion to Present at Investor Conferences,#N/A, 6/01/2015 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting,#N/A, 6/16/2014 09062X10    BW   Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis," 4/04/2011 45253H10 BW   ImmunoGen, Inc. Announces First Data for Its IMGN529 Product Candidate for Non-Hodgkin’s Lymphoma",#N/A, 9/27/2016 00BB3S-E     BW   Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration,#N/A,#N/A,#N/A,#N/A, 8/09/2010 PLYZ-US      BW   Webtradex International Corporation Appoints Chief Operating Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2014 45337C10 BW   FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted,#N/A,#N/A, 8/01/2011 G0176710 BW   Alkermes Reports First Quarter Fiscal 2012 Financial Results, 6/29/2011 15708510 BW   Cerus Corporation Announces Changes to Board of Directors,#N/A,#N/A,#N/A,#N/A, 9/28/2013 30161Q10 BW   Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013,11/27/2012 06B998-E  BW   Kala Pharmaceuticals Appoints Dr. Bernard Gilly to Its Board of Directors,10/10/2013 92532F10  BW   Vertex Changes Timing of Third Quarter 2013 Earnings Call On October 29,#N/A,#N/A,#N/A," 3/03/2011 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2012 46333X10 BW   Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2016 ALNY-US   BW   Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/20/2016 15117K10 BW   Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2011 0068K6-E BW   Acceleron Pharma to Present at the 29th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/04/2013 74587V10 BW   Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/11/2012 LGND-US   BW   Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association’s 72nd Scientific Sessions,#N/A, 6/06/2014 45232710    BW   Illumina Announces Pricing of Convertible Senior Notes,11/30/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Deutsche Bank’s 2012 dbAccess BioFEST in Boston on December 4th,#N/A, 6/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 2/01/2011 68375N10 BW   OPKO Health Acquires Biotechnology Company with Unique Platform Technology to Develop New Drugs,#N/A,#N/A, 5/29/2015 01535110 BW   Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Synageva,#N/A, 5/28/2015 81257810    BW   Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting,#N/A," 6/06/2014 09062X10    BW   FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children"," 3/30/2011 45253H10 BW   ImmunoGen, Inc. Announces Presentations at the 102nd Annual Meeting of the American Association for Cancer Research",#N/A, 9/21/2016 GILD-US      BW   Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis,#N/A,#N/A,#N/A,#N/A," 7/20/2010 NOVN-CH      BW   Zacks Analyst Blog Highlights: Jinpan International, Whole Foods Market, Amgen, Novartis’ and GlaxoSmithKline",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2014 45337C10 BW   Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 7/28/2011 G0176710 BW   BYDUREON™ Reply Submitted to FDA, 6/09/2011 15708510 BW   Cerus Corporation and Ilex Biotech LTD Initiate Distribution Agreements for the INTERCEPT Blood System in South Africa and Israel,#N/A,#N/A,#N/A,#N/A, 9/26/2013 30161Q10 BW   Exelixis Announces Full Patient Enrollment Target Has Been Achieved for COMET-1,11/26/2012 SNY-FR    BW   Genzyme Honors Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards, 9/30/2013 92532F10  BW   Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO™ (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations,#N/A,#N/A,#N/A," 2/08/2011 00422510 BW   ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/13/2011 SGYP-US  BW   Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/29/2015 ALNY-US   BW   Alnylam to Webcast Presentation at Goldman Sachs “Healthcare CEOs Unscripted: A View from the Top” Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/20/2016 15117K10 BW   Cellectis annonce qu’un premier patient a été traité dans le cadre de l’étude clinique de Phase 1 visant à tester UCART19 dans le traitement de la leucémie aiguë lymphoblastique à cellules B de l’enfant (B-ALL),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/29/2010 0068K6-E BW   Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2013 74587V10 BW   Puma Biotechnology to Present at Stifel Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/30/2012 GSK-GB    BW   Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C,#N/A, 6/04/2014 45232710    BW   Illumina to Offer $900 Million Convertible Senior Notes,11/27/2012 SPPI-US   BW   Spectrum Pharmaceuticals Expands Manufacturing Capacity to Ensure Long-Term Supply of FUSILEV® to Meet Needs of Patients and Physicians,#N/A, 5/28/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 1/10/2011 68375N10 BW   OPKO Health to Collaborate with Bristol-Myers Squibb on Blood Test for Alzheimer’s Disease,#N/A,#N/A, 5/06/2015 ALXN-US  BW   Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases,#N/A, 4/30/2015 81257810    BW   Seattle Genetics Reports First Quarter 2015 Financial Results,#N/A, 5/30/2014 09062X10    BW   Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses," 2/28/2011 IMGN-US  BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A, 9/15/2016 GILD-US      BW   Gilead Prices $5 Billion of Senior Unsecured Notes,#N/A,#N/A,#N/A,#N/A," 6/03/2010 NOVN-CH      BW   Zacks Analyst Blog Highlights: Amgen, Novartis, GlaxoSmithKline, Merck and Eli Lilly",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2014 45337C10 BW   Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies,#N/A,#N/A, 7/25/2011 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2012, 5/31/2011 15708510 BW   Cerus to Present at the Jefferies 2011 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 9/20/2013 30161Q10 BW   Exelixis Announces Webcast of September 27 Presentation at BioCentury’s NewsMakers in the Biotech Industry Conference,11/26/2012 ALNY-US   BW, 9/25/2013 92532F10  BW   Vertex to Announce Third Quarter 2013 Financial Results on October 29,#N/A,#N/A,#N/A, 1/10/2011 001DPF-E BW   ACADIA Pharmaceuticals Announces $15 Million Private Placement,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2011 46333X10 BW   Ironwood Pharmaceuticals Provides Third Quarter 2011 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/21/2015 ALNY-US   BW   Alnylam Files Clinical Trial Application (CTA) for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2016 15117K10 BW   Résultats de l’Assemblée Générale mixte des actionnaires de Cellectis S.A. du 17 mai 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/19/2010 0068K6-E BW   Acceleron Pharma Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2013 74587V10 BW   Puma Biotechnology Reports Second Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/14/2012 LGND-US   BW   CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4,#N/A, 5/05/2014 45232710    BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May and June,11/26/2012 SPPI-US   BW   Spectrum Pharmaceuticals' Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® National Award Finalist,#N/A, 5/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 1/06/2011 68375N10 BW   OPKO Health Announces Publication on Technology Underlying Blood Test for Alzheimer’s Disease,#N/A,#N/A, 5/05/2015 01535110 BW   Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (Soliris®) in Prevention of Acute Antibody-Mediated Rejection (AMR) in Sensitized Deceased-Donor Kidney Transplant Recipients,#N/A, 4/28/2015 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 5/28/2014 09062X10    BW   Biogen Idec 2014 Annual Shareholder Meeting Webcast," 2/08/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A, 9/06/2016 C-US         BW   Gilead Sciences to Present at Three Upcoming Investor Conferences in September,#N/A,#N/A,#N/A,#N/A," 6/01/2010 GSK-GB       BW   Zacks Analyst Blog Highlights: Ford Motor, General Motor, Tata Motors, Amgen and GlaxoSmithKline",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2014 45337C10 BW   Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information,#N/A,#N/A, 7/18/2011 G0176710 BW   Alkermes Provides Outlook for Alkermes plc and Update on Advancing Product Portfolio at Analyst and Investor Day, 4/28/2011 15708510 BW   Cerus Corporation Announces First Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A, 9/10/2013 30161Q10 BW   Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma,"11/21/2012 SNY-FR    BW   Genzyme’s Once-Daily, Oral AUBAGIO® Approved in Australia for Treatment of Relapsing Multiple Sclerosis", 9/05/2013 92532F10  BW   Vertex To Present at Morgan Stanley Healthcare Conference,#N/A,#N/A,#N/A,11/09/2010 00422510 BW   ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2011 46333X10 BW   Ironwood Pharmaceuticals to Present at Credit Suisse 2011 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2015 ALNY-US   BW   Alnylam Announces Updates to Company’s Board of Directors Supportive of Transition Towards Commercial Stage,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/19/2016 15117K10 BW   Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/19/2010 0068K6-E BW   Acceleron Announces Interim Findings from the ACE-041 Phase 1, First-in-Human Clinical Trial at 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/24/2013 74587V10 BW   Puma Biotechnology to Join Russell 3000 Index,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/07/2012 LGND-US   BW   Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17,#N/A, 4/29/2014 45232710    BW   Illumina Launches VeriSeq PGS,11/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Credit Suisse 2012 Healthcare Conference in Phoenix on November 15th,#N/A, 5/09/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 1/05/2011 68375N10 BW   OPKO Health to Present at the 29th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A, 4/29/2015 ALXN-US  BW   Alexion to Present at Investor Conferences,#N/A, 4/20/2015 81257810    BW   FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse,#N/A, 5/28/2014 09062X10    BW   Biogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS," 2/01/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2011",#N/A, 8/23/2016 GILD-US      BW   Kelly A. Kramer Joins Gilead Sciences’ Board of Directors,#N/A,#N/A,#N/A,#N/A," 5/24/2010 NOVN-CH      BW   Zacks Analyst Blog Highlights: Amgen, Novartis, Merck, GlaxoSmithKline and Eli Lilly",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/23/2014 45337C10 BW   Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera,#N/A,#N/A, 7/11/2011 G0176710 BW   Alkermes to Webcast Analyst and Investor Day," 4/20/2011 15708510 BW   Cerus Appoints William ""Obi"" Greenman as President and Chief Executive Officer",#N/A,#N/A,#N/A,#N/A, 9/04/2013 30161Q10 BW   Exelixis Announces Webcasts of Investor Conference Presentations in September,"11/21/2012 0BVD47-E  BW   Research and Markets: Sanofi-Aventis: Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report Provides Data on Company Financial Performance and Competitive Benchmarking", 9/03/2013 92532F10  BW   Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference,#N/A,#N/A,#N/A,11/09/2010 00422510 BW   ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson’s Disease,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2011 46333X10 BW   Ironwood Pharmaceuticals to Host Third Quarter 2011 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2015 ALNY-US   BW   Alnylam Initiates Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2016 15117K10 BW   Cellectis publie ses résultats financiers du premier trimestre 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2010 0068K6-E BW   Acceleron Awarded Grants from the Qualifying Therapeutic Discovery Project Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2013 74587V10 BW   Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/02/2012 53220K50  BW   Ligand Pharmaceuticals Reports First Quarter Results,#N/A," 4/25/2014 45232710    BW   Illumina Files New Patent Infringement Suit Against Ariosa Diagnostics, Inc.",11/07/2012 84763A10  BW   INSERTING and REPLACING Spectrum Pharmaceuticals Reports Strong Revenues and Profits for Third Quarter; Revenues of $69 million up 35% over last year and GAAP Diluted EPS of $0.33 and Non-GAAP Diluted EPS of $0.42,#N/A, 5/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,12/14/2010 68375N10 BW   TESARO and OPKO Health Sign Exclusive License Agreement for Rolapitant,#N/A,#N/A, 4/23/2015 01535110 BW   Alexion Reports First Quarter 2015 Results,#N/A, 4/16/2015 SGEN-US     BW   Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR) Annual Meeting,#N/A, 5/23/2014 09062X10    BW   CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union," 1/27/2011 45253H10 BW   ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2011 Financial Results",#N/A, 8/22/2016 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1,#N/A,#N/A,#N/A,#N/A," 5/03/2010 AMGN-US      BW   BIO Elects New Officers, Welcomes Nine New Board Members",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/14/2014 45337C10 BW   Incyte to Report Second Quarter 2014 Financial Results on July 31,#N/A,#N/A, 7/07/2011 G0176710 BW   Exenatide tQT Study Showed No Prolongation of QT Interval," 4/12/2011 15708510 BW   Cerus to Release First Quarter 2011 Results on April 28, 2011",#N/A,#N/A,#N/A,#N/A, 8/06/2013 30161Q10 BW   Exelixis Announces Second Quarter 2013 Financial Results,11/21/2012 ALNY-US   BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences, 7/29/2013 92532F10  BW   Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations,#N/A,#N/A,#N/A,"11/02/2010 00422510 BW   ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2011 46333X10 BW   Ironwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2015 ALNY-US   BW   Alnylam Pharmaceuticals to Present Path to “Alnylam 2020” at R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2016 CLLS-FR  BW   Cellectis Reports First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2010 0068K6-E BW   Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2013 74587V10 BW   Puma Biotechnology to Present at Goldman Sachs Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/16/2012 LGND-US   BW   Ligand to Report First Quarter Results on May 2nd,#N/A, 4/22/2014 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2014,11/01/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market,#N/A, 5/06/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,11/12/2010 68375N10 BW   OPKO Health to Present at the Lazard Capital Markets 7th Annual Healthcare Conference,#N/A,#N/A," 4/21/2015 0D7WM8-E BW   Audentes Therapeutics Appoints Stephen Squinto, Ph.D. to its Board of Directors",#N/A," 4/13/2015 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015",#N/A, 5/21/2014 09062X10    BW   Biogen Idec to Present at the Sanford Bernstein 30th Annual Strategic Decisions Conference," 1/20/2011 05RBVG-E BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results",#N/A, 7/25/2016 GILD-US      BW   Gilead Sciences Announces Third Quarter 2016 Dividend,#N/A,#N/A,#N/A,#N/A," 3/31/2010 AMGN-US      BW   Leading Biotechnology Mergers and Acquisitions for the 10-Year Period Ended December 31, 2009 Revealed by DealSearchOnline.com",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2014 NVS-CH   BW   Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan,#N/A,#N/A, 7/07/2011 G0176710 BW   Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder, 3/03/2011 15708510 BW   Cerus Corporation Reports Fourth Quarter and Year-End 2010 Results,#N/A,#N/A,#N/A,#N/A, 7/18/2013 30161Q10 BW   Exelixis Announces August 6th Webcast of Second Quarter 2013 Financial Results Conference Call,"11/13/2012 07G69B-E  BW   Research and Markets: Global Diabetes Drugs Market 2011-2015 Report Says Eli Lilly, Merck and Novo Nordisk A/S are Among the Main Players", 7/29/2013 92532F10  BW   Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs,#N/A,#N/A,#N/A,10/28/2010 00422510 BW   ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2011 46333X10 BW   Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/07/2015 ALNY-US   BW   Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2016 CLLS-FR  BW   Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2010 0068K6-E BW   FierceBiotech Names Acceleron Pharma as One of the “Fierce 15” of 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2013 74587V10 BW   Puma Biotechnology to Present at Jefferies Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/05/2012 53220K50  BW   Ligand to Present at the 24th Annual Roth Conference on March 12,#N/A," 4/07/2014 45232710    BW   Illumina to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014",10/31/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2012 Financial Results Teleconference and Webcast,#N/A, 5/02/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,"11/09/2010 68375N10 BW   OPKO Announces Restatement of Financial Statements to Properly Account for Series D Convertible Preferred Stock; No Impact on Cash, Revenues or Other Results from Operations",#N/A,#N/A," 4/13/2015 01535110 BW   Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris®) in Patients Undergoing Kidney Transplant",#N/A, 2/25/2015 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A," 5/12/2014 09062X10    BW   Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine"," 1/18/2011 45253H10 BW   ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs",#N/A, 7/25/2016 GILD-US      BW   Gilead Sciences Announces Second Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A, 3/09/2010 AMGN-US      BW   Fitch Affirms Amgen's IDR at 'A'; Rates New Issuance 'A'; Outlook Stable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2014 45337C10 BW   Incyte to Present at the 9th Annual JMP Securities Healthcare Conference,#N/A,#N/A, 6/30/2011 G0176710 BW   Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of Schizophrenia, 3/01/2011 15708510 BW   Cerus to Present at the Cowen and Company 31st Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A, 6/27/2013 30161Q10 BW   Exelixis Announces Webcast of July 10 Presentation at the JMP Securities 8th Annual Healthcare Conference,11/13/2012 SNY-FR    BW   Genzyme Announces Return to Full Supply of Thyrogen (thyrotropin alfa for injection), 7/25/2013 92532F10  BW   Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C,#N/A,#N/A,#N/A," 9/22/2010 00422510 BW   ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2011 ALM-ES   BW   Ironwood Announces Linaclotide European Regulatory Submission for the Treatment of Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2015 ALNY-US   BW   Alnylam Reports that ALN-CC5 Achieves Up to 99 Percent Knockdown of Serum C5 and Up to 98 Percent Inhibition of Serum Hemolytic Activity with Durability Supportive of Once Monthly and Possibly Once Quarterly Subcutaneous Dose Regimen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/21/2016 CLLS-FR  BW   Cellectis et Takara Bio Inc. concluent un accord de licence et d’approvisionnement en RetroNectin®,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2010 SHP-GB   BW   Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2013 74587V10 BW   Puma Biotechnology Comment on Trading Activity,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/21/2012 53220K50  BW   Ligand to Present at the Citi Global Health Care Conference on February 28th,#N/A, 4/02/2014 45232710    BW   Illumina Expands Product Portfolio to Support Oncology Clinical Research and Discovery,"10/29/2012 SPPI-US   BW   Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations",#N/A, 4/29/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,11/08/2010 OPK-US   BW   Fabrus Announces Conjugated Antibody Collaboration and New Phase of Growth,#N/A,#N/A, 4/10/2015 01535110 BW   Alexion erhält Genehmigung für bedeutende Aktualisierungen der EU-Fachinformation zu Soliris® (Eculizumab),#N/A, 2/18/2015 81257810    BW   Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse,#N/A, 5/12/2014 09062X10    BW   Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World, 1/10/2011 SIGA-US  BW,#N/A, 7/22/2016 080RQG-E     BW   European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2014 45337C10 BW   Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies,#N/A,#N/A," 6/27/2011 G0176710 BW   Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL®, Published in Leading Healthcare Policy Journal"," 2/25/2011 15708510 BW   Cerus to Release Fourth Quarter and Year-End 2010 Results on March 3, 2011",#N/A,#N/A,#N/A,#N/A, 6/05/2013 30161Q10 BW   Exelixis Announces Webcasts of Upcoming Investor Conference Presentations,11/12/2012 ALNY-US   BW   Alnylam and Tekmira Restructure Relationship and Settle All Litigation," 7/09/2013 92532F10  BW   Vertex Receives Australian Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)",#N/A,#N/A,#N/A, 9/07/2010 00422510 BW   ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2011 46333X10 BW   Ironwood Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/02/2015 ALNY-US   BW   Alnylam to Webcast R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/21/2016 CLLS-FR  BW   Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/19/2010 0068K6-E BW   Acceleron Pharma Receives FDA Orphan Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2013 74587V10 BW   Puma Biotechnology to Present at UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/21/2012 53220K50  BW   Ligand Licenses DARA Program to Retrophin,#N/A, 3/10/2014 45232710    BW   WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System,10/15/2012 SPPI-US   BW   Spectrum Pharmaceuticals Named One of the Best Places to Work in Southern Nevada,#N/A, 4/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,11/03/2010 68375N10 BW   OPKO Invests in Novel Antibody Biotechnology Company,#N/A,#N/A, 4/10/2015 01535110 BW   Alexion reçoit l'approbation visant d'importantes mises à jour de l'étiquette européenne de Soliris® (éculizumab),#N/A, 2/17/2015 81257810    BW   Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors,#N/A, 5/08/2014 09062X10    BW   Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference," 1/03/2011 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at J.P. Morgan 29th Annual Healthcare Conference",#N/A," 7/21/2016 GILD-US      BW   Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2014 45337C10 BW   Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer,#N/A,#N/A, 6/24/2011 G0176710 BW   Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years, 2/18/2011 15708510 BW   Cerus Corporation Postpones Fourth Quarter & Year-End 2010 Earnings Release and Conference Call,#N/A,#N/A,#N/A,#N/A," 6/02/2013 30161Q10 BW   Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer",11/09/2012 0CNFP0-E  BW   Sanofi and Genzyme Congratulate the 2012 Schwartz Center Compassionate Caregiver Award Winner, 6/27/2013 92532F10  BW   Vertex To Announce Second Quarter 2013 Financial Results On July 29,#N/A,#N/A,#N/A, 8/09/2010 00422510 BW   ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2011 46333X10 BW   Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/23/2015 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming December Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2016 15117K10 BW   Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2010 0068K6-E BW   Acceleron Pharma Receives FDA Fast Track Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2013 74587V10 BW   Puma Biotechnology Reports First Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/09/2012 53220K50  BW   Ligand to Present at the BIO CEO and Investor Conference on February 13,#N/A, 2/26/2014 45232710    BW   Illumina’s Non-Invasive verifi® Prenatal Test Using cfDNA Significantly Reduces False Positive Rate of Fetal Aneuploidy Detection Compared to Current Standard Pregnancy Screening Practices,10/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent,#N/A, 4/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 9/17/2010 68375N10 BW   CORRECTING and REPLACING OPKO Health to Present at UBS Global Life Sciences Conference,#N/A,#N/A, 4/10/2015 01535110 BW   Alexion Receives Approval for Important Updates to the European Label for Soliris® (eculizumab),#N/A, 2/10/2015 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results,#N/A, 5/01/2014 09062X10    BW   New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients,"12/10/2010 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer",#N/A," 7/18/2016 GILD-US      BW   Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2014 45337C10 BW   Incyte Announces Preliminary Results of a Phase I/II Study of Combination Immunotherapy in Patients with Melanoma,#N/A,#N/A, 6/24/2011 G0176710 BW   Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011, 2/16/2011 CERS-US  BW   Cerus' INTERCEPT Plasma Granted Orphan Drug Designation for Treatment of Thrombotic Thrombocytopenic Purpura (TTP),#N/A,#N/A,#N/A,#N/A, 6/01/2013 30161Q10 BW   Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer,11/05/2012 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial Results, 6/18/2013 92532F10  BW   Vertex Completes Redemption of Convertible Senior Subordinated Notes,#N/A,#N/A,#N/A," 8/02/2010 00422510 BW   ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 9, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2011 46333X10 BW   Ironwood Pharmaceuticals Provides Second Quarter 2011 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2015 ALNY-US   BW   Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholesterolemia Dose Regimen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2016 15117K10 BW   Cellectis et MabQuest annoncent un partenariat en immunothérapie concernant une nouvelle classe d’anticorps monoclonaux anti-PD-1,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2010 0068K6-E BW   Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2013 PBYI-US  BW   Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/07/2012 53220K50  BW   Ligand Reports Fourth Quarter and Full Year 2011 Financial Results,#N/A, 2/24/2014 45232710    BW   Science for Life Laboratory Joins the Illumina Genome Network,10/02/2012 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at the 11th Annual BIO Investor Forum in San Francisco on October 9th,#N/A, 3/25/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 6/04/2010 68375N10 BW   OPKO Health to Present at Jefferies 2010 Global Life Sciences Conference,#N/A,#N/A," 4/09/2015 01535110 BW   Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015",#N/A, 2/05/2015 81257810    BW   Seattle Genetics to Present at Leerink Global Healthcare Conference,#N/A, 4/30/2014 09062X10    BW   Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference,"12/04/2010 45253H10 BW   ImmunoGen, Inc. Announces Presentation of Positive Initial Clinical Data for IMGN901 Used in a Combination Regimen for Multiple Myeloma",#N/A, 7/08/2016 LGND-US      BW   Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2014 45337C10 BW   New Data for Multiple Incyte Cancer Programs to Be Presented at the 2014 American Society of Clinical Oncology (ASCO) Meeting,#N/A,#N/A, 6/24/2011 G0176710 BW   Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011," 2/08/2011 15708510 BW   Cerus to Release Fourth Quarter and Year-End 2010 Results on February 22, 2011",#N/A,#N/A,#N/A,#N/A, 5/31/2013 30161Q10 BW   Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,"11/05/2012 060RWY-E  BW   The Prostate Cancer Drug Market Will More than Double, Increasing from $4.1 Billion in 2011 to $9.1 Billion in 2021", 6/05/2013 92532F10  BW   Vertex annonce une diffusion Web de sa présentation lors de la 34e conférence annuelle internationale sur les soins de santé Goldman Sachs,#N/A,#N/A,#N/A, 7/29/2010 00422510 BW   ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson’s Disease Psychosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2011 46333X10 BW   Ironwood Pharmaceuticals to Present at Wedbush Securities 2011 Life Sciences Management Access Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2015 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2016 15117K10 BW   Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/23/2010 0068K6-E BW   Acceleron and Collaborators Publish Two Papers on ACE-041, a Novel Angiogenesis Inhibitor, in Journal of Experimental Medicine and Molecular Cancer Therapeutics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/01/2013 74587V10 BW   Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 2/07/2012 0012X3-E  BW   Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development",#N/A, 2/18/2014 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in March, 9/24/2012 SPPI-US   BW   Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL),#N/A, 3/14/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 2/22/2010 68375N10 BW   OPKO Health Announces Collaboration with Mexican Research Center,#N/A,#N/A," 3/07/2015 01535110 BW   New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities and Growth Deficiencies, Presented in Late-Breaking Oral Session at ENDO 2015",#N/A," 1/21/2015 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015",#N/A, 4/30/2014 09062X10    BW   New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity,"11/30/2010 45253H10 BW   ImmunoGen, Inc. Announces Initiation of Randomized Clinical Trial Evaluating IMGN901 for First-Line Treatment of Small-Cell Lung Cancer",#N/A, 7/08/2016 071VWR-E     BW   European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2014 45337C10 BW   Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies,#N/A,#N/A, 6/21/2011 G0176710 BW   BYDUREON™ Receives Marketing Authorization in Europe, 2/07/2011 15708510 BW   Cerus to Present at the 13th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A, 5/15/2013 30161Q10 BW   Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting,11/02/2012 0CN68B-E  BW   EquipNet to Conduct Live On Site and Webcast Auction by order of Panmira Pharmaceuticals, 6/05/2013 92532F10  BW   Vertex kündigt Datenpräsentation auf European Cystic Fibrosis Society Conference an,#N/A,#N/A,#N/A, 7/13/2010 ACAD-US  BW   Research and Markets: (ACAD)ACADIA PHARMACEUTICALS INC - Quantitative Valuation Report,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/09/2011 46333X10 BW   Ironwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 ALNY-US   BW   Alnylam to Present New Clinical Results with Investigational RNAi Therapeutics at 57th Annual Meeting of the American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2016 15117K10 BW   Cellectis publie ses résultats financiers du quatrième trimestre et de l’exercice 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2010 0068K6-E BW   Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/26/2013 PBYI-US  BW   Puma Biotechnology to Present at Cowen Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 2/01/2012 53220K50  BW   Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings",#N/A, 2/13/2014 45232710    BW   Novogene Acquires an Illumina HiSeq X Ten Sequencing System, 9/19/2012 SPPI-US   BW   Spectrum Pharmaceuticals Initiates Phase 3 Study of ZEVALIN® in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form of Aggressive Non-Hodgkin’s Lymphoma,#N/A, 3/07/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 2/18/2010 68375N10 BW   OPKO Health Acquires Mexican Pharmaceutical Company,#N/A,#N/A, 3/02/2015 01535110 BW   FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia,#N/A, 1/12/2015 81257810    BW   Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies,#N/A, 4/29/2014 09062X10    BW   Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting,"11/19/2010 45253H10 BW   ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for IMGN388 at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics",#N/A, 6/28/2016 06CR5C-E     BW   U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2014 45337C10 BW   Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies,#N/A,#N/A, 6/15/2011 G0176710 BW   Alkermes Initiates Clinical Study of ALKS 5461 for Treatment-Resistant Depression, 1/04/2011 PFE-US   BW   Maven Semantic: Lung Disease Research Database,#N/A,#N/A,#N/A,#N/A, 5/08/2013 30161Q10 BW   Exelixis Announces Webcasts of Upcoming Investor Conference Presentations,11/01/2012 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2012 Financial Results, 6/05/2013 VRTX-US   BW   Vertex dévoile la teneur des données qui seront présentées à la conférence de l'European Cystic Fibrosis Society,#N/A,#N/A,#N/A," 6/02/2010 00422510 BW   ACADIA Pharmaceuticals To Present at the Ninth Annual Needham Healthcare Conference on June 9, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2011 46333X10 BW   Ironwood Pharmaceuticals to Host Second Quarter 2011 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/03/2015 ALNY-US   BW   Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/07/2016 CLLS-FR  BW   Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2013 74587V10 BW   Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/01/2012 53220K50  BW   Ligand to Report Fourth Quarter Results on February 7,#N/A," 2/12/2014 45232710    BW   Illumina Launches the Illumina Accelerator Program, World’s First Genomics Incubator", 9/13/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at UBS Global Life Sciences Conference in New York City on September 20th,#N/A, 2/28/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A, 2/11/2010 68375N10 BW   OPKO Health Announces Development of Blood Test for Alzheimer’s Disease,#N/A,#N/A, 2/27/2015 01535110 BW   Alexion erhält positive Stellungnahmen des CHMP für wichtige Aktualisierungen der EU-Fachinformation zu Soliris® (Eculizumab),#N/A, 1/06/2015 81257810    BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A, 4/24/2014 BIIB-US     BW   Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership,"11/17/2010 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data Presentations at the 52nd ASH Annual Meeting and Exposition",#N/A," 6/23/2016 071VWR-E     BW   European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2014 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 6/14/2011 G0176710 BW   Alkermes' Corporate Presentation to be Webcast at the NASDAQ OMX 26th Investor Program,11/16/2010 15708510 BW   Cerus’ INTERCEPT Blood System for Plasma Receives Swiss Approval,#N/A,#N/A,#N/A,#N/A, 5/07/2013 30161Q10 BW   Exelixis Announces First Quarter 2013 Financial Results,10/31/2012 SNY-FR    BW   Genzyme Announces Publication of LEMTRADATM (alemtuzumab) Pivotal Studies in The Lancet, 6/05/2013 92532F10  BW   Vertex kündigt Webcast seiner Präsentation auf der 34. Jahreskonferenz zum Gesundheitswesen von Goldman Sachs an,#N/A,#N/A,#N/A, 5/10/2010 00422510 BW   ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/27/2011 46333X10 BW   Ironwood Pharmaceuticals and Depomed Announce Collaboration, Research and License Agreement",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2015 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming November Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/01/2016 CLLS-FR  BW   Calyxt, filiale de Cellectis, acquiert un terrain pour y installer son siège social",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/06/2013 74587V10 BW   Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/04/2012 53220K50  BW   Ligand to Present at the Biotech Showcase Conference on January 10th,#N/A, 1/28/2014 45232710    BW   Illumina Reports Strong Finish to Fourth Quarter and Fiscal Year 2013," 9/11/2012 SPPI-US   BW   Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer",#N/A, 2/26/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2015 01535110 BW   Alexion reçoit l'avis positif du CHMP en faveur d'importantes mises à jour de l'étiquette de Soliris® (éculizumab) dans l'UE,#N/A,12/18/2014 81257810    BW   Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia,#N/A, 4/23/2014 09062X10    BW   Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise,"11/10/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Lazard Capital Markets 7th Annual Healthcare Conference",#N/A," 6/20/2016 06TW1B-E     BW   Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2014 45337C10 BW   Incyte and MedImmune Announce Collaboration on Immuno-Oncology Combination Clinical Trial,#N/A,#N/A, 5/31/2011 G0176710 BW   Alkermes’ Corporate Presentation to Be Webcast at Two Upcoming Conferences,11/12/2010 15708510 BW   Cerus to Present at the Stephens Fall Investment Conference,#N/A,#N/A,#N/A,#N/A, 5/07/2013 30161Q10 BW   Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting,10/31/2012 SNY-FR    BW   Sanofi Selects Medidata Clinical Cloud as a Technology Standard Across Global R&D Organization, 6/05/2013 92532F10  BW   Vertex Announces Webcast of its Presentation at the Goldman Sachs 34th Annual Global Healthcare Conference,#N/A,#N/A,#N/A," 5/05/2010 00422510 BW   ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference on May 12, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2011 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentations at Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2015 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/01/2016 CLLS-FR  BW   Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2012 74587V10 BW   Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/21/2011 LGND-US   BW   Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly,#N/A, 1/21/2014 45232710    BW   Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®, 9/07/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present Corporate Update at Rodman & Renshaw Annual Global Investment Conference in New York City on September 10th and at Morgan Stanley Global Healthcare Conference in New York City on September 11th,#N/A, 2/13/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2015 ALXN-US  BW   Alexion Receives CHMP Positive Opinions for Important Updates to the EU Label for Soliris® (eculizumab),#N/A,12/10/2014 81257810    BW   Seattle Genetics und Takeda verkünden Vier-Jahres-Überlebensdaten der zulassungsrelevanten Studie zu ADCETRIS® (Brentuximab Vedotin) bei rezidiviertem oder refraktärem systemisch anaplastisch-großzelligem Lymphom auf der...,#N/A, 4/14/2014 09062X10    BW   Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting,"11/02/2010 45253H10 BW   ImmunoGen, Inc. Announces Presentations at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics",#N/A, 6/15/2016 0056YC-E     BW   AHF’s ‘Gilead Greed Kills!’ Protest Continues Shaming of AIDS & Hepatitis C Drug Maker over Pricing & Policies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2014 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/17/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the UBS Global Specialty Pharmaceuticals Conference,11/12/2010 15708510 BW   Cerus to Present at the Lazard Capital Markets 7th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A, 4/17/2013 30161Q10 BW   Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call,10/25/2012 80105N10  BW   Sanofi T3 2012 - Interview du Directeur Financier Jérôme Contamine, 6/05/2013 92532F10  BW   Vertex Announces Presentation of Data at European Cystic Fibrosis Society Conference,#N/A,#N/A,#N/A," 5/03/2010 00422510 BW   ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 10, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2011 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2011 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2015 ALNY-US   BW   Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/19/2016 15117K10 BW   Cellectis signe avec CELLforCURE un accord de production de lots cliniques de produit candidat UCART123 ciblant des tumeurs hématologiques,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2012 74587V10 BW   Puma Biotechnology Reports Third Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/12/2011 53220K50  BW   Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology,#N/A, 1/16/2014 45232710    BW   Illumina Unveils Strategic Roadmap for Market Expansion, 9/06/2012 ALTH-US   BW   Spectrum Pharmaceuticals Completes Acquisition of Allos Therapeutics; Effective and Swift Integration Expected to Result In Significant Synergies,#N/A, 2/06/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2015 01535110 BW   Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015,#N/A,12/09/2014 81257810    BW   Seattle Genetics e Takeda Anunciam Dados de Sobrevida em Quatro Anos do Estudo Principal do ADCETRIS® (Brentuximabe Vedotina) em Linfoma Anaplásico de Grandes Células Sistêmico Refratário ou Recidivante na Reunião Anual da ASH,#N/A, 4/10/2014 09062X10    BW   Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer,"10/28/2010 45253H10 BW   ImmunoGen, Inc. Reports First Quarter Fiscal Year 2011 Financial Results",#N/A," 6/13/2016 05KRQ7-E     BW   Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2014 45337C10 BW   Incyte Reports 2014 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 5/11/2011 G0176710 BW   Alkermes to Host Conference Call to Discuss Fiscal Year 2011 Financial Results,11/10/2010 15708510 BW   Cerus Corporation Prices Public Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A, 4/12/2013 07G69B-E BW,10/25/2012 80105N10  BW   Sanofi Q3 2012 - Interview with CFO Jérôme Contamine, 5/17/2013 VRTX-US   BW   Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015,#N/A,#N/A,#N/A, 4/14/2010 00422510 BW   Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals’ First Phase III Trial With Pimavanserin for Parkinson’s Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2011 46333X10 BW   Ironwood Pharmaceuticals to Host First Quarter 2011 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/14/2015 ALNY-US   BW   Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/19/2016 15117K10 BW   Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2012 74587V10 BW   Puma Biotechnology to Present at Lazard Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/07/2011 53220K50  BW   Ligand to Present at the Oppenheimer Healthcare Conference on December 14,#N/A, 1/15/2014 45232710    BW   Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test, 9/04/2012 ALTH-US   BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics,#N/A, 2/01/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2015 01535110 BW   Alexion to Present at Investor Conferences,#N/A,12/09/2014 81257810    BW   Seattle Genetics y Takeda anuncian datos de sobrevida a cuatro años del ensayo pivotal de ADCETRIS® (brentuximab vedotina) en pacientes con linfoma anaplásico de células grandes sistémico recurrente o refractario...,#N/A, 4/10/2014 09062X10    BW   Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A,"10/21/2010 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2011 Financial Results",#N/A, 6/09/2016 GILD-US      BW   AHF Zaps Gilead with Lively AIDS Drug Protest During Swank Goldman Sachs Confab in Rancho Palos Verdes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2014 45337C10 BW   Incyte to Report First Quarter 2014 Financial Results on May 1,#N/A,#N/A, 5/09/2011 G0176710 BW   Alkermes Presents Phase 2 Data of ALKS 37 in Late-Breaking Oral Session at Digestive Disease Week Meeting,"11/03/2010 15708510 BW   Cerus Awarded $489,000 Under U.S. Qualified Therapeutic Discovery Project Program",#N/A,#N/A,#N/A,#N/A, 4/09/2013 30161Q10 BW   Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model,10/23/2012 00DVZ0-E  BW   Aggredyne Names Two New Directors, 5/10/2013 VRTX-US   BW   Vertex Pharmaceuticals annonce des diffusions Web de ses présentations lors de deux conférences destinées aux investisseurs,#N/A,#N/A,#N/A," 3/09/2010 00422510 BW   ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2009",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2011 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at Bank of America Merrill Lynch 2011 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2015 ALNY-US   BW   Alnylam Advances New Innovations in RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 CLLS-FR  BW   Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2012 74587V10 BW   Puma Biotechnology Closes $138 Million Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/08/2011 53220K50  BW   Ligand Pharmaceuticals Announces Third Quarter Results,#N/A," 1/15/2014 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on Tuesday, January 28, 2014", 8/30/2012 84763A10  BW   Spectrum Pharmaceuticals to Present Corporate Update at Stifel Nicolaus Healthcare Conference in Boston on September 6th and at BioCentury NewsMakers Conference in New York City on September 7th,#N/A, 1/25/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2015 01535110 BW   New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset Hypophosphatasia Accepted as Late-Breaking Abstracts at the ENDO 2015 Annual Meeting,#N/A,"12/09/2014 81257810    BW   Seattle Genetics y Takeda dan a conocer datos del ensayo clínico de fase 3 AETHERA, de ADCETRIS® (brentuximab vedotina) en pacientes trasplantados por linfoma de Hodgkin con riesgo de recidiva en la Asamblea Anual de la Sociedad Estadounidense de....",#N/A," 3/31/2014 09062X10    BW   Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014","10/19/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 6/09/2016 05F9ZW-E     BW   Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2014 45337C10 BW   Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera,#N/A,#N/A, 5/09/2011 G0176710 BW   Alkermes to Merge with Elan Drug Technologies to Create Alkermes plc,10/28/2010 15708510 BW   Cerus Corporation Reports Third Quarter Results,#N/A,#N/A,#N/A,#N/A, 2/25/2013 30161Q10 BW   Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference,10/23/2012 VSTM-US   BW   Dr. Joanna Horobin Joins Verastem as Chief Medical Officer, 5/10/2013 92532F10  BW   Vertex Pharmaceuticals kündigt Webcasts seiner Präsentationen auf zwei Anlegerkonferenzen an,#N/A,#N/A,#N/A," 3/02/2010 00422510 BW   ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 9, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2011 46333X10 BW   Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/08/2015 ALNY-US   BW   Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/11/2016 15117K10 BW   Cellectis a élaboré une nouvelle architecture de CAR permettant de contrôler les fonctions des cellules CAR T,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/22/2012 PBYI-US  BW   Puma Biotechnology Announces Underwriters’ Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/07/2011 53220K50  BW   Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting,#N/A, 1/14/2014 45232710    BW   Illumina Launches the NextSeq™ 500 Sequencing System," 8/28/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012",#N/A, 1/24/2013 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2015 01535110 BW   Alexion to Present at the 2015 Leerink Global Healthcare Conference,#N/A,12/09/2014 81257810    BW   Seattle Genetics e Takeda divulgam dados do estudo clínico de fase III AETHERA do ADCETRIS® (Brentuximab Vedotin) em pacientes pós-transplante por linfoma de Hodgkin com risco de recaída no encontro anual da ASH,#N/A," 3/28/2014 09062X10    BW   FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart","10/11/2010 45253H10 BW   ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for Lorvotuzumab Mertansine at ESMO Annual Meeting",#N/A," 6/07/2016 GILD-US      BW   Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2014 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/03/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference,10/12/2010 15708510 BW   CSL Limited and Cerus Corporation Enter Distribution Agreement for the INTERCEPT Blood System in Australia and New Zealand,#N/A,#N/A,#N/A,#N/A, 2/21/2013 30161Q10 BW   Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ™ European Distributor for Medullary Thyroid Cancer,10/22/2012 80105N10  BW   Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia, 5/09/2013 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A," 2/01/2010 00422510 BW   ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2011 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at Cowen and Company Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/01/2015 ALNY-US   BW   Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2016 15117K10 BW   Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/18/2012 74587V10 BW   Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/02/2011 53220K50  BW   Ligand Announces Successful Phase II Results for Captisol®-Enabled Propylene Glycol-Free Melphalan,#N/A, 1/14/2014 45232710    BW   Illumina Introduces the HiSeq X™ Ten Sequencing System, 8/24/2012 84763A10  BW   Spectrum Pharmaceuticals Celebrates 10 Years of Delivering Better Treatment Options to Cancer Patients and Building Shareholder Value,#N/A,12/20/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/29/2015 01535110 BW   Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015",#N/A,"12/09/2014 81257810    BW   Seattle Genetics et Takeda présentent, à l’occasion du congrès annuel de l’ASH, les données de l'essai clinique AETHERA de phase III portant sur l’utilisation d’ADCETRIS® (brentuximab védotine) chez des patients atteints d’un ...",#N/A, 3/21/2014 09062X10    BW   Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B,"10/11/2010 45253H10 BW   ImmunoGen, Inc. Announces Conference Call at 8:30 am ET October 11, 2010 to Discuss New Collaboration and Updated Guidance for Fiscal Year 2011",#N/A," 5/31/2016 06CR5C-E     BW   AHF Calls on FDA, Congress to Investigate Gilead Sciences Over HIV/AIDS Drug Patent Manipulation",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2014 45337C10 BW   Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs,#N/A,#N/A," 4/27/2011 G0176710 BW   Data on VIVITROL®, the New FDA-Approved Medication for Prevention of Relapse to Opioid Dependence, Published in The Lancet","10/06/2010 15708510 BW   Cerus to Release Third Quarter Results on October 28, 2010",#N/A,#N/A,#N/A,#N/A, 2/21/2013 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results,10/18/2012 80105N10  BW, 4/30/2013 92532F10  BW   Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2011 46333X10 BW   Ironwood Pharmaceuticals Provides Fourth Quarter 2010 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/28/2015 ALNY-US   BW   Alnylam Granted Summary Judgment by United States District Court for the District of Massachusetts in Tuschl II Patent Inventorship Dispute,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2016 15117K10 BW   Cellectis annonce la nomination d’une directrice médicale,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2012 PBYI-US  BW   Puma Biotechnology to Present at UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/24/2011 53220K50  BW   Save-the-Date: Ligand Hosting Promacta Panel Discussion on November 7,#N/A, 1/09/2014 45232710    BW   Illumina Announces Recipients of Agricultural Greater Good Initiative Grants, 8/23/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Discuss Overall Business Strategy Including FUSILEV® Growth at the Southern California Investor Conference in Newport Beach,#N/A,12/18/2012 SHP-IE   BW   Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2015 01535110 BW   Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015,#N/A,12/08/2014 81257810    BW   Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting,#N/A, 3/18/2014 09062X10    BW   Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a),"10/11/2010 45253H10 BW   ImmunoGen, Inc. Announces Updated Guidance for 2011 Fiscal Year",#N/A," 5/27/2016 GILD-US      BW   SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2014 45337C10 BW   Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies,#N/A,#N/A, 4/15/2011 G0176710 BW   Bydureon™ Recommended for Approval in Europe, 9/27/2010 15708510 BW   Cerus' INTERCEPT Platelet System Succeeds in 3-Year French Study,#N/A,#N/A,#N/A,#N/A, 2/07/2013 30161Q10 BW   Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call,10/12/2012 SNY-FR    BW   Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability," 4/25/2013 92532F10  BW   Vertex gibt neue Daten bekannt, die hohe virale Heilungsraten bei einer Telaprevir-Kombinationsbehandlung von insgesamt 12 und 24 Wochen bei Hepatitis-C-Patienten (Genotyp 1) mit dem IL28B-CC-Genotyp zeigten",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2011 46333X10 BW   Ironwood Pharmaceuticals to Host Fourth Quarter 2010 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/28/2015 ALNY-US   BW   Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers and Oligomers in TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients with Familial Amyloidotic Polyneuropathy (FAP)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/23/2015 CLLS-FR  BW   Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/29/2012 PBYI-US  BW   Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/19/2011 53220K50  BW   Ligand to Report Third Quarter Results on November 8,#N/A, 1/09/2014 45232710    BW   Illumina to Provide Next-Generation Sequencing (NGS) Technologies to Quest Diagnostics, 8/17/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A,12/14/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/21/2015 01535110 BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015",#N/A,12/08/2014 81257810    BW   Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting,#N/A, 3/17/2014 BIIB-US     BW   Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec,"10/11/2010 45253H10 BW   ImmunoGen, Inc. Announces Collaboration for Rights to Use ImmunoGen’s TAP Technology",#N/A, 5/27/2016 080RQG-E     BW   European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/27/2014 45337C10 BW   Incyte to Report Fourth Quarter/Year-End 2013 Financial Results on February 12,#N/A,#N/A, 3/10/2011 G0176710 BW   Exenatide Once Monthly Showed Positive Results in Phase 2 Study, 9/23/2010 15708510 BW   Cerus Awarded $1.4 Million to Advance Development of Pathogen Inactivation for Red Blood Cells,#N/A,#N/A,#N/A,#N/A, 2/06/2013 30161Q10 BW   Exelixis Announces Webcast of February 12th Presentation at the 15th Annual BIO CEO & Investor Conference,10/09/2012 0632W7-E  BW   Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics," 4/25/2013 VRTX-US   BW   Vertex annonce de nouveaux résultats indiquant des taux de guérison virale élevés pour une durée totale de 12 et 24 semaines de traitement d'association avec le télaprévir, chez des patients atteints d'hépatite C de génotype...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/18/2011 46333X10 BW   Ironwood and Protagonist Establish Collaboration for Peptide Drug Discovery and Development,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/15/2015 ALNY-US   BW   Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/23/2015 15117K10 BW   Cellectis a soumis une demande d’essai clinique pour UCART19, un produit allogénique fondé sur des cellules CAR-T ciblant les tumeurs hématologiques",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/14/2012 74587V10 BW   Puma Biotechnology Reports Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/19/2011 53220K50  BW   Ligand Enters into Platform Captisol® License Agreement with SAGE Therapeutics,#N/A,12/23/2013 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Events in January, 8/15/2012 SPPI-US   BW   Spectrum Pharmaceuticals Launches a Broad-based FUSILEV® Marketing Campaign; Increases Sales Force Footprint,#N/A,12/07/2012 ARWR-US  BW   Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2015 01535110 BW   Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Data in Adults with HPP at ENDO 2015 Annual Meeting,#N/A,12/08/2014 81257810    BW   Seattle Genetics et Takeda annoncent les données de survie sur quatre ans issues de l’étude pivot ADCETRIS® (brentuximab vedotin) portant sur le lymphome anaplasique systémique à grandes cellules récurrent ou réfractaire...,#N/A, 3/05/2014 09062X10    BW   Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments,"10/08/2010 45253H10 BW   ImmunoGen, Inc. Announces Positive Interim Results in Randomized Clinical Trial Comparing Trastuzumab-DM1 vs. Standard First-Line Therapy for First-Line HER2+ Metastatic Breast Cancer",#N/A," 5/24/2016 GILD-US      BW   Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/14/2014 45337C10 BW   Incyte Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),#N/A,#N/A, 3/03/2011 G0176710 BW   DURATION-6 Top-Line Study Results Announced, 9/08/2010 15708510 BW   Cerus to Present at the Robert W. Baird 2010 Health Care Conference,#N/A,#N/A,#N/A,#N/A, 1/24/2013 30161Q10 BW   Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available in the U.S.,10/09/2012 SNY-FR    BW   Genzyme to Present New Data from AUBAGIO® and LEMTRADATM Clinical Development Programs at ECTRIMS, 4/24/2013 92532F10  BW   Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2011 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2015 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming September Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/21/2015 CLLS-FR  BW   Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2012 PBYI-US  BW   Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/10/2011 53220K50  BW   Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®,#N/A,11/19/2013 45232710    BW   Illumina’s MiSeqDxTM Receives FDA Premarket Clearance with Two Cystic Fibrosis Assays and Universal Kit for Open Use, 8/14/2012 SPPI-US   BW   Spectrum Pharmaceuticals Commences Patient Enrollment in Randomized Phase 2b Clinical Trial of Ozarelix for Hormone-Dependent Prostate Cancer,#N/A,12/06/2012 ARWR-US  BW   Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/07/2015 01535110 BW   Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients,#N/A,12/08/2014 81257810    BW   Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting,#N/A, 2/25/2014 09062X10    BW   Biogen Idec to Present at the Cowen & Company 34th Annual Health Care Conference," 9/21/2010 45253H10 BW   ImmunoGen, Inc. Announces Start of SAR566658 Clinical Testing",#N/A," 5/20/2016 GILD-US      BW   Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 45337C10 BW   Incyte Names Hervé Hoppenot President and Chief Executive Officer,#N/A,#N/A, 2/28/2011 G0176710 BW   Alkermes’ Corporate Presentation to Be Webcast at the Cowen Health Care Conference, 9/07/2010 15708510 BW   Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood System,#N/A,#N/A,#N/A,#N/A,12/13/2012 EXEL-US  BW   Exelixis Announces Webcast of January 9 Presentation at the J.P. Morgan 31st Annual Healthcare Conference,10/04/2012 SNY-FR    BW   Research and Markets: Sanofi (SAN): Company Profile and SWOT Analysis 2012 is Essential Reading for the Pharma Industry, 4/24/2013 VRTX-US   BW   L’étude de cinétique virale de l’ALS-2200 (VX-135) montre une réduction significative des taux d’ARN-VHC chez les personnes atteintes d’hépatite C de génotype et de la cirrhose...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at Credit Suisse 2010 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/08/2015 ALNY-US   BW   Alnylam Accelerates Development of ALN-GO1, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2015 CLLS-FR  BW   Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2012 PBYI-US  BW   Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/07/2011 53220K50  BW   Ligand to Present at the BioCentury NewsMakers Conference on October 21,#N/A,11/19/2013 45232710    BW   Illumina to Webcast Live Presentation at the Piper Jaffray Annual Healthcare Conference, 8/10/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Authorization Of Stock Repurchase Program up to $100 Million,#N/A,11/27/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2015 01535110 BW   Alexion to Present at the J.P. Morgan 33rd Annual Healthcare Conference,#N/A,12/08/2014 81257810    BW   Seattle Genetics und Takeda veröffentlichen auf ASH-Jahrestagung Daten der klinischen Phase-3-Studie AETHERA für ADCETRIS® (Brentuximab Vedotin) bei Hodgkin-Lymphom-Patienten mit Rückfallrisiko nach einer ...,#N/A, 2/18/2014 09062X10    BW   Biogen Idec to Present at the 2014 RBC Capital Markets’ Healthcare Conference," 9/02/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September",#N/A," 5/17/2016 00CK58-E     BW   Nimbus Therapeutics Announces Closing of Gilead Sciences’ Acquisition of Nimbus Apollo, Inc., and its Acetyl-CoA Carboxylase (ACC) Inhibitor Program",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2013 45337C10 BW   Incyte to Present at the 32nd Annual J. P. Morgan Healthcare Conference,#N/A,#N/A, 2/08/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the BIO CEO & Investor Conference, 9/02/2010 15708510 BW   Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet Study,#N/A,#N/A,#N/A,#N/A,11/29/2012 30161Q10 BW   Exelixis Announces EMA Acceptance of Marketing Authorization Application For COMETRIQ™ (cabozantinib),10/03/2012 SNY-FR    BW   Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement," 4/23/2013 92532F10  BW   ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 46333X10 BW   Ironwood Pharmaceuticals Provides Third Quarter 2010 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2015 ALNY-US   BW   ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2015 CLLS-FR  BW   Cellectis Announces Presentations at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2012 PBYI-US  BW   Puma Biotechnology to Present at Jefferies Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/26/2011 53220K50  BW   Ligand to Present at the Stifel Nicolaus Healthcare Conference on September 9,#N/A,"11/15/2013 00BDDM-E    BW   CORRECTING and REPLACING Oxford Nanopore Announces Secondary Placing, Divestment of Illumina"," 8/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals Reports Record Revenues and Strong Profits for Second Quarter; Revenues of $68.7 Million up 51.5% over Last Year and Strong non-GAAP EPS of $0.37, up 48% over Last Year",#N/A,11/13/2012 ARWR-US  BW   Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/30/2014 01535110 BW   Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia,#N/A,12/07/2014 81257810    BW   Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting,#N/A, 2/15/2014 09062X10    BW   William D. Young To Retire From Biogen Idec’s Board of Directors, 8/27/2010 45253H10 BW   Genentech Receives Refuse to File Letter from FDA for T-DM1,#N/A," 5/09/2016 07MDY1-E     BW   Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2013 45337C10 BW   Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Myelofibrosis,#N/A,#N/A, 1/27/2011 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2011, 8/24/2010 15708510 BW   Cerus Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOne,#N/A,#N/A,#N/A,#N/A,"11/29/2012 30161Q10 BW   FDA Approves COMETRIQ™ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer",10/02/2012 80105N10  BW   Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint," 4/19/2013 92532F10  BW   Behandlung mit VX-661 und Ivacaftor zeigte in Phase-2-Studie statistisch signifikante Verbesserungen der Lungenfunktion bei Patienten mit Mukoviszidose, die zwei Kopien der F508del-Mutation aufweisen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2015 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/19/2015 15117K10 BW   Servier exerce son option de licence exclusive et mondiale conclue avec Cellectis pour UCART19, une thérapie allogénique fondée sur des cellules CAR-T ciblant les tumeurs hématologiques",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/17/2012 PBYI-US  BW   Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/08/2011 GSK-GB    BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A,11/11/2013 45232710    BW   Illumina Names Francis deSouza as President, 8/03/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A,11/12/2012 ARWR-US  BW   Arrowhead Research to Present at BIO-Europe 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/15/2014 01535110 BW   Alexion Announces $500 Million Share Repurchase Program,#N/A,12/06/2014 81257810    BW   Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting,#N/A, 2/03/2014 09062X10    BW   TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis," 8/18/2010 45253H10 BW   ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer",#N/A," 4/29/2016 080RQG-E     BW   European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/09/2013 45337C10 BW   Jakafi® (ruxolitinib) Continues to Show Improved Overall Survival for Patients with Myelofibrosis in Further Analyses of Phase III Data Presented at 2013 ASH,#N/A,#N/A, 1/07/2011 G0176710 BW   Alkermes Provides Update on Advancing Product Portfolio and Outlines Business Goals for 2011, 7/29/2010 15708510 BW   Cerus Corporation Reports Second Quarter Revenues,#N/A,#N/A,#N/A,#N/A,11/07/2012 EXEL-US  BW   Exelixis Announces Third Quarter 2012 Financial Results,10/01/2012 SNY-FR    BW   Genzyme Announces Winners of Patient Advocacy Leadership Awards, 4/19/2013 92532F10  BW   Le traitement au VX-661 et à l'ivacaftor au cours d'une étude de phase II a révélé des améliorations statistiquement significatives de la fonction pulmonaire chez les personnes atteintes de mucoviscidose présentant deux copies...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2010 46333X10 BW   Almirall and Ironwood Announce Positive Results from the Second Phase 3 Trial of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2015 ALNY-US   BW   Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/19/2015 CLLS-FR  BW   Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2012 PBYI-US  BW   Puma Biotechnology to Present at BofA Merrill Lynch Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/01/2011 53220K50  BW   Ligand to Report Second Quarter Results on August 8th,#N/A,11/01/2013 006KW9-E    BW   Verinata Health’s verifi® Prenatal Test Available through the California Prenatal Screening Program, 8/02/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Publication in the Journal of Clinical Oncology of Encouraging ZEVALIN Data in Patients with Mantel-Cell Lymphoma,#N/A,10/29/2012 ARWR-US  BW   Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2014 0C6ZGM-E BW   X-Chem and Alexion Collaborate to Discover Novel Therapeutic Candidates to Treat Patients with Severe and Ultra-Rare Disorders,#N/A,12/06/2014 81257810    BW   Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting,#N/A, 1/30/2014 BIIB-US     BW   Biogen Idec Foundation Awards Museum of Science $2.5 Million to Support Hall of Human Life," 8/04/2010 45253H10 BW   ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results",#N/A, 4/28/2016 GILD-US      BW   Gilead Sciences Announces Second Quarter 2016 Dividend,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2013 45337C10 BW   Incyte to Present at the Oppenheimer 24th Annual Healthcare Conference,#N/A,#N/A, 1/04/2011 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference, 7/15/2010 CERS-US  BW   Aduro BioTech Announces Key Milestones in Advancing Its Leading Listeria-Based Immunotherapy Program,#N/A,#N/A,#N/A,#N/A,11/05/2012 30161Q10 BW   Exelixis Announces Webcasts of Upcoming Investor Conference Presentations in November, 9/25/2012 SNY-FR    BW   Scientists Rank Genzyme Among Best Employers, 4/18/2013 92532F10  BW   Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2010 46333X10 BW   Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2015 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2015 15117K10 BW   Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2012 74587V10 BW   Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/26/2011 53220K50  BW   Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta® PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia,#N/A,"10/28/2013 006X4F-E    BW   Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and Aggregating Complex Genomic Data", 8/01/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2012 Financial Results Teleconference and Webcast,#N/A,10/16/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/10/2014 01535110 BW   Neue, auf der Jahrestagung der ASH vorgestellte Ergebnisse vertiefen das klinische Verständnis von aHUS und PNH und bestätigen die Wirksamkeit der Behandlung mit Soliris® (Eculizumab)",#N/A,"11/18/2014 81257810    BW   Seattle Genetics Names New General Counsel and Executive Vice President, Legal Affairs",#N/A, 1/30/2014 09062X10    BW   Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia," 7/29/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences",#N/A, 4/28/2016 GILD-US      BW   Gilead Sciences Announces First Quarter 2016 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2013 45337C10 BW   Incyte Completes Offering of $750 Million of Convertible Senior Notes,#N/A,#N/A,12/08/2010 G0176710 BW   Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol Dependence," 7/12/2010 15708510 BW   Cerus to Release Second Quarter Results on July 29, 2010",#N/A,#N/A,#N/A,#N/A,10/25/2012 30161Q10 BW   Exelixis Announces November 7th Webcast of Third Quarter 2012 Financial Results Conference Call, 9/24/2012 SNY-FR    BW   Sanofi Selects BioClinica’s OnPoint as Enterprise CTMS, 4/05/2013 92532F10  BW   Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/27/2015 ALNY-US   BW   Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2015 15117K10 BW   Cellectis publie ses résultats financiers du troisième trimestre et pour les neuf premiers mois de 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2012 0C4KPC-E BW   Puma Biotechnology to Present at Cowen Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 6/29/2011 LGND-US   BW   Ligand Pharmaceuticals, Inc. Secures $10 Million from Square 1 Bank",#N/A,10/22/2013 45232710    BW   Illumina Launches TruGenome Undiagnosed Disease Test, 7/30/2012 84763A10  BW   Spectrum Pharmaceuticals Named One of the Best Places to Work in Orange County,#N/A, 9/05/2012 ARWR-US  BW   Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2014 01535110 BW   Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis,#N/A,11/07/2014 81257810    BW   Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014,#N/A, 1/29/2014 09062X10    BW   Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion," 7/28/2010 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2010 Financial Results",#N/A," 4/25/2016 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2013 45337C10 BW   Incyte Prices Offering of $700 Million of Convertible Senior Notes,#N/A,#N/A,11/16/2010 G0176710 BW   Alkermes Presents Promising Preclinical Data on ALKS 33 for Multiple Disease Indications at Annual Meeting of the Society for Neuroscience," 6/30/2010 15708510 BW   Study Results Presented at International Transfusion Congress Highlight Cerus' Progress Toward Improving the Safety of Platelets, Plasma and Red Blood Cells",#N/A,#N/A,#N/A,#N/A, 9/30/2012 EXEL-US  BW   Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2012 Congress," 9/21/2012 EXEL-US   BW   Research and Markets: Exelixis Inc. - Company Analysis: Assess the Potential of Cabozantinib Based on Market Size, Phase III Results, and Future Indications"," 4/01/2013 92532F10  BW   Vertex to Report First Quarter 2013 Financial Results on Tuesday, April 30",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2010 46333X10 BW   Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/20/2015 ALNY-US   BW   Alnylam Initiates Phase 3 Open Label Extension Study (“APOLLO-OLE”) with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 CLLS-FR  BW   Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 0C4KPC-E BW   Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 6/22/2011 53220K50  BW   Ligand to Advance Clinical Development of Captisol-enabled®, Propylene Glycol-Free Melphalan for Multiple Myeloma",#N/A,10/21/2013 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2013, 7/26/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Publication Demonstrating Enhanced Survival with ZEVALIN in Premier Medical Journal Blood,#N/A, 8/30/2012 008759-E BW   Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2014 01535110 BW   De nouvelles données présentées lors de l’Assemblée annuelle de l’ASH améliorent les connaissances cliniques sur le SHUa et la HPN et soulignent l’efficacité du traitement sous Soliris® (éculizumab),#N/A,11/04/2014 81257810    BW   Seattle Genetics to Present at Credit Suisse Healthcare Conference,#N/A," 1/15/2014 09062X10    BW   Biogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014"," 6/24/2010 45253H10 BW   ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial",#N/A," 4/21/2016 GILD-US      BW   Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2013 45337C10 BW   Incyte Announces Proposed Offering of $700 Million of Convertible Senior Notes,#N/A,#N/A,11/10/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference," 5/19/2010 15708510 BW   Cerus Appoints William ""Obi"" Greenman as Chief Business Officer",#N/A,#N/A,#N/A,#N/A, 9/30/2012 09H17G-E BW   Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012, 9/20/2012 SNY-FR    BW   Genzyme Convenes 4th Annual Gaucher Leadership Forum in Munich, 3/04/2013 92532F10  BW   VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2010 46333X10 BW   Almirall and Ironwood Announce Positive Results from a Phase 3 Trial with Linaclotide in Patients with Irritable Bowel Syndrome with Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2015 ALNY-US   BW   Alnylam to Reschedule First RNAi Roundtable Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 15117K10 BW   Cellectis : UCART19 : première preuve de concept chez l’humain présentée lors de la prochaine conférence annuelle de l’American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2012 0C4KPC-E BW   Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/20/2011 53220K50  BW   Reminder: Ligand to Webcast Analyst and Investor Day on June 23 in New York City,#N/A,"10/21/2013 45232710    BW   University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National Health Service Patients", 7/20/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/14/2012 ARWR-US  BW   Arrowhead Enters into Antibody Candidate Evaluation Agreement with Merck,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2014 01535110 BW   New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment,#N/A,10/30/2014 81257810    BW   Seattle Genetics Reports Third Quarter 2014 Financial Results,#N/A, 1/07/2014 09062X10    BW   Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference," 6/22/2010 45253H10 BW   ImmunoGen, Inc. Announces Vice President Promotions in Product Development",#N/A, 4/19/2016 0056YC-E     BW   AHF Seeks Partners to Distribute Standalone Version of Tenofovir (TAF); Files Amended Federal Complaint against Gilead over Disputed AIDS Drug Patent,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2013 45337C10 BW   Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs,#N/A,#N/A,11/05/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference, 5/18/2010 15708510 BW   Whittemore Peterson Institute and Cerus Confirm Inactivation of XMRV by the INTERCEPT Blood System,#N/A,#N/A,#N/A,#N/A, 9/29/2012 EXEL-US  BW   Exelixis Announces Data Presentation for GDC-0973 (XL518)," 9/20/2012 00CBJY-E  BW   Acton Pharmaceuticals Announces U.S. Food and Drug Administration Approval for AEROSPAN® (Flunisolide HFA, 80 mcg) Inhalation Aerosol for Asthma", 2/28/2013 92532F10  BW   Vertex meldet Einleitung eines Programms zulassungsrelevanter Studien zu VX-809 in Kombination mit Ivacaftor zur Behandlung von Patienten mit zwei Kopien der F508del-Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2015 02043Q10  BW   Alnylam to Host Second Annual Summer “RNAi Roundtable” Webcast Series,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2015 CLLS-FR  BW   Cellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/20/2011 53220K50  BW   Ligand Enters into Captisol® Commercial Supply Agreement with Merck,#N/A,10/14/2013 45232710    BW   Verinata Health’s verifi® Prenatal Test Expanded to Include Option to Test for Fetal Aneuploidy in Twin Pregnancies, 7/09/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the 2012 JMP Securities Healthcare Conference,#N/A, 8/13/2012 ARWR-US  BW   Arrowhead Reports Fiscal 2012 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2014 01535110 BW   NICE spricht endgültige positive Empfehlung für nationale Leistungsverrechnung von Soliris® (Eculizumab) für alle Patienten mit aHUS in England aus,#N/A,"10/14/2014 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial Results on October 30, 2014",#N/A, 1/02/2014 09062X10    BW   Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference," 6/07/2010 45253H10 BW   ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCO",#N/A, 4/16/2016 09966D-E     BW   Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2013 45337C10 BW   Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with Active Rheumatoid Arthritis,#N/A,#N/A,11/04/2010 G0176710 BW   Alkermes Reports Second Quarter Fiscal 2011 Financial Results, 4/29/2010 15708510 BW   Cerus Corporation Announces First Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A," 9/28/2012 EXEL-US  BW   Bristol-Myers Squibb Appoints Frances Heller Senior Vice President, Business Development"," 9/19/2012 060RWY-E  BW   BioTrends Announces a New Syndicated Report Series, LaunchTrends®: Aubagio", 2/27/2013 VRTX-US   BW   Vertex annonce le démarrage d’un programme pivot de Phase 3 portant sur le VX-809 pris en combinaison avec l’ivacaftor pour le traitement des personnes souffrant de fibrose kystique porteuses de deux copies de la mutation F508del,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2010 46333X10 BW   Ironwood Pharmaceuticals Provides Second Quarter 2010 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/23/2015 02043Q10  BW   Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2015 15117K10 BW   Implémentation réussie du processus de production de UCART19 selon les Bonnes Pratiques de Fabrication (BPF),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
" 6/06/2011 53220K50  BW   Ligand Presents Phase IIa Data on Captisol®-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011",#N/A,10/09/2013 45232710    BW   Illumina Launches Infinium® HTS-24 Arrays for Unparalleled Content and Sample Throughput Capacity, 7/06/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/13/2012 ARWR-US  BW   Arrowhead Raises $6.2 Million Through Registered Direct Offering of Common Stock and Warrants,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2014 01535110 BW   NICE publie une recommandation finale positive pour la mise en service nationale de Soliris® (eculizumab) pour tous les patients atteints du SHUa en Angleterre,#N/A,10/01/2014 81257810    BW   Seattle Genetics und Takeda berichten positive Ergebnisse der klinischen Phase-III-Studie AETHERA mit ADCETRIS® (Brentuximab Vedotin) zur Konsolidierung nach einer Transplantation bei Patienten mit Hodgkin-Lymphom,#N/A,12/17/2013 09062X10    BW   Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe," 6/05/2010 45253H10 BW   ImmunoGen, Inc. Announces Presentation of Clinical Data for Trastuzumab-DM1 at ASCO Annual Meeting",#N/A, 4/16/2016 09B1B0-E     BW   Gilead Presents New Data Highlighting Progress in Liver Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/10/2013 45337C10 BW   Incyte to Report Third Quarter 2013 Financial Results on October 31,#N/A,#N/A,10/28/2010 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011," 4/07/2010 15708510 BW   Cerus to Release First Quarter Results on April 29, 2010",#N/A,#N/A,#N/A,#N/A," 9/21/2012 EXEL-US  BW   Research and Markets: Exelixis Inc. - Company Analysis: Assess the Potential of Cabozantinib Based on Market Size, Phase III Results, and Future Indications"," 9/18/2012 060RWY-E  BW   More Than Half of Rheumatologists in Germany and Spain Reported they Tried Benlysta for their SLE Patients, According to a Recent BioTrends Report", 2/27/2013 92532F10  BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Second Quarter 2010 Investor Update Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/12/2015 02043Q10  BW   Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2015 15117K10 BW   Successful GMP Production Process for UCART19,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/06/2011 0786F6-E  BW   Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting,#N/A,"10/07/2013 45232710    BW   Illumina to Announce Third Quarter 2013 Financial Results on Monday, October 21, 2013", 7/03/2012 84763A10  BW   Spectrum Pharmaceuticals Launches Lucanthone Phase 2 Clinical Trial for the Treatment of Primary Glioblastoma Multiforme (GBM),#N/A, 8/09/2012 ARWR-US  BW   Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2014 01535110 BW   NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England,#N/A,10/01/2014 81257810    BW   Seattle Genetics y Takeda Anuncian Datos Positivos del Ensayo Clínico AETHERA de Fase 3 de DCETRIS® (Brentuximab Vedotina) para la Consolidación en el Linforma de Hodgkin Posterior al Trasplante,#N/A,12/09/2013 09062X10    BW   New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ and ELOCTATE™ Across Multiple Hemophilia Populations," 6/03/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences",#N/A, 4/15/2016 GILD-US      BW   Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/03/2013 INCY-US  BW   New ‘Voices of MPN’ Initiative Unites, Connects and Supports Community Affected by Rare Blood Cancers: Myeloproliferative Neoplasms (MPNs)",#N/A,#N/A,10/25/2010 G0176710 BW   Alkermes Announces Positive Results from Phase 1 Study of ALKS 33 in Combination with Buprenorphine for Treatment of Cocaine Addiction, 4/06/2010 15708510 BW   Cerus and Oxford Finance Corporation Enter into $10 Million Growth Capital Credit Facility,#N/A,#N/A,#N/A,#N/A, 9/17/2012 EXEL-US  BW   Exelixis Announces Data Presentations at ESMO 2012 Congress, 9/17/2012 RIBX-US   BW   Rib-X Pharmaceuticals Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Delafloxacin, 2/26/2013 92532F10  BW   Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Upcoming Presentation at Wedbush Life Sciences MAC Best Ideas 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2015 0098J6-E  BW   Dicerna Responds to Alnylam Complaint,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2015 15117K10 BW   Cellectis interviendra à l’occasion de plusieurs conférences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/03/2011 53220K50  BW   Ligand and The Medicines Company Agree to Worldwide License for Proprietary Captisol®-Enabled Intravenous Formulation of Clopidogrel,#N/A,10/07/2013 45232710    BW   Illumina Launches TruSight One Sequencing Panel, 6/21/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 8/07/2012 ARWR-US  BW   Arrowhead to Report Fiscal 2012 Third Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2014 01535110 BW   Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica,#N/A,10/01/2014 81257810    BW   Seattle Genetics e Takeda anunciam dados positivos do teste clínico de Fase III AETHERA do ADCETRIS® (Brentuximabe Vedotin) para consolidação pós-transplante por linfoma de Hodgkin,#N/A,"12/09/2013 BIIB-US     BW   Proteostasis Therapeutics Announces Collaboration with Biogen Idec for Research, Development and Commercialization of Therapies for Neurodegenerative Diseases"," 5/24/2010 45253H10 BW   ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting",#N/A," 4/04/2016 06CR5C-E     BW   U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2013 45337C10 BW   Incyte to Ring NASDAQ Stock Market Opening Bell in Support of Blood Cancer Awareness Month,#N/A,#N/A,10/12/2010 G0176710 BW   Alkermes Announces FDA Approval of VIVITROL® for Prevention of Relapse to Opioid Dependence, 3/31/2010 15708510 BW   Cerus Signs Agreement with Swiss Red Cross for Deployment of the INTERCEPT Blood System for Platelets,#N/A,#N/A,#N/A,#N/A, 8/30/2012 EXEL-US  BW   Exelixis Announces Webcasts of Upcoming Investor Conference Presentations, 9/13/2012 ALNY-US   BW   Alnylam to Webcast Presentation at UBS Global Life Sciences Conference," 2/02/2013 92532F10  BW   Republik Irland bewilligt Kostenübernahme für KALYDECO™ (Ivacaftor), das erste Arzneimittel zur Behandlung der zugrunde liegenden Ursache der Mukoviszidose bei Patienten mit einer bestimmten Genmutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/26/2010 46333X10 BW   Ironwood Pharmaceuticals Announces Participation in J.P. Morgan Biotech CEO/CFO Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2015 02043Q10  BW   Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2015 15117K10 BW   Cellectis Announces Presentations at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/11/2011 53220K50  BW   Ligand to Webcast Analyst and Investor Day on June 23 in New York City,#N/A, 9/25/2013 45232710    BW   Illumina Applies CE Mark to Expanded MiSeqDx™ System, 6/18/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces Outstanding ZEVALIN® Clinical Data In Aggressive Relapsed/Refratory Lymphoma; Presented at the 17th Congress of the European Hematology Association,#N/A, 8/06/2012 ALNY-US  BW   Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2014 01535110 BW   Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment,#N/A,10/01/2014 81257810    BW   Seattle Genetics et Takeda annoncent des données positives provenant de l’essai clinique de Phase 3 AETHERA portant sur l’ADCETRIS® (Brentuximab Vedotin) pour la consolidation des lymphomes hodgkiniens post-transplantation,#N/A,12/04/2013 09062X10    BW   The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX™ Effectively Controlled Bleeding in Hemophilia B Patients," 5/10/2010 45253H10 BW   ImmunoGen, Inc. Announces Exercise of Over-Allotment Option",#N/A, 4/04/2016 00CK58-E     BW   Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2013 45337C10 BW   Incyte to Present at the Morgan Stanley Global Healthcare Conference,#N/A,#N/A, 9/20/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the UBS Global Life Sciences Conference, 3/02/2010 15708510 BW   Cerus to Present at Cowen and Company Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A, 8/29/2012 30161Q10 BW   Exelixis Provides Update on ODAC Panel for Cabozantinib, 9/13/2012 07G69B-E  BW   Research and Markets: Pharmaceutical Industry in Russia 2012 - Complete With A SWOT Analysis of the Leading Companies in the Market," 2/01/2013 VRTX-US   BW   La République d'Irlande approuve le financement de KALYDECO™ (ivacaftor), le premier médicament pour le traitement de la cause sous-jacente de la mucoviscidose (fibrose kystique) des patients atteints d'une mutation génétique...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2010 46333X10 BW   Ironwood Pharmaceuticals Provides First Quarter 2010 Investor Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/08/2015 02043Q10  BW   Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 15117K10 BW   Cellectis Reports Second Quarter and First Half Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/10/2011 53220K50  BW   Ligand Pharmaceuticals Reports First Quarter Results,#N/A, 9/23/2013 45232710    BW   Illumina Names Dr. Richard Klausner as Senior Vice President and Chief Medical Officer, 6/07/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 7/11/2012 ARWR-US  BW   Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/10/2014 01535110 BW   Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015",#N/A, 9/29/2014 81257810    BW   Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma,#N/A,12/03/2013 09062X10    BW   Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting," 5/07/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the Bank of America Merrill Lynch Health Care Conference",#N/A, 3/31/2016 GILD-US      BW   Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/21/2013 45337C10 BW   Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients with Refractory Metastatic Pancreatic Cancer,#N/A,#N/A, 9/16/2010 G0176710 BW   Alkermes Announces FDA Advisory Committee Recommends Approval of VIVITROL® for Opioid Dependence, 2/23/2010 15708510 BW   Cerus Announces Fourth Quarter and Year-End 2009 Results,#N/A,#N/A,#N/A,#N/A, 8/09/2012 EXEL-US  BW   Exelixis Announces Pricing of Concurrent Offerings of 30 Million Shares of Common Stock and $250 Million Principal Amount of Convertible Senior Subordinated Notes," 9/12/2012 SNY-FR    BW   FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis"," 2/01/2013 VRTX-US   BW   Republic of Ireland Approves Funding for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2010 46333X10 BW   Ironwood Pharmaceuticals Announces First Quarter 2010 Investor Update Call and Upcoming Presentation at Bank of America Merrill Lynch 2010 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2015 02043Q10  BW   Alnylam to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2015 15117K10 BW   Cellectis publie ses résultats financiers du deuxième trimestre et du premier semestre 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/27/2011 53220K50  BW   Ligand to Report First Quarter Results on May 10th,#N/A, 9/19/2013 45232710    BW   Verinata Health Peer-Reviewed Publication Shows Circulating Cell-Free Fetal DNA Fractions Differ in Specific Aneuploidies, 6/05/2012 SPPI-US   BW   Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN® and Belinostat at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting,#N/A," 6/26/2012 ARWR-US  BW   Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2014 01535110 BW   Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting,#N/A," 9/26/2014 81257810    BW   Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS® (brentuximab vedotin) Phase 3 AETHERA Clinical Trial",#N/A,12/02/2013 09062X10    BW   Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™," 5/06/2010 45253H10 BW   ImmunoGen, Inc. Prices Public Offering of Common Stock",#N/A, 3/25/2016 0056YC-E     BW   AHF: Gilead Says it “Had No Duty to Develop …” Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2013 45337C10 BW   Incyte to Present at the Canaccord Genuity 33rd Annual Growth Conference,#N/A,#N/A, 9/16/2010 G0176710 BW   Alkermes Stock Trading Halted Today, 2/17/2010 15708510 BW   Data Presented at International Haemovigilance Seminar Confirm Safety of Cerus' INTERCEPT Blood System for Platelets and Plasma,#N/A,#N/A,#N/A,#N/A, 8/06/2012 EXEL-US  BW   Exelixis Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Debt," 9/11/2012 RIBX-US   BW   Rib-X Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance against New Objective Endpoints from FDA, from its Completed Phase 2b Study in Patients with Acute Bacterial Skin and Skin Structure Infections", 1/29/2013 92532F10  BW   Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2010 46333X10 BW   Ironwood and Forest Present Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2015 ALNY-US   BW   Alnylam to Webcast Presentations at Upcoming June Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2015 15117K10 BW   MD Anderson Cancer Center et Cellectis concluent une vaste alliance préclinique et clinique en immunothérapie contre le cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/20/2011 006N55-E  BW   Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter,#N/A, 9/04/2013 45232710    BW   Illumina to Supply Natera with Sequencing Instruments and Consumables for Non-Invasive Prenatal Testing (NIPT)," 5/31/2012 SPPI-US   BW   Spectrum Pharmaceuticals Highlights Seven Abstracts of Clinical Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 1-5, 2012",#N/A, 6/06/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2014 01535110 BW   Alexion Launches Every Day with HPP™ Campaign in Support of Hypophosphatasia (HPP) Awareness Week,#N/A, 9/24/2014 81257810    BW   Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress,#N/A,11/25/2013 09062X10    BW   Biogen Idec to Present at the 2013 Deutsche Bank BioFEST," 5/05/2010 45253H10 BW   ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock",#N/A," 3/10/2016 BCS-GB       BW   Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2013 45337C10 BW   Incyte Reports Second-Quarter 2013 Financial Results; Increases Revenue Guidance; Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 9/14/2010 G0176710 BW   Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting for VIVITROL® for Opioid Dependence, 2/09/2010 15708510 BW   Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development,#N/A,#N/A,#N/A,#N/A, 8/02/2012 EXEL-US  BW   Exelixis Announces Second Quarter 2012 Financial Results, 9/11/2012 06PD8S-E  BW   The CEO Roundtable on Cancer Joins Bilateral Effort to Promote Smoke-Free Workplaces in China," 1/15/2013 92532F10  BW   Vertex to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, January 29",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2010 46333X10 BW   Ironwood and Forest to Present Linaclotide Phase 3 Chronic Constipation Data,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/26/2015 02043Q10  BW   Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2015 15117K10 BW   MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/18/2011 53220K50  BW   Ligand Names Matthew W. Foehr Chief Operating Officer,#N/A, 8/27/2013 45232710    BW   Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference, 5/31/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference,#N/A, 5/22/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2014 01535110 BW   Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting,#N/A, 9/10/2014 81257810    BW   Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration,#N/A,11/22/2013 09062X10    BW   CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union," 4/29/2010 45253H10 BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2010 Financial Results",#N/A, 3/04/2016 GILD-US      BW   Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2013 45337C10 BW   Incyte to Report Second Quarter 2013 Financial Results on August 1,#N/A,#N/A, 8/05/2010 G0176710 BW   Alkermes Reports First Quarter Fiscal 2011 Financial Results, 2/08/2010 15708510 BW   Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells,#N/A,#N/A,#N/A,#N/A, 7/30/2012 30161Q10 BW   FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer," 9/07/2012 0BH0YB-E  BW   Research and Markets: Pharmaceutical Market in Vietnam 2011-2015 Report: GSK, Merck, Novartis, Pfizer, and Sanofi S.A. Dominate", 1/06/2013 VRTX-US   BW   Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2010 46333X10 BW   Ironwood Pharmaceuticals Files Annual Report on Form 10-K,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/20/2015 02043Q10  BW   Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigational RNAi Therapeutic for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2015 15117K10 BW   Cellectis présentera des données sur ses programmes d’immunothérapie fondés sur des cellules CAR T durant plusieurs conférences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/23/2011 53220K50  BW   Ligand to Present at the Citi 2011 Global Healthcare Conference on March 2,#N/A, 8/19/2013 45232710    BW   Illumina Launches New Reagent Kits for the MiSeq® System, 5/29/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Enrollment of First Group of Patients in Phase 1 Clinical Trial of RenaZorb®,#N/A, 5/09/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2014 01535110 BW   Alexion Reports Third Quarter 2014 Results,#N/A, 9/02/2014 81257810    BW   Seattle Genetics to Present at Morgan Stanley Healthcare Conference,#N/A,11/13/2013 09062X10    BW   Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A," 4/22/2010 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2010 Financial Results",#N/A," 3/04/2016 0024VM-E     BW   Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/16/2013 45337C10 BW   Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis,#N/A,#N/A, 7/29/2010 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2011," 2/04/2010 15708510 BW   Cerus to Release Fourth Quarter and Year-End 2009 Results on February 23, 2010",#N/A,#N/A,#N/A,#N/A, 7/26/2012 EXEL-US  BW   Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma, 9/05/2012 RIBX-US   BW   Rib-X Pharmaceuticals’ Antibiotic Development Programs to be Featured in 16 Posters and Symposium Sessions at ICAAC, 1/02/2013 0BWD27-E  BW   Kyruus Raises $11M Series B to Accelerate the Rapid Growth of Its Physician Network Management Solutions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/16/2010 46333X10 BW   Underwriters Exercise Over-Allotment Option for Ironwood Pharmaceuticals’ Initial Public Offering,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/17/2015 02043Q10  BW   Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/26/2015 15117K10 BW   Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/15/2011 53220K50  BW   Ligand Announces Fourth Quarter and Full Year 2010 Consolidated Financial Results,#N/A, 8/01/2013 006KW9-E    BW   Verinata Health Receives New York State Laboratory Permit for verifi® Prenatal Test, 5/24/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics,#N/A, 5/08/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2014 01535110 BW   Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia,#N/A, 8/12/2014 81257810    BW   Seattle Genetics Initiates Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma,#N/A,11/05/2013 09062X10    BW   Biogen Idec to Present at the Credit Suisse Healthcare Conference," 4/15/2010 45253H10 BW   ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its Trastuzumab-DM1 Regulatory Plans",#N/A," 3/03/2016 GILD-US      BW   L’administration américaine chargée des aliments et des médicaments approuve le deuxième schéma de traitement à comprimé unique de l'Odefsey® à base de TAF (emtricitabine, rilpivirine, tenofovir alafenamide) de Gilead...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2013 45337C10 BW   Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information,#N/A,#N/A, 6/26/2010 G0176710 BW   BYDUREON™ Safety and Tolerability Pooled Summary Data Presented at ADA 2010, 2/02/2010 15708510 BW   Cerus to Present at 12th Annual BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A, 7/19/2012 30161Q10 BW   Exelixis Announces August 2nd Webcast of Second Quarter 2012 Financial Results Conference Call, 9/04/2012 SNY-FR    BW   Impax Laboratories Announces Settlement of Litigation Relating to RENVELA® and RENAGEL®,"12/19/2012 92532F10  BW   NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 02043Q10  BW   Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2015 15117K10 BW   Cellectis annonce la publication dans Cancer Research d’une étude portant sur ses programmes d'immunothérapie à partir de cellules CAR T allogéniques,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/09/2011 53220K50  BW   Ligand Appoints John L. LaMattina to Board of Directors,#N/A, 7/23/2013 45232710    BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2013, 5/17/2012 SPPI-US   BW   Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd),#N/A, 5/03/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/09/2014 01535110 BW   Alexion Pharmaceuticals to Report Third Quarter 2014 Results on Thursday, October 23, 2014",#N/A, 7/31/2014 81257810    BW   Seattle Genetics Reports Second Quarter 2014 Financial Results,#N/A,10/28/2013 09062X10    BW   Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance," 3/18/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the 2010 Barclays Capital Global Healthcare Conference",#N/A," 3/03/2016 GILD-US      BW   US-amerikanische FDA erteilt Zulassung für Gileads zweites auf TAF beruhendes Einzeltablettenregime Odefsey® (Emtricitabin, Rilpivirin, Tenofoviralafenamid) zur Behandlung von HIV-1-Infektionen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/04/2013 45337C10 BW   Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis",#N/A,#N/A, 6/17/2010 G0176710 BW   Alkermes Announces Notification of Tentative FDA Advisory Committee Meeting to Review VIVITROL® for Opioid Dependence,#N/A,#N/A,#N/A,#N/A,#N/A, 7/10/2012 EXEL-US  BW   Exelixis Announces July 13th Webcast of Presentation at the JMP Securities 7th Annual Healthcare Conference," 9/04/2012 IMGN-US   BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",12/19/2012 92532F10  BW   Vertex Announces Update to U.S. Prescribing Information for INCIVEK® (telaprevir),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2015 02043Q10  BW   Alnylam to Webcast Conference Call Discussing First Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2015 15117K10 BW   Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/08/2011 53220K50  BW   Ligand to Report Fourth Quarter Results on February 15th,#N/A," 7/23/2013 45232710    BW   Illumina Acquires Advanced Liquid Logic, Leader in Digital Microfluidics Solutions", 5/10/2012 84763A10  BW   Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics,#N/A, 5/01/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2014 01535110 BW   Alexion Board of Directors Appoints New Chairman and Creates the New Position of Lead Independent Director,#N/A," 7/09/2014 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2014 Financial Results on July 31, 2014",#N/A,"10/07/2013 09062X10    BW   Biogen Idec to Report Third Quarter 2013 Financial Results on October 28, 2013"," 3/08/2010 45253H10 BW   ImmunoGen, Inc. Announces Orphan Drug Designation Granted to IMGN901 for Treatment of Merkel Cell Carcinoma by US FDA and EU COMP",#N/A," 3/03/2016 06CR5C-E     BW   L'ente statunitense preposto al controllo dei farmaci e degli alimenti approva il secondo regime monocompressa a base di TAF di Gilead, Odefsey® (emtricitabina, rilpivirina, tenofovir alafenamide)...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/01/2013 45337C10 BW   Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO",#N/A,#N/A, 6/15/2010 G0176710 BW   DURATION-4 Study Results: BYDUREON™ Efficacy and Tolerability Profile Extended to Monotherapy Treatment,#N/A,#N/A,#N/A,#N/A,#N/A," 7/09/2012 08J7QW-E BW   According to Surveyed Medical Oncologists and Urologists, Zytiga is Currently Prescribed to Nearly Half of All Mcrpc Patients Who Have No Response or Very Rapid Progression from Prior Docetaxel Treatment", 8/28/2012 ALNY-US   BW   Alnylam and Monsanto Form Strategic Alliance,12/18/2012 06680H-E  BW   The First Interferon-Free Regimens for Treatment of Hepatitis C Virus Are Expected to Launch in 2014 in the United States and Europe and Will Experience Aggressive and Widespread Uptake Through 2021,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2015 02043Q10  BW   Alnylam to Webcast Presentations at Upcoming May Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2015 15117K10 BW   Cellectis Reaches Milestone in Servier Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/07/2011 005Z10-E  BW   Cellerant Therapeutics Announces Key Additions to Sr. Management Team,#N/A, 7/22/2013 45232710    BW   HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing Platform of Choice, 5/08/2012 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference,#N/A, 4/11/2012 0C6S52-E BW   Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/07/2014 01535110 BW   Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Company’s Board of Directors",#N/A, 6/01/2014 81257810    BW   Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting,#N/A,10/04/2013 09062X10    BW   New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients," 3/01/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences",#N/A," 3/03/2016 06CR5C-E     BW   De U.S. Food and Drug Administration heeft goedkeuring verleend voor Odefsey® (emtricitabine, rilpivirine, tenofovir alafenamide), Gilead's tweede enkel-tabletregime voor de behandeling van hiv-1-infectie",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/22/2013 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 6/02/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A," 6/14/2012 005Z10-E BW   Cellerant Appoints Gisela Schwab, M.D., to Its Board of Directors and Names Lowell Sears as Chairman of the Board", 8/27/2012 80105N10  BW   Genzyme Provides Update on U.S. LEMTRADA™ Filing,12/13/2012 MVIR.B-SE BW   Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/21/2015 02043Q10  BW   Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2015 15117K10 BW   Cellectis atteint un jalon dans sa collaboration avec Servier,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/26/2011 LGND-US   BW   CyDex Pharmaceuticals Approves Merger with Ligand Pharmaceuticals,#N/A, 7/18/2013 45232710    BW   Illumina Announces Phasing Analysis Service for Human Whole-Genome Sequencing, 5/01/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference,#N/A, 3/07/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2014 ALXN-US  BW   Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function,#N/A, 5/31/2014 81257810    BW   Seattle Genetics Highlights Data from Multiple Collaborator Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting,#N/A,10/03/2013 09062X10    BW   New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity," 2/03/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2010",#N/A," 3/02/2016 GILD-US      BW   La Administración de Alimentos y Fármacos de EE.UU aprueba el segundo régimen de único comprimido basado en TAF de Gilead, Odefsey® (emtricitabina, rilpivirina, tenofovir alafenamida), para el tratamiento de la infección de VIH-1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2013 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 5/25/2010 G0176710 BW   Alkermes Announces Priority Review by FDA for VIVITROL® for Opioid Dependence,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2012 EXEL-US  BW   Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced Prostate Cancer, 8/24/2012 07G69B-E  BW   Research and Markets: North America Animal Health Care Market Outlook to 2016 - Recuperating US Veterinary Drugs Industry,"12/03/2012 92532F10  BW   Santé Canada approuve KALYDECO™ (ivacaftor), le premier médicament traitant la cause profonde de la fibrose kystique (FK) chez les personnes présentant une mutation génétique spécifique (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/13/2015 02043Q10  BW   Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2015 15117K10 BW   Cellectis annonce la publication d’une étude prometteuse portant sur une nouvelle génération de cellules ingénierées CAR T allogéniques,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/26/2011 53220K50  BW   Ligand Acquires CyDex Pharmaceuticals,#N/A," 7/09/2013 45232710    BW   Illumina to Announce Second Quarter 2013 Financial Results on Tuesday, July 23, 2013", 4/26/2012 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012,#N/A, 3/05/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/17/2014 01535110 BW   Alexion Strengthens and Broadens Its Executive Leadership Team,#N/A, 5/29/2014 81257810    BW   Seattle Genetics to Present at Jefferies Global Healthcare Conference,#N/A,10/01/2013 09062X10    BW   New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)," 2/02/2010 45253H10 BW   ImmunoGen, Inc. Announces Webcast of Presentation at the 12th Annual BIO CEO & Investor Conference",#N/A," 3/01/2016 06CR5C-E     BW   U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2013 45337C10 BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline",#N/A,#N/A, 5/19/2010 G0176710 BW   Data on VIVITROL® to be Presented at Upcoming American Psychiatric Association Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2012 EXEL-US  BW   Cabozantinib Meets Primary Endpoint of Progression Free Survival in Phase 3 Pivotal Trial in Medullary Thyroid Cancer, 8/23/2012 07G69B-E  BW   Research and Markets: Insulin Market Forecast to 2015,"12/03/2012 92532F10  BW   Health Canada Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2015 ALNY-US   BW   Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2015 15117K10 BW   Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/06/2011 53220K50  BW   Ligand Forms Strategic Drug Development Alliance with Chiva Pharmaceuticals,#N/A, 7/01/2013 45232710    BW   Illumina Applies CE Mark to MiSeqDx™ Cystic Fibrosis System, 4/23/2012 SPPI-US   BW   Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV®,#N/A, 2/29/2012 ARWR-US  BW   Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/16/2014 01535110 BW   On observe une prolongation de la survie chez les patients pédiatriques atteints d'hypophosphatasie sévère qui ont reçu pendant au plus cinq ans une enzymothérapie substitutive par l'asfotase alfa, un médicament expérimental",#N/A, 5/14/2014 81257810    BW   Seattle Genetics and Collaborators Will Present Data from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting,#N/A,10/01/2013 09062X10    BW   Les nouvelles analyses des données sur le PLEGRIDY™ (peginterféron bêta-1a) indiquent des améliorations sur le plan clinique et IRM," 1/28/2010 45253H10 BW   ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2010 Financial Results",#N/A, 2/29/2016 080RQG-E     BW   El CHMP europeo recibe una opinión positiva para la combinación de dosis fija de Descovy® (emtricitabina/tenofovir alafenamida) de Gilead para el tratamiento del VIH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2013 45337C10 BW   Incyte Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 5/13/2010 G0176710 BW   Alkermes Reports Financial Results for Fiscal 2010 and Provides Financial Expectations for Fiscal 2011,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2012 EXEL-US  BW   Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma, 8/20/2012 07G69B-E  BW   Research and Markets: Human Insulin Market in China 2011-2015: The Human Insulin Market in China to Grow at a CAGR of 19.2 Percent over the Period 2011-2015,11/16/2012 VRTX-US   BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/15/2015 02043Q10  BW   Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/09/2015 15117K10 BW   S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/22/2010 53220K50  BW   Ligand Earns $1 Million Upfront Payment from Pfizer on Sublicensing of Tanaproget,#N/A, 7/01/2013 45232710    BW   Verinata Health Announces Agreement with Teva Pharmaceutical Industries in Collaboration with MOR Institute for Medical Data to Commercialize the verifi® Prenatal Test in Israel, 4/20/2012 ALTH-US   BW   Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe,#N/A, 2/09/2012 ARWR-US  BW   Arrowhead Reports Fiscal 2012 First Quarter Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2014 01535110 BW   Verbessertes Überleben bei pädiatrischen Patienten mit schwerer Hypophosphatasie (HPP) nach bis zu fünf Jahren Therapie mit dem Prüfpräparat Asfotase Alfa,#N/A, 5/07/2014 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/01/2013 09062X10    BW   Neue Auswertungen von Studiendaten zeigen signifikante klinische und kernspintomographische Verbesserungen bei Behandlung mit PLEGRIDY™ (Peginterferon Beta-1a)," 1/21/2010 45253H10 BW   ImmunoGen, Inc. Announces Conference Call to Discuss Its Second Quarter Fiscal Year 2010 Financial Results",#N/A, 2/27/2016 GILD-US      BW   Europäische Arzneimittelagentur bestätigt Gileads Marktzulassungsantrag für Tenofovir Alafenamid (TAF) zur Behandlung der chronischen Hepatitis B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2013 45337C10 BW   Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development,#N/A,#N/A," 5/06/2010 G0176710 BW   BYDUREON™ FDA Review Timeline Set with PDUFA Action Date of October 22, 2010",#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2012 EXEL-US  BW   Cabozantinib Demonstrates Encouraging Activity in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma, 8/17/2012 07G69B-E  BW   Research and Markets: Global Veterinary Vaccines Market 2011-2015 Report Includes Players such as Lohmann Animal Health GmbH & Co. KG and Novartis AG,"11/15/2012 06VHPT-E  BW   Many Physicians who Treat HCV Have Begun ‘Warehousing’ and Preparing HCV Patients for the Next Generation of Interferon-Free Treatments to Become Available, According to a Recent BioTrends Report",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/13/2015 02043Q10  BW   Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2015 15117K10 BW   Cellectis présente ses résultats financiers pour le premier trimestre 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/04/2010 53220K50  BW   Ligand Announces Positive Preclinical Data on Small Molecule Erythropoietin Receptor Agonists,#N/A," 6/20/2013 ILMN-US     BW   Syntrix Biosystems Wins Final Judgment of $115 Million in Patent Case against Illumina, Inc.", 4/19/2012 84763A10  BW   Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index,#N/A, 2/02/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/14/2014 01535110 BW   Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years,#N/A, 5/01/2014 81257810    BW   Seattle Genetics Reports First Quarter 2014 Financial Results,#N/A," 9/24/2013 09062X10    BW   Biogen Idec, primera empresa biotecnológica estadounidense que entra en el Índice mundial de sostenibilidad de Dow Jones",#N/A,#N/A, 2/27/2016 GILD-US      BW   Le CHMP européen adopte un avis favorable pour l'association à dose fixe du Descovy® (emtricitabine/ténofovir alafenamide) de Gilead pour le traitement du VIH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/19/2013 INCY-US  BW   SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline",#N/A,#N/A, 5/05/2010 G0176710 BW   Alkermes to Host Conference Call to Discuss Fiscal Year 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2012 EXEL-US  BW   Exelixis Announces June 6th Webcast of Presentation at the Goldman Sachs 33rd Annual Global Healthcare Conference, 8/13/2012 07G69B-E  BW   Research and Markets: Global Breast Cancer Drugs Market 2011-2015: The Global Breast Cancer Drugs Market to Grow at a CAGR of 1.7 Percent over the Period 2011-2015,11/10/2012 VRTX-US   BW   Vertex présente de nouveaux résultats de phase 3 qui montrent que les patients atteints d’hépatite C ayant reçu un traitement de 2 doses quotidiennes de télaprévir ont obtenu des taux de guérison virale (SVR12) similaires aux patients ayant reçu...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2015 02043Q10  BW   Alnylam to Webcast Presentation at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2015 15117K10 BW   Cellectis Reports First Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
12/03/2010 53220K50  BW   Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting,#N/A, 5/29/2013 45232710    BW   Illumina to Webcast Live Presentation at the Goldman Sacks Global Healthcare Conference, 4/17/2012 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast,#N/A, 1/05/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/08/2014 01535110 BW   Asfotase Alfa Granted Orphan Drug Designation in Japan,#N/A," 4/30/2014 SGEN-US     BW   Idaho-Nevada Community Development Financial Institution, Inc. Joins Federal Home Loan Bank of Seattle",#N/A, 9/24/2013 09062X10    BW   Biogen Idec devient la première entreprise biotechnologique américaine à être classée dans le Dow Jones Sustainability World Index,#N/A,#N/A, 2/27/2016 GILD-US      BW   Europäisches CHMP kommt zu positiver Einschätzung der Festdosiskombination Descovy® (Emtricitabin/Tenofoviralafenamid) von Gilead für die Behandlung von HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2013 45337C10 BW   Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Incyte Corporation,#N/A,#N/A, 4/26/2010 G0176710 BW   Alkermes to Provide Update on Advancing Product Portfolio and Proprietary Platforms at R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2012 07G69B-E BW   Research and Markets: Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others - Profiles of 212 Companies, 8/13/2012 07G69B-E  BW   Research and Markets: The Cardiovascular Market Outlook to 2017,"11/10/2012 VRTX-US   BW   Les données issues d'une étude de cinétique virale ont démontré la réduction rapide de l'ARN du VHC avec l'ALS-2200 (VX-135), le promédicament oral analogue de l'uridine nucléotide de Vertex, dans le développement d'un traitement contre l'hépatite C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2015 02043Q10  BW   Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2015 15117K10 BW   Cellectis présentera des données sur ses programmes d’immunothérapie adoptive fondés sur des cellules CAR T allogéniques lors du congrès annuel de l’European Hematology Association,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/19/2010 53220K50  BW   Ligand Reverse Stock Split Effective Today,#N/A, 5/16/2013 45232710    BW   Illumina Launches BaseSpace® Apps, 4/16/2012 84763A10  BW   Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics,#N/A, 1/04/2012 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2014 01535110 BW   NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England,#N/A, 4/29/2014 SGEN-US     BW   Federal Home Loan Bank of Seattle Announces First Quarter 2014 Unaudited Preliminary Financial Highlights,#N/A, 9/24/2013 09062X10    BW   Biogen Idec als erstes US-Biotech-Unternehmen in Dow Jones Sustainability World Index aufgenommen,#N/A,#N/A, 2/27/2016 080RQG-E     BW   L’Agence européenne des médicaments accepte la demande d’autorisation de mise sur le marché de Gilead pour le ténofovir alafénamide (TAF) comme traitement de l’hépatite B chronique.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2013 45337C10 BW   Incyte to Report First Quarter 2013 Financial Results on May 2,#N/A,#N/A," 4/22/2010 G0176710 BW   Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON™",#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2012 EXEL-US  BW   Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer, 8/13/2012 07G69B-E  BW   Research and Markets: Global Hyperphosphatemia Drugs Market 2011-2015,"11/10/2012 VRTX-US   BW   Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex’s Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2015 02043Q10  BW   Alnylam to Webcast Presentation at 2015 RBC Capital Markets’ Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2015 15117K10 BW   Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/09/2010 53220K50  BW   Ligand Pharmaceuticals Announces Third Quarter Results,#N/A, 5/15/2013 45232710    BW   Illumina Announces Partnerships to Automate TruSeq® and Nextera® Sample Preparation Kits," 4/10/2012 SPPI-US   BW   PharmaVigilant Selected by Spectrum Pharmaceuticals, Inc. to Support 10 Studies",#N/A,12/20/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2014 01535110 BW   Alexion to Present at Investor Conferences,#N/A," 4/16/2014 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014",#N/A, 9/24/2013 09062X10    BW   Biogen Idec diventa la prima società biotecnologica statunitense a essere nominata per il Dow Jones Sustainability World Index,#N/A,#N/A, 2/26/2016 GILD-US      BW   L’agenzia europea preposta al controllo dei farmaci (European Medicines Agency) convalida la domanda di autorizzazione alla commercializzazione depositata da Gilead per tenofovir alafenamide (TAF) per il trattamento dell’epatite B cronica,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2013 45337C10 BW   Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Incyte Corporation,#N/A,#N/A," 4/19/2010 G0176710 BW   Alkermes to Webcast R&D Day on Monday, April 26, 2010",#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2012 30161Q10 BW   Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer, 8/13/2012 07G69B-E  BW   Research and Markets: Global Human Insulin Market 2011-2015,11/10/2012 VRTX-US   BW   Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/12/2015 02043Q10  BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2015 15117K10 BW   Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/09/2010 53220K50  BW   Ligand Announces 1-for-6 Reverse Stock Split,#N/A, 5/01/2013 45232710    BW   Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May, 4/05/2012 84763A10  BW   Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012,#N/A,12/19/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/25/2014 01535110 BW   Alexion lance l'essai d'homologation multinational de l'éculizumab pour la prévention du retard de fonctionnement du greffon (RFG) après une transplantation rénale,#N/A, 4/08/2014 81257810    BW   Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries,#N/A, 9/24/2013 09062X10    BW   Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index,#N/A,#N/A, 2/26/2016 080RQG-E     BW   Europese CHMP geeft een positieve mening over Gilead's vastedosiscombinatie Descovy® (emtricitabine/tenofoviralafenamide) voor de behandeling van hiv,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2013 45337C10 BW   Law Offices of Todd M. Garber Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Incyte Corporation,#N/A,#N/A, 4/13/2010 G0176710 BW   Alkermes Submits Supplemental New Drug Application for VIVITROL® for the Treatment of Opioid Dependence,#N/A,#N/A,#N/A,#N/A,#N/A," 5/16/2012 EXEL-US  BW   Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting"," 8/13/2012 099YFM-E  BW   BioJapan - The Leading Biotechnology Industry Partnering Event, Exhibition & Conference in Japan - Has Launched a New Online Partnering System",11/08/2012 VRTX-US   BW   Vertex Announces Webcast of its Presentation at the Credit Suisse 2012 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2015 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2015 15117K10 BW   Weill Cornell Medical College et Cellectis annoncent une alliance de recherche visant la découverte de médicaments et d’immunothérapies innovantes contre la leucémie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/02/2010 53220K50  BW   Ligand Announces Approval for Revolade® in Japan,#N/A, 4/25/2013 45232710    BW   Verinata Health Publishes Clinical Laboratory Performance Data for verifi® Prenatal Test, 4/05/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials,#N/A,12/15/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/25/2014 01535110 BW   Alexion beginnt multinationale Zulassungsstudie mit Eculizumab zur Prävention der verzögerten Transplantatfunktion nach einer Nierentransplantation,#N/A, 4/07/2014 81257810    BW   Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR,#N/A, 9/23/2013 09062X10    BW   Biogen Idec presentará nuevos datos ampliados de su sólida cartera de esclerosis múltiple en el Congreso ECTRIMS,#N/A,#N/A, 2/26/2016 GILD-US      BW   Il comitato europeo CHMP adotta un parere favorevole per il regime combinato a dosaggio fisso Descovy® (emtricitabina/tenofovir alafenamide) di Gilead per il trattamento dell'infezione da HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/25/2013 45337C10 BW   Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit against Incyte Corporation,#N/A,#N/A, 3/17/2010 G0176710 BW   Alkermes Announces Initiation of Multidose Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2012 30161Q10 BW   Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference, 8/10/2012 07G69B-E  BW   Research and Markets: Global Pharmaceuticals Market 2011-2015: The Global Pharmaceuticals market to grow at a CAGR of 7 percent over the period 2011-2015,11/01/2012 92532F10  BW   Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2015 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2015 15117K10 BW   Assemblée Générale mixte des actionnaires de Cellectis SA du 18 mai 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
11/02/2010 53220K50  BW   Ligand Awarded $2 Million from U.S. Government Under the Patient Protection and Affordable Care Act,#N/A, 4/22/2013 45232710    BW   Illumina Names Charles Dadswell as Senior Vice President and General Counsel, 3/27/2012 84763A10  BW   Spectrum Announces Launch of New Patient-to-Patient Educational Campaign for ZEVALIN® on ZEVALIN.com,#N/A,11/28/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/25/2014 01535110 BW   Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation,#N/A, 2/27/2014 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings,#N/A, 9/23/2013 09062X10    BW   Biogen Idec presenterà all'ECTRIMS numerosi nuovi dati relativi alla suo ampia gamma di prodotti per la sclerosi multipla,#N/A,#N/A, 2/26/2016 080RQG-E     BW   Europees Geneesmiddelenbureau bevestigt marktaanvraag Gilead voor tenofovir alafenamide (TAF) voor de behandeling van chronische hepatitis B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2013 45337C10 BW   Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Incyte Corporation,#N/A,#N/A," 3/15/2010 G0176710 BW   Amylin, Lilly and Alkermes Receive Complete Response Letter from FDA for exenatide Once Weekly Submission",#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2012 30161Q10 BW   Exelixis Announces First Quarter 2012 Financial Results, 8/06/2012 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial Results,11/01/2012 05TF66-E  BW   Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2015 02043Q10  BW   U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/19/2015 15117K10 BW   Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/29/2010 53220K50  BW   Ligand to Report Third Quarter Results on November 9,#N/A, 4/22/2013 45232710    BW   Illumina Reports Strong Start to Fiscal Year 2013, 3/12/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the 24th Annual ROTH Conference,#N/A,11/23/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/13/2014 01535110 BW   Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting,#N/A, 2/20/2014 SGEN-US     BW   Federal Home Loan Bank of Seattle Announces 2013 Unaudited Preliminary Financial Highlights,#N/A, 9/23/2013 09062X10    BW   Biogen Idec stellt umfangreiche neue Daten zu seinem robusten Portfolio für multiple Sklerose auf dem ECTRIMS-Kongress vor,#N/A,#N/A, 2/26/2016 GILD-US      BW   La Agencia Europea de Medicamentos valida la solicitud para la comercialización de tenofovir alafenamida (TAF) de Gilead para el tratamiento de la hepatitis B crónica,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/14/2013 45337C10 BW   Incyte Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of Possible Breaches of Fiduciary Duty",#N/A,#N/A, 3/02/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 30th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2012 30161Q10 BW   Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration, 8/06/2012 ALNY-US   BW,11/01/2012 GSK-GB    BW   Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/02/2015 02043Q10  BW   Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 15117K10 BW   Cellectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/25/2010 53220K50  BW   Ligand to Present at the Oppenheimer 21st Annual Healthcare Conference on November 2,#N/A, 4/18/2013 0BWZ9P-E    BW   Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia," 3/01/2012 84763A10  BW   Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011",#N/A,11/16/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2014 01535110 BW   Europäische Kommission erteilt Soliris® (Eculizumab) den Orphan-Arzneimittel-Status zur Behandlung von Patienten mit Myasthenia Gravis (MG),#N/A, 2/11/2014 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results,#N/A, 9/23/2013 09062X10    BW   Biogen Idec présentera de nouvelles données approfondies de son portefeuille étoffé sur la sclérose en plaques au congrès de l’ECTRIMS,#N/A,#N/A, 2/26/2016 080RQG-E     BW   European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/13/2013 45337C10 BW   Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Incyte Corporation,#N/A,#N/A, 2/25/2010 G0176710 BW   Exenatide Once Weekly New Drug Application Review Extended by FDA Due to Weather-Related Closure,#N/A,#N/A,#N/A,#N/A,#N/A, 5/02/2012 30161Q10 BW   Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference, 8/02/2012 07GVF3-E  BW   Research and Markets: Mexico Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery,11/01/2012 008KZN-E  BW   Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/29/2015 APOG-US   BW   Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2015 15117K10 BW   Cellectis S.A. présentera des données sur ses programmes d’immunothérapie adoptive fondés sur des cellules CAR T allogéniques lors de la conférence annuelle de l’American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/13/2010 53220K50  BW   Ligand Announces Market Launch of Bazedoxifene in Japan and Spain for the Treatment of Postmenopausal Osteoporosis,#N/A," 4/08/2013 45232710    BW   Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013", 2/24/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences,#N/A,11/14/2011 07J23G-E BW   Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2014 01535110 BW   La Commission européenne accorde le statut de médicament orphelin à Soliris® (éculizumab) pour le traitement des patients souffrant de myasthénie grave (MG),#N/A, 2/10/2014 81257810    BW   Seattle Genetics Announces Executive Promotions and Management Addition,#N/A, 9/23/2013 09062X10    BW   Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS,#N/A,#N/A, 2/25/2016 GILD-US      BW   European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2013 45337C10 BW   Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Incyte Corporation,#N/A,#N/A, 2/16/2010 G0176710 BW   Alkermes Announces Positive Results for Phase 1 Study of New Drug Candidate for Treatment of Opioid-Induced Constipation,#N/A,#N/A,#N/A,#N/A,#N/A, 4/19/2012 30161Q10 BW   Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call, 7/26/2012 80105N10  BW   Sanofi CEO Chris Viehbacher Comments on Results for Q2 2012,10/29/2012 92532F10  BW   Vertex Reschedules its Third Quarter 2012 Financial Results Conference Call and Webcast Due to Hurricane Sandy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2015 02043Q10  BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 15117K10 BW   Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/08/2010 53220K50  BW   Ligand Appoints Sunil Patel to Board of Directors,#N/A, 4/04/2013 ILMN-US     BW   Illumina Launches TruSight™ Tumor Content Set, 2/23/2012 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Fourth Quarter and Fiscal Year 2011 Financial Results Conference Call,#N/A,11/10/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2014 01535110 BW   European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG),#N/A, 2/06/2014 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A," 9/20/2013 09062X10    BW   I dipendenti di Biogen Idec partecipano al terzo ""Care Deeply Volunteer Day"" annuale",#N/A,#N/A, 2/25/2016 0DLW3C-E     BW   Gilead anuncia los datos de un nuevo estudio preclínico que evalúa un agonista del TLR7 experimental en simios con infección del virus de la inmunodeficiencia (SIV),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2013 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A, 2/04/2010 G0176710 BW   Alkermes Reports Third Quarter Fiscal 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2012 EXEL-US  BW   Cabozantinib to be Featured in Nine Presentations at 2012 ASCO Annual Meeting," 7/26/2012 80105N10  BW   Chris Viehbacher, DG de Sanofi, commente les résultats du 2ème trimestre 2012",10/16/2012 92532F10  BW   Vertex Announces the Date of its Third Quarter 2012 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2015 02043Q10  BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2015 15117K10 BW   Cellectis S.A. présentera des données sur ses programmes d’immunothérapie fondés sur des cellules CAR T allogéniques lors de la conférence annuelle de l’American Society of Gene & Cell Therapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
10/07/2010 53220K50  BW   Ligand to Divest Combinatorial Compound Library and Screening Technology for $1.8 Million,#N/A, 3/27/2013 45232710    BW   Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS), 2/07/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference,#N/A,11/07/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2014 01535110 BW   Europäische Arzneimittelbehörde akzeptiert Antrag auf Marktzulassung für Asfotase Alfa zur Behandlung von Patienten mit Hypophosphatasie,#N/A, 2/05/2014 81257810    BW   Seattle Genetics Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda,#N/A, 9/20/2013 09062X10    BW   Biogen Idec Employees Participate in Third Annual “Care Deeply Volunteer Day”,#N/A,#N/A, 2/25/2016 0DLW3C-E     BW   Gilead kondigt gegevens aan van een nieuwe preklinische studie ter beoordeling van een experimentele TLR7-agonist bij SIV-geïnfecteerde apen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2013 45337C10 BW   Incyte Reports 2012 Fourth-Quarter and Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders on Key Clinical Programs,#N/A,#N/A, 2/04/2010 G0176710 BW   Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS Disorders,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2012 30161Q10 BW   Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer, 7/13/2012 ALNY-US   BW   Alnylam and Collaborators Publish Scientific Paper Documenting Discovery of Second Generation MC3 Lipid Nanoparticles (LNPs),10/11/2012 06800C-E  BW   Präsentation der Ergebnisse aus der Phase-II-Kombinationsstudie zu VX-809 und Ivacaftor bei Probanden mit zystischer Fibrose und der häufigsten Genmutation (F508del) auf der North American Cystic Fibrosis Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/11/2015 02043Q10  BW   Alnylam Reports Initial Evidence for Potential Correction of the Hemophilia Phenotype in Phase 1 Study of ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2015 15117K10 BW   Cellectis Plant Sciences Becomes Calyxt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/17/2010 53220K50  BW   Ligand Enters into Agreement with Proximagen for CXCR4 Target,#N/A," 3/21/2013 45232710    BW   Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc."," 1/31/2012 128940-KR BW   Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals",#N/A,11/03/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2014 01535110 BW   L’agence européenne des médicaments accepte la demande d’autorisation de mise sur le marché pour l’Asfotase Alfa en tant que traitement destiné aux patients atteints d'hypophosphatasie,#N/A," 1/23/2014 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2013 Financial Results on February 11, 2014",#N/A, 9/20/2013 09062X10    BW   Los empleados de Biogen Idec participan en la tercera jornada anual “Care Deeply Volunteer Day”,#N/A,#N/A, 2/25/2016 GILD-US      BW   Gilead comunica i dati derivati da un nuovo studio pre-clinico inteso a valutare l’agonista del TLR7 sperimentale in scimmie con infezione da SIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/24/2013 45337C10 BW   Incyte to Report Fourth Quarter/Year-End 2012 Financial Results on February 14,#N/A,#N/A, 2/01/2010 G0176710 BW   Alkermes’ Corporate Presentation to be Webcast at the BIO CEO & Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2012 30161Q10 BW   Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference," 7/11/2012 07G69B-E  BW   Research and Markets: U.S. Market Report for Diabetes Monitoring, Treatment and Drug Delivery - Expected to exceed $17.87 billion by 2018","10/11/2012 06800C-E  BW   Les données d'une étude combinée de phase 2 sur le VX-809 et l'Ivacaftor chez les personnes atteintes de fibrose kystique, porteuses de la mutation génétique la plus courante (F508del)...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/09/2015 ALNY-US   BW   Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/04/2015 15117K10 BW   Cellectis Plant Sciences, Inc., filiale de Cellectis S.A., change de nom et devient Calyxt, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 9/10/2010 53220K50  BW   Ligand to Present at the Stifel Nicolaus Healthcare Conference on September 17,#N/A," 3/14/2013 45232710    BW   Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc.", 1/27/2012 84763A10  BW   Spectrum Pharmaceuticals Strengthens Commercial Operations,#N/A,11/02/2011 ARWR-US  BW   Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2014 01535110 BW   Alexion Reports Second Quarter 2014 Results,#N/A, 1/17/2014 81257810    BW   Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma,#N/A, 9/20/2013 09062X10    BW   Mitarbeiter von Biogen Idec nehmen am dritten jährlichen „Care Deeply Volunteer Day“ teil,#N/A,#N/A, 2/25/2016 0DLW3C-E     BW   Gilead annonce des données issues d'une nouvelle étude préclinique évaluant un agoniste expérimental du TLR7 chez des singes infectés par le VIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2012 INCY-US  BW   Incyte to Present at the 31st Annual J. P. Morgan Healthcare Conference,#N/A,#N/A, 1/28/2010 G0176710 BW   Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2010,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2012 30161Q10 BW   Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis," 7/03/2012 07GVF3-E  BW   Research and Markets: Healthcare, Regulatory and Reimbursement Landscape Vietnam",10/11/2012 VRTX-US   BW   Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2015 02043Q10  BW   Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/04/2015 15117K10 BW   Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 8/05/2010 53220K50  BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A, 2/21/2013 45232710    BW   Illumina Completes Acquisition of Verinata Health, 1/25/2012 84763A10  BW   Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®,#N/A,10/27/2011 ARWR-US  BW   Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/24/2014 01535110 BW   European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia,#N/A, 1/13/2014 81257810    BW   Seattle Genetics Highlights Key 2014 Milestones and Activities at J.P. Morgan Healthcare Conference,#N/A, 9/20/2013 09062X10    BW   Les employés de Biogen Idec participeront à la troisième journée annuelle « Care Deeply Volunteer Day »,#N/A,#N/A, 2/25/2016 GILD-US      BW   Gilead gibt Daten aus neuer präklinischer Studie zur Untersuchung eines in der Erprobungsphase befindlichen TLR7-Agonisten an SIV-infizierten Affen bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2012 INCY-US  BW   New Data for Jakafi® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/21/2012 30161Q10 BW   Exelixis Announces February 28 Webcast of Presentation at the Citi Global Health Care Conference, 6/29/2012 07G69B-E  BW   Research and Markets: Product Profiles: Insulin Antidiabetics - Key Developers Compete for Basal Insulins Market,10/01/2012 VRTX-US   BW   Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2015 02043Q10  BW   Alnylam to Webcast Presentation at 33rd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2015 15117K10 BW   Cellectis confirme son éligibilité au dispositif PEA-PME,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/26/2010 53220K50  BW   Ligand to Present at the BMO Capital Markets Healthcare Conference on August 5,#N/A, 2/20/2013 45232710    BW   Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference," 1/23/2012 84763A10  BW   ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer Society",#N/A,10/24/2011 ARWR-US  BW   Arrowhead Research Corporation Acquires Roche RNA Assets and Site,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/16/2014 01535110 BW   Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors",#N/A, 1/13/2014 81257810    BW   Seattle Genetics Appoints John A. Orwin to Board of Directors,#N/A," 9/04/2013 09062X10    BW   Biogen Idec’s ELOCTATE and ALPROLIX Will Grow the Hemophilia Market, a ZoomRx Study Finds",#N/A,#N/A, 2/25/2016 GILD-US      BW   Gilead gibt Ergebnisse der ersten Studie zur Untersuchung des Wechsels von Präparaten auf Basis von auf Truvada® (F/TDF) zu Präparaten auf Basis von F/TAF bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2012 INCY-US  BW   New Data for Jakafi® (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2012 30161Q10 BW   Exelixis Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares, 6/29/2012 07G69B-E  BW   Research and Markets: Pharmaceutical R&D Trends 2012, 9/25/2012 VRTX-US   BW   Vertex Announces Presentation of Data at North American Cystic Fibrosis Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/05/2015 02043Q10  BW   Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/15/2015 15117K10 BW   Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/22/2010 53220K50  BW   Ligand to Report Second Quarter Results on August 5th,#N/A," 2/01/2013 07G69B-E    BW   Research and Markets: Global Array Instruments Market 2012-2016 with Bio-Rad Laboratories Inc., Siemens and Illumina Inc. Dominating", 1/04/2012 84763A10  BW   Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference,#N/A,10/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/10/2014 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014",#N/A, 1/08/2014 81257810    BW   Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie,#N/A, 9/03/2013 09062X10    BW   Biogen Idec to Present at the Stifel Nicolaus 2013 Global Healthcare Conference,#N/A,#N/A, 2/24/2016 GILD-US      BW   Gilead annonce les résultats de la première étude visant à évaluer le basculement vers des régimes à base de F/TAF à partir de régimes (F/TDF) à base de Truvada®,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2012 INCY-US  BW   Incyte to Present at the Oppenheimer 23rd Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2012 30161Q10 BW   Exelixis Announces February 14 Webcast of Presentation at 14th Annual BIO CEO & Investor Conference," 6/25/2012 060RWY-E  BW   For the Treatment of Multiple Sclerosis, More Than 85 Percent of Surveyed Neurologists in the EU5 Expect to Prescribe Biogen Idec’s BG-12, Sanofi/Genzyme’s Aubagio and Sanofi/Genyzme/Bayer Healthcare’s Lemtrada"," 9/25/2012 008S9H-E  BW   Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/19/2014 02043Q10  BW   Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2015 15117K10 BW   Cellectis Plant Sciences acquiert des droits de propriété intellectuelle sur la technologie CRISPR appliquée aux plantes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 7/15/2010 53220K50  BW   Ligand Launches New Corporate Web Site,#N/A," 1/31/2013 0CNWYH-E    BW   Research and Markets: Global DNA Sequencing Products Market 2012-2016 with Hoffmann-La Roche Ltd., Knome Inc. and RainDance Technologies Inc. Dominating",12/12/2011 84763A10  BW   Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications,#N/A, 9/15/2011 05TJN5-E BW   Elan Announces Board of Director Changes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2014 01535110 BW   Alexion and Cincinnati Children’s Launch Rare Disease Innovation Fund,#N/A, 1/06/2014 81257810    BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A, 8/29/2013 09062X10    BW   Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference,#N/A,#N/A, 2/24/2016 GILD-US      BW   Gilead kondigt resultaten aan van de eerste studie voor het beoordelen van het overschakelen van op Truvada® (F/TDF) gebaseerde regimes naar op F/TAF gebaseerde regimes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/19/2012 INCY-US  BW   Incyte to Present at the 24th Annual Piper Jaffray Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2012 30161Q10 BW   Exelixis Announces Pricing of $60.5 Million Public Offering of Common Stock, 6/22/2012 07G69B-E  BW   Research and Markets: Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process," 9/25/2012 92532F10  BW   Vertex annonce de nouvelles données sur l'ALS-2200 chez les personnes atteintes d'une hépatite C, soutenant son passage aux études de phases 2 orales en 2012; fin du développement de l'ALS-2158",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2014 02043Q10  BW   Alnylam Elects Michael W. Bonney to Its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/14/2015 15117K10 BW   Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/15/2010 53220K50  BW   Ligand Board Authorizes Reverse Stock Split and $10 Million Share Repurchase,#N/A, 1/28/2013 45232710    BW   Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012,"12/12/2011 84763A10  BW   Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement",#N/A, 8/08/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/17/2014 01535110 BW   FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG),#N/A,12/10/2013 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data in Diffuse Large B-cell Lymphoma (DLBCL) at ASH 2013,#N/A, 7/26/2013 009GL4-E    BW   Biogen Idec and Adimab Expand Collaboration,#N/A,#N/A, 2/24/2016 GILD-US      BW   Gilead annuncia i risultati derivati dal primo studio inteso a valutare i regimi a base di F/TAF in sostituzione ai regimi a base di Truvada® (F/TDF),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2012 LLY-US   BW   Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 30161Q10 BW   Exelixis Announces Proposed Public Offering of Common Stock, 6/19/2012 0B7PKX-E  BW   BayBio: Ten U.S. High School Students Win Biotechnology Research Competition, 9/18/2012 VRTX-US   BW   Yuchun Lee Appointed to the Vertex Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/12/2014 02043Q10  BW   Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs”",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2015 15117K10 BW   Cellectis Plant Sciences publie une étude démontrant la réduction de la formation d’acrylamide dans les pommes de terre,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 6/02/2010 53220K50  BW   Ligand to Present at the Jefferies Global Life Sciences Conference on June 9,#N/A, 1/15/2013 45232710    BW   Illumina Announces Recipients of Agricultural Greater Good Initiative Grants,"12/09/2011 84763A10  BW   Spectrum Pharmaceuticals Affirms Strong Patent Protection for FUSILEV® (levoleucovorin) Through December 31, 2019",#N/A, 8/01/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2014 01535110 BW   Alexion to Present at Investor Conferences,#N/A,12/09/2013 81257810    BW   Seattle Genetics Highlights Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2013,#N/A, 7/25/2013 09062X10    BW   Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter 2013,#N/A,#N/A, 2/24/2016 GILD-US      BW   Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2012 45337C10 BW   Incyte to Present at the Jefferies 2012 Global Healthcare Conference (London),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2012 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2011 Financial Results," 6/18/2012 SNY-FR    BW   Sanofi Sponsors 2012 BIO International Convention, Jun 18 - 21, 2012, in Boston MA, US"," 9/07/2012 92532F10  BW   Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Vertex Pharmaceuticals Inc. for Securities Fraud",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/11/2014 02043Q10  BW   Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2015 15117K10 BW   Cellectis interviendra à l’occasion de plusieurs conférences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/21/2010 53220K50  BW   Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma,#N/A," 1/15/2013 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Monday, January 28, 2013","12/09/2011 84763A10  BW   Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011",#N/A, 7/26/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2014 01535110 BW   Auf dem ERA-EDTA-Kongress vorgelegte neue Daten demonstrieren die Wirksamkeit von Soliris® (Eculizumab) bei einer Reihe von Patienten mit atypischem hämolytisch-urämischen Syndrom (aHUS),#N/A,12/09/2013 81257810    BW   Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013,#N/A, 7/19/2013 09062X10    BW   US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review,#N/A,#N/A, 2/24/2016 GILD-US      BW   Gilead anuncia los resultados del primer estudio que evalúa el cambio de regimenes basados en Truvada® (F/TDF) a regimenes basados en F/TAF,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2012 45337C10 BW   Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/06/2012 30161Q10 BW   Exelixis Announces February 8th Webcast of Fourth Quarter & Full Year 2011 Financial Results Conference Call, 6/18/2012 07G69B-E  BW   Research and Markets: Slovenia Pharmaceuticals and Healthcare Report Q3 2012, 9/06/2012 VRTX-US   BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/11/2014 02043Q10  BW   Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/09/2015 15117K10 BW   Cellectis Announces Presentations at Upcoming Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/06/2010 53220K50  BW   Ligand to Present at the MDB Capital Group Bright Lights Conference on May 11,#N/A, 1/08/2013 45232710    BW   Illumina Announces Sequencing Technology Innovations,12/07/2011 NVS-CH    BW   Decision Resources to Release Bladder Cancer Drug Market Forecast Through 2020,#N/A, 6/21/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2014 01535110 BW   De nouvelles données présentées au congrès de l’ERA-EDTA démontrent l’efficacité de Soliris® (éculizumab) chez un large éventail de patients atteints du syndrome hémolytique et urémique atypique (SHUa),#N/A,12/07/2013 81257810    BW   Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013,#N/A, 7/04/2013 09062X10    BW   Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE™,#N/A,#N/A," 2/23/2016 RBCM-RU      BW   Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2012 INCY-US  BW   Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2012 30161Q10 BW   Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma," 6/14/2012 SNY-FR    BW   Sanofi Announces Results of ORIGIN, the World’s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes", 9/04/2012 92532F10  BW   Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/08/2014 02043Q10  BW   Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1 Trial",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/08/2015 15117K10 BW   Cellectis Opens Labs and Offices in Manhattan, New York",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 5/05/2010 53220K50  BW   Ligand Pharmaceuticals Announces First Quarter Results,#N/A, 1/07/2013 06V2JT-E    BW   Partners HealthCare and Illumina Announce Founding Members of GeneInsight Network,12/07/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference,#N/A, 6/16/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2014 01535110 BW   New Data Presented at the ERA-EDTA Congress Demonstrate Efficacy of Soliris® (eculizumab) in Broad Range of Patients with atypical Hemolytic Uremic Syndrome (aHUS),#N/A,11/11/2013 81257810    BW   Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013,#N/A," 7/03/2013 09062X10    BW   Biogen Idec to Report Second Quarter 2013 Financial Results on July 25, 2013",#N/A,#N/A, 2/23/2016 GILD-US      BW   Gilead lanza nuevo programa de subvenciones para apoyar tratamientos contra el VIH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2012 45337C10 BW   Incyte to Report Third Quarter 2012 Financial Results on November 1,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2012 07T337-E BW   Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma, 6/14/2012 066807-E  BW   Surveyed U.S. Cardiologists and MCOs Indicate That Reduced Incidence of Mortality is the Greatest Unmet Need in Post-Myocardial Infarction; Xarelto Has Demonstrated Potential to Significantly Fulfill This Unmet Need, 8/08/2012 LGND-US   BW   Ligand Pharmaceuticals Announces Second Quarter Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/07/2014 02043Q10  BW   Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2015 C-US     BW   Citi Appointed Depositary Bank for Cellectis’ ADR Programme,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/26/2010 53220K50  BW   Ligand to Report First Quarter Results on May 5th,#N/A," 1/07/2013 006KW9-E    BW   Illumina Strengthens Leadership Position in Reproductive Health with Agreement to Acquire Verinata Health, Inc.",12/05/2011 84763A10  BW   Spectrum Pharmaceuticals Files IND Application with U.S. FDA for SPI-014,#N/A, 6/09/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2014 01535110 BW   Alexion Initiates Voluntary Nationwide Recall of Certain Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion Due to the Presence of Visible Particulate Matter in a Single Lot,#N/A,11/06/2013 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 7/02/2013 09062X10    BW   Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX™,#N/A,#N/A, 2/23/2016 GILD-US      BW   Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2012 INCY-US  BW   National Myelofibrosis Awareness Day to Launch on September 20,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/21/2011 EXEL-US  BW   Exelixis Licenses PI3K-Delta Program to Merck, 6/13/2012 06PD8S-E  BW   Health Quest at Taconic Crossing Receives CEO Cancer Gold Standard Accreditation, 7/30/2012 92532F10  BW   Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/04/2014 02043Q10  BW   Alnylam to Webcast R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/24/2015 15117K10 BW   Cellectis fixe les termes définitifs de son offre d’American Depositary Shares dans le cadre de son introduction en bourse sur le Nasdaq aux États-Unis d’Amérique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 4/20/2010 53220K50  BW   Ligand Earns $6.5 Million Milestone Payment from Roche,#N/A, 1/02/2013 ILMN-US     BW   Illumina to Webcast Live Presentation at the J.P. Morgan Healthcare Conference,"11/28/2011 84763A10  BW   Spectrum Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on Tuesday, November 29, 2011",#N/A, 5/12/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/07/2014 01535110 BW   Neue Daten zu der schweren Erkrankung Hypophosphatasie (HPP) und Therapiewirkung von Asfotase Alfa bei Säuglingen, Kindern und Jugendlichen mit HPP auf der Jahrestagung der Pediatric Academic Societies vorgelegt",#N/A,11/05/2013 81257810    BW   Seattle Genetics Reports Third Quarter 2013 Financial Results,#N/A, 7/01/2013 BIIB-US     BW   Myelin Repair Foundation Grants License for Novel Mouse Model to Biogen Idec,#N/A,#N/A, 2/22/2016 GILD-US      BW   Gilead lanceert nieuw toelagenprogramma ter ondersteuning van hiv-genezing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2012 INCY-US  BW   Jakavi® (ruxolitinib) First Medication to Receive European Commission Approval to Treat Patients with Myelofibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/14/2011 30161Q10 BW   Exelixis Announces January 11 Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference, 6/13/2012 0BNPX5-E  BW   Patent Expirations Put More Than $290 Billion in Prescription Drug Sales at Risk Through 2018, 7/30/2012 92532F10  BW   Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/03/2014 02043Q10  BW   Alnylam to Webcast Presentation at the Oppenheimer 25th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/24/2015 15117K10 BW   Cellectis Prices Initial Public Offering of American Depositary Shares,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/29/2010 53220K50  BW   Ligand Presents First-in-Human Phase I Data on Lead SARM Molecule LGD-4033 at the International Congress of Endocrinology,#N/A,11/29/2012 ILMN-US     BW   Illumina Names Dr. Robert S. Epstein to its Board of Directors,11/21/2011 84763A10  BW   FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment,#N/A, 5/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/06/2014 01535110 BW   Nouvelles données sur la nature dévastatrice de l’hypophosphatasie (HPP) et l’effet du traitement par asfotase alfa chez les nourrissons, les enfants en bas âge et les jeunes atteints de HPP présentées lors du congrès des Sociétés académiques de pédiatrie",#N/A,"10/21/2013 81257810    BW   Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer",#N/A, 6/24/2013 09062X10    BW   Biogen Idec stellt Engagement für Fortschritte in der Hämophiliebehandlung auf dem ISTH-Kongress in den Vordergrund,#N/A,#N/A, 2/22/2016 GILD-US      BW   Gilead startet neues Finanzhilfeprogramm zur Unterstützung der Heilung von HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/23/2012 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/07/2011 30161Q10 BW   Exelixis’ Cabozantinib Shows Encouraging Clinical Activity in Patients With Metastatic Breast Cancer, 6/12/2012 05QZSX-E  BW   Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ (alemtuzumab) for Multiple Sclerosis," 7/27/2012 92532F10  BW   Vertex erhält europäische Zulassung für KALYDECO™ (Ivacaftor), das erste Medikament zur ursächlichen Behandlung von Mukoviszidose bei Menschen mit einer speziellen Genmutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/01/2014 02043Q10  BW   New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/24/2015 15117K10 BW   Cellectis annonce le dépôt d’une version modifiée de son document d’enregistrement “Form F-1” en vue de son introduction en bourse sur le Nasdaq aux États-Unis d’Amérique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/12/2010 53220K50  BW   Ligand Announces Approval for Revolade® in Europe,#N/A,"11/26/2012 GNOM.XX2-US BW   Illumina Announces New Ruling in its Patent Litigation Against Complete Genomics, Inc.",11/09/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference,#N/A, 5/03/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/05/2014 01535110 BW   New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting",#N/A,"10/15/2013 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5, 2013",#N/A, 6/24/2013 09062X10    BW   Biogen Idec Showcases Commitment to Advancing Hemophilia Treatment and Care at ISTH Congress,#N/A,#N/A, 2/22/2016 GILD-US      BW   Gilead lance un nouveau programme de subventions pour soutenir les traitements contre le VIH,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2012 INCY-US  BW   Incyte to Present at the 32nd Annual Canaccord Genuity Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/29/2011 30161Q10 BW   Reminder: Exelixis Announces Webcast of Annual R&D Day on This Thursday, December 1", 6/08/2012 05LWSW-E  BW   Global OTC Drug Market Analysis by Kalorama Information Now Available at MarketPublishers.com," 7/27/2012 92532F10  BW   Vertex reçoit l'approbation européenne pour le KALYDECO™ (ivacaftor), le premier médicament à traiter la cause à l'origine de la mucoviscidose chez les personnes présentant une mutation génétique spécifique (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2014 02043Q10  BW   Alnylam to Webcast Presentations at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/18/2015 15117K10 BW   Cellectis annonce le lancement de son introduction en bourse sur le Nasdaq aux Etats-Unis d’Amérique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 3/01/2010 53220K50  BW   Ligand to Present at the Cowen & Company 30th Annual Healthcare Conference on March 11,#N/A,11/14/2012 ILMN-US     BW   Illumina to Webcast Live Presentation at Piper Jaffray Health Care Conference,"10/28/2011 84763A10  BW   Spectrum Pharmaceuticals, Inc. Reports Strongest Financial Position in Company History: Record Revenues, Profits, and Cash Generated from Operations for the Three- and Nine-Month Periods Ended September 30, 2011",#N/A, 4/27/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2014 01535110 BW   FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS,#N/A,10/11/2013 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma,#N/A, 6/04/2013 09062X10    BW   Biogen Idec 2013 Annual Shareholder Meeting Webcast,#N/A,#N/A, 2/22/2016 GILD-US      BW   Gilead lancia un nuovo programma di sovvenzioni per promuovere la cura dell'infezione da HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/02/2012 NVS-CH   BW   CORRECTING and REPLACING Incyte Reports 2012 Second-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/28/2011 30161Q10 BW   Exelixis Signs CRADA With National Cancer Institute to Expand Development Plan of Cabozantinib, 6/04/2012 097TF8-E  BW   Cegedim Relationship Management Expands its Global Partnership with Sanofi to Deploy Next-Generation Commercial Effectiveness Solutions in Mature and Emerging Markets," 7/27/2012 92532F10  BW   Vertex Receives European Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2014 02043Q10  BW   Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2015 15117K10 BW   Cellectis: 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/19/2010 LGND-US   BW   A.P. Pharma Appoints Stephen R. Davis to Its Board of Directors,#N/A,"11/12/2012 05WNSJ-E    BW   VWR International, LLC to Distribute Illumina’s qPCR Portfolio",10/24/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Third Quarter and Nine-Month 2011 Financial Results Conference Call,#N/A, 4/06/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2014 01535110 BW   Alexion to Present at Investor Conferences,#N/A,10/02/2013 81257810    BW   Seattle Genetics Announces Clinical Leadership Appointments,#N/A, 5/29/2013 09062X10    BW   Biogen Idec afianza su compromiso con la comunidad EM en la 5ª edición anual del  Día Mundial de la Esclerosis Múltiple,#N/A,#N/A, 2/22/2016 GILD-US      BW   Gilead Launches New Grants Program to Support HIV Cure,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2012 45337C10 BW   Incyte to Report Second Quarter 2012 Financial Results on August 2,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/22/2011 30161Q10 BW   Exelixis Announces November 29th Webcast of Presentation at the Piper Jaffray Health Care Conference," 6/04/2012 ALNY-US   BW   Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting"," 7/19/2012 0CC5K6-E  BW   The Fallon Company, Vertex Pharmaceuticals Celebrate “Topping Off” of Fan Pier’s Second Commercial Tower",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/14/2014 02043Q10  BW   Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2015 15117K10 BW   Cellectis : les comptes consolidés pour l’exercice 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/09/2010 53220K50  BW   Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results,#N/A,11/07/2012 ILMN-US     BW   Illumina Announces Winners of MiSeq® Grant Program,10/19/2011 84763A10  BW   LifeSci Advisors Publishes FUSILEV Survey Results,#N/A, 3/08/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2014 01535110 BW   Alexion Reports First Quarter 2014 Results,#N/A, 9/04/2013 81257810    BW   Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference,#N/A, 5/29/2013 09062X10    BW   Biogen Idec renforce son engagement à l'égard de la communauté des personnes affectées par la sclérose en plaques lors de la 5e Journée mondiale de la SEP,#N/A,#N/A, 2/17/2016 GILD-US      BW   La FDA de EE.UU. aprueba dos indicaciones suplementarias de Harvoni® para pacientes con hepatitis C crónica con enfermedad hepática avanzada,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/26/2012 INCY-US  BW   Incyte to Present at the JMP Securities 7th Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2011 30161Q10 BW   Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women with Hormone Receptor-Positive Metastatic Breast Cancer and Bone Metastases," 6/01/2012 SNY-FR    BW   Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis", 7/18/2012 92532F10  BW   Vertex Announces the Date of its Second Quarter 2012 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2014 02043Q10  BW   Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/20/2015 15117K10 BW   Cellectis annonce le dépôt d'un document d’enregistrement “Form F-1” en vue de son projet d’introduction en bourse au Nasdaq aux États-Unis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 2/01/2010 53220K50  BW   Ligand to Report Fourth Quarter Results on February 9th,#N/A,11/07/2012 45232710    BW   Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service," 9/28/2011 84763A10  BW   Spectrum Pharmaceuticals Strengthens Commercial Operations with Appointment of Brian Holzer MD, MBA as Executive Director of Brand Management",#N/A, 2/10/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2014 01535110 BW   Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica (NMO) and Refractory Generalized Myasthenia Gravis (MG),#N/A, 8/15/2013 81257810    BW   Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma (DLBCL),#N/A, 5/29/2013 09062X10    BW   Biogen Idec rafforza l'impegno nei confronti della comunità della SM nella 5a Giornata Mondiale della Sclerosi Multipla,#N/A,#N/A, 2/17/2016 GILD-US      BW   FDA genehmigt in den USA zwei weitere Indikationen für Harvoni® bei Patienten mit chronischer Hepatitis C und fortgeschrittener Lebererkrankung,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/22/2012 07GVF3-E BW   Research and Markets: The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2011 30161Q10 BW   Exelixis Announces Webcast of Annual R&D Day on December 1, 5/30/2012 SNY-FR    BW   Genzyme Recognizes World MS Day, 6/29/2012 92532F10  BW   Abschließende Daten aus der Phase-II-Kombinationsstudie zu VX-809 und KALYDECO™ (Ivacaftor) zeigen statistisch signifikante Verbesserungen der Lungenfunktion bei Menschen mit Mukoviszidose mit zwei Exemplaren der F508del-Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2014 02043Q10  BW   Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2015 15117K10 BW   Assemblée Générale mixte des actionnaires de Cellectis SA du 16 février 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
 1/28/2010 53220K50  BW,#N/A,11/06/2012 ILMN-US     BW   Biomatters’ Molecular Profiler Now Available in Illumina’s BaseSpace Apps, 9/26/2011 84763A10  BW   Spectrum Pharmaceuticals Completes Enrollment in the Belinostat Pivotal Trial for Relapsed/Refractory Peripheral T-Cell Lymphoma,#N/A, 2/09/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2014 01535110 BW   European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation,#N/A, 7/31/2013 81257810    BW   Seattle Genetics Reports Second Quarter 2013 Financial Results,#N/A, 5/29/2013 09062X10    BW   Biogen Idec Reinforces Commitment to MS Community on 5th Annual World MS Day,#N/A,#N/A, 2/16/2016 GILD-US      BW   La FDA des États-Unis approuve deux indications supplémentaires pour le Harvoni® pour les patients atteints d'hépatite C chronique avec une maladie du foie à un stade avancé,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/04/2012 45337C10 BW   Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2011 30161Q10 BW   Exelixis’ Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic Analgesic Use in Patients with Previously Treated mCRPC, 5/30/2012 060RWY-E  BW   Russia’s Colorectal Cancer Drug Market Projected to Grow to More Than $480 Million in 2016, 6/29/2012 92532F10  BW   Les données finales d'une étude de phase 2 portant sur l'usage combiné de VX-809 et de KALYDECO™ (ivacaftor) ont démontré des améliorations statistiquement significatives de la fonction pulmonaire...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2014 02043Q10  BW   Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/17/2015 15117K10 BW   Cellectis SA Shareholders General Meeting of February 16, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/23/2012 45232710    BW   Illumina Reports Financial Results for Third Quarter of Fiscal Year 2012, 9/23/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference,#N/A, 2/04/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2014 01535110 BW   La Commission européenne accorde la désignation de médicament orphelin à Soliris® (Éculizumab) pour la prévention du rejet du greffon après une transplantation d’organe plein,#N/A," 7/17/2013 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2013 Financial Results on July 31, 2013",#N/A, 5/29/2013 09062X10    BW   Biogen Idec bekräftigt sein Engagement für die MS-Community auf 5. Welt-MS-Tag,#N/A,#N/A, 2/16/2016 GILD-US      BW   La FDA statunitense approva due indicazioni supplementari per Harvoni® per l'epatite C cronica in pazienti con epatopatia in stadio avanzato,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2012 45337C10 BW   New Data for Jakafi® (ruxolitinib) Presented at 2012 ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2011 30161Q10 BW   Preliminary Data Demonstrate that 40 mg Daily Dose of Cabozantinib Yields a High Rate of Bone Scan Response in mCRPC, 5/29/2012 SNY-FR    BW, 6/28/2012 92532F10  BW   Final Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/05/2014 02043Q10  BW   Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/13/2015 15117K10 BW   Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/18/2012 45232710    BW   Illumina Comments on a Ruling in its Patent Litigation Against Complete Genomics, Inc.", 9/20/2011 84763A10  BW   Spectrum Pharmaceuticals Receives Approximately $25 Million from Warrant Exercise,#N/A, 1/18/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2014 01535110 BW   Europäische Kommission erteilt Soliris® (Eculizumab) den Orphan-Arzneimittel-Status für die Prävention der Abstoßung nach Organtransplantation,#N/A, 7/15/2013 81257810    BW   Seattle Genetics Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML),#N/A, 5/28/2013 09062X10    BW   Biogen Idec to Present at the Jefferies 2013 Global Healthcare Conference,#N/A,#N/A, 2/16/2016 GILD-US      BW   De Amerikaanse FDA heeft twee bijkomende indicaties goedgekeurd voor Harvoni® bij patiënten met chronische hepatitis C met gevorderde leverziekte,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2012 INCY-US  BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2011 30161Q10 BW   Exelixis Announces November 15th Webcast of Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference," 5/23/2012 060RWY-E  BW   Since the Dialysis Bundle Legislation Was Implemented in January 2011, Bundling Appears to Have Limited Impact on Medications Used for Dialysis Patients According to a Recent BioTrends Chart Study"," 6/22/2012 07G69B-E  BW   Research and Markets: Global Hepatitis C Drugs Market 2011-2015 Features Players GlaxoSmithKline plc, Roche Holding Ltd and Merck & Co. Inc",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2014 02043Q10  BW   Alnylam to Webcast Presentation at the Nomura Biotechnology Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/13/2015 15117K10 BW   Cellectis et l’Ohio State University, via l’Ohio State Innovation Foundation, concluent un accord de licence portant sur la technologie CAR ciblant le myélome multiple",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/16/2012 ILMN-US     BW   Illumina Launches Infinium® HumanCore Arrays for Economical Large-Scale Genetic Studies, 9/19/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Impressive Responses in Difficult to Treat Carcinomas with SPI-1620 in a Phase I Study,#N/A, 1/18/2011 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2014 01535110 BW   Alexion Announces the Appointment of John T. Mollen to Its Board of Directors,#N/A," 6/27/2013 81257810    BW   Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration",#N/A, 5/24/2013 07G69B-E    BW   Research and Markets: PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022,#N/A,#N/A, 2/16/2016 GILD-US      BW   U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2012 07GVF3-E BW   Research and Markets: Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/31/2011 30161Q10 BW   Exelixis to Initiate Cabozantinib ‘306 Trial with Pain Endpoint in mCRPC, 5/22/2012 07G69B-E  BW   Research and Markets: 2012 Report on the $200 Billion US Pharmaceutical Manufacturing Industry, 6/18/2012 VRTX-US   BW   Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2014 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2015 15117K10 BW   Cellectis Plans to Conduct Registered Initial Public Offering in the U.S.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/15/2012 45232710    BW   Illumina to Announce Third Quarter 2012 Results on Tuesday, October 23, 2012", 9/16/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,12/22/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2014 01535110 BW   Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research,#N/A, 6/25/2013 81257810    BW   Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer,#N/A, 5/24/2013 07G69B-E    BW   Research and Markets: PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022,#N/A,#N/A, 2/08/2016 GILD-US      BW   Gilead Sciences to Participate in Two Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2012 45337C10 BW   Incyte to Present at the Bank of America Merrill Lynch 2012 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2011 30161Q10 BW   Exelixis Announces Third Quarter 2011 Financial Results, 5/18/2012 07G69B-E  BW   Research and Markets: Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion, 6/14/2012 VRTX-US   BW   Vertex Announces Webcast of its Presentation at the 2012 Wells Fargo Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/29/2014 02043Q10  BW   Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2015 15117K10 BW   Cellectis envisage une introduction en bourse aux États-Unis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 9/19/2012 064CYH-E    BW   Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening Solutions", 9/13/2011 84763A10  BW   Spectrum Pharmaceuticals Initiates Stock Repurchase Program,#N/A,12/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/10/2014 01535110 BW   Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014",#N/A, 6/21/2013 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at International Conference on Malignant Lymphoma,#N/A, 5/23/2013 09062X10    BW   Biogen Idec nomina Spyros Artavanis-Tsakonas Chief Scientific Officer,#N/A,#N/A, 2/06/2016 GILD-US      BW   Gilead Sciences gibt Finanzergebnisse für viertes Quartal und Gesamtjahr 2015 bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2012 45337C10 BW   Incyte Reports 2012 First-Quarter Financial Results; Updates Shareholders on Commercial Activity and Key Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2011 EXEL-US  BW   Exelixis Appoints Executive Vice President and Chief Commercial Officer, 5/11/2012 07G69B-E  BW   Research and Markets: Cambodia Pharmaceuticals and Healthcare Report Q2 2012, 6/08/2012 92532F10  BW   Vertex Appoints Ken Horton as Executive Vice President and Chief Legal Officer and Announces Retirement of Nancy Wysenski as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/28/2014 02043Q10  BW   Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2015 15117K10 BW   Cellectis annonce la délivrance par l'USPTO d'un brevet majeur sur l’ingénierie des génomes induite par nucléases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/18/2012 45232710    BW   Illumina Awarded FDA Contract for Next Generation Sequencing (NGS) Technology to Identify Foodborne Pathogens, 9/09/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference,#N/A,"12/16/2010 06GVMY-E BW   Arrowhead Research to Report Fiscal 2010 Fourth Quarter and Year-End Financial Results and Host Conference Call on Wednesday, December 22, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/10/2014 01535110 BW   Alexion Revises Upward 2014 Financial Guidance for Revenues and non-GAAP EPS,#N/A, 6/19/2013 81257810    BW   Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma,#N/A, 5/23/2013 09062X10    BW   Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer,#N/A,#N/A, 2/05/2016 GILD-US      BW   Gilead Sciences annonce ses résultats financiers pour le quatrième trimestre et l’exercice 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2012 NVS-CH   BW   Incyte Announces EU Regulatory Milestone for Ruxolitinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2011 30161Q10 BW   Exelixis’ Cabozantinib Meets Primary Endpoint in Phase 3 Clincial Trial for Medullary Thyroid Cancer, 5/10/2012 07GVF3-E  BW   Research and Markets: Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019, 6/07/2012 92532F10  BW   Daten aus der Nachfolgestudie zu KALYDECO™ (Ivacaftor) zeigen dauerhafte Verbesserungen der Lungenfunktion und anderer Krankheitsmesswerte bei Menschen mit Mukoviszidose mit einer speziellen Genmutation (G551D),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/20/2014 02043Q10  BW   Alnylam Launches Alnylam Assist™, Dedicated to Providing Support to Patients, Families, and Caregivers in Certain Genetic Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2015 15117K10 BW   Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based “gene editing” Method,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/18/2012 ILMN-US     BW   Illumina Introduces TruSeq® Stranded mRNA and Total RNA Sequencing Sample Preparation Solutions, 9/01/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference,#N/A,12/09/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2014 01535110 BW   Alexion to Present at the Barclays Global Healthcare Conference,#N/A, 6/10/2013 81257810    BW   Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse,#N/A, 5/23/2013 BIIB-US     BW   Biogen Idec nomme Spyros Artavanis-Tsakonas conseiller scientifique en chef,#N/A,#N/A, 2/05/2016 GILD-US      BW   Gilead Sciences maakt financiële resultaten van het vierde kwartaal en van het gehele jaar 2015 bekend,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/13/2012 07KV6X-E BW   U.S. Senators Carper and Coons Join Delaware Bio to Honor 2012 Annual Award Winners,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2011 30161Q10 BW   Exelixis Announces October 27th Webcast of Third Quarter 2011 Financial Results Conference Call, 5/10/2012 ALNY-US   BW, 6/07/2012 92532F10  BW   Les données issues de l'étude de suivi de KALYDECO™ (ivacaftor) ont démontré des améliorations de la fonction pulmonaire et d'autres mesures de maladie chez les personnes atteintes de mucoviscidose qui ont une mutation génétique spécifique (G551D),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/14/2014 02043Q10  BW   Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2014 15117K10 BW   Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 00CX0X-E    BW   Illumina Launches TruSightTM Targeted Sequencing Content Sets," 8/04/2011 84763A10  BW   Spectrum Pharmaceuticals Generates Cash from Operations, Reports Third Consecutive Profitable Quarter, and Record Revenue for the Three- and Six-Month Periods Ended June 30, 2011; Strongest Financial Position in Company History",#N/A,12/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/03/2014 01535110 BW   NICE Confirms AGNSS Positive Assessment that Eculizumab (Soliris®) is a Very Effective Treatment for aHUS Patients and Produces Substantial Quality-Adjusted Life Year Gains of a Magnitude Rarely Seen for a New Drug,#N/A, 6/02/2013 81257810    BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting,#N/A, 5/23/2013 09062X10    BW   Biogen Idec nombra Director Científico a Spyros Artavanis-Tsakonas,#N/A,#N/A, 2/05/2016 GILD-US      BW   Gilead Sciences comunica i risultati finanziari registrati nel quarto trimestre e nell’intero esercizio 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/10/2012 45337C10 BW   Incyte to Report First Quarter 2012 Financial Results on April 26,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2011 30161Q10 BW   Exelixis Announces September 27th Webcast of Presentation at the JMP Securities Healthcare Conference, 5/04/2012 08CP0Z-E  BW   Research and Markets: Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019, 6/07/2012 064Q9G-E  BW   Data From Follow-Up Study of KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2014 02043Q10  BW   Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2014 15117K10 BW   Cellectis plant sciences et la Fondation 2Blades ont conclu un accord de licence croisée sur les nucléases effectrices TAL,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 ILMN-US     BW   Illumina Announces Expedited Individual Genome Sequencing Service (IGS), 7/27/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Its Second Quarter and Six-Month 2011 Financial Results Conference Call,#N/A,11/29/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2014 01535110 BW   Alexion begeht gemeinsam mit Patientenorganisationen in aller Welt den Tag der seltenen Erkrankungen 2014,#N/A, 5/29/2013 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 5/23/2013 09062X10    BW   Biogen Idec ernennt Spyros Artavanis-Tsakonas zum Chief Scientific Officer,#N/A,#N/A, 2/03/2016 GILD-US      BW   Gilead Sciences anuncia declaración de dividendo en efectivo para el primer trimestre y aumentos en los programas de beneficios sobre la inversión de los accionistas,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/29/2012 45337C10 BW   Phase III studies of Jakafi™ (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2011 30161Q10 BW   Exelixis Announces Webcasts of Upcoming Investor Conference Presentations," 5/03/2012 80105N10  BW   Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant", 5/30/2012 0C8MHH-E  BW   Ember Therapeutics Expands Scientific Leadership to Advance Metabolic Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/01/2014 02043Q10  BW   Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2014 15117K10 BW   Cellectis annonce trois présentations orales lors du 56e congrès annuel de l’American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/11/2012 06V2JT-E    BW   Illumina and Partners HealthCare Announce Alliance to Introduce Next-Generation Sequencing Clinical Interpretation and Reporting Tools, 6/21/2011 84763A10  BW   Spectrum Pharmaceuticals Has Ample Supplies of FUSILEV® to Meet the Growing Demand of Colorectal Cancer Patients in the U.S.,#N/A,11/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2014 01535110 BW   Alexion rejoint les associations de patients à travers le monde pour reconnaître la Journée des maladies rares 2014,#N/A, 5/14/2013 81257810    BW   Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA,#N/A, 5/22/2013 09062X10    BW   Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference,#N/A,#N/A, 2/03/2016 GILD-US      BW   Gilead Sciences anuncia resultados financieros correspondientes al cuarto trimestre y al ejercicio completo 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2012 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2011 30161Q10 BW   Exelixis Reaches Pre-Specified Number of Events for Final Data Analysis in EXAM Trial," 5/01/2012 066807-E  BW   For Ulcerative Colitis, Remicade’s Efficacy in Inducing Remission is Comparable to That of Oral Prednisone and Intravenous Cyclosporine but is at a Disadvantage to Intravenous Methylprednisolone on This Measure", 5/30/2012 92532F10  BW   Vertex legt korrigierte und zusätzliche Daten aus der jüngsten Zwischenanalyse einer Phase-2-Kombinationsstudie über VX-809 und KALYDECO™ (Ivacaftor)...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2014 02043Q10  BW   Alnylam to Webcast Presentation at Leerink Partners Rare Disease Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2014 15117K10 BW   Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/10/2012 ILMN-US     BW   Illumina Names Paul Bianchi as Senior Vice President of Human Resources," 6/20/2011 84763A10  BW   Spectrum Pharmaceuticals’ ZEVALIN® Was Highlighted During Oral Presentations and Abstracts at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland",#N/A,11/04/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2014 01535110 BW   Alexion Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2014,#N/A, 5/09/2013 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 5/21/2013 BIIB-US     BW   Q1 Productions Hosts 2nd Annual Strengthening Patient Advocacy Relations across the Life Science Industry Conference,#N/A,#N/A, 2/03/2016 GILD-US      BW   Gilead Sciences annonce la déclaration du dividende en espèces du premier trimestre et des augmentations dans les programmes de rendements pour actionnaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2012 45337C10 BW   Incyte Reports 2011 Fourth-Quarter and Full-Year Financial Results; Provides 2012 Financial Guidance; Updates Shareholders on Key Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2011 30161Q10 BW   Exelixis Announces September 8th Webcast of Presentation at the Stifel Nicolaus Healthcare Conference, 4/30/2012 WBA-US    BW   Nation’s Top Employers Share Strategies to Improve Employee Well-Being While Reducing Health Care Spending at Walgreens Second Annual Employer Health and Wellness Executive Client Forum, 5/29/2012 92532F10  BW   Vertex corrige ses résultats et fournit des données complémentaires issues d’une récente analyse intermédiaire de l’étude de phase 2 du VX-809 et du KALYDECO™ (ivacaftor) pris en association chez les personnes atteintes...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/24/2014 02043Q10  BW   Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2014 15117K10 BW   Cellectis Received Proceeds of €13 Million Through the Exercise of Warrants,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/04/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in September, 6/15/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Authorization of Stock Repurchase Program up to $25 Million,#N/A,10/27/2010 ARWR-US  BW   NanoIntegris and Unidym Execute Global Distribution Agreement for HiPco Carbon Nanotubes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2014 01535110 BW   Alexion to Present at the Cowen and Company 34th Annual Health Care Conference,#N/A, 5/07/2013 81257810    BW   Seattle Genetics Reports First Quarter 2013 Financial Results,#N/A, 5/21/2013 09062X10    BW   Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY™ (Peginterferone Beta-1a) per la sclerosi multipla,#N/A,#N/A, 2/03/2016 GILD-US      BW   Gilead Sciences kündigt Bardividende für 1. Quartal und Erhöhungen der Aktionärsdividendenprogramme an,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2012 45337C10 BW   Incyte to Present at the Leerink Swann 2012 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2011 30161Q10 BW   Exelixis Announces August 10th Webcast of Presentation at the Canaccord Genuity Growth Conference," 4/27/2012 IMGN-US   BW   ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update", 5/29/2012 064Q9G-E  BW   Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/19/2014 02043Q10  BW   Alnylam to Webcast Presentation at 21st Annual NewsMakers in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2014 15117K10 BW   L’exercice des BSA a rapporté à Cellectis 13 millions d’euros de recettes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/29/2012 HLCSQ-US    BW   Illumina Announces Favorable Outcome of its Patent Litigation Against Helicos BioSciences Corporation, 6/14/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Annual Meeting of Shareholders,#N/A,10/26/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2014 01535110 BW   La Commission européenne accorde la désignation de médicament orphelin à Soliris® (Éculizumab) pour la prévention du retard de fonctionnement du greffon (DGF - Delayed Graft Function) après la transplantation d'organes pleins,#N/A, 4/29/2013 DHC-US      BW   Senior Housing Properties Trust Announces 2013 First Quarter Results,#N/A, 5/21/2013 09062X10    BW   Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis,#N/A,#N/A, 2/02/2016 GILD-US      BW   Gilead Sciences maakt declaratie bekend van dividend in contanten voor het eerste kwartaal en verhogingen in aandeelhoudersrendementprogramma's,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/26/2012 45337C10 BW   Incyte to Report Fourth Quarter/Year-End 2011 Financial Results on February 15,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/04/2011 30161Q10 BW   Exelixis Announces Second Quarter 2011 Financial Results, 4/27/2012 80105N10  BW   Sanofi CFO Jérôme Contamine Comments on Q1 2012 Results, 5/25/2012 VRTX-US   BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/16/2014 02043Q10  BW   Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2014 15117K10 BW   Cellectis : Technologie TALENTM : délivrance du brevet EP 2 510 096 par l’Office Européen des Brevets,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/07/2012 065C1X-E    BW   NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences, 6/13/2011 09ZV3Y-E  BW   Spectrum Pharmaceuticals’ Chairman and Chief Executive Officer Named an Ernst & Young Orange County Region Entrepreneur of the Year® Award Winner,#N/A,10/18/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2014 01535110 BW   Europäische Kommission erkennt Soliris® (Eculizumab) als Orphan-Medikament zur Prävention verzögerter Transplantatfunktionen nach soliden Organtransplantationen an,#N/A," 4/18/2013 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013",#N/A, 5/21/2013 BIIB-US     BW   Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY™ (peginterféron bêta-1a) contre la sclérose en plaques,#N/A,#N/A, 2/02/2016 GILD-US      BW   Gilead Sciences annuncia la dichiarazione del dividendo in contanti per il primo trimestre e degli aumenti per quanto concerne i programmi per la crescita del rendimento a favore degli azionisti,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/20/2011 45337C10 BW   Incyte to Present at the 30th Annual J. P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2011 EXEL-US  BW   Research and Markets: Investigational Drug Review and Outlook 2011," 4/27/2012 80105N10  BW   Jérôme Contamine, Directeur Financier de Sanofi, commente les résultats du T1 2012"," 5/25/2012 92532F10  BW   Vertex reçoit l'aval du CHMP, section européenne, pour KALYDECO™ (Ivacaftor), premier médicament pour le traitement de la cause sous-jacente de la fibrose kystique",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/15/2014 02043Q10  BW   Alnylam Strengthens Management Team with New Key Appointments,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2014 15117K10 BW   Cellectis: TALENTM Technology: Grant of EP 2 510 096 by the European Patent Office,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/24/2012 ILMN-US     BW   Illumina Reports Financial Results for Second Quarter of Fiscal Year 2012," 6/13/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management",#N/A, 9/29/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2014 01535110 BW   European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for Prevention of Delayed Graft Function (DGF) after Solid Organ Transplantation,#N/A, 4/09/2013 81257810    BW   Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR,#N/A, 5/21/2013 09062X10    BW   Biogen Idec reicht Zulassungsantrag für PLEGRIDY™ (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein,#N/A,#N/A, 2/02/2016 GILD-US      BW   Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/12/2011 45337C10 BW   First FDA-Approved Treatment for Myelofibrosis, Jakafi™ (ruxolitinib), Discussed in Multiple Presentations at 2011 ASH Annual Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2011 30161Q10 BW   Exelixis Announces August 4th Webcast of Second Quarter 2011 Financial Results Conference Call, 4/26/2012 05VJM5-E  BW   Research and Markets: OTC Pharmaceuticals Industry in Russia to Increase to a Value of $9.2 Billion by the End Of 2015," 5/25/2012 92532F10  BW   Vertex erhält positive Stellungnahme des europäischen CHMP zu KALYDECO™ (Ivacaftor), dem ersten Medikament zur ursächlichen Behandlung der Mukoviszidose",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/12/2014 02043Q10  BW   Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) for the Treatment of Hypertensive Disorders of Pregnancy (HDP), Including Preeclampsia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2014 15117K10 BW   Cellectis : Compte-rendu : Rencontre Actionnaires Individuels du 23 octobre 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/24/2012 ILMN-US     BW   Illumina Announces BaseSpace® Pricing for Data Storage and Processing, 5/31/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference,#N/A, 9/28/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 01535110 BW   Alexion Reports Fourth Quarter and Full Year 2013 Results and Provides Financial Guidance for 2014,#N/A," 3/21/2013 003LCZ-E    BW   Execs from Adobe, Gates Foundation, Nike, Oracle, Seattle Genetics and Starbucks among Powerhouse Presenter Lineup for LES (USA & Canada) Meeting May 14-16 in Seattle, WA",#N/A, 5/21/2013 09062X10    BW   Biogen Idec presenta solicitud ante la FDA para aprobación de PLEGRIDY™ (Peginterferón Beta-1a) sobre esclerosis múltiple,#N/A,#N/A, 2/02/2016 GILD-US      BW   Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2011 45337C10 BW   Incyte to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2011 30161Q10 BW   Exelixis Provides Update on Cabozantinib Development Activities, 4/24/2012 SAN-FR    BW   Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial," 5/25/2012 064Q9G-E  BW   Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2014 02043Q10  BW   Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/30/2014 15117K10 BW   Cellectis: Event Report: Individual Shareholders’ Meeting Held on October 23, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/23/2012 ILMN-US     BW   Illumina Introduces Universal Real-Time PCR Reagent Portfolio, 5/23/2011 84763A10  BW   Spectrum Pharmaceuticals Announces ZEVALIN® and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting,#N/A, 9/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/21/2014 01535110 BW   FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients,#N/A, 3/18/2013 81257810    BW   Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® (Brentuximab Vedotin) in Relapsed Hodgkin Lymphoma and Systemic ALCL,#N/A, 5/16/2013 07G69B-E    BW   Research and Markets: PharmaPoint Analysis: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022,#N/A,#N/A, 2/02/2016 GILD-US      BW   Gilead anuncia el ascenso de Katie Watson al puesto de Vicepresidenta ejecutiva de Recursos Humanos,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/18/2011 45337C10 BW   Incyte to Present at the 23rd Annual Piper Jaffray Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2011 30161Q10 BW   Exelixis’ Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer, 4/23/2012 SPPI-US   BW   Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV®," 5/24/2012 92532F10  BW   Vertex Appoints David Altshuler, M.D., Ph.D., to its Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/27/2014 02043Q10  BW   Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules of 19 to 52 Nucleotides in Length",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2014 15117K10 BW   Cellectis: Individual Shareholder Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/23/2012 008383-E    BW   Illumina Countersues IBS and Qiagen for Patent Infringement, 5/12/2011 84763A10  BW   Spectrum Pharmaceuticals’ Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® Regional Award Finalist,#N/A, 9/09/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/16/2014 01535110 BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014",#N/A, 2/27/2013 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A," 5/16/2013 BIIB-US     BW   Biogen Idec Foundation Awards $250,000 to East End House to Develop Genetics Education Program",#N/A,#N/A, 2/02/2016 GILD-US      BW   La Agencia Europea de Medicamentos valida la solicitud de variación de Tipo II de Gilead para Truvada® para reducir el riesgo de infección de VIH por transmisión sexual,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2011 45337C10 BW   FDA Approves Incyte’s Jakafi™ (ruxolitinib) for Patients with Myelofibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2011 30161Q10 BW   Exelixis’ Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor Types, 4/20/2012 SAN-FR    BW   Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials," 5/21/2012 098HNP-E  BW   Since Gaining European Authority Approval for Victrelis in July and Incivo in September, Protease Inhibitor Share Has Penetrated Nearly One-Third of the Genotype 1 Market and is Anticipated to Significantly Increase Over the Next Six Months",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/20/2014 02043Q10  BW   Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up to 25 Base Pairs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2014 15117K10 BW   Cellectis : Rencontre Actionnaires Individuels,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/17/2012 ILMN-US     BW   Illumina Introduces Nextera® Exome and Custom Enrichment Sample Preparation Kits," 5/04/2011 84763A10  BW   Spectrum Pharmaceuticals Reports Record Profit and Record Revenue for First Quarter 2011, a Four-Fold Revenue Increase over First Quarter 2010",#N/A, 8/19/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 01535110 BW   Alexion Pharmaceuticals et Moderna Therapeutics annoncent un accord stratégique exclusif de développement de messenger RNA Therapeutics™ pour les maladies rares,#N/A, 2/12/2013 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2012 Financial Results,#N/A, 5/15/2013 07GVF3-E    BW   Research and Markets: Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022,#N/A,#N/A, 2/02/2016 GILD-US      BW   Europäische Arzneimittelagentur validiert Gileads Änderungsantrag (Typ II) für Truvada® zur Senkung des Risikos sexuell übertragener HIV-Infektion,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2011 45337C10 BW   Incyte Reports Third Quarter 2011 Financial Results and Provides Update on Key Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2011 30161Q10 BW   Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian Cancer, 4/19/2012 80105N10  BW   Genzyme’s Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design, 5/18/2012 08B1XM-E  BW   Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2014 02043Q10  BW   Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2014 15117K10 BW   Cellectis: First-Half 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/13/2012 45232710    BW   Illumina to Announce Second Quarter 2012 Results on Tuesday, July 24, 2012", 4/29/2011 84763A10  BW   FDA Approves FUSILEV® for Use in Patients with Colorectal Cancer,#N/A, 8/12/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 01535110 BW   Alexion Pharmaceuticals und Moderna Therapeutics unterzeichnen exklusive strategische Vereinbarung zur Entwicklung von Messenger RNA Therapeutics™ für seltene Krankheiten,#N/A, 2/06/2013 81257810    BW   Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A,#N/A, 5/15/2013 07G69B-E    BW   Research and Markets: Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022,#N/A,#N/A," 2/02/2016 GILD-US      BW   Gilead maakt bevordering bekend van Katie Watson tot Executive Vice President, Human Resources",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/13/2011 45337C10 BW   Incyte to Report Third Quarter 2011 Financial Results and Provide Update on Key Clinical Programs on October 27,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2011 30161Q10 BW   Exelixis Announces Webcasts of June Investor Conference Presentations, 4/16/2012 80105N10  BW   Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis, 5/17/2012 92532F10  BW   La Fondation canadienne des maladies inflammatoires de l’intestin et Vertex annoncent leur collaboration dans le but de financer la recherche sur les maladies inflammatoires de l’intestin,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/07/2014 MDCO-US   BW   The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/30/2014 15117K10 BW   Cellectis : résultats du premier semestre 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/03/2012 TSRX-US     BW   Corporate Directors Forum Hosts Open Breakfast Event: ‘Power and Politics Inside the Boardroom’, 4/27/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Record Revenue and Record Profit in First Quarter 2011,#N/A, 8/10/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 01535110 BW   Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases,#N/A, 2/01/2013 81257810    BW   Santé Canada approuve l’ADCETRIS® (brentuximab védotin) comme traitement du lymphome de Hodgkin (LH) et du lymphome anaplasique à grandes cellules systémique (LAGCs) récidivants ou réfractaires,#N/A, 5/14/2013 0BDC8M-E    BW   Research and Markets: Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022,#N/A,#N/A," 2/02/2016 GILD-US      BW   L'Agence européenne des médicaments valide la demande de modification de type II émise par Gilead concernant le Truvada®, pour réduire le risque de VIH contracté par relations sexuelles",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2011 05FHM1-E BW   Alvine Pharmaceuticals Appoints James D. Watson as Senior Vice President and Chief Business Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/31/2011 30161Q10 BW   Reminder: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting"," 4/16/2012 060RWY-E  BW   For the Treatment of Advanced Non-Small-Cell Lung Cancer, Medical Oncologists Report That They are Rapidly Adopting the ALK-Positive Test into Their Treatment Practices to Identify Appropriate Patients for Xalkori (crizotinib)", 5/07/2012 92532F10  BW   Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/07/2014 02043Q10  BW   Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/29/2014 15117K10 BW   Cellectis Plant Sciences Launches Its New Website,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/20/2012 ILMN-US     BW   Illumina Announces RapidTrack Whole Genome Sequencing Service, 4/21/2011 84763A10  BW   Spectrum Pharmaceuticals Announces FDA Approval of FUSILEV®’s Ready-to-Use Formulation (RTU),#N/A, 8/05/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2014 01535110 BW   Alexion to Present at the JP Morgan 32nd Annual Healthcare Conference,#N/A, 2/01/2013 81257810    BW   Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL),#N/A, 5/14/2013 07GVF3-E    BW   Research and Markets: Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022,#N/A,#N/A," 2/01/2016 GILD-US      BW   Gilead annuncia la promozione di Katie Watson a vicepresidente esecutivo, Risorse Umane",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/30/2011 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2011 30161Q10 BW   Data From a Phase 1 Clinical Trial of Exelixis’ Cabozantinib Published in the Journal of Clinical Oncology, 4/12/2012 06PD8S-E  BW   Allegeant Receives CEO Cancer Gold Standard Accreditation, 5/07/2012 92532F10  BW   Les résultats provisoires de l’étude de phase 2 du VX-809 et du KALYDECO™ (ivacaftor) pris en association font apparaître des améliorations significatives de la fonction pulmonaire (VEMS ) chez les personnes atteintes de ...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2014 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2014 15117K10 BW   Cellectis : Individual Shareholder Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 6/18/2012 GNOM.XX2-US BW   Illumina Files Second Patent Infringement Suit Against Complete Genomics, Inc.", 3/28/2011 84763A10  BW   Independent Data Monitoring Committee Recommends Continuation of Spectrum Pharmaceuticals’ Pivotal Registrational Study of Belinostat in Peripheral T-Cell Lymphoma,#N/A, 6/23/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/13/2013 01535110 BW   Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion,#N/A," 1/29/2013 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013",#N/A, 5/13/2013 09062X10    BW   FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A,#N/A,#N/A, 2/01/2016 GILD-US      BW   Gilead gibt Beförderung von Katie Watson zum Executive Vice President Human Resources bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2011 45337C10 BW   FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2011 30161Q10 BW   Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights, 4/11/2012 06PD8S-E  BW   The Ohio State University Wexner Medical Center Receives CEO Cancer Gold StandardTM Accreditation, 5/07/2012 92532F10  BW   Interim-Daten aus einer Phase-2-Studie zur Kombination von VX-809 und KALYDECO™ (Ivacaftor) zeigen signifikante Verbesserungen der Lungenfunktion (FEV1) bei Menschen mit Mukoviszidose...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/29/2014 02043Q10  BW   Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2014 15117K10 BW   Cellectis : Rencontre Actionnaires Individuels,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 6/04/2012 LIFE.XX5-US BW   Affymetrix, Illumina and Life Technologies Hold Entrenched Leadership Positions in Key Gene Expression Profiling Market Segments Revealed in New Report from Percepta Associates", 3/22/2011 84763A10  BW   FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN® Submission for the Removal of the Bioscan,#N/A, 6/17/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/11/2013 01535110 BW   Nuevos datos presentados en la reunión anual de la ASH mejoran la comprensión de la HPN y el SHUa para optimizar el cuidado de los pacientes que padecen estos trastornos potencialmente mortales,#N/A, 1/25/2013 4503-JP     BW   Seattle Genetics Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer,#N/A, 4/25/2013 09062X10    BW   Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013,#N/A,#N/A, 2/01/2016 GILD-US      BW   European Medicines Agency valideert Gilead's type-II-variatietoepassing voor Truvada® voor het verlagen van het risico op seksueel opgelopen hiv,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2011 45337C10 BW   Incyte Reports Second Quarter 2011 Financial Results and Provides Update on Key Clinical Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/13/2011 30161Q10 BW   UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting", 4/10/2012 MKEA-FR   BW   Mauna Kea Technologies Appoints Gilles Brisson Chairman of the Board, 5/02/2012 92532F10  BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/22/2014 02043Q10  BW   Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2014 15117K10 BW   Compte-rendu : Cellectis R&D/ Analyst Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/31/2012 ILMN-US     BW   Illumina Introduces Nextera® XT DNA Sample Preparation Kits, 3/11/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the 23rd Annual ROTH OC Growth Stock Conference,#N/A, 6/15/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2013 01535110 BW   Novos Dados Apresentados na Reunião Anual da ASH Melhoram a Compreensão de HPN e SHUa para Proporcionar Tratamento Ideal para Pacientes com essas Doenças que Ameaçam a Vida,#N/A, 1/24/2013 4502-JP     BW   Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL),#N/A," 4/10/2013 09062X10    BW   Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013",#N/A,#N/A, 2/01/2016 GILD-US      BW   Gilead annonce la promotion de Katie Watson au poste de vice-présidente exécutive des ressources humaines,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/13/2011 45337C10 BW   Incyte Reports Second Quarter 2011 Financial Results and Provides Update on Key Clinical Programs on July 28,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2011 30161Q10 BW   CORRECTING and REPLACING Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 4/09/2012 06PD8S-E  BW   Allegeant Receives CEO Cancer Gold Standard Accreditation, 4/26/2012 92532F10  BW   Vertex Reports First Quarter 2012 Financial Results and Provides Update on Launch of KALYDECOTM,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2014 02043Q10  BW   Alnylam to Host “RNAi Roundtable” Webcast Series,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/16/2014 15117K10 BW   Event report: Cellectis R&D/ Analyst Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/30/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in June, 3/10/2011 84763A10  BW   Spectrum Pharmaceuticals Reports Profitable Fourth Quarter and Record Revenue Growth for 2010,#N/A, 6/14/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2013 01535110 BW   Auf der ASH-Jahrestagung vorgelegte neue Daten fördern Erkenntnisse über PNH und aHUS zur optimalen Behandlung dieser lebensbedrohlichen Krankheiten,#N/A, 1/03/2013 SGEN-US     BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A, 4/04/2013 09062X10    BW   The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis,#N/A,#N/A, 2/01/2016 GILD-US      BW   L'agenzia europea preposta al controllo dei farmaci convalida la domanda di variazione di tipo II depositata da Gilead per Truvada® per la riduzione del rischio di contrazione dell’infezione da HIV per via sessuale,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2011 45337C10 BW   Incyte Reports Additional Analyses of Symptomatic Improvement and Quality of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from the COMFORT-I Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2011 30161Q10 BW   Exelixis Announces May 10th Webcast of Presentation at the Bank of America Merrill Lynch Health Care Conference," 4/03/2012 00B8PL-E  BW   Docetaxel Dominates First-Line Metastatic Castrate-Resistant Prostate Cancer Treatment, But Total Patient Share of Zytiga and Jevtana Reach Nearly 50 Percent in the Second and Third-Line Settings According to Surveyed Physicians", 4/24/2012 92532F10  BW   INCIVEK™ (télaprévir) désormais couvert pour les personnes atteintes d'hépatite C au Québec et à la Saskatchewan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/02/2014 02043Q10  BW   Alnylam Elects Amy Schulman to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2014 15117K10 BW   Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/29/2012 ILMN-US     BW   Queensland Centre for Medical Genomics Adopts Illumina Sequencing for Australian ICGC Program, 3/07/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Fourth Quarter and Fiscal 2010 Corporate Update Conference Call,#N/A, 6/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2013 01535110 BW   De nouvelles données présentées lors de la réunion annuelle de l'ASH améliorent la compréhension de la HPN et du SHUa pour fournir des soins optimaux aux patients atteints de troubles potentiellement mortels,#N/A,12/11/2012 05RBVG-E    BW   Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting,#N/A, 4/03/2013 09062X10    BW   Biogen Idec completa la adquisición de todos los derechos y control de TYSABRI®,#N/A,#N/A," 2/01/2016 GILD-US      BW   Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2011 45337C10 BW   Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2011 30161Q10 BW   Exelixis Announces First Quarter 2011 Financial Results, 4/02/2012 06VY62-E  BW   VaxInnate Names Wayne Pisano as its New CEO, 4/18/2012 92532F10  BW   Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/30/2014 02043Q10  BW   Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/04/2014 15117K10 BW   Cellectis annonce la réalisation de la vente de sa filiale suédoise, Cellectis AB, à Takara Bio Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/23/2012 06NNTP-E    BW   Cold Spring Harbor Laboratory Joins the Illumina Genome Network, 3/02/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the 31st Annual Cowen and Company Health Care Conference,#N/A, 6/04/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2013 ALXN-US  BW   New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders,#N/A,12/10/2012 SGEN-US     BW   Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting,#N/A, 4/03/2013 09062X10    BW   Biogen Idec erwirbt umfassende Rechte an TYSABRI®,#N/A,#N/A, 2/01/2016 GILD-US      BW   European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2011 45337C10 BW   Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2011 30161Q10 BW   Exelixis Announces May 4th Webcast of Presentation at the Deutsche Bank Securities Health Care Conference, 3/29/2012 80105N10  BW, 4/18/2012 92532F10  BW   Vertex fait progresser INCIVEK™ (télaprévir) ainsi qu’un large portefeuille de médicaments au stade du développement avec comme objectif d’étendre et d’améliorer plus encore le traitement pour les personnes atteintes d’hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/19/2014 02043Q10  BW   Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2014 15117K10 BW   Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/22/2012 ILMN-US     BW   New York Genome Center Announces Formal Commencement of Collaborative Relationship with Illumina, 2/25/2011 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the RBC Capital Markets 2011 Health Care Investor Conference,#N/A, 6/01/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2013 01535110 BW   Soliris® (Eculizumab) hemmt die TMA und verbessert die Nierenfunktion bei pädiatrischen und erwachsenen Patienten mit atypischem hämolytisch-urämischen Syndrom (aHUS),#N/A,12/10/2012 SGEN-US     BW   Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting,#N/A, 4/03/2013 BIIB-US     BW   Biogen Idec completa l'acquisto di tutti i diritti e ottiene il pieno controllo di TYSABRI®,#N/A,#N/A," 1/29/2016 GILD-US      BW   John C. Martin, PhD de Gilead asumirá el cargo de Presidente ejecutivo del Consejo de Administración; John F. Milligan, PhD, será nombrado CEO y miembro del Consejo",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/24/2011 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2011 30161Q10 BW   Exelixis Announces May 3rd Webcast of Its First Quarter 2011 Financial Results Conference Call, 3/29/2012 80105N10  BW, 4/09/2012 92532F10  BW   Vertex Announces the Date of its First Quarter 2012 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/17/2014 02043Q10  BW   Alnylam to Webcast Presentation at 9th Annual JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2014 15117K10 BW   Cellectis : Ingénierie des génomes & lymphocytes CART : À la pointe de l’immuno-oncologie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/02/2012 ILMN-US     BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in May," 2/24/2011 84763A10  BW   Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development",#N/A, 5/28/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/11/2013 01535110 BW   Soliris® (eculizumab) inhibe la MAT et améliore la fonction rénale chez les enfants et les adultes atteints du syndrome hémolytique et urémique atypique (SHUa),#N/A,12/10/2012 SGEN-US     BW   Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting,#N/A, 4/02/2013 BIIB-US     BW   Biogen Idec finalise l’achat de l’intégralité des droits et du contrôle de TYSABRI®,#N/A,#N/A," 1/29/2016 GILD-US      BW   John C. Martin, PhD, de Gilead va assumer le rôle de président exécutif du conseil d’administration ; John F. Milligan, PhD, sera nommé président-directeur général et administrateur",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2011 45337C10 BW   Incyte Reports First Quarter 2011 Financial Results and Program Updates,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2011 30161Q10 BW   Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference, 3/01/2012 SNY-FR    BW   Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant, 3/06/2012 92532F10  BW   Les données d'une étude de phase 2 évaluant un traitement d'association à base d'INCIVEK® ont montré que 74 % des personnes infectées à la fois par l'hépatite C et le VIH présentaient ...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2014 02043Q10  BW   Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2014 15117K10 BW   Pfizer’s Stake in Cellectis’ Capital is Welcomed by Its Shareholders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/25/2012 45232710    BW   Illumina Introduces BaseSpace Apps, Solutions for Genome Informatics", 2/23/2011 SPPI-US   BW   Spectrum Pharmaceuticals to Present at the Citi Investment Research 2011 Global Health Care Investor Conference,#N/A, 5/27/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2013 01535110 BW   Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS),#N/A,12/10/2012 SGEN-US     BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting,#N/A, 4/02/2013 09062X10    BW   Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®,#N/A,#N/A," 1/29/2016 GILD-US      BW   Gilead’s John C. Martin, PhD wordt uitvoerend voorzitter van de raad van bestuur; John F. Milligan, PhD wordt aangesteld als president-directeur",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2011 45337C10 BW   Incyte to Present at the Bank of America Merrill Lynch Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/15/2011 30161Q10 BW   Exelixis Announces Exercise in Full of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock, 2/29/2012 SNY-FR    BW   Genzyme Recognizes International Rare Disease Day with Second Annual Patient Advocacy Grant Program, 3/06/2012 92532F10  BW   Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/09/2014 02043Q10  BW   Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2014 15117K10 BW   L’entrée de Pfizer au capital de Cellectis saluée par ses Actionnaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/24/2012 45232710    BW   Illumina Launches MyGenome® App for iPad®," 2/15/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Record Revenue Growth in Fourth Quarter and Fiscal Year 2010; Ends Year with $104 Million in Cash, Cash Equivalents and Investments",#N/A, 5/19/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2013 01535110 BW   Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS),#N/A,12/09/2012 SGEN-US     BW   Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL),#N/A, 4/02/2013 ELN-IE      BW   Elan Announces Closing of TYSABRI® Collaboration Transaction with Biogen Idec,#N/A,#N/A," 1/29/2016 GILD-US      BW   John C. Martin, PhD, di Gilead assumerà la carica di Presidente esecutivo del Consiglio di Amministrazione; John F. Milligan, PhD, sarà nominato Amministratore delegato (AD) e Direttore",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2011 45337C10 BW   Incyte to Report First Quarter 2011 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/11/2011 EXEL-US  BW   Exelixis Announces Updated Start Time for March 15 Webcast of Presentation at the Barclays Capital 2011 Global Healthcare Conference, 2/23/2012 SNY-FR    BW   Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis, 2/24/2012 92532F10  BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/04/2014 02043Q10  BW   Alnylam to Webcast Presentation at Goldman Sachs 35th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2014 15117K10 BW   Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/23/2012 45232710    BW   Illumina Reports Financial Results for First Quarter of Fiscal Year 2012, 2/08/2011 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference,#N/A, 5/13/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2013 01535110 BW   Researchers to Present Clinical Trial Data With Soliris® (eculizumab) Treatment in Both Approved Indications – PNH and aHUS – at ASH Annual Meeting,#N/A,12/09/2012 SGEN-US     BW   Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual Meeting,#N/A, 3/27/2013 09062X10    BW   Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis,#N/A,#N/A, 1/29/2016 GILD-US      BW   Gileads Dr. John C. Martin wird Executive Chairman of the Board – Dr. John F. Milligan wird zum Chief Executive Officer und Direktor berufen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 006ZF7-E BW   Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2011 EXEL-US  BW   Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock, 2/22/2012 066807-E  BW, 2/23/2012 92532F10  BW   Vertex annonce les données et la RVS4 sous traitement de 12 semaines d'une étude de phase 2 évaluant...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/21/2014 02043Q10  BW   Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2014 15117K10 BW   Cellectis cède sa filiale suédoise, Cellectis AB à la société japonaise Takara Bio Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/18/2012 ILMN-US     BW   Illumina Announces Preliminary Voting Results for 2012 Annual Meeting of Stockholders, 1/24/2011 84763A10  BW   Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN®,#N/A, 5/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2013 01535110 BW   Alexion to Present at Credit Suisse 2013 Healthcare Conference,#N/A,11/26/2012 SGEN-US     BW   Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides,#N/A," 3/25/2013 05J1LP-E    BW   Unilabs annonce que le test STRATIFY JCV® ELISA, doté du marquage CE, a franchi le cap de la deuxième année d'essais",#N/A,#N/A," 1/29/2016 GILD-US      BW   Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/15/2011 45337C10 BW   Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2011 30161Q10 BW   Exelixis Announces Proposed Public Offering of Common Stock, 2/17/2012 GSK-GB    BW   Research and Markets: The Global Vaccine Market to Grow At A CAGR Of 9.8 Percent over the Period 2010-2014," 2/23/2012 92532F10  BW   Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/13/2014 02043Q10  BW   Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/30/2014 15117K10 BW   Cellectis SA Combined General Shareholders’ Meeting of June 27, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/18/2012 ROG-CH      BW   Roche decides not to extend its tender offer for Illumina, Inc.", 1/10/2011 076XLQ-E  BW   Spectrum Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference,#N/A, 4/26/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2013 01535110 BW   Alexion Reports Third Quarter 2013 Results,#N/A,11/09/2012 SGEN-US     BW   Seattle Genetics to Present at Credit Suisse Healthcare Conference,#N/A, 3/25/2013 BIIB-US     BW   Unilabs Announces Second Year Status on CE Marked STRATIFY JCV® ELISA Testing,#N/A,#N/A," 1/26/2016 GILD-US      BW   Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/23/2011 45337C10 BW   Incyte to Present at the Cowen and Company 31st Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2011 30161Q10 BW   Exelixis Announces Webcasts of Investor Events in March, 2/15/2012 07GVF3-E  BW   Research and Markets: Australia Diabetes Care Devices Market Outlook to 2017 - Glucose Monitoring and Insulin Delivery, 2/15/2012 008THT-E  BW   Lycera Announces Key Appointments to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2014 02043Q10  BW   Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/30/2014 15117K10 BW   Assemblée Générale mixte des actionnaires de Cellectis SA du 27 juin 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/16/2012 45232710    BW   Illumina to Announce First Quarter 2012 Results on Monday, April 23, 2012", 1/06/2011 84763A10  BW   Spectrum Pharmaceuticals Announces Initiation of a Required Phase 1 Study of Apaziquone in Japan by Nippon Kayaku,#N/A, 4/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2013 01535110 BW   FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A,#N/A,11/07/2012 SGEN-US     BW   Seattle Genetics Reports Third Quarter 2012 Financial Results,#N/A, 3/22/2013 09062X10    BW   CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European Union,#N/A,#N/A, 1/20/2016 GILD-US      BW   Galapagos und Gilead vollziehen Abschluss ihrer globalen Kooperation bei Filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2011 INCY-US  BW   Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives and Financial Guidance,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2011 30161Q10 BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 2/09/2012 SNY-FR    BW   Osiris Therapeutics Provides Update Regarding the Genzyme/Sanofi Relationship, 2/13/2012 92532F10  BW   Vertex Announces Webcast of its Presentations at Three Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2014 02043Q10  BW   Alnylam Presents Key Scientific Data on Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/25/2014 15117K10 BW   Cellectis R&D / Analyst Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/12/2012 ILMN-US     BW   Roche issues statement regarding Illumina offer, 1/05/2011 84763A10  BW   Spectrum Pharmaceuticals to Develop Biosimilar Rituximab,#N/A, 4/15/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2013 01535110 BW   Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN Annual Meeting,#N/A,11/05/2012 SGEN-US     BW   Seattle Genetics’ ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody-Drug Conjugates (ADCs),#N/A, 3/20/2013 09062X10    BW   La Oficina de Patentes de Estados Unidos otorga patente sobre el régimen de administración de TECFIDERA TM (dimetilfumarato),#N/A,#N/A, 1/20/2016 GILD-US      BW   Galapagos en Gilead hebben de overeenkomst voor hun mondiale samenwerking voor filgotinib afgerond,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/28/2011 45337C10 BW   Incyte to Report 2010 Financial Results and Provide 2011 Key Objectives and Financial Guidance on February 10,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2011 EXEL-US  BW   Exelixis Announces March 1 Webcast of Presentation at the Citi 2011 Global Health Care Conference, 2/08/2012 SNY-FR    BW   Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints, 2/02/2012 92532F10  BW   Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2014 02043Q10  BW   Alnylam Pharmaceuticals Reports First Quarter 2014 Financial Results and Highlights Recent Period Activities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2014 15117K10 BW   Cellectis’ UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/11/2012 ROG-CH      BW   Roche sends open letter to Illumina shareholders, 1/04/2011 84763A10  BW   Spectrum Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for Ready-to-Use Formulation of FUSILEV® in Colorectal Cancer,#N/A, 4/12/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/10/2013 01535110 BW   Alexion Pharmaceuticals to Report Third Quarter 2013 Results on Thursday, October 24, 2013",#N/A,11/01/2012 4502-JP     BW   Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma,#N/A, 3/20/2013 09062X10    BW   Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a) Presented at AAN Meeting,#N/A,#N/A, 1/20/2016 GILD-US      BW   Galapagos et Gilead finalisent leur collaboration mondiale portant sur le filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/18/2011 099KLQ-E BW   Alkermes Elects Wendy L. Dixon, Ph.D., to Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2011 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2010 Financial Results," 2/08/2012 80105N10  BW   Chris Viehbacher, DG de Sanofi, commente les résultats 2011", 2/01/2012 VRYAF-US  BW   North American Utility Selects ViryaNet Mobile Workforce Management Solution,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/07/2014 02043Q10  BW   Alnylam to Webcast Presentation at Bank of America Merrill Lynch 2014 Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/23/2014 15117K10 BW   Cellectis : UCART19 reconnu comme Médicament de Thérapie Innovante par l'Agence Européenne du Médicament,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/10/2012 ILMN-US     BW   Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote for the Election of All Illumina Nominees Using Management’s WHITE Proxy Card,12/29/2010 84763A10  BW   Belinostat Plus Tarceva® Trial in Patients with Non-Small Cell Lung Cancer Enrolls First Patient,#N/A, 4/07/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/22/2013 01535110 BW   New Data Evaluating Asfotase Alfa in Infants and Young Children with Hypophosphatasia (HPP) Presented at Paediatric Endocrinology Meeting,#N/A,10/31/2012 4502-JP     BW   Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization,#N/A, 3/20/2013 BIIB-US     BW   Des résultats positifs pour la première année des essais de phase III ADVANCE du PLEGRIDYMC (interféron bêta-1a pégylé) présentés à la réunion de l'AAN,#N/A,#N/A, 1/20/2016 GILD-US      BW   Galapagos y Gilead cierran su acuerdo de colaboración mundial para filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2011 45337C10 BW   Incyte to Present at the 29th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2011 30161Q10 BW   Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer, 2/08/2012 80105N10  BW   Sanofi CEO Chris Viehbacher Comments on 2011 Results," 1/31/2012 064Q9G-E  BW   The Cystic Fibrosis Foundation Applauds FDA Approval of KALYDECO™, First Drug to Address the Underlying Cause of Cystic Fibrosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/06/2014 02043Q10  BW   Alnylam Advances Development Candidate for ALN-AAT, a Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) in Development for the Treatment of AAT Deficiency-Associated Liver Disease",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/19/2014 15117K10 BW   Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/09/2012 ILMN-US     BW   Illumina’s Board of Directors Sends Fourth Letter to Stockholders,"12/23/2010 84763A10  BW   Phase 2 Trial of Belinostat, a Novel HDAC Inhibitor, in the Treatment of Carcinoma of Unknown Primary (CUP) Meets Enrollment Target",#N/A, 3/22/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2013 01535110 BW   Alexion's Soliris® (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS,#N/A,10/31/2012 4502-JP     BW   Millennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin),#N/A, 3/20/2013 09062X10    BW   Risultati positivi per Biogen Idec per il primo anno della sperimentazione ADVANCE di fase 3 del PLEGRIDY™ (peginterferone beta-1a) presentati al convegno dell'AAN,#N/A,#N/A, 1/19/2016 GILD-US      BW   Galapagos e Gilead perfezionano il loro contratto di collaborazione globale per filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/20/2010 45337C10 BW   Incyte Announces Positive Top-Line Results from COMFORT-I Pivotal Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating, Life-Threatening Blood Cancer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2011 30161Q10 BW   Reminder: Exelixis to Hold February 17th Investor Briefing Webcast at the ASCO 2011 Genitourinary Cancers Symposium, 2/08/2012 80105N10  BW   Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex," 1/31/2012 92532F10  BW   FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/01/2014 02043Q10  BW   Alnylam to Webcast Conference Call Discussing First Quarter 2014 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2014 15117K10 BW   Pfizer and Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/06/2012 ROG-CH      BW   Roche disappointed with ISS recommendation,12/20/2010 84763A10  BW   Spectrum Pharmaceuticals Selected to Be Listed on NASDAQ Global Select MarketSM,#N/A, 3/18/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2013 01535110 BW   Alexion to Present at Morgan Stanley Global Healthcare Conference,#N/A,"10/24/2012 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2012 Financial Results on November 7, 2012",#N/A, 3/20/2013 09062X10    BW   Positive Ergebnisse nach einem Jahr der Phase-III-Studie ADVANCE zu PLEGRIDY™ (Peginterferon Beta-1a) von Biogen Idec auf der AAN-Tagung vorgelegt,#N/A,#N/A, 1/19/2016 GILD-US      BW   Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2010 45337C10 BW   Incyte Presents Positive Long-Term Results from Ongoing Phase II Trial of INCB18424 in Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) at the American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2011 30161Q10 BW   Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call, 2/07/2012 SAN-FR    BW   Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration, 1/17/2012 92532F10  BW   Vertex Announces the Date of its Full Year 2011 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/01/2014 02043Q10  BW   Alnylam Presents New Pre-clinical Data on Subcutaneously Delivered RNAi Therapeutics for Cardiovascular Metabolic Disease at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2014 ALCLS-FR BW   Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/06/2012 05LY6L-E    BW   Leading Proxy Advisory Firms Issue Reports in Strong Support of Illumina,12/07/2010 84763A10  BW   ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma,#N/A, 2/11/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/25/2013 01535110 BW   Alexion Reports Second Quarter 2013 Results,#N/A,10/23/2012 SGEN-US     BW   Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott,#N/A, 3/20/2013 09062X10    BW   Presentados en la Reunión anual de la AAN los resultados positivos de un año del ensayo ADVANCE de Fase 3 de PLEGRIDY TM (peginterferon Beta-1a) de Biogen Idec,#N/A,#N/A, 1/19/2016 0056YC-E     BW   AHF Files FDA Complaint Against Gilead for Truvada PrEP Ads Promoting Off-label Use,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/18/2010 45337C10 BW   Incyte to Present at the 22nd Annual Piper Jaffray Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2011 30161Q10 BW   Exelixis Announces February 17th Webcast of Investor Briefing at the ASCO 2011 Genitourinary Cancers Symposium, 2/01/2012 066807-E  BW   Surveyed U.S. Endocrinologists Indicate They Would Prescribe Amylin/Alkermes’ Bydureon to 20 Percent of Their Patients with Type 2 Diabetes, 1/08/2012 92532F10  BW   Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2014 02043Q10  BW   Alnylam to Webcast Presentation at Deutsche Bank 39th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2014 15117K10 BW   Pfizer et Cellectis annoncent une collaboration stratégique mondiale dans le domaine de l’immunothérapie contre le cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/04/2012 ROG-CH      BW   Roche sends second letter to Illumina shareholders,12/06/2010 84763A10  BW   Single Dose ZEVALIN in First-Ever Phase 2 Monotherapy Trial for Non-Hodgkin’s Lymphoma Shows Significant and Durable Clinical Responses,#N/A, 2/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2013 01535110 BW   Alexion’s Soliris® (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO),#N/A,10/17/2012 SGEN-US     BW   Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over,#N/A, 3/20/2013 09062X10    BW   L'Office américain des brevets octroie un brevet portant sur le schéma posologique de TECFIDERA™ (fumarate de diméthyle),#N/A,#N/A, 1/13/2016 GILD-US      BW   Galapagos et Gilead autorisés par la Commission fédérale du commerce des États-Unis à clôturer leur partenariat mondial sur le filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2010 45337C10 BW   Incyte’s Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2011 30161Q10 BW   Exelixis Announces February 14 Webcast of Presentation at the BIO CEO & Investor Conference, 2/01/2012 ALMDT-FR  BW   MEDIAN Technologies Has Signed a Landmark Contract with the Top Pharmaceutical Company SANOFI for Medical Image Interpretation and Management in a New Phase II Study on Small Cells Lung Cancer, 1/05/2012 05LVL0-E  BW   Metabolix Appoints Lynne H. Brum to Vice President of Marketing and Corporate Communications,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2014 02043Q10  BW   Alnylam Presents New Pre-clinical Data on RNAi Therapeutics Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2014 15117K10 BW   Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/03/2012 45232710    BW   Illumina’s Board of Directors Sends Third Letter to Stockholders,12/06/2010 84763A10  BW   ZEVALIN Demonstrates 35-Month Progression-Free Survival Benefit after Single Dose in Patients with Non-Hodgkin’s Lymphoma,#N/A, 2/08/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2013 01535110 BW   Soliris® (eculizumab) d’Alexion reçoit un avis favorable de la part du Comité des médicaments orphelins pour le traitement de la Neuromyélite Optique (NMO),#N/A,10/09/2012 SGEN-US     BW   Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development,#N/A, 3/19/2013 09062X10    BW   US-Patentamt erteilt Patent für TECFIDERA™-Dosierungsschema (Dimethylfumarat),#N/A,#N/A, 1/13/2016 GILD-US      BW   Galapagos und Gilead erhalten von US-amerikanischer Federal Trade Commission Genehmigung zu internationaler Partnerschaft bei Filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2010 45337C10 BW   Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/10/2011 003LN3-E BW   Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib, 1/31/2012 SAN-FR    BW   Christopher A. Viehbacher and Sanofi to host Venture Day at CED Life Science Conference 2012, 1/04/2012 92532F10  BW   Vertex Announces Webcast of its Presentation at the 30th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2014 02043Q10  BW   Alnylam and Collaborators Present New Clinical Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2014 15117K10 BW   Cellectis signe avec CELLforCURE un accord de production selon les normes cGMP pour fabriquer des lymphocytes CART allogéniques,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/03/2012 ILMN-US     BW   Knome Selected as a Genome Interpretation Partner for Illumina Genome Network,11/30/2010 84763A10  BW   Spectrum Pharmaceuticals Board Approves Replacement of Stockholder Rights Agreement,#N/A, 2/03/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2013 01535110 BW   Soliris® (Eculizumab) von Alexion erhält positive Stellungnahme vom Ausschuss für Arzneimittel für seltene Leiden für die Behandlung von Neuromyelitis optica,#N/A,10/01/2012 4502-JP     BW   Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma,#N/A, 3/19/2013 09062X10    BW   L'Ufficio Brevetti degli Stati Uniti concede il brevetto che descrive il regime posologico per TECFIDERA™ (dimetilfumarato),#N/A,#N/A, 1/13/2016 GILD-US      BW   Galapagos e Gilead autorizzate dalla Commissione Federale per il Commercio degli Stati Uniti a finalizzare la collaborazione a livello globale per lo sviluppo di filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/09/2010 45337C10 BW   Incyte Reports Third Quarter 2010 Financial Results and Provides Update on Drug Discovery and Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/17/2010 30161Q10 BW   Exelixis Announces January 12 Webcast of Presentation at the J.P. Morgan 29th Annual Healthcare Conference," 1/25/2012 060RWY-E  BW   Current Use of FDA-Approved Pharmacotherapy for MS-Related Symptoms Is Low, Regardless of the High Need Reported by US Neurologists, According to a Recent BioTrends Report",12/27/2011 NVS-CH    BW   Forma Expands Drug Discovery Team with Three Executive Appointments,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2014 02043Q10  BW   Alnylam’s McSwiggen Patent Upheld in European Opposition Proceedings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/09/2014 15117K10 BW   Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/03/2012 00BMWM-E    BW   Knome Expands Executive Management Team, Positions Company for Growth","11/29/2010 84763A10  BW   FDA Accepts for Review Spectrum’s Response on FUSILEV® as a Class 2 Submission, and Establishes April 29, 2011 as PDUFA Action Date",#N/A, 2/02/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/16/2013 01535110 BW   Alexion’s Soliris® (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO),#N/A, 9/25/2012 4502-JP     BW   Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma,#N/A, 3/19/2013 09062X10    BW   US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate),#N/A,#N/A, 1/13/2016 GILD-US      BW   Gilead presenta solicitud de nuevo fármaco a la Administración de Alimentos y Fármacos de EE.UU. para tenofovir alafenamide (TAF) para el tratamiento de la hepatitis B crónica,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/02/2010 45337C10 BW   Incyte Achieves $50 Million in Milestones for Initiation of a Joint Global Phase III Clinical Trial of Novel JAK1 and JAK2 Inhibitor INCB18424 in Patients with Polycythemia Vera,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/01/2010 30161Q10 BW   Update: Exelixis Announces Webcast of Annual R&D Day on December 2, 1/24/2012 0BP4MZ-E  BW   Blueprint Medicines Appoints Oncology Drug Development Leader Christoph Lengauer as Chief Scientific Officer,"12/15/2011 92532F10  BW   Die US-Arzneimittelbehörde FDA hat einem beschleunigten Zulassungsverfahren für KALYDECO™ (Ivacaftor) zugestimmt, das erste potenzielle Medikament, das auf die zugrunde liegende Ursache von Mukoviszidose abzielt",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2014 02043Q10  BW   Alnylam to Webcast Presentation at 13th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2014 15117K10 BW   Cellectis et Accelera (Groupe Nerviano Medical Sciences) signent un accord pour réaliser les études précliniques de UCART19, le produit phare de Cellectis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/03/2012 ROG-CH      BW   Roche disappointed by Illumina, Inc.’s Board of Directors’ rejection","11/18/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Presentation of Four Key Belinostat Abstracts at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on December 4-7, 2010",#N/A, 2/01/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/11/2013 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter 2013 Results on Thursday, July 25, 2013",#N/A, 9/05/2012 SGEN-US     BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 3/19/2013 09062X10    BW   Nuevos datos sobre TYSABRI confirman su notable eficacia en el tratamiento de pacientes con EM y demuestran la estabilidad de la condición de los anticuerpos contra el virus JC,#N/A,#N/A," 1/13/2016 GILD-US      BW   Galapagos y Gilead, autorizados por la Comisión Federal de Comercio de Estados Unidos para cerrar la alianza mundial sobre filgotinib",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2010 45337C10 BW   Incyte to Report Third Quarter 2010 Financial Results and Provide Update on Drug Discovery & Development Programs on November 9,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/23/2010 30161Q10 BW   Exelixis Announces Webcast of Annual R&D Day on December 2, 1/24/2012 SAN-FR    BW   Genzyme Announces FDA Approval of Framingham Manufacturing Plant,"12/15/2011 92532F10  BW   FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/02/2014 02043Q10  BW   Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2014 15117K10 BW   Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis’ Lead Product Candidate UCART19,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/02/2012 45232710    BW   Illumina’s Board Unanimously Rejects Roche’s Revised Unsolicited Offer,"11/15/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Presentation of Eleven (11) Key ZEVALIN Abstracts & Papers at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on December 4-7, 2010",#N/A, 1/20/2010 04280A10 BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2013 01535110 BW   Alexion’s Soliris® (eculizumab) Receives Orphan Drug Designation for the Treatment of Neuromyelitis Optica (NMO),#N/A, 8/24/2012 81257810    BW   Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma,#N/A, 3/18/2013 09062X10    BW   ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status,#N/A,#N/A, 1/13/2016 GILD-US      BW   Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2010 45337C10 BW   Incyte to Present at the Oppenheimer 21st Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/18/2010 30161Q10 BW   Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer Treated with XL184, 1/20/2012 80105N10  BW   Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients,12/15/2011 92532F10  BW   Vertex Announces CEO Succession Plan for 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/26/2014 02043Q10  BW   Genzyme Exercises its Right to Purchase Additional Shares of Alnylam Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2014 15117K10 BW   Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN™, a Leading Gene Editing Technology",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/02/2012 45232710    BW   Illumina Announces Preliminary Revenue for First Quarter 2012,11/12/2010 84763A10  BW   Spectrum Pharmaceuticals Ranked One of the Fastest Growing Companies in North America on Deloitte’s 2010 Technology Fast 500™,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/17/2013 01535110 BW   Alexion Breaks Ground on New Global Headquarters,#N/A, 8/08/2012 SGEN-US     BW   Seattle Genetics Reports Second Quarter 2012 Financial Results,#N/A, 3/18/2013 09062X10    BW   Nuovi dati sul TYSABRI ne confermano la notevole efficacia nel trattamento di pazienti affetti da SM e dimostrano la stabilità dello stato degli anticorpi anti-JCV,#N/A,#N/A, 1/13/2016 GILD-US      BW   Galapagos en Gilead krijgen toestemming van de US FTC om hun wereldwijde overeenkomst voor filgotinib af te ronden,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2010 45337C10 BW   Incyte Achieves $19 Million Milestone as Novel JAK1 and JAK2 Inhibitor Advances into Phase IIb Development for Rheumatoid Arthritis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/18/2010 30161Q10 BW   Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184, 1/18/2012 SAN-FR    BW   Genzyme Announces European Approval of Framingham Manufacturing Plant,12/09/2011 92532F10  BW   Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/21/2014 02043Q10  BW   Alnylam to Present Data from its RNAi Therapeutic Programs Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) at XIVth International Symposium on Amyloidosis (ISA),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/05/2014 15117K10 BW   Cellectis et Thermo Fisher Scientific annoncent une série d’accords portant sur les TALEN™, la technologie clé de l’ingénierie des génomes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/29/2012 ILMN-US     BW   Illumina Advises Stockholders to Defer Taking Any Action in Response to Roche’s Increased Offer,11/04/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Third Quarter 2010 Financial and Operating Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2013 01535110 BW   Alexion to Present at the Wells Fargo 2013 Healthcare Conference,#N/A," 7/26/2012 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2012 Financial Results on August 8, 2012",#N/A, 3/18/2013 09062X10    BW   Neue Daten zu TYSABRI bestätigen beträchtliche Wirksamkeit bei der Behandlung von MS-Patienten und demonstrieren die Stabilität des JCV-Antikörper-Status,#N/A,#N/A, 1/12/2016 GILD-US      BW   Gilead dient nieuwe geneesmiddelaanvraag in bij de U.S. Food and Drug Administration voor tenofovir alafenamide (TAF) voor de behandeling van chronische hepatitis B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/30/2010 ZAZA-US  BW   Zacks.com featured expert Kevin Matras highlights: Orient-Express Hotels Ltd., Incyte Corp., Dana Holding Corp., Toreador Resources Corp. and UAL Corp.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2010 30161Q10 BW   Reminder: Upcoming Exelixis Investor Events, 1/17/2012 06PD8S-E  BW   Hudson Valley Federal Credit Union Receives CEO Cancer Gold Standard Accreditation,11/22/2011 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual Piper Jaffray Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2014 02043Q10  BW   Alnylam to Webcast Presentation at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 15117K10 BW   Cellectis plant sciences reports improvement of oil content in algae,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/29/2012 ROG-CH      BW   Roche increases offer price for Illumina shares to US$ 51.00 per share,11/03/2010 84763A10  BW   Spectrum Pharmaceuticals Receives Nearly $1 Million in Grants for Qualifying Therapeutic Discovery Projects,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2013 01535110 BW   Alexion Update Regarding Presentations at Investor Conferences,#N/A, 7/20/2012 4502-JP     BW   Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European Union,#N/A, 3/18/2013 09062X10    BW   De nouvelles données sur le TYSABRI réaffirment qu’il a une efficacité importante dans le traitement des personnes atteintes de SEP et démontrent la stabilité des titres d'anticorps contre le virus JC,#N/A,#N/A, 1/12/2016 GILD-US      BW   Gilead soumet un dossier d’autorisation de mise sur le marché auprès de la U.S. Food and Drug Administration pour le ténofovir alafénamide (TAF) dans le traitement de l’hépatite B chronique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/15/2010 45337C10 BW   Phase I/II Data Published in New England Journal of Medicine Demonstrate that Incyte JAK Inhibitor, INCB18424, Provides Marked and Durable Clinical Benefits in Patients with Myelofibrosis, a Rare, Life-Threatening Blood Cancer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2010 30161Q10 BW   Update on Upcoming Exelixis Investor Events, 1/10/2012 06XJML-E  BW   Third Rock Ventures and Sanofi Announce Launch of Warp Drive Bio; Broad Strategic Partnership Builds Innovative Genomics Search Engine to Reveal Nature’s Drugs,11/09/2011 92532F10  BW   Présentation dans le cadre du colloque intitulé The Liver Meeting® des données provisoires encourageantes d’un essai de phase 2 mené sur une polythérapie à base d’INCIVEKMC (télaprévir) ...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2014 02043Q10  BW   Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiary,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2014 15117K10 BW   Cellectis plant sciences annonce avoir réussi à accroître la teneur en huile contenue dans les algues,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 45232710    BW   Illumina’s Board of Directors Sends Second Letter to Stockholders,11/02/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time for Third Quarter 2010 Corporate Update Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2013 01535110 BW   Soliris® obtient des résultats notablement supérieurs chez des patients atteints de SUHa lors d'études pivots publiées dans le New England Journal of Medicine,#N/A, 6/14/2012 SGEN-US     BW   Seattle Genetics Highlights Updated Survival Data from ADCETRIS® Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma,#N/A, 3/12/2013 BIIB-US     BW   Biogen Idec richiede alla FDA l'approvazione per la prima terapia a lungo termine per l'emofilia A basata sul fattore VIII,#N/A,#N/A, 1/12/2016 GILD-US      BW   Gilead reicht bei US-amerikanischer Food and Drug Administration Zulassungsantrag für Tenofovir Alafenamid (TAF) zur Behandlung chronischer Hepatitis B ein,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2010 45337C10 BW   Incyte Reaches Agreement with the FDA on a Special Protocol Assessment for the Phase III Clinical Trial of INCB18424 in Polycythemia Vera,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2010 30161Q10 BW   Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), 1/10/2012 09NWNQ-E  BW   Foundation Medicine Announces Collaboration with Sanofi,11/07/2011 92532F10  BW   Les données issues de la première partie d'un essai de phase 2 cautionnent l'approche du traitement de la forme la plus commune de mucoviscidose (fibrose kystique - F508del) par le ciblage de la cause sous-jacente de la maladie...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/27/2014 02043Q10  BW   Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2014 15117K10 BW   Cellectis plant sciences annonce la production de soja à haute teneur en acide oléique dans le Journal of Plant Biotechnology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 45232710    BW   Illumina Comments on Second Extension of Roche’s Unsolicited Tender Offer,11/01/2010 84763A10  BW   Spectrum Pharmaceuticals Submits Complete Response to FDA’s Complete Response Letter for FUSILEV in Colorectal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/06/2013 01535110 BW   Soliris® erzielte signifikant verbesserte Behandlungsergebnisse bei Patienten mit aHUS in zulassungsrelevanten Studien, so eine Veröffentlichung im New England Journal of Medicine",#N/A, 6/14/2012 086S40-E    BW   Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma,#N/A, 3/12/2013 09062X10    BW   Biogen Idec presenta solicitud ante la FDA para el primer tratamiento de factor VIII de acción prolongada contra la hemofilia A,#N/A,#N/A, 1/12/2016 GILD-US      BW   Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/02/2010 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2010 30161Q10 BW   Exelixis Announces Webcasts of Investor Events in November and December, 1/08/2012 06FW0H-E  BW,11/07/2011 92532F10  BW   Un essai de phase 3 du KALYDECO™ (ivacaftor) chez des enfants de 6 à 11 ans atteints d'une forme spécifique de mucoviscidose montre des améliorations significatives de la fonction pulmonaire...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2014 02043Q10  BW   Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2014 15117K10 BW   Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/26/2012 ILMN-US     BW   Roche extends tender offer for Illumina,10/12/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Appointment of Brett L. Scott as Senior Vice President and Acting Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2013 01535110 BW   Soliris® Significantly Improved Clinical Outcomes in Patients with aHUS in Pivotal Trials Published in New England Journal of Medicine,#N/A, 6/04/2012 4503-JP     BW   Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer,#N/A, 3/12/2013 09062X10    BW   Biogen Idec reicht Zulassungsantrag für erste langwirkende Faktor-VIII-Therapie zur Behandlung von Hämophilie A bei FDA ein,#N/A,#N/A, 1/12/2016 GILD-US      BW   Gilead deposita una domanda di approvazione di un nuovo farmaco presso l’ente statunitense preposto al controllo dei farmaci e degli alimenti per tenofovir alafenamide (TAF) per il trattamento dell’infezione cronica da virus dell'epatite B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2010 45337C10 BW   Incyte Reports Second Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 30161Q10 BW   Exelixis Announces Third Quarter 2010 Financial Results, 1/03/2012 003ZHQ-E  BW   Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes,11/06/2011 92532F10  BW   Phase-3-Studie über KALYDECO™ (Ivacaftor) zur Behandlung von Kindern im Alter von sechs bis elf Jahren mit einer spezifischen Form von Mukoviszidose zeigt signifikante Verbesserungen der Lungenfunktion und anderer Krankheitsmerkmale über 48 Wochen,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2014 02043Q10  BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2014 15117K10 BW   TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 3/22/2012 45232710    BW   Macrogen, Inc. Increases Investment in Illumina’s Next-Generation Sequencing Technology",10/04/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Jefferies 2010 Global Specialty Pharma & European Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2013 01535110 BW   Soliris® Significantly Improved Clinical Outcomes in Patients with aHUS in Pivotal Trials Published in New England Journal of Medicine,#N/A, 6/02/2012 SGEN-US     BW   Seattle Genetics Announces ADCETRIS® Clinical Data to be Reported in Multiple Presentations at ASCO Annual Meeting,#N/A, 3/12/2013 09062X10    BW   Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia A,#N/A,#N/A," 1/08/2016 GILD-US      BW   Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/20/2010 45337C10 BW   Incyte to Report Second Quarter 2010 Financial Results and Provide Update on Drug Discovery & Development Programs on August 5,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/26/2010 30161Q10 BW   Exelixis Announces November 4 Webcast of Third Quarter 2010 Financial Results Conference Call, 1/03/2012 06740Z-E  BW   Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE®,11/06/2011 92532F10  BW   Daten des ersten Teils einer Phase-2-Studie unterstützen den Behandlungsansatz für die häufigste Form von Mukoviszidose (F508del),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/06/2014 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2014 15117K10 BW   Nucléases effectrices TAL : L’USPTO1 délivre un quatrième brevet licencié à Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/20/2012 45232710    BW   Roche files definitive proxy statement," 9/27/2010 84763A10  BW   Spectrum Pharmaceuticals to Ring the NASDAQ Stock Market Opening Bell on Tuesday, September 28, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2013 01535110 BW   Alexion to Present at Investor Conferences,#N/A, 5/31/2012 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 3/12/2013 SOBI-SE     BW   Biogen Idec soumet une demande à la FDA pour le premier traitement à facteur VIII à action prolongée contre l'hémophilie A,#N/A,#N/A, 1/07/2016 0056YC-E     BW   AHF: Gilead Premieres HIV PrEP Party Drug Ad,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2010 45337C10 BW   Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented at ASCO,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/15/2010 30161Q10 BW   Exelixis Announces Webcast of Presentation at the NewsMakers in the Biotechnology Industry Conference,12/28/2011 060RWY-E  BW   New Study of Chronic Kidney Disease Patients Finds That Treatment with Phosphate Binders and Active Vitamin D is Significantly Higher When Nephrologists Suspect Arterial Calcification,11/05/2011 92532F10  BW   Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/04/2014 02043Q10  BW   Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2014 15117K10 BW   Cellectis: 2013 financial results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/19/2012 45232710    BW   Illumina Files Definitive Proxy Materials and Sends Letter to Stockholders, 9/15/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/30/2013 01535110 BW   Alexion to Present at the Jefferies 2013 Global Healthcare Conference,#N/A," 5/29/2012 065C1X-E    BW   NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics",#N/A, 3/07/2013 09062X10    BW   Biogen Idec stellt neue Ergebnisse zu vielfältigem neurologischen Portfolio auf der 65. AAN-Jahrestagung vor,#N/A,#N/A, 1/07/2016 GILD-US      BW   Gilead anuncia los resultados preliminares de dos estudios de Fase 3 que evalúan tenofovir alafenamide (TAF) para pacientes con infección por hepatitis B crónica,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/27/2010 45337C10 BW   Incyte to Present at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/11/2010 30161Q10 BW   Exelixis Licenses Programs to Bristol-Myers Squibb Company,12/22/2011 0778SC-E  BW   Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe,11/05/2011 92532F10  BW   Les données issues de la première partie d'un essai de phase 2 cautionnent l'approche du traitement de la forme la plus commune de mucoviscidose (fibrose kystique - F508del) par le ciblage de la cause sous-jacente de la maladie avec...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2014 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2014 15117K10 BW   Cellectis : résultats 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/07/2012 45232710    BW   Illumina Introduces TruSeq® Amplicon - Cancer Panel for MiSeq® System, 9/09/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/28/2013 01535110 BW   FDA Grants Breakthrough Therapy Designation to Asfotase Alfa for Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)",#N/A, 5/23/2012 81257810    BW   Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review,#N/A, 3/07/2013 09062X10    BW   Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas durante el 65º Congreso Anual de la AAN,#N/A,#N/A, 1/07/2016 GILD-US      BW   Gilead interrumpe estudio de Fase 2 de simtuzumab en pacientes con fibrosis pulmonar idiopática,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/25/2010 45337C10 BW   Incyte Appoints Wendy Dixon, Ph.D., to Its Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/09/2010 30161Q10 BW   Exelixis Announces Webcasts of Presentations at Upcoming Investor Conferences,12/20/2011 SAN-FR    BW   Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis,11/05/2011 92532F10  BW   Un essai de phase 3 du KALYDECO™ (ivacaftor) chez des enfants de 6 à 11 ans atteints d'une forme spécifique de mucoviscidose montre des améliorations significatives de la fonction pulmonaire et d'autres indicateurs...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 0BQS10-E  BW   Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2014 15117K10 BW   Cellectis confirme son éligibilité au dispositif PEA-PME,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/02/2012 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in March," 9/08/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Robert W. Baird & Co., Inc. 2010 Healthcare Conference",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2013 01535110 BW   Alexion to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference,#N/A, 5/16/2012 81257810    BW   Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting,#N/A, 3/07/2013 09062X10    BW   Biogen Idec presenterà i nuovi dati relativi al suo portafoglio di prodotti neurologici durante il 65° Meeting annuale dell'Accademia americana di neurologia,#N/A,#N/A, 1/06/2016 GILD-US      BW   Gilead maakt de belangrijkste resultaten bekend van twee fase-3-onderzoeken die Tenofovir Alafenamide (TAF) evalueren bij patiënten met chronische hepatitis B-infectie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2010 45337C10 BW   Incyte to Present at the Citi Investment Research 2010 Global Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2010 30161Q10 BW   Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4),"12/19/2011 06CVZ0-E  BW   European Facial Injectable Market Will Rebound Strongly in 2013, Reaching Double-Digit Growth by 2016",11/05/2011 92532F10  BW   Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/22/2014 02043Q10  BW   Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/31/2014 15117K10 BW   Cellectis Announces the Closing of €20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 3/01/2012 45232710    BW   Illumina Announces Outcome of First Phase of Its Patent Litigation Against LadaTech, LLC", 9/07/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2013 01535110 BW   Alexion to Present at the BofA Merrill Lynch 2013 Healthcare Conference,#N/A, 5/11/2012 SGEN-US     BW   Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference,#N/A, 3/06/2013 BIIB-US     BW   Biogen Idec présente de nouvelles données sur ses divers portefeuilles neurologiques lors de la 65e conférence annuelle de l'AAN,#N/A,#N/A, 1/06/2016 GILD-US      BW   Gilead beëindigt fase 2 onderzoek van simtuzumab bij patiënten met idiopatische longfibrose,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2010 45337C10 BW   Incyte Reports First Quarter 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2010 30161Q10 BW   Exelixis Announces August 12 Webcast of Presentation at the Canaccord Genuity 30th Annual Growth Conference,"12/14/2011 06680H-E  BW   Owing to the Uptake of Novel Stem-Cell Therapies, the Drug Market for Peripheral Arterial Disease Will Increase from $3.2 Billion in 2010 to $4.3 Billion in 2020",11/05/2011 92532F10  BW   Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting®,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 ALNY-US   BW   Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/31/2014 15117K10 BW   Cellectis annonce la réalisation définitive de l’augmentation de capital de 20,52 M€ souscrite le 24 mars 2014 par des investisseurs institutionnels spécialisés basés aux États-Unis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/01/2012 GSK-GB      BW   LadaTech announces Illumina Found to Infringe Patent, 8/11/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 Southern California Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2013 01535110 BW   Alexion Reports First Quarter 2013 Results,#N/A, 5/10/2012 SGEN-US     BW   Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma,#N/A, 3/06/2013 09062X10    BW   Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting,#N/A,#N/A, 1/06/2016 GILD-US      BW   Gilead arrête l'étude de phase 2 du simtuzumab chez des patients atteints de fibrose pulmonaire idiopathique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2010 45337C10 BW   Incyte to Present at the 2010 Bank of America Merrill Lynch Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/05/2010 30161Q10 BW   Exelixis Announces Second Quarter 2010 Financial Results,12/05/2011 MITI-US   BW   Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer,11/04/2011 92532F10  BW   Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/13/2014 ALNY-US   BW   Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2014 15117K10 BW   Cellectis et Servier annoncent un accord de collaboration dans le domaine de la thérapie cellulaire allogénique : UCART19 pour le traitement des leucémies et 5 candidats médicaments ciblant des tumeurs solides,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/27/2012 45232710    BW   Illumina Comments on Roche’s Unsolicited Tender Offer Extension, 8/09/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Second Quarter 2010 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/25/2013 01535110 BW   Alexion Broadens and Strengthens its Executive Leadership Team,#N/A, 5/08/2012 81257810    BW   Seattle Genetics Reports First Quarter 2012 Financial Results,#N/A, 3/04/2013 09062X10    BW   FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B,#N/A,#N/A, 1/06/2016 GILD-US      BW   Gilead beendet Phase 2 Studie von Simtuzumab in Patienten mit idiopathischer pulmonaler Fibrose,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/22/2010 45337C10 BW   Incyte to Report First Quarter 2010 Financial Results and Provide Update on Drug Discovery & Development Programs on May 6,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/29/2010 30161Q10 BW   Exelixis Announces August 5 Webcast of Second Quarter 2010 Financial Results Conference Call,12/01/2011 06PD8S-E  BW   Stowers Institute for Medical Research CEO Cancer Gold StandardTM Accreditation,"11/04/2011 92532F10  BW   New England Journal of Medicine veröffentlicht Daten aus Phase-3-Studie STRIVE über KALYDECOTM (Ivacaftor) in Probanden, die mindestens das 12. Lebensjahr vollendet haben und an einer bestimmten Art der Mukoviszidose leiden",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/12/2014 ALNY-US   BW   Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/17/2014 15117K10 BW   Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/27/2012 ILMN-US     BW   Roche extends tender offer for Illumina, 8/06/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date and Time of Second Quarter 2010 Corporate Update Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/11/2013 01535110 BW   Alexion Pharmaceuticals to Report First Quarter 2013 Results on Thursday, April 25, 2013",#N/A, 5/07/2012 81257810    BW   Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma,#N/A, 2/28/2013 BIIB-US     BW   2013 BIO International Convention to Host Orphan Disease Forum,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead gibt Topline-Ergebnisse aus zwei Phase-3-Studien zur Untersuchung von Tenofovir Alafenamid (TAF) bei Patienten mit chronischer Hepatitis-B-Infektion bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2010 45337C10 BW   Incyte to Present at the Cowen and Company 30th Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/30/2010 30161Q10 BW   Exelixis Announces Appointment of New CEO,"12/01/2011 SAN-FR    BW   Christopher Viehbacher, CEO of Sanofi, to Keynote CED Life Science Conference 2012",11/03/2011 92532F10  BW   Vertex Announces Webcasts of Two Investor Presentations,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/10/2014 02043Q10  BW   Alnylam Provides Key 2014 Goals for RNAi Therapeutics Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2014 15117K10 BW   Cellectis : retournement du marché des outils et services en 2013 ; perspectives de développement dans le domaine thérapeutique en 2014,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/16/2012 06XD04-E    BW   New York Genome Center Launches Major Initiative with the Feinstein Institute for Medical Research to Sequence Whole Genomes of Alzheimer’s Patients," 7/19/2010 84763A10  BW   Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2013 01535110 BW   Alexion se joint à la Fédération internationale des fondations du rein pour célébrer l’édition 2013 de la Journée mondiale du rein,#N/A," 4/24/2012 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012",#N/A, 2/27/2013 09062X10    BW   Biogen Idec to Present at the Cowen and Company 33rd Annual Healthcare Conference,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead annonce les résultats préliminaires de deux études de phase 3 évaluant le ténofovir alafénamide (TAF) chez des patients atteints d'hépatite B chronique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/18/2010 45337C10 BW   Incyte Reports 2009 Financial Results; Strengthens Balance Sheet; Provides 2010 Financial Guidance,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/21/2010 30161Q10 BW   Reminder: Exelixis Announces June 21 Webcast of Conference Call Update on Development Collaboration with Bristol-Myers Squibb Company for XL184,11/28/2011 060RWY-E  BW   Seventy-Four Percent of Surveyed U.S. Neurologists Indicate They Will Prescribe Biogen Idec’s BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis,11/03/2011 92532F10  BW   Phase 3 Study of KALYDECO™ (ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2014 02043Q10  BW   Alnylam to Webcast Presentation at 32nd Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2014 15117K10 BW   US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/16/2012 45232710    BW   Illumina Launches Cancer Analysis Service, 7/01/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Results of Annual Meeting of Shareholders,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2013 01535110 BW   Alexion begeht den Weltnierentag 2013 gemeinsam mit der Internationalen Gemeinschaft der Nierenstiftungen,#N/A, 4/12/2012 81257810    BW   Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies,#N/A, 2/22/2013 BIIB-US     BW   Elan Provides Update Post Restructuring Announcement of Tysabri Collaboration,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2010 45337C10 BW   Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/21/2010 30161Q10 BW   Exelixis Regains Full Rights to Develop and Commercialize XL184,11/28/2011 06286Q-E  BW   Rib-X Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering,11/03/2011 06800C-E  BW   Data from the First Part of a Phase 2 Study Support the Approach of Treating the Most Common Form of Cystic Fibrosis (F508del) by Targeting the Underlying Cause of the Disease With a Combination of KALYDECO™ (ivacaftor) and VX-809,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/20/2013 02043Q10  BW   Alnylam and Collaborators Publish Novel Method for Detection of Tissue-Specific, RNAi-Mediated Gene Silencing",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2014 15117K10 BW   Cellectis et l’Institut Pasteur ont été reconnus par les Offices de brevets américains comme les inventeurs des Méganucléases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/16/2012 GNOM.XX2-US BW   Illumina Announces Favorable Patent Claim Construction Ruling in Litigation Against Complete Genomics, Inc.", 6/23/2010 84763A10  BW   Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2013 01535110 BW   Alexion Joins the International Federation of Kidney Foundations in Celebrating World Kidney Day 2013,#N/A, 4/03/2012 SGEN-US     BW   Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR,#N/A, 2/20/2013 09062X10    BW   Biogen Idec to Present at the 2013 RBC Capital Markets Global Healthcare Conference,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead interrompere lo studio di Fase II su simtuzumab in pazienti affetti da fibrosi polmonare idiopatica,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/28/2010 45337C10 BW   Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2010 30161Q10 BW   Exelixis Announces June 21 Webcast of Conference Call Update on Development Collaboration with Bristol-Myers Squibb Company for XL184,11/28/2011 07P6FH-E  BW   Gilsbar Receives CEO Cancer Gold StandardTM Accreditation,"11/03/2011 92532F10  BW   Le New England Journal of Medicine publie les données de l'étude STRIVE de phase 3 évaluant KALYDECOTM (ivacaftor) chez des patients âgés de 12 ans ou plus, atteints d'un type particulier de fibrose kystique",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/19/2013 02043Q10  BW   Alnylam Presents New Pre-Clinical Data on Pharmacology of GalNAc-siRNA Conjugates,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2014 15117K10 BW   Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/15/2012 45232710    BW   The Broad Institute Joins the Illumina Genome Network," 6/18/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Adjournment of Annual Meeting of Shareholders until July 1, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2013 01535110 BW   Alexion to Present at the Barclays Global Healthcare Conference,#N/A, 3/29/2012 SGEN-US     BW   Seattle Genetics to Present at Needham Healthcare Conference,#N/A, 2/20/2013 0C9T8W-E    BW   Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead annuncia i risultati salienti derivati da due studi di Fase 3 intesi a valutare tenofovir alafenamide (TAF) per il trattamento di pazienti con infezione cronica da virus dell'epatite B,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/10/2010 30161Q10 BW   Exelixis Announces June 15 Webcast of Presentation at the Goldman Sachs 31st Annual Global Healthcare Conference,11/24/2011 SAN-FR    BW   Research and Markets: Partnering Agreements with Sanofi,11/03/2011 92532F10  BW   Le New England Journal of Medicine publie les résultats de l’étude STRIVE de Phase 3 portant sur KALYDECOTM (ivacaftor) administré chez des patients âgés d’au moins douze ans et atteints d’un type spécifique de fibrose,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/16/2013 02043Q10  BW   Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/04/2014 15117K10 BW   Cellectis concède à genOway une sous-licence exclusive sur sa technologie de recombinaison homologue dans le domaine des rongeurs, animaux modèles, génétiquement modifiés",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/08/2012 ILMN-US     BW   Faruqi & Faruqi, LLP Announces Investigation of Illumina, Inc.", 6/07/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at Two (2) Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/01/2013 ALXN-US  BW   Research and Markets: Alexion Pharmaceuticals, Inc.: Focus on Ultra-rare Diseases as a Revenue and Profit Driver",#N/A, 3/27/2012 09QXDQ-E    BW,#N/A, 2/19/2013 09062X10    BW   Biogen Idec to Present at the Citi 2013 Global Healthcare Conference,#N/A,#N/A," 1/05/2016 GILD-US      BW   Gilead anuncia la designación de revisión prioritaria por parte de la FDA de EE.UU., para sofosbuvir/velpatasvir para el tratamiento de la infección de hepatitis C crónica de todos los genotipos",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2010 30161Q10 BW   Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147 (SAR245408) to be Presented at ASCO,11/16/2011 80105N10  BW   Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs,11/02/2011 0B6G4F-E  BW   New England Journal of Medicine Publishes Data from Phase 3 STRIVE Study of KALYDECOTM (ivacaftor) in People Ages 12 and Older with a Specific Type of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/09/2013 02043Q10  BW   Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 15117K10 BW   Precision BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 2/08/2012 ROG-CH      BW   Roche disappointed by the actions of Illumina, Inc.’s Board of Directors"," 5/24/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference on Wednesday, May 26",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2013 ALXN-US  BW   Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013",#N/A, 3/26/2012 81257810    BW   Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology,#N/A, 2/15/2013 09062X10    BW   Cambridge Science Festival Announces Statewide Year-Round Science Outreach Initiative: Biogen Idec Foundation Science on the Street,#N/A,#N/A, 1/05/2016 GILD-US      BW   Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2010 30161Q10 BW   Exelixis Announces June 9 Webcast of Presentation at the Jefferies 2010 Global Life Sciences Conference,11/14/2011 SAN-FR    BW   Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis,10/27/2011 92532F10  BW   Vertex Reports Profitable Third Quarter and Provides Updates on INCIVEKTM (telaprevir) Launch and Medicines in Development,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/08/2013 02043Q10  BW   New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 15117K10 BW   Precision BioSciences et Cellectis SA ont conclu un accord transactionnel et convenu de licences croisées portant sur une technologie d’ingénierie des génomes.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/07/2012 45232710    BW   CORRECTING and REPLACING Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2011, 5/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Three Additional Belinostat Abstracts at the 2010 Annual Meeting of the American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2013 01535110 BW   Alexion ställer sig bakom EURORDIS, NORD och patientorganisationer runt om i världen för att uppmärksamma Sällsynta dagen 2013",#N/A, 3/21/2012 81257810    BW   Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors,#N/A, 2/08/2013 SOBI-SE     BW   New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B,#N/A,#N/A, 1/04/2016 GILD-US      BW   Gilead gibt beschleunigtes Prüfverfahren der US-FDA für Sofosbuvir/Velpatasvir zur Behandlung von Infektionen mit chronischer Hepatitis C aller Genotypen bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2010 30161Q10 BW   Exelixis Reports Updated Data from Multiple Clinical Trials of the Dual PI3K and mTOR Inhibitor XL765 (SAR245409) to be Presented at ASCO,11/10/2011 SAN-FR    BW   Genzyme Appoints Leaders for Multiple Sclerosis and Rare Disease Businesses,10/24/2011 92532F10  BW   Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/25/2013 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 15117K10 BW   Cellectis plant sciences et Bayer CropScience élargissent leur partenariat dédié à l’amélioration des cultures,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/07/2012 45232710    BW   Illumina’s Board Unanimously Rejects Roche’s Unsolicited Tender Offer as Inadequate, 5/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Belinostat PTCL Abstract at the 2010 Annual Meeting of the American Society of Clinical Oncology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2013 01535110 BW   Alexion begeht den Tag der seltenen Krankheiten 2013 gemeinsam mit EURORDIS und Patientenorganisationen weltweit,#N/A, 2/23/2012 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 2/06/2013 BIIB-US     BW   Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments,#N/A,#N/A, 1/04/2016 GILD-US      BW   Gilead annonce la désignation par la FDA américaine d’examen prioritaire pour le Sofosbuvir/Velpatasvir dans le traitement de tous les génotypes de l’hépatite C chronique,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2010 30161Q10 BW   Exelixis to Raise $160 Million through Financing Transactions with Silicon Valley Bank and Deerfield Management,"11/03/2011 80105N10  BW   Interview vidéo : Jérôme Contamine, Directeur Financier de Sanofi, commente les résultats du T3 2011",10/24/2011 92532F10  BW   Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK™ Combination Therapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/25/2013 ALNY-US   BW   Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2014 15117K10 BW   Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/31/2012 ILMN-US     BW   Illumina Comments on Roche’s Director Nominees and Proposals," 5/14/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 6th Annual Rodman & Renshaw Global Healthcare Conference on Tuesday, May 18th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2013 01535110 BW   Alexion Joins EURORDIS, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013",#N/A, 2/23/2012 81257810    BW   Seattle Genetics Provides Update on Commercial Leadership,#N/A, 2/06/2013 ELN-IE      BW   Elan Announces Restructuring of Tysabri Collaboration with Biogen Idec,#N/A,#N/A, 1/04/2016 GILD-US      BW   Gilead kondigt een aanduiding voor Prioritair Overzicht door de Amerikaanse FDA aan voor sofosbuvir/velpatasvir voor de behandeling van alle genotypen van chronische hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/03/2010 30161Q10 BW   Exelixis Announces Webcasts of ASCO Investor Briefings on June 5 and June 7,11/03/2011 80105N10  BW   Sanofi Video Q&A: CFO Jérôme Contamine Comments on Q3 2011 Results,"10/19/2011 92532F10  BW   Vertex Submits Application for Priority Review and Approval of KALYDECO™ (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/17/2013 02043Q10  BW   Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/17/2014 15117K10 BW   Axxam et Cellectis bioresearch annoncent leur collaboration pour offrir à l'industrie bio-pharmaceutique une nouvelle génération de tests cellulaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/31/2012 ROG-CH      BW   Roche to nominate slate of independent directors for election at Illumina, Inc.’s 2012 annual meeting", 5/10/2010 84763A10  BW   Spectrum Pharmaceuticals Announces First Quarter 2010 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2013 01535110 BW   Alexion se joint à EURORDIS, NORD et les organisations de patients dans le monde pour célébrer la Journée des maladies rares 2013",#N/A, 2/13/2012 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2011 Financial Results,#N/A, 1/28/2013 09062X10    BW   Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion,#N/A,#N/A, 1/04/2016 GILD-US      BW   Gilead annuncia la concessione da parte dell'FDA dello stato di esame prioritario per sofosbuvir/velpatasvir per il trattamento dell'infezione cronica da virus dell'epatite C di tutti i genotipi,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2010 30161Q10 BW   Exelixis Reports Updated Phase 2 Data for XL184 in Patients With Recurrent Glioblastoma to Be Presented at ASCO,11/01/2011 SAN-FR    BW   Broadway Star Ben Vereen Shows Diabetes Doesn’t Have to Hold You Back in New Public Service Announcement,10/11/2011 92532F10  BW   INCIVEK™ (télaprévir) disponible au Canada pour le traitement de l'hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/11/2013 02043Q10  BW   Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/17/2014 15117K10 BW   Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/27/2012 ILMN-US     BW   The Law Firm of Weiss & Lurie Investigates Illumina Inc., 5/07/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Date for First Quarter 2010 Corporate Update and Pipeline Review Conference Call,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2013 ALXN-US  BW   Alexion to Present at the Cowen and Company 33rd Annual Health Care Conference,#N/A, 2/08/2012 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conference,#N/A, 1/25/2013 09062X10    BW   Biogen Idec anuncia resultados positivos fundamentales del estudio de fase 3 de peginterferón beta-1a en la esclerosis múltiple,#N/A,#N/A, 1/04/2016 GILD-US      BW   Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2010 30161Q10 BW   Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive Randomized Discontinuation Trial of XL184 in Patients With Solid Tumors to be Presented at ASCO,10/25/2011 07YM31-E  BW   Hagens Berman Files Lawsuit Against Thalidomide Distributors and Producers,10/11/2011 92532F10  BW   INCIVEK™ (telaprevir) Now Available in Canada for People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/10/2013 02043Q10  BW   Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2014 15117K10 BW   Cellectis plant sciences franchit un nouveau jalon de son contrat avec Medicago pour l'amélioration des protéines thérapeutiques issues des feuilles de tabac,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 ILMN-US     BW   Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash"," 5/03/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 2010 BIO International Convention Business Forum on Wednesday, May 5, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2013 01535110 BW   Alexion Reports Fourth Quarter and Full Year 2012 Results,#N/A," 2/01/2012 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on February 13, 2012",#N/A, 1/24/2013 09062X10    BW   Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis,#N/A,#N/A,12/18/2015 GILD-US      BW   Galapagos e Gilead annunciano una collaborazione a livello globale per lo sviluppo di Filgotinib per il trattamento dell’artrite reumatoide e di altre malattie infiammatorie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2010 30161Q10 BW   Exelixis Reports Encouraging Interim Data From an Ongoing Phase 1b/2 Study of XL184 With or Without Erlotinib in Patients With Non-Small Lung Cancer to be Presented at ASCO,"10/25/2011 066807-E  BW   The Breast Cancer Drug Market Will Increase Marginally over the Next Decade, Despite Generic and Biosimilar Erosion of Key Agents",10/06/2011 92532F10  BW   Vertex Announces the Date of its Third Quarter 2011 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2013 02043Q10  BW   Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2014 15117K10 BW   Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 45232710    BW   Holzer Holzer & Fistel, LLC Announces Investigation into Potential Claims for Breaches of Fiduciary Duty by Illumina Inc’s Board of Directors", 4/21/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Belinostat Data Presentation at 101st Annual Meeting of the American Association for Cancer Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2013 01535110 BW   Alexion Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation,#N/A, 1/26/2012 4502-JP     BW   Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas,#N/A, 1/24/2013 BIIB-US     BW   Biogen Idec annonce des résultats positifs hautement fiables de l'étude de phase 3 sur le peginterféron bêta-1a dans le traitement de la sclérose en plaques,#N/A,#N/A,12/18/2015 GILD-US      BW   Galapagos y Gilead suscriben alianza mundial para desarrollar Filgotinib para el tratamiento de la artritis reumatoide y otras enfermedades inflamatorias,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2010 30161Q10 BW   Exelixis Reports Long-Term Phase 1 Results in a Cohort of Medullary Thyroid Cancer Patients Treated With XL184 to be Presented at ASCO,"10/25/2011 00CBJY-E  BW   Acton Pharmaceuticals, Inc. Announces License Agreement with Sanofi U.S. for NASACORT HFA™ (triamcinolone acetonide) Nasal Aerosol",10/03/2011 92532F10  BW   Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/06/2013 02043Q10  BW   Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2014 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/27/2012 45232710    BW   Johnson & Weaver, LLP Announces Investigation in Connection with the Possible Acquisition of Illumina, Inc. by Roche", 4/05/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2009 Corporate Update,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/31/2013 01535110 BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Results on Thursday, February 14, 2013",#N/A, 1/26/2012 81257810    BW   Seattle Genetics Announces Data from ADCETRIS™ in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma,#N/A, 1/24/2013 09062X10    BW   Biogen Idec annuncia risultati generali positivi per lo studio di Fase 3 sul peginterferone beta-1a nella sclerosi multipla,#N/A,#N/A,12/18/2015 GILD-US      BW   Galapagos et Gilead annoncent un partenariat mondial pour développer Filgotinib en vue du traitement de l'arthrite rhumatoïde et d'autres malades inflammatoires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/14/2010 30161Q10 BW   Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/24/2011 SAN-FR    BW   Sanofi Appoints David Meeker Chief Executive Officer of Genzyme, 9/30/2011 92532F10  BW   Vertex to Present New Data from Hepatitis C Development Program at AASLD Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/02/2013 02043Q10  BW   Alnylam Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/07/2014 15117K10 BW   Cellectis réorganise son pôle « Outils et services » en apportant, avec la Caisse des Dépôts, les titres d’Ectycell à Cellectis bioresearch",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/27/2012 ILMN-US     BW   Illumina’s Board of Directors to Review Unsolicited Tender Offer from Roche, 4/01/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Delay in Filing 2009 Annual Report on Form 10-K,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2013 ALXN-US  BW   AGNSS Recommends Soliris® (eculizumab) for aHUS and Concludes “Eculizumab would help save lives and improve the quality of life for children and adults with atypical haemolytic uraemic syndrome”,#N/A, 1/13/2012 81257810    BW   Seattle Genetics Announces Updates to ADCETRIS™ Prescribing Information,#N/A, 1/24/2013 09062X10    BW   Biogen Idec meldet positive Top-Line-Ergebnisse aus Phase-3-Studie zu Peginterferon Beta-1a bei Multipler Sklerose,#N/A,#N/A,12/18/2015 GILD-US      BW   Galapagos und Gilead geben globale Partnerschaft zur Entwicklung von Filgotinib zur Behandlung von rheumatoider Arthritis und anderen entzündlichen Erkrankungen bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/11/2010 30161Q10 BW   Exelixis Announces First Quarter 2010 Financial Results,10/22/2011 80105N10  BW   Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study, 9/16/2011 92532F10  BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/30/2013 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/07/2014 15117K10 BW   Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Dépôts, by Contributing Ectycell’s Shares to Cellectis Bioresearch",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 45232710    BW   Ryan & Maniskas, LLP Announces Investigation of Illumina, Inc.", 3/22/2010 84763A10  BW   Spectrum Pharmaceuticals Announces a National Cancer Institute-Sponsored Phase 1/2 Study of Belinostat in Thymic Malignancies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/21/2013 07GVF3-E BW   Research and Markets: B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012",#N/A, 1/04/2012 81257810    BW   Seattle Genetics to Present at the J.P. Morgan Healthcare Conference,#N/A, 1/16/2013 09062X10    BW   Biogen Idec et Elan soumettent leur demande d'utilisation en tant que traitement de première intention du TYSABRI chez les patients atteints de sclérose en plaques présentant des anticorps anti-JCV négatifs,#N/A,#N/A,12/17/2015 0056YC-E     BW   “PrEP: The Revolution That Didn’t Happen” Declares New AHF Advocacy Ad,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2010 30161Q10 BW   Exelixis Announces May 10 Webcast of Presentation at the Ninth Annual JMP Securities Research Conference,10/20/2011 4502-JP   BW   Research and Markets: Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value, 9/15/2011 92532F10  BW   Vertex nommée meilleur employeur dans le secteur du biopharmaceutique par le magazine Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/29/2013 02043Q10  BW   Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2013 15117K10 BW   Cellectis annonce l’accélération de son recentrage stratégique sur les domaines thérapeutique et agro-industriel,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/26/2012 ROG-CH      BW   Roche responds to adoption of shareholder rights plan by Illumina Board of Directors," 3/11/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the 22nd Annual Roth Capital Markets Growth Conference on Monday, March 15",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/18/2013 07GVF3-E BW   Research and Markets: Heart Transplantation - Pipeline Review, H2 2012 Considers Companies and Universities Involved",#N/A,12/13/2011 81257810    BW   Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting,#N/A, 1/16/2013 09062X10    BW   Biogen Idec und Elan stellen Anträge auf Zulassung von TYSABRI zur Erstbehandlung von JCV-Antikörper-negativen Patienten mit MS,#N/A,#N/A,12/17/2015 GILD-US      BW   Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/28/2010 30161Q10 BW   Exelixis Announces May 11 Webcast of First Quarter 2010 Financial Results Conference Call,10/19/2011 LLY-US    BW   CEOs Lead Cancer Fighting Effort, 9/15/2011 92532F10  BW   Vertex Named Top Biopharma Employer by Science,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/09/2013 02043Q10  BW   The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2013 0CDCWK-E BW   Cellectis announces an acceleration of its strategic refocusing on therapeutics and agrobusiness,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 ILMN-US     BW   San Diego Law Firm Robbins Umeda LLP Announces an Investigation of Illumina, Inc."," 2/25/2010 84763A10  BW   Spectrum Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference Panel on Wednesday, March 3rd in New York City",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2013 ALXN-US  BW   Alexion to Present at the JP Morgan 31st Annual Healthcare Conference,#N/A,12/12/2011 81257810    BW   Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting,#N/A, 1/16/2013 080RQG-E    BW   Biogen Idec ed Elan presentano una richiesta di utilizzo in prima linea di TYSABRI nei pazienti affetti da sclerosi multipla negativi agli anticorpi anti-JCV,#N/A,#N/A,12/09/2015 GILD-US      BW   Phase-III-Ergebnisse zu Zydelig® mit Bendamustin und Rituximab bei rezidivierender Form der chronischen lymphatischen Leukämie (CLL) im Rahmen der Jahresversammlung der American Society of Hematology vorgestellt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2010 30161Q10 BW   Exelixis Announces May 5 Webcast of Presentation at the Deutsche Bank 35th Annual Health Care Conference,10/18/2011 OXUR-BE   BW   Research and Markets: Biotechnology in Belgium. Essential Resource for Top-line data and Analysis, 9/14/2011 92532F10  BW   Le New England Journal of Medicine publie des données de l’étude de Phase 3 ILLUMINATE d’INCIVEKMC (Télaprévir) sur l’hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/08/2013 02043Q10  BW   Alnylam Advances Development Candidate for ALN-AS1, a Subcutaneously Administered RNAi Therapeutic Targeting Aminolevulinate Synthase 1 (ALAS-1) for the Treatment of Hepatic Porphyrias",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2013 15117K10 BW   Cellectis announces first-half 2013 financial results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/26/2012 45232710    BW   The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Illumina, Inc. in Connection with a Merger Proposal from Roche", 2/16/2010 SPPI-US   BW   Celldex Receives $3 Million Sublicense Income Payment from TopoTarget,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2012 ALXN-US  BW   New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting,#N/A,12/12/2011 81257810    BW   Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS™ (Brentuximab Vedotin) at ASH Annual Meeting,#N/A, 1/16/2013 09062X10    BW   Biogen Idec y Elan presentan solicitudes para el uso de primera línea de TYSABRI en pacientes con anticuerpos anti-JCV negativos con EM,#N/A,#N/A,12/09/2015 GILD-US      BW   Los resultados de fase 3 para Zydelig® con Bendamustina y Rituximab en el tratamiento de la leucemia linfocítica crónica recidivante (LLC) han sido presentados durante el congreso anual de la American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2010 30161Q10 BW   12 Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2010 ASCO Annual Meeting,10/18/2011 80105N10  BW   Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress, 9/14/2011 92532F10  BW   New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/30/2013 02043Q10  BW   Alnylam Completes Enrollment of Phase II Clinical Trial and Initiates Open-Label Extension (OLE) Study with ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/26/2013 15117K10 BW   Cellectis : résultats du premier semestre 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/26/2012 ILMN-US     BW   Illumina Adopts Stockholder Rights Agreement," 2/05/2010 84763A10  BW   Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/26/2012 0C8BZH-E BW   RBCC JV Target Amarantus Explores Orphan Drug Designation for MANF,#N/A,12/07/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conference,#N/A, 1/16/2013 09062X10    BW   Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS,#N/A,#N/A,12/09/2015 GILD-US      BW   I risultati di Fase III su Zydelig® in combinazione con bendamustina e rituximab per il trattamento della leucemia linfocitica cronica (LLC) recidivante sono stati presentati al Convegno annuale della Società americana...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2010 30161Q10 BW   Exelixis Announces March 24 Webcast of Presentation at the Barclays Capital Global Healthcare Conference,10/17/2011 07P9MD-E  BW   Hematology/Oncology Associates of Central NY Receives CEO Cancer Gold StandardTM Accreditation, 9/06/2011 92532F10  BW   Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2013 02043Q10  BW   Alnylam to Webcast Presentation at Leerink Swann Rare Disease Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2013 15117K10 BW   Cellectis Bioresearch Launches Compact TALENTM the Next Generation of TAL Effector Nucleases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 ILMN-US     BW   Law Offices of Howard G. Smith Announces Investigation of Illumina, Inc."," 2/02/2010 84763A10  BW   Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2012 ALXN-US  BW   Alexion to Present at the 24th Annual Piper Jaffray Healthcare Conference,#N/A,11/08/2011 81257810    BW   Seattle Genetics and Millennium Announce Presentation of ADCETRIS™ Data at American Society of Hematology Annual Meeting,#N/A, 1/16/2013 ELN-IE      BW   Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS,#N/A,#N/A,12/09/2015 GILD-US      BW   Les résultats de Phase 3 pour le Zydelig® combiné à la Bendamustine et au Rituximab dans le traitement de la leucémie lymphoïde chronique (LLC) récidivante ont été présentés lors de la réunion annuelle...,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2010 30161Q10 BW   Exelixis Announces Fourth Quarter and Full Year 2009 Financial Results,10/13/2011 0B6G4F-E  BW   Dual-Novel Combinations: A New Strategy for Developing Cancer Drugs, 9/01/2011 92532F10  BW   Vertex Announces Webcast of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/23/2013 02043Q10  BW   Alnylam Reports Positive Clinical Results – with up to 94% Knockdown of Serum Transthyretin (TTR) – for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/23/2013 15117K10 BW   Cellectis bioresearch lance Compact TALENTM, la nouvelle génération de nucléases effectrices TAL",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   MURRAY FRANK LLP Announces Investigation of Illumina, Inc.", 1/29/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Receipt of $16 Million from Asian Partners Related to Apaziquone Collaboration Agreements Announced in November 2009,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2012 01535110 BW   Alexion Announces $400 Million Share Repurchase Program,#N/A,11/07/2011 81257810    BW   Seattle Genetics to Present at Two Upcoming Investor Conferences,#N/A," 1/14/2013 09062X10    BW   Biogen Idec to Report Fourth Quarter & Year End 2012 Financial Results on January 28, 2013",#N/A,#N/A,12/08/2015 GILD-US      BW   Fase 3-resultaten voor Zydelig® met bendamustine en rituximab voor gerecidiveerde chronische lymfatische leukemie (CLL) gepresenteerd op de jaarvergadering van de American Society of Hematology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/08/2010 30161Q10 BW   Exelixis Announces Restructuring,10/11/2011 008X00-E  BW   AnaptysBio Appoints Carol G. Gallagher as Executive Chair and Promotes Senior Leaders Hamza Suria and David J. King, 8/22/2011 074T76-E  BW   What’s Next for Boston: Allen & Gerritsen Moves to the Innovation District,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2013 02043Q10  BW   Alnylam to Webcast Presentation at 20th Annual NewsMakers in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2013 15117K10 BW   Scéil(TM) : A New Offering for the General Public to Turn Adult Cells into Stem Cells and Store Them,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   CORRECTING and REPLACING Glancy Binkow & Goldberg LLP Announces Investigation of Illumina, Inc.", 1/27/2010 84763A10  BW   Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2012 ALXN-US  BW   Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting,#N/A,11/03/2011 81257810    BW   Seattle Genetics Reports Third Quarter 2011 Financial Results,#N/A, 1/07/2013 ACOR-US     BW   Acorda Therapeutics Provides Corporate Update at 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,12/08/2015 GILD-US      BW   Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/04/2010 30161Q10 BW   Exelixis Announces March 10 Webcast of Presentation at the Cowen and Company 30th Annual Healthcare Conference," 9/12/2011 07PHN9-E  BW   Mexican Consulate of New York to Host “5 Steps for Good Health” Initiative During Wellness Week, September 17 - 22", 8/22/2011 92532F10  BW   Santé Canada approuve INCIVEKMC (télaprévir) pour le traitement des personnes atteintes d’hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/03/2013 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/08/2013 15117K10 BW   Scéil(TM) : lancement d’une offre grand public dédiée à la transformation de cellules adultes en cellules souches iPS et à leur stockage,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Law Firm Brower Piven Announces Investigation in Connection With the Possible Acquisition of Illumina, Inc. by Roche", 1/25/2010 84763A10  BW   Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV® sNDA under Review for Advanced Metastatic Colorectal Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2012 ALXN-US  BW   Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS,#N/A,"10/26/2011 SGEN-US     BW   Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion",#N/A, 1/04/2013 09062X10    BW   Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B,#N/A,#N/A,12/04/2015 GILD-US      BW   European Medicines Agency valideert Gilead’s aanvraag voor een vergunning voor het in de handel brengen van de vastedosiscombinatie van Sofosbuvir/Velpatasvir voor de behandeling van hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2010 30161Q10 BW   Exelixis Announces March 9 Webcast of Its Fourth Quarter and Full Year 2009 Financial Results Conference Call," 9/06/2011 80105N10  BW   Interview vidéo : Chris Viehbacher, DG de Sanofi, commente les messages clés du Séminaire Relations Investisseurs", 7/28/2011 92532F10  BW   Vertex Reports Second Quarter 2011 Financial Results and Provides Updates on Launch of INCIVEKTM (telaprevir) and Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2013 02043Q10  BW   Alnylam and Collaborators Publish Clinical Trial Results with RNAi Therapeutics Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) in the New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/05/2013 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Rigrodsky & Long, P.A. Investigates Illumina, Inc.’s Offer to Be Acquired by Roche",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/03/2012 ALXN-US  BW   New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS,#N/A,10/25/2011 81257810    BW   Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma Malignancies,#N/A, 1/03/2013 09062X10    BW   Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS),#N/A,#N/A,"12/04/2015 GILD-US      BW   L’Agenzia europea per i medicinali (European Medicines Agency, EMA) convalida la domanda di Gilead di autorizzazione alla commercializzazione della terapia combinata a dosaggio fisso sofosbuvir/velpatasvir...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2010 30161Q10 BW   Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conference, 9/06/2011 80105N10  BW   Sanofi Video Q&A: CEO Chris Viehbacher Comments on Key Messages from the Investor Relations Seminar, 7/26/2011 92532F10  BW   Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/20/2013 02043Q10  BW   Alnylam Receives Additional Orphan Drug Designation from U.S. Food & Drug Administration for ALN-AT3, an RNAi Therapeutic for the Treatment of Hemophilia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/04/2013 15117K10 BW   Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2012 45232710    BW   Bernstein Liebhard LLP Announces Investigation of Offer for Illumina, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2012 01535110 BW   Alexion Reports Third Quarter 2012 Results,#N/A,"10/20/2011 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2011 Financial Results on November 3, 2011",#N/A, 1/02/2013 BIIB-US     BW   Biogen Idec to Present at the 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,12/04/2015 GILD-US      BW   L’Agence européenne des médicaments valide la demande d’autorisation de mise sur le marché de Gilead concernant la combinaison à dose fixe de sofosbuvir/velpatasvir pour le traitement de l’hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/17/2011 SAN-FR    BW   Genzyme Announces Winners of Patient Advocacy Leadership Awards, 7/06/2011 05M26N-E  BW   $355 Million Financing Arranged by HFF for Vertex Pharmaceuticals Campus at Fan Pier,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 8/14/2013 02043Q10  BW   Alnylam Receives Orphan Drug Designation from U.S. Food & Drug Administration for ALN-AT3, an RNAi Therapeutic for the Treatment of Hemophilia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/04/2013 15117K10 BW   Cellectis a établi la preuve de concept in vivo de son produit phare UCART19 comme traitement curatif de la leucémie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/25/2012 ILMN-US     BW   Harwood Feffer LLP Announces Investigation of Illumina Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/17/2012 01535110 BW   Alexion Pharmaceuticals to Report Third Quarter 2012 Results on Wednesday, October 24, 2012",#N/A, 9/24/2011 81257810    BW   Millennium und Seattle Genetics legen auf der EMCC-Jahrestagung klinische Daten zu ADCETRIS™ (Brentuximab Vedotin) bei pädiatrischen Patienten vor,#N/A,12/28/2012 ACOR-US     BW   Acorda Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,12/04/2015 GILD-US      BW   Europäische Arzneimittelbehörde bestätigt Gileads Vermarktungsantrag für Festdosiskombination von Sofosbuvir/Velpatasvir zur Behandlung von Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/11/2011 SAN-FR    BW   Research and Markets: Company Analysis - Sanofi-Aventis SA, 7/05/2011 92532F10  BW   Vertex Announces the Date of its Second Quarter 2011 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/08/2013 02043Q10  BW   Alnylam Pharmaceuticals Reports Second Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/26/2013 15117K10 BW   Cellectis a réussi à éditer le génome d’algues photosynthétiques dans le but de leur faire produire des biocarburants,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/25/2012 ILMN-US     BW   Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/10/2012 ALXN-US  BW   Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS and STEC-HUS at ASN Annual Meeting,#N/A," 9/24/2011 81257810    BW   Millennium et Seattle Genetics présentent, à l’occasion de la réunion annuelle de l’EMCC, des données cliniques concernant l’utilisation d’ADCETRIS™ (Brentuximab Vedotin) chez les patients pédiatriques",#N/A,12/20/2012 09062X10    BW   Biogen Idec ruft bislang einzigartiges Forschungskonsortium zur Identifizierung möglicher Arzneimitteltargets bei ALS ins Leben,#N/A,#N/A,12/04/2015 GILD-US      BW   La Agencia Europea del Medicamento valida la solicitud de comercialización de la combinación de dosis fija de Sofosbuvir/Velpatasvir para el tratamiento de la hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/03/2011 07G69B-E  BW   Research and Markets: The Vaccines Market in the US is set to Reach over $15 billion by 2015, 7/04/2011 VRTX-US   BW   Research and Markets: Vertex Pharmaceuticals Inc.: PharmaVitae Profile,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/01/2013 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/26/2013 15117K10 BW   Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/24/2012 ILMN-US     BW   Roche to host investor conference call regarding offer for Illumina, Inc.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2012 ALXN-US  BW   Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual Meeting,#N/A, 9/24/2011 81257810    BW   Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting,#N/A,12/20/2012 09062X10    BW   Biogen Idec forma un consorzio di ricerca primo nel suo genere per identificare target dei farmaci per la SLA,#N/A,#N/A,12/04/2015 GILD-US      BW   European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/28/2011 80105N10  BW   Interview vidéo : Chris Viehbacher, DG de Sanofi, commente les résultats du 2ème trimestre 2011", 6/22/2011 0B6G4F-E  BW   New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK™ (telaprevir) in Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/11/2013 02043Q10  BW   Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/18/2013 15117K10 BW   Cellectis SA Combined General Shareholders’ Meeting of June 14, 2013",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/24/2012 ROG-CH      BW   Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2012 081TWK-E BW   Six Winners Announced at 2012 Marcum Tech Top 40 Event,#N/A, 9/13/2011 009MJ0-E    BW   Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer,#N/A,12/20/2012 BIIB-US     BW   Biogen Idec Forms First-of-Its-Kind Research Consortium to Identify ALS Drug Targets,#N/A,#N/A,"11/24/2015 GILD-US      BW   Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2011 80105N10  BW   Sanofi Video Q&A: CEO Chris Viehbacher Comments on Results for Q2 2011, 6/17/2011 92532F10  BW   Vertex Announces Webcast of its Presentation at the Wells Fargo Securities 2011 Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/02/2013 02043Q10  BW   Alnylam to Webcast R&D Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/18/2013 15117K10 BW   Assemblée Générale mixte des actionnaires de Cellectis SA du 14 juin 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/17/2012 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Tuesday, January 31, 2012",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/18/2012 009MG4-E BW   Drug and medical-device companies can blossom in emerging nations, says Turner Investments commentary",#N/A, 9/08/2011 81257810    BW   Seattle Genetics to Present at Two Upcoming Investor Conferences,#N/A,12/20/2012 09062X10    BW   Biogen Idec crea el primer consorcio de investigación de su categoría para identificar nuevos fármacos contra la esclerosis lateral amiotrófica,#N/A,#N/A,"11/24/2015 GILD-US      BW   La Comisión Europea concede la autorización de comercialización al tratamiento de comprimido único Genvoya® (Elvitegravir, Cobicistat, Emtricitabina y Tenofovir Alafenamida) de Gilead para el tratamiento de la infección por VIH -1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2011 SAN-FR    BW, 6/13/2011 060RWY-E  BW   Massive Opportunity Exists in Hepatitis C Market for Recently Approved Protease Inhibitors Victrelis and Incivek According to a New Report by BioTrends Research Group,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/02/2013 02043Q10  BW   Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2013 15117K10 BW   Cellectis plant sciences CEO Luc Mathis joins Board of Directors of the French Association for Plant Biotechnology (AFBV),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2012 45232710    BW   Illumina Introduces the HiSeq 2500,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/05/2012 ALXN-US  BW   Alexion to Present at Morgan Stanley Global Healthcare Conference,#N/A, 8/23/2011 81257810    BW   Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Hodgkin Lymphoma,#N/A,12/20/2012 BIIB-US     BW   Biogen Idec forme un consortium de recherche novateur pour identifier des cibles médicamenteuses pour le traitement de la SLA,#N/A,#N/A,"11/24/2015 GILD-US      BW   Europäische Kommission erteilt Marktzulassung für das Einzeltablettenregime Genvoya® (Elvitegravir, Cobicistat, Emtricitabin und Tenofoviralafenamid) von Gilead für die Behandlung von Infektionen mit HIV-1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2011 500660-IN BW   Research and Markets: Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 - The Merchant Market for Generics Continues to Grow as the Competition Increases," 6/13/2011 92532F10  BW   Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex’s Efforts to Develop New Combinations of Medicines for Hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/01/2013 02043Q10  BW   Alnylam to Webcast Presentation at 8th Annual JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/06/2013 ALCLS-FR BW   Luc Mathis, Directeur général de Cellectis plant sciences, rejoint le Conseil d’administration de l’Association Française des Biotechnologies Végétales",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/09/2012 0BL1G4-E    BW   Aria Diagnostics Secures $52.7 Million in Oversubscribed Series C Financing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/29/2012 ALXN-US  BW   Alexion to Present at Investor Conferences,#N/A, 8/19/2011 81257810    BW   Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications,#N/A,12/18/2012 06680H-E    BW   U.S. Neurologists Report that 30 to 40 Percent of Treated Relapsing and Progressive Multiple Sclerosis Patients are Dissatisfied with Their Current Disease-Modifying Therapy (DMT) and would be Eager to Switch to a New Drug,#N/A,#N/A,"11/24/2015 GILD-US      BW   La Commission européenne accorde une autorisation de mise sur le marché pour Genvoya®, le comprimé à prise uniquotidienne (elvitégravir, cobicistat, emtricitabine et ténofovir alafénamide) de Gilead pour...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/19/2011 SAN-FR    BW   Rib-X Pharmaceuticals Receives $9 Million Milestone Payment from Sanofi in the RX-04 Collaboration, 6/10/2011 VRTX-US   BW   Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/30/2013 02043Q10  BW   Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2013 15117K10 BW   Nucléases effectrices TAL : L’USPTO1 délivre un troisième brevet licencié à Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/04/2012 ILMN-US     BW   Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2012 081TWK-E BW   Connecticut Technology Council Announces 2012 Marcum Tech Top 40 Winners,#N/A, 8/04/2011 81257810    BW   Seattle Genetics Reports Second Quarter 2011 Financial Results,#N/A,12/12/2012 05NDXX-E    BW   Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities,#N/A,#N/A,"11/24/2015 GILD-US      BW   De Europese Commissie verleent een vergunning voor het in de handel brengen van Gilead’s enkeltabletregime Genvoya® (elvitegravir, cobicistat, emtricitabine en tenofovir alafenamide) voor de behandeling...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2011 09R1H5-E  BW   Erythropoeitin Stimulating Agents Take a Hit as New Reimbursement Structure is Implemented in the US Dialysis Market and Future Changes Are Likely Still to Come, 6/09/2011 92532F10  BW   Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/20/2013 02043Q10  BW   Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/28/2013 ALCLS-FR BW   TAL-effector Nuclease: The USPTO Issues a Third Patent Licensed to Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/03/2012 45232710    BW   Illumina to Present at the J. P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/25/2012 01535110 BW   Alexion Reports Second Quarter 2012 Results,#N/A," 7/26/2011 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2011 Financial Results on August 4, 2011",#N/A,12/10/2012 00CX63-E    BW   PreCision Dermatology Names Garen Bohlin to Board of Directors,#N/A,#N/A,"11/23/2015 GILD-US      BW   La Commissione Europea rilascia l'autorizzazione alla commercializzazione per Genvoya® (elvitegravir, cobicistat, emtricitabina e tenofovir alafenamide), il regime monocompressa di Gilead per il trattamento...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2011 MITI-US   BW   Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen, 5/26/2011 92532F10  BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2013 02043Q10  BW   Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2013 ALCLS-FR BW   Cellectis : Compact TALENTM : La nouvelle génération de nucléases effectrices TAL,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/19/2011 45232710    BW   British Columbia Cancer Agency Joins the Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/11/2012 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter 2012 Results on Wednesday, July 25, 2012",#N/A, 7/14/2011 81257810    BW   Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS™ for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL,#N/A,"12/06/2012 060RWY-E    BW   Biologic Agents are Being Used Earlier and More Often to Treat Rheumatoid Arthritis in the EU5, According to Two Recent Reports from BioTrends",#N/A,#N/A,"11/23/2015 GILD-US      BW   European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2011 05QZSX-E  BW   Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™ (*)) in Multiple Sclerosis, 5/23/2011 92532F10  BW   FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2013 02043Q10  BW   Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2013 15117K10 BW   Cellectis: Compact TALENTM: the next generation of TAL effector nucleases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/15/2011 45232710    BW   Illumina Hires Laura Lauman as Vice President of Marketing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/17/2012 01535110 BW   New Data Show Majority of Patients with aHUS Experienced Systemic Multi-Organ Complications Prior to Treatment,#N/A, 7/14/2011 81257810    BW   Trading of Seattle Genetics Common Stock Halted,#N/A,11/29/2012 09062X10    BW   Biogen Idec Opens New RTP Facility,#N/A,#N/A,11/17/2015 GILD-US      BW   Zydelig® de Gilead combinado con Bendamustina y Rituximab muestra una eficacia superior a Bendamustina/Rituximab en un estudio de fase 3 de pacientes con leucemia linfocítica crónica recurrente,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/06/2011 80105N10  BW   Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics, 5/17/2011 92532F10  BW   Vertex Appoints Terrence C. Kearney to its Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/17/2013 02043Q10  BW   Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2013 15117K10 BW   Nucléases effectrices TAL : L’USPTO1 a délivré deux nouveaux brevets à Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/30/2011 05M967-E    BW   Research and Markets: Strategic Analysis of the U.S. Next-Generation Sequencing Services. A Convergence of Favorable Market Dynamics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/13/2012 ALXN-US  BW   Alexion to Present at Wells Fargo Securities Healthcare Conference,#N/A, 6/27/2011 81257810    BW   Seattle Genetics Achieves Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA,#N/A,11/26/2012 09062X10    BW   Biogen Idec to Present at the DB Access BioFEST Conference,#N/A,#N/A,11/17/2015 GILD-US      BW   Van Gilead Zydelig® gecombineerd met Bendamustine en Rituximab is superieure werkzaamheid aangetoond in vergelijking met Bendamustine/Rituximab in fase 3-onderzoek bij patiënten met terugkerende chronische lymfocytische leukemie,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/28/2011 80105N10  BW, 5/12/2011 92532F10  BW   Vertex Shareholders Approve Proxy Proposals at Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/15/2013 02043Q10  BW   Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/16/2013 15117K10 BW   Cellectis: TAL-effector nuclease: Issuance by the USPTO of Two New Patents,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/23/2011 45232710    BW   Illumina to Present at the Piper Jaffray Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/05/2012 ALXN-US  BW   Alexion to Present at William Blair & Company 32nd Annual Growth Stock Conference,#N/A, 6/17/2011 81257810    BW   Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer,#N/A,11/26/2012 ALNY-US     BW,#N/A,#N/A,"11/17/2015 GILD-US      BW   Le Zydelig® de Gilead, combiné à la bendamustine et au rituximab, démontre une efficacité supérieure à la combinaison bendamustine/rituximab dans une étude de phase 3 sur des patients atteints de leucémie lymphoïde chronique récidivante",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2011 BDX-US    BW   CEO Cancer Gold StandardTM Accreditation Awarded to BD, 5/11/2011 VRTX-US   BW   Product Commercialization Comes Into Focus at Emerging Leaders Workshop at 2011 BIO International Convention,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/08/2013 02043Q10  BW   Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2013 15117K10 BW   David Sourdive, Vice President of Corporate Development at Cellectis, has been appointed by French Foreign Trade Minister Nicole Bricq to boost France’s export performance in the health sector",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/31/2011 05L5JM-E    BW   Illumina Names Dr. Daniel S. Grosu Chief Medical Officer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/29/2012 ALXN-US  BW   Alexion to Present at Investor Conferences,#N/A, 6/16/2011 81257810    BW   Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL,#N/A,11/21/2012 ALNY-US     BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,11/16/2015 GILD-US      BW   Zydelig® di Gilead in combinazione con bendamustina e rituximab mostra efficacia superiore a bendamustina/rituximab nello studio di Fase 3 dei pazienti affetti da leucemia linfocitica cronica recidivante,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/22/2011 4578-JP   BW   Both Familiarity with and Use of Samsca and Vaprisol, Newer Agents to Treat Hyponatremia, Are Limited, Based on a New Report from BioTrends", 5/03/2011 92532F10  BW   Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2013 02043Q10  BW   Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/02/2013 ALCLS-FR BW   David Sourdive, Vice Président du développement corporate de Cellectis, a été mandaté par la Ministre du Commerce extérieur, Nicole Bricq, afin d’améliorer les performances françaises à l’exportation dans le domaine de la santé",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/25/2011 45232710    BW   Illumina Reports Financial Results for Third Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2012 01535110 BW   Alexion to Present at Bank of America Merrill Lynch 2012 Health Care Conference,#N/A, 6/15/2011 81257810    BW   Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Clinical Data at International Conference on Malignant Lymphoma,#N/A,11/12/2012 ALNY-US     BW   Alnylam and Tekmira Restructure Relationship and Settle All Litigation,#N/A,#N/A,11/16/2015 GILD-US      BW   Zydelig® von Gilead in Verbindung mit Bendamustin und Rituximab zeigt in Phase-III-Studie mit Patienten mit Rezidiven von chronischer lymphozytischer Leukämie höhere Wirksamkeit als Bendamustin/Rituximab alleine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/22/2011 06PD8S-E  BW   CoBiz Financial Receives CEO Cancer Gold StandardTM Accreditation, 5/02/2011 92532F10  BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2013 02043Q10  BW   Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2013 15117K10 BW   Cellectis: 2012 financial results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/18/2011 45232710    BW   Illumina to Announce Third Quarter 2011 Financial Results on Tuesday, October 25, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2012 01535110 BW   Alexion to Present at Deutsche Bank Securities 37th Annual Health Care Conference,#N/A, 6/11/2011 81257810    BW   Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting,#N/A,11/07/2012 BIIB-US     BW   Biogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference,#N/A,#N/A,11/16/2015 GILD-US      BW   Múltiples presentaciones científicas durante The Liver Meeting 2015 destacan la utilidad de los tratamientos contra la hepatitis C basados en sofosbuvir,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/20/2011 076Z70-E  BW   Genzyme Corporation Announces Expiration of Consent Solicitation and Receipt of Requisite Consents, 4/28/2011 92532F10  BW   FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2013 02043Q10  BW   Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2013 ALCLS-FR BW   Cellectis : résultats 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/12/2011 45232710    BW   Illumina Announces Novel Human Exome Content Available on Multiple BeadChip Formats,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/24/2012 ALXN-US  BW   Alexion Reports First Quarter 2012 Results,#N/A, 6/10/2011 4502-JP     BW   Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting,#N/A,11/05/2012 ALNY-US     BW   Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial Results,#N/A,#N/A,11/16/2015 GILD-US      BW   Gilead presenta nuevos datos durante el congreso The Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/16/2011 SNY-FR    BW   Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform, 4/28/2011 VRTX-US   BW   Trading of Vertex Common Stock Halted Today,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/18/2013 02043Q10  BW   Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2013 15117K10 BW   Cellectis Bioresearch Launches VizuCELL Cell Lines for Live Cell Imaging,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/11/2011 45232710    BW   Illumina Introduces Revolutionary Workflow Enhancements for MiSeq™,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/10/2012 01535110 BW   Alexion Pharmaceuticals to Report First Quarter 2012 Results on Tuesday, April 24, 2012",#N/A," 6/09/2011 81257810    BW   Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration",#N/A,11/01/2012 00CK58-E    BW   Nimbus Discovery Names Daniel S. Lynch Executive Chairman,#N/A,#N/A,11/16/2015 GILD-US      BW   Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/14/2011 06SG07-E  BW   ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission", 4/15/2011 92532F10  BW   Vertex Announces the Date of its First Quarter 2011 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/05/2013 02043Q10  BW   Alnylam to Webcast Presentation at Barclays Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/17/2013 ALCLS-FR BW   Cellectis bioresearch lance les lignées cellulaires VizuCELL dédiées à l’imagerie cellulaire,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/06/2011 45232710    BW   Illumina Announces Preliminary Revenue for Third Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/29/2012 ALXN-US  BW   Asfotase Alfa Significantly Decreased TNSALP Substrates and Improved 6-Minute Walk Test Results in Adolescents and Adults with Hypophosphatasia (HPP),#N/A, 6/06/2011 4502-JP     BW   Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting,#N/A,10/31/2012 09062X10    BW   Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A,#N/A,#N/A,11/15/2015 GILD-US      BW   Gilead présente de nouvelles données à la réunion The Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/14/2011 MITI-US   BW   Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer", 4/07/2011 92532F10  BW   Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/26/2013 02043Q10  BW   Alnylam to Webcast Presentation at Cowen and Company 33rd Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2013 15117K10 BW   Cellectis bioresearch lance les lignées cellulaires CanCELL™ qui permettent d’identifier de nouveaux médicaments pour lutter contre le cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/04/2011 45232710    BW   Illumina Enters Collaborative Research Agreement with UNTHSC for Next-Generation Sequencing in Forensic DNA Analysis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2012 01535110 BW   CORRECTING and REPLACING New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia,#N/A, 6/06/2011 81257810    BW   Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting,#N/A,10/31/2012 ACOR-US     BW   Acorda Therapeutics Reports Third Quarter 2012 Financial Results,#N/A,#N/A,11/15/2015 GILD-US      BW   Gilead presenta nuovi dati in occasione della Riunione sul fegato (The Liver Meeting) del 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2011 06PD8S-E  BW   The American Cancer Society Continues to Lead Workplace Wellness Effort," 3/31/2011 92532F10  BW   Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/11/2013 ALNY-US   BW   Corporate Leaders Receive Thirteenth Annual Emerald Asset Management “E-3 Awards”,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/08/2013 15117K10 BW   Launching of CanCELL™ cell lines, featuring knock-out of the major cancer relevant oncogenes and tumor suppressor genes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/29/2011 45232710    BW   Illumina Introduces Low-Cost Bovine BeadChip for Genotyping of Dairy Cattle,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2012 01535110 BW   Alexion to Present at Barclays Capital Global Healthcare Conference,#N/A, 6/01/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/30/2012 ACOR-US     BW   Acorda Therapeutics Receives Silver Awards from Medical Marketing & Media Magazine for AMPYRA.com Consumer Website and AMPYRA Healthcare Professional Print Campaign,#N/A,#N/A,11/15/2015 GILD-US      BW   Svariate presentazioni scientifiche tenute all'edizione del 2015 della Riunione sul fegato (The Liver Meeting) evidenziano ulteriormente l'utilità delle terapie a base di sofosbuvir per il trattamento dell'epatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/24/2011 80105N10  BW   Genzyme Corporation Commences Consent Solicitation Relating to its Outstanding 3.625% Senior Notes due 2015 and 5.000% Senior Notes due 2020, 3/31/2011 92532F10  BW   Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2013 02043Q10  BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/07/2013 ALCLS-FR BW   Cellectis et Stemgent s’associent pour fournir un service d’ingénierie des génomes personnalisé, appliqué aux cellules iPS",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/07/2011 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/29/2012 06TVH6-E BW   Alexion Joins EURORDIS, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2012",#N/A, 5/27/2011 SGEN-US     BW   Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association,#N/A,10/25/2012 09062X10    BW   Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter,#N/A,#N/A,11/15/2015 GILD-US      BW   Gilead presenteert nieuwe gegevens op The Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/28/2011 80105N10  BW   Interview vidéo : Jérôme Contamine, Directeur Financier de Sanofi-aventis, commente les résultats du T1 2011"," 3/31/2011 92532F10  BW   Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2013 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/07/2013 077TJT-E BW   Cellectis and Stemgent Partner to Provide Custom Genome-engineered iPS Cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/03/2011 45232710    BW   Illumina Announces New $100 Million Share Repurchase Authorization,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/27/2012 01535110 BW   Alexion to Present at the Cowen and Company 32nd Annual Health Care Conference,#N/A, 5/19/2011 81257810    BW   Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual Meeting,#N/A,"10/23/2012 ACOR-US     BW   Acorda Therapeutics to Host Conference Call to Discuss Third Quarter 2012 Financial Results on October 30, 2012",#N/A,#N/A,11/15/2015 GILD-US      BW   The Liver Meeting 2015: Gilead präsentiert neue Daten,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/28/2011 80105N10  BW   Sanofi-aventis Video Q&A: CFO Jérôme Contamine Comments on Q1 2011 Results, 3/29/2011 92532F10  BW   Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/05/2013 02043Q10  BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2013 15117K10 BW   Cellectis annonce la nomination de Pierre Schwich aux fonctions de Directeur financier Groupe,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 8/03/2011 05KQG6-E    BW   Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2012 01535110 BW   Alexion to Present at the Leerink Swann 2012 Global Healthcare Conference,#N/A, 5/05/2011 81257810    BW   Seattle Genetics Reports First Quarter 2011 Financial Results,#N/A,10/19/2012 09062X10    BW   Biogen Idec recibe notificación de la ampliación de la fecha de PDUFA,#N/A,#N/A,11/15/2015 GILD-US      BW   Zahlreiche wissenschaftliche Präsentationen beim Liver Meeting 2015 unterstreichen Nutzen von auf Sofosbuvir basierenden Hepatitis-C-Behandlungen noch deutlicher,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/28/2011 80105N10  BW   Genzyme Revenues Grow in First-Quarter 2011, 3/14/2011 92532F10  BW   Vertex Announces Webcast of its Presentation at the Barclays Capital 2011 Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2013 02043Q10  BW   The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2013 15117K10 BW   Cellectis announces appointment of Pierre Schwich as Group CFO,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/27/2011 45232710    BW   Illumina to Present at Leerink Swann Life Science Tools and Diagnostics Roundtable,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 01535110 BW   Alexion Reports Fourth Quarter and Full Year 2011 Results,#N/A, 5/02/2011 81257810    BW   Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL,#N/A,10/18/2012 09062X10    BW   Biogen Idec bénéficie d'un avis d'extension de la date de PDUFA,#N/A,#N/A,11/15/2015 GILD-US      BW   Diverse wetenschappelijke presentaties op The Liver Meeting 2015 leggen verdere nadruk op de bruikbaarheid van op Sofosbuvir gebaseerde hepatitis C-therapieën,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2011 80105N10  BW   Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases, 3/10/2011 92532F10  BW   Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2013 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2013 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/26/2011 45232710    BW   Illumina Reports Financial Results for Second Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/07/2012 06B9CH-E BW   Alexion Completes Acquisition of Enobia Pharma Corp.,#N/A, 4/27/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/18/2012 09062X10    BW   Biogen Idec meldet Verlängerung der PDUFA-Frist,#N/A,#N/A,11/15/2015 GILD-US      BW   De multiples présentations scientifiques dans le cadre de la réunion « The Liver Meeting 2015 » viennent souligner l’utilité de traitements de l’hépatite C basés sur le sofosbuvir,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2011 NVS-CH    BW   Fitch Solutions: European Healthcare Sector CDS Liquidity Rises on Growing Uncertainty, 3/07/2011 92532F10  BW   New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/30/2013 02043Q10  BW   Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/21/2012 15117K10 BW   Cellectis met en place une ligne pluriannuelle de financement en fonds propres,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/25/2011 45232710    BW   Illumina Announces First Customer Shipments of the Omni5 BeadChip,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/30/2012 01535110 BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2011 Results on Thursday, February 9, 2012",#N/A," 4/26/2011 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011",#N/A,10/18/2012 09062X10    BW   Biogen Idec Receives Notification of PDUFA Date Extension,#N/A,#N/A,11/14/2015 GILD-US      BW   Gilead Presents New Data at The Liver Meeting 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/14/2011 80105N10  BW   Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease, 3/03/2011 92532F10  BW   Vertex Announces Webcast of its Presentation at the Cowen 31st Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/16/2013 02043Q10  BW   Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2012 15117K10 BW   Cellectis : une approche anti-cancer innovante,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/14/2011 06N7LQ-E    BW   Illumina Selected as a Preferred Service Provider for Cancer Research UK,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2012 01535110 BW   Alexion to Present at the 30th Annual JP Morgan Healthcare Conference,#N/A, 4/19/2011 81257810    BW   Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration,#N/A,10/16/2012 ACOR-US     BW   Acorda Therapeutics Announces Hatch-Waxman Extension of AMPYRA® (dalfampridine) Sustained-Release Formulation Patent,#N/A,#N/A,11/14/2015 GILD-US      BW   Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2011 80105N10  BW   Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology, 3/02/2011 92532F10  BW   Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/15/2013 ALNY-US   BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/18/2012 15117K10 BW   Cellectis: An Innovative Anti-cancer Approach,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/13/2011 45232710    BW   Illumina Introduces TruSeq™ Custom Enrichment Kits for Next Generation Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/29/2011 06B9CH-E BW   Alexion to Host Conference Call This Morning to Discuss Company’s Proposed Acquisition of Enobia Pharma Corp.,#N/A," 4/18/2011 SGEN-US     BW   Seattle Genetics Appoints Vice President, Corporate Development and Announces Management Promotion",#N/A,10/15/2012 09062X10    BW   Los nuevos datos de los estudios de fase 3 proporcionan pruebas adicionales que respaldan el efecto del tratamiento con Oral BG-12 (dimetilfumarato) en la esclerosis múltiple.,#N/A,#N/A,"11/14/2015 GILD-US      BW   U.S. FDA geeft goedkeuring voor nieuwe indicaties voor Harvoni®, Gilead’s eenmaaldaagse enkel-tabletregime voor chronische hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/05/2011 071HFG-E  BW   In Europe, Emerging Novel Factor Xa Inhibitors Are Set to Displace Use of Low-Molecular-Weight Heparins and Unfractionated Heparins in the Management of Ischemic Complications Associated with Acute Coronary Syndrome", 2/25/2011 92532F10  BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/14/2013 ALNY-US   BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of $125 Million of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2012 ALCLS-FR BW   2012 Nobel laureate in medicine Shinya Yamanaka reaffirms commitment to CiRA-Cellectis partnership,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/12/2011 45232710    BW   Illumina to Announce Second Quarter 2011 Financial Results on Tuesday, July 26, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/28/2011 01535110 BW   Acquisition, par Alexion, d’Enobia Pharma Corp. et du premier traitement éventuel de l’hypophosphatasie",#N/A, 4/13/2011 81257810    BW   Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development,#N/A,10/12/2012 09062X10    BW   Neue Ergebnisse aus Phase-3-Studien untermauern die Wirksamkeit der oralen Behandlung mit BG-12 (Dimethylfumarat) bei multipler Sklerose,#N/A,#N/A,11/14/2015 GILD-US      BW   US-amerikanische FDA erteilt Zulassung für neue Indikationen für Harvoni®: Gileads einmal täglich einzunehmende Einzeltablettentherapie für chronische Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 80105N10  BW, 2/23/2011 92532F10  BW   Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/06/2013 02043Q10  BW   Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics Pipeline,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/12/2012 15117K10 BW   Le Pr. Shinya Yamanaka, Prix Nobel de médecine 2012, réaffirme son attachement à la coopération du CiRA avec le Groupe Cellectis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/29/2011 05H9L4-E    BW   University of Washington Department of Genome Sciences Joins Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/28/2011 01535110 BW   Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP),#N/A, 4/06/2011 81257810    BW   Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT Annual Meeting,#N/A,10/12/2012 09062X10    BW   Nuovi dati da studi di Fase 3 forniscono ulteriori prove a supporto dell'efficacia del trattamento della Sclerosi Multipla con BG-12 (dimetilfumarato) per via orale,#N/A,#N/A,"11/13/2015 GILD-US      BW   La FDA américaine approuve de nouvelles indications pour le Harvoni®, le schéma posologique de comprimé à prise uniquotidienne de Gilead pour l'hépatite C chronique",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/22/2011 80105N10  BW   Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health, 2/11/2011 92532F10  BW   Vertex Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2013 ALNY-US   BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/09/2012 15117K10 BW   Le Premier Ministre Jean-Marc Ayrault, accompagné de Madame Fleur Pellerin, Ministre déléguée auprès du Ministre du redressement productif, a visité ce vendredi 9 novembre 2012 la plate-forme industrielle de Cellectis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/08/2011 45232710    BW   Illumina Announces Bold Steps to Accelerate the Adoption of Individual Genome Sequencing,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/28/2011 01535110 BW   Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP),#N/A, 4/05/2011 81257810    BW   Seattle Genetics Highlights ADC Technology Research at AACR,#N/A,10/12/2012 09062X10    BW   New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis,#N/A,#N/A,"11/13/2015 GILD-US      BW   La FDA de Estados Unidos aprueba nuevas indicaciones para Harvoni®, el tratamiento de comprimido único y de una sola dosis diaria de Gilead para la hepatitis C crónica",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/17/2011 ALNY-US   BW   Alnylam Responds to Tekmira Complaint, 2/03/2011 92532F10  BW   Vertex Reports 2010 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/02/2013 ALNY-US   BW   Alnylam to Webcast Presentation at 31st Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2012 ALCLS-FR BW   Cellectis Presents Breakthrough in Fight against Cancer at ESGCT Congress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/31/2011 45232710    BW   Illumina to Webcast Live Presentations at Upcoming Investment Conferences in June,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/12/2011 01535110 BW   New Data Confirm Hemolysis as Predictor of Thromboembolism and Early Death in Patients with PNH and Demonstrate Need To Test High-Risk Patients for PNH,#N/A, 3/30/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/12/2012 BIIB-US     BW   De nouvelles données provenant d'études de Phase 3 fournissent des preuves supplémentaires à l’appui des effets du composé oral BG-12 (fumarate de diméthyle) dans le traitement de la sclérose en plaques,#N/A,#N/A,"11/12/2015 GILD-US      BW   U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2011 GENZ-US   BW   Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program, 1/21/2011 92532F10  BW   Vertex Pharmaceuticals Announces the Date of its Full Year 2010 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/10/2012 ALNY-US   BW   Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and Other Bleeding Disorders at 54th American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/29/2012 15117K10 BW   Cellectis a présenté des résultats inédits dans la lutte contre le cancer lors du congrès ESGCT,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/09/2011 45232710    BW   Illumina Reduces Price of Whole Human Genome Sequencing Through Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2011 01535110 BW   Soliris® (Eculizumab) erhält europäische Marktzulassung als Arzneimittel für Patienten mit atypischem hämolytisch-urämischen Syndrom (aHUS),#N/A, 3/22/2011 81257810    BW   Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott,#N/A,10/11/2012 09062X10    BW   Les données sur le TYSABRI® (natalizumab) lors du Congrès ECTRIMS réaffirment les effets positifs du traitement pour les personnes présentant des formes secondaires de sclérose en plaques (SEP),#N/A,#N/A,11/11/2015 00F8ZL-E     BW   X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/25/2011 06CR5C-E  BW   Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX®, 1/20/2011 92532F10  BW   U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2012 ALNY-US   BW   Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemoglobinopathies at 54th American Society of Hematology (ASH) Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2012 15117K10 BW   Cellectis extends its TAL technology intellectual property portfolio through the acquisition of two exclusive licenses from Iowa State University,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/26/2011 45232710    BW   Illumina Reports Financial Results for First Quarter 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/30/2011 01535110 BW   Soliris® (éculizumab) obtient une autorisation de mise sur le marché en Europe pour le traitement des patients atteints du syndrome hémolytique et urémique atypique (SHUa),#N/A, 3/15/2011 81257810    BW   Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration,#N/A,10/11/2012 09062X10    BW   Los datos de TYSABRI® (natalizumab) en ECTRIMS reafirman sus efectos positivos en el tratamiento de personas con formas recurrentes de EM,#N/A,#N/A,"11/10/2015 0056YC-E     BW   AHF: Gilead's ""New Drug"" Genvoya is a Dodge to Extend Patent/Profits",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/20/2010 SAN-FR    BW   Sanofi-aventis and Avila Therapeutics Sign Global Alliance to Develop Targeted Covalent Oncology Drugs, 1/10/2011 VRTX-US   BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/27/2012 ALNY-US   BW   Alnylam to Webcast Presentation at Deutsche Bank 2012 dbAccess BioFEST,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2012 15117K10 BW   Cellectis étend son portefeuille de propriété intellectuelle,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/26/2011 45232710    BW   Illumina to Present at Upcoming Investment Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/29/2011 01535110 BW   Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS),#N/A, 3/03/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/11/2012 09062X10    BW   Auf ECTRIMS-Kongress vorgelegte Daten zu TYSABRI® (Natalizumab) bestätigen positive Wirkung der Therapie bei Menschen mit rezidivierenden Formen von MS,#N/A,#N/A,"11/09/2015 GILD-US      BW   Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/13/2010 SAN-FR    BW   Zacks Bull and Bear of the Day Highlights: Sanofi-Aventis, Republic Services, Citigroup, American International and General Motors", 1/09/2011 06CR5C-E  BW   Vertex Announces Key Business Objectives To Support Planned Launch of Telaprevir in Hepatitis C and Continued Progress in Other Serious Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/26/2012 ALNY-US   BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/23/2012 15117K10 BW   Cellectis bioresearch Inc. wins a $6.9 million contract with The National Institutes of Health on iPS cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/14/2011 05MK3P-E    BW   Camstar Enterprise PlatformTM Selected by Illumina to Accelerate New Product Introductions,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/23/2011 01535110 BW   Alexion to Present at the 23rd Annual Piper Jaffray Health Care Conference,#N/A, 3/01/2011 81257810    BW   Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL,#N/A,10/11/2012 09062X10    BW   Dati sul TYSABRI® (natalizumab) all'ECTRIMS riaffermano effetti positivi del trattamento su persone affette da forme recidivanti di SM,#N/A,#N/A,"11/07/2015 GILD-US      BW   L'ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) approva il regime monocompressa Genvoya®...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/10/2010 SAN-FR    BW   Zacks Industry Outlook Highlights: Bayer, Sanofi-Aventis, Alcon, Gilead Sciences and Biogen Idec", 1/05/2011 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the 29th Annual J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/21/2012 ALNY-US   BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/23/2012 15117K10 BW   Cellectis bioresearch Inc. remporte un contrat portant sur 6,9 millions de dollars auprès du National Institute of Health pour produire des cellules iPS",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/12/2011 45232710    BW   Illumina to Announce First Quarter 2011 Financial Results on Tuesday, April 26, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/10/2011 01535110 BW   Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUS,#N/A, 2/28/2011 81257810    BW   Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL,#N/A,10/11/2012 09062X10    BW   Biogen Idecs Engagement für multiple Sklerose auf 28. ECTRIMS-Kongress durch bedeutende wissenschaftliche Ergebnisse unter Beweis gestellt,#N/A,#N/A,"11/07/2015 GILD-US      BW   US-amerikanische FDA erteilt Zulassung für Gileads Einzeltablettenregime Genvoya® (Elvitegravir, Cobicistat, Emtricitabin und Tenofoviralafenamid) für die Behandlung von HIV-1-Infektionen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2010 SAN-FR    BW   The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of BMP Sunstone Group by Sanofi-aventis,12/21/2010 92532F10  BW   Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaprevir and VX-222 for the Treatment of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/14/2012 ALNY-US   BW   Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/16/2012 063YF7-E BW   The National Institutes of Health awarded a contract to Cellectis bioresearch Inc.,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/30/2011 ILMN-US     BW   Expression Analysis Announces Recipients of Its Annual GWAS and Data Analysis Grant Co-Sponsored by Illumina,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/07/2011 01535110 BW   Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting,#N/A, 2/24/2011 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A,10/11/2012 09062X10    BW   TYSABRI® (natalizumab) DATA AT ECTRIMS REAFFIRM POSITIVE EFFECTS OF TREATMENT FOR PEOPLE WITH RELAPSING FORMS OF MS,#N/A,#N/A,"11/07/2015 GILD-US      BW   L’Agence américaine des médicaments et des produits alimentaires approuve la posologie à comprimé unique du Genvoya(R) (elvitégravir, cobicistat, emtricitabine et ténofovir alafénamide) de Gilead pour le traitement de l'infection par le VIH-1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/28/2010 SAN-FR    BW   The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into the Possible Breaches of Fiduciary Duty by the Board of BMP Sunstone Corporation in Connection with the Sale of the Company to Sanofi-Aventis S.A. – BJGP",12/03/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the NASDAQ OMX Investor Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2012 ALNY-US   BW   Alnylam to Webcast Conference Call to Discuss Restructuring of Relationship with Tekmira,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/16/2012 15117K10 BW   Cellectis bioresearch Inc. remporte un contrat auprès du National Institutes of Health, l’un des plus prestigieux centres de recherche au Monde, pour produire des cellules iPS",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/18/2011 45232710    BW   Illumina Closes $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2011 01535110 BW   Alexion Reports Third Quarter 2011 Results,#N/A, 2/08/2011 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2010 Financial Results,#N/A,10/11/2012 09062X10    BW   TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS,#N/A,#N/A,"11/07/2015 GILD-US      BW   U.S. Food and Drug Administration keurt Gilead’s enkel-tabletregime Genvoya® (elvitegravir, cobicistat, emtricitabine en tenofovir alafenamide) voor hiv-1-infectie goed",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/28/2010 80105N10  BW   Interview vidéo : Jérôme Contamine, le Directeur Financier de sanofi-aventis, commente les résultats du T3 2010",11/24/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the Piper Jaffray 22nd Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/12/2012 ALNY-US   BW   Alnylam and Tekmira Restructure Relationship and Settle All Litigation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2012 15117K10 BW   Cellectis : l’attribution du prix Nobel de médecine au professeur Yamanaka confirme la pertinence de la stratégie du Groupe en matière de cellules souches,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/15/2011 45232710    BW   Illumina Prices $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/06/2011 01535110 BW   Alexion Pharmaceuticals to Report Third Quarter 2011 Results on Thursday, October 20, 2011",#N/A, 2/03/2011 81257810    BW   Seattle Genetics Announces Exercise of Over-Allotment Option,#N/A,10/10/2012 09062X10    BW   L'impegno di Biogen Idec verso la sclerosi multipla dimostrato dagli importanti dati scientifici presentati al 28o congresso ECTRIMS,#N/A,#N/A,"11/06/2015 GILD-US      BW   La Administración de Fármacos y Alimentos de Estados Unidos aprueba el tratamiento de comprimido único de Gilead, Genvoya® (Elvitegravir, Cobicistat, Emtricitabina y Tenofovir Alafenamida) para el tratamiento de la infección por VIH-1",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/28/2010 80105N10  BW   Sanofi-aventis video Q&A: CFO Jérôme Contamine Comments on Results for Q3 2010,11/23/2010 92532F10  BW   Vertex Completes New Drug Application for Telaprevir for Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/05/2012 ALNY-US   BW   Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/08/2012 ALCLS-FR BW   Cellectis: the Award of Nobel Prize in Medicine to Professor Yamanaka Confirms the Relevance of the Group's Stem Cell Strategy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/14/2011 45232710    BW   Illumina to Offer $800 Million Convertible Senior Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2011 01535110 BW   FDA lässt Soliris® (Eculizumab) zur Behandlung aller Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS) zu,#N/A," 2/02/2011 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2010 Financial Results on February 8, 2011",#N/A,10/10/2012 09062X10    BW   El compromiso de Biogen Idec hacia la esclerosis múltiple se verá demostrado mediante la presentación de importantes datos científicos durante la 28 edición de ECTRIMS,#N/A,#N/A,"11/05/2015 GILD-US      BW   U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/11/2010 SAN-FR    BW   Zacks Analyst Blog Highlights: SNY,GENZ,LH,AVB,MU",11/18/2010 92532F10  BW   New England Journal of Medicine veröffentlicht Phase-2-Studie über VX-770 als neuer Ansatz für die Behandlung der zugrunde liegenden Ursache von Mukoviszidose,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2012 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/04/2012 15117K10 BW   Medicago et Cellectis mènent à bien la première étape de leur collaboration de recherche,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/02/2011 45232710    BW   Illumina to Present at Upcoming Investment Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2011 01535110 BW   Approbation par la FDA de Soliris® (éculizumab) pour tous les patients atteints du syndrome hémolytique et urémique atypique (SHUa),#N/A, 2/02/2011 81257810    BW   Seattle Genetics Prices Public Offering of Common Stock,#N/A,10/10/2012 09062X10    BW   Biogen Idec démontre son engagement pour la SEP à travers des données scientifiques significatives qui seront présentées lors du 28e Congrès de l'ECTRIMS,#N/A,#N/A,10/30/2015 GILD-US      BW   Gilead Sciences annonce ses résultats financiers pour le troisième trimestre 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/01/2010 UFPI-US   BW   Zacks Bull and Bear of the Day Highlights: Skyworks Solutions, Universal Forest Products, Sanofi-Aventis, Covance and Jack in the Box",11/17/2010 92532F10  BW   New England Journal of Medicine Publishes Phase 2 Study of VX-770 as a New Approach to Treat the Underlying Cause of Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2012 02043Q10  BW   Alnylam to Host Conference Call to Discuss Alliance with Genzyme to Develop and Commercialize RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis in Asia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/04/2012 15117K10 BW   Medicago and Cellectis Successfully Achieve First Step in Research Collaboration,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/08/2011 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2011 01535110 BW   Alexion obtient un avis favorable du Comité des médicaments à usage humain (CHMP) pour le Soliris® (eculizumab) dans le traitement des patients atteints du syndrome hémolytique et urémique atypique (SHUa) dans l'Union européenne,#N/A, 2/01/2011 81257810    BW   Seattle Genetics Announces Proposed Public Offering of Common Stock,#N/A,10/10/2012 09062X10    BW   Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS,#N/A,#N/A,10/30/2015 GILD-US      BW   Gilead Sciences annuncia i risultati finanziari registrati nel terzo trimestre dell'esercizio 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/29/2010 80105N10  BW   Sanofi-aventis video Q&A: CEO Chris Viehbacher comments on earnings for Q2 2010,11/10/2010 92532F10  BW   Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/22/2012 02043Q10  BW   Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2012 15117K10 BW   Cellectis publie des résultats ouvrant de nouvelles perspectives thérapeutiques pour la lutte contre le cancer et les maladies génétiques,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/01/2011 ILMN-US     BW   Expression Analysis Announces Research Acceleration Grant Focusing on Kinase Mutations and Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2011 01535110 BW   Alexion erhält positive CHMP-Stellungnahme für Soliris® (Eculizumab) zur Behandlung von Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS) in der EU,#N/A, 1/25/2011 SGEN-US     BW   Maven Semantic: Age-Related Macular Degeneration Research Database,#N/A,"10/09/2012 060RWY-E    BW   Significantly More Biologic-Treated Patients Have Seen an Improvement in Their Disease over the Past Year than Non-Biologic-Treated Patients, According to a New BioTrends Report Which Analyzes “Real World” Crohn’s Disease Patient Charts",#N/A,#N/A,10/30/2015 GILD-US      BW   Gilead Sciences maakt financiële resultaten derde kwartaal 2015 bekend,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/29/2010 80105N10  BW   Interview vidéo : le DG de Sanofi-aventis, Chris Viehbacher, commente les résultats du 2ème trimestre 2010","11/09/2010 VRYAF-US  BW   Vertex, a ViryaNet Partner, Licenses ViryaNet’s Mobile Workforce Management Solutions for Truckee Meadows Water Authority",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/09/2012 ALNY-US   BW   Alnylam Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/02/2012 0856D2-E BW   Cellectis Publishes Results Paving the Way for New Therapeutic Approaches against Cancer and Genetic Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/25/2011 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2010 Financial Results on Tuesday, February 8, 2011",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2011 01535110 BW   Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS),#N/A, 1/18/2011 TLRK-US     BW   Maven Semantic: Signal Transduction Database,#N/A,"10/09/2012 ACOR-US     BW   Acorda Therapeutics Names Jane Wasman President, International",#N/A,#N/A,10/30/2015 GILD-US      BW   Gilead Sciences gibt Finanzergebnisse für drittes Quartal 2015 bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/27/2010 80105N10  BW   Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture,11/08/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the Credit Suisse Annual Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/25/2012 ALNY-US   BW   Alnylam Wins Rulings in Patent Infringement Case against Tekmira,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2012 ALCLS-FR BW   Cellectis stem cells today announces the release of a new and improved user friendly format of stem cell derived cardiomyocytes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/18/2011 45232710    BW   Illumina to Open Latin America Office,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/23/2011 01535110 BW   Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union,#N/A, 1/10/2011 SIGA-US     BW,#N/A,"10/04/2012 09062X10    BW   Biogen Idec to Report Third Quarter 2012 Financial Results on October 25, 2012",#N/A,#N/A,10/29/2015 GILD-US      BW   Gilead dient nieuwe geneesmiddelaanvraag in bij de U.S. Food and Drug Administration voor de vaste-dosiscombinatie van Sofosbuvir/Velpatasvir voor de behandeling van alle zes genotypes hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/29/2010 SAN-FR    BW   Zacks Analyst Blog Highlights: Bristol-Myers, AstraZeneca, Merck, Amylin and Sanofi","10/30/2010 92532F10  BW   New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/13/2012 ALNY-US   BW   Alnylam to Webcast Presentation at UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/24/2012 15117K10 BW   Cellectis stem cells annonce aujourd'hui la commercialisation d’une version améliorée d’un produit de type cardiomyocyte issu de cellules souches,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/18/2011 45232710    BW   Illumina Launches the Illumina Agricultural Greater Good Initiative to Help Reduce Global Hunger, Malnutrition and Poverty",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/22/2011 09JWQ9-E BW   Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer",#N/A, 1/10/2011 VRTX-US     BW,#N/A, 9/26/2012 09062X10    BW   BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B,#N/A,#N/A,10/29/2015 GILD-US      BW   Gilead reicht New Drug Application für Festdosiskombination aus Sofosbuvir/Velpatasvir zur Therapie aller sechs Genotypen von Hepatitis C bei US-FDA ein,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/22/2010 80105N10  BW,10/25/2010 92532F10  BW   Vertex Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibrosis Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2012 ALNY-US   BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2012 ALCLS-FR BW   Cellectis : résultats du premier semestre 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/11/2011 45232710    BW   Illumina Acquires Epicentre Biotechnologies, Leading Provider of Nucleic Acid Sample Preparation Reagents and Specialty Enzymes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/14/2011 077MPN-E BW   Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting,#N/A, 1/06/2011 81257810    BW   Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer,#N/A," 9/20/2012 BIIB-US     BW   New England Journal of Medicine veröffentlicht zulassungsrelevante Daten, welche die Wirksamkeit und Sicherheit von oral verabreichtem BG-12 (Dimethylfumarat) bei multipler Sklerose zeigen",#N/A,#N/A,10/29/2015 GILD-US      BW   Gilead soumet une présentation de nouveau médicament à la Food and Drug Administration des États-Unis pour la combinaison à dose fixe de sofosbuvir/velpatasvir dans le traitement des six génotypes de l'hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/20/2010 SAN-FR    BW   The Zacks Small-Cap Profile Features Access Pharmaceuticals and Sanofi-Aventis,10/25/2010 92532F10  BW   Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/04/2012 ALNY-US   BW   Alnylam Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/20/2012 ALCLS-FR BW   Cellectis: 2012 first-half earnings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/11/2011 45232710    BW   Illumina Announces MiSeq™ Personal Sequencing System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/14/2011 01535110 BW   Alexion to Present at the UBS Global Life Sciences Conference,#N/A," 1/05/2011 06165P-E    BW   Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development",#N/A, 9/20/2012 09062X10    BW   The New England Journal of Medicine publica datos preliminares que demuestran la eficacia y seguridad de BG-12 oral (dimetilfumarato) en el tratamiento de la esclerosis múltiple.,#N/A,#N/A,10/29/2015 GILD-US      BW   Gilead presenta solicitud de nuevo fármaco ante la Administración de Alimentos y Fármacos de Estados Unidos para la combinación de dosis fija de Sofosbuvir/Velpatasvir para el tratamiento de los seis genotipos de la hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/05/2010 TRI-CA    BW   Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals Inc., Sanofi-Aventis, AstraZeneca, Interactive Data Corp. and Thompson Reuters",10/25/2010 VRTX-US   BW   Vertex Secures Contract Extension with DC Water to Continue to Host and Manage CIS and Billing Services,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/04/2012 05Q0XH-E  BW   Startup WikiCell Designs Secures $10 Million in Investment Capital from Flagship Ventures and Polaris Venture Partners,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2012 15117K10 BW   Cellectis : des progrès dans le développement d’une nouvelle approche thérapeutique du SIDA,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/11/2011 45232710    BW   Illumina Announces Preliminary Financial Results for Fourth Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/06/2011 01535110 BW   Alexion to Present at the Morgan Stanley Global Healthcare Conference,#N/A, 1/04/2011 81257810    BW   Seattle Genetics Announces Webcast of Presentation at J.P. Morgan Healthcare Conference,#N/A, 9/19/2012 BIIB-US     BW   Il New England Journal of Medicine ha pubblicato dati cruciali che dimostrano l'efficacia e la sicurezza del farmaco BG-12 (dimetilfumarato) per la sclerosi multipla somministrato per via orale,#N/A,#N/A,"10/29/2015 GILD-US      BW   Gilead deposita una domanda di approvazione di un nuovo farmaco presso l’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) per il regime combinato a dosaggio fisso a base di...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/03/2010 80105N10  BW   Sanofi-aventis, Massachusetts Life Sciences Center to Announce New Investment Partnership at BIO 2010",10/18/2010 92532F10  BW   Vertex Pharmaceuticals Initiates Clinical Trial to Evaluate Combination Regimens of VX-770 and VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/29/2012 ALNY-US   BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/10/2012 15117K10 BW   Cellectis: A step towards a new therapy for AIDS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2011 XGEN.XX1-US BW   Maven Semantic: Prostate Cancer Research Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/31/2011 01535110 BW   Alexion to Present at the Stifel Nicolaus Healthcare Conference 2011,#N/A,12/20/2010 XGEN.XX1-US BW   Maven Semantic: Kidney Disease Research Database,#N/A, 9/19/2012 0B6G4F-E    BW   Le New England Journal of Medicine publie des données essentielles démontrant l'efficacité et l'innocuité du composé oral BG-12 (Fumarate de diméthyle) dans le traitement de la sclérose en plaques,#N/A,#N/A,10/28/2015 GILD-US      BW   Gilead Sciences anuncia resultados financieros correspondientes al tercer trimestre de 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/29/2010 80105N10  BW   Interview vidéo : le Directeur Financier de Sanofi-aventis, Jérôme Contamine, commente les résultats du T1 2010",10/12/2010 92532F10  BW   Vertex Pharmaceuticals Announces the Date of its Third Quarter 2010 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/28/2012 ALNY-US   BW   Alnylam and Monsanto Form Strategic Alliance,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/04/2012 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/10/2011 45232710    BW   Illumina Introduces the Next Generation of iSelect® Custom Genotyping,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/26/2011 09MVFH-E BW   Alexion Pharmaceuticals Partners with the Connecticut Community Foundation to Award Scholarships to Eight Waterbury, Connecticut Public High School Graduates",#N/A,12/13/2010 06CR5C-E    BW   Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST,#N/A, 9/19/2012 BIIB-US     BW   The New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis,#N/A,#N/A,"10/28/2015 GILD-US      BW   Gilead Sciences anuncia dividendo correspondiente al cuarto trimestre, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/29/2010 80105N10  BW   Sanofi-aventis Video Q&A : CFO Jérôme Contamine Comments on Earnings for Q1 2010,10/01/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at Citi’s 5th Annual Biotech Day,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/22/2012 ALNY-US   BW   Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/25/2012 15117K10 BW   Assemblée Générale mixte des actionnaires de Cellectis du 22 juin 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 1/04/2011 ILMN-US     BW   Illumina to Present at J.P. Morgan Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/21/2011 01535110 BW   Alexion Reports Second Quarter 2011 Results,#N/A,12/07/2010 81257810    BW   Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual Meeting,#N/A," 9/14/2012 09062X10    BW   Los empleados de Biogen Idec participan en 80 proyectos voluntarios en 22 países como parte de la jornada anual ""Care Deeply Volunteer Day""",#N/A,#N/A,10/28/2015 GILD-US      BW   Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/08/2010 SAN-FR    BW   CureDM Partners Novel Diabetes Treatment with Sanofi-Aventis, 9/24/2010 92532F10  BW   Vertex Pharmaceuticals Announces Exercise of Underwriter’s Option to Purchase Additional Convertible Senior Subordinated Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2012 ALNY-US   BW   Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/25/2012 ALCLS-FR BW   Combined general meeting for Cellectis shareholders on June 22nd, 2012",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/15/2010 ILMN-US     BW   Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/07/2011 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter 2011 Results on Thursday, July 21, 2011",#N/A,12/05/2010 81257810    BW   Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting,#N/A," 9/14/2012 09062X10    BW   Gli impiegati di Biogen Idec partecipano a 80 progetti di volontariato in 22 paesi nell'ambito dell'evento annuale ""Care Deeply Volunteer Day""",#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences kondigt dividend aan voor het vierde kwartaal 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/25/2010 80105N10  BW   Traversa Therapeutics and sanofi-aventis Enter into a Research Agreement for the Development of Traversa’s RNAi Delivery Technology, 9/23/2010 92532F10  BW   Vertex Pharmaceuticals Announces Pricing of its Public Offering of Convertible Senior Subordinated Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/06/2012 ALNY-US   BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2012 15117K10 BW   Cellectis stem cells est fier d’annoncer le lancement du premier produit de type hépatocyte dérivé de cellules souches iPS humaines,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,12/14/2010 WAT-US      BW   Maven Semantic: High Content Analysis Database,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/20/2011 01535110 BW   Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in Germany,#N/A,11/30/2010 81257810    BW   Seattle Genetics Announces Additions to Commercial Leadership Team,#N/A," 9/14/2012 09062X10    BW   Les employés de Biogen Idec participent à 80 projets bénévoles dans 22 pays, dans le cadre de la journée annuelle « Care Deeply Volunteer Day »",#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences gibt Dividenden für viertes Quartal 2015 bekannt,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/15/2010 SAN-FR    BW   Cegedim Dendrite Announces Extension of Customer Relationship Management (CRM) Agreement with sanofi-aventis U.S., 9/22/2010 92532F10  BW   Vertex Pharmaceuticals Announces Proposed Public Offering of Convertible Senior Subordinated Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/31/2012 ALNY-US   BW   Alnylam to Webcast Conference Call Discussing Second Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/21/2012 ALCLS-FR BW   Cellectis stem cells today proudly announces the launch of the world’s very first human iPS cell-derived hepatocyte product,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/09/2010 45232710    BW   Illumina to Present at Upcoming Investment Conferences in November,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2011 01535110 BW   Alexion to Present at the Wells Fargo Securities Healthcare Conference,#N/A,11/29/2010 81257810    BW   Seattle Genetics to Present at Piper Jaffray Health Care Conference,#N/A, 9/14/2012 09062X10    BW   Biogen Idec Employees Participate in 80 Volunteer Projects in 22 Countries as Part of Annual “Care Deeply Volunteer Day”,#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences annonce son dividende du quatrième trimestre 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2010 80105N10  BW   Sanofi-aventis and Bristol-Myers Squibb Announce Important Updates to PLAVIX U.S. Prescribing Information, 9/21/2010 VRTX-US   BW   Vertex Expands Indian Footprint by Launching Joint Venture with Domestic Major Shell Transource,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/30/2012 ALNY-US   BW   Alnylam Earns Milestone Payment from GlaxoSmithKline in VaxiRNA Collaboration on Flu Vaccine Production,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/02/2012 15117K10 BW   Appointment of Mathieu Simon, MD, to the Position of Senior Vice-President of Cellectis Group",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/03/2010 45232710    BW   Illumina Introduces TruSeq™ Sample Prep and Exome Enrichment Kits,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2011 01535110 BW   Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS,#N/A,"11/10/2010 SGEN-US     BW   VELCADE® (bortezomib) Induction, Maintenance and Subcutaneous Data in Multiple Myeloma to Be Featured in Oral Presentations At American Society of Hematology Annual Meeting",#N/A, 9/14/2012 09062X10    BW   Beim diesjährigen „Care Deeply Volunteer Day“ beteiligen sich Mitarbeiter von Biogen Idec an 80 Freiwilligenprojekten in 22 Ländern,#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences annuncia il dividendo del quarto trimestre del 2015,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/09/2010 80105N10  BW   Sanofi-aventis and Merck to Create a Global Leader in Animal Health, 9/17/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/16/2012 ALNY-US   BW   Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of Serum Transthyretin (TTR) of up to 94% After Single Dose",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/02/2012 15117K10 BW   Nomination du Dr Mathieu Simon au poste de Senior vice-president du groupe Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,11/02/2010 ILMN-US     BW   Expression Analysis and Illumina Fund GWAS and Data Analysis Grant Program to Support Cancer Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2011 01535110 BW   New Data Show Renal Impairment Is Strong Predictor of Early Death in Patients with PNH,#N/A,11/08/2010 81257810    BW   Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual Meeting,#N/A, 9/13/2012 060RWY-E    BW   The Rheumatoid Arthritis Drug Market Will Experience Modest Growth as Sales Increase from $11.1 Billion in 2011 to $15.2 Billion in 2021,#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences Announces Third Quarter 2015 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2010 80105N10  BW   Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings, 9/10/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/13/2012 ALNY-US   BW   Alnylam and Collaborators Publish Scientific Paper Documenting Discovery of Second Generation MC3 Lipid Nanoparticles (LNPs),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/27/2012 15117K10 BW   CELLECTIS : COMMUNIQUÉ DE PRESSE,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/26/2010 45232710    BW   Illumina Reports Financial Results for Third Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/07/2011 01535110 BW   Alexion to Present at the 31st Annual William Blair & Company Growth Stock Conference,#N/A,11/03/2010 81257810    BW   Data from Brentuximab Vedotin (SGN-35) Phase I Clinical Trial Published in New England Journal of Medicine,#N/A, 9/12/2012 09062X10    BW   Biogen Idec Foundation Awards $1 Million to Museum of Science to Support Stem Education in Massachusetts,#N/A,#N/A,10/27/2015 GILD-US      BW   Gilead Sciences Announces Fourth Quarter 2015 Dividend,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/10/2010 80105N10  BW   Interview vidéo : le DG de Sanofi-aventis, Chris Viehbacher, commente les résultats 2009", 9/09/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/12/2012 0BNQ9C-E  BW   Alnylam and Ascletis Form Strategic Collaboration to Develop ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/23/2012 15117K10 BW   Cellectis : résultats 2011 Accélération de la stratégie de croissance et progression du chiffre d’affaires de 22%,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/26/2010 45232710    BW   Illumina Announces HiSeq 1000 Sequencing System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2011 01535110 BW   FDA Grants Priority Review for Alexion’s sBLA for Soliris® (eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS),#N/A,11/01/2010 81257810    BW   Seattle Genetics Reports Third Quarter 2010 Financial Results,#N/A, 9/11/2012 09062X10    BW   Biogen Idec vende los derechos de regalías de BENLYSTA al fondo gestionado por DRI Capital,#N/A,#N/A,"10/23/2015 GILD-US      BW   Gilead annonce des résultats de phase 3 relatifs au Genvoya® (elvitégravir, cobicistat, emtricitabine et ténofovir alafénamide), schéma posologique expérimental sous forme d’un comprimé unique à prise quotidienne...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2010 92532F10  BW   65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2012 02043Q10  BW   Alnylam Presents New Pre-clinical Data with its RNAi Therapeutic Program in Hemophilia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/21/2012 ALCLS-FR BW   Precision BioSciences Files Two New Infringement Lawsuits against Cellectis, Requests Permanent Injunction against Importation of Infringing Materials into U.S.",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,10/22/2010 ILMN-US     BW   CORRECTING and REPLACING Sage Science Signs Co-Marketing Agreement with Illumina to Automate DNA Sizing Steps in Next-Gen Sequencing Sample Preparation,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/31/2011 01535110 BW   Alexion to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference,#N/A,10/29/2010 81257810    BW   Seattle Genetics to Present at Oppenheimer Healthcare Conference,#N/A, 9/10/2012 GSK-GB      BW   Biogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund,#N/A,#N/A,"10/23/2015 GILD-US      BW   Gilead gibt Ergebnisse aus Phase 3 für Genvoya® (Elvitegravir, Cobicistat, Emtricitabin und Tenofoviralafenamid) bekannt: Einmal täglich einzunehmendes Einzeltablettenregime für HIV in der Prüfphase",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2010 VRTX-US   BW   Vertex Launches Working Warriors Program,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/03/2012 02043Q10  BW   Alnylam to Webcast Presentation at the Seventh Annual JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2012 15117K10 BW   Cellectis annonce le remboursement en actions des ORA souscrites par le FSI et Pierre Bastid pour un montant de 50 millions d’euros,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,"10/12/2010 45232710    BW   Illumina to Announce Third Quarter 2010 Financial Results on Tuesday, October 26, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2011 01535110 BW   Researchers to Present Nine Studies on Soliris® (eculizumab) in Patients with PNH and aHUS at EHA Congress,#N/A,10/25/2010 81257810    BW   Seattle Genetics and Millennium to Highlight Brentuximab Vedotin (SGN-35) at the International Symposium on Hodgkin Lymphoma,#N/A, 9/10/2012 09062X10    BW   Biogen Idec vend les droits de royalties de BENLYSTA au fonds administré par DRI Capital,#N/A,#N/A,"10/23/2015 GILD-US      BW   Gilead maakt fase-3-resultaten bekend van Genvoya® (Elvitegravir, Cobicistat, Emtricitabine en Tenofovir-alafenamide), een eenmaaldaags-, enkel-tablet-onderzoeksregime voor hiv",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Genuity 30th Annual Growth Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2012 ALNY-US   BW   Alnylam Expands and Develops Management Team,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2012 15117K10 BW   Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/15/2010 45232710    BW   Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/12/2011 01535110 BW   Alexion Shareholders Approve Increase in Authorized Shares for Previously Announced Stock Split,#N/A,"10/20/2010 81257810    BW   Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer",#N/A, 9/10/2012 09062X10    BW   Biogen Idec cede diritti sulle royalty di BENLYSTA ai fondi comuni d'investimento di DRI Capital,#N/A,#N/A,"10/23/2015 GILD-US      BW   Gilead annuncia i risultati di Fase III per Genvoya® (elvitegravir, cobicistat, emtricitabina e tenofovir alafenamide), un regime sperimentale monocompressa a somministrazione monogiornaliera per...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/10/2010 92532F10  BW   Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/19/2012 02043Q10  BW   Alnylam Receives Orphan Drug Designation from U.S. Food & Drug Administration for ALN-TTR02, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2012 0664SJ-E BW   Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 9/07/2010 45232710    BW   Illumina to Present at Upcoming Investment Conferences in September,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/05/2011 01535110 BW   Alexion to Present at Bank of America Merrill Lynch 2011 Health Care Conference,#N/A,"10/19/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010",#N/A, 9/10/2012 09062X10    BW   Biogen Idec verkauft Lizenzrechte zu BENLYSTA an Investmentfonds von DRI Capital,#N/A,#N/A,"10/23/2015 GILD-US      BW   Gilead anuncia los resultados de la fase 3 del estudio de Genvoya® (Elvitegravir, Cobicistat, Emtricitabina y Tenofovir Alafenamida), un régimen de un comprimido al día para el tratamiento del VIH en fase de investigación",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/28/2010 92532F10  BW   Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/12/2012 02043Q10  BW   Alnylam and Collaborators Publish New Pre-clinical Results with an RNAi Therapeutic Approach for Inducing Endogenous Erythropoiesis for the Treatment of Anemia,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2012 15117K10 BW   Cellectis Plant Sciences annonce la signature d'un partenariat stratégique avec SESVanderHave pour améliorer la betterave sucrière,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/27/2010 45232710    BW   Illumina Announces Creation of the Illumina Genome Network,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2011 01535110 BW   Alexion to Present at Deutsche Bank Securities 36th Annual Health Care Conference,#N/A,10/11/2010 81257810    BW   Seattle Genetics Reports Preliminary Data from Phase I Clinical Trial of SGN-75,#N/A, 9/05/2012 0C8BZH-E    BW   RBCC Opens Up Deal Pipeline,#N/A,#N/A,10/22/2015 GILD-US      BW   Gilead proporciona nueva información sobre el compuesto en fase de investigación GS-5734 para el tratamiento de la enfermedad por el virus del Ébola,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/13/2010 92532F10  BW   Vertex Pharmaceuticals Appoints Wayne J. Riley, M.D., to its Board of Directors",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/07/2012 02043Q10  BW   Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2012 15117K10 BW   Évolutions au sein de la Direction scientifique du Groupe et nomination du Directeur général de Cellectis Plant Sciences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/27/2010 45232710    BW   Illumina Announces Launch of the Eco™ Real-Time PCR System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2011 01535110 BW   Alexion Reports First Quarter 2011 Results,#N/A,10/11/2010 81257810    BW   Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCL,#N/A, 9/04/2012 09062X10    BW   Biogen Idec to Present at the Morgan Stanley Global Healthcare Unplugged Conference,#N/A,#N/A,"10/22/2015 GILD-US      BW   Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/12/2010 92532F10  BW   Vertex Pharmaceuticals Announces the Date of its Second Quarter 2010 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/04/2012 ALNY-US   BW   Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2012 15117K10 BW   Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/27/2010 45232710    BW   Illumina Reports Financial Results for Second Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2011 UP2-AT   BW   update CRM Expands Life Sciences Team in North America,#N/A,10/04/2010 81257810    BW   Seattle Genetics to Present SGN-75 Clinical Data at the European Society for Medical Oncology (ESMO) Congress,#N/A, 8/29/2012 BIIB-US     BW   Biogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012,#N/A,#N/A,10/22/2015 GILD-US      BW   Gilead liefert Update zu Prüfsubstanz GS-5734 zur Behandlung von Ebolafieber,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2010 VRTX-US   BW   Chesapeake Utilities Corporation Selects Vertex to Help Streamline Business Processes and Enhance Customer Service,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 5/30/2012 ALNY-US   BW   Alnylam Announces Top-Line Results of Phase IIb Clinical Trial of ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/23/2012 ALCLS-FR BW   Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/26/2010 45232710    BW   Illumina Announces New TruSeq™ SBS Sequencing Kit for the Genome Analyzer,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/08/2011 01535110 BW   Alexion Pharmaceuticals to Report First Quarter 2011 Results on Thursday, April 21, 2011",#N/A, 9/27/2010 81257810    BW   Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma,#N/A, 8/29/2012 ALNY-US     BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,10/22/2015 GILD-US      BW   Gilead geeft een update over het onderzoeksmiddel GS-5734 voor de behandeling van de ebolavirusziekte,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 6/24/2010 VRTX-US   BW   Vertex Extends Global Customer Management Outsourcing Reach by Acquiring Australian Provider, PCI",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/23/2012 02043Q10  BW   Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/16/2012 15117K10 BW   Medicago et Cellectis annoncent leur collaboration de recherche afin d’améliorer les protéines thérapeutiques grâce à la technologie des nucléases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/16/2010 45232710    BW   Illumina Announces Appointment of Melina Cimler as Vice President, Quality and Regulatory Affairs",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2011 01535110 BW   Alexion Submits Applications for Soliris® (Eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union,#N/A," 9/24/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical Trial",#N/A, 8/29/2012 0C8BZH-E    BW   RBCC Continues Negotiations With Amarantus,#N/A,#N/A,10/21/2015 GILD-US      BW   Gilead fornisce un aggiornamento sul composto sperimentale GS-5734 per il trattamento della malattia da virus Ebola,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/11/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/10/2012 ALNY-US   BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/16/2012 15117K10 BW   Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/14/2010 45232710    BW   Illumina to Announce Second Quarter 2010 Financial Results on Tuesday, July 27, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2011 01535110 BW   Alexion Announces Two-For-One Stock Split,#N/A, 9/14/2010 81257810    BW   Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research Collaboration,#N/A, 8/28/2012 ACOR-US     BW   Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction,#N/A,#N/A,"10/21/2015 GILD-US      BW   Gilead fait le point sur le composé expérimental GS-5734, destiné au traitement de la maladie à virus Ebola",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/09/2012 02043Q10  BW   Alnylam to Webcast Presentation at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2012 15117K10 BW   Cellectis lance un partenariat avec Total dans la recherche exploratoire sur les substituts aux produits pétroliers à partir de microalgues,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 7/07/2010 45232710    BW   Illumina Names Gerald Möller to Board of Directors,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/29/2011 01535110 BW   Alexion to Present at the 10th Annual Needham Healthcare Conference,#N/A, 9/13/2010 81257810    BW   Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint,#N/A, 8/24/2012 07G69B-E    BW   Research and Markets: Interferon Market Forecast to 2015,#N/A,#N/A,"10/21/2015 GILD-US      BW   Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/25/2010 92532F10  BW   75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/03/2012 02043Q10  BW   Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/09/2012 15117K10 BW   Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 7/02/2010 45232710    BW   Illumina Appoints Nicholas Naclerio Senior Vice President, Corporate Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2011 ALXN-US  BW   Alexion to Present at the Cowen and Company 31st Annual Health Care Conference,#N/A," 9/10/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Phase IIb Clinical Trial",#N/A," 8/17/2012 06NNYG-E    BW   Biogen Idec Foundation Donates $100,000 to Launch STEM Education Collaboration with Teach for America",#N/A,#N/A,"10/20/2015 GILD-US      BW   Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/25/2010 VRTX-US   BW   Vertex Extends and Expands Relationship With Truckee Meadows Water Authority,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/26/2012 02043Q10  BW   Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2012 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/09/2010 45232710    BW   Illumina to Present at Goldman Sachs Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/28/2011 01535110 BW   Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2011",#N/A, 9/07/2010 81257810    BW   Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences,#N/A, 8/13/2012 ACOR-US     BW   Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine-ER,#N/A,#N/A,10/05/2015 GILD-US      BW   La Administración de Medicamentos y Alimentos de EEUU aprueba nuevo tratamiento combinado de Letairis® con Tadalafil de Gilead para la hipertensión arterial pulmonar (grupo 1 de la OMS),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/13/2010 92532F10  BW   Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/23/2012 02043Q10  BW   Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2012 ALCLS-FR BW   Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/07/2010 45232710    BW   Illumina Announces Purchase of HiSeq™ 2000 Units by the Broad Institute,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2011 01535110 BW   Alexion to Present at the Citi 2011 Global Health Care Conference,#N/A," 9/02/2010 81257810    BW   Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas",#N/A, 8/09/2012 0C8BZH-E    BW   RBCC Partner n3D Courts ‘MAD’ Scientists With Cell Culturing Contest,#N/A,#N/A,10/05/2015 GILD-US      BW   US-amerikanische Arzneimittelzulassungsbehörde (FDA) lässt neue Behandlungskombination aus Letairis® von Gilead mit Tadalafil bei pulmonal-arterieller Hypertonie (WHO-Gruppe 1) zu,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/27/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/20/2012 ALNY-US   BW   Alnylam Reports Positive Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/03/2012 15117K10 BW   Cellectis plant sciences et Bayer CropScience renforcent leur partenariat dans l’ingénierie des génomes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/03/2010 45232710    BW   Illumina Announces New Pricing for its Individual Genome Sequencing Service,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/22/2011 09MMGD-E BW   Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board,#N/A, 8/04/2010 81257810    BW   Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference,#N/A, 8/06/2012 ALNY-US     BW,#N/A,#N/A,10/05/2015 GILD-US      BW   U.S. Food and Drug Administration keurt nieuwe combinatiebehandeling goed van Letairis® van Gilead met Tadalafil voor pulmonale arteriële hypertensie (WHO Groep 1),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/21/2010 92532F10  BW   Vertex Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/13/2012 02043Q10  BW   Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2011 08VP96-E BW   Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 6/02/2010 45232710    BW   Illumina Announces First Customer Shipments of Omni2.5 BeadChip,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2011 01535110 BW   Alexion Reports Fourth Quarter and Full Year 2010 Results,#N/A, 8/03/2010 81257810    BW   Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech,#N/A," 8/03/2012 0C8BZH-E    BW   RBCC: iPads, iPhones and Other Mobile Devices Inspire New Biotech Applications",#N/A,#N/A,"10/05/2015 GILD-US      BW   L'ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) approva la nuova terapia a base di Letairis®...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2010 92532F10  BW   Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/27/2012 02043Q10  BW   Alnylam to Webcast Presentation at 11th Annual Needham Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/08/2011 15117K10 BW   Cellectis bioresearch et Syngen nouent un partenariat pour le développement de lignées cellulaires personnalisées,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/18/2010 45232710    BW   Illumina Receives FDA 510(k) Clearance for VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/10/2011 01535110 BW   Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder",#N/A, 7/27/2010 81257810    BW   Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress,#N/A, 7/31/2012 ACOR-US     BW   Acorda Therapeutics Reports Second Quarter 2012 Financial Results,#N/A,#N/A,"10/04/2015 GILD-US      BW   L’administration américaine chargée des aliments et des médicaments autorise la nouvelle polythérapie au Letairis® et Tadalafil de Gilead, pour l'hypertension artérielle pulmonaire (groupe 1 de l'OMS)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/15/2010 92532F10  BW   59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/19/2012 02043Q10  BW   Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2011 15117K10 BW   Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 5/04/2010 45232710    BW   Illumina Receives FDA 510(k) Clearance for Its BeadXpress® Multiplex Analysis System,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/31/2011 007L42-E BW   Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio,#N/A," 7/20/2010 81257810    BW   Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer",#N/A, 7/26/2012 LIFE.XX5-US BW   Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry,#N/A,#N/A,10/02/2015 GILD-US      BW   U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1),#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/12/2010 VRTX-US   BW   Vertex Wins Contract with NorthWestern Energy to Streamline Operations and Enhance Customer Service,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/14/2012 02043Q10  BW   Alnylam Retains Key Claims for Kinesin Spindle Protein (KSP) RNAi Patent in Interference Proceedings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2011 15117K10 BW   Cellectis signe un accord de licence pour l’utilisation de brevets portant sur la recombinaison homologue avec une entreprise pharmaceutique d’envergure mondiale,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/30/2010 45232710    BW   Illumina Announces Appointments of Elizabeth Brady as Vice President, Global Supply Chain, and Emily Winn-Deen as Vice President, Diagnostics Development",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/27/2011 01535110 BW   Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2010 Results on Thursday, February 10, 2011",#N/A," 7/19/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010",#N/A, 7/25/2012 0C8BZH-E    BW   RBCC Extends Joint Venture Negotiations With Amarantus,#N/A,#N/A," 9/28/2015 GILD-US      BW   El CHMP europeo adopta opinión positiva para el tratamiento de comprimido único de Gilead, Genvoya® (elvitegravir, cobicistat, emtricitabina y tenofovir alafenamida), para el tratamiento del VIH",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/07/2010 92532F10  BW   New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/06/2012 02043Q10  BW   Alnylam to Webcast Presentation at Barclays Capital Global Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2011 15117K10 BW   Appointment of Philippe Valachs as Cellectis’ General Secretary,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/28/2010 45232710    BW   Illumina Reports Financial Results for First Quarter 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2011 01535110 BW   Alexion to Present at the 29th Annual JP Morgan Healthcare Conference,#N/A, 6/05/2010 81257810    BW   Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma,#N/A, 7/24/2012 BIIB-US     BW   CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter,#N/A,#N/A," 9/25/2015 GILD-US      BW   Europees CHMP aanvaardt positief advies voor Gilead’s enkeltabletregime Genvoya® (Elvitegravir, Cobicistat, Emtricitabine en Tenofovir Alafenamide) voor de behandeling van hiv",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2010 92532F10  BW   Vertex Pharmaceuticals Announces the Date of its First Quarter 2010 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2012 09X7KJ-E  BW   Alnylam and the University of Massachusetts Medical School Announce Tuschl I Patent Upheld in European Opposition Proceedings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/24/2011 15117K10 BW   Nomination de Philippe Valachs au poste de Secrétaire Général de Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/27/2010 45232710    BW   Illumina Now Shipping HiScan™SQ Platform,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/20/2010 MLNM-US  BW   Maven Semantic: Multiple Sclerosis Research Database,#N/A, 6/02/2010 81257810    BW   Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences,#N/A," 7/24/2012 ACOR-US     BW   Acorda Therapeutics to Host Conference Call to Discuss Second Quarter 2012 Financial Results on July 31, 2012",#N/A,#N/A," 9/25/2015 GILD-US      BW   Europäisches CHMP kommt zu positiver Einschätzung von Gileads Einzeltablettenregime Genvoya® (Elvitegravir, Cobicistat, Emtricitabin und Tenofoviralafenamid) für die Behandlung von HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/30/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcast of its Presentation at Canaccord Adams' Hepatitis C Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/29/2012 02043Q10  BW   Alnylam to Webcast Presentation at Cowen and Company 32nd Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2011 15117K10 BW   Cellectis: 2011 half-year earnings,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/27/2010 45232710    BW   Illumina to Present at Upcoming Investment Conferences in May,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/06/2010 01535110 BW   Long-Term Efficacy, Safety and Survival Outcomes of PNH Patients Treated with Soliris® (eculizumab) Reported at ASH Annual Meeting",#N/A, 5/24/2010 81257810    BW   Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial,#N/A, 7/17/2012 09062X10    BW   Biogen Idec anuncia colaboración con instituciones de investigación líderes para secuenciar el genoma de los pacientes con ELA,#N/A,#N/A," 9/25/2015 GILD-US      BW   Il Comitato europeo per i prodotti medicinali per uso umano (CHMP) esprime un parere positivo per Genvoya® (elvitegravir, cobicistat, emtricitabina e tenofovir alafenamide), il regime monocompressa di Gilead...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/16/2010 92532F10  BW   Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/15/2012 02043Q10  BW   Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2011 15117K10 BW   Cellectis : résultats du premier semestre 2011,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/16/2010 45232710    BW   Illumina Announces Its First Full Coverage DNA Sequencing of a Named Family,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/06/2010 01535110 BW   Hemolysis Is Associated with Increased Mortality and Thrombosis in Patients with PNH,#N/A," 5/24/2010 81257810    BW   Seattle Genetics Names Vice President, Sales and Announces Management Promotion",#N/A, 7/17/2012 BIIB-US     BW   Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS,#N/A,#N/A," 9/25/2015 GILD-US      BW   Le CHMP européen adopte une opinion positive à l'égard du traitement sous forme de comprimé unique Genvoya® (elvitégravir, cobicistat, emtricitabine et ténofovir alafénamide) de Gilead pour le traitement du VIH",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/12/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/14/2012 02043Q10  BW   Alnylam Pharmaceuticals Prices Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/06/2011 ALCLS-FR BW   Precision BioSciences Sues Cellectis for Patent Infringement,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 4/14/2010 45232710    BW   Illumina to Announce First Quarter 2010 Financial Results on Wednesday, April 28, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/05/2010 01535110 BW   Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting,#N/A, 5/21/2010 81257810    BW   Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual Meeting,#N/A, 7/17/2012 09062X10    BW   Biogen Idec annonce une collaboration avec des instituts de recherche majeurs en vue de séquencer le génome de patients atteints de SLA,#N/A,#N/A," 9/25/2015 GILD-US      BW   European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/01/2010 92532F10  BW   Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/13/2012 02043Q10  BW   Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/03/2011 15117K10 BW   CELLECTIS : INFORMATION CONCERNANT CERTAINES ACTIONS EN JUSTICE LIEES A LA DEFENSE DE LA PROPRIETE INTELLECTUELLE DE LA TECHNOLOGIE DES MEGANUCLEASES,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 4/07/2010 45232710    BW   Illumina Introduces VeraCode® ADME Core Panel for Pharmaceutical Research,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/24/2010 01535110 BW   Alexion to Present at the Piper Jaffray 22nd Annual Health Care Conference,#N/A, 4/28/2010 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 7/17/2012 09062X10    BW   Biogen Idec annuncia collaborazione con importanti istituti di ricerca per eseguire il sequenziamento dei genomi dei pazienti affetti da SLA,#N/A,#N/A, 9/24/2015 0056YC-E     BW   AHF: $750 Drug That Sells For $1 to Government Agencies Underscores Need for Drug Pricing Reform,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/25/2010 92532F10  BW   Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/10/2012 02043Q10  BW   Alnylam to Webcast Presentations at Upcoming Investor Conferences,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/03/2011 ALCLS-FR BW   Cellectis Issues Statement Regarding Patent Suits on Meganuclease Technology,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/16/2010 45232710    BW   Illumina Announces HumanOmniExpress+ Custom BeadChip,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/20/2010 01535110 BW   Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance,#N/A, 4/27/2010 81257810    BW   Seattle Genetics Reports First Quarter 2010 Financial Results,#N/A, 7/17/2012 09062X10    BW   Biogen Idec meldet Zusammenarbeit mit führenden Forschungsinstituten zur Sequenzierung des Genoms von Patienten mit ALS,#N/A,#N/A," 9/22/2015 GILD-US      BW   Gilead anuncia tasas SVR12 de cuatro estudios de fase 3 que evalúan la combinación de dosis fija, de una sola dosis diaria, de Sofosbuvir (SOF) y Velpatasvir (VEL) (GS-5816) para el tratamiento de los seis genotipos de hepatitis C",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/16/2010 92532F10  BW   Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 02043Q10  BW   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/15/2011 15117K10 BW   Cellectis annonce l'acquisition prochaine de Cellartis, leader européen des cellules souches, simultanément à une levée de fonds auprès du FSI et de Pierre Bastid et a l’attribution gratuite de bsa aux actionnaires actuels",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/11/2010 45232710    BW   Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/08/2010 01535110 BW   Researchers to Present New Long-Term Data on Soliris® (eculizumab) in Patients with PNH at the ASH Annual Meeting,#N/A, 4/21/2010 81257810    BW   Seattle Genetics Highlights ADC and SEA Technologies at AACR,#N/A," 7/05/2012 09062X10    BW   Biogen Idec to Report Second Quarter 2012 Financial Results on July 24, 2012",#N/A,#N/A," 9/22/2015 GILD-US      BW   Gilead kondigt SVR12-percentages aan van vier fase 3-onderzoeken voor het evalueren van een eenmaal daagse, vaste dosiscombinatie van sofosbuvir (SOF) en velpatasvir (VEL) (GS-5816) voor de behandeling van alle zes hepatitis C-genotypen",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/04/2010 92532F10  BW   Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/09/2012 02043Q10  BW   Alnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/24/2011 15117K10 BW   Cellectis bioresearch conclut un accord de license exclusive avec Recombinetics pour l’utilisation de ses nucléases modifiées sur gros animaux d’élevage,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 3/03/2010 45232710    BW   Illumina to Present at Upcoming Investment Conferences in March,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/04/2010 01535110 BW   Alexion to Present at the Credit Suisse 2010 Healthcare Conference,#N/A," 4/21/2010 81257810    BW   Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR",#N/A, 7/05/2012 09062X10    BW   Biogen Idec y Sobi inician ensayos clínicos mundiales de los candidatos a producto de acción prolongada para la hemofilia A y B en niños,#N/A,#N/A," 9/22/2015 GILD-US      BW   Gilead gibt SVR12-Quoten aus vier Phase-3-Studien bekannt, bei denen eine einmal täglich verabreichte Festdosiskombination aus Sofosbuvir (SOF) und Velpatasvir (VEL) (GS-5816) für die Behandlung aller sechs Genotypen von Hepatitis C...",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/03/2010 92532F10  BW   Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/02/2012 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/24/2011 15117K10 BW   Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A, 2/04/2010 45232710    BW   Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2009,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/27/2010 01535110 BW   Alexion to Present at the Oppenheimer 21st Annual Healthcare Conference,#N/A," 4/20/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010",#N/A, 7/05/2012 09062X10    BW   Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children,#N/A,#N/A, 9/22/2015 GILD-US      BW   Gilead annonce les taux de SVR12 de quatre études de phase 3 évaluant une combinaison à dose fixe à prise unique quotidienne de sofosbuvir (SOF) et de velpatasvir (VEL) (GS-5816) pour le traitement des six génotypes de l'hépatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/20/2010 92532F10  BW   Vertex Pharmaceuticals Announces the Date of its Full Year 2009 Financial Results Conference Call and Webcast,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/30/2012 02043Q10  BW   Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/20/2011 095XX4-E BW   Cellectis bioresearch and Lonza Achieve Significant Milestone on CHO-K1SV GS Knock-Out,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A," 1/21/2010 45232710    BW   Illumina to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Thursday, February 4, 2010",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/21/2010 01535110 BW   Alexion Reports Third Quarter 2010 Results,#N/A, 4/20/2010 81257810    BW   Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration,#N/A, 7/05/2012 09062X10    BW   Biogen Idec et Swedish Orphan Biovitrum entreprennent des essais cliniques à l’échelle mondiale sur des produits candidats à action prolongée pour le traitement de l’hémophilie A et B chez les enfants,#N/A,#N/A, 9/21/2015 GILD-US      BW   Gilead annuncia i tassi SVR12 ottenuti da quattro studi di Fase 3 che valutano una terapia combinata a dose fissa monogiornaliera di Sofosbuvir (SOF) e Velpatasvir (VEL) (GS-5816) per il trattamento di tutti i sei genotipi dell’epatite C,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/19/2012 02043Q10  BW   Alnylam to Restructure Organization, Aligning Resources with Focus on Highest Value Pipeline Opportunities in “Alnylam 5x15™” Product Strategy",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/20/2011 15117K10 BW   Cellectis bioresearch et Lonza franchissent un jalon décisif dans l’inactivation de la glutamine synthétase (GS) de la lignée CHO-K1SV,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2010 01535110 BW   Alexion Announces Interim Results from Phase 2 Trials of Eculizumab (Soliris®) in Patients with atypical Hemolytic Uremic Syndrome (aHUS),#N/A," 4/08/2010 81257810    BW   Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma",#N/A, 7/05/2012 09062X10    BW   Biogen Idec und Sobi starten weltweite klinische Studien mit lang wirkenden Produktkandidaten für Hämophilie A und B bei Kindern,#N/A,#N/A," 9/21/2015 GILD-US      BW   Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/17/2012 ALNY-US   BW   Alnylam Files Patent Infringement Suit Against Tekmira,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/11/2011 15117K10 BW   Le Dr. Andrew Scharenberg est nommé Directeur scientifique de Cellectis therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"10/07/2010 01535110 BW   Alexion Pharmaceuticals to Report Third Quarter Results on Thursday, October 21, 2010",#N/A, 3/12/2010 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 7/05/2012 09062X10    BW   Biogen Idec e Sobi danno il via a studi clinici globali sui prodotti candidati ad azione prolungata per l'emofilia di tipo A e B nei bambini,#N/A,#N/A," 9/15/2015 GILD-US      BW   Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/08/2012 06FW0H-E  BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/11/2011 15117K10 BW   Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis Therapeutics",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/27/2010 01535110 BW   Alexion Pharmaceuticals Earns the Connecticut Green Building Council Green Advocate Award and Two LEED Gold Certifications for Environmental Sustainability,#N/A, 3/11/2010 81257810    BW   Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio,#N/A, 6/29/2012 09062X10    BW,#N/A,#N/A," 9/10/2015 GILD-US      BW   Gilead bepaalt prijs van $ 10 miljard aan ongedekte, niet-achtergestelde promesses",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/06/2012 02043Q10  BW   Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/07/2011 15117K10 BW   Bilan semestriel du contrat de liquidité CELLECTIS contracté avec la société NATIXIS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/14/2010 01535110 BW   Alexion to Present at the UBS Global Life Sciences Conference,#N/A, 3/03/2010 81257810    BW   Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech,#N/A, 6/29/2012 09062X10    BW,#N/A,#N/A, 9/10/2015 GILD-US      BW   Gilead stabilisce il prezzo di 10 miliardi di dollari per i titoli privilegiati non garantiti,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2012 ALNY-US   BW   Adimab Expands Executive Team with Addition of Philip T. Chase as General Counsel,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2011 15117K10 BW   Cellectis et Pregenen signent un accord de collaboration sur le développement des méganucléases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/07/2010 01535110 BW   Alexion to Present at Investor Conferences,#N/A, 2/25/2010 81257810    BW   Seattle Genetics to Present at Upcoming Investor Conferences,#N/A, 6/29/2012 09062X10    BW,#N/A,#N/A, 9/10/2015 GILD-US      BW   Gilead bepreist vorrangig unbesicherte Schuldverschreibungen im Wert von 10 Milliarden US-Dollar,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/05/2012 02043Q10  BW,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/29/2011 15117K10 BW   Cellectis and Pregenen Sign Collaboration Agreement for the Development of Meganucleases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 8/23/2010 01535110 BW   Alexion Receives FDA Approval of Rhode Island Manufacturing Facility for Soliris® Supply,#N/A, 2/09/2010 81257810    BW   Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook,#N/A, 6/29/2012 IONS-US     BW,#N/A,#N/A, 9/10/2015 GILD-US      BW   Gilead fija el precio de sus obligaciones sin garantizar sénior en $10.000 millones,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 1/04/2012 02043Q10  BW   Alnylam to Webcast Presentation at 30th Annual J.P. Morgan Healthcare Conference 2012,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2011 15117K10 BW   André Choulika to Serve as Both Chairman and CEO of Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 7/22/2010 01535110 BW   Alexion Reports Second Quarter 2010 Results,#N/A, 2/03/2010 81257810    BW   Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma,#N/A, 6/29/2012 09062X10    BW,#N/A,#N/A, 9/10/2015 GILD-US      BW   Gilead fixe le prix de 10 milliards de dollars de billets de premier rang non garantis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 1/04/2012 02043Q10  BW   Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/27/2011 15117K10 BW   André Choulika est nommé Président Directeur général de Cellectis,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 7/12/2010 01535110 BW   Alexion Pharmaceuticals to Report Second Quarter Results on Thursday, July 22, 2010",#N/A," 2/02/2010 81257810    BW   Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010",#N/A," 6/25/2012 060RWY-E    BW   For the Treatment of Multiple Sclerosis, More Than 85 Percent of Surveyed Neurologists in the EU5 Expect to Prescribe Biogen Idec’s BG-12, Sanofi/Genzyme’s Aubagio and Sanofi/Genyzme/Bayer Healthcare’s Lemtrada",#N/A,#N/A, 9/09/2015 GILD-US      BW   Gilead Prices $10 Billion of Senior Unsecured Notes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"12/28/2011 ALNY-US   BW   Alnylam Announces Publication of Pre-clinical Results with ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington’s Disease, in Experimental Neurology",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2011 15117K10 BW   Cellectis et VitamFero collaborent au développement de nouveaux vaccins contre les infections parasitaires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/15/2010 01535110 BW   Early Clinical Experience and Basic Science Support Further Investigation of Soliris® (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy,#N/A,#N/A,#N/A, 6/13/2012 0BNPX5-E    BW   Patent Expirations Put More Than $290 Billion in Prescription Drug Sales at Risk Through 2018,#N/A,#N/A," 9/08/2015 GILD-US      BW   Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,12/13/2011 02043Q10  BW   Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/06/2011 0BJV4J-E BW   Cellectis and VitamFero Collaborate to Develop Vaccines against Parasitic Infection,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/14/2010 01535110 BW   Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association,#N/A,#N/A,#N/A, 6/12/2012 09062X10    BW   Biogen Idec to Highlight Innovative Pipeline and Commercial Strategy,#N/A,#N/A," 9/03/2015 0056YC-E     BW   S.F. Prep Study Shows 41% Decrease in Condom Use, Notes AHF",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/29/2011 02043Q10  BW   Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2011 15117K10 BW   Cellectis Bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/08/2010 01535110 BW   Alexion to Present at Investor Conferences,#N/A,#N/A,#N/A, 6/12/2012 09062X10    BW   Biogen Idec präsentiert Geschäftsstrategie und Innovationspipeline,#N/A,#N/A, 9/03/2015 GILD-US      BW   La combinación de dosis fija en fase de investigación de Gilead de emtricitabina/tenofovir alafenamida (F/TAF) cumple su objetivo principal de 48 semanas en el estudio de fase 3,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/22/2011 02043Q10  BW   Alnylam to Webcast Presentation at the Piper Jaffray 23rd Annual Health Care Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/18/2011 15117K10 BW   Cellectis bioresearch choisit Wako comme distributeur exclusif au Japon pour ses solutions de personnalisation des génomes,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2010 01535110 BW   Alexion to Present at Investor Conferences,#N/A,#N/A,#N/A, 6/12/2012 09062X10    BW   Biogen Idec présente son portefeuille innovateur et sa stratégie commerciale,#N/A,#N/A," 9/03/2015 GILD-US      BW   La combinaison à dose fixe expérimentale d'emtricitabine/ténofovir alafénamide (F/TAF) de Gilead, atteint l'objectif principal à 48 semaines lors d'une étude de phase 3",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,"11/21/2011 02043Q10  BW   Alnylam Presents Positive Preliminary Clinical Results for ALN-TTR01, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2011 15117K10 BW   Cellectis Strengthens Management Team to Support Stem Cell Activities,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/02/2010 01535110 BW   Alexion Accelerates Plans to Launch Soliris® (Eculizumab) in Japan,#N/A,#N/A,#N/A, 6/12/2012 09062X10    BW   Biogen Idec mette in evidenza i suoi progetti innovativi in fase di sviluppo e la sua strategia commerciale,#N/A,#N/A, 9/03/2015 GILD-US      BW   De experimentele vaste dosiscombinatie met emtricitabine/tenofovir alafenamide (F/TAF) van Gilead voldoet aan de primaire doelstelling van 48 weken in fase 3-onderzoek,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/16/2011 02043Q10  BW   Alnylam Pharmaceuticals Grants InterfeRx™ Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/11/2011 15117K10 BW   Cellectis renforce ses équipes pour accompagner le développement de ses activités dans les cellules souches,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 6/01/2010 01535110 BW   Alexion Announces the Appointment of Ann M. Veneman to Its Board of Directors,#N/A,#N/A,#N/A, 6/12/2012 ACOR-US     BW   Acorda Therapeutics to Present at Wells Fargo 2012 Healthcare Conference,#N/A,#N/A, 9/02/2015 09966D-E     BW   Prüfpräparat von Gilead mit Festdosis einer Kombination aus Emtricitabin und Tenofoviralafenamid (F/TAF) erreicht Hauptzielkriterium nach 48 Wochen einer Studie der Phase III,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/15/2011 02043Q10  BW   Alnylam to Present Phase I Clinical Data at VIIIth International Symposium on Familial Amyloidotic Polyneuropathy,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 15117K10 BW   Cellectis et la Caisse des Dépôts ont signé un accord portant sur un projet de développement industriel des cellules souches iPS,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/19/2010 01535110 BW   Alexion to Present at the Citi 2010 Global Health Care Conference,#N/A,#N/A,#N/A, 6/05/2012 09062X10    BW   Biogen Idec Announces Webcast of 2012 Analyst Day,#N/A,#N/A, 9/02/2015 GILD-US      BW   Il regime combinato a dosaggio fisso sperimentale di emtricitabina/tenofovir alafenamide (F/TAF) raggiunge l'obiettivo primario della settimana 48 nello studio di Fase 3,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2011 02043Q10  BW   Alnylam Pharmaceuticals Reports Third Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/05/2011 ALCLS-FR BW   Cellectis and Caisse des Dépôts sign agreement on a project for the industrial development of iPS cells,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 5/06/2010 01535110 BW   Alexion to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference,#N/A,#N/A,#N/A, 6/01/2012 09062X10    BW   Biogen Idec 2012 Annual Shareholders Meeting Webcast,#N/A,#N/A, 9/02/2015 GILD-US      BW   Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,11/01/2011 ALNY-US   BW   Alnylam and GlaxoSmithKline Form Collaboration on RNAi Technology for Vaccine Production,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2011 15117K10 BW   Cellectis reçoit un paiement pour une licence sur ses brevets de recombinaison homologue,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/30/2010 01535110 BW   Research to be Presented at the American Transplant Congress Examines the Role of Terminal Complement Inhibition in the Treatment of Kidney Transplantation Patients,#N/A,#N/A,#N/A, 5/30/2012 09062X10    BW   Biogen Idec continua nel suo sostegno alla comunità della sclerosi multipla con celebrazioni a livello internazionale in occasione della quarta Giornata mondiale della sclerosi multipla,#N/A,#N/A, 8/28/2015 GILD-US      BW   Les résultats de l'étude AMBITION évaluant un traitement de première ligne combinant Letairis et Tadalafil dans la prise en charge de l'hypertension artérielle pulmonaire sont publiés dans The New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/25/2011 02043Q10  BW   Alnylam to Webcast Conference Call Discussing Third Quarter 2011 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/04/2011 15117K10 BW   Cellectis receives payment for license to homologous recombination patents,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/22/2010 01535110 BW   Alexion Reports First Quarter 2010 Results,#N/A,#N/A,#N/A, 5/30/2012 09062X10    BW   Biogen Idec unterstützt MS-Gemeinde mit weltweiten Veranstaltungen zum 4. jährlichen Welt-MS-Tag,#N/A,#N/A, 8/28/2015 GILD-US      BW   Ergebnisse der AMBITION-Studie zur Erstbehandlung mit Letairis und Tadalafil bei pulmonalarterieller Hypertonie im The New England Journal of Medicine veröffentlicht,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/20/2011 02043Q10  BW   Alnylam to Webcast Presentation at the Newsmakers in the Biotech Industry 2011 Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/31/2011 15117K10 BW   Cellectis Publishes 2010 Financial Results,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/20/2010 01535110 BW   Alexion Completes Enrollment in All Four Clinical Trials of Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS),#N/A,#N/A,#N/A, 5/30/2012 09062X10    BW   Biogen Idec continue de soutenir la communauté de la sclérose en plaques (SEP) avec des célébrations internationales à l'occasion de la quatrième année de la journée mondiale de la SEP,#N/A,#N/A, 8/28/2015 GILD-US      BW   Resultaten van het AMBITION-onderzoek van de eerstelijnsbehandeling met Letairis en Tadalafil van pulmonale arteriële hypertensie gepubliceerd in The New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,10/11/2011 02043Q10  BW   Alnylam and Collaborators Publish New Pre-clinical Data on Delivery of RNAi Therapeutics to Key Cell Types Regulating Immune and Inflammatory Diseases,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/31/2011 15117K10 BW   Cellectis publie ses résultats financiers 2010,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 4/16/2010 01535110 BW   Alexion’s Soliris® (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),#N/A,#N/A,#N/A, 5/30/2012 07MPRB-E    BW   Biogen Idec Continues Support for MS Community with Worldwide Celebrations on Fourth Annual World MS Day,#N/A,#N/A," 8/28/2015 GILD-US      BW   Resultados del estudio AMBITION sobre tratamiento de primera línea con Letairis y tadalafilo para la hipertensión arterial pulmonar, publicados en The New England Journal of Medicine",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/26/2011 02043Q10  BW   Alnylam Initiates Phase I Clinical Study of ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/08/2011 15117K10 BW   Cellectis et l’Etablissement Français du Sang annoncent le démarrage opérationnel de StemRed, programme de production de globules rouges à partir de cellules souches",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 4/08/2010 01535110 BW   Alexion Pharmaceuticals to Report First Quarter Results on Thursday, April 22, 2010",#N/A,#N/A,#N/A," 5/22/2012 BIIB-US     BW   EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors",#N/A,#N/A, 8/27/2015 GILD-US      BW   I risultati derivati dallo studio AMBITION su Letairis e Tadalafil come terapia di prima linea per il trattamento dell'ipertensione polmonare arteriosa sono stati pubblicati nella rivista The New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/21/2011 02043Q10  BW   Alnylam to Webcast Presentation at the JMP Securities Healthcare Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 3/08/2011 15117K10 BW   Cellectis and the Etablissement Français du Sang Launch StemRed, a Program to Produce Red Blood Cells from Stem Cells",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 3/02/2010 01535110 BW   Alexion to Present at the Cowen and Company 30th Annual Health Care Conference,#N/A,#N/A,#N/A, 5/18/2012 09062X10    BW   Nuevo análisis de la estratificación del riego para TYSABRI® publicados en el New England Journal of Medicine,#N/A,#N/A, 8/26/2015 GILD-US      BW   Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2011 02043Q10  BW   Alnylam to Webcast Presentation at the UBS Global Life Sciences Conference,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/28/2011 15117K10 BW   Cellectis bioresearch met l’ingénierie des génomes à la portée de tous les laboratoires,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 2/26/2010 01535110 BW   Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2010",#N/A,#N/A,#N/A, 5/18/2012 09062X10    BW   Nuova analisi della stratificazione del rischio per TYSABRI® pubblicata nel New England Journal of Medicine,#N/A,#N/A," 8/24/2015 GILD-US      BW   La Agencia Europea de Medicamentos aprueba la solicitud de comercialización de un régimen de único comprimido de Gilead que contiene rilpivirina, emtricitabina y tenofovir alafenamida (R/F/TAF) para el tratamiento del VIH",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 9/12/2011 02043Q10  BW   Alnylam Scientists and Collaborators Report Significant New Advances in Delivery of RNAi Therapeutics at 2011 Oligonucleotides Therapeutics Society Meeting,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2011 15117K10 BW   Cellectis présentera ses travaux au Congrès « Gene Targeting » à Vienne,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/24/2010 01535110 BW   Alexion Appoints Andreas Rummelt to its Board of Directors,#N/A,#N/A,#N/A, 5/18/2012 09062X10    BW   Veröffentlichung einer neuen Risikostratifizierungsanalyse für TYSABRI® im New England Journal of Medicine,#N/A,#N/A," 8/21/2015 GILD-US      BW   L'Agence européenne des médicaments valide la demande d'autorisation de mise sur le marché de Gilead pour un régime thérapeutique contre le VIH à comprimé unique contenant Rilpivirine, Emtricitabine et Ténofovir Alafénamide (R/F/TAF)",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A," 9/08/2011 02043Q10  BW   Alnylam Expands “Alnylam 5x15” RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C for the Treatment of Hemophilia",#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A, 2/08/2011 15117K10 BW   Cellectis to Present at the Annual Congress “Gene Targeting” in Vienna,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A
